<SEC-DOCUMENT>0001129928-20-000012.txt : 20200306
<SEC-HEADER>0001129928-20-000012.hdr.sgml : 20200306
<ACCEPTANCE-DATETIME>20200306153802
ACCESSION NUMBER:		0001129928-20-000012
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		119
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200306
DATE AS OF CHANGE:		20200306

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38512
		FILM NUMBER:		20694424

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>oncyf2019-20f.htm
<DESCRIPTION>20-F
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sE6DCA9622D89556787A4A3024C79674D"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;text-indent:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 20-F</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:15%;"></td><td style="width:4%;"></td><td style="width:81%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OR</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For fiscal year ended</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OR</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from ____ to ____</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OR</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date of event requiring this shell company report:</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission file number: 001-38512</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:20pt;"><font style="font-family:inherit;font-size:20pt;">&#160;</font><font style="font-family:inherit;font-size:20pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of Registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Province of Alberta, Canada</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Jurisdiction of incorporation or organization)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Suite 210, 1167 Kensington Crescent, N.W. Calgary, Alberta, T2N 1X7</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Kirk Look</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Suite 210, 1167 Kensington Crescent, N.W. Calgary, Alberta, T2N 1X7</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tel: (403) 670-7377</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E-mail: info@oncolytics.ca</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities registered pursuant to Section 12(b) of the Act:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:81.8359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:30%;"></td><td style="width:24%;"></td><td style="width:46%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title of each class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trading Symbol</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name of each exchange on which registered</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common Shares, no par value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ONCY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nasdaq Capital Market</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities registered pursuant to Section 12(g) of the Act:  None</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: &#160;None</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate the number of outstanding shares of each of the Registrant&#8217;s classes of capital or common stock as of the close of the period covered by the annual report: </font><font style="font-family:inherit;font-size:10pt;">32,198,453</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares as at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;No </font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If this report is an annual or transition report, indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;No </font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes </font><font style="font-family:Wingdings;font-size:10pt;">&#253; </font><font style="font-family:inherit;font-size:10pt;">No </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically every&#160;Interactive Data File required to be submitted ursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;Yes </font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;No </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company.&#160;&#160;See definition of &#8220;large accelerated filer,&#8221;  &#8220;accelerated filer,&#8221; and &#8220;emerging growth company in Rule 12b-2 of the Exchange Act.&#160;&#160;(Check one)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:33%;"></td><td style="width:34%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large accelerated filer </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated filer </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Non-accelerated filer&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 13(a) of the Exchange Act.  </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;US GAAP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International Financial Reporting Standards as issued&#160;&#160;by the International Accounting Standards Board</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Other&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 17 </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Item 18&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If this is an annual report, indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;Yes </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;No </font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div><br></div><hr style="page-break-after:always"><div><a name="s0EC315348E1C5B26ADBCE1E354E75F4B"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FORM 20-F</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:75%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5016294DE585549099854CAF1222E7E9"><font style="font-family:inherit;font-size:10pt;">&#160;Item 1. &#160;&#160;&#160;&#160; Identity of Directors, Senior Management and Advisers</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5016294DE585549099854CAF1222E7E9">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBE845344ED2A5C74A03F3F952D2DC5E7"><font style="font-family:inherit;font-size:10pt;">&#160;Item 2.&#160; &#160;&#160;&#160; Offer Statistics and Expected Timetable</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBE845344ED2A5C74A03F3F952D2DC5E7">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAD7690DDD8F95D418D06D2520E1828B1"><font style="font-family:inherit;font-size:10pt;">&#160;Item 3. &#160;&#160;&#160; &#160;Key Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAD7690DDD8F95D418D06D2520E1828B1">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s287B5DA1C1AF57B88BB2E1CBAA9F8F24"><font style="font-family:inherit;font-size:10pt;">&#160;Item 4.&#160;&#160;&#160;&#160;&#160; Information on the Company</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s287B5DA1C1AF57B88BB2E1CBAA9F8F24">17</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s38294448EBB4564DB241C336B0B083C0"><font style="font-family:inherit;font-size:10pt;">&#160;Item 4A.    Unresolved Staff Comments</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s38294448EBB4564DB241C336B0B083C0">25</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6DE310FE60915FB496C3B26621CA7334"><font style="font-family:inherit;font-size:10pt;">&#160;Item 5.&#160; &#160;&#160;&#160; Operating and Financial Review and Prospects</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6DE310FE60915FB496C3B26621CA7334">25</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s44EB09EE10CB552697A18931F9F4C5DB"><font style="font-family:inherit;font-size:10pt;">&#160;Item 6.&#160; &#160;&#160; &#160;Directors, Senior Management and Employees</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s44EB09EE10CB552697A18931F9F4C5DB">26</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s325C462F5C4E5A49BB135AE0A7CDA855"><font style="font-family:inherit;font-size:10pt;">&#160;Item 7.&#160; &#160;&#160;&#160; Major Shareholders and Related Party Transactions</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s325C462F5C4E5A49BB135AE0A7CDA855">49</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE903E70659135762AF639D8EC9975FF6"><font style="font-family:inherit;font-size:10pt;">&#160;Item 8.&#160;&#160; &#160;&#160;&#160;Financial Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE903E70659135762AF639D8EC9975FF6">50</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9319A674FE8058ECB00DBD73C6DA8B25"><font style="font-family:inherit;font-size:10pt;">&#160;Item 9.&#160;&#160;&#160;&#160;&#160; The Offer and Listing</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9319A674FE8058ECB00DBD73C6DA8B25">51</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2D124AB70CE0558DACB322E09C907A6E"><font style="font-family:inherit;font-size:10pt;">&#160;Item 10.&#160;&#160;&#160; Additional Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2D124AB70CE0558DACB322E09C907A6E">51</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDCDC4EED1A47539D8CE93366FFCD8580"><font style="font-family:inherit;font-size:10pt;">&#160;Item 11.&#160;&#160;&#160; Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDCDC4EED1A47539D8CE93366FFCD8580">62</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s350674D56DED5214822CD60B8C5C3C2F"><font style="font-family:inherit;font-size:10pt;">&#160;Item 12.&#160;&#160;&#160; Description of Securities Other Than Equity Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s350674D56DED5214822CD60B8C5C3C2F">63</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7A040EF07988525E928BED348D34E5F2"><font style="font-family:inherit;font-size:10pt;">&#160;Item 13.&#160;&#160;&#160; Defaults, Dividend Arrearages and Delinquencies</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7A040EF07988525E928BED348D34E5F2">63</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s98EA3F770D625C5E8672E8B6010E5FB9"><font style="font-family:inherit;font-size:10pt;">&#160;Item 14.&#160;&#160;&#160; Material Modifications to the Rights of Security Holders and Use of Proceeds</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s98EA3F770D625C5E8672E8B6010E5FB9">63</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6088320C08FE57C1868BB56667D74C87"><font style="font-family:inherit;font-size:10pt;">&#160;Item 15.&#160;&#160;&#160;&#160; Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6088320C08FE57C1868BB56667D74C87">63</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA63A095625F354BC9DE1600DFCEB7FAE"><font style="font-family:inherit;font-size:10pt;">&#160;Item 16.     [Reserved]</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA63A095625F354BC9DE1600DFCEB7FAE">64</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s91841F7658B05717AE9A47E36AE37B3E"><font style="font-family:inherit;font-size:10pt;">&#160;Item 16A. &#160;Audit Committee Financial Expert</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s91841F7658B05717AE9A47E36AE37B3E">64</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s255B92B8DAEA53BDBA040AB60B49E92C"><font style="font-family:inherit;font-size:10pt;">&#160;Item 16B.&#160;&#160; Code of Ethics</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s255B92B8DAEA53BDBA040AB60B49E92C">64</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD163E2760EAF5ECC81C1E5E562110F30"><font style="font-family:inherit;font-size:10pt;">&#160;Item 16C.&#160;&#160;&#160;Principal Accountant Fees and Services</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD163E2760EAF5ECC81C1E5E562110F30">65</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA1C8CA2F2F8C54849C946EA1995A1AB9"><font style="font-family:inherit;font-size:10pt;">&#160;Item 16D.&#160; &#160;Exemptions from the Listing Standards for Audit Committees</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA1C8CA2F2F8C54849C946EA1995A1AB9">65</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7FFA744CEC9453098254B033B7F463B6"><font style="font-family:inherit;font-size:10pt;">&#160;Item 16E.&#160;&#160; Purchase of Equity Securities by the Issuer and Affiliated Purchases</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7FFA744CEC9453098254B033B7F463B6">65</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2AE932C7648757929FB2897404DF4C73"><font style="font-family:inherit;font-size:10pt;">&#160;Item 16F.&#160;&#160; Change in Registrant's Certifying Accountants</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2AE932C7648757929FB2897404DF4C73">65</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1717B8C6E4AF51DE97DA6BC10078377B"><font style="font-family:inherit;font-size:10pt;">&#160;Item 16G.&#160; Corporate Governance</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1717B8C6E4AF51DE97DA6BC10078377B">65</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5AE244C3A18F5E568504976629D16036"><font style="font-family:inherit;font-size:10pt;">&#160;Item 16H.   Mine Safety Disclosure</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5AE244C3A18F5E568504976629D16036">66</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3AD9F5C3BC4F5334BE9FC58A6C1B8B8D"><font style="font-family:inherit;font-size:10pt;">&#160;Item 17.&#160;&#160;&#160;&#160;&#160; Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3AD9F5C3BC4F5334BE9FC58A6C1B8B8D">66</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBFEC7325B7A6512082EBEF97739FCED5"><font style="font-family:inherit;font-size:10pt;">&#160;Item 18&#160;&#160;&#160;&#160;&#160;&#160; Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBFEC7325B7A6512082EBEF97739FCED5">66</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s992A5DE7829550238022B796652F0256"><font style="font-family:inherit;font-size:10pt;">&#160;Item 19.&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s992A5DE7829550238022B796652F0256">67</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE72D1CF35DE751F69B6B054834D99E61"><font style="font-family:inherit;font-size:10pt;">&#160;Signatures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE72D1CF35DE751F69B6B054834D99E61">68</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s829D1A942E155F61A9828CFCD43D5801"><font style="font-family:inherit;font-size:10pt;">&#160;Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s829D1A942E155F61A9828CFCD43D5801"><font style="font-family:inherit;font-size:10pt;">F1 - F29</font></a></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="sFBF87C8125DF5B0DA952B1D21F9E9845"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All references in this annual report on Form 20-F to the terms &#8220;we&#8221;, &#8220;our&#8221;, &#8220;us&#8221;, &#8220;the Company&#8221; and &#8220;Oncolytics&#8221; refer to Oncolytics Biotech Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain statements in this annual report on Form 20-F and the documents attached as exhibits to this annual report, constitute &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Oncolytics Biotech Inc., or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts, and include, but are not limited to, estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to the efficacy of our technologies; the timing and results of clinical studies related to our technologies; future operations, products and services; the impact of regulatory initiatives on our operations; the size of and opportunities related to the markets for our technologies; general industry and macroeconomic growth rates; expectations related to possible joint and/or strategic ventures and statements regarding future performance. Forward-looking statements generally, but not always, are identified by the words &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;projects&#8221;, &#8220;potential&#8221;, &#8220;possible&#8221; and similar expressions, or that events or conditions &#8220;will,&#8221; &#8220;may,&#8221; &#8220;could&#8221; or &#8220;should&#8221; occur.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The forward-looking statements in this annual report are subject to various risks and uncertainties, most of which are difficult to predict and generally beyond our control, including without limitation:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to all of our products, including pelareorep, being in the research and development stage and requiring further development and testing before they can be marketed commercially;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks inherent in pharmaceutical research and development;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to timing and possible delays in our clinical trials;  </font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to some of our clinical trials being conducted in, and subject to the laws of foreign countries;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our pharmaceutical products being subject to intense regulatory approval processes in the United States and other foreign jurisdictions;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to being subject to government manufacturing and testing regulations;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to the extremely competitive biotechnology industry and our competition with larger companies with greater resources;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our reliance on patents and proprietary rights to protect our technology;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to potential products liability claims;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our limited manufacturing experience and reliance on third parties to commercially manufacture our products, if and when developed;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our new products not being accepted by the medical community or consumers;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our technologies becoming obsolete;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to events outside of our control, such as natural disasters, wars&#160;or health epidemics;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our dependence on third-party relationships for research and clinical trials;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our license, development, supply and distribution agreement (the &#8220;Licensing Agreement&#8221;) with Adlai Nortye Biopharma Co. Ltd. (&#8220;Adlai&#8221;);</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our lack of operating revenues and history of losses;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">uncertainty regarding our ability to obtain third-party reimbursement for the costs of our product;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to other third-party arrangements; </font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our ability to obtain additional financing to fund future research and development of our products and to meet ongoing capital requirements;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to potential increases in the cost of director and officer liability insurance;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our dependence on key employees and collaborators;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to Barbados law, including those relating to the enforcement of judgments obtained in Canada or the United States;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to the effect of changes in the law on our corporate structure;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to expenses in foreign currencies and our exposure to foreign currency exchange rate fluctuations;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to data privacy laws;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our information technology systems and security breaches;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our compliance with the Sarbanes-Oxley Act of 2002, as amended;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our status as a foreign private issuer;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;risk related to&#160;&#160;possible &#8220;passive foreign investment company&#8221; status;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to fluctuations in interest rates;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to information technology systems; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks related to our common shares.&#160;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This list is not exhaustive of the factors that may affect any of the Company&#8217;s forward-looking statements.&#160;&#160;Some of the important risks and uncertainties that could affect forward-looking statements are described further under the section heading &#8220;Item 3. Key Information &#8211; D. Risk Factors&#8221; below.&#160;&#160;If one or more of these risks or uncertainties materializes, or if underlying assumptions prove incorrect, our actual results may vary materially from those expected, estimated or projected.&#160;&#160;Forward-looking statements in this document are not a prediction of future events or circumstances, and those future events or circumstances may not occur.&#160;&#160;Given these uncertainties, users of the information included herein, including investors and prospective investors are cautioned not to place undue reliance on such forward-looking statements.&#160;&#160;Investors should consult our quarterly and annual filings with the securities commissions or similar regulatory authorities in Canada and the SEC for additional information on risks and uncertainties relating to forward-looking statements.&#160;&#160;We do not assume responsibility for the accuracy and completeness of these statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward-looking statements are based on our beliefs, opinions and expectations at the time they are made, and we do not assume any obligation to update our forward-looking statements if those beliefs, opinions, or expectations, or other circumstances, should change, except as required by applicable law.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="s4B2DF61F7A815B87BD450248BA2472A0"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s5016294DE585549099854CAF1222E7E9"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sBE845344ED2A5C74A03F3F952D2DC5E7"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sAD7690DDD8F95D418D06D2520E1828B1"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 3. KEY INFORMATION</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Selected Financial Data</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The selected financial data presented below for the five years ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;is presented in Canadian dollars and is derived from our consolidated financial statements in Canadian dollars and in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;) as issued by the International Accounting Standards Board (&#8220;IASB&#8221;). The information set forth below should be read in conjunction with our consolidated financial statements (including notes thereto) included under Item 18 and "Operating and Financial Review and Prospects" included under Item 5. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:680px;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:270px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:76px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,122,888</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,037,225</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,616,851</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,139,979</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,722,995</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net comprehensive loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,266,291</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,803,451</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,797,181</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,346,897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,242,060</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per share</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)(2)(4)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.50</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.06</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.16</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,657,865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,150,449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,758,284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,383,798</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; equity</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)(4)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(107,894</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,195,363</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,283,846</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,689,620</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,674,306</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash dividends declared per share</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of common shares outstanding</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,137,990</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,016,366</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,936,387</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,618,942</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,854,047</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in consolidated net loss and loss per common share for 2019 is a non-cash change in fair value of warrant derivative expense of $12,608,808 (2018 - nil; 2017 - nil; 2016 - nil; 2015 - nil).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 22, 2018, we completed the consolidation of our common shares on the basis of </font><font style="font-family:inherit;font-size:10pt;">9.5</font><font style="font-family:inherit;font-size:10pt;">&#32;pre-consolidation common shares for each one post-consolidation common share (the "Share Consolidation"). Fractional interests were rounded down to the nearest whole number of common shares. Common shares, stock options, restricted share units and performance share units for all periods were similarly adjusted retroactively by the consolidation ratio. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in net loss and net loss per share for the year ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;are share based payment expenses of </font><font style="font-family:inherit;font-size:10pt;">$1,470,153</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,415,833</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">$578,703</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">$406,078</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">$429,537</font><font style="font-family:inherit;font-size:10pt;">). </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The calculation of basic and diluted loss per common share for all periods have been adjusted retroactively for the Share Consolidation. We issued </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">14,798,704</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for net cash proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$21,463,093</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2,472,909</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for net cash proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$13,299,136</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;- 20,547,500 pre-consolidation common shares (approximately </font><font style="font-family:inherit;font-size:10pt;">2,162,894</font><font style="font-family:inherit;font-size:10pt;">&#32;post-consolidation common shares) for net cash proceeds of </font><font style="font-family:inherit;font-size:10pt;">$12,812,704</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;- 3,106,600 pre-consolidation common shares (approximately </font><font style="font-family:inherit;font-size:10pt;">327,010</font><font style="font-family:inherit;font-size:10pt;">&#32;post-consolidation common shares) for net cash proceeds of </font><font style="font-family:inherit;font-size:10pt;">$956,133</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;- 24,639,128 pre-consolidation common shares (approximately </font><font style="font-family:inherit;font-size:10pt;">2,593,591</font><font style="font-family:inherit;font-size:10pt;">&#32;post-consolidation common shares) for net cash proceeds of </font><font style="font-family:inherit;font-size:10pt;">$23,667,654</font><font style="font-family:inherit;font-size:10pt;">).  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have not declared or paid any dividends since incorporation.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Capitalization and Indebtedness</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reasons for the Offer and Use of Proceeds</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk Factors</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment in our common shares ("Common Shares") involves a high degree of risk. You should carefully consider, among other matters, the following risk factors in addition to the other information in this Annual Report on Form 20-F when evaluating our business because these risk factors may have a significant impact on our business, financial condition, operating results or cash flow. If any of the material risks described below or in subsequent reports we file with the SEC actually occur, they may materially harm our business, financial condition, operating results or cash flow. Additional risks and uncertainties that we have not yet identified or that we presently consider to be immaterial may also materially harm our business, financial condition, operating results or cash flow.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Risks</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">All of our potential products, including pelareorep, are in the research and development stage and will require further development and testing before they can be marketed commercially.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prospects for companies in the biotechnology industry generally may be regarded as uncertain given the nature of the industry and, accordingly, investments in biotechnology companies should be regarded as speculative. We are currently in the research and development stage on one product, pelareorep, for human application, the riskiest stage for a company in the biotechnology industry. It is not possible to predict, based upon studies in animals and early-stage human clinical trials, whether pelareorep will prove to be safe and effective in humans. pelareorep will require additional research and development, including extensive additional clinical testing, before we will be able to obtain the approvals of the relevant regulatory authorities in applicable countries to market pelareorep commercially. There can be no assurance that the research and development programs we conduct will result in pelareorep or any other products becoming commercially viable products, and in the event that any product or products result from the research and development program, it is unlikely they will be commercially available for a number of years.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To achieve profitable operations we, alone or with others, must successfully develop, introduce and market our products. To obtain regulatory approvals for products being developed for human use, and to achieve commercial success, human clinical trials must demonstrate that the product is safe for human use and that the product shows efficacy. Unsatisfactory results obtained from a particular study relating to a program may cause us to abandon our commitment to that program or the product being tested. No assurances can be provided that any current or future animal or human test, if undertaken, will yield favourable results. If we are unable to establish that pelareorep is a safe, effective treatment for cancer, we may be required to abandon further development of the product and develop a new business strategy.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">There are inherent risks in pharmaceutical research and development.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical research and development is highly speculative and involves a high and significant degree of risk. The marketability of any product we develop will be affected by numerous factors beyond our control, including but not limited to:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the discovery of unexpected toxicities or lack of sufficient efficacy of products which make them unattractive or unsuitable for human use;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">preliminary results as seen in animal and/or limited human testing may not be substantiated in larger, controlled clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">manufacturing costs or other production factors may make manufacturing of products ineffective, impractical and non-competitive;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">proprietary rights of third parties or competing products or technologies may preclude commercialization;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">requisite regulatory approvals for the commercial distribution of products may not be obtained; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">other factors may become apparent during the course of research, up-scaling or manufacturing which may result in the discontinuation of research and other critical projects.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our products under development have never been manufactured on a commercial scale, and there can be no assurance that such products can be manufactured at a cost or in a quantity to render such products commercially viable. Production and utilization of our products may require the development of new manufacturing technologies and expertise. The impact on our business in the event that new manufacturing technologies and expertise are required to be developed is uncertain. There can be no assurance that we will successfully meet any of these technological challenges or others that may arise in the course of development.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Any failure or delay in clinical trials for our products, including pelareorep, may cause us to incur additional costs or delay or prevent the commercialization of our products and could severely harm our business.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We must conduct extensive clinical trials to demonstrate the safety and efficacy of our products in humans. Clinical testing, in particular, is expensive, difficult to design and implement, can take many years to complete and is uncertain as to the outcome.&#160;&#160;A failure of one or more of our clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during, or as a result of, the clinical trial process, which could delay or prevent us from receiving marketing approval or commercializing our product candidates, including the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our clinical trials may produce negative or inconclusive results, and we may decide, or regulatory authorities may require us, to conduct additional clinical trials or we may abandon projects that we expect to be promising;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The number of subjects required for our clinical trials may be larger than we anticipate, enrollment in our clinical trials may be slower than we anticipate, or participants may drop out of our clinical trials at a higher rate than we anticipate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We might have to suspend or terminate our clinical trials if the participants are being exposed to unacceptable health risks;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regulators or institutional review boards may require that we hold, suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or our clinical protocols;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regulators may refuse to accept or consider data from clinical trials for various reasons, including noncompliance with regulatory requirements or our clinical protocols;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may be subject to governmental or regulatory delays and changes in regulatory requirements, policy and guidelines, including guidelines specifically addressing requirements for the development of treatments for our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We might have difficulty adding new clinical trial sites on a timely basis, or at all;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The cost of our clinical trials may be greater than we anticipate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The supply, storage, distribution or quality of our products or other materials necessary to conduct our clinical trials may be insufficient or inadequate</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, subject enrollment, which is a significant factor in the timing of clinical trials, is affected by a variety of factors, including the following:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The size and nature of the subject population;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The proximity of subjects to clinical sites;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The eligibility criteria for the trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The design of the clinical trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Competing clinical trials; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinicians&#8217; and subjects&#8217; perceptions as to the potential advantages of the medication being studied in relation to other available therapies, including any new medications that may be approved for the indications we are investigating.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furthermore, we plan to rely on clinical trial sites to ensure the proper and timely conduct of our clinical trials, and while we have agreements governing their committed activities, we have limited influence over their actual performance. Any delays or unanticipated problems during clinical testing, such as enrollment in our clinical trials being slower than we anticipate or participants dropping out of our clinical trials at a higher rate than we anticipate, could increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenues.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Condition Risks</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have no operating revenues and a history of losses.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, we have not generated sufficient revenues to offset our research and development costs and accordingly have not generated positive cash flow or made an operating profit. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of $</font><font style="font-family:inherit;font-size:10pt;">344.6</font><font style="font-family:inherit;font-size:10pt;">&#32;million and we incurred net losses of </font><font style="font-family:inherit;font-size:10pt;">$33.1 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$17.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$15.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. We anticipate that we will continue to incur significant losses during </font><font style="font-family:inherit;font-size:10pt;">2020</font><font style="font-family:inherit;font-size:10pt;">&#32;and in the foreseeable future. We do not expect to reach profitability at least until after the successful and profitable commercialization of one or more of our products. Even if one or more of our products are profitably commercialized, the initial losses incurred by us may never be recovered. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to obtain third-party reimbursement for the cost of our product.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the US healthcare industry and elsewhere is </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">cost containment. Government authorities and these third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Uncertainty exists regarding the reimbursement status of newly-approved pharmaceutical products and reimbursement may not be available for pelareorep.&#160;&#160;Any reimbursements granted may not be maintained or limits on reimbursements available from third-party payors may reduce the demand for, or negatively affect the price of, these products. If pelareorep does not qualify for reimbursement, if reimbursement levels diminish, or if reimbursement is denied, our sales and profitability would be adversely affected.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Third-Party Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the normal course of our business, we have entered into contractual arrangements with third parties which subject us to the risk that such parties may default on their obligations. Oncolytics may be exposed to third-party credit risk through our contractual arrangements with our current contract manufacturer, the institutions which operate our clinical trials, or our contract research organizations and other parties.&#160;&#160;In the event such entities fail to meet their contractual obligations to Oncolytics, such failures could have a material adverse effect on Oncolytics and our operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may need additional financing in the future to fund the research and development of our products and to meet our ongoing capital requirements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of  </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents of </font><font style="font-family:inherit;font-size:10pt;">$14.1 million</font><font style="font-family:inherit;font-size:10pt;">. Working capital was approximately </font><font style="font-family:inherit;font-size:10pt;">$14.6 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;We anticipate that we will need additional financing in the future to fund research and development and to meet our ongoing capital requirements.&#160;&#160;The amount of future capital requirements will depend on many factors, including continued scientific progress in our drug discovery and development programs, progress in our pre-clinical and clinical evaluation of drug candidates, time and expense associated with filing, prosecuting and enforcing our patent claims and costs associated with obtaining regulatory approvals.&#160;&#160;In order to meet such capital requirements, we will consider contract fees, collaborative research and development arrangements, and additional public or private financings (including the incurrence of debt and the issuance of additional equity securities) to fund all or a part of particular programs as well as potential partnering or licensing opportunities.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oncolytics, from time to time, along with all other pharmaceutical research and development entities, may have restricted access to capital, bank debt and equity, and, from time to time, may face increased borrowing costs. Although our business and asset base have not changed, the lending capacity of all financial institutions fluctuates causing a corresponding change in risk premiums.   As future operations will be financed out of funds generated from financing activities, our ability to do so is dependent on, among other factors, the overall state of capital markets and investor appetite for investments in the pharmaceutical industry and our securities in particular.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Should we elect to satisfy our cash commitments through the issuance of securities, by way of either private placement or public offering or otherwise, there can be no assurance that our efforts to raise such funding will be successful, or achieved on terms favourable to us or our existing shareholders.&#160;&#160;If adequate funds are not available on terms favorable to us, we may have to reduce substantially or eliminate expenditures for research and development, testing, production and marketing of our proposed product, or obtain funds through arrangements with corporate partners that require us to relinquish rights to certain of our technologies or product.&#160;&#160;There can be no assurance that we will be able to raise additional capital if our current capital resources are exhausted.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Regulatory Risks</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pharmaceutical products are subject to intense regulatory approval processes.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The regulatory process for pharmaceuticals, which includes preclinical studies and multiple phases of clinical trials of each compound to establish its safety and efficacy, takes many years and requires the expenditure of substantial resources. Moreover, if regulatory approval of a drug is granted, such approval may entail limitations on the indicated uses for which it may be marketed. Failure to comply with applicable regulatory requirements can, among other things, result in suspension of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. Further, government policy may change, and additional government regulations may be established that could prevent or delay regulatory approvals for our products. In addition, a marketed drug and its manufacturer are subject to continual review. Later discovery of previously unknown problems with the product or manufacturer may result in restrictions on such product or manufacturer, including withdrawal of the product from the market.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The United States Food and Drug Administration (&#8220;FDA&#8221;) and similar regulatory authorities in other countries may deny approval of a new drug application if required regulatory criteria are not satisfied, or may require additional testing. Product approvals may be withdrawn if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. The FDA and similar regulatory authorities in other countries may require further testing and surveillance programs to monitor </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the pharmaceutical product that has been commercialized. Non-compliance with applicable requirements can result in fines and other judicially imposed sanctions, including product withdrawals, product seizures, injunction actions and criminal prosecutions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to our own pharmaceuticals, we may supply active pharmaceutical ingredients and advanced pharmaceutical intermediates for use in our customers&#8217; drug products. The final drug products in which the pharmaceutical ingredients and advanced pharmaceutical intermediates are used, however, are subject to regulation for safety and efficacy by the FDA and possibly other regulatory authorities in other jurisdictions.&#160;&#160;Such products must be approved by such agencies before they can be commercially marketed. The process of obtaining regulatory clearance for marketing is uncertain, costly and time consuming. We cannot predict how long the necessary regulatory approvals will take or whether our customers will ever obtain such approval for their products. To the extent that our customers do not obtain the necessary regulatory approvals for marketing new products, our product sales could be adversely affected.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA and other governmental regulators have increased requirements for drug purity and have increased environmental burdens upon the pharmaceutical industry. Because pharmaceutical drug manufacturing is a highly regulated industry, requiring significant documentation and validation of manufacturing processes and quality control assurance prior to the approval of the facility to manufacture a specific drug, our manufacturing facilities may never become approved of, or there can be considerable transition time between the initiation of a contract to manufacture a product and the actual initiation of manufacture of that product. Any lag time in the initiation of a contract to manufacture product and the actual initiation of manufacture could cause us to lose profits or incur liabilities.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pharmaceutical regulatory regime in Europe and other countries is generally similar to that of the United States. We could face similar risks in these other jurisdictions as the risks described above.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our operations and products may be subject to other government manufacturing and testing regulations.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securing regulatory approval for the marketing of therapeutics by the FDA in the United States and similar regulatory agencies in other countries is a long and expensive process, which can delay or prevent product development and marketing. Approval to market products may be for limited applications or may not be received at all.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The products we anticipate manufacturing will have to comply with the FDA&#8217;s current Good Manufacturing Practices (</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:10pt;">cGMP</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:10pt;">) and other FDA and local government guidelines and regulations, including other international regulatory requirements and guidelines. Additionally, certain of our customers may require the manufacturing facilities contracted by us to adhere to additional manufacturing standards, even if not required by the FDA. Compliance with cGMP regulations requires manufacturers to expend time, money and effort in production and to maintain precise records and quality control to ensure that the product meets applicable specifications and other requirements. The FDA and other regulatory bodies periodically inspect drug-manufacturing facilities to ensure compliance with applicable cGMP requirements. If the manufacturing facilities contracted by us fail to comply with the cGMP requirements, the facilities may become subject to possible FDA or other regulatory action and manufacturing at the facility could consequently be suspended. We may not be able to contract suitable alternative or back-up manufacturing facilities on terms acceptable to us or at all.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA or other regulatory agencies may also require the submission of any lot of a particular product for inspection. If the lot product fails to meet the FDA requirements, then the FDA could take any of the following actions: (i) restrict the release of the product; (ii) suspend manufacturing of the specific lot of the product; (iii) order a recall of the lot of the product; or (iv) order a seizure of the lot of the product.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to regulation by governments in many jurisdictions.&#160;&#160;If we do not comply with healthcare, drug, manufacturing and environmental regulations, among others, in such jurisdiction, our existing and future operations may be curtailed, and we could be subject to liability.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the regulatory approval process, we may be subject to regulations under local, provincial, state, federal and foreign law, including, but not limited to, requirements regarding occupational health, safety, laboratory practices, healthcare fraud and abuse, environmental protection and hazardous substance control, and may be subject to other present and future local, provincial, state, federal and foreign regulations.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intellectual Property Risks</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We rely on patents and proprietary rights to protect our technology.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our success will depend, in part, on our ability to obtain patents, maintain trade secret protection and operate without infringing the rights of third parties. We have received Granted Patents in countries throughout the world, including the United States, Canada, Europe, and Japan.&#160;&#160;We file our Applications for Patent in the United States and under the PCT, allowing us to subsequently file in other jurisdictions.&#160;&#160;Our success will depend, in part, on our ability to obtain, enforce and maintain patent protection for our technology in Canada, the United States and other countries. We cannot be assured that patents will issue from any pending applications or that claims now or in the future, if any, allowed under issued patents will be sufficiently broad to protect our technology. In addition, no assurance can be given that any patents issued to, or licensed by us, will not be challenged, invalidated, infringed or circumvented, or that the rights granted thereunder will provide continuing competitive advantages to us.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The patent positions of pharmaceutical and biotechnology firms, including us, are generally uncertain and involve complex legal and factual questions. In addition, it is not known whether any of our current research endeavors will result in the issuance of patents in Canada, the United States, or elsewhere, or if any patents already issued will provide significant proprietary protection or will be circumvented or invalidated. Since patent applications in the United States and Canada may be maintained in secrecy until at least 18 months after filing of the original priority application, and since publication of discoveries in the scientific or patent literature tends to lag behind actual discoveries by several months, we cannot be certain that we or any licensor were the first to create inventions claimed by pending patent applications or that we or the licensor were the first to file patent applications for such inventions. Loss of patent protection could lead to generic competition for these products, and others in the future, which would materially and adversely affect our financial prospects for these products.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Similarly, since patent applications filed before November 29, 2000 in the United States may be maintained in secrecy until the patents issue or foreign counterparts, if any, publish, we cannot be certain that we or any licensor were the first creator of inventions covered by pending patent applications or that we or such licensor were the first to file patent applications for such inventions. There is no assurance that our patents, if issued, would be held valid or enforceable by a court or that a competitor&#8217;s technology or product would be found to infringe such patents.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accordingly, we may not be able to obtain and enforce effective patents to protect our proprietary rights from use by competitors.&#160;&#160;If other such parties obtain patents for certain information relied on by us in conducting our business, then we may be required to stop using, or pay to use, certain intellectual property, and as such, our competitive position and profitability could suffer as a result.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Third parties may choose to file patent infringement claims against us; defending ourselves from such allegations would be costly, time-consuming, distracting to management and could materially affect our business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our development and commercialization activities, as well as any product candidates or products resulting from these activities, may infringe or be claimed to infringe patents and other intellectual property rights of third parties under which we do not hold sufficient licenses or other rights. Additionally, third parties may be successful in obtaining patent protection for technologies that cover development activities in which we are already engaged. Third parties may own or control these patents and intellectual property rights in the United States and abroad. These third parties may have substantially greater financial resources than us and could bring claims against us that could cause us to incur substantial expenses to defend against these claims and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement or other similar suit were brought against us, we could be forced to stop or delay development, manufacturing or sales of the product or product candidate that is the subject of the suit. Intellectual property litigation in the biopharmaceutical industry is common, and we expect this trend to continue.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of patent infringement or other similar claims, or to avoid potential claims, we may choose or be required to seek a license from the third party and be required to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we were able to obtain a license, the rights may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms, if at all, or if an injunction is granted against us, which could harm our business significantly.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our proprietary information and</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">know-how, the value of our technology and products could be adversely affected.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to patented technology, we rely upon unpatented proprietary technology, processes and know-how. However, these types of trade secrets can be difficult to protect. We seek to protect this confidential information, in part, through agreements with our employees, consultants and third parties as well as confidentiality policies and audits, although these may not be successful in protecting our trade secrets and confidential information.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These agreements may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known, including through a potential cybersecurity breach, or may be independently developed by competitors. If we are unable to protect the confidentiality of our proprietary information and know-how, competitors may be able to use this information to develop products that compete with our products, which could adversely impact our business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Business Risks</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our operations could be adversely affected by events outside of our control, such as natural disasters, wars&#160;or health epidemics.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may be impacted by business interruptions resulting from pandemics and public health emergencies, including those related to COVID-19 coronavirus, geopolitical actions, including war and terrorism or natural disasters including earthquakes, typhoons, floods and fires. An outbreak of infectious disease, a pandemic or a similar public health threat, such as the recent outbreak of the novel coronavirus known as COVID-19, or a fear of any of the foregoing, could adversely impact us by causing operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how the Company may affected if such an epidemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The biotechnology industry is extremely competitive and we must successfully compete with larger companies with substantially greater resources.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Technological competition in the pharmaceutical industry is intense and we expect competition to increase. Other companies are conducting research on therapeutics involving innate and adaptive immune responses as well as other novel treatments or therapeutics for the treatment of cancer which may compete with our product. Many of these competitors are more established, benefit from greater name recognition and have substantially greater financial, technical and marketing resources than us. In addition, many of these competitors have significantly greater experience in undertaking research, preclinical studies and human clinical trials of new pharmaceutical products, obtaining regulatory approvals and manufacturing and marketing such products. In addition, there are several other companies and products with which we may compete from time to time, and which may have significantly better and larger resources than we do. Accordingly, our competitors may succeed in manufacturing and/or commercializing products more rapidly or effectively, which could have a material adverse effect on our business, financial condition or results of operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We anticipate that we will face increased competition in the future as new products enter the market and advanced technologies become available. There can be no assurance that existing products or new products developed by our competitors will not be more effective, or be more effectively manufactured, marketed and sold, than any that may be developed or sold by us. Competitive products may render our products obsolete and uncompetitive prior to recovering research, development or commercialization expenses incurred with respect to any such products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our products may fail or cause harm, subjecting us to product liability claims.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Use of our product during current clinical trials may entail risk of product liability.&#160;&#160;We maintain clinical trial liability insurance; however, it is possible this coverage may not provide full protection against all risks.&#160;&#160;Given the scope and complexity of the clinical development process, the uncertainty of product liability litigation, and the shrinking capacity of insurance underwriters, it is not possible at this time to assess the adequacy of current clinical trial coverage, nor the ability to secure continuing coverage at the same level and at reasonable cost in the foreseeable future.&#160;&#160;While we carry, and intend to continue carrying amounts believed to be appropriate under the circumstances, it is not possible at this time to determine the adequacy of such coverage.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the sale and commercial use of our product entails risk of product liability. We currently do not carry any product liability insurance for this purpose. There can be no assurance that we will be able to obtain appropriate levels of product liability </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">insurance prior to any sale of our pharmaceutical products. An inability to obtain insurance on economically feasible terms or to otherwise protect against potential product liability claims could inhibit or prevent the commercialization of products developed by us. The obligation to pay any product liability claim or a recall of a product could have a material adverse effect on our business, financial condition and future prospects.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Future legal proceedings and the impact of any finding of liability or damages could adversely impact the company and its financial condition and results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we may be named as a defendant in various legal actions or other proceedings, including class action lawsuits. Certain of these actions include and future actual or threatened legal actions may include, claims for substantial and indeterminate amounts of damages, or may result in other results adverse to us. Management does not currently know of any pending, material legal proceedings against the Company, but such legal action could be brought in the future.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of possible future legal proceedings cannot be predicted with certainty. Accordingly, we cannot determine whether our insurance coverage would be sufficient to cover the costs or potential losses, if any. Regardless of merit, litigation may be both time-consuming and disruptive to our operations and cause significant expense and diversion of management attention. If we do not prevail in future legal proceedings, we may be faced with significant monetary damages or injunctive relief against us that may adversely affect our business, financial condition and results of operations, possibly materially.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have limited manufacturing experience and intend to rely on third parties to commercially manufacture our products, if and when developed.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, we have relied upon a contract manufacturer to manufacture small quantities of pelareorep. The manufacturer may encounter difficulties in scaling up production, including production yields, quality control and quality assurance. Only a limited number of manufacturers can supply therapeutic viruses and failure by the manufacturer to deliver the required quantities of pelareorep on a timely basis at a commercially reasonable price may have a material adverse effect on us. We have completed a program for the development of a commercial process for manufacturing pelareorep and have filed a number of patent applications related to the process. There can be no assurance that we will successfully obtain sufficient patent protection related to our manufacturing process.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">New products may not be accepted by the medical community or consumers.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our primary activity to date has been research and development and we have no experience in marketing or commercializing products. We will likely rely on third parties to market our products, assuming that they receive regulatory approvals. If we rely on third parties to market our products, the commercial success of such product will be subject to a number of risks that may be outside of our control, including:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">competition in relation to alternative treatments, including efficacy advantages and cost advantages;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">perceived ease of use;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the availability of coverage or reimbursement by third-party payors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">uncertainties regarding marketing and distribution support; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">distribution or use restrictions imposed by regulatory authorities.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Moreover, there can be no assurance that physicians, patients or the medical community will accept our product, even if it proves to be safe and effective and is approved for marketing by Health Canada, the FDA and other regulatory authorities. A failure to successfully market our product would have a material adverse effect on our revenue.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our technologies may become obsolete.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pharmaceutical industry is characterized by rapidly changing markets, technology, emerging industry standards and frequent introduction of new products. The introduction of new products embodying new technologies, including new manufacturing processes and the emergence of new industry standards may render our products obsolete, less competitive or less marketable. The process of developing our products is extremely complex and requires significant continuing development efforts and third-party commitments. Our failure to develop new technologies and products and the obsolescence of existing technologies could adversely affect our business.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may be unable to anticipate changes in our potential customer requirements that could make our existing technology obsolete. Our success will depend, in part, on our ability to continue to enhance our existing technologies, develop new technology that addresses the increasing sophistication and varied needs of the market, and respond to technological advances and emerging </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">industry standards and practices on a timely and cost-effective basis. The development of our proprietary technology entails significant technical and business risks. We may not be successful in using our new technologies or exploiting our niche markets effectively or adapting our businesses to evolving customer or medical requirements or preferences or emerging industry standards.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are highly dependent on third-party relationships for research and clinical trials.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely upon third-party relationships for assistance in the conduct of research efforts, pre-clinical development and clinical trials, and manufacturing. In addition, we expect to rely on third parties to seek regulatory approvals for and to market our product. Although we believe that our collaborative partners will have an economic motivation to commercialize our product included in any collaborative agreement, the amount and timing of resources diverted to these activities generally is expected to be controlled by the third party. Furthermore, if we cannot maintain these relationships, our business may suffer.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our license, development, supply and distribution agreement with Adlai Nortye Biopharma Co. is subject to certain risks and uncertainties related to our dependence on Adlai and doing business in foreign jurisdictions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 16, 2017, we announced that we had entered into a license, development, supply, and distribution agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea and Taiwan (the &#8220;Territories&#8221;). Pursuant to the Licensing Agreement, along with payments to be received by us upon meeting certain requirements and milestones, we are also eligible to receive royalty payments in excess of 10% associated with the commercialization of pelareorep for all indications, subject to regulatory approval. Under the terms of the Licensing Agreement, Adlai will be responsible for all clinical, regulatory and commercialization activities respecting pelareorep in the Territories and therefore the Company will be dependent upon Adlai in successfully undertaking those actions in a timely and economic manner and in compliance with all applicable legal and regulatory requirements within the Territories. If Adlai is unable to fulfill its obligations under the terms of the Licensing Agreement and in compliance with all applicable legal and regulatory requirements, including clinical, regulatory and commercialization of pelareorep, our prospective revenue from royalty payments related to the commercialization of pelareorep in the Territories may be materially diminished, delayed or never realized, which could negatively affect our operating results and financial condition.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further, conducting business with Adlai within the Territories, and specifically China, subjects us to certain economic, political, currency and legal risks and uncertainties regarding, among other things, the development and commercialization of pelareorep and the release and receipt of payments under the terms of the Licensing Agreement, including the payment of royalties upon commercialization of pelareorep. These risks include:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">different regulatory requirements for drug approvals in foreign countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">different standards of care in various countries that could complicate the evaluation of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">different U.S. and foreign drug import and export rules;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reduced protection for intellectual property rights in certain countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unexpected changes in tariffs, trade barriers and regulatory requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">different reimbursement systems and different competitive drugs indicated to treat the indications for which our product candidates are being developed;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">compliance with the FCPA, and other anti-corruption and anti-bribery laws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. and foreign taxes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">foreign currency fluctuations, which could result in reduced revenues, and other obligations incident to doing business in another country;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a reliance on CROs, clinical trial sites, principal investigators and other third parties that may be less experienced with clinical trials or have different methods of performing such clinical trials than we are used to in the U.S.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">potential liability resulting from development work conducted by foreign distributors; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The governments of the Territories, and specifically the Chinese government, exercise significant control over all aspects of their respective economies.&#160; Accordingly, any adverse change in the economy, the legal system or governmental, economic or other policies could have a material adverse effect on the business prospects of the Licensing Agreement with Adlai, including our ability to receive money out of China under the terms of the Licensing Agreement. Any disruption in relations, inability to work efficiently or disadvantageous treatment of Adlai by the governments of the Territories or other authorities could have a material adverse effect on our business prospects under the Licensing Agreement. Additionally, the regulatory environment in the Territories is evolving, and officials in the governments in the Territories exercise broad discretion in deciding how to interpret and apply </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulations. There can be no assurance that Adlai will be successful in the development and commercialization of pelareorep in the Territories.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The cost of director and officer liability insurance may increase substantially and may affect our ability to retain quality directors and officers.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We carry liability insurance on behalf of our directors and officers. Given a number of large director and officer liability insurance claims in the US equity markets, director and officer liability insurance has become increasingly more expensive with increased restrictions. Consequently, there is no assurance that we will continue to be offered this insurance or be able to obtain adequate coverage. The inability to acquire the appropriate insurance coverage may limit our ability to attract and maintain directors and officers as required to conduct our business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are dependent on our key employees and collaborators.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to develop the product will depend, to a great extent, on our ability to attract and retain highly qualified scientific personnel and to develop and maintain relationships with leading research institutions. Competition for such personnel and relationships is intense. We are highly dependent on the principal members of our management staff as well as our advisors and collaborators, the loss of whose services might impede the achievement of development objectives. The persons working with us are affected by a number of influences outside of our control. The loss of key employees and/or key collaborators may affect the speed and success of product development.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Barbados law differs from the laws in effect in Canada and the United States and may afford less protection to holders of our securities.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our assets and intellectual property are held by our wholly-owned subsidiary, Oncolytics Barbados, which is organized under the laws of Barbados. It may not be possible to enforce court judgments obtained in Canada or the United States against Oncolytics Barbados in Barbados based on the civil liabilities provisions of applicable securities laws. In addition, there is some doubt as to whether the courts of Barbados would recognize or enforce judgments of courts in Canada or the United States obtained against us or our directors or officers based on the civil liabilities provisions of Canadian and United States securities laws or hear actions against us or those persons based on such laws.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in law could adversely affect our business and corporate structure.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There can be no assurances that changes will not occur in corporate, tax, property and other laws in Canada and/or Barbados (or the interpretation thereof by regulatory or tax authorities) which may materially and adversely affect our businesses and corporate structure.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We incur some of our expenses in foreign currencies and therefore we are exposed to foreign currency exchange rate fluctuations.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We incur some of our manufacturing, clinical, collaborative and consulting expenses in foreign currencies, primarily the US dollar, the Euro and the British pound (&#8220;GBP&#8221;).&#160;&#160;We are therefore exposed to foreign currency rate fluctuations.&#160;&#160;Also, as we expand to other foreign jurisdictions there may be an increase in our foreign exchange exposure.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We earn interest income on our excess cash reserves and are exposed to changes in interest rates.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We invest our excess cash reserves in investment vehicles that provide a rate of return with little risk to principal. As interest rates change the amount of interest income we earn will be directly impacted.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our failure to comply with data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to complex laws and regulations that address privacy and data security. The legislative and regulatory landscape for data protection continues to evolve, and in recent years there has been an increasing focus on privacy and data security issues. In the US, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, disclosure, and protection of health-related and other personal information. For example, in June 2018, the State of California enacted the California Consumer Privacy Act of 2018 (the &#8220;CCPA&#8221;), which came into effect on January 1, 2020 and provides new data privacy rights for consumers and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">new operational requirements for companies, which may increase our compliance costs and potential liability. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA could mark the beginning of a trend toward more stringent state privacy legislation in the U.S., which could increase our potential liability and adversely affect our business.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, in the course of our business, we may obtain health information from third that is subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;). Although we are not directly subject to HIPAA (other than potentially with respect to providing certain employee benefits) we could be subject to criminal penalties if we knowingly obtain or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA/HITECH.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We could also be negatively impacted by existing and proposed laws and regulations, as well as government policies and practices related to cybersecurity, data privacy, data localization and data protection outside of the US, such as the General Data Protection Regulation (&#8220;GDPR&#8221;), which took effect in the EU in May 2018. The GDPR extends the geographical scope of EU data protection law to non-EU entities under certain conditions, tightens existing EU data protection principles and creates new obligations for companies and new rights for individuals. The GDPR may increase our responsibility and potential liability in relation to personal data that we process, expose us to substantial potential fines and increase our compliance costs.&#160;The GDPR could also cause our development costs to increase in connection with clinical trials we are currently conducting and may conduct in the future in the EU for our products and product candidates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Failure to comply with data protection laws and regulations both within and outside of the US could result in government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our operations may be adversely affected by disruptions to our information technology ("IT") systems, including disruptions from cybersecurity breaches of our IT infrastructure.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on information technology networks and systems, including those of third-party service providers, to process, transmit and store electronic information. In particular, we depend on our information technology infrastructure for a variety of functions, including financial reporting, data management, and email communications. Any of these systems may be susceptible to outages due to fire, floods, power loss, telecommunications failures, terrorist attacks, sabotage and similar events. Global cybersecurity threats and incidents can range from uncoordinated individual attempts to gain unauthorized access to our information technology systems to sophisticated and targeted measures known as advanced persistent threats. The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the unintentional dissemination or intentional destruction of confidential information stored in our systems or in non-encrypted portable media or storage devices. We could also experience a business interruption, information theft of confidential information, or reputational damage from industrial espionage attacks, malware or other cyber attacks, which may compromise our system infrastructure or lead to data leakage, either internally or at our third-party providers. Despite the implementation of network security measures and disaster recovery plans, our systems and those of third parties on which we rely may also be vulnerable to computer viruses, break-ins and similar disruptions. If we or our vendors are unable (or are perceived as unable) to prevent such outages and breaches, our operations may be disrupted and our business reputation could be adversely affected. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect that risks and exposures related to cybersecurity attacks will remain high for the foreseeable future due to the rapidly evolving nature and sophistication of these threats. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The Company may fail to achieve and maintain adequate internal control over financial reporting pursuant to the requirements of the Sarbanes-Oxley Act and equivalent Canadian legislation.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company documented and tested during its most recent fiscal year its internal control procedures in order to satisfy the requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002 (&#8220;SOX&#8221;) and equivalent Canadian legislation. SOX requires an annual assessment by management of the effectiveness of the Company&#8217;s internal control over financial reporting and an attestation report by the Company&#8217;s independent auditors addressing this assessment, if applicable. The Company may fail to achieve and maintain the adequacy of its internal control over financial reporting as such standards are modified, supplemented, or amended from time to time, and the Company may not be able to ensure that it can conclude, on an ongoing basis, that it has effective internal control over financial reporting in accordance with Section&#160;404 of SOX. The Company&#8217;s failure to satisfy the requirements of Section&#160;404 of SOX on an ongoing, timely basis could result in the loss of investor confidence in the reliability of its financial </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">statements, which in turn could harm the Company&#8217;s business and negatively impact the trading price of the common shares or the market value of its other securities. In addition, any failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm the Company&#8217;s operating results or cause it to fail to meet its reporting obligations. Future acquisitions of companies, if any, may provide the Company with challenges in implementing the required processes, procedures and controls in its acquired operations. No evaluation can provide complete assurance that the Company&#8217;s internal control over financial reporting will detect or uncover all failures of persons within the Company to disclose material information otherwise required to be reported. The effectiveness of the Company&#8217;s processes, procedures and controls could also be limited by simple errors or faulty judgments. In addition, if the Company expands, the challenges involved in implementing appropriate internal control over financial reporting will increase and will require that the Company continue to improve its internal control over financial reporting.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Because the Company is a Canadian Company and some of its directors and officers are resident outside the United States, it may be difficult for investors in the United States to enforce civil liabilities against the Company based solely upon the federal securities laws of the United States.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is a Canadian company, with its principal place of business in Canada. Some of the Company&#8217;s directors and officers, including the Company's Chief Executive Officer and Chief Financial Officer, are residents outside the United States and a significant portion of the Company&#8217;s assets are located outside the United States. Consequently, it may be difficult for US investors to effect service of process within the United States upon the Company or these directors or officers who are not residents of the United States, or to realize in the United States upon judgments of courts of the United States predicated upon civil liabilities under the US Securities Act of 1933, as amended. Investors should not assume that Canadian courts (1)&#160;would enforce judgments of US courts obtained in actions against the Company or such directors or officers predicated upon the civil liability provisions of the US federal securities laws or the securities or &#8220;blue sky&#8221; laws of any state within the United States or (2)&#160;would enforce, in original actions, liabilities against the Company or such directors or officers predicated upon the US federal securities laws or any such state securities or &#8220;blue sky&#8221; laws. In addition, the protections afforded by Canadian securities laws may not be available to investors in the United States.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">As a foreign private issuer, our shareholders may have less complete and timely data.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is a &#8220;foreign private issuer&#8221; as defined in Rule&#160;3b-4 under the United States Securities Exchange Act of 1934, as amended (the &#8220;US Exchange Act&#8221;). Equity securities of the Company are accordingly exempt from Sections&#160;14(a), 14(b), 14(c), 14(f) and 16 of the US Exchange Act pursuant to Rule&#160;3a12-3 of the US Exchange Act. Therefore, the Company is not required to file a Schedule&#160;14A proxy statement in relation to its annual meeting of shareholders. The submission of proxy and annual meeting of&#160;&#160;shareholder information on Form 6-K may result in shareholders having less complete and timely information in connection with shareholder actions. The exemption from Section&#160;16 rules regarding reports of beneficial ownership and purchases and sales of common shares by insiders and restrictions on insider trading in our securities may result in shareholders having less data and there being fewer restrictions on insiders&#8217; activities in our securities.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we were to lose our foreign private issuer status under US federal securities law, we would likely incur additional expenses associated with compliance with the US securities law applicable to US domestic issuers.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a foreign private issuer, as discussed above under the risk factor titled &#8220;As a foreign private issuer, our shareholders may have less complete and timely data&#8221;, we are exempt from certain provisions of the US federal securities law. The determination of foreign private issuer status is made annually on the last business day of an issuer&#8217;s most recently completed second fiscal quarter. We would lose our foreign private issuer status if, for example, more than 50% of our common shares are directly or indirectly held by residents of the United States and we fail to meet additional requirements necessary to maintain our foreign private issuer status. If we lose our foreign private issuer status on this date, we will be required to file with the SEC periodic reports and registration statements on U.S. domestic issuer forms, which are more detailed and extensive than the forms available to a foreign private issuer. We will also have to mandatorily comply with US federal proxy requirements, and our officers, directors and principal shareholders will become subject to the short-swing profit disclosure and recovery provisions of Section 16 of the Exchange Act. In addition, we will lose our ability to rely upon exemptions from certain corporate governance requirements under the Nasdaq listing rules. As a US listed public company that is not a foreign private issuer, we will incur significant additional legal, accounting and other expenses that we will not incur as a foreign private issuer, and accounting, reporting and other expenses in order to maintain a listing on a US securities exchange. These rules and regulations could also make it more difficult for us to attract and retain qualified members of our board of directors and more expensive to procure director and officer liability insurance. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The Company is likely a "passive foreign investment company" which may have adverse US federal income tax consequences for US shareholders.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US holders of Common Shares should be aware that the Company believes it was classified as a passive foreign investment company (&#8220;PFIC&#8221;) during the tax year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, and based on current business plans and financial expectations, the Company expects that it will be a PFIC for the current tax year and may be a PFIC in future taxable years.&#160;If the Company is a PFIC for any year during a US holder&#8217;s holding period of the Common Shares, then such US shareholder generally will be required to treat any gain realized upon a disposition of Common Shares, or any &#8220;excess distribution&#8221; received on its Common Shares, as ordinary income, and to pay an interest charge on a portion of such gain or distribution, unless the shareholder makes a timely and effective qualified electing fund election (&#8220;QEF Election&#8221;) or a mark-to-market election with respect to the Common Shares.&#160;&#160;A US holder who makes a QEF Election generally must report on a current basis its share of the Company's net capital gain and ordinary earnings for any year in which the Company is a PFIC, whether or not the Company distributes any amounts to its shareholders.&#160;However, US holders should be aware that there can be no assurance that the Company will satisfy the record keeping requirements that apply to a qualified electing fund, or that the Company will supply US holders with information that such U.S. holders require to report under the QEF Election rules, in the event that the Company is a PFIC and a U.S. holder wishes to make a QEF Election. </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">Thus, US holders may not be able to make a QEF Election with respect to their Common Shares. A US holder who makes the mark-to-market election generally must include as ordinary income each year the excess of the fair market value of the Common Shares over the taxpayer&#8217;s adjusted tax basis therein.&#160;&#160;This paragraph is qualified in its entirety by the discussion below under the heading &#8220;Material United States Federal Income Tax Considerations.&#8221;&#160;&#160;Each US holder should consult its own tax advisors regarding the PFIC rules and the US federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks related to our Common Shares</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Volatility of market price of the Common Shares.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The market price of the Common Shares may be volatile. The volatility may affect the ability of holders of Common Shares to sell the Common Shares at an advantageous price. Market price fluctuations in the Common Shares may be due to the Company&#8217;s operating results failing to meet the expectations of securities analysts or investors in any quarter, downward revision in securities analysts&#8217; estimates, governmental regulatory action, adverse change in general market conditions or economic trends, acquisitions, dispositions or other material public announcements by the Company or its competitors, along with a variety of additional factors, including, without limitation, those set forth under &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; in this annual report on Form 20-F. In addition, the market price for securities in the stock markets, including the NASDAQ and the TSX, recently experienced significant price and trading fluctuations. These fluctuations have resulted in volatility in the market prices of securities that often has been unrelated or disproportionate to changes in operating performance. These broad market fluctuations may adversely affect the market price of the Common Shares</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Potential dilution of present and prospective shareholdings.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to finance future operations and development efforts, the Company may raise funds through the issue of common shares or the issue of securities convertible into common shares. The Company cannot predict the size of future issues of common shares or the issue of securities convertible into common shares or the effect, if any, that future issues and sales of the Company&#8217;s common shares will have on the market price of its common shares. Any transaction involving the issue of previously authorized but unissued shares, or securities convertible into shares, would result in dilution, possibly substantial, to present and prospective holders of shares.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The Company does not intend to pay cash dividends in the foreseeable future.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has not declared or paid any dividends since its incorporation. The Company intends to retain earnings, if any, to finance the growth and development of its business and does not intend to pay cash dividends on the Common Shares in the foreseeable future. Any return on an investment in the common shares will come from the appreciation, if any, in the value of the Common Shares. The payment of future cash dividends, if any, will be reviewed periodically by the board of directors and will depend upon, among other things, conditions then existing including earnings, financial condition and capital requirements, restrictions in financing agreements, business opportunities and conditions and other factors.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s287B5DA1C1AF57B88BB2E1CBAA9F8F24"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 4.&#160;&#160;INFORMATION ON THE COMPANY</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">History and Development of the Company</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oncolytics Biotech Inc. was formed under the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Business Corporations Act</font><font style="font-family:inherit;font-size:10pt;">&#32;(Alberta) on April 2, 1998 as 779738 Alberta Ltd.&#160;&#160;On April 8, 1998, we changed our name to Oncolytics Biotech Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our principal executive office is located at 210, 1167 Kensington Cres. NW, Calgary, Alberta, Canada, T2N 1X7, telephone (403) 670-7377. Our agent for service in the US is Registered Agent Solutions, Inc., 9E Lookerman Street, Suite 311, Dover, Delaware 19901.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A description of the important events in our development including licensing transactions, our principal capital expenditures and divestitures and a description of acquisitions of material assets can be found in our MD&amp;A and in the notes to our financial statements included elsewhere in this annual report.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The SEC maintains a Website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC at https://www.sec.gov. The filings are also contained on the Company&#8217;s website at https://www.oncolyticsbiotech.com. Information on the Company's website is not incorporated by reference herein. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Business Overview </font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since our inception in April of 1998, Oncolytics Biotech Inc. has been a development stage company and we have focused our research and development efforts related to pelareorep, a systemically administered immuno-oncology (I-O) viral agent with the potential to treat a variety of cancers. We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts.&#160;We do not expect to generate significant revenues until, if and when, pelareorep becomes commercially viable.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our Business</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our potential product for human use, pelareorep, an unmodified reovirus, is a first in class systemically administered I-O viral agent for the treatment of solid tumors and hematological malignancies. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Scientific Background</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pelareorep&#8217;s anti-tumor activity is based on three modes of action which are complementary but not interdependent (Figure 1): </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selective viral replication in permissive cancer cells which leads to tumor cell lysis.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activation of innate immunity in response to the infection, which results in a cascade of chemokines/cytokines, causing natural killer (NK) cells to be activated and attack cancer cells.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A specific adaptive immune response triggered by tumor- and viral-associated antigens displayed by antigen-presenting cells (APCs), infected tumor cells and/or dendritic cells to T cells.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Summary of Research and Development highlights</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preclinical and translational research to date indicates the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pelareorep has anticancer effects in models of metastatic cancers that can prolong survival in these models when using immuno-competent rodents. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The survival benefit in animal models can be enhanced when pelareorep is given in combination with chemotherapy, immunotherapy or radiotherapy.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A toxic dose of pelareorep has not been reached/established in animal models and infection presents with minimal side-effects.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical data to date indicate the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">More than 1,400 patients have been enrolled in clinical studies conducted in the US, Canada and EU. Of these, more than 1,000 patients received pelareorep, with over 930 via intravenous (IV) administration.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pelareorep has been administered as single or multiple doses (intratumoral or intravenous), either as a mono-therapy or in combination with chemotherapy, immunotherapy (e.g., checkpoint inhibitors), and radiotherapy.  </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pelareorep is generally well-tolerated and has a manageable side effect profile for most patients. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When combined with chemotherapeutic agents, pelareorep does not appear to enhance either the frequency or severity of the adverse effects of the chemotherapeutic agents.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There is emerging evidence that pelareorep may impact overall survival (OS) in metastatic breast cancer (mBC) and metastatic adenocarcinoma of the pancreas (MAP): </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In a randomized, controlled Phase 2 study of paclitaxel with pelareorep versus paclitaxel alone in mBC (Canadian Cancer Trials Group IND.213) the median OS was greater for subjects treated with paclitaxel and pelareorep (median 17.4 months) than subjects treated with paclitaxel alone (10.4 months, hazard ratio (HR) 0.65). </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In a single-arm study with gemcitabine plus pelareorep in first-line MAP (REO 017) the median OS was 10 months with a 1 year and 2-year survival of 46% and 24%, respectively. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In a two-arm Phase 2 randomized study (NCI 8601), patients with MAP were randomized to receive either carboplatin, paclitaxel and pelareorep (test arm) or carboplatin and paclitaxel alone (control arm). The median OS was similar for both arms, but the probability of survival at Year 2 was 20% in the test arm vs 9% in the control arm.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Mechanism of Action</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 1. Proposed mechanism of action for pelareorep</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;"><img src="reolysinmoapanel4smalla02.jpg" alt="reolysinmoapanel4smalla02.jpg" style="height:358px;width:446px;"></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Direct cell lysis - Reovirus Replication in Permissive Cancer Cells</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selective viral replication and lysis in cancer cells and not normal cells is mediated by the host cellular protein dsRNA-activated protein kinase (PRK). In non-cancer cells that are infected with reovirus, PKR activates in the presence of the virus which in turn inhibits viral gene translation. However, in permissive cancer cells, PKR activation is inhibited, allowing for viral gene translation and eventual cell lysis. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It was originally established that selective lysis with reovirus was mediated by tumor cells with an activated rat sarcoma virus oncogene (RAS)-pathway, since active RAS inhibits PKR activation. However, more recent investigations have revealed that reovirus replication is not just restricted to cells with an active RAS pathway, oncogenic mutations and amplifications in upstream and downstream mediators of the RAS-pathway also allow for viral replication and oncolysis. Moreover, active RAS is known to stimulate over 18 downstream effector proteins, many of which have been shown to facilitate viral replication. Cells bearing dysfunctional or deleted tumor suppressor genes and or chemo- or radiation-induced cell stress also show increased sensitivity to reovirus replication and lysis.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Induction of Innate Immunity</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preclinical and clinical studies provide compelling evidence that pelareorep functions as an immunogenic agent. Indeed, preclinical studies demonstrated that cancer cells infected with pelareorep can produce an innate immune response triggering the release of inflammatory cytokines. This inflammatory environment promotes a chemotactic response in NK cells, dendritic cells, and cytotoxic T-cells, altering the tumor microenvironment to support bystander immune-mediated cancer cell death. Intriguingly, preclinical studies have also demonstrated that the beneficial immunogenic functions of pelareorep can occur independently of viral replication. Pelareorep performs this immunogenic function, in part, by activating dendritic cells, key regulators of both adaptive and innate immunity. Dendritic cells activated by reovirus, in turn, stimulate the innate antitumor activity of NK cells and aid in the priming of specific antitumor cytotoxic lymphocyte, demonstrating that dendritic cell recognition of reovirus may trigger a beneficial innate immune response.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A clinical trial with pelareorep (REO 013) provided an opportunity to study human NK cell activation in a controlled manner. Ten colorectal cancer patients with liver metastases received between one and five doses of pelareorep prior to surgical resection of their tumor. NK cell activation peaked 24-48 hours post-infection, coincident with a peak of pro-inflammatory cytokines. NK cells within reovirus-treated blood mononuclear cells were stimulated to kill tumor targets, but not normal hepatocytes. Moreover,  peripheral blood mononuclear cells were able to hand-off virus to tumors for direct oncolytic killing. Similarly, NK cells within liver mononuclear cells became selectively cytotoxic towards tumor cells when activated by reovirus. These results showed that reovirus modulates human NK cell activity in vivo and suggest that this may contribute to the therapeutic effect of pelareorep.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Induction of Adaptive Immunity</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adaptive anti-tumor immunity allows for elimination of existing cancer cells and performs constant surveillance, preventing relapse, and increases overall survival. An adaptive immune response requires two signals: a signal from an APC, as well as a co-stimulation signal in the form of cytokines. In the absence of both signals, the adaptive immune response fails. Therapy with pelareorep has the potential to activate both signals. Following its therapeutic administration, pelareorep enhances the expression of &#8216;foreign&#8217; antigens/markers on tumor cells. Oncolysis of tumor cells exposes tumor-associated antigens (TAAs) and viral-associated antigens (VAAs) for processing and presentation by APCs, such as dendritic cells. Through the combined actions of these immunological events, pelareorep facilitates the display of novel &#8216;foreign&#8217; antigens on the surface of infected tumor cells and APCs. Simultaneously, pelareorep induces an inflammatory response promoting the expression of co-stimulatory molecules and inflammatory cytokines. Together, pelareorep mediated immunological events over-rule tumor antigen presentation impairments and initiate adaptive anti-tumor immunity.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By promoting the expression of novel antigens and the release of inflammatory cytokines, pelareorep, promotes an inflamed tumor phenotype. An inflamed tumor phenotype is characterized by NK and T-cell infiltration, increased expression of chemokines/cytokines, and increased expression of checkpoint ligands. This phenotype correlates with an increase in overall survival and has a positive prognostic value for early-stage cancers. In patients with metastatic cancer, an inflamed tumor phenotype is associated with better clinical outcomes when treated with immunotherapies, including immune checkpoint blockade inhibitors, cancer vaccines, and adoptive T-cell therapies. By promoting an inflamed tumor phenotype, pelareorep primes an anti-cancer immune response (Figure 2).  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Figure 2. Pelareorep primes an anti-cancer immune response</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;"><img src="pelareorep-lga02.jpg" alt="pelareorep-lga02.jpg" style="height:345px;width:513px;"></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical Development Plan</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The ultimate objective of our clinical development plan is to obtain regulatory approval for pelareorep as quickly as possible and is based on the compelling efficacy data from previous studies in breast, multiple myeloma, and selected gastrointestinal cancers. Our clinical development program centers on key immunotherapy combinations. Specifically, immunotherapy combinations in which pelareorep has the potential to provoke a specific innate and adaptive immune responses when combined with checkpoint blockade therapy, chemotherapy and/or targeted therapies. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, we reported clinical results from our randomized clinical program which includes clinical study collaborations with the Canadian Cancer Trials Group (formerly known as the National Cancer Institute of Canada). Specifically, subgroup analysis in the IND 213 trial in mBC revealed a significant improvement in the overall survival of patients that are hormone receptor-positive (HR+) / human epidermal growth factor receptor 2 negative (HER2-). In HR+/HER2- patients, pelareorep therapy, in combination with paclitaxel, more than doubled the overall survival from 10.8 month with paclitaxel therapy alone, to 21.8 months with pelareorep plus paclitaxel. This increase in overall survival is consistent with previous survival data reported from our U.S. NCI pancreatic trial which suggests a long-term survival benefit when comparing test and control arms at 24 months, as well as test to historical data.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2019, we published our first data set from a clinical study that combined pelareorep with chemotherapy and pembrolizumab (Keytruda</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">) in patients with pancreatic cancer. This study, published in the journal of Clinical Cancer Research, demonstrated the safety and tolerability of this combination treatment regime and showed encouraging clinical efficacy with one patient achieving a partial response (six-month duration) and two patients with stable disease (lasting 126 and 221 days). In early 2019 we announced the regulatory approval of the AWARE-1 study which examines the use of pelareorep and atezolizumab&#160;(Tecentriq</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">)&#160;in a breast cancer window-of -opportunity study. Preliminary results from AWARE-1 were presented at the Society for Immunotherapy of Cancer (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">SITC) meeting </font><font style="font-family:inherit;font-size:10pt;">in November 2019 and demonstrated pelareorep mediated priming of the tumor microenvironment for checkpoint blockade therapy. In the second half of 2019, we initiated start-up activities for the BRACELET-1 (</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BR</font><font style="font-family:inherit;font-size:10pt;">east c</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A</font><font style="font-family:inherit;font-size:10pt;">n</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CE</font><font style="font-family:inherit;font-size:10pt;">r with the Oncolytic Reovirus Pe</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">L</font><font style="font-family:inherit;font-size:10pt;">areor</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E</font><font style="font-family:inherit;font-size:10pt;">p in Combina</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">T</font><font style="font-family:inherit;font-size:10pt;">ion with anti-PD-L1&#160;and Paclitaxel) study which will essentially repeat IND 213 in HR+/HER2- patients, with the addition of a third arm that includes pelareorep, paclitaxel and avelumab (Bavencio</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">) in mBC. This study is expected to begin enrollment in the first quarter of 2020. Additional studies in gastrointestinal indications are now being evaluated.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patents and Trade Secrets</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The patent positions and proprietary rights of pharmaceutical and biotechnology firms, including us, are generally uncertain and involve complex legal and factual questions. We believe there will continue to be significant litigation in the industry regarding patent and other intellectual property rights.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Currently, we have </font><font style="font-family:inherit;font-size:10pt;">399</font><font style="font-family:inherit;font-size:10pt;">&#32;issued patents including </font><font style="font-family:inherit;font-size:10pt;">48</font><font style="font-family:inherit;font-size:10pt;">&#32;issued in the US and </font><font style="font-family:inherit;font-size:10pt;">21</font><font style="font-family:inherit;font-size:10pt;">&#32;in Canada. We also have </font><font style="font-family:inherit;font-size:10pt;">16</font><font style="font-family:inherit;font-size:10pt;">&#32;patents pending in the US, Canada, and other jurisdictions, but we cannot be certain whether any given patent application filed by us will result in the issuance of a patent or if any given patent issued to us will later be challenged and invalidated. Nor can we be certain whether any given patent that may be issued to us will provide any significant proprietary protection to our product and business.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Litigation or other proceedings may also be necessary to enforce or defend our proprietary rights and patents. In Europe, patents can be revoked through opposition or nullity proceedings. In the United States patents may be revoked or invalidated in court actions or challenged in interference, post-grant review, inter partes review, derivation or re-examination proceedings by the United States Patent and Trademark Office ("USPTO"). Such litigation or proceedings could result in substantial cost or distraction to us, resulting in an adverse decision as to our or our licensors&#8217; patent applications and patents.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our commercial success depends, in part, on not infringing the patents or proprietary rights of others and not breaching licenses granted or that may be granted to us. Competitors may have filed patent applications, obtained patents, may in the future file patent applications, and/or obtain patents relevant to our product and technologies.&#160;&#160;We are not aware of competing intellectual property relating to our pelareorep project at this time.&#160;While we currently believe that we have the necessary freedom to operate in these areas, there can be no assurance that others will not challenge our position in the future.&#160;&#160;Litigation to defend our position could be costly and time consuming. We also cannot be certain that we will be successful. We may be required to obtain a license from a prevailing party in order to continue the portion of our business that relates to the proceeding. We may also be required to obtain licenses to other third-party technologies necessary in order to market our products. Such licenses may not be available to us on acceptable terms, or on any terms, and we may have to discontinue that portion of our business. Any failure to license any technologies required to commercialize our technologies or products at reasonable cost may have a material adverse effect on our business, results of operations, financial condition, cash flow and future prospects. We are not currently involved in any litigation concerning our competitors&#8217; patent applications and patents. We may be involved in such litigation in the future.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also rely on unpatented trade secrets and improvements, unpatented know-how and continuing technological innovation to develop and maintain our competitive position. No assurance can be given that others will not independently develop substantially equivalent proprietary information and techniques, or otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our rights to our unpatented trade secrets.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We require our employees and consultants to execute confidentiality agreements upon the commencement of employment and consulting relationships with us. These agreements provide that all confidential information developed by or made known to an individual during the course of the employment or consulting relationship generally must be kept confidential. In the case of employees, the agreements provide that all inventions conceived by the individual, while employed by us, relating to our business are our exclusive property. While we have implemented reasonable business processes and agreements with which to protect confidential information, these actions may not provide meaningful protection for our trade secrets in the event of unauthorized use or disclosure of such information.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business Strategy</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our business strategy is to develop and market pelareorep in an effective and timely manner, and access additional technologies at a time and in a manner that we believe is best for our development.&#160;&#160;We intend to achieve our business strategy by focusing on these key areas:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Develop pelareorep through our clinical development plan assessing the safety and efficacy in human subjects;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Establish collaborations with experts to assist us with scientific and clinical developments of this new potential pharmaceutical product;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Implement strategic alliances with select biopharmaceutical companies and laboratories, at a time and in a manner whereby such alliances may complement and expand our own research and development efforts. Such alliances may also result in an eventual expansion to include providing additive sales and marketing capabilities;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Utilize our broadening patent base and collaborator network as a mechanism to meet our strategic objectives; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Develop relationships with companies that could be instrumental in assisting us to access other innovative therapeutics.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our business strategy is based on attaining a number of commercial objectives, which, in turn, are supported by a number of product development goals.&#160;In the context of this Annual Report, statements of our "belief" are based primarily upon our results derived to date from our research and development program with animals, early-stage human trials and our most recent data in HR+/HER2- mBC patients, upon which we believe that we have a reasonable scientific basis to expect the particular results to occur.&#160;&#160;It is not possible to predict, based upon studies in animals, or early-stage human trials, whether a new therapeutic will ultimately prove to be safe and effective in humans.&#160; There are no assurances that the particular result expected by us will occur.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At this time we do not intend to become a fully integrated pharmaceutical company with substantial in-house research and development, marketing and distribution or manufacturing capabilities.&#160;&#160;We are pursuing a strategy of establishing relationships with larger companies as strategic partners.&#160;&#160;It is anticipated that future clinical development into large international or pivotal trials would generally occur in conjunction with a strategic partner or partners, who would contribute expertise and financial assistance.&#160;&#160;In exchange for certain product rights and commitments to market our products, the strategic partners would be expected to share in proceeds from the sale of our product or products.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Regulatory Requirements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The development of new pharmaceuticals is strongly influenced by a country's regulatory environment.&#160;&#160;The drug approval process in Canada is regulated by Health Canada.&#160;&#160;The primary regulatory body in the United States is the FDA and in Europe is the European Medicines Agency (the &#8220;EMA&#8221;).&#160;&#160;Similar processes are conducted in specific countries by equivalent regulatory bodies.&#160;&#160;Regulations in each jurisdiction require the licensing of manufacturing facilities and mandate strict research and product testing standards.&#160;&#160;Companies must establish the safety and efficacy of their products, comply with cGMP and potentially submit marketing materials before being allowed to market pharmaceutical products.&#160;&#160;While we plan to pursue or support the pursuit of the approval of our product, success in acquiring regulatory approval for any product is not assured.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to market our pharmaceutical product in Canada, the United States, Europe and other jurisdictions, we must successfully meet the requirements of those jurisdictions. The requirements of the appropriate regulatory authority will generally include the following stages as part of the regulatory process:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pre-Pharmacological Studies</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:10pt;">- Pre-Pharmacological studies involve extensive testing on laboratory animals to determine if a potential therapeutic product has utility in an </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;disease model and has any adverse toxicology in a disease model.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investigational New Drug Application</font><font style="font-family:inherit;font-size:10pt;">&#32;- An Investigational New Drug ("IND") Submission, or the equivalent, must be submitted to the appropriate regulatory authority prior to conducting Pharmacological Studies.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pharmacological Studies&#160;</font><font style="font-family:inherit;font-size:10pt;">(or Phase 1 Clinical Trials)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">- Pharmacological studies are designed to assess the potential harmful or other side effects that an individual receiving the therapeutic compound may experience.&#160;&#160;These studies, usually short in duration, are often conducted with healthy volunteers or actual patients and use up to the maximum expected therapeutic dose.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Therapeutic Studies</font><font style="font-family:inherit;font-size:10pt;">&#160;(or Phase 2 and 3 Clinical Trials) - Therapeutic studies are designed primarily to determine the appropriate manner for administering a drug to produce a preventive action or a significant beneficial effect against a disease.&#160;&#160;These studies are conducted using actual patients with the condition that the therapeutic is designed to remedy. Prior to initiating these studies, the organization sponsoring the program is required to satisfy a number of requirements via the submission of documentation to support the approval for a clinical trial.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">New Drug Submission </font><font style="font-family:inherit;font-size:10pt;">- After all three phases of a clinical trial have been completed, the results are submitted with the original IND Submission to the appropriate regulatory authority for marketing approval.&#160;&#160;Once marketing approval is granted, the product is approved for commercial sales.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marketing Approvals</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of the preclinical and clinical testing, together with manufacturing and controls information, are submitted to regulatory agencies in order to obtain approval to commence commercial sales. In responding to such an application, regulatory agencies may grant marketing approval, request additional information or further research, or deny the application if they determine that </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the application does not satisfy their regulatory approval criteria. Approval for a pharmaceutical or biologic product may not be granted on a timely basis, if at all.  If granted, the approval may not cover all the clinical indications for which approval is sought, or may contain significant limitations in the form of warnings, precautions or contraindications with respect to conditions of use.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The satisfaction of pre-market approval requirements for new drugs and biologics typically takes several years, with the actual time required varying substantially based upon the type, complexity and novelty of the product or targeted disease. Government regulation may delay or prevent marketing of potential products for a considerable period of time and impose costly procedures upon our activities. Success in early-stage clinical trials or with prior versions of products does not assure success in later-stage clinical trials. Data obtained from clinical activities are not always conclusive and may be susceptible to varying interpretations that could delay, limit or prevent regulatory approval.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Post-Marketing Regulations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Once approved, regulatory agencies may withdraw the product approval if compliance with pre- and/or post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. In addition, they may require post-marketing studies, referred to as Phase 4 studies, to monitor the effect of an approved product, and may limit further marketing of the product based on the results of these post-market studies. The FDA and other foreign regulatory agencies have broad post-market regulatory and enforcement powers, including the ability to levy fines and penalties, suspend or delay issuance of approvals, seize or recall products, or withdraw approvals.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Manufacturing Regulations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use contract toll manufacturers to produce pelareorep.&#160;&#160;Our toll manufacturers are subject to periodic inspection by the FDA, the United States Drug Enforcement Administration, or DEA, and other domestic and foreign authorities where applicable, and must comply with cGMP regulations. Manufacturers of biologics also must comply with general biological product standards. Failure to comply with the statutory and regulatory requirements subjects the manufacturer to possible legal or regulatory action, such as suspension of manufacturing, seizure of product, or mandatory or voluntary recall of a product.&#160;&#160;Adverse experiences with the product must be reported to the FDA and foreign agencies and could result in the imposition of market restrictions through labeling changes or in product removal. Product approvals may be withdrawn if compliance with regulatory requirements is not maintained or if problems concerning safety or efficacy of the product occur following approval.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Advertising and Promotion Regulations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to both pre- and post-market product advertising and promotion, the FDA and similar foreign agencies impose a number of complex regulations on entities that advertise and promote pharmaceuticals and biologics, which include, among other things, standards and regulations relating to direct-to-consumer advertising, on vs. off-label promotion, industry-sponsored scientific and educational activities, and promotional activities involving the Internet. These agencies have very broad enforcement authority and failure to abide by these regulations can result in penalties including the issuance of a warning letter directing the entity to correct deviations from requisite standards, a requirement that future advertising and promotional materials be pre-cleared by the FDA or relevant foreign agencies, and foreign, state and federal civil and criminal investigations, fines and prosecutions.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Government Regulations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to various laws and regulations regarding laboratory practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances in connection with our research. In each of these areas, as above, the government has broad regulatory and enforcement powers, including the ability to levy fines and civil penalties, suspend or delay issuance of approvals, seize or recall products, and withdraw approvals, any one or more of which could have a material adverse effect upon us.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Market and Competition </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">According to estimates for 2020 from the American Cancer Society, more than </font><font style="font-family:inherit;font-size:10pt;">1.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;Americans are expected to be diagnosed with cancer in the year, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">606,520</font><font style="font-family:inherit;font-size:10pt;">&#32;Americans are expected to die of cancer.&#160;Cancer is the second most common cause of death in the US, exceeded only by heart disease.&#160;In the United States, the relative lifetime risk of a male or female developing cancer is 1 in </font><font style="font-family:inherit;font-size:10pt;">2</font><font style="font-family:inherit;font-size:10pt;">&#32;and 1 in </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;">, respectively (Source: American Cancer Society's Cancer Facts &amp; Figures 2020). The prevalence of breast cancer in the United States in 2016 was 3.56 million, of which there were 2.6 million patients with HR+/HER2- subtype and 154,885 patients with HR+/HER2- stage IV breast cancer. (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Source: </font><font style="font-family:inherit;font-size:10pt;color:#282828;font-style:italic;">https://seer.cancer.gov/statfacts/html/breast.html. Accessed on March 28, 2017. Howlader, Nadia, et al. US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status. Journal of the National Cancer Institute. Accessed March 28, 2017).</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The costs of this disease state are also significant.&#160;&#160;In the United States, the American Cancer Society reported in its Cancer Facts &amp; Figures 2020 that the Agency for Healthcare Research and Quality estimated the 2015 direct medical costs for cancer were </font><font style="font-family:inherit;font-size:10pt;">$80.2 billion</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We face substantial competition in the development of products for cancer and other diseases. This competition from other manufacturers of the same types of products and from manufacturers of different types of products designed for the same uses is expected to continue in both US and international markets.&#160;&#160;Oncolytic virus therapies, our primary focus area, are rapidly evolving areas in the biotechnology industry and are expected to undergo many changes in the coming years as a result of technological advances. We are currently aware of a number of groups that are developing oncolytic virus therapies including early-stage and established biotechnology companies, pharmaceutical companies, academic institutions, government agencies and research institutions. We face competition from all of these groups in areas such as recruiting employees, acquiring technologies that might enhance our ability to commercialize products, establishing relationships with certain research and academic institutions, enrolling patients in clinical trials and seeking program partnerships and collaborations with larger pharmaceutical companies. It is possible that our competitors could achieve earlier market commercialization, could have superior patent protection, or could have safer, more effective or more cost-effective products. These factors could render our potential products less competitive, which could adversely affect our business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product Marketing Strategy</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The markets for the cancer product being developed by us may be large and could require substantial sales and marketing capability.&#160;&#160;Before or upon successful completion of the development of a cancer product, we intend to enter into one or more strategic partnerships or other collaborative arrangements with a pharmaceutical company or other company with marketing and distribution expertise to address this need.&#160;&#160;If necessary, we will establish arrangements with various partners for different geographical areas or specific applications at various times in the development process.&#160;&#160;Our management and consultants have relevant experience with the partnering process.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Seasonality of Business</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our results of operations have not been materially impacted by seasonality.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organizational Structure</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we had one material wholly-owned operating subsidiary; Oncolytics Biotech (Barbados) Inc. (&#8220;OBB&#8221;), a Barbados company.&#160;&#160;In addition, Oncolytics Biotech (US) Inc., a Delaware corporation, is a material wholly-owned subsidiary  of OBB.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.&#160;&#160;&#160;&#160;&#160;&#160;Property, Plant and Equipment</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently lease our head office in Calgary, Alberta, Canada as well as our office spaces in San Diego, California, US and Barbados. We do not own or lease any other office space, manufacturing facilities or equipment and do not have any current plans to construct or acquire any facilities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s38294448EBB4564DB241C336B0B083C0"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 4A.&#160;&#160;UNRESOLVED STAFF COMMENTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s6DE310FE60915FB496C3B26621CA7334"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Management Discussion and Analysis (&#8220;MD&amp;A&#8221;) contains forward-looking statements, including our belief as to the potential of pelareorep, a therapeutic reovirus, as a cancer therapeutic and our expectations as to the success of our research and development and manufacturing programs in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2020</font><font style="font-family:inherit;font-size:10pt;">&#32;and beyond, future financial position, business strategy and plans for future operations, and statements that are not historical facts, involve known and unknown risks and uncertainties, which could cause our actual results to differ materially from those in the forward-looking statements.&#160;&#160;See </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Cautionary Note Regarding Forward-Looking Statements&#8221;</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to the forward-looking statements made within our MD&amp;A, we have made numerous assumptions regarding among other things: our ability to obtain financing to fund our development program, our ability to receive regulatory approval to commence enrollment in our clinical trial program, the final results of our co-therapy clinical trials, our ability to maintain our supply of pelareorep and future expense levels being within our current expectations.&#160;&#160;Investors are cautioned against placing undue reliance </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">on forward-looking statements.&#160;&#160;We do not undertake to update these forward-looking statements except as required by applicable law.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Results</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Please see our </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;Management Discussion and Analysis in Exhibit 15.1, which is incorporated herein by reference.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Please see our </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;Management Discussion and Analysis in Exhibit 15.1, which is incorporated herein by reference.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development, Patents, and Licenses, etc.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Please see the disclosure in "Item 4.&#160;&#160;Information on the Company B. Business Overview" for information on the Company&#8217;s research and development policies.&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Trend Information</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is important to note that historical patterns of expenditures cannot be taken as an indication of future expenditures.&#160;&#160;The amount and timing of expenditures and availability of capital resources vary substantially from period to period, depending on the level of research and development activity being undertaken at any one time and the availability of funding from investors and prospective commercial partners. See our </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;Management Discussion and Analysis in Exhibit 15.1 for our comparative discussion on our expenditures between </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and our expectations for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2020</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except as disclosed elsewhere in our annual report, we know of no trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect on our liquidity or capital resources or that would cause reported financial information not necessarily to be indicative of future operating results or financial conditions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we had not entered into any off-balance sheet arrangements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">F.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tabular Disclosure of Contractual Obligations</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have the following contractual obligations as at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:580px;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:172px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:94px;"></td><td style="width:4px;"></td><td style="width:70px;"></td><td style="width:4px;"></td><td style="width:72px;"></td><td style="width:4px;"></td><td style="width:82px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Obligations</font></div></td><td colspan="10" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Payments Due by Period</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Less than 1 year</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2 -3 years</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4 - 5 years</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">After 5 years</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital lease obligations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">565,179</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,022</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174,157</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase obligations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,867,131</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,244,754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,622,377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long term obligations</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total contractual obligations</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,432,310</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,635,776</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,796,534</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to fund our capital expenditure requirements and commitments with existing working capital.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">G.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Safe Harbor</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We seek safe harbor for our forward-looking statements contained in Items 5.E and F.&#160;&#160;See &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cautionary Note Regarding Forward-Looking Statements&#8221;.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s44EB09EE10CB552697A18931F9F4C5DB"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Directors and Senior Management</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the names and places of residence of all our directors and officers as at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, as well as the positions and offices held by such persons and their principal occupations.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:116px;"></td><td style="width:101px;"></td><td style="width:380px;"></td><td style="width:86px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name and Place of Residence&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Position with the Company</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Principal Occupation</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Director of the Company Since</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deborah M. Brown, BSc, MBA, ICD.D</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)(2)</sup></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ontario, Canada</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ms. Brown is the Managing Partner at Accelera Canada, a specialty consultancy firm that assists emerging biopharma ventures in the United States and Europe with the development and implementation of Canadian market strategies. She held progressively senior roles at EMD Serono from 2000 to 2014, including Executive Vice President of Neuroimmunology for the company's U.S. operations, and President and Managing Director of the company's Canadian operations. In 2012, Ms. Brown was Chair of the National Pharmaceutical Organization (now Innovative Medicines Canada) and served on its Board of Directors from 2007 to 2014. She currently sits on the Boards of Life Sciences Ontario, the HBSPCA and Cardiol Therapeutics, Oncolytics Biotech Inc, and Sernova Corp. Ms. Brown holds an MBA from University of Western Ontario's Ivey School of Business, an Hons B.Sc. from the University of Guelph and completed the Merck executive development programme at the University of Hong Kong, INSEAD and Northwestern University's Kellogg School of Management. She most recently completed the Institute of Corporate Directors Designation (ICD.D).</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 2, 2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew C. Coffey, PhD, MBA</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alberta, Canada</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer and Director</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A co-founder of the Company, Dr. Coffey completed his doctorate degree in oncology at the University of Calgary with a focus on the oncolytic capabilities of the reovirus. The results of his research have been published in various respected scientific journals, including Science, Human Gene Therapy, and The EMBO Journal. Dr. Coffey took over as Chief Executive Officer in late 2016, prior to which he was Chief Operating Officer since December 2008. Since co-founding Oncolytics he has also held the positions of Chief Scientific Officer from December 2004 to December 2008, Vice-President of Product Development from July 1999 to December 2004 and Chief Financial Officer from September 1999 to May 2000.</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 11, 2011</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Andrew de Guttadauro</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">California, USA</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Andrew de Guttadauro has more than 25 years of biopharmaceutical commercialization and business development experience in. He has held executive and senior-level positions at leading pharmaceutical and biotechnology companies, working on initiatives across both developed and emerging markets globally.</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Mr. de Guttadauro began his career at TAP Pharmaceuticals, supporting the launch of blockbuster drugs, Lupron&#174;&#160;and Prevacid&#174;. He held a variety of marketing positions at Amgen, contributing to the success of Enbrel&#174;, Aranesp&#174;, and Epogen&#174;&#160;before joining MedImmune to lead marketing efforts for the FluMist&#174;&#160;inhaled influenza vaccine. Following a two-year assignment overseeing the commercial development of Zevalin&#174;, the first radioimmunotherapy product approved for use in the United States, Mr. de Guttadauro took on the role of Senior Director of Strategy at Biogen Idec. He then served as Vice President of Corporate Development at Vical, supporting the execution of distribution agreements for Allovectin&#174;. Prior to joining Oncolytics, Mr. de Guttadauro was a Principal at 1798 Consultants Inc., a healthcare consulting firm providing commercialization, market access, and compliance strategic advice to leading and emerging biopharmaceutical companies.</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Mr. de Guttadauro has a Bachelor of Science degree in engineering from the United States Military Academy at West Point.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:116px;"></td><td style="width:101px;"></td><td style="width:380px;"></td><td style="width:86px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name and Place of Residence&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Position with the Company</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Principal Occupation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Director of the Company Since</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allison Hagerman, P.Eng., PMP, MBT Alberta, Canada</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President, Product Development</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A Professional Engineer focused on biotechnology, Ms. Hagerman joined Oncolytics in 2010 and has been integral to the progress of its product development program ever since. Prior to being appointed as Vice President of Product Development, Ms. Hagerman was the Director, Manufacturing and Engineering from 2013-2017 and Project Manager from 2010-2013, during which time she led the process performance qualification for pelareorep drug substance. Ms. Hagerman is a Professional Engineer (P.Eng., APEGA) and Project Management Professional (PMP, PMI). She holds a Master of Biomedical Technology (MBT) degree from the University of Calgary, and B.Sc. degrees in both Chemical Engineering and Biological Sciences.</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Angela Holtham, MBA, FCPA, FCMA, ICD.D</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)(2)</sup></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ontario, Canada</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ms. Holtham held a number of financial positions over a 19-year career with the Canadian subsidiary of Nabisco Inc., rising to become Senior Vice President and Chief Financial Officer. In 2002, she joined Toronto, Ontario-based Hospital for Sick Children as Vice President, Finance and Chief Financial Officer, a position she held for eight years. Through her career she has participated in myriad initiatives ranging from traditional finance functions and operations oversight to intellectual property portfolio management and mergers and acquisitions. Ms. Holtham is an FCPA, FCMA, holds an MBA from the University of Toronto - Rotman School of Management and has completed the Institute of Corporate Directors Designation (ICD.D).</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 18, 2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leonard Kruimer, MBA, CPA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vinkenveen, The Netherlands</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. Kruimer has more than 30 years of experience in corporate finance, planning and strategy, including 20 years in senior management positions in private and publicly listed biotechnology and life science companies. Notably, Mr. Kruimer served as CFO and Executive Committee Member of Crucell from 1998 through 2011, when Crucell was acquired by Johnson &amp; Johnson. During his tenure, he led financing activities of the company and contributed to Crucell's strategic US$450 million acquisition of Swiss-based Berna Biotech. Currently, Mr. Kruimer serves as an independent director and Chairman of the Audit Committee for Zealand Pharma (Nasdaq: ZEAL), is Chairman of the Board of BioInvent AB (OMXS: BINV) and serves on the Investment Advisory Council of private equity firm, Karmijn Kapitaal Investments based in Amsterdam. Previously, he was CFO of SkylineDx, a DNA diagnostics company and as the Chairman of the Board of ProFibrix from 2011 through its acquisition by The Medicines Company (Nasdaq: MDCO) in 2013. In 2014 Mr. Kruimer served as interim CEO of Dutch biotech BBB Therapeutics. Prior to Crucell, Mr. Kruimer was Managing Director at TIP Europe, a GE Capital company. He was a consultant with McKinsey &amp; Company and started his career at Price Waterhouse in New York. Mr. Kruimer holds an MBA from Harvard Business School and is a Certified Public Accountant in New York State.</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 2, 2019</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:116px;"></td><td style="width:101px;"></td><td style="width:380px;"></td><td style="width:86px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name and Place of Residence&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Position with the Company</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Principal Occupation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Director of the Company Since</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rita Laeufle, M.D., PhD<br>California, USA</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Medical Officer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Laeufle brings more than 15 years of experience in drug development in oncology, most recently serving as Vice President of Clinical Development &amp; Medical Affairs at SFJ Pharmaceuticals where she developed a clinical program for a new drug substance class in colon cancer. Previously, Dr. Laeufle was Senior Vice President, Clinical Development of Oncology at Coherus Biosciences where she developed a biosimilar strategy for Avastin, prior to which she was Senior Medical Director, Global Medical Affairs at Clovis Oncology, where she led the Medical Affairs strategy for their PARP inhibitor, Rucaparib. Dr. Laeufle also served as Senior Medical Director, U.S. Medical Affairs, gastrointestinal (GI) cancers at Genentech where she led GI disease across molecules and indications, and as Senior PD Medical Director and Clinical Science Leader in Oncology at Roche, working with Avastin for the treatment of breast cancer where she successfully maintained approval for Avastin in first-line metastatic breast cancer in combination with paclitaxel in Europe and ROW (rest of world). She was Senior Medical Scientific Expert of Immunology and Infectious Diseases and Senior Pharmacovigilance Leader, Oncology at Novartis and began her pharmaceutical career as PD Medical Director and Medical Monitor (International Study Manager), Altana Pharma.</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Laeufle, a surgical oncologist, completed her general surgery residency at Buckland Hospital in Dover, England, Basel Switzerland and Ueberlingen, Germany, and was trained as a surgical oncologist at Staedtisches Krankenhaus, Singen Germany, where she focused on gastroenterological, thyroid and breast cancer. Dr. Laeufle completed medical school at Medical School Albert Ludwig University Freiburg i.Br. Germany, where she received her Ph.D. in exploring Her2 oncogenes in brain cancer. Dr. Laeufle's work has been published in The Lancet Oncology, the European Journal of Cancer, the Journal of Hepatology and Human Pathology and she has had multiple posters presented at the American Society of Clinical Oncology (ASCO), the World Congress on Gastrointestinal Cancer (WCGC) and the European Society for Medical Oncology (ESMO).</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk J. Look, CA</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alberta, Canada</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. Look is a Chartered Accountant with more than fifteen years of experience in accounting, finance, tax and treasury. Mr. Look joined Oncolytics as the Company's Controller in April 2003, and assumed the role of Chief Financial Officer in November 2012. Prior to joining Oncolytics, from 2000 to April 2003, Mr. Look was Manager of Audit and Assurance Services with Ernst &amp; Young LLP in Canada. From 1998 to the end of 1999, Mr. Look held the positions of Audit Manager and Senior Accountant at Ernst &amp; Young LLP in Chile.</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Michael Moore California, USA</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President, Investor Relations &amp; Corporate Communications</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Michael Moore has more than 20 years of experience in strategic communications and investor relations for the biotech industry, as well as personal finance. Before joining Oncolytics in February 2017, Mr. Moore was Senior Vice President and Manager of U.S. Operations for Equicom Investor Relations, where he worked with over 50 public and private biotech and medical device companies. Prior to Equicom, he was an Account Executive with Atkin + Associates and Fleishman Hillard.&#160; Earlier roles in the financial community included responsibilities as a personal banker and an investment representative for both Scotiabank and London Life, respectively.&#160; Mr. Moore serves as treasurer and board member of the San Diego chapter of the National Investor Relations Institute (NIRI).&#160; He holds a Bachelor of Commerce with a focus on marketing and finance from Mount Allison University.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:116px;"></td><td style="width:101px;"></td><td style="width:380px;"></td><td style="width:86px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name and Place of Residence&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Position with the Company</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Principal Occupation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Director of the Company Since</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wayne Pisano, MBA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)(5)</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pennsylvania, USA</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chair of the Board</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. Pisano has more than 30 years of experience as a pharmaceutical industry executive and was recognized in 2010 as Pharma Executive of the Year by the World Vaccine Congress. He served as the president and CEO of VaxInnate, a privately held biotech company from January 2012 to November 2016. He joined IMV Inc's Board in October 2011 with a depth of experience across the spectrum of commercial operations, public immunization policies and pipeline development. Mr. Pisano is the former president and CEO of Sanofi Pasteur, one of the largest vaccine companies in the world. He joined Sanofi Pasteur in 1997, assuming increasing levels of responsibility. He was promoted to President and CEO in 2007, the position he successfully held until his retirement in 2011. During his tenure as CEO, Mr. Pisano bolstered the Sanofi Pasteur pipeline with the acquisitions of Acambis PLC, a bio-tech based in Boston in 2008 and Shantha Biotechnics, a highly regarded Indian vaccine company in 2010. Prior to joining Sanofi Pasteur, he spent 11 years with Novartis (formerly Sandoz). He has a bachelor's degree in biology from St. John Fisher College, New York and an MBA from the University of Dayton, Ohio.</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 9, 2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William G. Rice, PhD</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)(4)</sup></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">California, USA</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Rice has held the position of Chairman, President and Chief Executive Officer of Aptose Biosciences Inc. since 2013. From 2003 to 2013, he served as Chairman, President and Chief Executive Officer of Cylene Pharmaceutics Inc., prior to which he was the Founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. He has also served as Senior Scientist and Head of the Drug Mechanism Laboratory at the National Cancer Institute-Frederick Cancer Research and Development Center, and as a faculty member in the Division of Pediatric Hematology and Oncology at Emory School of Medicine. Dr. Rice holds a PhD in biochemistry from Emory University and was a post-doctoral trainee in the Department of Internal Medicine, Division of Hematology and Oncology at the University of Michigan Medical Center.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 8, 2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bernd R. Seizinger, MD, PhD</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)(4)</sup></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New Jersey, USA and Munich, Germany</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Seizinger has been board member/chairman in multiple public and private biotech companies in the US and Europe. From 1998 to 2009, he served as President and Chief Executive Officer of GPC Biotech. He also served as Vice President of Oncology Drug Discovery and, in parallel, Vice President of Corporate and Academic Alliances at Bristol-Myers Squibb. Prior to his appointments in the biotechnology and pharmaceuticals sectors, Dr. Seizinger held professorships and senior staff appointments at Harvard Medical School, Princeton University and Massachusetts General Hospital.</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 8, 2015</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">Member of the Audit Committee.&#160;Ms. Holtham is Chair of this Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">Member of the Compensation Committee.&#160;Ms. Brown is Chair of this Committee. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">Member of the Governance Committee.&#160;Dr. Rice replaced Mark Lievonen, who did not stand for re-election as a director at the Company's annual general meeting of Shareholders, as Chair of the Governance Committee on May 2, 2019.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">Member of the Science and Technology Committee. Dr. Seizinger is Chair of this Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">Mr. Pisano, as Chair of the Board, serves as an ex-officio member of the Compensation, Audit, and Science and Technology Committees.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;">March&#160;5, 2020</font><font style="font-family:inherit;font-size:10pt;">, the directors and senior officers as a group beneficially owned, directly or indirectly, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">528,957</font><font style="font-family:inherit;font-size:10pt;">&#32;of our common shares, representing </font><font style="font-family:inherit;font-size:10pt;">1.26%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the issued and outstanding common shares.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our directors are associated with other companies, which may give rise to conflicts of interest.&#160;&#160;In accordance with the Alberta Business Corporations Act</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;(</font><font style="font-family:inherit;font-size:10pt;">ABCA), directors who have a material interest in any person who is a party to a material contract or a proposed material contract with us are required, subject to certain exceptions, to disclose that interest and abstain from voting on any resolution to approve that contract.&#160;&#160;In addition, the directors are required to act honestly and in good faith with a view to the best interests of Oncolytics Biotech Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None of our directors or officers are related by blood, marriage or adoption to any other director or officer.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not aware of any arrangement or understanding with major shareholders, customers, suppliers or others, pursuant to which any person referred to above was selected as a director or officer.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;Compensation</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Directors</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth information concerning the total compensation paid in </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;to each director.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:679px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:129px;"></td><td style="width:81px;"></td><td style="width:77px;"></td><td style="width:78px;"></td><td style="width:92px;"></td><td style="width:66px;"></td><td style="width:90px;"></td><td style="width:62px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fees Earned</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">($)</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)(3)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Based Awards</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">($)</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)(3)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Option-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Based Awards</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">($)</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-Equity Incentive Plan Compensation</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pension Value</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other Compensation</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">($)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deborah Brown</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,928</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,034</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Nil </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Nil </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Nil </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,962</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Angela Holtham</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,090</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,420</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Nil </font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Nil </font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A </font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Nil </font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,510</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leonard Kruimer</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)(8)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,988</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,129</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Nil </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Nil </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,117</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark Lievonen</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(9)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,976</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Nil </font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Nil </font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A </font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Nil </font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,976</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wayne Pisano</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(6)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,589</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,633</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Nil </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Nil </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Nil </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">132,222</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William Rice</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,058</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,034</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Nil </font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Nil </font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A </font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Nil </font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,092</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bernd Seizinger</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(7)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,757</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,167</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Nil </font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Nil </font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A </font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Nil </font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,924</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Directors are paid fees in US Dollars.&#160;These amounts are presented in Canadian dollars and have been converted at a US/CDN exchange rate of $</font><font style="font-family:inherit;font-size:10pt;">1.2988</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-36px;"><font style="font-family:inherit;font-size:10pt;">The value of share based and option based awards are based on the grant date assumptions as disclosed in note 10 "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share Based Payments" </font><font style="font-family:inherit;font-size:10pt;">in our </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;audited consolidated financial statements.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-36px;"><font style="font-family:inherit;font-size:10pt;">Directors, annually, may opt to take up to 100% of their respective annual retainer in restricted share awards. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-36px;"><font style="font-family:inherit;font-size:10pt;">Ms. Holtham elected to receive US$4,875 (8%) of her annual retainer in restricted share awards.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-36px;"><font style="font-family:inherit;font-size:10pt;">Mr. Kruimer elected to receive US$2,500 (20%) of his annual retainer in restricted share awards.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(6)</font></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-36px;"><font style="font-family:inherit;font-size:10pt;">Mr.&#160;Pisano elected to receive US$42,000 (44%) of his annual retainer in restricted share awards.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(7)</font></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-36px;"><font style="font-family:inherit;font-size:10pt;">Dr.&#160;Seizinger elected to receive US$24,000 (40%) of his annual retainer in restricted share awards.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(8)</font></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-36px;"><font style="font-family:inherit;font-size:10pt;">Mr. Kruimer was appointed as a director on October 2, 2019</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(9)</font></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-36px;"><font style="font-family:inherit;font-size:10pt;">Mr. Lievonen did not stand for re-election at the May 2, 2019 annual general meeting of Shareholders. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:left;text-indent:-36px;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Officers </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Summary Compensation Table</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth information concerning the total compensation paid to our officers in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:142px;"></td><td style="width:36px;"></td><td style="width:52px;"></td><td style="width:53px;"></td><td style="width:57px;"></td><td style="width:50px;"></td><td style="width:80px;"></td><td style="width:50px;"></td><td style="width:80px;"></td><td style="width:81px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Name and principal position</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Salary<br>$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Share-<br>based awards<br>$</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Option-<br>based </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">awards </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;&#160;$</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Bonus</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Non-equity incentive<br>plan compensation<br>$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Pension value<br>$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">All other compensation<br>  $</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total<br>compensation </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dr. Matthew C. Coffey</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></font></div><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">President and Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">525,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">157,239</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">212,625</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">69,813</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">964,677</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Kirk J. Look</font></div><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Chief Financial Officer</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">385,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">112,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">124,740</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;N/A </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;N/A </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59,013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">681,067</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dr. Rita Laeufle</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></font></div><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Chief Medical Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">526,014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">112,314</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">170,429</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,247</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">836,004</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Andrew de Guttadauro</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">President, Oncolytics Biotech (US) Inc.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">377,886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">89,851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">76,522</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,646</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">557,905</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Allison Hagerman</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Vice President, Product Development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">200,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">89,851</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,600</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">37,250</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">367,701</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Michael Moore</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Vice President, Investor Relations &amp; Corporate Communications</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">337,797</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">31,448</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">61,564</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,542</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">465,351</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The value of share and option based awards are based on the grant date assumptions as disclosed in note 10 "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share Based Payments" </font><font style="font-family:inherit;font-size:10pt;">in our </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;audited consolidated financial statements.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The dollar amounts set forth under this column are related to contributions to the officers' respective retirement savings plan and amounts provided for health care benefits by the Company. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None of the compensation paid to Dr. Coffey related to his role as a director of the Company.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US Employees are paid salaries, bonuses and other compensation in US Dollars.&#160;&#160;These amounts are presented in Canadian dollars and have been converted at a US/CDN exchange rate of $</font><font style="font-family:inherit;font-size:10pt;">1.2988</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Narrative Discussion</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into employment agreements with each of the following Executive Officers (each an "Employment Agreement").&#160;&#160;The following base salaries for 2020 were approved by the Board of Directors:</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:398px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:261px;"></td><td style="width:64px;"></td><td style="width:68px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name and principal position</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;Salary</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Matthew C. Coffey</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">540,750</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk J. Look, C.A.</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">396,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Rita Laeufle</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Medical Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">417,150</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Andrew de Guttadauro</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President, Oncolytics Biotech (US) Inc.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allison Hagerman</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President, Product Development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">225,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Michael Moore</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President, Investor Relations &amp; Corporate Communications</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">265,286</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 1:</font><font style="font-family:inherit;font-size:10pt;">&#160;US Employees are paid in US Dollars and salaries above for those US employees are presented in US dollars.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further, each Executive Officer is entitled to additional benefits and performance-based bonuses.&#160;&#160;As well, the Employment Agreements provide that each Executive Officer is subject to certain confidentiality and non-competition restrictions during and following the course of their respective employment with the Company.&#160;&#160;Each Employment Agreement shall continue until terminated by either party in accordance with the notice provisions thereof.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not provide pension plan benefits to its Executive Officers and employees. The Company does not currently have a stock appreciation rights plan.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Termination of Employment or Change of Control </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table reflects amounts payable to the Executive Officers based on each Executive Officer's employment agreement assuming that their employment was terminated on December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;without cause or due to a change of control of the Company.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:509px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:242px;"></td><td style="width:128px;"></td><td style="width:4px;"></td><td style="width:128px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Termination without Cause Severance</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Change of Control Severance</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr.&#160;Matthew C. Coffey<br>President and Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">613,342</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,226,684</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk J. Look, C.A.<br>Chief Financial Officer</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">457,245</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">914,490</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr.&#160;Rita Laeufle</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)<br></sup></font><font style="font-family:inherit;font-size:10pt;">Chief Medical Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">217,490</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">217,490</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Andrew de Guttadauro</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President, Oncolytics Biotech (US) Inc.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155,220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">620,880</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allison Hagerman</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President, Product Development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,407</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">266,813</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Michael Moore</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President, Investor Relations &amp; Corporate Communications</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,219</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292,438</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, all options granted to Officers had fully vested except for the options granted on March 8, 2018, November 19, 2018, November 29, 2018, December 14, 2018 and December 13, 2019. As a result, all Officers shall be entitled to exercise all or any part of their vested Options, within the period ending on the earlier of the date of expiration of the Option and the 90th day after the date such Officer is terminated unless otherwise approved by the Board of Directors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On a change of control of the Company, the Officers shall be entitled to exercise all or a part of their Options, whether vested or not, within the period ending on the earlier of the date of expiration of the Option and the 90th day after the date such Officer is terminated.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US Employees are paid in US Dollars and are presented in US dollars.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Board Practices</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our directors are elected by the shareholders at each Annual General Meeting (or Annual Special Meeting) and typically hold office until the next meeting, at which time they may be re-elected or replaced.&#160;&#160;Casual vacancies on the board are filled by the remaining directors and the persons filling those vacancies hold office until the next Annual General Meeting (or Annual Special Meeting), at which time they may be re-elected or replaced.&#160;&#160;The officers are appointed by the Board of Directors and hold office indefinitely at the pleasure of the Board of Directors.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:37%;"></td><td style="width:20%;"></td><td style="width:18%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name and Place of Residence</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Position with the Corporation</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Director of the Corporation Since</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date of Expiration of Current Term of Office</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew C. Coffey, PhD, MBA</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alberta, Canada</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer and Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 11, 2011</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of 2020 Annual General Meeting of the Shareholders</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deborah Brown, BSc, MBA, ICD.D</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ontario, Canada</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 2, 2017</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of 2020 Annual General Meeting of the Shareholders</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Angela Holtham, MBA, FCPA, FCMA, ICD.D</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ontario, Canada</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 18, 2014</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of 2020 Annual General Meeting of the Shareholders</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leonard Kruimer, MBA, CPA</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vinkeveen, Netherlands</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 2, 2019</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of 2020 Annual General Meeting of the Shareholders</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wayne Pisano, MBA</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New Jersey, USA</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chair and Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 9, 2013</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of 2020 Annual General Meeting of the Shareholders</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William G. Rice, PhD</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">California, USA</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 8, 2015</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of 2020 Annual General Meeting of the Shareholders</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bernd R. Seizinger, MD, PhD</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New Jersey, USA and Munich Germany</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 8, 2015</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of 2020 Annual General Meeting of the Shareholders</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Directors&#8217; Contracts</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We receive a director&#8217;s consent from each of the independent directors upon their acceptance of their director&#8217;s position.&#160;&#160;We also enter into an Indemnity Agreement and Directors Confidentiality and Intellectual Property Assignment Agreement with each director.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not have any contracts with any of its directors which provide for benefits upon the termination of employment.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Compensation of Directors</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each director who is not a salaried employee of the Company is entitled to the following fees:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Annual Retainer </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each director receives a base retainer of US$40,000. In addition to the base retainer directors are eligible to receive the following additional fees depending on committee involvement:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Additional Retainers (USD):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.44054580896686%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:80%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Board chair</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$40,000</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Audit Committee chair</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$20,000</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Governance &amp; Compensation Committee chair</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$10,000</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Science &amp; Technology Committee chair</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$15,000</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-chair member of the Audit Committee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$10,000</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-chair member of the Governance, Compensation or Science &amp; Technology  Committee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$5,000</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Directors, annually, may opt to take up to 100% of their respective annual retainer in restricted share awards. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted Share Units </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the combined retainer, the Corporation will grant annually US$30,000 of restricted share awards that will vest immediately. The annual restricted share unit award will be granted on or about October 1 of each year.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also grant to directors, from time to time, stock options in accordance with the Option Plan and the reimbursement of any reasonable expenses incurred by them while acting in their directors' capacity.&#160;&#160;During the year ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, total compensation of </font><font style="font-family:inherit;font-size:10pt;">$610,803</font><font style="font-family:inherit;font-size:10pt;">&#32;was paid to the independent directors which consisted of fee payments of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$380,386</font><font style="font-family:inherit;font-size:10pt;">, share based awards of </font><font style="font-family:inherit;font-size:10pt;">$215,288</font><font style="font-family:inherit;font-size:10pt;">&#32;and option based awards of </font><font style="font-family:inherit;font-size:10pt;">15,129</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Compensation Committee</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Corporation has formed a compensation committee (the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Compensation Committee</font><font style="font-family:inherit;font-size:10pt;">&#8221;) in accordance with Rule 5605(d)(1) of the Nasdaq Capital Market which consists of four outside, independent directors, Dr. Seizinger, Ms. Holtham, Ms. Brown, and Mr. Pisano, the Chair of the Board, each of whom is independent in accordance with Rule 5605(a)(2) and Rule 5605(d)(2)(A) of the Nasdaq Capital Market. Ms. Brown is the Chair of the Compensation Committee. No member of the Compensation Committee has been an employee or officer of the Company or any of its affiliates.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The objectives of the Corporation&#8217;s compensation arrangements are: (i)&#160;to attract and retain key personnel; (ii)&#160;to encourage commitment to the Corporation and its goals; (iii)&#160;to align executive interests with those of its shareholders; and (iv)&#160;to reward executives for performance in relation to overall corporate progress goals.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The key elements of the compensation program are the base salary, health benefits, and payments allocated to employees to be directed by them to their personal retirement accounts. Bonuses and the granting of Options (as defined herein) and Share Awards (as defined herein) are also part of the Corporation&#8217;s compensation program and are based on corporate performance. Part of corporate performance includes goals and objectives that are determined based on the strategic planning and budgeting process, which is conducted at least annually. The elements of the compensation plan are intended to reward performance, and the various elements are intended to provide a blend of short-term and long-term incentives to align the interests of management and the shareholders.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In arriving at its recommendations for compensation, the Compensation Committee considers the long-term interests of the Corporation as well as its current stage of development and the economic environment within which it operates. The market for biotechnology companies in the development phase is challenging. Based on these factors, the Compensation Committee recognized the need to strike a balance between compensation to retain employees and resources expended to maintain operations. In the past, the Compensation Committee has engaged specialist consultants to assist in benchmarking its compensation practices and provide recommendations to the committee with respect to compensation for directors and officers. In 2018, the Compensation Committee engaged Radford, an Aon Hewitt Company as a specialist consultant to assist with the benchmarking of director compensation for 2019.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following a review of the risks in the Corporation&#8217;s compensation policies and practices, the Compensation Committee found no risks that are reasonably likely to have a material adverse effect on the Corporation. The Compensation Committee&#8217;s role of approving the compensation policies and practices includes considering whether the compensation policies and practices could encourage an officer of the Company to take inappropriate or excessive risks.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Corporation&#8217;s corporate trading policy, insiders (including officers and directors) are not permitted to hedge their position in Common Shares, Options, Share Awards, deferred share units, performance share units, debentures or other debt instruments by use of any financial instrument, which would include but is not limited to options, puts, calls, warrants or short sells, designed to benefit the holder from a change in the market value of the Common Shares of the Corporation.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, the following guidelines were employed by the Board in granting bonuses, Options and Share Awards to the Corporation&#8217;s executive and senior officers. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Annual Bonus, Option Grants and Share Award Grants </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Chief Executive Officer of the Corporation is eligible for a cash bonus of up to 50% of his base salary, the Chief Financial Officer and the Chief Medical Officer are each eligible for a cash bonus of up to 40% of his/her base salary and the other senior officers are eligible for a cash bonus of up to 30% of their respective base salaries. In addition, when available, the officers are eligible for a combination of Option and Share Award grants. The amount of each grant is determined and approved by the Board with the actual bonus provided and the number of Options and Share Awards granted based upon the overall performance of the Corporation as assessed by the Compensation Committee and approved by the Board. The overall performance of the Corporation </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">is determined by the annual goals and objectives approved by the Board and includes specific objectives with respect to the clinical, manufacturing, and intellectual property plans in combination with financial goals. Previous grants are taken into account when considering new grants of Options and Share Awards.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Compensation Committee Mandate </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Policy Statement</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is the policy of Oncolytics Biotech Inc. (the "Corporation") to establish and maintain a Compensation Committee (the "Committee"), composed entirely of independent directors, to assist the Board of Directors of the Corporation (the "Board") in carrying out its responsibility for the Corporation&#8217;s human resources and compensation policies and processes.  The Committee will be provided with resources commensurate with the duties and responsibilities assigned to it by the Board, including administrative support.  If determined necessary by the Committee, it will have the discretion to investigate and conduct reviews of any human resource or compensation matter including the standing authority to retain experts and special counsel.  In the event of a conflict of interest or potential conflict of interest involving one or more of the directors or members of management, the Committee may modify the procedures and requirements set out in this Mandate restrict communication and sharing of information to independent directors or otherwise take reasonable measures to manage the conflict of interest or potential conflict of interest.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Composition of Committee</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Committee shall consist of a minimum of three (3) directors.  The Board shall appoint the members (&#8220;Members&#8221;) of the Committee and may seek the advice and assistance of the Governance Committee in identifying qualified candidates.  The Board shall appoint one Member of the Committee to be the Chair of the Committee, or delegate such authority to appoint the Chair of the Committee to the Committee.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Chair of the Committee shall be responsible for the leadership of the Committee, including preparing or approving the agenda, presiding over the meetings, and making committee assignments.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each director appointed to the Committee by the Board shall be an outside director who is unrelated.  An outside, unrelated director is a director who meets the requirements of NASDAQ Rule 5605 (a)(2) and 5605(d)(2) and National Instrument 58-101 who is independent of management and is free from any interest, any business or other relationship which could, or could reasonably be perceived, to materially interfere with the director&#8217;s ability to be independent of management and to act with a view to the best interests of the Corporation, including, but not limited to the source of compensation of such director, including any consulting, advisory or other compensatory fee paid by the Corporation to such director and whether such director is affiliated with the Corporation, a subsidiary of the Corporation or an affiliate of a subsidiary of the Corporation other than interests and relationships arising from shareholding.  In determining whether a director is independent of management, the Board shall make reference to the then current legislation, rules, policies and instruments of applicable regulatory authorities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each Member shall be appointed by the Board annually at the next scheduled meeting of the Board following the AGM.  The Members will be appointed to hold office until the next annual general meeting of shareholders or until their successors are appointed. The Board may remove a Member at any time and may fill any vacancy occurring on the Committee.  A Member may resign at any time and a Member will automatically cease to be a Member upon ceasing to be a director. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Chair of the Board shall be an ex officio Member of the committee. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Meetings of the Committee</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Committee shall meet a minimum of twice per year at such time and place as may be designated by the Chair of the Committee and whenever a meeting is requested by the Board, a Member of the Committee, or the Chief Executive Officer of the Corporation (the "CEO"). </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notice of each meeting of the Committee shall be given to each Member of the Committee.  The CEO shall attend each meeting of the Committee whenever requested to do so by a Member of the Committee.  The CEO may not be present during voting or deliberations on his or her compensation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notice of a meeting of the Committee shall:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">be in writing, including by electronic communication facilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">state the nature of the business to be transacted at the meeting in reasonable detail;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to the extent practicable, be accompanied by copies of documentation to be considered at the meeting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">be given at least two business days prior to the time stipulated for the meeting or such shorter period as the Members of the Committee may permit.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A quorum for the transaction of business at a meeting of the Committee shall consist of a majority of the Members of the Committee.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A Member or Members of the Committee may participate in a meeting of the Committee by means of such telephonic, electronic or other communication facilities, as permits all persons participating in the meeting to communicate adequately with each other.  A Member participating in such a meeting by any such means is deemed to be present at the meeting.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the absence of the Chair of the Committee, the Members of the Committee shall choose one of the Members present to be Chair of the meeting.  If the Board has appointed a Corporate Secretary, the Corporate Secretary shall be the secretary of the meeting.  If the Board has not appointed a Corporate Secretary, the Members of the Committee shall choose one of the persons present to be the secretary of the meeting or may have another person who is not a Member of the Committee present to record the minutes of the meeting.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Minutes shall be kept of all meetings of the Committee and shall be signed by the Chair and the secretary of the meeting.  Minutes of the meetings of the Committee shall be distributed to members of the Committee, to other members of the Board and, with the exception of &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in camera</font><font style="font-family:inherit;font-size:10pt;">&#8221; items, to the Chief Executive Officer and Chief Financial Officer.  Notwithstanding the foregoing, distribution of minutes of meetings or parts thereof may be restricted to independent directors in the event of a conflict of interest or potential conflict of interest or if otherwise necessary for the Committee to properly discharge its responsibilities, but only for as long as is reasonably necessary.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Duties and Responsibilities of the Committee</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Committee shall, at the earliest opportunity after each meeting, report to the Board the results of its activities and any reviews undertaken and make recommendations to the Board as deemed appropriate.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Committee&#8217;s primary duties and responsibilities are to review and make recommendations to the Board in respect of:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">human resource policies, practices and structures (to monitor consistency with the Corporation&#8217;s goals and near and long-term strategies, support of operational effectiveness and efficiency, and maximization of human resources potential);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">compensation policies and guidelines;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">management incentive and perquisite plans and any non-standard remuneration plans;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">senior management, executive and officer appointments and their compensation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">management succession plans, management training and development plans, termination policies and termination arrangements; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Board compensation matters.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In carrying out its duties and responsibilities, the Committee shall:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">annually assess and make a recommendation to the Board with regard to the competitiveness and appropriateness of the compensation package of the CEO, all other officers of the Corporation and such other key employees of the Corporation or any subsidiary of the Corporation as may be identified by the CEO and approved by the Committee (collectively, the "Designated Employees");</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">annually review the performance goals and criteria for the CEO and evaluate the performance of the CEO against such goals and criteria and recommend to the Board the amount of regular and incentive compensation to be paid to the CEO;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">annually, review and make a recommendation to the Board regarding the CEO&#8217;s performance evaluation of Designated Employees and the CEO&#8217;s recommendations with respect to the amount of regular and incentive compensation to be paid to such Designated Employees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review and make a recommendation to the Board regarding any employment contracts or arrangements with each of the Designated Employees, including any retiring allowance arrangements or any similar arrangements to take effect in the event of a termination of employment;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">periodically, review the compensation philosophy statement of the Corporation and make recommendations for change to the Board as considered necessary;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">from time to time, review and make recommendations to the Board in respect of the design, benefit provisions, investment options and text of applicable pension, retirement and savings plans or related matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">annually, in conjunction with the Corporation&#8217;s general and administrative budget, review and make recommendations to the Board regarding compensation guidelines for the forthcoming budget period;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">when requested by the CEO, review and make recommendations to the Board regarding short term incentive or reward plans and, to the extent delegated by the Board, approve awards to eligible participants;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ix)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review and make recommendations to the Board regarding incentive stock option plans or any other long term incentive plans and to the extent delegated by the Board, approve grants to participants and the magnitude and terms of their participation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(x)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">as required, fulfill the obligations assigned to the Committee pursuant to any other employee benefit plans approved by the Board;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(xi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">annually, prepare or review the report on executive compensation required to be disclosed in the Corporation&#8217;s information circular or any other human resource or compensation matter required to be publicly disclosed by the Corporation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(xii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">annually, review and make a recommendation to the Board regarding the compensation of the Board of Directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(xiii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">as determined in the sole discretion of the Committee, retain independent advice in respect of human resources and compensation matters from a compensation consultant, legal counsel or other advisor (the &#8220;Advisor&#8221;) and, if deemed necessary by the Committee, meet separately with the Advisor; the Committee shall be directly responsible for the appointment, compensation and oversight of the work of the Advisor retained by the Committee; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(xiv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">select, or receive advice from, an Advisor to the Committee, other than in-house legal counsel, after taking into consideration the following factors:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the provision of other services to the Corporation by the entity that employs the Advisor ;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the amount of fees received from the Corporation by the entity that employs the Advisor, as a percentage of the total revenue of the entity that employs the Advisor;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the policies and procedures of the entity that employs the Advisor that are designed to prevent conflicts of interest;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any business or personal relationship of the Advisor with a member of the Board;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any stock of the Corporation owned by the Advisor; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any business or personal relationship of the Advisor or the entity employing the Advisor with an executive officer of the Corporation;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provided however, none of the above factors shall prevent the Committee from retaining any Advisor as the Committee deems appropriate, in its sole discretion, after consideration of the above factors. </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(xv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review and consider the implications of the risks associated with the Corporation&#8217;s compensation policies and practices, specifically, situations that could potentially encourage an insider to expose the Corporation to inappropriate or excessive risks; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(xvi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">assess, on an annual basis, the adequacy of this Mandate and the performance of the Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the foregoing, the Committee shall undertake on behalf of the Board such other initiatives as may be necessary or desirable to assist the Board in discharging its responsibility for the Corporation&#8217;s human resources development, performance evaluation, compensation and succession planning programs are in place and operating effectively.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Committee shall assess, on an annual basis, the adequacy of this Mandate and the performance of the Committee.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reporting</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Committee shall, at the earliest opportunity after each meeting, report to the Board the results of its activities and any reviews undertaken and make recommendations to the Board as deemed appropriate.  The Committee may restrict such reports to independent directors in the event of a conflict of interest or potential conflict of interest or if otherwise necessary for the Committee to properly discharge its responsibilities, but only for as long as is reasonably necessary.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">External Advisors</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If, in order to properly discharge its function, duties and responsibilities, it is necessary, in the opinion of the Committee that the Committee obtains the advice and counsel of external advisors, the Chair shall, at the request of the Committee, engage the necessary experts. The Committee shall be directly responsible for the appointment, compensation and oversight of the work of any compensation consultant, legal counsel, and other advisor rtained by the Comimittee.  The Corporation will provide adequate funding, as determined by the Committee, for payment of such external advisors. The Committee will only engage a compensation consultant, legal counsel or other external advisor after taking into consideration the factors set forth in NASDAQ Rule 5605 (d)(3)(D) (See Appendix A). The Committee shall keep the Board apprised of both the selection of experts and the expert&#8217;s findings through the Committee&#8217;s regular reports to the Board.  The Committee may restrict such reports to independent directors in the event of a conflict of interest or potential conflict of interest or if otherwise necessary for the Committee to properly discharge its responsibilities, but only for as long as is reasonably necessary.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date of Mandate</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Mandate was last reviewed, amended and approved by the Board on March 5, 2020.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Audit Committee </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Corporation has formed an Audit Committee in accordance with Section 3(a)(58)(A) of the United States Securities Exchange Act of 1934, as amended ("Exchange Act"), consisting of four independent directors pursuant to the Rule 5605(a)(2) and Rule 5605(c)(2) of the Nasdaq Capital Market and Rule 10A-3 of the Exchange Act: Ms. Brown, Ms. Holtham, Mr. Kruimer and Mr. Pisano, none of whom are nor have been employees or officers of the Company or any of its affiliates.&#160;&#160;Ms. Holtham is presently the Chair of the Audit Committee.&#160;&#160;Each Audit Committee member is financially literate.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Audit Committee Mandate </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Policy Statement</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is the policy of Oncolytics Biotech Inc. (the "Corporation") to establish and maintain an Audit Committee, composed entirely of independent directors, to assist the Board of Directors (the "Board") in carrying out their oversight responsibility for the Corporation&#8217;s internal controls, financial reporting and financial risk management processes.  The Audit Committee will be provided with resources commensurate with the duties and responsibilities assigned to it by the Board including administrative support.  If determined necessary by the Audit Committee, it will have the discretion to institute investigations of improprieties, or suspected improprieties within the scope of its responsibilities, including the standing authority to retain special counsel or experts.  In the event of a conflict of interest or potential conflict of interest involving one or more of the directors or members of management, the Audit Committee may modify the procedures and requirements set out in this Mandate restrict communication and sharing of information to independent directors or otherwise take reasonable measures to manage the conflict of interest or potential conflict of interest.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Composition of the Committee</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall consist of a minimum of three (3) directors.   The Board shall appoint the members (&#8220;Members&#8221;) of the Audit Committee and may seek the advice and assistance of the Governance Committee in identifying qualified candidates.  The Board shall appoint one Member of the Audit Committee to be the Chair of the Audit Committee, or delegate such authority to appoint the Chair of the Audit Committee to the Audit Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Chair of the Committee shall be responsible for leadership of the Committee, including preparing or approving the agenda, presiding over the meetings, and making committee assignments.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each director appointed to the Audit Committee by the Board shall be an outside director who is unrelated and independent.  An outside, unrelated and independent director is a director who meets the requirements of NASDAQ Rule 5605(a)(2) and National Instrument 52-110. A director appointed to the audit committee shall also meet the requirements of NASDAQ Rule 5605(c)(2) and Rule 10A-3(b)(1) of the United States Securities Exchange Act of 1934, as amended. Such director shall be independent of management and free from any interest, any business or other relationship which could, or could reasonably be perceived, to materially interfere with the director&#8217;s ability to act with a view to the best interests of the Corporation, other than interests and relationships arising from shareholding.  In determining whether a director is independent of management, the Board shall make reference to the abovementioned rules and any applicable revisions thereto, and any additional relevant and then current legislation, rules, policies and instruments of applicable regulatory authorities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each Member of the Audit Committee shall be financially literate.  In order to be financially literate, a director must be, at a minimum, able to read and understand financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of the issues that can reasonably be expected to be raised by the Corporation's financial statements. At least one Member shall have accounting or related financial management expertise, meaning the ability to analyze and interpret a full set of financial statements, including the notes attached thereto, in accordance with generally accepted accounting principles and shall be a &#8220;financial expert&#8221; as defined in Item 407 of Regulation S-K promulgated by the U.S. Securities and Exchange Commission and &#8220;financially sophisticated&#8221; as defined in NASDAQ Rule 5605(c)(2).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In determining whether a Member of the Audit Committee is financially literate or has accounting or related financial expertise, reference shall be made to the then current legislation, rules, policies and instruments of applicable regulatory authorities. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each Member of the Audit Committee shall be appointed by the Board annually at the next scheduled meeting of the Board following the AGM.  The Members will be appointed to hold office until the next annual general meeting of shareholders or until their successors are appointed. The Board may remove a Member at any time and may fill any vacancy occurring on the Audit Committee.  A Member may resign at any time and a Member will automatically cease to be a Member upon ceasing to be a director.   </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Chair of the Board shall be an ex officio Member of the committee.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Meetings of the Committee</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall convene a minimum of four times each year at such times and places as may be designated by the Chair of the Audit Committee and whenever a meeting is requested by the Board, a Member of the Audit Committee, the auditors, or senior management of the Corporation.  Scheduled meetings of the Audit Committee shall correspond with the review of the year-end and quarterly financial statements and management discussion and analysis.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notice of each meeting of the Audit Committee shall be given to each Member of the Audit Committee and to the auditors. The auditors are entitled to attend meetings that pertain to the quarterly and year end financial reporting and, if there are any other meetings, only at the request of the Audit Committee.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notice of a meeting of the Audit Committee shall:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">be in writing, including by electronic communication facilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">state the nature of the business to be transacted at the meeting in reasonable detail;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to the extent practicable, be accompanied by copies of documentation to be considered at the meeting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">be given at least two business days prior to the time stipulated for the meeting or such shorter period as the Members of the Audit Committee may permit.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A quorum for the transaction of business at a meeting of the Audit Committee shall consist of a majority of the Members of the Audit Committee.  However, it shall be the practice of the Audit Committee to require review, and, if necessary, approval of certain important matters by all Members of the Audit Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A Member or Members of the Audit Committee may participate in a meeting of the Audit Committee by means of such telephonic, electronic or other communication facilities, as permits all persons participating in the meeting to communicate adequately with each other.  A Member participating in such a meeting by any such means is deemed to be present at the meeting.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the absence of the Chair of the Audit Committee, the Members of the Audit Committee shall choose one of the Members present to be Chair of the meeting.  If the Board has appointed a Corporate Secretary, the Corporate Secretary shall act as the secretary of the meeting.  If the Board has not appointed a Corporate Secretary, the Members of the Committee shall choose one of the persons present to be the secretary of the meeting or may have another person who is not a Member of the Committee present to record the minutes of the meeting.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A member of the Board, senior management of the Corporation, external auditors and other parties may attend meetings of the Audit Committee; however the Audit Committee (i) shall, at a meeting attended by the external auditor, meet with them independent of other individuals other than the Audit Committee; (ii) may exclude: (A) management, (B) directors who are not independent directors, or (C) any party that has a conflict of interest or potential conflict of interest, from part or all of a meeting of the Audit Committee if reasonably necessary for the Audit Committee to properly discharge its responsibilities; and (iii) may meet separately with management.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(h)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Chief Executive Officer and the Chief Financial Officer shall each attend meetings of the Audit Committee when requested to do so by a Member of the Audit Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Minutes shall be kept of all meetings of the Audit Committee and shall be signed by the Chair and the secretary of the meeting.  Minutes of the meetings of the Audit Committee shall be distributed to Members of the Audit Committee, to other members of the Board and, with the exception of &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in camera</font><font style="font-family:inherit;font-size:10pt;">&#8221; items, to the Chief Executive Officer and Chief Financial Officer.  Notwithstanding the foregoing, distribution of minutes of meetings or parts thereof may be restricted to independent directors in the event of a conflict of interest or potential conflict of interest or if otherwise necessary for the Audit Committee to properly discharge its responsibilities, but only for as long as is reasonably necessary.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Duties and Responsibilities of the Committee</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee&#8217;s primary duties and responsibilities are to:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">identify and monitor the management of the principal risks that could impact the financial reporting of the Corporation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">monitor the integrity of the Corporation&#8217;s financial reporting process and system of internal controls regarding financial reporting and accounting compliance;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">monitor the independence and performance of the Corporation&#8217;s external auditors. This will include receipt, review and evaluation, at least annually, of a formal written statement from the independent auditors confirming their independence, and qualifications, including their compliance with the requirements of the relevant oversight boards and actively engage in a dialogue with the auditors with respect to any disclosed relationships or services that may impact objectivity and independence of the auditors and take, or recommend that the full board take, appropriate action to oversee the independence of the external auditors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">deal directly with the external auditors to pre-approve external audit plans, other services (if any) and fees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">directly oversee the external audit process and results (in addition to items described in Section 4(d) below);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provide an avenue of communication among the external auditors, management and the Board; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">carry out a review designed to ensure that an effective "whistle blowing" procedure exists to permit stakeholders to express any concerns to an appropriately independent individual;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pre-approve any related party transactions to be entered into by the Company, and ensure appropriate disclosure thereof;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ix)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ensure financial disclosure incorporates inclusion of any material correcting adjustments required by the external auditors; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(x)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">require and ensure that the external auditors are directly responsible to the Audit Committee, to whom they report.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall have the authority to:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inspect any and all of the books and records of the Corporation and its affiliates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">discuss with the management of the Corporation and its affiliates, any affected party and the external auditors, such accounts, records and other matters as any Member of the Audit Committee considers necessary and appropriate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">engage independent counsel and other advisors as it determines necessary to carry out its duties.  The Audit Committee shall keep the Board apprised of both the selection of experts and the expert&#8217;s findings through the Audit Committee&#8217;s regular reports to the Board.  The Audit Committee may restrict such reports to independent directors in the event of a conflict of interest or potential conflict of interest or if otherwise necessary for the Audit Committee to properly discharge its responsibilities, but only for as long as is reasonably necessary; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">communicate directly with the external auditors; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">set and pay the compensation for (A) any external auditor engaged for the purpose of preparing or issuing an audit report or performing other audit, review, or attest services for the Corporation, (b) any advisors employed by the Audit Committee, and (C) ordinary administrative expenses of the Audit Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall, at the earliest opportunity after each meeting, report to the Board the results of its activities and any reviews undertaken and make recommendations to the Board as deemed appropriate.  The Audit Committee may restrict such reports to independent directors in the event of a conflict of interest or potential conflict of interest or if otherwise necessary for the Audit Committee to properly discharge its responsibilities, but only for as long as is reasonably necessary.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review the audit plan with the Corporation&#8217;s external auditors and with management;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review with the independent auditors the matters required to be discussed relating to the conduct of the audit, including (a) the proposed scope of their examination, with emphasis on accounting and financial areas where the Committee, the independent auditors or management believes special attention should be directed; (b) the results of their audit, including their audit findings report and resulting letter, if any, of recommendations for management; (c) their evaluation of the adequacy and effectiveness of the Company&#8217;s internal controls over financial reporting; (d) significant areas of disagreement, if any, with management; (e) co-operation received from management in the conduct of the audit; (f) significant accounting, reporting, regulatory or industry developments affecting the Company; and (g) any proposed changes in major accounting policies or principles proposed or contemplated by the independent auditors or management, the presentation and impact of material risks and uncertainties and key estimates and judgements of management that may be material to financial reporting;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review with management and with the external auditors material financial reporting issues arising during the most recent fiscal period and the resolution or proposed resolution of such issues;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review any problems experienced or concerns expressed by the external auditors in performing an audit, including any restrictions imposed by management or material accounting issues on which there was a disagreement with management;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review with senior management the process of identifying, monitoring and reporting the principal risks affecting financial reporting;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review audited annual financial statements (including management discussion and analysis) and related documents in conjunction with the report of the external auditors and obtain an explanation from management of all material variances between comparative reporting periods. Without restricting the generality of the foregoing, the committee will discuss with management and the independent auditors to the extent required, any issues and disclosure requirements regarding (a) the use of &#8220;pro forma&#8221; or &#8220;adjusted&#8221; non-GAAP information, as well as financial information and earnings guidance provided to analysts and rating agencies, (b) any off balance sheet arrangements, and (c) any going concern qualification.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">consider and review with management, the internal control memorandum or management letter containing the recommendations of the external auditors and management&#8217;s response, if any, including an evaluation of the adequacy and effectiveness of the internal financial controls of the Corporation and subsequent follow-up to any identified weaknesses;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review with financial management and the external auditors the quarterly unaudited financial statements, management discussion and analysis, letter to shareholders and press release (all to be considered the &#8220;Quarterly Financial Reports&#8221;) and recommend the Quarterly Financial Reports to the Board for approval by the Board before release to the public;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ix)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">before release, review and if appropriate, recommend for approval by the Board, all public disclosure documents containing audited or unaudited financial information, including any prospectuses, financial statements, including the notes thereto, annual reports, annual information forms, management discussion and analysis and press releases; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(x)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">oversee, any of the financial affairs of the Corporation or its affiliates, and, if deemed appropriate, make recommendations to the Board, external auditors or management.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">evaluate the independence and performance of the external auditors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">recommend the nomination of the external auditors to the Board for appointment by the shareholders at the Corporation&#8217;s annual general meeting;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;recommend the discharge of the external auditor when circumstances warrant;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">monitor the rotation of the audit partner of the external auditors as required by applicable law or regulations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">consider the recommendations of management in respect of the appointment of the external auditors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pre-approve all non-audit services to be provided to the Corporation or its subsidiary entities by its external auditors, or the external auditors of affiliates of the Corporation subject to the over-riding principle that the external auditors are not permitted to be retained by the Corporation to perform specifically listed categories of non-audit services as set forth by the Securities and Exchange Commission as well as internal audit outsourcing services, financial information systems work and expert services.  Notwithstanding, the foregoing the pre-approval of non-audit services may be delegated to a Member of the Audit Committee, with any decisions of the Member with the delegated authority reporting to the Audit Committee at the next scheduled meeting;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(vii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">approve the engagement letter for non-audit services to be provided by the external auditors or affiliates, together with estimated fees, and considering the potential impact of such services on the independence of the external auditors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">when there is to be a change of external auditors, review all issues and provide documentation related to the change, including the information to be included in the Notice of Change of Auditors and documentation required pursuant to the then current legislation, rules, policies and instruments of applicable regulatory authorities and the planned steps for an orderly transition period; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ix)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">review all reportable events, including disagreements, unresolved issues and consultations, as defined by applicable securities policies, on a routine basis, whether or not there is to be a change of external auditors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall enquire into and determine the appropriate resolution of any conflict of interest in respect of audit or financial matters, which are directed to the Audit Committee.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall review the Corporation&#8217;s accounting and reporting of revenues, costs, liabilities and contingencies.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(h)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall establish and maintain procedures for:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the receipt, retention and treatment of complaints received by the Corporation regarding accounting, internal controls, or auditing matters; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the confidential, anonymous submission by employees of the Corporation or concerns regarding questionable accounting or auditing matters.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall review and approve the Corporation's hiring policies regarding partners and employees and former partners and employees of the present and former external auditors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(j)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall review with the Corporation's legal counsel, on no less than an annual basis, any legal matter that could have a material impact on the Corporation's financial statements, and any enquiries received from regulators, or government agencies.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(k)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall review with management and the Corporation&#8217;s external auditors, on no less than an annual basis, any taxation matters that could have a material impact on the Corporation&#8217;s financial statements.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(l)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee, through the Chair, shall receive notice from management of any instance of non-trivial fraud or other failure or weakness of the control system promptly upon management becoming aware of such.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(m)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall review and approve the signing authority for the Corporation at least annually or when a change is required. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(n)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee shall assess, on an annual basis, the adequacy of this Mandate and the performance of the Audit Committee.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reporting</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Committee shall, at the earliest opportunity after each meeting, report to the Board the results of its activities and any reviews undertaken and make recommendations to the Board as deemed appropriate.  The Audit Committee may restrict such reports to independent directors in the event of a conflict of interest or potential conflict of interest or if otherwise necessary for the Audit Committee to properly discharge its responsibilities, but only for as long as is reasonably necessary.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date of Mandate</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Mandate was last reviewed and approved by the Board on March 5, 2020.  </font></div><div style="line-height:120%;padding-left:18px;text-indent:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;padding-right:30px;">D.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employees</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets out the number of our employees at the end of each of the last three fiscal years by activity and geographic location.</font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:512px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:349px;"></td><td style="width:58px;"></td><td style="width:52px;"></td><td style="width:52px;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Activity</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:462px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:310px;"></td><td style="width:52px;"></td><td style="width:46px;"></td><td style="width:52px;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Geographic location</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canada</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Ownership</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets out the share ownership and options held of our directors and officers as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;5, 2020</font><font style="font-family:inherit;font-size:10pt;">. Common shares, stock options and exercises prices for all periods have been adjusted retroactively for the Share Consolidation. </font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:660px;border-collapse:collapse;text-align:left;"><tr><td colspan="10" style="padding-top:4px;padding-bottom:4px;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="width:101px;"></td><td style="width:71px;"></td><td style="width:4px;"></td><td style="width:97px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:62px;"></td><td style="width:4px;"></td><td style="width:132px;"></td><td style="width:108px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">% of&#160;&#160;<br>Ownership</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;<br>Options</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise<br>Price</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expiry Date</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">% of Outstanding</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Officers</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Matthew C. Coffey</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,923</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;14, 2020</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,894</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40.95</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">July&#160;27, 2021</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,157</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;14, 2021</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,157</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;17, 2022</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;11, 2023</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,263</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.99</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;1, 2025</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January&#160;16, 2027</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,389</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.41</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;8, 2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;19, 2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.45</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;13, 2023</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">643,333</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.64%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk J. Look</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,923</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;14, 2020</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,684</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.96</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;14, 2021</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;13, 2022</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,210</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;17, 2022</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,842</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;11, 2023</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,842</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.99</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;1, 2025</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,578</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January&#160;16, 2027</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,705</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.41</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;8, 2022</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;19, 2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.45</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;13, 2023</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">366,544</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Rita Laeufle</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">July&#160;9, 2022</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.23</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;29, 2023</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;14, 2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.45</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;13, 2023</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Andrew de Guttadauro</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,157</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">July&#160;3, 2027</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,736</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.41</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;8, 2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;14, 2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.45</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;13, 2023</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,893</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Michael Moore</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,157</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February&#160;20, 2027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,736</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.41</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;8, 2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:660px;border-collapse:collapse;text-align:left;"><tr><td colspan="10" style="padding-top:4px;padding-bottom:4px;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="width:101px;"></td><td style="width:71px;"></td><td style="width:4px;"></td><td style="width:97px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:62px;"></td><td style="width:4px;"></td><td style="width:132px;"></td><td style="width:108px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Shares</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">% of&#160;&#160;<br>Ownership</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;<br>Options</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise<br>Price</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expiry Date</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">% of Outstanding</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;14, 2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.45</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;13, 2023</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,893</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allison Hagerman</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46.55</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;9, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;14, 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">842</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.96</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;14, 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">526</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;12, 2022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,105</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.53</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;11, 2023</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,421</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;11, 2024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,263</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;9, 2025</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,894</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;28, 2026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,526</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.41</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;8, 2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;14, 2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.45</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;13, 2023</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149,997</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Directors</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deborah Brown</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,827</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,263</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.42</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November&#160;7, 2027</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Angela Holtham</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June&#160;18, 2024</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leonard Kruimer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.54</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October&#160;2, 2024</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wayne Pisano</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,420</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May&#160;9, 2023</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,157</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.53</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;11, 2023</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,420</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William Rice</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,780</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June&#160;8, 2025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bernd Seizinger</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,107</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:0px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,263</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.60</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June&#160;8, 2025</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TOTAL:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">528,957</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,660,132</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">** Less than 1% ownership</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on </font><font style="font-family:inherit;font-size:10pt;">37,375,025</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares issued and outstanding on </font><font style="font-family:inherit;font-size:10pt;">March&#160;5, 2020</font><font style="font-family:inherit;font-size:10pt;">. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted to acquire common shares. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ownership percentage assumes aggregate beneficial ownership of common shares, common shares acquirable upon exercise of options and fully diluted shares outstanding of </font><font style="font-family:inherit;font-size:10pt;">42,119,348</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted Share Units</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets out the restricted share units held by our directors as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;5, 2020</font><font style="font-family:inherit;font-size:10pt;">. Restricted share awards have been adjusted retroactively for the Share Consolidation. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:383px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:133px;"></td><td style="width:88px;"></td><td style="width:4px;"></td><td style="width:76px;"></td><td style="width:4px;"></td><td style="width:71px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RSUs Granted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RSUs Vested and Released</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RSUs Unvested</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deborah Brown</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,932</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(44,827</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,105</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Angela Holtham</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(71,568</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,898</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leonard Kruimer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">789</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">789</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wayne Pisano</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(114,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,819</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William Rice</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,098</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(68,993</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,105</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bernd Seizinger</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134,470</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(91,107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520,889</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(390,810</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130,079</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets out the restricted share units held by our officers as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;5, 2020</font><font style="font-family:inherit;font-size:10pt;">. Restricted share awards have been adjusted retroactively for the Share Consolidation.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:425px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:149px;"></td><td style="width:96px;"></td><td style="width:4px;"></td><td style="width:86px;"></td><td style="width:4px;"></td><td style="width:80px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RSUs Granted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RSUs Vested and Released</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RSUs Unvested</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Andrew de Guttadauro</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,315</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,105</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,210</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,315</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,105</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,210</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Performance Share Units</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets out the performance share units held by our officers as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;5, 2020</font><font style="font-family:inherit;font-size:10pt;">. Performance share awards have been adjusted retroactively for the Share Consolidation. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:408px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:133px;"></td><td style="width:88px;"></td><td style="width:4px;"></td><td style="width:76px;"></td><td style="width:4px;"></td><td style="width:96px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PSUs Granted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PSUs Vested and Released</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PSUs Unvested</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew Coffey</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,736</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,736</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk Look</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Michael Moore</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,315</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,315</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,156</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,315</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,841</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Compensation Plan Information</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently have two share based compensation plans: the Stock Option Plan and the Share Award Plan.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Option Plan</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of the Corporation&#8217;s Amended and Restated Stock Option Plan (the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Option Plan</font><font style="font-family:inherit;font-size:10pt;">&#8221;) dated effective as of May 4, 2017.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Corporation, with the approval of its Shareholders, has established the Stock Option Plan. The number of Common Shares reserved for issuance under the Stock Option Plan and all other security based compensation arrangements of the Corporation (including the Share Award Plan) in aggregate shall not exceed 10% of the total number of issued and outstanding Common Shares from time to time. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Stock Option Plan, the Board of Directors or the Compensation Committee may from time to time designate directors, officers, employees of, or consultants to, the Corporation or any subsidiary of the Corporation (such persons being &#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Eligible Persons</font><font style="font-family:inherit;font-size:10pt;">&#8221;) to whom Options may be granted and the number of Options to be granted to each. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options may be exercised at a price (the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</font><font style="font-family:inherit;font-size:10pt;">&#8221;) which shall be fixed by the Board at the time the Option is granted. No Option can be granted with an Exercise Price at a discount to the market, which shall be the closing price of the Common </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares on the stock exchange upon which the Common Shares are listed on the first day preceding the date of grant on which at least one board lot of Common Shares traded on such exchange.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any Option shall be exercised or shall expire or terminate for any reason without having been exercised in full, any Common Shares to which such Option relates shall be available for the purposes of the granting of Options under the Stock Option Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The number of Shares that may be acquired under an Option granted to a participant under the Stock Option Plan shall be determined by the Board as at the time the Option is granted, provided that the aggregate number of Shares reserved for issuance to any one participant under the Stock Option Plan or any other security based compensation arrangement of the Corporation, shall not exceed five percent (5%) of the total number of issued and outstanding Common Shares (calculated on a non-diluted basis).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Without obtaining the approval of Shareholders in accordance with the rules of the TSX or the requirements of any other stock exchange on which the Common Shares are then listed, no Options shall be granted pursuant to the Stock Option Plan, if such grant together with grants pursuant to all other share compensation arrangements of the Corporation, could result, at any time, in:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a number of Common Shares issuable pursuant to Options granted to insiders exceeding ten percent (10%) of the number of outstanding Common Shares at any time;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the issuance within a one year period to insiders, of a number of Common Shares exceeding ten percent (10%) of the number of outstanding Common Shares; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the issuance to any one insider and such insider&#8217;s associates, within a one year period, of a number of Common Shares exceeding five percent (5%) of the number of outstanding Common Shares.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The value of Option grants to each non-employee director shall not exceed $150,000 annually for any individual non-employee director (other than initial Option grants to new directors).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options are generally granted for a term expiring on the tenth anniversary of the date of grant and typically either vest immediately or as to one-third on each of the first, second and third anniversary following the date of grant, as determined by the Board at the time the Option is granted. Options are not transferable or assignable except to the person or persons to whom the participant&#8217;s rights pass by the participant&#8217;s will or applicable law following the death or permanent disability of a participant.  The Stock Option Plan provides that if the expiration date of an Option occurs during a &#8220;blackout period&#8221; or within five (5) business days after a blackout period, such expiration date shall be deemed to be extended to the date which is the tenth (10</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;">) business day after the last day of the applicable blackout period.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to any written agreement between the Corporation and a participant providing otherwise, if any participant shall cease to be an Eligible Person for any reason other than the termination for cause or the death or permanent disability of the participant, such participant&#8217;s Option will terminate immediately as to the then unvested portion thereof and at 5:00 p.m. (Calgary time) on the earlier of the date of the expiration of the applicable option period and the ninetieth (90</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;">) day after the date such participant ceases to be an Eligible Person as to the then vested portion of the Option. If a participant ceases to be an Eligible Person as a result of the termination of such participant for cause, effective as of the date notice is given to the participant of such termination, all outstanding Options shall be terminated and all rights to receive Common Shares thereunder shall be forfeited by such participant, and the participant shall not be entitled to receive any Common Shares or other compensation in lieu thereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to any written agreement between the Corporation and a participant providing otherwise, if in the event of the death or permanent disability of a participant, any Option previously granted to such participant shall be exercisable until the end of the applicable option period or until the expiration of 12 months after the date of death or permanent disability of such participant, whichever is earlier, and then only: (i) by the person or persons to whom the participant&#8217;s rights under the Option shall pass by the participant&#8217;s will or applicable law; (ii) to the extent that he or she was entitled to exercise the Option as at the date of the participant&#8217;s death or permanent disability.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notwithstanding the foregoing, the Board may, at its sole discretion, extend the period during which any Options may be exercised, in the case of Options held by non-employee directors, by not more than one year, and in the case of Options held by other persons, by not more than three years, but in no case longer than the normal expiry of the Options.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the event of a change of control of the Corporation (as such term is defined in the Stock Option Plan), all Options which have not otherwise vested in accordance with their terms shall immediately vest and be exercisable, notwithstanding the other terms of the Options or the Stock Option Plan for a period of time ending on the earlier of the expiry time of the Option and the ninetieth (90</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;">) day following the change of control.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to any required approval of the TSX and any other stock exchange on which the Common Shares are then listed, the Stock Option Plan and any Options granted thereunder may be amended, modified or terminated by the Board without approval of any participant or Shareholder (provided that no such amendment may be made that will materially prejudice the rights of any participant under any Option previously granted to the participant without consent by such participant). Such changes may include, without limitation: </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">amending, modifying or terminating the Stock Option Plan with respect to all Common Shares in respect of Options which have not yet been granted thereunder; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">making any amendment of a &#8220;housekeeping nature&#8221;; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changing the provisions relating to the manner of exercise of Options; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">accelerating vesting or extending the expiration date of any Option (provided that such Option is not held by an insider), provided that the period during which an Option is exercisable does not exceed 10 years from the date the Option is granted;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adding a cashless exercise feature, payable in cash or securities, whether or not providing for a full deduction of the number of underlying Common Shares from the Stock Option Plan reserve; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">making any addition to, deletion from or alteration of the provisions of the Stock Option Plan or any Option that are necessary to comply with applicable law, the rules of the TSX, or the requirements of any other exchange on which the Shares are then listed and to avoid unanticipated consequences deemed by the Board to be inconsistent with the purpose of the Stock Option Plan.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notwithstanding the foregoing, Shareholder approval is required for any change to the Stock Option Plan or Options granted under it which:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increases the number of Common Shares reserved for issuance under the Stock Option Plan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">extends eligibility to participate in the Stock Option Plan to persons other than Eligible Persons;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">permits Options to be transferred, other than for normal estate settlement purposes or to an RRSP or similar plan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">permits awards other than Options to be made under the Stock Option Plan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">extends the term of an Option beyond the maximum expiry date set out in the Stock Option Plan (except where an expiry date would have fallen within a blackout period;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reduces the exercise price of an Option, except for the purpose of maintaining Option value in connection with a conversion, change, reclassification, redivision, redesignation, subdivision or consolidation of shares or a reorganization, amalgamation, consolidation, merger, takeover bid or similar transaction involving the Corporation (for this purpose, cancellation or termination of an Option prior to its expiry date for the purpose of reissuing Options to the same Option-holder with a lower exercise price will be considered an amendment to reduce the exercise price of an Option);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(vii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes the insider participation limitation at any time under the Stock Option Plan; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">amends the amending provision of the Stock Option Plan. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Award Plan</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of the Corporation&#8217;s Amended and Restated Incentive Share Award Plan (the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Award Plan</font><font style="font-family:inherit;font-size:10pt;">&#8221;) dated effective as of May 4, 2017.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Corporation, with the approval of its Shareholders, has established the Share Award Plan. Under the Share Award Plan, the Board may, at such times and in such amounts as the Board may deem advisable in its sole and absolute discretion, issue Performance Share Awards (&#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PSAs</font><font style="font-family:inherit;font-size:10pt;">&#8221;) to eligible employees, including officers, and Restricted Share Awards (&#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RSAs</font><font style="font-family:inherit;font-size:10pt;">&#8221; and, together with PSAs, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Awards</font><font style="font-family:inherit;font-size:10pt;">&#8221;) to Eligible Persons. The number of Common Shares reserved for issuance under the Share Award Plan and all other security based compensation arrangements of the Corporation (including the Stock Option Plan) in aggregate shall not exceed 10% of the total number of issued and outstanding Common Shares from time to time.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to earlier vesting in accordance with the terms of the Share Award Plan and unless otherwise determined by the Board, Share Awards granted under the Share Award Plan vest on the third anniversary date of the date of grant. Upon vesting, each RSA is deemed to be redeemed for no further consideration for one&#160;Common Share (subject to adjustment for dividend equivalents) and each PSA is deemed to be redeemed for no further consideration for one&#160;Common Share (subject to adjustment for dividend equivalents) multiplied by the percentage (&#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Vesting Percentage</font><font style="font-family:inherit;font-size:10pt;">&#8221;) of outstanding PSAs that will vest based upon the relative achievement of any performance-related measures or criteria as determined by the Board in its sole discretion, which may include the Corporation&#8217;s performance compared to identified operational or financial targets and the Corporation&#8217;s shareholder return.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate number of Common Shares issuable at any time to insiders, under all security based compensation arrangements of the Corporation shall not exceed 10% of the issued and outstanding Common Shares (calculated on a non-diluted basis). The aggregate number of Common Shares issued pursuant to all security based compensation arrangements of the Corporation, within a one year period, shall not exceed 10% of the issued and outstanding Common Shares (calculated on a non-diluted basis). The </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share Award Plan further provides that the aggregate number of Common Shares reserved for issuance to any one participant under all security based compensation arrangements of the Corporation, shall not exceed 5% of the total number of issued and outstanding Common Shares (calculated on a non-diluted basis).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The maximum number of Common Shares that may be reserved for issuance to non-employee directors pursuant to RSAs under the Share Award Plan is 1% of the Common Shares outstanding at the time of the grant (on a non-diluted basis), less the aggregate number of Common Shares reserved for issuance to such non-employee director under any other security based compensation arrangement, and the total annual grant of RSAs to any one non-employee director cannot exceed a grant value of $150,000 (less the amount awarded to such non-employee director).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Share Award Plan provides that if the issue date of any Share Award occurs during a blackout period, then the issue date for such Share Award shall not occur until the date which is the tenth (10</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;">) business day after the last day of the such blackout period.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise determined by the Board in its sole discretion, upon a Change of Control (as such term is defined in the Share Award Plan), all unvested Share Awards shall become automatically vested (in the case of PSAs, with a deemed Vesting Percentage of 100). Common Shares issuable in respect of Share Awards shall be, and shall be deemed to be, issued to participants effective immediately prior to the completion of the transaction which would result in the Change of Control unless issued prior thereto in accordance with the Share Award Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise determined by the Board or unless otherwise expressly set forth in a Share Award agreement pertaining to a particular Share Award or any written employment or other agreement governing a participant&#8217;s role as an Eligible Person if a participant ceases to be an Eligible Person as a result of the termination of such participant for cause or if a participant voluntarily ceases to be an Eligible Person for any reason other than as a result of the death, permanent disability or retirement of the participant, all outstanding Share Awards Agreements under which Share Awards have been granted to such participant shall be terminated. Upon the death, permanent disability or retirement of a participant (other than the early retirement of an eligible employees), all outstanding Share Awards shall immediately vest. If a participant ceases to be an Eligible Person other than in the circumstances provided above, all Share Awards awarded to such participant under any outstanding Share Awards shall fully vest effective as of the date of cessation of employment (the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cessation Date</font><font style="font-family:inherit;font-size:10pt;">&#8221;), unless otherwise determined by the Board, and the participant shall be entitled to receive the number of Common Shares equal to the number of Share Awards granted multiplied by a fraction (A) the numerator of which is the number of days from the date of grant thereof to the Cessation Date; and (B) the denominator of which is the total number of days during which such Share Award were scheduled to vest upon grant. In such circumstances, the Vesting Percentage in respect of PSAs shall be determined as of the Cessation Date.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Share Award Plan and any Share Awards granted thereunder may be amended, modified or terminated by the Board without approval of Shareholders, subject to any required approval of the TSX. Such changes may include, without limitation: </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">amending, modifying or terminating the Share Award Plan with respect to all Common Shares in respect of Share Awards which have not yet been granted thereunder; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">making any amendment of a &#8220;housekeeping nature&#8221;; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">making any addition to, deletion from or alteration of the provisions of this Plan or any Share Award that are necessary to comply with applicable law, the rules of the TSX, or the requirements of any other stock exchange on which the Common Shares are then listed and to avoid unanticipated consequences deemed by the Board to be inconsistent with the purpose of this Plan. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notwithstanding the foregoing, the Share Award Plan or a Share Award may not be amended without shareholder approval to:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increase the number of Common Shares issuable pursuant to outstanding Share Awards at any time;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">change the insider participation limit under the Share Award Plan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">expand the categories of individuals who are &#8220;eligible employees&#8221; who are eligible to participate in the Share Award Plan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(vii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">extend the term of any Share Award beyond the term of such awards provided for under the terms and conditions of the Share Award Plan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">permit the transfer or assignment of Share Awards, except to permit a transfer to a family member, an entity controlled by the holder of the Share Awards or a family member, a charity or for estate planning or estate settlement purposes; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(ix)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">change the amendment provisions of the Share Award Plan.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, no amendment to the Share Award Plan or any Share Awards granted pursuant thereto may be made without the consent of an Share Award Plan participant if it adversely alters or impairs the rights of such participant in respect of any Share Award previously granted to such participant under the Share Award Plan.</font></div><div><a name="s325C462F5C4E5A49BB135AE0A7CDA855"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Major Shareholders</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not directly or indirectly owned or controlled by another corporation(s) or by any foreign government. To the knowledge of our directors and senior officers, as at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;6, 2020</font><font style="font-family:inherit;font-size:10pt;">, we are not aware of any shareholder who beneficially owns, directly or indirectly, or exercises control or direction over, our common shares carrying more than 5% of the voting rights.   </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shares Held in the United States</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table indicates, as of </font><font style="font-family:inherit;font-size:10pt;">February&#160;29, 2020</font><font style="font-family:inherit;font-size:10pt;">, the total number of common shares issued and outstanding, the approximate total number of holders of record of common shares, the number of holders of record of common shares with US&#160;addresses, the portion of the outstanding common shares held by US&#160;holders of record, and the percentage of common shares held by US&#160;holders of record. This table does not indicate beneficial ownership of common&#160;shares.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:44%;"></td><td style="width:14%;"></td><td style="width:13%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Number of Holders of Record</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Number of Common Shares Issued and Outstanding</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of US&#160;Holders of Record</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Common Shares Held by US&#160;Holders of Record</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Percentage of Common Shares Held by US&#160;Holders of Record&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,090,525</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,154,463</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78.60</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common shares have been adjusted retroactively for the Share Consolidation. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Change of Control</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;6, 2020</font><font style="font-family:inherit;font-size:10pt;">, there were no arrangements known to the Company which may, at a subsequent date, result in a change of control of the Company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Control by Others</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the best of the Company&#8217;s knowledge, the Company is not directly or indirectly owned or controlled by another corporation, any foreign government, or any other natural or legal person, severally or jointly.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Related Party Transactions</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into employment contracts with each of our officers (see Item 6).&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since the beginning of the fiscal year ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;6, 2020</font><font style="font-family:inherit;font-size:10pt;">, we did not enter into any other related party transactions and we do not have any loans outstanding with any officer, director or major shareholder.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interests of Experts and Counsel</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sE903E70659135762AF639D8EC9975FF6"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 8. FINANCIAL INFORMATION</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements and Other Financial Statements</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Statements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements filed as part of this annual report are filed under Item 18.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The directors and the management of the Company do not know of any material, active or pending, legal proceedings against them; nor is the Company involved as a plaintiff in any material proceeding or pending litigation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The directors and the management of the Company know of no active or pending proceedings against anyone that might materially adversely affect an interest of the Company.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Dividend Policy</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has not paid any dividends on its common shares.&#160;&#160;The Company may pay dividends on its common shares in the future if it generates profits.&#160;&#160;Any decision to pay dividends on common shares in the future will be made by the board of directors on the basis of the earnings, financial requirements and other conditions existing at such time.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Changes</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No significant changes have occurred since the date of our annual financial statements included in this annual report on Form 20-F.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s9319A674FE8058ECB00DBD73C6DA8B25"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 9. THE OFFER AND LISTING</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Offering and Listing Details</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Common Shares are traded on the TSX and on the Nasdaq Capital Market under the symbol ONC and ONCY, respectively. Between November 5, 2015 and June 1, 2018, our Common Shares were quoted for trading on the OTCQX International ("OTCQX") under the symbols ONCYF and ONCYD, after our Common Shares were delisted from the Nasdaq on November 5, 2015. On June 1, 2018, our Common Shares were approved for listing and commenced trading on the Nasdaq Capital Market. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Market Price Volatility of Common Shares</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Market prices for the securities of biotechnology companies, including our securities, have historically been highly volatile, and the market has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. Factors, such as fluctuations in our operating results, the aftermath of our public announcements, and general market conditions, can have an adverse effect on the market price of our common shares and other securities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Plan of Distribution</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Markets</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Common Shares, no par value, are traded/quoted on the Nasdaq and the TSX under the symbol &#8220;ONCY" and &#8220;ONC&#8221;, respectively.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Selling Shareholders</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dilution</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">F.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expenses of the Issue</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s2D124AB70CE0558DACB322E09C907A6E"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 10.&#160; ADDITIONAL INFORMATION</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Capital</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Memorandum and Articles of Association</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Articles of Continuance</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are governed by our amended articles of incorporation (the "Articles") under the Business Corporations Act of Alberta (the &#8220;Act&#8221;) and by our by-laws (the&#160;"By-laws"). Our Alberta corporate access number is 207797382. Our Articles provide that there are no restrictions on the business we may carry on or on the powers we may exercise. Companies incorporated under the Act are not required to include specific objects or purposes in their articles or by-laws.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Directors</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to certain exceptions, including in respect of voting on any resolution to approve a contract that relates primarily to the director's remuneration, directors may not vote on resolutions to approve a material contract or material transaction if the director is a party to such contract or transaction. The directors are entitled to remuneration as shall from time to time be determined by the Board of Directors with no requirement for a quorum of independent directors. The directors have the ability under the Act to exercise our borrowing power, without authorization of the shareholders. The Act permits shareholders to restrict this authority through a company's articles or by-laws (or through a unanimous shareholder agreement), but no such restrictions are in place for us. Our Articles and By-laws do not require directors to hold shares for qualification.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rights, Preferences and Dividends Attaching to Shares</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The holders of common shares have the right to receive dividends if and when declared. Each holder of common shares, as of the record date prior to a meeting, is entitled to attend and to cast one vote for each common share held as of such record date at such annual and/or special meeting, including with respect to the election or re-election of directors. Subject to the provisions of our By-laws, all directors may, if still qualified to serve as directors, stand for re-election. The numbers of our Board of Directors are not replaced at staggered intervals but are elected annually.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On a distribution of assets on a winding-up, dissolution or other return of capital (subject to certain exceptions) the holders of common shares shall have a right to receive their </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">pro&#160;rata</font><font style="font-family:inherit;font-size:10pt;">&#32;share of such distribution. There are no sinking fund or redemption provisions in respect of the common shares. Our shareholders have no liability to further capital calls as all shares issued and outstanding are fully paid and non-assessable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No other classes of shares are currently permitted to be issued.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Action Necessary to Change the Rights of Shareholders</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The rights attaching to the different classes of shares may be varied by special resolution passed at a meeting of that class's shareholders.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Annual and Special Meetings of Shareholders</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Act and our By-laws, we are required to mail a Notice of Meeting and Management Information Circular to registered shareholders not less than 21&#160;days and not more than 50 days prior to the date of the meeting. Such materials must be filed concurrently with the applicable securities regulatory authorities in Canada and the US.&#160;Subject to certain provisions of the By-laws, a quorum of two or more shareholders in person or represented by proxy holding or representing by proxy not less than five (5%) percent of the total number of issued and outstanding shares enjoying voting rights at such meeting is required to properly constitute a meeting of shareholders.&#160;&#160;Shareholders and their duly appointed proxies and corporate representatives are entitled to be admitted to our annual and/or special meetings.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Limitations on the Rights to Own Shares</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Articles do not contain any limitations on the rights to own shares. Except as described below, there are currently no limitations imposed by Canadian federal or provincial laws on the rights of non-resident or foreign owners of Canadian securities to hold or vote the securities held. There are also no such limitations imposed by the Articles and By-laws with respect to our common&#160;shares.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Disclosure of Share Ownership</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In general, under applicable securities regulation in Canada, a person or company who beneficially owns, directly or indirectly, voting securities of an issuer or who exercises control or direction over voting securities of an issuer or a combination of both, carrying more than 10% of the voting rights attached to all the issuer's outstanding voting securities is an insider and must, within 10&#160;days of becoming an insider, file&#160;a report in the required form effective the date on which the person became an insider. The report must disclose any direct or indirect beneficial ownership of, or control or direction over, securities of the reporting issuer. Additionally, securities regulation in Canada provides for the filing of a report by an insider of a reporting issuer whose holdings change, which report must be filed within 10&#160;days from the day on which the change takes place.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The rules in the US governing the ownership threshold above which shareholder ownership must be disclosed are more stringent than those discussed above. Section 13 of the Exchange Act imposes reporting requirements on persons who acquire beneficial ownership (as such term is defined in Rule 13d-3 under the Exchange Act) of more than 5% of a class of an equity security registered under Section 12 of the Exchange Act.&#160;&#160;In general, such persons must file, within 10&#160;days after such acquisition, a report of beneficial ownership with the SEC containing the information prescribed by the regulations under Section&#160;13 of the Exchange Act. This information is also required to be sent to the issuer of the securities and to each exchange where the securities are&#160;traded.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Provisions of Articles and By-laws</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are no provisions in the Articles or By-laws:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delaying or prohibiting a change in control of our company that operate only with respect to a merger, acquisition or corporate restructuring;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">discriminating against any existing or prospective holder of shares as a result of such shareholder owning a substantial number of&#160;shares;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">requiring disclosure of share ownership; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">governing changes in capital, where such provisions are more stringent than those required by&#160;law.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Material Contracts</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have employment contracts with each of our officers as summarized in Item 6B. Other than these employment contracts and the Licensing Agreement described below, we have not entered into any other contract other than in the ordinary course of business over the last two years.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 16, 2017, the Company announced that it had, through its subsidiary, Oncolytics Biotech (Barbados) Inc., entered into the Licensing Agreement with Adlai, a biopharmaceutical company focused on discovering and developing new treatments for cancer and metabolic diseases.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea and Taiwan (the &#8220;Territories&#8221;). Pursuant to the Licensing Agreement, Oncolytics is entitled to receive an upfront payment of approximately US$5.3 million; payment of US$7.9 million upon certain regulatory milestones being achieved; and payment of up to US$65.4 million upon certain clinical, regulatory and commercialization milestones being achieved. Oncolytics is also eligible to receive royalty payments in excess of 10% associated with the commercialization of pelareorep for all indications, subject to regulatory approval.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Licensing Agreement, Adlai will be responsible for all clinical, regulatory and commercialization activities respecting pelareorep in the Territories. Oncolytics will maintain exclusive rights to pelareorep outside of the Territories and will be responsible for all development activities respecting pelareorep outside of the Territories.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In conjunction with the entering into of the Licensing Agreement, the Company and Adlai also entered into a warrant agreement,  on November 16, 2017, pursuant to which the Company issued to Adlai:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a common share purchase warrant (the &#8220;First Warrant&#8221;) entitling Adlai to purchase, for a period of 12 months from the date of the Warrant Agreement, up to US$2 million of common shares (&#8220;Common Shares&#8221;) of the Company, at a price equal to 120% of the five-day weighted average price of the Common Shares on the Toronto Stock Exchange (the &#8220;Principal Market&#8221;, unless the Common Shares begin trading on the Nasdaq Capital Market, in which case the Principal Market shall mean the Nasdaq Capital Market as of the date such trading commences) immediately preceding the exercise date; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a Common Share purchase warrant (the &#8220;Second Warrant&#8221;) entitling Adlai to purchase, for a period of 36 months from the date of the Warrant Agreement, up to US$6 million of Common Shares, at a price equal to 120% of the five-day weighted average price of the Common Shares on the Principal immediately preceding the exercise date.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Warrant Agreement, the Company has the right to require the exercise by Adlai, within five business days of receipt of notice thereof, of:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the First Warrant, upon the later of: (i) six months after the effective date of the Licensing Agreement; and (ii) the date of the enrollment of the first patient in the Global mBC Study (as such term is defined in the Licensing Agreement); and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)  the Second Warrant, upon the date of the enrollment of the fiftieth (50th) patient in the Global mBC Study.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exchange Controls</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canada has no system of exchange controls. There are no Canadian restrictions on the repatriation of capital or earnings of a Canadian public company to non-resident investors. There are no laws in Canada or exchange restrictions affecting the remittance of dividends, profits, interest, royalties and other payments to non-resident holders of our securities, except as discussed below in Section&#160;E,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Taxation</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restrictions on Share Ownership by Non-Canadians</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are no limitations under the laws of Canada or in our organizational documents on the right of foreigners to hold or vote securities of our company, except that the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investment Canada Act</font><font style="font-family:inherit;font-size:10pt;">&#32;(the "Investment Canada Act") may require review and approval by the Minister of Industry (Canada) of certain acquisitions of "control" of our Company by a "non-Canadian."</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investment Canada Act</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Investment Canada Act, transactions exceeding certain financial thresholds, and which involve the acquisition of control of a Canadian business by a non-Canadian, are subject to review and cannot be implemented unless the Minister of Industry and/or, in the case of a Canadian business engaged in cultural activities, the Minister of Canadian Heritage, are satisfied that the transaction is likely to be of "net benefit to Canada". If a transaction is subject to review (a&#160;"Reviewable Transaction"), an application for review must be filed with the Investment Review Division of Industry Canada and/or the Department of Canadian Heritage prior to the implementation of the Reviewable Transaction. The responsible Minister is then required to determine whether the Reviewable Transaction is likely to be of net benefit to Canada taking into account, among other things, certain factors specified in the Investment Canada Act and any written undertakings that may have been given by the applicant. The Investment Canada Act contemplates an initial review period of up to 45&#160;days after filing; however, if the responsible Minister has not completed the review by that date, the Minister may unilaterally extend the review period by up to 30&#160;days (or&#160;such longer period as may be agreed to by the applicant and the Minister) to permit completion of the review. Direct acquisitions of control of most Canadian businesses by or from World Trade Organization ("WTO") investors are reviewable under the Investment Canada Act only if, in the case of an acquisition of voting securities, the value of the worldwide assets of the Canadian business or, in the case of an acquisition of substantially all the assets of a Canadian business, the value of those assets exceed C$295 million for the year 2008 (this figure is adjusted annually to reflect inflation). Indirect acquisitions (e.g., an acquisition of a US corporation with a Canadian subsidiary) of control of such businesses by or from WTO investors are not subject to review, regardless of the value of the Canadian businesses' assets. Significantly lower review thresholds apply where neither the investor nor the Canadian business is WTO investor controlled or where the Canadian business is engaged in uranium mining, certain cultural businesses, financial services or transportation services.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Even if the transaction is not reviewable because it does not meet or exceed the applicable financial threshold, the non-Canadian investor must still give notice to Industry Canada and, in the case of a Canadian business engaged in cultural activities, Canadian Heritage, of its acquisition of control of a Canadian business within 30&#160;days of its implementation.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Competition Act</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Competition Act</font><font style="font-family:inherit;font-size:10pt;">&#32;(Canada) (the&#160;"Competition Act") requires that a pre-merger notification filing be submitted to the Commissioner of Competition (the&#160;"Commissioner") in respect of proposed transactions that exceed certain financial and other thresholds. If a proposed transaction is subject to pre-merger notification, a pre-merger notification filing must be submitted to the Commissioner and a waiting period must expire or be waived by the Commissioner before the transaction may be completed. The parties to a proposed transaction may choose to submit either a short-form filing (in&#160;respect of which there is a 14-day statutory waiting period) or a long-form filing (in&#160;respect of which there is a 42-day statutory waiting period). However, where the parties choose to submit a short-form filing, the Commissioner may, within 14&#160;days, require that the parties submit a long-form filing, in which case the proposed transaction generally may not be completed until 42&#160;days after the long-form filing is submitted by the&#160;parties.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Commissioner may, upon request, issue an advance ruling certificate ("ARC") in respect of a proposed transaction where she is satisfied that she would not have sufficient grounds on which to apply to the Competition Tribunal for an order under the merger provisions of the Competition Act. If the Commissioner issues an ARC in respect of a proposed transaction, the transaction is exempt from the pre-merger notification provisions. In addition, if the transaction to which the ARC relates is substantially completed within one year after the ARC is issued, the Commissioner cannot seek an order of the Competition Tribunal under the merger provisions of the Competition Act in respect of the transaction solely on the basis of information that is the same or substantially the same as the information on the basis of which the ARC was&#160;issued.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Commissioner is unwilling to issue an ARC, she may nevertheless issue a "no action" letter waiving notification and confirming that she is of the view that grounds do not then exist to initiate proceedings before the Competition Tribunal under the merger provisions of the Competition Act with respect to the proposed transaction, while preserving, during the three years following completion of the proposed transaction, her authority to initiate proceedings should circumstances change.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regardless of whether pre-merger notification is required, the Commissioner may apply to the Competition Tribunal (a special purpose tribunal) for an order under the merger provisions of the Competition Act. If the Competition Tribunal finds that the transaction is or is likely to prevent or lessen competition substantially, it may order that the parties not proceed with the transaction or part of it or, in the event that the transaction has already been completed, order its dissolution or the disposition of some of the assets or shares involved. In addition, the Competition Tribunal may, with the consent of the person against whom the order is directed and the Commissioner, order that person to take any other action as is deemed necessary to remedy any substantial lessening or prevention of competition that the Competition Tribunal determines would or would likely result from the transaction.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Taxation </font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a general summary of certain material U.S. federal income tax considerations applicable to a U.S. Holder (as defined below) arising from and relating to the acquisition, ownership and disposition of Common Shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">This summary is for general information purposes only and does not purport to be a complete analysis or listing of all potential U.S. federal income tax considerations that may apply to a U.S. Holder arising from and relating to the acquisition, ownership, and disposition of Common Shares. In addition, this summary does not take into account the individual facts and circumstances of any particular U.S. Holder that may affect the U.S. federal income tax consequences to such U.S. Holder,</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">including, without limitation, specific tax consequences to a U.S. Holder under an applicable income tax treaty. Accordingly, this summary is not intended to be, and should not be construed as, legal or U.S. federal income tax advice with respect to any U.S. Holder. This summary does not address the U.S. federal alternative minimum, U.S. federal net investment income, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences to U.S. Holders of the acquisition, ownership, and disposition of Common Shares. In addition, except as specifically set forth below, this summary does not discuss applicable tax reporting requirements. Each prospective U.S. Holder should consult its own tax advisors regarding the U.S. federal, U.S. federal alternative minimum, U.S. federal net investment income, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership and disposition of Common Shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No legal opinion from U.S. legal counsel or ruling from the Internal Revenue Service (the &#8220;IRS&#8221;) has been requested, or will be obtained, regarding the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.  This summary is not binding on the IRS, and the IRS is not precluded from taking a position that is different from, and contrary to, the positions taken in this summary. In addition, because the authorities on which this summary is based are subject to various interpretations, the IRS and the U.S. courts could disagree with one or more of the conclusions described in this summary.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Scope of this Summary</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Authorities</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This summary is based on the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), Treasury Regulations (whether final, temporary, or proposed), published rulings of the IRS, published administrative positions of the IRS, the Convention Between Canada and the United States of America with Respect to Taxes on Income and on Capital, signed September 26, 1980, as amended (the &#8220;Canada-U.S. Tax Convention&#8221;), and U.S. court decisions that are applicable, and, in each case, as in effect and available, as of the date of this document. Any of the authorities on which this summary is based could be changed in a material and adverse manner at any time, and any such change could be applied retroactively. This summary does not discuss the potential effects, whether adverse or beneficial, of any proposed legislation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">U.S. Holders</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For purposes of this summary, the term "U.S. Holder" means a beneficial owner of Common Shares that is for U.S. federal income tax purposes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:81px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an individual who is a citizen or resident of the United States;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:81px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) organized under the laws of the United States, any state thereof or the District of Columbia;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:81px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an estate whose income is subject to U.S. federal income taxation regardless of its source; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:81px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a trust that (1) is subject to the primary supervision of a court within the U.S. and the control of one or more U.S. persons for all substantial decisions or (2) has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:81px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">U.S. Holders Subject to Special U.S. Federal Income Tax Rules Not Addressed</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This summary does not address the U.S. federal income tax considerations applicable to U.S. Holders that are subject to special provisions under the Code, including, but not limited to, U.S. Holders that: (a) are tax-exempt organizations, qualified retirement plans, individual retirement accounts, or other tax-deferred accounts; (b) are financial institutions, underwriters, insurance companies, real estate investment trusts, or regulated investment companies; (c) are broker-dealers, dealers, or traders in securities or currencies that elect to apply a mark-to-market accounting method; (d) have a &#8220;functional currency&#8221; other than the U.S. dollar; (e) own Common Shares as part of a straddle, hedging transaction, conversion transaction, constructive sale, or other arrangement involving more than one position; (f) acquire Common Shares in connection with the exercise of employee stock options or otherwise as compensation for services; (g) hold Common Shares other than as a capital asset within the meaning of Section 1221 of the Code (generally, property held for investment purposes); (h) are required to accelerate the recognition of any item of gross income with respect to Common Shares as a result of such income being recognized on an applicable financial statement; or (i) own, have owned or will own (directly, indirectly, or by attribution) 10% or more of the total combined voting power or value of the outstanding shares of the Company. This summary also does not address the U.S. federal income tax considerations applicable to U.S. Holders who are: (a) U.S. expatriates or former long-term residents of the U.S.; (b) persons that have been, are, or will be a resident or deemed to be a resident in Canada for purposes of the Income Tax Act (Canada) (the &#8220;Tax Act&#8221;); (c) persons that use or hold, will use or hold, or that are or will be deemed to use or hold Common Shares in connection with carrying on a business in Canada; (d) persons whose Common Shares constitute &#8220;taxable Canadian property&#8221; under the Tax Act; or (e) persons that have a permanent establishment in Canada for the purposes of the Canada-U.S. Tax Convention. U.S. Holders that are subject to special provisions under the Code, including, but not limited to, U.S. Holders described immediately above, should consult their own tax advisors regarding the U.S. federal, U.S. federal alternative minimum, U.S. federal net investment income, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership and disposition of Common Shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an entity or arrangement that is classified as a partnership (or other &#8220;pass-through&#8221; entity) for U.S. federal income tax purposes holds Common Shares, the U.S. federal income tax consequences to such entity or arrangement and the partners (or other owners or participants) of such entity or arrangement generally will depend on the activities of the entity or arrangement and the status of such partners (or owners or participants). This summary does not address the tax consequences to any such partner (or owner or participants). Partners (or other owners or participants) of entities or arrangements that are classified as partnerships or as &#8220;pass-through&#8221; entities for U.S. federal income tax purposes should consult their own tax advisors regarding the U.S. federal income tax consequences arising from and relating to the acquisition, ownership and disposition of Common Shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Passive Foreign Investment Company Rules</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">PFIC Status of the Company</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company were to constitute a &#8220;passive foreign investment company&#8221; under the meaning of Section 1297 of the Code (a &#8220;PFIC&#8221;, as defined below) for any year during a U.S. Holder&#8217;s holding period, then certain potentially adverse rules would affect the U.S. federal income tax consequences to a U.S. Holder as a result of the acquisition, ownership and disposition of Common Shares. The Company believes that it was classified as a PFIC during the tax year ended December 31, 2019, and based on current business plans and financial expectations, the Company expects that it will be a PFIC for the current tax year and may be a PFIC in future tax years. No opinion of legal counsel or ruling from the IRS concerning the status of the Company as a PFIC has been obtained or is currently planned to be requested. The determination of whether any corporation was, or will be, a PFIC for a tax year depends, in part, on the application of complex U.S. federal income tax rules, which are subject to differing interpretations. In addition, whether any corporation will be a PFIC for any tax year depends on the assets and income of such corporation over the course of each such tax year and, as a result, cannot be predicted with certainty as of the date of this document. Accordingly, there can be no assurance that the IRS will not challenge any determination made by the Company (or any subsidiary of the Company) concerning its PFIC status. Each U.S. Holder should consult its own tax advisors regarding the PFIC status of the Company and each subsidiary of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In any year in which the Company is classified as a PFIC, a U.S. Holder will be required to file an annual report with the IRS containing such information as Treasury Regulations and/or other IRS guidance may require. In addition to penalties, a failure to satisfy such reporting requirements may result in an extension of the time period during which the IRS can assess a tax. U.S. Holders should consult their own tax advisors regarding the requirements of filing such information returns under these rules, including the requirement to file an IRS Form 8621 annually.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company generally will be a PFIC if, for a tax year, (a) 75% or more of the gross income of the Company is passive income (the &#8220;PFIC income test&#8221;) or (b) 50% or more of the value of the Company&#8217;s assets either produce passive income or are held for the production of passive income, based on the quarterly average of the fair market value of such assets (the &#8220;PFIC asset test&#8221;).  &#8220;Gross income&#8221; generally includes all sales revenues less the cost of goods sold, plus income from investments and from incidental or outside operations or sources, and &#8220;passive income&#8221; generally includes, for example, dividends, interest, certain rents and royalties, certain gains from the sale of stock and securities, and certain gains from commodities transactions.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For purposes of the PFIC income test and PFIC asset test described above, if the Company owns, directly or indirectly, 25% or more of the total value of the outstanding shares of another corporation, the Company will be treated as if it (a) held a proportionate share of the assets of such other corporation and (b) received directly a proportionate share of the income of such other corporation.  In addition, for purposes of the PFIC income test and PFIC asset test described above, and assuming certain other requirements are met, &#8220;passive income&#8221; does not include certain interest, dividends, rents, or royalties that are received or accrued by the Company from certain &#8220;related persons&#8221; (as defined in Section 954(d)(3) of the Code) also organized in Canada, to the extent such items are properly allocable to the income of such related person that is not passive income.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under certain attribution rules, if the Company is a PFIC, U.S. Holders will generally be deemed to own their proportionate share of the Company&#8217;s direct or indirect equity interest in any company that is also a PFIC (a &#8216;&#8216;Subsidiary PFIC&#8217;&#8217;), and will generally be subject to U.S. federal income tax on their proportionate share of (a) any &#8220;excess distributions,&#8221; as described below, on the stock of a Subsidiary PFIC and (b) a disposition or deemed disposition of the stock of a Subsidiary PFIC by the Company or another Subsidiary PFIC, both as if such U.S. Holders directly held the shares of such Subsidiary PFIC. In addition, U.S. Holders may be subject to U.S. federal income tax on any indirect gain realized on the stock of a Subsidiary PFIC on the sale or disposition of Common Shares. Accordingly, U.S. Holders should be aware that they could be subject to tax under the PFIC rules even if no distributions are received and no redemptions or other dispositions of Common Shares are made.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Default PFIC Rules Under Section 1291 of the Code</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company is a PFIC for any tax year during which a U.S. Holder owns Common Shares, the U.S. federal income tax consequences to such U.S. Holder of the acquisition, ownership, and disposition of Common Shares will depend on whether and when such U.S. Holder makes an election to treat the Company and each Subsidiary PFIC, if any, as a &#8220;qualified electing fund&#8221; or &#8220;QEF&#8221; under Section 1295 of the Code (a &#8220;QEF Election&#8221;) or makes a mark-to-market election under Section 1296 of the Code (a &#8220;Mark-to-Market Election&#8221;). A U.S. Holder that does not make either a QEF Election or a Mark-to-Market Election will be referred to in this summary as a &#8220;Non-Electing U.S. Holder.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A Non-Electing U.S. Holder will be subject to the rules of Section 1291 of the Code (described below) with respect to (a) any gain recognized on the sale or other taxable disposition of Common Shares and (b) any &#8220;excess distribution&#8221; received on the Common Shares. A distribution generally will be an &#8220;excess distribution&#8221; to the extent that such distribution (together with all other distributions received in the current tax year) exceeds 125% of the average distributions received during the three preceding tax years (or during a U.S. Holder&#8217;s holding period for the Common Shares, if shorter).</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under Section 1291 of the Code, any gain recognized on the sale or other taxable disposition of Common Shares (including an indirect disposition of the stock of any Subsidiary PFIC), and any &#8220;excess distribution&#8221; received on Common Shares or with respect to the stock of a Subsidiary PFIC, must be ratably allocated to each day in a Non-Electing U.S. Holder&#8217;s holding period for the respective Common Shares. The amount of any such gain or excess distribution allocated to the tax year of disposition or distribution of the excess distribution and to years before the entity became a PFIC, if any, would be taxed as ordinary income (and not eligible for certain preferred rates). The amounts allocated to any other tax year would be subject to U.S. federal income tax at the highest tax rate applicable to ordinary income in each such year, and an interest charge would be imposed on the tax liability for each such year, calculated as if such tax liability had been due in each such year. A Non-Electing U.S. Holder that is not a corporation must treat any such interest paid as &#8220;personal interest,&#8221; which is not deductible.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company is a PFIC for any tax year during which a Non-Electing U.S. Holder holds Common Shares, the Company will continue to be treated as a PFIC with respect to such Non-Electing U.S. Holder, regardless of whether the Company ceases to be a PFIC in one or more subsequent tax years. A Non-Electing U.S. Holder may terminate this deemed PFIC status by electing to recognize gain (which will be taxed under the rules of Section 1291 of the Code discussed above), but not loss, as if such Common Shares were sold on the last day of the last tax year for which the Company was a PFIC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">QEF Election</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder that makes a timely and effective QEF Election for the first tax year in which the holding period of its Common Shares begins generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to its Common Shares. A U.S. Holder that makes a timely and effective QEF Election will be subject to U.S. federal income tax on such U.S. Holder&#8217;s pro rata share of (a) the net capital gain of the Company, which will be taxed as long-term capital gain to such U.S. Holder, and (b) the ordinary earnings of the Company, which will be taxed as ordinary income to such U.S. Holder. Generally, &#8220;net capital gain&#8221; is the excess of (a) net long-term capital gain over (b) net short-term capital loss, and &#8220;ordinary earnings&#8221; are the excess of (a) &#8220;earnings and profits&#8221; over (b) net capital gain. A U.S. Holder that makes a QEF Election will be subject to U.S. federal income tax on such amounts for each tax year in which the Company is a PFIC, regardless of whether such amounts are actually distributed to such U.S. Holder by the Company. However, for any tax year in which the Company is a PFIC and has no net income or gain, U.S. Holders that have made a QEF Election would not have any income inclusions as a result of the QEF Election. If a U.S. Holder that made a QEF Election has an income inclusion, such a U.S. Holder may, subject to certain limitations, elect to defer payment of current U.S. federal income tax on such amounts, subject to an interest charge. If such U.S. Holder is not a corporation, any such interest paid will be treated as &#8220;personal interest,&#8221; which is not deductible.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder that makes a timely and effective QEF Election with respect to the Company generally (a) may receive a tax-free distribution from the Company to the extent that such distribution represents &#8220;earnings and profits&#8221; of the Company that were previously included in income by the U.S. Holder because of such QEF Election and (b) will adjust such U.S. Holder&#8217;s tax basis in the Common Shares to reflect the amount included in income or allowed as a tax-free distribution because of such QEF Election. In addition, a U.S. Holder that makes a QEF Election generally will recognize capital gain or loss on the sale or other taxable disposition of Common Shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The procedure for making a QEF Election, and the U.S. federal income tax consequences of making a QEF Election, will depend on whether such QEF Election is timely. A QEF Election will be treated as &#8220;timely&#8221; if such QEF Election is made for the first year in the U.S. Holder&#8217;s holding period for the Common Shares in which the Company was a PFIC. A U.S. Holder may make a timely QEF Election by filing the appropriate QEF Election documents at the time such U.S. Holder files a U.S. federal income tax return for such year. If a U.S. Holder does not make a timely and effective QEF Election for the first year in the U.S. Holder&#8217;s holding period for the Common Shares, the U.S. Holder may still be able to make a timely and effective QEF Election in a subsequent year if such U.S. Holder meets certain requirements and makes a &#8220;purging&#8221; election to recognize gain (which will be taxed under the rules of Section 1291 of the Code discussed above) as if such Common Shares were sold for their fair market value on the day the QEF Election is effective. If a U.S. Holder makes a QEF Election but does not make a &#8220;purging&#8221; election to recognize gain as discussed in the preceding sentence, then such U.S. Holder shall be subject to the QEF Election rules and shall continue to be subject to tax under the rules of Section 1291 discussed above with respect to its Common Shares.  If a U.S. Holder owns PFIC stock indirectly through another PFIC, separate QEF Elections must be made for the PFIC in which the U.S. Holder is a direct shareholder and the Subsidiary PFIC for the QEF rules to apply to both PFICs. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A QEF Election will apply to the tax year for which such QEF Election is timely made and to all subsequent tax years, unless such QEF Election is invalidated or terminated or the IRS consents to revocation of such QEF Election. If a U.S. Holder makes a QEF Election and, in a subsequent tax year, the Company ceases to be a PFIC, the QEF Election will remain in effect (although it will not be applicable) during those tax years in which the Company is not a PFIC. Accordingly, if the Company becomes a PFIC in another subsequent tax year, the QEF Election will be effective and the U.S. Holder will be subject to the QEF rules described above during any subsequent tax year in which the Company qualifies as a PFIC.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Corporation: (a) will make available to U.S. Holders, upon their written request, information as to its status as a PFIC and the PFIC status of any subsidiary in which the Corporation owns more than 50% of such subsidiary&#8217;s total aggregate voting power and (b) for each year in which the Corporation is a PFIC, provide to a U.S. Holder, upon written request, such information and documentation that a U.S. Holder making a QEF Election with respect to the Corporation and such more than 50% owned subsidiary which constitutes a PFIC is reasonably required to obtain for U.S. federal income tax purposes. The Corporation may elect to provide such information on its website. With respect to any Subsidiary PFIC in which the Corporation owns 50% or less of the aggregate voting power, upon the written request of a U.S. Holder acquiring Common Shares, the Corporation will request that such Subsidiary PFIC provide such U.S. Holder with the information that such U.S. Holder requires to report under the QEF rules; provided, however, the Corporation can provide no assurances that such Subsidiary PFIC will provide such information.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder makes a QEF Election by attaching a completed IRS Form 8621, including a PFIC Annual Information Statement, to a timely filed United States federal income tax return. However, if the Company does not provide the required information with regard to the Company or any of its Subsidiary PFICs, U.S. Holders will not be able to make a QEF Election for such entity and will continue to be subject to the rules of Section 1291 of the Code discussed above that apply to Non-Electing U.S. Holders with respect to the taxation of gains and excess distributions. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Mark-to-Market Election</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder may make a Mark-to-Market Election only if the Common Shares are marketable stock. The Common Shares generally will be &#8220;marketable stock&#8221; if the Common Shares are regularly traded on (a) a national securities exchange that is registered with the Securities and Exchange Commission, (b) the national market system established pursuant to section 11A of the U.S. Exchange Act, or (c) a foreign securities exchange that is regulated or supervised by a governmental authority of the country in which the market is located, provided that (i) such foreign exchange has trading volume, listing, financial disclosure, and surveillance requirements, and meets other requirements and the laws of the country in which such foreign exchange is located, together with the rules of such foreign exchange, ensure that such requirements are actually enforced and (ii) the rules of such foreign exchange effectively promote active trading of listed stocks.  If such stock is traded on such a qualified exchange or other market, such stock generally will be &#8220;regularly traded&#8221; for any calendar year during which such stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter.  Provided that the Common Shares are &#8220;regularly traded&#8221; as described in the preceding sentence, the Common Shares are expected to be marketable stock.  However, each U.S. Holder should consult its own tax advisor in this matter.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder that makes a Mark-to-Market Election with respect to its Common Shares generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to such Common Shares.  However, if a U.S. Holder does not make a Mark-to-Market Election beginning in the first tax year of such U.S. Holder&#8217;s holding period for the Common Shares for which the Company is a PFIC and such U.S. Holder has not made a timely QEF Election, the rules of Section&#160;1291 of the Code discussed above will apply to certain dispositions of, and distributions on, the Common Shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder that makes a Mark-to-Market Election will include in ordinary income, for each tax year in which the Company is a PFIC, an amount equal to the excess, if any, of (a) the fair market value of the Common Shares, as of the close of such tax year over (b) such U.S. Holder&#8217;s adjusted tax basis in such Common Shares.  A U.S. Holder that makes a Mark-to-Market Election will be allowed a deduction in an amount equal to the excess, if any, of (a) such U.S. Holder&#8217;s adjusted tax basis in the Common Shares, over (b) the fair market value of such Common Shares (but only to the extent of the net amount of previously included income as a result of the Mark-to-Market Election for prior tax years).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder that makes a Mark-to-Market Election generally also will adjust such U.S. Holder&#8217;s tax basis in the Common Shares to reflect the amount included in gross income or allowed as a deduction because of such Mark-to-Market Election.  In addition, upon a sale or other taxable disposition of Common Shares, a U.S. Holder that makes a Mark-to-Market Election will recognize ordinary income or ordinary loss (not to exceed the excess, if any, of (a) the amount included in ordinary income because of such Mark-to-Market Election for prior tax years over (b) the amount allowed as a deduction because of such Mark-to-Market Election for prior tax years).  Losses that exceed this limitation are subject to the rules generally applicable to losses provided in the Code and Treasury Regulations. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder makes a Mark-to-Market  Election by attaching a completed IRS Form 8621 to a timely filed United States federal income tax return.  A Mark-to-Market Election applies to the tax year in which such Mark-to-Market Election is made and to each subsequent tax year, unless the Common Shares cease to be &#8220;marketable stock&#8221; or the IRS consents to revocation of such election.  Each U.S. Holder should consult its own tax advisors regarding the availability of, and procedure for making, a Mark-to-Market Election.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although a U.S. Holder may be eligible to make a Mark-to-Market Election with respect to the Common Shares, no such election may be made with respect to the stock of any Subsidiary PFIC that a U.S. Holder is treated as owning, because such stock is not marketable.  Hence, the Mark-to-Market Election will not be effective to avoid the application of the default rules of Section 1291 of the Code described above with respect to deemed dispositions of Subsidiary PFIC stock or excess distributions from a Subsidiary PFIC to its shareholder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other PFIC Rules</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under Section 1291(f) of the Code, the IRS has issued proposed Treasury Regulations that, subject to certain exceptions, would cause a U.S. Holder that had not made a timely QEF Election to recognize gain (but not loss) upon certain transfers of Common Shares that would otherwise be tax-deferred (e.g., gifts and exchanges pursuant to corporate reorganizations).  However, the specific U.S. federal income tax consequences to a U.S. Holder may vary based on the manner in which Common Shares are transferred.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain additional adverse rules may apply with respect to a U.S. Holder if the Company is a PFIC, regardless of whether such U.S. Holder makes a QEF Election.  For example, under Section 1298(b)(6) of the Code, a U.S. Holder that uses Common Shares as security for a loan will, except as may be provided in Treasury Regulations, be treated as having made a taxable disposition of such Common Shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Special rules also apply to the amount of foreign tax credit that a U.S. Holder may claim on a distribution from a PFIC.  Subject to such special rules, foreign taxes paid with respect to any distribution in respect of stock in a PFIC are generally eligible for the foreign tax credit.  The rules relating to distributions by a PFIC and their eligibility for the foreign tax credit are complicated, and a U.S. Holder should consult with its own tax advisors regarding the availability of the foreign tax credit with respect to distributions by a PFIC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The PFIC rules are complex, and each U.S. Holder should consult its own tax advisors regarding the PFIC rules and how the PFIC rules may affect the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">General Rules Applicable to the Ownership and Disposition of Common Shares</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following discussion describes the general rules applicable to the ownership and disposition of the Common Shares but is subject in its entirety to the special rules described above under the heading &#8220;Passive Foreign Investment Company Rules.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Distributions on Common Shares</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A U.S. Holder that receives a distribution, including a constructive distribution, with respect to a Common Share will be required to include the amount of such distribution in gross income as a dividend (without reduction for any Canadian income tax withheld from such distribution) to the extent of the current and accumulated &#8220;earnings and profits&#8221; of the Company, as computed for U.S. federal income tax purposes.  A dividend generally will be taxed to a U.S. Holder at ordinary income tax rates if the Company is a PFIC for the tax year of such distribution or the preceding tax year.  To the extent that a distribution exceeds the current and accumulated &#8220;earnings and profits&#8221; of the Company, such distribution will be treated first as a tax-free return of capital to the extent of a U.S. Holder's tax basis in the Common Shares and thereafter as gain from the sale or exchange of such Common Shares.  (See &#8220;Sale or Other Taxable Disposition of Common Shares&#8221; below).  However, the Company may not maintain the calculations of its earnings and profits in accordance with U.S. federal income tax principles, and each U.S. Holder may have to assume that any distribution by the Company with respect to the Common Shares will constitute ordinary dividend income.  Dividends received on Common Shares by corporate U.S. Holders generally will not be eligible for the &#8220;dividends received deduction.&#8221;  Subject to applicable limitations and provided the Company is eligible for the benefits of the Canada-U.S. Tax Convention or the Common Shares are readily tradable on a United States securities market, dividends paid by the Company to non-corporate U.S. Holders, including individuals, generally will be eligible for the preferential tax rates applicable to long-term capital gains for dividends, provided certain holding period and other conditions are satisfied, including that the Company not be classified as a PFIC in the tax year of distribution or in the preceding tax year.  The dividend rules are complex, and each U.S. Holder should consult its own tax advisors regarding the application of such rules.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Sale or Other Taxable Disposition of Common Shares</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the sale or other taxable disposition of Common Shares, a U.S. Holder generally will recognize capital gain or loss in an amount equal to the difference between the U.S. dollar value of cash received plus the fair market value of any property received and such U.S. Holder's tax basis in such Common Shares sold or otherwise disposed of.  A U.S. Holder&#8217;s tax basis in Common Shares generally will be such holder&#8217;s U.S. dollar cost for such Common Shares.  Gain or loss recognized on such sale or other </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disposition generally will be long-term capital gain or loss if, at the time of the sale or other disposition, the Common Shares have been held for more than one year.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferential tax rates currently apply to long-term capital gain of a U.S. Holder that is an individual, estate, or trust.  There are currently no preferential tax rates for long-term capital gain of a U.S. Holder that is a corporation.  Deductions for capital losses are subject to significant limitations under the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Additional Considerations</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Receipt of Foreign Currency</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amount of any distribution paid to a U.S. Holder in foreign currency, or on the sale, exchange or other taxable disposition of Common Shares, generally will be equal to the U.S. dollar value of such foreign currency based on the exchange rate applicable on the date of receipt (regardless of whether such foreign currency is converted into U.S. dollars at that time).  A U.S. Holder will have a basis in the foreign currency equal to its U.S. dollar value on the date of receipt.  Any U.S. Holder who converts or otherwise disposes of the foreign currency after the date of receipt may have a foreign currency exchange gain or loss that would be treated as ordinary income or loss, and generally will be U.S. source income or loss for foreign tax credit purposes.  Different rules apply to U.S. Holders who use the accrual method of tax accounting.  Each U.S. Holder should consult its own U.S. tax advisors regarding the U.S. federal income tax consequences of receiving, owning, and disposing of foreign currency.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Foreign Tax Credit</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to the PFIC rules discussed above, a U.S. Holder that pays (whether directly or through withholding) Canadian income tax with respect to dividends paid on the Common Shares generally will be entitled, at the election of such U.S. Holder, to receive either a deduction or a credit for such Canadian income tax.  Generally, a credit will reduce a U.S. Holder&#8217;s U.S. federal income tax liability on a dollar-for-dollar basis, whereas a deduction will reduce a U.S. Holder&#8217;s income that is subject to U.S. federal income tax.  This election is made on a year-by-year basis and applies to all foreign taxes paid (whether directly or through withholding) by a U.S. Holder during a year.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The foreign tax credit rules are complex and involve the application of rules that depend on a U.S. Holder&#8217;s particular circumstances.  Accordingly, each U.S. Holder should consult its own U.S. tax advisors regarding the foreign tax credit rules.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Backup Withholding and Information Reporting</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under U.S. federal income tax law, certain categories of U.S. Holders must file information returns with respect to their investment in, or involvement in, a foreign corporation.  For example, U.S. return disclosure obligations (and related penalties) are imposed on individuals who are U.S. Holders that hold certain specified foreign financial assets in excess of certain thresholds.  The definition of specified foreign financial assets includes not only financial accounts maintained in foreign financial institutions, but also, unless held in accounts maintained by a financial institution, any stock or security issued by a non-U.S. person, any financial instrument or contract held for investment that has an issuer or counterparty other than a U.S. person and any interest in a foreign entity.  U.S. Holders may be subject to these reporting requirements unless their Common Shares are held in an account at certain financial institutions.  Penalties for failure to file certain of these information returns are substantial.  U.S. Holders should consult with their own tax advisors regarding the requirements of filing information returns, including the requirement to file an IRS Form 8938.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments made within the U.S., or by a U.S. payor or U.S. middleman, of dividends on, and proceeds arising from the sale or other taxable disposition of, Common Shares will generally be subject to information reporting and backup withholding tax if a U.S. Holder (a) fails to furnish such U.S. Holder&#8217;s correct U.S. taxpayer identification number (generally on Form W-9), (b) furnishes an incorrect U.S. taxpayer identification number, (c) is notified by the IRS that such U.S. Holder has previously failed to properly report items subject to backup withholding tax, or (d) fails to certify, under penalty of perjury, that such U.S. Holder has furnished its correct U.S. taxpayer identification number and that the IRS has not notified such U.S. Holder that it is subject to backup withholding tax.  However, certain exempt persons generally are excluded from these information reporting and backup withholding rules.  Backup withholding is not an additional tax.  Any amounts withheld under the U.S. backup withholding tax rules will be allowed as a credit against a U.S. Holder&#8217;s U.S. federal income tax liability, if any, or will be refunded, if such U.S. Holder furnishes required information to the IRS in a timely manner.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The discussion of reporting requirements set forth above is not intended to constitute a complete description of all reporting requirements that may apply to a U.S. Holder.  A failure to satisfy certain reporting requirements may result in an extension of the time period during which the IRS can assess a tax and, under certain circumstances, such an extension may apply to assessments </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of amounts unrelated to any unsatisfied reporting requirement.  Each U.S. Holder should consult its own tax advisors regarding the information reporting and backup withholding rules.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">THE ABOVE SUMMARY IS NOT INTENDED TO CONSTITUTE A COMPLETE ANALYSIS OF ALL TAX CONSIDERATIONS APPLICABLE TO U.S. HOLDERS WITH RESPECT TO THE ACQUISITION, OWNERSHIP, AND DISPOSITION OF COMMON SHARES.  U.S. HOLDERS SHOULD CONSULT THEIR OWN TAX ADVISORS AS TO THE TAX CONSIDERATIONS APPLICABLE TO THEM IN THEIR OWN PARTICULAR CIRCUMSTANCES.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">F.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dividends and Paying Agents</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">G.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Statements by Experts</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">H.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Documents on Display</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to the informational requirements of the Exchange Act and file reports and other information with the SEC. The SEC maintains a Website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC at https://www.sec.gov. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are required to file reports and other information with the securities commissions in Canada. You are invited to read and copy any reports, statements or other information, other than confidential filings, that we file with the provincial securities commissions. These filings are also electronically available from the Canadian System for Electronic Document Analysis and Retrieval ("SEDAR") (https://www.sedar.com), the Canadian equivalent of the SEC's electronic document gathering and retrieval system.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We "incorporate by reference" information that we file with the SEC, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this Form&#160;20-F and&#160;more recent information automatically updates and supersedes more dated information contained or incorporated by reference in this Form&#160;20-F.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the furnishing and content of proxy statements to shareholders.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will provide without charge to each person, including any beneficial owner, to whom a copy of this annual report has been delivered, on the written or oral request of such person, a copy of any or all documents referred to above which have been or may be incorporated by reference in this annual report (not&#160;including exhibits to such incorporated information that are not specifically incorporated by reference into such information). Requests for such copies should be directed to us at the following address: Oncolytics Biotech Inc., 210 &#8211; 1167 Kensington Crescent, NW, Calgary, Alberta, Canada, T2N 1X7, Attention:&#160;&#160;Kirk Look.&#160;&#160;Telephone (403) 670 - 7377. Facsimile (403)&#160;283-0858 EMAIL: info@oncolyticsbiotech.com.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">I.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsidiary Information</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sDCDC4EED1A47539D8CE93366FFCD8580"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 11.&#160;&#160; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Foreign Currency Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate primarily in Canada, the US, the U.K. and Europe.&#160;Therefore, we are exposed to foreign currency risk associated with our expenses outside of Canada.&#160;&#160;We do not use financial derivative instruments to manage this market risk.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Rate Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The primary objective of our policy for the investment of temporary cash surpluses is the protection of principal, and, accordingly, we generally invest in investment-grade debt securities with varying maturities.&#160;&#160;As it is our intent and policy to hold these investments until maturity, we do not have a material exposure to interest rate risk.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not currently have any long-term debt, nor do we currently utilize interest rate swap contracts to hedge against interest rate&#160;risk.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not use financial instruments for trading purposes and are not parties to any leverage derivatives.&#160;We do not currently engage in hedging transactions.&#160;See &#8220;Currency and Exchange Rates&#8221;, Item 4 &#8211; &#8220;Information on the Company&#8221; and Note 17 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments </font><font style="font-family:inherit;font-size:10pt;">in our audited consolidated financial statements</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s350674D56DED5214822CD60B8C5C3C2F"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 12.&#160;&#160; DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Debt Securities</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants and Rights</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Securities</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">American Depository Shares</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s Common Shares are not represented by American Depository Receipts.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sB31B653F45555A9BB8026CAA7C12DBA6"></a></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s7A040EF07988525E928BED348D34E5F2"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 13.&#160; &#160;DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s98EA3F770D625C5E8672E8B6010E5FB9"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 14.&#160;&#160; MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Modification of Instruments Defining Rights of Security Holders</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Modification or Issuance of Other Class of Securities</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Withdrawal or Substitution of Security</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Change of Trustee or Paying Agent</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">None</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Proceeds</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s6088320C08FE57C1868BB56667D74C87"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 15.&#160;&#160;CONTROLS AND PROCEDURES</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Evaluation of Disclosures and Procedures</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is the conclusion of our Chief Executive Officer and Chief Financial Officer that our Company's disclosure controls and procedures (as defined in Exchange Act rules 13a-15(e) and 15d-15(e)), based on their evaluation of these controls and procedures as of the end of the period covered by this annual report, are effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms, and that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Management's Annual Report on Internal Control Over Financial Reporting</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. As defined in Exchange Act Rule 13a-15(f), internal control over financial reporting is a process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer and effected by the board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with International Reporting Standards as issued by the International Accounting Standards Board ("IFRS"), and includes those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with  IFRS, and that receipts and expenditures of the Company are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management, including the Company&#8217;s Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, 2013 Framework, (COSO) in Internal Control-Integrated Framework.&#160;&#160;Based on this assessment, management believes that, as of December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s internal control over financial reporting was effective based on those criteria.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Attestation Report of the Registered Public Accounting Firms</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with Securities and Exchange Commission&#8217;s rules regarding non-accelerated filers, this Annual Report does not include an attestation report of the Company's independent registered public accounting firm regarding the Company's internal control over financial reporting.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in Internal Controls over Financial Reporting</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no changes in our internal controls over financial reporting that occurred during the period that is covered by this annual report that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sA63A095625F354BC9DE1600DFCEB7FAE"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16 .&#160; [RESERVED]</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s91841F7658B05717AE9A47E36AE37B3E"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16A.&#160; AUDIT COMMITTEE FINANCIAL EXPERT</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Board has determined that each of the Audit Committee members, Angela Holtham, Wayne Pisano, Deborah Brown and Leonard Kruimer is an audit committee financial expert and each is independent pursuant to the Rule 5605(d)(2) of the Nasdaq Capital Market and Rule 10A-3 of the Exchange Act.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s255B92B8DAEA53BDBA040AB60B49E92C"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16B.&#160; CODE OF ETHICS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Board of Directors has adopted a Code of Ethics for our Chief Executive Officer, Chief Financial Officer and Accounting Officer that applies to our Chief Executive Officer, Chief Financial Officer and Controller.&#160;&#160;A copy of this Code of Ethics may be found on the Company&#8217;s website at https://www.oncolyticsbiotech.com.&#160;&#160;Requests for such copies should be directed to us at the following address: Oncolytics Biotech Inc., 210 &#8211; 1167 Kensington Crescent, NW, Calgary, Alberta, Canada, T2N 1X7, Attention:&#160;&#160;Kirk Look &#160;Telephone (403) 670 - 7377. Facsimile (403)&#160;283-0858 EMAIL: info@oncolyticsbiotech.com.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no amendments to our Code of Ethics during the fiscal year ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">.  We did not grant any waivers to the provisions of our Code of Ethics during the fiscal year ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sD163E2760EAF5ECC81C1E5E562110F30"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16C.&#160; PRINCIPAL ACCOUNTANT FEES AND SERVICES</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Audit Fees and Services</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the financial years ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">, Ernst &amp; Young LLP received the following fees:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:245px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:133px;"></td><td style="width:51px;"></td><td style="width:4px;"></td><td style="width:51px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Audit fees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">374,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Audit-related fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax fees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,752</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,646</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All other fees</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Audit Fees</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Audit fees were for professional services rendered by Ernst &amp; Young, LLP for the audit of our annual financial statements and services provided in connection with statutory and regulatory filings or engagements, including review of interim financial statements, accounting consultations, assistance with prospectus filings and matters relating to the provision of a consent letter for various filings.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Audit-Related Fees</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Audit-related fees were for assurance and related services reasonably related to the performance of the audit or review of the annual statements and are not reported under the heading Audit Fees above.&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Tax Fees</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax fees were for tax return preparations, scientific research and development return and other tax consultation fees.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">All Other Fees</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other fees are for products and services other than those described under the headings Audit Fees, Audit-Related Fees and Tax Fees above.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Audit Committee pre-approves all audit services to be provided to us by our independent auditors. The Audit Committee&#8217;s policy regarding the pre-approval of non-audit services to be provided to us by our independent auditors is that all such services shall be pre-approved by the Audit Committee or by the Chair of the Audit Committee, who must report all such pre-approvals to the Audit Committee at their next meeting following the granting thereof. Non-audit services that are prohibited to be provided to us by our independent auditors may not be pre-approved. In addition, prior to the granting of any pre-approval, the Audit Committee or the Chair, as the case may be, must be satisfied that the performance of the services in question will not compromise the independence of the independent auditors.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sA1C8CA2F2F8C54849C946EA1995A1AB9"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s7FFA744CEC9453098254B033B7F463B6"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16E. PURCHASE OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASES</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s2AE932C7648757929FB2897404DF4C73"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16F.&#160; CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s1717B8C6E4AF51DE97DA6BC10078377B"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16G. CORPORATE GOVERNANCE</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NASDAQ CORPORATE GOVERNANCE</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our common shares are quoted for trading on the Nasdaq Capital Market. Section 5615(a)(3) of the Nasdaq Marketplace Rules permits the Nasdaq to grant exemptions to a foreign private issuer for the provisions of the Rule 5600 series, Rule 5250 (d), and Rules 5210(c) and 5255 related to qualitative listing requirements. We are organized under the laws of the Province of Alberta and our common shares are listed for trading on The Toronto Stock Exchange. We comply with the laws of the Province of Alberta and rules and regulations of The Toronto Stock Exchange, including rules related to corporate governance practices. A description of the significant ways in which our governance practices differ from those followed by domestic companies pursuant to the Nasdaq Marketplace Rules is as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Shareholder Meeting Quorum Requirement</font><font style="font-family:inherit;font-size:10pt;">: The Nasdaq minimum quorum requirement for a shareholder meeting under Section 5620(c) of the Nasdaq Marketplace Rules is one-third of the outstanding shares of common stock. In addition, a company listed on Nasdaq is required to state our quorum requirement in our bylaws.  Our quorum requirement is set forth in our corporate bylaws. A quorum for our shareholder meeting is two persons present and being, or representing by proxy, members holding not less than 5% of the issued shares entitled to be voted at such meeting.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The foregoing is consistent with the laws, customs and practices in Canada and the rules of The Toronto Stock Exchange.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s5AE244C3A18F5E568504976629D16036"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16H.&#160; MINE SAFETY DISCLOSURE</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s385DC572B5FC57F7ACD8FE3B86A97CF6"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s3AD9F5C3BC4F5334BE9FC58A6C1B8B8D"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 17. FINANCIAL STATEMENTS.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sBFEC7325B7A6512082EBEF97739FCED5"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 18 FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial statements appear on pages F-1 through F-29.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><a name="s992A5DE7829550238022B796652F0256"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 19. EXHIBITS. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following exhibits are filed as part of this annual report:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:15%;"></td><td style="width:85%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;">EXHIBIT</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;text-decoration:underline;">NUMBER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">DESCRIPTION</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Constating Documents</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Articles of Incorporation</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By-laws</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Securities</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex21exhibitdescriptionofse.htm"><font style="font-family:inherit;font-size:10pt;">Description of Securities Registered Under Section 12 of the Exchange Act</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Material Contracts</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1*</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex41august2013hagerman.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement, dated August 1, 2013 between Oncolytics Biotech Inc. and its Director, Manufacturing and Engineering, Allison Hagerman</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2*</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex42hagermandec2015.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated December 1, 2015 between Oncolytics Biotech Inc. and its Director, Manufacturing and Engineering, Allison Hagerman</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.3*</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex43moorejan2017.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement, dated January 31, 2017 between Oncolytics Biotech (U.S.) Inc. and its Vice President, Investor Relations and Communications, Michael Moore</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)*</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992818000028/ex443deguttadauro.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement, dated June 29, 2017 between Oncolytics Biotech (U.S.) Inc. and its President, Andrew de Guttadauro</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.5</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)#</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992818000028/ex444regionallicensingagre.htm"><font style="font-family:inherit;font-size:10pt;">License, development, supply and distribution agreement with Adlai Nortye Biopharma Co., Ltd dated November 14, 2017 </font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.6*</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex46november2018laeufle.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement, dated November 1, 2018 between Oncolytics Biotech (U.S.) Inc. and its Chief Medical Officer, Rita Laeufle</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.7</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">*</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex47hagermanamendment2019.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated January 1, 2019 between Oncolytics Biotech Inc. and its Vice President, Product Development, Allison Hagerman</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.8</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">*</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex48kirklook2019.htm"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated January 1, 2019 between Oncolytics Biotech Inc. and its Chief Financial Officer, Kirk Look</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.9*</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex49coffey2019.htm"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement, dated January 1, 2019 between Oncolytics Biotech Inc. and its Chief Executive Officer, Matthew Coffey</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.10*</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex410guttadauroamendment20.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated January 1, 2020 between Oncolytics Biotech (U.S.) Inc. and its President, Andrew de Guttadauro</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.11*</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex411mooreamendment2020.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated January 1, 2020 between Oncolytics Biotech (U.S.) Inc. and its Vice President, Investor Relations and Communications, Michael Moore</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.12*</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex412lauefleamendment2020.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated January 1, 2020 between Oncolytics Biotech (U.S.) Inc. and its Chief Medical Officer, Rita Laeufle</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.13*</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex413hagermanamendment2020.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated January 1, 2020 between Oncolytics Biotech Inc. and its Vice President, Product Development, Allison Hagerman</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.14*</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex414lookamendment2020.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated January 1, 2020 between Oncolytics Biotech Inc. and its Chief Financial Officer, Kirk Look</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.15*</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex415coffeyamendment2020.htm"><font style="font-family:inherit;font-size:10pt;">Amending Agreement, dated January 1, 2020 between Oncolytics Biotech Inc. and its Chief Executive Officer, Matthew Coffey</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsidiaries</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.0</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex80subsidiaries2019.htm"><font style="font-family:inherit;font-size:10pt;">List of subsidiaries</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certifications</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.1</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex121ceocertfication2019.htm"><font style="font-family:inherit;font-size:10pt;">Certificate of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.2</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex122cfocertification2019.htm"><font style="font-family:inherit;font-size:10pt;">Certificate of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.1</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex131ceocertification2019.htm"><font style="font-family:inherit;font-size:10pt;">Certificate of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.2</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex132cfocertification2019.htm"><font style="font-family:inherit;font-size:10pt;">Certificate of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Exhibits</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.1</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex151-2019mda.htm"><font style="font-family:inherit;font-size:10pt;">The Registrant's Management's Discussion and Analysis for the Year Ended December 31, 2019</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.2</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex152eyconsentletter2019.htm"><font style="font-family:inherit;font-size:10pt;">Consent of Ernst &amp; Young LLP</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.1</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interactive Data Files (XBRL-Related Documents)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">* - Denotes management contract or agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"># - Certain portions of this exhibit have been redacted pursuant to a confidential treatment request filed with the SEC on March 19, 2018</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Previously filed with the SEC on Form 20-F dated June 14, 2002.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Previously filed with the SEC on Form 20-F dated March 19, 2018.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div><a name="sE72D1CF35DE751F69B6B054834D99E61"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURE</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;6, 2020</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">/s/ Matthew Coffey&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">/s/&#160;Kirk Look&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Matthew Coffey, PhD, MBA&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk Look, CA</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><a name="s829D1A942E155F61A9828CFCD43D5801"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Consolidated Financial Statements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Oncolytics Biotech</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;color:#000000;text-decoration:none;">2018</font></div><div><br></div><hr style="page-break-after:always"><div><a name="sEA03677C878C50C1BC98DCDC07467B31"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STATEMENT OF MANAGEMENT&#8217;S RESPONSIBILITY</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management is responsible for the preparation and presentation of the consolidated financial statements, Management&#8217;s Discussion and Analysis (&#8220;MD&amp;A&#8221;) and all other information in the Annual Report.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In management&#8217;s opinion, the accompanying consolidated financial statements have been properly prepared within reasonable limits of materiality and in accordance with the appropriately selected International Financial Reporting Standards as issued by the International Accounting Standards Board consistently applied and summarized in the consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements include estimates that are necessary when transactions affecting the current accounting period cannot be finalized with certainty until after the balance sheet date.&#160;Based on careful judgments by management, such estimates have been properly reflected in the accompanying consolidated financial statements.&#160;The financial information presented elsewhere in the Annual Report has been reviewed to ensure consistency with that in the consolidated financial statements. The MD&amp;A also includes information regarding the impact of current transactions and events, sources of liquidity and capital resources and risks and uncertainty.&#160;Actual results in the future may differ materially from our present assessment of this information because future events and circumstances may not occur as expected.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Systems of internal controls, including organizational and procedural controls and internal controls over financial reporting, assessed as reasonable and appropriate in the circumstances, are designed and maintained by management to provide reasonable assurance that assets are safeguarded from loss or unauthorized use and to produce reliable records for preparation of financial statements. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ernst &amp; Young LLP, an independent firm of Charter Professional Accountants, has been engaged, as approved by a vote of the shareholders' at the Company's most recent Annual General Meeting, to audit and provide their independent audit opinions on the Company's consolidated financial statements as at and for the year ended December 31, 2019.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ernst &amp; Young have full and free access to our Board of Directors and its Committees to discuss audit, financial reporting and related matters.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Board of Directors is responsible for ensuring that management fulfills its responsibilities for financial reporting and internal control.&#160;The Board exercises this responsibility through the Audit Committee of the Board, which is comprised entirely of independent directors.&#160;This Committee meets with management and the external auditors to satisfy itself that management&#8217;s responsibilities are properly discharged and to review the consolidated financial statements and MD&amp;A before they are presented to the Board of Directors for approval. The consolidated financial statements have been approved by the Board on the recommendation of the Audit Committee.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/&#160;&#160;Matthew Coffey&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;/s/&#160;&#160;Kirk Look&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Matthew Coffey, PhD, MBA&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk Look, CA</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-1</font></div></div><hr style="page-break-after:always"><div><a name="s2E49BBC5966D51D590BED6E4DC67678B"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">To the Board of Directors and Shareholders of Oncolytics Biotech Inc.: </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Opinion on the Consolidated Financial Statements</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have audited the accompanying consolidated statements of financial position of Oncolytics Biotech Inc. (the &#8220;Company&#8221;) as of December 31, 2019 and 2018, the related consolidated statements of loss, comprehensive loss, shareholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2019, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as at December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019, in conformity with International Financial Reporting Standards (IFRSs) as issued by the International Accounting Standards Board.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis for Opinion</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have served as the Company's auditor since 1999.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:48%;"></td><td style="width:52%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="eysignaturea25.jpg" alt="eysignaturea25.jpg" style="height:73px;width:230px;"></div></td><td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:81px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Calgary, Canada</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;5, 2020</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-2</font></div></div><hr style="page-break-after:always"><div><a name="s156CB791997C557E99F5B3E972C0497B"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:536px;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:304px;"></td><td style="width:40px;"></td><td style="width:91px;"></td><td style="width:4px;"></td><td style="width:91px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14,148,021</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,699,881</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,068,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,713,591</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">700,986</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total current assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18,930,384</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,452,517</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">296,768</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">412,736</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Right-of-use assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">3, 7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">430,713</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total non-current assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">727,481</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">412,736</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19,657,865</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865,253</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liabilities And Shareholders&#8217; (Deficit) Equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Current Liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,173,218</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,825,853</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">927,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">3, 13</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">847,215</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,322</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">3, 7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">339,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant derivative</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8,508,764</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12,869,043</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,814,575</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,730,287</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,802,887</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,428</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">3, 7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">166,429</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total non-current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,896,716</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,855,315</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19,765,759</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,669,890</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Commitments and contingencies</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">13, 14 and 19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shareholders&#8217; (deficit) equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share capital<br>&#160;&#160;Authorized: unlimited<br>&#160;&#160;Issued: December 31, 2019 &#8211; 32,198,453  <br>  December 31, 2018 &#8211; 17,399,749  </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">311,077,859</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,193,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,617,570</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,570</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contributed surplus</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">29,338,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,260,613</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">464,101</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">607,504</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(344,606,273</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(311,483,385</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Total shareholders&#8217; (deficit) equity</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(107,894</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,195,363</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Total liabilities and shareholders' (deficit) equity</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19,657,865</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865,253</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes</font></div><div style="line-height:120%;text-align:left;padding-left:30px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:65.234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:47%;"></td><td style="width:53%;"></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;On behalf of the Board:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Angela Holtham</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Wayne Pisano</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Director&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Director&#160;&#160;&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-3</font></div></div><hr style="page-break-after:always"><div><a name="sA9C59FC4F3DE52459B6F1854755F19D0"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:657px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:314px;"></td><td style="width:65px;"></td><td style="width:84px;"></td><td style="width:4px;"></td><td style="width:90px;"></td><td style="width:4px;"></td><td style="width:90px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the years ending December 31,</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">10, 21, 22</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11,134,716</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,417,888</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,392,623</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Operating</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">10, 21, 22</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9,558,641</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,244,791</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,212,831</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss before the following</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(20,693,357</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,662,679</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,605,454</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Change in fair value of warrant derivative</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(12,608,808</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Interest income, net</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">179,277</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173,496</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130,101</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss before income taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(33,122,888</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,489,183</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,475,353</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(548,042</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(141,498</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(33,122,888</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,037,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,616,851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other comprehensive (loss) income items that may be<br>  reclassified to net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Translation adjustment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(143,403</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,774</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(180,330</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(33,266,291</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,803,451</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,797,181</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basic and diluted loss per common share</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">11</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1.50</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.06</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.12</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Weighted average number of shares (basic and diluted)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">22,137,990</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,016,366</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,936,387</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:60px;text-indent:-36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-4</font></div></div><hr style="page-break-after:always"><div><a name="s876C5AF2906E5986BD173B4F00758717"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CHANGES IN (DEFICIT) EQUITY</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:923px;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:312px;"></td><td style="width:62px;"></td><td style="width:82px;"></td><td style="width:4px;"></td><td style="width:83px;"></td><td style="width:4px;"></td><td style="width:76px;"></td><td style="width:4px;"></td><td style="width:100px;"></td><td style="width:4px;"></td><td style="width:99px;"></td><td style="width:4px;"></td><td style="width:79px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Capital<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contributed Surplus<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Other Comprehensive Income<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Deficit<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:normal;">As at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,321,825</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,643,044</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">554,060</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(278,829,309</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,689,620</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss and other comprehensive loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(180,330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,616,851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,797,181</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to stock option plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">536,949</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(193,509</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343,440</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" Agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,348,821</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,348,821</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to public offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,893,600</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,511,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">578,703</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">578,703</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,391,057</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,391,057</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:normal;">As at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,710,138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,028,238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">373,730</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(294,446,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,283,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss and other comprehensive income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,774</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,037,225</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,803,451</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" Agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">620,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">620,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to public offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,606,882</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,606,882</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to Common Stock Purchase Agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,314,097</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,314,097</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to stock option plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,245</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(73,707</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123,538</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to incentive share award plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,751</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(109,751</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to warrant agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(330</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,417</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,415,833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,415,833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,366,809</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,366,809</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,193,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,260,613</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">607,504</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(311,483,385</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,195,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss and other comprehensive income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(143,403</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,122,888</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,266,291</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to incentive share award plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,917</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(391,917</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to Common Stock Purchase Agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,403,385</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,403,385</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" Agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,476,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,476,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to public offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,314,429</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,314,429</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to warrant derivative exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">8, 9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,152,869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,152,869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,470,153</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,470,153</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(854,256</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(854,256</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">311,077,859</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,617,570</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">29,338,849</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">464,101</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(344,606,273</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(107,894</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-5</font></div></div><hr style="page-break-after:always"><div><a name="s3FBE3C7DF362524A84F17A17B22025A2"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:647px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:313px;"></td><td style="width:66px;"></td><td style="width:84px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the years ending December 31,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss for the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(33,122,888</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,037,225</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,616,851</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation - property and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">122,982</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,768</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation - right-of-use assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">362,592</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">10, 21, 22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,470,153</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,415,833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">578,703</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense on lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">94,817</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized foreign exchange gain</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">353,189</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(374,337</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(124,793</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Onerous lease contract</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,588</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization - lease incentive liability</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,189</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of warrant derivative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12,608,808</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net change in non-cash working capital</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">18</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1,795,777</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,904,339</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180,855</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash used in operating activities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(19,906,124</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,920,238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,891,318</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investing Activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition of property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(10,905</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(107,466</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(105,765</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redemption of short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,088,800</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash (used in) provided by investing activities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(10,905</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(107,466</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,983,035</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financing Activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123,538</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343,440</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from exercise of warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">8, 9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,465,867</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,417</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from Common Stock Purchase Agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5,360,247</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,533,980</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from "At the Market" equity distribution  agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8,131,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">451,675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,103,166</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from public offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,505,359</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,188,526</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,366,098</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of lease liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(447,497</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash provided by financing activities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">21,015,596</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,299,136</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,812,704</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase (decrease) in cash</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,098,567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,271,432</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(95,579</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13,699,881</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,836,119</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,034,282</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impact of foreign exchange on cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(650,427</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">592,330</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(102,584</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and cash equivalents, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14,148,021</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,699,881</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,836,119</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-6</font></div></div><hr style="page-break-after:always"><div><a name="s3DF416F1C09B51E487B8ACC392027B9E"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s8E73F4A5A1495EEB8E691AFA5D70EED0"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 1: Incorporation and Nature of Operations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oncolytics Biotech Inc. was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd.  On April 8, 1998, we changed our name to Oncolytics Biotech Inc.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our consolidated financial statements for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;5, 2020</font><font style="font-family:inherit;font-size:10pt;">. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Markets and the Toronto Stock Exchange. Our registered office is located at 210, 1167 Kensington Crescent NW, Calgary, Alberta, Canada.   </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. Our lead product, pelareorep, is a potential immuno-oncology viral-agent that may be a novel treatment for certain types of cancer and may be an alternative to or in combination with existing cytotoxic or cytostatic therapies. Our clinical development program for pelareorep emphasizes three programs: chemotherapy combinations to assist the escape of the virus from the vasculature and enhance its distribution in the tumor; immuno-therapy combinations to create an inflamed phenotype promoting synergies with immune checkpoint inhibitors; and immune modulator/targeted combinations to upregulate natural killer cells promoting synergies with targeted therapies. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sFBE25279E2AC521CA08E600FA7146C63"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 2: Basis of Financial Statement Presentation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our consolidated financial statements include our financial statements and the financial statements of our subsidiaries Oncolytics Biotech (Barbados) Inc., Oncolytics Biotech (US) Inc., and Oncolytics Biotech (UK) Ltd. and are presented in Canadian dollars, our functional currency.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accounts are prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of consolidation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our accounts include the accounts of Oncolytics Biotech Inc. and our subsidiaries. Subsidiaries are entities over which we have control which is achieved when we are exposed, or have the rights, to variable returns from our involvement with the investee and has the ability to affect those returns through our power to govern. Accounting policies of subsidiaries are consistent with our accounting policies and all intra-group transactions, balances, income and expenses are eliminated on consolidation.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A change in ownership interest of a subsidiary, without a change in control, is accounted for as an equity transaction.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s82D60253EB445091B2E474B2C8A83BAA"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 3: Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements have, in management's opinion, been properly prepared within reasonable limits of materiality and within the framework of the significant accounting policies summarized below.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Deferred income taxes</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We follow the liability method of accounting for income taxes.  Under the liability method, deferred income taxes are recognized for the difference between financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences).  Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled.  The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.  </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Financial instruments </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Classification and measurement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial assets</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under IFRS 9 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments ("IFRS 9")</font><font style="font-family:inherit;font-size:10pt;">, financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#8217;s business model for managing the assets; and whether the financial asset&#8217;s contractual cash flows represent &#8216;solely payments of principal and interest&#8217; on the principal amount outstanding (the &#8216;SPPI criterion&#8217;). </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial assets include cash and cash equivalents and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion. </font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial liabilities</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include trade accounts payable, other liabilities and warrant derivative. The classification and measurement of trade accounts payable and other liabilities are at amortized cost. The classification and measurement of warrant derivative is at FVPL.  </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under IFRS 9, accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IFRS 9 requires that we record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#8217;s original effective interest rate.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Derecognition</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A financial asset is derecognized when:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the contractual rights to the cash flows from the financial asset expire, or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A financial liability is derecognized when our obligations specified in the contract are discharged or canceled or expired. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments we prioritize the related inputs used in measuring fair value into the following hierarchy: </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Foreign currency translation</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exceptions to this are where the monetary items form part of the net investment in a foreign operation and the foreign operation's functional currency is the local currency.  These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.  </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Loss per common share</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per common share is determined using the weighted average number of common shares outstanding during the period.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the treasury stock method to calculate diluted loss per common share.  Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants, if dilutive. The number of additional common shares is calculated by assuming that any outstanding &#8220;in the money&#8221; options, restricted share units, performance share units and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Property and equipment </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives.  Depreciation is recorded using the declining balance method at the following annual rates:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.40350877192983%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:49%;"></td><td style="width:51%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office equipment and furniture</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Straight-line over the term of the lease</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At inception of a contract, we assess whether a contract is, or contains a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the contract involves the use of an identified asset;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we have the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we have the right to direct the use of the identified asset. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A right-of-use asset and corresponding lease liability is recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Research and development costs</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the treatment phase of clinical trials based on the total estimated cost of the treatment phase on a per patient basis and we expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized.  To date, all development costs have been expensed. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Revenue recognition</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The contract also provides for development and regulatory milestone payments, royalties and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract receivable</font><font style="font-family:inherit;font-size:10pt;">&#32;- Contract receivable includes amounts billed and currently due from customers. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts. We perform a review of our customer&#8217;s credit risk and payment histories, including payments made subsequent to year-end.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract liability</font><font style="font-family:inherit;font-size:10pt;">&#32;- Our contract liability includes upfront license fees and billings in excess of revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or noncurrent based on the timing of when we expect to recognize revenue.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Share based payments </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock option plan</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;stock option plan (the &#8220;Option Plan&#8221;) available to officers, directors, employees and consultants with grants under the Option Plan approved from time to time by our Board of Directors (the &#8220;Board&#8221;). Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines. Vesting is provided for at the discretion of the Board and the expiration of options is to be no greater than </font><font style="font-family:inherit;font-size:10pt;">10 years</font><font style="font-family:inherit;font-size:10pt;">&#32;from the date of grant. Exercised stock options are settled with common shares issued from treasury. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the fair value based method of accounting for stock option awards granted under the Option Plan.  We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black- Scholes valuation model. The fair value of stock options with a graded vesting schedule is determined based on different expected lives for the options that vest each year, as it would be if the award were viewed as several separate awards, each with a different vesting date, and it is accounted for over the respective vesting period taking into consideration forfeiture estimates.   Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of options that are expected to vest.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Incentive share award plan</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our incentive share award plan (the "Share Plan") is available to directors, officers and employees. Under our Share Plan, performance share units and restricted share units may be approved from time to time by the Board. Performance share units  ("PSUs") are an award to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share units ("RSUs") are an award to certain officers and employees and to non-employee directors to which common shares shall be issued in accordance with the Share Plan.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the date of grant based on the number of PSUs/RSUs expected to vest, recognized over the term of the vesting period. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Adoption of New Accounting Standards</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IFRS 16 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IFRS 16 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;IFRS 16&#8221;) replaces IAS 17 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;IAS 17&#8221;) and related interpretations for annual periods beginning on or after January 1, 2019. We have adopted IFRS 16 using the modified retrospective approach, under which the cumulative effect of the initial application is recognized in retained earnings at January 1, 2019. We have not restated comparatives for 2018. On transition to IFRS 16, we elected to apply the following practical expedients: </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Applied the exemption for short-term leases that have a remaining lease term of less than 12 months as at January 1, 2019; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Excluded initial direct costs for the measurement of right-of-use assets as at January 1, 2019; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Relied upon our assessment of whether leases are onerous under the requirement of IAS 37, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Provisions, contingent liabilities and contingent assets</font><font style="font-family:inherit;font-size:10pt;">&#32;as at December 31, 2018 as an alternative to reviewing our right-of-use assets for impairment; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Measured the right-of-use assets at an amount equal to the lease liability, adjusted by the amount of lease incentive liability related to that lease recognized in the statement of financial position immediately before the date of initial application. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On transition to IFRS 16, we recognized </font><font style="font-family:inherit;font-size:10pt;">$882,437</font><font style="font-family:inherit;font-size:10pt;">&#32;of lease liabilities. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate at January 1, 2019 as rates implicit in the leases were not readily determinable. The weighted-average rate applied was </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the impacts of adopting IFRS 16 on the consolidated financial statements:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:40%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Impact of changes</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported as at December 31, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Effects of IFRS 16 transition</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent to transition as at January 1, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Right-of-use assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current and non-current assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865,253</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865,253</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865,253</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,673,278</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,750</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(74,412</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,338</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">882,437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">882,437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current and non-current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,556,140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,556,140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,669,890</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,477,915</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total shareholders' equity</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,195,363</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,195,363</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to adopting IFRS 16, our total minimum operating lease commitments as at December 31, 2018 were </font><font style="font-family:inherit;font-size:10pt;">$961,575</font><font style="font-family:inherit;font-size:10pt;">. The difference between the total of the minimum lease payments set out in Note 11 of our 2018 annual consolidated financial statements and the total lease liabilities recognized on transition was a result of the effect of discounting on the minimum lease payments.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s1F03A39BCC9857AA90A044D606F4ACDE"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 4:  Significant Judgments, Estimates and Assumptions</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Judgments</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of our consolidated financial statements requires us to make judgments, estimates and assumptions that affect the reported amount of expenses, assets, liabilities, and the disclosure of contingent liabilities, at the end of the reporting period.  However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Estimates and assumptions</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates and such differences could be significant. Significant estimates made by management affecting our consolidated financial statements include:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue recognition</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered into a Licensing Agreement which provides, among other payments, for upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress towards completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Valuation of share based payments </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimating fair value for stock options granted requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility, dividend yield, and forfeiture rate and making assumptions about them. The assumptions and  inputs used for estimating fair value for stock options granted are disclosed in Note 10. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Valuation of warrant derivative </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimating fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period requires determining the most appropriate valuation model. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility and dividend yield, and making assumptions about them. The assumptions and  inputs used for estimating fair value of the warrant derivative are disclosed in Note 8.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income taxes</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income.  Currently, we are accumulating tax loss carry forward balances in various tax jurisdictions creating a deferred tax asset. Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date we have determined that none of our deferred tax assets should be recognized. Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable investment tax credits. These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries. As well, there are no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We make judgments in determining whether a contract contains an identified asset. The identified asset should be physically distinct or represent substantially all of the capacity of the asset, and should provide us with the right to substantially all of the economic benefits from the use of the asset.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also make judgments in determining whether or not we have the right to control the use of the identified asset. We have that right when we have the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In cases where the decisions about how and for what purpose the asset is used are predetermined, we have the right to direct the use of the asset if we have the right to operate the asset or if we designed the asset in a way that predetermines how and for what purpose the asset will be used.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We make judgments in determining the incremental borrowing rate used to measure our lease liability for each lease contract, including an estimate of the asset-specific security impact. The incremental borrowing rate should reflect the interest that we would have to pay to borrow at a similar term and with a similar security.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sD6C089FC07225DDF933EA05B57BECD47"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 5: Cash Equivalents </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Equivalents</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents consist of interest bearing deposits with our bank totaling $</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">13,058,092</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$9,977,409</font><font style="font-family:inherit;font-size:10pt;">).&#160;&#160;The current annual interest rate earned on these deposits is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.17%</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2.71%</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s4CDE9CAFBD3D540C89C47600B38D9614"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 6: Property and Equipment</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:164px;"></td><td style="width:80px;"></td><td style="width:4px;"></td><td style="width:87px;"></td><td style="width:4px;"></td><td style="width:79px;"></td><td style="width:4px;"></td><td style="width:76px;"></td><td style="width:4px;"></td><td style="width:90px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Computer Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Office Furniture</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Office Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Leasehold Improvements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,870</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">681,985</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">225,896</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">534,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,729,517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions, net of foreign exchange impact</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,202</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,542</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,763</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,163</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174,670</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposals</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(424,246</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85,096</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(646,834</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,378</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">345,941</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">247,438</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,229</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">498,367</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,257,353</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions, net of foreign exchange impact</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposals</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,378</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">352,955</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">247,438</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,229</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">498,367</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,264,367</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,334</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">549,564</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147,334</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,787</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">476,057</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,396,076</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,622</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,041</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,662</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposals</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,492</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(424,246</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85,096</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(646,834</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,464</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174,953</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,749</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">414,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">844,617</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,244</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,093</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,668</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,342</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,635</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,982</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposals</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,708</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224,046</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,417</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,170</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">448,258</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">967,599</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net book value</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15,670</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">128,909</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">75,021</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27,059</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">50,109</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">296,768</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,914</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170,988</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,689</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,401</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,744</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">412,736</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s6ece86dc374b4620a6fa45fb81c5b18e"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 7: Leases</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our portfolio of leases consists of office spaces with lease terms generally between </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">&#32;years. We currently do not have leases with variable lease payments, residual value guarantees, extension or termination options, or leases not yet commenced to which we are committed.  Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate as rates implicit in the leases were not readily determinable. The weighted-average rate applied was </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Right-of-use assets</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:374px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:301px;"></td><td style="width:68px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Office Spaces</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at January 1, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(362,592</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange impact</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,720</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">430,713</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Lease liabilities</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:372px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:298px;"></td><td style="width:68px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Office Spaces</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at January 1, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">882,437</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of lease liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(447,497</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense on lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,817</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange impact</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">506,275</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our total undiscounted lease liability as at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.94736842105263%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:69%;"></td><td style="width:30%;"></td><td style="width:1%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Maturity analysis - contractual undiscounted cash flows</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less than one year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One to five years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174,157</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">More than five years</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total undiscounted lease liability as at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">565,179</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sd2cad3952f444b9cbb79effd5c26bfa4"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 8: Warrant Derivative</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 16, 2019, pursuant to an underwritten public offering, </font><font style="font-family:inherit;font-size:10pt;">4,619,773</font><font style="font-family:inherit;font-size:10pt;">&#32;units were sold at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">US$0.81</font><font style="font-family:inherit;font-size:10pt;">&#32;per unit for gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">US$3,742,016</font><font style="font-family:inherit;font-size:10pt;">. Each unit included </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;common share and </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;common share purchase warrant (see Note 9). Each common share purchase warrant entitled the holder to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;common share at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">US$0.90</font><font style="font-family:inherit;font-size:10pt;">&#32;until August 16, 2024. We incurred transaction costs of </font><font style="font-family:inherit;font-size:10pt;">$699,427</font><font style="font-family:inherit;font-size:10pt;">&#32;of which </font><font style="font-family:inherit;font-size:10pt;">$466,284</font><font style="font-family:inherit;font-size:10pt;">&#32;were allocated to share issue costs and </font><font style="font-family:inherit;font-size:10pt;">$233,143</font><font style="font-family:inherit;font-size:10pt;">&#32;were allocated to operating expenses, based on their relative fair values.   </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under IFRS 9 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments</font><font style="font-family:inherit;font-size:10pt;">&#32;and IAS 32 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments: Presentation</font><font style="font-family:inherit;font-size:10pt;">, warrants with an exercise price denominated in a currency that differs from an entity's functional currency are treated as a derivative measured at fair value with subsequent changes in fair value accounted for through profit and loss. Our warrants with an exercise price of </font><font style="font-family:inherit;font-size:10pt;">US$0.90</font><font style="font-family:inherit;font-size:10pt;">&#32;meet this requirement and we have presented the fair value of these warrants as a current liability on the consolidated statement of financial position. As these warrants are exercised, the fair value at the date of exercise and the associated non-cash liability will be included in our share capital along with the proceeds from the exercise. If these warrants expire, the non-cash warrant liability is reversed through the consolidated statement of loss. There is no cash flow impact as a result of the accounting treatment for changes in the fair value of the warrant derivative or when warrants expire unexercised. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the change in fair value of the warrant derivative is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:513px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:258px;"></td><td style="width:122px;"></td><td style="width:4px;"></td><td style="width:123px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Warrants Outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value of Warrant Derivative<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued, August 16, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,619,773</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,657,214</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,935,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,687,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,608,808</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange impact</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(70,255</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,684,126</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,508,764</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2019, we received cash proceeds of US</font><font style="font-family:inherit;font-size:10pt;">$2,642,082</font><font style="font-family:inherit;font-size:10pt;">&#32;with respect to the warrants exercised. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the Black-Scholes valuation model to estimate fair value. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on U.S. Department </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of Treasury benchmark treasury yield rates with an approximate equivalent remaining term in effect at the time of valuation and the expected life represents the estimated length of time the warrants are expected to remain outstanding. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of the warrant derivative was determined using the following assumptions: </font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:455px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:273px;"></td><td style="width:90px;"></td><td style="width:90px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">August&#160;16, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value per warrant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US$3.89</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US$0.27</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Underlying share price</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US$4.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US$0.54</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.59%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.42%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected hold period to exercise</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.0 year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.0 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected share price volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90.00%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82.00%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s4E7C861443BB559CB890186DE5E0D69B"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 9: Share Capital</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Authorized:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unlimited number of no par value common shares</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Consolidation:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 22, 2018, we completed the consolidation of our common shares on the basis of </font><font style="font-family:inherit;font-size:10pt;">9.5</font><font style="font-family:inherit;font-size:10pt;">&#32;pre-consolidation common shares for each one post-consolidation common share (the "Share Consolidation"). Fractional interests were rounded down to the nearest whole number of common shares. Outstanding stock options, restricted share units and performance share units were similarly adjusted by the consolidation ratio. Outstanding warrants were adjusted such that, following the Share Consolidation, </font><font style="font-family:inherit;font-size:10pt;">9.5</font><font style="font-family:inherit;font-size:10pt;">&#32;equity-classified warrants will entitle the holder to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;whole common share until June 1, 2022.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:665px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:293px;"></td><td style="width:88px;"></td><td style="width:4px;"></td><td style="width:88px;"></td><td style="width:4px;"></td><td style="width:88px;"></td><td style="width:4px;"></td><td style="width:88px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued:</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121,258,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,321,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to stock option plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">801,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">536,949</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,301,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,348,821</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to public offering</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,893,600</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,391,057</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,805,722</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,710,138</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">519,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,335</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to stock option plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, May 22, 2018 - pre-consolidation</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,396,222</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272,268,722</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, May 22, 2018 - post-consolidation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,988,995</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272,268,722</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to public offering</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,532,278</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,606,882</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to warrant agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to stock option plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,329</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">158,976</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to incentive share award plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,297</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,751</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to Common Stock Purchase Agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(d)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">797,691</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,314,097</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(e)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,360</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,333,474</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,399,749</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,193,061</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,443,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,570</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to incentive share award plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">323,301</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,917</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to Common Stock Purchase Agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(d)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,494,943</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,403,385</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(e)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,425,040</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,476,454</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to public offering</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(f)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,619,773</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,314,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to warrant derivative exercised</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(f)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,935,647</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,152,869</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(854,256</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance, December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">32,198,453</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">311,077,859</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16,443,500</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,617,570</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 25, 2016, we entered into an "at-the-market" ("ATM") equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to </font><font style="font-family:inherit;font-size:10pt;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;which allows us to sell our common shares through the facilities of the Toronto Stock Exchange or other "marketplace&#8221; (as defined in National Instrument 21-101 Marketplace Operation) in Canada (our "Canadian ATM"). Subject to the terms of our Canadian ATM, we are able to determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility. During 2018, we sold </font><font style="font-family:inherit;font-size:10pt;">519,500</font><font style="font-family:inherit;font-size:10pt;">&#32;pre-consolidation shares (approximately </font><font style="font-family:inherit;font-size:10pt;">54,684</font><font style="font-family:inherit;font-size:10pt;">&#32;post-consolidation shares) (2017 - </font><font style="font-family:inherit;font-size:10pt;">3,301,500</font><font style="font-family:inherit;font-size:10pt;">&#32;pre-consolidation shares (approximately </font><font style="font-family:inherit;font-size:10pt;">347,526</font><font style="font-family:inherit;font-size:10pt;">&#32;post-consolidation shares) common shares for gross proceeds of $</font><font style="font-family:inherit;font-size:10pt;">553,650</font><font style="font-family:inherit;font-size:10pt;">&#32;(2017 - $</font><font style="font-family:inherit;font-size:10pt;">2,348,821</font><font style="font-family:inherit;font-size:10pt;">). We incurred share issue costs of $</font><font style="font-family:inherit;font-size:10pt;">33,335</font><font style="font-family:inherit;font-size:10pt;">&#32;(2017 - </font><font style="font-family:inherit;font-size:10pt;">$245,655</font><font style="font-family:inherit;font-size:10pt;">).</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 1, 2017, pursuant to an underwritten public offering, </font><font style="font-family:inherit;font-size:10pt;">16,445,000</font><font style="font-family:inherit;font-size:10pt;">&#32;units were sold at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$0.70</font><font style="font-family:inherit;font-size:10pt;">&#32;per unit for gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$11,511,500</font><font style="font-family:inherit;font-size:10pt;">.  Each unit included </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;pre-consolidation common share with an ascribed value of </font><font style="font-family:inherit;font-size:10pt;">$0.48</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">0.106</font><font style="font-family:inherit;font-size:10pt;">&#32;post-consolidation common share with an ascribed value of </font><font style="font-family:inherit;font-size:10pt;">$4.56</font><font style="font-family:inherit;font-size:10pt;">) and </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;pre-consolidation common share purchase warrant with an ascribed value of </font><font style="font-family:inherit;font-size:10pt;">$0.22</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;post-consolidation common share purchase warrant with an ascribed value of </font><font style="font-family:inherit;font-size:10pt;">$2.09</font><font style="font-family:inherit;font-size:10pt;">). These warrants were classified as equity. Each pre-consolidation common share purchase warrant entitled the holder to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;pre-consolidation common share at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.95</font><font style="font-family:inherit;font-size:10pt;">. Following the Share Consolidation, </font><font style="font-family:inherit;font-size:10pt;">9.5</font><font style="font-family:inherit;font-size:10pt;">&#32;pre-consolidation common share purchase warrants entitles the holder to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;post-consolidation common share in the capital of the Company until June 1, 2022, at an exercise price of approximately </font><font style="font-family:inherit;font-size:10pt;">$9.025</font><font style="font-family:inherit;font-size:10pt;">. The post-consolidation common share purchase warrants will be subject to acceleration if the volume weighted average price of the Company's common shares equals or exceeds </font><font style="font-family:inherit;font-size:10pt;">$23.75</font><font style="font-family:inherit;font-size:10pt;">&#32;for </font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;">&#32;consecutive trading dates.  The ascribed value was determined using the relative fair value method. The ascribed value of the common share purchase warrants was determined using the Black-Scholes valuation model. We incurred share issue costs of </font><font style="font-family:inherit;font-size:10pt;">$1,145,402</font><font style="font-family:inherit;font-size:10pt;">. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 5, 2018, pursuant to an underwritten public offering, </font><font style="font-family:inherit;font-size:10pt;">1,532,278</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares were sold at a purchase price of US</font><font style="font-family:inherit;font-size:10pt;">$5.83</font><font style="font-family:inherit;font-size:10pt;">&#32;per share for gross proceeds of US</font><font style="font-family:inherit;font-size:10pt;">$8,933,181</font><font style="font-family:inherit;font-size:10pt;">. We incurred share issue costs of </font><font style="font-family:inherit;font-size:10pt;">$1,418,356</font><font style="font-family:inherit;font-size:10pt;">.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 27, 2018, we entered into a Common Stock Purchase Agreement (the "Agreement") with Lincoln Park Capital Fund, LLC ("LPC"). Subject to the terms and conditions of the Agreement and at our sole discretion, we may sell up to US$</font><font style="font-family:inherit;font-size:10pt;">26,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;worth of common shares to LPC over the </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">-month term. The purchase price of the common shares will be based on the prevailing market prices immediately preceding the notice of sale without any fixed discount. Subject to the terms of the Agreement, we control the timing and amount of any future investment and LPC is obligated to make such purchases, if and when we elect. The Agreement does not impose any upper price limit restrictions, negative covenants or restrictions on our future financing activities. However, in no event will shares be sold to LPC on a day the closing sale price for the common shares is less than the floor price of US</font><font style="font-family:inherit;font-size:10pt;">$1.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per common share; or at a price per share that is less than the volume weighted average trading pricing of the common shares on the TSX for the five immediately preceding trading days, less the maximum applicable discount allowed by the TSX. The Agreement limits our sale of common shares to </font><font style="font-family:inherit;font-size:10pt;">19.99%</font><font style="font-family:inherit;font-size:10pt;">&#32;of our total outstanding common shares as at the date that the Common Stock Purchase Agreement was entered into, unless and until we have obtained shareholder approval under applicable Nasdaq rules. </font><font style="font-family:inherit;font-size:10pt;">As at December 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we have reached that limit. We can terminate the Agreement at any time at our sole discretion without any monetary cost or penalty. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, we sold </font><font style="font-family:inherit;font-size:10pt;">2,477,665</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">678,182</font><font style="font-family:inherit;font-size:10pt;">) common shares for gross proceeds of US</font><font style="font-family:inherit;font-size:10pt;">$4,055,725</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- US</font><font style="font-family:inherit;font-size:10pt;text-transform:default;">$2,055,207</font><font style="font-family:inherit;font-size:10pt;">) and issued </font><font style="font-family:inherit;font-size:10pt;text-transform:default;">17,278</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;text-transform:default;">119,509</font><font style="font-family:inherit;font-size:10pt;">) commitment shares. The commitment shares were fair valued at US</font><font style="font-family:inherit;font-size:10pt;">$29,758</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- US</font><font style="font-family:inherit;font-size:10pt;">$483,690</font><font style="font-family:inherit;font-size:10pt;">) and were recorded as share issue costs in addition to cash share issue costs of </font><font style="font-family:inherit;font-size:10pt;">$3,757</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">$208,726</font><font style="font-family:inherit;font-size:10pt;">).  </font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allows us, at our sole discretion, to issue common shares, at prevailing market price, with an aggregate offering value of up to US</font><font style="font-family:inherit;font-size:10pt;">$30,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;over the next </font><font style="font-family:inherit;font-size:10pt;">19 months</font><font style="font-family:inherit;font-size:10pt;">&#32;through the facilities of the NASDAQ in the United States. In </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, we sold </font><font style="font-family:inherit;font-size:10pt;">4,425,040</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">18,002</font><font style="font-family:inherit;font-size:10pt;">) common shares for gross proceeds of US</font><font style="font-family:inherit;font-size:10pt;">$6,390,691</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- US</font><font style="font-family:inherit;font-size:10pt;">$50,046</font><font style="font-family:inherit;font-size:10pt;">). We incurred share issue costs of </font><font style="font-family:inherit;font-size:10pt;">344,834</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;-  </font><font style="font-family:inherit;font-size:10pt;">$135,000</font><font style="font-family:inherit;font-size:10pt;">). </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 16, 2019, pursuant to an underwritten public offering, </font><font style="font-family:inherit;font-size:10pt;text-transform:default;">4,619,773</font><font style="font-family:inherit;font-size:10pt;">&#32;units were sold at a purchase price of US</font><font style="font-family:inherit;font-size:10pt;">$0.81</font><font style="font-family:inherit;font-size:10pt;">&#32;per unit for gross proceeds of US</font><font style="font-family:inherit;font-size:10pt;">$3,742,016</font><font style="font-family:inherit;font-size:10pt;">. Each unit included </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;common share with a fair value of US</font><font style="font-family:inherit;font-size:10pt;">$0.54</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;common share purchase warrant with a fair value of US</font><font style="font-family:inherit;font-size:10pt;">$0.27</font><font style="font-family:inherit;font-size:10pt;">. These warrants were classified as a financial liability (see Note 8). Each common share purchase warrant entitled the holder to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;common share at an exercise price of US</font><font style="font-family:inherit;font-size:10pt;">$0.90</font><font style="font-family:inherit;font-size:10pt;">&#32;until August 16, 2024. We incurred transaction costs of </font><font style="font-family:inherit;font-size:10pt;">$699,427</font><font style="font-family:inherit;font-size:10pt;">&#32;of which </font><font style="font-family:inherit;font-size:10pt;">$466,284</font><font style="font-family:inherit;font-size:10pt;">&#32;were allocated to share issue costs and </font><font style="font-family:inherit;font-size:10pt;">$233,143</font><font style="font-family:inherit;font-size:10pt;">&#32;were allocated to operating expenses, based on their relative fair values. In the fourth quarter of 2019, our share </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:24px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">capital included fair value of $</font><font style="font-family:inherit;font-size:10pt;">5,687,003</font><font style="font-family:inherit;font-size:10pt;">&#32;in addition to gross proceeds of US</font><font style="font-family:inherit;font-size:10pt;">$2,642,082</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">2,935,647</font><font style="font-family:inherit;font-size:10pt;">&#32;warrants that were exercised (see Note 8). </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Warrants</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our outstanding equity warrants at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">: </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:425px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:9px;"></td><td style="width:74px;"></td><td style="width:4px;"></td><td style="width:100px;"></td><td style="width:4px;"></td><td style="width:90px;"></td><td style="width:4px;"></td><td style="width:138px;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding, Beginning of the Year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding, End of the Year</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,443,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,443,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.42</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:78px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1)&#160;&#160;&#160;&#160; Exercisable into </font><font style="font-family:inherit;font-size:8pt;">1,730,894</font><font style="font-family:inherit;font-size:8pt;">&#32;common shares.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><a name="sB93DDFAD8BD359109446552F7D323884"></a></div><div style="line-height:120%;padding-top:1px;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 10: Share Based Payments</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Stock Option Plan</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:650px;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:158px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:74px;"></td><td style="width:4px;"></td><td style="width:82px;"></td><td style="width:80px;"></td><td style="width:4px;"></td><td style="width:81px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,249,361</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">647,156</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">912,995</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.42</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted during the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,020,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.42</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">750,467</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.97</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,625</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.60</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited during the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(12,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(105,338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(211,847</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.80</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired during the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(9,575</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">29.07</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,122</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.78</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,302</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.13</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised during the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(41,802</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.96</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(84,315</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.07</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,246,947</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5.31</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,249,361</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.73</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">647,156</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.20</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px solid #000000;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,327,845</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.22</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">777,245</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.04</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">573,984</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.36</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about the stock options outstanding and exercisable at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:182px;"></td><td style="width:96px;"></td><td style="width:4px;"></td><td style="width:100px;"></td><td style="width:100px;"></td><td style="width:96px;"></td><td style="width:4px;"></td><td style="width:100px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$0.54 - $1.42</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">100,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.81</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.96</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">66,667</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.75</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.43 - $1.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">900,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">300,009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.45</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.80 - $3.39</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">376,411</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.73</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">284,412</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.72</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$3.40 - $7.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">395,111</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">322,880</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.95</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$7.14 - $63.84</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">475,425</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.53</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16.74</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">353,877</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19.95</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,246,947</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.45</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.31</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,327,845</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.22</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-exercisable options vest annually over periods ranging from </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the Black-Scholes valuation model to estimate fair value. We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of stock options issued during the year was determined using the following weighted average assumptions: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:464px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:245px;"></td><td style="width:74px;"></td><td style="width:72px;"></td><td style="width:72px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.62%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.02%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.18%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected hold period to exercise</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.0 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected share price volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">97.90%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81.15%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90.73%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected forfeiture rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.67%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.67%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.67%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nil</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average fair value of options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$0.87</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.67</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.65</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incentive Share Award Plan</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Share Units</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have issued restricted share units ("RSUs") to non-employee directors through our incentive share award plan. Grants of RSUs to non-employee directors vest either immediately, on the third anniversary date from the grant date or when the director ceases to be a member of the board. We have also issued RSUs to certain officers and employees of the Company. Grants of RSUs to certain officers and employees of the Company vest over a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;year period. The following RSUs are outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:515px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:269px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">260,755</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190,407</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,237</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Granted during the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">270,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,855</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited during the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,210</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Vested during the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(321,196</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,297</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">209,657</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">260,755</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190,407</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:36px;"><font style="text-align:justify;font-family:inherit;font-size:8pt;padding-right:24px;">(1)</font><font style="font-family:inherit;font-size:8pt;">The weighted average fair value of the RSUs granted was </font><font style="font-family:inherit;font-size:8pt;">$0.80</font><font style="font-family:inherit;font-size:8pt;">&#32;in </font><font style="font-family:inherit;font-size:8pt;">2019</font><font style="font-family:inherit;font-size:8pt;">&#32;(</font><font style="font-family:inherit;font-size:8pt;">2018</font><font style="font-family:inherit;font-size:8pt;">&#32;- </font><font style="font-family:inherit;font-size:8pt;">$3.35</font><font style="font-family:inherit;font-size:8pt;">&#32;; </font><font style="font-family:inherit;font-size:8pt;">2017</font><font style="font-family:inherit;font-size:8pt;">&#32;- </font><font style="font-family:inherit;font-size:8pt;">$5.96</font><font style="font-family:inherit;font-size:8pt;">).</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Performance Share Units</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have also issued performance share units ("PSUs") to certain officers and employees of the Company. Grants of PSUs require completion of certain performance criteria and cliff vest after </font><font style="font-family:inherit;font-size:10pt;">3 years</font><font style="font-family:inherit;font-size:10pt;">&#32;or vest over a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;year period, depending on the grant. PSU grants to certain officers will vest immediately upon a change of control of the Company. If certain officers cease employment with the Company, vesting occurs on a pro rata basis prior to the third anniversary of the grant but after the first anniversary. The following PSUs are outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:521px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:274px;"></td><td style="width:79px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:75px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">63,156</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,734</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,419</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Granted during the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited during the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31,578</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested during the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(2,105</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">61,051</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,156</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,734</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:36px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) &#160;&#160;&#160;&#160;The weighted average fair value of the PSUs granted was </font><font style="font-family:inherit;font-size:8pt;">nil</font><font style="font-family:inherit;font-size:8pt;">&#32;in </font><font style="font-family:inherit;font-size:8pt;">2019</font><font style="font-family:inherit;font-size:8pt;">&#32;(</font><font style="font-family:inherit;font-size:8pt;">2018</font><font style="font-family:inherit;font-size:8pt;">&#32;- </font><font style="font-family:inherit;font-size:8pt;">nil</font><font style="font-family:inherit;font-size:8pt;">; </font><font style="font-family:inherit;font-size:8pt;">2017</font><font style="font-family:inherit;font-size:8pt;">&#32;- </font><font style="font-family:inherit;font-size:8pt;">$3.33</font><font style="font-family:inherit;font-size:8pt;">).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have reserved </font><font style="font-family:inherit;font-size:10pt;">3,219,845</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for issuance relating to our outstanding equity compensation plans. Compensation expense related to stock options, RSUs and PSUs for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$1,470,153</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">$1,415,833</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">$578,703</font><font style="font-family:inherit;font-size:10pt;">). </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s23B5D13E0A285D3E8F89990A9A4B4FCE"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 11: Loss Per Common Share</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss per common share is calculated using net loss for the year and the weighted average number of common shares outstanding for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">22,137,990</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">16,016,366</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">13,936,387</font><font style="font-family:inherit;font-size:10pt;">). The effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s0E06D5A7519857CEAB5ABA3298DADBC8"></a></div><div style="line-height:120%;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 12: Contract Liability and Receivable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Regional licensing agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered into a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Warrant purchase agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also entered into a warrant purchase agreement with Adlai. </font><font style="font-family:inherit;font-size:10pt;">As at December 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we were entitled to receive the following:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One common share purchase warrant of US</font><font style="font-family:inherit;font-size:10pt;">$6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;whereby, upon exercise, Adlai may purchase our common shares priced at a </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;">&#32;premium to the </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-day weighted average closing price immediately preceding the exercise date. We have the right to call this warrant upon the enrollment of the </font><font style="font-family:inherit;font-size:10pt;">50</font><font style="font-family:inherit;font-size:10pt;">th patient in the phase 3 metastatic breast cancer study. This common share purchase warrant expires on </font><font style="font-family:inherit;font-size:10pt;">November&#160;14, 2020</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contract liability</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">Our contract liability balance at December 31, which w</font><font style="font-family:inherit;font-size:10pt;">e expect to record in revenue over the next </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">, is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:443px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:236px;"></td><td style="width:102px;"></td><td style="width:4px;"></td><td style="width:96px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, beginning of the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,730,287</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,182,580</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regional licensing agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547,707</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue recognized in the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,730,287</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,730,287</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability - current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">927,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability - non-current</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,730,287</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,802,887</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,730,287</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,730,287</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sBBC8EB5F58B657B9B8DF8FE454384744"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 13: Commitments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are committed to payments totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4,867,131</font><font style="font-family:inherit;font-size:10pt;">&#32;for activities related to our clinical trial, manufacturing and collaboration programs which are expected to occur over the next two years. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our commitments include one-half of the committed payments related to our collaboration with Merck KGaA, Darmstadt, Germany,  and Pfizer Inc ("Pfizer"), known as BRACELET-1, as the cost of this phase 2 clinical trial will be shared equally between Oncolytics and Pfizer. </font><font style="font-family:inherit;font-size:10pt;">As at December 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we recorded US$</font><font style="font-family:inherit;font-size:10pt;">1,500,000</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">nil</font><font style="font-family:inherit;font-size:10pt;">) in other receivables related to an upfront payment of BRACELET-1 cost from Pfizer per the terms of the collaboration agreement with an offsetting US$</font><font style="font-family:inherit;font-size:10pt;">652,306</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">nil</font><font style="font-family:inherit;font-size:10pt;">) in other liabilities representing future trial costs to be incurred.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under a clinical trial agreement entered into with the Alberta Cancer Board (&#8220;ACB&#8221;), we have agreed to repay the amount funded under the agreement together with a royalty, to a combined maximum amount of </font><font style="font-family:inherit;font-size:10pt;">$400,000</font><font style="font-family:inherit;font-size:10pt;">&#32;plus an overhead repayment of </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;">, upon sales of a specified product.&#160;&#160;We agreed to repay the ACB in annual installments in an amount equal to the lesser of: (a) </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;">&#32;of gross sales of a specified product; or (b) </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;">&#32;per annum once sales of a specified product commence.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s86F2F676F9295FE38327FAB33A8356FE"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 14: Contingencies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Assumption Agreement</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 1999, we entered into an agreement that assumed certain obligations (the &#8220;Assumption Agreement&#8221;) in connection with a Share Purchase Agreement (the &#8220;Share Purchase Agreement&#8221;) between SYNSORB and our former shareholders to make milestone payments and royalty payments.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, a milestone payment was still outstanding for </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">, due within </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;">&#32;of the first receipt from an Appropriate Regulatory Authority, for marketing approval to sell pelareorep to the public or the approval of a new drug application for pelareorep.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This milestone payment, when payable, will be accounted for as research and development expense and will not be deductible for income tax purposes.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the milestone payment, payments may become due and payable in accordance with the Share Purchase Agreement upon realization of sales of pelareorep.&#160;&#160;If we receive royalty payments or other payments as a result of entering into partnerships or other arrangements for the development of the reovirus technology, we are obligated to pay to the founding shareholders </font><font style="font-family:inherit;font-size:10pt;">10.75%</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">10.75%</font><font style="font-family:inherit;font-size:10pt;">) of the royalty payments and other payments received.&#160;Alternatively, if we develop the reovirus treatment to the point where it may be marketed at a commercial level, the payments referred to in the foregoing sentence will be amended to a royalty payment of </font><font style="font-family:inherit;font-size:10pt;">2.15%</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">2.15%</font><font style="font-family:inherit;font-size:10pt;">) of Net Sales received for such products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">BRI &#8220;Work in Kind&#8221; Contribution</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered into an engineering and process development agreement with the Biotechnology Research Institute of the National Research Council of Canada (&#8220;BRI&#8221;).&#160;&#160;The terms of this agreement include a &#8220;work in kind&#8221; contribution from BRI.&#160;&#160;In exchange for this &#8220;work in kind&#8221; contribution, we agreed to provide a royalty, contingent upon receiving Sales Revenue, at the lesser of </font><font style="font-family:inherit;font-size:10pt;">0.5%</font><font style="font-family:inherit;font-size:10pt;">&#32;of Sales Revenue or </font><font style="font-family:inherit;font-size:10pt;">$20,000</font><font style="font-family:inherit;font-size:10pt;">&#32;per year.&#160;&#160;The total royalty under this Agreement is equal to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;times the &#8220;work in kind&#8221; contribution.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we estimate that the accumulated work in kind totals approximately </font><font style="font-family:inherit;font-size:10pt;">$301,000</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s83F6B6AC87FA53BAAA1FC40F14C02E6F"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 15: Income Taxes</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:583px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:316px;"></td><td style="width:76px;"></td><td style="width:13px;"></td><td style="width:78px;"></td><td style="width:11px;"></td><td style="width:78px;"></td><td style="width:11px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(33,122,888</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,489,183</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,475,353</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Statutory Canadian corporate tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">26.50</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.00</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.00</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Anticipated tax recovery</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(8,777,565</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,452,079</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,178,345</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign jurisdiction tax rate difference</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,088,811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,312,963</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,899,190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee share based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">389,591</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382,275</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,250</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of warrant derivative</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,341,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impact of Alberta rate change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,758,175</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment to opening tax pools</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11,973</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(238,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other permanent differences</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">149,294</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35,912</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,039</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in deferred tax benefits deemed not probable to <br>  be recovered</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1,961,613</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,579,017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,051,725</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">548,042</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">144,021</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment in respect to prior periods</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net current tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">548,042</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,498</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we have the following non-capital losses for income tax purposes in Canada:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:24.756335282651072%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:37%;"></td><td style="width:62%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expiry</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,809,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,170,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2029</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,009,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2030</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,774,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2031</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,343,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2032</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,873,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2033</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,457,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2034</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,472,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2035</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,125,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2036</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,430,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2037</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,812,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,056,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2039</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,900,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">69,230,000</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we have the following non-refundable federal investment tax credits for income tax purposes in Canada:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:190px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:97px;"></td><td style="width:88px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expiry</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">189,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">471,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">465,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">596,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2028</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">622,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2030</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2032</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">487,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2034</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2035</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2036</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2037</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">980</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2038</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,000</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5,482,980</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As well, we have unclaimed scientific research and experimental development expenditures available to reduce future years&#8217; taxable income of approximately </font><font style="font-family:inherit;font-size:10pt;">$27,560,000</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;We have not recorded the potential benefits of these tax pools in these consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available, against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilized. The components of our unrecognized deferred tax asset are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:612px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:345px;"></td><td style="width:84px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating losses carried forward</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19,625,642</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,664,345</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,160,218</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific research and experimental development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,338,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,406,169</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,406,099</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,222,016</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,988,606</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,988,325</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Undepreciated capital costs in excess of book value of property and equipment and intellectual property</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,908,320</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,949,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,927,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">611,072</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">696,346</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">493,343</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net capital losses carried forward</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,474</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,598</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,598</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrecognized deferred tax asset</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">32,712,066</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,712,675</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,983,223</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sD95B3EF3524E579995C867B9DCE614D9"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 16: Capital Disclosures</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our objective when managing capital is to maintain a strong statement of financial position. We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs and intellectual property expansion and protection.&#160;We include shareholders&#8217; equity and cash and cash equivalents in the definition of capital.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:72%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14,148,021</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,699,881</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; (deficit) equity</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(107,894</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,195,363</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not have any debt other than trade accounts payable and we have potential contingent obligations relating to the completion of our research and development of pelareorep.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;There are no assurances that funds will be made available to us when required.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 4, 2018, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to </font><font style="font-family:inherit;font-size:10pt;">$150,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the US or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Renewing our Base Shelf  provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until May 25, 2020. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Base Shelf allowed us to enter into our Common Stock Purchase Agreement in September 2018, our ATM equity offering sales agreement in October 2018, and our public offering in August 2019 (see Note 9). We will use these equity arrangements to assist us in achieving our capital objective. Each arrangement provides us with the opportunity to raise capital at our sole discretion providing us with the ability to better manage our cash resources. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s4BF7F233C7F15C7FA3B820A0287E8B8A"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 17: Financial Instruments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial instruments consist of cash and cash equivalents,&#160;other receivables, other liabilities, accounts payable and warrant derivative.&#160;As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the carrying amount of our cash and cash equivalents,&#160;other receivables, other liabilities and accounts payable approximated their fair value. The warrant derivative is a recurring Level 2 fair value measurement as these </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">warrants have not been listed on an exchange and therefore do not trade on an active market. </font><font style="font-family:inherit;font-size:10pt;">As at December 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the fair value of our warrant derivative was $</font><font style="font-family:inherit;font-size:10pt;">8,508,764</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">nil</font><font style="font-family:inherit;font-size:10pt;">).  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Credit risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;We are exposed to credit risk on our cash and cash equivalents and other receivables from Pfizer connected to the BRACELET-1 study (see Note 13) in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and other receivables. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our exposure to credit risk connected to our cash and cash equivalent by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our exposure to credit risk connected to our Pfizer other receivable by entering into collaborations with global biopharmaceutical companies.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest rate risk </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We are exposed to interest rate risk through our cash and cash equivalents.&#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign exchange risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. We are primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar, British pound and Euro as a portion of our financial assets and liabilities are denominated in such currencies. The impact of a </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;">&#32;increase in the value of the U.S. dollar against the Canadian dollar would have increased our net comprehensive loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$125,339</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;The impact of a </font><font style="font-family:inherit;font-size:10pt;">$0.10</font><font style="font-family:inherit;font-size:10pt;">&#32;increase in the value of the British pound against the Canadian dollar would have increased our net comprehensive loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$8,581</font><font style="font-family:inherit;font-size:10pt;">. The impact of a </font><font style="font-family:inherit;font-size:10pt;">$0.10</font><font style="font-family:inherit;font-size:10pt;">&#32;increase in the value of the Euro against the Canadian dollar would have increased our net comprehensive loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$32,426</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balances in foreign currencies at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:622px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:222px;"></td><td style="width:133px;"></td><td style="width:133px;"></td><td style="width:133px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">US dollars <br></font><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">British pounds<br></font><font style="font-family:inherit;font-size:10pt;">&#163;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Euro<br>&#8364;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,676,360</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,751</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,664</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,500,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and other liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,378,860)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,345)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(310,086)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant derivative</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,551,250)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,246,250</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,406</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(276,422)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;We manage liquidity risk through the management of our capital structure as outlined in Note 16. Accounts payable are all due within the current operating period.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-26</font></div></div><hr style="page-break-after:always"><div><a name="s7D373EBB2B455D248D6E9218F668FFA0"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 18: Additional Cash Flow Disclosures</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change In Non-Cash Working Capital</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:629px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:392px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Change in:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,767,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,767,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(2,017,122</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,924</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,680</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(2,012,605</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">475,077</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(915,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,347,365</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,858,170</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(384,641</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547,707</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,182,580</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">807,877</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,982</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash impact of foreign exchange</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">78,708</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,531</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,558</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in non-cash working capital related to operating activities</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1,795,777</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,904,339</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180,855</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Cash Flow Disclosures</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:517px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:342px;"></td><td style="width:58px;"></td><td style="width:4px;"></td><td style="width:51px;"></td><td style="width:4px;"></td><td style="width:51px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash interest received</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">274,094</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173,496</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130,101</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash taxes paid</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5,448</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,728</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136,163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s4BB293B518C6534EB9ECA4A1C9FBE316"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 19: Indemnification of Officers and Directors</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our corporate by-laws require that, except to the extent expressly prohibited by law, we will indemnify our officers and directors against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment reasonably incurred in respect of any civil, criminal or administrative action or proceeding as it relates to their services to the Company.&#160;The by-laws provide no limit to the amount of the indemnification.&#160;We have purchased directors&#8217; and officers&#8217; insurance coverage to cover claims made against the directors and officers during the applicable policy periods.&#160;The amounts and types of coverage have varied from period to period as dictated by market conditions.&#160;We believe that we have adequate insurance coverage; however, there is no guarantee that all indemnification payments will be covered under our existing insurance policies.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There is no pending litigation or proceeding involving any of our officers or directors as to which indemnification is being sought, nor are we aware of any threatened litigation that may result in claims for indemnification.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s27512B831C545955A454C3E0A7B627CC"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 20: Economic Dependence</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are economically dependent on our toll manufacturers. We primarily use </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;toll manufacturer in the US to produce the clinical grade pelareorep required for our clinical trial program.&#160;Any significant disruption of the services provided by our primary toll manufacturer has the potential to delay the progress of our clinical trial program.&#160;We have used another toll manufacturer in the U.K. that has also produced clinical grade pelareorep at a smaller scale.&#160;We have attempted to mitigate this risk by producing sufficient pelareorep in advance of patient enrollment in a particular clinical trial.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s44BF3A7C61405A78A3FE8D747A23E06B"></a></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 21:  Other Expenses and Adjustments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We present our expenses based on the function of each expense. We include realized foreign exchange gains and losses, unrealized non-cash foreign exchange gains and losses and non-cash share based compensation associated with research and development activity as a component of research and development expenses. We include depreciation of property and equipment, depreciation of right-of-use-asset, share based compensation associated with operating activities, and transaction costs related to our warrant derivative as a component of operating expenses.  </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:639px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:420px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:68px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Included in research and development expenses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Realized foreign exchange (gain) loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(39,362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,995</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(120,794</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized non-cash foreign exchange loss (gain)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">356,081</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(608,111</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,538</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">561,420</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">680,541</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230,141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Included in operating expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation - property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">122,982</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,375</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,768</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation - right-of-use assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">362,592</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">908,733</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">735,292</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">348,562</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transaction cost, warrant derivative</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">233,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Onerous lease contract</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,588</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization - lease incentive liability</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,189</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sE92A8D4123125590A064192C644B947E"></a></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 22:  Related Party Transactions</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Compensation of Key Management Personnel</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole. We have determined that key management personnel consists of the members of the Board of Directors along with certain officers of the Company.   </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:520px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:301px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:68px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term employee compensation and benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,786,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,680,621</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,596,082</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Termination benefits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">779,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,123,408</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,067,195</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">459,298</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,910,075</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,747,816</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,835,046</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assumption Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2017, with the signing of the Licensing Agreement with upfront license fees (see Note 12), the Company triggered a liability of US$</font><font style="font-family:inherit;font-size:10pt;">178,125</font><font style="font-family:inherit;font-size:10pt;">&#32;to an officer as detailed in the Assumption Agreement (see Note 14). The liability was fully repaid in 2018.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s47adc83b1070414589172b4d1fe943c9"></a></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 23:  Subsequent Events</font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Between </font><font style="font-family:inherit;font-size:10pt;">January&#160;1, 2020</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">March&#160;5, 2020</font><font style="font-family:inherit;font-size:10pt;">, we issued </font><font style="font-family:inherit;font-size:10pt;">3,921,790</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for gross proceeds of US$</font><font style="font-family:inherit;font-size:10pt;">12,726,383</font><font style="font-family:inherit;font-size:10pt;">&#32;through our October 2018 ATM equity offering sales agreement and we received gross proceeds of US$</font><font style="font-family:inherit;font-size:10pt;">1,030,669</font><font style="font-family:inherit;font-size:10pt;">&#32;as a result of </font><font style="font-family:inherit;font-size:10pt;">1,145,188</font><font style="font-family:inherit;font-size:10pt;">&#32;August 2019 public offering warrants that were exercised.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">February&#160;25, 2020</font><font style="font-family:inherit;font-size:10pt;">, we received the US</font><font style="font-family:inherit;font-size:10pt;">$1,500,000</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront payment of BRACELET-1 cost from Pfizer (see Note 13 for details).</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-29</font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>ex21exhibitdescriptionofse.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s797890DADF37FD1C866F9DF0F336F9C3"></a></div><div></div><div><br></div><div style="line-height:138%;padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 2.1</font></div><div style="line-height:138%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION OF RIGHTS OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 </font></div><div style="line-height:138%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our authorized capital consists of an unlimited number of Common Shares. The following is a summary of the provisions attached to our Common Shares:</font></div><div style="line-height:138%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The holders of our Common Shares are entitled to one vote per share at meetings of shareholders, to receive such dividends as declared by the Board and to receive our remaining property and assets upon dissolution or wind up. Our Common Shares are not subject to any future call or assessment and there are no pre-emptive, conversion or redemption rights attached to such shares. As at March 5, 2020, we have </font><font style="font-family:inherit;font-size:10pt;">37,375,025</font><font style="font-family:inherit;font-size:10pt;">&#32;Common Shares issued and outstanding. After giving effect to the exercise of all outstanding options to acquire Common Shares and all outstanding share awards granted under the Corporation&#8217;s Incentive Share Award Plan, we would have </font><font style="font-family:inherit;font-size:10pt;">42,119,348</font><font style="font-family:inherit;font-size:10pt;">&#32;Common Shares issued and outstanding. As at March 5, 2020, we have 16,443,500 (exercisable into 1,730,894 common shares) Common Share purchase warrants issued in 2017 (the &#8220;2017 Warrants&#8221;) and 538,938 Common Share purchase warrants issued in 2019 (the &#8220;2019 Warrants&#8221;) outstanding. 9.5 2017 Warrant entitles the holder to purchase one Common Share until June 1, 2022, at an exercise price of $9.05. The 2017 Warrants are subject to acceleration if the volume weighted average price of the Common Shares equals or exceeds $23.75 for a period of 15 consecutive trading dates. Each 2019 Warrant entitles the holder to purchase one Common Share until August 16, 2024, at an exercise price of US$0.90. In addition, as at March 5, 2020, the Corporation has a Common Share purchase warrant (the &#8220;Second Adlai Warrant&#8221;) exercisable by the holder thereof until November 14, 2020 to purchase such number of Common Shares as is calculated by dividing US$6,000,000 by the Exercise Price. For purposes of the Second Adlai Warrant, the term &#8220;Exercise Price&#8221; means an amount equal to 120% of the volume weighted average trading price of the Common Shares on the The NASDAQ Capital Market for the five trading days immediately preceding the exercise date. The Second Adlai Warrant is subject to a right to call by the Corporation upon the date of the enrollment of the fiftieth (50th) patient in a Phase III Study related to pelareorep. </font></div><div><br></div><div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>ex41august2013hagerman.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7A0D3C55C33A06412E159D3F1161AAE8"></a></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 1 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">EXHIBIT 4.1</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">EMPLOYMENT AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">THIS AGREEMENT </font><font style="font-family:Arial;font-size:12pt;">made the 1</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">st</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;day of August, 2013.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">BETWEEN:</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">("Oncolytics")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">-and-</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Allison Hagerman</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(the "Employee")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">WHEREAS Oncolytics is engaged in the business of developing pharmaceutical products;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">AND WHEREAS Oncolytics and the Employee entered into a Letter of Employment dated August 3, 2010; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">AND WHEREAS Oncolytics and the Employee wish to amend and restate the terms of employment pursuant to this Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">NOW THEREFORE the parties agree as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:0px;"><font style="padding-bottom:16px;padding-top:16px;text-align:left;font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;padding-right:96px;">Section 1 - </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Definitions and Interpretation</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">In this Agreement the following defined terms shall have the meanings indicated:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Arial;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">"Business" means the business currently carried on by Oncolytics, which is the development, testing, marketing and sale of pharmaceutical products together with such additional business as Oncolytics may decide to undertake from time to time;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Arial;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">"Commencement Date" means August 1, 2013;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Arial;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">"Confidential Information" means all confidential information of Oncolytics and includes:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">any data or information directly or indirectly related to the Business or arising directly or indirectly in the course of, or derived from the Employee's employment with Oncolytics whether related to products, equipment, inventions, ideas, designs, methods, systems, improvements, processes, research or otherwise;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">any of Oncolytics' technical or scientific know-how;</font></div></td></tr></table><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 2 -</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">financial and sales information, customer lists, pricing policies, lists of suppliers, proprietary computer programs in any format whatsoever, programming techniques, the manner of plans or methods of operation and the like relating to the Business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">patent applications, drawings, blueprints, manuals, letters, notebooks, reports and all other materials (written or otherwise) related to the Business or to the agents, joint venturers or contractors of Oncolytics; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">any information provided to or received by Oncolytics on a confidential basis;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Arial;font-size:12pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">"Good Reason" means any one of the following events occurring on or after the Commencement Date:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">any reduction in the Employee's then existing annual base compensation and benefits, unless comparable reductions are made for all other executive employees of Oncolytics;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">any material diminution of the Employee's duties, responsibilities, authority or reporting structure, excluding for this purpose an isolated or inadvertent action not taken in bad faith which is remedied by Oncolytics immediately after notice thereof is given by the Employee;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">any request that the Employee relocate to a work site that would increase the Employee's one-way commute distance by more than eighty (80) kilometers from the Employee's then principal residence, unless the Employee accepts such relocation opportunity; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">any material breach by Oncolytics of its obligations under this Agreement that is not remedied within thirty (30) days of written notice of such breach from the Employee;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Arial;font-size:12pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">"Intellectual Property" means all information, data, designs, processes, software, algorithms and inventions, including those that may be the subject of patent, copyright, industrial design, trademarks, trade secret or other forms of legal protection, made, conceived or developed by the Employee during the term of employment with Oncolytics, whether alone or jointly with others and whether during or after regular working hours, that relates to or in any way pertains to or connects with any matter developed, or under investigation or development by Oncolytics or related to the Business;</font></div></td></tr></table><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 3 -</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Arial;font-size:12pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">"Termination Event" means:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">breach by the Employee of any material provision of this Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">material violation by the Employee of any statutory or common law duty of loyalty to Oncolytics;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">the commission of an indictable offence by the Employee against Oncolytics; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">personal or professional conduct of the Employee which in the reasonable and good faith judgment of Oncolytics may significantly injure Oncolytics' Business or interfere with the Employee's job performance.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">This Agreement shall be governed by and construed in accordance with the laws in force in the Province of Alberta.  The parties hereby submit to the jurisdiction of the Courts of Alberta.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The following schedule is attached to and forms part of this Agreement:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Schedule "A" &#8211; Job Description</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Schedule "B" &#8211; Benefits</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 2 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Employment</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Oncolytics confirms the employment of the Employee in the position of Director, Manufacturing and Engineering and the Employee accepts the employment, starting on the Commencement Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee shall perform the duties and responsibilities associated with the position of Director, Manufacturing and Engineering, including those set out on the Job Description attached as Schedule "A".  The Employee shall report to the Chief Operating Officer of Oncolytics.  The Employee may, from time to time, be assigned or undertake additional duties and responsibilities consistent with those generally appropriate for a Director, Manufacturing and Engineering, and the Employee's duties and responsibilities may be modified or expanded from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee shall perform the duties and responsibilities set out in Section 2(2):</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 4 -</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Arial;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">diligently, faithfully and to the best of the Employee's ability; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Arial;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">in the best interests of Oncolytics.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee shall comply with the terms, conditions and requirements of Oncolytics' Policy Manual, as the same may be amended, revised or added to from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 3 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Remuneration</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Commencing August 1, 2013, Oncolytics shall pay to the Employee a salary of $88,000 per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of $3,666.67 CANADIAN DOLLARS on the 15</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;and last day of each month.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Oncolytics shall, on or before the anniversary date of this Agreement in each year, evaluate and set the Employee's salary for the next ensuing year.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Oncolytics shall reimburse the Employee for all out-of-pocket expenses incurred by the Employee in the performance of the Employee's obligations under this Agreement, subject to Oncolytics' policies then in force.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Oncolytics shall be entitled to withhold from any payments made to the Employee any amounts that Oncolytics is required to withhold pursuant to any Act in force that relates to income tax, unemployment insurance premiums or pension plan premiums in any jurisdiction under which such payments are required to be made by or on behalf of the Employee, including, without limitation, the Income Tax Act (Canada), the Employment Insurance Act (Canada), the Canada Pension Plan.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 4 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Benefits</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employee shall be entitled to participate in benefit plans described in Schedule "B" and in other benefit plans instituted by Oncolytics from time to time.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 5 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Vacations</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employee shall, in addition to all statutory holidays, be entitled to 20 days paid vacation during each twelve (12) month period of employment under this Agreement.  The Employee's vacation time shall be governed by applicable policies of Oncolytics.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 6 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Place of Employment</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employee shall perform the majority of the Employee's employment obligations from and out of Oncolytics' offices located in the City of Calgary, Alberta, Canada.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 5 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 7 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Confidential Information</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee confirms that the Confidential Information is the sole and exclusive property of Oncolytics and is held by the Employee in trust for the benefit of Oncolytics.  The Employee shall use the Employee's best efforts and exercise utmost diligence to protect and safeguard the Confidential Information.  Neither during the period of employment by Oncolytics nor thereafter for a period of three years shall the Employee, directly or indirectly, use or disclose to any other person any Confidential Information, whether or not acquired, learned or obtained or developed by the Employee alone or in conjunction with others, except as such disclosure or use may be required in connection with the employment with Oncolytics or as may be agreed to in writing by Oncolytics.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Subsection 7(1) shall not apply to Confidential Information that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Arial;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">is in the public domain at the time of its disclosure, or which, after disclosure, becomes part of the public domain other than by disclosure by the Employee;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Arial;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">the Employee can show was in the Employee's possession at the time of disclosure and was not acquired from Oncolytics; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Arial;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">was received by the Employee from a third party without a covenant of confidentiality, provided such third party is under no obligation of confidentiality with respect to the Confidential Information.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee shall keep informed of Oncolytics' policies and procedures for safeguarding Oncolytics' property including, without limitation, the Confidential Information and the confidentiality thereof, and will strictly comply therewith at all times.  The Employee shall not, except as required in the course of the employment with Oncolytics, remove from Oncolytics' premises any Oncolytics property including, without limitation, Confidential Information.  The Employee shall, immediately upon termination of employment with Oncolytics, return to Oncolytics all of Oncolytics' property in the Employee's possession, including, without limitation, all tangible parts of or relating to the Confidential Information as is in the Employee's possession or under the Employee's control without retaining any copies or record thereof or any other mechanical means that, alone or in combination with other means, would permit the Employee to reproduce or make available the Confidential Information.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee shall advise any future employer, associate or affiliate that the Employee has signed this Agreement and is bound by its terms and conditions.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 8 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Intellectual Property</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee confirms that any and all Intellectual Property shall be the sole and exclusive property of Oncolytics and shall be assigned by the Employee to </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 6 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Oncolytics.  The Employee agrees to disclose promptly to Oncolytics or its nominee any and all Intellectual Property and to execute written assignments of the Employee's right, title and interest in and to the Intellectual Property to Oncolytics or its nominee.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">With respect to any Intellectual Property, the Employee also agrees:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Arial;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">to assist Oncolytics or its nominee in preparing any necessary copyright and patent applications, including Canadian and foreign applications, covering the Intellectual Property;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Arial;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">to sign and deliver all such applications and their assignment to Oncolytics or its nominee; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Arial;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">generally to give all information and testimony, to co-operate with Oncolytics and its solicitors, to sign all lawful papers, and to do all lawful things that may be needed or requested by Oncolytics to obtain, extend, reissue, maintain or enforce Canadian and foreign copyrights or patents covering the Intellectual Property.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Oncolytics shall bear all expenses that are incurred in obtaining, extending, reissuing, maintaining and enforcing any and all copyrights or patents in respect of the Intellectual Property assigned to Oncolytics by the Employee, and in the vesting and perfecting of title thereto in Oncolytics and shall pay the Employee reasonable compensation for any time that Oncolytics may require the Employee to expend in order to accomplish the above subsequent to the termination of employment with Oncolytics.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee hereby waives in favour of Oncolytics, all moral rights in any and all copyright works authored or co-authored by the Employee during the term of this Agreement that directly relate to the Business of Oncolytics.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 9 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Term and Termination</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#32;(1)</font><font style="font-family:inherit;font-size:7pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:Arial;font-size:12pt;">The Employee's employment under this Agreement shall commence on the Commencement Date and shall continue until terminated in accordance with this Section 9.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:7pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:Arial;font-size:12pt;">Subject to Sections 9(3), (4) and (5), and notwithstanding any other provision contained herein to the contrary, the employment relationship between the Employee and Oncolytics arising out of this Agreement shall terminate upon forty-five (45) days notice being given to Oncolytics by the Employee or immediately upon notice being given to the Employee by Oncolytics.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:7pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:Arial;font-size:12pt;">If Oncolytics is entitled to terminate this Agreement as the result of a Termination Event, Oncolytics shall not be required to compensate the Employee in respect of such termination or provide any period of notice in lieu of compensation with respect to such termination.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 7 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:7pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:Arial;font-size:12pt;">Subject to Section 9(5), if this Agreement is terminated by Oncolytics at any time other than pursuant to Section 9(3), or if this Agreement is terminated by the Employee for Good Reason, the Employee shall be entitled to severance payment equal to three (3) months salary. The severance payment as provided pursuant to this Section 9(4) shall include an amount equal to the value of all benefits to which the Employee would otherwise have been entitled during the notice period.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(5)</font><font style="font-family:inherit;font-size:7pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:Arial;font-size:12pt;">Notwithstanding Section 9(4), if there is a change of control of Oncolytics, as defined herein, and if this Agreement is terminated by Oncolytics at any time within one (1) year following the change of control other than pursuant to Section 9(3), the Employee shall be entitled to severance payment equal to twice that determined pursuant to Section 9(4).  The severance payment as provided pursuant to this Section 9(5) shall include an amount equal to the value of all benefits to which the Employee would otherwise have been entitled during the notice period.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">For the purposes of this Section 9(5), &#8220;change of control&#8221; means any amalgamation, merger or other corporate reorganization which results in any change in the present effective voting control of Oncolytics, or will result in a change of the person or persons who own or control sufficient voting shares in Oncolytics to elect a majority of the directors of Oncolytics, or will result in a person acquiring sufficient voting shares in Oncolytics to elect a majority of the directors of Oncolytics, or any sale, lease, exchange, partnership, or other transfer (in one transaction or a series of transactions) of all or substantially all of the assets of Oncolytics or a plan of liquidation of Oncolytics and/or an agreement for the sale or liquidation of Oncolytics is approved and completed, or the Board of Directors determines in its sole discretion that a change of control has occurred, whether or not any event described above has occurred or is contemplated. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(6)</font><font style="font-family:inherit;font-size:7pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:Arial;font-size:12pt;">The Employee acknowledges and agrees that payment in lieu of notice in accordance with Section 9(4) or 9(5) shall be and is conclusively deemed to be reasonable compensation for termination of this Agreement and hereby waives any claim or potential claim that the Employee now has or may hereafter have, against Oncolytics for further severance compensation or notice other than that provided by the terms of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(7) &#160;&#160;&#160;&#160;The Employee confirms that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Arial;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">any breach of this Agreement or unauthorized disclosure of Confidential Information may result in irreparable harm to the Business of Oncolytics and considerable monetary damages to Oncolytics;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Arial;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">the damages suffered by Oncolytics may be difficult to establish; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Arial;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">interim and permanent injunctions may be the only suitable remedy for Oncolytics;</font></div></td></tr></table><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 8 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">but nothing herein shall in any way limit or restrict any other remedies available to Oncolytics at law or in equity including an action for damages.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(8) &#160;&#160;&#160;&#160;Termination of the Employee's employment with Oncolytics for any reason whatsoever shall not terminate the Employee's obligations under Sections 7, 8 and 10 of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 10 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Non-Competition</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee shall not, during the term of this Agreement, engage, hold an interest in or have any involvement, either directly or indirectly, in any business entity, venture or undertaking if such would materially interfere with or conflict with the Employee's duties and obligations to Oncolytics as provided for under this Agreement, provided that the acquisition of a non-control position in publicly traded companies will not contravene this Section.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee shall not, during the term of this Agreement, and for a period of one (1) year following the termination or expiration of this Agreement, either individually or in partnership or jointly or in conjunction with any person, firm or corporation as principal, employee, partner, director or as a shareholder or investor (if actually involved in the management of a business which is competitive with the Business of Oncolytics) carry on or be engaged in any business which is directly competitive with the Business of Oncolytics.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The parties agree that all of the restrictions contained in Subsection 10(2) hereof are reasonable and valid, and that all defences to the strict enforcement thereof by Oncolytics are hereby waived by the Employee.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee agrees that the remedy at law for any breach by the Employee of the provisions of this Section 10 may be inadequate and that in the event of such breach, Oncolytics may make an application to a court of competent jurisdiction for an order granting Oncolytics temporary, permanent or both kinds of injunctive relief against the Employee, without the necessity of proving actual damage to Oncolytics.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(5)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee agrees that any waiver by Oncolytics of a breach of this Agreement by the Employee shall only be a waiver with respect to the particular breach giving rise to the waiver.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 11 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Notices</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">All notices, reports, invoices, payments and formal communications (collectively referred to as "Notices") required or permitted to be given hereunder shall be in writing and shall be delivered personally or sent by prepaid registered mail or facsimile transmission to the following address or such other address as the relevant party may notify from time to time:</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 9 -</font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">TO:&#160;&#160;&#160;&#160;Oncolytics</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Suite 210, 1167 Kensington Crescent N.W.</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Calgary, Alberta</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">T2N 1X7</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Attention: President</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">TO:&#160;&#160;&#160;&#160;The Employee</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Allison Hagerman</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">[address redacted]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Notices sent by prepaid registered mail shall be deemed to be received by the addressee on the seventh day (excluding Saturdays, Sundays, Statutory Holidays and any period of postal disruption) following the mailing thereof.  Notices personally served shall be deemed to be received when actually delivered, provided such delivery shall be during normal business hours.</font></div><div style="line-height:180%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 12 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Enurement</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Agreement shall:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:Arial;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">replace and supercede the Letter of Employment dated August 3, 2010, and all amendments thereto; and</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(b)&#160;&#160;&#160;&#160;enure to the benefit of and be binding upon the parties hereto and:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(i)&#160;&#160;&#160;&#160;in the case of Oncolytics, its successors and permitted assigns; and</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:Arial;font-size:12pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">in the case of the Employee, her heirs, executors, administrators or other personal representatives.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">IN WITNESS WHEREOF the parties have executed this Agreement as of the day and year first above written.</font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:49.78632478632478%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="4"></td></tr><tr><td style="width:8%;"></td><td style="width:15%;"></td><td style="width:70%;"></td><td style="width:7%;"></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Matt Coffey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Kirk Look</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;text-decoration:underline;">/s/ Clare Percival</font><font style="font-family:Arial;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-style:italic;text-decoration:underline;">/s/ Allison Hagerman</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Witness&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Allison Hagerman</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s5ED0D35C26EC4DE74CF89D3F11AF1E37"></a></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 1 -</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">SCHEDULE "A"</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">JOB DESCRIPTION</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employee shall perform the duties and responsibilities associated with the position of Director, Manufacturing and Engineering.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s6FBD16169E3F1E39E9D29D3F11BAF16C"></a></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 1 -</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">SCHEDULE "B"</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">BENEFITS</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Oncolytics shall:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">commencing with the calendar year 2014 and annually thereafter, pay to the Employee's Registered Retirement Savings Plan, as directed by the Employee, an amount equal to ten (10%) percent of the Employee's annual salary as set out in Section 3(1), not to exceed the annual maximum allowable contribution.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee is presently entitled to designate an additional amount equal to a maximum eight and a quarter (8.25%) percent of the Employee's annual salary to be paid by Oncolytics, on a monthly basis, into an Employee Health Trust in accordance with the provisions of the Employee Health Trust Plan currently in place, and as such provisions may be revised from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee is entitled to the Physical Fitness Benefit in the amount of SEVEN HUNDRED AND FIFTY ($750.00) CANADIAN DOLLARS per annum to use towards an item or service that promotes physical activity; the details of which are outlined in the Company Policy Manual.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>4
<FILENAME>ex42hagermandec2015.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s41A7B6BB2E27039D9ECA9D410C6B9A38"></a></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">EXHIBIT 4.2</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">AMENDING AGREEMENT NO. 1</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">THIS AMENDING AGREEMENT</font><font style="font-family:Arial;font-size:12pt;">&#32;made effective as of the 1</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">st</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;day of December, 2015.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">BETWEEN:</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">ONCOYLYTICS BIOTECH INC.,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">("Oncolytics")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">- and -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Allison Hagerman</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(the "Employee")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">WHEREAS Oncolytics is engaged in the business of developing pharmaceutical products;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">AND WHEREAS Oncolytics and the Employee entered into a Letter of Employment dated August 3, 2010; </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">AND WHEREAS Oncolytics and the Employee entered into an Employment</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Agreement dated August 1, 2013;</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">AND WHEREAS Oncolytics and the Employee wish to amend the Employment Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">NOW THEREFORE the parties agree as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;text-decoration:underline;">Section 1 &#8211; Amendments</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employment Agreement is hereby amended by replacing Section 9(4) with the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#32;&#160;&#160;&#160;&#160;&#8220;Subject to Section 9(5), if this Agreement is terminated by Oncolytics at any time other than pursuant to Section 9(3), or if this Agreement is terminated by the Employee for Good Reason, the Employee shall be entitled to severance payment equal to six (6) months salary. The severance payment as provided pursuant to this Section 9(4) shall include an amount equal to the value of all benefits to which the Employee would otherwise have been entitled during the notice period.&#8221;</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#32;&#32;&#32;</font><font style="font-family:Arial;font-size:12pt;text-decoration:underline;">Section 2 &#8211; Effective Date</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)&#160;&#160;&#160;&#160;This Amending Agreement shall be effective from and after December 1, 2015.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)&#160;&#160;&#160;&#160;In all other respects the parties confirm that the Employment Agreement, as amended, shall remain in full force and effect.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:48%;"></td><td style="width:4%;"></td><td style="width:7%;"></td><td style="width:41%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Brad Thompson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Brad Thompson, Ph.D.</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">President &amp; Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Kirk Look</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Kirk Look</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:45%;"></td><td style="width:10%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Romit Chakrabarty</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Allison Hagerman</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">WITNESS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Allison Hagerman</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>5
<FILENAME>ex43moorejan2017.htm
<DESCRIPTION>EXHIBIT 4.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s0082139EC03B3986326D9D4356CE1C36"></a></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 1 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EXHIBIT 4.3</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EMPLOYMENT AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">THIS AGREEMENT </font><font style="font-family:inherit;font-size:11pt;">made the 31st day of January, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">BETWEEN:</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">ONCOLYTICS BIOTECH (U.S.), INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">("OBUS")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">-and-</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">MICHAEL MOORE</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(the "Employee")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WHEREAS:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">OBUS and its Affiliates are engaged in the business of developing pharmaceutical products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">OBUS has made an offer of employment to the Employee, subject to the terms and conditions contained herein, and subject to the termination of the Services Agreement concurrent with the commencement of employment under this Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Employee is prepared to accept the offer of employment;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">NOW THEREFORE the parties agree as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:0px;"><font style="padding-bottom:16px;padding-top:16px;text-align:left;font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;padding-right:96px;">Section 1 - </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Definitions and Interpretation</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">In this Agreement the following defined terms shall have the meanings indicated:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">&#8221;Affiliate&#8221; means any entity that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with a party.  For the purposes of this definition, control shall mean: (i) the direct or indirect ownership of fifty percent (50%) or more of the voting stock of a corporation; or (ii) the direct or indirect ownership of fifty (50%) or more of the ownership interest of any other entity; or (iii) the ability to elect a majority of the directors of the entity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">"Business" means the business currently carried on by OBUS and its Affiliates, which is the development, testing, marketing and sale of pharmaceutical products together with such additional business as OBUS or its Affiliates may decide to undertake from time to time;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">"Commencement Date" means February 20, 2017;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;Good Reason&#8221; means any one of the following events occurring on or after the Commencement Date:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Any reduction in the Employee&#8217;s then existing annual base compensation and benefits, unless comparable reductions are made for all other executive employees of Oncolytics;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Any material diminution of the Employee&#8217;s duties, responsibilities, authority or reporting structure, excluding for this purpose an isolated or inadvertent action </font></div></td></tr></table><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 2 -</font></div></div><div><br></div><div style="line-height:120%;padding-left:144px;padding-bottom:16px;text-align:left;"><font style="font-family:inherit;font-size:11pt;">not taken in bad faith which is remedied by Oncolytics immediately after notice thereof is given by the Employee;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Any request that the Employee relocate to a work site that would increase the Employee&#8217;s one-way commute distance by more than eighty (80) kilometers from the Employee&#8217;s then principal residence, unless the Employee accepts such relocation opportunity; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">Any material breach by Oncolytics of its obligations under this agreement that is not remedied within thirty (30) days of written notice of such breach from the Employee;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">"Confidential Information" means all confidential information of OBUS and its Affiliates, and includes:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">any data or information directly or indirectly related to the Business or arising directly or indirectly in the course of, or derived from the Employee's employment with OBUS whether related to products, equipment, inventions, ideas, designs, methods, systems, improvements, processes, research or otherwise;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">any technical or scientific know-how;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">financial and sales information, customer lists, pricing policies, lists of suppliers, proprietary computer programs in any format whatsoever, programming techniques, the manner of plans or methods of operation and the like relating to the Business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">patent applications, drawings, blueprints, manuals, letters, notebooks, reports and all other materials (written or otherwise) related to the Business or to the agents, joint venturers or contractors of OBUS or its Affiliates; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">any information provided to or received by OBUS or its Affiliates on a confidential basis;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">"Intellectual Property" means all information, data, designs, processes, software, algorithms and inventions, including those that may be the subject of patent, copyright, industrial design, trademarks, trade secret or other forms of legal protection, made, conceived or developed by the Employee during the term of employment with OBUS, whether alone or jointly with others and whether during or after regular working hours, that relates to or in any way pertains to or connects with any matter developed, or under investigation or development by OBUS or its Affiliates, or related to the Business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">"Termination Event" means:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">breach by the Employee of any material provision of this Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">material violation by the Employee of any statutory or common law duty of loyalty to OBUS and its Affiliates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">the commission of a criminal offence by the Employee against OBUS or its Affiliates; and</font></div></td></tr></table><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 3 -</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">personal or professional conduct of the Employee which in the reasonable and good faith judgment of OBUS may significantly injure OBUS' Business or interfere with the Employee's job performance.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">This Agreement shall be governed by and construed in accordance with the laws of California.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The following schedules are attached to and form part of this Agreement:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Schedule "A" &#8211; Job Description</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Schedule "B" &#8211; Benefits</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 2 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Employment</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">OBUS agrees to employ the Employee in the position of Vice President, Investor Relations and Communication and the Employee accepts the employment, starting on the Commencement Date.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee shall perform the duties and responsibilities associated with the position of Vice President, Investor Relations and Communications including those set out on the Job Description attached as Schedule "A".  The Employee may, from time to time, be assigned or undertake additional duties and responsibilities consistent with those generally appropriate for a Vice President, Investor Relations and Communications and the Employee's duties and responsibilities may be modified or expanded from time to time.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee shall perform the duties and responsibilities set out in Section 2(2):</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">diligently, faithfully and to the best of the Employee's ability; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">in the best interests of OBUS.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee shall comply with the terms, conditions and requirements of OBUS' Policy Manual and benefit plans, as the same may be amended, revised or added to from time to time.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 4 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 3 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Remuneration</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">OBUS shall pay to the Employee a salary of Two Hundred and Thirty Thousand ($230,000.00) United States dollars per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of Nine Thousand Five Hundred and Eighty-Three United States Dollars and Thirty-Three Cents ($9,583.33) on the fifteenth (15) and last day of each month.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">OBUS shall, on or before the anniversary date of this Agreement in each year, evaluate and set the Employee's salary for the next ensuing year.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">OBUS shall reimburse the Employee for all reasonable out-of-pocket expenses incurred by the Employee in the performance of the Employee's obligations under this Agreement, subject to OBUS' policies then in force.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">OBUS shall be entitled to withhold from any payments made to the Employee any amounts that OBUS is required to withhold pursuant to any Act in force that relates to income tax, social security, medicare or pension in any jurisdiction under which such payments are required to be made by or on behalf of the Employee.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 4 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Benefits and Equity Compensation</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Employee shall be entitled to participate in benefit plans described in Schedule "B" and in other benefit plans instituted or as amended by OBUS from time to time.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Performance Share Units</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Employee shall be granted 60,000 performance share units (&#8220;PSU&#8217;s&#8221;) on the Commencement Date under Oncolytic Biotech Inc.&#8217;s Incentive Award Plan.  The PSU&#8217;s will vest upon the proposal and implementation of an Investor Relations strategy and two years of service for one third of the PSUs with the remaining two thirds of the PSUs vesting after three years of service.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Stock Options</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Employee shall be granted 125,000 stock options on the Commencement Date under Oncolytics Biotech Inc.&#8217;s Stock Option Plan.  These options will be priced on the Commencement Date and 37,500 stock options will vest immediately, followed by 37,500 vesting after twelve (12) months from the Commencement Date and the final 50,000 vesting after twenty-four (24) months from the Commencement Date.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 5 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Vacations</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Employee shall, in addition to all statutory holidays, be entitled to twenty (20) Business Days paid vacation during each twelve (12) month period of employment under this Agreement.  The Employee's vacation time shall be governed by applicable policies of OBUS.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 6 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Place of Employment</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Employee shall be based within the greater</font><font style="font-family:inherit;font-size:11pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:11pt;">metropolitan area of San Diego, California, and shall perform the majority of his employment obligations within that area.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 5 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Employee will make provision in his home for an office space in which he can conduct OBUS business. The Employee will provide furnishings and equipment for the home office space along with such other items as are required to properly perform his duties.    OBUS will provide the use of a laptop computer and will reimburse the Employee for the use of a smart phone. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;The Employee shall be available to travel within the United States and outside the United States as required to fulfill his duties and responsibilities.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 7 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Confidential Information</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee confirms that the Confidential Information is the sole and exclusive property of OBUS or its Affiliates and is held by the Employee in trust for the benefit of OBUS and its Affiliates.  The Employee shall use the Employee's best efforts and exercise utmost diligence to protect and safeguard the Confidential Information. Neither during the period of employment by OBUS nor thereafter for a period of three years shall the Employee, directly or indirectly, use or disclose to any other person any Confidential Information, whether or not acquired, learned or obtained or developed by the Employee alone or in conjunction with others, except as such disclosure or use may be required in connection with the employment with OBUS or as may be agreed to in writing by OBUS.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Subsection 7(1) shall not apply to Confidential Information that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">is in the public domain at the time of its disclosure, or which, after disclosure, becomes part of the public domain other than by disclosure by the Employee;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">the Employee can show was in the Employee's possession at the time of disclosure and was not acquired from OBUS or its Affiliates; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">was received by the Employee from a third party without a covenant of confidentiality, provided such third party is under no obligation of confidentiality with respect to the Confidential Information.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee shall keep informed of OBUS' policies and procedures for safeguarding OBUS' property including, without limitation, the Confidential Information and the confidentiality thereof, and will strictly comply therewith at all times.  The Employee shall not, except as required in the course of the employment with OBUS, remove from OBUS' premises any OBUS property including, without limitation, Confidential Information.  The Employee shall, immediately upon termination of employment with OBUS, return to OBUS all of OBUS' property in the Employee's possession, including, without limitation, all tangible parts of or relating to the Confidential Information as is in the Employee's possession or under the Employee's control without retaining any copies or record thereof or any other mechanical means that, alone or in combination with other means, would permit the Employee to reproduce or make available the Confidential Information.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee shall advise any future employer, associate or affiliate that the Employee has signed this Agreement and is bound by its terms and conditions.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 8 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Intellectual Property</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee confirms that any and all Intellectual Property shall be the sole and exclusive property of OBUS or its Affiliates and shall be assigned by the Employee to OBUS, or its nominee.  The Employee agrees to disclose promptly to OBUS or its nominee any and all Intellectual Property and to </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 6 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">execute written assignments of the Employee's right, title and interest in and to the Intellectual Property to OBUS or its nominee.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">With respect to any Intellectual Property, the Employee also agrees:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">to assist OBUS or its nominee in preparing any necessary copyright and patent applications, including Canadian and foreign applications, covering the Intellectual Property;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">to sign and deliver all such applications and their assignment to OBUS or its nominee; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">generally to give all information and testimony, to co-operate with OBUS and its solicitors, to sign all lawful papers, and to do all lawful things that may be needed or requested by OBUS to obtain, extend, reissue, maintain or enforce copyrights or patents covering the Intellectual Property.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">OBUS shall bear all expenses that are incurred in obtaining, extending, reissuing, maintaining and enforcing any and all copyrights or patents in respect of the Intellectual Property assigned to OBUS or its nominee by the Employee, and in the vesting and perfecting of title thereto in OBUS or its nominee and shall pay the Employee reasonable compensation for any time that OBUS may require the Employee to expend in order to accomplish the above subsequent to the termination of employment with OBUS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee hereby waives in favour of OBUS and its Affiliates, all moral rights in any and all copyright works authored or co-authored by the Employee during the term of this Agreement that directly relate to the Business of OBUS or its Affiliates.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 9 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Term and Termination</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee's employment under this Agreement shall commence on the Commencement Date and shall continue until terminated in accordance with this Section 9.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Subject to Sections 9(3) and (4), and notwithstanding any other provision contained herein to the contrary, the employment relationship between the Employee and OBUS arising out of this Agreement shall terminate upon forty-five (45) days notice being given to OBUS by the Employee or immediately upon notice being given to the Employee by OBUS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">If OBUS is entitled to terminate this Agreement for cause, or as the result of a Termination Event, OBUS shall not be required to compensate the Employee in respect of such termination or provide any period of notice in lieu of compensation with respect to such termination.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Subject to Section 9(5), if this Agreement is terminated by OBUS at any time other than pursuant to Section 9(3), or if this Agreement is terminated by the Employee for Good Reason, the Employee shall be entitled to severance payment equal to six (6) months&#8217; salary. The severance payment as provided pursuant to this Section 9(4) shall include an amount equal to the value of all benefits to which the Employee would otherwise have been entitled during the notice period.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(5)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Notwithstanding Section 9(4), if there is a change of control of OBUS, as defined herein, and if this Agreement is terminated by OBUS at any time within one (1) year following the change of control </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 7 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">other than pursuant to Section 9(3), the Employee shall be entitled to severance payment equal to twice that determined pursuant to Section 9(4). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">For the purposes of this section 9(5), &#8220;change of control&#8221; means any amalgamation, merger or other corporation reorganization which results in any change in the present effective voting control of OBUS, or will result in a change of the person or persons who own or control sufficient voting shares in OBUS to elect a majority of the directors of OBUS, or will result in a person acquiring sufficient voting shares in OBUS to elect a majority of the directors of OBUS, or any sale, lease, exchange, partnership, or other transfer (in one transaction or a series of transactions) of all or substantially all of the assets of OBUS or a plan of liquidation of OBUS and/or an agreement for the sale or liquidation of OBUS is approved and completed, or the Board of Directors determines in its sole discretion the a change of control has occurred, whether or not any event described has occurred or is contemplated.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(6)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee acknowledges and agrees that notice or payment in lieu thereof, in accordance with Section 9(4) shall be and is conclusively deemed to be reasonable compensation for termination of this Agreement and hereby waives any claim or potential claim that the Employee now has or may hereafter have, against OBUS for further compensation or notice other than that provided by the terms of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(7)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee confirms that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">any breach of this Agreement or unauthorized disclosure of Confidential Information may result in irreparable harm to the Business of OBUS or its Affiliates and considerable monetary damages to OBUS and its Affiliates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">the damages suffered by OBUS may be difficult to establish; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">interim and permanent injunctions may be the only suitable remedy for OBUS;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">but nothing herein shall in any way limit or restrict any other remedies available to OBUS at law or in equity including an action for damages.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 8 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(8)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Termination of the Employee's employment with OBUS for any reason whatsoever shall not terminate the Employee's obligations under Sections 7, 8 and 10 of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 10 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Non-Competition</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee shall not, during the term of this Agreement, engage, hold an interest in or have any involvement, either directly or indirectly, in any business entity, venture or undertaking if such would materially interfere with or conflict with the Employee's duties and obligations to OBUS as provided for under this Agreement, provided that the acquisition of a non-control position in publicly traded companies will not contravene this Section.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee shall not, during the term of this Agreement, and for a period of one (1) year following the termination or expiration of this Agreement, either individually or in partnership or jointly or in conjunction with any person, firm or corporation as principal, employee, partner, director or as a shareholder or investor (if actually involved in the management of a business which is competitive with the Business of OBUS or its Affiliates) carry on or be engaged in any business which is directly competitive with the Business of OBUS or its Affiliates. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The parties agree that all of the restrictions contained in Subsection 10(2) hereof are reasonable and valid, and that all defenses to the strict enforcement thereof by OBUS are hereby waived by the Employee.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee agrees that the remedy at law for any breach by the Employee of the provisions of this Section 10 may be inadequate and that in the event of such breach, OBUS may make an application to a court of competent jurisdiction for an order granting OBUS temporary, permanent or both kinds of injunctive relief against the Employee, without the necessity of proving actual damage to OBUS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(5)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Employee agrees that any waiver by OBUS of a breach of this Agreement by the Employee shall only be a waiver with respect to the particular breach giving rise to the waiver.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 11 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Notices</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">All notices, reports, invoices, payments and formal communications (collectively referred to as "Notices") required or permitted to be given hereunder shall be in writing and shall be delivered personally or sent by prepaid registered mail or facsimile transmission to the following address or such other address as the relevant party may notify from time to time:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">TO:&#160;&#160;&#160;&#160;OBUS</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">ONCOLYTICS BIOTECH (U.S.), INC.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Attention: President</font></div><div style="line-height:120%;padding-top:16px;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WITH COPY TO:</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Suite 210, 1167 Kensington Crescent N.W.</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Calgary, Alberta</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">T2N 1X7</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 9 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Attention: President</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">TO:&#160;&#160;&#160;&#160;Employee</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Michael Moore</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[address redacted]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Notices sent by prepaid registered mail shall be deemed to be received by the addressee on the seventh day (excluding Saturdays, Sundays, Statutory Holidays and any period of postal disruption) following the mailing thereof.  Notices personally served shall be deemed to be received when actually delivered, provided such delivery shall be during normal business hours.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 12 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Enurement</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement shall enure to the benefit of and be binding upon the parties hereto and:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">in the case of OBUS, its successors and permitted assigns; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">in the case of the Employee, his heirs, executors, administrators or other personal representatives.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF the parties have executed this Agreement as of the day and year first above written.</font></div><div style="line-height:120%;text-align:right;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:52.991452991452995%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:14%;"></td><td style="width:86%;"></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ONCOLYTICS BIOTECH (U.S.), INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Per:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">/s/ Andres Gutierrez</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Andres Gutierrez</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Per:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">/s/ Gilles Gosselin</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Gilles Gosselin </font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">CFO</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;text-decoration:underline;">/s/ Ann Moore</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;text-decoration:underline;">/s/ Michael Moore&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Witness&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Michael Moore</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s7F35D530313CBD0E24399D4356EFB3C1"></a></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 1 -</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SCHEDULE "A"</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">JOB DESCRIPTION</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Basic Function:</font><font style="font-family:inherit;font-size:11pt;">&#160;The investor relations officer position is accountable for creating and presenting a consistently applied investment message to the investment community on behalf of a company, and for monitoring and presenting to management the opinions of the investment community regarding the company's performance.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Summary of Responsibilities:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Investor Relations Manager executes the Company&#8217;s Investor Relations program to effectively communicate the Company&#8217;s strategy, financial performance and products</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Must partner closely with senior management, internal legal counsel, corporate communications, and finance and key business areas across the organization</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Serves as a company spokesperson to the financial community by establishing and maintaining strong positive relationships with analysts and investors</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Leads the preparation and development of materials for conference calls, financial conferences, and Investor Days</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Develops an in-depth understanding of the business, including the clinical development plan, in order to develop materials regarding the company&#8217;s current and future performance</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Communicates with sell-side analysts and buy-side investors proactively and reactively by participating in conference calls and meetings, building rapport with the investment community</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Organizes conferences, road shows, earnings conference calls, and investor meetings</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Understands key differences between analyst consensus and Company forecasts in order to tailor communications to minimize gaps in expectations</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Creates investor marketing and targeting plan based upon analysis of institutional shareholder and target institution ownership trends, tracks activity and creates quarterly IR board reports</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Utilizes analyses of company and peer company stock trends to develop market and competitor intelligence and to communicate the Company&#8217;s valuation</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Conducts market research and analyses to support communications and presentation information, including economic, industry, and regulatory developments</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Monitors company, peer and industry specific sell-side research, consensus estimates, other key financial metrics and industry trends to understand and communicate the company&#8217;s investment community perception</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Responsible for maintaining accuracy of the company website</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Performs ad hoc research and reports</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Strong attention to detail with the ability to meet time-sensitive deadlines and carry out multiple priorities independently</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ability to adapt to a dynamic, rapidly changing business and technical environment</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Strong organizational and time management skills</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ability to prioritize, multi-task several projects/initiatives simultaneously</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ability to maintain confidentiality required</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sB5B83C56C0D5EF85F2D39D43572171EA"></a></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 1 -</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SCHEDULE "B"</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BENEFITS</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Physical Fitness Benefit:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Employee is entitled to the Physical Fitness Benefit in the amount of Seven Hundred and Fifty ($750.00) United States Dollars per annum to use towards an item or service that promotes physical activity; the details of which are outlined in the Company Policy Manual.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Deferred Compensation:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Employee shall, if qualified to do so, be entitled to allocate a portion of his salary to a 401(K) Plan established for the Employee, up to the prescribed maximum, and in accordance with the requirements thereof.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Benefit Plan Alternatives:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Alternative 1:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Employee can elect to receive an additional amount of 9.25% of base salary. Such amount shall be the employee&#8217;s full Health Benefit Allocation, and shall be taxable in accordance with the relevant regulations.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Alternative 2:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Employee can elect to direct (the lesser of the maximum available or allowable by the employee under the Flexible Spending Plan), a portion of the Health Benefit Allocation (9.25% of base salary) to a Flexible Spending Account, and receive the remainder (9.25% of base salary less the amount directed to the Flexible Spending Account) of the Health Benefit Allocation as a taxable amount in accordance with the relevant regulations.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Alternative 3:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Whether or not the Employee elects to participate in Alternative 2, the Employee can also elect to participate in an individual Health Insurance Program utilizing any amount still remaining from the Health Benefit Allocation. Any additional amounts required to be paid for this Program would be drawn from Employee&#8217;s net pay.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>6
<FILENAME>ex46november2018laeufle.htm
<DESCRIPTION>EXHIBIT 4.6
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sDC69E9120A8A030B4AC29D44EA31AD43"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:right;padding-left:81px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">EXHIBIT 4.6</font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:81px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">EMPLOYMENT AGREEMENT</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">THIS EMPLOYMENT AGREEMENT (&#8220;Agreement&#8221;), effective November 1, 2018 (&#8220;Effective Date&#8221;), is made between Oncolytics Biotech (U.S.), Inc., (&#8220;Employer&#8221; or the &#8220;Company&#8221;), and Rita Laeufle, MD PhD (&#8220;Employee&#8221;). Employee and the Company are sometimes referred to herein as the &#8220;Parties.&#8221;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:81px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">RECITALS</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:48px;">A.</font><font style="font-family:Arial;font-size:12pt;">Employer is in the business (the &#8220;Business&#8221;) of developing pharmaceutical products.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:48px;">B.</font><font style="font-family:Arial;font-size:12pt;">Employer desires to obtain the services of Employee as its Chief Medical Officer, in which capacity Employee has access to Employer&#8217;s Confidential Information (as hereinafter defined), and to obtain assurance that Employee will protect Employer&#8217;s Confidential Information and will not compete with Employer or solicit its customers or its other employees during the term of employment and for a reasonable period of time after termination of employment pursuant to this Agreement, and Employee is willing to agree to these terms.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:48px;">C.</font><font style="font-family:Arial;font-size:12pt;">Employee desires to be assured of the salary, bonus opportunity and other benefits in this Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:81px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">AGREEMENT</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">NOW, THEREFORE, </font><font style="font-family:Arial;font-size:12pt;">in consideration of the mutual covenants in this Agreement, and other good and valuable consideration, the parties agree as follows:</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Employment</font><font style="font-family:Arial;font-size:12pt;">. Employer hereby employs Employee, and Employee agrees to be employed as Chief Medical Officer. Employee will perform the duties of the Chief Medical Officer for Employer, its parent corporation, Oncolytics Biotech Inc. and other affiliated corporations. Employee will report initially to the President of Employer. Changes may be made from time to time by Employer in its sole discretion to the duties, reporting relationships and title of Employee. Employee will devote full time and attention to the duties on Exhibit A to this Agreement. Employee will comply with all rules, policies and procedures of Employer as modified from time to time, including without limitation, rules and procedures set forth in the Employer&#8217;s Employee Handbook and Company Policy Manual. Employee will perform all of Employee&#8217;s responsibilities in compliance with all applicable laws and will ensure that the operations that Employee manages are in compliance with all applicable laws. During Employee&#8217;s employment, Employee will not engage in any other business activity which, in the reasonable judgment of the President of Employer, conflicts with the duties of Employee under this Agreement, whether or not such activity is pursued for gain, profit or other pecuniary advantage.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Term of Employment</font><font style="font-family:Arial;font-size:12pt;">. The term of employment (&#8220;Term&#8221;) will not be for a definite period, but rather continue indefinitely until terminated in accordance with the terms and conditions of this Agreement.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sA7E8AB990889D501A5269D44EA61B926"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Compensation</font><font style="font-family:Arial;font-size:12pt;">. For the duration of Employee&#8217;s employment under this Agreement, the Employee will be entitled to compensation which will be computed and paid pursuant to the following subparagraphs.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">3.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Base Salary</font><font style="font-family:Arial;font-size:12pt;">. Employer will pay to Employee a base salary (&#8220;Base Salary&#8221;) at an annual rate of Four Hundred and Five Thousand Dollars ($405,000), payable in equal installments on the fifteenth and last day of each month, subject to withholdings and deductions as required or permitted by law. Employee&#8217;s Base Salary will be reviewed annually by the President of Employer and may be adjusted in the sole discretion of Employer based on such review, but will not be reduced by Employer unless a material adverse change in the financial condition or operations of Employer has occurred or unless Employee&#8217;s responsibilities are altered to reflect less responsibility.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">3.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Incentive Bonus. </font><font style="font-family:Arial;font-size:12pt;">Employee will participate in Employer&#8217;s annual incentive bonus plan under which Employee may earn an annual incentive bonus. The terms of the annual incentive bonus plan, including the criteria upon which Employee can earn the maximum bonus, will be determined annually by Employer&#8217;s Board of Directors or its President if so delegated. The Employee may earn an annual incentive of up to thirty five percent (35%) of Employee&#8217;s then Base Salary. Employee may also participate in other bonus or incentive plans adopted by Employer that are applicable to Employee&#8217;s position, as they may be changed from time to time, but nothing herein shall require the adoption or maintenance of any such plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Incentive Stock Options. </font><font style="font-family:Arial;font-size:12pt;">Upon commencement of employment, Employer will grant to Employee an incentive stock option to purchase 25,000 shares of Employer's Common Stock. The Stock Options will be priced at the time of the grant with 50% vesting on the second anniversary of employment and the remaining 50% vesting on the third anniversary. All Stock Option are pursuant and subject to the Stock Plan and Incentive Share Award Plan ("the Plans") of Oncolytics Biotech Inc. attached together as Exhibit  C to this agreement.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11.5pt;"><font style="font-family:Arial;font-size:11.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:54px;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Other Benefits</font><font style="font-family:Arial;font-size:12pt;">.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">4.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Certain Benefits. </font><font style="font-family:Arial;font-size:12pt;">Employee will be eligible to participate in all employee benefit programs as outlined in Exhibit B.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">4.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Vacations, Holidays and Expenses</font><font style="font-family:Arial;font-size:12pt;">. For the duration of Employee&#8217;s employment hereunder, Employee will be provided such holidays and sick leave as Employer makes available to its management level employees generally. Employee will be entitled to twenty (20) business days paid vacation per year of service and in addition to statutory holidays. Employer will reimburse Employee in accordance with company policies and procedures for reasonable expenses necessarily incurred in the performance of duties hereunder against appropriate receipts and vouchers indicating the specific business purpose for each such expenditure.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">4.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Right of Set-off</font><font style="font-family:Arial;font-size:12pt;">. By accepting this Agreement, Employee consents to a deduction from any amounts Employer owes Employee from time to time (including</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s4DD86E8DBDD7997054509D44EA84D3CA"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">amounts owed to Employee as wages or other compensation, fringe benefits, or vacation pay, as well as any other amounts owed to Employee by Employer), to the extent of the amounts Employee owes to Employer. Whether or not Employer elects to make any set- off in whole or in part, if Employer does not recover by means of set-off the full amount Employee owes it, calculated as set forth above, Employee agrees to pay immediately upon Employer&#8217;s demand, the unpaid balance to Employer.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:54px;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Termination Or Discharge By Employer</font><font style="font-family:Arial;font-size:12pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:121%;text-align:justify;padding-left:6px;text-indent:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">5.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">For Cause. </font><font style="font-family:Arial;font-size:12pt;">Employer will have the right to immediately terminate Employee&#8217;s services and this Agreement for Cause. &#8220;Cause&#8221; means the Employer&#8217;s belief that any of the following has occurred:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:144px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Employee&#8217;s breach of this Agreement by Employee, including, without limitation, breach of Employee&#8217;s covenants in Sections 8, 9 and 10.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:144px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Employee&#8217;s failure to perform Employee&#8217;s duties for the Company in a competent and effective manner as judged in good faith by either the Chief Executive Officer of the Company or the Company&#8217;s Board of Directors in their sole discretion. Employee shall be given written notice of Employee&#8217;s failure to perform Employee&#8217;s duties and thirty (30) days in which to cure such failure. Employee shall be entitled to only one notice and cure opportunity over the course of Employee&#8217;s employment with the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:144px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Employee&#8217;s material violation of any statutory or common law duty of loyalty to Employer and its Affiliates.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:198px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:150px;"><font style="font-family:Arial;font-size:12pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Employee&#8217;s commission of a felony.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:121%;text-align:justify;padding-left:6px;text-indent:144px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Employer&#8217;s reasonable belief that Employee engaged in a violation of any statute, rule or regulation, any of which in the judgment of Employer is harmful to the Business or to Employer&#8217;s reputation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:144px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(vi)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Employer&#8217;s reasonable belief that Employee engaged in unethical practices, dishonesty or disloyalty.</font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;"><br></font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s9924E66C88E9DB3C2D239D44EAB57A1B"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:150px;"><font style="font-family:Arial;font-size:12pt;">(vii)</font></div></td><td style="vertical-align:top;padding-left:144px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-144px;"><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:12pt;">Employer&#8217;s lack of funding sufficient to support Employee&#8217;s position.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div></div></div><div><a name="sE0C8AA8EF3E106EBA9AE9D44EAD6766F"></a></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Upon termination of Employee&#8217;s employment hereunder for Cause or upon the death or disability of Employee, Employee will have no rights to any unvested benefits or any other compensation or payments after the termination date or the last day of the month in which Employee&#8217;s death or disability occurred, respectively. For purposes of this Agreement, &#8220;disability&#8221; means the incapacity or inability of Employee, whether due to accident, sickness or otherwise, as determined by a medical doctor acceptable to the Board of Directors of Employer and confirmed in writing by such doctor, to perform the essential functions of Employee&#8217;s position under this Agreement, with or without reasonable accommodation (provided that no accommodation that imposes undue hardship on</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s775FA7A3592247D690609D44EB08A825"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Employer will be required) for an aggregate of ninety (90) days during any period of one hundred eighty (180) consecutive days, or such longer period as may be required under disability law.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">5.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Without Cause. </font><font style="font-family:Arial;font-size:12pt;">Employer may terminate Employee&#8217;s employment under this Agreement without Cause and without advance notice; provided , however, that Employer will continue to pay, as severance pay, Employee&#8217;s Base Salary at the rate in effect on the termination date through the date that is six (6) months from the termination date; provided,  further, that Employer will be entitled to offset any severance pay otherwise payable to Employee by the amount of any compensation or consulting fees being paid to Employee by another party while severance pay would otherwise be payable. Employee shall only be entitled to such severance pay if Employee signs (and then Employee does not rescind, as may be permitted by law) a general release of claims in favor of Employer in a form acceptable to Employer, provided, however, that such release of claims shall only require Employee to release Employer from claims relating directly to Employee&#8217;s employment and the termination thereof, and shall not require Employee to release claims relating to vested employee benefits or relating to other matters, including, but not limited to, claims relating to his status as a shareholder of the Company. Such payments will be at usual and customary pay intervals of Employer and will be subject to all appropriate deductions and withholdings. Upon termination, Employee will have no rights to any unvested benefits or any other compensation or payments except as stated in this paragraph.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Termination By Employee. </font><font style="font-family:Arial;font-size:12pt;">Employee may terminate Employee&#8217;s employment under this Agreement for any reason provided that Employee gives Employer at least thirty (30) days&#8217; notice in writing. Employer may, at its option, accelerate such termination date to any date at least two weeks after Employee&#8217;s notice of termination. Employer may also, at its option, relieve Employee of all duties and authority after notice of termination has been provided. All compensation, payments and unvested benefits will cease on the termination date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Delivery of Property</font><font style="font-family:Arial;font-size:12pt;">. Upon termination of this Agreement or upon request of the Company, Employee shall deliver to the Company all property, documents and materials pertaining to the Company&#8217;s Business including, but not limited to, memoranda, notes, records, drawings, manuals, disks, copies, representations, extracts, summaries and analyses, all inventory, demonstration units, and any other property, documents or media of the Company, and all equipment belonging to the Company, including but not limited to corporate cards, access cards, office keys, office equipment, laptop and desktop computers, cell phones and other wireless devices, thumb drives, zip drives and all other media storage devices.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Confidential Information</font><font style="font-family:Arial;font-size:12pt;">. Employee recognizes that Employer&#8217;s Business and continued success depend upon the use and protection of confidential and proprietary business information, including, without limitation, the information and technology developed by or available through licenses to Employer, to which Employee has access (all such information being &#8220;Confidential Information&#8221;). For purposes of this Agreement, the phrase &#8220;Confidential Information&#8221; includes, for Employer and its current</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s7AD3AB2791C4A18A82A49D44EB2A04B1"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">or future subsidiaries and affiliates, without limitation, and whether or not specifically designated as confidential or proprietary: all business plans and marketing strategies; information concerning existing and prospective markets and customers; financial information; information concerning the development of new products and services; information concerning any personnel of Employer (including, without limitation, skills and compensation information); and technical and non-technical data related to software programs, designs, specifications, compilations, inventions, improvements, methods, processes, procedures and techniques; provided, however, that the phrase does not include information that (a) was lawfully in Employee&#8217;s possession prior to disclosure of such information by Employer; (b) was, or at any time becomes, available in the public domain other than through a violation of this Agreement; (c) is documented by Employee as having been developed by Employee outside the scope of Employee&#8217;s employment and independently; or (d) is furnished to Employee by a third party not under an obligation of confidentiality to Employer. Employee agrees that during Employee&#8217;s employment and after termination of employment irrespective of cause, Employee will use Confidential Information only for the benefit of Employer and will not directly or indirectly use or divulge, or permit others to use or divulge, any Confidential Information for any reason, except as authorized by Employer. Employee&#8217;s obligation under this Agreement is in addition to any obligations Employee has under state or federal law. Employee agrees to deliver to Employer immediately upon termination of Employee&#8217;s employment, or at any time Employer so requests, all tangible items containing any Confidential Information (including, without limitation, all memoranda, photographs, records, reports, manuals, drawings, blueprints, prototypes, notes taken by or provided to Employee, and any other documents or items of a confidential nature belonging to Employer) whether in hard copy, electronic, or other format, together with all copies of such material in Employee&#8217;s possession or control. Employee agrees that in the course of Employee&#8217;s employment with Employer, Employee will not violate in any way the rights that any entity has with regard to trade secrets or proprietary or confidential information. Employee&#8217;s obligations under this Section 8 are indefinite in term and shall survive the termination of this Agreement. However, Employee further understands that nothing in this Agreement prohibits Employee from reporting to any governmental authority information concerning possible violations of law or regulation and that Employee may disclose Confidential Information to a government official or to an attorney and use it in certain court proceedings without fear of prosecution or liability, provided Employee files any document containing Confidential Information under seal and does not disclose the Confidential Information, except pursuant to court order.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Work Product and Copyrights. </font><font style="font-family:Arial;font-size:12pt;">Employee agrees that all right, title and interest in and to the materials resulting from the performance of Employee&#8217;s duties at Employer and all copies thereof, including works in progress, in whatever media, (the &#8220;Work&#8221;), will be and remain in Employer upon their creation. Employee will mark all Work with Employer&#8217;s copyright or other proprietary notice as directed by Employer. Employee further agrees:</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:121%;text-align:justify;padding-left:6px;text-indent:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">9.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">To the extent that any portion of the Work constitutes a work protectable under the copyright laws of the United States (the &#8220;Copyright Law&#8221;), that all such Work will be considered a &#8220;work made for hire&#8221; as such term is used and defined in</font></div><div style="line-height:121%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sA9A0B5EA651B27AD14609D44EB5B14CE"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">the Copyright Law, and that Employer will be considered the &#8220;author&#8221; of such portion of the Work and the sole and exclusive owner throughout the world of such copyright;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">9.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">If any portion of the Work does not qualify as a &#8220;work made for hire&#8221; as such term is used and defined in the Copyright Law, that Employee hereby assigns and agrees to assign to Employer, without further consideration, all right, title and interest in and to such Work or in any such portion of such Work and any copyright in such Work and further agrees to execute and deliver to Employer, upon request, appropriate assignments of such Work and copyright in such Work and such other documents and instruments as Employer may request to fully and completely assign such Work and copyright in such Work to Employer, its successors or nominees, and that Employee appoints Employer as attorney-in-fact to execute and deliver any such documents on Employee&#8217;s behalf in the event Employee should fail or refuse to do so within a reasonable period following Employer&#8217;s request;</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">9.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">To waive and agree not to assert any moral rights Employee may have or acquire in any Inventions and agree to provide written waivers from time to time as requested by Employer; and</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">9.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Assist Employer (at Employer&#8217;s expense) in obtaining and maintaining copyright registrations with respect to such Works.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Inventions and Patents. </font><font style="font-family:Arial;font-size:12pt;">For purposes of this Agreement, &#8220;Inventions&#8221; includes, without limitation, information, inventions, contributions, improvements, ideas, or discoveries, whether protectable or not, and whether or not conceived or made during work hours. Employee agrees that all Inventions conceived or made by Employee during the period of employment with Employer belong to Employer, provided they grow out of Employee&#8217;s work with Employer or are related in some manner to the Business, including, without limitation, research and product development, and projected business of Employer or its affiliated companies. Accordingly, Employee will:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">10.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Make adequate written records of such Inventions, which records will be Employer&#8217;s property;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:121%;text-align:justify;padding-left:6px;text-indent:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">10.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Assign to Employer, at its request, and does hereby assign to Employer, any rights Employee may have to such Inventions for the U.S. and all foreign countries; and</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">10.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Assist Employer (at Employer&#8217;s expense) in obtaining and maintaining patents registrations with respect to such Inventions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Employee further agrees that Employee will promptly disclose in writing to Employer during the term of Employee&#8217;s employment and for one (1) year thereafter, all Inventions whether developed during the time of such employment or thereafter (whether or not Employer has rights in such Inventions) so that Employee&#8217;s rights and Employer&#8217;s rights in such Inventions can be determined. Except as set forth on the initialed Exhibit D (List of Inventions) to this Agreement, if any, Employee represents and warrants that Employee has no Inventions, software, writings or other works of authorship useful to</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sE3000F46A7A89065AA399D44EB7D3BEE"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Employer in the normal course of the Business, which were conceived, made or written prior to the date of this Agreement and which are excluded from the operation of this Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">NOTICE</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">: This Section 10 does not apply to Inventions for which no equipment, supplies, facility, or trade secret information of Employer was used and which was developed entirely on Employee&#8217;s own time, unless: (a) the Invention relates (i) directly to the business of Employer or (ii) to Employer&#8217;s actual or demonstrably anticipated research or development, or (b) the Invention results from any work performed by Employee for Employer.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">In accordance with California Labor Code Section 2870, Employee is notified that:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:82px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:54px;"><font style="font-family:Arial;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:Arial;font-size:12pt;">Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer&#8217;s equipment, supplies, facilities, or trade secret information except for those inventions that either:</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:138px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:121%;font-size:12pt;padding-left:102px;"><font style="font-family:Arial;font-size:12pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:121%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Relate at the time of conception or reduction to practice of the invention to the Employer&#8217;s Business, or actual or demonstrably anticipated research or development of the employer; or</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:138px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:102px;"><font style="font-family:Arial;font-size:12pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Result from any work performed by the employee for the employer.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">11.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Remedies</font><font style="font-family:Arial;font-size:12pt;">. Notwithstanding other provisions of this Agreement regarding dispute resolution, Employee agrees that Employee&#8217;s violation of any of Sections 8, 9 or</font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">10 of this Agreement would cause Employer irreparable harm which would not be adequately compensated by monetary damages and that an injunction may be granted by any court or courts having jurisdiction, restraining Employee from violation of the terms of this Agreement, upon any breach or threatened breach of Employee of the obligations set forth in any of Sections 8, 9 or 10. The preceding sentence shall not be construed to limit Employer from any other relief or damages to which it may be entitled as a result of Employee&#8217;s breach of any provision of this Agreement, including Sections 8, 9 or 10. Employee also agrees that a violation of any of Sections 8, 9 or 10 would entitle Employer, in addition to all other remedies available at law or equity, to recover from Employee any and all funds, including, without limitation, wages, salary and profits, which will be held by Employee in constructive trust for Employer, received by Employee in connection with such violation.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">12.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Dispute Resolution. </font><font style="font-family:Arial;font-size:12pt;">Except for the right of Employer and Employee to seek injunctive relief in court, any controversy, claim or dispute of any type arising out of or relating to Employee&#8217;s employment or the provisions of this Agreement shall be resolved in accordance with this Section 12 regarding resolution of disputes, which will be the sole and exclusive procedure for the resolution of any disputes. This Agreement shall  be  enforced  in  accordance  with  the  Federal Arbitration Act,  the  enforcement</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sED88AB7E7BBE773BAA079D44EBB0301D"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">provisions of which are incorporated by this reference. Matters subject to these provisions include, without limitation, claims or disputes based on statute, contract, common law and tort and will include, for example, matters pertaining to termination, discrimination, harassment, compensation and benefits. Matters to be resolved under these procedures also include claims and disputes arising out of statutes such as the Fair Labor Standards Act, Title VII of the Civil Rights Act, the Age Discrimination in Employment Act, and any state laws related to employment. Nothing in this provision is intended to restrict Employee from submitting any matter to an administrative agency with jurisdiction over such matter.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">12.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Mediation. </font><font style="font-family:Arial;font-size:12pt;">Employer and Employee will make a good faith attempt to resolve any and all claims and disputes by submitting them to mediation in San Diego, California before resorting to arbitration or any other dispute resolution procedure. The mediation of any claim or dispute must be conducted in accordance with the then-current JAMS procedures for the resolution of employment disputes by mediation, by a mediator who has had both training and experience as a mediator of general employment and commercial matters. If the parties to this Agreement cannot agree on a mediator, then the mediator will be selected by JAMS in accordance with JAMS&#8217; strike list method. Within thirty (30) days after the selection of the mediator, Employer and Employee and their respective attorneys will meet with the mediator for one mediation session of at least four hours. If the claim or dispute cannot be settled during such mediation session or mutually agreed continuation of the session, either Employer or Employee may give the mediator and the other party to the claim or dispute written notice declaring the end of the mediation process. All discussions connected with this mediation provision will be confidential and treated as compromise and settlement discussions. Nothing disclosed in such discussions, which is not independently discoverable, may be used for any purpose in any later proceeding. The mediator&#8217;s fees will be paid in equal portions by Employer and Employee, unless Employer agrees to pay all such fees.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">12.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Arbitration. </font><font style="font-family:Arial;font-size:12pt;">If any claim or dispute has not been resolved in accordance with Section 12.1, then the claim or dispute will be determined by arbitration in accordance with the then-current JAMS employment arbitration rules and procedures, except as modified herein. The arbitration will be conducted by a sole neutral arbitrator who has had both training and experience as an arbitrator of general employment and commercial matters and who is and for at least ten (10) years has been, a partner, a shareholder, or a member in a law firm. If Employer and Employee cannot agree on an arbitrator, then the arbitrator will be selected by JAMS in accordance with Rule 15 of the JAMS employment arbitration rules and procedures. No person who has served as a mediator under the mediation provision, however, may be selected as the arbitrator for the same claim or dispute. Reasonable discovery will be permitted and the arbitrator may decide any issue as to discovery. The arbitrator may decide any issue as to whether or as to the extent to which any dispute is subject to the dispute resolution provisions in Section 12 and the arbitrator may award any relief permitted by law. The arbitrator must base the arbitration award on the provisions of Section 12 and applicable law and must render the award in writing, including an explanation of the reasons for the award. Judgment upon the award may be entered by any court having jurisdiction of the matter, and the decision of the arbitrator will be final and binding.  The statute of limitations</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s7D711462CB9E4A52ABD39D44EBD10DB9"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">applicable to the commencement of a lawsuit will apply to the commencement of an arbitration under Section 12.2. The arbitrator&#8217;s fees will be paid in equal portions by Employer and Employee, unless Employer agrees to pay all such fees.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">13.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Fees Related to Dispute Resolution</font><font style="font-family:Arial;font-size:12pt;">. Unless otherwise agreed, the prevailing party will be entitled to its costs and attorneys&#8217; fees incurred in any litigation or dispute relating to the interpretation or enforcement of this Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:121%;text-align:justify;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">14.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Disclosure</font><font style="font-family:Arial;font-size:12pt;">. Employee agrees fully and completely to reveal the terms of this Agreement to any future employer or potential employer of Employee and authorizes Employer, at its election, to make such disclosure.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">15.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Representation of Employee</font><font style="font-family:Arial;font-size:12pt;">. Employee represents and warrants to Employer that Employee is free to enter into this Agreement and has no contract, commitment, arrangement or understanding to or with any party that restrains or is in conflict with Employee&#8217;s performance of the covenants, services and duties provided for in this Agreement. Employee agrees to indemnify Employer and to hold it harmless against any and all liabilities or claims arising out of any unauthorized act or acts by Employee that, the foregoing representation and warranty to the contrary notwithstanding, are in violation, or constitute a breach, of any such contract, commitment, arrangement or understanding.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">16.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Conditions of Employment. </font><font style="font-family:Arial;font-size:12pt;">Employer&#8217;s obligations to Employee under this Agreement are conditioned upon Employee&#8217;s timely compliance with requirements of the United States immigration laws.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">17.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Assignability</font><font style="font-family:Arial;font-size:12pt;">. During Employee&#8217;s employment, this Agreement may not be assigned by either party without the written consent of the other; provided, however, that Employer may assign its rights and obligations under this Agreement without Employee&#8217;s consent to a successor by sale, merger or liquidation, if such successor carries on the Business substantially in the form in which it is being conducted at the time of the sale, merger or liquidation. This Agreement is binding upon Employee, Employee&#8217;s heirs, personal representatives and permitted assigns and on Employer, its successors and assigns.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">18.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Notices. </font><font style="font-family:Arial;font-size:12pt;">Any notices required or permitted to be given hereunder are sufficient if in writing and delivered by hand, by facsimile, by registered or certified mail, or by overnight courier, to Employee at [address redacted] or to the President of Employer at 4660 La Jolla Village Drive, Suite 850, San Diego, California, 92122 with a copy sent to Oncolytics Biotech Inc., 210, 1167 Kensington Crescent N.W, Calgary, Alberta, Canada T2N 1X7. Notices shall be deemed to have been given (i) upon delivery, if delivered by hand, (ii) seven days after mailing, if mailed, (iii) one business day after delivery, if delivered by courier, and (iv) one business day following receipt of an appropriate electronic confirmation, if by facsimile.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:122%;text-align:justify;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">19.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Severability</font><font style="font-family:Arial;font-size:12pt;">. If any provision of this Agreement or compliance by any of the parties with any provision of this Agreement constitutes a violation of any law, or is or</font></div><div style="line-height:122%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s1A0E75FE74E13C32C9689D44EC02D4EE"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">becomes unenforceable or void, then such provision, to the extent only that it is in violation of law, unenforceable or void, shall be deemed modified to the extent necessary so that it is no longer in violation of law, unenforceable or void, and such provision will be enforced to the fullest extent permitted by law. The Parties shall engage in good faith negotiations to modify and replace any provision which is declared invalid or unenforceable with a valid and enforceable provision, the economic effect of which comes as close as possible to that of the invalid or unenforceable provision which it replaces. If such modification is not possible, said provision, to the extent that it is in violation of law, unenforceable or void, shall be deemed severable from the remaining provisions of this Agreement, which provisions will remain binding on the parties.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">20.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Waivers. </font><font style="font-family:Arial;font-size:12pt;">No failure on the part of either party to exercise, and no delay in exercising, any right or remedy hereunder will operate as a waiver thereof; nor will any single or partial waiver of a breach of any provision of this Agreement operate or be construed as a waiver of any subsequent breach; nor will any single or partial exercise of any right or remedy hereunder preclude any other or further exercise thereof or the exercise of any other right or remedy granted hereby or by law.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">21.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Governing Law. </font><font style="font-family:Arial;font-size:12pt;">Except as provided in Section 12 above, the validity, construction and performance of this Agreement shall be governed by the laws of the State of California without regard to the conflicts of law provisions of such laws. California shall have exclusive jurisdiction of any lawsuit arising from or relating to Employee&#8217;s employment with, or termination from, Employer, or arising from or relating to this Agreement. Employee consents to such venue and personal jurisdiction.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">22.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">409A Savings Clause</font><font style="font-family:Arial;font-size:12pt;">. The parties intend that payments or benefits payable under this Agreement not be subject to the additional tax imposed pursuant to Section 409A of the Code (&#8220;Section 409A&#8221;), and the provisions of this Agreement shall be construed and administered in accordance with such intent. To the extent such potential payments or benefits could become subject to Section 409A, the parties shall cooperate to amend this Agreement with the goal of giving Executive the economic benefits described herein in a manner that does not result in such tax being imposed. If the parties are unable to agree on a mutually acceptable amendment, the Company may, without Executive&#8217;s consent and in such manner as it deems appropriate or desirable, amend or modify this Agreement or delay the payment of any amounts hereunder to the minimum extent necessary to meet the requirements of Section 409A.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">23.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Counterparts. </font><font style="font-family:Arial;font-size:12pt;">This agreement may be executed in counterpart in different places, at different times and on different dates, and in that case all executed counterparts taken together collectively constitute a single binding agreement. Delivery of an executed counterpart signature hereof by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:54px;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">24.</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Costs and Fees Related to Negotiation and Execution of Agreement.</font></div></td></tr></table><div style="line-height:138%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Each Party Shall be responsible for the payment of its own costs and expenses, including</font></div><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sC6D94C4A5601DADF299E9D44EC23A887"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">legal fees and expenses, in connection with the negotiation and execution of this Agreement. Neither Party will be liable for the payment of any commissions or compensation in the nature of finders' fees or brokers' fees, gratuity or other similar thing or amount in consideration of the other Party entering into this Agreement to any broker, agent or third party acting on behalf of the other Party.</font></div><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">25. </font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Entire Agreement. </font><font style="font-family:Arial;font-size:12pt;">This instrument contains the entire agreement of the parties with respect to the relationship between Employee and Employer and supersedes all prior agreements and understandings, and there are no other representations or agreements other than as stated in this Agreement related to the terms and conditions of Employee's employment. This Agreement may be changed only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension or discharge is sought, and any such modification will be signed by the President of Employer.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:125%;text-align:justify;padding-left:9px;text-indent:45px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">IN </font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">WITNESS WHEREOF, </font><font style="font-family:Arial;font-size:12pt;">the parties have duly signed and delivered this Agreement as of the day and year first above written.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">&#32;EMPLOYER</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:6px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:30.97713097713098%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:24%;"></td><td style="width:76%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">By</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-style:italic;">/s/ Matt Coffey</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Title</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Director</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:30.97713097713098%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:24%;"></td><td style="width:76%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">By</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-style:italic;">/s/ Gilles Gosselin</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Title</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Director</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">&#32;EMPLOYEE</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:6px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:41.16424116424117%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:36%;"></td><td style="width:64%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">By</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-style:italic;">/s/ Rita Laeufle</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Print Name:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Rita Laeufle, MD PhD</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s205D18B0973B1B696BE69D44EC569212"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:164px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">EXHIBIT A</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:164px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">INITIAL DUTIES AND RESPONSIBILITIES</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:13px;text-align:left;padding-left:6px;font-size:11.5pt;"><font style="font-family:Arial;font-size:11.5pt;font-weight:bold;">Position Summary:  </font><font style="font-family:Arial;font-size:11.5pt;">The primary role of the CMO will be to provide leadership and direction for the Company&#8217;s clinical development program.  The CMO will be responsible for the strategy, direction and execution of the Company&#8217;s clinical development plans.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11.5pt;"><font style="font-family:Arial;font-size:11.5pt;font-weight:bold;">Essential Duties and Responsibilities:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:54px;"><font style="font-family:Arial;font-size:11.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:Arial;font-size:11.5pt;">Direct the development of clinical strategies</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:54px;"><font style="font-family:Arial;font-size:11.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:Arial;font-size:11.5pt;">Orchestrate and manage clinical aspects of regulatory strategies and interactions with Health Authorities</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:54px;"><font style="font-family:Arial;font-size:11.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:Arial;font-size:11.5pt;">Oversee the analysis and interpretation of clinical trial data and the reporting of clinical trial results</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:54px;"><font style="font-family:Arial;font-size:11.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:Arial;font-size:11.5pt;">Lead interactions with academic thought leaders, investigators, cooperative groups, and other clinical stakeholders</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:54px;"><font style="font-family:Arial;font-size:11.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:Arial;font-size:11.5pt;">Provide clinical support and work with other members of the management team to develop and communicate the overall corporate strategy</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11.5pt;padding-left:54px;"><font style="font-family:Arial;font-size:11.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11.5pt;"><font style="font-family:Arial;font-size:11.5pt;">Represent the Company and its programs to external audiences, including the investment, medical and regulatory communities, as well as pharmaceutical or biotechnology industry collaborators/partners</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11.5pt;"><font style="font-family:Arial;font-size:11.5pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sAC075F9DA68D91CDCC3E9D44EC793227"></a></div><div></div><div><br></div><div style="line-height:224%;padding-top:2px;text-align:center;padding-left:278px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">EXHIBIT B BENEFITS</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Physical Fitness Benefit:</font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The Employee is entitled to the Physical Fitness Benefit in the amount of Seven Hundred and Fifty ($750.00) United States Dollars per annum to use towards an item or service that promotes physical activity; the details of which are outlined in the Company Policy Manual.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Deferred Compensation:</font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Employee shall, if qualified to do so, be entitled to allocate a portion of his salary to a 401(K) Plan established for the Employee, up to the prescribed maximum, and in accordance with the requirements thereof.</font></div><div style="line-height:126%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The employer will match the employee contribution up to 4% of the employee&#8217;s base salary or the</font></div><div style="line-height:126%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">annual compensation limit set by the IRS, whichever is lower.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Health Care Benefit:</font></div><div style="line-height:121%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Employee shall, if qualified to do so, be entitled to access the health care menu sponsored by the employer. The menu includes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:34px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:121%;font-size:11pt;padding-left:10px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:121%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Plans for which the employer will contribute towards the premium at 100% for the employee and at 75% for the dependents:</font></div></td></tr></table><div style="line-height:129%;text-align:left;padding-left:58px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;">Medical HMO for California based employees</font></div><div style="line-height:112%;text-align:left;padding-left:58px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;">Medical PPO </font><font style="font-family:inherit;font-size:11pt;">o&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;">Medical HSA </font><font style="font-family:inherit;font-size:11pt;">o&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;">Dental PPO </font><font style="font-family:inherit;font-size:11pt;">o&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;">Vision PPO</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:34px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:118%;font-size:11pt;padding-left:10px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:118%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Insurance contributed at 100% of the premium for:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:82px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:131%;font-size:11pt;padding-left:58px;"><font style="font-family:inherit;font-size:11pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:131%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Life Insurance and AD&amp;D</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:82px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:127%;font-size:11pt;padding-left:58px;"><font style="font-family:inherit;font-size:11pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:127%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Short Term Disability</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:82px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:128%;font-size:11pt;padding-left:58px;"><font style="font-family:inherit;font-size:11pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:128%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Long Term Disability</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:34px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:122%;font-size:11pt;padding-left:10px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:122%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Voluntary life insurance may be added for the employer and/or the dependents at the</font></div></td></tr></table><div style="line-height:126%;text-align:left;padding-left:34px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">employee&#8217;s expense</font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Further details are outlined in the Enrollment Guide.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sF6AF41167FC74F4AABE69D44ECA9FFDF"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:81px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">EXHIBIT C</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:224%;text-align:center;padding-left:81px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">STOCK OPTION PLAN AND INCENTIVE SHARE AWARD PLAN AMENDED AND RESTATED STOCK OPTION PLAN</font></div><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">The Plan</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Board of Directors of Oncolytics Biotech Inc. (the &#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Corporation</font><font style="font-family:Arial;font-size:12pt;">&#8221;) has adopted this Stock Option Plan (the &#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Plan</font><font style="font-family:Arial;font-size:12pt;">&#8221;) governing the issuance of Options (as defined herein) of the Corporation to Eligible Persons (as defined herein).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Purpose</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The purpose of this Plan is to advance the interests of the Corporation by encouraging the Directors, Officers, Employees and Consultants to acquire Shares, thereby (i) increasing the proprietary interests of such persons in the Corporation; (ii) aligning the interests of such persons with the interests of the Corporation&#8217;s shareholders generally;</font></div><div style="line-height:121%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(iii) encouraging such persons to remain associated with the Corporation; and (iv) furnishing such persons with an additional incentive in their efforts on behalf of the Corporation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Definitions</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:24px;">(a)</font><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">associate</font><font style="font-family:Arial;font-size:12pt;">&#8221; has the meaning ascribed thereto in the TSX Policies.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:24px;">(b)</font><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Board</font><font style="font-family:Arial;font-size:12pt;">&#8221; means the board of directors of the Corporation as constituted from time to time and shall be deemed to include any committee thereof to which the Board has, fully or partially, delegated the administration and operation of this Plan pursuant to Section 4 of this Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Change of Control</font><font style="font-family:Arial;font-size:12pt;">&#8221; means:</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:121%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">the acceptance by the holders of Shares, representing in the aggregate of more than 50 percent (50%) of all issued and outstanding Shares, of any offer, whether by way of a takeover bid or otherwise, for all or any of the Shares;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">the acquisition, by whatever means (including, without limitation, amalgamation, arrangement, consolidation or merger), by a person (or two or more persons who in such acquisition have acted jointly or in concert or intend to exercise jointly or in concert any voting rights attaching to the Shares acquired), directly or indirectly, of the beneficial ownership of such number of Shares, which together with such person&#8217;s then owned Shares, if any, represent more than 50 percent (50%) of the Corporation&#8217;s then outstanding Shares;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">the sale, lease or other disposition of all or substantially all of the assets of the Corporation;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s6409DB7D591C8DC26A089D44ECCB2714"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">the passing of a resolution by the board of directors of the Corporation or shareholders of the Corporation to substantially liquidate assets or windup its business or significantly rearrange its affairs in one or more transactions or series of transactions or the commencement of proceedings for such a liquidation, winding-up or re-arrangement (except where such re-arrangement is part of a </font><font style="font-family:Arial;font-size:12pt;font-style:italic;">bona fide </font><font style="font-family:Arial;font-size:12pt;">reorganization of the Corporation in circumstances where the business of the Corporation is continued and where the shareholdings remain substantially the same following the re-arrangement as existed prior to the re-arrangement);</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">individuals who were members of the board of directors of the Corporation immediately prior to a meeting of the shareholders of the Corporation involving a contest for or, an item of business relating to the election of directors shall not constitute a majority of the board of directors of the Corporation following such election;</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(vi)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">the completion of any transaction or the first of a series of transactions which would have the same or similar effect as any transaction or series of transactions referred to in subsections (i), (ii), (iii), (iv) or (v) referred to above; or</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(vii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">a determination by the board of directors of the Corporation that there has been a change, whether by way of a change in the holding of the Shares, in the ownership of the Corporation&#8217;s assets or by any other means, as a result of which any person or group of persons acting jointly or in concert is in a position to exercise effective control of the Corporation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Corporation</font><font style="font-family:Arial;font-size:12pt;">&#8221; means Oncolytics Biotech Inc.</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:Arial;font-size:12pt;padding-right:24px;">(e)</font><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Consultant</font><font style="font-family:Arial;font-size:12pt;">&#8221; means an individual or Consultant Corporation, other than a Director, Officer or Employee, that:</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">is engaged to provide on an ongoing </font><font style="font-family:Arial;font-size:12pt;font-style:italic;">bona fide </font><font style="font-family:Arial;font-size:12pt;">basis, consulting, technical, management or other services to the Corporation or a subsidiary of the Corporation, other than services in relation to a distribution;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">provides the services under a written contract for an initial, renewable or extended period of twelve months or more; and</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">spends or will spend a significant amount of time and attention on the affairs of the Corporation or a subsidiary of the Corporation.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Consultant  Corporation</font><font style="font-family:Arial;font-size:12pt;">&#8221;  means  for  an  individual  consultant,  a  company  or</font></div></td></tr></table><div style="line-height:138%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">partnership of which the individual is an employee, shareholder or partner.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Director</font><font style="font-family:Arial;font-size:12pt;">&#8221; means a director of the Corporation or any subsidiary of the Corporation.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">(h)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:138%;text-align:left;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Eligible  Person</font><font style="font-family:Arial;font-size:12pt;">&#8221;  means  a  Director,  Officer,  Employee  or  Consultant  of  the</font></div></td></tr></table><div style="line-height:138%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Corporation or its subsidiaries.</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sECB9C473423AD9DC33499D44ECFC898B"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Employee</font><font style="font-family:Arial;font-size:12pt;">&#8221; means a person who would be considered an &#8216;employee&#8217; under the Tax Act, or who works full-time or for a specified number of hours per week on a continuing regular basis and is subject to the same control and direction by the Corporation or a subsidiary of the company over the details and methods of work as an employee of the company, but for whom tax and other deductions are not made at source.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:121%;padding-left:54px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:24px;">(j)</font><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Exchange</font><font style="font-family:Arial;font-size:12pt;">&#8221; means the Toronto Stock Exchange and such other stock exchange(s) on which the Shares are then listed and posted for trading from time to time.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">(k)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">insider</font><font style="font-family:Arial;font-size:12pt;">&#8221; has the meaning ascribed thereto in the TSX Policies.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">(l)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">insider participation limit</font><font style="font-family:Arial;font-size:12pt;">&#8221; has the meaning ascribed thereto in the TSX Policies.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:24px;">(m)</font><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Market Price</font><font style="font-family:Arial;font-size:12pt;">&#8221; means the closing price of the Shares on the TSX (or, if the Shares are not then listed and posted for trading on the TSX or are then listed and posted for trading on more than one Exchange, on such Exchange on which the Shares are then listed and posted for trading as may be selected for such purpose by the Board acting reasonably and in good faith) on the last trading date prior to the date of grant of an Option hereunder.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(n) "</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Non-Employee Director</font><font style="font-family:Arial;font-size:12pt;">" means any Director who is not also an Employee.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:24px;">(o)</font><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Officer</font><font style="font-family:Arial;font-size:12pt;">&#8221; means an officer of the Corporation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">(p)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Option</font><font style="font-family:Arial;font-size:12pt;">&#8221; means an option to purchase Shares granted pursuant to this Plan.</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:Arial;font-size:12pt;padding-right:24px;">(q)</font><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Participant</font><font style="font-family:Arial;font-size:12pt;">&#8221; means each of the Eligible Persons granted an Option pursuant to this Plan and their heirs, executors and administrators.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">(r)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Plan</font><font style="font-family:Arial;font-size:12pt;">&#8221; means this Stock Option Plan.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">(s)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Security Based Compensation Arrangement</font><font style="font-family:Arial;font-size:12pt;">&#8221; has the meaning ascribed thereto in</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">the TSX Policies.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:24px;">(t)</font><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Shares</font><font style="font-family:Arial;font-size:12pt;">&#8221; means common shares in the capital of the Corporation and shall be deemed to include any other listed securities that may be acquired by a Participant upon the exercise of an Option the terms of which have been modified in accordance with Section 17.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(u) &#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Tax Act</font><font style="font-family:Arial;font-size:12pt;">&#8221; means the </font><font style="font-family:Arial;font-size:12pt;font-style:italic;">Income Tax Act </font><font style="font-family:Arial;font-size:12pt;">(Canada), as amended from time to time.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">(v)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">TSX</font><font style="font-family:Arial;font-size:12pt;">&#8221; means the Toronto Stock Exchange.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">(w)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">TSX Policies</font><font style="font-family:Arial;font-size:12pt;">&#8221; means the policies included in the TSX Company Manual.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s3AD1E3ED02FC849D68559D44ED223FB0"></a></div><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">4.</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Administration</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:25px;">(a)</font><font style="font-family:Arial;font-size:12pt;">The Plan shall be administered by the Board and, for greater certainty, the board of directors of the Corporation shall have the right to delegate the administration and operation of this Plan, in whole or in part, to a committee of the board of directors that has been assigned the responsibility of determining the Corporation&#8217;s policies with respect to executive compensation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:25px;">(b)</font><font style="font-family:Arial;font-size:12pt;">Subject to the terms and conditions set forth herein and the TSX Policies, the Board is authorized to provide for the granting, exercise and method of exercise of Options, all on such terms (which may vary between Options granted from time to time) as it shall determine. In addition, the Board shall have the authority to:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">construe and interpret this Plan and all option agreements entered into hereunder,</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:76px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:56px;"><font style="font-family:Arial;font-size:12pt;">(ii)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:Arial;font-size:12pt;">prescribe, amend and rescind rules and regulations relating to this Plan; And</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">make all other determinations necessary or advisable for the administration of this Plan. All determinations and interpretations made by the Board shall be binding on all Participants and on their legal, personal representatives and beneficiaries.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:121%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:25px;">(c)</font><font style="font-family:Arial;font-size:12pt;">Options shall be evidenced by an agreement, signed on behalf of the Corporation and by the person to whom an Option is granted, which agreement shall be in such form as the Board shall approve or authorize from time to time.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Shares Subject to this Plan</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:25px;">(a)</font><font style="font-family:Arial;font-size:12pt;">Subject to Section 17, the securities that may be acquired by Participants under this Plan shall consist of authorized but unissued Shares.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:121%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:25px;">(b)</font><font style="font-family:Arial;font-size:12pt;">The number of Shares reserved for issuance under this Plan and all other Security Based Compensation Arrangements in aggregate shall not exceed ten percent (10%) of the total number of issued and outstanding Shares from time to time.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:25px;">(c)</font><font style="font-family:Arial;font-size:12pt;">If any Option granted under this Plan shall be exercised or shall expire or terminate for any reason without having been exercised in full, any Shares to which such Option relates shall be available for the purposes of the granting of Options under this Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Maintenance of Sufficient Capital</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Corporation shall at all times during the term of this Plan ensure that the number of Shares it is authorized to issue shall be sufficient to satisfy the requirements of this Plan.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Eligibility and Participation</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s0C6B6DC641C5315135E29D44ED872410"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Board may from time to time, in its discretion, grant an Option to any Eligible Person, upon such terms, conditions and limitations as the Board may determine, including the terms, conditions and limitations set forth herein, provided that Options granted to any Participant shall be approved by the shareholders of the Corporation if the TSX Policies or the requirements of any other Exchange on which the Shares are listed require such approval.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Exercise Price</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:121%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Options may be exercised at a price (the &#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Exercise Price</font><font style="font-family:Arial;font-size:12pt;">&#8221;) which shall be fixed by the Board at the time that the Option is granted. No Option shall be granted with an Exercise Price at a discount to the Market Price.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Number of Optioned Shares</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The number of Shares that may be acquired under an Option granted to a Participant shall be determined by the Board as at the time the Option is granted, provided that the aggregate number of Shares reserved for issuance to any one Participant under this Plan or any other Security Based Compensation Arrangement, shall not exceed five percent (5%) of the total number of issued and outstanding Shares (calculated on a non-diluted basis).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Term</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The period during which an Option may be exercised (the &#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Option Period</font><font style="font-family:Arial;font-size:12pt;">&#8221;) shall be determined by the Board at the time the Option is granted, subject to any vesting limitations which may be imposed by the Board in its sole unfettered discretion at the time such Option is granted, provided that:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:24px;">(a)</font><font style="font-family:Arial;font-size:12pt;">no Option shall be exercisable for a period exceeding ten (10) years from the date the Option is granted;</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:24px;">(b)</font><font style="font-family:Arial;font-size:12pt;">the Option Period shall be automatically reduced in accordance with Sections 12 and 13 upon the occurrence of any of the events referred to therein; and</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:24px;">(c)</font><font style="font-family:Arial;font-size:12pt;">no Option in respect of which shareholder approval is required under the TSX Policies or the requirements of any other Exchange on which the Shares are then listed shall be exercisable until such time as the Option has been approved by the shareholders of the Corporation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Notwithstanding the foregoing, if the Option Period of an Option expires during a Blackout Period (as defined below) or within five (5) business days after a Blackout Period, such Option Period shall be deemed to be extended to the date which is the tenth (10</font><font style="font-family:Arial;font-size:7pt;">th</font><font style="font-family:Arial;font-size:12pt;">) business day after the last day of the applicable Black Out Period. For the purposes of this Plan, Blackout Period means, with respect to an Option, any period during which the holder of such Option is not permitted to trade Shares pursuant to the policies of the Corporation.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sAD333AF4F04CA063F6239D44EDD61F78"></a></div><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Method of Exercise of Option</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:121%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:25px;">(a)</font><font style="font-family:Arial;font-size:12pt;">Except as set forth in Sections 12 and 13 or as otherwise determined by the Board, no Option may be exercised unless the holder of such Option is, at the time the Option is exercised, an Eligible Person.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:25px;">(b)</font><font style="font-family:Arial;font-size:12pt;">Options may be exercised in whole or in part and may be exercised on a cumulative basis where a vesting limitation has been imposed at the time of grant.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:25px;">(c)</font><font style="font-family:Arial;font-size:12pt;">Any Participant (or his legal, personal representative) wishing to exercise an Option shall deliver to the Corporation, at its principal office in the City of Calgary, Alberta:</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">a written notice expressing the intention of such Participant (or his legal, personal representative) to exercise his Option and specifying the number of Shares in respect of which the Option is exercised; and (ii) a cash payment, cheque or bank draft, representing the full purchase price of the Shares in respect of which the Option is exercised. For greater certainty, the Corporation shall not provide financial assistance in regards to the exercise of an Option.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:25px;">(d)</font><font style="font-family:Arial;font-size:12pt;">Upon the exercise of an Option as aforesaid, the Corporation shall use its reasonable efforts to forthwith deliver, or cause the registrar and transfer agent of the Shares to deliver, to the relevant Participant (or his legal, personal representative) or to the order thereof, a certificate representing the aggregate number of fully paid and non-assessable Shares as the Participant (or his legal, personal representative) shall have then paid for.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:28px;">(e)</font><font style="font-family:Arial;font-size:12pt;">In order to fulfill the Corporation&#8217;s obligations under the Tax Act in respect of withholding and remittance on account of tax payable by Participants on the exercise of Options under this Section 11, the Corporation shall advise each Participant, on receiving such Participant&#8217;s notice of intention to exercise, of the amount of such remittance (the &#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Remittance Amount</font><font style="font-family:Arial;font-size:12pt;">&#8221;) required under the Tax Act. Prior to the delivery of the Shares, the Corporation may, in its sole discretion:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">require the Participant to pay to the Corporation, as an additional amount on the exercise of their Options, the Remittance Amount;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">withhold from any remuneration or consideration payable to the Participant an amount equal to the Remittance Amount;</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">retain and sell on behalf of the Participant such number of Shares to obtain proceeds from the sale of such shares on the principal stock exchange on which the common shares are traded sufficient to satisfy the Remittance Amount; or</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:81px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:54px;"><font style="font-family:Arial;font-size:12pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">any combination of the above.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:121%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Upon receipt or payment of this amount in the manner described above, the Corporation shall in accordance with Section 11(d) issue to the Participant the Shares (or in the case of subsection 11(d)(iii), the remaining Shares) for which the Option was exercised.</font></div><div style="line-height:121%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sBA25BE54A985FB06BC359D44EE4FD7CA"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(f) Notwithstanding anything else contained herein, each Participant shall be responsible for the payment of all applicable taxes, including, but not limited to, income taxes payable in connection with the exercise of any Options under this Plan and the Corporation, its Directors, Officers, Employees and agents shall bear no liability in connection with the payment of such taxes.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Ceasing to be an Eligible Person</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Subject to any written agreement between the Corporation and a Participant providing otherwise, if any Participant shall cease to be an Eligible Person for any reason other than the termination for cause or the death or permanent disability of the Participant, such Participant&#8217;s Option will terminate immediately as to the then unvested portion thereof and at 5:00 p.m. (Calgary time) on the earlier of the date of the expiration of the Option Period and the ninetieth (90</font><font style="font-family:Arial;font-size:7pt;">th</font><font style="font-family:Arial;font-size:12pt;">) day after the date such Participant ceases to be an Eligible Person as to the then vested portion of the Option.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">If a Participant ceases to be an Eligible Person as a result of the termination of such Participant for cause, effective as of the date notice is given to the Participant of such termination, all outstanding Option Agreements under which Options have been granted to such Participant shall be terminated and all rights to receive Shares thereunder shall be forfeited by such Participant, and the Participant shall not be entitled to receive any Shares or other compensation in lieu thereof.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Neither the selection of any person as a Participant nor the granting of an Option to any Participant under this Plan shall (i) confer upon such Participant any right to continue as a Director, Officer, Employee or Consultant of the Corporation or a subsidiary thereof, as the case may be, or (ii) be construed as a guarantee that the Participant will continue as a Director, Officer, Employee or Consultant of the Corporation or a subsidiary thereof, as the case may be.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Notwithstanding the foregoing, the Board may, at its sole discretion, extend the period during which any Options may be exercised by a Participant that has ceased to be an Eligible Person, in the case of Options held by non-management Directors, by not more than one (1) year, and in the case of Options held by other persons, by not more than three (3) years, but in no case longer than the original expiry date of the Options established at the time of grant.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Death or Permanent Disability of a Participant</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Subject to any written agreement between the Corporation and a Participant providing otherwise, if in the event of the death or permanent disability of a Participant, any Option previously granted to such Participant shall be exercisable until the end of the Option Period or until the expiration of 12 months after the date of death or permanent disability of such Participant, whichever is earlier, and then only:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(a) by the person or persons to whom the Participant&#8217;s rights under the Option shall pass by the Participant&#8217;s will or applicable law;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sC2FFC5AA3C9ED756B07B9D44EE8FBA17"></a></div><div></div><div><br></div><div style="line-height:138%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(b) to the extent that he was entitled to exercise the Option as at the date of the</font></div><div style="line-height:138%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Participant&#8217;s death or permanent disability.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Change of Control</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Notwithstanding any other provision hereof, in the event of a Change of Control, all Options which have not otherwise vested in accordance with their terms shall immediately vest and be exercisable, notwithstanding the other terms of the Options or this Plan for a period of time ending on the earlier of the expiry time of the Option and the ninetieth (90</font><font style="font-family:Arial;font-size:7pt;">th</font><font style="font-family:Arial;font-size:12pt;">) day following the Change of Control.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">15.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Transferability</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">All benefits, rights and Options accruing to any Participant in accordance with the terms and conditions of this Plan shall not be transferable or assignable unless specifically provided herein. The Corporation shall not recognize any attempted exercise of any purported assignee of a Participant. During the lifetime of a Participant any Options granted hereunder may only be exercised by the Participant and in the event of the death or permanent disability of a Participant, by the person or persons to whom the Participant&#8217;s rights under the Option pass by the Participant&#8217;s will or applicable law.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">16.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Amendment and Termination of Plan</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:24px;">(a)</font><font style="font-family:Arial;font-size:12pt;">The Board may, at any time, suspend or terminate this Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:24px;">(b)</font><font style="font-family:Arial;font-size:12pt;">Subject to Section 16(c) and 16(d), the Board may, at any time and from time to time, amend this Plan or any Option, subject to applicable TSX Policies and the requirements of any other Exchange on which the Shares are then listed, without the consent or approval from any Participant or shareholder of the Corporation (provided that no such amendment may be made that will materially prejudice the rights of any Participant under any Option previously granted to the Participant without consent by such Participant) including without limitation:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">to amend, modify or terminate this Plan with respect to all Shares in respect of Options which have not yet been granted thereunder;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(ii) to make any amendment of a &#8220;housekeeping nature&#8221;, including to make any amendment typographical, grammatical, clerical or administrative nature or clarification correcting or rectifying any ambiguity, immaterial inconsistency, defective provision, mistake, or error or omission in this Plan or any Option;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:54px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:30px;">(iii)</font><font style="font-family:Arial;font-size:12pt;">to change the provisions relating to the manner of exercise of Options, including changing or adding any form of financial assistance provided by the Corporation or adding or amending provisions relating to a cashless exercise of Options;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:54px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:30px;">(iv)</font><font style="font-family:Arial;font-size:12pt;">accelerating vesting or extending the expiration date of any Option (provided that such Option is not held by an insider), provided that the period during which</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sBC7B30B74D487B0A8B359D44EEF7E129"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">an Option is exercisable does not exceed 10 years from the date the Option is granted;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:121%;padding-left:54px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:30px;">(v)</font><font style="font-family:Arial;font-size:12pt;">adding a cashless exercise feature, payable in cash or securities, whether or not providing for a full deduction of the number of underlying Shares from this Plan reserve; and</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:54px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:30px;">(vi)</font><font style="font-family:Arial;font-size:12pt;">to make any addition to, deletion from or alteration of the provisions of this Plan or any Option that are necessary to comply with applicable law, the TSX Policies, or the requirements of any other Exchange on which the Shares are then listed and to avoid unanticipated consequences deemed by the Board to be inconsistent with the purpose of this Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:24px;">(c)</font><font style="font-family:Arial;font-size:12pt;">Notwithstanding Section 16(b), the Board may not, without approval of the holders of a majority of Shares present and voting in person or by proxy at a meeting of holders of Shares, amend this Plan or any Option to:</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">increase the number of Shares reserved for issuance pursuant to this Plan;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">extend eligibility to participate in this Plan to persons other than Eligible Persons;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">permit Options to be transferred, other than for normal estate settlement purposes or to an RRSP or similar plan;</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:81px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:54px;"><font style="font-family:Arial;font-size:12pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">permit awards other than Options to be made under this Plan;</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">amend or delete Section 10(a) to extend the term of any Option beyond the Option Period of such Option or allow for such Option to be exercisable for a period exceeding ten (10) years from the date the Option is granted, or extend any Option benefitting an insider other than as otherwise provided for under this Plan; or</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(vi)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">reduce the Exercise Price of an Option, except for the purpose of maintaining Option value in connection with a conversion, change, reclassification, redivision, redesignation, subdivision or consolidation of shares or a reorganization, amalgamation, consolidation, merger, takeover bid or similar transaction involving the Corporation (for this purpose, cancellation or termination of an Option prior to its expiry date for the purpose of reissuing Options to the same option-holder with a lower Exercise Price will be considered an amendment to reduce the Exercise Price of an Option); or</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:56px;"><font style="font-family:Arial;font-size:12pt;">(vii)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:Arial;font-size:12pt;">change the insider participation limitation under this Plan; or</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:88px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:54px;"><font style="font-family:Arial;font-size:12pt;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">amend this Section 16.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:122%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:24px;">(d)</font><font style="font-family:Arial;font-size:12pt;">Notwithstanding Section 16(b), no amendment or revision to this Plan or any Option pursuant to Section 16(b) shall in any manner materially adversely affect the rights of any</font></div><div style="line-height:122%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s80BEC693BCF4488B40D19D44EF5409CE"></a></div><div></div><div><br></div><div style="line-height:138%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Participant under any Options granted under this Plan prior to such amendment or</font></div><div style="line-height:138%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">revision without such Participant&#8217;s consent.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">17.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Necessary Approvals</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:24px;">(a)</font><font style="font-family:Arial;font-size:12pt;">The obligation of the Corporation to issue and deliver Shares in accordance with this Plan is subject to applicable securities legislation and to the receipt of any approvals that may be required from any regulatory authority or any Exchange on which the Shares are then listed. If Shares cannot be issued to a Participant upon the exercise of an Option for any reason whatsoever, the obligation of the Corporation to issue such Shares shall terminate and any funds paid to the Corporation in connection with the exercise of such Option will be returned to the relevant Participant as soon as practicable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:24px;">(b)</font><font style="font-family:Arial;font-size:12pt;">Without obtaining the approval of the shareholders of the Corporation in accordance with the TSX Policies or the requirements of any other Exchange on which the Shares are then listed, no Options shall be granted pursuant to this Plan, if such grant together with grants pursuant to all other share compensation arrangements of the Corporation, could result, at any time, in:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">a number of Shares issuable pursuant to Options granted to insiders exceeding ten percent (10%) of the number of outstanding Shares at any time;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:122%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">the issuance within a one year period to insiders, of a number of Shares exceeding ten percent (10%) of the number of outstanding Shares; or</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(iii) the issuance to any one insider and such insider&#8217;s associates, within a one year period, of a number of Shares exceeding five percent (5%) of the number of outstanding Shares.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:24px;">(c)</font><font style="font-family:Arial;font-size:12pt;">The total annual grant of Options to any one Non-Employee Director cannot exceed a grant value of $150,000.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">18.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Stock Exchange Rules</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Plan and any option agreements entered into hereunder shall comply with the TSX Policies and the requirements of any other Exchange on which the Shares are then listed.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">19.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Right to Issue Other Shares</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:121%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Corporation shall not by virtue of this Plan be in any way restricted from declaring and paying stock dividends, issuing further Shares, varying or amending its share capital or corporate structure or conducting its business in any way whatsoever.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">20.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Notice</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s9152882296AEC41E9ACE9D44EF93D30E"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Any notice required to be given by this Plan shall be in writing and shall be given by registered mail, postage prepaid or delivered by courier or by facsimile or email transmission addressed, if to the Corporation, at its principal address in Calgary, Alberta (being currently 210, 1167 Kensington Crescent N.W., Calgary, Alberta T2N 1X7), Attention: Chief Financial Officer; or if to a Participant, to such Participant at his address as it appears on the books of the Corporation or in the event of the address of any such Participant not so appearing then to the last known address of such Participant; or if to any other person, to the last known address of such person.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">21.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Gender</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Whenever used herein words importing the masculine gender shall include the feminine and neuter genders and vice versa.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;">22.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Interpretation</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:122%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Plan will be governed by and construed in accordance with the laws of the Province of Alberta.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">[DATED: May 4, 2017]</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s4140D2E8D4E37BC16A0E9D44EF9B4A5A"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:81px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">AMENDED AND RESTATED INCENTIVE SHARE AWARD PLAN</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:121%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Board of Directors of Oncolytics Biotech Inc. (the &#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Corporation</font><font style="font-family:Arial;font-size:12pt;">&#8221;) has adopted this Incentive Share Award Plan (the &#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Plan</font><font style="font-family:Arial;font-size:12pt;">&#8221;) governing the issuance of: (i) Restricted Share Awards to Eligible Persons; and (ii) Performance Share Awards to Employees.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Purposes</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The principal purposes of the Plan are as follows:</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:25px;">(a)</font><font style="font-family:Arial;font-size:12pt;">to retain and attract qualified directors, officers, employees and consultants for the Corporation;</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:25px;">(b)</font><font style="font-family:Arial;font-size:12pt;">to promote ownership of common shares of the Corporation by such directors, officers, employees and consultants and to encourage such persons to remain in the employ or service of the Corporation and put forth maximum efforts for the success of the affairs of the Corporation; and</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:122%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:25px;">(c)</font><font style="font-family:Arial;font-size:12pt;">to focus management of the Corporation on operating and financial performance and total long-term shareholder return.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Definitions</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Where used herein, the following terms shall have the following meanings, respectively:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:25px;">(a)</font><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Black-Out Period</font><font style="font-family:Arial;font-size:12pt;">&#8221; means any period during which the holder of a Share Award is not permitted to trade Shares pursuant to the policies of the Corporation.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:25px;">(b)</font><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Board</font><font style="font-family:Arial;font-size:12pt;">&#8221; means the board of directors of the Corporation as constituted from time to time and shall be deemed to include any committee thereof to which the Board has, fully or partially, delegated the administration and operation of this Plan pursuant to Section 3 of this Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:121%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:25px;">(c)</font><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Business Day</font><font style="font-family:Arial;font-size:12pt;">&#8221; means each day other than a Saturday, Sunday, a statutory holiday in Alberta or any day on which the principal chartered banks located in Calgary, Alberta are not open for business during normal business hours.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:25px;">(d)</font><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Cessation Date</font><font style="font-family:Arial;font-size:12pt;">&#8221; means, in respect of a Participant, the last day of active employment or service of the Participant with the Corporation, regardless of the reason for the cessation of employment or service and regardless of whether any or any adequate or proper advance notice of termination or resignation is provided in respect of such cessation of employment or service.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:32px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Change of Control</font><font style="font-family:Arial;font-size:12pt;">&#8221; means:</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">the acceptance by the holders of Shares, representing in the aggregate of more than 50 percent (50%) of all issued and outstanding Shares, of any offer, whether by way of a takeover bid or otherwise, for all or any of the Shares;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s68DC72E30DEF551865689D44EFB9EAA7"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">the acquisition, by whatever means (including, without limitation, amalgamation, arrangement, consolidation or merger), by a person (or two or more persons who in such acquisition have acted jointly or in concert or intend to exercise jointly or in concert any voting rights attaching to the Shares acquired), directly or indirectly, of the beneficial ownership of such number of Shares, which together with such person's then owned Shares, if any, represent more than 50 percent (50%) of the Corporation's then outstanding Shares;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:122%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">the sale, lease or other disposition of all or substantially all of the assets of the Corporation;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">the passing of a resolution by the board of directors of the Corporation or shareholders of the Corporation to substantially liquidate assets or windup its business or significantly rearrange its affairs in one or more transactions or series of transactions or the commencement of proceedings for such a liquidation, winding-up or re-arrangement (except where such re-arrangement is part of a bona fide reorganization of the Corporation in circumstances where the business of the Corporation is continued and where the shareholdings remain substantially the same following the re-arrangement as existed prior to the re-arrangement);</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">individuals who were members of the board of directors of the Corporation immediately prior to a meeting of the shareholders of the Corporation involving a contest for or, an item of business relating to the election of directors shall not constitute a majority of the board of directors of the Corporation following such election;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:121%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(vi)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">the completion of any transaction or the first of a series of transactions which would have the same or similar effect as any transaction or series of transactions referred to in subsections (i), (ii), (iii), (iv) or (v) referred to above; or</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(vii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">a determination by the board of directors of the Corporation that there has been a change, whether by way of a change in the holding of the Shares, in the ownership of the Corporation's assets or by any other means, as a result of which any person or group of persons acting jointly or in concert is in a position to exercise effective control of the Corporation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">"</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Consultant</font><font style="font-family:Arial;font-size:12pt;">" means an individual or Consultant Corporation, other than an Employee or a Non- Employee Director, that:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:121%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:30px;">(a)</font><font style="font-family:Arial;font-size:12pt;">is engaged to provide on an ongoing bona fide basis, consulting, technical, management or other services to the Corporation or a subsidiary of the Corporation, other than services in relation to a distribution;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:30px;">(b)</font><font style="font-family:Arial;font-size:12pt;">provides the services under a written contract for an initial, renewable or extended period of twelve months or more; and</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:30px;">(c)</font><font style="font-family:Arial;font-size:12pt;">spends or will spend a significant amount of time and attention on the affairs of the Corporation or a subsidiary of the Corporation.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s32904594A01AB1D0819C9D44EFEB59A2"></a></div><div></div><div><br></div><div style="line-height:120%;padding-left:6px;padding-top:2px;text-align:justify;text-indent:0px;"><font style="padding-top:2px;text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:30px;">(d)</font><font style="font-family:Arial;font-size:12pt;">"</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Consultant Corporation</font><font style="font-family:Arial;font-size:12pt;">" means for an individual consultant, a company or partnership of which the individual is an employee, shareholder or partner.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Eligible Person</font><font style="font-family:Arial;font-size:12pt;">&#8221; means an Employee, a Non-Employee Director or a Consultant.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:30px;">(f)</font><font style="font-family:Arial;font-size:12pt;">"</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Employee</font><font style="font-family:Arial;font-size:12pt;">" means a persons who would be considered an 'employee' under the Tax Act, or who works full-time or for a specified number of hours per week on a continuing regular basis and is subject to the same control and direction by the Corporation or a subsidiary of the company over the details and methods of work as an employee of the company, but for whom tax and other deductions are not made at source.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Exchange</font><font style="font-family:Arial;font-size:12pt;">&#8221; means the TSX and such other stock exchange(s) on which the Shares</font></div></td></tr></table><div style="line-height:138%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">are then listed and posted for trading from time to time.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(h)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Grant Date</font><font style="font-family:Arial;font-size:12pt;">&#8221; means the grant date for a Share Award.</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(i)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:Arial;font-size:12pt;">"</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">insider</font><font style="font-family:Arial;font-size:12pt;">" has the meaning ascribed thereto in the TSX Policies.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(j)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:Arial;font-size:12pt;">"</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">insider participation limit</font><font style="font-family:Arial;font-size:12pt;">" has the meaning ascribed thereto in the TSX Policies.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(k)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:138%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Issue Date</font><font style="font-family:Arial;font-size:12pt;">&#8221; means the date on which Shares are issued to a Participant in respect</font></div></td></tr></table><div style="line-height:138%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">of a Share Award following completion of the applicable Vesting Period.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(l)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Non-Employee Director</font><font style="font-family:Arial;font-size:12pt;">&#8221; means any director of the Corporation (including, for greater</font></div></td></tr></table><div style="line-height:138%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">certainty, any subsidiary of the Corporation) who is not also an Employee.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(m)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">"</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Officer</font><font style="font-family:Arial;font-size:12pt;">" means an officer of the Corporation.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(n)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Participant</font><font style="font-family:Arial;font-size:12pt;">&#8221; means an Eligible Person to whom a Share Award has been granted.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:30px;">(o)</font><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Performance Criteria</font><font style="font-family:Arial;font-size:12pt;">&#8221; means any performance-related measures or criteria as determined by the Board in its sole discretion at Grant Date to be taken into consideration over the Vesting Period of a Performance Share Award for purposes of determining the applicable Vesting Percentage, which measures or criteria may include, the Corporation&#8217; performance compared to identified operational or financial targets, the Corporation&#8217; shareholder return, and any such other performance-related measures or criteria matters as the Board may determine, in its sole discretion.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:30px;">(p)</font><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Performance Share Award</font><font style="font-family:Arial;font-size:12pt;">&#8221; means an award to an Employee under the Plan pursuant to which Shares shall be issued on the Issue Dates, as applicable, determined in accordance with Section 5 hereof, based upon achieving the applicable Performance Criteria and subject to adjustment in accordance with the terms of the Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:30px;">(q)</font><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Restricted Share Award</font><font style="font-family:Arial;font-size:12pt;">&#8221; means an award to an Eligible Person under the Plan pursuant to which Shares shall be issued on the Issue Dates, as applicable, determined in accordance with Section 5 hereof, subject to adjustment in accordance with the terms of the Plan.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s04ED51DBA71A6491D5CB9D44F00BD3F4"></a></div><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(r)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Security Based Compensation Arrangement</font><font style="font-family:Arial;font-size:12pt;">&#8221; has the meaning ascribed thereto in</font></div></td></tr></table><div style="line-height:138%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">the TSX Policies.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(s)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Share</font><font style="font-family:Arial;font-size:12pt;">&#8221; mean a common share in the capital of the Corporation.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(t)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:138%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Share Award</font><font style="font-family:Arial;font-size:12pt;">&#8221; means a Performance Share Award or Restricted Share Award, as</font></div></td></tr></table><div style="line-height:138%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">applicable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(u)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Share Award Agreement</font><font style="font-family:Arial;font-size:12pt;">&#8221; has the meaning set forth in Section 5 hereof.</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(v)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Shareholder</font><font style="font-family:Arial;font-size:12pt;">&#8221; means a holder of Shares.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(w)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">TSX</font><font style="font-family:Arial;font-size:12pt;">&#8221; means the Toronto Stock Exchange.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(x)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">TSX Policies</font><font style="font-family:Arial;font-size:12pt;">&#8221; means the policies included in the TSX Company Manual.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:30px;">(y)</font><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Vested</font><font style="font-family:Arial;font-size:12pt;">&#8221; means the applicable Vesting Period having been completed and additionally in the case of Performance Share Awards, the applicable Performance Criteria in relation to a whole or percentage of the number of Shares covered by such Performance Share Award determined by the Board having been met, where &#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Vesting</font><font style="font-family:Arial;font-size:12pt;">&#8221; (or any applicable derivative term) has a comparable meaning.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:30px;">(z)</font><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Vesting Percentage</font><font style="font-family:Arial;font-size:12pt;">&#8221; means the percentage of outstanding Performance Share Awards that will vest based upon the relative achievement of the Performance Criteria for such award during the Vesting Period, where such percentage will range from 0 percent to 100 percent reflecting the Board&#8217;s determination, in its sole discretion, of the achievement of the Performance Criteria.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(aa) </font><font style="font-family:Arial;font-size:12pt;">&#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Vesting Period</font><font style="font-family:Arial;font-size:12pt;">&#8221; means the period over which Share Awards granted under the Plan shall vest in accordance with Section 5(b)(i), subject to adjustment or modification pursuant to the terms and conditions of the Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">3.</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Administration</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:25px;">(a)</font><font style="font-family:Arial;font-size:12pt;">The Plan shall be administered by the Board and, for greater certainty, the board of directors of the Corporation shall have the right to delegate the administration and operation of this Plan, in whole or in part, to a committee of the board of directors that has been assigned the responsibility of determining the Corporation&#8217;s policies with respect to executive compensation. The Board shall have the authority in its sole and absolute discretion to administer the Plan and to exercise all the powers and authorities either specifically granted to it under the Plan or necessary or advisable in the administration of the Plan including, without limitation, the authority to:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">grant Restricted Share Awards to Eligible Persons and Performance Share Awards to Employees;</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:76px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:54px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(ii)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:Arial;font-size:12pt;">determine the Grant Date for Share Awards;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sB7CF500BD3989C854F7A9D44F0712001"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">determine the Eligible Persons who may participate in this Plan and designate any officer or employee of the Corporation as being an Employee under this Plan;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:81px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:54px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">determine Performance Criteria applicable to any Performance Share Award;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">approve the form and determine the terms and provisions of Share Award Agreements (which need not be identical) entered into in connection with Share Awards;</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:81px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:54px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">interpret the Plan and the Share Award Agreements;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:54px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(vii)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:Arial;font-size:12pt;">prescribe, amend and rescind rules and regulations relating to the Plan;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(viii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">determine whether and the extent to which adjustments shall be made pursuant to the Plan; and</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(ix)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">make all other determinations deemed necessary or advisable for the administration of the Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:25px;">(b)</font><font style="font-family:Arial;font-size:12pt;">For greater certainty and without limiting the discretion conferred on the Board pursuant to this Section 3, the Board&#8217;s decision to approve the grant of a Share Award in any period shall not require the Board to approve the grant of a Share Award to any Participant in any other period; nor shall the Board&#8217;s decision with respect to the amount or terms and conditions of a Share Award in any period require it to approve the grant of a Share Award of the same or similar amount or with the same or similar terms and conditions to any Participant in any other period. The Board shall not be precluded from approving the grant of a Share Award to any Participant solely because such Participant may previously have been granted a Share Award under this Plan or any other Security Based Compensation Arrangement. No Participant has any claim or right to be granted a Share Award. There is no obligation for uniformity of treatment of Non-Employee Directors, Employees or Consultants, or any group of Non-Employee Directors, Employees or Consultants.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:25px;">(c)</font><font style="font-family:Arial;font-size:12pt;">Any interpretation, rule, regulation, determination or other act of the Board hereunder shall be made in its sole discretion and shall be final and conclusively binding upon the Corporation and all persons affected by the Plan. No member of the Board shall be liable for any action or determination made in good faith pursuant to the Plan or any instrument of grant evidencing any Share Award awarded under the Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Reservation of Shares; Participation Limits</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:25px;">(a)</font><font style="font-family:Arial;font-size:12pt;">The number of Shares reserved for issuance under the Plan and all other Security Based Compensation Arrangements in aggregate shall not exceed 10% of the total number of issued and outstanding Shares from time to time.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:25px;">(b)</font><font style="font-family:Arial;font-size:12pt;">The number of Shares issuable to Insiders at any time, under all Security Based Compensation Arrangements of the Corporation, shall not exceed 10% of the issued and outstanding Shares.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s6A6208E4DEF3FA90DE369D44F089E2F0"></a></div><div></div><div><br></div><div style="line-height:120%;padding-left:6px;padding-top:2px;text-align:justify;text-indent:0px;"><font style="padding-top:2px;text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:25px;">(c)</font><font style="font-family:Arial;font-size:12pt;">The number of Shares issued to Insiders, within any one-year period, under all Security Based Compensation Arrangements of the Corporation, shall not exceed 10% of the issued and outstanding Shares.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:25px;">(d)</font><font style="font-family:Arial;font-size:12pt;">The number of Shares reserved for issuance under all Security Based Compensation Arrangements of the Corporation to any one Participant shall not exceed 5% of the total number of issued and outstanding Shares.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:25px;">(e)</font><font style="font-family:Arial;font-size:12pt;">Notwithstanding any other provision of this Plan, Performance Share Awards may only be granted to Employees.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:25px;">(f)</font><font style="font-family:Arial;font-size:12pt;">Share Awards that are vested and redeemed, or are cancelled, terminated or expire prior to the settlement of all or a portion thereof, shall result in the Shares that were reserved for issuance thereunder being available for a subsequent grant of Share Awards pursuant to this Plan.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:25px;">(g)</font><font style="font-family:Arial;font-size:12pt;">The maximum number of Shares that may be reserved for issuance to Non-Employee Directors pursuant to Restricted Share Awards under the Plan is 1% of the Shares outstanding at the time of the grant (on a non-diluted basis), less the aggregate number of Shares reserved for issuance to such Non-Employee Director under any other Security Based Compensation Arrangement, and the total annual grant of Restricted Share Awards to any one Non-Employee Director cannot exceed a grant value of $150,000 (less the amount awarded to such Non-Employee Director in the year pursuant to any other Security Based Compensation Arrangement).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Terms and Conditions of Share Awards</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Each Share Award granted under the Plan shall be subject to the terms and conditions of the Plan and evidenced by a written agreement between the Corporation and the Participant or an award letter from the Corporation to the Participant (a &#8220;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Share Award Agreement</font><font style="font-family:Arial;font-size:12pt;">&#8221;) which agreement shall comply with, and be subject to, the requirements of the Exchange and the following terms and conditions (and with such other terms and conditions as the Board, in its discretion, shall establish):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:24px;">(a)</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Number of Share Awards </font><font style="font-family:Arial;font-size:12pt;">- The Board may determine the number of Share Awards to be awarded to a Participant in its sole discretion.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Vesting of Share Awards </font><font style="font-family:Arial;font-size:12pt;">-</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Unless otherwise determined by the Board, the Vesting Period in respect of Share Awards granted hereunder shall be three (3) years from the Grant Date of such Share Awards. The Board may, in its sole discretion, accelerate the vesting of all or any Share Awards at any time and from time to time.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Upon vesting, each Restricted Share Award and each Performance Share Award (following application of the applicable Vesting Percentage) so vested will entitle the holder to receive one Share (subject to adjustment in accordance with the terms of this Plan) on the applicable Issue Date. For greater certainty, a</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sA11391B51FE51DA8B8739D44F09F2898"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Participant shall have no right to receive any Shares or other consideration in respect of any Performance Share Awards other than for the Vesting Percentage of such Performance Share Awards.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Board shall determine the Performance Criteria for each grant of Performance Share Awards at the time of the grant of the award and, the Board shall, as soon as reasonably practicable following the completion of the Vesting Period applicable to a particular grant of Performance Share Awards determine, in its sole discretion, the applicable &#8220;Vesting Percentage&#8221;.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Notwithstanding any other provision of this Plan, no term or condition of a grant of Share Awards hereunder or any Share Award Agreement may have the effect of causing any Shares to be issued pursuant to any Share Award under the Plan to a Participant in satisfaction of such Participant&#8217;s Performance Share Awards under the Plan (or any portion thereof) to occur after December 31 in the third (3</font><font style="font-family:Arial;font-size:7pt;">rd</font><font style="font-family:Arial;font-size:12pt;">) calendar year following the calendar year in respect of which such Share Awards were granted.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:24px;">(c)</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Issuance of Shares </font><font style="font-family:Arial;font-size:12pt;">- Shares that are issuable to the Participant on the Issue Date shall be issued from treasury as fully paid and non-assessable Shares. No fractional Shares will be issued and all fractional entitlements shall be rounded down to the nearest whole number.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:24px;">(d)</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Delivery of Shares </font><font style="font-family:Arial;font-size:12pt;">- The Issue Date shall occur as soon as practicable and in any event within 31 days following the completion of the Vesting Period applicable to a Share Award. Subject to the remainder of this Section 5(d), on the Issue Date, the Corporation will issue from treasury to the Participant that number of Shares to which the Participant is entitled to receive in respect of such Share Award in accordance with this Section 5, subject to Section 7 hereof, and sent by pre-paid mail or delivered to the Participant. Notwithstanding the foregoing, if on the Issue Date a Black-Out Period has been imposed upon a Participant which is still in effect, then the Issue Date shall not occur until the date which is the tenth (10</font><font style="font-family:Arial;font-size:7pt;">th</font><font style="font-family:Arial;font-size:12pt;">) business day after the last day of the applicable Black Out Period.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:24px;">(e)</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Change of Control </font><font style="font-family:Arial;font-size:12pt;">- Unless otherwise determined by the Board in its sole discretion, upon a Change of Control, all unvested Share Awards shall become automatically vested (in the case of Performance Share Awards, with a deemed Vesting Percentage of 100). Shares issuable in respect of Share Awards shall be, and shall be deemed to be, issued to Participants effective immediately prior to the completion of the transaction which would result in the Change of Control unless issued prior thereto in accordance with this Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:24px;">(f)</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Board Discretion </font><font style="font-family:Arial;font-size:12pt;">- Notwithstanding anything else in this Plan, the Board may, in its sole discretion, but subject to the limits described in Sections 4 and 9 hereof and any other applicable requirements of the Exchange or other regulatory authority:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:121%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:22px;">(i)</font><font style="font-family:Arial;font-size:12pt;">make any additional adjustments to the Vesting Percentage (in respect of any Performance Share Awards) or the number of Shares to be issued or delivered to a Participant in connection with any Share Award if, in the sole discretion of the Board, such</font></div><div style="line-height:121%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sA093C6C35713EEBAF39F9D44F0B82A99"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">adjustments are appropriate in the circumstances having regard to the principal purposes of the Plan;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:122%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:22px;">(ii)</font><font style="font-family:Arial;font-size:12pt;">change the Issue Date (including amending the Vesting Period related thereto) for all or any Share Awards at any time and from time to time; and</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:22px;">(iii)</font><font style="font-family:Arial;font-size:12pt;">otherwise amend or modify the terms and conditions regarding any grant of Share Awards or payments in respect of any Share Awards hereunder, provided, however, that no such amendment or modification may, without the consent of the affected Participant, impair or adversely affect a Share Award granted to the Participant under the Plan prior to the date of such amendment or modification.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Effect of Certain Changes </font><font style="font-family:Arial;font-size:12pt;">- In the event:</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">of any change in the Shares through subdivision, consolidation, reclassification, recapitalization or similar transaction; or</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">that any rights are granted to Shareholders to purchase Shares at prices substantially below fair market value, and such events do not constitute a Change of Control, then, in any such case, the Board may make such adjustments to the Plan, to any Share Awards and to any Share Award Agreements outstanding under the Plan as the Board may, in its sole discretion, consider appropriate in the circumstances to prevent dilution or enlargement of the rights granted to Participants hereunder.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:24px;">(h)</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Ceasing to be an Eligible Person </font><font style="font-family:Arial;font-size:12pt;">- Unless otherwise determined by the Board or unless otherwise expressly set forth in a Share Award Agreement pertaining to a particular Share Award or any written employment or other agreement governing a Participant&#8217;s role as an Eligible Person, the following provisions shall apply in the event that a Participant ceases to be an Eligible Person:</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-style:italic;">Termination for Cause </font><font style="font-family:Arial;font-size:12pt;">&#8211; If a Participant ceases to be an Eligible Person as a result of the termination of such Participant for cause, effective as of the date notice is given to the Participant of such termination, all outstanding Share Awards Agreements under which Share Awards have been granted to such Participant shall be terminated and all rights to receive Shares thereunder shall be forfeited by such Participant, and the Participant shall not be entitled to receive any Shares or other compensation in lieu thereof.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-style:italic;">Voluntary Resignation </font><font style="font-family:Arial;font-size:12pt;">- If a Participant voluntarily ceases to be an Eligible Person for any reason other than as a result of the death, permanent disability or retirement of the Participant as set forth in Section 7(h)(iii), effective as of the date notice is given by the Participant of such resignation, unless otherwise determined by the Board, all outstanding Share Award Agreements under which Share Awards have been made to such Participant shall be terminated and all rights to receive Shares thereunder shall be forfeited by the Participant, and the Participant shall not be entitled to receive any Shares or other compensation in lieu thereof.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s373DB3FC357726B0812A9D44F0E544E3"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-style:italic;">Termination Upon Death or Permanent Disability or Retirement </font><font style="font-family:Arial;font-size:12pt;">&#8211; Upon the death, permanent disability or retirement of a Participant (other than the early retirement of an Eligible Employee), all outstanding Share Award Agreements under which Share Awards have been made to such Participant prior to the Cessation Date shall immediately vest as of the Cessation Date, and the Issue Date in respect of all Share Awards held by such Participant shall be the earlier of:</font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">the 90</font><font style="font-family:Arial;font-size:7pt;">th </font><font style="font-family:Arial;font-size:12pt;">day following the Cessation Date; and (B) the original Issue Date contemplated by Section 5(d) of this Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-style:italic;">Termination not for Cause </font><font style="font-family:Arial;font-size:12pt;">- If a Participant ceases to be an Eligible Person other than as set forth in Sections 7(h)(i), (ii) or (iii), effective as of the Cessation Date all Share Awards awarded to such Participant under any outstanding Share Award Agreements shall fully vest effective as of the Cessation Date, unless otherwise determined by the Board. On the applicable Issue Date in respect of such Share Awards, the Participant shall be entitled to receive the number of Shares equal to the number of Share Awards granted multiplied by a fraction (A) the numerator of which is the number of days from the Grant Date in respect of the applicable Share Award to the Cessation Date; and (B) the denominator of which is the total number of days comprising the Vesting Period in respect of such Share Award. In such circumstances, the Vesting Percentage in respect of Performance Share Awards shall be determined as of the Cessation Date. The Issue Date in respect of any such Awards shall be the earlier of: (A) the 90</font><font style="font-family:Arial;font-size:7pt;">th </font><font style="font-family:Arial;font-size:12pt;">day following the Cessation Date; and (B) the original Issue Date contemplated by Section 5(d) of this Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(i) </font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Rights as a Shareholder </font><font style="font-family:Arial;font-size:12pt;">- Until the Shares underlying any Share Award have been issued in accordance with the terms of the Plan, the Participant to whom such Share Award has been made shall not possess any incidents of ownership of such Shares including, for greater certainty and without limitation, the right to exercise voting rights in respect of such Shares. Such Participant shall only be considered a Shareholder in respect of such Shares when such issuance has been entered upon the records of the duly authorized transfer agent of the Corporation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Ratification and Approval by Shareholders</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Notwithstanding any other provision of this Plan:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(a) </font><font style="font-family:Arial;font-size:12pt;">no Shares may be issued pursuant to any Share Award until the Plan has been approved by the Shareholders at a duly called meeting of the Shareholders; and </font><font style="font-family:Arial;font-size:12pt;color:#010000;">(b) </font><font style="font-family:Arial;font-size:12pt;">any grants of Share Awards by the Board prior to the Plan being approved by the Shareholders must be ratified by the Shareholders at the meeting of the Shareholders at which the Shareholders approve the Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Withholding Taxes</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:122%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">When a Participant or other person becomes entitled to receive Shares under any Share Award, the Corporation shall have the right to require the Participant or such other person</font></div><div style="line-height:122%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s4B89600E56EE5EFF90D59D44F1060E15"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">to remit to the Corporation an amount sufficient to satisfy any withholding tax requirements relating thereto. Unless otherwise prohibited by the Board or by applicable law, satisfaction of the withholding tax obligation may be accomplished by any of the following methods or by a combination of such methods:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:26px;">(a)</font><font style="font-family:Arial;font-size:12pt;">the tendering by the Participant of cash payment to the Corporation in an amount equal to the total withholding tax obligation;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:26px;">(b)</font><font style="font-family:Arial;font-size:12pt;">the withholding or sale by the Corporation from the Shares otherwise due to the Participant, of such number of Shares having a value determined by the Corporation in its sole discretion, acting reasonably, equal to the amount of the total withholding tax obligation (and in the case of a treasury issuance of Shares to settle Share Awards hereunder, such sale of Shares shall be automatically made on or as soon as practicable after the applicable Issue Date for the purposes of satisfying withholding tax obligations, unless otherwise agreed to by the Corporation and the Participant);</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:26px;">(c)</font><font style="font-family:Arial;font-size:12pt;">the withholding by the Corporation from any cash payment otherwise due to the Participant of such amount of cash as is equal to the amount of the total withholding tax obligation; or</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:26px;">(d)</font><font style="font-family:Arial;font-size:12pt;">any other method determined by the Corporation in its sole discretion, acting reasonably, provided, however, that the sum of any cash so paid or withheld and the value of any Shares so withheld or sold is, sufficient, in the reasonable estimation of the Corporation, to satisfy the total withholding tax obligation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Non-Transferability</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The right to receive Shares pursuant to a Share Award granted to a Participant may only be settled by such Participant personally or through the Participant&#8217;s personal representative or estate and no assignment, sale, transfer, pledge or charge of a Share Award, whether voluntary, involuntary, by operation of law or otherwise (except by will or the laws of descent and distribution), vests any interest or right in such Share Award whatsoever in any assignee or transferee and, immediately upon any assignment, sale, transfer, pledge or charge or attempt to assign, sell, transfer, pledge or charge, such Share Award shall terminate and be of no further force or effect.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">9.</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Amendment and Termination of Plan</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:24px;">(a)</font><font style="font-family:Arial;font-size:12pt;">The Board may, at any time, suspend or terminate this Plan.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:24px;">(b)</font><font style="font-family:Arial;font-size:12pt;">Subject to Section 9(c), the Board may, at any time and from time to time, amend this Plan or any Share Award, subject to applicable TSX Policies and the requirements of any other Exchange on which the Shares are then listed, without the consent or approval from any Participant or shareholder of the Corporation, including without limitation:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">to amend, modify or terminate this Plan with respect to all Shares in respect of Share Awards which have not yet been granted thereunder;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sD00C287FBFDC6BEC5D3B9D44F139CF76"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">to make any amendment of a "housekeeping nature", including to make any amendment typographical, grammatical, clerical or administrative nature or clarification correcting or rectifying any ambiguity, immaterial inconsistency, defective provision, mistake, or error or omission in this Plan or any Share Award; and</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">to make any addition to, deletion from or alteration of the provisions of this Plan or any Share Award that are necessary to comply with applicable law, the TSX Policies, or the requirements of any other Exchange on which the Shares are then listed and to avoid unanticipated consequences deemed by the Board to be inconsistent with the purpose of this Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:24px;">(c)</font><font style="font-family:Arial;font-size:12pt;">Notwithstanding Section 9(b), the Plan or any Share Award may not be amended without Shareholder approval to:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:122%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">increase the number of Shares issuable pursuant to outstanding Share Awards at any time pursuant to Section 4 hereof;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:76px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:54px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(ii)</font></div></td><td style="vertical-align:top;padding-left:1.3333333333333333px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-1.3333333333333333px;"><font style="font-family:Arial;font-size:12pt;">change the insider participation limitation under this Plan;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">expand the categories of individuals contained in the definition of "Employee" who are eligible to participate in the Plan;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:122%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">extend the term of any Share Award beyond the term of such awards provided for under the terms and conditions of this Plan;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">permit the transfer or assignment of Share Awards, except to permit a transfer to a family member, an entity controlled by the holder of the Share Awards or a family member, a charity or for estate planning or estate settlement purposes; or</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:81px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:54px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">amend this Section 9.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:24px;">(d)</font><font style="font-family:Arial;font-size:12pt;">In addition, no amendment to the Plan or Share Awards granted pursuant to the Plan may be made without the consent of the Participant, if such amendment adversely alters or impairs the rights of any Participant in respect of any Share Award previously granted to such Participant under the Plan.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Miscellaneous</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:22px;">(a)</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Effect of Headings </font><font style="font-family:Arial;font-size:12pt;">- The Section headings contained herein are for convenience only and shall not affect the construction hereof.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:25px;">(b)</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Compliance with Legal Requirements </font><font style="font-family:Arial;font-size:12pt;">- The Corporation shall not be obliged to issue any Shares if such issuance would violate any law or regulation or any rule of any government authority or Exchange. The Corporation, in its sole discretion, may postpone the issuance or delivery of Shares under any Share Award as the Board may consider</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s6D1AA7A4A4B9649C528D9D44F15A3C28"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">appropriate, and may require any Participant to make such representations and furnish such information as it may consider appropriate in connection with the issuance or delivery of Shares in compliance with applicable laws, rules and regulations. The Corporation shall not be required to qualify for resale pursuant to a prospectus or similar document any Shares awarded under the Plan, provided that, if required, the Corporation shall notify the Exchange and any other appropriate regulatory bodies in Canada of the existence of the Plan and the granting of Share Awards hereunder in accordance with any such requirements.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:24px;">(c)</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">No Right to Continued Employment </font><font style="font-family:Arial;font-size:12pt;">- Nothing in the Plan or in any Share Award Agreement entered into pursuant hereto shall confer upon any Participant the right to continue in the employ or service of the Corporation, to be entitled to any remuneration or benefits not set forth in the Plan or a Share Award Agreement or to interfere with or limit in any way the right of the Corporation to terminate Participant&#8217;s employment or service arrangement with the Corporation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:29px;">(d)</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Expenses </font><font style="font-family:Arial;font-size:12pt;">- All expenses in connection with the Plan shall be borne by the Corporation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:22px;">(e)</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Governing Language </font><font style="font-family:Arial;font-size:12pt;">-This Plan is drawn up in the English language and each notice, instrument, certificate or other communication to be given under or in connection with this Plan shall be in the English language. If this Plan or any notice, instrument, certificate or other communication is translated into any other language, the English language text shall prevail.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:18px;">(f)</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Market Fluctuations </font><font style="font-family:Arial;font-size:12pt;">- No amount will be paid to, or in respect of, a Participant under the Plan to compensate for a downward fluctuation in the price of Shares which impacts the Share Award, nor will any other form of benefit be conferred upon, or in respect of, a Participant for such purpose. The Corporation makes no representations or warranties to a Participant with respect to the Plan or the Share Awards whatsoever. In seeking the benefits of participation in the Plan, a Participant agrees to exclusively accept all risks associated with a decline in the market price of Shares and all other risks associated with the holding of Share Awards.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:25px;">(g)</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Currency </font><font style="font-family:Arial;font-size:12pt;">- Any payments and benefits under the Plan to be paid in cash shall be determined in the lawful currency of Canada and paid in the local currency of the Participant&#8217;s country of residence using the currency exchange rate available to the Corporation at the time of payment.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;color:#010000;padding-right:22px;">(h)</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Participation is Voluntary; No Additional Rights </font><font style="font-family:Arial;font-size:12pt;">- Participation in the Plan shall be entirely voluntary and any decision by a Participant not to participate shall not affect any Participant&#8217;s employment or service with the Corporation. In such instance where a Participant provides notice in writing to the Corporation of his or her intent to not participate in a Share Award, such award shall be immediately terminated and the Participant shall not be eligible to receive any form of in lieu compensation.</font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Governing Law</font></div></td></tr></table><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s108EE8B6A842FFB8AF089D44F18B5A32"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Plan shall be governed by, interpreted and construed in accordance with the laws in force in the Province of Alberta.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:Arial;font-size:12pt;color:#010000;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Effective Date</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Plan shall take effect on May </font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">[4]</font><font style="font-family:Arial;font-size:12pt;">, 2017. The issuance of Shares under the Plan is subject to the acceptance of the Plan by the Exchange and any other relevant regulatory authorities and approval of the Shareholders.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sF65118DA2740C024F15F9D44F1AC5E13"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:21px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">EXHIBIT D</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:21px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">LIST OF INVENTIONS</font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">None</font></div><div><br></div><div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.7
<SEQUENCE>7
<FILENAME>ex47hagermanamendment2019.htm
<DESCRIPTION>EXHIBIT 4.7
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s4C78CC30C05B4FBA0BE39D4974D5C78A"></a></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">EXHIBIT 4.7</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">AMENDING AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">THIS AMENDING AGREEMENT</font><font style="font-family:Arial;font-size:12pt;">&#32;made effective as of the 1</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">st</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;day of January, 2019.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">BETWEEN:</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">ONCOYLYTICS BIOTECH INC.,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">("ONCOLYTICS")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">- and -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Allison Hagerman,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(the "Employee")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">WHEREAS Oncolytics and the Employee entered into a Letter of Employment dated August 3, 2010;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">AND WHEREAS Oncolytics and the Employee entered into an Employment Agreement dated August 1, 2013;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">AND WHEREAS Oncolytics and the Employee wish to amend the Employment Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Interpretation</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument. In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Amendment to the Employment Agreement</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employment Agreement Section 2 &#8211; Employment is amended as follows:</font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:48px;">(1)</font><font style="font-family:Arial;font-size:12pt;">Oncolytics confirms the employment of the Employee in the position of Vice President, Product Development and the Employee accepts the employment, effective January 1</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">st</sup></font><font style="font-family:Arial;font-size:12pt;">, 2017;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employment Agreement Section 3 &#8211; Remuneration is amended as follows:</font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:0px;"><font style="padding-bottom:16px;text-align:justify;font-family:Arial;font-size:12pt;padding-right:48px;">(1)</font><font style="font-family:Arial;font-size:12pt;">Commencing January 1, 2019, Oncolytics shall pay to the Employee a salary of TWO HUNDRED THOUSAND ($200,000.00) CANADIAN DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of EIGHT THOUSAND THREE HUNDRED THIRTY-THREE DOLLARS and THIRTY-THREE CENTS ($8,333.33) on the 15</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;and last day of each month.  </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Confirmation</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Miscellaneous</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Agreement shall be governed by and construed in accordance with the laws in force in the Province of Alberta.  The parties hereby submit to the jurisdiction of the Courts of Alberta.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written.</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:49%;"></td><td style="width:3%;"></td><td style="width:7%;"></td><td style="width:41%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Matt Coffey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Matt Coffey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Kirk Look</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Kirk Look</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Jody Kehler&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;/s/ Allison Hagerman</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">___________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;________________________________</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Witness&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">ALLISON HAGERMAN</font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.8
<SEQUENCE>8
<FILENAME>ex48kirklook2019.htm
<DESCRIPTION>EXHIBIT 4.8
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s912B36B41AE87F0BD2E69D4E822C0C99"></a></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 1 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">EXHIBIT 4.8</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">EXECUTIVE EMPLOYMENT AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">THIS AGREEMENT </font><font style="font-family:Arial;font-size:12pt;">made the 1</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">st</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;day of January, 2019.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">BETWEEN:</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">("Oncolytics")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">-and-</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">KIRK LOOK</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(the "Employee")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">WHEREAS Oncolytics is engaged in the business of developing pharmaceutical products;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">AND WHEREAS Oncolytics and the Employee entered into an Executive Employment Agreement dated January 1, 2013, which has been amended;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">AND WHEREAS Oncolytics and the Employee wish to further amend and restate the terms of employment pursuant to this Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">NOW THEREFORE the parties agree as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:0px;"><font style="padding-bottom:16px;padding-top:16px;text-align:left;font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;padding-right:96px;">Section 1 - </font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Definitions and Interpretation</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">In this Agreement the following defined terms shall have the meanings indicated:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">"Business" means the business currently carried on by Oncolytics, which is the development, testing, marketing and sale of pharmaceutical products together with such additional business as Oncolytics may decide to undertake from time to time;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">"Commencement Date" means November 9, 2012;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">"Confidential Information" means all confidential information of Oncolytics and includes:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">any data or information directly or indirectly related to the Business or arising directly or indirectly in the course of, or derived from the Employee's employment with Oncolytics whether related to products, equipment, inventions, ideas, designs, methods, systems, improvements, processes, research or otherwise;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">any of Oncolytics' technical or scientific know-how;</font></div></td></tr></table><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 2 -</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">financial and sales information, customer lists, pricing policies, lists of suppliers, proprietary computer programs in any format whatsoever, programming techniques, the manner of plans or methods of operation and the like relating to the Business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">patent applications, drawings, blueprints, manuals, letters, notebooks, reports and all other materials (written or otherwise) related to the Business or to the agents, joint venturers or contractors of Oncolytics; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">any information provided to or received by Oncolytics on a confidential basis;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">"Good Reason" means any one of the following events occurring on or after the Commencement Date:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">any reduction in the Employee's then existing annual base compensation and benefits, unless comparable reductions are made for all other executive employees of Oncolytics;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">any material diminution of the Employee's duties, responsibilities, authority or reporting structure, excluding for this purpose an isolated or inadvertent action not taken in bad faith which is remedied by Oncolytics immediately after notice thereof is given by the Employee;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">any request that the Employee relocate to a work site that would increase the Employee's one-way commute distance by more than eighty (80) kilometers from the Employee's then principal residence, unless the Employee accepts such relocation opportunity; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">any material breach by Oncolytics of its obligations under this Agreement that is not remedied within thirty (30) days of written notice of such breach from the Employee;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">"Intellectual Property" means all information, data, designs, processes, software, algorithms and inventions, including those that may be the subject of patent, copyright, industrial design, trademarks, trade secret or other forms of legal protection, made, conceived or developed by the Employee during the term of employment with Oncolytics, whether alone or jointly with others and whether during or after regular working hours, that relates to or in any way pertains to or connects with any matter developed, or under investigation or development by Oncolytics or related to the Business;</font></div></td></tr></table><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 3 -</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">"Termination Event" means:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">breach by the Employee of any material provision of this Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">material violation by the Employee of any statutory or common law duty of loyalty to Oncolytics;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">the commission of an indictable offence by the Employee against Oncolytics; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">personal or professional conduct of the Employee which in the reasonable and good faith judgment of Oncolytics may significantly injure Oncolytics' Business or interfere with the Employee's job performance.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">This Agreement shall be governed by and construed in accordance with the laws in force in the Province of Alberta.  The parties hereby submit to the jurisdiction of the Courts of Alberta.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The following schedules are attached to and form part of this Agreement:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Schedule "A" &#8211; Job Description</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Schedule "B" &#8211; Benefits</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 2 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Employment</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Oncolytics agrees to employ the Employee in the position of Chief Financial Officer and the Employee accepts the employment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee shall perform the duties and responsibilities associated with the position of Chief Financial Officer, including those set out on the Job Description attached as Schedule "A".  The Employee shall report to the President and CEO of Oncolytics.  The Employee may, from time to time, be assigned or undertake additional duties and responsibilities consistent with those generally appropriate for a Chief Financial Officer, and the Employee's duties and responsibilities may be modified or expanded from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee shall perform the duties and responsibilities set out in Section 2(2):</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">diligently, faithfully and to the best of the Employee's ability; and</font></div></td></tr></table><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 4 -</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">in the best interests of Oncolytics.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee shall comply with the terms, conditions and requirements of Oncolytics' Policy Manual, as the same may be amended, revised or added to from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 3 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Remuneration</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Commencing January 1, 2019, Oncolytics shall pay to the Employee a salary of  $385,000 CANADIAN DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of $16,041.67 CANADIAN DOLLARS on the 15</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;and last day of each month.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Oncolytics shall, on or before the anniversary date of this Agreement in each year, evaluate and set the Employee's salary for the next ensuing year.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Oncolytics shall reimburse the Employee for all reasonable out-of-pocket expenses incurred by the Employee in the performance of the Employee's obligations under this Agreement, subject to Oncolytics' policies then in force.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Oncolytics shall be entitled to withhold from any payments made to the Employee any amounts that Oncolytics is required to withhold pursuant to any Act in force that relates to income tax, unemployment insurance premiums or pension plan premiums in any jurisdiction under which such payments are required to be made by or on behalf of the Employee, including, without limitation, the Income Tax Act (Canada), the Employment Insurance Act (Canada), the Canada Pension Plan.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 4 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Benefits</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employee shall be entitled to participate in benefit plans described in Schedule "B" and in other benefit plans instituted by Oncolytics from time to time.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 5 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Vacations</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employee shall, in addition to all statutory holidays, be entitled to 20 days paid vacation during each twelve (12) month period of employment under this Agreement.  The Employee's vacation time shall be governed by applicable policies of Oncolytics.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 6 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Place of Employment</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employee shall perform the majority of the Employee's employment obligations from and out of Oncolytics' offices located in the City of Calgary, Alberta, Canada.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 7 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Confidential Information</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 5 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee confirms that the Confidential Information is the sole and exclusive property of Oncolytics and is held by the Employee in trust for the benefit of Oncolytics.  The Employee shall use the Employee's best efforts and exercise utmost diligence to protect and safeguard the Confidential Information.  Neither during the period of employment by Oncolytics nor thereafter for a period of three years shall the Employee, directly or indirectly, use or disclose to any other person any Confidential Information, whether or not acquired, learned or obtained or developed by the Employee alone or in conjunction with others, except as such disclosure or use may be required in connection with the employment with Oncolytics or as may be agreed to in writing by Oncolytics.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Subsection 7(1) shall not apply to Confidential Information that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">is in the public domain at the time of its disclosure, or which, after disclosure, becomes part of the public domain other than by disclosure by the Employee;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">the Employee can show was in the Employee's possession at the time of disclosure and was not acquired from Oncolytics; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">was received by the Employee from a third party without a covenant of confidentiality, provided such third party is under no obligation of confidentiality with respect to the Confidential Information.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee shall keep informed of Oncolytics' policies and procedures for safeguarding Oncolytics' property including, without limitation, the Confidential Information and the confidentiality thereof, and will strictly comply therewith at all times.  The Employee shall not, except as required in the course of the employment with Oncolytics, remove from Oncolytics' premises any Oncolytics property including, without limitation, Confidential Information.  The Employee shall, immediately upon termination of employment with Oncolytics, return to Oncolytics all of Oncolytics' property in the Employee's possession, including, without limitation, all tangible parts of or relating to the Confidential Information as is in the Employee's possession or under the Employee's control without retaining any copies or record thereof or any other mechanical means that, alone or in combination with other means, would permit the Employee to reproduce or make available the Confidential Information.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee shall advise any future employer, associate or affiliate that the Employee has signed this Agreement and is bound by its terms and conditions.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 8 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Intellectual Property</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee confirms that any and all Intellectual Property shall be the sole and exclusive property of Oncolytics and shall be assigned by the Employee to Oncolytics.  The Employee agrees to disclose promptly to Oncolytics or its nominee any </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 6 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">and all Intellectual Property and to execute written assignments of the Employee's right, title and interest in and to the Intellectual Property to Oncolytics or its nominee.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">With respect to any Intellectual Property, the Employee also agrees:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">to assist Oncolytics or its nominee in preparing any necessary copyright and patent applications, including Canadian and foreign applications, covering the Intellectual Property;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">to sign and deliver all such applications and their assignment to Oncolytics or its nominee; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">generally to give all information and testimony, to co-operate with Oncolytics and its solicitors, to sign all lawful papers, and to do all lawful things that may be needed or requested by Oncolytics to obtain, extend, reissue, maintain or enforce Canadian and foreign copyrights or patents covering the Intellectual Property.</font></div></td></tr></table><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 7 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Oncolytics shall bear all expenses that are incurred in obtaining, extending, reissuing, maintaining and enforcing any and all copyrights or patents in respect of the Intellectual Property assigned to Oncolytics by the Employee, and in the vesting and perfecting of title thereto in Oncolytics and shall pay the Employee reasonable compensation for any time that Oncolytics may require the Employee to expend in order to accomplish the above subsequent to the termination of employment with Oncolytics.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee hereby waives in favour of Oncolytics, all moral rights in any and all copyright works authored or co-authored by the Employee during the term of this Agreement that directly relate to the Business of Oncolytics.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 9 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Term and Termination</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee's employment under this Agreement shall commence on the Commencement Date and shall continue until terminated in accordance with this Section 9.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Subject to Sections 9(3), (4) and (5), and notwithstanding any other provision contained herein to the contrary, the employment relationship between the Employee and Oncolytics arising out of this Agreement shall terminate upon forty-five (45) days notice being given to Oncolytics by the Employee or immediately upon notice being given to the Employee by Oncolytics.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">If Oncolytics is entitled to terminate this Agreement as the result of a Termination Event, Oncolytics shall not be required to compensate the Employee in respect of such termination or provide any period of notice in lieu of compensation with respect to such termination.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Subject to Section 9(5), if this Agreement is terminated by Oncolytics at any time other than pursuant to Section 9(3), or if this Agreement is terminated by the Employee for Good Reason, the Employee shall be entitled to severance payment equal to 12 months salary.  Such severance compensation shall be paid to the Employee so as to maximize any reduction in income tax payable thereon as permitted by the Income Tax Act (Canada).  The severance payment as provided pursuant to this Section 9(4) shall include an amount equal to the value of all benefits to which the Employee would otherwise have been entitled during the notice period.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(5)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Notwithstanding Section 9(4), if there is a change of control of Oncolytics, as defined herein, and if this Agreement is terminated by Oncolytics at any time within one (1) year following the change of control other than pursuant to Section 9(3), the Employee shall be entitled to severance payment equal to twice that determined pursuant to Section 9(4).  Such severance compensation shall be paid to the Employee so as to maximize any reduction in income tax payable thereon as permitted by the Income Tax Act (Canada).</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 8 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">For the purposes of this Section 9(5), &#8220;change of control&#8221; means any amalgamation, merger or other corporate reorganization which results in any change in the present effective voting control of Oncolytics, or will result in a change of the person or persons who own or control sufficient voting shares in Oncolytics to elect a majority of the directors of Oncolytics, or will result in a person acquiring sufficient voting shares in Oncolytics to elect a majority of the directors of Oncolytics or any sale, lease, exchange, partnership, or other transfer (in one transaction or a series of transactions) of all or substantially all of the assets of Oncolytics or a plan of liquidation of Oncolytics and/or an agreement for the sale or liquidation of Oncolytics is approved and completed, or the Board of Directors determines in its sole discretion that a change of control has occurred, whether or not any event described above has occurred or is contemplated.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(6)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee acknowledges and agrees that payment in lieu of notice in accordance with Section 9(4) or 9(5) shall be and is conclusively deemed to be reasonable compensation for termination of this Agreement and hereby waives any claim or potential claim that the Employee now has or may hereafter have, against Oncolytics for further severance compensation or notice other than that provided by the terms of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(7)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee confirms that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">any breach of this Agreement or unauthorized disclosure of Confidential Information may result in irreparable harm to the Business of Oncolytics and considerable monetary damages to Oncolytics;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">the damages suffered by Oncolytics may be difficult to establish; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">interim and permanent injunctions may be the only suitable remedy for Oncolytics;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">but nothing herein shall in any way limit or restrict any other remedies available to Oncolytics at law or in equity including an action for damages.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 9 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(8)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Termination of the Employee's employment with Oncolytics for any reason whatsoever shall not terminate the Employee's obligations under Sections 7, 8 and 10 of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 10 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Non-Competition</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee shall not, during the term of this Agreement, engage, hold an interest in or have any involvement, either directly or indirectly, in any business entity, venture or undertaking if such would materially interfere with or conflict with the Employee's duties and obligations to Oncolytics as provided for under this Agreement, provided that the acquisition of a non-control position in publicly traded companies will not contravene this Section.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee shall not, during the term of this Agreement, and for a period of one (1) year following the termination or expiration of this Agreement, either individually or in partnership or jointly or in conjunction with any person, firm or corporation as principal, employee, partner, director or as a shareholder or investor (if actually involved in the management of a business which is competitive with the Business of Oncolytics) carry on or be engaged in any business which is directly competitive with the Business of Oncolytics.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The parties agree that all of the restrictions contained in Subsection 10(2) hereof are reasonable and valid, and that all defences to the strict enforcement thereof by Oncolytics are hereby waived by the Employee.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee agrees that the remedy at law for any breach by the Employee of the provisions of this Section 10 may be inadequate and that in the event of such breach, Oncolytics may make an application to a court of competent jurisdiction for an order granting Oncolytics temporary, permanent or both kinds of injunctive relief against the Employee, without the necessity of proving actual damage to Oncolytics.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(5)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee agrees that any waiver by Oncolytics of a breach of this Agreement by the Employee shall only be a waiver with respect to the particular breach giving rise to the waiver.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 11 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Notices</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">All notices, reports, invoices, payments and formal communications (collectively referred to as "Notices") required or permitted to be given hereunder shall be in writing and shall be delivered personally or sent by prepaid registered mail or facsimile transmission to the following address or such other address as the relevant party may notify from time to time:</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 10 -</font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">TO:&#160;&#160;&#160;&#160;Oncolytics</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Suite 210, 1167 Kensington Crescent N.W.</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Calgary, Alberta</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">T2N 1X7</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Attention: President &amp; CEO</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">TO:&#160;&#160;&#160;&#160;The Employee</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">KIRK LOOK</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">[address redacted]</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Notices sent by prepaid registered mail shall be deemed to be received by the addressee on the seventh day (excluding Saturdays, Sundays, Statutory Holidays and any period of postal disruption) following the mailing thereof.  Notices personally served shall be deemed to be received when actually delivered, provided such delivery shall be during normal business hours.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 12 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Enurement</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Agreement shall enure to the benefit of and be binding upon the parties hereto and:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">in the case of Oncolytics, its successors and permitted assigns; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">in the case of the Employee, her heirs, executors, administrators or other personal representatives.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">IN WITNESS WHEREOF the parties have executed this Agreement as of the day and year first above written.</font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:49.78632478632478%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="4"></td></tr><tr><td style="width:8%;"></td><td style="width:15%;"></td><td style="width:70%;"></td><td style="width:7%;"></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Wayne Pisano</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Wayne Pisano</font></div><div style="font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Chairman</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Deborah Brown</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Deborah M. Brown</font></div><div style="font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Chair, Compensation Committee</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;text-decoration:underline;">__/s/ Matt Coffey</font><font style="font-family:Arial;font-size:12pt;">_________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-style:italic;text-decoration:underline;">__/s/ Kirk Look</font><font style="font-family:Arial;font-size:12pt;">___________________</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Witness&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">KIRK LOOK</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s417D243373FDD62608079D4E825EB93B"></a></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 1 -</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">SCHEDULE "A"</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">JOB DESCRIPTION</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Summary: </font><font style="font-family:Arial;font-size:12pt;">In this position the incumbent will be responsible for the financial reporting, internal controls and financial affairs of the organization. As a key member of the executive team the incumbent will contribute to the short-term and long-term planning and execution of approved plans for the development of the Corporation and provide leadership and direction in furtherance of the Corporation&#8217;s goals and objectives.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Responsibilities</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:147%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:147%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Ensure the Corporation meets its financial reporting and disclosure obligations.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:147%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:147%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Ensure the Corporation meets its Corporate filing obligations to the relevant securities commissions and stock exchanges.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:147%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:147%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Interact with the audit committee and the board of directors as expected of a CFO</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:147%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:147%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Ensure the maintenance of effective financial systems</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:147%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:147%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Ensure the board, audit committee, and the President and CEO are provided timely and accurate financial, budget and strategic planning information</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:147%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:147%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Participate with the board and executive in the establishment of the Strategic Plan and goals and objectives established to further the attainment of the Plan</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:147%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:147%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Provide guidance, assistance and direction to all areas of the Corporation by applying financial and business experience </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:147%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:147%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Assist in the contract review process for the Corporation, ensuring co-ordination of contracts, appropriate approvals and actions derived therefrom</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:147%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:147%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Ensure adequate and appropriate technology resources are employed and directed to establish an effective technology platform for the Corporation</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:147%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:147%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Develop external financial contacts, source and put in place financial reserves in accordance with corporate goals</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:147%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:147%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">As a key member of the management team, ensure policies and procedures are put in place and appropriately approved and monitored to meet expectations of the board and management</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:147%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:147%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">In conjunction with the President and CEO direct the communications and investor relations efforts of the Corporation</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s871E87398D820B0DD9FC9D4E827FD55A"></a></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 1 -</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">SCHEDULE "B"</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">BENEFITS</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Oncolytics shall:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">pay the Employee Health Care Premiums for the Employee; and the Employee's spouse and dependent children; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">commencing with the calendar year 2013 and annually thereafter, pay to the Employee's Registered Retirement Savings Plan, as directed by the Employee, an amount equal to ten (10%) percent of the Employee's annual salary as set out in Section 3(1), not to exceed the annual maximum allowable contribution.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee is presently entitled to designate an additional amount equal to a maximum 8.25% percent of the Employee's annual salary to be paid by Oncolytics, on a monthly basis, into an Employee Health Trust in accordance with the provisions of the Employee Health Trust Plan currently in place, and as such provisions may be revised from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;color:#242424;">The Employee is entitled to the Physical Fitness Benefit in the amount of $750</font><font style="font-family:Arial;font-size:12pt;">.</font><font style="font-family:Arial;font-size:12pt;color:#242424;">00 CANADIAN DOLLARS per annum to use towards an item or service that promotes physical activity; the details of which are outlined in the Company Policy Manual.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.9
<SEQUENCE>9
<FILENAME>ex49coffey2019.htm
<DESCRIPTION>EXHIBIT 4.9
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s55A2A1671AC4CE659F3E9D50A87C30CE"></a></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 1 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">EXHIBIT 4.9</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">EXECUTIVE EMPLOYMENT AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">THIS AGREEMENT </font><font style="font-family:Arial;font-size:12pt;">made the 1</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">st</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;day of January, 2019.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">BETWEEN:</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">("Oncolytics")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">-and-</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">MATTHEW C. COFFEY</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(the "Employee")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">WHEREAS Oncolytics is engaged in the business of developing pharmaceutical products;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">AND WHEREAS Oncolytics and the Employee entered into an Executive Employment Agreement dated January 1, 2013, which has been amended;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">AND WHEREAS Oncolytics and the Employee wish to further amend and restate the terms of employment pursuant to this Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">NOW THEREFORE the parties agree as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:0px;"><font style="padding-bottom:16px;padding-top:16px;text-align:left;font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;padding-right:96px;">Section 1 - </font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Definitions and Interpretation</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">In this Agreement the following defined terms shall have the meanings indicated:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">"Business" means the business currently carried on by Oncolytics, which is the development, testing, marketing and sale of pharmaceutical products together with such additional business as Oncolytics may decide to undertake from time to time;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">"Commencement Date" means July 29, 1999;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">"Confidential Information" means all confidential information of Oncolytics and includes:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">any data or information directly or indirectly related to the Business or arising directly or indirectly in the course of, or derived from the Employee's employment with Oncolytics whether related to products, equipment, inventions, ideas, designs, methods, systems, improvements, processes, research or otherwise;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">any of Oncolytics' technical or scientific know-how;</font></div></td></tr></table><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 2 -</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">financial and sales information, customer lists, pricing policies, lists of suppliers, proprietary computer programs in any format whatsoever, programming techniques, the manner of plans or methods of operation and the like relating to the Business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">patent applications, drawings, blueprints, manuals, letters, notebooks, reports and all other materials (written or otherwise) related to the Business or to the agents, joint venturers or contractors of Oncolytics; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">any information provided to or received by Oncolytics on a confidential basis;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">"Good Reason" means any one of the following events occurring on or after the Commencement Date:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">any reduction in the Employee's then existing annual base compensation and benefits, unless comparable reductions are made for all other executive employees of Oncolytics;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">any material diminution of the Employee's duties, responsibilities, authority or reporting structure, excluding for this purpose an isolated or inadvertent action not taken in bad faith which is remedied by Oncolytics immediately after notice thereof is given by the Employee;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">any request that the Employee relocate to a work site that would increase the Employee's one-way commute distance by more than eighty (80) kilometers from the Employee's then principal residence, unless the Employee accepts such relocation opportunity; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">any material breach by Oncolytics of its obligations under this Agreement that is not remedied within thirty (30) days of written notice of such breach from the Employee;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">"Intellectual Property" means all information, data, designs, processes, software, algorithms and inventions, including those that may be the subject of patent, copyright, industrial design, trademarks, trade secret or other forms of legal protection, made, conceived or developed by the Employee during the term of employment with Oncolytics, whether alone or jointly with others and whether during or after regular working hours, that relates to or in any way pertains to or connects with any matter developed, or under investigation or development by Oncolytics or related to the Business;</font></div></td></tr></table><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 3 -</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">"Termination Event" means:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">breach by the Employee of any material provision of this Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">material violation by the Employee of any statutory or common law duty of loyalty to Oncolytics;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">the commission of an indictable offence by the Employee against Oncolytics; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">personal or professional conduct of the Employee which in the reasonable and good faith judgment of Oncolytics may significantly injure Oncolytics' Business or interfere with the Employee's job performance.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">This Agreement shall be governed by and construed in accordance with the laws in force in the Province of Alberta.  The parties hereby submit to the jurisdiction of the Courts of Alberta.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The following schedules are attached to and form part of this Agreement:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Schedule "A" &#8211; Job Description</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Schedule "B" &#8211; Benefits</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 2 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Employment</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Oncolytics agrees to employ the Employee in the position of President and Chief Executive Officer and the Employee accepts the employment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee shall perform the duties and responsibilities associated with the position of President and Chief Executive Officer, including those set out on the Job Description attached as Schedule "A".  The Employee shall report to the Board of Directors of Oncolytics.  The Employee may, from time to time, be assigned or undertake additional duties and responsibilities consistent with those generally appropriate for a President and Chief Executive Officer, and the Employee's duties and responsibilities may be modified or expanded from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee shall perform the duties and responsibilities set out in Section 2(2):</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">diligently, faithfully and to the best of the Employee's ability; and</font></div></td></tr></table><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 4 -</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">in the best interests of Oncolytics.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee shall comply with the terms, conditions and requirements of Oncolytics' Policy Manual, as the same may be amended, revised or added to from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 3 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Remuneration</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Commencing January 1, 2019, Oncolytics shall pay to the Employee a salary of  $525,000 CANADIAN DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of $21,875.00 CANADIAN DOLLARS on the 15</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;and last day of each month.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Oncolytics shall, on or before the anniversary date of this Agreement in each year, evaluate and set the Employee's salary for the next ensuing year.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Oncolytics shall reimburse the Employee for all reasonable out-of-pocket expenses incurred by the Employee in the performance of the Employee's obligations under this Agreement, subject to Oncolytics' policies then in force.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Oncolytics shall be entitled to withhold from any payments made to the Employee any amounts that Oncolytics is required to withhold pursuant to any Act in force that relates to income tax, unemployment insurance premiums or pension plan premiums in any jurisdiction under which such payments are required to be made by or on behalf of the Employee, including, without limitation, the Income Tax Act (Canada), the Employment Insurance Act (Canada), the Canada Pension Plan.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 4 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Benefits</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employee shall be entitled to participate in benefit plans described in Schedule "B" and in other benefit plans instituted by Oncolytics from time to time.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 5 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Vacations</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employee shall, in addition to all statutory holidays, be entitled to 20 days paid vacation during each twelve (12) month period of employment under this Agreement.  The Employee's vacation time shall be governed by applicable policies of Oncolytics.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 6 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Place of Employment</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employee shall perform the majority of the Employee's employment obligations from and out of Oncolytics' offices located in the City of Calgary, Alberta, Canada.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 7 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Confidential Information</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 5 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee confirms that the Confidential Information is the sole and exclusive property of Oncolytics and is held by the Employee in trust for the benefit of Oncolytics.  The Employee shall use the Employee's best efforts and exercise utmost diligence to protect and safeguard the Confidential Information.  Neither during the period of employment by Oncolytics nor thereafter for a period of three years shall the Employee, directly or indirectly, use or disclose to any other person any Confidential Information, whether or not acquired, learned or obtained or developed by the Employee alone or in conjunction with others, except as such disclosure or use may be required in connection with the employment with Oncolytics or as may be agreed to in writing by Oncolytics.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Subsection 7(1) shall not apply to Confidential Information that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">is in the public domain at the time of its disclosure, or which, after disclosure, becomes part of the public domain other than by disclosure by the Employee;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">the Employee can show was in the Employee's possession at the time of disclosure and was not acquired from Oncolytics; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">was received by the Employee from a third party without a covenant of confidentiality, provided such third party is under no obligation of confidentiality with respect to the Confidential Information.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee shall keep informed of Oncolytics' policies and procedures for safeguarding Oncolytics' property including, without limitation, the Confidential Information and the confidentiality thereof, and will strictly comply therewith at all times.  The Employee shall not, except as required in the course of the employment with Oncolytics, remove from Oncolytics' premises any Oncolytics property including, without limitation, Confidential Information.  The Employee shall, immediately upon termination of employment with Oncolytics, return to Oncolytics all of Oncolytics' property in the Employee's possession, including, without limitation, all tangible parts of or relating to the Confidential Information as is in the Employee's possession or under the Employee's control without retaining any copies or record thereof or any other mechanical means that, alone or in combination with other means, would permit the Employee to reproduce or make available the Confidential Information.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee shall advise any future employer, associate or affiliate that the Employee has signed this Agreement and is bound by its terms and conditions.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 8 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Intellectual Property</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee confirms that any and all Intellectual Property shall be the sole and exclusive property of Oncolytics and shall be assigned by the Employee to Oncolytics.  The Employee agrees to disclose promptly to Oncolytics or its nominee any </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 6 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">and all Intellectual Property and to execute written assignments of the Employee's right, title and interest in and to the Intellectual Property to Oncolytics or its nominee.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">With respect to any Intellectual Property, the Employee also agrees:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">to assist Oncolytics or its nominee in preparing any necessary copyright and patent applications, including Canadian and foreign applications, covering the Intellectual Property;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">to sign and deliver all such applications and their assignment to Oncolytics or its nominee; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">generally to give all information and testimony, to co-operate with Oncolytics and its solicitors, to sign all lawful papers, and to do all lawful things that may be needed or requested by Oncolytics to obtain, extend, reissue, maintain or enforce Canadian and foreign copyrights or patents covering the Intellectual Property.</font></div></td></tr></table><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 7 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Oncolytics shall bear all expenses that are incurred in obtaining, extending, reissuing, maintaining and enforcing any and all copyrights or patents in respect of the Intellectual Property assigned to Oncolytics by the Employee, and in the vesting and perfecting of title thereto in Oncolytics and shall pay the Employee reasonable compensation for any time that Oncolytics may require the Employee to expend in order to accomplish the above subsequent to the termination of employment with Oncolytics.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee hereby waives in favour of Oncolytics, all moral rights in any and all copyright works authored or co-authored by the Employee during the term of this Agreement that directly relate to the Business of Oncolytics.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 9 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Term and Termination</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee's employment under this Agreement shall commence on the Commencement Date and shall continue until terminated in accordance with this Section 9.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Subject to Sections 9(3), (4) and (5), and notwithstanding any other provision contained herein to the contrary, the employment relationship between the Employee and Oncolytics arising out of this Agreement shall terminate upon forty-five (45) days notice being given to Oncolytics by the Employee or immediately upon notice being given to the Employee by Oncolytics.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">If Oncolytics is entitled to terminate this Agreement as the result of a Termination Event, Oncolytics shall not be required to compensate the Employee in respect of such termination or provide any period of notice in lieu of compensation with respect to such termination.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Subject to Section 9(5), if this Agreement is terminated by Oncolytics at any time other than pursuant to Section 9(3), or if this Agreement is terminated by the Employee for Good Reason, the Employee shall be entitled to severance payment equal to 12 months salary.  Such severance compensation shall be paid to the Employee so as to maximize any reduction in income tax payable thereon as permitted by the Income Tax Act (Canada).  The severance payment as provided pursuant to this Section 9(4) shall include an amount equal to the value of all benefits to which the Employee would otherwise have been entitled during the notice period.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(5)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Notwithstanding Section 9(4), if there is a change of control of Oncolytics, as defined herein, and if this Agreement is terminated by Oncolytics at any time within one (1) year following the change of control other than pursuant to Section 9(3), the Employee shall be entitled to severance payment equal to twice that determined pursuant to Section 9(4).  Such severance compensation shall be paid to the Employee so as to maximize any reduction in income tax payable thereon as permitted by the Income Tax Act (Canada).</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 8 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">For the purposes of this Section 9(5), &#8220;change of control&#8221; means any amalgamation, merger or other corporate reorganization which results in any change in the present effective voting control of Oncolytics, or will result in a change of the person or persons who own or control sufficient voting shares in Oncolytics to elect a majority of the directors of Oncolytics, or will result in a person acquiring sufficient voting shares in Oncolytics to elect a majority of the directors of Oncolytics or any sale, lease, exchange, partnership, or other transfer (in one transaction or a series of transactions) of all or substantially all of the assets of Oncolytics or a plan of liquidation of Oncolytics and/or an agreement for the sale or liquidation of Oncolytics is approved and completed, or the Board of Directors determines in its sole discretion that a change of control has occurred, whether or not any event described above has occurred or is contemplated.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(6)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee acknowledges and agrees that payment in lieu of notice in accordance with Section 9(4) or 9(5) shall be and is conclusively deemed to be reasonable compensation for termination of this Agreement and hereby waives any claim or potential claim that the Employee now has or may hereafter have, against Oncolytics for further severance compensation or notice other than that provided by the terms of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(7)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee confirms that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">any breach of this Agreement or unauthorized disclosure of Confidential Information may result in irreparable harm to the Business of Oncolytics and considerable monetary damages to Oncolytics;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">the damages suffered by Oncolytics may be difficult to establish; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">interim and permanent injunctions may be the only suitable remedy for Oncolytics;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">but nothing herein shall in any way limit or restrict any other remedies available to Oncolytics at law or in equity including an action for damages.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 9 -</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(8)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Termination of the Employee's employment with Oncolytics for any reason whatsoever shall not terminate the Employee's obligations under Sections 7, 8 and 10 of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 10 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Non-Competition</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee shall not, during the term of this Agreement, engage, hold an interest in or have any involvement, either directly or indirectly, in any business entity, venture or undertaking if such would materially interfere with or conflict with the Employee's duties and obligations to Oncolytics as provided for under this Agreement, provided that the acquisition of a non-control position in publicly traded companies will not contravene this Section.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee shall not, during the term of this Agreement, and for a period of one (1) year following the termination or expiration of this Agreement, either individually or in partnership or jointly or in conjunction with any person, firm or corporation as principal, employee, partner, director or as a shareholder or investor (if actually involved in the management of a business which is competitive with the Business of Oncolytics) carry on or be engaged in any business which is directly competitive with the Business of Oncolytics.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The parties agree that all of the restrictions contained in Subsection 10(2) hereof are reasonable and valid, and that all defences to the strict enforcement thereof by Oncolytics are hereby waived by the Employee.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee agrees that the remedy at law for any breach by the Employee of the provisions of this Section 10 may be inadequate and that in the event of such breach, Oncolytics may make an application to a court of competent jurisdiction for an order granting Oncolytics temporary, permanent or both kinds of injunctive relief against the Employee, without the necessity of proving actual damage to Oncolytics.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(5)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee agrees that any waiver by Oncolytics of a breach of this Agreement by the Employee shall only be a waiver with respect to the particular breach giving rise to the waiver.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 11 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Notices</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">All notices, reports, invoices, payments and formal communications (collectively referred to as "Notices") required or permitted to be given hereunder shall be in writing and shall be delivered personally or sent by prepaid registered mail or facsimile transmission to the following address or such other address as the relevant party may notify from time to time:</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 10 -</font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">TO:&#160;&#160;&#160;&#160;Oncolytics</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Suite 210, 1167 Kensington Crescent N.W.</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Calgary, Alberta</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">T2N 1X7</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Attention: President &amp; CEO</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">TO:&#160;&#160;&#160;&#160;The Employee</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">MATTHEW C. COFFEY</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">[address redacted]</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Notices sent by prepaid registered mail shall be deemed to be received by the addressee on the seventh day (excluding Saturdays, Sundays, Statutory Holidays and any period of postal disruption) following the mailing thereof.  Notices personally served shall be deemed to be received when actually delivered, provided such delivery shall be during normal business hours.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Section 12 -</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Enurement</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Agreement shall enure to the benefit of and be binding upon the parties hereto and:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">in the case of Oncolytics, its successors and permitted assigns; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">in the case of the Employee, her heirs, executors, administrators or other personal representatives.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">IN WITNESS WHEREOF the parties have executed this Agreement as of the day and year first above written.</font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:49.78632478632478%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="4"></td></tr><tr><td style="width:8%;"></td><td style="width:15%;"></td><td style="width:70%;"></td><td style="width:7%;"></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Wayne Pisano</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Wayne Pisano</font></div><div style="font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Chairman</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Deborah Brown</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Deborah M. Brown</font></div><div style="font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Chair, Compensation Committee, Board Director</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;text-decoration:underline;">__/s/ Kirk Look</font><font style="font-family:Arial;font-size:12pt;font-style:italic;">_______________</font><font style="font-family:Arial;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-style:italic;text-decoration:underline;">_/s/ Matthew Coffey</font><font style="font-family:Arial;font-size:12pt;">__________</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Witness&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">MATTHEW C. COFFEY</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sD9E63D99D60B349C1E309D50A89F8557"></a></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 1 -</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">SCHEDULE "A"</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">JOB DESCRIPTION</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Summary: </font><font style="font-family:Arial;font-size:12pt;">In this position the incumbent will be responsible for the overall direction and performance of the Corporation</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Responsibilities</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:147%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:147%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Providing leadership, general supervision, management and control of the operations of the Corporation on a day-to-day basis in accordance with the strategic plans and policies approved by the board;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:147%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:147%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Providing leadership and vision in developing the tactics and business plans necessary to realize corporate objectives;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:147%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:147%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Managing the Corporation to ensure strategic and business plans are effectively implemented, the results are monitored and reported to the Board, and financial and operational objectives are attained;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:147%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:147%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Keeping the Board fully informed of all significant operational, financial and other matters relevant to the Corporation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:147%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:147%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Managing and overseeing the required interfaces between the Corporation and the public and acting as the principal spokesperson for the Corporation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:147%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:147%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Developing an executive team as required, and providing direction to the team in the fulfillment of their requirements in the furtherance of the Corporation&#8217;s objectives;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:147%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:147%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Implementing and supporting policies and procedures as approved by the Board and as required by the relevant regulatory authorities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:147%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:147%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Meeting all then current legal and regulatory requirements including the then current certifications required to meet the Corporation&#8217;s filing obligations; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:147%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:147%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Undertaking and directing other activities as defined by the Board or as determined are required to further the Corporation&#8217;s progress</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sF59B7FD144D28126916F9D50A8CFB95A"></a></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 1 -</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">SCHEDULE "B"</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">BENEFITS</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">Oncolytics shall:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">pay the Employee Health Care Premiums for the Employee; and the Employee's spouse and dependent children; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">commencing with the calendar year 2013 and annually thereafter, pay to the Employee's Registered Retirement Savings Plan, as directed by the Employee, an amount equal to ten (10%) percent of the Employee's annual salary as set out in Section 3(1), not to exceed the annual maximum allowable contribution.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;">The Employee is presently entitled to designate an additional amount equal to a maximum 8.25% percent of the Employee's annual salary to be paid by Oncolytics, on a monthly basis, into an Employee Health Trust in accordance with the provisions of the Employee Health Trust Plan currently in place, and as such provisions may be revised from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;color:#242424;">The Employee is entitled to the Physical Fitness Benefit in the amount of $750</font><font style="font-family:Arial;font-size:12pt;">.</font><font style="font-family:Arial;font-size:12pt;color:#242424;">00 CANADIAN DOLLARS per annum to use towards an item or service that promotes physical activity; the details of which are outlined in the Company Policy Manual.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.10
<SEQUENCE>10
<FILENAME>ex410guttadauroamendment20.htm
<DESCRIPTION>EXHIBIT 4.10
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1BC5F692D30BEC7746729D4AFD5373EE"></a></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">EXHIBIT 4.10</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">AMENDING AGREEMENT #3</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">THIS AMENDING AGREEMENT</font><font style="font-family:Arial;font-size:12pt;">&#32;made effective as of the 1</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">st </sup></font><font style="font-family:Arial;font-size:12pt;">day of January, 2020.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">BETWEEN:</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">ONCOYLYTICS BIOTECH (U.S.), INC.,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">("OBUS")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">- and -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">ANDREW DE GUTTADAURO</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(the "Employee")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">WHEREAS the Employee is an officer of OBUS whose terms of employment are set forth in the Employment Agreement dated effective June 29, 2017, as amended by Amending Agreement #1 and Amending Agreement #2 (collectively the &#8220;Employment Agreement&#8221;);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">AND WHEREAS OBUS and the Employee wish to further amend the Employment Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Interpretation</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument.  In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Amendment to the Employment Agreement</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employment Agreement Section 3 &#8211; Remuneration is amended as follows:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:11pt;">Commencing January 1, 2020, OBUS shall pay to the Employee a salary of THREE HUNDRED ($300,000.00) UNITED STATES DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of TWELVE THOUSAND FIVE HUNDRED UNITED STATES DOLLARS ($12,500.00) on the 15th and last day of each month.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Confirmation</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)&#160;&#160;&#160;&#160;The parties confirm that the increase in Base Salary is a result of an assessment of increases in cost-of-living indices and salary benchmarking.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)&#160;&#160;&#160;&#160;The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Miscellaneous</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:48px;">(a)</font><font style="font-family:Arial;font-size:12pt;">This Agreement shall be governed by and construed in accordance with the laws of California.  </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:48px;">(b)</font><font style="font-family:Arial;font-size:12pt;">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:48px;">(c)</font><font style="font-family:Arial;font-size:12pt;">This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which together shall constitute one document.  Delivery of an executed counterpart signature hereof by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written.   </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:48%;"></td><td style="width:4%;"></td><td style="width:7%;"></td><td style="width:41%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH (U.S.), INC.</font></div><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Matt Coffey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Matt Coffey</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Director</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Gilles Gosselin</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Gilles Gosselin</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Director</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:240px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;text-decoration:underline;">__/s/ Jody Kehler</font><font style="font-family:Arial;font-size:12pt;">__________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;           </font><font style="font-family:Arial;font-size:12pt;font-style:italic;text-decoration:underline;">__/s/ Andrew de Guttadauro</font><font style="font-family:Arial;font-size:12pt;">_________</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Witness&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">ANDREW DE GUTTADAURO</font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.11
<SEQUENCE>11
<FILENAME>ex411mooreamendment2020.htm
<DESCRIPTION>EXHIBIT 4.11
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s10DD3080D92BEAF4DBA19D4CF932616B"></a></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">EXHIBIT 4.11</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">AMENDING AGREEMENT #4</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">THIS AMENDING AGREEMENT</font><font style="font-family:Arial;font-size:12pt;">&#32;made effective as of the 1</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">st</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;day of January, 2020.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">BETWEEN:</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">ONCOYLYTICS BIOTECH (U.S.), INC.,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">("OBUS")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">- and -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">MICHAEL MOORE</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(the "Employee")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">WHEREAS the Employee is an officer of OBUS whose terms of employment are set forth in the Employment Agreement dated effective June 29, 2017, which has been amended by Amending Agreements (collectively the &#8220;Employment Agreement&#8221;);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">AND WHEREAS OBUS and the Employee wish to amend the Employment Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Interpretation</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument.  In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Amendment to the Employment Agreement</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employment Agreement Section 3 &#8211; Remuneration is amended as follows:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)&#160;&#160;&#160;&#160;Commencing January 1, 2020, OBUS shall pay to the Employee a salary of TWO HUNDRED SIXTY-FIVE THOUSAND TWO HUNDRED EIGHTY-FIVE UNITED STATES DOLLARS and SIXTY-EIGHT CENTS ($265,285.68) per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of ELEVEN THOUSAND FIFTY-THREE UNITED STATES DOLLARS and FIFTY-SEVEN CENTS ($11,053.57) on the 15th and last day of each month.</font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Confirmation</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)&#160;&#160;&#160;&#160;The parties confirm that the increase in Base Salary is a result of an assessment of increases in cost-of-living indices and salary benchmarking.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)&#160;&#160;&#160;&#160;The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Miscellaneous</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:48px;">(a)</font><font style="font-family:Arial;font-size:12pt;">This Agreement shall be governed by and construed in accordance with the laws of California.  </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:48px;">(b)</font><font style="font-family:Arial;font-size:12pt;">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:48px;">(c)</font><font style="font-family:Arial;font-size:12pt;">This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which together shall constitute one document.  Delivery of an executed counterpart signature hereof by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">IN WITNESS WHEREOF the parties hereto have executed this Amending </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Agreement as of the date and year first above written.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:48%;"></td><td style="width:4%;"></td><td style="width:7%;"></td><td style="width:41%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH (U.S.), INC.</font></div><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Matt Coffey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Matt Coffey</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Director</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Gilles Gosselin</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Gilles Gosselin</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Director</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:192px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;text-decoration:underline;">/s/ Jody Kehler</font><font style="font-family:Arial;font-size:12pt;font-style:italic;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:Arial;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;        </font><font style="font-family:Arial;font-size:12pt;font-style:italic;text-decoration:underline;">&#160;&#160;&#160;&#160;/s/ Michael Moore     </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Witness&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">MICHAEL MOORE</font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.12
<SEQUENCE>12
<FILENAME>ex412lauefleamendment2020.htm
<DESCRIPTION>EXHIBIT 4.12
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s5EBB8DD7EFFCF4D5E915AD57608FA984"></a></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">EXHIBIT 4.12</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">AMENDING AGREEMENT #1</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">THIS AMENDING AGREEMENT</font><font style="font-family:Arial;font-size:12pt;">&#32;made effective as of the 1</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">st </sup></font><font style="font-family:Arial;font-size:12pt;">day of January, 2020.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">BETWEEN:</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">ONCOYLYTICS BIOTECH (U.S.), INC.,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">("OBUS")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">- and -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">RITA LAEUFLE</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(the "Employee")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">WHEREAS the Employee is an officer of OBUS whose terms of employment are set forth in the Employment Agreement dated effective November 1, 2018, (the &#8220;Employment Agreement&#8221;);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">AND WHEREAS OBUS and the Employee wish to amend the Employment Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Interpretation</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument.  In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Amendment to the Employment Agreement</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employment Agreement Section 3.1 &#8211; Base Salary is amended as follows:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Commencing January 1, 2020, OBUS shall pay to the Employee a Base Salary at an annual rate of FOUR HUNDRED AND SEVENTEEN THOUSAND ONE HUNDRED AND FIFTY ($417,150.00) UNITED STATES DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of SEVENTEEN THOUSAND THREE HUNDRED EIGHTY-ONE UNITED STATES DOLLARS and TWENTY-FIVE CENTS ($17,381.25) on the 15th and last day of each month.</font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:Arial;font-size:12pt;font-weight:bold;padding-right:48px;">3</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Confirmation</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(1)&#160;&#160;&#160;&#160;The parties confirm that the increase in Base Salary is a result of an assessment of increases in cost-of-living indices and salary benchmarking.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(2)&#160;&#160;&#160;&#160;The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:Arial;font-size:12pt;font-weight:bold;padding-right:48px;">4</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Miscellaneous</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:48px;">(a)</font><font style="font-family:Arial;font-size:12pt;">This Agreement shall be governed by and construed in accordance with the laws of California.  </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:48px;">(b)</font><font style="font-family:Arial;font-size:12pt;">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:Arial;font-size:12pt;padding-right:48px;">(c)</font><font style="font-family:Arial;font-size:12pt;">This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which together shall constitute one document.  Delivery of an executed counterpart signature hereof by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written. </font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:50%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:15%;"></td><td style="width:85%;"></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH (U.S.), INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Matt Coffey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Matt Coffey</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Director</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Gilles Gosselin</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Gilles Gosselin</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Director</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;text-decoration:underline;">____/s/ Jody Kehler</font><font style="font-family:Arial;font-size:12pt;">_________________&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-style:italic;text-decoration:underline;">___/s/ Rita Laeufle</font><font style="font-family:Arial;font-size:12pt;">_________________</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Witness&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">RITA LAEUFLE</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.13
<SEQUENCE>13
<FILENAME>ex413hagermanamendment2020.htm
<DESCRIPTION>EXHIBIT 4.13
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sCE85BE0190933A827880AD5A1F73E024"></a></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">EXHIBIT 4.13</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">AMENDING AGREEMENT</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">THIS AMENDING AGREEMENT</font><font style="font-family:Arial;font-size:12pt;">&#32;made effective as of the 1</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">st</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;day of January, 2020.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">BETWEEN:</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Oncolytics Biotech Inc.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">("Oncolytics")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">- and -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Allison Hagerman,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(the "Employee")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">WHEREAS Oncolytics and the Employee entered into a Letter of Employment dated August 3, 2010;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">AND WHEREAS Oncolytics and the Employee entered into an Employment Agreement dated August 1, 2013, which has been amended (collectively the &#8220;Employment Agreement&#8221;);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">AND WHEREAS Oncolytics and the Employee wish to further amend the Employment Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Interpretation</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument. In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Amendment to the Employment Agreement</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employment Agreement Section 3 &#8211; Remuneration is amended as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:0px;"><font style="padding-bottom:16px;text-align:justify;font-family:Arial;font-size:12pt;padding-right:48px;">(1)</font><font style="font-family:Arial;font-size:12pt;">Commencing January 1, 2020, Oncolytics shall pay to the Employee a salary of TWO HUNDRED TWENTY-FIVE THOUSAND ($225,000.00) CANADIAN DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal </font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;"><font style="font-family:Arial;font-size:12pt;">installments of NINE THOUSAND THREE HUNDRED SEVENTY-FIVE DOLLARS ($9,375.00) on the 15</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;and last day of each month.  </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Confirmation</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Miscellaneous</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Agreement shall be governed by and construed in accordance with the laws in force in the Province of Alberta.  The parties hereby submit to the jurisdiction of the Courts of Alberta.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which together shall constitute one document.  Delivery of an executed counterpart signature hereof by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written. </font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:50%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:15%;"></td><td style="width:85%;"></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Matt Coffey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Matt Coffey</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">President and CEO</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Kirk Look</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Kirk Look</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">CFO</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">__</font><font style="font-family:Arial;font-size:12pt;font-style:italic;text-decoration:underline;">/s/ Jody Kehler</font><font style="font-family:Arial;font-size:12pt;">_____________&#160;&#160;&#160;&#160;       &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;text-decoration:underline;">_</font><font style="font-family:Arial;font-size:12pt;font-style:italic;text-decoration:underline;">/s/ Allison Hagerman</font><font style="font-family:Arial;font-size:12pt;">____</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Witness&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">ALLISON HAGERMAN</font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.14
<SEQUENCE>14
<FILENAME>ex414lookamendment2020.htm
<DESCRIPTION>EXHIBIT 4.14
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sBB2DBB0EC91C09681F03AD5E1B6A1A0C"></a></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">EXHIBIT 4.14</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">AMENDING AGREEMENT #1</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">THIS AMENDING AGREEMENT</font><font style="font-family:Arial;font-size:12pt;">&#32;made effective as of the 1</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">st</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;day of January, 2020.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">BETWEEN:</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Oncolytics Biotech Inc.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">("Oncolytics")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">- and -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Kirk Look</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(the &#8220;Employee&#8221;)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">WHEREAS Oncolytics and the Employee entered into an Executive Employment Agreement dated January 1, 2019 (the &#8220;Employment Agreement&#8221;);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">AND WHEREAS Oncolytics and the Employee wish to amend the Employment Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Interpretation</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument. In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Amendment to the Employment Agreement</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employment Agreement Section 3 &#8211; Remuneration is amended as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:0px;"><font style="padding-bottom:16px;text-align:justify;font-family:Arial;font-size:12pt;padding-right:48px;">(1)</font><font style="font-family:Arial;font-size:12pt;">Commencing January 1, 2020, Oncolytics shall pay to the Employee a salary of THREE HUNDRED NINETY-SIX THOUSAND FIVE HUNDRED FIFTY ($396,550.00) CANADIAN DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of SIXTEEN THOUSAND FIVE HUNDRED TWENTY-TWO DOLLARS and NINETY-TWO CENTS ($16,522.92) on the 15</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;and last day of each month.  </font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Confirmation</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Miscellaneous</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Agreement shall be governed by and construed in accordance with the laws in force in the Province of Alberta.  The parties hereby submit to the jurisdiction of the Courts of Alberta.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which together shall constitute one document.  Delivery of an executed counterpart signature hereof by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written. </font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:50%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:15%;"></td><td style="width:85%;"></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Wayne Pisano</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Wayne Pisano</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Chairman</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Deborah Brown</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Deborah M. Brown</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Chair, Compensation Committee</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;text-decoration:underline;">___/s/ Jody Kehler</font><font style="font-family:Arial;font-size:12pt;">_________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-style:italic;text-decoration:underline;">__/s/ Kirk Look</font><font style="font-family:Arial;font-size:12pt;">___________________</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Witness&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">KIRK LOOK</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.15
<SEQUENCE>15
<FILENAME>ex415coffeyamendment2020.htm
<DESCRIPTION>EXHIBIT 4.15
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s38042265279483634F54AD5FF0199BD2"></a></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">EXHIBIT 4.15</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">AMENDING AGREEMENT #1</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">THIS AMENDING AGREEMENT</font><font style="font-family:Arial;font-size:12pt;">&#32;made effective as of the 1</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">st</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;day of January, 2020.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">BETWEEN:</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Oncolytics Biotech Inc.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">("Oncolytics")</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">- and -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Matt Coffey</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(the &#8220;Employee&#8221;)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">WHEREAS Oncolytics and the Employee entered into an Executive Employment Agreement dated January 1, 2019 (the &#8220;Employment Agreement&#8221;);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">AND WHEREAS Oncolytics and the Employee wish to amend the Employment Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Interpretation</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument. In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Amendment to the Employment Agreement</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The Employment Agreement Section 3 &#8211; Remuneration is amended as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:0px;"><font style="padding-bottom:16px;text-align:justify;font-family:Arial;font-size:12pt;padding-right:48px;">(1)</font><font style="font-family:Arial;font-size:12pt;">Commencing January 1, 2020, Oncolytics shall pay to the Employee a salary of FIVE HUNDRED FORTY THOUSAND SEVEN HUNDRED FIFTY ($540,750.00) CANADIAN DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of TWENTY-TWO THOUSAND FIVE HUNDRED THIRTY-ONE DOLLARS and TWENTY-FIVE CENTS ($22,531.25) on the 15</font><font style="font-family:Arial;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:Arial;font-size:12pt;">&#32;and last day of each month.  </font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Confirmation</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:12pt;">4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Miscellaneous</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Agreement shall be governed by and construed in accordance with the laws in force in the Province of Alberta.  The parties hereby submit to the jurisdiction of the Courts of Alberta.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which together shall constitute one document.  Delivery of an executed counterpart signature hereof by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written. </font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:50%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:15%;"></td><td style="width:85%;"></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Wayne Pisano</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Wayne Pisano</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Chairman</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Per:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;">/s/ Deborah Brown</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Deborah M. Brown</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Chair, Compensation Committee</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-style:italic;text-decoration:underline;">_/s/ Jody Kehler</font><font style="font-family:Arial;font-size:12pt;">______________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;__</font><font style="font-family:Arial;font-size:12pt;font-style:italic;text-decoration:underline;">/s/ Matt Coffey</font><font style="font-family:Arial;font-size:12pt;">________________</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Witness&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">MATT COFFEY</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.0
<SEQUENCE>16
<FILENAME>ex80subsidiaries2019.htm
<DESCRIPTION>EXHIBIT 8.0
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s257378C7F9105F76AF7A48332E74EBF4"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT 8.0</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LIST OF SUBSIDIARIES</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2019</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.4609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:73%;"></td><td style="width:27%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Jurisdiction</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oncolytics Biotech (Barbados) Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Barbados</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oncolytics Biotech (US) Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delaware</font></div></td></tr></table></div></div><div style="line-height:144%;padding-bottom:6px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>17
<FILENAME>ex121ceocertfication2019.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD18EE8B3035856ABB62B361BBFC59469"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 12.1</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Matthew Coffey, certify that:</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this annual report on Form 20-F of Oncolytics Biotech Inc.;</font></div></td></tr></table><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</font></div></td></tr></table><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5. </font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:7%;"></td><td style="width:41%;"></td><td style="width:7%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;6, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">/s/ Matthew Coffey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Matthew Coffey, PhD, MBA</font></div><div style="padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div><div style="padding-bottom:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>18
<FILENAME>ex122cfocertification2019.htm
<DESCRIPTION>EXHIBIT 12.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sE3D48EAC472256A993F3F9DA68592D19"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 12.2</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Kirk Look, certify that:</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 20-F of Oncolytics Biotech Inc.;</font></div><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</font></div><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</font></div><div style="line-height:144%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5. </font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><div style="line-height:144%;text-align:left;padding-left:96px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:9px;text-align:left;padding-left:96px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:6%;"></td><td style="width:41%;"></td><td style="width:6%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;6, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Kirk Look</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk Look, CA</font></div><div style="padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div><div style="padding-bottom:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal Accounting and Financial Officer</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>19
<FILENAME>ex131ceocertification2019.htm
<DESCRIPTION>EXHIBIT 13.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9BB468D7AD8B56C3BC1E913866D7D361"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 13.1</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18 U.S.C. &#167;1350,</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the annual report of Oncolytics Biotech Inc. (the &#8220;Company&#8221;) on Form 20-F for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;as filed with the Securities and Exchange Commission on the date here of (the &#8220;Report&#8221;), I, Matthew Coffey, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div><div style="line-height:144%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Matthew Coffey</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_________________________________</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Matthew Coffey, PhD, MBA</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal Executive Officer</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;6, 2020</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A signed original of this written statement required by Section 906 has been provided to Oncolytics Biotech Inc. and will be retained by Oncolytics Biotech Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>20
<FILENAME>ex132cfocertification2019.htm
<DESCRIPTION>EXHIBIT 13.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s47F136E3D2D75B15B68F17D2BFF09D47"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 13.2</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18 U.S.C. &#167;1350,</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the annual report of Oncolytics Biotech Inc. (the &#8220;Company&#8221;) on Form 20-F for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;as filed with the Securities and Exchange Commission on the date here of (the &#8220;Report&#8221;), I, Kirk Look, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></div><div style="line-height:144%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div><div style="line-height:144%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Kirk Look</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________________________________</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk Look, CA</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal Accounting and Financial Officer</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;6, 2020</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A signed original of this written statement required by Section 906 has been provided to Oncolytics Biotech Inc. and will be retained by Oncolytics Biotech Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>21
<FILENAME>ex151-2019mda.htm
<DESCRIPTION>EXHIBIT 15.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sA998B87247C95B6D97AB9EC5B4A34502"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:left;"><img src="oncolyticslogotaglinebluea05.jpg" alt="oncolyticslogotaglinebluea05.jpg" style="height:298px;width:682px;"></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">MANAGEMENT DISCUSSION &amp; ANALYSIS</font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;color:#000000;font-weight:bold;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:16pt;font-weight:bold;">&#32;</font></div><div><br></div><hr style="page-break-after:always"><div><a name="s19BEC05EBCCA5521AF335CEBFC82FBAE"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;color:#000000;font-weight:bold;text-decoration:none;">March&#160;5, 2020</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BASIS OF PRESENTATION </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Management Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) should be read in conjunction with our </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;audited consolidated financial statements and notes thereto, which have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). This MD&amp;A along with our consolidated financial statements for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;5, 2020</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s18107F8D183A5BAB9A6867E0326E9296"></a></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following discussion contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and under applicable Canadian provincial securities legislation. Forward-looking statements, including: our belief as to the potential of pelareorep, an intravenously delivered immuno-oncolytic virus, as a cancer therapeutic; our expectation that we will not generate significant revenues until and unless pelareorep becomes commercially viable; our business strategy, goals and objectives for the development of pelareorep; our plan to actively manage the development of our clinical trial program, our pre-clinical and collaborative programs, our manufacturing process and pelareorep supply; our plans respecting regulatory approval for pelareorep; our planned clinical development program, including the timing thereof; our expectations regarding enrollment under our various clinical trials and the intended and anticipated results, benefits and opportunities therefrom; our planned 2020 development activity for pelareorep, our 2020 manufacturing program; our anticipated 2020 expenses relating to clinical trials, manufacturing, intellectual property, research collaborations and other research and development and operating expenses; our plans respecting the maintenance of adequate cash reserves to support our planned activities; our plans for funding our capital expenditure requirements; our approach to foreign exchange risk mitigation; and statements that are not historical facts, involve known and unknown risks and uncertainties, which could cause our actual results to differ materially from those in the forward-looking statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Such risks and uncertainties include, among others, the need for and availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, our ability to successfully commercialize pelareorep, uncertainties related to the research, development and manufacturing of pelareorep, uncertainties related to competition, changes in technology, the regulatory process and general changes to the economic environment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to the forward-looking statements made within this MD&amp;A, we have made numerous assumptions regarding among other things: our ability to obtain financing to fund our clinical development plan, our ability to receive regulatory approval to commence enrollment in the clinical studies which are part of our clinical development plan, our ability to maintain our supply of pelareorep and future expense levels being within our current expectations.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investors should consult our quarterly and annual filings with the Canadian and US securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Forward-looking statements are based on assumptions, projections, estimates, and expectations of management at the time such forward-looking statements are made, and such assumptions, projections, estimates and/or expectations could change or prove to be incorrect or inaccurate. Investors are cautioned against placing undue reliance on forward-looking statements. We do not undertake to update these forward-looking statements except as required by applicable law.</font></div><div><a name="sAC9206CA121D55859A75F74D4A6E2FFE"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Pelareorep Development Update For </font><font style="font-family:inherit;font-size:16pt;color:#000000;font-weight:bold;text-decoration:none;">2019</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Oncolytics Biotech Inc. is a Development Stage Company</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since our inception in April of 1998, Oncolytics Biotech Inc. has been a development stage company. We have focused our research and development efforts on the development of pelareorep, an intravenously delivered immuno-oncolytic virus (IOV) with the potential to treat a variety of cancers. We have not been profitable since our inception and expect to continue to incur substantial </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">losses as we continue research and development efforts. We do not expect to generate significant revenues until, and unless, pelareorep becomes commercially viable.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our goal each year is to advance pelareorep through the various steps and stages of development required for potential pharmaceutical products.  In order to achieve this goal, we proactively manage all aspects of the development of our clinical trial program, our pre-clinical and collaborative programs, our manufacturing process and pelareorep</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">supply, and our intellectual property.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s2225485CE8155138946BF2F2F6023A32"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Clinical Trial Program</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The ultimate objective of our clinical development plan is to obtain regulatory approval for pelareorep as quickly as possible and is based on the compelling efficacy data from previous studies in breast, multiple myeloma, and selected gastrointestinal cancers. Our clinical development program centers on key immunotherapy combinations. Specifically, immunotherapy combinations in which pelareorep has the potential to provoke a specific innate and adaptive immune responses when combined with checkpoint blockade therapy, chemotherapy and/or targeted therapies. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-style:italic;font-weight:bold;">2019</font><font style="font-family:inherit;font-size:14pt;font-style:italic;font-weight:bold;">&#32;Developments:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Clinical studies aiding registration program</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Collaboration with Pfizer Inc. and Merck KGaA, Darmstadt, Germany: BRACELET-1 study </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2019, we entered into an agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody, for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative (HR+ / HER2-) mBC. The cost of this phase 2 clinical trial will be shared equally between Oncolytics and Pfizer. The study, known as BRACELET-1 (</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BR</font><font style="font-family:inherit;font-size:10pt;">east c</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A</font><font style="font-family:inherit;font-size:10pt;">n</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CE</font><font style="font-family:inherit;font-size:10pt;">r with the Oncolytic Reovirus Pe</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">L</font><font style="font-family:inherit;font-size:10pt;">areor</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E</font><font style="font-family:inherit;font-size:10pt;">p in Combina</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">T</font><font style="font-family:inherit;font-size:10pt;">ion with anti-PD-L1&#160;and Paclitaxel), is an open-label study planned to enroll 45 patients into three cohorts with 15 patients per cohort: paclitaxel alone, paclitaxel in combination with pelareorep, and paclitaxel in combination with both pelareorep and avelumab (Bavencio</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">). The study will examine the expression of immune-related biomarkers to identify changes in T cell population between pre-treatment and on-therapy biopsies to confirm our previously identified biomarker and is designed to assess efficacy in terms of overall response rate at week 16 per RECIST 1.1 and iRECIST. The safety of the combination will also be evaluated.&#160;Similar to the AWARE-1 study (see below), the results of this study may provide an opportunity to add an arm to our proposed phase 3 study that includes a checkpoint inhibitor in addition to the chemotherapy-virus combination. Furthermore, the results of the BRACELET-1 study will provide important confirmatory data in the same patient population where we presented compelling metastatic breast cancer survival data at the 2017 AACR Annual Meeting. These endpoints, including the biomarker data, are expected to further de-risk our planned phase 3 registration study, permitting for a smaller study with a higher likelihood of clinical success.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2019, we announced our collaboration with PrECOG LLC, a leading cancer research network, in which PrECOG LLC will run the BRACELET-1 study. The study is anticipated to begin enrollment in the first quarter of 2020.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Collaboration with SOLTI: AWARE-1 study</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2019, we received approval for our AWARE-1 study, which was announced in September 2018, from the Spanish Agency for Medicine and Health Products. This clinical collaboration with SOLTI, an academic research group dedicated to breast cancer research, is a window of opportunity study in the neoadjuvant setting for breast cancer using pelareorep in combination with F. Hoffmann-La Roche (Roche)'s anti-PD-L1 checkpoint inhibitor, atezolizumab (Tecentriq</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">), which we are utilizing under our Master Clinical Supply Agreement with Roche. In July 2019, we announced preliminary trial data demonstrating viral replication and promotion of inflammation following systemic administration of pelareorep when combined with Tecentriq</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. Early data suggest a correlation between high peripheral T cell clonality (our candidate biomarker) and beneficial changes within the tumor microenviornment. We have also received a favorable recommendation from the Steering Committee to advance into the next phase of the AWARE-1 study. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The study plans to enroll 38 patients. Data generated from this study is intended to confirm that the virus is acting as a novel immunotherapy in breast cancer and to confirm biomarker data for breast cancer. The primary objective of this study is to supplement the existing randomized phase 2 results by providing key biomarker data points to enhance our probability of success in the phase 3 registration study. The results of this study may also provide an opportunity to add an arm to our proposed phase 3 study that includes a checkpoint inhibitor in addition to the chemotherapy-virus combination. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Additional checkpoint inhibitor combinations </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pancreatic cancer study combining pelareorep and Keytruda</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup>&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2019, we continued patient enrollment and treatment in our investigator sponsored study (IST) supported by Merck Inc. (Merck), Northwestern University and Oncolytics. This study, an extension of our phase 1 study (REO 024), will investigate pelareorep in combination with Merck&#8217;s anti-PD1 checkpoint inhibitor Keytruda</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, to treat second-line pancreatic cancer patients. The study plans to enroll approximately 40 patients. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Multiple myeloma study combining pelareorep and Opdivo</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup>&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2019, we continued patient enrollment in the safety cohort of our IST with Emory University and the University of Utah investigating the combination of pelareorep and Bristol-Myers Squibb's anti-PD1 checkpoint inhibitor Opdivo</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;in 40 - 50 relapsed or refractory myeloma patients. The safety cohort will investigate the combination of a proteasome inhibitor with the checkpoint inhibitor prior to the addition of pelareorep. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Pre-clinical/Research collaborations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, the following presentations and journal publication were delivered to demonstrate clinical evidence that pelareorep can boost PD-L1 expression and has the potential to serve as a backbone for immune checkpoint inhibition and can be effectively delivered intravenously across a wide range of cancers, as well as a predictive and prognostic biomarker can be derived from a simple blood draw: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:19%;"></td><td style="width:16%;"></td><td style="width:16%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Title</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Author/Presenter</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Publication</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/Location</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Description/Conclusion</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chandini M. Thirukkumaram, University of Calgary <br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Blood Advances, March 12, 2019 edition<br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The article demonstrates that the combination of reovirus and bortezomib can overcome drug resistance, a major hurdle in the treatment of multiple myeloma. Further, the combination modifies the tumor microenvironment to overcome the immune suppressive environment caused by multiple myeloma cells in the bone marrow. This combination promotes a pro-inflammatory signal within the tumor microenvironment, upregulates the PD-L1/PD-1 axis and enhances immune cell infiltration. Collectively, this suggests the possibility of synergies and increased efficacy with the addition of checkpoint blockade to the combination.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exploratory analysis of T cell repertoire dynamics upon systemic treatment with the oncolytic virus pelareorep in combination with pembrolizumab and chemotherapy in patients with advanced pancreatic adenocarcinoma</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Grey Wilkinson, PhD, Translational Scientist, Oncolytics Biotech Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">American Association for Cancer Research (AACR) Annual Meeting 2019, Atlanta, Georgia</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Data presented in the poster demonstrated:</font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">Patients treated with pelareorep in combination with chemotherapy and pembrolizumab showed changes in their T cell repertories with high turnover and significant expansion during treatment</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">These post-treatment expanded T cell populations, are "new" clones not present at baseline, suggesting effective priming of the immune system</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">Higher T cell clonality at baseline correlates with longer progression free survival (HR=0.05, p=0.01) and overall survival (HR=0.12, p=0.01) demonstrating the predictive value of the assay</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">Enhanced T cell clonality after the first cycle of treatment correlates with improved overall survival (HR=0.08, p=0.01) and serves as an on-treatment prognostic biomarker</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">Early expanded T cell clones, detected at day 8 of treatment (prior to pembrolizumab), most strongly correlate with survival time which suggests that early versus late clonal expansion may be elicited by pelareorep treatment</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">T cell clonality has significant potential as a predictive and prognostic on-treatment biomarker to pelareorep therapy</font></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:19%;"></td><td style="width:16%;"></td><td style="width:16%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Title</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Presenter</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Location</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Description/Conclusion</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Prediction of response to pelareorep plus pembrolizumab in pancreatic ductal adenocarcinoma (PDAC)<br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Christos Fountzilas, Assistant Professor, Dept. of Medicine - GI Medical Oncology, Roswell Park Comprehensive Cancer Center<br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">American Society of Clinical Oncology (ASCO) 2019 Annual Meeting<br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Key data and conclusions demonstrated:</font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">Clonal T cell diversity was expanded during therapy, broadening the potential repertoire of T cells that can target tumor cells;</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">~30% of expanded clones at day eight of pelareorep therapy were durable after one cycle of treatment suggesting a refinement of T cell clones that target the best tumor cell antigens;</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">Gene expression analysis in peripheral blood mononuclear cells (PBMCs) helps to validate the changes in T cell diversity, where responding patients had higher levels of pro-inflammatory cytokines expressed by activated T cells, compared to non-responders. Importantly, there was a statistically significant upregulation of genes that aid in the recruitment and activation of T cells including IL17F, CCL7, and ICOS (raw p &lt; 0.05); and</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">Gene expression analysis in PBMCs may serve as a separate and independent biomarker, and helps to corroborate our previously published blood-based T cell clonality biomarker for pelareorep therapy.</font></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Systemic administration of oncolytic reovirus, pelareorep, a metanalysis on the efficiency of tumor delivery</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Grey Wilkinson, PhD, Translational Scientist, Oncolytics Biotech Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International Oncolytic Virus Conference (IOVC) 2019, Rochester, Minnesota</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The analyses examined the effectiveness of viral replication within the tumors of patients treated systemically with pelareorep. The data demonstrated that, unlike other oncolytic viruses that require intra-tumoral delivery, intravenous (IV) systemic delivery of pelareorep resulted in 81% of patient tumor samples across multiple types of cancer testing positive for virus replication, with no infection in normal tissue. These results are from studies across a broad range of solid and liquid tumors, including metastatic disease.<br><br>Key Findings from the Metanalysis:</font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">After IV delivery, 81% of patient tumor samples are positive for replicating reovirus (the average increases to 96% when melanoma and skin biopsies are excluded)</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">Tumor types that showed a high proportion of active viral replication: breast cancer, pancreatic adenocarcinoma, multiple myeloma, colorectal cancer patients with liver metastases and high-grade glioma</font></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">A window-of-opportunity Study of pelareorep in Early Breast Cancer (AWARE-1)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aleix Prat, MD, PhD, et al., Head, Medical Oncology Department, Hospital Clinic of Barcelona &amp; Associate Professor, University of Barcelona, SOLTI - Breast Cancer Research Group</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Society for Immunotherapy of Cancer (SITC) 2019, National Harbor, Maryland</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The primary objective of this study is to evaluate changes in the immune environment of patients diagnosed with breast cancer. Importantly, an increase in CelTIL score, which means a change or expansion of infiltrating immune cells, known to correlate with a positive patient outcome.&#160;<br><br>Initial data indicate viral replication exclusively in breast cancer tumor tissue and an increase in CelTIL score through the expansion of existing T cells and the creation of new T cell clones. <br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:19%;"></td><td style="width:16%;"></td><td style="width:16%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Title</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Presenter</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Location</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Description/Conclusion</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Carfilzomib Impairs the Innate Antiviral Immune Response and promotes cytotoxic T-cell Expansion in Oncolytic Virus Treated Multiple Myeloma Patients</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Flavia Pichiorri, Associate Professor in the Judy and Bernard Briskin Center for Multiple Myeloma Research within the Hematologic Malignancies and Stem Cell Transplantation Institute at the City of Hope</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019 American Society of Hematology Annual Meeting &amp; Exhibition, San Diego, California </font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Key data and conclusions demonstrated:</font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">Pelareorep treatment selectively infected multiple myeloma cells and not normal bone marrow cells;</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">Carfilzomib enhances reovirus entry, infection, and killing of multiple myeloma cells;</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">Reovirus significantly increases the frequency and activation of certain killer T cells, and increases the anti-tumor activity of immune cells in multiple myeloma; and</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">Data supports that the combination of pelareorep, and carfilzomib potentiates the expansion of CD8+ killer T cells.</font></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-style:italic;font-weight:bold;">Post </font><font style="font-family:inherit;font-size:14pt;font-style:italic;font-weight:bold;">2019</font><font style="font-family:inherit;font-size:14pt;font-style:italic;font-weight:bold;">&#32;Developments:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 27, 2020, we announced a poster presentation highlighting statistically significant data identifying CEACAM6 as a prospective biomarker for pelareorep in the treatment of pancreatic cancer.&#160;The presentation was delivered at the 2020 Gastrointestinal Cancers Symposium sponsored by ASCO in San Francisco.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:19%;"></td><td style="width:16%;"></td><td style="width:16%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Title</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Presenter</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Location</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Description/Conclusion</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">CEACAM6 as a candidate biomarker for pelareorep sensitivity in pancreatic adenocarcinoma (PDAC)</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Anne Noonan, Department of Medical Oncology, Ohio State University Wexner Medical Center, Richard Solove Research Institute and James Cancer Hospital, and Dr. Tanios Bekaii-Saab Senior, Associate Consultant, Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Phoenix, Arizona.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020 Gastrointestinal Cancers Symposium, San Francisco, California</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Key data and conclusions demonstrated:</font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">CEACAM6 was the most differentially expressed gene, with an eight-fold decrease in levels of mRNA, in long-term responders compared to early progressors in patients receiving pelareorep.</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">Low levels of CEACAM6 mRNA expression were associated with prolonged PFS in pelareorep-treated patients (p=0.05). This treatment effect was not seen in patients that were not treated with pelareorep (p=0.35).</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">In pelareorep treated patients, CEACAM6 mRNA expression level was very influential with a hazard ratio of 1.54 (p=0.01), suggesting that one unit increase in CEACAM6, corresponds to an increase in the risk of progression and/or death by 54% in this arm. There was no significant relationship seen in patients that were not treated with pelareorep.</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">CEACAM6 may be included as a candidate biomarker of resistance to pelareorep and, in theory, could inhibit viral trafficking in tumor cells.</font></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s8BE30866A4CF5A939D8178E2C3B03853"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Manufacturing and Process Development </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Throughout </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, as we continued our production of 100-litre current Good Manufacturing Practices (cGMP) batches, we supplied our clinical development program with previously filled product from our existing stock of pelareorep, labeled for the applicable usage. As well, we continued our activities to develop clinical and commercial production capabilities to fill pelareorep into vials, the next step in the process validation master plan. Process validation is required to ensure that the resulting product meets required specifications and quality standards and will form part of the Company&#8217;s submission to regulators, including the FDA, for product approval. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sC18B9C15B5245243B15E719AE74C181B"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Intellectual Property</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the end of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">, we had been issued </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">399</font><font style="font-family:inherit;font-size:10pt;">&#32;patents including </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">48</font><font style="font-family:inherit;font-size:10pt;">&#32;US and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">21</font><font style="font-family:inherit;font-size:10pt;">&#32;Canadian patents as well as issuances in other jurisdictions. We have an extensive patent portfolio covering the oncolytic reovirus that we use in our clinical trial program including a composition of matter patent that expires in 2028.  Our patent portfolio also includes methods for treating proliferative disorders using modified adenovirus, HSV, parapoxvirus and vaccinia virus.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="s98E0441FC7BC5D4FABD0A32F9EA4FE63"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:100%;font-size:3pt;"><font style="font-family:inherit;font-size:3pt;"><br></font></div><div><a name="sCD26650F5EBC5F6C9EE9BBFBF3526C4F"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Financing Activity</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Public offering</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 16, 2019, pursuant to an underwritten public offering, </font><font style="font-family:inherit;font-size:10pt;">4,619,773</font><font style="font-family:inherit;font-size:10pt;">&#32;units were sold at a purchase price of US</font><font style="font-family:inherit;font-size:10pt;">$0.81</font><font style="font-family:inherit;font-size:10pt;">&#32;per unit for gross proceeds of US</font><font style="font-family:inherit;font-size:10pt;">$3,742,016</font><font style="font-family:inherit;font-size:10pt;">. Each unit included </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;common share with a fair value of US</font><font style="font-family:inherit;font-size:10pt;">$0.54</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;common share purchase warrant with a fair value of US</font><font style="font-family:inherit;font-size:10pt;">$0.27</font><font style="font-family:inherit;font-size:10pt;">. Each common share purchase warrant entitles the holder to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;common share at an exercise price of US</font><font style="font-family:inherit;font-size:10pt;">$0.90</font><font style="font-family:inherit;font-size:10pt;">&#32;until August 16, 2024. We incurred transaction costs of </font><font style="font-family:inherit;font-size:10pt;">$699,427</font><font style="font-family:inherit;font-size:10pt;">&#32;of which </font><font style="font-family:inherit;font-size:10pt;">$466,284</font><font style="font-family:inherit;font-size:10pt;">&#32;were allocated to share issue costs and </font><font style="font-family:inherit;font-size:10pt;">$233,143</font><font style="font-family:inherit;font-size:10pt;">&#32;were allocated to operating expenses, based on their relative fair values. In the fourth quarter of 2019, </font><font style="font-family:inherit;font-size:10pt;">2,935,647</font><font style="font-family:inherit;font-size:10pt;">&#32;warrants were exercised for gross proceeds of  US</font><font style="font-family:inherit;font-size:10pt;">$2,642,082</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">U.S. "at-the-market" equity distribution agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, we sold </font><font style="font-family:inherit;font-size:10pt;">4,425,040</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for gross proceeds of US</font><font style="font-family:inherit;font-size:10pt;">$6,390,691</font><font style="font-family:inherit;font-size:10pt;">. We incurred share issue costs of $</font><font style="font-family:inherit;font-size:10pt;">344,834</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock Purchase Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, we sold </font><font style="font-family:inherit;font-size:10pt;">2,477,665</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for gross proceeds of US</font><font style="font-family:inherit;font-size:10pt;">$4,055,725</font><font style="font-family:inherit;font-size:10pt;">&#32;and issued </font><font style="font-family:inherit;font-size:10pt;">17,278</font><font style="font-family:inherit;font-size:10pt;">&#32;commitment shares. The commitment shares were fair valued at US</font><font style="font-family:inherit;font-size:10pt;">$29,758</font><font style="font-family:inherit;font-size:10pt;">&#32;and were recorded as share issue costs in addition to cash share issue costs of </font><font style="font-family:inherit;font-size:10pt;">$3,757</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s502EB28B68625053889F0D0C6A060354"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Financial Impact</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We had estimated that our cash requirements for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;to fund operations for the year would be between $18 - $20 million. Our actual cash usage for the year was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$19,906,124</font><font style="font-family:inherit;font-size:10pt;">&#32;for operating activities, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10,905</font><font style="font-family:inherit;font-size:10pt;">&#32;for the acquisition of property and equipment and $</font><font style="font-family:inherit;font-size:10pt;">447,497</font><font style="font-family:inherit;font-size:10pt;">&#32;for the payment of office leases. Our net loss for the year was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$33,122,888</font><font style="font-family:inherit;font-size:10pt;">, which included a non-cash change in fair value of warrant derivative expense of $</font><font style="font-family:inherit;font-size:10pt;">12,608,808</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s15FBCBBE7B3A5DE981AAF12631D40C22"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Cash Resources </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;with cash and cash equivalents totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$14,148,021</font><font style="font-family:inherit;font-size:10pt;">&#32;(see </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Liquidity and Capital Resources&#8221;)</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s07470ed7fbe44bc99b0a19aff564ab89"></a></div><div style="line-height:120%;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Between </font><font style="font-family:inherit;font-size:10pt;">January&#160;1, 2020</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">March&#160;5, 2020</font><font style="font-family:inherit;font-size:10pt;">, we issued </font><font style="font-family:inherit;font-size:10pt;">3,921,790</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for gross proceeds of US$</font><font style="font-family:inherit;font-size:10pt;">12,726,383</font><font style="font-family:inherit;font-size:10pt;">&#32;through our October 2018 ATM equity offering sales agreement and we received gross proceeds of US$</font><font style="font-family:inherit;font-size:10pt;">1,030,669</font><font style="font-family:inherit;font-size:10pt;">&#32;as a result of </font><font style="font-family:inherit;font-size:10pt;">1,145,188</font><font style="font-family:inherit;font-size:10pt;">&#32;August 2019 public offering warrants that were exercised.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">February&#160;25, 2020</font><font style="font-family:inherit;font-size:10pt;">, we received the US</font><font style="font-family:inherit;font-size:10pt;">$1,500,000</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront payment of BRACELET-1 cost from Pfizer (see Note 13 of our audited consolidated financial statements).</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><a name="s548E1C97AB475AC384859BB9BAB9D62D"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Expected Pelareorep Development For 2020</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our planned 2020 development activity for pelareorep focuses on our clinical development plan along with our manufacturing and intellectual property programs. Our 2020 clinical objective is to incorporate our immuno-oncology combination strategy that includes checkpoint inhibitors, prove the usefulness of biomarkers across various indications, and combine with other anti-cancer agents as we develop our registration strategy and clinical protocol in preparation for a phase 3 clinical study in mBC. In the first half of 2020, we expect to announce additional interim data and complete enrollment of AWARE-1, continue study initiating activities related to BRACELET-1, and announce interim data related to the REO 024 extension combination study. In the second half of 2020, we expect to announce AWARE-1 final data, announce interim data related to Opdivo</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">combination study, complete enrollment and announce interim data related to the BRACELET-1 study, as well as complete enrollment and announce final data related to the REO 024 extension combination study. We expect these combination studies will assist us in refining our phase 3 protocol for mBC and may also support further development around the innate and adaptive immunity components of the mechanism of action. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our 2020 manufacturing program includes completing production of 100-litre cGMP batches along with the related analytical testing and product filling, as well as labeling, packaging and shipping of pelareorep to our various clinical sites for ongoing and </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">upcoming activities. These activities are consistent with our process validation master plan. Finally, our intellectual property program includes filings for additional patents along with monitoring activities required to protect our patent portfolio.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently estimate the cash requirements to fund our operations for </font><font style="font-family:inherit;font-size:10pt;">2020</font><font style="font-family:inherit;font-size:10pt;">&#32;will be approximately $20 - $22 million but will depend on our ultimate clinical program.  (see </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Liquidity and Capital Resources&#8221;</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sC4446A1B0E275400A1411E88E40BC654"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Our Accounting Policies </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In preparing our financial statements we use IFRS as issued by the International Accounting Standards Board.  IFRS requires that we make certain estimates, judgments and assumptions that we believe are reasonable based upon the information available in selecting our accounting policies. Our selection of accounting policies, along with our estimates and assumptions affect the reported amounts of our assets and liabilities at the date of the financial statements and the reported amounts of expenses during the periods presented. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sD3E9BEAD361B58F09DB0B59A285B4D83"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Critical Accounting Policies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In preparing our financial statements, we are required to make certain estimates, judgments and assumptions that we believe are reasonable based upon the information available. These estimates and assumptions affect the reported amounts of assets at the date of the financial statements and the reported amounts of expenses during the periods presented.  Significant estimates are used for, but not limited to, the treatment of our research and development expenditures, revenue recognition, the calculation of share based compensation and warrant derivative (see Note 4 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">" Significant Judgments, Estimates and Assumptions</font><font style="font-family:inherit;font-size:10pt;">") of our audited consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The significant accounting policies which we believe are the most critical to aid in fully understanding and evaluating our reported financial results include the following:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities.We generally accrue costs associated with the treatment phase of clinical trials based on the total estimated cost of the treatment phase on a per patient basis and we expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized.  To date, all development costs have been expensed. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue recognition</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue relates to a long-term contract associated with the Licensing Agreement with Adlai. The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The contract also provides for development and regulatory milestone payments, royalties and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.</font></div><div><a name="s2BE14F6F1F435679A97BD5DB8039B3E7"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Significant Estimates</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue recognition</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered into a Licensing Agreement which provides, among other payments, for upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress towards completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Valuation of share based payments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimating fair value for stock options granted requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant. We have chosen to use the Black Scholes valuation model (&#8220;Black Scholes&#8221; or the &#8220;Model&#8221;) to calculate the fair value of our stock options. Black Scholes is currently widely used and accepted by other publicly traded companies. Therefore, we have concluded that Black Scholes is the appropriate option pricing model to use for our stock options at this time. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility, dividend yield, and forfeiture rate and making assumptions about them. The assumptions and  inputs used for estimating fair value for stock options granted issued are disclosed in Note 10 of our audited consolidated financial statements. Consequently, in complying with IFRS and selecting what we believe are the most appropriate assumptions under the circumstances, we have recorded non-cash share based payment expense for the year of </font><font style="font-family:inherit;font-size:10pt;">$1,470,153</font><font style="font-family:inherit;font-size:10pt;">. However, given the above discussion, these amounts could have been different and still be in accordance with IFRS.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Valuation of warrant derivative </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimating fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period requires determining the most appropriate valuation model. We have chosen to use Black Scholes to calculate the fair value of our warrant derivative. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility, dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value for warrant derivative are disclosed in Note 8 of our audited consolidated financial statements. Consequently, in complying with IFRS and selecting what we believe are the most appropriate assumptions under the circumstances, we have recorded a non-cash change in fair value of warrant derivative for the year of  </font><font style="font-family:inherit;font-size:10pt;">$12,608,808</font><font style="font-family:inherit;font-size:10pt;">. However, given the above discussion, these amounts could have been different and still be in accordance with IFRS.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s487CFB88738258189FE6BEA29A3C37FD"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Adoption of New Accounting Standards</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IFRS 16 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IFRS 16 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;IFRS 16&#8221;) replaces IAS 17 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;IAS 17&#8221;) and related interpretations for annual periods beginning on or after January 1, 2019. We have adopted IFRS 16 using the modified retrospective approach, under which the cumulative effect of the initial application is recognized in retained earnings at January 1, 2019. We have not restated comparatives for 2018. On transition to IFRS 16, we elected to apply the following practical expedients: </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Applied the exemption for short-term leases that have a remaining lease term of less than 12 months as at January 1, 2019; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Excluded initial direct costs for the measurement of right-of-use assets as at January 1, 2019; </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Relied upon our assessment of whether leases are onerous under the requirement of IAS 37, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Provisions, contingent liabilities and contingent assets</font><font style="font-family:inherit;font-size:10pt;">&#32;as at December 31, 2018 as an alternative to reviewing our right-of-use assets for impairment; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Measured the right-of-use assets at an amount equal to the lease liability, adjusted by the amount of lease incentive liability related to that lease recognized in the statement of financial position immediately before the date of initial application. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On transition to IFRS 16, we recognized </font><font style="font-family:inherit;font-size:10pt;">$882,437</font><font style="font-family:inherit;font-size:10pt;">&#32;of lease liabilities. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate at January 1, 2019 as rates implicit in the leases were not readily determinable. The weighted-average rate applied was </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the impacts of adopting IFRS 16 on the consolidated financial statements:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:40%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Impact of changes</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported as at December 31, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Effects of IFRS 16 transition</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent to transition as at January 1, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Right-of-use assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current and non-current assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865,253</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865,253</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865,253</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,673,278</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,750</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(74,412</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,338</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">882,437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">882,437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current and non-current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,556,140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,556,140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,669,890</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,477,915</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total shareholders' equity</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,195,363</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,195,363</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to adopting IFRS 16, our total minimum operating lease commitments as at December 31, 2018 were </font><font style="font-family:inherit;font-size:10pt;">$961,575</font><font style="font-family:inherit;font-size:10pt;">. The difference between the total of the minimum lease payments set out in Note 11 of our 2018 annual consolidated financial statements and the total lease liabilities recognized on transition was a result of the effect of discounting on the minimum lease payments.  </font></div><div><a name="s69C57DD9A0A150A4B43F210322EE576A"></a></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div><a name="s9B46DD2B73645C39AA2AF70BD505DE30"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Selected Annual Information</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:586px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:318px;"></td><td style="width:84px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(33,122,888</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,037,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,616,851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per share</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1.50</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.06</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19,657,865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,150,449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash dividends declared per share</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="7" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Notes:</font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1)  Included in consolidated net loss and loss per common share for 2019 is a non-cash change in fair value of warrant derivative expense of $12,608,808 (2018 - nil; 2017 - nil).</font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2)  Included in consolidated net loss and loss per common share for 2019, 2018, and 2017 are share based payment expenses of $1,470,153, $1,415,833 and $578,703, respectively.</font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3)  The calculation of basic and diluted loss per common share for all periods has been adjusted retrospectively for the Share Consolidation. We issued 14,798,704 common shares for net cash proceeds of $21.5 million in 2019 (2018 - 2,472,909 common shares for net cash proceeds of $13.3 million; 2017 - 20,547,500 pre-consolidation common shares (approximately 2,162,894  post-consolidation common shares) for net cash proceeds of $12.8 million).  </font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(4)  We have not declared or paid any dividends since incorporation.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s476DA3215D5B5048A10182AD69547AF7"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss for the year was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$33,122,888</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$17,037,225</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$15,616,851</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. Net loss in 2019 included a non-cash change in fair value of warrant derivative expense of $</font><font style="font-family:inherit;font-size:10pt;">12,608,808</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Research and Development Expenses (&#8220;R&amp;D&#8221;)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:624px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:384px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:75px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,189,622</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,938,911</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,475,918</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and related process development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,776,288</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,073,726</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,726,432</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenditures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">827,375</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">869,991</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">847,650</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaboration expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">143,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">362,622</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252,482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other R&amp;D expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,319,326</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,102,203</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,925,256</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange loss (gain) </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">316,719</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(610,106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(65,256</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">561,420</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">680,541</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230,141</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11,134,716</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,417,888</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,392,623</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Clinical Trial Program</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses include those costs associated with our clinical trial program which primarily included expenses related to the preparation and development of our breast cancer registration study and immunotherapy combinations. Included in clinical trial expenses are regulatory and consulting activities, contract research organization expenses, data management expenses and other costs associated with our clinical trial program.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:602px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:376px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:68px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,189,622</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,938,911</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,475,918</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, our clinical trial expenses were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2,189,622</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2,938,911</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2,475,918</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. In all three years, our clinical trial program focused mainly on the preparation and development of our breast cancer registration study. In 2019, these costs included startup activities and patient enrollment and treatment for our AWARE-1 study and our portion of trial initiation activities related to the BRACELET-1 study. As well, we incurred costs to complete our supporting regulatory documents and key opinion leader activities. In 2018, these costs included phase 3 development activities, activities related to obtaining the SPA from the FDA and the window of opportunity study in collaboration with SOLTI. In 2017, these activities included costs to complete our supporting regulatory documents, regulatory filing fees, planning for and attending scientific advisory meetings with the FDA and the European Medicines Agency (EMA), and key opinion leader activities. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2019 and 2018, in addition to activities related to our breast cancer program, we also incurred close-out costs related to our fully enrolled legacy clinical trials, patient enrollment and/or treatment in our checkpoint inhibitor pancreatic cancer study investigating Keytruda</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">in combination with pelareorep. In 2017, our other clinical activities included patient enrollment in our checkpoint inhibitor pancreatic cancer study investigating Keytruda</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">in combination with pelareorep. In addition, with the signing of the Licensing Agreement that included upfront licensing fees in November 2017, we triggered payments of $640,579 as detailed in our Assumption Agreement (see Notes 12 and 14 of our audited consolidated financial statements). Our 2017 costs were partially offset as we continued to close out legacy clinical trial sites truing up our cost estimates with the actual costs incurred.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect our clinical trial expenses to increase in </font><font style="font-family:inherit;font-size:10pt;">2020</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">. During </font><font style="font-family:inherit;font-size:10pt;">2020</font><font style="font-family:inherit;font-size:10pt;">, we expect to finalize the development of our registration program, generate clinical data with checkpoint inhibitors and prove the effectiveness of biomarkers across various indications. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Manufacturing &amp; Related Process Development (&#8220;M&amp;P&#8221;)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">M&amp;P expenses include product manufacturing and process development activities. Product manufacturing expenses include third-party direct manufacturing costs, quality control testing, fill, label, packaging and storage costs and are net of any recoveries that are received from any R&amp;D collaborators. Process development expenses include costs associated with studies that examine components of our manufacturing and analytical processes looking for improvements and costs associated with the creation of our process validation master plan and related conformity testing. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.6484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:61%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product manufacturing expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,535,632</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,667,481</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,054,903</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Process development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">240,656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">406,245</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">671,529</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and related process development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,776,288</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,073,726</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,726,432</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our M&amp;P expenses for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3,776,288</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2,073,726</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,726,432</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. In 2019, our product manufacturing costs primarily related to the completion of training and engineering production runs required to support our clinical development plan and the associated product testing, shipping and storage costs of our bulk and vialed product, and an ongoing product fill. In 2018, our product manufacturing activities mainly related to shipping and storage costs of our bulk and vialed product along with startup costs for a product fill and a production run. We also incurred costs related to relabeling activities in line with extended stability data. During 2017, our product manufacturing activities mainly related to shipping and storage costs of our bulk and vialed product. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our process development expenses for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$240,656</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$406,245</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$671,529</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. During 2019, our process development activities focused on analytic development studies. During 2018, our process development activities focused on analytic development and stability studies. During 2017, our process development activities focused on stability, process optimization studies, assay development and biodistribution studies. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect our M&amp;P expenses for </font><font style="font-family:inherit;font-size:10pt;">2020</font><font style="font-family:inherit;font-size:10pt;">&#32;to increase compared to </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">. In </font><font style="font-family:inherit;font-size:10pt;">2020</font><font style="font-family:inherit;font-size:10pt;">, we expect to complete the cGMP production run, fill, label and store sufficient product as well as continue to perform analytical development and other non-clinical projects to support our clinical development program and other collaborative requirements. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intellectual Property Expenses</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenses include legal and filing fees associated with our patent portfolio.  </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.1796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:64%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">827,375</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">869,991</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">847,650</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our intellectual property expenses for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$827,375</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$869,991</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$847,650</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. At the end of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">, we had been issued over </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">399</font><font style="font-family:inherit;font-size:10pt;">&#32;patents including </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">48</font><font style="font-family:inherit;font-size:10pt;">&#32;US and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">21</font><font style="font-family:inherit;font-size:10pt;">&#32;Canadian patents, as well as issuances in other jurisdictions.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect that our intellectual property expenses will remain consistent in </font><font style="font-family:inherit;font-size:10pt;">2020</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research Collaborations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaborations are intended to expand our intellectual property related to pelareorep and identify potential licensing opportunities arising from our technology base.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.5234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:67%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaborations</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">143,966</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">362,622</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252,482</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">, our research collaboration expenses were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$143,966</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$362,622</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$252,482</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. In 2019, 2018 and 2017, our research collaborations included studies investigating the interaction of the immune system with pelareorep, and biomarker studies.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect that our research collaborations in </font><font style="font-family:inherit;font-size:10pt;">2020</font><font style="font-family:inherit;font-size:10pt;">&#32;will increase compared to </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">. We expect to complete our ongoing collaborative program carried over from </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and will continue to be selective in the types of new collaborations we enter into in </font><font style="font-family:inherit;font-size:10pt;">2020</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Research and Development Expenses</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other research and development expenses include compensation expenses for employees (excluding share based payments), travel and other miscellaneous R&amp;D expenses.  </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.2578125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:61%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">R&amp;D salaries and benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,096,231</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,868,251</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,662,638</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other R&amp;D expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">223,095</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,952</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other Research and Development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,319,326</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,102,203</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,925,256</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:normal;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">, our Other Research and Development expenses were </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:normal;text-decoration:none;">$3,319,326</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:normal;text-decoration:none;">$3,102,203</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:normal;text-decoration:none;">$3,925,256</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:normal;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:normal;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. Our Other Research and Development activities focused on supporting our clinical development program along with other third-party trials and clinical trials sponsored by Oncolytics. R&amp;D salaries and benefits in 2017 included severance payments of $779,666 to certain officers of the Company. Normalizing for these payments, our 2018 R&amp;D salaries and benefits is consistent compared to 2017. The change in R&amp;D salaries and benefits in 2019 compared to 2018 and 2017 was due to the timing of filling open positions in our U.S. office and a change in salary level, partly offset by personnel cost recovery from Pfizer related to BRACELET-1.    </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The change in Other R&amp;D expenses in 2017 compared to 2019 and 2018 was due to an increase in conference attendance and related travel expenses.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect our Other Research and Development expenses to remain consistent in </font><font style="font-family:inherit;font-size:10pt;">2020</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Exchange Loss (Gain)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.2578125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:61%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange loss (gain)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">316,719</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(610,106</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(65,256</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the year ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, our foreign exchange loss (gain) was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$316,719</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$(610,106)</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$(65,256)</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;for the years ending December 31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. The foreign exchange loss (gain) incurred in 2019 and 2018 was primarily due to unrealized translation loss (gain) on U.S. dollar denominated cash balances. The foreign exchange gain incurred in 2017 was primarily a result of the fluctuations in the US dollar, Euro and Pound Sterling exchange rates. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Based Payments</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.2578125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:61%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">561,420</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">680,541</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230,141</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based payments for the year ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$561,420</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$680,541</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$230,141</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. We incurred share based payment expenses associated with the vesting of options and share awards to officers and employees. In 2018, we also recognized a recovery of share based payment expenses due to the departure of the former Chief Medical Officer and the forfeiture of unvested share awards and options.   </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Operating Expenses</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.2578125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:61%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Public company related expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5,089,918</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,041,226</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,027,029</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,074,416</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,372,898</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,746,472</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation - property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">122,982</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,375</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,768</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation - right-of-use assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">362,592</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">908,733</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">735,292</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">348,562</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9,558,641</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,244,791</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,212,831</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Public company related expenses include costs associated with investor relations and business development and financial advisory activities, legal and accounting fees, corporate insurance, director fees and transfer agent and other fees relating to our U.S. and Canadian stock listings. In </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">, we incurred public company related expenses of </font><font style="font-family:inherit;font-size:10pt;">$5,089,918</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$3,041,226</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$3,027,029</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. The change in public company related expenses in 2019 compared to 2018 was due to increased investor relations and business development activities, transaction costs of $233,143 related to our August 2019 public offering (see Note 8 and 9 of our audited consolidated financial statements), as well as increased insurance premiums. This is partly offset by lower professional fees, including legal fees and costs related to the special meeting of shareholders held in February 2018. Our 2018 public company related expenses are consistent compared to 2017 as a result of an increase in expenses related to the Nasdaq listing, an increase in legal fees and costs related to the special meeting of shareholders held in February 2018 and an increase in travel expenses, offset by lower business development consulting fees in 2018 compared to 2017. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office expenses include compensation costs (excluding share based payments), rent related to short term leases, and other office related costs.  In </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">, we incurred office expenses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$3,074,416</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$3,372,898</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2,746,472</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. The change in office expenses in 2019 compared to 2018 was due to a reduction in office rent expense following the adoption of IFRS 16 with an increase in depreciation of the newly created right-of-use assets (see Note 3 of our audited consolidated financial statements) and personnel cost recovery from Pfizer related to BRACELET-1, and is partly offset by change in salary level. The change in office expense in 2018 compared to 2017 was mainly due to an investment in our in-house business development group and an increase in office expenses related to the opening and relocation of our U.S. office. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">, our non-cash share based payment expenses were </font><font style="font-family:inherit;font-size:10pt;">$908,733</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$735,292</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$348,562</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. In </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and  </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, we incurred share based payment expenses associated with the vesting of granted options and share awards to officers, employees, consultants and independent board members.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect our operating expenses in </font><font style="font-family:inherit;font-size:10pt;">2020</font><font style="font-family:inherit;font-size:10pt;">&#32;to decrease compared to </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">.    </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Change in Fair Value of Warrant Derivative</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We issued warrants in connection with our August 2019 underwritten public offering. Warrants issued with an exercise price denominated in a foreign currency are reported as a liability until they are exercised or expire. These warrants are adjusted to fair value at each exercise date and at each reporting period and any change in fair value is recorded in the consolidated statements of loss and comprehensive loss. Gains and losses resulting from the revaluation of the warrant derivative are non-cash and do not impact our cash flows. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.2578125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:61%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of warrant derivative</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12,608,808</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2019, we recognized a loss of $</font><font style="font-family:inherit;font-size:10pt;">12,608,808</font><font style="font-family:inherit;font-size:10pt;">&#32;on the change in fair value of our warrant derivative (2018 and 2017 - nil). The change in fair value was based on several factors including changes in the market price of our shares to US$4.76 on December 31, 2019 from US$0.54 at warrant issuance, the revaluation on warrants exercised, as well as a decrease in the remaining term of the warrants and changes in estimated future volatility of our common shares. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sC7ECD9B998AE5C04849513BDCC1D6CFD"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Summary of Quarterly Results</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:663px;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:225px;"></td><td style="width:9px;"></td><td style="width:36px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:39px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:40px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:43px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:43px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:46px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:43px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:42px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="12" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td colspan="12" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dec.</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sept.</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dec.</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sept.</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)(2)</sup></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,402</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,529</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,254</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,939</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,819</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,336</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,211</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,671</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per common share</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,658</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,285</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,302</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,461</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,150</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,693</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,127</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,276</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,741</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,745</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash dividends declared</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Included in consolidated net loss and loss per common share for the fourth and third quarters of 2019 is a non-cash change in fair value of warrant derivative expense of $</font><font style="font-family:inherit;font-size:8pt;">12,486,310</font><font style="font-family:inherit;font-size:8pt;">&#32;and $</font><font style="font-family:inherit;font-size:8pt;">122,498</font><font style="font-family:inherit;font-size:8pt;">, respectively. </font><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">There was no change in fair value of warrant derivative expense between June 2019 and January 2018.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The calculation of basic and diluted loss per common share for all periods have been adjusted retroactively for the Share Consolidation. Included in net loss and loss per common share between December 2019 and January 2018 are quarterly share based payment expenses of </font><font style="font-family:inherit;font-size:8pt;">$658,662</font><font style="font-family:inherit;font-size:8pt;">, $250,384 $260,184, $300,923, $483,016, $236,607, $157,092, and $539,118, respectively.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">We issued </font><font style="font-family:inherit;font-size:8pt;">14,798,704</font><font style="font-family:inherit;font-size:8pt;">&#32;common shares for net cash proceeds of $21.5 million in </font><font style="font-family:inherit;font-size:8pt;">2019</font><font style="font-family:inherit;font-size:8pt;">&#32;(</font><font style="font-family:inherit;font-size:8pt;">2018</font><font style="font-family:inherit;font-size:8pt;">&#32;- 2,472,909 common shares for net cash proceeds of </font><font style="font-family:inherit;font-size:8pt;">$13.3 million</font><font style="font-family:inherit;font-size:8pt;">).  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">We have not declared or paid any dividends since incorporation.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><a name="s11C5DDD03B53590F9676F894AFB251CF"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Fourth Quarter</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Statement of loss for the three month period ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:495px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:325px;"></td><td style="width:83px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three month periods ending December 31,</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Research and development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,810,722</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,508,175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Operating</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,132,548</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,375,174</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss before the following</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(6,943,270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,883,349</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Change in fair value of warrant derivative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(12,486,310</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Interest income, net</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27,938</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,188</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(19,401,642</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,819,161</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(19,401,642</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,819,246</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Other comprehensive gain (loss) - translation adjustment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(56,754</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,362</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(19,458,396</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,670,884</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basic and diluted loss per common share</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(0.71</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Weighted average number of shares (basic and diluted)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27,200,947</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,115,040</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s5FDE3C61416D5ACF8ACDCEFEDE88A71A"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Fourth Quarter Review of Operations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three month period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, our net loss was </font><font style="font-family:inherit;font-size:10pt;">$19,401,642</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$4,819,246</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three month period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. Net loss for the three month period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;included a non-cash change in fair value of warrant derivative expense of $</font><font style="font-family:inherit;font-size:10pt;">12,486,310</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Research and Development Expenses (&#8220;R&amp;D&#8221;)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:544px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:384px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:75px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">581,436</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">626,977</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and related process development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">474,077</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">862,451</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">68,036</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,734</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaboration expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">41,391</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other R&amp;D expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,295,083</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,127,526</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange loss (gain)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">114,279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(500,591</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">236,420</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242,072</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,810,722</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,508,175</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Clinical Trial Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.8828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">581,436</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">626,977</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, our clinical trial expenses were </font><font style="font-family:inherit;font-size:10pt;">$581,436</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$626,977</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. In the fourth quarter of 2019, these activities mainly related to patient enrollment and treatment for our AWARE-1 study and trial initiation activities related to our BRACELET-1 study. In the fourth quarter of 2018, these activities mainly related to study initiation activities related to AWARE-1. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the activities related to our breast cancer program, in the fourth quarters of 2019 and 2018, we also incurred costs related to patient enrollment and/or treatment in our checkpoint inhibitor pancreatic cancer study investigating Keytruda&#174; in </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">combination with pelareorep and close-out costs related to our fully enrolled legacy clinical trials. In the fourth quarter of 2018, our clinical activities also included costs related to a research collaboration in phase 1 dose escalation study combining pelareorep and carfilzomib with the checkpoint inhibitor, Opdivo</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Manufacturing &amp; Related Process Development Expenses (&#8220;M&amp;P&#8221;)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.90625%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product manufacturing expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">393,309</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">837,010</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Process development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">80,768</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,441</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and related process development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">474,077</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">862,451</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">, our M&amp;P expenses were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$474,077</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$862,451</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">.  During the fourth quarter of 2019, our product manufacturing costs mainly related to shipping and storage costs of our bulk and vialed product, as well as costs related to an ongoing product fill and product test. During the fourth quarters of 2018, our product manufacturing costs mainly related to shipping and storage costs of our bulk and vialed product along with startup costs for a production run required to support our clinical development plan. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our process development activity for the fourth quarter of 2019 related to analytic development studies compared to analytic development and biodistribution studies for the fourth quarter of 2018. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intellectual Property Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.9296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">68,036</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,734</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our intellectual property expenses for the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$68,036</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$55,734</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">. At the end of the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, we had been issued over </font><font style="font-family:inherit;font-size:10pt;">399</font><font style="font-family:inherit;font-size:10pt;">&#32;patents including </font><font style="font-family:inherit;font-size:10pt;">48</font><font style="font-family:inherit;font-size:10pt;">&#32;US and </font><font style="font-family:inherit;font-size:10pt;">21</font><font style="font-family:inherit;font-size:10pt;">&#32;Canadian patents, as well as issuances in other jurisdictions. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research Collaboration Expenses </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.7109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:70%;"></td><td style="width:15%;"></td><td style="width:15%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaboration expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">41,391</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,006</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our research collaboration expenses were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$41,391</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$94,006</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">.  During the fourth quarters of 2019 and 2018, our research collaborations were primarily focused on studies investigating the interaction of the immune system and pelareorep. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Research and Development Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.9296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">R&amp;D salaries and benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,219,536</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,046,889</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other R&amp;D expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">75,547</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,295,083</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,127,526</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our other research and development expenses were </font><font style="font-family:inherit;font-size:10pt;">$1,295,083</font><font style="font-family:inherit;font-size:10pt;">&#32;in the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$1,127,526</font><font style="font-family:inherit;font-size:10pt;">&#32;in the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. Our R&amp;D salaries and benefits increased in the fourth quarter of 2019 compared to 2018 primarily due to the timing of filling open positions in our U.S. office and a change in salary level, partly offset by personnel cost recovery from Pfizer related to BRACELET-1. Our Other R&amp;D expenses in the fourth quarter of 2019 were consistent with 2018.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Exchange Loss (Gain)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.9296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange loss (gain)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">114,279</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(500,591</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our foreign exchange loss was </font><font style="font-family:inherit;font-size:10pt;font-weight:normal;">$114,279</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to a gain of </font><font style="font-family:inherit;font-size:10pt;font-weight:normal;">$500,591</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. The foreign exchange loss (gain) incurred in 2019 and 2018 was primarily due to unrealized translation loss (gain) on U.S. dollar denominated cash balance. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Based Payments</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.9296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">236,420</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242,072</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the fourth quarters of </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, we incurred share based payment expenses associated with the vesting of granted options and share awards to officers and employees.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Operating Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:531px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:377px;"></td><td style="width:72px;"></td><td style="width:4px;"></td><td style="width:72px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Public company related expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,590,135</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">951,035</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,004,988</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,155,502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation - property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">24,792</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,693</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation - right-of-use assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">90,391</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">422,242</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">240,944</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,132,548</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,375,174</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our operating expenses for the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$4,132,548</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$2,375,174</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. Public company related expenses include costs associated with investor relations, business development and financial advisory activities, legal and accounting fees, corporate insurance, director fees and transfer agent and other fees relating to our Canadian and U.S. stock listings. During the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, our public company related expenses were $</font><font style="font-family:inherit;font-size:10pt;">2,590,135</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to $</font><font style="font-family:inherit;font-size:10pt;">951,035</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. The change was primarily due to increased investor relations activities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office expenses include compensation costs (excluding share based payments), rent related to short term leases, and other office related costs. During the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, our office expenses were $</font><font style="font-family:inherit;font-size:10pt;">1,004,988</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to $</font><font style="font-family:inherit;font-size:10pt;">1,155,502</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. The change in the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;was due to a reduction in office rent expense following the adoption of IFRS 16 with an increase in depreciation of the newly created right-of-use assets (see Note 3 of our audited consolidated financial statements), a decrease in U.S. office headcount and personnel cost recovery from Pfizer related to BRACELET-1.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our non-cash share based payment expenses in the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;were $</font><font style="font-family:inherit;font-size:10pt;">422,242</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to $</font><font style="font-family:inherit;font-size:10pt;">240,944</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. We incurred share based payment expenses associated with the vesting of granted options and share awards to officers, employees, consultants and independent board members.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Change in Fair Value of Warrant Derivative</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.59375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:66%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of warrant derivative</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12,486,310</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the fourth quarter of 2019, we recognized a loss of $</font><font style="font-family:inherit;font-size:10pt;">12,486,310</font><font style="font-family:inherit;font-size:10pt;">&#32;on the change in fair value of our warrant derivative (2018 - nil). The change in fair value was based on several factors including changes in the market price of our shares to US$4.76 on December 31, 2019 from US$0.57 on September 30, 2019, the revaluation on warrants exercised in the quarter, as well as a </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">decrease in the remaining term of the warrants and changes in estimated future volatility of our common shares. Gains and losses resulting from the revaluation of the warrant derivative are non-cash and do not impact our cash flows. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s230862558C595428BEF10DB462D843E2"></a></div><div style="line-height:120%;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><a name="s45208258823652018957265AC4DFEAD3"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share Consolidation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 22, 2018, we completed the consolidation of our common shares on the basis of 9.5 pre-consolidation common shares for each one post-consolidation common share. Fractional interests were rounded down to the nearest whole number of common shares. Outstanding stock options, restricted share units and performance share units were similarly adjusted by the consolidation ratio. Outstanding warrants were adjusted such that, following the Share Consolidation, 9.5 warrants issued in 2017 will entitle the holder to purchase one whole common share until June 1, 2022.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">&#32;Financing Activities </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Public offering</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 16, 2019, pursuant to an underwritten public offering, </font><font style="font-family:inherit;font-size:10pt;">4,619,773</font><font style="font-family:inherit;font-size:10pt;">&#32;units were sold at a purchase price of US</font><font style="font-family:inherit;font-size:10pt;">$0.81</font><font style="font-family:inherit;font-size:10pt;">&#32;per unit for gross proceeds of US</font><font style="font-family:inherit;font-size:10pt;">$3,742,016</font><font style="font-family:inherit;font-size:10pt;">. Each unit included </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;common share with a fair value of US</font><font style="font-family:inherit;font-size:10pt;">$0.54</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;common share purchase warrant with a fair value of US</font><font style="font-family:inherit;font-size:10pt;">$0.27</font><font style="font-family:inherit;font-size:10pt;">. Each common share purchase warrant entitles the holder to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;common share at an exercise price of US</font><font style="font-family:inherit;font-size:10pt;">$0.90</font><font style="font-family:inherit;font-size:10pt;">&#32;until August 16, 2024. We incurred transaction costs of </font><font style="font-family:inherit;font-size:10pt;">$699,427</font><font style="font-family:inherit;font-size:10pt;">&#32;of which </font><font style="font-family:inherit;font-size:10pt;">$466,284</font><font style="font-family:inherit;font-size:10pt;">&#32;were allocated to share issue costs and </font><font style="font-family:inherit;font-size:10pt;">$233,143</font><font style="font-family:inherit;font-size:10pt;">&#32;were allocated to operating expenses, based on their relative fair values.  In 2019,  </font><font style="font-family:inherit;font-size:10pt;">2,935,647</font><font style="font-family:inherit;font-size:10pt;">&#32;warrants were exercised for gross proceeds of  US</font><font style="font-family:inherit;font-size:10pt;">$2,642,082</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">U.S. "at-the-market" equity distribution agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, we sold </font><font style="font-family:inherit;font-size:10pt;">4,425,040</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for gross proceeds of US</font><font style="font-family:inherit;font-size:10pt;">$6,390,691</font><font style="font-family:inherit;font-size:10pt;">. We incurred share issue costs of $</font><font style="font-family:inherit;font-size:10pt;">344,834</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock Purchase Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, we sold </font><font style="font-family:inherit;font-size:10pt;">2,477,665</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for gross proceeds of US</font><font style="font-family:inherit;font-size:10pt;">$4,055,725</font><font style="font-family:inherit;font-size:10pt;">&#32;and issued </font><font style="font-family:inherit;font-size:10pt;">17,278</font><font style="font-family:inherit;font-size:10pt;">&#32;commitment shares. The commitment shares were fair valued at US</font><font style="font-family:inherit;font-size:10pt;">$29,758</font><font style="font-family:inherit;font-size:10pt;">&#32;and were recorded as share issue costs in addition to cash share issue costs of </font><font style="font-family:inherit;font-size:10pt;">$3,757</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sDB7E956975CF57B6B895BA099D17CCBD"></a></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">2018</font><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">&#32;Financing Activities </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Listing on the Nasdaq Capital Market</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 1, 2018, we announced that our common shares were approved for listing and commenced trading on the Nasdaq Capital Market. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Public offering</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 5, 2018, we closed a public offering whereby we sold 1,532,278 post-consolidation common shares at a purchase price of US$5.83 per share for gross proceeds of US$8,933,181. We incurred share issue costs of $1,418,356.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock Purchase Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2018, we issued 797,691 common shares for gross proceeds of approximately US$2.1 million. The commitment common shares fair valued at US$74,190 were recorded as share issue costs in addition to cash share issue costs of $208,726. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Canadian "at-the-market" equity distribution agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the first quarter of 2018, we sold 519,500 pre-consolidation common shares (approximately 54,684 post-consolidation common shares) for net proceeds of $520,315. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">U.S. "at-the-market" equity distribution agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2018, we sold 18,002 common shares for gross proceeds of approximately US$50,000. We incurred share issue costs of $135,000. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Options</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2018, we received cash proceeds of $123,538 with respect to the exercise of 41,802 post-consolidation options (approximately 397,120 pre-consolidation options) by former employees.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Warrants</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2018, we received cash proceeds of $1,417 with respect to the exercise of 1,500 warrants.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><a name="s44096A8283F25FE9BEDB47F26079CA5F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents and working capital positions as follows: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.9296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:67%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14,148,021</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,699,881</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital position</font></div></td><td style="vertical-align:middle;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14,570,105</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,587,340</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The increase in our cash and cash equivalent reflects the cash usage from our operating activities of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$19.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;along with the cash provided by our financing activities of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$21.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We desire to maintain adequate cash reserves to support our planned activities which include our clinical trial program, product manufacturing, administrative costs, and our intellectual property expansion and protection.  To date, we have funded our operations mainly through the issue of additional capital via public and private offerings and through the exercise of warrants and stock options. In 2019, we were able to raise funds through our public offering, Common Stock Purchase Agreement, and U.S. ATM. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have no assurances that we will be able to raise additional funds through the sale of our common shares, consequently, we will continue to evaluate all types of financing arrangements. On May 4, 2018, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to 150,000,000 of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the US or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Renewing our Base Shelf  provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until May 25, 2020.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Base Shelf allowed us to enter into our Common Stock Purchase Agreement in September 2018, our ATM equity offering sales agreement in October 2018, and our public offering in August 2019 (see Note 9 of our audited consolidated financial statements). We will use these equity arrangements to assist us in achieving our capital objective. Our Common Stock Purchase Agreement and ATM equity offering sales agreement provide us with the opportunity to raise capital at our sole discretion providing us with the ability to better manage our cash resources. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Common Stock Purchase Agreement and ATM equity offering sales agreement provide us with access to, subject to the respective terms and conditions, US$56.0 million of which we have raised gross proceeds of approximately US$12.6 million at December 31, 2019. Our Common Stock Purchase Agreement limits our sale of common shares to 19.99% of our total outstanding common shares as at the date that the Common Stock Purchase Agreement was entered into, unless and until we have obtained shareholder approval under applicable Nasdaq rules. As at December 31, 2019, we have reached that limit. However, we expect to continue to access our ATM equity offering sales agreement to help support our current clinical trial, manufacturing, intellectual property and collaboration programs. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We anticipate that the expected cash usage from our operations in </font><font style="font-family:inherit;font-size:10pt;">2020</font><font style="font-family:inherit;font-size:10pt;">&#32;will be approximately $20 - $22 million. We continue to manage our research and development plan with the objective of ensuring optimal use of our existing resources. Additional activities continue to be subject to adequate resources and we believe we will have sufficient cash resources and access to additional cash resources through our Financing Arrangements to fund our presently planned operations into </font><font style="font-family:inherit;font-size:10pt;">2020</font><font style="font-family:inherit;font-size:10pt;">. Factors that will affect our anticipated cash usage in </font><font style="font-family:inherit;font-size:10pt;">2020</font><font style="font-family:inherit;font-size:10pt;">, and for which additional funding might be required include, but are not limited to, expansion of our clinical trial program, the timing of patient enrollment in our approved clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of R&amp;D activity with our clinical trial research collaborations, the number, timing and costs of manufacturing runs required to conclude the validation process and supply product to our clinical trial program, and the level of collaborative activity undertaken.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><a name="sACEA7C8A6DCB5BE0ADFC3F12C50C0961"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Contractual Obligations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have the following contractual obligations as at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.14634146341464%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:30%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Obligations</font></div></td><td colspan="10" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Payments Due by Period</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Less than 1 year</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2 -3 years</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4 - 5 years</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">More than </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5 years</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital lease obligations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">565,179</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,022</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174,157</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase obligations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,867,131</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,244,754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,622,377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long term obligations</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total contractual obligations</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,432,310</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,635,776</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,796,534</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to fund our capital expenditure requirements and commitments with existing working capital.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s8CFEBF0D790D5A0897F0319845CC4CA2"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we had not entered into any off-balance sheet arrangements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s22F1893DE5CD57D9B18C0FFC00C36884"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Transactions with Related Parties</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, with the signing of our Licensing Agreement with upfront license fees (see Note 12 of our audited consolidated financial statements), we triggered a liability of US$178,125 to an officer as detailed in the Assumption Agreement (see Note 14 of our audited consolidated financial statements). The liability was fully paid in 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, we did not enter into any other related party transactions other than compensation paid to Key Management Personnel disclosed in Note 22 of our audited consolidated financial statements.  </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s0114EDC8A47D5A8D9D830F484FB5E748"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Financial Instruments and Other Instruments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial instruments consist of cash and cash equivalents,&#160;other receivables, accounts payable and warrant derivative.&#160;As at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the carrying amount of our cash and cash equivalents,&#160;other receivables and accounts payable approximated their fair value. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and therefore do not trade on an active market. </font><font style="font-family:inherit;font-size:10pt;">As at December 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the fair value of our warrant derivative was $</font><font style="font-family:inherit;font-size:10pt;">8,508,764</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">nil</font><font style="font-family:inherit;font-size:10pt;">).  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Credit risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;We are exposed to credit risk on our cash and cash equivalents and other receivables from Pfizer connected to the BRACELET-1 study (see Note 13 of our audited consolidated financial statements) in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and other receivables. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our exposure to credit risk connected to our cash and cash equivalent by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our exposure to credit risk connected to our Pfizer other receivable by entering into collaborations with global biopharmaceutical companies.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest rate risk </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We are exposed to interest rate risk through our cash and cash equivalents.&#160;We mitigate this risk through our investment </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign exchange risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. We are primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar, British pound and Euro as a portion of our financial assets and liabilities are denominated such currencies. The impact of a </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;">&#32;increase in the value of the U.S. dollar against the Canadian dollar would have increased our net comprehensive loss in </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;">$125,339</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;The impact of a </font><font style="font-family:inherit;font-size:10pt;">$0.10</font><font style="font-family:inherit;font-size:10pt;">&#32;increase in the value of the British pound against the Canadian dollar would have increased our net comprehensive loss in </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;">$8,581</font><font style="font-family:inherit;font-size:10pt;">. The impact of a </font><font style="font-family:inherit;font-size:10pt;">$0.10</font><font style="font-family:inherit;font-size:10pt;">&#32;increase in the value of the Euro against the Canadian dollar would have increased our net comprehensive loss in </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;">$32,426</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balances in foreign currencies at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:628px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:229px;"></td><td style="width:133px;"></td><td style="width:133px;"></td><td style="width:133px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">US dollars <br></font><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">British pounds<br></font><font style="font-family:inherit;font-size:10pt;">&#163;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Euro<br>&#8364;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,676,360</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,751</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,664</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,500,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and other liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,378,860)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,345)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(310,086)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant derivative</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,551,250)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,246,250</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,406</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(276,422)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities. We manage liquidity risk through the management of our capital structure as outlined in the notes to our audited financial statements.  Accounts payable are all due within the current operating period.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s43EA27FBD42F59158A8BD3D499EFE464"></a></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Other MD&amp;A Requirements </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have </font><font style="font-family:inherit;font-size:10pt;">37,375,025</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares outstanding at </font><font style="font-family:inherit;font-size:10pt;">March&#160;5, 2020</font><font style="font-family:inherit;font-size:10pt;">.  If all of our options, restricted share units and performance share units (</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2,474,491</font><font style="font-family:inherit;font-size:10pt;">), common share purchase warrants with a $9.025 exercise price (16,443,500 warrants exercisable into </font><font style="font-family:inherit;font-size:10pt;">1,730,894</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares) and common share purchase warrants with a US$0.90 exercise price (</font><font style="font-family:inherit;font-size:10pt;">538,938</font><font style="font-family:inherit;font-size:10pt;">), were exercised or were to vest, we would have </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">42,119,348</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares outstanding.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;annual report on Form 20-F will be available on www.sedar.com.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sA6F440B2FFE553ACA3B0E0CFDE8B0895"></a></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Disclosure Controls and Procedures</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Evaluation of Disclosure Controls and Procedures</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our chief executive and financial officers reviewed and evaluated our disclosure controls and procedures.  Based on that evaluation, they have concluded that our disclosure controls and procedures are effective in providing them with timely material information relating to the Company.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Management's Annual Report on Internal Control Over Financial Reporting</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, and has designed such internal control over financial reporting to provide reasonable assurance regarding the reliability of financial reporting and the preparation and fair presentation of financial statements for external purposes in accordance with International Financial Reporting Standards.   </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management, including the Chief Executive Officer and Chief Financial Officer, does not expect that our internal controls and procedures over financial reporting will prevent all error and all fraud. A control system can provide only reasonable, not absolute, </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">assurance that the objectives of the control system are met.  Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving our stated goals under all potential future conditions. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management has evaluated the design and operation of our internal control over financial reporting as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, and has concluded that such internal control over financial reporting is effective as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">. There are no material weaknesses that have been identified by management in this regard. This assessment was based on criteria for effective internal control over financial reporting described in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework).  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Changes in Internal Controls over Financial Reporting</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no changes in our internal control over financial reporting that occurred during the last fiscal year that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sFDCCD086EC7751F5AB164A7F22EB48CA"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Risk Factors Affecting Future Performance</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General Risk Factors</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prospects for biotechnology companies in the research and development stage should generally be regarded as speculative.  It is not possible to predict, based upon studies in animals, or early studies in humans, whether a new therapeutic will ultimately prove to be safe and effective in humans, or whether necessary and sufficient data can be developed through the clinical trial process to support a successful product application and approval. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a product is approved for sale, product manufacturing at a commercial scale and significant sales to end users at a commercially reasonable price may not be successful.  There can be no assurance that we will generate adequate funds to continue development, or will ever achieve significant revenues or profitable operations. Many factors (e.g. competition, patent protection, appropriate regulatory approvals) can influence the revenue and product profitability potential.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In developing a pharmaceutical product, we rely upon our employees, contractors, consultants and collaborators and other third-party relationships, including the ability to obtain appropriate product liability insurance. There can be no assurance that this reliance and these relationships will continue as required.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to developmental and operational considerations, market prices for securities of biotechnology companies generally are volatile, and may or may not move in a manner consistent with the progress we have made or are making.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">All of our potential products, including pelareorep, are in the research and development stage and will require further development and testing before they can be marketed commercially.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prospects for companies in the biotechnology industry generally may be regarded as uncertain given the nature of the industry and, accordingly, investments in biotechnology companies should be regarded as speculative. We are currently in the research and development stage on one product, pelareorep, for human application, the riskiest stage for a company in the biotechnology industry. It is not possible to predict, based upon studies in animals and early-stage human clinical trials, whether pelareorep will prove to be safe and effective in humans. Pelareorep will require additional research and development, including extensive clinical testing, before we will be able to obtain the approval of the relevant regulatory authorities in applicable countries to market pelareorep commercially. There can be no assurance that the research and development programs conducted by us will result in pelareorep or any other products becoming commercially viable products, and in the event that any product or products result from the research and development program, it is unlikely they will be commercially available for a number of years.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To achieve profitable operations, we, alone or with others, must successfully develop, introduce and market our products. To obtain regulatory approvals for products being developed for human use, and to achieve commercial success, human clinical trials must demonstrate that the product is safe for human use and that the product shows efficacy. Unsatisfactory results obtained from a </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">particular study relating to a program may cause us to abandon our commitment to that program or the product being tested. No assurances can be provided that any current or future animal or human test, if undertaken, will yield favorable results. If we are unable to establish that pelareorep is a safe, effective treatment for cancer, we may be required to abandon further development of the product and develop a new business strategy.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">There are inherent risks in pharmaceutical research and development.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical research and development is highly speculative and involves a high and significant degree of risk. The marketability of any product we develop will be affected by numerous factors beyond our control, including but not limited to:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the discovery of unexpected toxicities or lack of sufficient efficacy of products which make them unattractive or unsuitable for human use;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">preliminary results as seen in animal and/or limited human testing may not be substantiated in larger, controlled clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">manufacturing costs or other production factors may make manufacturing of products ineffective, impractical and non-competitive;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">proprietary rights of third parties or competing products or technologies may preclude commercialization;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">requisite regulatory approvals for the commercial distribution of products may not be obtained; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">other factors may become apparent during the course of research, up-scaling or manufacturing which may result in the discontinuation of research and other critical projects.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our products under development have never been manufactured on a commercial scale, and there can be no assurance that such products can be manufactured at a cost or in a quantity to render such products commercially viable. Production and utilization of our products may require the development of new manufacturing technologies and expertise. The impact on our business in the event that new manufacturing technologies and expertise are required to be developed is uncertain. There can be no assurance that we will successfully meet any of these technological challenges or others that may arise in the course of development.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pharmaceutical products are subject to intense regulatory approval processes.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The regulatory process for pharmaceuticals, which includes preclinical studies and multiple phases of clinical trials of each compound to establish its safety and efficacy, takes many years and requires the expenditure of substantial resources. Moreover, if regulatory approval of a drug is granted, such approval may entail limitations on the indicated uses for which it may be marketed. Failure to comply with applicable regulatory requirements can, among other things, result in the suspension of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. Further, government policy may change, and additional government regulations may be established that could prevent or delay regulatory approvals for our products. In addition, a marketed drug and its manufacturer are subject to continual review. Later discovery of previously unknown problems with the product or manufacturer may result in restrictions on such product or manufacturer, including withdrawal of the product from the market.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA and similar regulatory authorities in other countries may deny approval of a new drug application if required regulatory criteria are not satisfied, or may require additional testing. Product approvals may be withdrawn if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. The FDA and similar regulatory authorities in other countries may require further testing and surveillance programs to monitor the pharmaceutical product that has been commercialized. Non-compliance with applicable requirements can result in fines and other judicially imposed sanctions, including product withdrawals, product seizures, injunction actions and criminal prosecutions. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to our own pharmaceuticals, we may supply active pharmaceutical ingredients and advanced pharmaceutical intermediates for use in our customers&#8217; drug products. The final drug products in which the pharmaceutical ingredients and advanced pharmaceutical intermediates are used, however, are subject to regulation for safety and efficacy by the FDA and possibly other regulatory authorities in other jurisdictions.&#160;&#160;Such products must be approved by such agencies before they can be commercially marketed. The process of obtaining regulatory clearance for marketing is uncertain, costly and time consuming. We cannot predict how long the necessary regulatory approvals will take or whether our customers will ever obtain such approval for their products. To the extent that our customers do not obtain the necessary regulatory approvals for marketing new products, our product sales could be adversely affected.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA and other governmental regulators have increased requirements for drug purity and have increased environmental burdens upon the pharmaceutical industry. Because pharmaceutical drug manufacturing is a highly regulated industry, requiring significant documentation and validation of manufacturing processes and quality control assurance prior to the approval of the facility to manufacture a specific drug, our manufacturing facilities may never become approved of, or there can be considerable transition </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">time between the initiation of a contract to manufacture a product and the actual initiation of manufacture of that product. Any lag time in the initiation of a contract to manufacture product and the actual initiation of manufacture could cause us to lose profits or incur liabilities. Any lag time in the initiation of a contract to manufacture the product and the actual initiation of manufacture could cause us to lose profits or incur liabilities.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pharmaceutical regulatory regime in Europe and other countries is generally similar to that of the United States. We could face similar risks in these other jurisdictions as the risks described above.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our operations and products may be subject to other government manufacturing and testing regulations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securing regulatory approval for the marketing of therapeutics by the FDA in the United States and similar regulatory agencies in other countries is a long and expensive process, which can delay or prevent product development and marketing. Approval to market products may be for limited applications or may not be received at all.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The products we anticipate manufacturing will have to comply with the FDA&#8217;s cGMP and other FDA and local government guidelines and regulations, including other international regulatory requirements and guidelines. Additionally, certain of our customers may require the manufacturing facilities contracted by us to adhere to additional manufacturing standards, even if not required by the FDA. Compliance with cGMP regulations requires manufacturers to expend time, money and effort in production and to maintain precise records and quality control to ensure that the product meets applicable specifications and other requirements. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA and other regulatory bodies periodically inspect drug-manufacturing facilities to ensure compliance with applicable cGMP requirements. If the manufacturing facilities contracted by us fail to comply with the cGMP requirements, the facilities may become subject to possible FDA or other regulatory action and manufacturing at the facility could consequently be suspended. We may not be able to contract suitable alternative or back-up manufacturing facilities on terms acceptable to us or at all.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA or other regulatory agencies may also require the submission of any lot of a particular product for inspection. If the lot product fails to meet the FDA requirements, then the FDA could take any of the following actions: (i) restrict the release of the product; (ii) suspend manufacturing of the specific lot of the product; (iii) order a recall of the lot of the product; or (iv) order a seizure of the lot of the product.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to regulation by governments in many jurisdictions.&#160;&#160;If we do not comply with healthcare, drug, manufacturing and environmental regulations, among others, in such jurisdiction, our existing and future operations may be curtailed, and we could be subject to liability.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the regulatory approval process, we may be subject to regulations under local, provincial, state, federal and foreign law, including, but not limited to, requirements regarding occupational health, safety, laboratory practices, healthcare fraud and abuse, environmental protection and hazardous substance control, and may be subject to other present and future local, provincial, state, federal and foreign regulations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our products may fail or cause harm, subjecting us to product liability claims, which are uninsured.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Use of our product during current clinical trials may entail risk of product liability.&#160;&#160;We maintain clinical trial liability insurance; however, it is possible this coverage may not provide full protection against all risks.&#160;&#160;Given the scope and complexity of the clinical development process, the uncertainty of product liability litigation, and the shrinking capacity of insurance underwriters, it is not possible at this time to assess the adequacy of current clinical trial coverage, nor the ability to secure continuing coverage at the same level and at reasonable cost in the foreseeable future.&#160;&#160;While we carry, and intend to continue carrying amounts believed to be appropriate under the circumstances, it is not possible at this time to determine the adequacy of such coverage.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the sale and commercial use of our product entails risk of product liability. We currently do not carry any product liability insurance for this purpose. There can be no assurance that we will be able to obtain appropriate levels of product liability insurance prior to any sale of our pharmaceutical products. An inability to obtain insurance on economically feasible terms or to otherwise protect against potential product liability claims could inhibit or prevent the commercialization of products developed by us. The obligation to pay any product liability claim or a recall of a product could have a material adverse effect on our business, financial condition and future prospects.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our technologies may become obsolete.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pharmaceutical industry is characterized by rapidly changing markets, technology, emerging industry standards and frequent introduction of new products. The introduction of new products embodying new technologies, including new manufacturing processes and the emergence of new industry standards may render our products obsolete, less competitive or less marketable. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The process of developing our products is extremely complex and requires significant continuing development efforts and third-party commitments. Our failure to develop new technologies and products and the obsolescence of existing technologies could adversely affect our business.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may be unable to anticipate changes in our potential customer requirements that could make our existing technology obsolete. Our success will depend, in part, on our ability to continue to enhance our existing technologies, develop new technology that addresses the increasing sophistication and varied needs of the market, and respond to technological advances and emerging industry standards and practices on a timely and cost-effective basis. The development of our proprietary technology entails significant technical and business risks. We may not be successful in using our new technologies or exploiting our niche markets effectively or adapting our businesses to evolving customer or medical requirements or preferences or emerging industry standards.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our license, development, supply and distribution agreement with Adlai Nortye Biopharma Co. is subject to certain risks and uncertainties related to our dependence on Adlai and doing business in foreign jurisdictions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 16, 2017, we announced that we had entered into the Licensing Agreement with Adlai. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea and Taiwan (the &#8220;Territories&#8221;). Pursuant to the Licensing Agreement, along with payments to be received by us upon meeting certain requirements and milestones, we are also eligible to receive royalty payments in excess of 10% associated with the commercialization of pelareorep for all indications, subject to regulatory approval. Under the terms of the Licensing Agreement, Adlai will be responsible for all clinical, regulatory and commercialization activities respecting pelareorep in the Territories and therefore the Company will be dependent upon Adlai in successfully undertaking those actions in a timely and economic manner and in compliance with all applicable legal and regulatory requirements within the Territories.  If Adlai is unable to fulfill its obligations under the terms of the Licensing Agreement and in compliance with all applicable legal and regulatory requirements, including clinical, regulatory and commercialization of pelareorep, our prospective revenue from royalty payments related to the commercialization of pelareorep in the Territories may be materially diminished, delayed or never realized, which could negatively effect our operating results and financial condition.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further, conducting business with Adlai within the Territories, and specifically China, subjects us to certain economic, political, currency and legal risks and uncertainties regarding, among other things, the development and commercialization of pelareorep and the release and receipt of payments under the terms of the Licensing Agreement, including the payment of royalties upon commercialization of pelareorep.  These risks include:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">different regulatory requirements for drug approvals in foreign countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">different standards of care in various countries that could complicate the evaluation of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">different U.S. and foreign drug import and export rules;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reduced protection for intellectual property rights in certain countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unexpected changes in tariffs, trade barriers and regulatory requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">different reimbursement systems and different competitive drugs indicated to treat the indications for which our product candidates are being developed;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">compliance with the FCPA, and other anti-corruption and anti-bribery laws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. and foreign taxes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">foreign currency fluctuations, which could result in reduced revenues, and other obligations incident to doing business in another country;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a reliance on CROs, clinical trial sites, principal investigators and other third parties that may be less experienced with clinical trials or have different methods of performing such clinical trials than we are used to in the U.S.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">potential liability resulting from development work conducted by foreign distributors; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The government&#8217;s of the Territories, and specifically the Chinese government, exercise significant control over all aspects of their respective economies.&#160; Accordingly, any adverse change in the economy, the legal system or governmental, economic or other policies could have a material adverse effect on the business prospects of the Licensing Agreement with Adlai, including our ability to receive and transfer money out of China under the terms of the Licensing Agreement. Any disruption in relations, inability to work efficiently or disadvantageous treatment of Adlai by the governments of the Territories or other authorities could have a material adverse effect on our business prospects under the Licensing Agreement. Additionally, the regulatory environment in the Territories is evolving, and officials in the governments in the Territories exercise broad discretion in deciding how to interpret and apply regulations. There can be no assurance that Adlai will be successful in the development and commercialization of pelareorep in the Territories.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We have no operating revenues and a history of losses.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, we have not generated sufficient revenues to offset our research and development costs and accordingly have not generated positive cash flow or made an operating profit.  As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of $</font><font style="font-family:inherit;font-size:10pt;">344.6</font><font style="font-family:inherit;font-size:10pt;">&#32;million and we incurred net losses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$33.1 million</font><font style="font-family:inherit;font-size:10pt;">,  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$17.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$15.6 million</font><font style="font-family:inherit;font-size:10pt;">, for the years ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. We anticipate that we will continue to incur significant losses during </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2020</font><font style="font-family:inherit;font-size:10pt;">&#32;and in the foreseeable future. We do not expect to reach profitability at least until after successful and profitable commercialization of one or more of our products. Even if one or more of our products are profitably commercialized, the initial losses incurred by us may never be recovered.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We may need additional financing in the future to fund the research and development of our products and to meet our ongoing capital requirements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We anticipate that we may need additional financing in the future to fund research and development and to meet our ongoing capital requirements. The amount of future capital requirements will depend on many factors, including continued scientific progress in our drug discovery and development programs, progress in our pre-clinical and clinical evaluation of drug candidates, time and expense associated with filing, prosecuting and enforcing our patent claims and costs associated with obtaining regulatory approvals. In order to meet such capital requirements, we will consider contract fees, collaborative research and development arrangements, and additional public or private financings (including the incurrence of debt and the issuance of additional equity securities) to fund all or a part of particular programs as well as potential partnering or licensing opportunities. There can be no assurance that additional funding will be available or, if available, that it will be available on acceptable terms. If adequate funds are not available on terms favorable to us, we may have to reduce substantially or eliminate expenditures for research and development, testing, production and marketing of our proposed product, or obtain funds through arrangements with corporate partners that require us to relinquish rights to certain of our technologies or product. There can be no assurance that we will be able to raise additional capital if our current capital resources are exhausted.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The cost of director and officer liability insurance may continue to increase substantially or may not be available to us and may affect our ability to retain quality directors and officers.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We carry liability insurance on behalf of our directors and officers. Given a number of large director and officer liability insurance claims in the US equity markets, director and officer liability insurance has become increasingly more expensive with increased restrictions. Consequently, there is no assurance that we will continue to be offered this insurance or be able to obtain adequate coverage. The inability to acquire the appropriate insurance coverage may limit our ability to attract and maintain directors and officers as required to conduct our business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We incur some of our expenses in foreign currencies and therefore are exposed to foreign currency exchange rate fluctuations.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We incur some of our manufacturing, clinical, collaborative and consulting expenses in foreign currencies, primarily the US dollar, the Euro and the British pound.&#160;&#160;We are therefore exposed to foreign currency rate fluctuations.&#160;&#160;Also, as we expand to other foreign jurisdictions there may be an increase in our foreign exchange exposure.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We earn interest income on our excess cash reserves and are exposed to changes in interest rates.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We invest our excess cash reserves in investment vehicles that provide a rate of return with little risk to principal. As interest rates change the amount of interest income we earn will be directly impacted.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.2
<SEQUENCE>22
<FILENAME>ex152eyconsentletter2019.htm
<DESCRIPTION>EXHIBIT 15.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s3D224D0D65ED54A4B78F1A0DF3257B3B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EXHIBIT 15.2</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We consent to the use of our reports dated March 5, 2020 with respect to the consolidated financial statements of Oncolytics Biotech Inc. (&#8220;Oncolytics&#8221;) as at December 31, 2019 and 2018 and for each of the years in the three year period ended December 31, 2019 included as an exhibit to or incorporated by reference in the Annual Report (Form 20-F) for 2019.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also consent to the incorporation by reference in the Registration Statement on Form F-10 (Nos. 333-224432) and Registration Statements on Form S-8 (Nos. 333-171625 and 333-205708) of our report dated March 5, 2020 with respect to the consolidated financial statements of Oncolytics as at December 31, 2019 and 2018 and for each of the years in the three year period ended December 31, 2019 included in the Annual Report on Form 20-F of Oncolytics for the year ended December 31, 2019, as filed with the SEC.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.1171875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:30%;"></td><td style="width:35%;"></td><td style="width:35%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Calgary, Alberta</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ernst &amp; Young LLP</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 6, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chartered Professional Accountants</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>23
<FILENAME>oncyf-20191231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:555577B3D6AE5858B27F27034711F557,x:bf736f8fb9244460983efe1bc219885c-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:deprecated1="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:deprecated2="http://www.xbrl.org/2009/role/deprecated" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:full_ifrs_entry_point="http://xbrl.ifrs.org/taxonomy/2019-03-27/ifrs/full_ifrs_entry_point" xmlns:gen="http://xbrl.org/2008/generic" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2019-03-27/ifrs-full" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:label="http://xbrl.org/2008/label" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:oncyf="http://www.oncolyticsbiotech.com/20191231" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:reference1="http://xbrl.org/2008/reference" xmlns:rol_dim="http://xbrl.ifrs.org/role/ifrs/dimensions" xmlns:rol_ias_10_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ias_10_2019-03-27" xmlns:rol_ias_12_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ias_12_2019-03-27" xmlns:rol_ias_16_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ias_16_2019-03-27" xmlns:rol_ias_19_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ias_19_2019-03-27" xmlns:rol_ias_1_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ias_1_2019-03-27" xmlns:rol_ias_20_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ias_20_2019-03-27" xmlns:rol_ias_21_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ias_21_2019-03-27" xmlns:rol_ias_23_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ias_23_2019-03-27" xmlns:rol_ias_24_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ias_24_2019-03-27" xmlns:rol_ias_26_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ias_26_2019-03-27" xmlns:rol_ias_27_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ias_27_2019-03-27" xmlns:rol_ias_29_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ias_29_2019-03-27" xmlns:rol_ias_2_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ias_2_2019-03-27" xmlns:rol_ias_33_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ias_33_2019-03-27" xmlns:rol_ias_34_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ias_34_2019-03-27" xmlns:rol_ias_36_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ias_36_2019-03-27" xmlns:rol_ias_37_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ias_37_2019-03-27" xmlns:rol_ias_38_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ias_38_2019-03-27" xmlns:rol_ias_40_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ias_40_2019-03-27" xmlns:rol_ias_41_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ias_41_2019-03-27" xmlns:rol_ias_7_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ias_7_2019-03-27" xmlns:rol_ias_8_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ias_8_2019-03-27" xmlns:rol_ifric_2_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ifric_2_2019-03-27" xmlns:rol_ifric_5_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ifric_5_2019-03-27" xmlns:rol_ifrs_12_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_12_2019-03-27" xmlns:rol_ifrs_13_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_13_2019-03-27" xmlns:rol_ifrs_14_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_14_2019-03-27" xmlns:rol_ifrs_15_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_15_2019-03-27" xmlns:rol_ifrs_16_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_16_2019-03-27" xmlns:rol_ifrs_17_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_17_2019-03-27" xmlns:rol_ifrs_1_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_1_2019-03-27" xmlns:rol_ifrs_2_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_2_2019-03-27" xmlns:rol_ifrs_3_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_3_2019-03-27" xmlns:rol_ifrs_4_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_4_2019-03-27" xmlns:rol_ifrs_5_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_5_2019-03-27" xmlns:rol_ifrs_6_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_6_2019-03-27" xmlns:rol_ifrs_7_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_7_2019-03-27" xmlns:rol_ifrs_8_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_ifrs_8_2019-03-27" xmlns:rol_sic_29_2019-03-27="http://xbrl.ifrs.org/role/ifrs/rol_sic_29_2019-03-27" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="oncyf-20191231.xsd" xlink:type="simple" />
	<xbrli:context id="FD2019Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_ComponentsOfEquityAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderSharePurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_ComponentsOfEquityAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_ComponentsOfEquityAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderSharePurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_ComponentsOfEquityAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderSharePurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderSharePurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_ComponentsOfEquityAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderWarrantAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderCommonStockPurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderWarrantAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderCommonStockPurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderCommonStockPurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderWarrantAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Jan1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Jan1_ifrs-full_InitiallyAppliedIFRSsAxis_oncyf_EffectsofIFRS16TransitionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:InitiallyAppliedIFRSsAxis">oncyf:EffectsofIFRS16TransitionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q3Aug16_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q4Dec31_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-12-31</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q3Aug16_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-08-16</xbrli:startDate>
			<xbrli:endDate>2019-08-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2109Q4Aug17-Dec31_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-08-17</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q3Aug16_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderWarrantAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-08-16</xbrli:startDate>
			<xbrli:endDate>2019-08-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q3Aug16_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderWarrantAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-08-16</xbrli:startDate>
			<xbrli:endDate>2019-08-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q3Aug16_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderWarrantAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q3Aug16_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderWarrantAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q3Aug16_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderWarrantAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q3Aug16_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderWarrantAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-08-16</xbrli:startDate>
			<xbrli:endDate>2019-08-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2May22_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-05-22</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Jun1_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-01</xbrli:startDate>
			<xbrli:endDate>2017-06-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun1_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementCanadianMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementCanadianMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4QTD_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun1_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q4Oct24_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-24</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun1_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q3Sep27_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Jun5_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-05</xbrli:startDate>
			<xbrli:endDate>2018-06-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Sep28-Dec31_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderCommonStockPurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-09-28</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementCanadianMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementCanadianMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2May22">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-05-22</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Oct24_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-24</xbrli:startDate>
			<xbrli:endDate>2018-10-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2106Q1Feb26_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementCanadianMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementCanadianMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-02-25</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q3Sep27_oncyf_SaleOfStockAxis_oncyf_SharesUnderCommonStockPurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_InitialCommitmentFeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:InitialCommitmentFeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementCanadianMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementCanadianMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Jun5_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-05</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q3Sep27_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-09-27</xbrli:startDate>
			<xbrli:endDate>2018-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_InitialCommitmentFeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:InitialCommitmentFeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementCanadianMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementCanadianMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementCanadianMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementCanadianMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun1_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q3Sep27_oncyf_SaleOfStockAxis_oncyf_SharesUnderCommonStockPurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-09-27</xbrli:startDate>
			<xbrli:endDate>2018-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderCommonStockPurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Jan1-May21_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-05-21</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4May22-Dec31_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-22</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4May22-Dec31_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderStockOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-22</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4May22-Dec31_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-22</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4May22-Dec31_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderWarrantAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-22</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderWarrantAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4May22-Dec31_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderIncentiveAwardPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-22</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2May21_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-05-21</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2May21_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-05-21</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2May22_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-05-22</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderStockOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderIncentiveAwardPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4May22-Dec31_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-22</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Jan1-May21_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderStockOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-05-21</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4May22-Dec31_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderCommonStockPurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-22</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2May22_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-05-22</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4May22-Dec31_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderWarrantAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-22</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Jan1-May21_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-05-21</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2May22">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-22</xbrli:startDate>
			<xbrli:endDate>2018-05-22</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ifrs-full_ReserveOfSharebasedPaymentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Nov1-30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-11-01</xbrli:startDate>
			<xbrli:endDate>2017-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_ClassesOfProvisionsAxis_oncyf_CollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">oncyf:CollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_ClassesOfProvisionsAxis_oncyf_CollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">oncyf:CollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_CounterpartiesAxis_oncyf_SYNSORBMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">oncyf:SYNSORBMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_ifrs-full_CounterpartiesAxis_oncyf_SYNSORBMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">oncyf:SYNSORBMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_InvestmentTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnusedCapitalLossCarryForwardNetMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnusedCapitalLossCarryForwardNetMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_ShareIssueCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_InvestmentTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnusedNetOperatingLossCarryForwardsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnusedNetOperatingLossCarryForwardsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_ShareIssueCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnusedCapitalLossCarryForwardNetMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_ShareIssueCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnusedNetOperatingLossCarryForwardsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_InvestmentTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentySevenMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySevenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentySixMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtySevenMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtySevenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyThreeMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyThreeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyFiveMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyFiveMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyTwoMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyFourMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyFourMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyEightMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyEightMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyOneMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyNineMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyNineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyNineMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyNineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtySixMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtySixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyFourMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyFourMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyThreeMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyThreeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyTwoMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyOneMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentySevenMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySevenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyFiveMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyFiveMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtySevenMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtySevenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyFiveMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyFiveMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyThreeMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyThreeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyEightMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyEightMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyOneMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentySixMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyFourMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyFourMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyNineMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyNineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyTwoMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtySixMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtySixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyEightMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyEightMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2May4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-05-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_oncyf_Currency1Axis_currency_GBP">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:Currency1Axis">currency:GBP</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_oncyf_Currency1Axis_currency_EUR">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:Currency1Axis">currency:EUR</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_oncyf_Currency1Axis_currency_USD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:Currency1Axis">currency:USD</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_oncyf_Currency1Axis_currency_GBP">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:Currency1Axis">currency:GBP</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_oncyf_Currency1Axis_currency_EUR">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:Currency1Axis">currency:EUR</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_oncyf_Currency1Axis_currency_USD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:Currency1Axis">currency:USD</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_oncyf_ConcentrationRiskType1Axis_oncyf_SupplierConcentrationRisk1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:ConcentrationRiskType1Axis">oncyf:SupplierConcentrationRisk1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember_oncyf_SaleOfStockAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember_oncyf_SaleOfStockAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_ResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_ResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_ResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember_oncyf_SaleOfStockAxis_oncyf_WarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Nov30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-11-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2020Q1Jan1-Mar5_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ifrs-full_MajorOrdinaryShareTransactionsMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2020Q1Feb25_ifrs-full_ClassesOfProvisionsAxis_oncyf_CollaborationAgreementMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ifrs-full_EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">oncyf:CollaborationAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-02-25</xbrli:startDate>
			<xbrli:endDate>2020-02-25</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2020Q1Jan1-Mar5_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ifrs-full_MajorOrdinaryShareTransactionsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="CAD_PER_shares">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:CAD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="plan">
		<xbrli:measure>oncyf:plan</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="year">
		<xbrli:measure>oncyf:year</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="cad">
		<xbrli:measure>iso4217:CAD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="patient">
		<xbrli:measure>oncyf:patient</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="eur">
		<xbrli:measure>iso4217:EUR</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="gbp">
		<xbrli:measure>iso4217:GBP</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="manufacturer">
		<xbrli:measure>oncyf:manufacturer</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2019Q4YTD" id="Fact-30C3BACB012E756D52009CFE2C284033">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2019Q4YTD" id="Fact-2773EB05DDE98F3CD2759CFE2C293B17">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2019Q4YTD" id="Fact-8DEB2509E5C88F9B10DE9CFE2C2980F8">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2019Q4YTD" id="Fact-A36DD899BE396A86F48D9CFE2BCC32E1">2019</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2019Q4YTD" id="Fact-688AE4CC6914C8BB60149CFE2C27D0A3">2019-12-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2019Q4YTD" id="Fact-7C5DC67BC85A4A548DF39CFE2C261A22">20-F</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2019Q4YTD" id="Fact-28F6CC22C08A03E7AA729CFE2C2797E0">0001129928</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="FI2019Q4" decimals="INF" id="Fact-262BFCE94223777594DD9CFE2C27F134" unitRef="shares">32198453</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2019Q4YTD" id="Fact-C5D41CBF51975CC77F6F9CFE2BCC8D78">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityEmergingGrowthCompany contextRef="FD2019Q4YTD" id="Fact-A719AA6D3C8501949D689CFE2C29F478">false</dei:EntityEmergingGrowthCompany>
	<dei:EntityFilerCategory contextRef="FD2019Q4YTD" id="Fact-6AB40C9304E3C29564369CFE2C264118">Non-accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2019Q4YTD" id="Fact-AE0F3638155BF73D0D6A9CFE2C28EB68">ONCOLYTICS BIOTECH INC</dei:EntityRegistrantName>
	<dei:EntityShellCompany contextRef="FD2019Q4YTD" id="Fact-591D821CDA24F362C3079CFE2BCD7CE4">false</dei:EntityShellCompany>
	<dei:EntityVoluntaryFilers contextRef="FD2019Q4YTD" id="Fact-E568392AD21747DD3EDD9CFE2C2711D2">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="FD2019Q4YTD" id="Fact-4FD77535E2F87335CA749CFE2C2834FB">No</dei:EntityWellKnownSeasonedIssuer>
	<ifrs-full:AccountingProfit contextRef="FD2017Q4YTD" decimals="0" id="Fact-B7E05AA944B624A1FC6D9CFE2C1DAB23" unitRef="cad">-15475353</ifrs-full:AccountingProfit>
	<ifrs-full:AccountingProfit contextRef="FD2018Q4YTD" decimals="0" id="Fact-3703F1FDF5E94A3A09F69CFE2C1A1795" unitRef="cad">-16489183</ifrs-full:AccountingProfit>
	<ifrs-full:AccountingProfit contextRef="FD2019Q4YTD" decimals="0" id="Fact-5E6A326DC959BB4D7D509CFE2C271B6F" unitRef="cad">-33122888</ifrs-full:AccountingProfit>
	<ifrs-full:AccumulatedOtherComprehensiveIncome contextRef="FI2018Q4" decimals="0" id="Fact-0EA3634C29B8964CFDD39CFE2BDF8403" unitRef="cad">607504</ifrs-full:AccumulatedOtherComprehensiveIncome>
	<ifrs-full:AccumulatedOtherComprehensiveIncome contextRef="FI2019Q4" decimals="0" id="Fact-6627BE6C889A844474FE9CFE2BD72DFC" unitRef="cad">464101</ifrs-full:AccumulatedOtherComprehensiveIncome>
	<ifrs-full:AdditionalPaidinCapital contextRef="FI2018Q4" decimals="0" id="Fact-9C88F9DD541C17DD0B6E9CFE2BD51D51" unitRef="cad">28260613</ifrs-full:AdditionalPaidinCapital>
	<ifrs-full:AdditionalPaidinCapital contextRef="FI2019Q4" decimals="0" id="Fact-A0555D1325592EB192D19CFE2BD6BC0F" unitRef="cad">29338849</ifrs-full:AdditionalPaidinCapital>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember" decimals="0" id="Fact-7981DA085B5B173F62C29CFE2C231942" unitRef="cad">95375</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-5D8085A90AFAC8886C169CFE2C2A84E1" unitRef="cad">49635</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-B3C5EA45020FB30024F59CFE2C20AEDD" unitRef="cad">10415</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-B4035975097D8197E9669CFE2C1305BF" unitRef="cad">23662</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-9478EBF74DE700DB61769CFE2C36DD35" unitRef="cad">4041</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-EE0CDE888CF7165E4FAB9CFE2C3CB4F8" unitRef="cad">7622</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember" decimals="0" id="Fact-FA3CA1F94DA50F13F62B9CFE2BD4F400" unitRef="cad">174670</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-11954781BA52FA9502D29CFE2C35F08B" unitRef="cad">88202</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-43A98E4CDD3F7588023D9CFE2BFEA643" unitRef="cad">21542</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-793DF7FAF7F240EA98B59CFE2C354BC9" unitRef="cad">49163</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-CA2B83CB6DE71BC75C749CFE2C2CCF70" unitRef="cad">15763</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-56D137FBB91F4E5D08799CFE2C3269E6" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember" decimals="0" id="Fact-87B25E9671BCA4904D509CFE2C278C41" unitRef="cad">122982</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-4BE67192E73ED86F05DC9CFE2C3B1690" unitRef="cad">49093</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-4034D74A2AF0D459BB529CFE2C24BA9F" unitRef="cad">14668</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-6231DF8F30F977BF81749CFE2C291134" unitRef="cad">33635</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-C48D62F177471D02CA289CFE2C32B937" unitRef="cad">5342</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-26D7D56F7A246D2662C49CFE2C259F6F" unitRef="cad">20244</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember" decimals="0" id="Fact-E1C46D5A539FB1A7AC889CFE2C1FAF61" unitRef="cad">7014</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-42B2D9AF291CD7C249AC9CFE2C328B76" unitRef="cad">7014</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-DDD307B8C451C290C7299CFE2C334857" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-C53073677918CE168B979CFE2C295C78" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-C7F061A6B0D2DB86F6A19CFE2C063EF5" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-609FF14B0E8DD5276F4F9CFE2C3B0388" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
	<ifrs-full:AdjustedWeightedAverageShares contextRef="FD2017Q4YTD" decimals="0" id="Fact-2EAFE19CF6C2E4BC05E59CFE2C219ECC" unitRef="shares">13936387</ifrs-full:AdjustedWeightedAverageShares>
	<ifrs-full:AdjustedWeightedAverageShares contextRef="FD2018Q4YTD" decimals="0" id="Fact-FCC30D66A67F8A0ED5999CFE2C2157D8" unitRef="shares">16016366</ifrs-full:AdjustedWeightedAverageShares>
	<ifrs-full:AdjustedWeightedAverageShares contextRef="FD2019Q4YTD" decimals="0" id="Fact-B6AC82BDACADE596BC8B9CFE2C21FD2E" unitRef="shares">22137990</ifrs-full:AdjustedWeightedAverageShares>
	<ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod contextRef="FD2017Q4YTD" decimals="0" id="Fact-9066A8459966E1FFB88C9CFE2C37AC56" unitRef="cad">-2523</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
	<ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod contextRef="FD2018Q4YTD" decimals="0" id="Fact-F079D2ECFF9832B153259CFE2C20C1B3" unitRef="cad">0</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
	<ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod contextRef="FD2019Q4YTD" decimals="0" id="Fact-37142485F7965F915C849CFE2C255F69" unitRef="cad">0</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
	<ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="FD2017Q4YTD" decimals="0" id="Fact-332E460102AC2E1DBCAB9CFE2C12A69A" unitRef="cad">16680</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
	<ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="FD2018Q4YTD" decimals="0" id="Fact-0AD88DB4438338FC09B09CFE2C190D02" unitRef="cad">-13924</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
	<ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="FD2019Q4YTD" decimals="0" id="Fact-EA637B03CE2A79230C549CFE2C0D18F8" unitRef="cad">-2017122</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
	<ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="FD2017Q4YTD" decimals="0" id="Fact-0D85E91C5282751045B19CFE2C1DFCCB" unitRef="cad">90768</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
	<ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="FD2018Q4YTD" decimals="0" id="Fact-9E146F4F9453C2A212E19CFE2C1636C7" unitRef="cad">95375</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
	<ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="FD2019Q4YTD" decimals="0" id="Fact-8F94ED75CB406EED8DAB9CFE2C1A40B5" unitRef="cad">122982</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
	<ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables contextRef="FD2017Q4YTD" decimals="0" id="Fact-D73EA39FBE45F00B0DB79CFE2C0E13CA" unitRef="cad">0</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
	<ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables contextRef="FD2018Q4YTD" decimals="0" id="Fact-7B44E3078C75E881CF819CFE2C14CEA4" unitRef="cad">-27982</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
	<ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables contextRef="FD2019Q4YTD" decimals="0" id="Fact-51F7E27A648A0CE2E8719CFE2C1A3825" unitRef="cad">807877</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
	<ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="FD2017Q4YTD" decimals="0" id="Fact-3523ACF2CE3BE81BD4D79CFE2C0C4C84" unitRef="cad">-384641</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
	<ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="FD2018Q4YTD" decimals="0" id="Fact-67A51F182B0FF646F8839CFE2C1B74D9" unitRef="cad">-1858170</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
	<ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="FD2019Q4YTD" decimals="0" id="Fact-75459A7852C5848A9BBD9CFE2C152E28" unitRef="cad">1347365</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
	<ifrs-full:AdjustmentsForProvisions contextRef="FD2017Q4YTD" decimals="0" id="Fact-9E79F4DCA36091B2337D9CFE2C3C805E" unitRef="cad">0</ifrs-full:AdjustmentsForProvisions>
	<ifrs-full:AdjustmentsForProvisions contextRef="FD2017Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember" decimals="0" id="Fact-ABE2C6E73D065D50547B9CFE2BECDC88" unitRef="cad">0</ifrs-full:AdjustmentsForProvisions>
	<ifrs-full:AdjustmentsForProvisions contextRef="FD2018Q4YTD" decimals="0" id="Fact-5719E7577CF74A3152419CFE2C139C5C" unitRef="cad">67588</ifrs-full:AdjustmentsForProvisions>
	<ifrs-full:AdjustmentsForProvisions contextRef="FD2018Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember" decimals="0" id="Fact-1AED7C5076B19C76046A9CFE2BE4BE0F" unitRef="cad">67588</ifrs-full:AdjustmentsForProvisions>
	<ifrs-full:AdjustmentsForProvisions contextRef="FD2019Q4YTD" decimals="0" id="Fact-D1B59E100051D629BDAE9CFE2C0D6149" unitRef="cad">0</ifrs-full:AdjustmentsForProvisions>
	<ifrs-full:AdjustmentsForProvisions contextRef="FD2019Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember" decimals="0" id="Fact-4AACF81212E749F256399CFE2BEFBE88" unitRef="cad">0</ifrs-full:AdjustmentsForProvisions>
	<ifrs-full:AdjustmentsForSharebasedPayments contextRef="FD2017Q4YTD" decimals="0" id="Fact-B5BFE146F278C9F1DDDD9CFE2C3C95A1" unitRef="cad">578703</ifrs-full:AdjustmentsForSharebasedPayments>
	<ifrs-full:AdjustmentsForSharebasedPayments contextRef="FD2018Q4YTD" decimals="0" id="Fact-C039719FDB65F26941479CFE2C0C160E" unitRef="cad">1415833</ifrs-full:AdjustmentsForSharebasedPayments>
	<ifrs-full:AdjustmentsForSharebasedPayments contextRef="FD2019Q4YTD" decimals="0" id="Fact-40EE36EF6A4ABE0CCD2D9CFE2C0F8572" unitRef="cad">1470153</ifrs-full:AdjustmentsForSharebasedPayments>
	<ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="FD2017Q4YTD" decimals="0" id="Fact-D03DA0D5884CEDD75CBE9CFE2C1C20B7" unitRef="cad">-124793</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
	<ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="FD2017Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_ResearchAndDevelopmentMember" decimals="0" id="Fact-390E9D367EAE3ADA868A9CFE2BE7695B" unitRef="cad">55538</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
	<ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="FD2018Q4YTD" decimals="0" id="Fact-0A524F67F573D35109BE9CFE2C1845C4" unitRef="cad">-374337</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
	<ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="FD2018Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_ResearchAndDevelopmentMember" decimals="0" id="Fact-010A465D00D2B6F2C9689CFE2BE97BCF" unitRef="cad">-608111</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
	<ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="FD2019Q4YTD" decimals="0" id="Fact-CB06540BD13B219CC2849CFE2C0CD368" unitRef="cad">353189</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
	<ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="FD2019Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_ResearchAndDevelopmentMember" decimals="0" id="Fact-9F0FAAD76934A30E0C1C9CFE2BEEA19F" unitRef="cad">356081</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
	<ifrs-full:AmortisationExpense contextRef="FD2017Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember" decimals="0" id="Fact-F4931C6315F20D3553D89CFE2BE6FF84" unitRef="cad">90768</ifrs-full:AmortisationExpense>
	<ifrs-full:AmortisationExpense contextRef="FD2018Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember" decimals="0" id="Fact-217DBB97EDFC6ADDEE449CFE2BE7FBA2" unitRef="cad">95375</ifrs-full:AmortisationExpense>
	<ifrs-full:AmortisationExpense contextRef="FD2019Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember" decimals="0" id="Fact-2BDA0559821A0CF6050F9CFE2BDBFAB0" unitRef="cad">122982</ifrs-full:AmortisationExpense>
	<ifrs-full:ApplicableTaxRate contextRef="FD2017Q4YTD" decimals="INF" id="Fact-552382E6D03C43670CAD9CFE2C30A2A5" unitRef="number">0.27</ifrs-full:ApplicableTaxRate>
	<ifrs-full:ApplicableTaxRate contextRef="FD2018Q4YTD" decimals="INF" id="Fact-A91225575682DC2A8EE69CFE2C25486D" unitRef="number">0.27</ifrs-full:ApplicableTaxRate>
	<ifrs-full:ApplicableTaxRate contextRef="FD2019Q4YTD" decimals="INF" id="Fact-32CA14F4AF3CAF2847359CFE2C1C1E0B" unitRef="number">0.265</ifrs-full:ApplicableTaxRate>
	<ifrs-full:Assets contextRef="FI2018Q4" decimals="0" id="Fact-E5B4EBA7E7BE8BC1CC749CFE2BD81D2E" unitRef="cad">14865253</ifrs-full:Assets>
	<ifrs-full:Assets contextRef="FI2019Q4" decimals="0" id="Fact-4307C1126D48F72DFA499CFE2BDC8F3A" unitRef="cad">19657865</ifrs-full:Assets>
	<ifrs-full:Assets contextRef="I2019Q1Jan1" decimals="0" id="Fact-1AC5002CBB3FF021F2C29CFE2C08B92F" unitRef="cad">15673278</ifrs-full:Assets>
	<ifrs-full:Assets contextRef="I2019Q1Jan1_ifrs-full_InitiallyAppliedIFRSsAxis_oncyf_EffectsofIFRS16TransitionMember" decimals="0" id="Fact-0975CAF4275026E0B9CA9CFE2BFFEED1" unitRef="cad">808025</ifrs-full:Assets>
	<ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="FD2017Q4YTD" decimals="2" id="Fact-7BBAF06A8CD93342844D9CFE2C059ABC" unitRef="CAD_PER_shares">-1.12</ifrs-full:BasicAndDilutedEarningsLossPerShare>
	<ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="FD2018Q4YTD" decimals="2" id="Fact-D5E0CB01468A462C33C39CFE2C036F2E" unitRef="CAD_PER_shares">-1.06</ifrs-full:BasicAndDilutedEarningsLossPerShare>
	<ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="FD2019Q4YTD" decimals="2" id="Fact-67D55D08354A1C41BE1B9CFE2C044783" unitRef="CAD_PER_shares">-1.50</ifrs-full:BasicAndDilutedEarningsLossPerShare>
	<ifrs-full:CashAndCashEquivalents contextRef="FI2016Q4" decimals="0" id="Fact-B2108778DD0DE7841EF79CFE2C166DAE" unitRef="cad">12034282</ifrs-full:CashAndCashEquivalents>
	<ifrs-full:CashAndCashEquivalents contextRef="FI2017Q4" decimals="0" id="Fact-89D84259E21472623EF59CFE2C1AC017" unitRef="cad">11836119</ifrs-full:CashAndCashEquivalents>
	<ifrs-full:CashAndCashEquivalents contextRef="FI2018Q4" decimals="0" id="Fact-CBD4B0B0883F0C83BAA29CFE2BD7DBED" unitRef="cad">13699881</ifrs-full:CashAndCashEquivalents>
	<ifrs-full:CashAndCashEquivalents contextRef="FI2019Q4" decimals="0" id="Fact-08C189F4B7444698EBC99CFE2BD3A98C" unitRef="cad">14148021</ifrs-full:CashAndCashEquivalents>
	<ifrs-full:CashAndCashEquivalents contextRef="FI2019Q4_oncyf_Currency1Axis_currency_EUR" decimals="0" id="Fact-682DD4095E59C1F67B1D9CFE2BD07F0B" unitRef="eur">33664</ifrs-full:CashAndCashEquivalents>
	<ifrs-full:CashAndCashEquivalents contextRef="FI2019Q4_oncyf_Currency1Axis_currency_GBP" decimals="0" id="Fact-B8D0F8FB7B69849C1F749CFE2BD1DE04" unitRef="gbp">26751</ifrs-full:CashAndCashEquivalents>
	<ifrs-full:CashAndCashEquivalents contextRef="FI2019Q4_oncyf_Currency1Axis_currency_USD" decimals="0" id="Fact-2B7D1FBFB2970F10DFD09CFE2BCE5D6A" unitRef="usd">9676360</ifrs-full:CashAndCashEquivalents>
	<ifrs-full:CashEquivalents contextRef="FI2018Q4" decimals="0" id="Fact-020362E71B5192E2A1809CFE2C17E2C1" unitRef="cad">9977409</ifrs-full:CashEquivalents>
	<ifrs-full:CashEquivalents contextRef="FI2019Q4" decimals="0" id="Fact-EEE20A60A363603A69289CFE2BD3B6FA" unitRef="cad">13058092</ifrs-full:CashEquivalents>
	<ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments contextRef="FD2017Q4YTD" decimals="0" id="Fact-5956A20CE1C573D377829CFE2C3CBC83" unitRef="cad">2088800</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
	<ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments contextRef="FD2018Q4YTD" decimals="0" id="Fact-262F2E3B5BA4C5E6995F9CFE2C11B279" unitRef="cad">0</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
	<ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments contextRef="FD2019Q4YTD" decimals="0" id="Fact-C9FB01E4224CA6354E959CFE2C1E5931" unitRef="cad">0</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
	<ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="FD2017Q4YTD" decimals="0" id="Fact-DF2F4ADA24C4534222D59CFE2C0D036B" unitRef="cad">12812704</ifrs-full:CashFlowsFromUsedInFinancingActivities>
	<ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="FD2018Q4YTD" decimals="0" id="Fact-CD3681A0375C4D2654489CFE2C17854B" unitRef="cad">13299136</ifrs-full:CashFlowsFromUsedInFinancingActivities>
	<ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="FD2019Q4YTD" decimals="0" id="Fact-3C1798894085A05649E29CFE2C1D776A" unitRef="cad">21015596</ifrs-full:CashFlowsFromUsedInFinancingActivities>
	<ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="FD2017Q4YTD" decimals="0" id="Fact-E21DF60AE31C0566A3289CFE2C128FDB" unitRef="cad">1983035</ifrs-full:CashFlowsFromUsedInInvestingActivities>
	<ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="FD2018Q4YTD" decimals="0" id="Fact-549735135E508482BEC39CFE2C3C146F" unitRef="cad">-107466</ifrs-full:CashFlowsFromUsedInInvestingActivities>
	<ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="FD2019Q4YTD" decimals="0" id="Fact-53B3252ED80B0080DE4C9CFE2C0F3F9A" unitRef="cad">-10905</ifrs-full:CashFlowsFromUsedInInvestingActivities>
	<ifrs-full:CashFlowsFromUsedInOperations contextRef="FD2017Q4YTD" decimals="0" id="Fact-69EC0792D71E90CC4C349CFE2C1B4293" unitRef="cad">-14891318</ifrs-full:CashFlowsFromUsedInOperations>
	<ifrs-full:CashFlowsFromUsedInOperations contextRef="FD2018Q4YTD" decimals="0" id="Fact-9E66271E1BCBDC07E5439CFE2C14286F" unitRef="cad">-11920238</ifrs-full:CashFlowsFromUsedInOperations>
	<ifrs-full:CashFlowsFromUsedInOperations contextRef="FD2019Q4YTD" decimals="0" id="Fact-DA9AFD90470A17EF21459CFE2C117B02" unitRef="cad">-19906124</ifrs-full:CashFlowsFromUsedInOperations>
	<ifrs-full:CashOutflowForLeases contextRef="FD2019Q4YTD" decimals="0" id="Fact-54CE3F691CD835F1D7849CFE2C155D55" unitRef="cad">447497</ifrs-full:CashOutflowForLeases>
	<ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions contextRef="FD2019Q4YTD_ifrs-full_CounterpartiesAxis_oncyf_SYNSORBMember" decimals="-5" id="Fact-EF68E5431D7D22EC451B9CFE2C2B87AC" unitRef="cad">1000000</ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions>
	<ifrs-full:ComprehensiveIncome contextRef="FD2017Q4YTD" decimals="0" id="Fact-EDEBE6C7986EBD96F6359CFE2C050677" unitRef="cad">-15797181</ifrs-full:ComprehensiveIncome>
	<ifrs-full:ComprehensiveIncome contextRef="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-286AB7BE319015E727D19CFE2BFDD5A3" unitRef="cad">-180330</ifrs-full:ComprehensiveIncome>
	<ifrs-full:ComprehensiveIncome contextRef="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember" decimals="0" id="Fact-3AD1926E168EAC8EBB1E9CFE2C04A495" unitRef="cad">-15616851</ifrs-full:ComprehensiveIncome>
	<ifrs-full:ComprehensiveIncome contextRef="FD2018Q4YTD" decimals="0" id="Fact-123A7D2B5450B32A67B59CFE2C058D1B" unitRef="cad">-16803451</ifrs-full:ComprehensiveIncome>
	<ifrs-full:ComprehensiveIncome contextRef="FD2018Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-008066E8AA5A26B791179CFE2C064447" unitRef="cad">233774</ifrs-full:ComprehensiveIncome>
	<ifrs-full:ComprehensiveIncome contextRef="FD2018Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember" decimals="0" id="Fact-A607407D634B5EC308A19CFE2C052350" unitRef="cad">-17037225</ifrs-full:ComprehensiveIncome>
	<ifrs-full:ComprehensiveIncome contextRef="FD2019Q4YTD" decimals="0" id="Fact-5C414AF3A9E86FA2DE669CFE2C035A95" unitRef="cad">-33266291</ifrs-full:ComprehensiveIncome>
	<ifrs-full:ComprehensiveIncome contextRef="FD2019Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-50513172BC341C4A58909CFE2BF1AE6C" unitRef="cad">-143403</ifrs-full:ComprehensiveIncome>
	<ifrs-full:ComprehensiveIncome contextRef="FD2019Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember" decimals="0" id="Fact-CFCA11AAAE72FD6764029CFE2BEEB0A8" unitRef="cad">-33122888</ifrs-full:ComprehensiveIncome>
	<ifrs-full:ContractLiabilities contextRef="FI2017Q4" decimals="0" id="Fact-82CB84B12820BA22128D9CFE2BCD02B5" unitRef="usd">6182580</ifrs-full:ContractLiabilities>
	<ifrs-full:ContractLiabilities contextRef="FI2018Q4" decimals="0" id="Fact-72996F5EDFE816134D0F9CFE2BCD8374" unitRef="cad">6730287</ifrs-full:ContractLiabilities>
	<ifrs-full:ContractLiabilities contextRef="FI2018Q4" decimals="0" id="Fact-9969E9AB1D52CE7100289CFE2BD217EE" unitRef="usd">6730287</ifrs-full:ContractLiabilities>
	<ifrs-full:ContractLiabilities contextRef="FI2019Q4" decimals="0" id="Fact-DC09F37F1FBBC4000F499CFE2BD2FF2E" unitRef="cad">6730287</ifrs-full:ContractLiabilities>
	<ifrs-full:ContractLiabilities contextRef="FI2019Q4" decimals="0" id="Fact-C11D4D7DB18CB5C5062B9CFE2BD02751" unitRef="usd">6730287</ifrs-full:ContractLiabilities>
	<ifrs-full:CurrentAssets contextRef="FI2018Q4" decimals="0" id="Fact-1ED8A6A2B077878B91469CFE2BDEB722" unitRef="cad">14452517</ifrs-full:CurrentAssets>
	<ifrs-full:CurrentAssets contextRef="FI2019Q4" decimals="0" id="Fact-F828D4EC0FCD4017DA689CFE2BD8B4EE" unitRef="cad">18930384</ifrs-full:CurrentAssets>
	<ifrs-full:CurrentContractLiabilities contextRef="FI2018Q4" decimals="0" id="Fact-CAFF5A2129470C84B7059CFE2BDBCD81" unitRef="cad">927400</ifrs-full:CurrentContractLiabilities>
	<ifrs-full:CurrentContractLiabilities contextRef="FI2019Q4" decimals="0" id="Fact-AB9BD4CF7734B81D49989CFE2BDF10FC" unitRef="cad">0</ifrs-full:CurrentContractLiabilities>
	<ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="FI2018Q4" decimals="0" id="Fact-7714B414CC4C72489973A825C5A0E0F3" unitRef="cad">0</ifrs-full:CurrentDerivativeFinancialLiabilities>
	<ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="FI2018Q4_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember" decimals="0" id="Fact-7F4278039F62F22E49DA9CFE2BD74FCF" unitRef="cad">0</ifrs-full:CurrentDerivativeFinancialLiabilities>
	<ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="FI2019Q4" decimals="0" id="Fact-7851C517E57DF74BE077A825C59CE6B3" unitRef="cad">8508764</ifrs-full:CurrentDerivativeFinancialLiabilities>
	<ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="FI2019Q4_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember" decimals="0" id="Fact-663D1A4FE70BD6D834339CFE2BDF0B6B" unitRef="cad">8508764</ifrs-full:CurrentDerivativeFinancialLiabilities>
	<ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="FI2019Q4_oncyf_Currency1Axis_currency_EUR" decimals="0" id="Fact-AE54D92D32EF4C6D32819CFE2BCEC86F" unitRef="eur">0</ifrs-full:CurrentDerivativeFinancialLiabilities>
	<ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="FI2019Q4_oncyf_Currency1Axis_currency_GBP" decimals="0" id="Fact-1D13ED9ABC0E88741D6E9CFE2BCF33E7" unitRef="gbp">0</ifrs-full:CurrentDerivativeFinancialLiabilities>
	<ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="FI2019Q4_oncyf_Currency1Axis_currency_USD" decimals="0" id="Fact-CD883E419849D1428F109CFE2BD15F50" unitRef="usd">6551250</ifrs-full:CurrentDerivativeFinancialLiabilities>
	<ifrs-full:CurrentLeaseLiabilities contextRef="FI2019Q4" decimals="0" id="Fact-F1553C2F5850CD87F0909CFE2BDBA287" unitRef="cad">339846</ifrs-full:CurrentLeaseLiabilities>
	<ifrs-full:CurrentLiabilities contextRef="FI2018Q4" decimals="0" id="Fact-68AE96B362539C9740E49CFE2BE236A6" unitRef="cad">2814575</ifrs-full:CurrentLiabilities>
	<ifrs-full:CurrentLiabilities contextRef="FI2019Q4" decimals="0" id="Fact-4F80FF27D4379D4CAEA39CFE2BDF6EAA" unitRef="cad">12869043</ifrs-full:CurrentLiabilities>
	<ifrs-full:CurrentPrepaidExpenses contextRef="FI2018Q4" decimals="0" id="Fact-F95689FAA178B73924B69CFE2BDDDA5D" unitRef="cad">700986</ifrs-full:CurrentPrepaidExpenses>
	<ifrs-full:CurrentPrepaidExpenses contextRef="FI2019Q4" decimals="0" id="Fact-CDFA472877B27B0261399CFE2BE2E53A" unitRef="cad">2713591</ifrs-full:CurrentPrepaidExpenses>
	<ifrs-full:CurrentTaxExpenseIncome contextRef="FD2017Q4YTD" decimals="0" id="Fact-F9E539075253D405C04A9CFE2C2359FD" unitRef="cad">144021</ifrs-full:CurrentTaxExpenseIncome>
	<ifrs-full:CurrentTaxExpenseIncome contextRef="FD2018Q4YTD" decimals="0" id="Fact-60AB668975952B12CE999CFE2C34FDDF" unitRef="cad">548042</ifrs-full:CurrentTaxExpenseIncome>
	<ifrs-full:CurrentTaxExpenseIncome contextRef="FD2019Q4YTD" decimals="0" id="Fact-DAE379BAAB12715369C99CFE2C1A75FD" unitRef="cad">0</ifrs-full:CurrentTaxExpenseIncome>
	<ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods contextRef="FD2017Q4YTD" decimals="0" id="Fact-09AAEE08E4501A279FAF9CFE2C388E83" unitRef="cad">141498</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
	<ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods contextRef="FD2018Q4YTD" decimals="0" id="Fact-AE5F44C906C66B32B1ED9CFE2C291776" unitRef="cad">548042</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
	<ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods contextRef="FD2019Q4YTD" decimals="0" id="Fact-28069B732F06C8A0D36E9CFE2C28FA86" unitRef="cad">0</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
	<ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities contextRef="FD2018Q4YTD" decimals="0" id="Fact-118CEEC08A66A5D1C3B69CFE2BD7398E" unitRef="usd">0</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
	<ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities contextRef="FD2019Q4YTD" decimals="0" id="Fact-6AF197A253F4819A0FCC9CFE2BD1C986" unitRef="usd">0</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2017Q4" decimals="0" id="Fact-93A14CA762618F61B4FD9CFE2C3A7386" unitRef="cad">32983223</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_InvestmentTaxCreditsMember" decimals="0" id="Fact-5976E30F22FB758E78829CFE2C397C1F" unitRef="cad">3988325</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" decimals="0" id="Fact-ECB9C0AD6EBA5812BD229CFE2C3C6A39" unitRef="cad">1927640</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_ShareIssueCostsMember" decimals="0" id="Fact-6CCEEE34FBB659E53F719CFE2C3DB9CD" unitRef="cad">493343</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" decimals="0" id="Fact-789FF1FF010778A5880F9CFE2C3E41E0" unitRef="cad">7406099</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnusedCapitalLossCarryForwardNetMember" decimals="0" id="Fact-A3A9178C02864173BA469CFE2C3DDE57" unitRef="cad">7598</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2017Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnusedNetOperatingLossCarryForwardsMember" decimals="0" id="Fact-81419CB11D39D3C1DDA19CFE2C3DC49A" unitRef="cad">19160218</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2018Q4" decimals="0" id="Fact-91CBE33A99DA96ABAF7C9CFE2C3A99E0" unitRef="cad">34712675</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2018Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_InvestmentTaxCreditsMember" decimals="0" id="Fact-20F971C6561414ED9E5E9CFE2C3B3F75" unitRef="cad">3988606</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2018Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" decimals="0" id="Fact-1F1EB84C0E609A9CB87F9CFE2C3C19B6" unitRef="cad">1949611</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2018Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_ShareIssueCostsMember" decimals="0" id="Fact-C81D26693C83728B087B9CFE2C3A9A80" unitRef="cad">696346</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2018Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" decimals="0" id="Fact-90017FA779CD148605D49CFE2C3A6F56" unitRef="cad">7406169</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2018Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnusedCapitalLossCarryForwardNetMember" decimals="0" id="Fact-2826FB02DFDC863E2A4D9CFE2C3888FF" unitRef="cad">7598</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2018Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnusedNetOperatingLossCarryForwardsMember" decimals="0" id="Fact-0A2A4FEE12B68569EC039CFE2C3F19FE" unitRef="cad">20664345</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2019Q4" decimals="0" id="Fact-B9CB6ACC787C1C7F4D259CFE2C39F9CB" unitRef="cad">32712066</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2019Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_InvestmentTaxCreditsMember" decimals="0" id="Fact-1B5666F3612815E288D59CFE2C3E6CAD" unitRef="cad">4222016</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2019Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" decimals="0" id="Fact-673B0D7D65F8193D547D9CFE2C39B09A" unitRef="cad">1908320</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2019Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_ShareIssueCostsMember" decimals="0" id="Fact-CA2E0C9468F790B190F19CFE2C3DEFAF" unitRef="cad">611072</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2019Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" decimals="0" id="Fact-06DA28179BE62A1AB6469CFE2C3F580E" unitRef="cad">6338542</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2019Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnusedCapitalLossCarryForwardNetMember" decimals="0" id="Fact-CC5CCDAFDE8295EA89849CFE2C391756" unitRef="cad">6474</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="FI2019Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnusedNetOperatingLossCarryForwardsMember" decimals="0" id="Fact-DB3554D6C5A1E545E5399CFE2C3BC596" unitRef="cad">19625642</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
	<ifrs-full:DepreciationRightofuseAssets contextRef="FD2019Q4YTD" decimals="0" id="Fact-9C6FA7C5D0EE29C043949CFE2C179C82" unitRef="cad">362592</ifrs-full:DepreciationRightofuseAssets>
	<ifrs-full:DepreciationRightofuseAssets contextRef="FD2019Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember" decimals="0" id="Fact-1738C0AF302BC1E5F5DB9CFE2BE7C3D7" unitRef="usd">362592</ifrs-full:DepreciationRightofuseAssets>
	<ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="D2019Q3Aug16_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember" decimals="4" id="Fact-25EBF8001C39B3AB24D69CFE2BF2CD4F" unitRef="number">0.8200</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
	<ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="D2019Q4Dec31_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember" decimals="4" id="Fact-0B421BB687D8A8C543F09CFE2BEF4206" unitRef="number">0.9000</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
	<ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="FD2017Q4YTD" decimals="4" id="Fact-20D74BA7F91FA4A5B5899CFE2C20D90F" unitRef="number">0.9073</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
	<ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="FD2018Q4YTD" decimals="4" id="Fact-4453DDB93FB12DBF46909CFE2C2D6A0C" unitRef="number">0.8115</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
	<ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="FD2019Q4YTD" decimals="4" id="Fact-1262071AD57A98096F0B9CFE2C3175A3" unitRef="number">0.9790</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
	<ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="D2019Q3Aug16_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember" decimals="INF" id="Fact-7B5C21538C78448881079CFE2C15B3AC" unitRef="year">4</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
	<ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="D2019Q4Dec31_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember" decimals="INF" id="Fact-EF273BBC5AE7C93239D29CFE2C2F7630" unitRef="year">1</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
	<ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="FD2017Q4YTD" decimals="1" id="Fact-041C5CEB96F887B1C37D9CFE2C2A880E" unitRef="year">3.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
	<ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="FD2018Q4YTD" decimals="1" id="Fact-D800165B95F85D24FF4F9CFE2C2E0D18" unitRef="year">3.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
	<ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="FD2019Q4YTD" decimals="1" id="Fact-9D266775D42386782E9D9CFE2C3DD2CC" unitRef="year">3.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
	<ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="D2019Q3Aug16_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember" decimals="4" id="Fact-06ECA5022EFF1ECF0CCE9CFE2BF5FE50" unitRef="number">0.0142</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
	<ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="FD2017Q4YTD" decimals="4" id="Fact-11B522FB568F80FEC6F79CFE2C2D22B7" unitRef="number">0.0118</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
	<ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="FD2018Q4YTD" decimals="4" id="Fact-C8DE4026D45C56E22F5F9CFE2BE6C605" unitRef="number">0.0202</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
	<ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="FD2019Q4YTD" decimals="4" id="Fact-95E3CF81ACB2AD377A619CFE2BE0E810" unitRef="number">0.0162</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
	<ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="FD2019Q4YTD_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember" decimals="4" id="Fact-905394ECD12BD8FCC8009CFE2C312C41" unitRef="number">0.0159</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember" decimals="0" id="Fact-45D0D0D597BF8BE659FD9CFE2C258053" unitRef="cad">646834</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-92F87869ABD0E7E7BB279CFE2C356539" unitRef="cad">424246</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-2E418F9CAC1F935CAC669CFE2C288C13" unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-B410BAB8E5877ECF20FD9CFE2C299F94" unitRef="cad">85096</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-2DA2BDD1829882CC10BA9CFE2BD012A0" unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-237AD3EFFB857BE56B9F9CFE2C357730" unitRef="cad">137492</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember" decimals="0" id="Fact-0D1A3CD9E225888741C29CFE2C25CD2E" unitRef="cad">646834</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-D91861D1903AF6BEF0279CFE2C24D229" unitRef="cad">424246</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-F247DE8EB772453EFD2E9CFE2C22CCAD" unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-2EA0CD3BB18D5BD008BD9CFE2C324DB6" unitRef="cad">85096</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-84AAD3BB53B0FAC539B29CFE2BE3598F" unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2018Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-553B2D8155D746F6B9F09CFE2C2B8738" unitRef="cad">137492</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember" decimals="0" id="Fact-60E8C4892E2AFA1063379CFE2C20E48A" unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-53D1B96EBAE7C3D9A1AA9CFE2C2306C2" unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-3E1183E5DC2B8B3F1A9E9CFE2C2C8438" unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-F3910D869CA80F410A879CFE2C2393CB" unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-5196EE8FF084E94B9B8F9CFE2C3674FE" unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-8BCB0BD77D329A35DC9E9CFE2C2E7281" unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember" decimals="0" id="Fact-0D7EE8FEE21442170C949CFE2C2A7D1C" unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-A31021EDC7B4AE5C75129CFE2C15C859" unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-D5D5295F90F2CE56A4189CFE2BDAB38F" unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-72F37CA7FFF96B204E0E9CFE2C2E100F" unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-D1F7C672AF6FDF8D34739CFE2C38B35E" unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="FD2019Q4YTD_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-E7CC823906F7D0BFC8809CFE2BD870EF" unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
	<ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="FD2017Q4YTD" decimals="0" id="Fact-4E01AC18D375D915CA669CFE2C12AA9E" unitRef="cad">-102584</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
	<ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="FD2018Q4YTD" decimals="0" id="Fact-3425D876AC12C5BA87CA9CFE2C106CD4" unitRef="cad">592330</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
	<ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="FD2019Q4YTD" decimals="0" id="Fact-091AA2A6ED4943133F119CFE2C3A7AF2" unitRef="cad">-650427</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
	<ifrs-full:Equity contextRef="FI2016Q4" decimals="0" id="Fact-6845A5B97C15BFCED3B69CFE2BFCED01" unitRef="cad">10689620</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2016Q4_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember" decimals="0" id="Fact-81D969A9B3F67C82BCE39CFE2C0AAC53" unitRef="cad">262321825</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2016Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember" decimals="0" id="Fact-199B1D6A4D73B2C028FE9CFE2BFB1833" unitRef="cad">0</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2016Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-4C36B0A8CF48B94A09D49CFE2BFA6AAD" unitRef="cad">554060</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2016Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-F0A985B92EEB550612A09CFE2BED5CD8" unitRef="cad">262321825</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2016Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember" decimals="0" id="Fact-AE56D7D1A6BFAC763D379CFE2BFF74BC" unitRef="cad">-278829309</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2016Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember" decimals="0" id="Fact-FCB08179AC77FEB7101F9CFE2BF67615" unitRef="cad">26643044</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2016Q4_ifrs-full_ComponentsOfEquityAxis_oncyf_WarrantsMember" decimals="0" id="Fact-24892B78299F29CA7BC99CFE2BF83D30" unitRef="cad">0</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2017Q4" decimals="0" id="Fact-859F65B68699AFFAC53F9CFE2BFD4EE2" unitRef="cad">8283846</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2017Q4_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember" decimals="0" id="Fact-94B2A8C0F2774DF20FFC9CFE2BF1807A" unitRef="cad">271710138</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2017Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember" decimals="0" id="Fact-9C7EBB07CC52D79993FB9CFE2BF0A64B" unitRef="cad">3617900</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2017Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-B6484B0569D7E906F1019CFE2BFA737B" unitRef="cad">373730</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2017Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-A751170B3C3AC5FC2AD09CFE2BF6B459" unitRef="cad">271710138</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2017Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember" decimals="0" id="Fact-C80741A4B4954123BA869CFE2C00A8E0" unitRef="cad">-294446160</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2017Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember" decimals="0" id="Fact-D5A3565BA5D70F68318B9CFE2C06C946" unitRef="cad">27028238</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2017Q4_ifrs-full_ComponentsOfEquityAxis_oncyf_WarrantsMember" decimals="0" id="Fact-F1B5FE8D98A22DA469DD9CFE2C024D65" unitRef="cad">3617900</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2018Q4" decimals="0" id="Fact-BF4F856622707D45F9479CFE2BE0A5EF" unitRef="cad">6195363</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2018Q4_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-DF6238724C537FB6EF6E9CFE2BFA1AE0" unitRef="cad">285193061</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2018Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember" decimals="0" id="Fact-92F0062BAE64F8CAB7829CFE2BEFA406" unitRef="cad">3617570</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2018Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-9EBD33704FA9C9DEE92A9CFE2C06A95A" unitRef="cad">607504</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2018Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-FA5E537EF21BCC3EAB899CFE2C0092DF" unitRef="cad">285193061</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2018Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember" decimals="0" id="Fact-FD661533DBF87556B9B29CFE2BFECE4A" unitRef="cad">-311483385</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2018Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember" decimals="0" id="Fact-DF08681DD2EE076BD3589CFE2C00BE7E" unitRef="cad">28260613</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2018Q4_ifrs-full_ComponentsOfEquityAxis_oncyf_WarrantsMember" decimals="0" id="Fact-142C3C3AA5E441DAA2889CFE2BEFAE5F" unitRef="cad">3617570</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2019Q4" decimals="0" id="Fact-BB9F73BB0B5B3498B2349CFE2BD41A0A" unitRef="cad">-107894</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2019Q4_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-EDB34DC0CF1E7B28D7909CFE2BFE9241" unitRef="cad">311077859</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2019Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember" decimals="0" id="Fact-5717F2116FE8C32BD5C59CFE2C09D186" unitRef="cad">3617570</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2019Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-E320C65530F3DC299BBB9CFE2C0786B2" unitRef="cad">464101</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2019Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-E9BD15E93FF571437DA09CFE2C04F002" unitRef="cad">311077859</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2019Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember" decimals="0" id="Fact-F8CB5E3BC8B277FA2A2D9CFE2BFD131A" unitRef="cad">-344606273</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2019Q4_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember" decimals="0" id="Fact-05E4AB2C70BB4CFC7F329CFE2BFB331D" unitRef="cad">29338849</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="FI2019Q4_ifrs-full_ComponentsOfEquityAxis_oncyf_WarrantsMember" decimals="0" id="Fact-A0DB0B4039EE992F228A9CFE2BFAA204" unitRef="cad">3617570</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="I2018Q2May21_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember" decimals="0" id="Fact-E32F413A7B6C5EA04F7D9CFE2BF8DBCC" unitRef="cad">272268722</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="I2018Q2May21_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember" decimals="0" id="Fact-10CED553D95174569BDA9CFE2BFAA170" unitRef="cad">3617900</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="I2018Q2May22_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-AFC0CF9B99F2C65A6DCB9CFE2BEADCE1" unitRef="cad">272268722</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="I2018Q2May22_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember" decimals="0" id="Fact-5BFF40EC99B9850564709CFE2BFAA723" unitRef="cad">3617900</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="I2019Q1Jan1" decimals="0" id="Fact-D99493A233C7BBAF2F989CFE2C25845E" unitRef="cad">6195363</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="I2019Q1Jan1_ifrs-full_InitiallyAppliedIFRSsAxis_oncyf_EffectsofIFRS16TransitionMember" decimals="0" id="Fact-1EBDE7E60BF115554A109CFE2BE9BCB6" unitRef="cad">0</ifrs-full:Equity>
	<ifrs-full:Equity contextRef="I2106Q1Feb26_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementCanadianMember" decimals="-5" id="Fact-B3E423752F2D3FE688B19CFE2BD439F5" unitRef="cad">4600000</ifrs-full:Equity>
	<ifrs-full:EquityAndLiabilities contextRef="FI2018Q4" decimals="0" id="Fact-00280D307CBAFCC6D3DD9CFE2BDAC3DA" unitRef="cad">14865253</ifrs-full:EquityAndLiabilities>
	<ifrs-full:EquityAndLiabilities contextRef="FI2019Q4" decimals="0" id="Fact-4BEDE99D7CCF90932AE19CFE2BDCD44E" unitRef="cad">19657865</ifrs-full:EquityAndLiabilities>
	<ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="FI2019Q4_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFiveMember" decimals="2" id="Fact-75CD7F8C0BAB8EF0DB059CFE2BDE3EBB" unitRef="CAD_PER_shares">7.14</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
	<ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="FI2019Q4_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFourMember" decimals="2" id="Fact-325BF3AA93424F1A82429CFE2C2A3150" unitRef="CAD_PER_shares">3.40</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
	<ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="FI2019Q4_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeOneMember" decimals="2" id="Fact-286BC9ACA593170450BC9CFE2C26F468" unitRef="CAD_PER_shares">0.54</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
	<ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="FI2019Q4_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeThreeMember" decimals="2" id="Fact-37A782CF29090E6F72E59CFE2C043BB8" unitRef="CAD_PER_shares">1.80</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
	<ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="FI2019Q4_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeTwoMember" decimals="2" id="Fact-C9A22B3F78B2A687B4389CFE2C3058EC" unitRef="CAD_PER_shares">1.43</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
	<ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="FI2019Q4_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFiveMember" decimals="2" id="Fact-551184B64DC571C6B49A9CFE2C04A18C" unitRef="CAD_PER_shares">63.84</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
	<ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="FI2019Q4_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFourMember" decimals="2" id="Fact-600B2DF1DF0AD9B48A499CFE2C1B2B0E" unitRef="CAD_PER_shares">7.13</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
	<ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="FI2019Q4_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeOneMember" decimals="2" id="Fact-3C0E01C4909C696ABCE59CFE2C037CBB" unitRef="CAD_PER_shares">1.42</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
	<ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="FI2019Q4_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeThreeMember" decimals="2" id="Fact-A75DE649FFA372021FFF9CFE2C27E523" unitRef="CAD_PER_shares">3.39</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
	<ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="FI2019Q4_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeTwoMember" decimals="2" id="Fact-7A760005C0DD01E0478A9CFE2BDB109B" unitRef="CAD_PER_shares">1.79</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
	<ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="I2017Q2Jun1_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="2" id="Fact-B42455A5C07A54B2DE109CFE2BD95992" unitRef="CAD_PER_shares">0.95</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
	<ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="I2018Q2May22_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="3" id="Fact-C40058FD921680B40A4F9CFE2BEE399A" unitRef="CAD_PER_shares">9.025</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
	<ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="I2019Q3Aug16_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember" decimals="2" id="Fact-B36586AD972CBE2FD5F99CFE2BD56F16" unitRef="usdPerShare">0.90</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
	<ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="FD2017Q4YTD" decimals="INF" id="Fact-21209F2CEE22AC0200149CFE2C2DDD57" unitRef="number">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
	<ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="FD2018Q4YTD" decimals="INF" id="Fact-652FDB5309A7CDD467489CFE2C2A90F1" unitRef="number">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
	<ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="FD2019Q4YTD" decimals="INF" id="Fact-10F90FED82DDA6404F199CFE2C338489" unitRef="number">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
	<ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="FD2017Q4YTD" decimals="0" id="Fact-A4D9251C39E25A3F9E1D9CFE2BFEF7F4" unitRef="cad">578703</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
	<ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="FD2017Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember" decimals="0" id="Fact-9E04B0DFABAC533A07739CFE2BE63008" unitRef="cad">348562</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
	<ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="FD2017Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_ResearchAndDevelopmentMember" decimals="0" id="Fact-C643F4EBAA0067DFDA569CFE2BEF624E" unitRef="cad">230141</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
	<ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="FD2018Q4YTD" decimals="0" id="Fact-3ECACE033E6F379B144E9CFE2BF163EF" unitRef="cad">1415833</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
	<ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="FD2018Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember" decimals="0" id="Fact-105D69E4CEE1AC4951369CFE2BE9E7B6" unitRef="cad">735292</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
	<ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="FD2018Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_ResearchAndDevelopmentMember" decimals="0" id="Fact-859766F82E07BBB062DF9CFE2BE855A4" unitRef="cad">680541</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
	<ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="FD2019Q4YTD" decimals="0" id="Fact-6BFD25F2F9A4AF5C95309CFE2BF30D2F" unitRef="cad">1470153</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
	<ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="FD2019Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember" decimals="0" id="Fact-4FE393AAD47F58F4A91B9CFE2BEE6C7D" unitRef="cad">908733</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
	<ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="FD2019Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_ResearchAndDevelopmentMember" decimals="0" id="Fact-920E0EA84D647E4D5C309CFE2BDB204F" unitRef="cad">561420</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
	<ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives contextRef="D2109Q4Aug17-Dec31_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember" decimals="0" id="Fact-DDAF50736270CA6DB3A69CFE2C2081B6" unitRef="cad">12608808</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
	<ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives contextRef="FD2017Q4YTD" decimals="0" id="Fact-9898BEE16754487C47699CFE2C09B700" unitRef="cad">0</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
	<ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives contextRef="FD2018Q4YTD" decimals="0" id="Fact-109F7FC9D535F49D31B79CFE2C083235" unitRef="cad">0</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
	<ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives contextRef="FD2019Q4YTD" decimals="0" id="Fact-490F9B9D483A1DDED5E79CFE2C03C6D2" unitRef="cad">-12608808</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
	<ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="FD2017Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_ResearchAndDevelopmentMember" decimals="0" id="Fact-974C89AD52CD8ADCF61B9CFE2BEEDB98" unitRef="cad">120794</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
	<ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="FD2018Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_ResearchAndDevelopmentMember" decimals="0" id="Fact-1D8537674BC0357DF90D9CFE2BF56990" unitRef="cad">1995</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
	<ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="FD2019Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_ResearchAndDevelopmentMember" decimals="0" id="Fact-76975AE9D3C0C46AF8F89CFE2BE5E611" unitRef="cad">39362</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
	<ifrs-full:GrossLeaseLiabilities contextRef="FI2018Q4" decimals="0" id="Fact-316D8BE908A91CA992319CFE2BF92FFE" unitRef="cad">961575</ifrs-full:GrossLeaseLiabilities>
	<ifrs-full:GrossLeaseLiabilities contextRef="FI2019Q4" decimals="0" id="Fact-066E842292C10AA1C5049CFE2BD7DFF5" unitRef="cad">565179</ifrs-full:GrossLeaseLiabilities>
	<ifrs-full:GrossLeaseLiabilities contextRef="FI2019Q4_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember" decimals="0" id="Fact-6504BA086C284837189A9CFE2BE00461" unitRef="cad">0</ifrs-full:GrossLeaseLiabilities>
	<ifrs-full:GrossLeaseLiabilities contextRef="FI2019Q4_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" decimals="0" id="Fact-A24C007863EDF62E94AE9CFE2BD21B55" unitRef="cad">174157</ifrs-full:GrossLeaseLiabilities>
	<ifrs-full:GrossLeaseLiabilities contextRef="FI2019Q4_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember" decimals="0" id="Fact-A1A320709B10A99D7FC29CFE2BCDF658" unitRef="cad">391022</ifrs-full:GrossLeaseLiabilities>
	<ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="FD2017Q4YTD" decimals="0" id="Fact-AA3C166C80368FB398809CFE2C0705C9" unitRef="cad">141498</ifrs-full:IncomeTaxExpenseContinuingOperations>
	<ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="FD2018Q4YTD" decimals="0" id="Fact-F36FDEF0F8B14A7BD0E09CFE2C05B121" unitRef="cad">548042</ifrs-full:IncomeTaxExpenseContinuingOperations>
	<ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="FD2019Q4YTD" decimals="0" id="Fact-BD22376DFD59A3F955B69CFE2C03D4F8" unitRef="cad">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
	<ifrs-full:IncomeTaxesPaidRefund contextRef="FD2017Q4YTD" decimals="0" id="Fact-4BF635A9F1F08F4D9C5D9CFE2C252F46" unitRef="cad">136163</ifrs-full:IncomeTaxesPaidRefund>
	<ifrs-full:IncomeTaxesPaidRefund contextRef="FD2018Q4YTD" decimals="0" id="Fact-505DEFB29D81ED2A0EA09CFE2C2289A2" unitRef="cad">15728</ifrs-full:IncomeTaxesPaidRefund>
	<ifrs-full:IncomeTaxesPaidRefund contextRef="FD2019Q4YTD" decimals="0" id="Fact-4558D35C8D0546C6849B9CFE2C22F019" unitRef="cad">5448</ifrs-full:IncomeTaxesPaidRefund>
	<ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="FD2017Q4YTD" decimals="0" id="Fact-43451DB741E4761A804B9CFE2C1B3B35" unitRef="cad">-95579</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
	<ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="FD2018Q4YTD" decimals="0" id="Fact-DFB628852F4D31CD1F289CFE2C3A01CF" unitRef="cad">1271432</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
	<ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="FD2019Q4YTD" decimals="0" id="Fact-54B8063304DB0527A8EF9CFE2C1CBDC5" unitRef="cad">1098567</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
	<ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="FD2017Q4YTD" decimals="0" id="Fact-5CC5D25FA2AE1753150E9CFE2C174836" unitRef="cad">-180855</ifrs-full:IncreaseDecreaseInWorkingCapital>
	<ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="FD2018Q4YTD" decimals="0" id="Fact-D56D7F04891594F3E5CB9CFE2C1A81BB" unitRef="cad">-3904339</ifrs-full:IncreaseDecreaseInWorkingCapital>
	<ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="FD2019Q4YTD" decimals="0" id="Fact-A96A370DBD6695F5C28C9CFE2C3ED784" unitRef="cad">1795777</ifrs-full:IncreaseDecreaseInWorkingCapital>
	<ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="FD2017Q4YTD" decimals="0" id="Fact-32638F0A19E8C35F73F19CFE2BFFCC9F" unitRef="cad">343440</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
	<ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-8DDC007411DD0804D4C89CFE2C04187E" unitRef="cad">536949</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
	<ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember" decimals="0" id="Fact-58AFAAEF34938C01A6A39CFE2BFFA25B" unitRef="cad">-193509</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
	<ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="FD2018Q4YTD" decimals="0" id="Fact-4E8EBB827EC62B9A2EAD9CFE2BFC6E1D" unitRef="cad">123538</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
	<ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="FD2018Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-D5F429C4C59790B10C759CFE2C017D42" unitRef="cad">197245</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
	<ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="FD2018Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember" decimals="0" id="Fact-975378D3027218F004509CFE2C02C5B8" unitRef="cad">-73707</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
	<ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="FD2018Q4YTD" decimals="0" id="Fact-AAEDA19F419855B32F9D9CFE2C0693E0" unitRef="cad">1417</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
	<ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="FD2018Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-628159DA3BB2FCD417069CFE2C0212AC" unitRef="cad">1747</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
	<ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="FD2018Q4YTD_ifrs-full_ComponentsOfEquityAxis_oncyf_WarrantsMember" decimals="0" id="Fact-70AFD0E830B15CBBC8069CFE2BFADA5B" unitRef="cad">-330</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
	<ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="FD2019Q4YTD" decimals="0" id="Fact-615A809DB381B9C5FE039CFE2BF9A702" unitRef="cad">9152869</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
	<ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="FD2019Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-C2C228EB816B3A1346429CFE2C0772AB" unitRef="cad">9152869</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
	<ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets contextRef="FD2017Q4YTD" decimals="0" id="Fact-F28E7860B5DCD69F0ABC9CFE2C0D9367" unitRef="cad">48558</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
	<ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets contextRef="FD2018Q4YTD" decimals="0" id="Fact-BF5B18367A54B860DC259CFE2C16E4B6" unitRef="cad">14531</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
	<ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets contextRef="FD2019Q4YTD" decimals="0" id="Fact-D4AAAAD85B3501AB87879CFE2C137976" unitRef="cad">78708</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
	<ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="FD2017Q4YTD" decimals="0" id="Fact-454E3AA07A51CF1A5A2B9CFE2BFF08FF" unitRef="cad">578703</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
	<ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember" decimals="0" id="Fact-46BB7C6CBC440C5319029CFE2C08A51C" unitRef="cad">578703</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
	<ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="FD2018Q4YTD" decimals="0" id="Fact-C700276D47949E0687DC9CFE2BFB1B1B" unitRef="cad">1415833</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
	<ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="FD2018Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember" decimals="0" id="Fact-F4F4E0B27642F732EB219CFE2BFCF914" unitRef="cad">1415833</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
	<ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="FD2019Q4YTD" decimals="0" id="Fact-BB2D7E15EB49127FE6359CFE2BFE6D33" unitRef="cad">1470153</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
	<ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="FD2019Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember" decimals="0" id="Fact-551B0F58775A53EA3AAC9CFE2BEE8E4C" unitRef="cad">1470153</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
	<ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="FD2017Q4YTD" decimals="0" id="Fact-40F16B198841DF3324999CFE2C3DDD9C" unitRef="cad">0</ifrs-full:InterestExpenseOnLeaseLiabilities>
	<ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="FD2018Q4YTD" decimals="0" id="Fact-F2A3C527225B7956DCAE9CFE2C1829C2" unitRef="cad">0</ifrs-full:InterestExpenseOnLeaseLiabilities>
	<ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="FD2019Q4YTD" decimals="0" id="Fact-9CE3DD316C60689FB7C29CFE2C1E9AE0" unitRef="cad">94817</ifrs-full:InterestExpenseOnLeaseLiabilities>
	<ifrs-full:InterestIncomeOnCashAndCashEquivalents contextRef="FD2017Q4YTD" decimals="0" id="Fact-309464139E22F3421A099CFE2C07C6DA" unitRef="cad">130101</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
	<ifrs-full:InterestIncomeOnCashAndCashEquivalents contextRef="FD2018Q4YTD" decimals="0" id="Fact-0F633EA6C8EC0684EB2F9CFE2C050480" unitRef="cad">173496</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
	<ifrs-full:InterestIncomeOnCashAndCashEquivalents contextRef="FD2019Q4YTD" decimals="0" id="Fact-23A08043C2AD978C39A29CFE2C0BE0EE" unitRef="cad">179277</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
	<ifrs-full:IssueOfEquity contextRef="D2018Q2Jan1-May21_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="0" id="Fact-2C52CBF0773456ECBDAC9CFE2BFDB831" unitRef="cad">553650</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="D2018Q2Jan1-May21_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderStockOptionPlanMember" decimals="0" id="Fact-95C70364B4BB64B3A1029CFE2BFE303B" unitRef="cad">38269</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="D2018Q4May22-Dec31_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-994519E691022BAA48179CFE2C0B0690" unitRef="cad">11606882</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="D2018Q4May22-Dec31_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="0" id="Fact-B322EC591694DA8122BD9CFE2BFAD63D" unitRef="cad">66360</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="D2018Q4May22-Dec31_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderCommonStockPurchaseAgreementMember" decimals="0" id="Fact-CDAC96F6E5849250C8749CFE2BF641C1" unitRef="cad">3314097</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="D2018Q4May22-Dec31_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderIncentiveAwardPlanMember" decimals="0" id="Fact-59BB7B9629929E01979D9CFE2BF7B614" unitRef="cad">109751</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="D2018Q4May22-Dec31_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderStockOptionPlanMember" decimals="0" id="Fact-18D3050651F81C2FA5319CFE2C0C34EB" unitRef="cad">158976</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="D2018Q4May22-Dec31_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember" decimals="0" id="Fact-64D7A75C04547BA81E619CFE2BF284F3" unitRef="cad">1747</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="D2018Q4May22-Dec31_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember" decimals="0" id="Fact-D04F6EF68D143772F45E9CFE2BE7F3E4" unitRef="cad">-330</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-6A90286F35EAAE2369389CFE2C0DA049" unitRef="cad">7893600</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderStockOptionPlanMember" decimals="0" id="Fact-0590551004B27BA37E7D9CFE2BF5DF19" unitRef="cad">536949</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-9CB087343F1317DE19149CFE2C0F0926" unitRef="cad">3617900</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-6DF2AAEE384DC4ACF35D9CFE2BEFDC15" unitRef="cad">7893600</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="0" id="Fact-980566C9A730B01A0BA89CFE2C05FB6E" unitRef="cad">2348821</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_oncyf_WarrantsMember" decimals="0" id="Fact-7B345B422279B63D70559CFE2C00E8BC" unitRef="cad">3617900</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2017Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-C5BCC51E8F5509E739529CFE2C04F1A0" unitRef="cad">11511500</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2017Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="0" id="Fact-ED1CDFE9F048BF86B0319CFE2BFD2052" unitRef="cad">2348821</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2018Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-D5E111341CB8FC4D68029CFE2BF1CA87" unitRef="cad">11606882</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2018Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="0" id="Fact-0A32178C67DEC1FD72739CFE2BF4AE1D" unitRef="cad">620010</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2018Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember" decimals="0" id="Fact-05526A4370A14B5BC5B39CFE2C012523" unitRef="cad">3314097</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2018Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-7D4BB8EE1C50D754A7599CFE2BF7E337" unitRef="cad">11606882</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2018Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="0" id="Fact-FEC71473100DADA655E29CFE2BFC17BD" unitRef="cad">620010</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2018Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember" decimals="0" id="Fact-E0B125037A68FD1A3FFD9CFE2BF9E94B" unitRef="cad">3314097</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2019Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-65D2A68C9C852B30A4769CFE2C0A1068" unitRef="cad">3314429</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2019Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="0" id="Fact-647CA50458EAC3C575C89CFE2BF5DCFF" unitRef="cad">8476454</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2019Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderCommonStockPurchaseAgreementMember" decimals="0" id="Fact-46756919D95F03984A499CFE2BED95E1" unitRef="cad">5403385</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2019Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderIncentiveAwardPlanMember" decimals="0" id="Fact-76A6224E18AFAE0947DA9CFE2BFB2EA1" unitRef="cad">391917</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2019Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember" decimals="0" id="Fact-6241A217B54A17054E469CFE2BF8C745" unitRef="cad">9152869</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2019Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-F86B6342241C86CBAD4C9CFE2BF30F74" unitRef="cad">3314429</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2019Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="0" id="Fact-E622CD34E0595A3D47019CFE2C014EF1" unitRef="cad">8476454</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2019Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember" decimals="0" id="Fact-5CFF745A9D71601DBE419CFE2C063EA3" unitRef="cad">5403385</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2019Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-DB58C4CE20750DAC42589CFE2C03FF3F" unitRef="cad">3314429</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2019Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="0" id="Fact-D0C6037710D50EB928079CFE2C0030A8" unitRef="cad">8476454</ifrs-full:IssueOfEquity>
	<ifrs-full:IssueOfEquity contextRef="FD2019Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderSharePurchaseAgreementMember" decimals="0" id="Fact-874064E1B4CDE7CA79989CFE2BF0B345" unitRef="cad">5403385</ifrs-full:IssueOfEquity>
	<ifrs-full:IssuedCapital contextRef="FI2018Q4" decimals="0" id="Fact-BBB883B85DB5EC17288D9CFE2BD98A10" unitRef="cad">285193061</ifrs-full:IssuedCapital>
	<ifrs-full:IssuedCapital contextRef="FI2019Q4" decimals="0" id="Fact-9C789E51243732F403459CFE2BDE28D2" unitRef="cad">311077859</ifrs-full:IssuedCapital>
	<ifrs-full:KeyManagementPersonnelCompensation contextRef="FD2017Q4YTD" decimals="0" id="Fact-2E8A8FAB819F86F6F90F9CFE2C3785A4" unitRef="cad">3835046</ifrs-full:KeyManagementPersonnelCompensation>
	<ifrs-full:KeyManagementPersonnelCompensation contextRef="FD2018Q4YTD" decimals="0" id="Fact-0009926BC7FA20CEF7729CFE2C32B690" unitRef="cad">3747816</ifrs-full:KeyManagementPersonnelCompensation>
	<ifrs-full:KeyManagementPersonnelCompensation contextRef="FD2019Q4YTD" decimals="0" id="Fact-EEE1284369214AD4436F9CFE2BCC9654" unitRef="cad">4910075</ifrs-full:KeyManagementPersonnelCompensation>
	<ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="FD2017Q4YTD" decimals="0" id="Fact-69E32D6E52A2EBE41E599CFE2C18373E" unitRef="cad">459298</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
	<ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="FD2018Q4YTD" decimals="0" id="Fact-750EA05C19935DE8157F9CFE2C1C0002" unitRef="cad">1067195</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
	<ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="FD2019Q4YTD" decimals="0" id="Fact-ECB9E01D862DD5D62F1D9CFE2C17E49A" unitRef="cad">1123408</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
	<ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="FD2017Q4YTD" decimals="0" id="Fact-17360E22A7A5C3876A2A9CFE2C2F45A4" unitRef="cad">2596082</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
	<ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="FD2018Q4YTD" decimals="0" id="Fact-9D331BDC4F514DCEFBBB9CFE2BCD55EC" unitRef="cad">2680621</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
	<ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="FD2019Q4YTD" decimals="0" id="Fact-66FC4E28BF0FFFE7091B9CFE2BF37EC0" unitRef="cad">3786667</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
	<ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="FD2017Q4YTD" decimals="0" id="Fact-F020B7BC663697746FDA9CFE2C3BAC52" unitRef="cad">779666</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
	<ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="FD2018Q4YTD" decimals="0" id="Fact-4BFC6A1EE645AEA536589CFE2C3B273A" unitRef="cad">0</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
	<ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="FD2019Q4YTD" decimals="0" id="Fact-08D08A842D194B3F159B9CFE2C202E86" unitRef="cad">0</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
	<ifrs-full:LeaseLiabilities contextRef="FI2019Q4" decimals="0" id="Fact-993D0A1F2DF3ADC9A3799CFE2C18923E" unitRef="cad">506275</ifrs-full:LeaseLiabilities>
	<ifrs-full:LeaseLiabilities contextRef="I2019Q1Jan1" decimals="0" id="Fact-1D1D94D2F6B622948B619CFE2C0838CA" unitRef="cad">882437</ifrs-full:LeaseLiabilities>
	<ifrs-full:LeaseLiabilities contextRef="I2019Q1Jan1_ifrs-full_InitiallyAppliedIFRSsAxis_oncyf_EffectsofIFRS16TransitionMember" decimals="0" id="Fact-0EDEBAC3BA6C346C67DC9CFE2C0B0A49" unitRef="cad">882437</ifrs-full:LeaseLiabilities>
	<ifrs-full:Liabilities contextRef="FI2018Q4" decimals="0" id="Fact-95A03D533B711C649FB29CFE2BD48367" unitRef="cad">8669890</ifrs-full:Liabilities>
	<ifrs-full:Liabilities contextRef="FI2019Q4" decimals="0" id="Fact-79EE9D173F30590CB10E9CFE2BDB3440" unitRef="cad">19765759</ifrs-full:Liabilities>
	<ifrs-full:Liabilities contextRef="I2019Q1Jan1" decimals="0" id="Fact-DFF2A7160EE6B9D8314E9CFE2BFC0390" unitRef="cad">9477915</ifrs-full:Liabilities>
	<ifrs-full:Liabilities contextRef="I2019Q1Jan1_ifrs-full_InitiallyAppliedIFRSsAxis_oncyf_EffectsofIFRS16TransitionMember" decimals="0" id="Fact-3CA587D3821C542CCEC39CFE2BFCE99B" unitRef="cad">808025</ifrs-full:Liabilities>
	<ifrs-full:NoncurrentAssets contextRef="FI2018Q4" decimals="0" id="Fact-825B1BF234BF6789DF7B9CFE2BD59AB2" unitRef="cad">412736</ifrs-full:NoncurrentAssets>
	<ifrs-full:NoncurrentAssets contextRef="FI2019Q4" decimals="0" id="Fact-4F86A64431834CE3EDFB9CFE2BDAF552" unitRef="cad">727481</ifrs-full:NoncurrentAssets>
	<ifrs-full:NoncurrentContractLiabilities contextRef="FI2018Q4" decimals="0" id="Fact-386E76A01DB59F0D17699CFE2BD26478" unitRef="cad">5802887</ifrs-full:NoncurrentContractLiabilities>
	<ifrs-full:NoncurrentContractLiabilities contextRef="FI2019Q4" decimals="0" id="Fact-48D5FFE766101792CFAE9CFE2BD4D0FC" unitRef="cad">6730287</ifrs-full:NoncurrentContractLiabilities>
	<ifrs-full:NoncurrentLeaseLiabilities contextRef="FI2019Q4" decimals="0" id="Fact-FE52D5CDA9556BA054C19CFE2BDAA844" unitRef="cad">166429</ifrs-full:NoncurrentLeaseLiabilities>
	<ifrs-full:NoncurrentLiabilities contextRef="FI2018Q4" decimals="0" id="Fact-51F2FC75B15503FD55979CFE2BDD7857" unitRef="cad">5855315</ifrs-full:NoncurrentLiabilities>
	<ifrs-full:NoncurrentLiabilities contextRef="FI2019Q4" decimals="0" id="Fact-9EF89E9FD29626E9A59E9CFE2BD49A95" unitRef="cad">6896716</ifrs-full:NoncurrentLiabilities>
	<ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="FD2017Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-DEB005D0A6107ABEA59D9CFE2C20A9A2" unitRef="shares">6315</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
	<ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="FD2017Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-2445491F9D8B0F7AD4199CFE2BE7FD2E" unitRef="shares">51170</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
	<ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="FD2018Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-5B1C8B8EE7CC35FC41729CFE2C24D2D2" unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
	<ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="FD2018Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-E7C0C89D18413430D2059CFE2C21187E" unitRef="shares">102855</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
	<ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="FD2019Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-A50164D98EBB589086989CFE2C28DDCD" unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
	<ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="FD2019Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-84BB4FCB78E8679ED5599CFE2C1F4BF7" unitRef="shares">270098</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
	<ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="FD2017Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-A10566B23C5736437E229CFE2C233915" unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="FD2017Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-65E938C0BDEE639B4CD49CFE2C26D9F6" unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="FD2018Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-EE38C4C428C7FC9166249CFE2C1E55C2" unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="FD2018Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-57C47BC9F46A320323429CFE2BE9CCC9" unitRef="shares">28297</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="FD2019Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-27C87558BD8E89AE052F9CFE2C2177B9" unitRef="shares">2105</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="FD2019Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-B0CAE5545AD463B9B6579CFE2C2869A1" unitRef="shares">321196</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="FD2017Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-75D2F0D694B897694FDD9CFE2C22825C" unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="FD2017Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-F3CD04B8569C997C4A529CFE2C2134BA" unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="FD2018Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-8BEF8E52BD7BEB0361C89CFE2C2667BF" unitRef="shares">31578</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="FD2018Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-D7A2EC769F7826A57B309CFE2C2BFEAE" unitRef="shares">4210</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="FD2019Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-CA2E7EDBCF38928208109CFE2C1EBE7A" unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="FD2019Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-8E28AC403F18B04C70C69CFE2C24700C" unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="FI2016Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-B90B437222C8C549DF679CFE2C1E7C4F" unitRef="shares">88419</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="FI2016Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-89DC9DCA32EB2394E08E9CFE2C240DE6" unitRef="shares">139237</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="FI2017Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-289B9AA6E1F5F580239D9CFE2C2CF4BB" unitRef="shares">94734</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="FI2017Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-A82182DFAA188AC71A109CFE2C226608" unitRef="shares">190407</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="FI2018Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-3A29370775323C21BAEA9CFE2C1C15AD" unitRef="shares">63156</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="FI2018Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-471DB57110C0118C2B149CFE2BEBD6E0" unitRef="shares">260755</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="FI2019Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-D7F0C11DA062F631BCEB9CFE2C229A7E" unitRef="shares">61051</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="FI2019Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-01EA0514E7E21CB725DB9CFE2BEC9F68" unitRef="shares">209657</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfOutstandingShareOptions contextRef="FI2016Q4" decimals="INF" id="Fact-234FDA531CDEDC24CECC9CFE2BE28DDD" unitRef="shares">912995</ifrs-full:NumberOfOutstandingShareOptions>
	<ifrs-full:NumberOfOutstandingShareOptions contextRef="FI2017Q4" decimals="INF" id="Fact-FF4BDA16D748C7D1D0039CFE2BE5823C" unitRef="shares">647156</ifrs-full:NumberOfOutstandingShareOptions>
	<ifrs-full:NumberOfOutstandingShareOptions contextRef="FI2018Q4" decimals="INF" id="Fact-1DF9F4FDF28CDE1D5F629CFE2BEDC85D" unitRef="shares">1249361</ifrs-full:NumberOfOutstandingShareOptions>
	<ifrs-full:NumberOfOutstandingShareOptions contextRef="FI2019Q4" decimals="INF" id="Fact-75BD1B98B90F3A2E2D4E9CFE2BE42537" unitRef="shares">2246947</ifrs-full:NumberOfOutstandingShareOptions>
	<ifrs-full:NumberOfOutstandingShareOptions contextRef="FI2019Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFiveMember" decimals="INF" id="Fact-8C6C4A5C20F435ADA8779CFE2BCD8D71" unitRef="shares">475425</ifrs-full:NumberOfOutstandingShareOptions>
	<ifrs-full:NumberOfOutstandingShareOptions contextRef="FI2019Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFourMember" decimals="INF" id="Fact-179A3389A48F7169F6109CFE2BCF1C44" unitRef="shares">395111</ifrs-full:NumberOfOutstandingShareOptions>
	<ifrs-full:NumberOfOutstandingShareOptions contextRef="FI2019Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeOneMember" decimals="INF" id="Fact-894C4186EAEAE260C94C9CFE2C0AC18C" unitRef="shares">100000</ifrs-full:NumberOfOutstandingShareOptions>
	<ifrs-full:NumberOfOutstandingShareOptions contextRef="FI2019Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeThreeMember" decimals="INF" id="Fact-D22C986CEF2A3580FA339CFE2BE55461" unitRef="shares">376411</ifrs-full:NumberOfOutstandingShareOptions>
	<ifrs-full:NumberOfOutstandingShareOptions contextRef="FI2019Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeTwoMember" decimals="INF" id="Fact-503CFCCD72DF19C361719CFE2BDC271B" unitRef="shares">900000</ifrs-full:NumberOfOutstandingShareOptions>
	<ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="FI2017Q4" decimals="INF" id="Fact-7CE77020E07E54D1802C9CFE2BE816EB" unitRef="shares">573984</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="FI2018Q4" decimals="INF" id="Fact-6539312182D4E86C5CB89CFE2BF2691C" unitRef="shares">777245</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="FI2019Q4" decimals="INF" id="Fact-44727DDC97DADE8034FB9CFE2BE21D8A" unitRef="shares">1327845</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="FI2019Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFiveMember" decimals="INF" id="Fact-4E0637ECDBCF94D475CF9CFE2BD14B79" unitRef="shares">353877</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="FI2019Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFourMember" decimals="INF" id="Fact-A6C83841BC41830C8A789CFE2C2A9DB8" unitRef="shares">322880</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="FI2019Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeOneMember" decimals="INF" id="Fact-5CEE021847D5431C25AE9CFE2BEC042E" unitRef="shares">66667</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="FI2019Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeThreeMember" decimals="INF" id="Fact-CCD75E9C708E3A0229249CFE2C2A000D" unitRef="shares">284412</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="FI2019Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeTwoMember" decimals="INF" id="Fact-A9983B2EDB46C4F85CF99CFE2C372DD2" unitRef="shares">300009</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="FD2017Q4YTD" decimals="INF" id="Fact-2942018C3F3564BD957D9CFE2BF72F99" unitRef="shares">84315</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="FD2018Q4YTD" decimals="INF" id="Fact-723F5591569C1165D35B9CFE2BDDF0B4" unitRef="shares">41802</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="FD2019Q4YTD" decimals="INF" id="Fact-2B2430900C9D9433C5289CFE2BF13FEB" unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="FD2017Q4YTD" decimals="INF" id="Fact-C8FE93CE1786EA9C7BDB9CFE2BEA67CA" unitRef="shares">12302</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="FD2018Q4YTD" decimals="INF" id="Fact-24B73D0B70BA0B0223269CFE2BECF9E0" unitRef="shares">1122</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="FD2019Q4YTD" decimals="INF" id="Fact-0E2236877490CB9F44769CFE2BE59D51" unitRef="shares">9575</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="FD2017Q4YTD" decimals="INF" id="Fact-28BA0F488727B74A7CDC9CFE2BF6D25A" unitRef="shares">211847</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="FD2018Q4YTD" decimals="INF" id="Fact-FA2D1F1C61774FBF22259CFE2BE9ADBD" unitRef="shares">105338</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="FD2019Q4YTD" decimals="INF" id="Fact-D481B4B617DE8AE140F19CFE2BF447F7" unitRef="shares">12839</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="FD2017Q4YTD" decimals="INF" id="Fact-0459BCB925DF25C9EC999CFE2BE3FCFE" unitRef="shares">42625</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="FD2018Q4YTD" decimals="INF" id="Fact-402166D9943D6F92E1E49CFE2BED3FB5" unitRef="shares">750467</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="FD2019Q4YTD" decimals="INF" id="Fact-F6202D059D3476A1DCA29CFE2BECF0F1" unitRef="shares">1020000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
	<ifrs-full:NumberOfSharesIssued contextRef="FI2016Q4_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember" decimals="INF" id="Fact-E0A1E661E9B8602600339CFE2BEAFA06" unitRef="shares">121258222</ifrs-full:NumberOfSharesIssued>
	<ifrs-full:NumberOfSharesIssued contextRef="FI2016Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember" decimals="INF" id="Fact-9D5A46C1618AB48D0FBD9CFE2BF03D21" unitRef="shares">0</ifrs-full:NumberOfSharesIssued>
	<ifrs-full:NumberOfSharesIssued contextRef="FI2017Q4_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember" decimals="INF" id="Fact-7CD17ECACF147EB36A369CFE2C0C815F" unitRef="shares">141805722</ifrs-full:NumberOfSharesIssued>
	<ifrs-full:NumberOfSharesIssued contextRef="FI2017Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember" decimals="INF" id="Fact-87F8E566DBA58EC3C6889CFE2BFCB270" unitRef="shares">16445000</ifrs-full:NumberOfSharesIssued>
	<ifrs-full:NumberOfSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-4AF9140A2DC1C77023C39CFE2BD4281F" unitRef="shares">17399749</ifrs-full:NumberOfSharesIssued>
	<ifrs-full:NumberOfSharesIssued contextRef="FI2018Q4_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="INF" id="Fact-9DEA14871FFC4B6D78129CFE2BF411AF" unitRef="shares">17399749</ifrs-full:NumberOfSharesIssued>
	<ifrs-full:NumberOfSharesIssued contextRef="FI2018Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember" decimals="INF" id="Fact-433A0AF6B62DAEE01DFD9CFE2C34F17F" unitRef="shares">16443500</ifrs-full:NumberOfSharesIssued>
	<ifrs-full:NumberOfSharesIssued contextRef="FI2019Q4" decimals="INF" id="Fact-1D19BE7F96FF9596B9CB9CFE2BD5B1CB" unitRef="shares">32198453</ifrs-full:NumberOfSharesIssued>
	<ifrs-full:NumberOfSharesIssued contextRef="FI2019Q4_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="INF" id="Fact-EFE3D2AFE2BE7B2E1BB09CFE2BF4FA8A" unitRef="shares">32198453</ifrs-full:NumberOfSharesIssued>
	<ifrs-full:NumberOfSharesIssued contextRef="FI2019Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember" decimals="INF" id="Fact-3A27DBB9D0A1231C2CC89CFE2C36334A" unitRef="shares">16443500</ifrs-full:NumberOfSharesIssued>
	<ifrs-full:NumberOfSharesIssued contextRef="I2018Q2May21_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember" decimals="INF" id="Fact-1DAB9C8A175324BB0BF59CFE2BF34ACC" unitRef="shares">142396222</ifrs-full:NumberOfSharesIssued>
	<ifrs-full:NumberOfSharesIssued contextRef="I2018Q2May21_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember" decimals="INF" id="Fact-621074DE0B4F81F9067E9CFE2BE91A6A" unitRef="shares">16445000</ifrs-full:NumberOfSharesIssued>
	<ifrs-full:NumberOfSharesIssued contextRef="I2018Q2May22_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="INF" id="Fact-BCBC11FA844DFA9708709CFE2C0BF07C" unitRef="shares">14988995</ifrs-full:NumberOfSharesIssued>
	<ifrs-full:NumberOfSharesIssued contextRef="I2018Q2May22_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember" decimals="INF" id="Fact-870CD714496128101AFD9CFE2C0C4087" unitRef="shares">16445000</ifrs-full:NumberOfSharesIssued>
	<ifrs-full:OperatingExpense contextRef="FD2017Q4YTD" decimals="0" id="Fact-A1BFE1E2E956184B28429CFE2C0BD038" unitRef="cad">6212831</ifrs-full:OperatingExpense>
	<ifrs-full:OperatingExpense contextRef="FD2018Q4YTD" decimals="0" id="Fact-E6BB3CF686C86E4D7B239CFE2C07B82B" unitRef="cad">7244791</ifrs-full:OperatingExpense>
	<ifrs-full:OperatingExpense contextRef="FD2019Q4YTD" decimals="0" id="Fact-5DDDD4FDC8A78E1F4D739CFE2C0A085F" unitRef="cad">9558641</ifrs-full:OperatingExpense>
	<ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="FD2017Q4YTD" decimals="0" id="Fact-60AB16719D49839FDDF09CFE2C07E633" unitRef="cad">-180330</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
	<ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="FD2018Q4YTD" decimals="0" id="Fact-AB9DC94EDF6371390A079CFE2C0751ED" unitRef="cad">233774</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
	<ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="FD2019Q4YTD" decimals="0" id="Fact-73E84FAD7EA89F82E43C9CFE2C09B014" unitRef="cad">-143403</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
	<ifrs-full:OtherCurrentLiabilities contextRef="FI2018Q4" decimals="0" id="Fact-275EB7900DCEDEFAAF4F9CFE2BDCE9A7" unitRef="cad">61322</ifrs-full:OtherCurrentLiabilities>
	<ifrs-full:OtherCurrentLiabilities contextRef="FI2018Q4_ifrs-full_ClassesOfProvisionsAxis_oncyf_CollaborationAgreementMember" decimals="INF" id="Fact-8032E9870F1B0409E54F9CFE2BEAC058" unitRef="usd">0</ifrs-full:OtherCurrentLiabilities>
	<ifrs-full:OtherCurrentLiabilities contextRef="FI2019Q4" decimals="0" id="Fact-89B8EDDE730D6E07DABF9CFE2BE08AAB" unitRef="cad">847215</ifrs-full:OtherCurrentLiabilities>
	<ifrs-full:OtherCurrentLiabilities contextRef="FI2019Q4_ifrs-full_ClassesOfProvisionsAxis_oncyf_CollaborationAgreementMember" decimals="0" id="Fact-6EA855EEE32139F9992A9CFE2BDCEE51" unitRef="cad">652306</ifrs-full:OtherCurrentLiabilities>
	<ifrs-full:OtherCurrentReceivables contextRef="FI2018Q4" decimals="0" id="Fact-F20E03662144829595D99CFE2BE26206" unitRef="cad">51650</ifrs-full:OtherCurrentReceivables>
	<ifrs-full:OtherCurrentReceivables contextRef="FI2019Q4" decimals="0" id="Fact-8941B2EB99731420209B9CFE2BE16628" unitRef="cad">2068772</ifrs-full:OtherCurrentReceivables>
	<ifrs-full:OtherCurrentReceivables contextRef="FI2019Q4_oncyf_Currency1Axis_currency_EUR" decimals="0" id="Fact-F71593677F5ED1BA03479CFE2BD13B90" unitRef="eur">0</ifrs-full:OtherCurrentReceivables>
	<ifrs-full:OtherCurrentReceivables contextRef="FI2019Q4_oncyf_Currency1Axis_currency_GBP" decimals="0" id="Fact-172B9E465016637D222B9CFE2BD08E4A" unitRef="gbp">0</ifrs-full:OtherCurrentReceivables>
	<ifrs-full:OtherCurrentReceivables contextRef="FI2019Q4_oncyf_Currency1Axis_currency_USD" decimals="0" id="Fact-6DBAEB7972ADDD2DC8B09CFE2BCE568A" unitRef="usd">1500000</ifrs-full:OtherCurrentReceivables>
	<ifrs-full:OtherLiabilities contextRef="FI2018Q4" decimals="0" id="Fact-E712C4985605754BFC749CFE2BF47B37" unitRef="cad">113750</ifrs-full:OtherLiabilities>
	<ifrs-full:OtherLiabilities contextRef="I2019Q1Jan1" decimals="0" id="Fact-58EA0AFD4E6E6596E10B9CFE2C01DE66" unitRef="cad">39338</ifrs-full:OtherLiabilities>
	<ifrs-full:OtherLiabilities contextRef="I2019Q1Jan1_ifrs-full_InitiallyAppliedIFRSsAxis_oncyf_EffectsofIFRS16TransitionMember" decimals="0" id="Fact-2D8EDF436316D81636709CFE2C1445F3" unitRef="cad">-74412</ifrs-full:OtherLiabilities>
	<ifrs-full:OtherNoncurrentLiabilities contextRef="FI2018Q4" decimals="0" id="Fact-2A039B685E185B2C3A459CFE2BE195CA" unitRef="cad">52428</ifrs-full:OtherNoncurrentLiabilities>
	<ifrs-full:OtherNoncurrentLiabilities contextRef="FI2019Q4" decimals="0" id="Fact-4DB04EF1B7DC437C0C7C9CFE2BD682B2" unitRef="cad">0</ifrs-full:OtherNoncurrentLiabilities>
	<ifrs-full:OtherReceivables contextRef="FI2018Q4_ifrs-full_ClassesOfProvisionsAxis_oncyf_CollaborationAgreementMember" decimals="INF" id="Fact-968418FF76E5835414D09CFE2BED9F59" unitRef="usd">0</ifrs-full:OtherReceivables>
	<ifrs-full:OtherReceivables contextRef="FI2019Q4_ifrs-full_ClassesOfProvisionsAxis_oncyf_CollaborationAgreementMember" decimals="0" id="Fact-9B7CBA8CDBC0854E0ED19CFE2BEAD0FD" unitRef="usd">1500000</ifrs-full:OtherReceivables>
	<ifrs-full:ProceedsFromExerciseOfOptions contextRef="FD2017Q4YTD" decimals="0" id="Fact-D3309C3C901CA216EFD89CFE2C1B7214" unitRef="cad">343440</ifrs-full:ProceedsFromExerciseOfOptions>
	<ifrs-full:ProceedsFromExerciseOfOptions contextRef="FD2018Q4YTD" decimals="0" id="Fact-5F694F72C51C196A35D29CFE2C150525" unitRef="cad">123538</ifrs-full:ProceedsFromExerciseOfOptions>
	<ifrs-full:ProceedsFromExerciseOfOptions contextRef="FD2019Q4YTD" decimals="0" id="Fact-18154027303D6A84809E9CFE2C3EA2C0" unitRef="cad">0</ifrs-full:ProceedsFromExerciseOfOptions>
	<ifrs-full:ProceedsFromIssuingShares contextRef="FD2017Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-C54737902E7FDFB26A709CFE2C15A9D2" unitRef="cad">10366098</ifrs-full:ProceedsFromIssuingShares>
	<ifrs-full:ProceedsFromIssuingShares contextRef="FD2017Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="0" id="Fact-8403228D906D5761552A9CFE2C3EE252" unitRef="cad">2103166</ifrs-full:ProceedsFromIssuingShares>
	<ifrs-full:ProceedsFromIssuingShares contextRef="FD2017Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderCommonStockPurchaseAgreementMember" decimals="0" id="Fact-FAAC07DFD475A252947F9CFE2C3D5C41" unitRef="cad">0</ifrs-full:ProceedsFromIssuingShares>
	<ifrs-full:ProceedsFromIssuingShares contextRef="FD2017Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember" decimals="0" id="Fact-227D38D1267108A1055F9CFE2C1BAC2B" unitRef="cad">0</ifrs-full:ProceedsFromIssuingShares>
	<ifrs-full:ProceedsFromIssuingShares contextRef="FD2018Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-DF106ABBCD5F8579F9369CFE2C19E40D" unitRef="cad">10188526</ifrs-full:ProceedsFromIssuingShares>
	<ifrs-full:ProceedsFromIssuingShares contextRef="FD2018Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="0" id="Fact-EA652C998DEC38BD40DC9CFE2C1D4774" unitRef="cad">451675</ifrs-full:ProceedsFromIssuingShares>
	<ifrs-full:ProceedsFromIssuingShares contextRef="FD2018Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderCommonStockPurchaseAgreementMember" decimals="0" id="Fact-D0146C6641F094D00ACC9CFE2C0E11CE" unitRef="cad">2533980</ifrs-full:ProceedsFromIssuingShares>
	<ifrs-full:ProceedsFromIssuingShares contextRef="FD2018Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember" decimals="0" id="Fact-1C65D23F7E47E9B5DD249CFE2C3E9619" unitRef="cad">1417</ifrs-full:ProceedsFromIssuingShares>
	<ifrs-full:ProceedsFromIssuingShares contextRef="FD2019Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-846F812FF4DB722BF2599CFE2C19A8B0" unitRef="cad">4505359</ifrs-full:ProceedsFromIssuingShares>
	<ifrs-full:ProceedsFromIssuingShares contextRef="FD2019Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="0" id="Fact-4F4E115323DCEBAE24779CFE2C1938DA" unitRef="cad">8131620</ifrs-full:ProceedsFromIssuingShares>
	<ifrs-full:ProceedsFromIssuingShares contextRef="FD2019Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderCommonStockPurchaseAgreementMember" decimals="0" id="Fact-32E5332FEEA13DD062D79CFE2C1B61B6" unitRef="cad">5360247</ifrs-full:ProceedsFromIssuingShares>
	<ifrs-full:ProceedsFromIssuingShares contextRef="FD2019Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember" decimals="0" id="Fact-1F7FB2AC9F510EB912229CFE2C3BE221" unitRef="cad">3465867</ifrs-full:ProceedsFromIssuingShares>
	<ifrs-full:ProfitLoss contextRef="FD2017Q4YTD" decimals="0" id="Fact-B9C89F820AB9C4043FB79CFE2C027D4F" unitRef="cad">-15616851</ifrs-full:ProfitLoss>
	<ifrs-full:ProfitLoss contextRef="FD2018Q4YTD" decimals="0" id="Fact-A75EA7B2FDB01416F0E49CFE2C0916ED" unitRef="cad">-17037225</ifrs-full:ProfitLoss>
	<ifrs-full:ProfitLoss contextRef="FD2019Q4YTD" decimals="0" id="Fact-04195BE6B4BF2EC083E09CFE2C0638CF" unitRef="cad">-33122888</ifrs-full:ProfitLoss>
	<ifrs-full:ProfitLossBeforeTax contextRef="FD2017Q4YTD" decimals="0" id="Fact-16BF848D489CF54C9A469CFE2C0B9DEB" unitRef="cad">-15475353</ifrs-full:ProfitLossBeforeTax>
	<ifrs-full:ProfitLossBeforeTax contextRef="FD2018Q4YTD" decimals="0" id="Fact-A4F6A4270721CE33D8619CFE2C0A9D4C" unitRef="cad">-16489183</ifrs-full:ProfitLossBeforeTax>
	<ifrs-full:ProfitLossBeforeTax contextRef="FD2019Q4YTD" decimals="0" id="Fact-07A97D1245189545C70D9CFE2C083603" unitRef="cad">-33122888</ifrs-full:ProfitLossBeforeTax>
	<ifrs-full:ProfitLossFromOperatingActivities contextRef="FD2017Q4YTD" decimals="0" id="Fact-3EE62E7AE368F5B97D649CFE2C094D28" unitRef="cad">-15605454</ifrs-full:ProfitLossFromOperatingActivities>
	<ifrs-full:ProfitLossFromOperatingActivities contextRef="FD2018Q4YTD" decimals="0" id="Fact-8240944580417C7C5C8A9CFE2C0BCCD0" unitRef="cad">-16662679</ifrs-full:ProfitLossFromOperatingActivities>
	<ifrs-full:ProfitLossFromOperatingActivities contextRef="FD2019Q4YTD" decimals="0" id="Fact-2CACCBE59F856D88B60E9CFE2C042A89" unitRef="cad">-20693357</ifrs-full:ProfitLossFromOperatingActivities>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember" decimals="0" id="Fact-04EDB528C6CA9B3B12709CFE2BD34136" unitRef="cad">1396076</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-FF631CECD62205E309BC9CFE2C367476" unitRef="cad">549564</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-DCEE8AC8C5B20BA1A7049CFE2C33C69C" unitRef="cad">147334</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-4BE34A04F884A66C58A19CFE2C3E45FF" unitRef="cad">476057</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-14BE2D310090EB1C90009CFE2C37BCBF" unitRef="cad">68787</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-BFF91C3D0985F5BC17379CFE2C2F26B3" unitRef="cad">154334</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember" decimals="0" id="Fact-00D4BF3DCDD49748D1159CFE2C349A20" unitRef="cad">1729517</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-946CAACF96D8755336B39CFE2C3ADF95" unitRef="cad">681985</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-49B876D09D3EAB1A9F179CFE2C29C717" unitRef="cad">225896</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-A0908C2956C43156169E9CFE2C34B23B" unitRef="cad">534300</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-A515E204F8490A9067309CFE2BD26851" unitRef="cad">89466</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2017Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-04C30D19EE080EEA16F39CFE2C36F928" unitRef="cad">197870</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2018Q4" decimals="0" id="Fact-CE03B872A85689F55FEE9CFE2BE2D7C6" unitRef="cad">412736</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2018Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember" decimals="0" id="Fact-E453324BDFB63F195D249CFE2C3CC3C4" unitRef="cad">844617</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2018Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-1FCA3ABF6D423D8846429CFE2C27C585" unitRef="cad">174953</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2018Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-78DDF4A1DE9F501687D49CFE2BCF1C43" unitRef="cad">157749</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2018Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-305FD5C7ECCD9DC462159CFE2C2E0319" unitRef="cad">414623</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2018Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-ADA677E413FAD4CAD9FD9CFE2C3E36A4" unitRef="cad">72828</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2018Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-FF6DFA1CA1D346909B669CFE2C1FF320" unitRef="cad">24464</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2018Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember" decimals="0" id="Fact-6AFD24FD2F83864CF2BA9CFE2C22896E" unitRef="cad">1257353</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2018Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-A9FF75B21FB76BBEDCF29CFE2C35D26D" unitRef="cad">345941</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2018Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-C91344AA0A5B30F61D039CFE2C35DD63" unitRef="cad">247438</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2018Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-D15D2027E7055DC177DE9CFE2C39DE1B" unitRef="cad">498367</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2018Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-F74B4CF9454FCD502FA69CFE2C37AEDB" unitRef="cad">105229</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2018Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-A70D4D9021873DCE6C1D9CFE2C221BA0" unitRef="cad">60378</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2018Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-FF6C7AB649B8636C9A429CFE2C26C7AE" unitRef="cad">170988</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2018Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-5322FDBA4FE05C0D11289CFE2BFF40B6" unitRef="cad">89689</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2018Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-92F0C6C6FB2A70E58EA39CFE2C2F2943" unitRef="cad">83744</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2018Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-371DB649B3F8B81D48019CFE2C32C6A0" unitRef="cad">32401</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2018Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-0E2D47BDA87DBFFF2AD49CFE2C23EC58" unitRef="cad">35914</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2019Q4" decimals="0" id="Fact-3F7D4A53E38009DFC4B39CFE2BE17D1C" unitRef="cad">296768</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2019Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember" decimals="0" id="Fact-BE3312ADCCD1ED8CE75B9CFE2C3222AD" unitRef="cad">967599</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2019Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-EF11ED360F74F04A0BF19CFE2BD966B3" unitRef="cad">224046</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2019Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-5D72EE03025BB427AA209CFE2C2B43F7" unitRef="cad">172417</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2019Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-37A96CB9D4C4AF5DE0729CFE2C2CB2D7" unitRef="cad">448258</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2019Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-D66FAFA913927780340C9CFE2BD78647" unitRef="cad">78170</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2019Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-834321CE719171543EB69CFE2C363D1C" unitRef="cad">44708</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2019Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember" decimals="0" id="Fact-292592A76F815BF7BC219CFE2C25F5AB" unitRef="cad">1264367</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2019Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-ADAD7C88C2646F243F2D9CFE2C380E51" unitRef="cad">352955</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2019Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-C36D2F7B4413354146339CFE2C1EE21B" unitRef="cad">247438</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2019Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-1D2CAF049A1A7257C3429CFE2C3947F3" unitRef="cad">498367</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2019Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-65EB5B959B992794427E9CFE2BD52CC8" unitRef="cad">105229</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2019Q4_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-CCBB0051A03C309C04579CFE2C2E2D85" unitRef="cad">60378</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2019Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="0" id="Fact-C43393D428B04259002E9CFE2BCE2D11" unitRef="cad">128909</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2019Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_FixturesAndFittingsMember" decimals="0" id="Fact-A9A571D620DC8AC8BBEC9CFE2C14A04C" unitRef="cad">75021</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2019Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember" decimals="0" id="Fact-3455CF1C932D585C54A49CFE2C1EB31D" unitRef="cad">50109</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2019Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="0" id="Fact-CCE353638E41729E7F4B9CFE2BD86EE2" unitRef="cad">27059</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PropertyPlantAndEquipment contextRef="FI2019Q4_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="0" id="Fact-0ACA5EA71D6EF1B6AF159CFE2C33FFDD" unitRef="cad">15670</ifrs-full:PropertyPlantAndEquipment>
	<ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="FD2017Q4YTD" decimals="0" id="Fact-8F679BC82CE563F0C4AB9CFE2C3F45C5" unitRef="cad">105765</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
	<ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="FD2018Q4YTD" decimals="0" id="Fact-6E200527B5DAA3584DA49CFE2C1108E2" unitRef="cad">107466</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
	<ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="FD2019Q4YTD" decimals="0" id="Fact-35FFB685B888DA9267589CFE2C3D1EF3" unitRef="cad">10905</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
	<ifrs-full:ResearchAndDevelopmentExpense contextRef="FD2017Q4YTD" decimals="0" id="Fact-ADF8DFBD7D10A24976679CFE2C087CA9" unitRef="cad">9392623</ifrs-full:ResearchAndDevelopmentExpense>
	<ifrs-full:ResearchAndDevelopmentExpense contextRef="FD2018Q4YTD" decimals="0" id="Fact-33EAA5B2997F68DA64DB9CFE2C086BD7" unitRef="cad">9417888</ifrs-full:ResearchAndDevelopmentExpense>
	<ifrs-full:ResearchAndDevelopmentExpense contextRef="FD2019Q4YTD" decimals="0" id="Fact-5F82C6757D8B85D635C59CFE2C0172CA" unitRef="cad">11134716</ifrs-full:ResearchAndDevelopmentExpense>
	<ifrs-full:RetainedEarnings contextRef="FI2018Q4" decimals="0" id="Fact-F52226DA8060E2566C1A9CFE2BD97DA5" unitRef="cad">-311483385</ifrs-full:RetainedEarnings>
	<ifrs-full:RetainedEarnings contextRef="FI2019Q4" decimals="0" id="Fact-8848E6BF60FDFC2AD9CA9CFE2BE0A5E7" unitRef="cad">-344606273</ifrs-full:RetainedEarnings>
	<ifrs-full:RevenueFromContractsWithCustomers contextRef="FD2018Q4YTD" decimals="0" id="Fact-1A093499A70C3E22D4BE9CFE2C2468D3" unitRef="cad">547707</ifrs-full:RevenueFromContractsWithCustomers>
	<ifrs-full:RevenueFromContractsWithCustomers contextRef="FD2019Q4YTD" decimals="0" id="Fact-F2A7F4F17BFBC5B9B1B89CFE2BCD6398" unitRef="cad">0</ifrs-full:RevenueFromContractsWithCustomers>
	<ifrs-full:RightofuseAssets contextRef="FI2019Q4" decimals="0" id="Fact-869DCD898EA76D8200939CFE2BD8CFEE" unitRef="cad">430713</ifrs-full:RightofuseAssets>
	<ifrs-full:RightofuseAssets contextRef="I2019Q1Jan1" decimals="0" id="Fact-411B87AC11045BD7C76E9CFE2C0049A8" unitRef="cad">808025</ifrs-full:RightofuseAssets>
	<ifrs-full:RightofuseAssets contextRef="I2019Q1Jan1_ifrs-full_InitiallyAppliedIFRSsAxis_oncyf_EffectsofIFRS16TransitionMember" decimals="0" id="Fact-624BFE6BEC834EA767899CFE2C2DFBFA" unitRef="cad">808025</ifrs-full:RightofuseAssets>
	<ifrs-full:ShareIssueRelatedCost contextRef="D2017Q2Jun1_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-C94633D3809DA04E89F99CFE2BF27098" unitRef="cad">1145402</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="D2018Q2Jan1-May21_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember" decimals="0" id="Fact-F1F8209D7B9DF18D38A49CFE2BE8B60F" unitRef="cad">33335</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="D2018Q2Jun5_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-467467344E276D71A22E9CFE2BE140A2" unitRef="cad">1418356</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="D2018Q4May22-Dec31_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-78DB5AA0E9A3FC5F332A9CFE2BF4A596" unitRef="cad">2333474</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="D2018Q4Sep28-Dec31_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderCommonStockPurchaseAgreementMember" decimals="0" id="Fact-1645BA4A2117073AD5149CFE2BD8A3B1" unitRef="cad">208726</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="D2019Q3Aug16_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember" decimals="INF" id="Fact-437F18784518D83DCB209CFE2C2B9EA0" unitRef="cad">466284</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="D2019Q3Aug16_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember" decimals="INF" id="Fact-378F1E6DACF2F66847919CFE2BCFDF13" unitRef="cad">233143</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="D2019Q3Aug16_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember" decimals="INF" id="Fact-23FF10E76C3E5FD2BD1F9CFE2BD47034" unitRef="cad">699427</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2017Q4YTD" decimals="0" id="Fact-7ABA28CA316AEB24AD069CFE2C073BBF" unitRef="cad">1391057</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember" decimals="0" id="Fact-8075A88F6DE091D8435B9CFE2BEB14FE" unitRef="cad">1391057</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2017Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-FB7AA42CD7CB94270D7F9CFE2BFD70BA" unitRef="cad">1391057</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2017Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember_oncyf_SaleOfStockAxis_oncyf_WarrantsMember" decimals="0" id="Fact-7AB43D36A8AE961AEDE09CFE2BE6AEC3" unitRef="cad">0</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2017Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementCanadianMember" decimals="0" id="Fact-D8D348194EBDD3D500F59CFE2BD74BE3" unitRef="cad">245655</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2018Q4YTD" decimals="0" id="Fact-DFBE06C3BCBE6A70400E9CFE2BFEC40D" unitRef="cad">2366809</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2018Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-397277925954E5AE1E639CFE2C03A2FA" unitRef="cad">2366809</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2018Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember_oncyf_SaleOfStockAxis_oncyf_WarrantsMember" decimals="0" id="Fact-255780ECFAAE90EBD0D09CFE2BE713B7" unitRef="cad">0</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2018Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementCanadianMember" decimals="0" id="Fact-41C7C5B2F7FC5C66371D9CFE2BDCCA1D" unitRef="cad">33335</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2018Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" decimals="0" id="Fact-82D74CE3C89C15820B629CFE2BDF37A0" unitRef="cad">135000</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2019Q4YTD" decimals="0" id="Fact-10E1F3A52228068F21AF9CFE2BED2C25" unitRef="cad">854256</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2019Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-6FD2A4C0E3EC22293DE29CFE2BF9E715" unitRef="cad">854256</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2019Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderCommonStockPurchaseAgreementMember" decimals="0" id="Fact-379DA091045C2C42E9FD9CFE2BDCD548" unitRef="cad">3757</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2019Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-394BFF0DE5EFD68781089CFE2BFEEFA2" unitRef="cad">854256</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2019Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember_oncyf_SaleOfStockAxis_oncyf_WarrantsMember" decimals="0" id="Fact-BC7F3C167D1885304FF69CFE2BF1595C" unitRef="cad">233143</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:ShareIssueRelatedCost contextRef="FD2019Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" decimals="0" id="Fact-AC6E7D09C61E3714831C9CFE2BD50793" unitRef="cad">344834</ifrs-full:ShareIssueRelatedCost>
	<ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares contextRef="FI2019Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ifrs-full_ReserveOfSharebasedPaymentsMember" decimals="INF" id="Fact-57BBEC034C32E96DE50C9CFE2BF76627" unitRef="shares">3219845</ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares>
	<ifrs-full:TaxEffectFromChangeInTaxRate contextRef="FD2017Q4YTD" decimals="0" id="Fact-64777C1E336C9456D0499CFE2C365078" unitRef="cad">0</ifrs-full:TaxEffectFromChangeInTaxRate>
	<ifrs-full:TaxEffectFromChangeInTaxRate contextRef="FD2018Q4YTD" decimals="0" id="Fact-4BAE4A1AF53BEAAB3E159CFE2C3668C4" unitRef="cad">0</ifrs-full:TaxEffectFromChangeInTaxRate>
	<ifrs-full:TaxEffectFromChangeInTaxRate contextRef="FD2019Q4YTD" decimals="0" id="Fact-17B1F72AB5143FC9A52C9CFE2C2C5232" unitRef="cad">3758175</ifrs-full:TaxEffectFromChangeInTaxRate>
	<ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="FD2017Q4YTD" decimals="0" id="Fact-D1FABD56EF4F8E44AD239CFE2C20454C" unitRef="cad">53039</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
	<ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="FD2018Q4YTD" decimals="0" id="Fact-3F69D8A888F435FC6FA79CFE2C23DE2A" unitRef="cad">-35912</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
	<ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="FD2019Q4YTD" decimals="0" id="Fact-3B43DB139DD85C40E44C9CFE2C3478C9" unitRef="cad">149294</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
	<ifrs-full:TaxEffectOfForeignTaxRates contextRef="FD2017Q4YTD" decimals="0" id="Fact-2009FC393D6631B146F59CFE2C1F9001" unitRef="cad">2899190</ifrs-full:TaxEffectOfForeignTaxRates>
	<ifrs-full:TaxEffectOfForeignTaxRates contextRef="FD2018Q4YTD" decimals="0" id="Fact-D07D1E91D8ABC9EBFE0E9CFE2C1C5016" unitRef="cad">3312963</ifrs-full:TaxEffectOfForeignTaxRates>
	<ifrs-full:TaxEffectOfForeignTaxRates contextRef="FD2019Q4YTD" decimals="0" id="Fact-0BA0663E1DD9B3DC3E179CFE2C2956FC" unitRef="cad">3088811</ifrs-full:TaxEffectOfForeignTaxRates>
	<ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="FD2017Q4YTD" decimals="0" id="Fact-1D1F1A057139BD18DB5F9CFE2C1AAFB7" unitRef="cad">-4178345</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
	<ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="FD2018Q4YTD" decimals="0" id="Fact-4439A02BB42B3748D29C9CFE2C35D8FF" unitRef="cad">-4452079</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
	<ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="FD2019Q4YTD" decimals="0" id="Fact-273CCFE250E006591ECE9CFE2BEA0E97" unitRef="cad">-8777565</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
	<ifrs-full:TradeAndOtherCurrentPayables contextRef="FI2018Q4" decimals="0" id="Fact-7AA4F83535F8C9E038029CFE2BD91A09" unitRef="cad">1825853</ifrs-full:TradeAndOtherCurrentPayables>
	<ifrs-full:TradeAndOtherCurrentPayables contextRef="FI2019Q4" decimals="0" id="Fact-67379CF52BB7F01DFDCC9CFE2BD6189F" unitRef="cad">3173218</ifrs-full:TradeAndOtherCurrentPayables>
	<ifrs-full:TradeAndOtherCurrentPayables contextRef="FI2019Q4_oncyf_Currency1Axis_currency_EUR" decimals="0" id="Fact-2DEE3F55B49B004CFF3C9CFE2BCF0806" unitRef="eur">310086</ifrs-full:TradeAndOtherCurrentPayables>
	<ifrs-full:TradeAndOtherCurrentPayables contextRef="FI2019Q4_oncyf_Currency1Axis_currency_GBP" decimals="0" id="Fact-99DDCA90F93D366F36369CFE2BD0FC99" unitRef="gbp">6345</ifrs-full:TradeAndOtherCurrentPayables>
	<ifrs-full:TradeAndOtherCurrentPayables contextRef="FI2019Q4_oncyf_Currency1Axis_currency_USD" decimals="0" id="Fact-AEE60EC4AE533549D68C9CFE2BCE839A" unitRef="usd">1378860</ifrs-full:TradeAndOtherCurrentPayables>
	<ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties contextRef="I2017Q4Nov30" decimals="0" id="Fact-0015D38ADEF0F1A5C4F49CFE2C38C082" unitRef="usd">178125</ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyEightMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="-3" id="Fact-74294862C3826DC760AE9CFE2C16FDB1" unitRef="cad">19000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyFiveMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="-3" id="Fact-B1466ED66F0450F71A4B9CFE2C10D916" unitRef="cad">183000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyFourMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="-4" id="Fact-BE690BB8EE0BFA590AF89CFE2C170298" unitRef="cad">270000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="-3" id="Fact-7BFE692086A100049C659CFE2C15383C" unitRef="cad">91000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyOneMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="-3" id="Fact-46195D01232401CBBAE29CFE2C10C4AB" unitRef="cad">114000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtySevenMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="-1" id="Fact-57A2DDC0F33FA2ED9BA69CFE2C16907C" unitRef="cad">980</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtySixMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="-3" id="Fact-FDD19623453A0341ED069CFE2C12713F" unitRef="cad">41000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyThreeMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="-3" id="Fact-6645AD9BB2F83E64155D9CFE2C18CD29" unitRef="cad">487000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyTwoMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="-3" id="Fact-01AD39BF50142DEA04449CFE2C189879" unitRef="cad">381000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyEightMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="-3" id="Fact-CCA468A0F457D904F4219CFE2C146472" unitRef="cad">622000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyFiveMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="-3" id="Fact-640EAFFEC28C34A931C39CFE2C11DD50" unitRef="cad">271000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyFourMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="-3" id="Fact-CF9F9450A1B20F96CBC39CFE2C13C572" unitRef="cad">228000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="-3" id="Fact-21CA7F9EF1325FACD7609CFE2C1730D3" unitRef="cad">189000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyNineMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="-3" id="Fact-25B7A82910A5422AD7399CFE2C10B4F6" unitRef="cad">173000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyOneMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="-3" id="Fact-AC91CF4EE0E45AF59FDC9CFE2C1455B3" unitRef="cad">471000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentySevenMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="-3" id="Fact-90281F1658573D3408629CFE2C16846A" unitRef="cad">596000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentySixMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="-4" id="Fact-154AF0CC20CCE9B00FFA9CFE2C18EB98" unitRef="cad">520000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyThreeMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="-3" id="Fact-6AF39436E4FC1025E1AC9CFE2C120AE8" unitRef="cad">361000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyTwoMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="-3" id="Fact-589F9ED44D6054EF07069CFE2C167E43" unitRef="cad">465000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxCreditsMember" decimals="0" id="Fact-6802C0C8BFB5B55DFC519CFE2C11AFD2" unitRef="cad">5482980</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" decimals="-4" id="Fact-D2E9382902B5BDFC4A799CFE2BF0C599" unitRef="cad">27560000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyEightMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-3" id="Fact-8703ACCEB4E4FB3F02119CFE2C30AE5B" unitRef="cad">5056000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyFiveMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-3" id="Fact-0C613C8E2A63F6E080B59CFE2C2E2968" unitRef="cad">3125000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyFourMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-3" id="Fact-C2477D4A1401A4F83F6C9CFE2C30612F" unitRef="cad">2472000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-3" id="Fact-33814B2B2A1633F986039CFE2C31A9C7" unitRef="cad">4774000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyNineMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-5" id="Fact-1001DBBF69F1A0EECB699CFE2C30B27E" unitRef="cad">6900000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyOneMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-3" id="Fact-79F97ECEAA3C38F1E9E39CFE2C2FA0D3" unitRef="cad">4343000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtySevenMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-3" id="Fact-2B1FDE31119CF7013F7B9CFE2C2E2E3B" unitRef="cad">4812000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtySixMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-4" id="Fact-A4415E2D3B2EFC5DFB0D9CFE2C31F5DE" unitRef="cad">6430000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyThreeMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-3" id="Fact-75096FE807CCDB5176EC9CFE2C30E6A8" unitRef="cad">2457000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyThirtyTwoMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-3" id="Fact-23BBF6F0477D98BA4B099CFE2C2E4307" unitRef="cad">2873000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentyNineMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-3" id="Fact-D89E3A853B164935EC6A9CFE2C314FF0" unitRef="cad">4009000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentySevenMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-4" id="Fact-C7348DEB41E42874DC1D9CFE2C2F72A9" unitRef="cad">12170000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_MaturityAxis_oncyf_TwentyTwentySixMember_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-3" id="Fact-8AA2B9C478DE7F3D62969CFE2C30D6AF" unitRef="cad">9809000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="FI2019Q4_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember" decimals="-4" id="Fact-7B40BC19780E0C8D679F9CFE2C325DA5" unitRef="cad">69230000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 contextRef="FI2017Q4" decimals="2" id="Fact-585B7B25A7BC0D20F09E9CFE2BEB029D" unitRef="CAD_PER_shares">14.36</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 contextRef="FI2018Q4" decimals="2" id="Fact-EAF1CED91AB5DB63350A9CFE2BE34975" unitRef="CAD_PER_shares">11.04</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 contextRef="FI2019Q4" decimals="2" id="Fact-51F338B7AD540ADF2AF99CFE2BEC2744" unitRef="CAD_PER_shares">7.22</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 contextRef="FI2019Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFiveMember" decimals="2" id="Fact-A34CBC463E2BF88D79549CFE2BCCD830" unitRef="CAD_PER_shares">19.95</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 contextRef="FI2019Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFourMember" decimals="2" id="Fact-E576C3611F7052AD608C9CFE2BD9EC01" unitRef="CAD_PER_shares">3.95</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 contextRef="FI2019Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeOneMember" decimals="2" id="Fact-3E2A964B61A1ED86D5419CFE2BDC172E" unitRef="CAD_PER_shares">0.75</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 contextRef="FI2019Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeThreeMember" decimals="2" id="Fact-923AF67936953D4E455B9CFE2BE60399" unitRef="CAD_PER_shares">2.72</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 contextRef="FI2019Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeTwoMember" decimals="2" id="Fact-3919B47633B037DF4D499CFE2BF8F9AE" unitRef="CAD_PER_shares">1.45</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019 contextRef="FD2017Q4YTD" decimals="2" id="Fact-DD63F10528DAEF3253A59CFE2BF86AC1" unitRef="CAD_PER_shares">4.07</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019 contextRef="FD2018Q4YTD" decimals="2" id="Fact-3E46C284B8B90A9EDD4D9CFE2BEA9A59" unitRef="CAD_PER_shares">2.96</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019 contextRef="FD2019Q4YTD" decimals="2" id="Fact-3959235B937FF78C1A309CFE2BF627B8" unitRef="CAD_PER_shares">0.00</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019 contextRef="FD2017Q4YTD" decimals="2" id="Fact-C29A7C82C86EAF8462ED9CFE2BF7D15B" unitRef="CAD_PER_shares">21.13</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019 contextRef="FD2018Q4YTD" decimals="2" id="Fact-8BAD7BD8C368034B60B89CFE2BEBC96A" unitRef="CAD_PER_shares">13.78</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019 contextRef="FD2019Q4YTD" decimals="2" id="Fact-A37D144B379AEF344F229CFE2BE8BFC3" unitRef="CAD_PER_shares">29.07</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019 contextRef="FD2017Q4YTD" decimals="2" id="Fact-EFF8712D90806494D3749CFE2BE8693E" unitRef="CAD_PER_shares">32.80</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019 contextRef="FD2018Q4YTD" decimals="2" id="Fact-3ED846F84772B08E05339CFE2BF881BE" unitRef="CAD_PER_shares">11.67</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019 contextRef="FD2019Q4YTD" decimals="2" id="Fact-A7EFA01E8C5EEB8FAE459CFE2BE7EF91" unitRef="CAD_PER_shares">11.35</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 contextRef="FD2017Q4YTD" decimals="2" id="Fact-B74A193DCA9D375CF6BA9CFE2BE12FB5" unitRef="CAD_PER_shares">4.60</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 contextRef="FD2018Q4YTD" decimals="2" id="Fact-3F370BDF2490AF5574669CFE2BE1AB6E" unitRef="CAD_PER_shares">4.97</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 contextRef="FD2019Q4YTD" decimals="2" id="Fact-9BD9190B993220CDA87B9CFE2BF9E6CA" unitRef="CAD_PER_shares">1.42</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="FI2016Q4" decimals="2" id="Fact-BA9AECBBB343B5F269699CFE2BEDDC00" unitRef="CAD_PER_shares">17.42</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="FI2017Q4" decimals="2" id="Fact-E42E2C774D3C34389E439CFE2BDD829E" unitRef="CAD_PER_shares">13.20</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="FI2018Q4" decimals="2" id="Fact-2A732F202FDFD6C8D1569CFE2BE14409" unitRef="CAD_PER_shares">8.73</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="FI2019Q4" decimals="2" id="Fact-964563E58D98BF40BDF29CFE2BE495D2" unitRef="CAD_PER_shares">5.31</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="FI2019Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFiveMember" decimals="2" id="Fact-96F2130EFB0AB7314AEC9CFE2BF03978" unitRef="CAD_PER_shares">16.74</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="FI2019Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFourMember" decimals="2" id="Fact-BA48FBA9E172F2A178309CFE2C04C096" unitRef="CAD_PER_shares">3.88</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="FI2019Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeOneMember" decimals="2" id="Fact-5573454C6FAF8FB16C8D9CFE2C3814C9" unitRef="CAD_PER_shares">0.96</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="FI2019Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeThreeMember" decimals="2" id="Fact-14F9F46CC65248CBCA079CFE2BD6B7BF" unitRef="CAD_PER_shares">2.73</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 contextRef="FI2019Q4_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeTwoMember" decimals="2" id="Fact-C9C243D2A574683765589CFE2BDD4F3D" unitRef="CAD_PER_shares">1.45</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
	<ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted contextRef="FI2017Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-6404596B76D3E15865D29CFE2BF71015" unitRef="cad">3.33</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
	<ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted contextRef="FI2017Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="2" id="Fact-3723DC1C9CEB8C00A7139CFE2BF18F30" unitRef="cad">5.96</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
	<ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted contextRef="FI2018Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="2" id="Fact-0C82B4319A352537E4CB9CFE2BF92F56" unitRef="cad">3.35</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
	<ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted contextRef="FI2019Q4_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="2" id="Fact-218F4DA9211910CCFEFF9CFE2BFF68B1" unitRef="cad">0.80</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
	<ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="FI2017Q4" decimals="2" id="Fact-D7F8F537F26F226472E09CFE2BE5E9A5" unitRef="cad">2.65</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
	<ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="FI2018Q4" decimals="2" id="Fact-8120AB95AB37400A03049CFE2C19F59C" unitRef="cad">2.67</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
	<ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="FI2019Q4" decimals="2" id="Fact-632A4F68027651EECF909CFE2C2DE3F1" unitRef="cad">0.87</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
	<ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16 contextRef="FI2019Q4" decimals="2" id="Fact-8019C710C355831345139CFE2C0A62B6" unitRef="number">0.15</ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16>
	<ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16 contextRef="I2019Q1Jan1" decimals="2" id="Fact-EDFFDC1A40E1BECA04049CFE2BD73002" unitRef="number">0.15</ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16>
	<ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="FD2019Q4YTD" id="Fact-A9F60174751E8691890A9CFE2BEF6744">P4Y5M12D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
	<ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="FD2019Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember" id="Fact-54A265E6096789D1F9E19CFE2C35D55E">P2Y5M1D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
	<ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="FD2019Q4YTD_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFiveMember" id="Fact-E1FA23C0CC97D76EB1F29CFE2C36612C">P2Y6M11D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
	<ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="FD2019Q4YTD_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeFourMember" id="Fact-ABCB0334541004AB6E3C9CFE2BE653CC">P4Y10M17D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
	<ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="FD2019Q4YTD_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeOneMember" id="Fact-B73F4C447E09B692CA9A9CFE2BCEF42B">P4Y9M22D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
	<ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="FD2019Q4YTD_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeThreeMember" id="Fact-BCEA18DB61472E6A03269CFE2BE68EBE">P5Y1M10D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
	<ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="FD2019Q4YTD_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_oncyf_ExercisePriceRangeTwoMember" id="Fact-6E19A023AE6FCD89E79A9CFE2C3DE840">P4Y11M12D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
	<ifrs-full:WeightedAverageShares contextRef="FD2017Q4YTD" decimals="0" id="Fact-2798A2BADB4CAC109A9A9CFE2C09C566" unitRef="shares">13936387</ifrs-full:WeightedAverageShares>
	<ifrs-full:WeightedAverageShares contextRef="FD2018Q4YTD" decimals="0" id="Fact-4E42B8C22BCCD6887DD99CFE2C0820DE" unitRef="shares">16016366</ifrs-full:WeightedAverageShares>
	<ifrs-full:WeightedAverageShares contextRef="FD2019Q4YTD" decimals="0" id="Fact-0403AC4CF03133302E849CFE2C061F2F" unitRef="shares">22137990</ifrs-full:WeightedAverageShares>
	<oncyf:AccruedRoyalties1 contextRef="FI2019Q4" decimals="-3" id="Fact-9910B8383F902A5275AE9CFE2C2D6672" unitRef="cad">301000</oncyf:AccruedRoyalties1>
	<oncyf:AdjustmentsforDecreaseIncreaseinContractReceivable contextRef="FD2017Q4YTD" decimals="0" id="Fact-E0D513697DA466897C7A9CFE2C18DBCE" unitRef="cad">-4767100</oncyf:AdjustmentsforDecreaseIncreaseinContractReceivable>
	<oncyf:AdjustmentsforDecreaseIncreaseinContractReceivable contextRef="FD2018Q4YTD" decimals="0" id="Fact-17497F6625DC8C165FAF9CFE2C150540" unitRef="cad">4767100</oncyf:AdjustmentsforDecreaseIncreaseinContractReceivable>
	<oncyf:AdjustmentsforDecreaseIncreaseinContractReceivable contextRef="FD2019Q4YTD" decimals="0" id="Fact-FDE2445F78DAE8620DE89CFE2C19744D" unitRef="cad">0</oncyf:AdjustmentsforDecreaseIncreaseinContractReceivable>
	<oncyf:AdjustmentsforIncreaseDecreaseinContractLiabilities contextRef="FD2017Q4YTD" decimals="0" id="Fact-4436C82C1D337AEB5D5C9CFE2C0ED470" unitRef="cad">6182580</oncyf:AdjustmentsforIncreaseDecreaseinContractLiabilities>
	<oncyf:AdjustmentsforIncreaseDecreaseinContractLiabilities contextRef="FD2018Q4YTD" decimals="0" id="Fact-41623D6FC6A448C671559CFE2C0F868D" unitRef="cad">547707</oncyf:AdjustmentsforIncreaseDecreaseinContractLiabilities>
	<oncyf:AdjustmentsforIncreaseDecreaseinContractLiabilities contextRef="FD2019Q4YTD" decimals="0" id="Fact-48802980BCC5BA5FB14E9CFE2C180069" unitRef="cad">0</oncyf:AdjustmentsforIncreaseDecreaseinContractLiabilities>
	<oncyf:AdjustmentsforLeaseAmortization contextRef="FD2017Q4YTD" decimals="0" id="Fact-67732FECBDB3547223BA9CFE2C0F1E09" unitRef="cad">0</oncyf:AdjustmentsforLeaseAmortization>
	<oncyf:AdjustmentsforLeaseAmortization contextRef="FD2017Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember" decimals="0" id="Fact-4A592AFB127F82A246D99CFE2BECE777" unitRef="cad">0</oncyf:AdjustmentsforLeaseAmortization>
	<oncyf:AdjustmentsforLeaseAmortization contextRef="FD2018Q4YTD" decimals="0" id="Fact-80F32C6ADF896319FD199CFE2C131CB5" unitRef="cad">8189</oncyf:AdjustmentsforLeaseAmortization>
	<oncyf:AdjustmentsforLeaseAmortization contextRef="FD2018Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember" decimals="0" id="Fact-8406ACC007E09B22C6949CFE2BE81CD6" unitRef="cad">8189</oncyf:AdjustmentsforLeaseAmortization>
	<oncyf:AdjustmentsforLeaseAmortization contextRef="FD2019Q4YTD" decimals="0" id="Fact-934492E007B34621E2019CFE2C15FC32" unitRef="cad">0</oncyf:AdjustmentsforLeaseAmortization>
	<oncyf:AdjustmentsforLeaseAmortization contextRef="FD2019Q4YTD_oncyf_IncomeStatementLocation1Axis_oncyf_OperatingExpensesMember" decimals="0" id="Fact-95BE62EBEA19C55A6C7A9CFE2BF0F310" unitRef="cad">0</oncyf:AdjustmentsforLeaseAmortization>
	<oncyf:AnnualContingentPayment contextRef="FI2019Q4" decimals="INF" id="Fact-BF71417FFF008C61B80E9CFE2BE4F475" unitRef="cad">100000</oncyf:AnnualContingentPayment>
	<oncyf:AnnualContingentPaymentGrossSalesPercent contextRef="FI2019Q4" decimals="INF" id="Fact-4D450A41445B3992B8CA9CFE2BDE7026" unitRef="number">0.05</oncyf:AnnualContingentPaymentGrossSalesPercent>
	<oncyf:BalanceHeldInForeignCurrencyNet contextRef="FI2019Q4_oncyf_Currency1Axis_currency_EUR" decimals="0" id="Fact-0121522532C53A3356F99CFE2BD16A77" unitRef="eur">-276422</oncyf:BalanceHeldInForeignCurrencyNet>
	<oncyf:BalanceHeldInForeignCurrencyNet contextRef="FI2019Q4_oncyf_Currency1Axis_currency_GBP" decimals="0" id="Fact-13408498BDAC7B6C28709CFE2BD207B3" unitRef="gbp">20406</oncyf:BalanceHeldInForeignCurrencyNet>
	<oncyf:BalanceHeldInForeignCurrencyNet contextRef="FI2019Q4_oncyf_Currency1Axis_currency_USD" decimals="0" id="Fact-7A21BB092329A1DFFF089CFE2BD12170" unitRef="usd">3246250</oncyf:BalanceHeldInForeignCurrencyNet>
	<oncyf:CashEquivalentsInterestRate contextRef="FD2018Q4YTD" decimals="4" id="Fact-C701FF49CC1AF008C1A69CFE2C273169" unitRef="number">0.0271</oncyf:CashEquivalentsInterestRate>
	<oncyf:CashEquivalentsInterestRate contextRef="FD2019Q4YTD" decimals="4" id="Fact-B7195DAAAD58BE768CEE9CFE2C346091" unitRef="number">0.0117</oncyf:CashEquivalentsInterestRate>
	<oncyf:ClassOfWarrantOrRightOutstanding1 contextRef="FI2019Q4_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember" decimals="INF" id="Fact-F850687552AB23B0A2419CFE2C194129" unitRef="shares">1684126</oncyf:ClassOfWarrantOrRightOutstanding1>
	<oncyf:ClassOfWarrantOrRightOutstanding1 contextRef="I2019Q3Aug16_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember" decimals="INF" id="Fact-C78BAD5609370B29C1559CFE2C147624" unitRef="shares">4619773</oncyf:ClassOfWarrantOrRightOutstanding1>
	<oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2 contextRef="I2019Q3Aug16_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember" decimals="2" id="Fact-6EEACDC9C76B4775BC199CFE2C3EB3FB" unitRef="usdPerShare">0.90</oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2>
	<oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1 contextRef="I2017Q2Jun1_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="INF" id="Fact-D5E21B6D4F8AD59C046B9CFE2BF34259" unitRef="shares">1</oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1>
	<oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1 contextRef="I2018Q2May22" decimals="INF" id="Fact-849BE4CAABDF503EC1319CFE2BD70286" unitRef="shares">1</oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1>
	<oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1 contextRef="I2019Q3Aug16_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember" decimals="INF" id="Fact-5B41D8294A56C8A0C3679CFE2C2AE705" unitRef="shares">1</oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1>
	<oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1 contextRef="FI2019Q4" decimals="INF" id="Fact-1C1C80D5905B19785F789CFE2BDE8454" unitRef="shares">1730894</oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1>
	<oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1 contextRef="I2018Q2May22" decimals="1" id="Fact-5D37FD2617060917FD589CFE2BE02C76" unitRef="shares">9.5</oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1>
	<oncyf:ClassofWarrantorRightNumberofWarrantsExercised contextRef="D2109Q4Aug17-Dec31_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember" decimals="INF" id="Fact-194CE3FF9FE07A70E66EA73CA7BA7A08" unitRef="shares">-2935647</oncyf:ClassofWarrantorRightNumberofWarrantsExercised>
	<oncyf:ClassofWarrantorRightNumberofWarrantsExercised contextRef="FD2019Q4QTD_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember" decimals="INF" id="Fact-C3B2BBD88C02A5B42E449CFE2BD941D3" unitRef="shares">2935647</oncyf:ClassofWarrantorRightNumberofWarrantsExercised>
	<oncyf:ClassofWarrantorRightWarrantsExercised contextRef="D2109Q4Aug17-Dec31_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember" decimals="0" id="Fact-A21C625281FA34C55299A73CA7CEC81E" unitRef="cad">-5687003</oncyf:ClassofWarrantorRightWarrantsExercised>
	<oncyf:ClassofWarrantorRightWarrantsExercised contextRef="FD2019Q4QTD_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember" decimals="0" id="Fact-FF4A457C21F09020CC139CFE2C16DB89" unitRef="cad">5687003</oncyf:ClassofWarrantorRightWarrantsExercised>
	<oncyf:CommitmentsAndContingencies1 contextRef="FI2018Q4" id="Fact-8A93E3807349B0759D289CFE2C377C94" unitRef="cad" xsi:nil="true" />
	<oncyf:CommitmentsAndContingencies1 contextRef="FI2019Q4" id="Fact-53356E97D7367BF574CB9CFE2C375EDE" unitRef="cad" xsi:nil="true" />
	<oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue contextRef="FD2019Q4YTD_ifrs-full_CounterpartiesAxis_oncyf_SYNSORBMember" id="Fact-DD1C663BD550B19818E49CFE2C2B5C96">P90D</oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue>
	<oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage contextRef="FD2018Q4YTD_ifrs-full_CounterpartiesAxis_oncyf_SYNSORBMember" decimals="INF" id="Fact-921CCCE84B2B16F911BD9CFE2C2C0E9C" unitRef="number">0.0215</oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage>
	<oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage contextRef="FD2019Q4YTD_ifrs-full_CounterpartiesAxis_oncyf_SYNSORBMember" decimals="INF" id="Fact-BA8A884E3B5584329B6D9CFE2C2C26F3" unitRef="number">0.0215</oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage>
	<oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage contextRef="FD2018Q4YTD_ifrs-full_CounterpartiesAxis_oncyf_SYNSORBMember" decimals="INF" id="Fact-1D245A07AF71C31E0D749CFE2C2CF75F" unitRef="number">0.1075</oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage>
	<oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage contextRef="FD2019Q4YTD_ifrs-full_CounterpartiesAxis_oncyf_SYNSORBMember" decimals="INF" id="Fact-998AA450A4CE2DC450619CFE2C2BDD61" unitRef="number">0.1075</oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage>
	<oncyf:CommonSharePurchaseWarrantPerUnit contextRef="I2017Q2Jun1_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="INF" id="Fact-C199A84696033FFABDBB9CFE2BE3C8B2" unitRef="shares">1</oncyf:CommonSharePurchaseWarrantPerUnit>
	<oncyf:CommonSharePurchaseWarrantPerUnit contextRef="I2017Q2Jun1_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="INF" id="Fact-BE639E1D6FD35C92BA469CFE2BD8345F" unitRef="shares">1</oncyf:CommonSharePurchaseWarrantPerUnit>
	<oncyf:CommonSharesPerUnit contextRef="I2017Q2Jun1_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="INF" id="Fact-D052E9ACF3568AEB2A4F9CFE2BDF08C2" unitRef="shares">1</oncyf:CommonSharesPerUnit>
	<oncyf:CommonSharesPerUnit contextRef="I2017Q2Jun1_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="INF" id="Fact-DA1BCF02DBF628FCB0CE9CFE2BE3A0B6" unitRef="shares">0.106</oncyf:CommonSharesPerUnit>
	<oncyf:CommonSharesPerUnit contextRef="I2019Q3Aug16_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember" decimals="INF" id="Fact-E904F1EF17FBBA98A28B9CFE2C26F1CC" unitRef="shares">1</oncyf:CommonSharesPerUnit>
	<oncyf:CommonSharesPerUnit contextRef="I2019Q3Aug16_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember" decimals="INF" id="Fact-39011E68AF6C4E4467F89CFE2BD9B135" unitRef="shares">1</oncyf:CommonSharesPerUnit>
	<oncyf:ConcentrationRiskNumber contextRef="FD2019Q4YTD_oncyf_ConcentrationRiskType1Axis_oncyf_SupplierConcentrationRisk1Member" decimals="INF" id="Fact-11351F7333FC0DE9963B9CFE2C1D94A0" unitRef="manufacturer">1</oncyf:ConcentrationRiskNumber>
	<oncyf:ContingentRoyaltyPaymentAnnualMaximum contextRef="FD2019Q4YTD" decimals="INF" id="Fact-AC81B5189721F0DE6BF49CFE2C2DA497" unitRef="cad">20000</oncyf:ContingentRoyaltyPaymentAnnualMaximum>
	<oncyf:ContingentRoyaltyPaymentContributionRate contextRef="FD2019Q4YTD" decimals="INF" id="Fact-2A66C6068210926B31C09CFE2C2B19BC" unitRef="number">2</oncyf:ContingentRoyaltyPaymentContributionRate>
	<oncyf:ContingentRoyaltyPaymentPercentOfSalesRevenue contextRef="FI2019Q4" decimals="INF" id="Fact-BAB611EF8F5EECDD6A7B9CFE2C2CB309" unitRef="number">0.005</oncyf:ContingentRoyaltyPaymentPercentOfSalesRevenue>
	<oncyf:ContractLiabilityRecognitionPeriod contextRef="D2017Q4Nov1-30" decimals="INF" id="Fact-B2312D643EACA8E377399CFE2BCFE016" unitRef="year">5</oncyf:ContractLiabilityRecognitionPeriod>
	<oncyf:DividendYieldPercent contextRef="D2019Q3Aug16_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember" decimals="INF" id="Fact-BB4E4F4FE3AD2E3FDC6B9D428B1184C9" unitRef="number">0</oncyf:DividendYieldPercent>
	<oncyf:DividendYieldPercent contextRef="D2019Q4Dec31_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember" decimals="INF" id="Fact-DE4E9B6703FF124641509D428978D445" unitRef="number">0</oncyf:DividendYieldPercent>
	<oncyf:EquityAuthorized contextRef="I2018Q2May4" decimals="INF" id="Fact-AE779538F57486F6706E9CFE2C13250B" unitRef="cad">150000000</oncyf:EquityAuthorized>
	<oncyf:ExercisePriceofOutstandingWarrants contextRef="FI2019Q4_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember" decimals="3" id="Fact-180C264F9A4281041C289CFE2C3547CD" unitRef="cad">9.025</oncyf:ExercisePriceofOutstandingWarrants>
	<oncyf:ExpectedForfeitureShareOptionsGranted contextRef="FD2017Q4YTD" decimals="4" id="Fact-DFDE687A9D5B822E37CD9CFE2C3A434C" unitRef="number">0.0367</oncyf:ExpectedForfeitureShareOptionsGranted>
	<oncyf:ExpectedForfeitureShareOptionsGranted contextRef="FD2018Q4YTD" decimals="4" id="Fact-68675B3E36A5074A491B9CFE2BDF270C" unitRef="number">0.0367</oncyf:ExpectedForfeitureShareOptionsGranted>
	<oncyf:ExpectedForfeitureShareOptionsGranted contextRef="FD2019Q4YTD" decimals="4" id="Fact-7687A2C48174E46315F19CFE2C302CD4" unitRef="number">0.0367</oncyf:ExpectedForfeitureShareOptionsGranted>
	<oncyf:FairValueofWarrantIssuedPerWarrant contextRef="FI2019Q4_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember" decimals="2" id="Fact-2BF151A9CBDCACA3D92A9CFE2BDA8407" unitRef="usdPerShare">3.89</oncyf:FairValueofWarrantIssuedPerWarrant>
	<oncyf:FairValueofWarrantIssuedPerWarrant contextRef="I2019Q3Aug16_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember" decimals="2" id="Fact-E2B384DD19838493AAC29CFE2BF33EB7" unitRef="usdPerShare">0.27</oncyf:FairValueofWarrantIssuedPerWarrant>
	<oncyf:ForeignExchangeImpactRightofUseAssets contextRef="FD2019Q4YTD" decimals="0" id="Fact-66D9DEC402C7E61AE4C99CFE2BEC63E6" unitRef="cad">-14720</oncyf:ForeignExchangeImpactRightofUseAssets>
	<oncyf:FundedandRoyaltyRepayment contextRef="FI2019Q4" decimals="INF" id="Fact-C17B919F5EC405AB0F3F9CFE2BEB7C64" unitRef="cad">400000</oncyf:FundedandRoyaltyRepayment>
	<oncyf:GainsLossesfromForeignExchangeImpact contextRef="D2109Q4Aug17-Dec31_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember" decimals="0" id="Fact-E56B9DE1343288533C5D9CFE2C208DA8" unitRef="cad">-70255</oncyf:GainsLossesfromForeignExchangeImpact>
	<oncyf:GainsLossesfromForeignExchangeImpact contextRef="FD2019Q4YTD" decimals="0" id="Fact-D1C1DC324464A5565D4A9CFE2BE4AF19" unitRef="cad">-23482</oncyf:GainsLossesfromForeignExchangeImpact>
	<oncyf:GrossProceedsFromIssueOfOrdinaryShares contextRef="D2017Q2Jun1_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-FC15AEAD834B4E19CC839CFE2BE9DF58" unitRef="cad">11511500</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
	<oncyf:GrossProceedsFromIssueOfOrdinaryShares contextRef="D2018Q2Jun5_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-01FB4C1C12E90AA3A25A9CFE2BDC0B53" unitRef="usd">8933181</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
	<oncyf:GrossProceedsFromIssueOfOrdinaryShares contextRef="D2019Q3Aug16_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember" decimals="0" id="Fact-8F0D3C087A2604EC55AE9CFE2C133ABC" unitRef="usd">3742016</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
	<oncyf:GrossProceedsFromIssueOfOrdinaryShares contextRef="D2020Q1Jan1-Mar5_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ifrs-full_MajorOrdinaryShareTransactionsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="0" id="Fact-F32F49E78E722AE368E09CFE2C11315F" unitRef="usd">1030669</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
	<oncyf:GrossProceedsFromIssueOfOrdinaryShares contextRef="D2020Q1Jan1-Mar5_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ifrs-full_MajorOrdinaryShareTransactionsMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" decimals="0" id="Fact-F27F18E14765875F63299CFE2C13C612" unitRef="usd">12726383</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
	<oncyf:GrossProceedsFromIssueOfOrdinaryShares contextRef="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementCanadianMember" decimals="0" id="Fact-9E2F405BE6E7C81C71ED9CFE2BD7A9C1" unitRef="cad">2348821</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
	<oncyf:GrossProceedsFromIssueOfOrdinaryShares contextRef="FD2018Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-27E3F670DE7AC2C82CB69CFE2BDD21F4" unitRef="usd">2055207</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
	<oncyf:GrossProceedsFromIssueOfOrdinaryShares contextRef="FD2018Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_InitialCommitmentFeeMember" decimals="0" id="Fact-9DC57C365411A030EFC79CFE2BD8CAFF" unitRef="usd">483690</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
	<oncyf:GrossProceedsFromIssueOfOrdinaryShares contextRef="FD2018Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementCanadianMember" decimals="INF" id="Fact-00516F35EA6F4EFA5F9A9CFE2BD51E78" unitRef="cad">553650</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
	<oncyf:GrossProceedsFromIssueOfOrdinaryShares contextRef="FD2018Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" decimals="0" id="Fact-1E945FDD71613418DD3C9CFE2BDE4569" unitRef="usd">50046</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
	<oncyf:GrossProceedsFromIssueOfOrdinaryShares contextRef="FD2019Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-84216A27B6F445E1A3679CFE2BF02639" unitRef="usd">4055725</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
	<oncyf:GrossProceedsFromIssueOfOrdinaryShares contextRef="FD2019Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_InitialCommitmentFeeMember" decimals="0" id="Fact-9D4A0CCCD486AD2D434D9CFE2BDF5FD3" unitRef="usd">29758</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
	<oncyf:GrossProceedsFromIssueOfOrdinaryShares contextRef="FD2019Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" decimals="0" id="Fact-5C998E4F3C7BD42683709CFE2BD63437" unitRef="usd">6390691</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
	<oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity contextRef="FD2018Q4YTD" decimals="0" id="Fact-415ED2BF2F69A8D424209CFE2C02F08F" unitRef="cad">0</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
	<oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity contextRef="FD2018Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-AF807E4AB29DDBE44C919CFE2C01DAD8" unitRef="cad">109751</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
	<oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity contextRef="FD2018Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember" decimals="0" id="Fact-150B40E901475FE760599CFE2BFB2BD2" unitRef="cad">-109751</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
	<oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity contextRef="FD2019Q4YTD" decimals="0" id="Fact-2A3678E3E5AE25A0F2CA9CFE2BF8C4C6" unitRef="cad">0</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
	<oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity contextRef="FD2019Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" decimals="0" id="Fact-9F64F99D31C3DA6074BF9CFE2BF5F2E7" unitRef="cad">391917</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
	<oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity contextRef="FD2019Q4YTD_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember" decimals="0" id="Fact-87CAB9D8990846EFA6529CFE2BFD448D" unitRef="cad">-391917</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
	<oncyf:IncreaseDecreaseinPrepaidExpense1 contextRef="FD2017Q4YTD" decimals="0" id="Fact-CEFD67C6008E0C884D229CFE2C1CCC62" unitRef="cad">-915222</oncyf:IncreaseDecreaseinPrepaidExpense1>
	<oncyf:IncreaseDecreaseinPrepaidExpense1 contextRef="FD2018Q4YTD" decimals="0" id="Fact-7BDE6093453A65D6E0FC9CFE2C19BA0A" unitRef="cad">475077</oncyf:IncreaseDecreaseinPrepaidExpense1>
	<oncyf:IncreaseDecreaseinPrepaidExpense1 contextRef="FD2019Q4YTD" decimals="0" id="Fact-AAA47A18D4547F3FD1C29CFE2C13A029" unitRef="cad">-2012605</oncyf:IncreaseDecreaseinPrepaidExpense1>
	<oncyf:IssueOfEquityShares contextRef="D2017Q2Jun1_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="INF" id="Fact-D9DDD8C4EFF95DABAD639CFE2BD6CF11" unitRef="shares">16445000</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="D2018Q2Jan1-May21_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="INF" id="Fact-2DA036C712C9FF3ADD1A9CFE2C0AE092" unitRef="shares">519500</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="D2018Q2Jan1-May21_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderStockOptionPlanMember" decimals="INF" id="Fact-4D533EDB3A19D42322959CFE2BEB6E32" unitRef="shares">71000</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="D2018Q2Jun5_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="INF" id="Fact-460D2B310276A959870D9CFE2BE952B5" unitRef="shares">1532278</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="D2018Q4May22-Dec31_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="INF" id="Fact-9FF29E563FE6DFB68BB19CFE2BEE35CA" unitRef="shares">1532278</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="D2018Q4May22-Dec31_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="INF" id="Fact-F75F4F2A2A9B730A904C9CFE2C09EDB3" unitRef="shares">18002</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="D2018Q4May22-Dec31_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderCommonStockPurchaseAgreementMember" decimals="INF" id="Fact-17B1471C12D6D6E5C0C29CFE2BF2709A" unitRef="shares">797691</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="D2018Q4May22-Dec31_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderIncentiveAwardPlanMember" decimals="INF" id="Fact-AE3DA4E8E233590469B59CFE2BFC464F" unitRef="shares">28297</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="D2018Q4May22-Dec31_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderStockOptionPlanMember" decimals="INF" id="Fact-E5C0D7C631B16F9BF1609CFE2BFBB4A5" unitRef="shares">34329</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="D2018Q4May22-Dec31_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember" decimals="INF" id="Fact-528E4CBA7F6980C060229CFE2C0A3BCE" unitRef="shares">157</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="D2018Q4May22-Dec31_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember" decimals="INF" id="Fact-877C71D41337FBCC0F0E9CFE2BF4D909" unitRef="shares">-1500</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="D2019Q3Aug16_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember" decimals="INF" id="Fact-FE016815BD84637D073C9CFE2C231A4A" unitRef="shares">4619773</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="D2020Q1Jan1-Mar5_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ifrs-full_MajorOrdinaryShareTransactionsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="INF" id="Fact-988245A99DE9C6592B6C9CFE2C112307" unitRef="shares">1145188</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="D2020Q1Jan1-Mar5_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ifrs-full_MajorOrdinaryShareTransactionsMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" decimals="INF" id="Fact-ADB7832374359228921A9CFE2C128231" unitRef="shares">3921790</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="INF" id="Fact-F3B7DDB56D7A05D585159CFE2BFDE70F" unitRef="shares">16445000</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementCanadianMember" decimals="INF" id="Fact-A87D30729310C0D787AA9CFE2BDAD5AA" unitRef="shares">3301500</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderStockOptionPlanMember" decimals="INF" id="Fact-3BA2C4FD6B16498BA6289CFE2BF73204" unitRef="shares">801000</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2017Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="INF" id="Fact-0B202E3494FA2B9173CA9CFE2C090A64" unitRef="shares">16445000</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2017Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementCanadianMember" decimals="INF" id="Fact-B49D9BB415933977BF629CFE2BDAE845" unitRef="shares">347526</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2018Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="INF" id="Fact-5CC70F2F283EF9351FE79CFE2BEF5B95" unitRef="shares">678182</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2018Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_InitialCommitmentFeeMember" decimals="INF" id="Fact-CF24A879C389498642459CFE2BDDFDEA" unitRef="shares">119509</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2018Q4YTD_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementCanadianMember" decimals="INF" id="Fact-B7BA6F230147D368D2A99CFE2BE6D328" unitRef="shares">519500</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2018Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementCanadianMember" decimals="INF" id="Fact-6735E14949455A11ACC29CFE2BD30F0E" unitRef="shares">54684</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2018Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" decimals="INF" id="Fact-1F9BF12F7BFBE19EC1269CFE2BEC4703" unitRef="shares">18002</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2019Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember" decimals="INF" id="Fact-76518A1E676CF5AD40539CFE2BDB0704" unitRef="shares">2477665</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2019Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_InitialCommitmentFeeMember" decimals="INF" id="Fact-827F5B273514B1A237B29CFE2BED9046" unitRef="shares">17278</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2019Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="INF" id="Fact-86C9997776C03DEE345C9CFE2C0C18F3" unitRef="shares">4619773</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2019Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementMember" decimals="INF" id="Fact-99AE1FE9B80D6CBECEF99CFE2C0B371B" unitRef="shares">4425040</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2019Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderCommonStockPurchaseAgreementMember" decimals="INF" id="Fact-3F53B241670B05D92EC09CFE2BF4EDDF" unitRef="shares">2494943</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2019Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderIncentiveAwardPlanMember" decimals="INF" id="Fact-7F83ABFA1043C9FE169B9CFE2C0BE1C3" unitRef="shares">323301</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2019Q4YTD_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember" decimals="INF" id="Fact-1E98446211BC64AE1DD89CFE2BFC730B" unitRef="shares">2935647</oncyf:IssueOfEquityShares>
	<oncyf:IssueOfEquityShares contextRef="FD2019Q4YTD_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" decimals="INF" id="Fact-BED5861CA62DD66E26429CFE2BDBB6C2" unitRef="shares">4425040</oncyf:IssueOfEquityShares>
	<oncyf:MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement contextRef="FD2019Q4YTD" id="Fact-541C13C6EA5D66671B2D9CFE2C0232B6">P10Y</oncyf:MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement>
	<oncyf:NumberOfStockOptionPlans contextRef="FI2019Q4" decimals="INF" id="Fact-2F8ABFE2F107F5D3C99F9CFE2C039648" unitRef="plan">1</oncyf:NumberOfStockOptionPlans>
	<oncyf:NumberofPatients contextRef="D2017Q4Nov1-30" decimals="INF" id="Fact-BB7C371FAAAF9A68B0969CFE2BCF6615" unitRef="patient">50</oncyf:NumberofPatients>
	<oncyf:NumberofSharesOutstandingPercent contextRef="D2018Q3Sep27_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember_srt_RangeAxis_srt_MaximumMember" decimals="INF" id="Fact-CC8796758B97D7A749709CFE2BE5F1E1" unitRef="number">0.1999</oncyf:NumberofSharesOutstandingPercent>
	<oncyf:OperatingLeaseRemainingLeaseTerm contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember" id="Fact-A8874A142479787C85169CFE2C02071C">P5Y</oncyf:OperatingLeaseRemainingLeaseTerm>
	<oncyf:OperatingLeaseRemainingLeaseTerm contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember" id="Fact-7739214C629D91D5A3AF9CFE2C08C9FE">P3Y</oncyf:OperatingLeaseRemainingLeaseTerm>
	<oncyf:OtherCurrentandNoncurrentAssets contextRef="FI2018Q4" decimals="0" id="Fact-E2AA0992807BA48015319CFE2C00DC98" unitRef="cad">14865253</oncyf:OtherCurrentandNoncurrentAssets>
	<oncyf:OtherCurrentandNoncurrentAssets contextRef="I2019Q1Jan1" decimals="0" id="Fact-C9216E892194CF836FF09CFE2BF6974E" unitRef="cad">14865253</oncyf:OtherCurrentandNoncurrentAssets>
	<oncyf:OtherCurrentandNoncurrentAssets contextRef="I2019Q1Jan1_ifrs-full_InitiallyAppliedIFRSsAxis_oncyf_EffectsofIFRS16TransitionMember" decimals="0" id="Fact-1B8AD742301AF9E0BC1E9CFE2C33B7BE" unitRef="cad">0</oncyf:OtherCurrentandNoncurrentAssets>
	<oncyf:OtherCurrentandNoncurrentLiabilities contextRef="FI2018Q4" decimals="0" id="Fact-0AD711A1873AAFD5C4619CFE2BE48088" unitRef="cad">8556140</oncyf:OtherCurrentandNoncurrentLiabilities>
	<oncyf:OtherCurrentandNoncurrentLiabilities contextRef="I2019Q1Jan1" decimals="0" id="Fact-4A7035F8D710F6516E679CFE2C17F3C1" unitRef="cad">8556140</oncyf:OtherCurrentandNoncurrentLiabilities>
	<oncyf:OtherCurrentandNoncurrentLiabilities contextRef="I2019Q1Jan1_ifrs-full_InitiallyAppliedIFRSsAxis_oncyf_EffectsofIFRS16TransitionMember" decimals="0" id="Fact-3DC2CB215DFCDDE0540A9CFE2C09E838" unitRef="cad">0</oncyf:OtherCurrentandNoncurrentLiabilities>
	<oncyf:OverheadRepayment contextRef="FI2019Q4" decimals="INF" id="Fact-56CAF50FED4C6B8ABD4B9CFE2BDDED05" unitRef="cad">100000</oncyf:OverheadRepayment>
	<oncyf:ProceedsFromCollaborationAgreement contextRef="D2020Q1Feb25_ifrs-full_ClassesOfProvisionsAxis_oncyf_CollaborationAgreementMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ifrs-full_EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember" decimals="0" id="Fact-1A61015890C035C29D4A9CFE2C13D623" unitRef="usd">1500000</oncyf:ProceedsFromCollaborationAgreement>
	<oncyf:ProceedsfromInterestReceived contextRef="FD2017Q4YTD" decimals="0" id="Fact-3B31B3CDD4AC3BD7BAAD9CFE2C215B8D" unitRef="cad">130101</oncyf:ProceedsfromInterestReceived>
	<oncyf:ProceedsfromInterestReceived contextRef="FD2018Q4YTD" decimals="0" id="Fact-C9357EE932B187700B669CFE2C24B14F" unitRef="cad">173496</oncyf:ProceedsfromInterestReceived>
	<oncyf:ProceedsfromInterestReceived contextRef="FD2019Q4YTD" decimals="0" id="Fact-2BE5071DA3D77825F77A9CFE2C215D2F" unitRef="cad">274094</oncyf:ProceedsfromInterestReceived>
	<oncyf:ProceedsfromWarrantExercises1 contextRef="FD2019Q4QTD" decimals="0" id="Fact-74E25C2A31CE8CD7EC0B9CFE2BE538F1" unitRef="usd">2642082</oncyf:ProceedsfromWarrantExercises1>
	<oncyf:PropertyPlantandEquipmentAnnualDepreciationRate contextRef="FD2019Q4YTD_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember" decimals="INF" id="Fact-2F38CDC56DC1ED4B4B009CFE2C31F106" unitRef="number">0.3</oncyf:PropertyPlantandEquipmentAnnualDepreciationRate>
	<oncyf:PropertyPlantandEquipmentAnnualDepreciationRate contextRef="FD2019Q4YTD_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OfficeEquipmentMember" decimals="INF" id="Fact-4C683E0AB89D2EAD9E489CFE2C052D40" unitRef="number">0.2</oncyf:PropertyPlantandEquipmentAnnualDepreciationRate>
	<oncyf:PropertyPlantandEquipmentAnnualDepreciationRate contextRef="FD2019Q4YTD_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_oncyf_MedicalEquipmentMember" decimals="INF" id="Fact-9790B510848DA4A55B459CFE2C2EE321" unitRef="number">0.2</oncyf:PropertyPlantandEquipmentAnnualDepreciationRate>
	<oncyf:PurchaseObligation1 contextRef="FI2019Q4" decimals="0" id="Fact-2105E45F4FAA3BE6F5119CFE2BDE56A3" unitRef="cad">4867131</oncyf:PurchaseObligation1>
	<oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount contextRef="FD2019Q4YTD_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_oncyf_Currency1Axis_currency_EUR" decimals="INF" id="Fact-EAE6D88C0A76355A082C9CFE2C0CA67F" unitRef="cad">0.10</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount>
	<oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount contextRef="FD2019Q4YTD_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_oncyf_Currency1Axis_currency_GBP" decimals="INF" id="Fact-D53AC1E7DC8B2CD683B99CFE2C105BB8" unitRef="cad">0.10</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount>
	<oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount contextRef="FD2019Q4YTD_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_oncyf_Currency1Axis_currency_USD" decimals="INF" id="Fact-8A31D6BEE8B1935581C79CFE2C11A09C" unitRef="cad">0.01</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount>
	<oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings contextRef="FD2019Q4YTD_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_oncyf_Currency1Axis_currency_EUR" decimals="0" id="Fact-F9095A7A688216405EAD9CFE2C1452F0" unitRef="cad">32426</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings>
	<oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings contextRef="FD2019Q4YTD_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_oncyf_Currency1Axis_currency_GBP" decimals="0" id="Fact-CCFA6A15D04E6AC9BA199CFE2C0DDDE2" unitRef="cad">8581</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings>
	<oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings contextRef="FD2019Q4YTD_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_oncyf_Currency1Axis_currency_USD" decimals="0" id="Fact-0998D9A435AB05285B7E9CFE2C0D65ED" unitRef="cad">125339</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings>
	<oncyf:SharePricePremiumPercent contextRef="D2017Q4Nov1-30" decimals="INF" id="Fact-0CCD4757AB7DE577A2A79CFE2BD066C5" unitRef="number">0.2</oncyf:SharePricePremiumPercent>
	<oncyf:SharePurchaseAgreementAmount contextRef="I2018Q3Sep27_oncyf_SaleOfStockAxis_oncyf_SharesUnderCommonStockPurchaseAgreementMember" decimals="INF" id="Fact-DFB63B1A3EAA03A0937E9CFE2BDA3B01" unitRef="usd">26000000</oncyf:SharePurchaseAgreementAmount>
	<oncyf:SharePurchaseAgreementAmount contextRef="I2018Q4Oct24_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" decimals="INF" id="Fact-29EAB0C97483250A8AD49CFE2BF386D7" unitRef="usd">30000000</oncyf:SharePurchaseAgreementAmount>
	<oncyf:SharePurchaseAgreementTerm contextRef="D2018Q3Sep27_oncyf_SaleOfStockAxis_oncyf_SharesUnderCommonStockPurchaseAgreementMember" id="Fact-FAC04D5B6BBC9F0405E79CFE2BEDA053">P30M</oncyf:SharePurchaseAgreementTerm>
	<oncyf:SharePurchaseAgreementTerm contextRef="D2018Q4Oct24_oncyf_SaleOfStockAxis_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" id="Fact-38E475B849C0B5235FBF9CFE2BE14083">P19M</oncyf:SharePurchaseAgreementTerm>
	<oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1 contextRef="FD2019Q4YTD_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember" decimals="INF" id="Fact-CF3E77EA206FCCFDDFE19CFE2BFF6328" unitRef="number">1.0</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
	<oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1 contextRef="FD2019Q4YTD_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember" decimals="INF" id="Fact-4C248A0A953775ED61509CFE2BF875A0" unitRef="number">3.0</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
	<oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1 contextRef="FD2019Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_PerformanceShareUnitsMember" decimals="INF" id="Fact-D8BFC67455F6808E48969CFE2BFD3B48" unitRef="number">3</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
	<oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1 contextRef="FD2019Q4YTD_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_oncyf_RestrictedShareUnitsMember" decimals="INF" id="Fact-44BC710D04FA0EA4080C9CFE2BF7A783" unitRef="number">3</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
	<oncyf:SharesIssuedPricePerShare1 contextRef="I2017Q2Jun1_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="INF" id="Fact-7C26FADC82AEDB714A199CFE2BD52ABA" unitRef="CAD_PER_shares">0.48</oncyf:SharesIssuedPricePerShare1>
	<oncyf:SharesIssuedPricePerShare1 contextRef="I2017Q2Jun1_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="INF" id="Fact-351EFE6C6156C27391779CFE2BD36876" unitRef="CAD_PER_shares">4.56</oncyf:SharesIssuedPricePerShare1>
	<oncyf:SharesIssuedPricePerShare1 contextRef="I2017Q2Jun1_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="INF" id="Fact-3A78B65D3948A70941D59CFE2BE28A9E" unitRef="CAD_PER_shares">0.70</oncyf:SharesIssuedPricePerShare1>
	<oncyf:SharesIssuedPricePerShare1 contextRef="I2018Q2Jun5_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="INF" id="Fact-A14232FE46FBBF96E10C9CFE2BEEFE03" unitRef="usdPerShare">5.83</oncyf:SharesIssuedPricePerShare1>
	<oncyf:SharesIssuedPricePerShare1 contextRef="I2018Q3Sep27_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember_srt_RangeAxis_srt_MinimumMember" decimals="INF" id="Fact-78207706C39096EC3C739CFE2BE8140D" unitRef="usdPerShare">1.00</oncyf:SharesIssuedPricePerShare1>
	<oncyf:SharesIssuedPricePerShare1 contextRef="I2019Q3Aug16_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember" decimals="INF" id="Fact-D7CD6117FECB05FE8DBB9CFE2BEF2440" unitRef="usdPerShare">0.27</oncyf:SharesIssuedPricePerShare1>
	<oncyf:SharesIssuedPricePerShare1 contextRef="I2019Q3Aug16_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_IssuedCapitalMember_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember" decimals="INF" id="Fact-E5980650F4ACFE1718CC9CFE2BD4BDDC" unitRef="usdPerShare">0.54</oncyf:SharesIssuedPricePerShare1>
	<oncyf:SharesIssuedPricePerShare1 contextRef="I2019Q3Aug16_oncyf_SaleOfStockAxis_oncyf_SharesUnderWarrantAgreementMember" decimals="INF" id="Fact-8D58145610E112DC113B9CFE2BD19442" unitRef="usdPerShare">0.81</oncyf:SharesIssuedPricePerShare1>
	<oncyf:SharesIssuedWarrantPricePerShare contextRef="I2017Q2Jun1_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_PreviouslyStatedMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="INF" id="Fact-7A130985EB6F54BEAF9F9CFE2BE96BDD" unitRef="CAD_PER_shares">0.22</oncyf:SharesIssuedWarrantPricePerShare>
	<oncyf:SharesIssuedWarrantPricePerShare contextRef="I2017Q2Jun1_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="INF" id="Fact-D0E1346AC759AE9F4F0A9CFE2BE02580" unitRef="CAD_PER_shares">2.09</oncyf:SharesIssuedWarrantPricePerShare>
	<oncyf:StockholdersEquityNoteStockSplitConversionRatio contextRef="D2018Q2May22" decimals="5" id="Fact-CA3D59FA4ACDE76171499CFE2C2DD67D" unitRef="number">0.10526</oncyf:StockholdersEquityNoteStockSplitConversionRatio>
	<oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative contextRef="FD2017Q4YTD" decimals="0" id="Fact-E29CE5B7EC0BCA00DBEF9CFE2C1FAF3A" unitRef="cad">0</oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative>
	<oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative contextRef="FD2018Q4YTD" decimals="0" id="Fact-40E543712EC2DA556B959CFE2C2FC8AC" unitRef="cad">0</oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative>
	<oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative contextRef="FD2019Q4YTD" decimals="0" id="Fact-4DF5A2DB9AE77A7B186E9CFE2C1F0E91" unitRef="cad">3341334</oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative>
	<oncyf:TaxEffectOfStockBasedCompensation contextRef="FD2017Q4YTD" decimals="0" id="Fact-BC3498A73019D5ECA17B9CFE2C249B9A" unitRef="cad">-156250</oncyf:TaxEffectOfStockBasedCompensation>
	<oncyf:TaxEffectOfStockBasedCompensation contextRef="FD2018Q4YTD" decimals="0" id="Fact-DFEC2E4E98C49A34DA909CFE2C254029" unitRef="cad">-382275</oncyf:TaxEffectOfStockBasedCompensation>
	<oncyf:TaxEffectOfStockBasedCompensation contextRef="FD2019Q4YTD" decimals="0" id="Fact-01EF576B73353998BEF19CFE2C26A7A4" unitRef="cad">-389591</oncyf:TaxEffectOfStockBasedCompensation>
	<oncyf:TaxEffectOfTaxPools contextRef="FD2017Q4YTD" decimals="0" id="Fact-B2C6DA25E57F766CCA5F9CFE2C2889DD" unitRef="cad">162162</oncyf:TaxEffectOfTaxPools>
	<oncyf:TaxEffectOfTaxPools contextRef="FD2018Q4YTD" decimals="0" id="Fact-6AF40184D4B0B4AB9AE79CFE2C228CD8" unitRef="cad">-238222</oncyf:TaxEffectOfTaxPools>
	<oncyf:TaxEffectOfTaxPools contextRef="FD2019Q4YTD" decimals="0" id="Fact-3B535A0A2A69D47CACB69CFE2C1F5FEB" unitRef="cad">11973</oncyf:TaxEffectOfTaxPools>
	<oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1 contextRef="FD2017Q4YTD" decimals="0" id="Fact-7C52FC560572B15196CA9CFE2C248C8E" unitRef="cad">-1051725</oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1>
	<oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1 contextRef="FD2018Q4YTD" decimals="0" id="Fact-F381449487A685CCB5839CFE2C0E4185" unitRef="cad">-1579017</oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1>
	<oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1 contextRef="FD2019Q4YTD" decimals="0" id="Fact-3E305FE2DDC3D37F44459CFE2C2F4E91" unitRef="cad">1961613</oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1>
	<oncyf:WarrantIssuedUnderlyingSharePrice contextRef="D2019Q3Aug16_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember" decimals="2" id="Fact-965B08AE7B26DD0CF2E39CFE2BD5D503" unitRef="usdPerShare">0.54</oncyf:WarrantIssuedUnderlyingSharePrice>
	<oncyf:WarrantIssuedUnderlyingSharePrice contextRef="D2019Q4Dec31_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember" decimals="2" id="Fact-646B79C9E17E941B7C8C9CFE2BF3C0FA" unitRef="usdPerShare">4.76</oncyf:WarrantIssuedUnderlyingSharePrice>
	<oncyf:WarrantPricePerShareAccelerationThreshold contextRef="I2017Q2Jun1_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="INF" id="Fact-347A10E0D57B1849FF819CFE2BE759AF" unitRef="CAD_PER_shares">23.75</oncyf:WarrantPricePerShareAccelerationThreshold>
	<oncyf:WarrantPricePerShareAccelerationThresholdTradingDays contextRef="I2017Q2Jun1_ifrs-full_ClassesOfShareCapitalAxis_oncyf_WarrantsMember_oncyf_SaleOfStockAxis_oncyf_SharesPublicOfferingMember" decimals="INF" id="Fact-CE68213FD047AF8972B89CFE2BDBAA60" unitRef="number">15</oncyf:WarrantPricePerShareAccelerationThresholdTradingDays>
	<oncyf:WarrantPurchaseAgreement contextRef="D2017Q4Nov1-30" decimals="-6" id="Fact-6DE839E439C4B59545DC9CFE2BCF6234" unitRef="usd">6000000</oncyf:WarrantPurchaseAgreement>
	<oncyf:WarrantsAndRightsOutstanding1 contextRef="FI2019Q4_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember" decimals="0" id="Fact-AB9A5B4A4E0485A143E09CFE2C1D5412" unitRef="cad">8508764</oncyf:WarrantsAndRightsOutstanding1>
	<oncyf:WarrantsAndRightsOutstanding1 contextRef="I2019Q3Aug16_ifrs-full_ClassesOfLiabilitiesAxis_oncyf_WarrantsMember" decimals="0" id="Fact-D08A81858700ADC266639CFE2C1F3E83" unitRef="cad">1657214</oncyf:WarrantsAndRightsOutstanding1>
	<oncyf:WarrantsandRightsOutstanding contextRef="FI2018Q4" decimals="0" id="Fact-BFFECF6ADFBDB4E2F29C9CFE2BD33F61" unitRef="cad">3617570</oncyf:WarrantsandRightsOutstanding>
	<oncyf:WarrantsandRightsOutstanding contextRef="FI2019Q4" decimals="0" id="Fact-E50002B57752B0FEF1A49CFE2BDFD9B7" unitRef="cad">3617570</oncyf:WarrantsandRightsOutstanding>
	<oncyf:WeightedAverageClosingPriceDuration contextRef="D2017Q4Nov1-30" decimals="INF" id="Fact-C96FADEB38B95C673A299CFE2BCE5A11" unitRef="number">5</oncyf:WeightedAverageClosingPriceDuration>
	<ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory contextRef="FD2019Q4YTD" id="Fact-8FE12C8C1C198F5EBF539CFE2C0A3C1E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We follow the liability method of accounting for income taxes.  Under the liability method, deferred income taxes are recognized for the difference between financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences).  Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled.  The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory>
	<ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="FD2019Q4YTD" id="Fact-45D389188A1C02432C729CFE2C33D8C3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic loss per common share is determined using the weighted average number of common shares outstanding during the period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We use the treasury stock method to calculate diluted loss per common share.  Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants, if dilutive. The number of additional common shares is calculated by assuming that any outstanding &amp;#8220;in the money&amp;#8221; options, restricted share units, performance share units and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
	<ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory contextRef="FD2019Q4YTD" id="Fact-0B1D9538FECD19AC65B29CFE2C31FB61">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments we prioritize the related inputs used in measuring fair value into the following hierarchy: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;font-weight:bold;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
	<ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory contextRef="FD2019Q4YTD" id="Fact-33C87C804736D8DA109D9CFE2C323EEC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under IFRS 9 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments ("IFRS 9")&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&amp;#8217;s business model for managing the assets; and whether the financial asset&amp;#8217;s contractual cash flows represent &amp;#8216;solely payments of principal and interest&amp;#8217; on the principal amount outstanding (the &amp;#8216;SPPI criterion&amp;#8217;). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our financial assets include cash and cash equivalents and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory>
	<ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory contextRef="FD2019Q4YTD" id="Fact-08DC9BEDE8CBB5BBB7819CFE2C396FFA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include trade accounts payable, other liabilities and warrant derivative. The classification and measurement of trade accounts payable and other liabilities are at amortized cost. The classification and measurement of warrant derivative is at FVPL.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory>
	<ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="FD2019Q4YTD" id="Fact-1E527BEF8C7052488BAD9CFE2C3BBEDF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exceptions to this are where the monetary items form part of the net investment in a foreign operation and the foreign operation's functional currency is the local currency.  These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;font-weight:bold;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
	<ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory contextRef="FD2019Q4YTD" id="Fact-044673812928600689589CFE2C3BCD60">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under IFRS 9, accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IFRS 9 requires that we record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&amp;#8217;s original effective interest rate.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory>
	<ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="FD2019Q4YTD" id="Fact-6C3DC654EAFF8DD06462A691B9092D69">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At inception of a contract, we assess whether a contract is, or contains a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;the contract involves the use of an identified asset;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;we have the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;we have the right to direct the use of the identified asset. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A right-of-use asset and corresponding lease liability is recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
	<ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="FD2019Q4YTD" id="Fact-6FEDE426F442710A65EE9CFE2C39664F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives.  Depreciation is recorded using the declining balance method at the following annual rates:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.40350877192983%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:51%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Office equipment and furniture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Medical equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Straight-line over the term of the lease&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
	<ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="FD2019Q4YTD" id="Fact-318B7C485C56CA8A6D769CFE2C1D7518">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The contract also provides for development and regulatory milestone payments, royalties and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contract receivable&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - Contract receivable includes amounts billed and currently due from customers. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts. We perform a review of our customer&amp;#8217;s credit risk and payment histories, including payments made subsequent to year-end.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contract liability&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - Our contract liability includes upfront license fees and billings in excess of revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or noncurrent based on the timing of when we expect to recognize revenue.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
	<ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory contextRef="FD2019Q4YTD" id="Fact-F618AACB65403D8977A79CFE2C392C93">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the treatment phase of clinical trials based on the total estimated cost of the treatment phase on a per patient basis and we expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized.  To date, all development costs have been expensed. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
	<ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="FD2019Q4YTD" id="Fact-08576581E8AC562C14419CFE2C04AAB2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock option plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; stock option plan (the &amp;#8220;Option Plan&amp;#8221;) available to officers, directors, employees and consultants with grants under the Option Plan approved from time to time by our Board of Directors (the &amp;#8220;Board&amp;#8221;). Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines. Vesting is provided for at the discretion of the Board and the expiration of options is to be no greater than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from the date of grant. Exercised stock options are settled with common shares issued from treasury. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We use the fair value based method of accounting for stock option awards granted under the Option Plan.  We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black- Scholes valuation model. The fair value of stock options with a graded vesting schedule is determined based on different expected lives for the options that vest each year, as it would be if the award were viewed as several separate awards, each with a different vesting date, and it is accounted for over the respective vesting period taking into consideration forfeiture estimates.   Compensation expense is adjusted for subsequent changes in management&amp;#8217;s estimate of the number of options that are expected to vest.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Incentive share award plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our incentive share award plan (the "Share Plan") is available to directors, officers and employees. Under our Share Plan, performance share units and restricted share units may be approved from time to time by the Board. Performance share units  ("PSUs") are an award to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share units ("RSUs") are an award to certain officers and employees and to non-employee directors to which common shares shall be issued in accordance with the Share Plan.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the date of grant based on the number of PSUs/RSUs expected to vest, recognized over the term of the vesting period. Compensation expense is adjusted for subsequent changes in management&amp;#8217;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
	<ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations contextRef="FD2019Q4YTD" id="Fact-0734C9C09EA49620BE5D9CFE2C2B0E61">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IFRS 16 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;IFRS 16&amp;#8221;) replaces IAS 17 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;IAS 17&amp;#8221;) and related interpretations for annual periods beginning on or after January 1, 2019. We have adopted IFRS 16 using the modified retrospective approach, under which the cumulative effect of the initial application is recognized in retained earnings at January 1, 2019. We have not restated comparatives for 2018. On transition to IFRS 16, we elected to apply the following practical expedients: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Applied the exemption for short-term leases that have a remaining lease term of less than 12 months as at January 1, 2019; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Excluded initial direct costs for the measurement of right-of-use assets as at January 1, 2019; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Relied upon our assessment of whether leases are onerous under the requirement of IAS 37, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Provisions, contingent liabilities and contingent assets&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as at December 31, 2018 as an alternative to reviewing our right-of-use assets for impairment; and &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Measured the right-of-use assets at an amount equal to the lease liability, adjusted by the amount of lease incentive liability related to that lease recognized in the statement of financial position immediately before the date of initial application. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On transition to IFRS 16, we recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$882,437&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of lease liabilities. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate at January 1, 2019 as rates implicit in the leases were not readily determinable. The weighted-average rate applied was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the impacts of adopting IFRS 16 on the consolidated financial statements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Impact of changes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As reported as at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Effects of IFRS 16 transition&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Subsequent to transition as at January 1, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Right-of-use assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;808,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;808,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other current and non-current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,865,253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,865,253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,865,253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;808,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,673,278&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;113,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(74,412&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,338&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;882,437&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;882,437&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other current and non-current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,556,140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,556,140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,669,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;808,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,477,915&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total shareholders' equity&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,195,363&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,195,363&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prior to adopting IFRS 16, our total minimum operating lease commitments as at December 31, 2018 were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$961,575&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The difference between the total of the minimum lease payments set out in Note 11 of our 2018 annual consolidated financial statements and the total lease liabilities recognized on transition was a result of the effect of discounting on the minimum lease payments.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations>
	<ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations contextRef="FD2019Q4YTD" id="Fact-AEA21C7D02E5FFF24D649CFE2C347598">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the impacts of adopting IFRS 16 on the consolidated financial statements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Impact of changes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As reported as at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Effects of IFRS 16 transition&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Subsequent to transition as at January 1, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Right-of-use assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;808,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;808,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other current and non-current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,865,253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,865,253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,865,253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;808,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,673,278&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;113,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(74,412&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,338&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;882,437&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;882,437&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other current and non-current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,556,140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,556,140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,669,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;808,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,477,915&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total shareholders' equity&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,195,363&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,195,363&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations>
	<ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory contextRef="FD2019Q4YTD" id="Fact-D6EAE6E60AEA5F09EAF49CFE2C03DE40">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Significant Judgments, Estimates and Assumptions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Judgments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of our consolidated financial statements requires us to make judgments, estimates and assumptions that affect the reported amount of expenses, assets, liabilities, and the disclosure of contingent liabilities, at the end of the reporting period.  However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Estimates and assumptions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates and such differences could be significant. Significant estimates made by management affecting our consolidated financial statements include:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We entered into a Licensing Agreement which provides, among other payments, for upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress towards completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Valuation of share based payments &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Estimating fair value for stock options granted requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility, dividend yield, and forfeiture rate and making assumptions about them. The assumptions and  inputs used for estimating fair value for stock options granted are disclosed in Note 10. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Valuation of warrant derivative &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Estimating fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period requires determining the most appropriate valuation model. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility and dividend yield, and making assumptions about them. The assumptions and  inputs used for estimating fair value of the warrant derivative are disclosed in Note 8.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income.  Currently, we are accumulating tax loss carry forward balances in various tax jurisdictions creating a deferred tax asset. Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;To date we have determined that none of our deferred tax assets should be recognized. Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable investment tax credits. These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries. As well, there are no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We make judgments in determining whether a contract contains an identified asset. The identified asset should be physically distinct or represent substantially all of the capacity of the asset, and should provide us with the right to substantially all of the economic benefits from the use of the asset.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We also make judgments in determining whether or not we have the right to control the use of the identified asset. We have that right when we have the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In cases where the decisions about how and for what purpose the asset is used are predetermined, we have the right to direct the use of the asset if we have the right to operate the asset or if we designed the asset in a way that predetermines how and for what purpose the asset will be used.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We make judgments in determining the incremental borrowing rate used to measure our lease liability for each lease contract, including an estimate of the asset-specific security impact. The incremental borrowing rate should reflect the interest that we would have to pay to borrow at a similar term and with a similar security.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
	<ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="FD2019Q4YTD" id="Fact-D850426FFF761E356A1F9CFE2C0EB635">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Basis of Financial Statement Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our consolidated financial statements include our financial statements and the financial statements of our subsidiaries Oncolytics Biotech (Barbados) Inc., Oncolytics Biotech (US) Inc., and Oncolytics Biotech (UK) Ltd. and are presented in Canadian dollars, our functional currency.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accounts are prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Basis of consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our accounts include the accounts of Oncolytics Biotech Inc. and our subsidiaries. Subsidiaries are entities over which we have control which is achieved when we are exposed, or have the rights, to variable returns from our involvement with the investee and has the ability to affect those returns through our power to govern. Accounting policies of subsidiaries are consistent with our accounting policies and all intra-group transactions, balances, income and expenses are eliminated on consolidation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A change in ownership interest of a subsidiary, without a change in control, is accounted for as an equity transaction.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
	<ifrs-full:DisclosureOfCashFlowStatementExplanatory contextRef="FD2019Q4YTD" id="Fact-F9C941500229D4B2A5E69CFE2C166C37">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Additional Cash Flow Disclosures&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net Change In Non-Cash Working Capital&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:629px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:392px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Change in:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contract receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,767,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,767,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other receivables&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(2,017,122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13,924&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(2,012,605&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;475,077&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(915,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts payable and accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,347,365&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,858,170&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(384,641&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contract liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;547,707&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,182,580&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;807,877&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(27,982&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-cash impact of foreign exchange&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;78,708&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,531&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,558&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in non-cash working capital related to operating activities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(1,795,777&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,904,339&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;180,855&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Other Cash Flow Disclosures&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:517px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:342px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:58px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:51px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:51px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash interest received&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;274,094&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;173,496&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;130,101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash taxes paid&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;5,448&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,728&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;136,163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCashFlowStatementExplanatory>
	<ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="FD2019Q4YTD" id="Fact-81DFC31CD93D20A3A4969CFE2BD93ED3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Authorized:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unlimited number of no par value common shares&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Share Consolidation:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On May 22, 2018, we completed the consolidation of our common shares on the basis of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.5&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; pre-consolidation common shares for each one post-consolidation common share (the "Share Consolidation"). Fractional interests were rounded down to the nearest whole number of common shares. Outstanding stock options, restricted share units and performance share units were similarly adjusted by the consolidation ratio. Outstanding warrants were adjusted such that, following the Share Consolidation, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.5&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; equity-classified warrants will entitle the holder to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; whole common share until June 1, 2022.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:665px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:293px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:88px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:88px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:88px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:88px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amount&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amount&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;121,258,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;262,321,825&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to stock option plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;801,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;536,949&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to "At the Market" equity distribution agreement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,301,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,348,821&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to public offering&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(b)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,445,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,893,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,445,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,617,900&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share issue costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,391,057&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;141,805,722&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;271,710,138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,445,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,617,900&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to "At the Market" equity distribution agreement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;519,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;553,650&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share issue costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(33,335&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to stock option plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;71,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38,269&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, May 22, 2018 - pre-consolidation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;142,396,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;272,268,722&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,445,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,617,900&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, May 22, 2018 - post-consolidation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,988,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;272,268,722&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,445,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,617,900&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to public offering&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(c)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,532,278&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,606,882&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to warrant agreement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(b)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;157&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,747&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(330&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to stock option plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,329&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;158,976&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to incentive share award plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28,297&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;109,751&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to Common Stock Purchase Agreement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(d)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;797,691&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,314,097&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to "At the Market" equity distribution agreement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(e)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,002&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;66,360&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share issue costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,333,474&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,399,749&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;285,193,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,443,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,617,570&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to incentive share award plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;323,301&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;391,917&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to Common Stock Purchase Agreement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(d)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,494,943&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,403,385&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to "At the Market" equity distribution agreement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(e)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,425,040&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,476,454&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to public offering&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(f)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,619,773&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,314,429&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to warrant derivative exercised&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(f)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,935,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,152,869&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share issue costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(854,256&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balance, December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;32,198,453&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;311,077,859&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;16,443,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3,617,570&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February 25, 2016, we entered into an "at-the-market" ("ATM") equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; which allows us to sell our common shares through the facilities of the Toronto Stock Exchange or other "marketplace&amp;#8221; (as defined in National Instrument 21-101 Marketplace Operation) in Canada (our "Canadian ATM"). Subject to the terms of our Canadian ATM, we are able to determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility. During 2018, we sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;519,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; pre-consolidation shares (approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;54,684&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; post-consolidation shares) (2017 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,301,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; pre-consolidation shares (approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;347,526&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; post-consolidation shares) common shares for gross proceeds of $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;553,650&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (2017 - $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,348,821&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;). We incurred share issue costs of $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,335&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (2017 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$245,655&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On June 1, 2017, pursuant to an underwritten public offering, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,445,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; units were sold at a purchase price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.70&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per unit for gross proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$11,511,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  Each unit included &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; pre-consolidation common share with an ascribed value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.48&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.106&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; post-consolidation common share with an ascribed value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.56&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; pre-consolidation common share purchase warrant with an ascribed value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.22&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; post-consolidation common share purchase warrant with an ascribed value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.09&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;). These warrants were classified as equity. Each pre-consolidation common share purchase warrant entitled the holder to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; pre-consolidation common share at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.95&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Following the Share Consolidation, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.5&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; pre-consolidation common share purchase warrants entitles the holder to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; post-consolidation common share in the capital of the Company until June 1, 2022, at an exercise price of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.025&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The post-consolidation common share purchase warrants will be subject to acceleration if the volume weighted average price of the Company's common shares equals or exceeds &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$23.75&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consecutive trading dates.  The ascribed value was determined using the relative fair value method. The ascribed value of the common share purchase warrants was determined using the Black-Scholes valuation model. We incurred share issue costs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,145,402&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(c)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On June 5, 2018, pursuant to an underwritten public offering, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,532,278&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares were sold at a purchase price of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.83&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share for gross proceeds of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8,933,181&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. We incurred share issue costs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,418,356&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(d)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On September 27, 2018, we entered into a Common Stock Purchase Agreement (the "Agreement") with Lincoln Park Capital Fund, LLC ("LPC"). Subject to the terms and conditions of the Agreement and at our sole discretion, we may sell up to US$&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; worth of common shares to LPC over the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-month term. The purchase price of the common shares will be based on the prevailing market prices immediately preceding the notice of sale without any fixed discount. Subject to the terms of the Agreement, we control the timing and amount of any future investment and LPC is obligated to make such purchases, if and when we elect. The Agreement does not impose any upper price limit restrictions, negative covenants or restrictions on our future financing activities. However, in no event will shares be sold to LPC on a day the closing sale price for the common shares is less than the floor price of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per common share; or at a price per share that is less than the volume weighted average trading pricing of the common shares on the TSX for the five immediately preceding trading days, less the maximum applicable discount allowed by the TSX. The Agreement limits our sale of common shares to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19.99%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of our total outstanding common shares as at the date that the Common Stock Purchase Agreement was entered into, unless and until we have obtained shareholder approval under applicable Nasdaq rules. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we have reached that limit. We can terminate the Agreement at any time at our sole discretion without any monetary cost or penalty. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,477,665&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;678,182&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) common shares for gross proceeds of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4,055,725&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;text-transform:default;"&gt;$2,055,207&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) and issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;text-transform:default;"&gt;17,278&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;text-transform:default;"&gt;119,509&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) commitment shares. The commitment shares were fair valued at US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$29,758&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$483,690&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) and were recorded as share issue costs in addition to cash share issue costs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3,757&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$208,726&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(e)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allows us, at our sole discretion, to issue common shares, at prevailing market price, with an aggregate offering value of up to US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$30,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; over the next &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19 months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; through the facilities of the NASDAQ in the United States. In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,425,040&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,002&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) common shares for gross proceeds of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6,390,691&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50,046&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;). We incurred share issue costs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;344,834&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; -  &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$135,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;). &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(f)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On August 16, 2019, pursuant to an underwritten public offering, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;text-transform:default;"&gt;4,619,773&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; units were sold at a purchase price of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.81&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per unit for gross proceeds of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3,742,016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Each unit included &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common share with a fair value of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.54&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common share purchase warrant with a fair value of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.27&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. These warrants were classified as a financial liability (see Note 8). Each common share purchase warrant entitled the holder to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common share at an exercise price of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.90&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; until August 16, 2024. We incurred transaction costs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$699,427&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$466,284&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were allocated to share issue costs and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$233,143&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were allocated to operating expenses, based on their relative fair values. In the fourth quarter of 2019, our share capital included fair value of $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,687,003&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in addition to gross proceeds of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2,642,082&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,935,647&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; warrants that were exercised (see Note 8). &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
	<ifrs-full:DisclosureOfCommitmentsExplanatory contextRef="FD2019Q4YTD" id="Fact-5816846541E0065104019CFE2BE3C845">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Commitments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We are committed to payments totaling &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$4,867,131&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for activities related to our clinical trial, manufacturing and collaboration programs which are expected to occur over the next two years. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our commitments include one-half of the committed payments related to our collaboration with Merck KGaA, Darmstadt, Germany,  and Pfizer Inc ("Pfizer"), known as BRACELET-1, as the cost of this phase 2 clinical trial will be shared equally between Oncolytics and Pfizer. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we recorded US$&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nil&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) in other receivables related to an upfront payment of BRACELET-1 cost from Pfizer per the terms of the collaboration agreement with an offsetting US$&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;652,306&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nil&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) in other liabilities representing future trial costs to be incurred.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under a clinical trial agreement entered into with the Alberta Cancer Board (&amp;#8220;ACB&amp;#8221;), we have agreed to repay the amount funded under the agreement together with a royalty, to a combined maximum amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$400,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; plus an overhead repayment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$100,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, upon sales of a specified product.&amp;#160;&amp;#160;We agreed to repay the ACB in annual installments in an amount equal to the lesser of: (a) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of gross sales of a specified product; or (b) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$100,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per annum once sales of a specified product commence.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCommitmentsExplanatory>
	<ifrs-full:DisclosureOfContingentLiabilitiesExplanatory contextRef="FD2019Q4YTD" id="Fact-D6FA40F310C2DC41D6259CFE2C2D6073">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Assumption Agreement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In 1999, we entered into an agreement that assumed certain obligations (the &amp;#8220;Assumption Agreement&amp;#8221;) in connection with a Share Purchase Agreement (the &amp;#8220;Share Purchase Agreement&amp;#8221;) between SYNSORB and our former shareholders to make milestone payments and royalty payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, a milestone payment was still outstanding for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, due within &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90 days&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the first receipt from an Appropriate Regulatory Authority, for marketing approval to sell pelareorep to the public or the approval of a new drug application for pelareorep.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;This milestone payment, when payable, will be accounted for as research and development expense and will not be deductible for income tax purposes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In addition to the milestone payment, payments may become due and payable in accordance with the Share Purchase Agreement upon realization of sales of pelareorep.&amp;#160;&amp;#160;If we receive royalty payments or other payments as a result of entering into partnerships or other arrangements for the development of the reovirus technology, we are obligated to pay to the founding shareholders &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.75%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.75%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) of the royalty payments and other payments received.&amp;#160;Alternatively, if we develop the reovirus treatment to the point where it may be marketed at a commercial level, the payments referred to in the foregoing sentence will be amended to a royalty payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.15%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.15%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) of Net Sales received for such products.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;BRI &amp;#8220;Work in Kind&amp;#8221; Contribution&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We entered into an engineering and process development agreement with the Biotechnology Research Institute of the National Research Council of Canada (&amp;#8220;BRI&amp;#8221;).&amp;#160;&amp;#160;The terms of this agreement include a &amp;#8220;work in kind&amp;#8221; contribution from BRI.&amp;#160;&amp;#160;In exchange for this &amp;#8220;work in kind&amp;#8221; contribution, we agreed to provide a royalty, contingent upon receiving Sales Revenue, at the lesser of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of Sales Revenue or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per year.&amp;#160;&amp;#160;The total royalty under this Agreement is equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; times the &amp;#8220;work in kind&amp;#8221; contribution.&amp;#160;&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we estimate that the accumulated work in kind totals approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$301,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfContingentLiabilitiesExplanatory>
	<ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory contextRef="FD2019Q4YTD" id="Fact-4C1A3E0F68E72091031C9CFE2C1BAFA2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation is recorded using the declining balance method at the following annual rates:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.40350877192983%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:51%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Office equipment and furniture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Medical equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Straight-line over the term of the lease&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:164px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:80px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:87px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:79px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:76px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:90px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Medical Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Computer Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Office Furniture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Office Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Leasehold Improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;197,870&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;681,985&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;225,896&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;89,466&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;534,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,729,517&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Additions, net of foreign exchange impact&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;88,202&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,542&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,763&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49,163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;174,670&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Disposals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(137,492&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(424,246&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(85,096&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(646,834&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;60,378&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;345,941&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;247,438&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;105,229&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;498,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,257,353&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Additions, net of foreign exchange impact&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Disposals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As at December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;60,378&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;352,955&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;247,438&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;105,229&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;498,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,264,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;154,334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;549,564&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;147,334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;68,787&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;476,057&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,396,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49,635&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,415&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,041&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,662&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;95,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Disposals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(137,492&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(424,246&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(85,096&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(646,834&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,464&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;174,953&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;157,749&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72,828&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;414,623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;844,617&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,244&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49,093&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,668&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,342&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,635&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;122,982&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Disposals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As at December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;44,708&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;224,046&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;172,417&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78,170&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;448,258&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;967,599&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net book value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As at December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;15,670&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;128,909&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;75,021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;27,059&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;50,109&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;296,768&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,914&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;170,988&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;89,689&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,401&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;412,736&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
	<ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="FD2019Q4YTD" id="Fact-4B17ACC38454EC4C09E49CFE2BFAB359">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Loss Per Common Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss per common share is calculated using net loss for the year and the weighted average number of common shares outstanding for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;22,137,990&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;16,016,366&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;13,936,387&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;). The effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
	<ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="FD2019Q4YTD" id="Fact-CF8051C12FA647A214CE9CFE2C1201AA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Subsequent Events&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Between &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January&amp;#160;1, 2020&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;5, 2020&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,921,790&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares for gross proceeds of US$&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,726,383&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; through our October 2018 ATM equity offering sales agreement and we received gross proceeds of US$&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,030,669&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as a result of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,145,188&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; August 2019 public offering warrants that were exercised.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;February&amp;#160;25, 2020&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we received the US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront payment of BRACELET-1 cost from Pfizer (see Note 13 for details).&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
	<ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory contextRef="FD2019Q4YTD" id="Fact-D5094AEBAB0061F1A7529CFE2C305162">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A reconciliation of the change in fair value of the warrant derivative is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:513px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:258px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:122px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:123px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number of Warrants Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value of Warrant Derivative&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued, August 16, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,619,773&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,657,214&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,935,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,687,003&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in fair value &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,608,808&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign exchange impact&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(70,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,684,126&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,508,764&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The estimated fair value of the warrant derivative was determined using the following assumptions: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:455px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:273px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:90px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:90px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;August&amp;#160;16, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value per warrant&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$3.89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$0.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Underlying share price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$4.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$0.54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.59%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.42%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected hold period to exercise&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.0 year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected share price volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90.00%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;82.00%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nil&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nil&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory>
	<ifrs-full:DisclosureOfFinancialInstrumentsExplanatory contextRef="FD2019Q4YTD" id="Fact-24770285741C21351F7D9CFE2C11E774">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our financial instruments consist of cash and cash equivalents,&amp;#160;other receivables, other liabilities, accounts payable and warrant derivative.&amp;#160;As at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the carrying amount of our cash and cash equivalents,&amp;#160;other receivables, other liabilities and accounts payable approximated their fair value. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and therefore do not trade on an active market. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the fair value of our warrant derivative was $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,508,764&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nil&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Credit risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&amp;#160;We are exposed to credit risk on our cash and cash equivalents and other receivables from Pfizer connected to the BRACELET-1 study (see Note 13) in the event of non-performance by counterparties, but we do not anticipate such non-performance.&amp;#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and other receivables. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We mitigate our exposure to credit risk connected to our cash and cash equivalent by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&amp;#160;For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We mitigate our exposure to credit risk connected to our Pfizer other receivable by entering into collaborations with global biopharmaceutical companies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Interest rate risk &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&amp;#160;We are exposed to interest rate risk through our cash and cash equivalents.&amp;#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Foreign exchange risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. We are primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar, British pound and Euro as a portion of our financial assets and liabilities are denominated in such currencies. The impact of a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.01&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; increase in the value of the U.S. dollar against the Canadian dollar would have increased our net comprehensive loss in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; by approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$125,339&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160;&amp;#160;The impact of a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.10&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; increase in the value of the British pound against the Canadian dollar would have increased our net comprehensive loss in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; by approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$8,581&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The impact of a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.10&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; increase in the value of the Euro against the Canadian dollar would have increased our net comprehensive loss in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; by approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$32,426&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balances in foreign currencies at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:622px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:222px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:133px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:133px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:133px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;US dollars &lt;br clear="none"/&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;British pounds&lt;br clear="none"/&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#163;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Euro&lt;br clear="none"/&gt;&amp;#8364;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,676,360&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26,751&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,664&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other receivables&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts payable and other liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,378,860)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,345)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(310,086)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrant derivative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,551,250)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,246,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,406&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(276,422)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Liquidity risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&amp;#160;We manage liquidity risk through the management of our capital structure as outlined in Note 16. Accounts payable are all due within the current operating period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
	<ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory contextRef="FD2019Q4YTD" id="Fact-E784B90B7D3C2B91ED659CFE2BD21907">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Warrant Derivative&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On August 16, 2019, pursuant to an underwritten public offering, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,619,773&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; units were sold at a purchase price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$0.81&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per unit for gross proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$3,742,016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Each unit included &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common share and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common share purchase warrant (see Note 9). Each common share purchase warrant entitled the holder to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common share at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$0.90&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; until August 16, 2024. We incurred transaction costs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$699,427&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$466,284&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were allocated to share issue costs and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$233,143&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were allocated to operating expenses, based on their relative fair values.   &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under IFRS 9 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and IAS 32 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments: Presentation&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, warrants with an exercise price denominated in a currency that differs from an entity's functional currency are treated as a derivative measured at fair value with subsequent changes in fair value accounted for through profit and loss. Our warrants with an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$0.90&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; meet this requirement and we have presented the fair value of these warrants as a current liability on the consolidated statement of financial position. As these warrants are exercised, the fair value at the date of exercise and the associated non-cash liability will be included in our share capital along with the proceeds from the exercise. If these warrants expire, the non-cash warrant liability is reversed through the consolidated statement of loss. There is no cash flow impact as a result of the accounting treatment for changes in the fair value of the warrant derivative or when warrants expire unexercised. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A reconciliation of the change in fair value of the warrant derivative is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:513px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:258px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:122px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:123px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number of Warrants Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value of Warrant Derivative&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued, August 16, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,619,773&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,657,214&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,935,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,687,003&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in fair value &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,608,808&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign exchange impact&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(70,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,684,126&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,508,764&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In 2019, we received cash proceeds of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2,642,082&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; with respect to the warrants exercised. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We use the Black-Scholes valuation model to estimate fair value. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on U.S. Department of Treasury benchmark treasury yield rates with an approximate equivalent remaining term in effect at the time of valuation and the expected life represents the estimated length of time the warrants are expected to remain outstanding. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The estimated fair value of the warrant derivative was determined using the following assumptions: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:455px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:273px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:90px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:90px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;August&amp;#160;16, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value per warrant&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$3.89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$0.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Underlying share price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$4.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US$0.54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.59%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.42%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected hold period to exercise&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.0 year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected share price volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90.00%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;82.00%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nil&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nil&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory>
	<ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory contextRef="FD2019Q4YTD" id="Fact-9256A7E083B6DBE3666D9CFE2BFB891F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Incorporation and Nature of Operations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Oncolytics Biotech Inc. was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd.  On April 8, 1998, we changed our name to Oncolytics Biotech Inc.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our consolidated financial statements for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;March&amp;#160;5, 2020&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Markets and the Toronto Stock Exchange. Our registered office is located at 210, 1167 Kensington Crescent NW, Calgary, Alberta, Canada.   &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We are a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. Our lead product, pelareorep, is a potential immuno-oncology viral-agent that may be a novel treatment for certain types of cancer and may be an alternative to or in combination with existing cytotoxic or cytostatic therapies. Our clinical development program for pelareorep emphasizes three programs: chemotherapy combinations to assist the escape of the virus from the vasculature and enhance its distribution in the tumor; immuno-therapy combinations to create an inflamed phenotype promoting synergies with immune checkpoint inhibitors; and immune modulator/targeted combinations to upregulate natural killer cells promoting synergies with targeted therapies.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
	<ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="FD2019Q4YTD" id="Fact-10A6753D3A4B338196B89CFE2BF1BF25">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:583px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:316px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:76px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss before income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(33,122,888&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(16,489,183&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(15,475,353&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Statutory Canadian corporate tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;26.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Anticipated tax recovery&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(8,777,565&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,452,079&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,178,345&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign jurisdiction tax rate difference&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3,088,811&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,312,963&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,899,190&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employee share based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;389,591&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;382,275&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;156,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in fair value of warrant derivative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3,341,334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Impact of Alberta rate change&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3,758,175&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Adjustment to opening tax pools&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;11,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(238,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;162,162&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other permanent differences&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;149,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(35,912&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53,039&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in deferred tax benefits deemed not probable to &lt;br clear="none"/&gt;  be recovered&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(1,961,613&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,579,017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,051,725&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;548,042&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;144,021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Adjustment in respect to prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,523&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net current tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;548,042&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;141,498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we have the following non-capital losses for income tax purposes in Canada:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:24.756335282651072%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:37%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Expiry&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2026&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,809,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,170,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,009,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2030&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,774,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,343,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2032&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,873,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2033&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,457,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2034&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,472,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2035&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,125,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2036&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,430,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2037&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,812,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2038&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,056,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2039&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,900,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;69,230,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we have the following non-refundable federal investment tax credits for income tax purposes in Canada:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:190px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:97px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:88px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Expiry&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;189,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;471,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;465,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;361,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;228,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;271,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2026&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;520,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;596,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2028&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;622,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;173,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2030&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;114,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2032&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;381,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2033&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;487,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2034&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;270,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2035&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;183,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2036&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2037&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;980&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2038&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;5,482,980&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As well, we have unclaimed scientific research and experimental development expenditures available to reduce future years&amp;#8217; taxable income of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$27,560,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160;&amp;#160;We have not recorded the potential benefits of these tax pools in these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available, against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilized. The components of our unrecognized deferred tax asset are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:612px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:345px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:84px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:84px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:84px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net operating losses carried forward&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;19,625,642&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,664,345&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,160,218&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Scientific research and experimental development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,338,542&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,406,169&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,406,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Investment tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;4,222,016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,988,606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,988,325&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Undepreciated capital costs in excess of book value of property and equipment and intellectual property&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,908,320&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,949,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,927,640&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share issue costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;611,072&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;696,346&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;493,343&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net capital losses carried forward&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,474&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,598&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,598&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unrecognized deferred tax asset&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;32,712,066&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,712,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,983,223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
	<ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory contextRef="FD2019Q4YTD" id="Fact-5BB61C513DDFC974E5E39CFE2BF60D38">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The estimated fair value of stock options issued during the year was determined using the following weighted average assumptions: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:464px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:245px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:74px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1.62%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.02%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.18%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected hold period to exercise&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected share price volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;97.90%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;81.15%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90.73%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected forfeiture rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3.67%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.67%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.67%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Nil&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nil&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nil&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average fair value of options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$0.87&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.67&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
	<ifrs-full:DisclosureOfLeasesExplanatory contextRef="FD2019Q4YTD" id="Fact-F4C99AE471C3C35193F19CFE2C0617EC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our portfolio of leases consists of office spaces with lease terms generally between &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years. We currently do not have leases with variable lease payments, residual value guarantees, extension or termination options, or leases not yet commenced to which we are committed.  Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate as rates implicit in the leases were not readily determinable. The weighted-average rate applied was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Right-of-use assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;                   &lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:374px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:301px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Office Spaces&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at January 1, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;808,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(362,592&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign exchange impact&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(14,720&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;430,713&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;                    &lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:372px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:298px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Office Spaces&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at January 1, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;882,437&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Payment of lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(447,497&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Interest expense on lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94,817&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign exchange impact&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(23,482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;506,275&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our total undiscounted lease liability as at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.94736842105263%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:30%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Maturity analysis - contractual undiscounted cash flows&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less than one year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;391,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;One to five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;174,157&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;More than five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total undiscounted lease liability as at December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;565,179&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
	<ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory contextRef="FD2019Q4YTD" id="Fact-91945E9E6058B9A14DD99CFE2C38D42B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our total undiscounted lease liability as at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.94736842105263%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:30%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Maturity analysis - contractual undiscounted cash flows&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less than one year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;391,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;One to five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;174,157&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;More than five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total undiscounted lease liability as at December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;565,179&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory>
	<ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory contextRef="FD2019Q4YTD" id="Fact-BFA33C30D3CB0871C0FC9CFE2BF7E651">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following RSUs are outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:515px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:269px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, beginning of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;260,755&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;190,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;139,237&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Granted during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;270,098&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;102,855&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;51,170&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,210&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Vested during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(321,196&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(28,297&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, end of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;209,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;260,755&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;190,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:36px;"&gt;&lt;font style="text-align:justify;font-family:inherit;font-size:8pt;padding-right:24px;"&gt;(1)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;The weighted average fair value of the RSUs granted was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$0.80&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$3.35&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; ; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$5.96&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The following PSUs are outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:521px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:274px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:79px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:75px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, beginning of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;63,156&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94,734&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;88,419&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Granted during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,315&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(31,578&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(2,105&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, end of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;61,051&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;63,156&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94,734&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:36px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(1) &amp;#160;&amp;#160;&amp;#160;&amp;#160;The weighted average fair value of the PSUs granted was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;nil&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;nil&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$3.33&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
	<ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory contextRef="FD2019Q4YTD" id="Fact-10C954EE042F6E5F35989CFE2BFE84D5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:650px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:158px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:75px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:84px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:74px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:82px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:80px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:81px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, beginning of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,249,361&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;8.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;647,156&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;912,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,020,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;750,467&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42,625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(12,839&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;11.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(105,338&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.67&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(211,847&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expired during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(9,575&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;29.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13.78&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(12,302&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(41,802&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(84,315&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, end of the&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2,246,947&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;5.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,249,361&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;647,156&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercisable, end of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,327,845&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;7.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;777,245&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;573,984&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14.36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
	<ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory contextRef="FD2019Q4YTD" id="Fact-0A3090B30C161776F7059CFE2BE44BC6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes our outstanding equity warrants at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;         &lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:425px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:74px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:100px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:90px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:138px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Outstanding, Beginning of the Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Outstanding, End of the Year&lt;/font&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Remaining Contractual Life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,443,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,443,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:78px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(1)&amp;#160;&amp;#160;&amp;#160;&amp;#160; Exercisable into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,730,894&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; common shares.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes information about the stock options outstanding and exercisable at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:182px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:100px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:100px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:100px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Range of Exercise Prices&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Number Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Remaining Contractual Life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Number Exercisable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$0.54 - $1.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;100,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;4.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;66,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$1.43 - $1.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;900,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;4.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;300,009&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$1.80 - $3.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;376,411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;5.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;284,412&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$3.40 - $7.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;395,111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;4.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;322,880&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$7.14 - $63.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;475,425&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;16.74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;353,877&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;19.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2,246,947&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;4.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;5.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1,327,845&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;7.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory>
	<ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory contextRef="FD2019Q4YTD" id="Fact-F6E6F30F720077CF22889CFE2BD21F6C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Capital Disclosures&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our objective when managing capital is to maintain a strong statement of financial position. We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs and intellectual property expansion and protection.&amp;#160;We include shareholders&amp;#8217; equity and cash and cash equivalents in the definition of capital.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;14,148,021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,699,881&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shareholders&amp;#8217; (deficit) equity&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(107,894&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,195,363&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We do not have any debt other than trade accounts payable and we have potential contingent obligations relating to the completion of our research and development of pelareorep.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&amp;#8217;s activity.&amp;#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&amp;#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&amp;#160;There are no assurances that funds will be made available to us when required.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On May 4, 2018, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$150,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the US or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Renewing our Base Shelf  provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until May 25, 2020. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our Base Shelf allowed us to enter into our Common Stock Purchase Agreement in September 2018, our ATM equity offering sales agreement in October 2018, and our public offering in August 2019 (see Note 9). We will use these equity arrangements to assist us in achieving our capital objective. Each arrangement provides us with the opportunity to raise capital at our sole discretion providing us with the ability to better manage our cash resources. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory>
	<ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory contextRef="FD2019Q4YTD" id="Fact-303119D5CFCB6FB8AFA29CFE2BD359A9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Other Expenses and Adjustments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We present our expenses based on the function of each expense. We include realized foreign exchange gains and losses, unrealized non-cash foreign exchange gains and losses and non-cash share based compensation associated with research and development activity as a component of research and development expenses. We include depreciation of property and equipment, depreciation of right-of-use-asset, share based compensation associated with operating activities, and transaction costs related to our warrant derivative as a component of operating expenses.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:639px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:420px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Included in research and development expenses:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Realized foreign exchange (gain) loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(39,362&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(120,794&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unrealized non-cash foreign exchange loss (gain)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;356,081&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(608,111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;55,538&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-cash share based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;561,420&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;680,541&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;230,141&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Included in operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation - property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;122,982&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;95,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90,768&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation - right-of-use assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;362,592&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-cash share based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;908,733&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;735,292&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;348,562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Transaction cost, warrant derivative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;233,143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Onerous lease contract&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amortization - lease incentive liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,189&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory>
	<ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="FD2019Q4YTD" id="Fact-5E2E4DCB28FA8DF7C4229CFE2C0FF5A5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Property and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:164px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:80px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:87px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:79px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:76px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:90px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Medical Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Computer Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Office Furniture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Office Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Leasehold Improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;197,870&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;681,985&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;225,896&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;89,466&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;534,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,729,517&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Additions, net of foreign exchange impact&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;88,202&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,542&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,763&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49,163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;174,670&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Disposals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(137,492&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(424,246&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(85,096&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(646,834&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;60,378&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;345,941&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;247,438&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;105,229&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;498,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,257,353&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Additions, net of foreign exchange impact&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Disposals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As at December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;60,378&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;352,955&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;247,438&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;105,229&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;498,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,264,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;154,334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;549,564&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;147,334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;68,787&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;476,057&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,396,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49,635&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,415&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,041&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,662&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;95,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Disposals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(137,492&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(424,246&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(85,096&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(646,834&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,464&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;174,953&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;157,749&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72,828&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;414,623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;844,617&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,244&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49,093&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,668&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,342&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,635&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;122,982&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Disposals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As at December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;44,708&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;224,046&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;172,417&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78,170&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;448,258&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;967,599&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net book value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As at December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;15,670&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;128,909&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;75,021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;27,059&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;50,109&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;296,768&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,914&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;170,988&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;89,689&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,401&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;412,736&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
	<ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory contextRef="FD2019Q4YTD" id="Fact-E6816EFA080C19E1DC1E9CFE2C377FD9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Right-of-use assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;                   &lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:374px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:301px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Office Spaces&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at January 1, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;808,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(362,592&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign exchange impact&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(14,720&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;430,713&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;                    &lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:372px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:298px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Office Spaces&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at January 1, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;882,437&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Payment of lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(447,497&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Interest expense on lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94,817&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign exchange impact&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(23,482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;506,275&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory>
	<ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory contextRef="FD2019Q4YTD" id="Fact-98DDF3E20022EA07433F9CFE2BF4A2C8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes information about the stock options outstanding and exercisable at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:182px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:100px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:100px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:100px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Range of Exercise Prices&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Number Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Remaining Contractual Life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Number Exercisable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$0.54 - $1.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;100,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;4.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;66,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$1.43 - $1.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;900,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;4.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;300,009&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$1.80 - $3.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;376,411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;5.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;284,412&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$3.40 - $7.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;395,111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;4.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;322,880&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$7.14 - $63.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;475,425&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;16.74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;353,877&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;19.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2,246,947&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;4.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;5.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1,327,845&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;7.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory>
	<ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="FD2019Q4YTD" id="Fact-D8F3A8681805922B04829CFE2C335035">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Related Party Transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Compensation of Key Management Personnel&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole. We have determined that key management personnel consists of the members of the Board of Directors along with certain officers of the Company.   &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:520px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:301px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3,786,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,680,621&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,596,082&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Termination benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;779,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share-based payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,123,408&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,067,195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;459,298&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;4,910,075&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,747,816&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,835,046&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Assumption Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In November 2017, with the signing of the Licensing Agreement with upfront license fees (see Note 12), the Company triggered a liability of US$&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;178,125&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to an officer as detailed in the Assumption Agreement (see Note 14). The liability was fully repaid in 2018.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
	<ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory contextRef="FD2019Q4YTD" id="Fact-05DEFA7E02658C1A1A339CFE2BCEC985">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Contract Liability and Receivable&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Regional licensing agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We entered into a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Warrant purchase agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We also entered into a warrant purchase agreement with Adlai. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we were entitled to receive the following:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;One common share purchase warrant of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; whereby, upon exercise, Adlai may purchase our common shares priced at a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; premium to the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-day weighted average closing price immediately preceding the exercise date. We have the right to call this warrant upon the enrollment of the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;th patient in the phase 3 metastatic breast cancer study. This common share purchase warrant expires on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;November&amp;#160;14, 2020&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Contract liability&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#333333;"&gt;Our contract liability balance at December 31, which w&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;e expect to record in revenue over the next &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:443px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:236px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:102px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, beginning of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,730,287&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,182,580&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Regional licensing agreement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;547,707&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue recognized in the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, end of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,730,287&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,730,287&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contract liability - current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;927,400&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contract liability - non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,730,287&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,802,887&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,730,287&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,730,287&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory>
	<ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="FD2019Q4YTD" id="Fact-C4321997EACC99B61F699CFE2BE59EA9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Share Capital&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Authorized:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unlimited number of no par value common shares&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Share Consolidation:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On May 22, 2018, we completed the consolidation of our common shares on the basis of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.5&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; pre-consolidation common shares for each one post-consolidation common share (the "Share Consolidation"). Fractional interests were rounded down to the nearest whole number of common shares. Outstanding stock options, restricted share units and performance share units were similarly adjusted by the consolidation ratio. Outstanding warrants were adjusted such that, following the Share Consolidation, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.5&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; equity-classified warrants will entitle the holder to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; whole common share until June 1, 2022.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:665px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:293px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:88px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:88px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:88px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:88px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amount&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amount&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;121,258,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;262,321,825&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to stock option plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;801,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;536,949&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to "At the Market" equity distribution agreement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,301,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,348,821&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to public offering&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(b)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,445,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,893,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,445,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,617,900&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share issue costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,391,057&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;141,805,722&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;271,710,138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,445,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,617,900&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to "At the Market" equity distribution agreement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;519,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;553,650&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share issue costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(33,335&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to stock option plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;71,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38,269&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, May 22, 2018 - pre-consolidation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;142,396,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;272,268,722&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,445,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,617,900&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, May 22, 2018 - post-consolidation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,988,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;272,268,722&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,445,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,617,900&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to public offering&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(c)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,532,278&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,606,882&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to warrant agreement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(b)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;157&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,747&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(330&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to stock option plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,329&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;158,976&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to incentive share award plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28,297&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;109,751&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to Common Stock Purchase Agreement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(d)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;797,691&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,314,097&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to "At the Market" equity distribution agreement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(e)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,002&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;66,360&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share issue costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,333,474&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,399,749&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;285,193,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,443,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,617,570&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to incentive share award plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;323,301&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;391,917&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to Common Stock Purchase Agreement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(d)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,494,943&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,403,385&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to "At the Market" equity distribution agreement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(e)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,425,040&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,476,454&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to public offering&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(f)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,619,773&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,314,429&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issued pursuant to warrant derivative exercised&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(f)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,935,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,152,869&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share issue costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(854,256&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balance, December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;32,198,453&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;311,077,859&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;16,443,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3,617,570&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February 25, 2016, we entered into an "at-the-market" ("ATM") equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; which allows us to sell our common shares through the facilities of the Toronto Stock Exchange or other "marketplace&amp;#8221; (as defined in National Instrument 21-101 Marketplace Operation) in Canada (our "Canadian ATM"). Subject to the terms of our Canadian ATM, we are able to determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility. During 2018, we sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;519,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; pre-consolidation shares (approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;54,684&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; post-consolidation shares) (2017 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,301,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; pre-consolidation shares (approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;347,526&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; post-consolidation shares) common shares for gross proceeds of $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;553,650&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (2017 - $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,348,821&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;). We incurred share issue costs of $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,335&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (2017 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$245,655&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On June 1, 2017, pursuant to an underwritten public offering, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,445,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; units were sold at a purchase price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.70&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per unit for gross proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$11,511,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  Each unit included &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; pre-consolidation common share with an ascribed value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.48&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.106&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; post-consolidation common share with an ascribed value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.56&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; pre-consolidation common share purchase warrant with an ascribed value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.22&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; post-consolidation common share purchase warrant with an ascribed value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.09&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;). These warrants were classified as equity. Each pre-consolidation common share purchase warrant entitled the holder to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; pre-consolidation common share at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.95&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Following the Share Consolidation, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.5&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; pre-consolidation common share purchase warrants entitles the holder to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; post-consolidation common share in the capital of the Company until June 1, 2022, at an exercise price of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.025&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The post-consolidation common share purchase warrants will be subject to acceleration if the volume weighted average price of the Company's common shares equals or exceeds &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$23.75&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consecutive trading dates.  The ascribed value was determined using the relative fair value method. The ascribed value of the common share purchase warrants was determined using the Black-Scholes valuation model. We incurred share issue costs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,145,402&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(c)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On June 5, 2018, pursuant to an underwritten public offering, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,532,278&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares were sold at a purchase price of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.83&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share for gross proceeds of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8,933,181&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. We incurred share issue costs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,418,356&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(d)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On September 27, 2018, we entered into a Common Stock Purchase Agreement (the "Agreement") with Lincoln Park Capital Fund, LLC ("LPC"). Subject to the terms and conditions of the Agreement and at our sole discretion, we may sell up to US$&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; worth of common shares to LPC over the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-month term. The purchase price of the common shares will be based on the prevailing market prices immediately preceding the notice of sale without any fixed discount. Subject to the terms of the Agreement, we control the timing and amount of any future investment and LPC is obligated to make such purchases, if and when we elect. The Agreement does not impose any upper price limit restrictions, negative covenants or restrictions on our future financing activities. However, in no event will shares be sold to LPC on a day the closing sale price for the common shares is less than the floor price of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per common share; or at a price per share that is less than the volume weighted average trading pricing of the common shares on the TSX for the five immediately preceding trading days, less the maximum applicable discount allowed by the TSX. The Agreement limits our sale of common shares to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19.99%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of our total outstanding common shares as at the date that the Common Stock Purchase Agreement was entered into, unless and until we have obtained shareholder approval under applicable Nasdaq rules. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we have reached that limit. We can terminate the Agreement at any time at our sole discretion without any monetary cost or penalty. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,477,665&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;678,182&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) common shares for gross proceeds of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4,055,725&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;text-transform:default;"&gt;$2,055,207&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) and issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;text-transform:default;"&gt;17,278&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;text-transform:default;"&gt;119,509&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) commitment shares. The commitment shares were fair valued at US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$29,758&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$483,690&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) and were recorded as share issue costs in addition to cash share issue costs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3,757&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$208,726&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(e)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allows us, at our sole discretion, to issue common shares, at prevailing market price, with an aggregate offering value of up to US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$30,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; over the next &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19 months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; through the facilities of the NASDAQ in the United States. In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,425,040&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,002&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) common shares for gross proceeds of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6,390,691&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50,046&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;). We incurred share issue costs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;344,834&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; -  &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$135,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;). &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(f)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On August 16, 2019, pursuant to an underwritten public offering, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;text-transform:default;"&gt;4,619,773&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; units were sold at a purchase price of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.81&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per unit for gross proceeds of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3,742,016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Each unit included &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common share with a fair value of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.54&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common share purchase warrant with a fair value of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.27&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. These warrants were classified as a financial liability (see Note 8). Each common share purchase warrant entitled the holder to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common share at an exercise price of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.90&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; until August 16, 2024. We incurred transaction costs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$699,427&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$466,284&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were allocated to share issue costs and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$233,143&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were allocated to operating expenses, based on their relative fair values. In the fourth quarter of 2019, our share capital included fair value of $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,687,003&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in addition to gross proceeds of US&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2,642,082&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,935,647&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; warrants that were exercised (see Note 8). &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Equity Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes our outstanding equity warrants at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;         &lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:425px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:74px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:100px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:90px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:138px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Outstanding, Beginning of the Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Outstanding, End of the Year&lt;/font&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Remaining Contractual Life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,443,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,443,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:78px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(1)&amp;#160;&amp;#160;&amp;#160;&amp;#160; Exercisable into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,730,894&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; common shares.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
	<ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="FD2019Q4YTD" id="Fact-5CE2303DCFF43AABA64F9CFE2BF2994E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:1px;text-align:justify;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Share Based Payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;font-weight:bold;"&gt;Stock Option Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:650px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:158px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:75px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:84px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:74px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:82px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:80px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:81px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, beginning of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,249,361&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;8.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;647,156&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;912,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,020,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;750,467&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42,625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(12,839&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;11.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(105,338&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.67&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(211,847&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expired during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(9,575&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;29.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13.78&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(12,302&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(41,802&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(84,315&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, end of the&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2,246,947&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;5.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,249,361&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;647,156&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercisable, end of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,327,845&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;7.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;777,245&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;573,984&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14.36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes information about the stock options outstanding and exercisable at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:182px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:100px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:100px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:100px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Range of Exercise Prices&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Number Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Remaining Contractual Life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Number Exercisable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$0.54 - $1.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;100,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;4.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;66,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$1.43 - $1.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;900,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;4.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;300,009&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$1.80 - $3.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;376,411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;5.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;284,412&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$3.40 - $7.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;395,111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;4.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;322,880&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$7.14 - $63.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;475,425&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;16.74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;353,877&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;19.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2,246,947&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;4.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;5.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1,327,845&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;7.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-exercisable options vest annually over periods ranging from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We use the Black-Scholes valuation model to estimate fair value. We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The estimated fair value of stock options issued during the year was determined using the following weighted average assumptions: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:464px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:245px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:74px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1.62%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.02%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.18%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected hold period to exercise&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected share price volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;97.90%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;81.15%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90.73%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected forfeiture rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3.67%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.67%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.67%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Nil&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nil&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nil&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average fair value of options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$0.87&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.67&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;font-weight:bold;"&gt;Incentive Share Award Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Restricted Share Units&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have issued restricted share units ("RSUs") to non-employee directors through our incentive share award plan. Grants of RSUs to non-employee directors vest either immediately, on the third anniversary date from the grant date or when the director ceases to be a member of the board. We have also issued RSUs to certain officers and employees of the Company. Grants of RSUs to certain officers and employees of the Company vest over a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; year period. The following RSUs are outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:515px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:269px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, beginning of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;260,755&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;190,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;139,237&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Granted during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;270,098&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;102,855&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;51,170&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,210&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Vested during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(321,196&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(28,297&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, end of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;209,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;260,755&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;190,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:36px;"&gt;&lt;font style="text-align:justify;font-family:inherit;font-size:8pt;padding-right:24px;"&gt;(1)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;The weighted average fair value of the RSUs granted was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$0.80&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$3.35&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; ; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$5.96&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Performance Share Units&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have also issued performance share units ("PSUs") to certain officers and employees of the Company. Grants of PSUs require completion of certain performance criteria and cliff vest after &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or vest over a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; year period, depending on the grant. PSU grants to certain officers will vest immediately upon a change of control of the Company. If certain officers cease employment with the Company, vesting occurs on a pro rata basis prior to the third anniversary of the grant but after the first anniversary. The following PSUs are outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:521px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:274px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:79px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:75px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, beginning of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;63,156&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94,734&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;88,419&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Granted during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,315&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(31,578&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested during the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(2,105&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, end of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;61,051&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;63,156&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94,734&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:36px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(1) &amp;#160;&amp;#160;&amp;#160;&amp;#160;The weighted average fair value of the PSUs granted was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;nil&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;nil&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$3.33&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have reserved &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,219,845&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares for issuance relating to our outstanding equity compensation plans. Compensation expense related to stock options, RSUs and PSUs for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,470,153&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,415,833&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$578,703&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
	<ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory contextRef="FD2019Q4YTD" id="Fact-95AF6F654EDCD1C9213A9CFE2C3B0B81">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The consolidated financial statements have, in management's opinion, been properly prepared within reasonable limits of materiality and within the framework of the significant accounting policies summarized below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;font-weight:bold;"&gt;Deferred income taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We follow the liability method of accounting for income taxes.  Under the liability method, deferred income taxes are recognized for the difference between financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences).  Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled.  The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;font-weight:bold;"&gt;Financial instruments &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Classification and measurement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under IFRS 9 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments ("IFRS 9")&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&amp;#8217;s business model for managing the assets; and whether the financial asset&amp;#8217;s contractual cash flows represent &amp;#8216;solely payments of principal and interest&amp;#8217; on the principal amount outstanding (the &amp;#8216;SPPI criterion&amp;#8217;). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our financial assets include cash and cash equivalents and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include trade accounts payable, other liabilities and warrant derivative. The classification and measurement of trade accounts payable and other liabilities are at amortized cost. The classification and measurement of warrant derivative is at FVPL.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Impairment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under IFRS 9, accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IFRS 9 requires that we record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&amp;#8217;s original effective interest rate.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Derecognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A financial asset is derecognized when:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;the contractual rights to the cash flows from the financial asset expire, or&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A financial liability is derecognized when our obligations specified in the contract are discharged or canceled or expired. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value Measurement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments we prioritize the related inputs used in measuring fair value into the following hierarchy: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;font-weight:bold;"&gt;Foreign currency translation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exceptions to this are where the monetary items form part of the net investment in a foreign operation and the foreign operation's functional currency is the local currency.  These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;font-weight:bold;"&gt;Loss per common share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic loss per common share is determined using the weighted average number of common shares outstanding during the period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We use the treasury stock method to calculate diluted loss per common share.  Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants, if dilutive. The number of additional common shares is calculated by assuming that any outstanding &amp;#8220;in the money&amp;#8221; options, restricted share units, performance share units and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;font-weight:bold;"&gt;Property and equipment &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives.  Depreciation is recorded using the declining balance method at the following annual rates:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.40350877192983%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:51%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Office equipment and furniture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Medical equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Straight-line over the term of the lease&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;font-weight:bold;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At inception of a contract, we assess whether a contract is, or contains a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;the contract involves the use of an identified asset;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;we have the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;we have the right to direct the use of the identified asset. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A right-of-use asset and corresponding lease liability is recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;font-weight:bold;"&gt;Research and development costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the treatment phase of clinical trials based on the total estimated cost of the treatment phase on a per patient basis and we expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized.  To date, all development costs have been expensed. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;font-weight:bold;"&gt;Revenue recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The contract also provides for development and regulatory milestone payments, royalties and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contract receivable&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - Contract receivable includes amounts billed and currently due from customers. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts. We perform a review of our customer&amp;#8217;s credit risk and payment histories, including payments made subsequent to year-end.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contract liability&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - Our contract liability includes upfront license fees and billings in excess of revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or noncurrent based on the timing of when we expect to recognize revenue.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;font-weight:bold;"&gt;Share based payments &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock option plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; stock option plan (the &amp;#8220;Option Plan&amp;#8221;) available to officers, directors, employees and consultants with grants under the Option Plan approved from time to time by our Board of Directors (the &amp;#8220;Board&amp;#8221;). Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines. Vesting is provided for at the discretion of the Board and the expiration of options is to be no greater than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from the date of grant. Exercised stock options are settled with common shares issued from treasury. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We use the fair value based method of accounting for stock option awards granted under the Option Plan.  We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black- Scholes valuation model. The fair value of stock options with a graded vesting schedule is determined based on different expected lives for the options that vest each year, as it would be if the award were viewed as several separate awards, each with a different vesting date, and it is accounted for over the respective vesting period taking into consideration forfeiture estimates.   Compensation expense is adjusted for subsequent changes in management&amp;#8217;s estimate of the number of options that are expected to vest.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Incentive share award plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our incentive share award plan (the "Share Plan") is available to directors, officers and employees. Under our Share Plan, performance share units and restricted share units may be approved from time to time by the Board. Performance share units  ("PSUs") are an award to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share units ("RSUs") are an award to certain officers and employees and to non-employee directors to which common shares shall be issued in accordance with the Share Plan.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the date of grant based on the number of PSUs/RSUs expected to vest, recognized over the term of the vesting period. Compensation expense is adjusted for subsequent changes in management&amp;#8217;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Adoption of New Accounting Standards&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;IFRS 16 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IFRS 16 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;IFRS 16&amp;#8221;) replaces IAS 17 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;IAS 17&amp;#8221;) and related interpretations for annual periods beginning on or after January 1, 2019. We have adopted IFRS 16 using the modified retrospective approach, under which the cumulative effect of the initial application is recognized in retained earnings at January 1, 2019. We have not restated comparatives for 2018. On transition to IFRS 16, we elected to apply the following practical expedients: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Applied the exemption for short-term leases that have a remaining lease term of less than 12 months as at January 1, 2019; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Excluded initial direct costs for the measurement of right-of-use assets as at January 1, 2019; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Relied upon our assessment of whether leases are onerous under the requirement of IAS 37, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Provisions, contingent liabilities and contingent assets&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as at December 31, 2018 as an alternative to reviewing our right-of-use assets for impairment; and &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Measured the right-of-use assets at an amount equal to the lease liability, adjusted by the amount of lease incentive liability related to that lease recognized in the statement of financial position immediately before the date of initial application. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On transition to IFRS 16, we recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$882,437&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of lease liabilities. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate at January 1, 2019 as rates implicit in the leases were not readily determinable. The weighted-average rate applied was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the impacts of adopting IFRS 16 on the consolidated financial statements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Impact of changes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As reported as at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Effects of IFRS 16 transition&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Subsequent to transition as at January 1, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Right-of-use assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;808,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;808,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other current and non-current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,865,253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,865,253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,865,253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;808,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,673,278&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;113,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(74,412&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,338&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;882,437&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;882,437&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other current and non-current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,556,140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,556,140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,669,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;808,025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,477,915&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total shareholders' equity&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,195,363&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,195,363&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prior to adopting IFRS 16, our total minimum operating lease commitments as at December 31, 2018 were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$961,575&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The difference between the total of the minimum lease payments set out in Note 11 of our 2018 annual consolidated financial statements and the total lease liabilities recognized on transition was a result of the effect of discounting on the minimum lease payments.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
	<ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory contextRef="FD2019Q4YTD" id="Fact-B60302F461B9F77EA4329CFE2BF2F33E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available, against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilized. The components of our unrecognized deferred tax asset are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:612px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:345px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:84px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:84px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:84px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net operating losses carried forward&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;19,625,642&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,664,345&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,160,218&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Scientific research and experimental development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,338,542&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,406,169&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,406,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Investment tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;4,222,016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,988,606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,988,325&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Undepreciated capital costs in excess of book value of property and equipment and intellectual property&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,908,320&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,949,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,927,640&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share issue costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;611,072&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;696,346&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;493,343&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net capital losses carried forward&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,474&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,598&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,598&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unrecognized deferred tax asset&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;32,712,066&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,712,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,983,223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we have the following non-capital losses for income tax purposes in Canada:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:24.756335282651072%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:37%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Expiry&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2026&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,809,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,170,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,009,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2030&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,774,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,343,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2032&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,873,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2033&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,457,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2034&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,472,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2035&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,125,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2036&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,430,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2037&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,812,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2038&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,056,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2039&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,900,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;69,230,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we have the following non-refundable federal investment tax credits for income tax purposes in Canada:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:190px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:97px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:88px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Expiry&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;189,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;471,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;465,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;361,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;228,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;271,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2026&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;520,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;596,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2028&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;622,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;173,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2030&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;114,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2032&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;381,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2033&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;487,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2034&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;270,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2035&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;183,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2036&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2037&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;980&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2038&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;5,482,980&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory>
	<ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="FD2019Q4YTD" id="Fact-BE8B0223292F3D3E260C9CFE2C331474">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:520px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:301px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3,786,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,680,621&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,596,082&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Termination benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;779,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share-based payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,123,408&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,067,195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;459,298&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;4,910,075&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,747,816&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,835,046&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
	<ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory contextRef="FD2019Q4YTD" id="Fact-66C4D3F8BF379945B7149CFE2BD06A1C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#333333;"&gt;Our contract liability balance at December 31, which w&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;e expect to record in revenue over the next &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:443px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:236px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:102px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, beginning of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,730,287&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,182,580&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Regional licensing agreement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;547,707&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue recognized in the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, end of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,730,287&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,730,287&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contract liability - current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;927,400&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contract liability - non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,730,287&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,802,887&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,730,287&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,730,287&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory>
	<oncyf:CashEquivalentsAndShortTermInvestmentsTextBlock contextRef="FD2019Q4YTD" id="Fact-672BA468F3FDC167F7979CFE2C34E2C5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Cash Equivalents &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents consist of interest bearing deposits with our bank totaling $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;13,058,092&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8211; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$9,977,409&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).&amp;#160;&amp;#160;The current annual interest rate earned on these deposits is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;1.17%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8211; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2.71%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</oncyf:CashEquivalentsAndShortTermInvestmentsTextBlock>
	<oncyf:CashFlowOperatingCapital1TableTextBlock contextRef="FD2019Q4YTD" id="Fact-FE42A487E0FDB3FCA1449CFE2C104090">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net Change In Non-Cash Working Capital&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:629px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:392px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Change in:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contract receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,767,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,767,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other receivables&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(2,017,122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13,924&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(2,012,605&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;475,077&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(915,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts payable and accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,347,365&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,858,170&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(384,641&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contract liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;547,707&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,182,580&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;807,877&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(27,982&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-cash impact of foreign exchange&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;78,708&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,531&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,558&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in non-cash working capital related to operating activities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(1,795,777&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,904,339&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;180,855&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</oncyf:CashFlowOperatingCapital1TableTextBlock>
	<oncyf:DisclosureOfCapitalComponentsTableTextBlock contextRef="FD2019Q4YTD" id="Fact-91FBB9729F4C8B34FB999CFE2BEB0743">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;14,148,021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,699,881&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shareholders&amp;#8217; (deficit) equity&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(107,894&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,195,363&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</oncyf:DisclosureOfCapitalComponentsTableTextBlock>
	<oncyf:DisclosureOfEconomicDependenceTextBlock contextRef="FD2019Q4YTD" id="Fact-9BDB41CC84C9CA42B9C49CFE2C1DCF48">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Economic Dependence&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We are economically dependent on our toll manufacturers. We primarily use &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; toll manufacturer in the US to produce the clinical grade pelareorep required for our clinical trial program.&amp;#160;Any significant disruption of the services provided by our primary toll manufacturer has the potential to delay the progress of our clinical trial program.&amp;#160;We have used another toll manufacturer in the U.K. that has also produced clinical grade pelareorep at a smaller scale.&amp;#160;We have attempted to mitigate this risk by producing sufficient pelareorep in advance of patient enrollment in a particular clinical trial.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</oncyf:DisclosureOfEconomicDependenceTextBlock>
	<oncyf:DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock contextRef="FD2019Q4YTD" id="Fact-5E7EA17E94E4B98F8EC59CFE2C1B59FA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:16pt;"&gt;&lt;font style="font-family:inherit;font-size:16pt;font-weight:bold;"&gt;Indemnification of Officers and Directors&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our corporate by-laws require that, except to the extent expressly prohibited by law, we will indemnify our officers and directors against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment reasonably incurred in respect of any civil, criminal or administrative action or proceeding as it relates to their services to the Company.&amp;#160;The by-laws provide no limit to the amount of the indemnification.&amp;#160;We have purchased directors&amp;#8217; and officers&amp;#8217; insurance coverage to cover claims made against the directors and officers during the applicable policy periods.&amp;#160;The amounts and types of coverage have varied from period to period as dictated by market conditions.&amp;#160;We believe that we have adequate insurance coverage; however, there is no guarantee that all indemnification payments will be covered under our existing insurance policies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;There is no pending litigation or proceeding involving any of our officers or directors as to which indemnification is being sought, nor are we aware of any threatened litigation that may result in claims for indemnification.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</oncyf:DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock>
	<oncyf:OtherExpensesAndAdjustmentsTableTextBlock contextRef="FD2019Q4YTD" id="Fact-F4122A9051BE3E94C8F99CFE2BE88FFE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:639px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:420px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:68px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Included in research and development expenses:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Realized foreign exchange (gain) loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(39,362&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(120,794&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unrealized non-cash foreign exchange loss (gain)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;356,081&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(608,111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;55,538&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-cash share based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;561,420&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;680,541&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;230,141&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Included in operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation - property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;122,982&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;95,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90,768&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation - right-of-use assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;362,592&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-cash share based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;908,733&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;735,292&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;348,562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Transaction cost, warrant derivative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;233,143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Onerous lease contract&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amortization - lease incentive liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,189&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</oncyf:OtherExpensesAndAdjustmentsTableTextBlock>
	<oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock contextRef="FD2019Q4YTD" id="Fact-35385475A290328BA9F49CFE2C104FA6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balances in foreign currencies at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:622px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:222px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:133px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:133px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:133px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;US dollars &lt;br clear="none"/&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;British pounds&lt;br clear="none"/&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#163;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Euro&lt;br clear="none"/&gt;&amp;#8364;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,676,360&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26,751&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,664&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other receivables&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts payable and other liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,378,860)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,345)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(310,086)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrant derivative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,551,250)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,246,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,406&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(276,422)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock>
	<oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock contextRef="FD2019Q4YTD" id="Fact-C8F6EF591DF3EB48D11C9CFE2C0FA208">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Other Cash Flow Disclosures&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:517px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:342px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:58px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:51px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:51px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash interest received&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;274,094&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;173,496&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;130,101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash taxes paid&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;5,448&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,728&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;136,163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock>
	<oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock contextRef="FD2019Q4YTD" id="Fact-184026BA7AA2E42F14B49CFE2BF244C8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:583px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:316px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:76px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:78px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;br clear="none"/&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss before income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(33,122,888&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(16,489,183&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(15,475,353&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Statutory Canadian corporate tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;26.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Anticipated tax recovery&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(8,777,565&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,452,079&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,178,345&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign jurisdiction tax rate difference&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3,088,811&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,312,963&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,899,190&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employee share based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;389,591&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;382,275&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;156,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in fair value of warrant derivative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3,341,334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Impact of Alberta rate change&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3,758,175&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Adjustment to opening tax pools&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;11,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(238,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;162,162&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other permanent differences&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;149,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(35,912&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53,039&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in deferred tax benefits deemed not probable to &lt;br clear="none"/&gt;  be recovered&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(1,961,613&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,579,017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,051,725&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;548,042&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;144,021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Adjustment in respect to prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,523&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net current tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;548,042&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;141,498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>24
<FILENAME>oncyf-20191231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.oncolyticsbiotech.com/20191231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:oncyf="http://www.oncolyticsbiotech.com/20191231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.ifrs.org/taxonomy/2019-03-27/ifrs-full" schemaLocation="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AdditionalCashFlowDisclosures" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures">
        <link:definition>2152100 - Disclosure - Additional Cash Flow Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails">
        <link:definition>2452402 - Disclosure - Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails">
        <link:definition>2452403 - Disclosure - Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosuresTables" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables">
        <link:definition>2352301 - Disclosure - Additional Cash Flow Disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfFinancialStatementPresentation" roleURI="http://www.oncolyticsbiotech.com/role/BasisOfFinancialStatementPresentation">
        <link:definition>2104100 - Disclosure - Basis of Financial Statement Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalDisclosures" roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosures">
        <link:definition>2146100 - Disclosure - Capital Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalDisclosuresDetails" roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails">
        <link:definition>2446402 - Disclosure - Capital Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalDisclosuresTables" roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables">
        <link:definition>2346301 - Disclosure - Capital Disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalents" roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalents">
        <link:definition>2113100 - Disclosure - Cash Equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsNarrativeDetails">
        <link:definition>2413401 - Disclosure - Cash Equivalents - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Commitments" roleURI="http://www.oncolyticsbiotech.com/role/Commitments">
        <link:definition>2137100 - Disclosure - Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsDetails" roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsDetails">
        <link:definition>2437401 - Disclosure - Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfChangesInDeficitEquity" roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfChangesInDeficitEquity">
        <link:definition>1003000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN (DEFICIT) EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfFinancialPosition" roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPosition">
        <link:definition>1001000 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfFinancialPositionParenthetical" roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPositionParenthetical">
        <link:definition>1001001 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfLossAndComprehensiveLoss" roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss">
        <link:definition>1002000 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.oncolyticsbiotech.com/role/Contingencies">
        <link:definition>2140100 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ContingenciesDetails">
        <link:definition>2440401 - Disclosure - Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiabilityAndReceivable" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivable">
        <link:definition>2134100 - Disclosure - Contract Liability and Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiabilityAndReceivableNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableNarrativeDetails">
        <link:definition>2434402 - Disclosure - Contract Liability and Receivable - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiabilityAndReceivableScheduleOfContractRevenuesAndLiabilitiesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableScheduleOfContractRevenuesAndLiabilitiesDetails">
        <link:definition>2434403 - Disclosure - Contract Liability and Receivable - Schedule of Contract Revenues and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiabilityAndReceivableTables" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableTables">
        <link:definition>2334301 - Disclosure - Contract Liability and Receivable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.oncolyticsbiotech.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EconomicDependence" roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependence">
        <link:definition>2156100 - Disclosure - Economic Dependence</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EconomicDependenceDetails" roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails">
        <link:definition>2456401 - Disclosure - Economic Dependence (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstruments">
        <link:definition>2149100 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>2449402 - Disclosure - Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleOfBalancesInForeignCurrenciesDetails" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleOfBalancesInForeignCurrenciesDetails">
        <link:definition>2449403 - Disclosure - Financial Instruments - Schedule of Balances in Foreign Currencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables">
        <link:definition>2349301 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxes">
        <link:definition>2143100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesProvisionForIncomeTaxesDetails" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionForIncomeTaxesDetails">
        <link:definition>2443402 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfUnrecognizedDeferredTaxAssetsDetails" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleOfUnrecognizedDeferredTaxAssetsDetails">
        <link:definition>2443405 - Disclosure - Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryOfNonCapitalLossesDetails" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonCapitalLossesDetails">
        <link:definition>2443403 - Disclosure - Income Taxes - Summary of Non-capital Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryOfNonRefundableFederalInvestmentTaxCreditsDetails" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonRefundableFederalInvestmentTaxCreditsDetails">
        <link:definition>2443404 - Disclosure - Income Taxes - Summary of Non-refundable Federal Investment Tax Credits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables">
        <link:definition>2343301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncorporationAndNatureOfOperations" roleURI="http://www.oncolyticsbiotech.com/role/IncorporationAndNatureOfOperations">
        <link:definition>2101100 - Disclosure - Incorporation and Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndemnificationOfOfficersAndDirectors" roleURI="http://www.oncolyticsbiotech.com/role/IndemnificationOfOfficersAndDirectors">
        <link:definition>2155100 - Disclosure - Indemnification of Officers and Directors</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.oncolyticsbiotech.com/role/Leases">
        <link:definition>2119100 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails">
        <link:definition>2419402 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesRightOfUseAssetsAndLeaseLiabilitiesDetails" roleURI="http://www.oncolyticsbiotech.com/role/LeasesRightOfUseAssetsAndLeaseLiabilitiesDetails">
        <link:definition>2419403 - Disclosure - Leases - Right-of-use Assets and Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.oncolyticsbiotech.com/role/LeasesTables">
        <link:definition>2319301 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTotalUndiscountedLeaseLiabilityDetails" roleURI="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails">
        <link:definition>2419404 - Disclosure - Leases - Total Undiscounted Lease Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShare" roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShare">
        <link:definition>2131100 - Disclosure - Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareDetails" roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails">
        <link:definition>2431401 - Disclosure - Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpensesAndAdjustments" roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustments">
        <link:definition>2157100 - Disclosure - Other Expenses and Adjustments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpensesAndAdjustmentsDetails" roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsDetails">
        <link:definition>2457402 - Disclosure - Other Expenses and Adjustments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpensesAndAdjustmentsTables" roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsTables">
        <link:definition>2357301 - Disclosure - Other Expenses and Adjustments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipment" roleURI="http://www.oncolyticsbiotech.com/role/PropertyAndEquipment">
        <link:definition>2116100 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentDetails" roleURI="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentDetails">
        <link:definition>2416402 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentTables" roleURI="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentTables">
        <link:definition>2316301 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions">
        <link:definition>2158100 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2458402 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsTables" roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables">
        <link:definition>2358301 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPayments">
        <link:definition>2128100 - Disclosure - Share Based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDisclosureWeightedAverageAssumptionsAndFairValueOfOptionsDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsAndFairValueOfOptionsDetails">
        <link:definition>2428405 - Disclosure - Share Based Payments - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails">
        <link:definition>2428403 - Disclosure - Share Based Payments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleOfNumberOfOtherEquityInstrumentsDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfNumberOfOtherEquityInstrumentsDetails">
        <link:definition>2428406 - Disclosure - Share Based Payments - Schedule of Number of Other Equity Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleOfStockOptionsAndWeightedAverageExercisePricesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsAndWeightedAverageExercisePricesDetails">
        <link:definition>2428402 - Disclosure - Share Based Payments - Schedule of Stock Options and Weighted Average Exercise Prices (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails">
        <link:definition>2428404 - Disclosure - Share Based Payments - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables">
        <link:definition>2328301 - Disclosure - Share Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapital" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapital">
        <link:definition>2125100 - Disclosure - Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalNarrativeDetails">
        <link:definition>2425402 - Disclosure - Share Capital - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalScheduleOfShareCapitalDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalDetails">
        <link:definition>2425403 - Disclosure - Share Capital - Schedule of Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalScheduleOfShareCapitalFootnotesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalFootnotesDetails">
        <link:definition>2425404 - Disclosure - Share Capital - Schedule of Share Capital Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalSummaryOfOutstandingWarrantsDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryOfOutstandingWarrantsDetails">
        <link:definition>2425405 - Disclosure - Share Capital - Summary of Outstanding Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalTables" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalTables">
        <link:definition>2325301 - Disclosure - Share Capital (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantJudgmentsEstimatesAndAssumptions" roleURI="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesAndAssumptions">
        <link:definition>2110100 - Disclosure - Significant Judgments, Estimates and Assumptions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEvents">
        <link:definition>2159100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails">
        <link:definition>2459401 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2107100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesIfrs16LeasesDetails" roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesIfrs16LeasesDetails">
        <link:definition>2407405 - Disclosure - Summary of Significant Accounting Policies - IFRS 16 Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2407404 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2207201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfDepreciationRatesDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2307302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivative" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivative">
        <link:definition>2122100 - Disclosure - Warrant Derivative</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivativeNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails">
        <link:definition>2422402 - Disclosure - Warrant Derivative - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivativeReconciliationOfChangeInFairValueOfWarrantDerivativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationOfChangeInFairValueOfWarrantDerivativeDetails">
        <link:definition>2422403 - Disclosure - Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivativeSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForWarrantsDetails" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForWarrantsDetails">
        <link:definition>2422404 - Disclosure - Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivativeTables" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables">
        <link:definition>2322301 - Disclosure - Warrant Derivative (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="oncyf_AccruedRoyalties1" name="AccruedRoyalties1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable" name="AdjustmentsforDecreaseIncreaseinContractReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities" name="AdjustmentsforIncreaseDecreaseinContractLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="oncyf_AdjustmentsforLeaseAmortization" name="AdjustmentsforLeaseAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="oncyf_AnnualContingentPayment" name="AnnualContingentPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="oncyf_AnnualContingentPaymentGrossSalesPercent" name="AnnualContingentPaymentGrossSalesPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="oncyf_BalanceHeldInForeignCurrencyNet" name="BalanceHeldInForeignCurrencyNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="oncyf_CashEquivalentsAndShortTermInvestmentsAbstract" name="CashEquivalentsAndShortTermInvestmentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock" name="CashEquivalentsAndShortTermInvestmentsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_CashEquivalentsInterestRate" name="CashEquivalentsInterestRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_CashFlowOperatingCapital1TableTextBlock" name="CashFlowOperatingCapital1TableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ClassOfWarrantOrRightOutstanding1" name="ClassOfWarrantOrRightOutstanding1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2" name="ClassofWarrantorRightExercisePriceofWarrantsorRights2" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" name="ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" name="ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="oncyf_ClassofWarrantorRightNumberofWarrantsExercised" name="ClassofWarrantorRightNumberofWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ClassofWarrantorRightWarrantsExercised" name="ClassofWarrantorRightWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_CollaborationAgreementMember" name="CollaborationAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_CommitmentsAbstract" name="CommitmentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_CommitmentsAndContingencies1" name="CommitmentsAndContingencies1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" name="CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" name="CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" name="CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_CommonSharePurchaseWarrantPerUnit" name="CommonSharePurchaseWarrantPerUnit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="oncyf_CommonSharesPerUnit" name="CommonSharesPerUnit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="oncyf_ConcentrationRisk1Table" name="ConcentrationRisk1Table" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ConcentrationRiskNumber" name="ConcentrationRiskNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_ConcentrationRiskType1Axis" name="ConcentrationRiskType1Axis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_ConcentrationRiskType1Domain" name="ConcentrationRiskType1Domain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_ConcentrationRiskType1LineItems" name="ConcentrationRiskType1LineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_ContingenciesAbstract" name="ContingenciesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ContingentRoyaltyPaymentAnnualMaximum" name="ContingentRoyaltyPaymentAnnualMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ContingentRoyaltyPaymentContributionRate" name="ContingentRoyaltyPaymentContributionRate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue" name="ContingentRoyaltyPaymentPercentOfSalesRevenue" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="oncyf_ContractLiabilityRecognitionPeriod" name="ContractLiabilityRecognitionPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" name="CorporateInformationAndStatementOfIFRSComplianceAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_Currency1Axis" name="Currency1Axis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_Currency1LineItems" name="Currency1LineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_Currency1Table" name="Currency1Table" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_DisclosureOfCapitalComponentsTableTextBlock" name="DisclosureOfCapitalComponentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_DisclosureOfEconomicDependenceAbstract" name="DisclosureOfEconomicDependenceAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_DisclosureOfEconomicDependenceTextBlock" name="DisclosureOfEconomicDependenceTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" name="DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" name="DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" name="DisclosureOfNotesAndOtherExplanatoryInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract" name="DisclosureOfSharebasedPaymentArrangementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" name="DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_DisclosureofeventsafterreportingperiodAbstract" name="DisclosureofeventsafterreportingperiodAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_DisclosureofincometaxAbstract" name="DisclosureofincometaxAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_DisclosureofrelatedpartyAbstract" name="DisclosureofrelatedpartyAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" name="DisclosureofrevenuefromcontractswithcustomersAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_DisclosureofsharebasedpaymentarrangementAbstract" name="DisclosureofsharebasedpaymentarrangementAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_DividendYieldPercent" name="DividendYieldPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_EffectsofIFRS16TransitionMember" name="EffectsofIFRS16TransitionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_EquityAuthorized" name="EquityAuthorized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="oncyf_ExercisePriceRangeFiveMember" name="ExercisePriceRangeFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_ExercisePriceRangeFourMember" name="ExercisePriceRangeFourMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_ExercisePriceRangeOneMember" name="ExercisePriceRangeOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_ExercisePriceRangeThreeMember" name="ExercisePriceRangeThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_ExercisePriceRangeTwoMember" name="ExercisePriceRangeTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ExercisePriceofOutstandingWarrants" name="ExercisePriceofOutstandingWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="oncyf_ExpectedForfeitureShareOptionsGranted" name="ExpectedForfeitureShareOptionsGranted" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_FairValueofWarrantIssuedPerWarrant" name="FairValueofWarrantIssuedPerWarrant" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="oncyf_ForeignExchangeImpactRightofUseAssets" name="ForeignExchangeImpactRightofUseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="oncyf_FundedandRoyaltyRepayment" name="FundedandRoyaltyRepayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="oncyf_GainsLossesfromForeignExchangeImpact" name="GainsLossesfromForeignExchangeImpact" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="oncyf_GrossProceedsFromIssueOfOrdinaryShares" name="GrossProceedsFromIssueOfOrdinaryShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_IncomeStatementLocation1Axis" name="IncomeStatementLocation1Axis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_IncomeStatementLocation1Domain" name="IncomeStatementLocation1Domain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" name="IncreaseDecreaseThroughIncentiveShareAwardsEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="oncyf_IncreaseDecreaseinPrepaidExpense1" name="IncreaseDecreaseinPrepaidExpense1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_InitialCommitmentFeeMember" name="InitialCommitmentFeeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_InvestmentTaxCreditsMember" name="InvestmentTaxCreditsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_IssueOfEquityShares" name="IssueOfEquityShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" name="MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_MedicalEquipmentMember" name="MedicalEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_NumberOfStockOptionPlans" name="NumberOfStockOptionPlans" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="oncyf_NumberofPatients" name="NumberofPatients" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_NumberofSharesOutstandingPercent" name="NumberofSharesOutstandingPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_OperatingExpensesMember" name="OperatingExpensesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_OperatingLeaseRemainingLeaseTerm" name="OperatingLeaseRemainingLeaseTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_OtherCurrentandNoncurrentAssets" name="OtherCurrentandNoncurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="oncyf_OtherCurrentandNoncurrentLiabilities" name="OtherCurrentandNoncurrentLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="oncyf_OtherExpensesAndAdjustmentsLineItems" name="OtherExpensesAndAdjustmentsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_OtherExpensesAndAdjustmentsTable" name="OtherExpensesAndAdjustmentsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_OtherExpensesAndAdjustmentsTableTextBlock" name="OtherExpensesAndAdjustmentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_OverheadRepayment" name="OverheadRepayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="oncyf_PerformanceShareUnitsMember" name="PerformanceShareUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ProceedsFromCollaborationAgreement" name="ProceedsFromCollaborationAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ProceedsfromInterestReceived" name="ProceedsfromInterestReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ProceedsfromWarrantExercises1" name="ProceedsfromWarrantExercises1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" name="PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" name="PropertyPlantandEquipmentAnnualDepreciationRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_PurchaseObligation1" name="PurchaseObligation1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="oncyf_ResearchAndDevelopmentMember" name="ResearchAndDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_RestrictedShareUnitsMember" name="RestrictedShareUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_SYNSORBMember" name="SYNSORBMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_SaleOfStockAxis" name="SaleOfStockAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_SaleOfStockDomain" name="SaleOfStockDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" name="ScheduleOfForeignCurrencyHeldTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" name="ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" name="ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" name="SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" name="SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_ShareIssueCostsMember" name="ShareIssueCostsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_SharePricePremiumPercent" name="SharePricePremiumPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_SharePurchaseAgreementAmount" name="SharePurchaseAgreementAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="oncyf_SharePurchaseAgreementTerm" name="SharePurchaseAgreementTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" name="SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_SharesIssuedPricePerShare1" name="SharesIssuedPricePerShare1" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="oncyf_SharesIssuedWarrantPricePerShare" name="SharesIssuedWarrantPricePerShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="oncyf_SharesPublicOfferingMember" name="SharesPublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_SharesUnderAtthemarketAgreementCanadianMember" name="SharesUnderAtthemarketAgreementCanadianMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_SharesUnderAtthemarketAgreementMember" name="SharesUnderAtthemarketAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" name="SharesUnderAtthemarketAgreementUnitedStatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_SharesUnderCommonStockPurchaseAgreementMember" name="SharesUnderCommonStockPurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_SharesUnderIncentiveAwardPlanMember" name="SharesUnderIncentiveAwardPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_SharesUnderSharePurchaseAgreementMember" name="SharesUnderSharePurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_SharesUnderStockOptionPlanMember" name="SharesUnderStockOptionPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_SharesUnderWarrantAgreementMember" name="SharesUnderWarrantAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" name="SignificantJudgmentsEstimatesAndAssumptionsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_Statement1LineItems" name="Statement1LineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_Statement1Table" name="Statement1Table" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_StockholdersEquityNoteStockSplitConversionRatio" name="StockholdersEquityNoteStockSplitConversionRatio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_SummaryOfSignificantAccountingPoliciesAbstract" name="SummaryOfSignificantAccountingPoliciesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_SupplierConcentrationRisk1Member" name="SupplierConcentrationRisk1Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" name="TaxEffectOfChangeinFairValueOfWarrantDerivative" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="oncyf_TaxEffectOfStockBasedCompensation" name="TaxEffectOfStockBasedCompensation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="oncyf_TaxEffectOfTaxPools" name="TaxEffectOfTaxPools" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyThirtyEightMember" name="TwentyThirtyEightMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyThirtyFiveMember" name="TwentyThirtyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyThirtyFourMember" name="TwentyThirtyFourMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyThirtyMember" name="TwentyThirtyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyThirtyNineMember" name="TwentyThirtyNineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyThirtyOneMember" name="TwentyThirtyOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyThirtySevenMember" name="TwentyThirtySevenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyThirtySixMember" name="TwentyThirtySixMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyThirtyThreeMember" name="TwentyThirtyThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyThirtyTwoMember" name="TwentyThirtyTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyTwentyEightMember" name="TwentyTwentyEightMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyTwentyFiveMember" name="TwentyTwentyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyTwentyFourMember" name="TwentyTwentyFourMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyTwentyMember" name="TwentyTwentyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyTwentyNineMember" name="TwentyTwentyNineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyTwentyOneMember" name="TwentyTwentyOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyTwentySevenMember" name="TwentyTwentySevenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyTwentySixMember" name="TwentyTwentySixMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyTwentyThreeMember" name="TwentyTwentyThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_TwentyTwentyTwoMember" name="TwentyTwentyTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" name="UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_UnusedCapitalLossCarryForwardNetMember" name="UnusedCapitalLossCarryForwardNetMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="oncyf_UnusedNetOperatingLossCarryForwardsMember" name="UnusedNetOperatingLossCarryForwardsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" name="ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="oncyf_WarrantIssuedUnderlyingSharePrice" name="WarrantIssuedUnderlyingSharePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_WarrantPricePerShareAccelerationThreshold" name="WarrantPricePerShareAccelerationThreshold" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="oncyf_WarrantPricePerShareAccelerationThresholdTradingDays" name="WarrantPricePerShareAccelerationThresholdTradingDays" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant" />
  <xsd:element id="oncyf_WarrantPurchaseAgreement" name="WarrantPurchaseAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="oncyf_WarrantsAndRightsOutstanding1" name="WarrantsAndRightsOutstanding1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="oncyf_WarrantsMember" name="WarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="oncyf_WarrantsandRightsOutstanding" name="WarrantsandRightsOutstanding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="oncyf_WeightedAverageClosingPriceDuration" name="WeightedAverageClosingPriceDuration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>25
<FILENAME>oncyf-20191231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:href="oncyf-20191231.xsd#AdditionalCashFlowDisclosures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:href="oncyf-20191231.xsd#AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:href="oncyf-20191231.xsd#AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:href="oncyf-20191231.xsd#AdditionalCashFlowDisclosuresTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/BasisOfFinancialStatementPresentation" xlink:href="oncyf-20191231.xsd#BasisOfFinancialStatementPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:href="oncyf-20191231.xsd#CapitalDisclosures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:href="oncyf-20191231.xsd#CapitalDisclosuresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:href="oncyf-20191231.xsd#CapitalDisclosuresTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalents" xlink:href="oncyf-20191231.xsd#CashEquivalents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsNarrativeDetails" xlink:href="oncyf-20191231.xsd#CashEquivalentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Commitments" xlink:href="oncyf-20191231.xsd#Commitments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsDetails" xlink:href="oncyf-20191231.xsd#CommitmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="oncyf-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfChangesInDeficitEquity" xlink:href="oncyf-20191231.xsd#ConsolidatedStatementsOfChangesInDeficitEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPosition" xlink:href="oncyf-20191231.xsd#ConsolidatedStatementsOfFinancialPosition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPositionParenthetical" xlink:href="oncyf-20191231.xsd#ConsolidatedStatementsOfFinancialPositionParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss" xlink:href="oncyf-20191231.xsd#ConsolidatedStatementsOfLossAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Contingencies" xlink:href="oncyf-20191231.xsd#Contingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContingenciesDetails" xlink:href="oncyf-20191231.xsd#ContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivable" xlink:href="oncyf-20191231.xsd#ContractLiabilityAndReceivable" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableNarrativeDetails" xlink:href="oncyf-20191231.xsd#ContractLiabilityAndReceivableNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableScheduleOfContractRevenuesAndLiabilitiesDetails" xlink:href="oncyf-20191231.xsd#ContractLiabilityAndReceivableScheduleOfContractRevenuesAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableTables" xlink:href="oncyf-20191231.xsd#ContractLiabilityAndReceivableTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/DocumentAndEntityInformation" xlink:href="oncyf-20191231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:href="oncyf-20191231.xsd#EconomicDependence" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:href="oncyf-20191231.xsd#EconomicDependenceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:href="oncyf-20191231.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:href="oncyf-20191231.xsd#FinancialInstrumentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleOfBalancesInForeignCurrenciesDetails" xlink:href="oncyf-20191231.xsd#FinancialInstrumentsScheduleOfBalancesInForeignCurrenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:href="oncyf-20191231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:href="oncyf-20191231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionForIncomeTaxesDetails" xlink:href="oncyf-20191231.xsd#IncomeTaxesProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleOfUnrecognizedDeferredTaxAssetsDetails" xlink:href="oncyf-20191231.xsd#IncomeTaxesScheduleOfUnrecognizedDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonCapitalLossesDetails" xlink:href="oncyf-20191231.xsd#IncomeTaxesSummaryOfNonCapitalLossesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonRefundableFederalInvestmentTaxCreditsDetails" xlink:href="oncyf-20191231.xsd#IncomeTaxesSummaryOfNonRefundableFederalInvestmentTaxCreditsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:href="oncyf-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncorporationAndNatureOfOperations" xlink:href="oncyf-20191231.xsd#IncorporationAndNatureOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IndemnificationOfOfficersAndDirectors" xlink:href="oncyf-20191231.xsd#IndemnificationOfOfficersAndDirectors" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Leases" xlink:href="oncyf-20191231.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:href="oncyf-20191231.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesRightOfUseAssetsAndLeaseLiabilitiesDetails" xlink:href="oncyf-20191231.xsd#LeasesRightOfUseAssetsAndLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesTables" xlink:href="oncyf-20191231.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:href="oncyf-20191231.xsd#LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShare" xlink:href="oncyf-20191231.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails" xlink:href="oncyf-20191231.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustments" xlink:href="oncyf-20191231.xsd#OtherExpensesAndAdjustments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsDetails" xlink:href="oncyf-20191231.xsd#OtherExpensesAndAdjustmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsTables" xlink:href="oncyf-20191231.xsd#OtherExpensesAndAdjustmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyAndEquipment" xlink:href="oncyf-20191231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentDetails" xlink:href="oncyf-20191231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentTables" xlink:href="oncyf-20191231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:href="oncyf-20191231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:href="oncyf-20191231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:href="oncyf-20191231.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPayments" xlink:href="oncyf-20191231.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsAndFairValueOfOptionsDetails" xlink:href="oncyf-20191231.xsd#ShareBasedPaymentsDisclosureWeightedAverageAssumptionsAndFairValueOfOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails" xlink:href="oncyf-20191231.xsd#ShareBasedPaymentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfNumberOfOtherEquityInstrumentsDetails" xlink:href="oncyf-20191231.xsd#ShareBasedPaymentsScheduleOfNumberOfOtherEquityInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsAndWeightedAverageExercisePricesDetails" xlink:href="oncyf-20191231.xsd#ShareBasedPaymentsScheduleOfStockOptionsAndWeightedAverageExercisePricesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails" xlink:href="oncyf-20191231.xsd#ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables" xlink:href="oncyf-20191231.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:href="oncyf-20191231.xsd#ShareCapital" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalNarrativeDetails" xlink:href="oncyf-20191231.xsd#ShareCapitalNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalDetails" xlink:href="oncyf-20191231.xsd#ShareCapitalScheduleOfShareCapitalDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalFootnotesDetails" xlink:href="oncyf-20191231.xsd#ShareCapitalScheduleOfShareCapitalFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryOfOutstandingWarrantsDetails" xlink:href="oncyf-20191231.xsd#ShareCapitalSummaryOfOutstandingWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:href="oncyf-20191231.xsd#ShareCapitalTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesAndAssumptions" xlink:href="oncyf-20191231.xsd#SignificantJudgmentsEstimatesAndAssumptions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEvents" xlink:href="oncyf-20191231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails" xlink:href="oncyf-20191231.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="oncyf-20191231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesIfrs16LeasesDetails" xlink:href="oncyf-20191231.xsd#SummaryOfSignificantAccountingPoliciesIfrs16LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="oncyf-20191231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="oncyf-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" xlink:href="oncyf-20191231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="oncyf-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivative" xlink:href="oncyf-20191231.xsd#WarrantDerivative" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails" xlink:href="oncyf-20191231.xsd#WarrantDerivativeNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationOfChangeInFairValueOfWarrantDerivativeDetails" xlink:href="oncyf-20191231.xsd#WarrantDerivativeReconciliationOfChangeInFairValueOfWarrantDerivativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForWarrantsDetails" xlink:href="oncyf-20191231.xsd#WarrantDerivativeSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables" xlink:href="oncyf-20191231.xsd#WarrantDerivativeTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_6b824fce-62f6-c699-28f6-62c865932459" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable" xlink:label="loc_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable_99a52c10-3f69-67e8-7f1d-9cfe3aff26f3" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_6b824fce-62f6-c699-28f6-62c865932459" xlink:to="loc_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable_99a52c10-3f69-67e8-7f1d-9cfe3aff26f3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_04f405dc-516d-c8b9-5e42-84c051ace821" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_6b824fce-62f6-c699-28f6-62c865932459" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_04f405dc-516d-c8b9-5e42-84c051ace821" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IncreaseDecreaseinPrepaidExpense1" xlink:label="loc_oncyf_IncreaseDecreaseinPrepaidExpense1_595ab820-c31d-d797-a412-9cfe3a748464" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_6b824fce-62f6-c699-28f6-62c865932459" xlink:to="loc_oncyf_IncreaseDecreaseinPrepaidExpense1_595ab820-c31d-d797-a412-9cfe3a748464" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_2b7200c8-a072-18d7-0476-3a4f964e9d66" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_6b824fce-62f6-c699-28f6-62c865932459" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_2b7200c8-a072-18d7-0476-3a4f964e9d66" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities" xlink:label="loc_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities_b9c61756-560d-cdb2-54f4-9cfe3a9e993c" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_6b824fce-62f6-c699-28f6-62c865932459" xlink:to="loc_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities_b9c61756-560d-cdb2-54f4-9cfe3a9e993c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_99d94c36-309f-e7b4-1f80-6af7c1a64458" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_6b824fce-62f6-c699-28f6-62c865932459" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_99d94c36-309f-e7b4-1f80-6af7c1a64458" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_92822c35-662f-5c10-3e7b-06887bc8d81f" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_6b824fce-62f6-c699-28f6-62c865932459" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_92822c35-662f-5c10-3e7b-06887bc8d81f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/BasisOfFinancialStatementPresentation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalentsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/Commitments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CommitmentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_b790542f-3518-0d1d-1a9e-706ef69164b2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_50519123-7f13-1484-043d-3f7495b06b46" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_b790542f-3518-0d1d-1a9e-706ef69164b2" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_50519123-7f13-1484-043d-3f7495b06b46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_a1abd9e1-dee4-121d-318e-70ec00d5724b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_50519123-7f13-1484-043d-3f7495b06b46" xlink:to="loc_ifrs-full_ProfitLoss_a1abd9e1-dee4-121d-318e-70ec00d5724b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_16fe9348-0d20-c03b-805c-9566961021e9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_50519123-7f13-1484-043d-3f7495b06b46" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_16fe9348-0d20-c03b-805c-9566961021e9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_ae3109a6-9423-a785-97f3-0b0b71cdeb38" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_50519123-7f13-1484-043d-3f7495b06b46" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_ae3109a6-9423-a785-97f3-0b0b71cdeb38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_2ed43723-f336-9ca5-c938-0ce22baecc68" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_50519123-7f13-1484-043d-3f7495b06b46" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_2ed43723-f336-9ca5-c938-0ce22baecc68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_3b2e7409-bcec-efe6-2542-c30bc0d01b47" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_50519123-7f13-1484-043d-3f7495b06b46" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_3b2e7409-bcec-efe6-2542-c30bc0d01b47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_f9b7fe62-a954-cd80-a239-02854026afb8" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_50519123-7f13-1484-043d-3f7495b06b46" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_f9b7fe62-a954-cd80-a239-02854026afb8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="loc_ifrs-full_AdjustmentsForProvisions_37c15f40-6d51-29e9-bfe9-3ddf8be2bbb2" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_50519123-7f13-1484-043d-3f7495b06b46" xlink:to="loc_ifrs-full_AdjustmentsForProvisions_37c15f40-6d51-29e9-bfe9-3ddf8be2bbb2" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_AdjustmentsforLeaseAmortization" xlink:label="loc_oncyf_AdjustmentsforLeaseAmortization_894d938d-53a4-1775-953e-9cfe3aa31b8a" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_50519123-7f13-1484-043d-3f7495b06b46" xlink:to="loc_oncyf_AdjustmentsforLeaseAmortization_894d938d-53a4-1775-953e-9cfe3aa31b8a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_1d792e8a-6f41-7b76-8c65-099fda925bd0" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_50519123-7f13-1484-043d-3f7495b06b46" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_1d792e8a-6f41-7b76-8c65-099fda925bd0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_6b824fce-62f6-c699-28f6-62c865932459" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_50519123-7f13-1484-043d-3f7495b06b46" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_6b824fce-62f6-c699-28f6-62c865932459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_2f99f0e0-7106-d43d-6188-22488b7dc63f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_b790542f-3518-0d1d-1a9e-706ef69164b2" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_2f99f0e0-7106-d43d-6188-22488b7dc63f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_91c4bdfd-2424-1f0c-26c2-d508c33660c7" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_2f99f0e0-7106-d43d-6188-22488b7dc63f" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_91c4bdfd-2424-1f0c-26c2-d508c33660c7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:label="loc_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_89cf4534-0bd9-5d9a-72b9-9906f2e8c30c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_2f99f0e0-7106-d43d-6188-22488b7dc63f" xlink:to="loc_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_89cf4534-0bd9-5d9a-72b9-9906f2e8c30c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_b065511a-9dcc-f029-73a4-4a56f20f6aec" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_b790542f-3518-0d1d-1a9e-706ef69164b2" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_b065511a-9dcc-f029-73a4-4a56f20f6aec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_55594be5-351d-2866-6d31-c6012902fe76" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_b065511a-9dcc-f029-73a4-4a56f20f6aec" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_55594be5-351d-2866-6d31-c6012902fe76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_ddcdf06e-a4dd-d03d-a55f-e86a96f1cef2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_b065511a-9dcc-f029-73a4-4a56f20f6aec" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_ddcdf06e-a4dd-d03d-a55f-e86a96f1cef2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashOutflowForLeases" xlink:label="loc_ifrs-full_CashOutflowForLeases_93e30ff5-5640-9a83-910a-54b7b838dedb" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_b065511a-9dcc-f029-73a4-4a56f20f6aec" xlink:to="loc_ifrs-full_CashOutflowForLeases_93e30ff5-5640-9a83-910a-54b7b838dedb" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfChangesInDeficitEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPosition" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-full_EquityAndLiabilities_2477c5e1-1b2e-a156-1b81-39788e3dae17" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_86812f62-f283-6bf6-ddf5-558f8b5df456" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_2477c5e1-1b2e-a156-1b81-39788e3dae17" xlink:to="loc_ifrs-full_Equity_86812f62-f283-6bf6-ddf5-558f8b5df456" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital_c1fe242d-e7ea-3b58-a1f7-52ce0f037282" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_86812f62-f283-6bf6-ddf5-558f8b5df456" xlink:to="loc_ifrs-full_IssuedCapital_c1fe242d-e7ea-3b58-a1f7-52ce0f037282" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsandRightsOutstanding" xlink:label="loc_oncyf_WarrantsandRightsOutstanding_24b28c52-7b6f-f8dd-4ba5-9cfe3a9938fc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_86812f62-f283-6bf6-ddf5-558f8b5df456" xlink:to="loc_oncyf_WarrantsandRightsOutstanding_24b28c52-7b6f-f8dd-4ba5-9cfe3a9938fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionalPaidinCapital" xlink:label="loc_ifrs-full_AdditionalPaidinCapital_25f367d5-bc37-35fa-7f3f-965f7af0663a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_86812f62-f283-6bf6-ddf5-558f8b5df456" xlink:to="loc_ifrs-full_AdditionalPaidinCapital_25f367d5-bc37-35fa-7f3f-965f7af0663a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_6bbfa81e-8fad-f14a-47a3-c389d92c7e47" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_86812f62-f283-6bf6-ddf5-558f8b5df456" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_6bbfa81e-8fad-f14a-47a3-c389d92c7e47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings_1f89b280-d784-6af6-6695-75ea63b8045a" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_86812f62-f283-6bf6-ddf5-558f8b5df456" xlink:to="loc_ifrs-full_RetainedEarnings_1f89b280-d784-6af6-6695-75ea63b8045a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_723a7ddb-bc44-afb4-d385-83ed1a6239d3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_2477c5e1-1b2e-a156-1b81-39788e3dae17" xlink:to="loc_ifrs-full_Liabilities_723a7ddb-bc44-afb4-d385-83ed1a6239d3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities_fff10a9b-1f57-5f08-85f6-142e4a6557fc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_723a7ddb-bc44-afb4-d385-83ed1a6239d3" xlink:to="loc_ifrs-full_CurrentLiabilities_fff10a9b-1f57-5f08-85f6-142e4a6557fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_62ca976c-b70b-e6f9-f27b-44378597c436" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_fff10a9b-1f57-5f08-85f6-142e4a6557fc" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_62ca976c-b70b-e6f9-f27b-44378597c436" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="loc_ifrs-full_CurrentContractLiabilities_dbd0019d-45a3-243c-1ba2-8abfcea3919f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_fff10a9b-1f57-5f08-85f6-142e4a6557fc" xlink:to="loc_ifrs-full_CurrentContractLiabilities_dbd0019d-45a3-243c-1ba2-8abfcea3919f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_6d76a5f6-5bfe-69b3-9b55-b480106c437f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_fff10a9b-1f57-5f08-85f6-142e4a6557fc" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_6d76a5f6-5bfe-69b3-9b55-b480106c437f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_7d3a8e16-6c56-f7e1-03e9-bff4f15351b9" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_fff10a9b-1f57-5f08-85f6-142e4a6557fc" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_7d3a8e16-6c56-f7e1-03e9-bff4f15351b9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_9cbd58af-1b73-faf1-ea1e-52014c91bfff" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_fff10a9b-1f57-5f08-85f6-142e4a6557fc" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_9cbd58af-1b73-faf1-ea1e-52014c91bfff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-full_NoncurrentLiabilities_85da2d85-bfc6-721f-f1fd-7e1b926d0588" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_723a7ddb-bc44-afb4-d385-83ed1a6239d3" xlink:to="loc_ifrs-full_NoncurrentLiabilities_85da2d85-bfc6-721f-f1fd-7e1b926d0588" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_141772e1-dd71-691b-6c26-56bec9b50de0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_85da2d85-bfc6-721f-f1fd-7e1b926d0588" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_141772e1-dd71-691b-6c26-56bec9b50de0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_f055e257-aa0c-10e6-3614-86037064e106" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_85da2d85-bfc6-721f-f1fd-7e1b926d0588" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_f055e257-aa0c-10e6-3614-86037064e106" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_221560c7-26d3-e735-1d03-2025a19c3db2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_85da2d85-bfc6-721f-f1fd-7e1b926d0588" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_221560c7-26d3-e735-1d03-2025a19c3db2" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CommitmentsAndContingencies1" xlink:label="loc_oncyf_CommitmentsAndContingencies1_7c494cda-4cb9-deed-2b6d-9cfe3ad2d09b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_2477c5e1-1b2e-a156-1b81-39788e3dae17" xlink:to="loc_oncyf_CommitmentsAndContingencies1_7c494cda-4cb9-deed-2b6d-9cfe3ad2d09b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_d05234d6-3b70-344e-5f6e-798ff1569135" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets_8860176f-5651-5974-2a18-49d5eb8ec5c1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_d05234d6-3b70-344e-5f6e-798ff1569135" xlink:to="loc_ifrs-full_CurrentAssets_8860176f-5651-5974-2a18-49d5eb8ec5c1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_407b29fa-efd0-3404-37dd-edd516e04e72" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_8860176f-5651-5974-2a18-49d5eb8ec5c1" xlink:to="loc_ifrs-full_CashAndCashEquivalents_407b29fa-efd0-3404-37dd-edd516e04e72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-full_OtherCurrentReceivables_93546bd0-494c-a757-452e-a9845b5eb5bb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_8860176f-5651-5974-2a18-49d5eb8ec5c1" xlink:to="loc_ifrs-full_OtherCurrentReceivables_93546bd0-494c-a757-452e-a9845b5eb5bb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_0dabc4ff-3a75-60ff-71d7-4799d5aa349f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_8860176f-5651-5974-2a18-49d5eb8ec5c1" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_0dabc4ff-3a75-60ff-71d7-4799d5aa349f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets_1afbb7d9-169a-cd32-aa3f-cf152574bf13" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_d05234d6-3b70-344e-5f6e-798ff1569135" xlink:to="loc_ifrs-full_NoncurrentAssets_1afbb7d9-169a-cd32-aa3f-cf152574bf13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_cd35e591-f101-fe7b-9b80-6c7ba971774c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_1afbb7d9-169a-cd32-aa3f-cf152574bf13" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_cd35e591-f101-fe7b-9b80-6c7ba971774c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_a304783b-188d-c0bd-9f3b-662dfd46f77a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_1afbb7d9-169a-cd32-aa3f-cf152574bf13" xlink:to="loc_ifrs-full_RightofuseAssets_a304783b-188d-c0bd-9f3b-662dfd46f77a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPositionParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_85cd8f77-c17e-0b32-7622-7b8f3a278d9f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_a1abd9e1-dee4-121d-318e-70ec00d5724b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_85cd8f77-c17e-0b32-7622-7b8f3a278d9f" xlink:to="loc_ifrs-full_ProfitLoss_a1abd9e1-dee4-121d-318e-70ec00d5724b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_3ba038a1-d9df-a1b7-c5f2-a2406b4de178" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_a1abd9e1-dee4-121d-318e-70ec00d5724b" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_3ba038a1-d9df-a1b7-c5f2-a2406b4de178" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_6a880689-7739-b7d7-30d4-8a31c63fd91a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_3ba038a1-d9df-a1b7-c5f2-a2406b4de178" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_6a880689-7739-b7d7-30d4-8a31c63fd91a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_d7d267e5-cac9-5279-1565-579e95baa586" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_6a880689-7739-b7d7-30d4-8a31c63fd91a" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_d7d267e5-cac9-5279-1565-579e95baa586" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingExpense" xlink:label="loc_ifrs-full_OperatingExpense_a357a678-e48c-9019-86b3-81f11ca77ef7" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_6a880689-7739-b7d7-30d4-8a31c63fd91a" xlink:to="loc_ifrs-full_OperatingExpense_a357a678-e48c-9019-86b3-81f11ca77ef7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_1d792e8a-6f41-7b76-8c65-099fda925bd0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_3ba038a1-d9df-a1b7-c5f2-a2406b4de178" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_1d792e8a-6f41-7b76-8c65-099fda925bd0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_3f3513cc-e8f7-a563-4d87-4b1778fd099b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_3ba038a1-d9df-a1b7-c5f2-a2406b4de178" xlink:to="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_3f3513cc-e8f7-a563-4d87-4b1778fd099b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_091c0ae1-0d9c-b0c4-52e8-e20a60849b4f" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_a1abd9e1-dee4-121d-318e-70ec00d5724b" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_091c0ae1-0d9c-b0c4-52e8-e20a60849b4f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_b881e803-81ba-aafe-7ee6-03eaea8f68a8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_85cd8f77-c17e-0b32-7622-7b8f3a278d9f" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_b881e803-81ba-aafe-7ee6-03eaea8f68a8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/Contingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContingenciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivable" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableScheduleOfContractRevenuesAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContractLiabilities" xlink:label="loc_ifrs-full_ContractLiabilities_b0ec03eb-1961-3916-8ab5-494faf2eb02c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="loc_ifrs-full_CurrentContractLiabilities_dbd0019d-45a3-243c-1ba2-8abfcea3919f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ContractLiabilities_b0ec03eb-1961-3916-8ab5-494faf2eb02c" xlink:to="loc_ifrs-full_CurrentContractLiabilities_dbd0019d-45a3-243c-1ba2-8abfcea3919f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_141772e1-dd71-691b-6c26-56bec9b50de0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ContractLiabilities_b0ec03eb-1961-3916-8ab5-494faf2eb02c" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_141772e1-dd71-691b-6c26-56bec9b50de0" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleOfBalancesInForeignCurrenciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_72e72b9e-b6fa-65aa-ade7-813a54bc8eef" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_b4979993-4332-ba60-d6ba-91a3b2dc49c0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_72e72b9e-b6fa-65aa-ade7-813a54bc8eef" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_b4979993-4332-ba60-d6ba-91a3b2dc49c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_2abbcdbc-c854-d8b1-4c6b-24d21dd377da" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_b4979993-4332-ba60-d6ba-91a3b2dc49c0" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_2abbcdbc-c854-d8b1-4c6b-24d21dd377da" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxEffectOfForeignTaxRates" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates_8bb8be7d-84e5-fddf-4c4f-1f11305c7e44" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_b4979993-4332-ba60-d6ba-91a3b2dc49c0" xlink:to="loc_ifrs-full_TaxEffectOfForeignTaxRates_8bb8be7d-84e5-fddf-4c4f-1f11305c7e44" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TaxEffectOfStockBasedCompensation" xlink:label="loc_oncyf_TaxEffectOfStockBasedCompensation_46ee52ed-b25a-1828-89d7-9cfe3ac17c8a" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_b4979993-4332-ba60-d6ba-91a3b2dc49c0" xlink:to="loc_oncyf_TaxEffectOfStockBasedCompensation_46ee52ed-b25a-1828-89d7-9cfe3ac17c8a" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:label="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_9299637d-5dad-874b-e9c0-9cfe3a63b64d" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_b4979993-4332-ba60-d6ba-91a3b2dc49c0" xlink:to="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_9299637d-5dad-874b-e9c0-9cfe3a63b64d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxEffectFromChangeInTaxRate" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate_58071e01-c676-e1d4-5a5a-6eac6303e807" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_b4979993-4332-ba60-d6ba-91a3b2dc49c0" xlink:to="loc_ifrs-full_TaxEffectFromChangeInTaxRate_58071e01-c676-e1d4-5a5a-6eac6303e807" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TaxEffectOfTaxPools" xlink:label="loc_oncyf_TaxEffectOfTaxPools_f4d160c1-5de7-26f3-de78-9cfe3ab5a0d5" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_b4979993-4332-ba60-d6ba-91a3b2dc49c0" xlink:to="loc_oncyf_TaxEffectOfTaxPools_f4d160c1-5de7-26f3-de78-9cfe3ab5a0d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_69cb2b88-a734-5122-a7da-a97c35da9d98" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_b4979993-4332-ba60-d6ba-91a3b2dc49c0" xlink:to="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_69cb2b88-a734-5122-a7da-a97c35da9d98" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:label="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_4105fe95-130a-40c0-57b1-9cfe3acb989c" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_b4979993-4332-ba60-d6ba-91a3b2dc49c0" xlink:to="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_4105fe95-130a-40c0-57b1-9cfe3acb989c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:label="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_5f3864f6-d68f-cbf7-c232-26008c3a2117" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_72e72b9e-b6fa-65aa-ade7-813a54bc8eef" xlink:to="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_5f3864f6-d68f-cbf7-c232-26008c3a2117" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleOfUnrecognizedDeferredTaxAssetsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonCapitalLossesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonRefundableFederalInvestmentTaxCreditsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncorporationAndNatureOfOperations" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IndemnificationOfOfficersAndDirectors" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/Leases" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesRightOfUseAssetsAndLeaseLiabilitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerCommonShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_e35e8d35-6096-b06f-f9e4-f0b6af76138b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_9acdc7c3-8771-4948-f749-ec1bbc32b713" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_e35e8d35-6096-b06f-f9e4-f0b6af76138b" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_9acdc7c3-8771-4948-f749-ec1bbc32b713" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_c5650b1b-c707-9150-da65-47a2c68fe501" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_e35e8d35-6096-b06f-f9e4-f0b6af76138b" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_c5650b1b-c707-9150-da65-47a2c68fe501" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_ffefeb1b-fd45-9200-f219-28e55f64d0a9" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_e35e8d35-6096-b06f-f9e4-f0b6af76138b" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_ffefeb1b-fd45-9200-f219-28e55f64d0a9" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsAndFairValueOfOptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfNumberOfOtherEquityInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsAndWeightedAverageExercisePricesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalFootnotesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryOfOutstandingWarrantsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesAndAssumptions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesIfrs16LeasesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivative" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationOfChangeInFairValueOfWarrantDerivativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForWarrantsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>26
<FILENAME>oncyf-20191231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:href="oncyf-20191231.xsd#AdditionalCashFlowDisclosures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:href="oncyf-20191231.xsd#AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:href="oncyf-20191231.xsd#AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:href="oncyf-20191231.xsd#AdditionalCashFlowDisclosuresTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/BasisOfFinancialStatementPresentation" xlink:href="oncyf-20191231.xsd#BasisOfFinancialStatementPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:href="oncyf-20191231.xsd#CapitalDisclosures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:href="oncyf-20191231.xsd#CapitalDisclosuresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:href="oncyf-20191231.xsd#CapitalDisclosuresTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalents" xlink:href="oncyf-20191231.xsd#CashEquivalents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsNarrativeDetails" xlink:href="oncyf-20191231.xsd#CashEquivalentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Commitments" xlink:href="oncyf-20191231.xsd#Commitments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsDetails" xlink:href="oncyf-20191231.xsd#CommitmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="oncyf-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfChangesInDeficitEquity" xlink:href="oncyf-20191231.xsd#ConsolidatedStatementsOfChangesInDeficitEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPosition" xlink:href="oncyf-20191231.xsd#ConsolidatedStatementsOfFinancialPosition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPositionParenthetical" xlink:href="oncyf-20191231.xsd#ConsolidatedStatementsOfFinancialPositionParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss" xlink:href="oncyf-20191231.xsd#ConsolidatedStatementsOfLossAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Contingencies" xlink:href="oncyf-20191231.xsd#Contingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContingenciesDetails" xlink:href="oncyf-20191231.xsd#ContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivable" xlink:href="oncyf-20191231.xsd#ContractLiabilityAndReceivable" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableNarrativeDetails" xlink:href="oncyf-20191231.xsd#ContractLiabilityAndReceivableNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableScheduleOfContractRevenuesAndLiabilitiesDetails" xlink:href="oncyf-20191231.xsd#ContractLiabilityAndReceivableScheduleOfContractRevenuesAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableTables" xlink:href="oncyf-20191231.xsd#ContractLiabilityAndReceivableTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/DocumentAndEntityInformation" xlink:href="oncyf-20191231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:href="oncyf-20191231.xsd#EconomicDependence" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:href="oncyf-20191231.xsd#EconomicDependenceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:href="oncyf-20191231.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:href="oncyf-20191231.xsd#FinancialInstrumentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleOfBalancesInForeignCurrenciesDetails" xlink:href="oncyf-20191231.xsd#FinancialInstrumentsScheduleOfBalancesInForeignCurrenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:href="oncyf-20191231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:href="oncyf-20191231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionForIncomeTaxesDetails" xlink:href="oncyf-20191231.xsd#IncomeTaxesProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleOfUnrecognizedDeferredTaxAssetsDetails" xlink:href="oncyf-20191231.xsd#IncomeTaxesScheduleOfUnrecognizedDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonCapitalLossesDetails" xlink:href="oncyf-20191231.xsd#IncomeTaxesSummaryOfNonCapitalLossesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonRefundableFederalInvestmentTaxCreditsDetails" xlink:href="oncyf-20191231.xsd#IncomeTaxesSummaryOfNonRefundableFederalInvestmentTaxCreditsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:href="oncyf-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncorporationAndNatureOfOperations" xlink:href="oncyf-20191231.xsd#IncorporationAndNatureOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IndemnificationOfOfficersAndDirectors" xlink:href="oncyf-20191231.xsd#IndemnificationOfOfficersAndDirectors" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Leases" xlink:href="oncyf-20191231.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:href="oncyf-20191231.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesRightOfUseAssetsAndLeaseLiabilitiesDetails" xlink:href="oncyf-20191231.xsd#LeasesRightOfUseAssetsAndLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesTables" xlink:href="oncyf-20191231.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:href="oncyf-20191231.xsd#LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShare" xlink:href="oncyf-20191231.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails" xlink:href="oncyf-20191231.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustments" xlink:href="oncyf-20191231.xsd#OtherExpensesAndAdjustments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsDetails" xlink:href="oncyf-20191231.xsd#OtherExpensesAndAdjustmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsTables" xlink:href="oncyf-20191231.xsd#OtherExpensesAndAdjustmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyAndEquipment" xlink:href="oncyf-20191231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentDetails" xlink:href="oncyf-20191231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentTables" xlink:href="oncyf-20191231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:href="oncyf-20191231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:href="oncyf-20191231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:href="oncyf-20191231.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPayments" xlink:href="oncyf-20191231.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsAndFairValueOfOptionsDetails" xlink:href="oncyf-20191231.xsd#ShareBasedPaymentsDisclosureWeightedAverageAssumptionsAndFairValueOfOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails" xlink:href="oncyf-20191231.xsd#ShareBasedPaymentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfNumberOfOtherEquityInstrumentsDetails" xlink:href="oncyf-20191231.xsd#ShareBasedPaymentsScheduleOfNumberOfOtherEquityInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsAndWeightedAverageExercisePricesDetails" xlink:href="oncyf-20191231.xsd#ShareBasedPaymentsScheduleOfStockOptionsAndWeightedAverageExercisePricesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails" xlink:href="oncyf-20191231.xsd#ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables" xlink:href="oncyf-20191231.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:href="oncyf-20191231.xsd#ShareCapital" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalNarrativeDetails" xlink:href="oncyf-20191231.xsd#ShareCapitalNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalDetails" xlink:href="oncyf-20191231.xsd#ShareCapitalScheduleOfShareCapitalDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalFootnotesDetails" xlink:href="oncyf-20191231.xsd#ShareCapitalScheduleOfShareCapitalFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryOfOutstandingWarrantsDetails" xlink:href="oncyf-20191231.xsd#ShareCapitalSummaryOfOutstandingWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:href="oncyf-20191231.xsd#ShareCapitalTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesAndAssumptions" xlink:href="oncyf-20191231.xsd#SignificantJudgmentsEstimatesAndAssumptions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEvents" xlink:href="oncyf-20191231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails" xlink:href="oncyf-20191231.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="oncyf-20191231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesIfrs16LeasesDetails" xlink:href="oncyf-20191231.xsd#SummaryOfSignificantAccountingPoliciesIfrs16LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="oncyf-20191231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="oncyf-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" xlink:href="oncyf-20191231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="oncyf-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivative" xlink:href="oncyf-20191231.xsd#WarrantDerivative" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails" xlink:href="oncyf-20191231.xsd#WarrantDerivativeNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationOfChangeInFairValueOfWarrantDerivativeDetails" xlink:href="oncyf-20191231.xsd#WarrantDerivativeReconciliationOfChangeInFairValueOfWarrantDerivativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForWarrantsDetails" xlink:href="oncyf-20191231.xsd#WarrantDerivativeSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables" xlink:href="oncyf-20191231.xsd#WarrantDerivativeTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/BasisOfFinancialStatementPresentation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalentsNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/Commitments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CommitmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_2F95792481FC493CAD919CFE7E237784" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_5ACC3592B5984E8B409E9CFE7E229E79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_2F95792481FC493CAD919CFE7E237784" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_5ACC3592B5984E8B409E9CFE7E229E79" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_B2985E1165D7CDF440049CFE7E22F1EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_5ACC3592B5984E8B409E9CFE7E229E79" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_B2985E1165D7CDF440049CFE7E22F1EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherProvisionsMember" xlink:label="loc_ifrs-full_OtherProvisionsMember_555BE089A395562308BF9CFE7E223119_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_B2985E1165D7CDF440049CFE7E22F1EB" xlink:to="loc_ifrs-full_OtherProvisionsMember_555BE089A395562308BF9CFE7E223119_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherProvisionsMember" xlink:label="loc_ifrs-full_OtherProvisionsMember_555BE089A395562308BF9CFE7E223119" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_B2985E1165D7CDF440049CFE7E22F1EB" xlink:to="loc_ifrs-full_OtherProvisionsMember_555BE089A395562308BF9CFE7E223119" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CollaborationAgreementMember" xlink:label="loc_oncyf_CollaborationAgreementMember_6C2210EF879BAD5BB4A99CFE7E22990A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_555BE089A395562308BF9CFE7E223119" xlink:to="loc_oncyf_CollaborationAgreementMember_6C2210EF879BAD5BB4A99CFE7E22990A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherReceivables" xlink:label="loc_ifrs-full_OtherReceivables_3B5D5386014FFBE38C509CFE7E231A20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_2F95792481FC493CAD919CFE7E237784" xlink:to="loc_ifrs-full_OtherReceivables_3B5D5386014FFBE38C509CFE7E231A20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_97A7A3C418BCBF8806E69CFE7E239236" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_2F95792481FC493CAD919CFE7E237784" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_97A7A3C418BCBF8806E69CFE7E239236" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_Statement1LineItems" xlink:label="loc_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_Statement1Table" xlink:label="loc_oncyf_Statement1Table_3117261B4B66306B3DFE9CFE7F3FAC50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4" xlink:to="loc_oncyf_Statement1Table_3117261B4B66306B3DFE9CFE7F3FAC50" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockAxis" xlink:label="loc_oncyf_SaleOfStockAxis_B086B7FD46E18CD12C2D9CFE7F401C2C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_Statement1Table_3117261B4B66306B3DFE9CFE7F3FAC50" xlink:to="loc_oncyf_SaleOfStockAxis_B086B7FD46E18CD12C2D9CFE7F401C2C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_E99B018FBDAC7B45BF849CFE7F40692F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_B086B7FD46E18CD12C2D9CFE7F401C2C" xlink:to="loc_oncyf_SaleOfStockDomain_E99B018FBDAC7B45BF849CFE7F40692F_default" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_E99B018FBDAC7B45BF849CFE7F40692F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_B086B7FD46E18CD12C2D9CFE7F401C2C" xlink:to="loc_oncyf_SaleOfStockDomain_E99B018FBDAC7B45BF849CFE7F40692F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderWarrantAgreementMember" xlink:label="loc_oncyf_SharesUnderWarrantAgreementMember_2564080B2639513B86149CFE7F4076A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_E99B018FBDAC7B45BF849CFE7F40692F" xlink:to="loc_oncyf_SharesUnderWarrantAgreementMember_2564080B2639513B86149CFE7F4076A6" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderCommonStockPurchaseAgreementMember" xlink:label="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_435B752D7D821FE18EA39CFE7F40181A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_E99B018FBDAC7B45BF849CFE7F40692F" xlink:to="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_435B752D7D821FE18EA39CFE7F40181A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderAtthemarketAgreementMember" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_B87836EFE6E2A91C4D619CFE7F405665" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_E99B018FBDAC7B45BF849CFE7F40692F" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_B87836EFE6E2A91C4D619CFE7F405665" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesPublicOfferingMember" xlink:label="loc_oncyf_SharesPublicOfferingMember_BC06988F5C3AC4881AD79CFE7F416F5D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_E99B018FBDAC7B45BF849CFE7F40692F" xlink:to="loc_oncyf_SharesPublicOfferingMember_BC06988F5C3AC4881AD79CFE7F416F5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_8527488FB430AE417B6C9CFE7F4159D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:to="loc_ifrs-full_ProfitLoss_8527488FB430AE417B6C9CFE7F4159D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_511F49FFDDE4761531309CFE7F424160" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_511F49FFDDE4761531309CFE7F424160" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_2F7AE4103A02FE2EC9BA9CFE7F42ADB6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_2F7AE4103A02FE2EC9BA9CFE7F42ADB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_3EA110865B32CFA0B1F99CFE7F427EE2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_3EA110865B32CFA0B1F99CFE7F427EE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_C862DA753096F1C975209CFE7F426BF0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_C862DA753096F1C975209CFE7F426BF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_7C51434FD82E2BA572789CFE7F426C2A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_7C51434FD82E2BA572789CFE7F426C2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="loc_ifrs-full_AdjustmentsForProvisions_28EAD194F1A23409E9519CFE7F424E8A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:to="loc_ifrs-full_AdjustmentsForProvisions_28EAD194F1A23409E9519CFE7F424E8A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_AdjustmentsforLeaseAmortization" xlink:label="loc_oncyf_AdjustmentsforLeaseAmortization_AAF21EB1F4794F0ED71F9CFE7F43A5C6" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:to="loc_oncyf_AdjustmentsforLeaseAmortization_AAF21EB1F4794F0ED71F9CFE7F43A5C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_6EEE1FB2818D2BC6B7E79CFE7F43676C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_6EEE1FB2818D2BC6B7E79CFE7F43676C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_ADAAC49E1CA4D9272FD59CFE7F4370DF" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_ADAAC49E1CA4D9272FD59CFE7F4370DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_4015E62566044D69F2F19CFE7F43D7C9" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_4015E62566044D69F2F19CFE7F43D7C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_64BE9F6DD7B8179B407E9CFE7F4354FC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_64BE9F6DD7B8179B407E9CFE7F4354FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_9ED595B3F2726B9BAF7E9CFE7F43CB97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_64BE9F6DD7B8179B407E9CFE7F4354FC" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_9ED595B3F2726B9BAF7E9CFE7F43CB97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:label="loc_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_7DDF74F66B967B6A5A709CFE7F448EC8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_64BE9F6DD7B8179B407E9CFE7F4354FC" xlink:to="loc_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_7DDF74F66B967B6A5A709CFE7F448EC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_7111E4979D9DF46B6E8A9CFE7F440E86" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_64BE9F6DD7B8179B407E9CFE7F4354FC" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_7111E4979D9DF46B6E8A9CFE7F440E86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_29EAF9F900576EC666279CFE7F4488D3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_29EAF9F900576EC666279CFE7F4488D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_EBD25F37EB23A2BB9A029CFE7F4484B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_29EAF9F900576EC666279CFE7F4488D3" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_EBD25F37EB23A2BB9A029CFE7F4484B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_81C964343C59B17095D29CFE7F44C502" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_29EAF9F900576EC666279CFE7F4488D3" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_81C964343C59B17095D29CFE7F44C502" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashOutflowForLeases" xlink:label="loc_ifrs-full_CashOutflowForLeases_01A4DB36F8AC7FDB0CCD9CFE7F458C49" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_29EAF9F900576EC666279CFE7F4488D3" xlink:to="loc_ifrs-full_CashOutflowForLeases_01A4DB36F8AC7FDB0CCD9CFE7F458C49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_A6706F34A95877FD2DC09CFE7F453B75" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_29EAF9F900576EC666279CFE7F4488D3" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_A6706F34A95877FD2DC09CFE7F453B75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_4DBD622DB4465BB62CF09CFE7F45E49C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_4DBD622DB4465BB62CF09CFE7F45E49C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_BD89341FD15DEEA698269CFE7F45A099" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4" xlink:to="loc_ifrs-full_CashAndCashEquivalents_BD89341FD15DEEA698269CFE7F45A099" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_681CBFA55F627A07D5E49CFE7F455831" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_681CBFA55F627A07D5E49CFE7F455831" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfChangesInDeficitEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_C85411ABA5023210E0CFACF623245769" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_C85411ABA5023210E0CFACF623245769" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_9C208DA46E0FA0E304CDACF6232474E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_C85411ABA5023210E0CFACF623245769" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_9C208DA46E0FA0E304CDACF6232474E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_B9453EAB0D75A8AB8647ACF6232426AB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_9C208DA46E0FA0E304CDACF6232474E9" xlink:to="loc_ifrs-full_EquityMember_B9453EAB0D75A8AB8647ACF6232426AB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_B9453EAB0D75A8AB8647ACF6232426AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_9C208DA46E0FA0E304CDACF6232474E9" xlink:to="loc_ifrs-full_EquityMember_B9453EAB0D75A8AB8647ACF6232426AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_80FBA3F09F72996CB436ACF62324A552" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_B9453EAB0D75A8AB8647ACF6232426AB" xlink:to="loc_ifrs-full_IssuedCapitalMember_80FBA3F09F72996CB436ACF62324A552" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_CFDD84710FFE8EAB51DCACF62325858D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_B9453EAB0D75A8AB8647ACF6232426AB" xlink:to="loc_oncyf_WarrantsMember_CFDD84710FFE8EAB51DCACF62325858D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharePremiumMember" xlink:label="loc_ifrs-full_SharePremiumMember_70C2E7623CCED1A17587ACF623253CB2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_B9453EAB0D75A8AB8647ACF6232426AB" xlink:to="loc_ifrs-full_SharePremiumMember_70C2E7623CCED1A17587ACF623253CB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_AF3071FEAB454B2B4743ACF62325AECC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_B9453EAB0D75A8AB8647ACF6232426AB" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_AF3071FEAB454B2B4743ACF62325AECC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember_C88B5CD38E874BA4BDBBACF62325A449" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_B9453EAB0D75A8AB8647ACF6232426AB" xlink:to="loc_ifrs-full_RetainedEarningsMember_C88B5CD38E874BA4BDBBACF62325A449" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockAxis" xlink:label="loc_oncyf_SaleOfStockAxis_E84D8E4B519C72A874D6ACF623258A2A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_C85411ABA5023210E0CFACF623245769" xlink:to="loc_oncyf_SaleOfStockAxis_E84D8E4B519C72A874D6ACF623258A2A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_517650B56FB0FA86BE27ACF6232665B4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_E84D8E4B519C72A874D6ACF623258A2A" xlink:to="loc_oncyf_SaleOfStockDomain_517650B56FB0FA86BE27ACF6232665B4_default" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_517650B56FB0FA86BE27ACF6232665B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_E84D8E4B519C72A874D6ACF623258A2A" xlink:to="loc_oncyf_SaleOfStockDomain_517650B56FB0FA86BE27ACF6232665B4" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderAtthemarketAgreementMember" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_C459A844B50C11A00C87ACF62326DF5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_517650B56FB0FA86BE27ACF6232665B4" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_C459A844B50C11A00C87ACF62326DF5B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesPublicOfferingMember" xlink:label="loc_oncyf_SharesPublicOfferingMember_82DD24F9816288714018ACF62326ADDE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_517650B56FB0FA86BE27ACF6232665B4" xlink:to="loc_oncyf_SharesPublicOfferingMember_82DD24F9816288714018ACF62326ADDE" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderSharePurchaseAgreementMember" xlink:label="loc_oncyf_SharesUnderSharePurchaseAgreementMember_8DF9D9EA8EA46E6B460CACF623260850" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_517650B56FB0FA86BE27ACF6232665B4" xlink:to="loc_oncyf_SharesUnderSharePurchaseAgreementMember_8DF9D9EA8EA46E6B460CACF623260850" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_18ADFE32B582CF682AA5ACF62327A313" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:to="loc_ifrs-full_Equity_18ADFE32B582CF682AA5ACF62327A313" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_6F0DE793C7308E56FEA0ACF62327033B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:to="loc_ifrs-full_ComprehensiveIncome_6F0DE793C7308E56FEA0ACF62327033B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:label="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_C2255625113F736101D3ACF623275483" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:to="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_C2255625113F736101D3ACF623275483" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_7879F91B43F52554FD34ACF623275B77" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_7879F91B43F52554FD34ACF623275B77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_AD583F47885FD2776FD2ACF62327D60B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:to="loc_ifrs-full_IssueOfEquity_AD583F47885FD2776FD2ACF62327D60B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_D49C7AD827E580137511ACF62328EE7D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_D49C7AD827E580137511ACF62328EE7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_E126DD9EDEEE9F405437ACF62328F49D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_E126DD9EDEEE9F405437ACF62328F49D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_A78BAABA563CD57EBFA5ACF6232DDF4E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_A78BAABA563CD57EBFA5ACF6232DDF4E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPosition" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPositionParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/Contingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_E84E5E68FF768B670164A339610B217D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_6DDE0BF97177E2BA5E88A339610A9472" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_E84E5E68FF768B670164A339610B217D" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_6DDE0BF97177E2BA5E88A339610A9472" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-full_CounterpartiesAxis_AB03847E6DD28513DB3CA339610A961F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_6DDE0BF97177E2BA5E88A339610A9472" xlink:to="loc_ifrs-full_CounterpartiesAxis_AB03847E6DD28513DB3CA339610A961F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-full_CounterpartiesMember_B28AE487282FCDAE622DA339610B5D47_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_AB03847E6DD28513DB3CA339610A961F" xlink:to="loc_ifrs-full_CounterpartiesMember_B28AE487282FCDAE622DA339610B5D47_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-full_CounterpartiesMember_B28AE487282FCDAE622DA339610B5D47" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_AB03847E6DD28513DB3CA339610A961F" xlink:to="loc_ifrs-full_CounterpartiesMember_B28AE487282FCDAE622DA339610B5D47" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SYNSORBMember" xlink:label="loc_oncyf_SYNSORBMember_FD1C0B69E8A942658A7BA339610BBECF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_B28AE487282FCDAE622DA339610B5D47" xlink:to="loc_oncyf_SYNSORBMember_FD1C0B69E8A942658A7BA339610BBECF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:label="loc_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_DF4AE4A54F5EA15CE95FA339610B6E1A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_E84E5E68FF768B670164A339610B217D" xlink:to="loc_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_DF4AE4A54F5EA15CE95FA339610B6E1A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_D719AD6C1877201ED969A339610CE4EC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_E84E5E68FF768B670164A339610B217D" xlink:to="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_D719AD6C1877201ED969A339610CE4EC" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_A91FABEF192E17D7ADC0A339610C3597" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_E84E5E68FF768B670164A339610B217D" xlink:to="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_A91FABEF192E17D7ADC0A339610C3597" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_E4A82B815EDD22760AF3A339610CE71F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_E84E5E68FF768B670164A339610B217D" xlink:to="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_E4A82B815EDD22760AF3A339610CE71F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivable" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableScheduleOfContractRevenuesAndLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ConcentrationRiskType1LineItems" xlink:label="loc_oncyf_ConcentrationRiskType1LineItems_61BB0FEB7E430980EE279CFE7E29B3E1" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ConcentrationRisk1Table" xlink:label="loc_oncyf_ConcentrationRisk1Table_321AE68CE01BCF4D08E59CFE7E28BA0F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems_61BB0FEB7E430980EE279CFE7E29B3E1" xlink:to="loc_oncyf_ConcentrationRisk1Table_321AE68CE01BCF4D08E59CFE7E28BA0F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ConcentrationRiskType1Axis" xlink:label="loc_oncyf_ConcentrationRiskType1Axis_DD1628D636E0238452189CFE7E28C25C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_ConcentrationRisk1Table_321AE68CE01BCF4D08E59CFE7E28BA0F" xlink:to="loc_oncyf_ConcentrationRiskType1Axis_DD1628D636E0238452189CFE7E28C25C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ConcentrationRiskType1Domain" xlink:label="loc_oncyf_ConcentrationRiskType1Domain_2F6B9A8F93D56871CF349CFE7E29A8DF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_ConcentrationRiskType1Axis_DD1628D636E0238452189CFE7E28C25C" xlink:to="loc_oncyf_ConcentrationRiskType1Domain_2F6B9A8F93D56871CF349CFE7E29A8DF_default" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ConcentrationRiskType1Domain" xlink:label="loc_oncyf_ConcentrationRiskType1Domain_2F6B9A8F93D56871CF349CFE7E29A8DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_ConcentrationRiskType1Axis_DD1628D636E0238452189CFE7E28C25C" xlink:to="loc_oncyf_ConcentrationRiskType1Domain_2F6B9A8F93D56871CF349CFE7E29A8DF" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SupplierConcentrationRisk1Member" xlink:label="loc_oncyf_SupplierConcentrationRisk1Member_B9A38C910366D73492559CFE7E292D7D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ConcentrationRiskType1Domain_2F6B9A8F93D56871CF349CFE7E29A8DF" xlink:to="loc_oncyf_SupplierConcentrationRisk1Member_B9A38C910366D73492559CFE7E292D7D" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ConcentrationRiskNumber" xlink:label="loc_oncyf_ConcentrationRiskNumber_A25AF3CCD2CD91961BC69CFE7E294858" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems_61BB0FEB7E430980EE279CFE7E29B3E1" xlink:to="loc_oncyf_ConcentrationRiskNumber_A25AF3CCD2CD91961BC69CFE7E294858" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_43A35A9342D53467920AA7434B17635A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5330F63BA4F1976374A9A7434B17D188" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_43A35A9342D53467920AA7434B17635A" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5330F63BA4F1976374A9A7434B17D188" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_09B0E26E1E43869B2D3FA7D00E87C175" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5330F63BA4F1976374A9A7434B17D188" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_09B0E26E1E43869B2D3FA7D00E87C175" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_120CC4EEFB1C5AF12C4FA7D1B8A6C4E6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_09B0E26E1E43869B2D3FA7D00E87C175" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_120CC4EEFB1C5AF12C4FA7D1B8A6C4E6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_120CC4EEFB1C5AF12C4FA7D1B8A6C4E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_09B0E26E1E43869B2D3FA7D00E87C175" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_120CC4EEFB1C5AF12C4FA7D1B8A6C4E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_8BA3A1E7521EFB98AA8CA7D05615D2E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_120CC4EEFB1C5AF12C4FA7D1B8A6C4E6" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_8BA3A1E7521EFB98AA8CA7D05615D2E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_963D21F4188DF90FBA48A7434B17B8D9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5330F63BA4F1976374A9A7434B17D188" xlink:to="loc_ifrs-full_TypesOfRisksAxis_963D21F4188DF90FBA48A7434B17B8D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_4006E99ADE823319600EA7434B17C4EA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_963D21F4188DF90FBA48A7434B17B8D9" xlink:to="loc_ifrs-full_TypesOfRisksMember_4006E99ADE823319600EA7434B17C4EA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_4006E99ADE823319600EA7434B17C4EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_963D21F4188DF90FBA48A7434B17B8D9" xlink:to="loc_ifrs-full_TypesOfRisksMember_4006E99ADE823319600EA7434B17C4EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember_844CB93577A121C80EFAA7434B17D05B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_4006E99ADE823319600EA7434B17C4EA" xlink:to="loc_ifrs-full_CurrencyRiskMember_844CB93577A121C80EFAA7434B17D05B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_Currency1Axis" xlink:label="loc_oncyf_Currency1Axis_A7238C6A26FEDE6BE9E1A7434B177CDA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5330F63BA4F1976374A9A7434B17D188" xlink:to="loc_oncyf_Currency1Axis_A7238C6A26FEDE6BE9E1A7434B177CDA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_4883E80C372768C88001A7434B170EAD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_Currency1Axis_A7238C6A26FEDE6BE9E1A7434B177CDA" xlink:to="loc_currency_AllCurrenciesDomain_4883E80C372768C88001A7434B170EAD_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_4883E80C372768C88001A7434B170EAD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_Currency1Axis_A7238C6A26FEDE6BE9E1A7434B177CDA" xlink:to="loc_currency_AllCurrenciesDomain_4883E80C372768C88001A7434B170EAD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_USD" xlink:label="loc_currency_USD_B91EA2F65641422E5111A7434B179A18" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_4883E80C372768C88001A7434B170EAD" xlink:to="loc_currency_USD_B91EA2F65641422E5111A7434B179A18" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_ED00049E5BCBD7D27BF2A7434B17637F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_4883E80C372768C88001A7434B170EAD" xlink:to="loc_currency_GBP_ED00049E5BCBD7D27BF2A7434B17637F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_71A78E87A242258860A0A7434B17EE5D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_4883E80C372768C88001A7434B170EAD" xlink:to="loc_currency_EUR_71A78E87A242258860A0A7434B17EE5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_8E1A76470D0EDF71DAF4A7434B1BB4A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_43A35A9342D53467920AA7434B17635A" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_8E1A76470D0EDF71DAF4A7434B1BB4A7" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_510A3D9A64A7AED3A721A7434B1B24B7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_43A35A9342D53467920AA7434B17635A" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_510A3D9A64A7AED3A721A7434B1B24B7" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_6D96D594EA1456A9E006A7434B1BFFFC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_43A35A9342D53467920AA7434B17635A" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_6D96D594EA1456A9E006A7434B1BFFFC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleOfBalancesInForeignCurrenciesDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_Currency1LineItems" xlink:label="loc_oncyf_Currency1LineItems_A03B3995CDFEDBADD26BA81F7EB07BFD" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_Currency1Table" xlink:label="loc_oncyf_Currency1Table_F094A305589401A92997A81F7EAEB869" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_Currency1LineItems_A03B3995CDFEDBADD26BA81F7EB07BFD" xlink:to="loc_oncyf_Currency1Table_F094A305589401A92997A81F7EAEB869" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_Currency1Axis" xlink:label="loc_oncyf_Currency1Axis_6F1EA6CAFDE192AF758FA81F7EAE0EC9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_Currency1Table_F094A305589401A92997A81F7EAEB869" xlink:to="loc_oncyf_Currency1Axis_6F1EA6CAFDE192AF758FA81F7EAE0EC9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_59B68FCC08E88309E261A81F7EAFED81_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_Currency1Axis_6F1EA6CAFDE192AF758FA81F7EAE0EC9" xlink:to="loc_currency_AllCurrenciesDomain_59B68FCC08E88309E261A81F7EAFED81_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_59B68FCC08E88309E261A81F7EAFED81" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_Currency1Axis_6F1EA6CAFDE192AF758FA81F7EAE0EC9" xlink:to="loc_currency_AllCurrenciesDomain_59B68FCC08E88309E261A81F7EAFED81" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_USD" xlink:label="loc_currency_USD_0AA03C3095082BD7D60DA81F7EAFB51E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_59B68FCC08E88309E261A81F7EAFED81" xlink:to="loc_currency_USD_0AA03C3095082BD7D60DA81F7EAFB51E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_98F2425978A76C20F16FA81F7EAFC6D1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_59B68FCC08E88309E261A81F7EAFED81" xlink:to="loc_currency_GBP_98F2425978A76C20F16FA81F7EAFC6D1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_E3CF8DA4DF7BF8909834A81F7EB00EA2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_59B68FCC08E88309E261A81F7EAFED81" xlink:to="loc_currency_EUR_E3CF8DA4DF7BF8909834A81F7EB00EA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_06C4206758D45B59247AA81F7EB01D0E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_A03B3995CDFEDBADD26BA81F7EB07BFD" xlink:to="loc_ifrs-full_CashAndCashEquivalents_06C4206758D45B59247AA81F7EB01D0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-full_OtherCurrentReceivables_66A734E662D8585F8908A81F7EB0E75C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_A03B3995CDFEDBADD26BA81F7EB07BFD" xlink:to="loc_ifrs-full_OtherCurrentReceivables_66A734E662D8585F8908A81F7EB0E75C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_A20D7F659CB474F753E6A81F7EB0D707" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_A03B3995CDFEDBADD26BA81F7EB07BFD" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_A20D7F659CB474F753E6A81F7EB0D707" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_AC6E82A33B3A9EEFE30EA81F7EB07BAD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_A03B3995CDFEDBADD26BA81F7EB07BFD" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_AC6E82A33B3A9EEFE30EA81F7EB07BAD" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_BalanceHeldInForeignCurrencyNet" xlink:label="loc_oncyf_BalanceHeldInForeignCurrencyNet_5C27DAB1BF714F3F9418A81F7EB10030" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_A03B3995CDFEDBADD26BA81F7EB07BFD" xlink:to="loc_oncyf_BalanceHeldInForeignCurrencyNet_5C27DAB1BF714F3F9418A81F7EB10030" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionForIncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleOfUnrecognizedDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_D2CB68D40A091E2EDEE19CFE7E7D2B83" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_9B9BA40BE875104C52A79CFE7E7A3CA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_D2CB68D40A091E2EDEE19CFE7E7D2B83" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_9B9BA40BE875104C52A79CFE7E7A3CA7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ABDC7E9C671BE186296E9CFE7E7BBDEA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_9B9BA40BE875104C52A79CFE7E7A3CA7" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ABDC7E9C671BE186296E9CFE7E7BBDEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_C5154722F1CFBD0D66529CFE7E7B58BD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ABDC7E9C671BE186296E9CFE7E7BBDEA" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_C5154722F1CFBD0D66529CFE7E7B58BD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_C5154722F1CFBD0D66529CFE7E7B58BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ABDC7E9C671BE186296E9CFE7E7BBDEA" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_C5154722F1CFBD0D66529CFE7E7B58BD" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:label="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_61A9EF54C6AF873A16819CFE7E7B9696" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_C5154722F1CFBD0D66529CFE7E7B58BD" xlink:to="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_61A9EF54C6AF873A16819CFE7E7B9696" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_23859A827F9E270607FF9CFE7E7C4A1D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_C5154722F1CFBD0D66529CFE7E7B58BD" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_23859A827F9E270607FF9CFE7E7C4A1D" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_InvestmentTaxCreditsMember" xlink:label="loc_oncyf_InvestmentTaxCreditsMember_764BE0C2135B047D2A0B9CFE7E7C0E8F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_C5154722F1CFBD0D66529CFE7E7B58BD" xlink:to="loc_oncyf_InvestmentTaxCreditsMember_764BE0C2135B047D2A0B9CFE7E7C0E8F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" xlink:label="loc_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_477B54D5277C652A91569CFE7E7C73C8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_C5154722F1CFBD0D66529CFE7E7B58BD" xlink:to="loc_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_477B54D5277C652A91569CFE7E7C73C8" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ShareIssueCostsMember" xlink:label="loc_oncyf_ShareIssueCostsMember_6A560FA56BD6795341EC9CFE7E7C60AF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_C5154722F1CFBD0D66529CFE7E7B58BD" xlink:to="loc_oncyf_ShareIssueCostsMember_6A560FA56BD6795341EC9CFE7E7C60AF" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:label="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_B4C3CCC958C5C00064CE9CFE7E7D1CBB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_C5154722F1CFBD0D66529CFE7E7B58BD" xlink:to="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_B4C3CCC958C5C00064CE9CFE7E7D1CBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_C1576EA69B47C18E30119CFE7E7D50D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_D2CB68D40A091E2EDEE19CFE7E7D2B83" xlink:to="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_C1576EA69B47C18E30119CFE7E7D50D3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonCapitalLossesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_CA94C02FC650DD0C50B89CFE7F741F80" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ADCDFF9E8E669B9977899CFE7F709427" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_CA94C02FC650DD0C50B89CFE7F741F80" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ADCDFF9E8E669B9977899CFE7F709427" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_853028AF1E641F3AC6499CFE7F719BF9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ADCDFF9E8E669B9977899CFE7F709427" xlink:to="loc_ifrs-full_MaturityAxis_853028AF1E641F3AC6499CFE7F719BF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_853028AF1E641F3AC6499CFE7F719BF9" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_853028AF1E641F3AC6499CFE7F719BF9" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentySixMember" xlink:label="loc_oncyf_TwentyTwentySixMember_260326053A1D3DE1B5559CFE7F71154A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyTwentySixMember_260326053A1D3DE1B5559CFE7F71154A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentySevenMember" xlink:label="loc_oncyf_TwentyTwentySevenMember_01A40582701C528ECCCB9CFE7F718398" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyTwentySevenMember_01A40582701C528ECCCB9CFE7F718398" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyNineMember" xlink:label="loc_oncyf_TwentyTwentyNineMember_B084DAC1F4A717001E9E9CFE7F722E79" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyTwentyNineMember_B084DAC1F4A717001E9E9CFE7F722E79" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyMember" xlink:label="loc_oncyf_TwentyThirtyMember_9385978711F07FA456DF9CFE7F729C9D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyThirtyMember_9385978711F07FA456DF9CFE7F729C9D" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyOneMember" xlink:label="loc_oncyf_TwentyThirtyOneMember_C83828689FCEE12224459CFE7F72B907" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyThirtyOneMember_C83828689FCEE12224459CFE7F72B907" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyTwoMember" xlink:label="loc_oncyf_TwentyThirtyTwoMember_3160433D34F3DBCDBD219CFE7F72FD16" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyThirtyTwoMember_3160433D34F3DBCDBD219CFE7F72FD16" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyThreeMember" xlink:label="loc_oncyf_TwentyThirtyThreeMember_BBC21835AE93F4D40EC99CFE7F7229B5" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyThirtyThreeMember_BBC21835AE93F4D40EC99CFE7F7229B5" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyFourMember" xlink:label="loc_oncyf_TwentyThirtyFourMember_CD12154D0B53AF29B97F9CFE7F72A917" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyThirtyFourMember_CD12154D0B53AF29B97F9CFE7F72A917" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyFiveMember" xlink:label="loc_oncyf_TwentyThirtyFiveMember_EAD393919CB8C0A2B3289CFE7F725EAB" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyThirtyFiveMember_EAD393919CB8C0A2B3289CFE7F725EAB" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtySixMember" xlink:label="loc_oncyf_TwentyThirtySixMember_1D3C9E404E0DEFC6C15F9CFE7F73F09F" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyThirtySixMember_1D3C9E404E0DEFC6C15F9CFE7F73F09F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtySevenMember" xlink:label="loc_oncyf_TwentyThirtySevenMember_8771EBDF1FDF956DE5649CFE7F73A085" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyThirtySevenMember_8771EBDF1FDF956DE5649CFE7F73A085" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyEightMember" xlink:label="loc_oncyf_TwentyThirtyEightMember_5F6693E3A43FE72A306E9CFE7F73A956" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyThirtyEightMember_5F6693E3A43FE72A306E9CFE7F73A956" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyNineMember" xlink:label="loc_oncyf_TwentyThirtyNineMember_6F226F44C5F84DE128319CFE7F736A8E" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyThirtyNineMember_6F226F44C5F84DE128319CFE7F736A8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0E868D7B0D37106158919CFE7F73C37E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ADCDFF9E8E669B9977899CFE7F709427" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0E868D7B0D37106158919CFE7F73C37E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1A65B9CCF7664250A94F9CFE7F7316DE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0E868D7B0D37106158919CFE7F73C37E" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1A65B9CCF7664250A94F9CFE7F7316DE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1A65B9CCF7664250A94F9CFE7F7316DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0E868D7B0D37106158919CFE7F73C37E" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1A65B9CCF7664250A94F9CFE7F7316DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_8E1C2C5FEF2159EB9B3D9CFE7F74E948" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1A65B9CCF7664250A94F9CFE7F7316DE" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_8E1C2C5FEF2159EB9B3D9CFE7F74E948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_CEC69F8272B5BD4C8C2A9CFE7F74EE9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_CA94C02FC650DD0C50B89CFE7F741F80" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_CEC69F8272B5BD4C8C2A9CFE7F74EE9C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonRefundableFederalInvestmentTaxCreditsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_963084CD10B5BDB4C13D9CFE7EC4B0E2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_4F6AEEF77540B6BC8BB99CFE7EBF4DC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_963084CD10B5BDB4C13D9CFE7EC4B0E2" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_4F6AEEF77540B6BC8BB99CFE7EBF4DC8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_32A4AC23E96E90E592219CFE7EBF0760" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_4F6AEEF77540B6BC8BB99CFE7EBF4DC8" xlink:to="loc_ifrs-full_MaturityAxis_32A4AC23E96E90E592219CFE7EBF0760" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_32A4AC23E96E90E592219CFE7EBF0760" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_32A4AC23E96E90E592219CFE7EBF0760" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyMember" xlink:label="loc_oncyf_TwentyTwentyMember_095D7C258B9B08E0C8699CFE7EBF73B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyTwentyMember_095D7C258B9B08E0C8699CFE7EBF73B1" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyOneMember" xlink:label="loc_oncyf_TwentyTwentyOneMember_0AC7BE4B64D281F0CB9C9CFE7EC0B688" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyTwentyOneMember_0AC7BE4B64D281F0CB9C9CFE7EC0B688" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyTwoMember" xlink:label="loc_oncyf_TwentyTwentyTwoMember_C6E219FE86738E2D18E19CFE7EC07F6E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyTwentyTwoMember_C6E219FE86738E2D18E19CFE7EC07F6E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyThreeMember" xlink:label="loc_oncyf_TwentyTwentyThreeMember_B44AA8B3F2FD0B4A73A19CFE7EC00ADD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyTwentyThreeMember_B44AA8B3F2FD0B4A73A19CFE7EC00ADD" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyFourMember" xlink:label="loc_oncyf_TwentyTwentyFourMember_000FC33C99EBD6627CD89CFE7EC0704A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyTwentyFourMember_000FC33C99EBD6627CD89CFE7EC0704A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyFiveMember" xlink:label="loc_oncyf_TwentyTwentyFiveMember_8D0C07B5FE41566F61719CFE7EC0A192" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyTwentyFiveMember_8D0C07B5FE41566F61719CFE7EC0A192" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentySixMember" xlink:label="loc_oncyf_TwentyTwentySixMember_9C58A062645DC00CF7559CFE7EC1E17B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyTwentySixMember_9C58A062645DC00CF7559CFE7EC1E17B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentySevenMember" xlink:label="loc_oncyf_TwentyTwentySevenMember_C4ABC32C8DEAC3758E869CFE7EC1B644" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyTwentySevenMember_C4ABC32C8DEAC3758E869CFE7EC1B644" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyEightMember" xlink:label="loc_oncyf_TwentyTwentyEightMember_41EF8A95140304163C4C9CFE7EC16213" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyTwentyEightMember_41EF8A95140304163C4C9CFE7EC16213" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyNineMember" xlink:label="loc_oncyf_TwentyTwentyNineMember_35554267BE9ABC9E80699CFE7EC1AC97" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyTwentyNineMember_35554267BE9ABC9E80699CFE7EC1AC97" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyMember" xlink:label="loc_oncyf_TwentyThirtyMember_182E77111B11997C1AC79CFE7EC12CBE" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyThirtyMember_182E77111B11997C1AC79CFE7EC12CBE" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyOneMember" xlink:label="loc_oncyf_TwentyThirtyOneMember_6593E99D61CE52668BAF9CFE7EC1B850" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyThirtyOneMember_6593E99D61CE52668BAF9CFE7EC1B850" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyTwoMember" xlink:label="loc_oncyf_TwentyThirtyTwoMember_91D634D4636F22B5B2C49CFE7EC24B2F" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyThirtyTwoMember_91D634D4636F22B5B2C49CFE7EC24B2F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyThreeMember" xlink:label="loc_oncyf_TwentyThirtyThreeMember_379C96969339844BC6E59CFE7EC28795" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyThirtyThreeMember_379C96969339844BC6E59CFE7EC28795" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyFourMember" xlink:label="loc_oncyf_TwentyThirtyFourMember_F89ACE52C2F41F971E089CFE7EC2F353" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyThirtyFourMember_F89ACE52C2F41F971E089CFE7EC2F353" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyFiveMember" xlink:label="loc_oncyf_TwentyThirtyFiveMember_028F372222628BD005869CFE7EC2D7B2" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyThirtyFiveMember_028F372222628BD005869CFE7EC2D7B2" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtySixMember" xlink:label="loc_oncyf_TwentyThirtySixMember_1A3CDA0F2AE58CA093439CFE7EC2266D" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyThirtySixMember_1A3CDA0F2AE58CA093439CFE7EC2266D" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtySevenMember" xlink:label="loc_oncyf_TwentyThirtySevenMember_951DB9A958329245320E9CFE7EC32347" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyThirtySevenMember_951DB9A958329245320E9CFE7EC32347" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyEightMember" xlink:label="loc_oncyf_TwentyThirtyEightMember_8746C19FC91592ECBD059CFE7EC31AC4" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyThirtyEightMember_8746C19FC91592ECBD059CFE7EC31AC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_DF3FF0C05F988813F4149CFE7EC3D737" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_4F6AEEF77540B6BC8BB99CFE7EBF4DC8" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_DF3FF0C05F988813F4149CFE7EC3D737" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1C0E7B8373EEBB336B209CFE7EC3E438_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_DF3FF0C05F988813F4149CFE7EC3D737" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1C0E7B8373EEBB336B209CFE7EC3E438_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1C0E7B8373EEBB336B209CFE7EC3E438" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_DF3FF0C05F988813F4149CFE7EC3D737" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1C0E7B8373EEBB336B209CFE7EC3E438" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnusedTaxCreditsMember" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember_B9FD6EAAC43E338F430B9CFE7EC376C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1C0E7B8373EEBB336B209CFE7EC3E438" xlink:to="loc_ifrs-full_UnusedTaxCreditsMember_B9FD6EAAC43E338F430B9CFE7EC376C5" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_6EE0A320448F9FEA6A299CFE7EC3EACB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1C0E7B8373EEBB336B209CFE7EC3E438" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_6EE0A320448F9FEA6A299CFE7EC3EACB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:label="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_9BF85856D8E2DAA4E7369CFE7EC41910" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_963084CD10B5BDB4C13D9CFE7EC4B0E2" xlink:to="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_9BF85856D8E2DAA4E7369CFE7EC41910" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncorporationAndNatureOfOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IndemnificationOfOfficersAndDirectors" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/Leases" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2CF1BBBBFA29D357F00B9CFE7F84798F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_DE90D4A9A4071970BEBF9CFE7F839897" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2CF1BBBBFA29D357F00B9CFE7F84798F" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_DE90D4A9A4071970BEBF9CFE7F839897" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_F2034FE58736AC9B09809CFE7F83B7D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_DE90D4A9A4071970BEBF9CFE7F839897" xlink:to="loc_srt_RangeAxis_F2034FE58736AC9B09809CFE7F83B7D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_B4CA3763CD7DECB373FE9CFE7F84E826_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_F2034FE58736AC9B09809CFE7F83B7D5" xlink:to="loc_ifrs-full_RangesMember_B4CA3763CD7DECB373FE9CFE7F84E826_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_B4CA3763CD7DECB373FE9CFE7F84E826" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_F2034FE58736AC9B09809CFE7F83B7D5" xlink:to="loc_ifrs-full_RangesMember_B4CA3763CD7DECB373FE9CFE7F84E826" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_50321E0B317A01A2331B9CFE7F84868A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_B4CA3763CD7DECB373FE9CFE7F84E826" xlink:to="loc_srt_MinimumMember_50321E0B317A01A2331B9CFE7F84868A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_385051B8D8BF46727A5D9CFE7F842427" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_B4CA3763CD7DECB373FE9CFE7F84E826" xlink:to="loc_srt_MaximumMember_385051B8D8BF46727A5D9CFE7F842427" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OperatingLeaseRemainingLeaseTerm" xlink:label="loc_oncyf_OperatingLeaseRemainingLeaseTerm_B5CCBB94944AFAFFE5EB9CFE7F8517F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2CF1BBBBFA29D357F00B9CFE7F84798F" xlink:to="loc_oncyf_OperatingLeaseRemainingLeaseTerm_B5CCBB94944AFAFFE5EB9CFE7F8517F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:label="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_12DCEC6745A922BCF9FD9CFE7F8585AA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2CF1BBBBFA29D357F00B9CFE7F84798F" xlink:to="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_12DCEC6745A922BCF9FD9CFE7F8585AA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesRightOfUseAssetsAndLeaseLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_EF9E900068473FD703E8A8191CD4F6D7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_28781C854F8F0F3B312CA8191CD3A9F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_EF9E900068473FD703E8A8191CD4F6D7" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_28781C854F8F0F3B312CA8191CD3A9F5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_110A30C841F93F8946CFA8191CD3EEBF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_28781C854F8F0F3B312CA8191CD3A9F5" xlink:to="loc_ifrs-full_MaturityAxis_110A30C841F93F8946CFA8191CD3EEBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_8D63E57DF4C23AA2551CA8191CD3C4CA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_110A30C841F93F8946CFA8191CD3EEBF" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_8D63E57DF4C23AA2551CA8191CD3C4CA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_8D63E57DF4C23AA2551CA8191CD3C4CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_110A30C841F93F8946CFA8191CD3EEBF" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_8D63E57DF4C23AA2551CA8191CD3C4CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_49511A9A4D0AD36F7673A8191CD423CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_8D63E57DF4C23AA2551CA8191CD3C4CA" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_49511A9A4D0AD36F7673A8191CD423CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_3015620E393808566EE9A8191CD45F7B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_8D63E57DF4C23AA2551CA8191CD3C4CA" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_3015620E393808566EE9A8191CD45F7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_ADE4FAE8F15BB4131D68A8191CD486BA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_8D63E57DF4C23AA2551CA8191CD3C4CA" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_ADE4FAE8F15BB4131D68A8191CD486BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossLeaseLiabilities" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_A2CC5E688919238E00A4A8191F6CC773" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_EF9E900068473FD703E8A8191CD4F6D7" xlink:to="loc_ifrs-full_GrossLeaseLiabilities_A2CC5E688919238E00A4A8191F6CC773" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerCommonShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OtherExpensesAndAdjustmentsTable" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTable_3A313FE7984EAB98D82D9D034C2967FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsTable_3A313FE7984EAB98D82D9D034C2967FA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IncomeStatementLocation1Axis" xlink:label="loc_oncyf_IncomeStatementLocation1Axis_828B53062F2AC6CEC78F9D034C2A46E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_3A313FE7984EAB98D82D9D034C2967FA" xlink:to="loc_oncyf_IncomeStatementLocation1Axis_828B53062F2AC6CEC78F9D034C2A46E8" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IncomeStatementLocation1Domain" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_3E4F4688CED2E17A34809D034C2A4F06_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_828B53062F2AC6CEC78F9D034C2A46E8" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_3E4F4688CED2E17A34809D034C2A4F06_default" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IncomeStatementLocation1Domain" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_3E4F4688CED2E17A34809D034C2A4F06" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_828B53062F2AC6CEC78F9D034C2A46E8" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_3E4F4688CED2E17A34809D034C2A4F06" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ResearchAndDevelopmentMember" xlink:label="loc_oncyf_ResearchAndDevelopmentMember_E7B327F4DCB1A2CCCF2C9D034C2A4983" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_3E4F4688CED2E17A34809D034C2A4F06" xlink:to="loc_oncyf_ResearchAndDevelopmentMember_E7B327F4DCB1A2CCCF2C9D034C2A4983" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OperatingExpensesMember" xlink:label="loc_oncyf_OperatingExpensesMember_EF3773D7A2102B6F63299D034C2A868E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_3E4F4688CED2E17A34809D034C2A4F06" xlink:to="loc_oncyf_OperatingExpensesMember_EF3773D7A2102B6F63299D034C2A868E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockAxis" xlink:label="loc_oncyf_SaleOfStockAxis_17A7B6578C9F597D59C99D034C2B467A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_3A313FE7984EAB98D82D9D034C2967FA" xlink:to="loc_oncyf_SaleOfStockAxis_17A7B6578C9F597D59C99D034C2B467A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_FF7E082CDC133798204B9D034C2B7885_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_17A7B6578C9F597D59C99D034C2B467A" xlink:to="loc_oncyf_SaleOfStockDomain_FF7E082CDC133798204B9D034C2B7885_default" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_FF7E082CDC133798204B9D034C2B7885" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_17A7B6578C9F597D59C99D034C2B467A" xlink:to="loc_oncyf_SaleOfStockDomain_FF7E082CDC133798204B9D034C2B7885" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_253149D438136F5070389D034C2B2E43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_FF7E082CDC133798204B9D034C2B7885" xlink:to="loc_oncyf_WarrantsMember_253149D438136F5070389D034C2B2E43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_B34F4D46118D8F1250BC9D034C2C0D56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_B34F4D46118D8F1250BC9D034C2C0D56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_B2B6FC3F7C74D4E311FC9D034C2C121F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_B2B6FC3F7C74D4E311FC9D034C2C121F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_FA4C5C819BBCCC410C0F9D034C2C7F47" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_FA4C5C819BBCCC410C0F9D034C2C7F47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AmortisationExpense" xlink:label="loc_ifrs-full_AmortisationExpense_CB7177A13F4BA7750D699D034C2C8B92" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:to="loc_ifrs-full_AmortisationExpense_CB7177A13F4BA7750D699D034C2C8B92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_9704915AF66214B4C7B59D034C2CFF35" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_9704915AF66214B4C7B59D034C2CFF35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_5344F24627328C5B324A9D034C2DEBF5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_5344F24627328C5B324A9D034C2DEBF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="loc_ifrs-full_AdjustmentsForProvisions_B05FCDE80428B3F7CD869D034C2D7DF4" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:to="loc_ifrs-full_AdjustmentsForProvisions_B05FCDE80428B3F7CD869D034C2D7DF4" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_AdjustmentsforLeaseAmortization" xlink:label="loc_oncyf_AdjustmentsforLeaseAmortization_87EDFFC44276E0443F969D034C2D8BE3" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:to="loc_oncyf_AdjustmentsforLeaseAmortization_87EDFFC44276E0443F969D034C2D8BE3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_14DD8E1CD0CD63F57FF19CFE7EB45667" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_E036C4C538383B9B9DD09CFE7EB15F36" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_14DD8E1CD0CD63F57FF19CFE7EB45667" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_E036C4C538383B9B9DD09CFE7EB15F36" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5A67AB9A0710E93BCC149CFE7EB235DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_E036C4C538383B9B9DD09CFE7EB15F36" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5A67AB9A0710E93BCC149CFE7EB235DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_904BA2778CD804ACA8C69CFE7EB2E4C9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5A67AB9A0710E93BCC149CFE7EB235DA" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_904BA2778CD804ACA8C69CFE7EB2E4C9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_904BA2778CD804ACA8C69CFE7EB2E4C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5A67AB9A0710E93BCC149CFE7EB235DA" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_904BA2778CD804ACA8C69CFE7EB2E4C9" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_MedicalEquipmentMember" xlink:label="loc_oncyf_MedicalEquipmentMember_49000A47021E8964AE429CFE7EB2C38F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_904BA2778CD804ACA8C69CFE7EB2E4C9" xlink:to="loc_oncyf_MedicalEquipmentMember_49000A47021E8964AE429CFE7EB2C38F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-full_ComputerEquipmentMember_67E4113C5F2A6B8692B69CFE7EB2DDD9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_904BA2778CD804ACA8C69CFE7EB2E4C9" xlink:to="loc_ifrs-full_ComputerEquipmentMember_67E4113C5F2A6B8692B69CFE7EB2DDD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FixturesAndFittingsMember" xlink:label="loc_ifrs-full_FixturesAndFittingsMember_B78D68CA068E16B9093B9CFE7EB3C872" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_904BA2778CD804ACA8C69CFE7EB2E4C9" xlink:to="loc_ifrs-full_FixturesAndFittingsMember_B78D68CA068E16B9093B9CFE7EB3C872" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="loc_ifrs-full_OfficeEquipmentMember_4CE896552FEA39E30D9B9CFE7EB3CAE7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_904BA2778CD804ACA8C69CFE7EB2E4C9" xlink:to="loc_ifrs-full_OfficeEquipmentMember_4CE896552FEA39E30D9B9CFE7EB3CAE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_130F1D3CAA00832C33789CFE7EB3AA1F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_904BA2778CD804ACA8C69CFE7EB2E4C9" xlink:to="loc_ifrs-full_LeaseholdImprovementsMember_130F1D3CAA00832C33789CFE7EB3AA1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CDD06685E80DE81D046B9CFE7EB30406" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_E036C4C538383B9B9DD09CFE7EB15F36" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CDD06685E80DE81D046B9CFE7EB30406" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_DF68B4E84C871CB675439CFE7EB3184E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CDD06685E80DE81D046B9CFE7EB30406" xlink:to="loc_ifrs-full_CarryingAmountMember_DF68B4E84C871CB675439CFE7EB3184E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_DF68B4E84C871CB675439CFE7EB3184E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CDD06685E80DE81D046B9CFE7EB30406" xlink:to="loc_ifrs-full_CarryingAmountMember_DF68B4E84C871CB675439CFE7EB3184E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_C8D77C29F6ACECE0AD3B9CFE7EB4A1DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_DF68B4E84C871CB675439CFE7EB3184E" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_C8D77C29F6ACECE0AD3B9CFE7EB4A1DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_3640086B7DA683CF71949CFE7EB487C5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_DF68B4E84C871CB675439CFE7EB3184E" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_3640086B7DA683CF71949CFE7EB487C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_61FA93BE16FE9234DBEF9CFE7EB46F08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_14DD8E1CD0CD63F57FF19CFE7EB45667" xlink:to="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_61FA93BE16FE9234DBEF9CFE7EB46F08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_9AF8A5675D60819A60259CFE7EB487F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_61FA93BE16FE9234DBEF9CFE7EB46F08" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_9AF8A5675D60819A60259CFE7EB487F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_9F5B2D266D16FBAEF5F89CFE7EB5A88D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_61FA93BE16FE9234DBEF9CFE7EB46F08" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_9F5B2D266D16FBAEF5F89CFE7EB5A88D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_255B3E31CCD04B63FCD69CFE7EB50053" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_61FA93BE16FE9234DBEF9CFE7EB46F08" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_255B3E31CCD04B63FCD69CFE7EB50053" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsAndFairValueOfOptionsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8B15DF416AB54A7D4C96A68362E6BCC2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_ADC346E79448E28C6A3AA68362E40C49" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8B15DF416AB54A7D4C96A68362E6BCC2" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_ADC346E79448E28C6A3AA68362E40C49" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_AA2912FB4048CC0E0F2EA68362E427A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_ADC346E79448E28C6A3AA68362E40C49" xlink:to="loc_ifrs-full_RangeAxis_AA2912FB4048CC0E0F2EA68362E427A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_44DEDA420C89BC457916A68362E49C99_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_AA2912FB4048CC0E0F2EA68362E427A4" xlink:to="loc_ifrs-full_RangesMember_44DEDA420C89BC457916A68362E49C99_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_44DEDA420C89BC457916A68362E49C99" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_AA2912FB4048CC0E0F2EA68362E427A4" xlink:to="loc_ifrs-full_RangesMember_44DEDA420C89BC457916A68362E49C99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_94573E18DAE59814FDD5A68362E5D8E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_44DEDA420C89BC457916A68362E49C99" xlink:to="loc_ifrs-full_BottomOfRangeMember_94573E18DAE59814FDD5A68362E5D8E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_2AC4DFFFF76ABCA7BD5DA68362E5819B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_44DEDA420C89BC457916A68362E49C99" xlink:to="loc_ifrs-full_TopOfRangeMember_2AC4DFFFF76ABCA7BD5DA68362E5819B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_FB1E0B9C6A1C10F86AC1A68362E5D794" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_ADC346E79448E28C6A3AA68362E40C49" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_FB1E0B9C6A1C10F86AC1A68362E5D794" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_F8738FBA9FEF50C8FA3FA68362E5E1B2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_FB1E0B9C6A1C10F86AC1A68362E5D794" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_F8738FBA9FEF50C8FA3FA68362E5E1B2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_F8738FBA9FEF50C8FA3FA68362E5E1B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_FB1E0B9C6A1C10F86AC1A68362E5D794" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_F8738FBA9FEF50C8FA3FA68362E5E1B2" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_RestrictedShareUnitsMember" xlink:label="loc_oncyf_RestrictedShareUnitsMember_A686AA923F50B3998B4AA68362E6E983" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_F8738FBA9FEF50C8FA3FA68362E5E1B2" xlink:to="loc_oncyf_RestrictedShareUnitsMember_A686AA923F50B3998B4AA68362E6E983" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_PerformanceShareUnitsMember" xlink:label="loc_oncyf_PerformanceShareUnitsMember_B78DBD2FAC203B6EE087A68362E6C0C1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_F8738FBA9FEF50C8FA3FA68362E5E1B2" xlink:to="loc_oncyf_PerformanceShareUnitsMember_B78DBD2FAC203B6EE087A68362E6C0C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_B5934BBA4FC6DD07FA6CA68362E65AB8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_F8738FBA9FEF50C8FA3FA68362E5E1B2" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_B5934BBA4FC6DD07FA6CA68362E65AB8" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_DDD30FF7AD349B5D2937A68362E741AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8B15DF416AB54A7D4C96A68362E6BCC2" xlink:to="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_DDD30FF7AD349B5D2937A68362E741AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:label="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_72464A34CE37DE43ED1CA68362E767E1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8B15DF416AB54A7D4C96A68362E6BCC2" xlink:to="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_72464A34CE37DE43ED1CA68362E767E1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfNumberOfOtherEquityInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_91674D281DB922AFE3219CFE7ED7F53E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_F72D952E5549C0D336A29CFE7ED6332F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_91674D281DB922AFE3219CFE7ED7F53E" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_F72D952E5549C0D336A29CFE7ED6332F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_7C8A8ADAEC40824FA29B9CFE7ED6DB06" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_F72D952E5549C0D336A29CFE7ED6332F" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_7C8A8ADAEC40824FA29B9CFE7ED6DB06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_76C51A52D909D2077DB59CFE7ED61EC3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_7C8A8ADAEC40824FA29B9CFE7ED6DB06" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_76C51A52D909D2077DB59CFE7ED61EC3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_76C51A52D909D2077DB59CFE7ED61EC3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_7C8A8ADAEC40824FA29B9CFE7ED6DB06" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_76C51A52D909D2077DB59CFE7ED61EC3" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_RestrictedShareUnitsMember" xlink:label="loc_oncyf_RestrictedShareUnitsMember_58A101EC7A0B7BDE05EE9CFE7ED745A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_76C51A52D909D2077DB59CFE7ED61EC3" xlink:to="loc_oncyf_RestrictedShareUnitsMember_58A101EC7A0B7BDE05EE9CFE7ED745A4" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_PerformanceShareUnitsMember" xlink:label="loc_oncyf_PerformanceShareUnitsMember_7D40F457C6A0FCDA7B299CFE7ED74BBD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_76C51A52D909D2077DB59CFE7ED61EC3" xlink:to="loc_oncyf_PerformanceShareUnitsMember_7D40F457C6A0FCDA7B299CFE7ED74BBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_352A29F5C696827C21209CFE7ED7E87F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_91674D281DB922AFE3219CFE7ED7F53E" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_352A29F5C696827C21209CFE7ED7E87F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_430070B269544EFF86FD9CFE7ED7C663" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_91674D281DB922AFE3219CFE7ED7F53E" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_430070B269544EFF86FD9CFE7ED7C663" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_29F57E8A8FF3172D3F769CFE7ED8ADB7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_91674D281DB922AFE3219CFE7ED7F53E" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_29F57E8A8FF3172D3F769CFE7ED8ADB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_CD181AFCBFCC8874AC5E9CFE7ED861DD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_91674D281DB922AFE3219CFE7ED7F53E" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_CD181AFCBFCC8874AC5E9CFE7ED861DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_CA00C1DEC256F65B91799CFE7ED876BA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_91674D281DB922AFE3219CFE7ED7F53E" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_CA00C1DEC256F65B91799CFE7ED876BA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsAndWeightedAverageExercisePricesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_C0348BC8204AC49E2EFB9D034CBFBD48" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_787727BD35A16555CD5C9D034CBDCA08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_C0348BC8204AC49E2EFB9D034CBFBD48" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_787727BD35A16555CD5C9D034CBDCA08" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_4883A1C62F74FA7733159D034CBD012A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_787727BD35A16555CD5C9D034CBDCA08" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_4883A1C62F74FA7733159D034CBD012A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_C336E682560CC5AB69349D034CBD2E55_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_4883A1C62F74FA7733159D034CBD012A" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_C336E682560CC5AB69349D034CBD2E55_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_C336E682560CC5AB69349D034CBD2E55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_4883A1C62F74FA7733159D034CBD012A" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_C336E682560CC5AB69349D034CBD2E55" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ExercisePriceRangeOneMember" xlink:label="loc_oncyf_ExercisePriceRangeOneMember_CB417BC64E16568037609D034CBE8ED4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_C336E682560CC5AB69349D034CBD2E55" xlink:to="loc_oncyf_ExercisePriceRangeOneMember_CB417BC64E16568037609D034CBE8ED4" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ExercisePriceRangeTwoMember" xlink:label="loc_oncyf_ExercisePriceRangeTwoMember_0B52B52BAF8BE973C58B9D034CBEFC97" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_C336E682560CC5AB69349D034CBD2E55" xlink:to="loc_oncyf_ExercisePriceRangeTwoMember_0B52B52BAF8BE973C58B9D034CBEFC97" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ExercisePriceRangeThreeMember" xlink:label="loc_oncyf_ExercisePriceRangeThreeMember_8A0030A5F24DD0D48B509D034CBE001C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_C336E682560CC5AB69349D034CBD2E55" xlink:to="loc_oncyf_ExercisePriceRangeThreeMember_8A0030A5F24DD0D48B509D034CBE001C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ExercisePriceRangeFourMember" xlink:label="loc_oncyf_ExercisePriceRangeFourMember_A1C4301F796867209EC39D034CBEB0F1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_C336E682560CC5AB69349D034CBD2E55" xlink:to="loc_oncyf_ExercisePriceRangeFourMember_A1C4301F796867209EC39D034CBEB0F1" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ExercisePriceRangeFiveMember" xlink:label="loc_oncyf_ExercisePriceRangeFiveMember_984D3F661B6CD944B0FC9D034CBE6DD8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_C336E682560CC5AB69349D034CBD2E55" xlink:to="loc_oncyf_ExercisePriceRangeFiveMember_984D3F661B6CD944B0FC9D034CBE6DD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_8FEF9B0478B38C84E9349D034CBFE53F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_C0348BC8204AC49E2EFB9D034CBFBD48" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_8FEF9B0478B38C84E9349D034CBFE53F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1F85CDFDE36FC18FF5959D24F556053F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_C0348BC8204AC49E2EFB9D034CBFBD48" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1F85CDFDE36FC18FF5959D24F556053F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_A3B2781E07F1563F7A179D2551CDB58B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_C0348BC8204AC49E2EFB9D034CBFBD48" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_A3B2781E07F1563F7A179D2551CDB58B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_3BD728B6BEC25A2011FE9D034CBF9806" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_C0348BC8204AC49E2EFB9D034CBFBD48" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_3BD728B6BEC25A2011FE9D034CBF9806" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_7B1CE31B99587E7D2C269D258F38B9ED" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_C0348BC8204AC49E2EFB9D034CBFBD48" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_7B1CE31B99587E7D2C269D258F38B9ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_4743EC40FBE30D6FBCDC9D034CC2D346" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_089D88B7F16DEBD253F09D034CC012D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_4743EC40FBE30D6FBCDC9D034CC2D346" xlink:to="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_089D88B7F16DEBD253F09D034CC012D7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_930DC4EDDCCCB4926D3D9D034CC03508" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_089D88B7F16DEBD253F09D034CC012D7" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_930DC4EDDCCCB4926D3D9D034CC03508" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_5929444ED60B9C593E159D034CC1D4CA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_089D88B7F16DEBD253F09D034CC012D7" xlink:to="loc_ifrs-full_RangeAxis_5929444ED60B9C593E159D034CC1D4CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_BC71AEC3DA4C466F99719D034CC221EF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_5929444ED60B9C593E159D034CC1D4CA" xlink:to="loc_ifrs-full_RangesMember_BC71AEC3DA4C466F99719D034CC221EF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_BC71AEC3DA4C466F99719D034CC221EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_5929444ED60B9C593E159D034CC1D4CA" xlink:to="loc_ifrs-full_RangesMember_BC71AEC3DA4C466F99719D034CC221EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_138CB41166D1E80880DF9D034CC2E135" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_BC71AEC3DA4C466F99719D034CC221EF" xlink:to="loc_ifrs-full_BottomOfRangeMember_138CB41166D1E80880DF9D034CC2E135" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_E90E50B59EDC4BAFCF8C9D034CC2988D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_BC71AEC3DA4C466F99719D034CC221EF" xlink:to="loc_ifrs-full_TopOfRangeMember_E90E50B59EDC4BAFCF8C9D034CC2988D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_073354358577BDB7C00F9D2A48DB70C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_4743EC40FBE30D6FBCDC9D034CC2D346" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_073354358577BDB7C00F9D2A48DB70C5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_65E65F39CC83AED90332A1D3EBF44749" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_324EADD657E2792BD9CBA1D3EBF1D1D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_65E65F39CC83AED90332A1D3EBF44749" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_324EADD657E2792BD9CBA1D3EBF1D1D1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_44F22FF1546D8C553DECA1D3EBF1536F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_324EADD657E2792BD9CBA1D3EBF1D1D1" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_44F22FF1546D8C553DECA1D3EBF1536F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_46AB4636E86F38A8D43CA1D3EBF1F1AA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_44F22FF1546D8C553DECA1D3EBF1536F" xlink:to="loc_ifrs-full_RestatedMember_46AB4636E86F38A8D43CA1D3EBF1F1AA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_46AB4636E86F38A8D43CA1D3EBF1F1AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_44F22FF1546D8C553DECA1D3EBF1536F" xlink:to="loc_ifrs-full_RestatedMember_46AB4636E86F38A8D43CA1D3EBF1F1AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="loc_ifrs-full_PreviouslyStatedMember_497AEBD82329B8A90205A1D3EBF2572A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RestatedMember_46AB4636E86F38A8D43CA1D3EBF1F1AA" xlink:to="loc_ifrs-full_PreviouslyStatedMember_497AEBD82329B8A90205A1D3EBF2572A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_F73919743BD42AB279D0A1D3EBF27C7B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_324EADD657E2792BD9CBA1D3EBF1D1D1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_F73919743BD42AB279D0A1D3EBF27C7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_90140288279F2A7278E0A1D3EBF21BF7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_F73919743BD42AB279D0A1D3EBF27C7B" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_90140288279F2A7278E0A1D3EBF21BF7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_90140288279F2A7278E0A1D3EBF21BF7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_F73919743BD42AB279D0A1D3EBF27C7B" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_90140288279F2A7278E0A1D3EBF21BF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_EF42A40FC22AAC9998F2A1D3EBF32857" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_90140288279F2A7278E0A1D3EBF21BF7" xlink:to="loc_ifrs-full_IssuedCapitalMember_EF42A40FC22AAC9998F2A1D3EBF32857" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_0D2DAC654ECB83B7F958A1D3EBF3A9C3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_90140288279F2A7278E0A1D3EBF21BF7" xlink:to="loc_oncyf_WarrantsMember_0D2DAC654ECB83B7F958A1D3EBF3A9C3" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockAxis" xlink:label="loc_oncyf_SaleOfStockAxis_9D0F17569C740B42F100A1D3EBF3A4CD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_324EADD657E2792BD9CBA1D3EBF1D1D1" xlink:to="loc_oncyf_SaleOfStockAxis_9D0F17569C740B42F100A1D3EBF3A4CD" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_5204A7DE53C5621D9D18A1D3EBF33228_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_9D0F17569C740B42F100A1D3EBF3A4CD" xlink:to="loc_oncyf_SaleOfStockDomain_5204A7DE53C5621D9D18A1D3EBF33228_default" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_5204A7DE53C5621D9D18A1D3EBF33228" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_9D0F17569C740B42F100A1D3EBF3A4CD" xlink:to="loc_oncyf_SaleOfStockDomain_5204A7DE53C5621D9D18A1D3EBF33228" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderIncentiveAwardPlanMember" xlink:label="loc_oncyf_SharesUnderIncentiveAwardPlanMember_D808CC015BBD057CCD6CA1D3EBF3FCE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_5204A7DE53C5621D9D18A1D3EBF33228" xlink:to="loc_oncyf_SharesUnderIncentiveAwardPlanMember_D808CC015BBD057CCD6CA1D3EBF3FCE0" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderCommonStockPurchaseAgreementMember" xlink:label="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_CC9EEEF1073030051587A1D3EBF4287C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_5204A7DE53C5621D9D18A1D3EBF33228" xlink:to="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_CC9EEEF1073030051587A1D3EBF4287C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderAtthemarketAgreementMember" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_4026C1437C48B8D253FFA1D3EBF44C5E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_5204A7DE53C5621D9D18A1D3EBF33228" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_4026C1437C48B8D253FFA1D3EBF44C5E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderStockOptionPlanMember" xlink:label="loc_oncyf_SharesUnderStockOptionPlanMember_8757F78487C78FFD3112A1D3EBF4056C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_5204A7DE53C5621D9D18A1D3EBF33228" xlink:to="loc_oncyf_SharesUnderStockOptionPlanMember_8757F78487C78FFD3112A1D3EBF4056C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesPublicOfferingMember" xlink:label="loc_oncyf_SharesPublicOfferingMember_5189506C1E08492FEB0AA1D3EBF4600A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_5204A7DE53C5621D9D18A1D3EBF33228" xlink:to="loc_oncyf_SharesPublicOfferingMember_5189506C1E08492FEB0AA1D3EBF4600A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderWarrantAgreementMember" xlink:label="loc_oncyf_SharesUnderWarrantAgreementMember_C72DCC300B78A4D2DDB8A1D3EBF4DAE3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_5204A7DE53C5621D9D18A1D3EBF33228" xlink:to="loc_oncyf_SharesUnderWarrantAgreementMember_C72DCC300B78A4D2DDB8A1D3EBF4DAE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_22A704DD6395F6A67524A1D3EBF51E01" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_65E65F39CC83AED90332A1D3EBF44749" xlink:to="loc_ifrs-full_Equity_22A704DD6395F6A67524A1D3EBF51E01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_889CE6F97BB9F9DE9F2CA1D3EBF57154" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_65E65F39CC83AED90332A1D3EBF44749" xlink:to="loc_ifrs-full_NumberOfSharesIssued_889CE6F97BB9F9DE9F2CA1D3EBF57154" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_07E7EA485BA0103CC751A1D3EBF50CA1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_65E65F39CC83AED90332A1D3EBF44749" xlink:to="loc_ifrs-full_IssueOfEquity_07E7EA485BA0103CC751A1D3EBF50CA1" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IssueOfEquityShares" xlink:label="loc_oncyf_IssueOfEquityShares_D4BF034A919EC3ED6C1FA1D3EBF58347" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_65E65F39CC83AED90332A1D3EBF44749" xlink:to="loc_oncyf_IssueOfEquityShares_D4BF034A919EC3ED6C1FA1D3EBF58347" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_714744BBF78547125AC8A1D3EBF53E4B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_65E65F39CC83AED90332A1D3EBF44749" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_714744BBF78547125AC8A1D3EBF53E4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_164ADE18045C48E03BA7A1D3EBF68EE2" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_65E65F39CC83AED90332A1D3EBF44749" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_164ADE18045C48E03BA7A1D3EBF68EE2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_22D348D6D361BE484797A7434D198B6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_22D348D6D361BE484797A7434D198B6E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_6F430E641D6D2A39620EA7434D1A5E9E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_22D348D6D361BE484797A7434D198B6E" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_6F430E641D6D2A39620EA7434D1A5E9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_8C840E3DF2F577B45F79A7434D1B73CD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_6F430E641D6D2A39620EA7434D1A5E9E" xlink:to="loc_ifrs-full_LiabilitiesMember_8C840E3DF2F577B45F79A7434D1B73CD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_8C840E3DF2F577B45F79A7434D1B73CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_6F430E641D6D2A39620EA7434D1A5E9E" xlink:to="loc_ifrs-full_LiabilitiesMember_8C840E3DF2F577B45F79A7434D1B73CD" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_C0FC382A0D5BB09BF4E1A7434D1B9EEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_8C840E3DF2F577B45F79A7434D1B73CD" xlink:to="loc_oncyf_WarrantsMember_C0FC382A0D5BB09BF4E1A7434D1B9EEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_E7520725F6A6C8A9ECC5A7434D1BF1EC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_22D348D6D361BE484797A7434D198B6E" xlink:to="loc_srt_RangeAxis_E7520725F6A6C8A9ECC5A7434D1BF1EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_0F5C47BC872D7232781BA7434D1B0001_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_E7520725F6A6C8A9ECC5A7434D1BF1EC" xlink:to="loc_ifrs-full_RangesMember_0F5C47BC872D7232781BA7434D1B0001_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_0F5C47BC872D7232781BA7434D1B0001" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_E7520725F6A6C8A9ECC5A7434D1BF1EC" xlink:to="loc_ifrs-full_RangesMember_0F5C47BC872D7232781BA7434D1B0001" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_5B4CE0FEDB448DCE3DF9A7434D1BA5A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_0F5C47BC872D7232781BA7434D1B0001" xlink:to="loc_srt_MinimumMember_5B4CE0FEDB448DCE3DF9A7434D1BA5A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_B63C5396DD44FEDBBD4BA7434D1D7DBC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_0F5C47BC872D7232781BA7434D1B0001" xlink:to="loc_srt_MaximumMember_B63C5396DD44FEDBBD4BA7434D1D7DBC" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockAxis" xlink:label="loc_oncyf_SaleOfStockAxis_DE7F2474172B0C8A41D8A7434D1D8A88" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_22D348D6D361BE484797A7434D198B6E" xlink:to="loc_oncyf_SaleOfStockAxis_DE7F2474172B0C8A41D8A7434D1D8A88" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_6A64DBAC24CBF2C06DDBA7434D1E63A7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_DE7F2474172B0C8A41D8A7434D1D8A88" xlink:to="loc_oncyf_SaleOfStockDomain_6A64DBAC24CBF2C06DDBA7434D1E63A7_default" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_6A64DBAC24CBF2C06DDBA7434D1E63A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_DE7F2474172B0C8A41D8A7434D1D8A88" xlink:to="loc_oncyf_SaleOfStockDomain_6A64DBAC24CBF2C06DDBA7434D1E63A7" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderAtthemarketAgreementCanadianMember" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementCanadianMember_DE8BF3733375CC65687FA7434D1E8936" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_6A64DBAC24CBF2C06DDBA7434D1E63A7" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementCanadianMember_DE8BF3733375CC65687FA7434D1E8936" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesPublicOfferingMember" xlink:label="loc_oncyf_SharesPublicOfferingMember_B5F9885783B887CC776DA7434D1E998F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_6A64DBAC24CBF2C06DDBA7434D1E63A7" xlink:to="loc_oncyf_SharesPublicOfferingMember_B5F9885783B887CC776DA7434D1E998F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_9FA2B90666443E789973A7434D20BB1C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_6A64DBAC24CBF2C06DDBA7434D1E63A7" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_9FA2B90666443E789973A7434D20BB1C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderCommonStockPurchaseAgreementMember" xlink:label="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_0EF705A43895D48EC1D0A7434D20B782" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_6A64DBAC24CBF2C06DDBA7434D1E63A7" xlink:to="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_0EF705A43895D48EC1D0A7434D20B782" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_InitialCommitmentFeeMember" xlink:label="loc_oncyf_InitialCommitmentFeeMember_F6831B2B23F0F57483A0A7434D20E94C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_0EF705A43895D48EC1D0A7434D20B782" xlink:to="loc_oncyf_InitialCommitmentFeeMember_F6831B2B23F0F57483A0A7434D20E94C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderWarrantAgreementMember" xlink:label="loc_oncyf_SharesUnderWarrantAgreementMember_2E59044F8C97BBEB3C5EA7C3BAA9A255" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_6A64DBAC24CBF2C06DDBA7434D1E63A7" xlink:to="loc_oncyf_SharesUnderWarrantAgreementMember_2E59044F8C97BBEB3C5EA7C3BAA9A255" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_B82FD73C9BC397BF788EA7434D21B0B2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_22D348D6D361BE484797A7434D198B6E" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_B82FD73C9BC397BF788EA7434D21B0B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_B4714E35AF71AC466113A7434D212254_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_B82FD73C9BC397BF788EA7434D21B0B2" xlink:to="loc_ifrs-full_RestatedMember_B4714E35AF71AC466113A7434D212254_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_B4714E35AF71AC466113A7434D212254" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_B82FD73C9BC397BF788EA7434D21B0B2" xlink:to="loc_ifrs-full_RestatedMember_B4714E35AF71AC466113A7434D212254" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="loc_ifrs-full_PreviouslyStatedMember_ECF89D3C3F0C76A312EDA7434D218EDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RestatedMember_B4714E35AF71AC466113A7434D212254" xlink:to="loc_ifrs-full_PreviouslyStatedMember_ECF89D3C3F0C76A312EDA7434D218EDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_7B755BF370FF7CE4ED21A7434D21624C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_22D348D6D361BE484797A7434D198B6E" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_7B755BF370FF7CE4ED21A7434D21624C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_3C66F1658C37A309CF72A7434D213DFE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_7B755BF370FF7CE4ED21A7434D21624C" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_3C66F1658C37A309CF72A7434D213DFE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_3C66F1658C37A309CF72A7434D213DFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_7B755BF370FF7CE4ED21A7434D21624C" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_3C66F1658C37A309CF72A7434D213DFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_9FB5A3C034008DF4D134A7434D237DE3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_3C66F1658C37A309CF72A7434D213DFE" xlink:to="loc_ifrs-full_IssuedCapitalMember_9FB5A3C034008DF4D134A7434D237DE3" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_958B227D82EF1C7DE809A7434D249F98" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_3C66F1658C37A309CF72A7434D213DFE" xlink:to="loc_oncyf_WarrantsMember_958B227D82EF1C7DE809A7434D249F98" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IncomeStatementLocation1Axis" xlink:label="loc_oncyf_IncomeStatementLocation1Axis_0487E822F906756892FAA7434D24CCE6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_22D348D6D361BE484797A7434D198B6E" xlink:to="loc_oncyf_IncomeStatementLocation1Axis_0487E822F906756892FAA7434D24CCE6" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IncomeStatementLocation1Domain" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_662153533CEE304079B4A7434D24B285_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_0487E822F906756892FAA7434D24CCE6" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_662153533CEE304079B4A7434D24B285_default" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IncomeStatementLocation1Domain" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_662153533CEE304079B4A7434D24B285" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_0487E822F906756892FAA7434D24CCE6" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_662153533CEE304079B4A7434D24B285" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OperatingExpensesMember" xlink:label="loc_oncyf_OperatingExpensesMember_90ACFED8FAB9F68EC49FA7434D25F968" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_662153533CEE304079B4A7434D24B285" xlink:to="loc_oncyf_OperatingExpensesMember_90ACFED8FAB9F68EC49FA7434D25F968" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_5950C41C458069BEDA6CA7434D2622F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_ifrs-full_Equity_5950C41C458069BEDA6CA7434D2622F9" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IssueOfEquityShares" xlink:label="loc_oncyf_IssueOfEquityShares_D6D3D765981B294A01C4A7434D273518" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_IssueOfEquityShares_D6D3D765981B294A01C4A7434D273518" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_E9A98FE9D27A506D93C9A7434D2708F1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_E9A98FE9D27A506D93C9A7434D2708F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_7236E9E7319BFA0FA166A7434D290E8C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_7236E9E7319BFA0FA166A7434D290E8C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesIssuedPricePerShare1" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_A5D248A418E2C4AA71E0A7434D2AEBA3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_A5D248A418E2C4AA71E0A7434D2AEBA3" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CommonSharesPerUnit" xlink:label="loc_oncyf_CommonSharesPerUnit_FE5F3B557B8BC0C428B1A7434D2B2143" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_CommonSharesPerUnit_FE5F3B557B8BC0C428B1A7434D2B2143" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CommonSharePurchaseWarrantPerUnit" xlink:label="loc_oncyf_CommonSharePurchaseWarrantPerUnit_8E8C680CEEB6E4245C82A7434D2BBB4F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_CommonSharePurchaseWarrantPerUnit_8E8C680CEEB6E4245C82A7434D2BBB4F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesIssuedWarrantPricePerShare" xlink:label="loc_oncyf_SharesIssuedWarrantPricePerShare_9BC0F33B7DE6E622C286A7434D2BEED6" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_SharesIssuedWarrantPricePerShare_9BC0F33B7DE6E622C286A7434D2BEED6" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_3D7906FD81DF54D8F249A7434D2B9613" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_3D7906FD81DF54D8F249A7434D2B9613" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_B201DA13845CCE528BE5A7434D2C8C4E" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_B201DA13845CCE528BE5A7434D2C8C4E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_E179A5409EA9B6122E6FA7434D2C4C28" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_E179A5409EA9B6122E6FA7434D2C4C28" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantPricePerShareAccelerationThreshold" xlink:label="loc_oncyf_WarrantPricePerShareAccelerationThreshold_B5866DE8EF4E87FBB0DFA7434D2DB16B" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_WarrantPricePerShareAccelerationThreshold_B5866DE8EF4E87FBB0DFA7434D2DB16B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantPricePerShareAccelerationThresholdTradingDays" xlink:label="loc_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_346E89D5B982D48DB402A7434D2EDD9E" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_346E89D5B982D48DB402A7434D2EDD9E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharePurchaseAgreementAmount" xlink:label="loc_oncyf_SharePurchaseAgreementAmount_1DD6C0BD67C480C5EF67A7434D2EF76E" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_SharePurchaseAgreementAmount_1DD6C0BD67C480C5EF67A7434D2EF76E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharePurchaseAgreementTerm" xlink:label="loc_oncyf_SharePurchaseAgreementTerm_C29597566DE123144A4EA7434D2EBE9C" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_SharePurchaseAgreementTerm_C29597566DE123144A4EA7434D2EBE9C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_NumberofSharesOutstandingPercent" xlink:label="loc_oncyf_NumberofSharesOutstandingPercent_270F667549839406ABCCA7434D2E5084" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_NumberofSharesOutstandingPercent_270F667549839406ABCCA7434D2E5084" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightWarrantsExercised" xlink:label="loc_oncyf_ClassofWarrantorRightWarrantsExercised_6BA1011FA8F6B85BCB5CA7434D2FB3E5" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_ClassofWarrantorRightWarrantsExercised_6BA1011FA8F6B85BCB5CA7434D2FB3E5" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ProceedsfromWarrantExercises1" xlink:label="loc_oncyf_ProceedsfromWarrantExercises1_A65F9371E29E51B40D99A7434D2F5786" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_ProceedsfromWarrantExercises1_A65F9371E29E51B40D99A7434D2F5786" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_DDC2145D7090E5BA6283A7434D2FF210" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_DDC2145D7090E5BA6283A7434D2FF210" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryOfOutstandingWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_656820D426F467B811E3A1D3E6743631" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_4215A84C1E303F43220EA1D3E672089E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_656820D426F467B811E3A1D3E6743631" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_4215A84C1E303F43220EA1D3E672089E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_7BED781A39BEA4C018E9A1D3E673296A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_4215A84C1E303F43220EA1D3E672089E" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_7BED781A39BEA4C018E9A1D3E673296A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_0D0AC2D221BFB0EBF348A1D3E673B399_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_7BED781A39BEA4C018E9A1D3E673296A" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_0D0AC2D221BFB0EBF348A1D3E673B399_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_0D0AC2D221BFB0EBF348A1D3E673B399" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_7BED781A39BEA4C018E9A1D3E673296A" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_0D0AC2D221BFB0EBF348A1D3E673B399" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_317EAB8F43006C947DADA1D3E673D679" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_0D0AC2D221BFB0EBF348A1D3E673B399" xlink:to="loc_oncyf_WarrantsMember_317EAB8F43006C947DADA1D3E673D679" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ExercisePriceofOutstandingWarrants" xlink:label="loc_oncyf_ExercisePriceofOutstandingWarrants_4984249835BACB353242A1D3E674017B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_656820D426F467B811E3A1D3E6743631" xlink:to="loc_oncyf_ExercisePriceofOutstandingWarrants_4984249835BACB353242A1D3E674017B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_D44BB0690CDE0A939D41A1D3E67B6E54" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_656820D426F467B811E3A1D3E6743631" xlink:to="loc_ifrs-full_NumberOfSharesIssued_D44BB0690CDE0A939D41A1D3E67B6E54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_D11BB88EB0F57D525134A1D3E67BBDCE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_656820D426F467B811E3A1D3E6743631" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_D11BB88EB0F57D525134A1D3E67BBDCE" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_B1635E1A025BB95F0876A1D3E67B1E52" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_656820D426F467B811E3A1D3E6743631" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_B1635E1A025BB95F0876A1D3E67B1E52" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesAndAssumptions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_F3107E1131DC61F848FCA6836229F4F8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_903A8FF7DE0EF4A5535BA6836226136D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_F3107E1131DC61F848FCA6836229F4F8" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_903A8FF7DE0EF4A5535BA6836226136D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_F4AA4A99E78C9F7A97F8A68362273A57" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_903A8FF7DE0EF4A5535BA6836226136D" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_F4AA4A99E78C9F7A97F8A68362273A57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_95E14724F5FA6C901597A68362273729_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_F4AA4A99E78C9F7A97F8A68362273A57" xlink:to="loc_ifrs-full_NonadjustingEventsMember_95E14724F5FA6C901597A68362273729_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_95E14724F5FA6C901597A68362273729" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_F4AA4A99E78C9F7A97F8A68362273A57" xlink:to="loc_ifrs-full_NonadjustingEventsMember_95E14724F5FA6C901597A68362273729" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_BA4C4A24ABE7932542CDA6836227052B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_95E14724F5FA6C901597A68362273729" xlink:to="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_BA4C4A24ABE7932542CDA6836227052B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember" xlink:label="loc_ifrs-full_EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember_225A0D8A8274F6DCC0BBA68362286307" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_95E14724F5FA6C901597A68362273729" xlink:to="loc_ifrs-full_EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember_225A0D8A8274F6DCC0BBA68362286307" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockAxis" xlink:label="loc_oncyf_SaleOfStockAxis_A979112AF2AADCC39913A6836228B7A8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_903A8FF7DE0EF4A5535BA6836226136D" xlink:to="loc_oncyf_SaleOfStockAxis_A979112AF2AADCC39913A6836228B7A8" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_1B89F87E483D9E972D69A68362284BB0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_A979112AF2AADCC39913A6836228B7A8" xlink:to="loc_oncyf_SaleOfStockDomain_1B89F87E483D9E972D69A68362284BB0_default" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_1B89F87E483D9E972D69A68362284BB0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_A979112AF2AADCC39913A6836228B7A8" xlink:to="loc_oncyf_SaleOfStockDomain_1B89F87E483D9E972D69A68362284BB0" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_578B33304B27DDB47162A6836228692C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_1B89F87E483D9E972D69A68362284BB0" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_578B33304B27DDB47162A6836228692C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesPublicOfferingMember" xlink:label="loc_oncyf_SharesPublicOfferingMember_B1FF7B86605FBE426115A68362288FBC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_1B89F87E483D9E972D69A68362284BB0" xlink:to="loc_oncyf_SharesPublicOfferingMember_B1FF7B86605FBE426115A68362288FBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_556FA240AC1E3E805F24A6836229A71E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_903A8FF7DE0EF4A5535BA6836226136D" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_556FA240AC1E3E805F24A6836229A71E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherProvisionsMember" xlink:label="loc_ifrs-full_OtherProvisionsMember_91633B3FF8E7DE98FF2FA6836229411A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_556FA240AC1E3E805F24A6836229A71E" xlink:to="loc_ifrs-full_OtherProvisionsMember_91633B3FF8E7DE98FF2FA6836229411A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherProvisionsMember" xlink:label="loc_ifrs-full_OtherProvisionsMember_91633B3FF8E7DE98FF2FA6836229411A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_556FA240AC1E3E805F24A6836229A71E" xlink:to="loc_ifrs-full_OtherProvisionsMember_91633B3FF8E7DE98FF2FA6836229411A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CollaborationAgreementMember" xlink:label="loc_oncyf_CollaborationAgreementMember_B6E8047A8B452CE6005DA6836229D79C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_91633B3FF8E7DE98FF2FA6836229411A" xlink:to="loc_oncyf_CollaborationAgreementMember_B6E8047A8B452CE6005DA6836229D79C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IssueOfEquityShares" xlink:label="loc_oncyf_IssueOfEquityShares_060361E09DF1B21E948BA6836229BD0F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_F3107E1131DC61F848FCA6836229F4F8" xlink:to="loc_oncyf_IssueOfEquityShares_060361E09DF1B21E948BA6836229BD0F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_FE24AB54EBCF6C6D203DA683622AA7A7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_F3107E1131DC61F848FCA6836229F4F8" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_FE24AB54EBCF6C6D203DA683622AA7A7" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ProceedsFromCollaborationAgreement" xlink:label="loc_oncyf_ProceedsFromCollaborationAgreement_C291D57B5089EFF3498DA6B73617F3DA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_F3107E1131DC61F848FCA6836229F4F8" xlink:to="loc_oncyf_ProceedsFromCollaborationAgreement_C291D57B5089EFF3498DA6B73617F3DA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesIfrs16LeasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_7C1098E25E407059327EAB7942A9AF5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530" xlink:to="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_7C1098E25E407059327EAB7942A9AF5D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsAxis" xlink:label="loc_ifrs-full_InitiallyAppliedIFRSsAxis_091E66C37B7FB9BF69EBAB7942A99B63" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_7C1098E25E407059327EAB7942A9AF5D" xlink:to="loc_ifrs-full_InitiallyAppliedIFRSsAxis_091E66C37B7FB9BF69EBAB7942A99B63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsMember" xlink:label="loc_ifrs-full_InitiallyAppliedIFRSsMember_71F78FD855DC9A26A511AB7942A98015_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_InitiallyAppliedIFRSsAxis_091E66C37B7FB9BF69EBAB7942A99B63" xlink:to="loc_ifrs-full_InitiallyAppliedIFRSsMember_71F78FD855DC9A26A511AB7942A98015_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsMember" xlink:label="loc_ifrs-full_InitiallyAppliedIFRSsMember_71F78FD855DC9A26A511AB7942A98015" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_InitiallyAppliedIFRSsAxis_091E66C37B7FB9BF69EBAB7942A99B63" xlink:to="loc_ifrs-full_InitiallyAppliedIFRSsMember_71F78FD855DC9A26A511AB7942A98015" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_EffectsofIFRS16TransitionMember" xlink:label="loc_oncyf_EffectsofIFRS16TransitionMember_6CFBD5AF93F32AB9C486AB7942A91AE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InitiallyAppliedIFRSsMember_71F78FD855DC9A26A511AB7942A98015" xlink:to="loc_oncyf_EffectsofIFRS16TransitionMember_6CFBD5AF93F32AB9C486AB7942A91AE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_517F71CC52A4690A3AA2AB7942AAB822" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530" xlink:to="loc_ifrs-full_RightofuseAssets_517F71CC52A4690A3AA2AB7942AAB822" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OtherCurrentandNoncurrentAssets" xlink:label="loc_oncyf_OtherCurrentandNoncurrentAssets_67EB0798C12AE09E1E97AB7942AA69F9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530" xlink:to="loc_oncyf_OtherCurrentandNoncurrentAssets_67EB0798C12AE09E1E97AB7942AA69F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_F196BF840E89E479C06BAB7942AA9839" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530" xlink:to="loc_ifrs-full_Assets_F196BF840E89E479C06BAB7942AA9839" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherLiabilities" xlink:label="loc_ifrs-full_OtherLiabilities_CAD1E8D5518A80CCFE5AAB7942AA23AA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530" xlink:to="loc_ifrs-full_OtherLiabilities_CAD1E8D5518A80CCFE5AAB7942AA23AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-full_LeaseLiabilities_B3B7B5A98BEF2DCF6A2AAB7942AB0FFD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530" xlink:to="loc_ifrs-full_LeaseLiabilities_B3B7B5A98BEF2DCF6A2AAB7942AB0FFD" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OtherCurrentandNoncurrentLiabilities" xlink:label="loc_oncyf_OtherCurrentandNoncurrentLiabilities_7D8FE27B4B53862F4BACAB7942AB65B8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530" xlink:to="loc_oncyf_OtherCurrentandNoncurrentLiabilities_7D8FE27B4B53862F4BACAB7942AB65B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_3B501346646EAF1644ECAB7942AB44F4" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530" xlink:to="loc_ifrs-full_Liabilities_3B501346646EAF1644ECAB7942AB44F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_92681CCC9EDC68BF57F8AB7942AB0C3D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530" xlink:to="loc_ifrs-full_Equity_92681CCC9EDC68BF57F8AB7942AB0C3D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_E705784DBB7631ADCB2EA6836486D671" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_B4D793B9AE49251F889CA6836484C48E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_E705784DBB7631ADCB2EA6836486D671" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_B4D793B9AE49251F889CA6836484C48E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_BEE67BCE5F9BD76DE56EA6836484B87A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_B4D793B9AE49251F889CA6836484C48E" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_BEE67BCE5F9BD76DE56EA6836484B87A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_595ECE6E1B021DE38060A68364855548_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_BEE67BCE5F9BD76DE56EA6836484B87A" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_595ECE6E1B021DE38060A68364855548_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_595ECE6E1B021DE38060A68364855548" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_BEE67BCE5F9BD76DE56EA6836484B87A" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_595ECE6E1B021DE38060A68364855548" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="loc_ifrs-full_OfficeEquipmentMember_11A7A223B5CA9D282633A6836485FBC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_595ECE6E1B021DE38060A68364855548" xlink:to="loc_ifrs-full_OfficeEquipmentMember_11A7A223B5CA9D282633A6836485FBC4" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_MedicalEquipmentMember" xlink:label="loc_oncyf_MedicalEquipmentMember_5E5B93AC84D7AE9FA636A6836485AEC0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_595ECE6E1B021DE38060A68364855548" xlink:to="loc_oncyf_MedicalEquipmentMember_5E5B93AC84D7AE9FA636A6836485AEC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-full_ComputerEquipmentMember_9FC707BF53D133A0195DA683648620D5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_595ECE6E1B021DE38060A68364855548" xlink:to="loc_ifrs-full_ComputerEquipmentMember_9FC707BF53D133A0195DA683648620D5" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:label="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_8D774DDED0389C308BBFA68364864384" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_E705784DBB7631ADCB2EA6836486D671" xlink:to="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_8D774DDED0389C308BBFA68364864384" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivative" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_CCC45D0C806213D735FAA82F243E9FD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_CCC45D0C806213D735FAA82F243E9FD5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_D6E37D1C4511E381C870A82B191B83B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_CCC45D0C806213D735FAA82F243E9FD5" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_D6E37D1C4511E381C870A82B191B83B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_E744E544A32F9709D6FBA82B191BB2B3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_D6E37D1C4511E381C870A82B191B83B5" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_E744E544A32F9709D6FBA82B191BB2B3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_E744E544A32F9709D6FBA82B191BB2B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_D6E37D1C4511E381C870A82B191B83B5" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_E744E544A32F9709D6FBA82B191BB2B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_F9783C2C8EA2F3DBBFA4A82B191C2E90" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_E744E544A32F9709D6FBA82B191BB2B3" xlink:to="loc_ifrs-full_IssuedCapitalMember_F9783C2C8EA2F3DBBFA4A82B191C2E90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_EFF64443B067F509481DA82B191CEA6F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_CCC45D0C806213D735FAA82F243E9FD5" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_EFF64443B067F509481DA82B191CEA6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_03F500BF47EDC281D4E9A82B191C70FA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_EFF64443B067F509481DA82B191CEA6F" xlink:to="loc_ifrs-full_LiabilitiesMember_03F500BF47EDC281D4E9A82B191C70FA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_03F500BF47EDC281D4E9A82B191C70FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_EFF64443B067F509481DA82B191CEA6F" xlink:to="loc_ifrs-full_LiabilitiesMember_03F500BF47EDC281D4E9A82B191C70FA" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_63E4E187543C6A74CC63A82B191C5BA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_03F500BF47EDC281D4E9A82B191C70FA" xlink:to="loc_oncyf_WarrantsMember_63E4E187543C6A74CC63A82B191C5BA6" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IncomeStatementLocation1Axis" xlink:label="loc_oncyf_IncomeStatementLocation1Axis_B5FFDCE386BFDD02EEAEA82B191D056E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_CCC45D0C806213D735FAA82F243E9FD5" xlink:to="loc_oncyf_IncomeStatementLocation1Axis_B5FFDCE386BFDD02EEAEA82B191D056E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IncomeStatementLocation1Domain" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_ACEB9811AF54CD105357A82B191D6C7F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_B5FFDCE386BFDD02EEAEA82B191D056E" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_ACEB9811AF54CD105357A82B191D6C7F_default" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IncomeStatementLocation1Domain" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_ACEB9811AF54CD105357A82B191D6C7F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_B5FFDCE386BFDD02EEAEA82B191D056E" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_ACEB9811AF54CD105357A82B191D6C7F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OperatingExpensesMember" xlink:label="loc_oncyf_OperatingExpensesMember_3D7A1FFCE56AA07AD72BA82B191D8A8B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_ACEB9811AF54CD105357A82B191D6C7F" xlink:to="loc_oncyf_OperatingExpensesMember_3D7A1FFCE56AA07AD72BA82B191D8A8B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockAxis" xlink:label="loc_oncyf_SaleOfStockAxis_10B7706FE6FAB7ADAB3FA82B191DF7AD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_CCC45D0C806213D735FAA82F243E9FD5" xlink:to="loc_oncyf_SaleOfStockAxis_10B7706FE6FAB7ADAB3FA82B191DF7AD" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_C052C5EC0CF62FAA04FEA82B191E2F43_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_10B7706FE6FAB7ADAB3FA82B191DF7AD" xlink:to="loc_oncyf_SaleOfStockDomain_C052C5EC0CF62FAA04FEA82B191E2F43_default" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_C052C5EC0CF62FAA04FEA82B191E2F43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_10B7706FE6FAB7ADAB3FA82B191DF7AD" xlink:to="loc_oncyf_SaleOfStockDomain_C052C5EC0CF62FAA04FEA82B191E2F43" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderWarrantAgreementMember" xlink:label="loc_oncyf_SharesUnderWarrantAgreementMember_3160BED89BAB15529014A82B191ED404" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_C052C5EC0CF62FAA04FEA82B191E2F43" xlink:to="loc_oncyf_SharesUnderWarrantAgreementMember_3160BED89BAB15529014A82B191ED404" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IssueOfEquityShares" xlink:label="loc_oncyf_IssueOfEquityShares_B281460633254AAF5038A82B19237F6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82" xlink:to="loc_oncyf_IssueOfEquityShares_B281460633254AAF5038A82B19237F6E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesIssuedPricePerShare1" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_9960F02FF2FC1EF0DD87A82B19247CB0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_9960F02FF2FC1EF0DD87A82B19247CB0" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_BC9D6CC770E21432873AA82B19240CF5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_BC9D6CC770E21432873AA82B19240CF5" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CommonSharesPerUnit" xlink:label="loc_oncyf_CommonSharesPerUnit_226597899CE2924DBC61A82B1924168E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82" xlink:to="loc_oncyf_CommonSharesPerUnit_226597899CE2924DBC61A82B1924168E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8A40CB8EA62BC4489169A82B192412D2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8A40CB8EA62BC4489169A82B192412D2" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2" xlink:label="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_E131D8C01E738CAACDC1A82B1924DE66" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82" xlink:to="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_E131D8C01E738CAACDC1A82B1924DE66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_C2B6D94C0EAC6EF44797A82B1925C298" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_C2B6D94C0EAC6EF44797A82B1925C298" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ProceedsfromWarrantExercises1" xlink:label="loc_oncyf_ProceedsfromWarrantExercises1_7AE00932F539022CE002A82B19255330" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82" xlink:to="loc_oncyf_ProceedsfromWarrantExercises1_7AE00932F539022CE002A82B19255330" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationOfChangeInFairValueOfWarrantDerivativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07A7659EA50AED5637DBA82E2E2A7289" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_90C741990C833EE52880A82E2E1CDF0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07A7659EA50AED5637DBA82E2E2A7289" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_90C741990C833EE52880A82E2E1CDF0D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_703C9EDE055DE686DCADA8273882B595" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_90C741990C833EE52880A82E2E1CDF0D" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_703C9EDE055DE686DCADA8273882B595" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_9633A20E079022843BA6A8273883D242_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_703C9EDE055DE686DCADA8273882B595" xlink:to="loc_ifrs-full_LiabilitiesMember_9633A20E079022843BA6A8273883D242_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_9633A20E079022843BA6A8273883D242" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_703C9EDE055DE686DCADA8273882B595" xlink:to="loc_ifrs-full_LiabilitiesMember_9633A20E079022843BA6A8273883D242" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_BD3A344288552D465C7EA82738837F61" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_9633A20E079022843BA6A8273883D242" xlink:to="loc_oncyf_WarrantsMember_BD3A344288552D465C7EA82738837F61" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassOfWarrantOrRightOutstanding1" xlink:label="loc_oncyf_ClassOfWarrantOrRightOutstanding1_2F08EBE178AD77F606CEA8273883DB91" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07A7659EA50AED5637DBA82E2E2A7289" xlink:to="loc_oncyf_ClassOfWarrantOrRightOutstanding1_2F08EBE178AD77F606CEA8273883DB91" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_E8ABA4A793BF342E727BA827388433C8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07A7659EA50AED5637DBA82E2E2A7289" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_E8ABA4A793BF342E727BA827388433C8" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsAndRightsOutstanding1" xlink:label="loc_oncyf_WarrantsAndRightsOutstanding1_CA56ECA0FB35CDD68D24A82738846B12" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07A7659EA50AED5637DBA82E2E2A7289" xlink:to="loc_oncyf_WarrantsAndRightsOutstanding1_CA56ECA0FB35CDD68D24A82738846B12" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightWarrantsExercised" xlink:label="loc_oncyf_ClassofWarrantorRightWarrantsExercised_6D9D819648BCB5AA140CA827388446CC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07A7659EA50AED5637DBA82E2E2A7289" xlink:to="loc_oncyf_ClassofWarrantorRightWarrantsExercised_6D9D819648BCB5AA140CA827388446CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_B00C2E010090C1591502A8273884A731" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07A7659EA50AED5637DBA82E2E2A7289" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_B00C2E010090C1591502A8273884A731" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_GainsLossesfromForeignExchangeImpact" xlink:label="loc_oncyf_GainsLossesfromForeignExchangeImpact_4F2E06DD9B43119FEDF3A82738857339" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07A7659EA50AED5637DBA82E2E2A7289" xlink:to="loc_oncyf_GainsLossesfromForeignExchangeImpact_4F2E06DD9B43119FEDF3A82738857339" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_58D72643E95A2B1A8F10A82EC24A16CB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_FDEF8BFA9633D77700CBA82EC244B484" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_58D72643E95A2B1A8F10A82EC24A16CB" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_FDEF8BFA9633D77700CBA82EC244B484" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_6B3D91CAB4378C65FC19A82B18EF8097" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_FDEF8BFA9633D77700CBA82EC244B484" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_6B3D91CAB4378C65FC19A82B18EF8097" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_513E2D56FF8009F9F166A82B18EFBF4B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_6B3D91CAB4378C65FC19A82B18EF8097" xlink:to="loc_ifrs-full_LiabilitiesMember_513E2D56FF8009F9F166A82B18EFBF4B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_513E2D56FF8009F9F166A82B18EFBF4B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_6B3D91CAB4378C65FC19A82B18EF8097" xlink:to="loc_ifrs-full_LiabilitiesMember_513E2D56FF8009F9F166A82B18EFBF4B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_83C96C5B008310387E99A82B18F0F23A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_513E2D56FF8009F9F166A82B18EFBF4B" xlink:to="loc_oncyf_WarrantsMember_83C96C5B008310387E99A82B18F0F23A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_FairValueofWarrantIssuedPerWarrant" xlink:label="loc_oncyf_FairValueofWarrantIssuedPerWarrant_9F0875F7D157F1D9CC22A82B18F55BC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_58D72643E95A2B1A8F10A82EC24A16CB" xlink:to="loc_oncyf_FairValueofWarrantIssuedPerWarrant_9F0875F7D157F1D9CC22A82B18F55BC1" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantIssuedUnderlyingSharePrice" xlink:label="loc_oncyf_WarrantIssuedUnderlyingSharePrice_481D127FA0C5099CDB46A82B18F5BF15" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_58D72643E95A2B1A8F10A82EC24A16CB" xlink:to="loc_oncyf_WarrantIssuedUnderlyingSharePrice_481D127FA0C5099CDB46A82B18F5BF15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_9EFABCDEA5A1908F17DBA82B18F614FF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_58D72643E95A2B1A8F10A82EC24A16CB" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_9EFABCDEA5A1908F17DBA82B18F614FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_6662CD1BCC5EA0CB379BA82B18F69C49" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_58D72643E95A2B1A8F10A82EC24A16CB" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_6662CD1BCC5EA0CB379BA82B18F69C49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_1E1D9DB0CE06E872BC16A82B18F6559B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_58D72643E95A2B1A8F10A82EC24A16CB" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_1E1D9DB0CE06E872BC16A82B18F6559B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DividendYieldPercent" xlink:label="loc_oncyf_DividendYieldPercent_F00887EB6C3ABE26C9D2A82B18F6A249" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_58D72643E95A2B1A8F10A82EC24A16CB" xlink:to="loc_oncyf_DividendYieldPercent_F00887EB6C3ABE26C9D2A82B18F6A249" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>27
<FILENAME>oncyf-20191231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract_5BA193E900956BE267A19CFE7F8E0A9A_label_en-US" xlink:label="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract_5BA193E900956BE267A19CFE7F8E0A9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Presentation of leases for lessee [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_5BA193E900956BE267A19CFE7F8E0A9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_5BA193E900956BE267A19CFE7F8E0A9A" xlink:to="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract_5BA193E900956BE267A19CFE7F8E0A9A" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_6F9927B55D4524FCDB0D9CFE7F8EAD6D_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_6F9927B55D4524FCDB0D9CFE7F8EAD6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets and Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_6F9927B55D4524FCDB0D9CFE7F8EAD6D_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_6F9927B55D4524FCDB0D9CFE7F8EAD6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_6F9927B55D4524FCDB0D9CFE7F8EAD6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_6F9927B55D4524FCDB0D9CFE7F8EAD6D" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_6F9927B55D4524FCDB0D9CFE7F8EAD6D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_CECCA55D4AB4BBD2602A9CFE7F8F2C69_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_CECCA55D4AB4BBD2602A9CFE7F8F2C69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total undiscounted lease liability</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_CECCA55D4AB4BBD2602A9CFE7F8F2C69_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_CECCA55D4AB4BBD2602A9CFE7F8F2C69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_CECCA55D4AB4BBD2602A9CFE7F8F2C69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_CECCA55D4AB4BBD2602A9CFE7F8F2C69" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_CECCA55D4AB4BBD2602A9CFE7F8F2C69" xlink:type="arc" />
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_9479FC7C77A43C790E179CFE7E1DAB30_label_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract_9479FC7C77A43C790E179CFE7E1DAB30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_9479FC7C77A43C790E179CFE7E1DAB30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_9479FC7C77A43C790E179CFE7E1DAB30" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract_9479FC7C77A43C790E179CFE7E1DAB30" xlink:type="arc" />
    <link:label id="lab_oncyf_ProceedsfromInterestReceived_C8CC80491659D009108D9CFE7E1EF4EE_terseLabel_en-US" xlink:label="lab_oncyf_ProceedsfromInterestReceived_C8CC80491659D009108D9CFE7E1EF4EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash interest received</link:label>
    <link:label id="lab_oncyf_ProceedsfromInterestReceived_C8CC80491659D009108D9CFE7E1EF4EE_label_en-US" xlink:label="lab_oncyf_ProceedsfromInterestReceived_C8CC80491659D009108D9CFE7E1EF4EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:label id="lab_oncyf_ProceedsfromInterestReceived_C8CC80491659D009108D9CFE7E1EF4EE_documentation_en-US" xlink:label="lab_oncyf_ProceedsfromInterestReceived_C8CC80491659D009108D9CFE7E1EF4EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ProceedsfromInterestReceived" xlink:label="loc_oncyf_ProceedsfromInterestReceived_C8CC80491659D009108D9CFE7E1EF4EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ProceedsfromInterestReceived_C8CC80491659D009108D9CFE7E1EF4EE" xlink:to="lab_oncyf_ProceedsfromInterestReceived_C8CC80491659D009108D9CFE7E1EF4EE" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefund_EC7E088E6F5A46BEDA599CFE7E1E16DF_terseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefund_EC7E088E6F5A46BEDA599CFE7E1E16DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash taxes paid</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefund_EC7E088E6F5A46BEDA599CFE7E1E16DF_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefund_EC7E088E6F5A46BEDA599CFE7E1E16DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefund" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefund_EC7E088E6F5A46BEDA599CFE7E1E16DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefund_EC7E088E6F5A46BEDA599CFE7E1E16DF" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefund_EC7E088E6F5A46BEDA599CFE7E1E16DF" xlink:type="arc" />
    <link:label id="lab_oncyf_DisclosureofrelatedpartyAbstract_03E65B5E55D8AB4361A09CFE7E1B758F_label_en-US" xlink:label="lab_oncyf_DisclosureofrelatedpartyAbstract_03E65B5E55D8AB4361A09CFE7E1B758F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of related party [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofrelatedpartyAbstract_03E65B5E55D8AB4361A09CFE7E1B758F_documentation_en-US" xlink:label="lab_oncyf_DisclosureofrelatedpartyAbstract_03E65B5E55D8AB4361A09CFE7E1B758F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of related party [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofrelatedpartyAbstract" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract_03E65B5E55D8AB4361A09CFE7E1B758F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_03E65B5E55D8AB4361A09CFE7E1B758F" xlink:to="lab_oncyf_DisclosureofrelatedpartyAbstract_03E65B5E55D8AB4361A09CFE7E1B758F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_DC34FEFD2B8394B598AB9CFE7E1C6C8F_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_DC34FEFD2B8394B598AB9CFE7E1C6C8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of related party transactions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_DC34FEFD2B8394B598AB9CFE7E1C6C8F_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_DC34FEFD2B8394B598AB9CFE7E1C6C8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_DC34FEFD2B8394B598AB9CFE7E1C6C8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_DC34FEFD2B8394B598AB9CFE7E1C6C8F" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_DC34FEFD2B8394B598AB9CFE7E1C6C8F" xlink:type="arc" />
    <link:label id="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_ADE178556D54CBE92135A82B191BE28D_label_en-US" xlink:label="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_ADE178556D54CBE92135A82B191BE28D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_ADE178556D54CBE92135A82B191BE28D_documentation_en-US" xlink:label="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_ADE178556D54CBE92135A82B191BE28D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_ADE178556D54CBE92135A82B191BE28D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_ADE178556D54CBE92135A82B191BE28D" xlink:to="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_ADE178556D54CBE92135A82B191BE28D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_CCC45D0C806213D735FAA82F243E9FD5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_CCC45D0C806213D735FAA82F243E9FD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_CCC45D0C806213D735FAA82F243E9FD5_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_CCC45D0C806213D735FAA82F243E9FD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_CCC45D0C806213D735FAA82F243E9FD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_CCC45D0C806213D735FAA82F243E9FD5" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_CCC45D0C806213D735FAA82F243E9FD5" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_D6E37D1C4511E381C870A82B191B83B5_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis_D6E37D1C4511E381C870A82B191B83B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_D6E37D1C4511E381C870A82B191B83B5_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis_D6E37D1C4511E381C870A82B191B83B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_D6E37D1C4511E381C870A82B191B83B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_D6E37D1C4511E381C870A82B191B83B5" xlink:to="lab_ifrs-full_ClassesOfShareCapitalAxis_D6E37D1C4511E381C870A82B191B83B5" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalMember_E744E544A32F9709D6FBA82B191BB2B3_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember_E744E544A32F9709D6FBA82B191BB2B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital [member]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalMember_E744E544A32F9709D6FBA82B191BB2B3_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember_E744E544A32F9709D6FBA82B191BB2B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share capital [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_E744E544A32F9709D6FBA82B191BB2B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_E744E544A32F9709D6FBA82B191BB2B3" xlink:to="lab_ifrs-full_ClassesOfShareCapitalMember_E744E544A32F9709D6FBA82B191BB2B3" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IssuedCapitalMember_F9783C2C8EA2F3DBBFA4A82B191C2E90_verboseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember_F9783C2C8EA2F3DBBFA4A82B191C2E90" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_F9783C2C8EA2F3DBBFA4A82B191C2E90_label_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember_F9783C2C8EA2F3DBBFA4A82B191C2E90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_F9783C2C8EA2F3DBBFA4A82B191C2E90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember_F9783C2C8EA2F3DBBFA4A82B191C2E90" xlink:to="lab_ifrs-full_IssuedCapitalMember_F9783C2C8EA2F3DBBFA4A82B191C2E90" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_EFF64443B067F509481DA82B191CEA6F_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis_EFF64443B067F509481DA82B191CEA6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_EFF64443B067F509481DA82B191CEA6F_label_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis_EFF64443B067F509481DA82B191CEA6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_EFF64443B067F509481DA82B191CEA6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_EFF64443B067F509481DA82B191CEA6F" xlink:to="lab_ifrs-full_ClassesOfLiabilitiesAxis_EFF64443B067F509481DA82B191CEA6F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_LiabilitiesMember_03F500BF47EDC281D4E9A82B191C70FA_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesMember_03F500BF47EDC281D4E9A82B191C70FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities [member]</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesMember_03F500BF47EDC281D4E9A82B191C70FA_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesMember_03F500BF47EDC281D4E9A82B191C70FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_03F500BF47EDC281D4E9A82B191C70FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesMember_03F500BF47EDC281D4E9A82B191C70FA" xlink:to="lab_ifrs-full_LiabilitiesMember_03F500BF47EDC281D4E9A82B191C70FA" xlink:type="arc" />
    <link:label id="lab_oncyf_WarrantsMember_63E4E187543C6A74CC63A82B191C5BA6_verboseLabel_en-US" xlink:label="lab_oncyf_WarrantsMember_63E4E187543C6A74CC63A82B191C5BA6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_oncyf_WarrantsMember_63E4E187543C6A74CC63A82B191C5BA6_label_en-US" xlink:label="lab_oncyf_WarrantsMember_63E4E187543C6A74CC63A82B191C5BA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants [Member]</link:label>
    <link:label id="lab_oncyf_WarrantsMember_63E4E187543C6A74CC63A82B191C5BA6_documentation_en-US" xlink:label="lab_oncyf_WarrantsMember_63E4E187543C6A74CC63A82B191C5BA6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_63E4E187543C6A74CC63A82B191C5BA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantsMember_63E4E187543C6A74CC63A82B191C5BA6" xlink:to="lab_oncyf_WarrantsMember_63E4E187543C6A74CC63A82B191C5BA6" xlink:type="arc" />
    <link:label id="lab_oncyf_IncomeStatementLocation1Axis_B5FFDCE386BFDD02EEAEA82B191D056E_terseLabel_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Axis_B5FFDCE386BFDD02EEAEA82B191D056E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location1 [Axis]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Axis_B5FFDCE386BFDD02EEAEA82B191D056E_label_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Axis_B5FFDCE386BFDD02EEAEA82B191D056E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location1 [Axis]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Axis_B5FFDCE386BFDD02EEAEA82B191D056E_documentation_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Axis_B5FFDCE386BFDD02EEAEA82B191D056E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Statement Location1 [Axis]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IncomeStatementLocation1Axis" xlink:label="loc_oncyf_IncomeStatementLocation1Axis_B5FFDCE386BFDD02EEAEA82B191D056E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_B5FFDCE386BFDD02EEAEA82B191D056E" xlink:to="lab_oncyf_IncomeStatementLocation1Axis_B5FFDCE386BFDD02EEAEA82B191D056E" xlink:type="arc" />
    <link:label id="lab_oncyf_IncomeStatementLocation1Domain_ACEB9811AF54CD105357A82B191D6C7F_terseLabel_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Domain_ACEB9811AF54CD105357A82B191D6C7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location1 [Domain]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Domain_ACEB9811AF54CD105357A82B191D6C7F_label_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Domain_ACEB9811AF54CD105357A82B191D6C7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location1 [Domain]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Domain_ACEB9811AF54CD105357A82B191D6C7F_documentation_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Domain_ACEB9811AF54CD105357A82B191D6C7F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Income Statement Location1 [Axis]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IncomeStatementLocation1Domain" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_ACEB9811AF54CD105357A82B191D6C7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_ACEB9811AF54CD105357A82B191D6C7F" xlink:to="lab_oncyf_IncomeStatementLocation1Domain_ACEB9811AF54CD105357A82B191D6C7F" xlink:type="arc" />
    <link:label id="lab_oncyf_OperatingExpensesMember_3D7A1FFCE56AA07AD72BA82B191D8A8B_terseLabel_en-US" xlink:label="lab_oncyf_OperatingExpensesMember_3D7A1FFCE56AA07AD72BA82B191D8A8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Included in operating expenses</link:label>
    <link:label id="lab_oncyf_OperatingExpensesMember_3D7A1FFCE56AA07AD72BA82B191D8A8B_label_en-US" xlink:label="lab_oncyf_OperatingExpensesMember_3D7A1FFCE56AA07AD72BA82B191D8A8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Member]</link:label>
    <link:label id="lab_oncyf_OperatingExpensesMember_3D7A1FFCE56AA07AD72BA82B191D8A8B_documentation_en-US" xlink:label="lab_oncyf_OperatingExpensesMember_3D7A1FFCE56AA07AD72BA82B191D8A8B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Expenses [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OperatingExpensesMember" xlink:label="loc_oncyf_OperatingExpensesMember_3D7A1FFCE56AA07AD72BA82B191D8A8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OperatingExpensesMember_3D7A1FFCE56AA07AD72BA82B191D8A8B" xlink:to="lab_oncyf_OperatingExpensesMember_3D7A1FFCE56AA07AD72BA82B191D8A8B" xlink:type="arc" />
    <link:label id="lab_oncyf_SaleOfStockAxis_10B7706FE6FAB7ADAB3FA82B191DF7AD_terseLabel_en-US" xlink:label="lab_oncyf_SaleOfStockAxis_10B7706FE6FAB7ADAB3FA82B191DF7AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:label id="lab_oncyf_SaleOfStockAxis_10B7706FE6FAB7ADAB3FA82B191DF7AD_label_en-US" xlink:label="lab_oncyf_SaleOfStockAxis_10B7706FE6FAB7ADAB3FA82B191DF7AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:label id="lab_oncyf_SaleOfStockAxis_10B7706FE6FAB7ADAB3FA82B191DF7AD_documentation_en-US" xlink:label="lab_oncyf_SaleOfStockAxis_10B7706FE6FAB7ADAB3FA82B191DF7AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockAxis" xlink:label="loc_oncyf_SaleOfStockAxis_10B7706FE6FAB7ADAB3FA82B191DF7AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SaleOfStockAxis_10B7706FE6FAB7ADAB3FA82B191DF7AD" xlink:to="lab_oncyf_SaleOfStockAxis_10B7706FE6FAB7ADAB3FA82B191DF7AD" xlink:type="arc" />
    <link:label id="lab_oncyf_SaleOfStockDomain_C052C5EC0CF62FAA04FEA82B191E2F43_terseLabel_en-US" xlink:label="lab_oncyf_SaleOfStockDomain_C052C5EC0CF62FAA04FEA82B191E2F43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:label id="lab_oncyf_SaleOfStockDomain_C052C5EC0CF62FAA04FEA82B191E2F43_label_en-US" xlink:label="lab_oncyf_SaleOfStockDomain_C052C5EC0CF62FAA04FEA82B191E2F43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:label id="lab_oncyf_SaleOfStockDomain_C052C5EC0CF62FAA04FEA82B191E2F43_documentation_en-US" xlink:label="lab_oncyf_SaleOfStockDomain_C052C5EC0CF62FAA04FEA82B191E2F43" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_C052C5EC0CF62FAA04FEA82B191E2F43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SaleOfStockDomain_C052C5EC0CF62FAA04FEA82B191E2F43" xlink:to="lab_oncyf_SaleOfStockDomain_C052C5EC0CF62FAA04FEA82B191E2F43" xlink:type="arc" />
    <link:label id="lab_oncyf_SharesUnderWarrantAgreementMember_3160BED89BAB15529014A82B191ED404_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderWarrantAgreementMember_3160BED89BAB15529014A82B191ED404" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_oncyf_SharesUnderWarrantAgreementMember_3160BED89BAB15529014A82B191ED404_label_en-US" xlink:label="lab_oncyf_SharesUnderWarrantAgreementMember_3160BED89BAB15529014A82B191ED404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Under Warrant Agreement [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderWarrantAgreementMember_3160BED89BAB15529014A82B191ED404_documentation_en-US" xlink:label="lab_oncyf_SharesUnderWarrantAgreementMember_3160BED89BAB15529014A82B191ED404" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Under Warrant Agreement [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderWarrantAgreementMember" xlink:label="loc_oncyf_SharesUnderWarrantAgreementMember_3160BED89BAB15529014A82B191ED404" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderWarrantAgreementMember_3160BED89BAB15529014A82B191ED404" xlink:to="lab_oncyf_SharesUnderWarrantAgreementMember_3160BED89BAB15529014A82B191ED404" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82" xlink:type="arc" />
    <link:label id="lab_oncyf_IssueOfEquityShares_B281460633254AAF5038A82B19237F6E_terseLabel_en-US" xlink:label="lab_oncyf_IssueOfEquityShares_B281460633254AAF5038A82B19237F6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued (shares)</link:label>
    <link:label id="lab_oncyf_IssueOfEquityShares_B281460633254AAF5038A82B19237F6E_label_en-US" xlink:label="lab_oncyf_IssueOfEquityShares_B281460633254AAF5038A82B19237F6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue Of Equity, Shares</link:label>
    <link:label id="lab_oncyf_IssueOfEquityShares_B281460633254AAF5038A82B19237F6E_documentation_en-US" xlink:label="lab_oncyf_IssueOfEquityShares_B281460633254AAF5038A82B19237F6E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issue Of Equity, Shares</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IssueOfEquityShares" xlink:label="loc_oncyf_IssueOfEquityShares_B281460633254AAF5038A82B19237F6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IssueOfEquityShares_B281460633254AAF5038A82B19237F6E" xlink:to="lab_oncyf_IssueOfEquityShares_B281460633254AAF5038A82B19237F6E" xlink:type="arc" />
    <link:label id="lab_oncyf_SharesIssuedPricePerShare1_9960F02FF2FC1EF0DD87A82B19247CB0_terseLabel_en-US" xlink:label="lab_oncyf_SharesIssuedPricePerShare1_9960F02FF2FC1EF0DD87A82B19247CB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price (cad per share)</link:label>
    <link:label id="lab_oncyf_SharesIssuedPricePerShare1_9960F02FF2FC1EF0DD87A82B19247CB0_label_en-US" xlink:label="lab_oncyf_SharesIssuedPricePerShare1_9960F02FF2FC1EF0DD87A82B19247CB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share1</link:label>
    <link:label id="lab_oncyf_SharesIssuedPricePerShare1_9960F02FF2FC1EF0DD87A82B19247CB0_documentation_en-US" xlink:label="lab_oncyf_SharesIssuedPricePerShare1_9960F02FF2FC1EF0DD87A82B19247CB0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share1</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesIssuedPricePerShare1" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_9960F02FF2FC1EF0DD87A82B19247CB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesIssuedPricePerShare1_9960F02FF2FC1EF0DD87A82B19247CB0" xlink:to="lab_oncyf_SharesIssuedPricePerShare1_9960F02FF2FC1EF0DD87A82B19247CB0" xlink:type="arc" />
    <link:label id="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares_BC9D6CC770E21432873AA82B19240CF5_terseLabel_en-US" xlink:label="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares_BC9D6CC770E21432873AA82B19240CF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds from common shares</link:label>
    <link:label id="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares_BC9D6CC770E21432873AA82B19240CF5_label_en-US" xlink:label="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares_BC9D6CC770E21432873AA82B19240CF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Proceeds From Issue Of Ordinary Shares</link:label>
    <link:label id="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares_BC9D6CC770E21432873AA82B19240CF5_documentation_en-US" xlink:label="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares_BC9D6CC770E21432873AA82B19240CF5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross Proceeds From Issue Of Ordinary Shares</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_BC9D6CC770E21432873AA82B19240CF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_BC9D6CC770E21432873AA82B19240CF5" xlink:to="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares_BC9D6CC770E21432873AA82B19240CF5" xlink:type="arc" />
    <link:label id="lab_oncyf_CommonSharesPerUnit_226597899CE2924DBC61A82B1924168E_terseLabel_en-US" xlink:label="lab_oncyf_CommonSharesPerUnit_226597899CE2924DBC61A82B1924168E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares per unit (shares)</link:label>
    <link:label id="lab_oncyf_CommonSharesPerUnit_226597899CE2924DBC61A82B1924168E_label_en-US" xlink:label="lab_oncyf_CommonSharesPerUnit_226597899CE2924DBC61A82B1924168E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Shares Per Unit</link:label>
    <link:label id="lab_oncyf_CommonSharesPerUnit_226597899CE2924DBC61A82B1924168E_documentation_en-US" xlink:label="lab_oncyf_CommonSharesPerUnit_226597899CE2924DBC61A82B1924168E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Shares Per Unit</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CommonSharesPerUnit" xlink:label="loc_oncyf_CommonSharesPerUnit_226597899CE2924DBC61A82B1924168E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommonSharesPerUnit_226597899CE2924DBC61A82B1924168E" xlink:to="lab_oncyf_CommonSharesPerUnit_226597899CE2924DBC61A82B1924168E" xlink:type="arc" />
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8A40CB8EA62BC4489169A82B192412D2_terseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8A40CB8EA62BC4489169A82B192412D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of common shares issuable per warrant (shares)</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8A40CB8EA62BC4489169A82B192412D2_label_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8A40CB8EA62BC4489169A82B192412D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8A40CB8EA62BC4489169A82B192412D2_documentation_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8A40CB8EA62BC4489169A82B192412D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8A40CB8EA62BC4489169A82B192412D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8A40CB8EA62BC4489169A82B192412D2" xlink:to="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8A40CB8EA62BC4489169A82B192412D2" xlink:type="arc" />
    <link:label id="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_E131D8C01E738CAACDC1A82B1924DE66_terseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_E131D8C01E738CAACDC1A82B1924DE66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (usd per share)</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_E131D8C01E738CAACDC1A82B1924DE66_label_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_E131D8C01E738CAACDC1A82B1924DE66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights2</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_E131D8C01E738CAACDC1A82B1924DE66_documentation_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_E131D8C01E738CAACDC1A82B1924DE66" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights2</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2" xlink:label="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_E131D8C01E738CAACDC1A82B1924DE66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_E131D8C01E738CAACDC1A82B1924DE66" xlink:to="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_E131D8C01E738CAACDC1A82B1924DE66" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_C2B6D94C0EAC6EF44797A82B1925C298_terseLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost_C2B6D94C0EAC6EF44797A82B1925C298" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issue related cost</link:label>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_C2B6D94C0EAC6EF44797A82B1925C298_label_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost_C2B6D94C0EAC6EF44797A82B1925C298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share issue related cost</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_C2B6D94C0EAC6EF44797A82B1925C298" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareIssueRelatedCost_C2B6D94C0EAC6EF44797A82B1925C298" xlink:to="lab_ifrs-full_ShareIssueRelatedCost_C2B6D94C0EAC6EF44797A82B1925C298" xlink:type="arc" />
    <link:label id="lab_oncyf_ProceedsfromWarrantExercises1_7AE00932F539022CE002A82B19255330_terseLabel_en-US" xlink:label="lab_oncyf_ProceedsfromWarrantExercises1_7AE00932F539022CE002A82B19255330" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds from warrant exercises</link:label>
    <link:label id="lab_oncyf_ProceedsfromWarrantExercises1_7AE00932F539022CE002A82B19255330_label_en-US" xlink:label="lab_oncyf_ProceedsfromWarrantExercises1_7AE00932F539022CE002A82B19255330" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises1</link:label>
    <link:label id="lab_oncyf_ProceedsfromWarrantExercises1_7AE00932F539022CE002A82B19255330_documentation_en-US" xlink:label="lab_oncyf_ProceedsfromWarrantExercises1_7AE00932F539022CE002A82B19255330" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises1</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ProceedsfromWarrantExercises1" xlink:label="loc_oncyf_ProceedsfromWarrantExercises1_7AE00932F539022CE002A82B19255330" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ProceedsfromWarrantExercises1_7AE00932F539022CE002A82B19255330" xlink:to="lab_oncyf_ProceedsfromWarrantExercises1_7AE00932F539022CE002A82B19255330" xlink:type="arc" />
    <link:label id="lab_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_582AAD2FD270E4FB06469D034CBD5363_label_en-US" xlink:label="lab_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_582AAD2FD270E4FB06469D034CBD5363" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Share-based Payment Arrangements [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_582AAD2FD270E4FB06469D034CBD5363_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_582AAD2FD270E4FB06469D034CBD5363" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Share-based Payment Arrangements [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:label="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_582AAD2FD270E4FB06469D034CBD5363" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_582AAD2FD270E4FB06469D034CBD5363" xlink:to="lab_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_582AAD2FD270E4FB06469D034CBD5363" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_787727BD35A16555CD5C9D034CBDCA08_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_787727BD35A16555CD5C9D034CBDCA08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_787727BD35A16555CD5C9D034CBDCA08_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_787727BD35A16555CD5C9D034CBDCA08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_787727BD35A16555CD5C9D034CBDCA08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_787727BD35A16555CD5C9D034CBDCA08" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_787727BD35A16555CD5C9D034CBDCA08" xlink:type="arc" />
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_4883A1C62F74FA7733159D034CBD012A_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_4883A1C62F74FA7733159D034CBD012A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_4883A1C62F74FA7733159D034CBD012A_label_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_4883A1C62F74FA7733159D034CBD012A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_4883A1C62F74FA7733159D034CBD012A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_4883A1C62F74FA7733159D034CBD012A" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_4883A1C62F74FA7733159D034CBD012A" xlink:type="arc" />
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_C336E682560CC5AB69349D034CBD2E55_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_C336E682560CC5AB69349D034CBD2E55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [member]</link:label>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_C336E682560CC5AB69349D034CBD2E55_label_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_C336E682560CC5AB69349D034CBD2E55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_C336E682560CC5AB69349D034CBD2E55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_C336E682560CC5AB69349D034CBD2E55" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_C336E682560CC5AB69349D034CBD2E55" xlink:type="arc" />
    <link:label id="lab_oncyf_ExercisePriceRangeOneMember_CB417BC64E16568037609D034CBE8ED4_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeOneMember_CB417BC64E16568037609D034CBE8ED4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$0.54 - $1.42</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeOneMember_CB417BC64E16568037609D034CBE8ED4_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeOneMember_CB417BC64E16568037609D034CBE8ED4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeOneMember_CB417BC64E16568037609D034CBE8ED4_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeOneMember_CB417BC64E16568037609D034CBE8ED4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ExercisePriceRangeOneMember" xlink:label="loc_oncyf_ExercisePriceRangeOneMember_CB417BC64E16568037609D034CBE8ED4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeOneMember_CB417BC64E16568037609D034CBE8ED4" xlink:to="lab_oncyf_ExercisePriceRangeOneMember_CB417BC64E16568037609D034CBE8ED4" xlink:type="arc" />
    <link:label id="lab_oncyf_ExercisePriceRangeTwoMember_0B52B52BAF8BE973C58B9D034CBEFC97_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeTwoMember_0B52B52BAF8BE973C58B9D034CBEFC97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$1.43 - $1.79</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeTwoMember_0B52B52BAF8BE973C58B9D034CBEFC97_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeTwoMember_0B52B52BAF8BE973C58B9D034CBEFC97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeTwoMember_0B52B52BAF8BE973C58B9D034CBEFC97_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeTwoMember_0B52B52BAF8BE973C58B9D034CBEFC97" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ExercisePriceRangeTwoMember" xlink:label="loc_oncyf_ExercisePriceRangeTwoMember_0B52B52BAF8BE973C58B9D034CBEFC97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeTwoMember_0B52B52BAF8BE973C58B9D034CBEFC97" xlink:to="lab_oncyf_ExercisePriceRangeTwoMember_0B52B52BAF8BE973C58B9D034CBEFC97" xlink:type="arc" />
    <link:label id="lab_oncyf_ExercisePriceRangeThreeMember_8A0030A5F24DD0D48B509D034CBE001C_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeThreeMember_8A0030A5F24DD0D48B509D034CBE001C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$1.80 - $3.39</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeThreeMember_8A0030A5F24DD0D48B509D034CBE001C_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeThreeMember_8A0030A5F24DD0D48B509D034CBE001C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeThreeMember_8A0030A5F24DD0D48B509D034CBE001C_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeThreeMember_8A0030A5F24DD0D48B509D034CBE001C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ExercisePriceRangeThreeMember" xlink:label="loc_oncyf_ExercisePriceRangeThreeMember_8A0030A5F24DD0D48B509D034CBE001C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeThreeMember_8A0030A5F24DD0D48B509D034CBE001C" xlink:to="lab_oncyf_ExercisePriceRangeThreeMember_8A0030A5F24DD0D48B509D034CBE001C" xlink:type="arc" />
    <link:label id="lab_oncyf_ExercisePriceRangeFourMember_A1C4301F796867209EC39D034CBEB0F1_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFourMember_A1C4301F796867209EC39D034CBEB0F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$3.40 - $7.13</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFourMember_A1C4301F796867209EC39D034CBEB0F1_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFourMember_A1C4301F796867209EC39D034CBEB0F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFourMember_A1C4301F796867209EC39D034CBEB0F1_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFourMember_A1C4301F796867209EC39D034CBEB0F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ExercisePriceRangeFourMember" xlink:label="loc_oncyf_ExercisePriceRangeFourMember_A1C4301F796867209EC39D034CBEB0F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeFourMember_A1C4301F796867209EC39D034CBEB0F1" xlink:to="lab_oncyf_ExercisePriceRangeFourMember_A1C4301F796867209EC39D034CBEB0F1" xlink:type="arc" />
    <link:label id="lab_oncyf_ExercisePriceRangeFiveMember_984D3F661B6CD944B0FC9D034CBE6DD8_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFiveMember_984D3F661B6CD944B0FC9D034CBE6DD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$7.14 - $63.84</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFiveMember_984D3F661B6CD944B0FC9D034CBE6DD8_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFiveMember_984D3F661B6CD944B0FC9D034CBE6DD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFiveMember_984D3F661B6CD944B0FC9D034CBE6DD8_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFiveMember_984D3F661B6CD944B0FC9D034CBE6DD8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ExercisePriceRangeFiveMember" xlink:label="loc_oncyf_ExercisePriceRangeFiveMember_984D3F661B6CD944B0FC9D034CBE6DD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeFiveMember_984D3F661B6CD944B0FC9D034CBE6DD8" xlink:to="lab_oncyf_ExercisePriceRangeFiveMember_984D3F661B6CD944B0FC9D034CBE6DD8" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_C0348BC8204AC49E2EFB9D034CBFBD48_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_C0348BC8204AC49E2EFB9D034CBFBD48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_C0348BC8204AC49E2EFB9D034CBFBD48_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_C0348BC8204AC49E2EFB9D034CBFBD48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_C0348BC8204AC49E2EFB9D034CBFBD48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_C0348BC8204AC49E2EFB9D034CBFBD48" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_C0348BC8204AC49E2EFB9D034CBFBD48" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_8FEF9B0478B38C84E9349D034CBFE53F_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions_8FEF9B0478B38C84E9349D034CBFE53F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number Outstanding (options)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_8FEF9B0478B38C84E9349D034CBFE53F_label_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions_8FEF9B0478B38C84E9349D034CBFE53F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_8FEF9B0478B38C84E9349D034CBFE53F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions_8FEF9B0478B38C84E9349D034CBFE53F" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions_8FEF9B0478B38C84E9349D034CBFE53F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1F85CDFDE36FC18FF5959D24F556053F_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1F85CDFDE36FC18FF5959D24F556053F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Life (years)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1F85CDFDE36FC18FF5959D24F556053F_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1F85CDFDE36FC18FF5959D24F556053F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1F85CDFDE36FC18FF5959D24F556053F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1F85CDFDE36FC18FF5959D24F556053F" xlink:to="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1F85CDFDE36FC18FF5959D24F556053F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_A3B2781E07F1563F7A179D2551CDB58B_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_A3B2781E07F1563F7A179D2551CDB58B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_A3B2781E07F1563F7A179D2551CDB58B_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_A3B2781E07F1563F7A179D2551CDB58B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_A3B2781E07F1563F7A179D2551CDB58B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_A3B2781E07F1563F7A179D2551CDB58B" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_A3B2781E07F1563F7A179D2551CDB58B" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_3BD728B6BEC25A2011FE9D034CBF9806_verboseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_3BD728B6BEC25A2011FE9D034CBF9806" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number Exercisable (options)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_3BD728B6BEC25A2011FE9D034CBF9806_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_3BD728B6BEC25A2011FE9D034CBF9806" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_3BD728B6BEC25A2011FE9D034CBF9806" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_3BD728B6BEC25A2011FE9D034CBF9806" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_3BD728B6BEC25A2011FE9D034CBF9806" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_7B1CE31B99587E7D2C269D258F38B9ED_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_7B1CE31B99587E7D2C269D258F38B9ED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_7B1CE31B99587E7D2C269D258F38B9ED_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_7B1CE31B99587E7D2C269D258F38B9ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_7B1CE31B99587E7D2C269D258F38B9ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_7B1CE31B99587E7D2C269D258F38B9ED" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_7B1CE31B99587E7D2C269D258F38B9ED" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_089D88B7F16DEBD253F09D034CC012D7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_089D88B7F16DEBD253F09D034CC012D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_089D88B7F16DEBD253F09D034CC012D7_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_089D88B7F16DEBD253F09D034CC012D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_089D88B7F16DEBD253F09D034CC012D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_089D88B7F16DEBD253F09D034CC012D7" xlink:to="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_089D88B7F16DEBD253F09D034CC012D7" xlink:type="arc" />
    <link:label id="lab_ifrs-full_RangeAxis_5929444ED60B9C593E159D034CC1D4CA_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeAxis_5929444ED60B9C593E159D034CC1D4CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
    <link:label id="lab_ifrs-full_RangeAxis_5929444ED60B9C593E159D034CC1D4CA_label_en-US" xlink:label="lab_ifrs-full_RangeAxis_5929444ED60B9C593E159D034CC1D4CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_5929444ED60B9C593E159D034CC1D4CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis_5929444ED60B9C593E159D034CC1D4CA" xlink:to="lab_ifrs-full_RangeAxis_5929444ED60B9C593E159D034CC1D4CA" xlink:type="arc" />
    <link:label id="lab_ifrs-full_RangesMember_BC71AEC3DA4C466F99719D034CC221EF_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesMember_BC71AEC3DA4C466F99719D034CC221EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ranges [member]</link:label>
    <link:label id="lab_ifrs-full_RangesMember_BC71AEC3DA4C466F99719D034CC221EF_label_en-US" xlink:label="lab_ifrs-full_RangesMember_BC71AEC3DA4C466F99719D034CC221EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_BC71AEC3DA4C466F99719D034CC221EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesMember_BC71AEC3DA4C466F99719D034CC221EF" xlink:to="lab_ifrs-full_RangesMember_BC71AEC3DA4C466F99719D034CC221EF" xlink:type="arc" />
    <link:label id="lab_ifrs-full_BottomOfRangeMember_138CB41166D1E80880DF9D034CC2E135_terseLabel_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember_138CB41166D1E80880DF9D034CC2E135" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_138CB41166D1E80880DF9D034CC2E135_label_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember_138CB41166D1E80880DF9D034CC2E135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bottom of range [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_138CB41166D1E80880DF9D034CC2E135" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember_138CB41166D1E80880DF9D034CC2E135" xlink:to="lab_ifrs-full_BottomOfRangeMember_138CB41166D1E80880DF9D034CC2E135" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TopOfRangeMember_E90E50B59EDC4BAFCF8C9D034CC2988D_terseLabel_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember_E90E50B59EDC4BAFCF8C9D034CC2988D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_ifrs-full_TopOfRangeMember_E90E50B59EDC4BAFCF8C9D034CC2988D_label_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember_E90E50B59EDC4BAFCF8C9D034CC2988D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top of range [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_E90E50B59EDC4BAFCF8C9D034CC2988D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember_E90E50B59EDC4BAFCF8C9D034CC2988D" xlink:to="lab_ifrs-full_TopOfRangeMember_E90E50B59EDC4BAFCF8C9D034CC2988D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_4743EC40FBE30D6FBCDC9D034CC2D346_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_4743EC40FBE30D6FBCDC9D034CC2D346" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_4743EC40FBE30D6FBCDC9D034CC2D346_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_4743EC40FBE30D6FBCDC9D034CC2D346" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_4743EC40FBE30D6FBCDC9D034CC2D346" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_4743EC40FBE30D6FBCDC9D034CC2D346" xlink:to="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_4743EC40FBE30D6FBCDC9D034CC2D346" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_073354358577BDB7C00F9D2A48DB70C5_terseLabel_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_073354358577BDB7C00F9D2A48DB70C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (cad per share)</link:label>
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_073354358577BDB7C00F9D2A48DB70C5_label_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_073354358577BDB7C00F9D2A48DB70C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price of outstanding share options</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_073354358577BDB7C00F9D2A48DB70C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_073354358577BDB7C00F9D2A48DB70C5" xlink:to="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_073354358577BDB7C00F9D2A48DB70C5" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_B25B9B922185F14E434C9D034C29712C_label_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_B25B9B922185F14E434C9D034C29712C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_B25B9B922185F14E434C9D034C29712C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_B25B9B922185F14E434C9D034C29712C" xlink:to="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_B25B9B922185F14E434C9D034C29712C" xlink:type="arc" />
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTable_3A313FE7984EAB98D82D9D034C2967FA_terseLabel_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTable_3A313FE7984EAB98D82D9D034C2967FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Table]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTable_3A313FE7984EAB98D82D9D034C2967FA_label_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTable_3A313FE7984EAB98D82D9D034C2967FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Table]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTable_3A313FE7984EAB98D82D9D034C2967FA_documentation_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTable_3A313FE7984EAB98D82D9D034C2967FA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Table]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OtherExpensesAndAdjustmentsTable" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTable_3A313FE7984EAB98D82D9D034C2967FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_3A313FE7984EAB98D82D9D034C2967FA" xlink:to="lab_oncyf_OtherExpensesAndAdjustmentsTable_3A313FE7984EAB98D82D9D034C2967FA" xlink:type="arc" />
    <link:label id="lab_oncyf_ResearchAndDevelopmentMember_E7B327F4DCB1A2CCCF2C9D034C2A4983_terseLabel_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentMember_E7B327F4DCB1A2CCCF2C9D034C2A4983" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Included in research and development expenses:</link:label>
    <link:label id="lab_oncyf_ResearchAndDevelopmentMember_E7B327F4DCB1A2CCCF2C9D034C2A4983_label_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentMember_E7B327F4DCB1A2CCCF2C9D034C2A4983" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development [Member]</link:label>
    <link:label id="lab_oncyf_ResearchAndDevelopmentMember_E7B327F4DCB1A2CCCF2C9D034C2A4983_documentation_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentMember_E7B327F4DCB1A2CCCF2C9D034C2A4983" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ResearchAndDevelopmentMember" xlink:label="loc_oncyf_ResearchAndDevelopmentMember_E7B327F4DCB1A2CCCF2C9D034C2A4983" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ResearchAndDevelopmentMember_E7B327F4DCB1A2CCCF2C9D034C2A4983" xlink:to="lab_oncyf_ResearchAndDevelopmentMember_E7B327F4DCB1A2CCCF2C9D034C2A4983" xlink:type="arc" />
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C_terseLabel_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Line Items]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C_label_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Line Items]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C_documentation_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Other Expenses And Adjustments [Table]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:to="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:type="arc" />
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_B34F4D46118D8F1250BC9D034C2C0D56_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_B34F4D46118D8F1250BC9D034C2C0D56" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Realized foreign exchange (gain) loss</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_B34F4D46118D8F1250BC9D034C2C0D56_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_B34F4D46118D8F1250BC9D034C2C0D56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_B34F4D46118D8F1250BC9D034C2C0D56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_B34F4D46118D8F1250BC9D034C2C0D56" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_B34F4D46118D8F1250BC9D034C2C0D56" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_B2B6FC3F7C74D4E311FC9D034C2C121F_verboseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_B2B6FC3F7C74D4E311FC9D034C2C121F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized non-cash foreign exchange loss (gain)</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_B2B6FC3F7C74D4E311FC9D034C2C121F_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_B2B6FC3F7C74D4E311FC9D034C2C121F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for unrealised foreign exchange losses (gains)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_B2B6FC3F7C74D4E311FC9D034C2C121F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_B2B6FC3F7C74D4E311FC9D034C2C121F" xlink:to="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_B2B6FC3F7C74D4E311FC9D034C2C121F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_FA4C5C819BBCCC410C0F9D034C2C7F47_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_FA4C5C819BBCCC410C0F9D034C2C7F47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash share based compensation</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_FA4C5C819BBCCC410C0F9D034C2C7F47_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_FA4C5C819BBCCC410C0F9D034C2C7F47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from share-based payment transactions with employees</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_FA4C5C819BBCCC410C0F9D034C2C7F47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_FA4C5C819BBCCC410C0F9D034C2C7F47" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_FA4C5C819BBCCC410C0F9D034C2C7F47" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AmortisationExpense_CB7177A13F4BA7750D699D034C2C8B92_terseLabel_en-US" xlink:label="lab_ifrs-full_AmortisationExpense_CB7177A13F4BA7750D699D034C2C8B92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation - property and equipment</link:label>
    <link:label id="lab_ifrs-full_AmortisationExpense_CB7177A13F4BA7750D699D034C2C8B92_label_en-US" xlink:label="lab_ifrs-full_AmortisationExpense_CB7177A13F4BA7750D699D034C2C8B92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortisation expense</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AmortisationExpense" xlink:label="loc_ifrs-full_AmortisationExpense_CB7177A13F4BA7750D699D034C2C8B92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationExpense_CB7177A13F4BA7750D699D034C2C8B92" xlink:to="lab_ifrs-full_AmortisationExpense_CB7177A13F4BA7750D699D034C2C8B92" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_9704915AF66214B4C7B59D034C2CFF35_terseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets_9704915AF66214B4C7B59D034C2CFF35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation - right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_9704915AF66214B4C7B59D034C2CFF35_label_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets_9704915AF66214B4C7B59D034C2CFF35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, right-of-use assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_9704915AF66214B4C7B59D034C2CFF35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationRightofuseAssets_9704915AF66214B4C7B59D034C2CFF35" xlink:to="lab_ifrs-full_DepreciationRightofuseAssets_9704915AF66214B4C7B59D034C2CFF35" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AdjustmentsForProvisions_B05FCDE80428B3F7CD869D034C2D7DF4_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForProvisions_B05FCDE80428B3F7CD869D034C2D7DF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Onerous lease contract</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForProvisions_B05FCDE80428B3F7CD869D034C2D7DF4_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForProvisions_B05FCDE80428B3F7CD869D034C2D7DF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for provisions</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="loc_ifrs-full_AdjustmentsForProvisions_B05FCDE80428B3F7CD869D034C2D7DF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForProvisions_B05FCDE80428B3F7CD869D034C2D7DF4" xlink:to="lab_ifrs-full_AdjustmentsForProvisions_B05FCDE80428B3F7CD869D034C2D7DF4" xlink:type="arc" />
    <link:label id="lab_oncyf_AdjustmentsforLeaseAmortization_87EDFFC44276E0443F969D034C2D8BE3_terseLabel_en-US" xlink:label="lab_oncyf_AdjustmentsforLeaseAmortization_87EDFFC44276E0443F969D034C2D8BE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization - lease incentive liability</link:label>
    <link:label id="lab_oncyf_AdjustmentsforLeaseAmortization_87EDFFC44276E0443F969D034C2D8BE3_label_en-US" xlink:label="lab_oncyf_AdjustmentsforLeaseAmortization_87EDFFC44276E0443F969D034C2D8BE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for Lease Amortization</link:label>
    <link:label id="lab_oncyf_AdjustmentsforLeaseAmortization_87EDFFC44276E0443F969D034C2D8BE3_documentation_en-US" xlink:label="lab_oncyf_AdjustmentsforLeaseAmortization_87EDFFC44276E0443F969D034C2D8BE3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments for Lease Amortization</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_AdjustmentsforLeaseAmortization" xlink:label="loc_oncyf_AdjustmentsforLeaseAmortization_87EDFFC44276E0443F969D034C2D8BE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AdjustmentsforLeaseAmortization_87EDFFC44276E0443F969D034C2D8BE3" xlink:to="lab_oncyf_AdjustmentsforLeaseAmortization_87EDFFC44276E0443F969D034C2D8BE3" xlink:type="arc" />
    <link:label id="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_C7BE54D45B0F5438F88DA683648ED27F_label_en-US" xlink:label="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_C7BE54D45B0F5438F88DA683648ED27F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_C7BE54D45B0F5438F88DA683648ED27F_documentation_en-US" xlink:label="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_C7BE54D45B0F5438F88DA683648ED27F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_C7BE54D45B0F5438F88DA683648ED27F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_C7BE54D45B0F5438F88DA683648ED27F" xlink:to="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_C7BE54D45B0F5438F88DA683648ED27F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_80CA16A38903114E69ADA683648E41DF_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_80CA16A38903114E69ADA683648E41DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of depreciation rates</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_80CA16A38903114E69ADA683648E41DF_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_80CA16A38903114E69ADA683648E41DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_80CA16A38903114E69ADA683648E41DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_80CA16A38903114E69ADA683648E41DF" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_80CA16A38903114E69ADA683648E41DF" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_06A289ECB1C7EC7B4710A683648E0ACB_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_06A289ECB1C7EC7B4710A683648E0ACB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption of new accounting standards</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_06A289ECB1C7EC7B4710A683648E0ACB_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_06A289ECB1C7EC7B4710A683648E0ACB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of initial application of standards or interpretations [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:label="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_06A289ECB1C7EC7B4710A683648E0ACB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_06A289ECB1C7EC7B4710A683648E0ACB" xlink:to="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_06A289ECB1C7EC7B4710A683648E0ACB" xlink:type="arc" />
    <link:label id="lab_oncyf_CommitmentsAbstract_9B43D59EE8CB6AE8E0D49CFE7F1FF2DA_label_en-US" xlink:label="lab_oncyf_CommitmentsAbstract_9B43D59EE8CB6AE8E0D49CFE7F1FF2DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments [Abstract]</link:label>
    <link:label id="lab_oncyf_CommitmentsAbstract_9B43D59EE8CB6AE8E0D49CFE7F1FF2DA_documentation_en-US" xlink:label="lab_oncyf_CommitmentsAbstract_9B43D59EE8CB6AE8E0D49CFE7F1FF2DA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CommitmentsAbstract" xlink:label="loc_oncyf_CommitmentsAbstract_9B43D59EE8CB6AE8E0D49CFE7F1FF2DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommitmentsAbstract_9B43D59EE8CB6AE8E0D49CFE7F1FF2DA" xlink:to="lab_oncyf_CommitmentsAbstract_9B43D59EE8CB6AE8E0D49CFE7F1FF2DA" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_0002E3CCA421442E4C6F9CFE7F2052BC_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_0002E3CCA421442E4C6F9CFE7F2052BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_0002E3CCA421442E4C6F9CFE7F2052BC_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_0002E3CCA421442E4C6F9CFE7F2052BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of commitments [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_0002E3CCA421442E4C6F9CFE7F2052BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_0002E3CCA421442E4C6F9CFE7F2052BC" xlink:to="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_0002E3CCA421442E4C6F9CFE7F2052BC" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_8AEC44FCF7EAF12359549CFE7F6A7A91_verboseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_8AEC44FCF7EAF12359549CFE7F6A7A91" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_8AEC44FCF7EAF12359549CFE7F6A7A91_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_8AEC44FCF7EAF12359549CFE7F6A7A91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk free interest rate, share options granted</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_8AEC44FCF7EAF12359549CFE7F6A7A91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_8AEC44FCF7EAF12359549CFE7F6A7A91" xlink:to="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_8AEC44FCF7EAF12359549CFE7F6A7A91" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_82ED12DACA37796F9E8C9CFE7F6B2542_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_82ED12DACA37796F9E8C9CFE7F6B2542" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected hold period to exercise</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_82ED12DACA37796F9E8C9CFE7F6B2542_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_82ED12DACA37796F9E8C9CFE7F6B2542" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option life, share options granted</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_82ED12DACA37796F9E8C9CFE7F6B2542" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_82ED12DACA37796F9E8C9CFE7F6B2542" xlink:to="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_82ED12DACA37796F9E8C9CFE7F6B2542" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_B5ECF462A52CC7453BCC9CFE7F6B7B2E_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_B5ECF462A52CC7453BCC9CFE7F6B7B2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected share price volatility</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_B5ECF462A52CC7453BCC9CFE7F6B7B2E_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_B5ECF462A52CC7453BCC9CFE7F6B7B2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected volatility, share options granted</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_B5ECF462A52CC7453BCC9CFE7F6B7B2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_B5ECF462A52CC7453BCC9CFE7F6B7B2E" xlink:to="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_B5ECF462A52CC7453BCC9CFE7F6B7B2E" xlink:type="arc" />
    <link:label id="lab_oncyf_ExpectedForfeitureShareOptionsGranted_6872A691DEC25795DB919CFE7F6B36C3_terseLabel_en-US" xlink:label="lab_oncyf_ExpectedForfeitureShareOptionsGranted_6872A691DEC25795DB919CFE7F6B36C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected forfeiture rate</link:label>
    <link:label id="lab_oncyf_ExpectedForfeitureShareOptionsGranted_6872A691DEC25795DB919CFE7F6B36C3_label_en-US" xlink:label="lab_oncyf_ExpectedForfeitureShareOptionsGranted_6872A691DEC25795DB919CFE7F6B36C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Forfeiture, Share Options Granted</link:label>
    <link:label id="lab_oncyf_ExpectedForfeitureShareOptionsGranted_6872A691DEC25795DB919CFE7F6B36C3_documentation_en-US" xlink:label="lab_oncyf_ExpectedForfeitureShareOptionsGranted_6872A691DEC25795DB919CFE7F6B36C3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected Forfeiture, Share Options Granted</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ExpectedForfeitureShareOptionsGranted" xlink:label="loc_oncyf_ExpectedForfeitureShareOptionsGranted_6872A691DEC25795DB919CFE7F6B36C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExpectedForfeitureShareOptionsGranted_6872A691DEC25795DB919CFE7F6B36C3" xlink:to="lab_oncyf_ExpectedForfeitureShareOptionsGranted_6872A691DEC25795DB919CFE7F6B36C3" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_199E91DC36EB9C980E8E9CFE7F6BD54D_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_199E91DC36EB9C980E8E9CFE7F6BD54D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_199E91DC36EB9C980E8E9CFE7F6BD54D_label_en-US" xlink:label="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_199E91DC36EB9C980E8E9CFE7F6BD54D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected dividend as percentage, share options granted</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_199E91DC36EB9C980E8E9CFE7F6BD54D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_199E91DC36EB9C980E8E9CFE7F6BD54D" xlink:to="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_199E91DC36EB9C980E8E9CFE7F6BD54D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_EF2C07BC566561F4D8AD9CFE7F6B42E6_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_EF2C07BC566561F4D8AD9CFE7F6B42E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value of options (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_EF2C07BC566561F4D8AD9CFE7F6B42E6_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_EF2C07BC566561F4D8AD9CFE7F6B42E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average fair value at measurement date, share options granted</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_EF2C07BC566561F4D8AD9CFE7F6B42E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_EF2C07BC566561F4D8AD9CFE7F6B42E6" xlink:to="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_EF2C07BC566561F4D8AD9CFE7F6B42E6" xlink:type="arc" />
    <link:label id="lab_oncyf_ContingenciesAbstract_5A6FA890DFAF92DD979C9CFE7EB94D55_label_en-US" xlink:label="lab_oncyf_ContingenciesAbstract_5A6FA890DFAF92DD979C9CFE7EB94D55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingencies [Abstract]</link:label>
    <link:label id="lab_oncyf_ContingenciesAbstract_5A6FA890DFAF92DD979C9CFE7EB94D55_documentation_en-US" xlink:label="lab_oncyf_ContingenciesAbstract_5A6FA890DFAF92DD979C9CFE7EB94D55" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingencies [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ContingenciesAbstract" xlink:label="loc_oncyf_ContingenciesAbstract_5A6FA890DFAF92DD979C9CFE7EB94D55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ContingenciesAbstract_5A6FA890DFAF92DD979C9CFE7EB94D55" xlink:to="lab_oncyf_ContingenciesAbstract_5A6FA890DFAF92DD979C9CFE7EB94D55" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_85726CF90CE4ECB4EF509CFE7EB95964_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_85726CF90CE4ECB4EF509CFE7EB95964" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_85726CF90CE4ECB4EF509CFE7EB95964_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_85726CF90CE4ECB4EF509CFE7EB95964" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of contingent liabilities [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_85726CF90CE4ECB4EF509CFE7EB95964" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_85726CF90CE4ECB4EF509CFE7EB95964" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_85726CF90CE4ECB4EF509CFE7EB95964" xlink:type="arc" />
    <link:label id="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_8B683ECD4A21B1F0C4A29CFE7E321793_label_en-US" xlink:label="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_8B683ECD4A21B1F0C4A29CFE7E321793" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of revenue from contracts with customers [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_8B683ECD4A21B1F0C4A29CFE7E321793_documentation_en-US" xlink:label="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_8B683ECD4A21B1F0C4A29CFE7E321793" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of revenue from contracts with customers [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_8B683ECD4A21B1F0C4A29CFE7E321793" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_8B683ECD4A21B1F0C4A29CFE7E321793" xlink:to="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_8B683ECD4A21B1F0C4A29CFE7E321793" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ContractLiabilities_CD22C8BC58630B74AC899CFE7E322666_periodStartLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities_CD22C8BC58630B74AC899CFE7E322666" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, beginning of the year</link:label>
    <link:label id="lab_ifrs-full_ContractLiabilities_CD22C8BC58630B74AC899CFE7E322666_label_en-US" xlink:label="lab_ifrs-full_ContractLiabilities_CD22C8BC58630B74AC899CFE7E322666" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContractLiabilities" xlink:label="loc_ifrs-full_ContractLiabilities_CD22C8BC58630B74AC899CFE7E322666" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractLiabilities_CD22C8BC58630B74AC899CFE7E322666" xlink:to="lab_ifrs-full_ContractLiabilities_CD22C8BC58630B74AC899CFE7E322666" xlink:type="arc" />
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_CCD289440265DE97FA5D9CFE7E32BFFB_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers_CCD289440265DE97FA5D9CFE7E32BFFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regional licensing agreement</link:label>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_CCD289440265DE97FA5D9CFE7E32BFFB_label_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers_CCD289440265DE97FA5D9CFE7E32BFFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from contracts with customers</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_CCD289440265DE97FA5D9CFE7E32BFFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromContractsWithCustomers_CCD289440265DE97FA5D9CFE7E32BFFB" xlink:to="lab_ifrs-full_RevenueFromContractsWithCustomers_CCD289440265DE97FA5D9CFE7E32BFFB" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_410CB30432C7EB8DFB269CFE7E32E268_terseLabel_en-US" xlink:label="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_410CB30432C7EB8DFB269CFE7E32E268" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized in the year</link:label>
    <link:label id="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_410CB30432C7EB8DFB269CFE7E32E268_label_en-US" xlink:label="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_410CB30432C7EB8DFB269CFE7E32E268" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through performance obligation being satisfied, contract liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:label="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_410CB30432C7EB8DFB269CFE7E32E268" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_410CB30432C7EB8DFB269CFE7E32E268" xlink:to="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_410CB30432C7EB8DFB269CFE7E32E268" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ContractLiabilities_E9C69913798542F464039CFE7E323375_periodEndLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities_E9C69913798542F464039CFE7E323375" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, end of the year</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContractLiabilities" xlink:label="loc_ifrs-full_ContractLiabilities_E9C69913798542F464039CFE7E323375" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractLiabilities_E9C69913798542F464039CFE7E323375" xlink:to="lab_ifrs-full_ContractLiabilities_E9C69913798542F464039CFE7E323375" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_033853B4D35A239E38A89CFE7E338928_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities_033853B4D35A239E38A89CFE7E338928" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract liability - current</link:label>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_033853B4D35A239E38A89CFE7E338928_label_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities_033853B4D35A239E38A89CFE7E338928" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current contract liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="loc_ifrs-full_CurrentContractLiabilities_033853B4D35A239E38A89CFE7E338928" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentContractLiabilities_033853B4D35A239E38A89CFE7E338928" xlink:to="lab_ifrs-full_CurrentContractLiabilities_033853B4D35A239E38A89CFE7E338928" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_3F408A687637DE95768B9CFE7E335CFD_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities_3F408A687637DE95768B9CFE7E335CFD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract liability - non-current</link:label>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_3F408A687637DE95768B9CFE7E335CFD_label_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities_3F408A687637DE95768B9CFE7E335CFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current contract liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_3F408A687637DE95768B9CFE7E335CFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentContractLiabilities_3F408A687637DE95768B9CFE7E335CFD" xlink:to="lab_ifrs-full_NoncurrentContractLiabilities_3F408A687637DE95768B9CFE7E335CFD" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ContractLiabilities_B88EB08138F1F66D854A9CFE7E338D21_totalLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities_B88EB08138F1F66D854A9CFE7E338D21" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContractLiabilities" xlink:label="loc_ifrs-full_ContractLiabilities_B88EB08138F1F66D854A9CFE7E338D21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractLiabilities_B88EB08138F1F66D854A9CFE7E338D21" xlink:to="lab_ifrs-full_ContractLiabilities_B88EB08138F1F66D854A9CFE7E338D21" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_C99E48F642AEEB2FA4269CFE7F1E163E_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_C99E48F642AEEB2FA4269CFE7F1E163E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_C99E48F642AEEB2FA4269CFE7F1E163E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_C99E48F642AEEB2FA4269CFE7F1E163E" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_C99E48F642AEEB2FA4269CFE7F1E163E" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_20EB8C8B7D65D6A78E689CFE7F1EF419_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_20EB8C8B7D65D6A78E689CFE7F1EF419" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_20EB8C8B7D65D6A78E689CFE7F1EF419" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_20EB8C8B7D65D6A78E689CFE7F1EF419" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_20EB8C8B7D65D6A78E689CFE7F1EF419" xlink:type="arc" />
    <link:label id="lab_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable_2DE52C6FF47771BA1CE19CFE7E742456_terseLabel_en-US" xlink:label="lab_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable_2DE52C6FF47771BA1CE19CFE7E742456" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract receivable</link:label>
    <link:label id="lab_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable_2DE52C6FF47771BA1CE19CFE7E742456_label_en-US" xlink:label="lab_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable_2DE52C6FF47771BA1CE19CFE7E742456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for Decrease (Increase) in Contract Receivable</link:label>
    <link:label id="lab_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable_2DE52C6FF47771BA1CE19CFE7E742456_documentation_en-US" xlink:label="lab_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable_2DE52C6FF47771BA1CE19CFE7E742456" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments for Decrease (Increase) in Contract Receivable</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable" xlink:label="loc_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable_2DE52C6FF47771BA1CE19CFE7E742456" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable_2DE52C6FF47771BA1CE19CFE7E742456" xlink:to="lab_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable_2DE52C6FF47771BA1CE19CFE7E742456" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_581C19E59644BBA676E99CFE7E749184_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_581C19E59644BBA676E99CFE7E749184" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_581C19E59644BBA676E99CFE7E749184_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_581C19E59644BBA676E99CFE7E749184" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in other operating receivables</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_581C19E59644BBA676E99CFE7E749184" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_581C19E59644BBA676E99CFE7E749184" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_581C19E59644BBA676E99CFE7E749184" xlink:type="arc" />
    <link:label id="lab_oncyf_IncreaseDecreaseinPrepaidExpense1_05DFC203BF89D141BF299CFE7E745CD5_terseLabel_en-US" xlink:label="lab_oncyf_IncreaseDecreaseinPrepaidExpense1_05DFC203BF89D141BF299CFE7E745CD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseinPrepaidExpense1_05DFC203BF89D141BF299CFE7E745CD5_label_en-US" xlink:label="lab_oncyf_IncreaseDecreaseinPrepaidExpense1_05DFC203BF89D141BF299CFE7E745CD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense1</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseinPrepaidExpense1_05DFC203BF89D141BF299CFE7E745CD5_documentation_en-US" xlink:label="lab_oncyf_IncreaseDecreaseinPrepaidExpense1_05DFC203BF89D141BF299CFE7E745CD5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense1</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IncreaseDecreaseinPrepaidExpense1" xlink:label="loc_oncyf_IncreaseDecreaseinPrepaidExpense1_05DFC203BF89D141BF299CFE7E745CD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncreaseDecreaseinPrepaidExpense1_05DFC203BF89D141BF299CFE7E745CD5" xlink:to="lab_oncyf_IncreaseDecreaseinPrepaidExpense1_05DFC203BF89D141BF299CFE7E745CD5" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_2E3F56CCE1CD56B70AA99CFE7E74CB66_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_2E3F56CCE1CD56B70AA99CFE7E74CB66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_2E3F56CCE1CD56B70AA99CFE7E74CB66_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_2E3F56CCE1CD56B70AA99CFE7E74CB66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_2E3F56CCE1CD56B70AA99CFE7E74CB66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_2E3F56CCE1CD56B70AA99CFE7E74CB66" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_2E3F56CCE1CD56B70AA99CFE7E74CB66" xlink:type="arc" />
    <link:label id="lab_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities_E212F578F15B66B69E639CFE7E7554CC_terseLabel_en-US" xlink:label="lab_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities_E212F578F15B66B69E639CFE7E7554CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liability</link:label>
    <link:label id="lab_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities_E212F578F15B66B69E639CFE7E7554CC_label_en-US" xlink:label="lab_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities_E212F578F15B66B69E639CFE7E7554CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for Increase (Decrease) in Contract Liabilities</link:label>
    <link:label id="lab_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities_E212F578F15B66B69E639CFE7E7554CC_documentation_en-US" xlink:label="lab_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities_E212F578F15B66B69E639CFE7E7554CC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments for Increase (Decrease) in Contract Liabilities</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities" xlink:label="loc_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities_E212F578F15B66B69E639CFE7E7554CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities_E212F578F15B66B69E639CFE7E7554CC" xlink:to="lab_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities_E212F578F15B66B69E639CFE7E7554CC" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_9CD92B7AA5BAB1C4C5229CFE7E7591AB_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_9CD92B7AA5BAB1C4C5229CFE7E7591AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_9CD92B7AA5BAB1C4C5229CFE7E7591AB_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_9CD92B7AA5BAB1C4C5229CFE7E7591AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in other operating payables</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_9CD92B7AA5BAB1C4C5229CFE7E7591AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_9CD92B7AA5BAB1C4C5229CFE7E7591AB" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_9CD92B7AA5BAB1C4C5229CFE7E7591AB" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_3D8F50953BC3C86969E59CFE7E750786_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_3D8F50953BC3C86969E59CFE7E750786" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash impact of foreign exchange</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_3D8F50953BC3C86969E59CFE7E750786_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_3D8F50953BC3C86969E59CFE7E750786" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through foreign exchange, financial assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_3D8F50953BC3C86969E59CFE7E750786" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_3D8F50953BC3C86969E59CFE7E750786" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_3D8F50953BC3C86969E59CFE7E750786" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_145DD60D9D76E577CCC59CFE7E759205_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_145DD60D9D76E577CCC59CFE7E759205" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Change in non-cash working capital related to operating activities</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_145DD60D9D76E577CCC59CFE7E759205_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_145DD60D9D76E577CCC59CFE7E759205" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in working capital</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_145DD60D9D76E577CCC59CFE7E759205" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_145DD60D9D76E577CCC59CFE7E759205" xlink:to="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_145DD60D9D76E577CCC59CFE7E759205" xlink:type="arc" />
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_EACDADBB1F80ED0F5173A33960114ACA_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_EACDADBB1F80ED0F5173A33960114ACA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term employee compensation and benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_EACDADBB1F80ED0F5173A33960114ACA_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_EACDADBB1F80ED0F5173A33960114ACA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_EACDADBB1F80ED0F5173A33960114ACA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_EACDADBB1F80ED0F5173A33960114ACA" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_EACDADBB1F80ED0F5173A33960114ACA" xlink:type="arc" />
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_C8693E426EB5E61425AEA33960126455_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_C8693E426EB5E61425AEA33960126455" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_C8693E426EB5E61425AEA33960126455_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_C8693E426EB5E61425AEA33960126455" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, termination benefits</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_C8693E426EB5E61425AEA33960126455" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_C8693E426EB5E61425AEA33960126455" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_C8693E426EB5E61425AEA33960126455" xlink:type="arc" />
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_F4BBB6DD9DE69F93B6A2A3396012582A_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_F4BBB6DD9DE69F93B6A2A3396012582A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payments</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_F4BBB6DD9DE69F93B6A2A3396012582A_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_F4BBB6DD9DE69F93B6A2A3396012582A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, share-based payment</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_F4BBB6DD9DE69F93B6A2A3396012582A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_F4BBB6DD9DE69F93B6A2A3396012582A" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_F4BBB6DD9DE69F93B6A2A3396012582A" xlink:type="arc" />
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_6513CD1E53C874142E67A33960122C5D_totalLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation_6513CD1E53C874142E67A33960122C5D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Compensation of key management personnel</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_6513CD1E53C874142E67A33960122C5D_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation_6513CD1E53C874142E67A33960122C5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_6513CD1E53C874142E67A33960122C5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_6513CD1E53C874142E67A33960122C5D" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensation_6513CD1E53C874142E67A33960122C5D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_D91886DA9D8110A64FB6A3396012BFA0_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_D91886DA9D8110A64FB6A3396012BFA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability to officer</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_D91886DA9D8110A64FB6A3396012BFA0_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_D91886DA9D8110A64FB6A3396012BFA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current payables to related parties</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_D91886DA9D8110A64FB6A3396012BFA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_D91886DA9D8110A64FB6A3396012BFA0" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_D91886DA9D8110A64FB6A3396012BFA0" xlink:type="arc" />
    <link:label id="lab_oncyf_PurchaseObligation1_756042FEFF1490CC9CAE9CFE7E216BE3_terseLabel_en-US" xlink:label="lab_oncyf_PurchaseObligation1_756042FEFF1490CC9CAE9CFE7E216BE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment for payment</link:label>
    <link:label id="lab_oncyf_PurchaseObligation1_756042FEFF1490CC9CAE9CFE7E216BE3_label_en-US" xlink:label="lab_oncyf_PurchaseObligation1_756042FEFF1490CC9CAE9CFE7E216BE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation1</link:label>
    <link:label id="lab_oncyf_PurchaseObligation1_756042FEFF1490CC9CAE9CFE7E216BE3_documentation_en-US" xlink:label="lab_oncyf_PurchaseObligation1_756042FEFF1490CC9CAE9CFE7E216BE3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Obligation1</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_PurchaseObligation1" xlink:label="loc_oncyf_PurchaseObligation1_756042FEFF1490CC9CAE9CFE7E216BE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PurchaseObligation1_756042FEFF1490CC9CAE9CFE7E216BE3" xlink:to="lab_oncyf_PurchaseObligation1_756042FEFF1490CC9CAE9CFE7E216BE3" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsTable_5ACC3592B5984E8B409E9CFE7E229E79_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsTable_5ACC3592B5984E8B409E9CFE7E229E79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsTable_5ACC3592B5984E8B409E9CFE7E229E79_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsTable_5ACC3592B5984E8B409E9CFE7E229E79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_5ACC3592B5984E8B409E9CFE7E229E79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_5ACC3592B5984E8B409E9CFE7E229E79" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsTable_5ACC3592B5984E8B409E9CFE7E229E79" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_B2985E1165D7CDF440049CFE7E22F1EB_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis_B2985E1165D7CDF440049CFE7E22F1EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of other provisions [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_B2985E1165D7CDF440049CFE7E22F1EB_label_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis_B2985E1165D7CDF440049CFE7E22F1EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of other provisions [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_B2985E1165D7CDF440049CFE7E22F1EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_B2985E1165D7CDF440049CFE7E22F1EB" xlink:to="lab_ifrs-full_ClassesOfProvisionsAxis_B2985E1165D7CDF440049CFE7E22F1EB" xlink:type="arc" />
    <link:label id="lab_ifrs-full_OtherProvisionsMember_555BE089A395562308BF9CFE7E223119_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherProvisionsMember_555BE089A395562308BF9CFE7E223119" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other provisions [member]</link:label>
    <link:label id="lab_ifrs-full_OtherProvisionsMember_555BE089A395562308BF9CFE7E223119_label_en-US" xlink:label="lab_ifrs-full_OtherProvisionsMember_555BE089A395562308BF9CFE7E223119" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other provisions [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherProvisionsMember" xlink:label="loc_ifrs-full_OtherProvisionsMember_555BE089A395562308BF9CFE7E223119" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherProvisionsMember_555BE089A395562308BF9CFE7E223119" xlink:to="lab_ifrs-full_OtherProvisionsMember_555BE089A395562308BF9CFE7E223119" xlink:type="arc" />
    <link:label id="lab_oncyf_CollaborationAgreementMember_6C2210EF879BAD5BB4A99CFE7E22990A_terseLabel_en-US" xlink:label="lab_oncyf_CollaborationAgreementMember_6C2210EF879BAD5BB4A99CFE7E22990A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BRACELET-1 collaboration agreement</link:label>
    <link:label id="lab_oncyf_CollaborationAgreementMember_6C2210EF879BAD5BB4A99CFE7E22990A_label_en-US" xlink:label="lab_oncyf_CollaborationAgreementMember_6C2210EF879BAD5BB4A99CFE7E22990A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
    <link:label id="lab_oncyf_CollaborationAgreementMember_6C2210EF879BAD5BB4A99CFE7E22990A_documentation_en-US" xlink:label="lab_oncyf_CollaborationAgreementMember_6C2210EF879BAD5BB4A99CFE7E22990A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CollaborationAgreementMember" xlink:label="loc_oncyf_CollaborationAgreementMember_6C2210EF879BAD5BB4A99CFE7E22990A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CollaborationAgreementMember_6C2210EF879BAD5BB4A99CFE7E22990A" xlink:to="lab_oncyf_CollaborationAgreementMember_6C2210EF879BAD5BB4A99CFE7E22990A" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems_2F95792481FC493CAD919CFE7E237784_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems_2F95792481FC493CAD919CFE7E237784" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems_2F95792481FC493CAD919CFE7E237784_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems_2F95792481FC493CAD919CFE7E237784" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_2F95792481FC493CAD919CFE7E237784" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_2F95792481FC493CAD919CFE7E237784" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems_2F95792481FC493CAD919CFE7E237784" xlink:type="arc" />
    <link:label id="lab_ifrs-full_OtherReceivables_3B5D5386014FFBE38C509CFE7E231A20_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherReceivables_3B5D5386014FFBE38C509CFE7E231A20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_ifrs-full_OtherReceivables_3B5D5386014FFBE38C509CFE7E231A20_label_en-US" xlink:label="lab_ifrs-full_OtherReceivables_3B5D5386014FFBE38C509CFE7E231A20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherReceivables" xlink:label="loc_ifrs-full_OtherReceivables_3B5D5386014FFBE38C509CFE7E231A20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReceivables_3B5D5386014FFBE38C509CFE7E231A20" xlink:to="lab_ifrs-full_OtherReceivables_3B5D5386014FFBE38C509CFE7E231A20" xlink:type="arc" />
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_97A7A3C418BCBF8806E69CFE7E239236_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities_97A7A3C418BCBF8806E69CFE7E239236" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_97A7A3C418BCBF8806E69CFE7E239236_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities_97A7A3C418BCBF8806E69CFE7E239236" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_97A7A3C418BCBF8806E69CFE7E239236" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentLiabilities_97A7A3C418BCBF8806E69CFE7E239236" xlink:to="lab_ifrs-full_OtherCurrentLiabilities_97A7A3C418BCBF8806E69CFE7E239236" xlink:type="arc" />
    <link:label id="lab_oncyf_FundedandRoyaltyRepayment_FE2DC9DD32A123780B4E9CFE7E23FF98_terseLabel_en-US" xlink:label="lab_oncyf_FundedandRoyaltyRepayment_FE2DC9DD32A123780B4E9CFE7E23FF98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment, maximum</link:label>
    <link:label id="lab_oncyf_FundedandRoyaltyRepayment_FE2DC9DD32A123780B4E9CFE7E23FF98_label_en-US" xlink:label="lab_oncyf_FundedandRoyaltyRepayment_FE2DC9DD32A123780B4E9CFE7E23FF98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Funded and Royalty Repayment</link:label>
    <link:label id="lab_oncyf_FundedandRoyaltyRepayment_FE2DC9DD32A123780B4E9CFE7E23FF98_documentation_en-US" xlink:label="lab_oncyf_FundedandRoyaltyRepayment_FE2DC9DD32A123780B4E9CFE7E23FF98" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Funded and Royalty Repayment</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_FundedandRoyaltyRepayment" xlink:label="loc_oncyf_FundedandRoyaltyRepayment_FE2DC9DD32A123780B4E9CFE7E23FF98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_FundedandRoyaltyRepayment_FE2DC9DD32A123780B4E9CFE7E23FF98" xlink:to="lab_oncyf_FundedandRoyaltyRepayment_FE2DC9DD32A123780B4E9CFE7E23FF98" xlink:type="arc" />
    <link:label id="lab_oncyf_OverheadRepayment_B77FDF51ACD02B2E9E349CFE7E231FFF_terseLabel_en-US" xlink:label="lab_oncyf_OverheadRepayment_B77FDF51ACD02B2E9E349CFE7E231FFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overhead repayment</link:label>
    <link:label id="lab_oncyf_OverheadRepayment_B77FDF51ACD02B2E9E349CFE7E231FFF_label_en-US" xlink:label="lab_oncyf_OverheadRepayment_B77FDF51ACD02B2E9E349CFE7E231FFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Overhead Repayment</link:label>
    <link:label id="lab_oncyf_OverheadRepayment_B77FDF51ACD02B2E9E349CFE7E231FFF_documentation_en-US" xlink:label="lab_oncyf_OverheadRepayment_B77FDF51ACD02B2E9E349CFE7E231FFF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Overhead Repayment</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OverheadRepayment" xlink:label="loc_oncyf_OverheadRepayment_B77FDF51ACD02B2E9E349CFE7E231FFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OverheadRepayment_B77FDF51ACD02B2E9E349CFE7E231FFF" xlink:to="lab_oncyf_OverheadRepayment_B77FDF51ACD02B2E9E349CFE7E231FFF" xlink:type="arc" />
    <link:label id="lab_oncyf_AnnualContingentPaymentGrossSalesPercent_22BC4F1577E5CD8A9CFB9CFE7E24340F_terseLabel_en-US" xlink:label="lab_oncyf_AnnualContingentPaymentGrossSalesPercent_22BC4F1577E5CD8A9CFB9CFE7E24340F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual installment of gross sales of product, percent</link:label>
    <link:label id="lab_oncyf_AnnualContingentPaymentGrossSalesPercent_22BC4F1577E5CD8A9CFB9CFE7E24340F_label_en-US" xlink:label="lab_oncyf_AnnualContingentPaymentGrossSalesPercent_22BC4F1577E5CD8A9CFB9CFE7E24340F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Contingent Payment, Gross Sales, Percent</link:label>
    <link:label id="lab_oncyf_AnnualContingentPaymentGrossSalesPercent_22BC4F1577E5CD8A9CFB9CFE7E24340F_documentation_en-US" xlink:label="lab_oncyf_AnnualContingentPaymentGrossSalesPercent_22BC4F1577E5CD8A9CFB9CFE7E24340F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual Contingent Payment, Gross Sales, Percent</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_AnnualContingentPaymentGrossSalesPercent" xlink:label="loc_oncyf_AnnualContingentPaymentGrossSalesPercent_22BC4F1577E5CD8A9CFB9CFE7E24340F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AnnualContingentPaymentGrossSalesPercent_22BC4F1577E5CD8A9CFB9CFE7E24340F" xlink:to="lab_oncyf_AnnualContingentPaymentGrossSalesPercent_22BC4F1577E5CD8A9CFB9CFE7E24340F" xlink:type="arc" />
    <link:label id="lab_oncyf_AnnualContingentPayment_EAC8588795C7E20DB3A69CFE7E24467E_terseLabel_en-US" xlink:label="lab_oncyf_AnnualContingentPayment_EAC8588795C7E20DB3A69CFE7E24467E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual installment of annual product sales</link:label>
    <link:label id="lab_oncyf_AnnualContingentPayment_EAC8588795C7E20DB3A69CFE7E24467E_label_en-US" xlink:label="lab_oncyf_AnnualContingentPayment_EAC8588795C7E20DB3A69CFE7E24467E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Contingent Payment</link:label>
    <link:label id="lab_oncyf_AnnualContingentPayment_EAC8588795C7E20DB3A69CFE7E24467E_documentation_en-US" xlink:label="lab_oncyf_AnnualContingentPayment_EAC8588795C7E20DB3A69CFE7E24467E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual Contingent Payment</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_AnnualContingentPayment" xlink:label="loc_oncyf_AnnualContingentPayment_EAC8588795C7E20DB3A69CFE7E24467E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AnnualContingentPayment_EAC8588795C7E20DB3A69CFE7E24467E" xlink:to="lab_oncyf_AnnualContingentPayment_EAC8588795C7E20DB3A69CFE7E24467E" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory_115FFA229E6B52A98BF29CFE7F99B952_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory_115FFA229E6B52A98BF29CFE7F99B952" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Cash Flow Disclosures</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory_115FFA229E6B52A98BF29CFE7F99B952_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory_115FFA229E6B52A98BF29CFE7F99B952" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of cash flow statement [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory_115FFA229E6B52A98BF29CFE7F99B952" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory_115FFA229E6B52A98BF29CFE7F99B952" xlink:to="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory_115FFA229E6B52A98BF29CFE7F99B952" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfLeasesExplanatory_429713E11AC053A6A93B9CFE7F498932_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory_429713E11AC053A6A93B9CFE7F498932" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfLeasesExplanatory_429713E11AC053A6A93B9CFE7F498932_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory_429713E11AC053A6A93B9CFE7F498932" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of leases [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory_429713E11AC053A6A93B9CFE7F498932" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfLeasesExplanatory_429713E11AC053A6A93B9CFE7F498932" xlink:to="lab_ifrs-full_DisclosureOfLeasesExplanatory_429713E11AC053A6A93B9CFE7F498932" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_C48E0765F1AAB51324D1A7434B169902_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_C48E0765F1AAB51324D1A7434B169902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_C48E0765F1AAB51324D1A7434B169902" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_C48E0765F1AAB51324D1A7434B169902" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_C48E0765F1AAB51324D1A7434B169902" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5330F63BA4F1976374A9A7434B17D188_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5330F63BA4F1976374A9A7434B17D188" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5330F63BA4F1976374A9A7434B17D188_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5330F63BA4F1976374A9A7434B17D188" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5330F63BA4F1976374A9A7434B17D188" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5330F63BA4F1976374A9A7434B17D188" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5330F63BA4F1976374A9A7434B17D188" xlink:type="arc" />
    <link:label id="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_09B0E26E1E43869B2D3FA7D00E87C175_terseLabel_en-US" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_09B0E26E1E43869B2D3FA7D00E87C175" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
    <link:label id="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_09B0E26E1E43869B2D3FA7D00E87C175_label_en-US" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_09B0E26E1E43869B2D3FA7D00E87C175" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_09B0E26E1E43869B2D3FA7D00E87C175" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_09B0E26E1E43869B2D3FA7D00E87C175" xlink:to="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_09B0E26E1E43869B2D3FA7D00E87C175" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember_120CC4EEFB1C5AF12C4FA7D1B8A6C4E6_terseLabel_en-US" xlink:label="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember_120CC4EEFB1C5AF12C4FA7D1B8A6C4E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All levels of fair value hierarchy [member]</link:label>
    <link:label id="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember_120CC4EEFB1C5AF12C4FA7D1B8A6C4E6_label_en-US" xlink:label="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember_120CC4EEFB1C5AF12C4FA7D1B8A6C4E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All levels of fair value hierarchy [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_120CC4EEFB1C5AF12C4FA7D1B8A6C4E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_120CC4EEFB1C5AF12C4FA7D1B8A6C4E6" xlink:to="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember_120CC4EEFB1C5AF12C4FA7D1B8A6C4E6" xlink:type="arc" />
    <link:label id="lab_ifrs-full_Level2OfFairValueHierarchyMember_8BA3A1E7521EFB98AA8CA7D05615D2E1_terseLabel_en-US" xlink:label="lab_ifrs-full_Level2OfFairValueHierarchyMember_8BA3A1E7521EFB98AA8CA7D05615D2E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_ifrs-full_Level2OfFairValueHierarchyMember_8BA3A1E7521EFB98AA8CA7D05615D2E1_label_en-US" xlink:label="lab_ifrs-full_Level2OfFairValueHierarchyMember_8BA3A1E7521EFB98AA8CA7D05615D2E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Level 2 of fair value hierarchy [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_8BA3A1E7521EFB98AA8CA7D05615D2E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level2OfFairValueHierarchyMember_8BA3A1E7521EFB98AA8CA7D05615D2E1" xlink:to="lab_ifrs-full_Level2OfFairValueHierarchyMember_8BA3A1E7521EFB98AA8CA7D05615D2E1" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_963D21F4188DF90FBA48A7434B17B8D9_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis_963D21F4188DF90FBA48A7434B17B8D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_963D21F4188DF90FBA48A7434B17B8D9_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis_963D21F4188DF90FBA48A7434B17B8D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_963D21F4188DF90FBA48A7434B17B8D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksAxis_963D21F4188DF90FBA48A7434B17B8D9" xlink:to="lab_ifrs-full_TypesOfRisksAxis_963D21F4188DF90FBA48A7434B17B8D9" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TypesOfRisksMember_4006E99ADE823319600EA7434B17C4EA_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksMember_4006E99ADE823319600EA7434B17C4EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risks [member]</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksMember_4006E99ADE823319600EA7434B17C4EA_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksMember_4006E99ADE823319600EA7434B17C4EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_4006E99ADE823319600EA7434B17C4EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksMember_4006E99ADE823319600EA7434B17C4EA" xlink:to="lab_ifrs-full_TypesOfRisksMember_4006E99ADE823319600EA7434B17C4EA" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrencyRiskMember_844CB93577A121C80EFAA7434B17D05B_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember_844CB93577A121C80EFAA7434B17D05B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency risk</link:label>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_844CB93577A121C80EFAA7434B17D05B_label_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember_844CB93577A121C80EFAA7434B17D05B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency risk [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember_844CB93577A121C80EFAA7434B17D05B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrencyRiskMember_844CB93577A121C80EFAA7434B17D05B" xlink:to="lab_ifrs-full_CurrencyRiskMember_844CB93577A121C80EFAA7434B17D05B" xlink:type="arc" />
    <link:label id="lab_oncyf_Currency1Axis_A7238C6A26FEDE6BE9E1A7434B177CDA_terseLabel_en-US" xlink:label="lab_oncyf_Currency1Axis_A7238C6A26FEDE6BE9E1A7434B177CDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency1 [Axis]</link:label>
    <link:label id="lab_oncyf_Currency1Axis_A7238C6A26FEDE6BE9E1A7434B177CDA_label_en-US" xlink:label="lab_oncyf_Currency1Axis_A7238C6A26FEDE6BE9E1A7434B177CDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency1 [Axis]</link:label>
    <link:label id="lab_oncyf_Currency1Axis_A7238C6A26FEDE6BE9E1A7434B177CDA_documentation_en-US" xlink:label="lab_oncyf_Currency1Axis_A7238C6A26FEDE6BE9E1A7434B177CDA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Currency1 [Axis]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_Currency1Axis" xlink:label="loc_oncyf_Currency1Axis_A7238C6A26FEDE6BE9E1A7434B177CDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Currency1Axis_A7238C6A26FEDE6BE9E1A7434B177CDA" xlink:to="lab_oncyf_Currency1Axis_A7238C6A26FEDE6BE9E1A7434B177CDA" xlink:type="arc" />
    <link:label id="lab_currency_AllCurrenciesDomain_4883E80C372768C88001A7434B170EAD_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain_4883E80C372768C88001A7434B170EAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_4883E80C372768C88001A7434B170EAD_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain_4883E80C372768C88001A7434B170EAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_4883E80C372768C88001A7434B170EAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain_4883E80C372768C88001A7434B170EAD" xlink:to="lab_currency_AllCurrenciesDomain_4883E80C372768C88001A7434B170EAD" xlink:type="arc" />
    <link:label id="lab_currency_USD_B91EA2F65641422E5111A7434B179A18_terseLabel_en-US" xlink:label="lab_currency_USD_B91EA2F65641422E5111A7434B179A18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US dollars $</link:label>
    <link:label id="lab_currency_USD_B91EA2F65641422E5111A7434B179A18_label_en-US" xlink:label="lab_currency_USD_B91EA2F65641422E5111A7434B179A18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_USD" xlink:label="loc_currency_USD_B91EA2F65641422E5111A7434B179A18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD_B91EA2F65641422E5111A7434B179A18" xlink:to="lab_currency_USD_B91EA2F65641422E5111A7434B179A18" xlink:type="arc" />
    <link:label id="lab_currency_GBP_ED00049E5BCBD7D27BF2A7434B17637F_terseLabel_en-US" xlink:label="lab_currency_GBP_ED00049E5BCBD7D27BF2A7434B17637F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">British pounds &#163;</link:label>
    <link:label id="lab_currency_GBP_ED00049E5BCBD7D27BF2A7434B17637F_label_en-US" xlink:label="lab_currency_GBP_ED00049E5BCBD7D27BF2A7434B17637F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_ED00049E5BCBD7D27BF2A7434B17637F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP_ED00049E5BCBD7D27BF2A7434B17637F" xlink:to="lab_currency_GBP_ED00049E5BCBD7D27BF2A7434B17637F" xlink:type="arc" />
    <link:label id="lab_currency_EUR_71A78E87A242258860A0A7434B17EE5D_terseLabel_en-US" xlink:label="lab_currency_EUR_71A78E87A242258860A0A7434B17EE5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Euro &#8364;</link:label>
    <link:label id="lab_currency_EUR_71A78E87A242258860A0A7434B17EE5D_label_en-US" xlink:label="lab_currency_EUR_71A78E87A242258860A0A7434B17EE5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_71A78E87A242258860A0A7434B17EE5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_71A78E87A242258860A0A7434B17EE5D" xlink:to="lab_currency_EUR_71A78E87A242258860A0A7434B17EE5D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_43A35A9342D53467920AA7434B17635A_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_43A35A9342D53467920AA7434B17635A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_43A35A9342D53467920AA7434B17635A_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_43A35A9342D53467920AA7434B17635A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_43A35A9342D53467920AA7434B17635A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_43A35A9342D53467920AA7434B17635A" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_43A35A9342D53467920AA7434B17635A" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_8E1A76470D0EDF71DAF4A7434B1BB4A7_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_8E1A76470D0EDF71DAF4A7434B1BB4A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant derivative</link:label>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_8E1A76470D0EDF71DAF4A7434B1BB4A7_label_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_8E1A76470D0EDF71DAF4A7434B1BB4A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current derivative financial liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_8E1A76470D0EDF71DAF4A7434B1BB4A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_8E1A76470D0EDF71DAF4A7434B1BB4A7" xlink:to="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_8E1A76470D0EDF71DAF4A7434B1BB4A7" xlink:type="arc" />
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_510A3D9A64A7AED3A721A7434B1B24B7_terseLabel_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_510A3D9A64A7AED3A721A7434B1B24B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of increase in value of currency, amount</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_510A3D9A64A7AED3A721A7434B1B24B7_label_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_510A3D9A64A7AED3A721A7434B1B24B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Amount</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_510A3D9A64A7AED3A721A7434B1B24B7_documentation_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_510A3D9A64A7AED3A721A7434B1B24B7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A reference variable for a specific type of market risk, defined in non-percentage terms. Positive value indicates an increase; negative value indicates a decrease.</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_510A3D9A64A7AED3A721A7434B1B24B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_510A3D9A64A7AED3A721A7434B1B24B7" xlink:to="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_510A3D9A64A7AED3A721A7434B1B24B7" xlink:type="arc" />
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_6D96D594EA1456A9E006A7434B1BFFFC_negatedTerseLabel_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_6D96D594EA1456A9E006A7434B1BFFFC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Increase) decrease in net loss due to change in currency value</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_6D96D594EA1456A9E006A7434B1BFFFC_label_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_6D96D594EA1456A9E006A7434B1BFFFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_6D96D594EA1456A9E006A7434B1BFFFC_documentation_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_6D96D594EA1456A9E006A7434B1BFFFC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_6D96D594EA1456A9E006A7434B1BFFFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_6D96D594EA1456A9E006A7434B1BFFFC" xlink:to="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_6D96D594EA1456A9E006A7434B1BFFFC" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_2C9D441EF9C78449D009A7B39102CB70_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_2C9D441EF9C78449D009A7B39102CB70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Derivative</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_2C9D441EF9C78449D009A7B39102CB70_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_2C9D441EF9C78449D009A7B39102CB70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_2C9D441EF9C78449D009A7B39102CB70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_2C9D441EF9C78449D009A7B39102CB70" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_2C9D441EF9C78449D009A7B39102CB70" xlink:type="arc" />
    <link:label id="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_1126701DB10B8824FEDE9CFE7ECD868C_label_en-US" xlink:label="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_1126701DB10B8824FEDE9CFE7ECD868C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Judgments, Estimates And Assumptions [Abstract]</link:label>
    <link:label id="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_1126701DB10B8824FEDE9CFE7ECD868C_documentation_en-US" xlink:label="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_1126701DB10B8824FEDE9CFE7ECD868C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Significant Judgments, Estimates And Assumptions [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:label="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_1126701DB10B8824FEDE9CFE7ECD868C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_1126701DB10B8824FEDE9CFE7ECD868C" xlink:to="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_1126701DB10B8824FEDE9CFE7ECD868C" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_4004C00AD6EE697196B59CFE7ECE6C5A_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_4004C00AD6EE697196B59CFE7ECE6C5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Judgments, Estimates and Assumptions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_4004C00AD6EE697196B59CFE7ECE6C5A_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_4004C00AD6EE697196B59CFE7ECE6C5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of accounting judgements and estimates [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_4004C00AD6EE697196B59CFE7ECE6C5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_4004C00AD6EE697196B59CFE7ECE6C5A" xlink:to="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_4004C00AD6EE697196B59CFE7ECE6C5A" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_88FCB4813D6808C4444FA1D3F307601A_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_88FCB4813D6808C4444FA1D3F307601A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Capital</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_88FCB4813D6808C4444FA1D3F307601A_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_88FCB4813D6808C4444FA1D3F307601A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_88FCB4813D6808C4444FA1D3F307601A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_88FCB4813D6808C4444FA1D3F307601A" xlink:to="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_88FCB4813D6808C4444FA1D3F307601A" xlink:type="arc" />
    <link:label id="lab_oncyf_DocumentAndEntityInformationAbstract_CE3419E08C21BB84806FA33962B84CF6_label_en-US" xlink:label="lab_oncyf_DocumentAndEntityInformationAbstract_CE3419E08C21BB84806FA33962B84CF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_oncyf_DocumentAndEntityInformationAbstract_CE3419E08C21BB84806FA33962B84CF6_documentation_en-US" xlink:label="lab_oncyf_DocumentAndEntityInformationAbstract_CE3419E08C21BB84806FA33962B84CF6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DocumentAndEntityInformationAbstract" xlink:label="loc_oncyf_DocumentAndEntityInformationAbstract_CE3419E08C21BB84806FA33962B84CF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_CE3419E08C21BB84806FA33962B84CF6" xlink:to="lab_oncyf_DocumentAndEntityInformationAbstract_CE3419E08C21BB84806FA33962B84CF6" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_EFA9079EE1708E38C542A33962B8F59D_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_EFA9079EE1708E38C542A33962B8F59D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_EFA9079EE1708E38C542A33962B8F59D_label_en-US" xlink:label="lab_dei_EntityRegistrantName_EFA9079EE1708E38C542A33962B8F59D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_EFA9079EE1708E38C542A33962B8F59D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_EFA9079EE1708E38C542A33962B8F59D" xlink:to="lab_dei_EntityRegistrantName_EFA9079EE1708E38C542A33962B8F59D" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_CF3213EC33564260E03BA33962B91D80_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_CF3213EC33564260E03BA33962B91D80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_CF3213EC33564260E03BA33962B91D80_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_CF3213EC33564260E03BA33962B91D80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_CF3213EC33564260E03BA33962B91D80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_CF3213EC33564260E03BA33962B91D80" xlink:to="lab_dei_EntityCentralIndexKey_CF3213EC33564260E03BA33962B91D80" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_79C14B86A52B40A11907A33962B9C82C_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_79C14B86A52B40A11907A33962B9C82C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_79C14B86A52B40A11907A33962B9C82C_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_79C14B86A52B40A11907A33962B9C82C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_79C14B86A52B40A11907A33962B9C82C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_79C14B86A52B40A11907A33962B9C82C" xlink:to="lab_dei_CurrentFiscalYearEndDate_79C14B86A52B40A11907A33962B9C82C" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_131A5769AE322912B762A33962B97577_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_131A5769AE322912B762A33962B97577" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_131A5769AE322912B762A33962B97577_label_en-US" xlink:label="lab_dei_EntityFilerCategory_131A5769AE322912B762A33962B97577" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_131A5769AE322912B762A33962B97577" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_131A5769AE322912B762A33962B97577" xlink:to="lab_dei_EntityFilerCategory_131A5769AE322912B762A33962B97577" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_BD19F778984D6ADDFF6DA33962B97272_terseLabel_en-US" xlink:label="lab_dei_DocumentType_BD19F778984D6ADDFF6DA33962B97272" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_BD19F778984D6ADDFF6DA33962B97272_label_en-US" xlink:label="lab_dei_DocumentType_BD19F778984D6ADDFF6DA33962B97272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_BD19F778984D6ADDFF6DA33962B97272" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_BD19F778984D6ADDFF6DA33962B97272" xlink:to="lab_dei_DocumentType_BD19F778984D6ADDFF6DA33962B97272" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_BDA7EC3A5B7A48F0AA2EA33962B961DB_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_BDA7EC3A5B7A48F0AA2EA33962B961DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_BDA7EC3A5B7A48F0AA2EA33962B961DB_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_BDA7EC3A5B7A48F0AA2EA33962B961DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_BDA7EC3A5B7A48F0AA2EA33962B961DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_BDA7EC3A5B7A48F0AA2EA33962B961DB" xlink:to="lab_dei_DocumentPeriodEndDate_BDA7EC3A5B7A48F0AA2EA33962B961DB" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_A09574CB8A66CE7D7781A33962B9E641_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_A09574CB8A66CE7D7781A33962B9E641" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_A09574CB8A66CE7D7781A33962B9E641_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_A09574CB8A66CE7D7781A33962B9E641" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_A09574CB8A66CE7D7781A33962B9E641" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_A09574CB8A66CE7D7781A33962B9E641" xlink:to="lab_dei_DocumentFiscalYearFocus_A09574CB8A66CE7D7781A33962B9E641" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_921577928460BBC99605A33962BACE11_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_921577928460BBC99605A33962BACE11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_921577928460BBC99605A33962BACE11_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_921577928460BBC99605A33962BACE11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_921577928460BBC99605A33962BACE11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_921577928460BBC99605A33962BACE11" xlink:to="lab_dei_DocumentFiscalPeriodFocus_921577928460BBC99605A33962BACE11" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_31E78E9C535C76BD7D8FA33962BA9C6E_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_31E78E9C535C76BD7D8FA33962BA9C6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_31E78E9C535C76BD7D8FA33962BA9C6E_label_en-US" xlink:label="lab_dei_AmendmentFlag_31E78E9C535C76BD7D8FA33962BA9C6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_31E78E9C535C76BD7D8FA33962BA9C6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_31E78E9C535C76BD7D8FA33962BA9C6E" xlink:to="lab_dei_AmendmentFlag_31E78E9C535C76BD7D8FA33962BA9C6E" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_E1A1B7829DF3D9A138F0A33962BAB003_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_E1A1B7829DF3D9A138F0A33962BAB003" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_E1A1B7829DF3D9A138F0A33962BAB003_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_E1A1B7829DF3D9A138F0A33962BAB003" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_E1A1B7829DF3D9A138F0A33962BAB003" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_E1A1B7829DF3D9A138F0A33962BAB003" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_E1A1B7829DF3D9A138F0A33962BAB003" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_BFD00E3B76E9EF05B913A33962BA8FAA_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_BFD00E3B76E9EF05B913A33962BA8FAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_BFD00E3B76E9EF05B913A33962BA8FAA_label_en-US" xlink:label="lab_dei_EntityShellCompany_BFD00E3B76E9EF05B913A33962BA8FAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_BFD00E3B76E9EF05B913A33962BA8FAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_BFD00E3B76E9EF05B913A33962BA8FAA" xlink:to="lab_dei_EntityShellCompany_BFD00E3B76E9EF05B913A33962BA8FAA" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4CA097D72D0EE0B7C076A33962BA122F_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_4CA097D72D0EE0B7C076A33962BA122F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4CA097D72D0EE0B7C076A33962BA122F_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_4CA097D72D0EE0B7C076A33962BA122F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_4CA097D72D0EE0B7C076A33962BA122F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_4CA097D72D0EE0B7C076A33962BA122F" xlink:to="lab_dei_EntityEmergingGrowthCompany_4CA097D72D0EE0B7C076A33962BA122F" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_929FBC109515472EE927A33962BAF8BF_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_929FBC109515472EE927A33962BAF8BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_929FBC109515472EE927A33962BAF8BF_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_929FBC109515472EE927A33962BAF8BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_929FBC109515472EE927A33962BAF8BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_929FBC109515472EE927A33962BAF8BF" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_929FBC109515472EE927A33962BAF8BF" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_E47855B564597DB0A565A33962BAB335_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_E47855B564597DB0A565A33962BAB335" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_E47855B564597DB0A565A33962BAB335_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_E47855B564597DB0A565A33962BAB335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_E47855B564597DB0A565A33962BAB335" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_E47855B564597DB0A565A33962BAB335" xlink:to="lab_dei_EntityVoluntaryFilers_E47855B564597DB0A565A33962BAB335" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_8D694C069EDD81B4717CA33962BB01DE_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_8D694C069EDD81B4717CA33962BB01DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_8D694C069EDD81B4717CA33962BB01DE_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_8D694C069EDD81B4717CA33962BB01DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_8D694C069EDD81B4717CA33962BB01DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_8D694C069EDD81B4717CA33962BB01DE" xlink:to="lab_dei_EntityCurrentReportingStatus_8D694C069EDD81B4717CA33962BB01DE" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_E0DBB909E637D5CCE2CFA33962BB7A3D_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_E0DBB909E637D5CCE2CFA33962BB7A3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_E0DBB909E637D5CCE2CFA33962BB7A3D_label_en-US" xlink:label="lab_dei_EntityPublicFloat_E0DBB909E637D5CCE2CFA33962BB7A3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_E0DBB909E637D5CCE2CFA33962BB7A3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_E0DBB909E637D5CCE2CFA33962BB7A3D" xlink:to="lab_dei_EntityPublicFloat_E0DBB909E637D5CCE2CFA33962BB7A3D" xlink:type="arc" />
    <link:label id="lab_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_E14983DB7F1423683F2D9CFE7E154CCF_label_en-US" xlink:label="lab_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_E14983DB7F1423683F2D9CFE7E154CCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Short Term Investments [Abstract]</link:label>
    <link:label id="lab_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_E14983DB7F1423683F2D9CFE7E154CCF_documentation_en-US" xlink:label="lab_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_E14983DB7F1423683F2D9CFE7E154CCF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Short Term Investments [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="loc_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_E14983DB7F1423683F2D9CFE7E154CCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_E14983DB7F1423683F2D9CFE7E154CCF" xlink:to="lab_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_E14983DB7F1423683F2D9CFE7E154CCF" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CashEquivalents_D9A79DFAC73EA161FF129CFE7E16123F_terseLabel_en-US" xlink:label="lab_ifrs-full_CashEquivalents_D9A79DFAC73EA161FF129CFE7E16123F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashEquivalents_D9A79DFAC73EA161FF129CFE7E16123F_label_en-US" xlink:label="lab_ifrs-full_CashEquivalents_D9A79DFAC73EA161FF129CFE7E16123F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashEquivalents" xlink:label="loc_ifrs-full_CashEquivalents_D9A79DFAC73EA161FF129CFE7E16123F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashEquivalents_D9A79DFAC73EA161FF129CFE7E16123F" xlink:to="lab_ifrs-full_CashEquivalents_D9A79DFAC73EA161FF129CFE7E16123F" xlink:type="arc" />
    <link:label id="lab_oncyf_CashEquivalentsInterestRate_4C5FF56C1852F44559259CFE7E1601AB_terseLabel_en-US" xlink:label="lab_oncyf_CashEquivalentsInterestRate_4C5FF56C1852F44559259CFE7E1601AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current annual interest rate</link:label>
    <link:label id="lab_oncyf_CashEquivalentsInterestRate_4C5FF56C1852F44559259CFE7E1601AB_label_en-US" xlink:label="lab_oncyf_CashEquivalentsInterestRate_4C5FF56C1852F44559259CFE7E1601AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, Interest Rate</link:label>
    <link:label id="lab_oncyf_CashEquivalentsInterestRate_4C5FF56C1852F44559259CFE7E1601AB_documentation_en-US" xlink:label="lab_oncyf_CashEquivalentsInterestRate_4C5FF56C1852F44559259CFE7E1601AB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Equivalents, Interest Rate</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CashEquivalentsInterestRate" xlink:label="loc_oncyf_CashEquivalentsInterestRate_4C5FF56C1852F44559259CFE7E1601AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CashEquivalentsInterestRate_4C5FF56C1852F44559259CFE7E1601AB" xlink:to="lab_oncyf_CashEquivalentsInterestRate_4C5FF56C1852F44559259CFE7E1601AB" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_DE90D4A9A4071970BEBF9CFE7F839897_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_DE90D4A9A4071970BEBF9CFE7F839897" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_DE90D4A9A4071970BEBF9CFE7F839897_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_DE90D4A9A4071970BEBF9CFE7F839897" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_DE90D4A9A4071970BEBF9CFE7F839897" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_DE90D4A9A4071970BEBF9CFE7F839897" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_DE90D4A9A4071970BEBF9CFE7F839897" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_F2034FE58736AC9B09809CFE7F83B7D5_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_F2034FE58736AC9B09809CFE7F83B7D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_F2034FE58736AC9B09809CFE7F83B7D5_label_en-US" xlink:label="lab_srt_RangeAxis_F2034FE58736AC9B09809CFE7F83B7D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_F2034FE58736AC9B09809CFE7F83B7D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_F2034FE58736AC9B09809CFE7F83B7D5" xlink:to="lab_srt_RangeAxis_F2034FE58736AC9B09809CFE7F83B7D5" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_50321E0B317A01A2331B9CFE7F84868A_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_50321E0B317A01A2331B9CFE7F84868A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_50321E0B317A01A2331B9CFE7F84868A_label_en-US" xlink:label="lab_srt_MinimumMember_50321E0B317A01A2331B9CFE7F84868A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_50321E0B317A01A2331B9CFE7F84868A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_50321E0B317A01A2331B9CFE7F84868A" xlink:to="lab_srt_MinimumMember_50321E0B317A01A2331B9CFE7F84868A" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_385051B8D8BF46727A5D9CFE7F842427_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_385051B8D8BF46727A5D9CFE7F842427" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_385051B8D8BF46727A5D9CFE7F842427_label_en-US" xlink:label="lab_srt_MaximumMember_385051B8D8BF46727A5D9CFE7F842427" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_385051B8D8BF46727A5D9CFE7F842427" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_385051B8D8BF46727A5D9CFE7F842427" xlink:to="lab_srt_MaximumMember_385051B8D8BF46727A5D9CFE7F842427" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2CF1BBBBFA29D357F00B9CFE7F84798F_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2CF1BBBBFA29D357F00B9CFE7F84798F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2CF1BBBBFA29D357F00B9CFE7F84798F_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2CF1BBBBFA29D357F00B9CFE7F84798F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2CF1BBBBFA29D357F00B9CFE7F84798F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2CF1BBBBFA29D357F00B9CFE7F84798F" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2CF1BBBBFA29D357F00B9CFE7F84798F" xlink:type="arc" />
    <link:label id="lab_oncyf_OperatingLeaseRemainingLeaseTerm_B5CCBB94944AFAFFE5EB9CFE7F8517F5_terseLabel_en-US" xlink:label="lab_oncyf_OperatingLeaseRemainingLeaseTerm_B5CCBB94944AFAFFE5EB9CFE7F8517F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_oncyf_OperatingLeaseRemainingLeaseTerm_B5CCBB94944AFAFFE5EB9CFE7F8517F5_label_en-US" xlink:label="lab_oncyf_OperatingLeaseRemainingLeaseTerm_B5CCBB94944AFAFFE5EB9CFE7F8517F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Remaining Lease Term</link:label>
    <link:label id="lab_oncyf_OperatingLeaseRemainingLeaseTerm_B5CCBB94944AFAFFE5EB9CFE7F8517F5_documentation_en-US" xlink:label="lab_oncyf_OperatingLeaseRemainingLeaseTerm_B5CCBB94944AFAFFE5EB9CFE7F8517F5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OperatingLeaseRemainingLeaseTerm" xlink:label="loc_oncyf_OperatingLeaseRemainingLeaseTerm_B5CCBB94944AFAFFE5EB9CFE7F8517F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OperatingLeaseRemainingLeaseTerm_B5CCBB94944AFAFFE5EB9CFE7F8517F5" xlink:to="lab_oncyf_OperatingLeaseRemainingLeaseTerm_B5CCBB94944AFAFFE5EB9CFE7F8517F5" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_12DCEC6745A922BCF9FD9CFE7F8585AA_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_12DCEC6745A922BCF9FD9CFE7F8585AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average rate</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_12DCEC6745A922BCF9FD9CFE7F8585AA_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_12DCEC6745A922BCF9FD9CFE7F8585AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:label="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_12DCEC6745A922BCF9FD9CFE7F8585AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_12DCEC6745A922BCF9FD9CFE7F8585AA" xlink:to="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_12DCEC6745A922BCF9FD9CFE7F8585AA" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_7C1098E25E407059327EAB7942A9AF5D_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_7C1098E25E407059327EAB7942A9AF5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of initial application of standards or interpretations [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_7C1098E25E407059327EAB7942A9AF5D_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_7C1098E25E407059327EAB7942A9AF5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of initial application of standards or interpretations [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_7C1098E25E407059327EAB7942A9AF5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_7C1098E25E407059327EAB7942A9AF5D" xlink:to="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_7C1098E25E407059327EAB7942A9AF5D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_InitiallyAppliedIFRSsAxis_091E66C37B7FB9BF69EBAB7942A99B63_terseLabel_en-US" xlink:label="lab_ifrs-full_InitiallyAppliedIFRSsAxis_091E66C37B7FB9BF69EBAB7942A99B63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initially applied IFRSs [axis]</link:label>
    <link:label id="lab_ifrs-full_InitiallyAppliedIFRSsAxis_091E66C37B7FB9BF69EBAB7942A99B63_label_en-US" xlink:label="lab_ifrs-full_InitiallyAppliedIFRSsAxis_091E66C37B7FB9BF69EBAB7942A99B63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initially applied IFRSs [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsAxis" xlink:label="loc_ifrs-full_InitiallyAppliedIFRSsAxis_091E66C37B7FB9BF69EBAB7942A99B63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InitiallyAppliedIFRSsAxis_091E66C37B7FB9BF69EBAB7942A99B63" xlink:to="lab_ifrs-full_InitiallyAppliedIFRSsAxis_091E66C37B7FB9BF69EBAB7942A99B63" xlink:type="arc" />
    <link:label id="lab_ifrs-full_InitiallyAppliedIFRSsMember_71F78FD855DC9A26A511AB7942A98015_terseLabel_en-US" xlink:label="lab_ifrs-full_InitiallyAppliedIFRSsMember_71F78FD855DC9A26A511AB7942A98015" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initially applied IFRSs [member]</link:label>
    <link:label id="lab_ifrs-full_InitiallyAppliedIFRSsMember_71F78FD855DC9A26A511AB7942A98015_label_en-US" xlink:label="lab_ifrs-full_InitiallyAppliedIFRSsMember_71F78FD855DC9A26A511AB7942A98015" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initially applied IFRSs [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsMember" xlink:label="loc_ifrs-full_InitiallyAppliedIFRSsMember_71F78FD855DC9A26A511AB7942A98015" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InitiallyAppliedIFRSsMember_71F78FD855DC9A26A511AB7942A98015" xlink:to="lab_ifrs-full_InitiallyAppliedIFRSsMember_71F78FD855DC9A26A511AB7942A98015" xlink:type="arc" />
    <link:label id="lab_oncyf_EffectsofIFRS16TransitionMember_6CFBD5AF93F32AB9C486AB7942A91AE9_terseLabel_en-US" xlink:label="lab_oncyf_EffectsofIFRS16TransitionMember_6CFBD5AF93F32AB9C486AB7942A91AE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effects of IFRS 16 transition</link:label>
    <link:label id="lab_oncyf_EffectsofIFRS16TransitionMember_6CFBD5AF93F32AB9C486AB7942A91AE9_label_en-US" xlink:label="lab_oncyf_EffectsofIFRS16TransitionMember_6CFBD5AF93F32AB9C486AB7942A91AE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effects of IFRS 16 Transition [Member]</link:label>
    <link:label id="lab_oncyf_EffectsofIFRS16TransitionMember_6CFBD5AF93F32AB9C486AB7942A91AE9_documentation_en-US" xlink:label="lab_oncyf_EffectsofIFRS16TransitionMember_6CFBD5AF93F32AB9C486AB7942A91AE9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effects of IFRS 16 Transition [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_EffectsofIFRS16TransitionMember" xlink:label="loc_oncyf_EffectsofIFRS16TransitionMember_6CFBD5AF93F32AB9C486AB7942A91AE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_EffectsofIFRS16TransitionMember_6CFBD5AF93F32AB9C486AB7942A91AE9" xlink:to="lab_oncyf_EffectsofIFRS16TransitionMember_6CFBD5AF93F32AB9C486AB7942A91AE9" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of initial application of standards or interpretations [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of initial application of standards or interpretations [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530" xlink:to="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530" xlink:type="arc" />
    <link:label id="lab_ifrs-full_RightofuseAssets_517F71CC52A4690A3AA2AB7942AAB822_terseLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets_517F71CC52A4690A3AA2AB7942AAB822" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_517F71CC52A4690A3AA2AB7942AAB822_label_en-US" xlink:label="lab_ifrs-full_RightofuseAssets_517F71CC52A4690A3AA2AB7942AAB822" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_517F71CC52A4690A3AA2AB7942AAB822" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets_517F71CC52A4690A3AA2AB7942AAB822" xlink:to="lab_ifrs-full_RightofuseAssets_517F71CC52A4690A3AA2AB7942AAB822" xlink:type="arc" />
    <link:label id="lab_oncyf_OtherCurrentandNoncurrentAssets_67EB0798C12AE09E1E97AB7942AA69F9_terseLabel_en-US" xlink:label="lab_oncyf_OtherCurrentandNoncurrentAssets_67EB0798C12AE09E1E97AB7942AA69F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current and non-current assets</link:label>
    <link:label id="lab_oncyf_OtherCurrentandNoncurrentAssets_67EB0798C12AE09E1E97AB7942AA69F9_label_en-US" xlink:label="lab_oncyf_OtherCurrentandNoncurrentAssets_67EB0798C12AE09E1E97AB7942AA69F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current and Non-current Assets</link:label>
    <link:label id="lab_oncyf_OtherCurrentandNoncurrentAssets_67EB0798C12AE09E1E97AB7942AA69F9_documentation_en-US" xlink:label="lab_oncyf_OtherCurrentandNoncurrentAssets_67EB0798C12AE09E1E97AB7942AA69F9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Current and Non-current Assets</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OtherCurrentandNoncurrentAssets" xlink:label="loc_oncyf_OtherCurrentandNoncurrentAssets_67EB0798C12AE09E1E97AB7942AA69F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherCurrentandNoncurrentAssets_67EB0798C12AE09E1E97AB7942AA69F9" xlink:to="lab_oncyf_OtherCurrentandNoncurrentAssets_67EB0798C12AE09E1E97AB7942AA69F9" xlink:type="arc" />
    <link:label id="lab_ifrs-full_Assets_F196BF840E89E479C06BAB7942AA9839_terseLabel_en-US" xlink:label="lab_ifrs-full_Assets_F196BF840E89E479C06BAB7942AA9839" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_ifrs-full_Assets_F196BF840E89E479C06BAB7942AA9839_label_en-US" xlink:label="lab_ifrs-full_Assets_F196BF840E89E479C06BAB7942AA9839" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_F196BF840E89E479C06BAB7942AA9839" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets_F196BF840E89E479C06BAB7942AA9839" xlink:to="lab_ifrs-full_Assets_F196BF840E89E479C06BAB7942AA9839" xlink:type="arc" />
    <link:label id="lab_ifrs-full_OtherLiabilities_CAD1E8D5518A80CCFE5AAB7942AA23AA_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherLiabilities_CAD1E8D5518A80CCFE5AAB7942AA23AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherLiabilities_CAD1E8D5518A80CCFE5AAB7942AA23AA_label_en-US" xlink:label="lab_ifrs-full_OtherLiabilities_CAD1E8D5518A80CCFE5AAB7942AA23AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherLiabilities" xlink:label="loc_ifrs-full_OtherLiabilities_CAD1E8D5518A80CCFE5AAB7942AA23AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherLiabilities_CAD1E8D5518A80CCFE5AAB7942AA23AA" xlink:to="lab_ifrs-full_OtherLiabilities_CAD1E8D5518A80CCFE5AAB7942AA23AA" xlink:type="arc" />
    <link:label id="lab_ifrs-full_LeaseLiabilities_B3B7B5A98BEF2DCF6A2AAB7942AB0FFD_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities_B3B7B5A98BEF2DCF6A2AAB7942AB0FFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_B3B7B5A98BEF2DCF6A2AAB7942AB0FFD_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities_B3B7B5A98BEF2DCF6A2AAB7942AB0FFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-full_LeaseLiabilities_B3B7B5A98BEF2DCF6A2AAB7942AB0FFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities_B3B7B5A98BEF2DCF6A2AAB7942AB0FFD" xlink:to="lab_ifrs-full_LeaseLiabilities_B3B7B5A98BEF2DCF6A2AAB7942AB0FFD" xlink:type="arc" />
    <link:label id="lab_oncyf_OtherCurrentandNoncurrentLiabilities_7D8FE27B4B53862F4BACAB7942AB65B8_terseLabel_en-US" xlink:label="lab_oncyf_OtherCurrentandNoncurrentLiabilities_7D8FE27B4B53862F4BACAB7942AB65B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current and non-current liabilities</link:label>
    <link:label id="lab_oncyf_OtherCurrentandNoncurrentLiabilities_7D8FE27B4B53862F4BACAB7942AB65B8_label_en-US" xlink:label="lab_oncyf_OtherCurrentandNoncurrentLiabilities_7D8FE27B4B53862F4BACAB7942AB65B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current and Non-current Liabilities</link:label>
    <link:label id="lab_oncyf_OtherCurrentandNoncurrentLiabilities_7D8FE27B4B53862F4BACAB7942AB65B8_documentation_en-US" xlink:label="lab_oncyf_OtherCurrentandNoncurrentLiabilities_7D8FE27B4B53862F4BACAB7942AB65B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Current and Non-current Liabilities</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OtherCurrentandNoncurrentLiabilities" xlink:label="loc_oncyf_OtherCurrentandNoncurrentLiabilities_7D8FE27B4B53862F4BACAB7942AB65B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherCurrentandNoncurrentLiabilities_7D8FE27B4B53862F4BACAB7942AB65B8" xlink:to="lab_oncyf_OtherCurrentandNoncurrentLiabilities_7D8FE27B4B53862F4BACAB7942AB65B8" xlink:type="arc" />
    <link:label id="lab_ifrs-full_Liabilities_3B501346646EAF1644ECAB7942AB44F4_terseLabel_en-US" xlink:label="lab_ifrs-full_Liabilities_3B501346646EAF1644ECAB7942AB44F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_ifrs-full_Liabilities_3B501346646EAF1644ECAB7942AB44F4_label_en-US" xlink:label="lab_ifrs-full_Liabilities_3B501346646EAF1644ECAB7942AB44F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_3B501346646EAF1644ECAB7942AB44F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Liabilities_3B501346646EAF1644ECAB7942AB44F4" xlink:to="lab_ifrs-full_Liabilities_3B501346646EAF1644ECAB7942AB44F4" xlink:type="arc" />
    <link:label id="lab_ifrs-full_Equity_92681CCC9EDC68BF57F8AB7942AB0C3D_terseLabel_en-US" xlink:label="lab_ifrs-full_Equity_92681CCC9EDC68BF57F8AB7942AB0C3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders&#8217; (deficit) equity</link:label>
    <link:label id="lab_ifrs-full_Equity_92681CCC9EDC68BF57F8AB7942AB0C3D_label_en-US" xlink:label="lab_ifrs-full_Equity_92681CCC9EDC68BF57F8AB7942AB0C3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_92681CCC9EDC68BF57F8AB7942AB0C3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity_92681CCC9EDC68BF57F8AB7942AB0C3D" xlink:to="lab_ifrs-full_Equity_92681CCC9EDC68BF57F8AB7942AB0C3D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_GrossLeaseLiabilities_15D34891B81717676E5DAB7942AB1D2B_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossLeaseLiabilities_15D34891B81717676E5DAB7942AB1D2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total minimum operating lease commitments</link:label>
    <link:label id="lab_ifrs-full_GrossLeaseLiabilities_15D34891B81717676E5DAB7942AB1D2B_label_en-US" xlink:label="lab_ifrs-full_GrossLeaseLiabilities_15D34891B81717676E5DAB7942AB1D2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossLeaseLiabilities" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_15D34891B81717676E5DAB7942AB1D2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossLeaseLiabilities_15D34891B81717676E5DAB7942AB1D2B" xlink:to="lab_ifrs-full_GrossLeaseLiabilities_15D34891B81717676E5DAB7942AB1D2B" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_28781C854F8F0F3B312CA8191CD3A9F5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_28781C854F8F0F3B312CA8191CD3A9F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_28781C854F8F0F3B312CA8191CD3A9F5_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_28781C854F8F0F3B312CA8191CD3A9F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_28781C854F8F0F3B312CA8191CD3A9F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_28781C854F8F0F3B312CA8191CD3A9F5" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_28781C854F8F0F3B312CA8191CD3A9F5" xlink:type="arc" />
    <link:label id="lab_ifrs-full_MaturityAxis_110A30C841F93F8946CFA8191CD3EEBF_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityAxis_110A30C841F93F8946CFA8191CD3EEBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
    <link:label id="lab_ifrs-full_MaturityAxis_110A30C841F93F8946CFA8191CD3EEBF_label_en-US" xlink:label="lab_ifrs-full_MaturityAxis_110A30C841F93F8946CFA8191CD3EEBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_110A30C841F93F8946CFA8191CD3EEBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAxis_110A30C841F93F8946CFA8191CD3EEBF" xlink:to="lab_ifrs-full_MaturityAxis_110A30C841F93F8946CFA8191CD3EEBF" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_8D63E57DF4C23AA2551CA8191CD3C4CA_terseLabel_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember_8D63E57DF4C23AA2551CA8191CD3C4CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregated time bands [member]</link:label>
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_8D63E57DF4C23AA2551CA8191CD3C4CA_label_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember_8D63E57DF4C23AA2551CA8191CD3C4CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregated time bands [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_8D63E57DF4C23AA2551CA8191CD3C4CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_8D63E57DF4C23AA2551CA8191CD3C4CA" xlink:to="lab_ifrs-full_AggregatedTimeBandsMember_8D63E57DF4C23AA2551CA8191CD3C4CA" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_49511A9A4D0AD36F7673A8191CD423CD_terseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember_49511A9A4D0AD36F7673A8191CD423CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_49511A9A4D0AD36F7673A8191CD423CD_label_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember_49511A9A4D0AD36F7673A8191CD423CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not later than one year [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_49511A9A4D0AD36F7673A8191CD423CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneYearMember_49511A9A4D0AD36F7673A8191CD423CD" xlink:to="lab_ifrs-full_NotLaterThanOneYearMember_49511A9A4D0AD36F7673A8191CD423CD" xlink:type="arc" />
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_3015620E393808566EE9A8191CD45F7B_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_3015620E393808566EE9A8191CD45F7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One to five years</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_3015620E393808566EE9A8191CD45F7B_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_3015620E393808566EE9A8191CD45F7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than five years [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_3015620E393808566EE9A8191CD45F7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_3015620E393808566EE9A8191CD45F7B" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_3015620E393808566EE9A8191CD45F7B" xlink:type="arc" />
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_ADE4FAE8F15BB4131D68A8191CD486BA_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember_ADE4FAE8F15BB4131D68A8191CD486BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">More than five years</link:label>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_ADE4FAE8F15BB4131D68A8191CD486BA_label_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember_ADE4FAE8F15BB4131D68A8191CD486BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than five years [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_ADE4FAE8F15BB4131D68A8191CD486BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFiveYearsMember_ADE4FAE8F15BB4131D68A8191CD486BA" xlink:to="lab_ifrs-full_LaterThanFiveYearsMember_ADE4FAE8F15BB4131D68A8191CD486BA" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_EF9E900068473FD703E8A8191CD4F6D7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_EF9E900068473FD703E8A8191CD4F6D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_EF9E900068473FD703E8A8191CD4F6D7_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_EF9E900068473FD703E8A8191CD4F6D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_EF9E900068473FD703E8A8191CD4F6D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_EF9E900068473FD703E8A8191CD4F6D7" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_EF9E900068473FD703E8A8191CD4F6D7" xlink:type="arc" />
    <link:label id="lab_ifrs-full_GrossLeaseLiabilities_A2CC5E688919238E00A4A8191F6CC773_verboseLabel_en-US" xlink:label="lab_ifrs-full_GrossLeaseLiabilities_A2CC5E688919238E00A4A8191F6CC773" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total undiscounted lease liability as at December 31, 2019</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossLeaseLiabilities" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_A2CC5E688919238E00A4A8191F6CC773" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossLeaseLiabilities_A2CC5E688919238E00A4A8191F6CC773" xlink:to="lab_ifrs-full_GrossLeaseLiabilities_A2CC5E688919238E00A4A8191F6CC773" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IncomeStatementAbstract_3F96A799B4F919E53D6BACF62339B609_label_en-US" xlink:label="lab_ifrs-full_IncomeStatementAbstract_3F96A799B4F919E53D6BACF62339B609" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit or loss [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-full_IncomeStatementAbstract_3F96A799B4F919E53D6BACF62339B609" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3F96A799B4F919E53D6BACF62339B609" xlink:to="lab_ifrs-full_IncomeStatementAbstract_3F96A799B4F919E53D6BACF62339B609" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ExpenseByNatureAbstract_988E08021469E376C56AACF623395C92_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseByNatureAbstract_988E08021469E376C56AACF623395C92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_ifrs-full_ExpenseByNatureAbstract_988E08021469E376C56AACF623395C92_label_en-US" xlink:label="lab_ifrs-full_ExpenseByNatureAbstract_988E08021469E376C56AACF623395C92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expenses by nature [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseByNatureAbstract" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract_988E08021469E376C56AACF623395C92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_988E08021469E376C56AACF623395C92" xlink:to="lab_ifrs-full_ExpenseByNatureAbstract_988E08021469E376C56AACF623395C92" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_68D0091B202381F323D5ACF623391AA4_terseLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense_68D0091B202381F323D5ACF623391AA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_68D0091B202381F323D5ACF623391AA4_label_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense_68D0091B202381F323D5ACF623391AA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_68D0091B202381F323D5ACF623391AA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_68D0091B202381F323D5ACF623391AA4" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense_68D0091B202381F323D5ACF623391AA4" xlink:type="arc" />
    <link:label id="lab_ifrs-full_OperatingExpense_4AEB5E273614219D07B2ACF6233AF167_terseLabel_en-US" xlink:label="lab_ifrs-full_OperatingExpense_4AEB5E273614219D07B2ACF6233AF167" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating</link:label>
    <link:label id="lab_ifrs-full_OperatingExpense_4AEB5E273614219D07B2ACF6233AF167_label_en-US" xlink:label="lab_ifrs-full_OperatingExpense_4AEB5E273614219D07B2ACF6233AF167" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expense</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingExpense" xlink:label="loc_ifrs-full_OperatingExpense_4AEB5E273614219D07B2ACF6233AF167" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OperatingExpense_4AEB5E273614219D07B2ACF6233AF167" xlink:to="lab_ifrs-full_OperatingExpense_4AEB5E273614219D07B2ACF6233AF167" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_0BD6A340C133BF7B86E5ACF6233A0102_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities_0BD6A340C133BF7B86E5ACF6233A0102" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before the following</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_0BD6A340C133BF7B86E5ACF6233A0102_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities_0BD6A340C133BF7B86E5ACF6233A0102" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from operating activities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_0BD6A340C133BF7B86E5ACF6233A0102" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_0BD6A340C133BF7B86E5ACF6233A0102" xlink:to="lab_ifrs-full_ProfitLossFromOperatingActivities_0BD6A340C133BF7B86E5ACF6233A0102" xlink:type="arc" />
    <link:label id="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_C0BE5BDAF98C0F2169FBACF6233A67F1_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_C0BE5BDAF98C0F2169FBACF6233A67F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant derivative</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_C0BE5BDAF98C0F2169FBACF6233A67F1_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_C0BE5BDAF98C0F2169FBACF6233A67F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on change in fair value of derivatives</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_C0BE5BDAF98C0F2169FBACF6233A67F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_C0BE5BDAF98C0F2169FBACF6233A67F1" xlink:to="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_C0BE5BDAF98C0F2169FBACF6233A67F1" xlink:type="arc" />
    <link:label id="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents_D18146F81A86F03B93F5ACF6233A082D_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents_D18146F81A86F03B93F5ACF6233A082D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents_D18146F81A86F03B93F5ACF6233A082D_label_en-US" xlink:label="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents_D18146F81A86F03B93F5ACF6233A082D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income on cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_D18146F81A86F03B93F5ACF6233A082D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_D18146F81A86F03B93F5ACF6233A082D" xlink:to="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents_D18146F81A86F03B93F5ACF6233A082D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_6C1A5F76EA26B8960BBFACF6233A3E57_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax_6C1A5F76EA26B8960BBFACF6233A3E57" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_6C1A5F76EA26B8960BBFACF6233A3E57_label_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax_6C1A5F76EA26B8960BBFACF6233A3E57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) before tax</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_6C1A5F76EA26B8960BBFACF6233A3E57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_6C1A5F76EA26B8960BBFACF6233A3E57" xlink:to="lab_ifrs-full_ProfitLossBeforeTax_6C1A5F76EA26B8960BBFACF6233A3E57" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_E696B9602E534574FD33ACF6233B06BF_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_E696B9602E534574FD33ACF6233B06BF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_E696B9602E534574FD33ACF6233B06BF_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_E696B9602E534574FD33ACF6233B06BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_E696B9602E534574FD33ACF6233B06BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_E696B9602E534574FD33ACF6233B06BF" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_E696B9602E534574FD33ACF6233B06BF" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ProfitLoss_81670788B58C1B17E850ACF6233B4080_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss_81670788B58C1B17E850ACF6233B4080" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_81670788B58C1B17E850ACF6233B4080_label_en-US" xlink:label="lab_ifrs-full_ProfitLoss_81670788B58C1B17E850ACF6233B4080" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_81670788B58C1B17E850ACF6233B4080" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss_81670788B58C1B17E850ACF6233B4080" xlink:to="lab_ifrs-full_ProfitLoss_81670788B58C1B17E850ACF6233B4080" xlink:type="arc" />
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_31043ADA1A12C61329FDACF6233B546D_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract_31043ADA1A12C61329FDACF6233B546D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) income items that may be reclassified to net loss</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_31043ADA1A12C61329FDACF6233B546D_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract_31043ADA1A12C61329FDACF6233B546D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_31043ADA1A12C61329FDACF6233B546D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_31043ADA1A12C61329FDACF6233B546D" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeAbstract_31043ADA1A12C61329FDACF6233B546D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_0B50952336C157D30ED1ACF6233B518D_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_0B50952336C157D30ED1ACF6233B518D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation adjustment</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_0B50952336C157D30ED1ACF6233B518D_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_0B50952336C157D30ED1ACF6233B518D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_0B50952336C157D30ED1ACF6233B518D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_0B50952336C157D30ED1ACF6233B518D" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_0B50952336C157D30ED1ACF6233B518D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ComprehensiveIncome_887D3E9778000AF8A05CACF6233BC731_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome_887D3E9778000AF8A05CACF6233BC731" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net comprehensive loss</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_887D3E9778000AF8A05CACF6233BC731_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome_887D3E9778000AF8A05CACF6233BC731" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_887D3E9778000AF8A05CACF6233BC731" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome_887D3E9778000AF8A05CACF6233BC731" xlink:to="lab_ifrs-full_ComprehensiveIncome_887D3E9778000AF8A05CACF6233BC731" xlink:type="arc" />
    <link:label id="lab_ifrs-full_BasicAndDilutedEarningsLossPerShare_3A3E1240B55B2A4A6991ACF6233BC606_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicAndDilutedEarningsLossPerShare_3A3E1240B55B2A4A6991ACF6233BC606" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted loss per common share (cad per share)</link:label>
    <link:label id="lab_ifrs-full_BasicAndDilutedEarningsLossPerShare_3A3E1240B55B2A4A6991ACF6233BC606_label_en-US" xlink:label="lab_ifrs-full_BasicAndDilutedEarningsLossPerShare_3A3E1240B55B2A4A6991ACF6233BC606" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings (loss) per share</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:label="loc_ifrs-full_BasicAndDilutedEarningsLossPerShare_3A3E1240B55B2A4A6991ACF6233BC606" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicAndDilutedEarningsLossPerShare_3A3E1240B55B2A4A6991ACF6233BC606" xlink:to="lab_ifrs-full_BasicAndDilutedEarningsLossPerShare_3A3E1240B55B2A4A6991ACF6233BC606" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageShares_377EB3E299F7CF5E35EDACF6233C3CE0_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares_377EB3E299F7CF5E35EDACF6233C3CE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares (basic) (shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_377EB3E299F7CF5E35EDACF6233C3CE0_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares_377EB3E299F7CF5E35EDACF6233C3CE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares outstanding</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares_377EB3E299F7CF5E35EDACF6233C3CE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares_377EB3E299F7CF5E35EDACF6233C3CE0" xlink:to="lab_ifrs-full_WeightedAverageShares_377EB3E299F7CF5E35EDACF6233C3CE0" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_5F00C1427F2B71791BE2ACF6233C346D_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares_5F00C1427F2B71791BE2ACF6233C346D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares (diluted) (shares)</link:label>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_5F00C1427F2B71791BE2ACF6233C346D_label_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares_5F00C1427F2B71791BE2ACF6233C346D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjusted weighted average number of ordinary shares outstanding</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_5F00C1427F2B71791BE2ACF6233C346D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares_5F00C1427F2B71791BE2ACF6233C346D" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares_5F00C1427F2B71791BE2ACF6233C346D" xlink:type="arc" />
    <link:label id="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract_D70B3856B3F16AB0D8709D034C1C45ED_label_en-US" xlink:label="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract_D70B3856B3F16AB0D8709D034C1C45ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of events after reporting period [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract_D70B3856B3F16AB0D8709D034C1C45ED_documentation_en-US" xlink:label="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract_D70B3856B3F16AB0D8709D034C1C45ED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of events after reporting period [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:label="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract_D70B3856B3F16AB0D8709D034C1C45ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract_D70B3856B3F16AB0D8709D034C1C45ED" xlink:to="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract_D70B3856B3F16AB0D8709D034C1C45ED" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_2EE313CA37BCBC8FECAC9D034C1D7B93_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_2EE313CA37BCBC8FECAC9D034C1D7B93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_2EE313CA37BCBC8FECAC9D034C1D7B93_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_2EE313CA37BCBC8FECAC9D034C1D7B93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of events after reporting period [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_2EE313CA37BCBC8FECAC9D034C1D7B93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_2EE313CA37BCBC8FECAC9D034C1D7B93" xlink:to="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_2EE313CA37BCBC8FECAC9D034C1D7B93" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable_6DDE0BF97177E2BA5E88A339610A9472_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable_6DDE0BF97177E2BA5E88A339610A9472" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of contingent liabilities [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable_6DDE0BF97177E2BA5E88A339610A9472_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable_6DDE0BF97177E2BA5E88A339610A9472" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of contingent liabilities [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_6DDE0BF97177E2BA5E88A339610A9472" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_6DDE0BF97177E2BA5E88A339610A9472" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable_6DDE0BF97177E2BA5E88A339610A9472" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CounterpartiesAxis_AB03847E6DD28513DB3CA339610A961F_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis_AB03847E6DD28513DB3CA339610A961F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparties [axis]</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesAxis_AB03847E6DD28513DB3CA339610A961F_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis_AB03847E6DD28513DB3CA339610A961F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparties [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-full_CounterpartiesAxis_AB03847E6DD28513DB3CA339610A961F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesAxis_AB03847E6DD28513DB3CA339610A961F" xlink:to="lab_ifrs-full_CounterpartiesAxis_AB03847E6DD28513DB3CA339610A961F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CounterpartiesMember_B28AE487282FCDAE622DA339610B5D47_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesMember_B28AE487282FCDAE622DA339610B5D47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparties [member]</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesMember_B28AE487282FCDAE622DA339610B5D47_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesMember_B28AE487282FCDAE622DA339610B5D47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparties [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-full_CounterpartiesMember_B28AE487282FCDAE622DA339610B5D47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesMember_B28AE487282FCDAE622DA339610B5D47" xlink:to="lab_ifrs-full_CounterpartiesMember_B28AE487282FCDAE622DA339610B5D47" xlink:type="arc" />
    <link:label id="lab_oncyf_SYNSORBMember_FD1C0B69E8A942658A7BA339610BBECF_terseLabel_en-US" xlink:label="lab_oncyf_SYNSORBMember_FD1C0B69E8A942658A7BA339610BBECF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SYNSORB</link:label>
    <link:label id="lab_oncyf_SYNSORBMember_FD1C0B69E8A942658A7BA339610BBECF_label_en-US" xlink:label="lab_oncyf_SYNSORBMember_FD1C0B69E8A942658A7BA339610BBECF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SYNSORB [Member]</link:label>
    <link:label id="lab_oncyf_SYNSORBMember_FD1C0B69E8A942658A7BA339610BBECF_documentation_en-US" xlink:label="lab_oncyf_SYNSORBMember_FD1C0B69E8A942658A7BA339610BBECF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SYNSORB [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SYNSORBMember" xlink:label="loc_oncyf_SYNSORBMember_FD1C0B69E8A942658A7BA339610BBECF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SYNSORBMember_FD1C0B69E8A942658A7BA339610BBECF" xlink:to="lab_oncyf_SYNSORBMember_FD1C0B69E8A942658A7BA339610BBECF" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_E84E5E68FF768B670164A339610B217D_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_E84E5E68FF768B670164A339610B217D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of contingent liabilities [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_E84E5E68FF768B670164A339610B217D_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_E84E5E68FF768B670164A339610B217D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of contingent liabilities [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_E84E5E68FF768B670164A339610B217D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_E84E5E68FF768B670164A339610B217D" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_E84E5E68FF768B670164A339610B217D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_DF4AE4A54F5EA15CE95FA339610B6E1A_terseLabel_en-US" xlink:label="lab_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_DF4AE4A54F5EA15CE95FA339610B6E1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment in connection with Share Purchase Agreement</link:label>
    <link:label id="lab_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_DF4AE4A54F5EA15CE95FA339610B6E1A_label_en-US" xlink:label="lab_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_DF4AE4A54F5EA15CE95FA339610B6E1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments made by entity, related party transactions</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:label="loc_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_DF4AE4A54F5EA15CE95FA339610B6E1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_DF4AE4A54F5EA15CE95FA339610B6E1A" xlink:to="lab_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_DF4AE4A54F5EA15CE95FA339610B6E1A" xlink:type="arc" />
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_D719AD6C1877201ED969A339610CE4EC_terseLabel_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_D719AD6C1877201ED969A339610CE4EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment due period</link:label>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_D719AD6C1877201ED969A339610CE4EC_label_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_D719AD6C1877201ED969A339610CE4EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments Made By Entity, Related Party Transactions, Period Due</link:label>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_D719AD6C1877201ED969A339610CE4EC_documentation_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_D719AD6C1877201ED969A339610CE4EC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments Made By Entity, Related Party Transactions, Period Due</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_D719AD6C1877201ED969A339610CE4EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_D719AD6C1877201ED969A339610CE4EC" xlink:to="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_D719AD6C1877201ED969A339610CE4EC" xlink:type="arc" />
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_A91FABEF192E17D7ADC0A339610C3597_terseLabel_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_A91FABEF192E17D7ADC0A339610C3597" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payment due to founding shareholders, percent</link:label>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_A91FABEF192E17D7ADC0A339610C3597_label_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_A91FABEF192E17D7ADC0A339610C3597" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments Made By Entity, Related Party Transactions, Royalty Payment Received,Percentage</link:label>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_A91FABEF192E17D7ADC0A339610C3597_documentation_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_A91FABEF192E17D7ADC0A339610C3597" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments Made By Entity, Related Party Transactions, Royalty Payment Received, Percentage</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_A91FABEF192E17D7ADC0A339610C3597" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_A91FABEF192E17D7ADC0A339610C3597" xlink:to="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_A91FABEF192E17D7ADC0A339610C3597" xlink:type="arc" />
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_E4A82B815EDD22760AF3A339610CE71F_terseLabel_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_E4A82B815EDD22760AF3A339610CE71F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payment on net sales due to founding shareholders, percent</link:label>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_E4A82B815EDD22760AF3A339610CE71F_label_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_E4A82B815EDD22760AF3A339610CE71F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments Made By Entity, Related Party Transactions, Royalty Payment Net Sales, Percentage</link:label>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_E4A82B815EDD22760AF3A339610CE71F_documentation_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_E4A82B815EDD22760AF3A339610CE71F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments Made By Entity, Related Party Transactions, Royalty Payment Net Sales, Percentage</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_E4A82B815EDD22760AF3A339610CE71F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_E4A82B815EDD22760AF3A339610CE71F" xlink:to="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_E4A82B815EDD22760AF3A339610CE71F" xlink:type="arc" />
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_AA8C05918D47B5C3FF0EA339610CC88E_terseLabel_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_AA8C05918D47B5C3FF0EA339610CC88E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payment on sales revenue, percent</link:label>
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_AA8C05918D47B5C3FF0EA339610CC88E_label_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_AA8C05918D47B5C3FF0EA339610CC88E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Royalty Payment, Percent Of Sales Revenue</link:label>
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_AA8C05918D47B5C3FF0EA339610CC88E_documentation_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_AA8C05918D47B5C3FF0EA339610CC88E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Royalty Payment, Percent Of Sales Revenue</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue" xlink:label="loc_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_AA8C05918D47B5C3FF0EA339610CC88E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_AA8C05918D47B5C3FF0EA339610CC88E" xlink:to="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_AA8C05918D47B5C3FF0EA339610CC88E" xlink:type="arc" />
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum_A6E4238FC1662D35EE0DA339610C9309_terseLabel_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum_A6E4238FC1662D35EE0DA339610C9309" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payment maximum</link:label>
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum_A6E4238FC1662D35EE0DA339610C9309_label_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum_A6E4238FC1662D35EE0DA339610C9309" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Royalty Payment, Annual Maximum</link:label>
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum_A6E4238FC1662D35EE0DA339610C9309_documentation_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum_A6E4238FC1662D35EE0DA339610C9309" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Royalty Payment, Annual Maximum</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ContingentRoyaltyPaymentAnnualMaximum" xlink:label="loc_oncyf_ContingentRoyaltyPaymentAnnualMaximum_A6E4238FC1662D35EE0DA339610C9309" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ContingentRoyaltyPaymentAnnualMaximum_A6E4238FC1662D35EE0DA339610C9309" xlink:to="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum_A6E4238FC1662D35EE0DA339610C9309" xlink:type="arc" />
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentContributionRate_C84D88FD9B72FAE11559A339610C03AD_terseLabel_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentContributionRate_C84D88FD9B72FAE11559A339610C03AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty, multiple of work in kind contribution</link:label>
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentContributionRate_C84D88FD9B72FAE11559A339610C03AD_label_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentContributionRate_C84D88FD9B72FAE11559A339610C03AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Royalty Payment, Contribution Rate</link:label>
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentContributionRate_C84D88FD9B72FAE11559A339610C03AD_documentation_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentContributionRate_C84D88FD9B72FAE11559A339610C03AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Royalty Payment, Contribution Rate</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ContingentRoyaltyPaymentContributionRate" xlink:label="loc_oncyf_ContingentRoyaltyPaymentContributionRate_C84D88FD9B72FAE11559A339610C03AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ContingentRoyaltyPaymentContributionRate_C84D88FD9B72FAE11559A339610C03AD" xlink:to="lab_oncyf_ContingentRoyaltyPaymentContributionRate_C84D88FD9B72FAE11559A339610C03AD" xlink:type="arc" />
    <link:label id="lab_oncyf_AccruedRoyalties1_8C04B756E712D7220377A339610D0DD0_terseLabel_en-US" xlink:label="lab_oncyf_AccruedRoyalties1_8C04B756E712D7220377A339610D0DD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated accumulated work in kind total</link:label>
    <link:label id="lab_oncyf_AccruedRoyalties1_8C04B756E712D7220377A339610D0DD0_label_en-US" xlink:label="lab_oncyf_AccruedRoyalties1_8C04B756E712D7220377A339610D0DD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties1</link:label>
    <link:label id="lab_oncyf_AccruedRoyalties1_8C04B756E712D7220377A339610D0DD0_documentation_en-US" xlink:label="lab_oncyf_AccruedRoyalties1_8C04B756E712D7220377A339610D0DD0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Royalties1</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_AccruedRoyalties1" xlink:label="loc_oncyf_AccruedRoyalties1_8C04B756E712D7220377A339610D0DD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AccruedRoyalties1_8C04B756E712D7220377A339610D0DD0" xlink:to="lab_oncyf_AccruedRoyalties1_8C04B756E712D7220377A339610D0DD0" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_F72D952E5549C0D336A29CFE7ED6332F_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_F72D952E5549C0D336A29CFE7ED6332F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_F72D952E5549C0D336A29CFE7ED6332F_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_F72D952E5549C0D336A29CFE7ED6332F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_F72D952E5549C0D336A29CFE7ED6332F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_F72D952E5549C0D336A29CFE7ED6332F" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_F72D952E5549C0D336A29CFE7ED6332F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_7C8A8ADAEC40824FA29B9CFE7ED6DB06_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_7C8A8ADAEC40824FA29B9CFE7ED6DB06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_7C8A8ADAEC40824FA29B9CFE7ED6DB06_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_7C8A8ADAEC40824FA29B9CFE7ED6DB06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_7C8A8ADAEC40824FA29B9CFE7ED6DB06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_7C8A8ADAEC40824FA29B9CFE7ED6DB06" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_7C8A8ADAEC40824FA29B9CFE7ED6DB06" xlink:type="arc" />
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_76C51A52D909D2077DB59CFE7ED61EC3_terseLabel_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember_76C51A52D909D2077DB59CFE7ED61EC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_76C51A52D909D2077DB59CFE7ED61EC3_label_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember_76C51A52D909D2077DB59CFE7ED61EC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_76C51A52D909D2077DB59CFE7ED61EC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_76C51A52D909D2077DB59CFE7ED61EC3" xlink:to="lab_ifrs-full_SharebasedPaymentArrangementsMember_76C51A52D909D2077DB59CFE7ED61EC3" xlink:type="arc" />
    <link:label id="lab_oncyf_RestrictedShareUnitsMember_58A101EC7A0B7BDE05EE9CFE7ED745A4_terseLabel_en-US" xlink:label="lab_oncyf_RestrictedShareUnitsMember_58A101EC7A0B7BDE05EE9CFE7ED745A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted share units</link:label>
    <link:label id="lab_oncyf_RestrictedShareUnitsMember_58A101EC7A0B7BDE05EE9CFE7ED745A4_label_en-US" xlink:label="lab_oncyf_RestrictedShareUnitsMember_58A101EC7A0B7BDE05EE9CFE7ED745A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Units [Member]</link:label>
    <link:label id="lab_oncyf_RestrictedShareUnitsMember_58A101EC7A0B7BDE05EE9CFE7ED745A4_documentation_en-US" xlink:label="lab_oncyf_RestrictedShareUnitsMember_58A101EC7A0B7BDE05EE9CFE7ED745A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Share Units [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_RestrictedShareUnitsMember" xlink:label="loc_oncyf_RestrictedShareUnitsMember_58A101EC7A0B7BDE05EE9CFE7ED745A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_RestrictedShareUnitsMember_58A101EC7A0B7BDE05EE9CFE7ED745A4" xlink:to="lab_oncyf_RestrictedShareUnitsMember_58A101EC7A0B7BDE05EE9CFE7ED745A4" xlink:type="arc" />
    <link:label id="lab_oncyf_PerformanceShareUnitsMember_7D40F457C6A0FCDA7B299CFE7ED74BBD_terseLabel_en-US" xlink:label="lab_oncyf_PerformanceShareUnitsMember_7D40F457C6A0FCDA7B299CFE7ED74BBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance share units</link:label>
    <link:label id="lab_oncyf_PerformanceShareUnitsMember_7D40F457C6A0FCDA7B299CFE7ED74BBD_label_en-US" xlink:label="lab_oncyf_PerformanceShareUnitsMember_7D40F457C6A0FCDA7B299CFE7ED74BBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Share Units [Member]</link:label>
    <link:label id="lab_oncyf_PerformanceShareUnitsMember_7D40F457C6A0FCDA7B299CFE7ED74BBD_documentation_en-US" xlink:label="lab_oncyf_PerformanceShareUnitsMember_7D40F457C6A0FCDA7B299CFE7ED74BBD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Share Units [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_PerformanceShareUnitsMember" xlink:label="loc_oncyf_PerformanceShareUnitsMember_7D40F457C6A0FCDA7B299CFE7ED74BBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PerformanceShareUnitsMember_7D40F457C6A0FCDA7B299CFE7ED74BBD" xlink:to="lab_oncyf_PerformanceShareUnitsMember_7D40F457C6A0FCDA7B299CFE7ED74BBD" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_91674D281DB922AFE3219CFE7ED7F53E_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_91674D281DB922AFE3219CFE7ED7F53E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_91674D281DB922AFE3219CFE7ED7F53E_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_91674D281DB922AFE3219CFE7ED7F53E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_91674D281DB922AFE3219CFE7ED7F53E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_91674D281DB922AFE3219CFE7ED7F53E" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_91674D281DB922AFE3219CFE7ED7F53E" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_352A29F5C696827C21209CFE7ED7E87F_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_352A29F5C696827C21209CFE7ED7E87F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_352A29F5C696827C21209CFE7ED7E87F_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_352A29F5C696827C21209CFE7ED7E87F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_352A29F5C696827C21209CFE7ED7E87F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_352A29F5C696827C21209CFE7ED7E87F" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_352A29F5C696827C21209CFE7ED7E87F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_430070B269544EFF86FD9CFE7ED7C663_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_430070B269544EFF86FD9CFE7ED7C663" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_430070B269544EFF86FD9CFE7ED7C663_label_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_430070B269544EFF86FD9CFE7ED7C663" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments granted in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_430070B269544EFF86FD9CFE7ED7C663" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_430070B269544EFF86FD9CFE7ED7C663" xlink:to="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_430070B269544EFF86FD9CFE7ED7C663" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_29F57E8A8FF3172D3F769CFE7ED8ADB7_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_29F57E8A8FF3172D3F769CFE7ED8ADB7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_29F57E8A8FF3172D3F769CFE7ED8ADB7_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_29F57E8A8FF3172D3F769CFE7ED8ADB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_29F57E8A8FF3172D3F769CFE7ED8ADB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_29F57E8A8FF3172D3F769CFE7ED8ADB7" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_29F57E8A8FF3172D3F769CFE7ED8ADB7" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_CD181AFCBFCC8874AC5E9CFE7ED861DD_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_CD181AFCBFCC8874AC5E9CFE7ED861DD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_CD181AFCBFCC8874AC5E9CFE7ED861DD_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_CD181AFCBFCC8874AC5E9CFE7ED861DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_CD181AFCBFCC8874AC5E9CFE7ED861DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_CD181AFCBFCC8874AC5E9CFE7ED861DD" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_CD181AFCBFCC8874AC5E9CFE7ED861DD" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_5BD261D12266E27EE2D59CFE7ED86BBF_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_5BD261D12266E27EE2D59CFE7ED86BBF" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, end of the year (shares)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_5BD261D12266E27EE2D59CFE7ED86BBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_5BD261D12266E27EE2D59CFE7ED86BBF" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_5BD261D12266E27EE2D59CFE7ED86BBF" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_CA00C1DEC256F65B91799CFE7ED876BA_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_CA00C1DEC256F65B91799CFE7ED876BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value at measurement date, other equity instruments granted</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_CA00C1DEC256F65B91799CFE7ED876BA_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_CA00C1DEC256F65B91799CFE7ED876BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average fair value at measurement date, other equity instruments granted</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_CA00C1DEC256F65B91799CFE7ED876BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_CA00C1DEC256F65B91799CFE7ED876BA" xlink:to="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_CA00C1DEC256F65B91799CFE7ED876BA" xlink:type="arc" />
    <link:label id="lab_oncyf_NumberOfStockOptionPlans_82011BB6D7B5A15FBE81A683647CC8DE_terseLabel_en-US" xlink:label="lab_oncyf_NumberOfStockOptionPlans_82011BB6D7B5A15FBE81A683647CC8DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of plans</link:label>
    <link:label id="lab_oncyf_NumberOfStockOptionPlans_82011BB6D7B5A15FBE81A683647CC8DE_label_en-US" xlink:label="lab_oncyf_NumberOfStockOptionPlans_82011BB6D7B5A15FBE81A683647CC8DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Stock Option Plans</link:label>
    <link:label id="lab_oncyf_NumberOfStockOptionPlans_82011BB6D7B5A15FBE81A683647CC8DE_documentation_en-US" xlink:label="lab_oncyf_NumberOfStockOptionPlans_82011BB6D7B5A15FBE81A683647CC8DE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Stock Option Plans</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_NumberOfStockOptionPlans" xlink:label="loc_oncyf_NumberOfStockOptionPlans_82011BB6D7B5A15FBE81A683647CC8DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberOfStockOptionPlans_82011BB6D7B5A15FBE81A683647CC8DE" xlink:to="lab_oncyf_NumberOfStockOptionPlans_82011BB6D7B5A15FBE81A683647CC8DE" xlink:type="arc" />
    <link:label id="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_BF19F19BF632D198F835A683647C462F_terseLabel_en-US" xlink:label="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_BF19F19BF632D198F835A683647C462F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum option expiration term</link:label>
    <link:label id="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_BF19F19BF632D198F835A683647C462F_label_en-US" xlink:label="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_BF19F19BF632D198F835A683647C462F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Term Of Options Granted For Share-based Payment Arrangement</link:label>
    <link:label id="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_BF19F19BF632D198F835A683647C462F_documentation_en-US" xlink:label="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_BF19F19BF632D198F835A683647C462F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Term Of Options Granted For Share-based Payment Arrangement</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:label="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_BF19F19BF632D198F835A683647C462F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_BF19F19BF632D198F835A683647C462F" xlink:to="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_BF19F19BF632D198F835A683647C462F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_F5109232D1E0D3B268FFA7AEBA33339C_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_F5109232D1E0D3B268FFA7AEBA33339C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of change in fair value of warrant derivative</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_F5109232D1E0D3B268FFA7AEBA33339C_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_F5109232D1E0D3B268FFA7AEBA33339C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_F5109232D1E0D3B268FFA7AEBA33339C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_F5109232D1E0D3B268FFA7AEBA33339C" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_F5109232D1E0D3B268FFA7AEBA33339C" xlink:type="arc" />
    <link:label id="lab_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_4699A9EA06F44ABFBF5A9CFE7EADE899_terseLabel_en-US" xlink:label="lab_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_4699A9EA06F44ABFBF5A9CFE7EADE899" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_4699A9EA06F44ABFBF5A9CFE7EADE899_label_en-US" xlink:label="lab_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_4699A9EA06F44ABFBF5A9CFE7EADE899" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Short Term Investments [Text Block]</link:label>
    <link:label id="lab_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_4699A9EA06F44ABFBF5A9CFE7EADE899_documentation_en-US" xlink:label="lab_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_4699A9EA06F44ABFBF5A9CFE7EADE899" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Short Term Investments [Text Block]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="loc_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_4699A9EA06F44ABFBF5A9CFE7EADE899" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_4699A9EA06F44ABFBF5A9CFE7EADE899" xlink:to="lab_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_4699A9EA06F44ABFBF5A9CFE7EADE899" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_E036C4C538383B9B9DD09CFE7EB15F36_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_E036C4C538383B9B9DD09CFE7EB15F36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_E036C4C538383B9B9DD09CFE7EB15F36_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_E036C4C538383B9B9DD09CFE7EB15F36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_E036C4C538383B9B9DD09CFE7EB15F36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_E036C4C538383B9B9DD09CFE7EB15F36" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_E036C4C538383B9B9DD09CFE7EB15F36" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5A67AB9A0710E93BCC149CFE7EB235DA_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5A67AB9A0710E93BCC149CFE7EB235DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5A67AB9A0710E93BCC149CFE7EB235DA_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5A67AB9A0710E93BCC149CFE7EB235DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5A67AB9A0710E93BCC149CFE7EB235DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5A67AB9A0710E93BCC149CFE7EB235DA" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5A67AB9A0710E93BCC149CFE7EB235DA" xlink:type="arc" />
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_904BA2778CD804ACA8C69CFE7EB2E4C9_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember_904BA2778CD804ACA8C69CFE7EB2E4C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [member]</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_904BA2778CD804ACA8C69CFE7EB2E4C9_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember_904BA2778CD804ACA8C69CFE7EB2E4C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_904BA2778CD804ACA8C69CFE7EB2E4C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_904BA2778CD804ACA8C69CFE7EB2E4C9" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentMember_904BA2778CD804ACA8C69CFE7EB2E4C9" xlink:type="arc" />
    <link:label id="lab_oncyf_MedicalEquipmentMember_49000A47021E8964AE429CFE7EB2C38F_terseLabel_en-US" xlink:label="lab_oncyf_MedicalEquipmentMember_49000A47021E8964AE429CFE7EB2C38F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical equipment</link:label>
    <link:label id="lab_oncyf_MedicalEquipmentMember_49000A47021E8964AE429CFE7EB2C38F_label_en-US" xlink:label="lab_oncyf_MedicalEquipmentMember_49000A47021E8964AE429CFE7EB2C38F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Equipment [Member]</link:label>
    <link:label id="lab_oncyf_MedicalEquipmentMember_49000A47021E8964AE429CFE7EB2C38F_documentation_en-US" xlink:label="lab_oncyf_MedicalEquipmentMember_49000A47021E8964AE429CFE7EB2C38F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medical Equipment [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_MedicalEquipmentMember" xlink:label="loc_oncyf_MedicalEquipmentMember_49000A47021E8964AE429CFE7EB2C38F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_MedicalEquipmentMember_49000A47021E8964AE429CFE7EB2C38F" xlink:to="lab_oncyf_MedicalEquipmentMember_49000A47021E8964AE429CFE7EB2C38F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_67E4113C5F2A6B8692B69CFE7EB2DDD9_terseLabel_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember_67E4113C5F2A6B8692B69CFE7EB2DDD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_67E4113C5F2A6B8692B69CFE7EB2DDD9_label_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember_67E4113C5F2A6B8692B69CFE7EB2DDD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer equipment [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-full_ComputerEquipmentMember_67E4113C5F2A6B8692B69CFE7EB2DDD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerEquipmentMember_67E4113C5F2A6B8692B69CFE7EB2DDD9" xlink:to="lab_ifrs-full_ComputerEquipmentMember_67E4113C5F2A6B8692B69CFE7EB2DDD9" xlink:type="arc" />
    <link:label id="lab_ifrs-full_FixturesAndFittingsMember_B78D68CA068E16B9093B9CFE7EB3C872_terseLabel_en-US" xlink:label="lab_ifrs-full_FixturesAndFittingsMember_B78D68CA068E16B9093B9CFE7EB3C872" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office Furniture</link:label>
    <link:label id="lab_ifrs-full_FixturesAndFittingsMember_B78D68CA068E16B9093B9CFE7EB3C872_label_en-US" xlink:label="lab_ifrs-full_FixturesAndFittingsMember_B78D68CA068E16B9093B9CFE7EB3C872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixtures and fittings [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FixturesAndFittingsMember" xlink:label="loc_ifrs-full_FixturesAndFittingsMember_B78D68CA068E16B9093B9CFE7EB3C872" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FixturesAndFittingsMember_B78D68CA068E16B9093B9CFE7EB3C872" xlink:to="lab_ifrs-full_FixturesAndFittingsMember_B78D68CA068E16B9093B9CFE7EB3C872" xlink:type="arc" />
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_4CE896552FEA39E30D9B9CFE7EB3CAE7_verboseLabel_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember_4CE896552FEA39E30D9B9CFE7EB3CAE7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Office Equipment</link:label>
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_4CE896552FEA39E30D9B9CFE7EB3CAE7_label_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember_4CE896552FEA39E30D9B9CFE7EB3CAE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office equipment [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="loc_ifrs-full_OfficeEquipmentMember_4CE896552FEA39E30D9B9CFE7EB3CAE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OfficeEquipmentMember_4CE896552FEA39E30D9B9CFE7EB3CAE7" xlink:to="lab_ifrs-full_OfficeEquipmentMember_4CE896552FEA39E30D9B9CFE7EB3CAE7" xlink:type="arc" />
    <link:label id="lab_ifrs-full_LeaseholdImprovementsMember_130F1D3CAA00832C33789CFE7EB3AA1F_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseholdImprovementsMember_130F1D3CAA00832C33789CFE7EB3AA1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_ifrs-full_LeaseholdImprovementsMember_130F1D3CAA00832C33789CFE7EB3AA1F_label_en-US" xlink:label="lab_ifrs-full_LeaseholdImprovementsMember_130F1D3CAA00832C33789CFE7EB3AA1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold improvements [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_130F1D3CAA00832C33789CFE7EB3AA1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseholdImprovementsMember_130F1D3CAA00832C33789CFE7EB3AA1F" xlink:to="lab_ifrs-full_LeaseholdImprovementsMember_130F1D3CAA00832C33789CFE7EB3AA1F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CDD06685E80DE81D046B9CFE7EB30406_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CDD06685E80DE81D046B9CFE7EB30406" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CDD06685E80DE81D046B9CFE7EB30406_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CDD06685E80DE81D046B9CFE7EB30406" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CDD06685E80DE81D046B9CFE7EB30406" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CDD06685E80DE81D046B9CFE7EB30406" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CDD06685E80DE81D046B9CFE7EB30406" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CarryingAmountMember_DF68B4E84C871CB675439CFE7EB3184E_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember_DF68B4E84C871CB675439CFE7EB3184E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountMember_DF68B4E84C871CB675439CFE7EB3184E_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember_DF68B4E84C871CB675439CFE7EB3184E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_DF68B4E84C871CB675439CFE7EB3184E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountMember_DF68B4E84C871CB675439CFE7EB3184E" xlink:to="lab_ifrs-full_CarryingAmountMember_DF68B4E84C871CB675439CFE7EB3184E" xlink:type="arc" />
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_C8D77C29F6ACECE0AD3B9CFE7EB4A1DA_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember_C8D77C29F6ACECE0AD3B9CFE7EB4A1DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_C8D77C29F6ACECE0AD3B9CFE7EB4A1DA_label_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember_C8D77C29F6ACECE0AD3B9CFE7EB4A1DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross carrying amount [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_C8D77C29F6ACECE0AD3B9CFE7EB4A1DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember_C8D77C29F6ACECE0AD3B9CFE7EB4A1DA" xlink:to="lab_ifrs-full_GrossCarryingAmountMember_C8D77C29F6ACECE0AD3B9CFE7EB4A1DA" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_3640086B7DA683CF71949CFE7EB487C5_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_3640086B7DA683CF71949CFE7EB487C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_3640086B7DA683CF71949CFE7EB487C5_label_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_3640086B7DA683CF71949CFE7EB487C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated depreciation and amortisation [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_3640086B7DA683CF71949CFE7EB487C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_3640086B7DA683CF71949CFE7EB487C5" xlink:to="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_3640086B7DA683CF71949CFE7EB487C5" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_14DD8E1CD0CD63F57FF19CFE7EB45667_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_14DD8E1CD0CD63F57FF19CFE7EB45667" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_14DD8E1CD0CD63F57FF19CFE7EB45667_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_14DD8E1CD0CD63F57FF19CFE7EB45667" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_14DD8E1CD0CD63F57FF19CFE7EB45667" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_14DD8E1CD0CD63F57FF19CFE7EB45667" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_14DD8E1CD0CD63F57FF19CFE7EB45667" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_61FA93BE16FE9234DBEF9CFE7EB46F08_terseLabel_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_61FA93BE16FE9234DBEF9CFE7EB46F08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in property, plant and equipment [abstract]</link:label>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_61FA93BE16FE9234DBEF9CFE7EB46F08_label_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_61FA93BE16FE9234DBEF9CFE7EB46F08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in property, plant and equipment [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_61FA93BE16FE9234DBEF9CFE7EB46F08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_61FA93BE16FE9234DBEF9CFE7EB46F08" xlink:to="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_61FA93BE16FE9234DBEF9CFE7EB46F08" xlink:type="arc" />
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_9AF8A5675D60819A60259CFE7EB487F0_periodStartLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment_9AF8A5675D60819A60259CFE7EB487F0" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_9AF8A5675D60819A60259CFE7EB487F0_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment_9AF8A5675D60819A60259CFE7EB487F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_9AF8A5675D60819A60259CFE7EB487F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment_9AF8A5675D60819A60259CFE7EB487F0" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment_9AF8A5675D60819A60259CFE7EB487F0" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_9F5B2D266D16FBAEF5F89CFE7EB5A88D_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_9F5B2D266D16FBAEF5F89CFE7EB5A88D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_9F5B2D266D16FBAEF5F89CFE7EB5A88D_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_9F5B2D266D16FBAEF5F89CFE7EB5A88D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_9F5B2D266D16FBAEF5F89CFE7EB5A88D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_9F5B2D266D16FBAEF5F89CFE7EB5A88D" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_9F5B2D266D16FBAEF5F89CFE7EB5A88D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_255B3E31CCD04B63FCD69CFE7EB50053_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_255B3E31CCD04B63FCD69CFE7EB50053" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Disposals</link:label>
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_255B3E31CCD04B63FCD69CFE7EB50053_label_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_255B3E31CCD04B63FCD69CFE7EB50053" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals, property, plant and equipment</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_255B3E31CCD04B63FCD69CFE7EB50053" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_255B3E31CCD04B63FCD69CFE7EB50053" xlink:to="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_255B3E31CCD04B63FCD69CFE7EB50053" xlink:type="arc" />
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_7A648843F9B75998567A9CFE7EB54093_periodEndLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment_7A648843F9B75998567A9CFE7EB54093" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_7A648843F9B75998567A9CFE7EB54093" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment_7A648843F9B75998567A9CFE7EB54093" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment_7A648843F9B75998567A9CFE7EB54093" xlink:type="arc" />
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_342AB707FD3134F6B2009D034CACFE6E_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract_342AB707FD3134F6B2009D034CACFE6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_342AB707FD3134F6B2009D034CACFE6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_342AB707FD3134F6B2009D034CACFE6E" xlink:to="lab_ifrs-full_EarningsPerShareAbstract_342AB707FD3134F6B2009D034CACFE6E" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageShares_7EE9E13EEC557FC927909D034CAC6D21_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares_7EE9E13EEC557FC927909D034CAC6D21" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding (shares)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares_7EE9E13EEC557FC927909D034CAC6D21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares_7EE9E13EEC557FC927909D034CAC6D21" xlink:to="lab_ifrs-full_WeightedAverageShares_7EE9E13EEC557FC927909D034CAC6D21" xlink:type="arc" />
    <link:label id="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_C3E4CBEE2F3F007A55A59CFE7E0C9341_label_en-US" xlink:label="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_C3E4CBEE2F3F007A55A59CFE7E0C9341" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Notes And Other Explanatory Information [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_C3E4CBEE2F3F007A55A59CFE7E0C9341_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_C3E4CBEE2F3F007A55A59CFE7E0C9341" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Notes And Other Explanatory Information [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_C3E4CBEE2F3F007A55A59CFE7E0C9341" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_C3E4CBEE2F3F007A55A59CFE7E0C9341" xlink:to="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_C3E4CBEE2F3F007A55A59CFE7E0C9341" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_A47D27F45FB095E4030B9CFE7E0C058B_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_A47D27F45FB095E4030B9CFE7E0C058B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incorporation and Nature of Operations</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_A47D27F45FB095E4030B9CFE7E0C058B_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_A47D27F45FB095E4030B9CFE7E0C058B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of general information about financial statements [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_A47D27F45FB095E4030B9CFE7E0C058B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_A47D27F45FB095E4030B9CFE7E0C058B" xlink:to="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_A47D27F45FB095E4030B9CFE7E0C058B" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_2104FF7A9AF8F9F187259CFE7EA0A999_terseLabel_en-US" xlink:label="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_2104FF7A9AF8F9F187259CFE7EA0A999" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liability balances</link:label>
    <link:label id="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_2104FF7A9AF8F9F187259CFE7EA0A999_label_en-US" xlink:label="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_2104FF7A9AF8F9F187259CFE7EA0A999" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Explanation of significant changes in contract assets and contract liabilities [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:label="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_2104FF7A9AF8F9F187259CFE7EA0A999" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_2104FF7A9AF8F9F187259CFE7EA0A999" xlink:to="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_2104FF7A9AF8F9F187259CFE7EA0A999" xlink:type="arc" />
    <link:label id="lab_ifrs-full_RightofuseAssets_A60B310B5177C99E69EAA1A52F417754_periodStartLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets_A60B310B5177C99E69EAA1A52F417754" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_A60B310B5177C99E69EAA1A52F417754" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets_A60B310B5177C99E69EAA1A52F417754" xlink:to="lab_ifrs-full_RightofuseAssets_A60B310B5177C99E69EAA1A52F417754" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_A77B9BE24960A8F7A444A1A52F427426_negatedLabel_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets_A77B9BE24960A8F7A444A1A52F427426" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_A77B9BE24960A8F7A444A1A52F427426" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationRightofuseAssets_A77B9BE24960A8F7A444A1A52F427426" xlink:to="lab_ifrs-full_DepreciationRightofuseAssets_A77B9BE24960A8F7A444A1A52F427426" xlink:type="arc" />
    <link:label id="lab_oncyf_ForeignExchangeImpactRightofUseAssets_A4848A8A1C006CDCA3FFA1A52F42EA6A_terseLabel_en-US" xlink:label="lab_oncyf_ForeignExchangeImpactRightofUseAssets_A4848A8A1C006CDCA3FFA1A52F42EA6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange impact</link:label>
    <link:label id="lab_oncyf_ForeignExchangeImpactRightofUseAssets_A4848A8A1C006CDCA3FFA1A52F42EA6A_label_en-US" xlink:label="lab_oncyf_ForeignExchangeImpactRightofUseAssets_A4848A8A1C006CDCA3FFA1A52F42EA6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Impact, Right-of-Use Assets</link:label>
    <link:label id="lab_oncyf_ForeignExchangeImpactRightofUseAssets_A4848A8A1C006CDCA3FFA1A52F42EA6A_documentation_en-US" xlink:label="lab_oncyf_ForeignExchangeImpactRightofUseAssets_A4848A8A1C006CDCA3FFA1A52F42EA6A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign Exchange Impact, Right-of-Use Assets</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ForeignExchangeImpactRightofUseAssets" xlink:label="loc_oncyf_ForeignExchangeImpactRightofUseAssets_A4848A8A1C006CDCA3FFA1A52F42EA6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ForeignExchangeImpactRightofUseAssets_A4848A8A1C006CDCA3FFA1A52F42EA6A" xlink:to="lab_oncyf_ForeignExchangeImpactRightofUseAssets_A4848A8A1C006CDCA3FFA1A52F42EA6A" xlink:type="arc" />
    <link:label id="lab_ifrs-full_RightofuseAssets_19DF4AC0F525C93F89EDA25609047A85_periodEndLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets_19DF4AC0F525C93F89EDA25609047A85" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_19DF4AC0F525C93F89EDA25609047A85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets_19DF4AC0F525C93F89EDA25609047A85" xlink:to="lab_ifrs-full_RightofuseAssets_19DF4AC0F525C93F89EDA25609047A85" xlink:type="arc" />
    <link:label id="lab_ifrs-full_LeaseLiabilities_1EDBFD18B4323967F847A1A52F42C510_periodStartLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities_1EDBFD18B4323967F847A1A52F42C510" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-full_LeaseLiabilities_1EDBFD18B4323967F847A1A52F42C510" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities_1EDBFD18B4323967F847A1A52F42C510" xlink:to="lab_ifrs-full_LeaseLiabilities_1EDBFD18B4323967F847A1A52F42C510" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CashOutflowForLeases_09BA399C590F95986D9FA1A52F42C75D_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases_09BA399C590F95986D9FA1A52F42C75D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of lease liabilities</link:label>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_09BA399C590F95986D9FA1A52F42C75D_label_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases_09BA399C590F95986D9FA1A52F42C75D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash outflow for leases</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashOutflowForLeases" xlink:label="loc_ifrs-full_CashOutflowForLeases_09BA399C590F95986D9FA1A52F42C75D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashOutflowForLeases_09BA399C590F95986D9FA1A52F42C75D" xlink:to="lab_ifrs-full_CashOutflowForLeases_09BA399C590F95986D9FA1A52F42C75D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_86B7EDD83C55CC435028A1A52F425FCB_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_86B7EDD83C55CC435028A1A52F425FCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_86B7EDD83C55CC435028A1A52F425FCB_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_86B7EDD83C55CC435028A1A52F425FCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_86B7EDD83C55CC435028A1A52F425FCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_86B7EDD83C55CC435028A1A52F425FCB" xlink:to="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_86B7EDD83C55CC435028A1A52F425FCB" xlink:type="arc" />
    <link:label id="lab_oncyf_GainsLossesfromForeignExchangeImpact_EB900C981774FB394FD4A1A52F42F2AD_terseLabel_en-US" xlink:label="lab_oncyf_GainsLossesfromForeignExchangeImpact_EB900C981774FB394FD4A1A52F42F2AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange impact</link:label>
    <link:label id="lab_oncyf_GainsLossesfromForeignExchangeImpact_EB900C981774FB394FD4A1A52F42F2AD_label_en-US" xlink:label="lab_oncyf_GainsLossesfromForeignExchangeImpact_EB900C981774FB394FD4A1A52F42F2AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (Losses) from Foreign Exchange Impact</link:label>
    <link:label id="lab_oncyf_GainsLossesfromForeignExchangeImpact_EB900C981774FB394FD4A1A52F42F2AD_documentation_en-US" xlink:label="lab_oncyf_GainsLossesfromForeignExchangeImpact_EB900C981774FB394FD4A1A52F42F2AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gains (Losses) from Foreign Exchange Impact</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_GainsLossesfromForeignExchangeImpact" xlink:label="loc_oncyf_GainsLossesfromForeignExchangeImpact_EB900C981774FB394FD4A1A52F42F2AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_GainsLossesfromForeignExchangeImpact_EB900C981774FB394FD4A1A52F42F2AD" xlink:to="lab_oncyf_GainsLossesfromForeignExchangeImpact_EB900C981774FB394FD4A1A52F42F2AD" xlink:type="arc" />
    <link:label id="lab_ifrs-full_LeaseLiabilities_2C04F88D4D04D2F8CE0CA256855127D7_periodEndLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities_2C04F88D4D04D2F8CE0CA256855127D7" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-full_LeaseLiabilities_2C04F88D4D04D2F8CE0CA256855127D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities_2C04F88D4D04D2F8CE0CA256855127D7" xlink:to="lab_ifrs-full_LeaseLiabilities_2C04F88D4D04D2F8CE0CA256855127D7" xlink:type="arc" />
    <link:label id="lab_oncyf_FairValueofWarrantIssuedPerWarrant_9F0875F7D157F1D9CC22A82B18F55BC1_terseLabel_en-US" xlink:label="lab_oncyf_FairValueofWarrantIssuedPerWarrant_9F0875F7D157F1D9CC22A82B18F55BC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value per warrant (usd per share)</link:label>
    <link:label id="lab_oncyf_FairValueofWarrantIssuedPerWarrant_9F0875F7D157F1D9CC22A82B18F55BC1_label_en-US" xlink:label="lab_oncyf_FairValueofWarrantIssuedPerWarrant_9F0875F7D157F1D9CC22A82B18F55BC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Warrant Issued, Per Warrant</link:label>
    <link:label id="lab_oncyf_FairValueofWarrantIssuedPerWarrant_9F0875F7D157F1D9CC22A82B18F55BC1_documentation_en-US" xlink:label="lab_oncyf_FairValueofWarrantIssuedPerWarrant_9F0875F7D157F1D9CC22A82B18F55BC1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value of Warrant Issued, Per Warrant</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_FairValueofWarrantIssuedPerWarrant" xlink:label="loc_oncyf_FairValueofWarrantIssuedPerWarrant_9F0875F7D157F1D9CC22A82B18F55BC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_FairValueofWarrantIssuedPerWarrant_9F0875F7D157F1D9CC22A82B18F55BC1" xlink:to="lab_oncyf_FairValueofWarrantIssuedPerWarrant_9F0875F7D157F1D9CC22A82B18F55BC1" xlink:type="arc" />
    <link:label id="lab_oncyf_WarrantIssuedUnderlyingSharePrice_481D127FA0C5099CDB46A82B18F5BF15_terseLabel_en-US" xlink:label="lab_oncyf_WarrantIssuedUnderlyingSharePrice_481D127FA0C5099CDB46A82B18F5BF15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying share price (usd per share)</link:label>
    <link:label id="lab_oncyf_WarrantIssuedUnderlyingSharePrice_481D127FA0C5099CDB46A82B18F5BF15_label_en-US" xlink:label="lab_oncyf_WarrantIssuedUnderlyingSharePrice_481D127FA0C5099CDB46A82B18F5BF15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Issued, Underlying Share Price</link:label>
    <link:label id="lab_oncyf_WarrantIssuedUnderlyingSharePrice_481D127FA0C5099CDB46A82B18F5BF15_documentation_en-US" xlink:label="lab_oncyf_WarrantIssuedUnderlyingSharePrice_481D127FA0C5099CDB46A82B18F5BF15" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Issued, Underlying Share Price</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantIssuedUnderlyingSharePrice" xlink:label="loc_oncyf_WarrantIssuedUnderlyingSharePrice_481D127FA0C5099CDB46A82B18F5BF15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantIssuedUnderlyingSharePrice_481D127FA0C5099CDB46A82B18F5BF15" xlink:to="lab_oncyf_WarrantIssuedUnderlyingSharePrice_481D127FA0C5099CDB46A82B18F5BF15" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_9EFABCDEA5A1908F17DBA82B18F614FF_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_9EFABCDEA5A1908F17DBA82B18F614FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_9EFABCDEA5A1908F17DBA82B18F614FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_9EFABCDEA5A1908F17DBA82B18F614FF" xlink:to="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_9EFABCDEA5A1908F17DBA82B18F614FF" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_6662CD1BCC5EA0CB379BA82B18F69C49_verboseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_6662CD1BCC5EA0CB379BA82B18F69C49" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected hold period to exercise</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_6662CD1BCC5EA0CB379BA82B18F69C49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_6662CD1BCC5EA0CB379BA82B18F69C49" xlink:to="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_6662CD1BCC5EA0CB379BA82B18F69C49" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_1E1D9DB0CE06E872BC16A82B18F6559B_verboseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_1E1D9DB0CE06E872BC16A82B18F6559B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Volatility in the price of the Company's shares</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_1E1D9DB0CE06E872BC16A82B18F6559B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_1E1D9DB0CE06E872BC16A82B18F6559B" xlink:to="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_1E1D9DB0CE06E872BC16A82B18F6559B" xlink:type="arc" />
    <link:label id="lab_oncyf_DividendYieldPercent_F00887EB6C3ABE26C9D2A82B18F6A249_verboseLabel_en-US" xlink:label="lab_oncyf_DividendYieldPercent_F00887EB6C3ABE26C9D2A82B18F6A249" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_oncyf_DividendYieldPercent_F00887EB6C3ABE26C9D2A82B18F6A249_label_en-US" xlink:label="lab_oncyf_DividendYieldPercent_F00887EB6C3ABE26C9D2A82B18F6A249" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend Yield, Percent</link:label>
    <link:label id="lab_oncyf_DividendYieldPercent_F00887EB6C3ABE26C9D2A82B18F6A249_documentation_en-US" xlink:label="lab_oncyf_DividendYieldPercent_F00887EB6C3ABE26C9D2A82B18F6A249" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dividend Yield, Percent</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DividendYieldPercent" xlink:label="loc_oncyf_DividendYieldPercent_F00887EB6C3ABE26C9D2A82B18F6A249" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DividendYieldPercent_F00887EB6C3ABE26C9D2A82B18F6A249" xlink:to="lab_oncyf_DividendYieldPercent_F00887EB6C3ABE26C9D2A82B18F6A249" xlink:type="arc" />
    <link:label id="lab_oncyf_DisclosureofincometaxAbstract_4A925B745C5067F49BAE9CFE7F70D629_label_en-US" xlink:label="lab_oncyf_DisclosureofincometaxAbstract_4A925B745C5067F49BAE9CFE7F70D629" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofincometaxAbstract_4A925B745C5067F49BAE9CFE7F70D629_documentation_en-US" xlink:label="lab_oncyf_DisclosureofincometaxAbstract_4A925B745C5067F49BAE9CFE7F70D629" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofincometaxAbstract" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_4A925B745C5067F49BAE9CFE7F70D629" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_4A925B745C5067F49BAE9CFE7F70D629" xlink:to="lab_oncyf_DisclosureofincometaxAbstract_4A925B745C5067F49BAE9CFE7F70D629" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ADCDFF9E8E669B9977899CFE7F709427_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ADCDFF9E8E669B9977899CFE7F709427" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ADCDFF9E8E669B9977899CFE7F709427_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ADCDFF9E8E669B9977899CFE7F709427" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ADCDFF9E8E669B9977899CFE7F709427" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ADCDFF9E8E669B9977899CFE7F709427" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ADCDFF9E8E669B9977899CFE7F709427" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyTwentySixMember_260326053A1D3DE1B5559CFE7F71154A_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentySixMember_260326053A1D3DE1B5559CFE7F71154A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_oncyf_TwentyTwentySixMember_260326053A1D3DE1B5559CFE7F71154A_label_en-US" xlink:label="lab_oncyf_TwentyTwentySixMember_260326053A1D3DE1B5559CFE7F71154A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Twenty Six [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentySixMember_260326053A1D3DE1B5559CFE7F71154A_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentySixMember_260326053A1D3DE1B5559CFE7F71154A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Twenty Six [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentySixMember" xlink:label="loc_oncyf_TwentyTwentySixMember_260326053A1D3DE1B5559CFE7F71154A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentySixMember_260326053A1D3DE1B5559CFE7F71154A" xlink:to="lab_oncyf_TwentyTwentySixMember_260326053A1D3DE1B5559CFE7F71154A" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyTwentySevenMember_01A40582701C528ECCCB9CFE7F718398_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentySevenMember_01A40582701C528ECCCB9CFE7F718398" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_oncyf_TwentyTwentySevenMember_01A40582701C528ECCCB9CFE7F718398_label_en-US" xlink:label="lab_oncyf_TwentyTwentySevenMember_01A40582701C528ECCCB9CFE7F718398" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Twenty Seven [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentySevenMember_01A40582701C528ECCCB9CFE7F718398_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentySevenMember_01A40582701C528ECCCB9CFE7F718398" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Twenty Seven [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentySevenMember" xlink:label="loc_oncyf_TwentyTwentySevenMember_01A40582701C528ECCCB9CFE7F718398" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentySevenMember_01A40582701C528ECCCB9CFE7F718398" xlink:to="lab_oncyf_TwentyTwentySevenMember_01A40582701C528ECCCB9CFE7F718398" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyTwentyNineMember_B084DAC1F4A717001E9E9CFE7F722E79_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyNineMember_B084DAC1F4A717001E9E9CFE7F722E79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_oncyf_TwentyTwentyNineMember_B084DAC1F4A717001E9E9CFE7F722E79_label_en-US" xlink:label="lab_oncyf_TwentyTwentyNineMember_B084DAC1F4A717001E9E9CFE7F722E79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Twenty Nine [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyNineMember_B084DAC1F4A717001E9E9CFE7F722E79_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyNineMember_B084DAC1F4A717001E9E9CFE7F722E79" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Twenty Nine [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyNineMember" xlink:label="loc_oncyf_TwentyTwentyNineMember_B084DAC1F4A717001E9E9CFE7F722E79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyNineMember_B084DAC1F4A717001E9E9CFE7F722E79" xlink:to="lab_oncyf_TwentyTwentyNineMember_B084DAC1F4A717001E9E9CFE7F722E79" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyThirtyMember_9385978711F07FA456DF9CFE7F729C9D_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyMember_9385978711F07FA456DF9CFE7F729C9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030</link:label>
    <link:label id="lab_oncyf_TwentyThirtyMember_9385978711F07FA456DF9CFE7F729C9D_label_en-US" xlink:label="lab_oncyf_TwentyThirtyMember_9385978711F07FA456DF9CFE7F729C9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Thirty [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyMember_9385978711F07FA456DF9CFE7F729C9D_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyMember_9385978711F07FA456DF9CFE7F729C9D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Thirty [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyMember" xlink:label="loc_oncyf_TwentyThirtyMember_9385978711F07FA456DF9CFE7F729C9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyMember_9385978711F07FA456DF9CFE7F729C9D" xlink:to="lab_oncyf_TwentyThirtyMember_9385978711F07FA456DF9CFE7F729C9D" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyThirtyOneMember_C83828689FCEE12224459CFE7F72B907_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyOneMember_C83828689FCEE12224459CFE7F72B907" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2031</link:label>
    <link:label id="lab_oncyf_TwentyThirtyOneMember_C83828689FCEE12224459CFE7F72B907_label_en-US" xlink:label="lab_oncyf_TwentyThirtyOneMember_C83828689FCEE12224459CFE7F72B907" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Thirty One [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyOneMember_C83828689FCEE12224459CFE7F72B907_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyOneMember_C83828689FCEE12224459CFE7F72B907" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Thirty One [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyOneMember" xlink:label="loc_oncyf_TwentyThirtyOneMember_C83828689FCEE12224459CFE7F72B907" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyOneMember_C83828689FCEE12224459CFE7F72B907" xlink:to="lab_oncyf_TwentyThirtyOneMember_C83828689FCEE12224459CFE7F72B907" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyThirtyTwoMember_3160433D34F3DBCDBD219CFE7F72FD16_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyTwoMember_3160433D34F3DBCDBD219CFE7F72FD16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2032</link:label>
    <link:label id="lab_oncyf_TwentyThirtyTwoMember_3160433D34F3DBCDBD219CFE7F72FD16_label_en-US" xlink:label="lab_oncyf_TwentyThirtyTwoMember_3160433D34F3DBCDBD219CFE7F72FD16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Thirty Two [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyTwoMember_3160433D34F3DBCDBD219CFE7F72FD16_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyTwoMember_3160433D34F3DBCDBD219CFE7F72FD16" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Thirty Two [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyTwoMember" xlink:label="loc_oncyf_TwentyThirtyTwoMember_3160433D34F3DBCDBD219CFE7F72FD16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyTwoMember_3160433D34F3DBCDBD219CFE7F72FD16" xlink:to="lab_oncyf_TwentyThirtyTwoMember_3160433D34F3DBCDBD219CFE7F72FD16" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyThirtyThreeMember_BBC21835AE93F4D40EC99CFE7F7229B5_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyThreeMember_BBC21835AE93F4D40EC99CFE7F7229B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2033</link:label>
    <link:label id="lab_oncyf_TwentyThirtyThreeMember_BBC21835AE93F4D40EC99CFE7F7229B5_label_en-US" xlink:label="lab_oncyf_TwentyThirtyThreeMember_BBC21835AE93F4D40EC99CFE7F7229B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Thirty Three [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyThreeMember_BBC21835AE93F4D40EC99CFE7F7229B5_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyThreeMember_BBC21835AE93F4D40EC99CFE7F7229B5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Thirty Three [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyThreeMember" xlink:label="loc_oncyf_TwentyThirtyThreeMember_BBC21835AE93F4D40EC99CFE7F7229B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyThreeMember_BBC21835AE93F4D40EC99CFE7F7229B5" xlink:to="lab_oncyf_TwentyThirtyThreeMember_BBC21835AE93F4D40EC99CFE7F7229B5" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyThirtyFourMember_CD12154D0B53AF29B97F9CFE7F72A917_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyFourMember_CD12154D0B53AF29B97F9CFE7F72A917" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2034</link:label>
    <link:label id="lab_oncyf_TwentyThirtyFourMember_CD12154D0B53AF29B97F9CFE7F72A917_label_en-US" xlink:label="lab_oncyf_TwentyThirtyFourMember_CD12154D0B53AF29B97F9CFE7F72A917" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Thirty Four [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyFourMember_CD12154D0B53AF29B97F9CFE7F72A917_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyFourMember_CD12154D0B53AF29B97F9CFE7F72A917" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Thirty Four [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyFourMember" xlink:label="loc_oncyf_TwentyThirtyFourMember_CD12154D0B53AF29B97F9CFE7F72A917" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyFourMember_CD12154D0B53AF29B97F9CFE7F72A917" xlink:to="lab_oncyf_TwentyThirtyFourMember_CD12154D0B53AF29B97F9CFE7F72A917" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyThirtyFiveMember_EAD393919CB8C0A2B3289CFE7F725EAB_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyFiveMember_EAD393919CB8C0A2B3289CFE7F725EAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2035</link:label>
    <link:label id="lab_oncyf_TwentyThirtyFiveMember_EAD393919CB8C0A2B3289CFE7F725EAB_label_en-US" xlink:label="lab_oncyf_TwentyThirtyFiveMember_EAD393919CB8C0A2B3289CFE7F725EAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Thirty Five [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyFiveMember_EAD393919CB8C0A2B3289CFE7F725EAB_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyFiveMember_EAD393919CB8C0A2B3289CFE7F725EAB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Thirty Five [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyFiveMember" xlink:label="loc_oncyf_TwentyThirtyFiveMember_EAD393919CB8C0A2B3289CFE7F725EAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyFiveMember_EAD393919CB8C0A2B3289CFE7F725EAB" xlink:to="lab_oncyf_TwentyThirtyFiveMember_EAD393919CB8C0A2B3289CFE7F725EAB" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyThirtySixMember_1D3C9E404E0DEFC6C15F9CFE7F73F09F_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtySixMember_1D3C9E404E0DEFC6C15F9CFE7F73F09F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2036</link:label>
    <link:label id="lab_oncyf_TwentyThirtySixMember_1D3C9E404E0DEFC6C15F9CFE7F73F09F_label_en-US" xlink:label="lab_oncyf_TwentyThirtySixMember_1D3C9E404E0DEFC6C15F9CFE7F73F09F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Thirty Six [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtySixMember_1D3C9E404E0DEFC6C15F9CFE7F73F09F_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtySixMember_1D3C9E404E0DEFC6C15F9CFE7F73F09F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Thirty Six [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtySixMember" xlink:label="loc_oncyf_TwentyThirtySixMember_1D3C9E404E0DEFC6C15F9CFE7F73F09F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtySixMember_1D3C9E404E0DEFC6C15F9CFE7F73F09F" xlink:to="lab_oncyf_TwentyThirtySixMember_1D3C9E404E0DEFC6C15F9CFE7F73F09F" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyThirtySevenMember_8771EBDF1FDF956DE5649CFE7F73A085_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtySevenMember_8771EBDF1FDF956DE5649CFE7F73A085" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2037</link:label>
    <link:label id="lab_oncyf_TwentyThirtySevenMember_8771EBDF1FDF956DE5649CFE7F73A085_label_en-US" xlink:label="lab_oncyf_TwentyThirtySevenMember_8771EBDF1FDF956DE5649CFE7F73A085" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Thirty Seven [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtySevenMember_8771EBDF1FDF956DE5649CFE7F73A085_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtySevenMember_8771EBDF1FDF956DE5649CFE7F73A085" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Thirty Seven [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtySevenMember" xlink:label="loc_oncyf_TwentyThirtySevenMember_8771EBDF1FDF956DE5649CFE7F73A085" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtySevenMember_8771EBDF1FDF956DE5649CFE7F73A085" xlink:to="lab_oncyf_TwentyThirtySevenMember_8771EBDF1FDF956DE5649CFE7F73A085" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyThirtyEightMember_5F6693E3A43FE72A306E9CFE7F73A956_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyEightMember_5F6693E3A43FE72A306E9CFE7F73A956" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2038</link:label>
    <link:label id="lab_oncyf_TwentyThirtyEightMember_5F6693E3A43FE72A306E9CFE7F73A956_label_en-US" xlink:label="lab_oncyf_TwentyThirtyEightMember_5F6693E3A43FE72A306E9CFE7F73A956" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Thirty Eight [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyEightMember_5F6693E3A43FE72A306E9CFE7F73A956_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyEightMember_5F6693E3A43FE72A306E9CFE7F73A956" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Thirty Eight [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyEightMember" xlink:label="loc_oncyf_TwentyThirtyEightMember_5F6693E3A43FE72A306E9CFE7F73A956" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyEightMember_5F6693E3A43FE72A306E9CFE7F73A956" xlink:to="lab_oncyf_TwentyThirtyEightMember_5F6693E3A43FE72A306E9CFE7F73A956" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyThirtyNineMember_6F226F44C5F84DE128319CFE7F736A8E_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyNineMember_6F226F44C5F84DE128319CFE7F736A8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2039</link:label>
    <link:label id="lab_oncyf_TwentyThirtyNineMember_6F226F44C5F84DE128319CFE7F736A8E_label_en-US" xlink:label="lab_oncyf_TwentyThirtyNineMember_6F226F44C5F84DE128319CFE7F736A8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Thirty Nine [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyNineMember_6F226F44C5F84DE128319CFE7F736A8E_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyNineMember_6F226F44C5F84DE128319CFE7F736A8E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Thirty Nine [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyNineMember" xlink:label="loc_oncyf_TwentyThirtyNineMember_6F226F44C5F84DE128319CFE7F736A8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyNineMember_6F226F44C5F84DE128319CFE7F736A8E" xlink:to="lab_oncyf_TwentyThirtyNineMember_6F226F44C5F84DE128319CFE7F736A8E" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0E868D7B0D37106158919CFE7F73C37E_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0E868D7B0D37106158919CFE7F73C37E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0E868D7B0D37106158919CFE7F73C37E_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0E868D7B0D37106158919CFE7F73C37E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0E868D7B0D37106158919CFE7F73C37E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0E868D7B0D37106158919CFE7F73C37E" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0E868D7B0D37106158919CFE7F73C37E" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1A65B9CCF7664250A94F9CFE7F7316DE_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1A65B9CCF7664250A94F9CFE7F7316DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1A65B9CCF7664250A94F9CFE7F7316DE_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1A65B9CCF7664250A94F9CFE7F7316DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1A65B9CCF7664250A94F9CFE7F7316DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1A65B9CCF7664250A94F9CFE7F7316DE" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1A65B9CCF7664250A94F9CFE7F7316DE" xlink:type="arc" />
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_8E1C2C5FEF2159EB9B3D9CFE7F74E948_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember_8E1C2C5FEF2159EB9B3D9CFE7F74E948" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-capital losses</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_8E1C2C5FEF2159EB9B3D9CFE7F74E948_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember_8E1C2C5FEF2159EB9B3D9CFE7F74E948" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused tax losses [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_8E1C2C5FEF2159EB9B3D9CFE7F74E948" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesMember_8E1C2C5FEF2159EB9B3D9CFE7F74E948" xlink:to="lab_ifrs-full_UnusedTaxLossesMember_8E1C2C5FEF2159EB9B3D9CFE7F74E948" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_CA94C02FC650DD0C50B89CFE7F741F80_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_CA94C02FC650DD0C50B89CFE7F741F80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_CA94C02FC650DD0C50B89CFE7F741F80_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_CA94C02FC650DD0C50B89CFE7F741F80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_CA94C02FC650DD0C50B89CFE7F741F80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_CA94C02FC650DD0C50B89CFE7F741F80" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_CA94C02FC650DD0C50B89CFE7F741F80" xlink:type="arc" />
    <link:label id="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_CEC69F8272B5BD4C8C2A9CFE7F74EE9C_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_CEC69F8272B5BD4C8C2A9CFE7F74EE9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unused tax losses</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_CEC69F8272B5BD4C8C2A9CFE7F74EE9C_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_CEC69F8272B5BD4C8C2A9CFE7F74EE9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused tax losses for which no deferred tax asset recognised</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_CEC69F8272B5BD4C8C2A9CFE7F74EE9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_CEC69F8272B5BD4C8C2A9CFE7F74EE9C" xlink:to="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_CEC69F8272B5BD4C8C2A9CFE7F74EE9C" xlink:type="arc" />
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_BDCBED0B1C4B1224A2539CFE7E187E82_label_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract_BDCBED0B1C4B1224A2539CFE7E187E82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_BDCBED0B1C4B1224A2539CFE7E187E82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_BDCBED0B1C4B1224A2539CFE7E187E82" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract_BDCBED0B1C4B1224A2539CFE7E187E82" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_12B97AF58E65F24909599CFE7E186D5E_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued_12B97AF58E65F24909599CFE7E186D5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital issued (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_12B97AF58E65F24909599CFE7E186D5E_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued_12B97AF58E65F24909599CFE7E186D5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares issued</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_12B97AF58E65F24909599CFE7E186D5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued_12B97AF58E65F24909599CFE7E186D5E" xlink:to="lab_ifrs-full_NumberOfSharesIssued_12B97AF58E65F24909599CFE7E186D5E" xlink:type="arc" />
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_3AA8C0FD701600358D0B9CFE7E972786_label_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_3AA8C0FD701600358D0B9CFE7E972786" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_3AA8C0FD701600358D0B9CFE7E972786_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_3AA8C0FD701600358D0B9CFE7E972786" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:label="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_3AA8C0FD701600358D0B9CFE7E972786" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_3AA8C0FD701600358D0B9CFE7E972786" xlink:to="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_3AA8C0FD701600358D0B9CFE7E972786" xlink:type="arc" />
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_7B1307084AD3726B276A9CFE7E971574_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_7B1307084AD3726B276A9CFE7E971574" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indemnification of Officers and Directors</link:label>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_7B1307084AD3726B276A9CFE7E971574_label_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_7B1307084AD3726B276A9CFE7E971574" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Text Block]</link:label>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_7B1307084AD3726B276A9CFE7E971574_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_7B1307084AD3726B276A9CFE7E971574" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Text Block]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:label="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_7B1307084AD3726B276A9CFE7E971574" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_7B1307084AD3726B276A9CFE7E971574" xlink:to="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_7B1307084AD3726B276A9CFE7E971574" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_22C5F379DF0A137C4A989CFE7EAB578B_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_22C5F379DF0A137C4A989CFE7EAB578B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Per Common Share</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_22C5F379DF0A137C4A989CFE7EAB578B_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_22C5F379DF0A137C4A989CFE7EAB578B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of earnings per share [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_22C5F379DF0A137C4A989CFE7EAB578B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_22C5F379DF0A137C4A989CFE7EAB578B" xlink:to="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_22C5F379DF0A137C4A989CFE7EAB578B" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_8B51C37D3E7215E3319D9CFE7EDC0DBD_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_8B51C37D3E7215E3319D9CFE7EDC0DBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_8B51C37D3E7215E3319D9CFE7EDC0DBD_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_8B51C37D3E7215E3319D9CFE7EDC0DBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of related party [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_8B51C37D3E7215E3319D9CFE7EDC0DBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_8B51C37D3E7215E3319D9CFE7EDC0DBD" xlink:to="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_8B51C37D3E7215E3319D9CFE7EDC0DBD" xlink:type="arc" />
    <link:label id="lab_oncyf_Statement1Table_3117261B4B66306B3DFE9CFE7F3FAC50_terseLabel_en-US" xlink:label="lab_oncyf_Statement1Table_3117261B4B66306B3DFE9CFE7F3FAC50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_oncyf_Statement1Table_3117261B4B66306B3DFE9CFE7F3FAC50_label_en-US" xlink:label="lab_oncyf_Statement1Table_3117261B4B66306B3DFE9CFE7F3FAC50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement1 [Table]</link:label>
    <link:label id="lab_oncyf_Statement1Table_3117261B4B66306B3DFE9CFE7F3FAC50_documentation_en-US" xlink:label="lab_oncyf_Statement1Table_3117261B4B66306B3DFE9CFE7F3FAC50" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Statement1 [Table]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_Statement1Table" xlink:label="loc_oncyf_Statement1Table_3117261B4B66306B3DFE9CFE7F3FAC50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Statement1Table_3117261B4B66306B3DFE9CFE7F3FAC50" xlink:to="lab_oncyf_Statement1Table_3117261B4B66306B3DFE9CFE7F3FAC50" xlink:type="arc" />
    <link:label id="lab_oncyf_SharesUnderCommonStockPurchaseAgreementMember_435B752D7D821FE18EA39CFE7F40181A_verboseLabel_en-US" xlink:label="lab_oncyf_SharesUnderCommonStockPurchaseAgreementMember_435B752D7D821FE18EA39CFE7F40181A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Purchase Agreement</link:label>
    <link:label id="lab_oncyf_SharesUnderCommonStockPurchaseAgreementMember_435B752D7D821FE18EA39CFE7F40181A_label_en-US" xlink:label="lab_oncyf_SharesUnderCommonStockPurchaseAgreementMember_435B752D7D821FE18EA39CFE7F40181A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Under Common Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderCommonStockPurchaseAgreementMember_435B752D7D821FE18EA39CFE7F40181A_documentation_en-US" xlink:label="lab_oncyf_SharesUnderCommonStockPurchaseAgreementMember_435B752D7D821FE18EA39CFE7F40181A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Under Common Stock Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderCommonStockPurchaseAgreementMember" xlink:label="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_435B752D7D821FE18EA39CFE7F40181A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_435B752D7D821FE18EA39CFE7F40181A" xlink:to="lab_oncyf_SharesUnderCommonStockPurchaseAgreementMember_435B752D7D821FE18EA39CFE7F40181A" xlink:type="arc" />
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementMember_B87836EFE6E2A91C4D619CFE7F405665_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementMember_B87836EFE6E2A91C4D619CFE7F405665" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-the-market agreement</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementMember_B87836EFE6E2A91C4D619CFE7F405665_label_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementMember_B87836EFE6E2A91C4D619CFE7F405665" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Under At-the-market Agreement [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementMember_B87836EFE6E2A91C4D619CFE7F405665_documentation_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementMember_B87836EFE6E2A91C4D619CFE7F405665" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Under At-the-market Agreement [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderAtthemarketAgreementMember" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_B87836EFE6E2A91C4D619CFE7F405665" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderAtthemarketAgreementMember_B87836EFE6E2A91C4D619CFE7F405665" xlink:to="lab_oncyf_SharesUnderAtthemarketAgreementMember_B87836EFE6E2A91C4D619CFE7F405665" xlink:type="arc" />
    <link:label id="lab_oncyf_SharesPublicOfferingMember_BC06988F5C3AC4881AD79CFE7F416F5D_verboseLabel_en-US" xlink:label="lab_oncyf_SharesPublicOfferingMember_BC06988F5C3AC4881AD79CFE7F416F5D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Public offering</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingMember_BC06988F5C3AC4881AD79CFE7F416F5D_label_en-US" xlink:label="lab_oncyf_SharesPublicOfferingMember_BC06988F5C3AC4881AD79CFE7F416F5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Public Offering [Member]</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingMember_BC06988F5C3AC4881AD79CFE7F416F5D_documentation_en-US" xlink:label="lab_oncyf_SharesPublicOfferingMember_BC06988F5C3AC4881AD79CFE7F416F5D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Public Offering [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesPublicOfferingMember" xlink:label="loc_oncyf_SharesPublicOfferingMember_BC06988F5C3AC4881AD79CFE7F416F5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesPublicOfferingMember_BC06988F5C3AC4881AD79CFE7F416F5D" xlink:to="lab_oncyf_SharesPublicOfferingMember_BC06988F5C3AC4881AD79CFE7F416F5D" xlink:type="arc" />
    <link:label id="lab_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4_terseLabel_en-US" xlink:label="lab_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4_label_en-US" xlink:label="lab_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4_documentation_en-US" xlink:label="lab_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Statement1 [Table]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_Statement1LineItems" xlink:label="loc_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4" xlink:to="lab_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ProfitLoss_8527488FB430AE417B6C9CFE7F4159D3_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss_8527488FB430AE417B6C9CFE7F4159D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss for the year</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_8527488FB430AE417B6C9CFE7F4159D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss_8527488FB430AE417B6C9CFE7F4159D3" xlink:to="lab_ifrs-full_ProfitLoss_8527488FB430AE417B6C9CFE7F4159D3" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_511F49FFDDE4761531309CFE7F424160_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_511F49FFDDE4761531309CFE7F424160" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation - property and equipment</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_511F49FFDDE4761531309CFE7F424160_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_511F49FFDDE4761531309CFE7F424160" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for depreciation and amortisation expense</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_511F49FFDDE4761531309CFE7F424160" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_511F49FFDDE4761531309CFE7F424160" xlink:to="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_511F49FFDDE4761531309CFE7F424160" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_3EA110865B32CFA0B1F99CFE7F427EE2_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments_3EA110865B32CFA0B1F99CFE7F427EE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_3EA110865B32CFA0B1F99CFE7F427EE2_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments_3EA110865B32CFA0B1F99CFE7F427EE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for share-based payments</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_3EA110865B32CFA0B1F99CFE7F427EE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments_3EA110865B32CFA0B1F99CFE7F427EE2" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments_3EA110865B32CFA0B1F99CFE7F427EE2" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_7C51434FD82E2BA572789CFE7F426C2A_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_7C51434FD82E2BA572789CFE7F426C2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized foreign exchange gain</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_7C51434FD82E2BA572789CFE7F426C2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_7C51434FD82E2BA572789CFE7F426C2A" xlink:to="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_7C51434FD82E2BA572789CFE7F426C2A" xlink:type="arc" />
    <link:label id="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_6EEE1FB2818D2BC6B7E79CFE7F43676C_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_6EEE1FB2818D2BC6B7E79CFE7F43676C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant derivative</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_6EEE1FB2818D2BC6B7E79CFE7F43676C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_6EEE1FB2818D2BC6B7E79CFE7F43676C" xlink:to="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_6EEE1FB2818D2BC6B7E79CFE7F43676C" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_ADAAC49E1CA4D9272FD59CFE7F4370DF_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_ADAAC49E1CA4D9272FD59CFE7F4370DF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net change in non-cash working capital</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_ADAAC49E1CA4D9272FD59CFE7F4370DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_ADAAC49E1CA4D9272FD59CFE7F4370DF" xlink:to="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_ADAAC49E1CA4D9272FD59CFE7F4370DF" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperations_4015E62566044D69F2F19CFE7F43D7C9_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperations_4015E62566044D69F2F19CFE7F43D7C9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperations_4015E62566044D69F2F19CFE7F43D7C9_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperations_4015E62566044D69F2F19CFE7F43D7C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operations</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_4015E62566044D69F2F19CFE7F43D7C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_4015E62566044D69F2F19CFE7F43D7C9" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperations_4015E62566044D69F2F19CFE7F43D7C9" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_64BE9F6DD7B8179B407E9CFE7F4354FC_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_64BE9F6DD7B8179B407E9CFE7F4354FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing Activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_64BE9F6DD7B8179B407E9CFE7F4354FC_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_64BE9F6DD7B8179B407E9CFE7F4354FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_64BE9F6DD7B8179B407E9CFE7F4354FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_64BE9F6DD7B8179B407E9CFE7F4354FC" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_64BE9F6DD7B8179B407E9CFE7F4354FC" xlink:type="arc" />
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_9ED595B3F2726B9BAF7E9CFE7F43CB97_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_9ED595B3F2726B9BAF7E9CFE7F43CB97" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of property and equipment</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_9ED595B3F2726B9BAF7E9CFE7F43CB97_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_9ED595B3F2726B9BAF7E9CFE7F43CB97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_9ED595B3F2726B9BAF7E9CFE7F43CB97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_9ED595B3F2726B9BAF7E9CFE7F43CB97" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_9ED595B3F2726B9BAF7E9CFE7F43CB97" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_7DDF74F66B967B6A5A709CFE7F448EC8_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_7DDF74F66B967B6A5A709CFE7F448EC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption of short-term investments</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_7DDF74F66B967B6A5A709CFE7F448EC8_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_7DDF74F66B967B6A5A709CFE7F448EC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) decrease (increase) in short-term deposits and investments</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:label="loc_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_7DDF74F66B967B6A5A709CFE7F448EC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_7DDF74F66B967B6A5A709CFE7F448EC8" xlink:to="lab_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_7DDF74F66B967B6A5A709CFE7F448EC8" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_7111E4979D9DF46B6E8A9CFE7F440E86_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_7111E4979D9DF46B6E8A9CFE7F440E86" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash (used in) provided by investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_7111E4979D9DF46B6E8A9CFE7F440E86_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_7111E4979D9DF46B6E8A9CFE7F440E86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_7111E4979D9DF46B6E8A9CFE7F440E86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_7111E4979D9DF46B6E8A9CFE7F440E86" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_7111E4979D9DF46B6E8A9CFE7F440E86" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_29EAF9F900576EC666279CFE7F4488D3_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_29EAF9F900576EC666279CFE7F4488D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_29EAF9F900576EC666279CFE7F4488D3_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_29EAF9F900576EC666279CFE7F4488D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_29EAF9F900576EC666279CFE7F4488D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_29EAF9F900576EC666279CFE7F4488D3" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_29EAF9F900576EC666279CFE7F4488D3" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfOptions_EBD25F37EB23A2BB9A029CFE7F4484B8_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions_EBD25F37EB23A2BB9A029CFE7F4484B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfOptions_EBD25F37EB23A2BB9A029CFE7F4484B8_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions_EBD25F37EB23A2BB9A029CFE7F4484B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_EBD25F37EB23A2BB9A029CFE7F4484B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromExerciseOfOptions_EBD25F37EB23A2BB9A029CFE7F4484B8" xlink:to="lab_ifrs-full_ProceedsFromExerciseOfOptions_EBD25F37EB23A2BB9A029CFE7F4484B8" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_81C964343C59B17095D29CFE7F44C502_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares_81C964343C59B17095D29CFE7F44C502" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from share issuance</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_81C964343C59B17095D29CFE7F44C502_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares_81C964343C59B17095D29CFE7F44C502" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuing shares</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_81C964343C59B17095D29CFE7F44C502" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares_81C964343C59B17095D29CFE7F44C502" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares_81C964343C59B17095D29CFE7F44C502" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CashOutflowForLeases_01A4DB36F8AC7FDB0CCD9CFE7F458C49_negatedLabel_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases_01A4DB36F8AC7FDB0CCD9CFE7F458C49" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashOutflowForLeases" xlink:label="loc_ifrs-full_CashOutflowForLeases_01A4DB36F8AC7FDB0CCD9CFE7F458C49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashOutflowForLeases_01A4DB36F8AC7FDB0CCD9CFE7F458C49" xlink:to="lab_ifrs-full_CashOutflowForLeases_01A4DB36F8AC7FDB0CCD9CFE7F458C49" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_A6706F34A95877FD2DC09CFE7F453B75_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_A6706F34A95877FD2DC09CFE7F453B75" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash provided by financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_A6706F34A95877FD2DC09CFE7F453B75_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_A6706F34A95877FD2DC09CFE7F453B75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_A6706F34A95877FD2DC09CFE7F453B75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_A6706F34A95877FD2DC09CFE7F453B75" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_A6706F34A95877FD2DC09CFE7F453B75" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_4DBD622DB4465BB62CF09CFE7F45E49C_totalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_4DBD622DB4465BB62CF09CFE7F45E49C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_4DBD622DB4465BB62CF09CFE7F45E49C_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_4DBD622DB4465BB62CF09CFE7F45E49C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_4DBD622DB4465BB62CF09CFE7F45E49C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_4DBD622DB4465BB62CF09CFE7F45E49C" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_4DBD622DB4465BB62CF09CFE7F45E49C" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_BD89341FD15DEEA698269CFE7F45A099_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents_BD89341FD15DEEA698269CFE7F45A099" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_BD89341FD15DEEA698269CFE7F45A099_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents_BD89341FD15DEEA698269CFE7F45A099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_BD89341FD15DEEA698269CFE7F45A099" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents_BD89341FD15DEEA698269CFE7F45A099" xlink:to="lab_ifrs-full_CashAndCashEquivalents_BD89341FD15DEEA698269CFE7F45A099" xlink:type="arc" />
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_681CBFA55F627A07D5E49CFE7F455831_terseLabel_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_681CBFA55F627A07D5E49CFE7F455831" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of foreign exchange on cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_681CBFA55F627A07D5E49CFE7F455831_label_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_681CBFA55F627A07D5E49CFE7F455831" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_681CBFA55F627A07D5E49CFE7F455831" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_681CBFA55F627A07D5E49CFE7F455831" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_681CBFA55F627A07D5E49CFE7F455831" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_34AF911C15F7F307394E9CFE7F457601_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents_34AF911C15F7F307394E9CFE7F457601" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_34AF911C15F7F307394E9CFE7F457601" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents_34AF911C15F7F307394E9CFE7F457601" xlink:to="lab_ifrs-full_CashAndCashEquivalents_34AF911C15F7F307394E9CFE7F457601" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_4222F07048955A1FB5F89D034CD098BE_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions_4222F07048955A1FB5F89D034CD098BE" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of the year (shares)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_4222F07048955A1FB5F89D034CD098BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions_4222F07048955A1FB5F89D034CD098BE" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions_4222F07048955A1FB5F89D034CD098BE" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_28459D86E1F9FC968A089D034CD1C542_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_28459D86E1F9FC968A089D034CD1C542" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_28459D86E1F9FC968A089D034CD1C542_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_28459D86E1F9FC968A089D034CD1C542" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_28459D86E1F9FC968A089D034CD1C542" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_28459D86E1F9FC968A089D034CD1C542" xlink:to="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_28459D86E1F9FC968A089D034CD1C542" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_3A6CA2FBE4B3B47E17359D034CD18BA1_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_3A6CA2FBE4B3B47E17359D034CD18BA1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_3A6CA2FBE4B3B47E17359D034CD18BA1_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_3A6CA2FBE4B3B47E17359D034CD18BA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_3A6CA2FBE4B3B47E17359D034CD18BA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_3A6CA2FBE4B3B47E17359D034CD18BA1" xlink:to="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_3A6CA2FBE4B3B47E17359D034CD18BA1" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_FB951303E618B55ADD279D034CD16C64_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_FB951303E618B55ADD279D034CD16C64" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_FB951303E618B55ADD279D034CD16C64_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_FB951303E618B55ADD279D034CD16C64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options expired in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_FB951303E618B55ADD279D034CD16C64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_FB951303E618B55ADD279D034CD16C64" xlink:to="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_FB951303E618B55ADD279D034CD16C64" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_6B2964902623AEBFAECA9D034CD132A8_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_6B2964902623AEBFAECA9D034CD132A8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_6B2964902623AEBFAECA9D034CD132A8_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_6B2964902623AEBFAECA9D034CD132A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_6B2964902623AEBFAECA9D034CD132A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_6B2964902623AEBFAECA9D034CD132A8" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_6B2964902623AEBFAECA9D034CD132A8" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_AC9817B3CB6DFC524D8C9D034CD1F767_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions_AC9817B3CB6DFC524D8C9D034CD1F767" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, end of the year (shares)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_AC9817B3CB6DFC524D8C9D034CD1F767" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions_AC9817B3CB6DFC524D8C9D034CD1F767" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions_AC9817B3CB6DFC524D8C9D034CD1F767" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_D6F77F955D969C839ECA9D034CD2A9DE_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_D6F77F955D969C839ECA9D034CD2A9DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, end of the year (shares)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_D6F77F955D969C839ECA9D034CD2A9DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_D6F77F955D969C839ECA9D034CD2A9DE" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_D6F77F955D969C839ECA9D034CD2A9DE" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_38652D5F549C683C8A249D0BCBADDE6C_periodStartLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_38652D5F549C683C8A249D0BCBADDE6C" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of the year (cad per share)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_38652D5F549C683C8A249D0BCBADDE6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_38652D5F549C683C8A249D0BCBADDE6C" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_38652D5F549C683C8A249D0BCBADDE6C" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_401C4F16BE1818CB9E909D0C0943DA3C_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_401C4F16BE1818CB9E909D0C0943DA3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_401C4F16BE1818CB9E909D0C0943DA3C_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_401C4F16BE1818CB9E909D0C0943DA3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_401C4F16BE1818CB9E909D0C0943DA3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_401C4F16BE1818CB9E909D0C0943DA3C" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_401C4F16BE1818CB9E909D0C0943DA3C" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_D497B0FD493E54E2BE629D0C4858CAB3_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_D497B0FD493E54E2BE629D0C4858CAB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_D497B0FD493E54E2BE629D0C4858CAB3_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_D497B0FD493E54E2BE629D0C4858CAB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_D497B0FD493E54E2BE629D0C4858CAB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_D497B0FD493E54E2BE629D0C4858CAB3" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_D497B0FD493E54E2BE629D0C4858CAB3" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_537C250E9A5C5787E9589D0C83525412_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_537C250E9A5C5787E9589D0C83525412" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_537C250E9A5C5787E9589D0C83525412_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_537C250E9A5C5787E9589D0C83525412" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options expired in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_537C250E9A5C5787E9589D0C83525412" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_537C250E9A5C5787E9589D0C83525412" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_537C250E9A5C5787E9589D0C83525412" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_85EEE039378DC81E888F9D0CE5590A29_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_85EEE039378DC81E888F9D0CE5590A29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_85EEE039378DC81E888F9D0CE5590A29_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_85EEE039378DC81E888F9D0CE5590A29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options exercised in share-based payment arrangement</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_85EEE039378DC81E888F9D0CE5590A29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_85EEE039378DC81E888F9D0CE5590A29" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_85EEE039378DC81E888F9D0CE5590A29" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_2F9BCF5DC8E1DE6B00FC9D287A73349A_periodEndLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_2F9BCF5DC8E1DE6B00FC9D287A73349A" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of the year (cad per share)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_2F9BCF5DC8E1DE6B00FC9D287A73349A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_2F9BCF5DC8E1DE6B00FC9D287A73349A" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_2F9BCF5DC8E1DE6B00FC9D287A73349A" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_3FC147D388D7414B5AF99D0D1436A90A_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_3FC147D388D7414B5AF99D0D1436A90A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, end of the year (cad per share)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_3FC147D388D7414B5AF99D0D1436A90A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_3FC147D388D7414B5AF99D0D1436A90A" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_3FC147D388D7414B5AF99D0D1436A90A" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_D723DAAA1FDEC629D57A9CFE7F9BC646_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_D723DAAA1FDEC629D57A9CFE7F9BC646" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_D723DAAA1FDEC629D57A9CFE7F9BC646_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_D723DAAA1FDEC629D57A9CFE7F9BC646" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_D723DAAA1FDEC629D57A9CFE7F9BC646" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_D723DAAA1FDEC629D57A9CFE7F9BC646" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_D723DAAA1FDEC629D57A9CFE7F9BC646" xlink:type="arc" />
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_DD6CDF78F31DF130AE689CFE7F215493_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract_DD6CDF78F31DF130AE689CFE7F215493" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_DD6CDF78F31DF130AE689CFE7F215493" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_DD6CDF78F31DF130AE689CFE7F215493" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract_DD6CDF78F31DF130AE689CFE7F215493" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_5BDA0BF3D4FEEA3960DE9CFE7F22F9E3_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_5BDA0BF3D4FEEA3960DE9CFE7F22F9E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital Disclosures</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_5BDA0BF3D4FEEA3960DE9CFE7F22F9E3_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_5BDA0BF3D4FEEA3960DE9CFE7F22F9E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of objectives, policies and processes for managing capital [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_5BDA0BF3D4FEEA3960DE9CFE7F22F9E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_5BDA0BF3D4FEEA3960DE9CFE7F22F9E3" xlink:to="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_5BDA0BF3D4FEEA3960DE9CFE7F22F9E3" xlink:type="arc" />
    <link:label id="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio_035075D77784DD0AC71CA1D3EE3D910D_terseLabel_en-US" xlink:label="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio_035075D77784DD0AC71CA1D3EE3D910D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock conversion ratio</link:label>
    <link:label id="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio_035075D77784DD0AC71CA1D3EE3D910D_label_en-US" xlink:label="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio_035075D77784DD0AC71CA1D3EE3D910D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:label id="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio_035075D77784DD0AC71CA1D3EE3D910D_documentation_en-US" xlink:label="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio_035075D77784DD0AC71CA1D3EE3D910D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_StockholdersEquityNoteStockSplitConversionRatio" xlink:label="loc_oncyf_StockholdersEquityNoteStockSplitConversionRatio_035075D77784DD0AC71CA1D3EE3D910D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_StockholdersEquityNoteStockSplitConversionRatio_035075D77784DD0AC71CA1D3EE3D910D" xlink:to="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio_035075D77784DD0AC71CA1D3EE3D910D" xlink:type="arc" />
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_60BCFCAA5A4866ADC6FCA1D3EE3D66C3_terseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_60BCFCAA5A4866ADC6FCA1D3EE3D66C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercisable into common shares (shares)</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_60BCFCAA5A4866ADC6FCA1D3EE3D66C3_label_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_60BCFCAA5A4866ADC6FCA1D3EE3D66C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights1</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_60BCFCAA5A4866ADC6FCA1D3EE3D66C3_documentation_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_60BCFCAA5A4866ADC6FCA1D3EE3D66C3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights1</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_60BCFCAA5A4866ADC6FCA1D3EE3D66C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_60BCFCAA5A4866ADC6FCA1D3EE3D66C3" xlink:to="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_60BCFCAA5A4866ADC6FCA1D3EE3D66C3" xlink:type="arc" />
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceAbstract_FB857AD21A355AE90D2A9CFE7ED10A2B_label_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceAbstract_FB857AD21A355AE90D2A9CFE7ED10A2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Economic Dependence [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceAbstract_FB857AD21A355AE90D2A9CFE7ED10A2B_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceAbstract_FB857AD21A355AE90D2A9CFE7ED10A2B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Economic Dependence [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureOfEconomicDependenceAbstract" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceAbstract_FB857AD21A355AE90D2A9CFE7ED10A2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceAbstract_FB857AD21A355AE90D2A9CFE7ED10A2B" xlink:to="lab_oncyf_DisclosureOfEconomicDependenceAbstract_FB857AD21A355AE90D2A9CFE7ED10A2B" xlink:type="arc" />
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_5427863652C87344FEAF9CFE7ED24005_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_5427863652C87344FEAF9CFE7ED24005" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Economic Dependence</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_5427863652C87344FEAF9CFE7ED24005_label_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_5427863652C87344FEAF9CFE7ED24005" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Economic Dependence [Text Block]</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_5427863652C87344FEAF9CFE7ED24005_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_5427863652C87344FEAF9CFE7ED24005" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Economic Dependence [Text Block]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceTextBlock_5427863652C87344FEAF9CFE7ED24005" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceTextBlock_5427863652C87344FEAF9CFE7ED24005" xlink:to="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_5427863652C87344FEAF9CFE7ED24005" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_22D348D6D361BE484797A7434D198B6E_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_22D348D6D361BE484797A7434D198B6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_22D348D6D361BE484797A7434D198B6E_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_22D348D6D361BE484797A7434D198B6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_22D348D6D361BE484797A7434D198B6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_22D348D6D361BE484797A7434D198B6E" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_22D348D6D361BE484797A7434D198B6E" xlink:type="arc" />
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementCanadianMember_DE8BF3733375CC65687FA7434D1E8936_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementCanadianMember_DE8BF3733375CC65687FA7434D1E8936" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canadian ATM</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementCanadianMember_DE8BF3733375CC65687FA7434D1E8936_label_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementCanadianMember_DE8BF3733375CC65687FA7434D1E8936" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Under At-the-market Agreement, Canadian [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementCanadianMember_DE8BF3733375CC65687FA7434D1E8936_documentation_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementCanadianMember_DE8BF3733375CC65687FA7434D1E8936" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Under At-the-market Agreement, Canadian [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderAtthemarketAgreementCanadianMember" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementCanadianMember_DE8BF3733375CC65687FA7434D1E8936" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderAtthemarketAgreementCanadianMember_DE8BF3733375CC65687FA7434D1E8936" xlink:to="lab_oncyf_SharesUnderAtthemarketAgreementCanadianMember_DE8BF3733375CC65687FA7434D1E8936" xlink:type="arc" />
    <link:label id="lab_oncyf_SharesPublicOfferingMember_B5F9885783B887CC776DA7434D1E998F_terseLabel_en-US" xlink:label="lab_oncyf_SharesPublicOfferingMember_B5F9885783B887CC776DA7434D1E998F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesPublicOfferingMember" xlink:label="loc_oncyf_SharesPublicOfferingMember_B5F9885783B887CC776DA7434D1E998F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesPublicOfferingMember_B5F9885783B887CC776DA7434D1E998F" xlink:to="lab_oncyf_SharesPublicOfferingMember_B5F9885783B887CC776DA7434D1E998F" xlink:type="arc" />
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_9FA2B90666443E789973A7434D20BB1C_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_9FA2B90666443E789973A7434D20BB1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States ATM</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_9FA2B90666443E789973A7434D20BB1C_label_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_9FA2B90666443E789973A7434D20BB1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Under At-the-market Agreement, United States [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_9FA2B90666443E789973A7434D20BB1C_documentation_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_9FA2B90666443E789973A7434D20BB1C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Under At-the-market Agreement, United States [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_9FA2B90666443E789973A7434D20BB1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_9FA2B90666443E789973A7434D20BB1C" xlink:to="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_9FA2B90666443E789973A7434D20BB1C" xlink:type="arc" />
    <link:label id="lab_oncyf_SharesUnderCommonStockPurchaseAgreementMember_0EF705A43895D48EC1D0A7434D20B782_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderCommonStockPurchaseAgreementMember_0EF705A43895D48EC1D0A7434D20B782" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderCommonStockPurchaseAgreementMember" xlink:label="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_0EF705A43895D48EC1D0A7434D20B782" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_0EF705A43895D48EC1D0A7434D20B782" xlink:to="lab_oncyf_SharesUnderCommonStockPurchaseAgreementMember_0EF705A43895D48EC1D0A7434D20B782" xlink:type="arc" />
    <link:label id="lab_oncyf_InitialCommitmentFeeMember_F6831B2B23F0F57483A0A7434D20E94C_terseLabel_en-US" xlink:label="lab_oncyf_InitialCommitmentFeeMember_F6831B2B23F0F57483A0A7434D20E94C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial commitment fee</link:label>
    <link:label id="lab_oncyf_InitialCommitmentFeeMember_F6831B2B23F0F57483A0A7434D20E94C_label_en-US" xlink:label="lab_oncyf_InitialCommitmentFeeMember_F6831B2B23F0F57483A0A7434D20E94C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Commitment Fee [Member]</link:label>
    <link:label id="lab_oncyf_InitialCommitmentFeeMember_F6831B2B23F0F57483A0A7434D20E94C_documentation_en-US" xlink:label="lab_oncyf_InitialCommitmentFeeMember_F6831B2B23F0F57483A0A7434D20E94C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial Commitment Fee [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_InitialCommitmentFeeMember" xlink:label="loc_oncyf_InitialCommitmentFeeMember_F6831B2B23F0F57483A0A7434D20E94C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_InitialCommitmentFeeMember_F6831B2B23F0F57483A0A7434D20E94C" xlink:to="lab_oncyf_InitialCommitmentFeeMember_F6831B2B23F0F57483A0A7434D20E94C" xlink:type="arc" />
    <link:label id="lab_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_B82FD73C9BC397BF788EA7434D21B0B2_terseLabel_en-US" xlink:label="lab_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_B82FD73C9BC397BF788EA7434D21B0B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retrospective application and retrospective restatement [axis]</link:label>
    <link:label id="lab_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_B82FD73C9BC397BF788EA7434D21B0B2_label_en-US" xlink:label="lab_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_B82FD73C9BC397BF788EA7434D21B0B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retrospective application and retrospective restatement [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_B82FD73C9BC397BF788EA7434D21B0B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_B82FD73C9BC397BF788EA7434D21B0B2" xlink:to="lab_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_B82FD73C9BC397BF788EA7434D21B0B2" xlink:type="arc" />
    <link:label id="lab_ifrs-full_RestatedMember_B4714E35AF71AC466113A7434D212254_terseLabel_en-US" xlink:label="lab_ifrs-full_RestatedMember_B4714E35AF71AC466113A7434D212254" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currently stated [member]</link:label>
    <link:label id="lab_ifrs-full_RestatedMember_B4714E35AF71AC466113A7434D212254_label_en-US" xlink:label="lab_ifrs-full_RestatedMember_B4714E35AF71AC466113A7434D212254" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currently stated [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_B4714E35AF71AC466113A7434D212254" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RestatedMember_B4714E35AF71AC466113A7434D212254" xlink:to="lab_ifrs-full_RestatedMember_B4714E35AF71AC466113A7434D212254" xlink:type="arc" />
    <link:label id="lab_ifrs-full_PreviouslyStatedMember_ECF89D3C3F0C76A312EDA7434D218EDE_terseLabel_en-US" xlink:label="lab_ifrs-full_PreviouslyStatedMember_ECF89D3C3F0C76A312EDA7434D218EDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-Consolidation</link:label>
    <link:label id="lab_ifrs-full_PreviouslyStatedMember_ECF89D3C3F0C76A312EDA7434D218EDE_label_en-US" xlink:label="lab_ifrs-full_PreviouslyStatedMember_ECF89D3C3F0C76A312EDA7434D218EDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Previously stated [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="loc_ifrs-full_PreviouslyStatedMember_ECF89D3C3F0C76A312EDA7434D218EDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PreviouslyStatedMember_ECF89D3C3F0C76A312EDA7434D218EDE" xlink:to="lab_ifrs-full_PreviouslyStatedMember_ECF89D3C3F0C76A312EDA7434D218EDE" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:type="arc" />
    <link:label id="lab_ifrs-full_Equity_5950C41C458069BEDA6CA7434D2622F9_verboseLabel_en-US" xlink:label="lab_ifrs-full_Equity_5950C41C458069BEDA6CA7434D2622F9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_5950C41C458069BEDA6CA7434D2622F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity_5950C41C458069BEDA6CA7434D2622F9" xlink:to="lab_ifrs-full_Equity_5950C41C458069BEDA6CA7434D2622F9" xlink:type="arc" />
    <link:label id="lab_oncyf_CommonSharePurchaseWarrantPerUnit_8E8C680CEEB6E4245C82A7434D2BBB4F_terseLabel_en-US" xlink:label="lab_oncyf_CommonSharePurchaseWarrantPerUnit_8E8C680CEEB6E4245C82A7434D2BBB4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common share purchase warrant per unit (shares)</link:label>
    <link:label id="lab_oncyf_CommonSharePurchaseWarrantPerUnit_8E8C680CEEB6E4245C82A7434D2BBB4F_label_en-US" xlink:label="lab_oncyf_CommonSharePurchaseWarrantPerUnit_8E8C680CEEB6E4245C82A7434D2BBB4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Share Purchase Warrant Per Unit</link:label>
    <link:label id="lab_oncyf_CommonSharePurchaseWarrantPerUnit_8E8C680CEEB6E4245C82A7434D2BBB4F_documentation_en-US" xlink:label="lab_oncyf_CommonSharePurchaseWarrantPerUnit_8E8C680CEEB6E4245C82A7434D2BBB4F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Share Purchase Warrant Per Unit</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CommonSharePurchaseWarrantPerUnit" xlink:label="loc_oncyf_CommonSharePurchaseWarrantPerUnit_8E8C680CEEB6E4245C82A7434D2BBB4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommonSharePurchaseWarrantPerUnit_8E8C680CEEB6E4245C82A7434D2BBB4F" xlink:to="lab_oncyf_CommonSharePurchaseWarrantPerUnit_8E8C680CEEB6E4245C82A7434D2BBB4F" xlink:type="arc" />
    <link:label id="lab_oncyf_SharesIssuedWarrantPricePerShare_9BC0F33B7DE6E622C286A7434D2BEED6_terseLabel_en-US" xlink:label="lab_oncyf_SharesIssuedWarrantPricePerShare_9BC0F33B7DE6E622C286A7434D2BEED6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price (cad per share)</link:label>
    <link:label id="lab_oncyf_SharesIssuedWarrantPricePerShare_9BC0F33B7DE6E622C286A7434D2BEED6_label_en-US" xlink:label="lab_oncyf_SharesIssuedWarrantPricePerShare_9BC0F33B7DE6E622C286A7434D2BEED6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Warrant Price Per Share</link:label>
    <link:label id="lab_oncyf_SharesIssuedWarrantPricePerShare_9BC0F33B7DE6E622C286A7434D2BEED6_documentation_en-US" xlink:label="lab_oncyf_SharesIssuedWarrantPricePerShare_9BC0F33B7DE6E622C286A7434D2BEED6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Issued, Warrant Price Per Share</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesIssuedWarrantPricePerShare" xlink:label="loc_oncyf_SharesIssuedWarrantPricePerShare_9BC0F33B7DE6E622C286A7434D2BEED6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesIssuedWarrantPricePerShare_9BC0F33B7DE6E622C286A7434D2BEED6" xlink:to="lab_oncyf_SharesIssuedWarrantPricePerShare_9BC0F33B7DE6E622C286A7434D2BEED6" xlink:type="arc" />
    <link:label id="lab_oncyf_WarrantPricePerShareAccelerationThreshold_B5866DE8EF4E87FBB0DFA7434D2DB16B_terseLabel_en-US" xlink:label="lab_oncyf_WarrantPricePerShareAccelerationThreshold_B5866DE8EF4E87FBB0DFA7434D2DB16B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acceleration threshold weighted average price (cad per share)</link:label>
    <link:label id="lab_oncyf_WarrantPricePerShareAccelerationThreshold_B5866DE8EF4E87FBB0DFA7434D2DB16B_label_en-US" xlink:label="lab_oncyf_WarrantPricePerShareAccelerationThreshold_B5866DE8EF4E87FBB0DFA7434D2DB16B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Price Per Share, Acceleration Threshold</link:label>
    <link:label id="lab_oncyf_WarrantPricePerShareAccelerationThreshold_B5866DE8EF4E87FBB0DFA7434D2DB16B_documentation_en-US" xlink:label="lab_oncyf_WarrantPricePerShareAccelerationThreshold_B5866DE8EF4E87FBB0DFA7434D2DB16B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Price Per Share, Acceleration Threshold</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantPricePerShareAccelerationThreshold" xlink:label="loc_oncyf_WarrantPricePerShareAccelerationThreshold_B5866DE8EF4E87FBB0DFA7434D2DB16B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantPricePerShareAccelerationThreshold_B5866DE8EF4E87FBB0DFA7434D2DB16B" xlink:to="lab_oncyf_WarrantPricePerShareAccelerationThreshold_B5866DE8EF4E87FBB0DFA7434D2DB16B" xlink:type="arc" />
    <link:label id="lab_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_346E89D5B982D48DB402A7434D2EDD9E_terseLabel_en-US" xlink:label="lab_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_346E89D5B982D48DB402A7434D2EDD9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acceleration threshold weighted average price, trading days</link:label>
    <link:label id="lab_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_346E89D5B982D48DB402A7434D2EDD9E_label_en-US" xlink:label="lab_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_346E89D5B982D48DB402A7434D2EDD9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Price Per Share, Acceleration Threshold Trading Days</link:label>
    <link:label id="lab_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_346E89D5B982D48DB402A7434D2EDD9E_documentation_en-US" xlink:label="lab_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_346E89D5B982D48DB402A7434D2EDD9E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Price Per Share, Acceleration Threshold Trading Days</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantPricePerShareAccelerationThresholdTradingDays" xlink:label="loc_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_346E89D5B982D48DB402A7434D2EDD9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_346E89D5B982D48DB402A7434D2EDD9E" xlink:to="lab_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_346E89D5B982D48DB402A7434D2EDD9E" xlink:type="arc" />
    <link:label id="lab_oncyf_SharePurchaseAgreementAmount_1DD6C0BD67C480C5EF67A7434D2EF76E_terseLabel_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementAmount_1DD6C0BD67C480C5EF67A7434D2EF76E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementAmount_1DD6C0BD67C480C5EF67A7434D2EF76E_label_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementAmount_1DD6C0BD67C480C5EF67A7434D2EF76E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Purchase Agreement, Amount</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementAmount_1DD6C0BD67C480C5EF67A7434D2EF76E_documentation_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementAmount_1DD6C0BD67C480C5EF67A7434D2EF76E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Purchase Agreement, Amount</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharePurchaseAgreementAmount" xlink:label="loc_oncyf_SharePurchaseAgreementAmount_1DD6C0BD67C480C5EF67A7434D2EF76E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharePurchaseAgreementAmount_1DD6C0BD67C480C5EF67A7434D2EF76E" xlink:to="lab_oncyf_SharePurchaseAgreementAmount_1DD6C0BD67C480C5EF67A7434D2EF76E" xlink:type="arc" />
    <link:label id="lab_oncyf_SharePurchaseAgreementTerm_C29597566DE123144A4EA7434D2EBE9C_terseLabel_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementTerm_C29597566DE123144A4EA7434D2EBE9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement term</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementTerm_C29597566DE123144A4EA7434D2EBE9C_label_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementTerm_C29597566DE123144A4EA7434D2EBE9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Purchase Agreement, Term</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementTerm_C29597566DE123144A4EA7434D2EBE9C_documentation_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementTerm_C29597566DE123144A4EA7434D2EBE9C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Purchase Agreement, Term</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharePurchaseAgreementTerm" xlink:label="loc_oncyf_SharePurchaseAgreementTerm_C29597566DE123144A4EA7434D2EBE9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharePurchaseAgreementTerm_C29597566DE123144A4EA7434D2EBE9C" xlink:to="lab_oncyf_SharePurchaseAgreementTerm_C29597566DE123144A4EA7434D2EBE9C" xlink:type="arc" />
    <link:label id="lab_oncyf_NumberofSharesOutstandingPercent_270F667549839406ABCCA7434D2E5084_terseLabel_en-US" xlink:label="lab_oncyf_NumberofSharesOutstandingPercent_270F667549839406ABCCA7434D2E5084" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares outstanding, percent</link:label>
    <link:label id="lab_oncyf_NumberofSharesOutstandingPercent_270F667549839406ABCCA7434D2E5084_label_en-US" xlink:label="lab_oncyf_NumberofSharesOutstandingPercent_270F667549839406ABCCA7434D2E5084" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Shares Outstanding, Percent</link:label>
    <link:label id="lab_oncyf_NumberofSharesOutstandingPercent_270F667549839406ABCCA7434D2E5084_documentation_en-US" xlink:label="lab_oncyf_NumberofSharesOutstandingPercent_270F667549839406ABCCA7434D2E5084" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Shares Outstanding, Percent</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_NumberofSharesOutstandingPercent" xlink:label="loc_oncyf_NumberofSharesOutstandingPercent_270F667549839406ABCCA7434D2E5084" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberofSharesOutstandingPercent_270F667549839406ABCCA7434D2E5084" xlink:to="lab_oncyf_NumberofSharesOutstandingPercent_270F667549839406ABCCA7434D2E5084" xlink:type="arc" />
    <link:label id="lab_oncyf_ClassofWarrantorRightWarrantsExercised_6BA1011FA8F6B85BCB5CA7434D2FB3E5_terseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightWarrantsExercised_6BA1011FA8F6B85BCB5CA7434D2FB3E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightWarrantsExercised_6BA1011FA8F6B85BCB5CA7434D2FB3E5_label_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightWarrantsExercised_6BA1011FA8F6B85BCB5CA7434D2FB3E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Warrants Exercised</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightWarrantsExercised_6BA1011FA8F6B85BCB5CA7434D2FB3E5_documentation_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightWarrantsExercised_6BA1011FA8F6B85BCB5CA7434D2FB3E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Warrants Exercised</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightWarrantsExercised" xlink:label="loc_oncyf_ClassofWarrantorRightWarrantsExercised_6BA1011FA8F6B85BCB5CA7434D2FB3E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRightWarrantsExercised_6BA1011FA8F6B85BCB5CA7434D2FB3E5" xlink:to="lab_oncyf_ClassofWarrantorRightWarrantsExercised_6BA1011FA8F6B85BCB5CA7434D2FB3E5" xlink:type="arc" />
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_DDC2145D7090E5BA6283A7434D2FF210_terseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_DDC2145D7090E5BA6283A7434D2FF210" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised (shares)</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_DDC2145D7090E5BA6283A7434D2FF210_label_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_DDC2145D7090E5BA6283A7434D2FF210" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Warrants Exercised</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_DDC2145D7090E5BA6283A7434D2FF210_documentation_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_DDC2145D7090E5BA6283A7434D2FF210" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Warrants Exercised</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_DDC2145D7090E5BA6283A7434D2FF210" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_DDC2145D7090E5BA6283A7434D2FF210" xlink:to="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_DDC2145D7090E5BA6283A7434D2FF210" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_74CC908B5BA6F28C34999CFE7F894606_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_74CC908B5BA6F28C34999CFE7F894606" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Based Payments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_74CC908B5BA6F28C34999CFE7F894606_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_74CC908B5BA6F28C34999CFE7F894606" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_74CC908B5BA6F28C34999CFE7F894606" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_74CC908B5BA6F28C34999CFE7F894606" xlink:to="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_74CC908B5BA6F28C34999CFE7F894606" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_F14B75D661F53C8FC3D79CFE7F0A2419_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_F14B75D661F53C8FC3D79CFE7F0A2419" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Liability and Receivable</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_F14B75D661F53C8FC3D79CFE7F0A2419_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_F14B75D661F53C8FC3D79CFE7F0A2419" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of revenue from contracts with customers [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_F14B75D661F53C8FC3D79CFE7F0A2419" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_F14B75D661F53C8FC3D79CFE7F0A2419" xlink:to="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_F14B75D661F53C8FC3D79CFE7F0A2419" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_59D55D2B6365CB34345B9CFE7EEE7759_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_59D55D2B6365CB34345B9CFE7EEE7759" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_59D55D2B6365CB34345B9CFE7EEE7759_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_59D55D2B6365CB34345B9CFE7EEE7759" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_59D55D2B6365CB34345B9CFE7EEE7759" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_59D55D2B6365CB34345B9CFE7EEE7759" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_59D55D2B6365CB34345B9CFE7EEE7759" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyTwentyMember_095D7C258B9B08E0C8699CFE7EBF73B1_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyMember_095D7C258B9B08E0C8699CFE7EBF73B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_oncyf_TwentyTwentyMember_095D7C258B9B08E0C8699CFE7EBF73B1_label_en-US" xlink:label="lab_oncyf_TwentyTwentyMember_095D7C258B9B08E0C8699CFE7EBF73B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Twenty [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyMember_095D7C258B9B08E0C8699CFE7EBF73B1_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyMember_095D7C258B9B08E0C8699CFE7EBF73B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Twenty [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyMember" xlink:label="loc_oncyf_TwentyTwentyMember_095D7C258B9B08E0C8699CFE7EBF73B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyMember_095D7C258B9B08E0C8699CFE7EBF73B1" xlink:to="lab_oncyf_TwentyTwentyMember_095D7C258B9B08E0C8699CFE7EBF73B1" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyTwentyOneMember_0AC7BE4B64D281F0CB9C9CFE7EC0B688_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyOneMember_0AC7BE4B64D281F0CB9C9CFE7EC0B688" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_oncyf_TwentyTwentyOneMember_0AC7BE4B64D281F0CB9C9CFE7EC0B688_label_en-US" xlink:label="lab_oncyf_TwentyTwentyOneMember_0AC7BE4B64D281F0CB9C9CFE7EC0B688" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Twenty One [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyOneMember_0AC7BE4B64D281F0CB9C9CFE7EC0B688_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyOneMember_0AC7BE4B64D281F0CB9C9CFE7EC0B688" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Twenty One [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyOneMember" xlink:label="loc_oncyf_TwentyTwentyOneMember_0AC7BE4B64D281F0CB9C9CFE7EC0B688" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyOneMember_0AC7BE4B64D281F0CB9C9CFE7EC0B688" xlink:to="lab_oncyf_TwentyTwentyOneMember_0AC7BE4B64D281F0CB9C9CFE7EC0B688" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyTwentyTwoMember_C6E219FE86738E2D18E19CFE7EC07F6E_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyTwoMember_C6E219FE86738E2D18E19CFE7EC07F6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_oncyf_TwentyTwentyTwoMember_C6E219FE86738E2D18E19CFE7EC07F6E_label_en-US" xlink:label="lab_oncyf_TwentyTwentyTwoMember_C6E219FE86738E2D18E19CFE7EC07F6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyTwoMember_C6E219FE86738E2D18E19CFE7EC07F6E_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyTwoMember_C6E219FE86738E2D18E19CFE7EC07F6E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyTwoMember" xlink:label="loc_oncyf_TwentyTwentyTwoMember_C6E219FE86738E2D18E19CFE7EC07F6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyTwoMember_C6E219FE86738E2D18E19CFE7EC07F6E" xlink:to="lab_oncyf_TwentyTwentyTwoMember_C6E219FE86738E2D18E19CFE7EC07F6E" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyTwentyThreeMember_B44AA8B3F2FD0B4A73A19CFE7EC00ADD_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyThreeMember_B44AA8B3F2FD0B4A73A19CFE7EC00ADD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_oncyf_TwentyTwentyThreeMember_B44AA8B3F2FD0B4A73A19CFE7EC00ADD_label_en-US" xlink:label="lab_oncyf_TwentyTwentyThreeMember_B44AA8B3F2FD0B4A73A19CFE7EC00ADD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Twenty Three [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyThreeMember_B44AA8B3F2FD0B4A73A19CFE7EC00ADD_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyThreeMember_B44AA8B3F2FD0B4A73A19CFE7EC00ADD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Twenty Three [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyThreeMember" xlink:label="loc_oncyf_TwentyTwentyThreeMember_B44AA8B3F2FD0B4A73A19CFE7EC00ADD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyThreeMember_B44AA8B3F2FD0B4A73A19CFE7EC00ADD" xlink:to="lab_oncyf_TwentyTwentyThreeMember_B44AA8B3F2FD0B4A73A19CFE7EC00ADD" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyTwentyFourMember_000FC33C99EBD6627CD89CFE7EC0704A_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyFourMember_000FC33C99EBD6627CD89CFE7EC0704A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_oncyf_TwentyTwentyFourMember_000FC33C99EBD6627CD89CFE7EC0704A_label_en-US" xlink:label="lab_oncyf_TwentyTwentyFourMember_000FC33C99EBD6627CD89CFE7EC0704A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Twenty Four [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyFourMember_000FC33C99EBD6627CD89CFE7EC0704A_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyFourMember_000FC33C99EBD6627CD89CFE7EC0704A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Twenty Four [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyFourMember" xlink:label="loc_oncyf_TwentyTwentyFourMember_000FC33C99EBD6627CD89CFE7EC0704A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyFourMember_000FC33C99EBD6627CD89CFE7EC0704A" xlink:to="lab_oncyf_TwentyTwentyFourMember_000FC33C99EBD6627CD89CFE7EC0704A" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyTwentyFiveMember_8D0C07B5FE41566F61719CFE7EC0A192_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyFiveMember_8D0C07B5FE41566F61719CFE7EC0A192" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_oncyf_TwentyTwentyFiveMember_8D0C07B5FE41566F61719CFE7EC0A192_label_en-US" xlink:label="lab_oncyf_TwentyTwentyFiveMember_8D0C07B5FE41566F61719CFE7EC0A192" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyFiveMember_8D0C07B5FE41566F61719CFE7EC0A192_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyFiveMember_8D0C07B5FE41566F61719CFE7EC0A192" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyFiveMember" xlink:label="loc_oncyf_TwentyTwentyFiveMember_8D0C07B5FE41566F61719CFE7EC0A192" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyFiveMember_8D0C07B5FE41566F61719CFE7EC0A192" xlink:to="lab_oncyf_TwentyTwentyFiveMember_8D0C07B5FE41566F61719CFE7EC0A192" xlink:type="arc" />
    <link:label id="lab_oncyf_TwentyTwentyEightMember_41EF8A95140304163C4C9CFE7EC16213_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyEightMember_41EF8A95140304163C4C9CFE7EC16213" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_oncyf_TwentyTwentyEightMember_41EF8A95140304163C4C9CFE7EC16213_label_en-US" xlink:label="lab_oncyf_TwentyTwentyEightMember_41EF8A95140304163C4C9CFE7EC16213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Twenty Eight [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyEightMember_41EF8A95140304163C4C9CFE7EC16213_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyEightMember_41EF8A95140304163C4C9CFE7EC16213" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Twenty Eight [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyEightMember" xlink:label="loc_oncyf_TwentyTwentyEightMember_41EF8A95140304163C4C9CFE7EC16213" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyEightMember_41EF8A95140304163C4C9CFE7EC16213" xlink:to="lab_oncyf_TwentyTwentyEightMember_41EF8A95140304163C4C9CFE7EC16213" xlink:type="arc" />
    <link:label id="lab_ifrs-full_UnusedTaxCreditsMember_B9FD6EAAC43E338F430B9CFE7EC376C5_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsMember_B9FD6EAAC43E338F430B9CFE7EC376C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-refundable federal investment tax credits</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsMember_B9FD6EAAC43E338F430B9CFE7EC376C5_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsMember_B9FD6EAAC43E338F430B9CFE7EC376C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused tax credits [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnusedTaxCreditsMember" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember_B9FD6EAAC43E338F430B9CFE7EC376C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxCreditsMember_B9FD6EAAC43E338F430B9CFE7EC376C5" xlink:to="lab_ifrs-full_UnusedTaxCreditsMember_B9FD6EAAC43E338F430B9CFE7EC376C5" xlink:type="arc" />
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_6EE0A320448F9FEA6A299CFE7EC3EACB_terseLabel_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_6EE0A320448F9FEA6A299CFE7EC3EACB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unclaimed scientific research and experimental development expenditures</link:label>
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_6EE0A320448F9FEA6A299CFE7EC3EACB_label_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_6EE0A320448F9FEA6A299CFE7EC3EACB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unclaimed Scientific Research And Experimental Development Expenditures [Member]</link:label>
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_6EE0A320448F9FEA6A299CFE7EC3EACB_documentation_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_6EE0A320448F9FEA6A299CFE7EC3EACB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unclaimed Scientific Research And Experimental Development Expenditures [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_6EE0A320448F9FEA6A299CFE7EC3EACB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_6EE0A320448F9FEA6A299CFE7EC3EACB" xlink:to="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_6EE0A320448F9FEA6A299CFE7EC3EACB" xlink:type="arc" />
    <link:label id="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_9BF85856D8E2DAA4E7369CFE7EC41910_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_9BF85856D8E2DAA4E7369CFE7EC41910" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unused tax credits</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_9BF85856D8E2DAA4E7369CFE7EC41910_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_9BF85856D8E2DAA4E7369CFE7EC41910" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused tax credits for which no deferred tax asset recognised</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:label="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_9BF85856D8E2DAA4E7369CFE7EC41910" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_9BF85856D8E2DAA4E7369CFE7EC41910" xlink:to="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_9BF85856D8E2DAA4E7369CFE7EC41910" xlink:type="arc" />
    <link:label id="lab_oncyf_ConcentrationRisk1Table_321AE68CE01BCF4D08E59CFE7E28BA0F_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRisk1Table_321AE68CE01BCF4D08E59CFE7E28BA0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk1 [Table]</link:label>
    <link:label id="lab_oncyf_ConcentrationRisk1Table_321AE68CE01BCF4D08E59CFE7E28BA0F_label_en-US" xlink:label="lab_oncyf_ConcentrationRisk1Table_321AE68CE01BCF4D08E59CFE7E28BA0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk1 [Table]</link:label>
    <link:label id="lab_oncyf_ConcentrationRisk1Table_321AE68CE01BCF4D08E59CFE7E28BA0F_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRisk1Table_321AE68CE01BCF4D08E59CFE7E28BA0F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration Risk1 [Table]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ConcentrationRisk1Table" xlink:label="loc_oncyf_ConcentrationRisk1Table_321AE68CE01BCF4D08E59CFE7E28BA0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRisk1Table_321AE68CE01BCF4D08E59CFE7E28BA0F" xlink:to="lab_oncyf_ConcentrationRisk1Table_321AE68CE01BCF4D08E59CFE7E28BA0F" xlink:type="arc" />
    <link:label id="lab_oncyf_ConcentrationRiskType1Axis_DD1628D636E0238452189CFE7E28C25C_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Axis_DD1628D636E0238452189CFE7E28C25C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Axis]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Axis_DD1628D636E0238452189CFE7E28C25C_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Axis_DD1628D636E0238452189CFE7E28C25C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Axis]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Axis_DD1628D636E0238452189CFE7E28C25C_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Axis_DD1628D636E0238452189CFE7E28C25C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Axis]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ConcentrationRiskType1Axis" xlink:label="loc_oncyf_ConcentrationRiskType1Axis_DD1628D636E0238452189CFE7E28C25C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskType1Axis_DD1628D636E0238452189CFE7E28C25C" xlink:to="lab_oncyf_ConcentrationRiskType1Axis_DD1628D636E0238452189CFE7E28C25C" xlink:type="arc" />
    <link:label id="lab_oncyf_ConcentrationRiskType1Domain_2F6B9A8F93D56871CF349CFE7E29A8DF_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Domain_2F6B9A8F93D56871CF349CFE7E29A8DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Domain]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Domain_2F6B9A8F93D56871CF349CFE7E29A8DF_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Domain_2F6B9A8F93D56871CF349CFE7E29A8DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Domain]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Domain_2F6B9A8F93D56871CF349CFE7E29A8DF_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Domain_2F6B9A8F93D56871CF349CFE7E29A8DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Concentration Risk Type1 [Axis]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ConcentrationRiskType1Domain" xlink:label="loc_oncyf_ConcentrationRiskType1Domain_2F6B9A8F93D56871CF349CFE7E29A8DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskType1Domain_2F6B9A8F93D56871CF349CFE7E29A8DF" xlink:to="lab_oncyf_ConcentrationRiskType1Domain_2F6B9A8F93D56871CF349CFE7E29A8DF" xlink:type="arc" />
    <link:label id="lab_oncyf_SupplierConcentrationRisk1Member_B9A38C910366D73492559CFE7E292D7D_terseLabel_en-US" xlink:label="lab_oncyf_SupplierConcentrationRisk1Member_B9A38C910366D73492559CFE7E292D7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Toll manufacturer</link:label>
    <link:label id="lab_oncyf_SupplierConcentrationRisk1Member_B9A38C910366D73492559CFE7E292D7D_label_en-US" xlink:label="lab_oncyf_SupplierConcentrationRisk1Member_B9A38C910366D73492559CFE7E292D7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Concentration Risk1 [Member]</link:label>
    <link:label id="lab_oncyf_SupplierConcentrationRisk1Member_B9A38C910366D73492559CFE7E292D7D_documentation_en-US" xlink:label="lab_oncyf_SupplierConcentrationRisk1Member_B9A38C910366D73492559CFE7E292D7D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplier Concentration Risk1 [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SupplierConcentrationRisk1Member" xlink:label="loc_oncyf_SupplierConcentrationRisk1Member_B9A38C910366D73492559CFE7E292D7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SupplierConcentrationRisk1Member_B9A38C910366D73492559CFE7E292D7D" xlink:to="lab_oncyf_SupplierConcentrationRisk1Member_B9A38C910366D73492559CFE7E292D7D" xlink:type="arc" />
    <link:label id="lab_oncyf_ConcentrationRiskType1LineItems_61BB0FEB7E430980EE279CFE7E29B3E1_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1LineItems_61BB0FEB7E430980EE279CFE7E29B3E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Line Items]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1LineItems_61BB0FEB7E430980EE279CFE7E29B3E1_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1LineItems_61BB0FEB7E430980EE279CFE7E29B3E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Line Items]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1LineItems_61BB0FEB7E430980EE279CFE7E29B3E1_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1LineItems_61BB0FEB7E430980EE279CFE7E29B3E1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Concentration Risk Type1 [Table]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ConcentrationRiskType1LineItems" xlink:label="loc_oncyf_ConcentrationRiskType1LineItems_61BB0FEB7E430980EE279CFE7E29B3E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems_61BB0FEB7E430980EE279CFE7E29B3E1" xlink:to="lab_oncyf_ConcentrationRiskType1LineItems_61BB0FEB7E430980EE279CFE7E29B3E1" xlink:type="arc" />
    <link:label id="lab_oncyf_ConcentrationRiskNumber_A25AF3CCD2CD91961BC69CFE7E294858_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskNumber_A25AF3CCD2CD91961BC69CFE7E294858" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration, number</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskNumber_A25AF3CCD2CD91961BC69CFE7E294858_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskNumber_A25AF3CCD2CD91961BC69CFE7E294858" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Number</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskNumber_A25AF3CCD2CD91961BC69CFE7E294858_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskNumber_A25AF3CCD2CD91961BC69CFE7E294858" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration Risk, Number</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ConcentrationRiskNumber" xlink:label="loc_oncyf_ConcentrationRiskNumber_A25AF3CCD2CD91961BC69CFE7E294858" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskNumber_A25AF3CCD2CD91961BC69CFE7E294858" xlink:to="lab_oncyf_ConcentrationRiskNumber_A25AF3CCD2CD91961BC69CFE7E294858" xlink:type="arc" />
    <link:label id="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_964A9C2D4F8E83A9A3DB9CFE7F76E4A1_terseLabel_en-US" xlink:label="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_964A9C2D4F8E83A9A3DB9CFE7F76E4A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_964A9C2D4F8E83A9A3DB9CFE7F76E4A1_label_en-US" xlink:label="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_964A9C2D4F8E83A9A3DB9CFE7F76E4A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]</link:label>
    <link:label id="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_964A9C2D4F8E83A9A3DB9CFE7F76E4A1_documentation_en-US" xlink:label="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_964A9C2D4F8E83A9A3DB9CFE7F76E4A1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:label="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_964A9C2D4F8E83A9A3DB9CFE7F76E4A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_964A9C2D4F8E83A9A3DB9CFE7F76E4A1" xlink:to="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_964A9C2D4F8E83A9A3DB9CFE7F76E4A1" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_2454F996A8A243D125909CFE7F76CCE0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_2454F996A8A243D125909CFE7F76CCE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of unrecognized non-capital losses, non-refundable credits and deferred tax assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_2454F996A8A243D125909CFE7F76CCE0_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_2454F996A8A243D125909CFE7F76CCE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_2454F996A8A243D125909CFE7F76CCE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_2454F996A8A243D125909CFE7F76CCE0" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_2454F996A8A243D125909CFE7F76CCE0" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_B5934BBA4FC6DD07FA6CA68362E65AB8_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_B5934BBA4FC6DD07FA6CA68362E65AB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserve of share-based payments</link:label>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_B5934BBA4FC6DD07FA6CA68362E65AB8_label_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_B5934BBA4FC6DD07FA6CA68362E65AB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve of share-based payments [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_B5934BBA4FC6DD07FA6CA68362E65AB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_B5934BBA4FC6DD07FA6CA68362E65AB8" xlink:to="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_B5934BBA4FC6DD07FA6CA68362E65AB8" xlink:type="arc" />
    <link:label id="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_DDD30FF7AD349B5D2937A68362E741AB_verboseLabel_en-US" xlink:label="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_DDD30FF7AD349B5D2937A68362E741AB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_DDD30FF7AD349B5D2937A68362E741AB_label_en-US" xlink:label="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_DDD30FF7AD349B5D2937A68362E741AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1</link:label>
    <link:label id="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_DDD30FF7AD349B5D2937A68362E741AB_documentation_en-US" xlink:label="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_DDD30FF7AD349B5D2937A68362E741AB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_DDD30FF7AD349B5D2937A68362E741AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_DDD30FF7AD349B5D2937A68362E741AB" xlink:to="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_DDD30FF7AD349B5D2937A68362E741AB" xlink:type="arc" />
    <link:label id="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_72464A34CE37DE43ED1CA68362E767E1_terseLabel_en-US" xlink:label="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_72464A34CE37DE43ED1CA68362E767E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares reserved for issuance (shares)</link:label>
    <link:label id="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_72464A34CE37DE43ED1CA68362E767E1_label_en-US" xlink:label="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_72464A34CE37DE43ED1CA68362E767E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares reserved for issue under options and contracts for sale of shares</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:label="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_72464A34CE37DE43ED1CA68362E767E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_72464A34CE37DE43ED1CA68362E767E1" xlink:to="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_72464A34CE37DE43ED1CA68362E767E1" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_7F37A9C26D88240235769CFE7F8036E1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_7F37A9C26D88240235769CFE7F8036E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_7F37A9C26D88240235769CFE7F8036E1_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_7F37A9C26D88240235769CFE7F8036E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial instruments [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_7F37A9C26D88240235769CFE7F8036E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_7F37A9C26D88240235769CFE7F8036E1" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_7F37A9C26D88240235769CFE7F8036E1" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AccountingProfit_3774068E36A4707A633A9CFE7EF36C64_terseLabel_en-US" xlink:label="lab_ifrs-full_AccountingProfit_3774068E36A4707A633A9CFE7EF36C64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_ifrs-full_AccountingProfit_3774068E36A4707A633A9CFE7EF36C64_label_en-US" xlink:label="lab_ifrs-full_AccountingProfit_3774068E36A4707A633A9CFE7EF36C64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting profit</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccountingProfit" xlink:label="loc_ifrs-full_AccountingProfit_3774068E36A4707A633A9CFE7EF36C64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccountingProfit_3774068E36A4707A633A9CFE7EF36C64" xlink:to="lab_ifrs-full_AccountingProfit_3774068E36A4707A633A9CFE7EF36C64" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ApplicableTaxRate_E72C1B682F3F9116C95C9CFE7EF39FE7_terseLabel_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate_E72C1B682F3F9116C95C9CFE7EF39FE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statutory Canadian corporate tax rate</link:label>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_E72C1B682F3F9116C95C9CFE7EF39FE7_label_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate_E72C1B682F3F9116C95C9CFE7EF39FE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Applicable tax rate</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate_E72C1B682F3F9116C95C9CFE7EF39FE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ApplicableTaxRate_E72C1B682F3F9116C95C9CFE7EF39FE7" xlink:to="lab_ifrs-full_ApplicableTaxRate_E72C1B682F3F9116C95C9CFE7EF39FE7" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_6B980CAE5AA6414668EC9CFE7EF38A87_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_6B980CAE5AA6414668EC9CFE7EF38A87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anticipated tax recovery</link:label>
    <link:label id="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_6B980CAE5AA6414668EC9CFE7EF38A87_label_en-US" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_6B980CAE5AA6414668EC9CFE7EF38A87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income) at applicable tax rate</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_6B980CAE5AA6414668EC9CFE7EF38A87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_6B980CAE5AA6414668EC9CFE7EF38A87" xlink:to="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_6B980CAE5AA6414668EC9CFE7EF38A87" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TaxEffectOfForeignTaxRates_FA9FD3DF3851E45BB4169CFE7EF30FD5_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectOfForeignTaxRates_FA9FD3DF3851E45BB4169CFE7EF30FD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign jurisdiction tax rate difference</link:label>
    <link:label id="lab_ifrs-full_TaxEffectOfForeignTaxRates_FA9FD3DF3851E45BB4169CFE7EF30FD5_label_en-US" xlink:label="lab_ifrs-full_TaxEffectOfForeignTaxRates_FA9FD3DF3851E45BB4169CFE7EF30FD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax effect of foreign tax rates</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxEffectOfForeignTaxRates" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates_FA9FD3DF3851E45BB4169CFE7EF30FD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectOfForeignTaxRates_FA9FD3DF3851E45BB4169CFE7EF30FD5" xlink:to="lab_ifrs-full_TaxEffectOfForeignTaxRates_FA9FD3DF3851E45BB4169CFE7EF30FD5" xlink:type="arc" />
    <link:label id="lab_oncyf_TaxEffectOfStockBasedCompensation_EBA15295945DDF09EE8D9CFE7EF44BDC_negatedTerseLabel_en-US" xlink:label="lab_oncyf_TaxEffectOfStockBasedCompensation_EBA15295945DDF09EE8D9CFE7EF44BDC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Employee share based compensation</link:label>
    <link:label id="lab_oncyf_TaxEffectOfStockBasedCompensation_EBA15295945DDF09EE8D9CFE7EF44BDC_label_en-US" xlink:label="lab_oncyf_TaxEffectOfStockBasedCompensation_EBA15295945DDF09EE8D9CFE7EF44BDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effect Of Stock Based Compensation</link:label>
    <link:label id="lab_oncyf_TaxEffectOfStockBasedCompensation_EBA15295945DDF09EE8D9CFE7EF44BDC_documentation_en-US" xlink:label="lab_oncyf_TaxEffectOfStockBasedCompensation_EBA15295945DDF09EE8D9CFE7EF44BDC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effect Of Stock Based Compensation</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TaxEffectOfStockBasedCompensation" xlink:label="loc_oncyf_TaxEffectOfStockBasedCompensation_EBA15295945DDF09EE8D9CFE7EF44BDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TaxEffectOfStockBasedCompensation_EBA15295945DDF09EE8D9CFE7EF44BDC" xlink:to="lab_oncyf_TaxEffectOfStockBasedCompensation_EBA15295945DDF09EE8D9CFE7EF44BDC" xlink:type="arc" />
    <link:label id="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_5EA4419FA8656974F4869CFE7EF409BD_terseLabel_en-US" xlink:label="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_5EA4419FA8656974F4869CFE7EF409BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant derivative</link:label>
    <link:label id="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_5EA4419FA8656974F4869CFE7EF409BD_label_en-US" xlink:label="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_5EA4419FA8656974F4869CFE7EF409BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effect Of Change in Fair Value Of Warrant Derivative</link:label>
    <link:label id="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_5EA4419FA8656974F4869CFE7EF409BD_documentation_en-US" xlink:label="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_5EA4419FA8656974F4869CFE7EF409BD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effect Of Change in Fair Value Of Warrant Derivative</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:label="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_5EA4419FA8656974F4869CFE7EF409BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_5EA4419FA8656974F4869CFE7EF409BD" xlink:to="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_5EA4419FA8656974F4869CFE7EF409BD" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TaxEffectFromChangeInTaxRate_ADB22AEBA3AF4CFCF1649CFE7EF4D476_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectFromChangeInTaxRate_ADB22AEBA3AF4CFCF1649CFE7EF4D476" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of Alberta rate change</link:label>
    <link:label id="lab_ifrs-full_TaxEffectFromChangeInTaxRate_ADB22AEBA3AF4CFCF1649CFE7EF4D476_label_en-US" xlink:label="lab_ifrs-full_TaxEffectFromChangeInTaxRate_ADB22AEBA3AF4CFCF1649CFE7EF4D476" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax effect from change in tax rate</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxEffectFromChangeInTaxRate" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate_ADB22AEBA3AF4CFCF1649CFE7EF4D476" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectFromChangeInTaxRate_ADB22AEBA3AF4CFCF1649CFE7EF4D476" xlink:to="lab_ifrs-full_TaxEffectFromChangeInTaxRate_ADB22AEBA3AF4CFCF1649CFE7EF4D476" xlink:type="arc" />
    <link:label id="lab_oncyf_TaxEffectOfTaxPools_AC8D43D590129693D68D9CFE7EF44993_terseLabel_en-US" xlink:label="lab_oncyf_TaxEffectOfTaxPools_AC8D43D590129693D68D9CFE7EF44993" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to opening tax pools</link:label>
    <link:label id="lab_oncyf_TaxEffectOfTaxPools_AC8D43D590129693D68D9CFE7EF44993_label_en-US" xlink:label="lab_oncyf_TaxEffectOfTaxPools_AC8D43D590129693D68D9CFE7EF44993" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effect Of Tax Pools</link:label>
    <link:label id="lab_oncyf_TaxEffectOfTaxPools_AC8D43D590129693D68D9CFE7EF44993_documentation_en-US" xlink:label="lab_oncyf_TaxEffectOfTaxPools_AC8D43D590129693D68D9CFE7EF44993" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effect Of Tax Pools</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TaxEffectOfTaxPools" xlink:label="loc_oncyf_TaxEffectOfTaxPools_AC8D43D590129693D68D9CFE7EF44993" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TaxEffectOfTaxPools_AC8D43D590129693D68D9CFE7EF44993" xlink:to="lab_oncyf_TaxEffectOfTaxPools_AC8D43D590129693D68D9CFE7EF44993" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_DCA844C83563F928E65F9CFE7EF4230D_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_DCA844C83563F928E65F9CFE7EF4230D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other permanent differences</link:label>
    <link:label id="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_DCA844C83563F928E65F9CFE7EF4230D_label_en-US" xlink:label="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_DCA844C83563F928E65F9CFE7EF4230D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax effect of expense not deductible in determining taxable profit (tax loss)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_DCA844C83563F928E65F9CFE7EF4230D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_DCA844C83563F928E65F9CFE7EF4230D" xlink:to="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_DCA844C83563F928E65F9CFE7EF4230D" xlink:type="arc" />
    <link:label id="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_163991F796241785D70B9CFE7EF45A16_negatedTerseLabel_en-US" xlink:label="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_163991F796241785D70B9CFE7EF45A16" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in deferred tax benefits deemed not probable to be recovered</link:label>
    <link:label id="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_163991F796241785D70B9CFE7EF45A16_label_en-US" xlink:label="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_163991F796241785D70B9CFE7EF45A16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1</link:label>
    <link:label id="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_163991F796241785D70B9CFE7EF45A16_documentation_en-US" xlink:label="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_163991F796241785D70B9CFE7EF45A16" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:label="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_163991F796241785D70B9CFE7EF45A16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_163991F796241785D70B9CFE7EF45A16" xlink:to="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_163991F796241785D70B9CFE7EF45A16" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_7BDBD46EA332CBB8FCB89CFE7EF52F5E_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome_7BDBD46EA332CBB8FCB89CFE7EF52F5E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Current income taxes</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_7BDBD46EA332CBB8FCB89CFE7EF52F5E_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome_7BDBD46EA332CBB8FCB89CFE7EF52F5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax expense (income)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_7BDBD46EA332CBB8FCB89CFE7EF52F5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_7BDBD46EA332CBB8FCB89CFE7EF52F5E" xlink:to="lab_ifrs-full_CurrentTaxExpenseIncome_7BDBD46EA332CBB8FCB89CFE7EF52F5E" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_85E5A6A5F8E471CE39FF9CFE7EF571DF_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_85E5A6A5F8E471CE39FF9CFE7EF571DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment in respect to prior periods</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_85E5A6A5F8E471CE39FF9CFE7EF571DF_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_85E5A6A5F8E471CE39FF9CFE7EF571DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for current tax of prior periods</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:label="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_85E5A6A5F8E471CE39FF9CFE7EF571DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_85E5A6A5F8E471CE39FF9CFE7EF571DF" xlink:to="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_85E5A6A5F8E471CE39FF9CFE7EF571DF" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_95B36AC021BEBD85610C9CFE7EF5F4DE_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_95B36AC021BEBD85610C9CFE7EF5F4DE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net current tax expense</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_95B36AC021BEBD85610C9CFE7EF5F4DE_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_95B36AC021BEBD85610C9CFE7EF5F4DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax expense (income) and adjustments for current tax of prior periods</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_95B36AC021BEBD85610C9CFE7EF5F4DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_95B36AC021BEBD85610C9CFE7EF5F4DE" xlink:to="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_95B36AC021BEBD85610C9CFE7EF5F4DE" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_903A8FF7DE0EF4A5535BA6836226136D_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_903A8FF7DE0EF4A5535BA6836226136D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_903A8FF7DE0EF4A5535BA6836226136D_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_903A8FF7DE0EF4A5535BA6836226136D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_903A8FF7DE0EF4A5535BA6836226136D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_903A8FF7DE0EF4A5535BA6836226136D" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_903A8FF7DE0EF4A5535BA6836226136D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_F4AA4A99E78C9F7A97F8A68362273A57_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_F4AA4A99E78C9F7A97F8A68362273A57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_F4AA4A99E78C9F7A97F8A68362273A57_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_F4AA4A99E78C9F7A97F8A68362273A57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_F4AA4A99E78C9F7A97F8A68362273A57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_F4AA4A99E78C9F7A97F8A68362273A57" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_F4AA4A99E78C9F7A97F8A68362273A57" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NonadjustingEventsMember_95E14724F5FA6C901597A68362273729_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsMember_95E14724F5FA6C901597A68362273729" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [member]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsMember_95E14724F5FA6C901597A68362273729_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsMember_95E14724F5FA6C901597A68362273729" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_95E14724F5FA6C901597A68362273729" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsMember_95E14724F5FA6C901597A68362273729" xlink:to="lab_ifrs-full_NonadjustingEventsMember_95E14724F5FA6C901597A68362273729" xlink:type="arc" />
    <link:label id="lab_ifrs-full_MajorOrdinaryShareTransactionsMember_BA4C4A24ABE7932542CDA6836227052B_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorOrdinaryShareTransactionsMember_BA4C4A24ABE7932542CDA6836227052B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share transactions</link:label>
    <link:label id="lab_ifrs-full_MajorOrdinaryShareTransactionsMember_BA4C4A24ABE7932542CDA6836227052B_label_en-US" xlink:label="lab_ifrs-full_MajorOrdinaryShareTransactionsMember_BA4C4A24ABE7932542CDA6836227052B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major ordinary share transactions [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_BA4C4A24ABE7932542CDA6836227052B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_BA4C4A24ABE7932542CDA6836227052B" xlink:to="lab_ifrs-full_MajorOrdinaryShareTransactionsMember_BA4C4A24ABE7932542CDA6836227052B" xlink:type="arc" />
    <link:label id="lab_ifrs-full_EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember_225A0D8A8274F6DCC0BBA68362286307_terseLabel_en-US" xlink:label="lab_ifrs-full_EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember_225A0D8A8274F6DCC0BBA68362286307" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receipt of upfront payment</link:label>
    <link:label id="lab_ifrs-full_EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember_225A0D8A8274F6DCC0BBA68362286307_label_en-US" xlink:label="lab_ifrs-full_EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember_225A0D8A8274F6DCC0BBA68362286307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entering into significant commitments or contingent liabilities [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember" xlink:label="loc_ifrs-full_EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember_225A0D8A8274F6DCC0BBA68362286307" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember_225A0D8A8274F6DCC0BBA68362286307" xlink:to="lab_ifrs-full_EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember_225A0D8A8274F6DCC0BBA68362286307" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_F3107E1131DC61F848FCA6836229F4F8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_F3107E1131DC61F848FCA6836229F4F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_F3107E1131DC61F848FCA6836229F4F8_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_F3107E1131DC61F848FCA6836229F4F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_F3107E1131DC61F848FCA6836229F4F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_F3107E1131DC61F848FCA6836229F4F8" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_F3107E1131DC61F848FCA6836229F4F8" xlink:type="arc" />
    <link:label id="lab_oncyf_ProceedsFromCollaborationAgreement_C291D57B5089EFF3498DA6B73617F3DA_terseLabel_en-US" xlink:label="lab_oncyf_ProceedsFromCollaborationAgreement_C291D57B5089EFF3498DA6B73617F3DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_oncyf_ProceedsFromCollaborationAgreement_C291D57B5089EFF3498DA6B73617F3DA_label_en-US" xlink:label="lab_oncyf_ProceedsFromCollaborationAgreement_C291D57B5089EFF3498DA6B73617F3DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Collaboration Agreement</link:label>
    <link:label id="lab_oncyf_ProceedsFromCollaborationAgreement_C291D57B5089EFF3498DA6B73617F3DA_documentation_en-US" xlink:label="lab_oncyf_ProceedsFromCollaborationAgreement_C291D57B5089EFF3498DA6B73617F3DA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Collaboration Agreement</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ProceedsFromCollaborationAgreement" xlink:label="loc_oncyf_ProceedsFromCollaborationAgreement_C291D57B5089EFF3498DA6B73617F3DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ProceedsFromCollaborationAgreement_C291D57B5089EFF3498DA6B73617F3DA" xlink:to="lab_oncyf_ProceedsFromCollaborationAgreement_C291D57B5089EFF3498DA6B73617F3DA" xlink:type="arc" />
    <link:label id="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_F1622D2A51510F1012D09CFE7E25AB45_terseLabel_en-US" xlink:label="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_F1622D2A51510F1012D09CFE7E25AB45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of balances in foreign currencies</link:label>
    <link:label id="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_F1622D2A51510F1012D09CFE7E25AB45_label_en-US" xlink:label="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_F1622D2A51510F1012D09CFE7E25AB45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Foreign Currency Held [Table Text Block]</link:label>
    <link:label id="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_F1622D2A51510F1012D09CFE7E25AB45_documentation_en-US" xlink:label="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_F1622D2A51510F1012D09CFE7E25AB45" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Foreign Currency Held [Table Text Block]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:label="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_F1622D2A51510F1012D09CFE7E25AB45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_F1622D2A51510F1012D09CFE7E25AB45" xlink:to="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_F1622D2A51510F1012D09CFE7E25AB45" xlink:type="arc" />
    <link:label id="lab_oncyf_WarrantPurchaseAgreement_97CD8CD5F0ED4F42BB32A7434C20271D_terseLabel_en-US" xlink:label="lab_oncyf_WarrantPurchaseAgreement_97CD8CD5F0ED4F42BB32A7434C20271D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant purchase agreement</link:label>
    <link:label id="lab_oncyf_WarrantPurchaseAgreement_97CD8CD5F0ED4F42BB32A7434C20271D_label_en-US" xlink:label="lab_oncyf_WarrantPurchaseAgreement_97CD8CD5F0ED4F42BB32A7434C20271D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Purchase Agreement</link:label>
    <link:label id="lab_oncyf_WarrantPurchaseAgreement_97CD8CD5F0ED4F42BB32A7434C20271D_documentation_en-US" xlink:label="lab_oncyf_WarrantPurchaseAgreement_97CD8CD5F0ED4F42BB32A7434C20271D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Purchase Agreement</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantPurchaseAgreement" xlink:label="loc_oncyf_WarrantPurchaseAgreement_97CD8CD5F0ED4F42BB32A7434C20271D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantPurchaseAgreement_97CD8CD5F0ED4F42BB32A7434C20271D" xlink:to="lab_oncyf_WarrantPurchaseAgreement_97CD8CD5F0ED4F42BB32A7434C20271D" xlink:type="arc" />
    <link:label id="lab_oncyf_SharePricePremiumPercent_F49F14A66C3E33C67FE4A7434C20FE4B_terseLabel_en-US" xlink:label="lab_oncyf_SharePricePremiumPercent_F49F14A66C3E33C67FE4A7434C20FE4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common share premium</link:label>
    <link:label id="lab_oncyf_SharePricePremiumPercent_F49F14A66C3E33C67FE4A7434C20FE4B_label_en-US" xlink:label="lab_oncyf_SharePricePremiumPercent_F49F14A66C3E33C67FE4A7434C20FE4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price Premium, Percent</link:label>
    <link:label id="lab_oncyf_SharePricePremiumPercent_F49F14A66C3E33C67FE4A7434C20FE4B_documentation_en-US" xlink:label="lab_oncyf_SharePricePremiumPercent_F49F14A66C3E33C67FE4A7434C20FE4B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Price Premium, Percent</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharePricePremiumPercent" xlink:label="loc_oncyf_SharePricePremiumPercent_F49F14A66C3E33C67FE4A7434C20FE4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharePricePremiumPercent_F49F14A66C3E33C67FE4A7434C20FE4B" xlink:to="lab_oncyf_SharePricePremiumPercent_F49F14A66C3E33C67FE4A7434C20FE4B" xlink:type="arc" />
    <link:label id="lab_oncyf_WeightedAverageClosingPriceDuration_914B7B4A2B6D9418A6F9A7434C20CAA1_terseLabel_en-US" xlink:label="lab_oncyf_WeightedAverageClosingPriceDuration_914B7B4A2B6D9418A6F9A7434C20CAA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average closing price term</link:label>
    <link:label id="lab_oncyf_WeightedAverageClosingPriceDuration_914B7B4A2B6D9418A6F9A7434C20CAA1_label_en-US" xlink:label="lab_oncyf_WeightedAverageClosingPriceDuration_914B7B4A2B6D9418A6F9A7434C20CAA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Closing Price Duration</link:label>
    <link:label id="lab_oncyf_WeightedAverageClosingPriceDuration_914B7B4A2B6D9418A6F9A7434C20CAA1_documentation_en-US" xlink:label="lab_oncyf_WeightedAverageClosingPriceDuration_914B7B4A2B6D9418A6F9A7434C20CAA1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Closing Price Duration</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WeightedAverageClosingPriceDuration" xlink:label="loc_oncyf_WeightedAverageClosingPriceDuration_914B7B4A2B6D9418A6F9A7434C20CAA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WeightedAverageClosingPriceDuration_914B7B4A2B6D9418A6F9A7434C20CAA1" xlink:to="lab_oncyf_WeightedAverageClosingPriceDuration_914B7B4A2B6D9418A6F9A7434C20CAA1" xlink:type="arc" />
    <link:label id="lab_oncyf_NumberofPatients_CD5F52BE286B095F24ACA7434C200913_terseLabel_en-US" xlink:label="lab_oncyf_NumberofPatients_CD5F52BE286B095F24ACA7434C200913" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patients</link:label>
    <link:label id="lab_oncyf_NumberofPatients_CD5F52BE286B095F24ACA7434C200913_label_en-US" xlink:label="lab_oncyf_NumberofPatients_CD5F52BE286B095F24ACA7434C200913" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Patients</link:label>
    <link:label id="lab_oncyf_NumberofPatients_CD5F52BE286B095F24ACA7434C200913_documentation_en-US" xlink:label="lab_oncyf_NumberofPatients_CD5F52BE286B095F24ACA7434C200913" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Patients</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_NumberofPatients" xlink:label="loc_oncyf_NumberofPatients_CD5F52BE286B095F24ACA7434C200913" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberofPatients_CD5F52BE286B095F24ACA7434C200913" xlink:to="lab_oncyf_NumberofPatients_CD5F52BE286B095F24ACA7434C200913" xlink:type="arc" />
    <link:label id="lab_oncyf_ContractLiabilityRecognitionPeriod_57FB06CF0788A648FAC3A7434C203EAC_terseLabel_en-US" xlink:label="lab_oncyf_ContractLiabilityRecognitionPeriod_57FB06CF0788A648FAC3A7434C203EAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected recognition period</link:label>
    <link:label id="lab_oncyf_ContractLiabilityRecognitionPeriod_57FB06CF0788A648FAC3A7434C203EAC_label_en-US" xlink:label="lab_oncyf_ContractLiabilityRecognitionPeriod_57FB06CF0788A648FAC3A7434C203EAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Liability, Recognition Period</link:label>
    <link:label id="lab_oncyf_ContractLiabilityRecognitionPeriod_57FB06CF0788A648FAC3A7434C203EAC_documentation_en-US" xlink:label="lab_oncyf_ContractLiabilityRecognitionPeriod_57FB06CF0788A648FAC3A7434C203EAC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Liability, Recognition Period</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ContractLiabilityRecognitionPeriod" xlink:label="loc_oncyf_ContractLiabilityRecognitionPeriod_57FB06CF0788A648FAC3A7434C203EAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ContractLiabilityRecognitionPeriod_57FB06CF0788A648FAC3A7434C203EAC" xlink:to="lab_oncyf_ContractLiabilityRecognitionPeriod_57FB06CF0788A648FAC3A7434C203EAC" xlink:type="arc" />
    <link:label id="lab_oncyf_SharesUnderIncentiveAwardPlanMember_D808CC015BBD057CCD6CA1D3EBF3FCE0_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderIncentiveAwardPlanMember_D808CC015BBD057CCD6CA1D3EBF3FCE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incentive award plan</link:label>
    <link:label id="lab_oncyf_SharesUnderIncentiveAwardPlanMember_D808CC015BBD057CCD6CA1D3EBF3FCE0_label_en-US" xlink:label="lab_oncyf_SharesUnderIncentiveAwardPlanMember_D808CC015BBD057CCD6CA1D3EBF3FCE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Under Incentive Award Plan [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderIncentiveAwardPlanMember_D808CC015BBD057CCD6CA1D3EBF3FCE0_documentation_en-US" xlink:label="lab_oncyf_SharesUnderIncentiveAwardPlanMember_D808CC015BBD057CCD6CA1D3EBF3FCE0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Under Incentive Award Plan [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderIncentiveAwardPlanMember" xlink:label="loc_oncyf_SharesUnderIncentiveAwardPlanMember_D808CC015BBD057CCD6CA1D3EBF3FCE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderIncentiveAwardPlanMember_D808CC015BBD057CCD6CA1D3EBF3FCE0" xlink:to="lab_oncyf_SharesUnderIncentiveAwardPlanMember_D808CC015BBD057CCD6CA1D3EBF3FCE0" xlink:type="arc" />
    <link:label id="lab_oncyf_SharesUnderStockOptionPlanMember_8757F78487C78FFD3112A1D3EBF4056C_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderStockOptionPlanMember_8757F78487C78FFD3112A1D3EBF4056C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option plan</link:label>
    <link:label id="lab_oncyf_SharesUnderStockOptionPlanMember_8757F78487C78FFD3112A1D3EBF4056C_label_en-US" xlink:label="lab_oncyf_SharesUnderStockOptionPlanMember_8757F78487C78FFD3112A1D3EBF4056C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Under Stock Option Plan [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderStockOptionPlanMember_8757F78487C78FFD3112A1D3EBF4056C_documentation_en-US" xlink:label="lab_oncyf_SharesUnderStockOptionPlanMember_8757F78487C78FFD3112A1D3EBF4056C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Under Stock Option Plan [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderStockOptionPlanMember" xlink:label="loc_oncyf_SharesUnderStockOptionPlanMember_8757F78487C78FFD3112A1D3EBF4056C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderStockOptionPlanMember_8757F78487C78FFD3112A1D3EBF4056C" xlink:to="lab_oncyf_SharesUnderStockOptionPlanMember_8757F78487C78FFD3112A1D3EBF4056C" xlink:type="arc" />
    <link:label id="lab_ifrs-full_Equity_22A704DD6395F6A67524A1D3EBF51E01_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Equity_22A704DD6395F6A67524A1D3EBF51E01" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_22A704DD6395F6A67524A1D3EBF51E01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity_22A704DD6395F6A67524A1D3EBF51E01" xlink:to="lab_ifrs-full_Equity_22A704DD6395F6A67524A1D3EBF51E01" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_889CE6F97BB9F9DE9F2CA1D3EBF57154_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued_889CE6F97BB9F9DE9F2CA1D3EBF57154" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Share capital issued, beginning (shares)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_889CE6F97BB9F9DE9F2CA1D3EBF57154" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued_889CE6F97BB9F9DE9F2CA1D3EBF57154" xlink:to="lab_ifrs-full_NumberOfSharesIssued_889CE6F97BB9F9DE9F2CA1D3EBF57154" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IssueOfEquity_07E7EA485BA0103CC751A1D3EBF50CA1_verboseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfEquity_07E7EA485BA0103CC751A1D3EBF50CA1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issued shares</link:label>
    <link:label id="lab_ifrs-full_IssueOfEquity_07E7EA485BA0103CC751A1D3EBF50CA1_label_en-US" xlink:label="lab_ifrs-full_IssueOfEquity_07E7EA485BA0103CC751A1D3EBF50CA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue of equity</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_07E7EA485BA0103CC751A1D3EBF50CA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssueOfEquity_07E7EA485BA0103CC751A1D3EBF50CA1" xlink:to="lab_ifrs-full_IssueOfEquity_07E7EA485BA0103CC751A1D3EBF50CA1" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_164ADE18045C48E03BA7A1D3EBF68EE2_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost_164ADE18045C48E03BA7A1D3EBF68EE2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share issue costs</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_164ADE18045C48E03BA7A1D3EBF68EE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareIssueRelatedCost_164ADE18045C48E03BA7A1D3EBF68EE2" xlink:to="lab_ifrs-full_ShareIssueRelatedCost_164ADE18045C48E03BA7A1D3EBF68EE2" xlink:type="arc" />
    <link:label id="lab_ifrs-full_Equity_84F15F501BED306837A8A1D3EBF68384_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Equity_84F15F501BED306837A8A1D3EBF68384" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_84F15F501BED306837A8A1D3EBF68384" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity_84F15F501BED306837A8A1D3EBF68384" xlink:to="lab_ifrs-full_Equity_84F15F501BED306837A8A1D3EBF68384" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_8D444D7DF3805019F96AA1D3EBF6189F_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued_8D444D7DF3805019F96AA1D3EBF6189F" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Share capital issued ending (shares)</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_8D444D7DF3805019F96AA1D3EBF6189F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued_8D444D7DF3805019F96AA1D3EBF6189F" xlink:to="lab_ifrs-full_NumberOfSharesIssued_8D444D7DF3805019F96AA1D3EBF6189F" xlink:type="arc" />
    <link:label id="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_2D2F0E1749C3602680A39CFE7E38E82E_label_en-US" xlink:label="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_2D2F0E1749C3602680A39CFE7E38E82E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share-based payment arrangement [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_2D2F0E1749C3602680A39CFE7E38E82E_documentation_en-US" xlink:label="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_2D2F0E1749C3602680A39CFE7E38E82E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of share-based payment arrangement [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:label="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_2D2F0E1749C3602680A39CFE7E38E82E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_2D2F0E1749C3602680A39CFE7E38E82E" xlink:to="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_2D2F0E1749C3602680A39CFE7E38E82E" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_28C2DE468CDADEDD0CFC9CFE7E3834D3_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_28C2DE468CDADEDD0CFC9CFE7E3834D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of stock options and weighted average exercise prices of share options</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_28C2DE468CDADEDD0CFC9CFE7E3834D3_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_28C2DE468CDADEDD0CFC9CFE7E3834D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_28C2DE468CDADEDD0CFC9CFE7E3834D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_28C2DE468CDADEDD0CFC9CFE7E3834D3" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_28C2DE468CDADEDD0CFC9CFE7E3834D3" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_713DFF1C7F5B479A69CB9CFE7E389C50_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_713DFF1C7F5B479A69CB9CFE7E389C50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of stock options outstanding and exercisable by range of exercise price</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_713DFF1C7F5B479A69CB9CFE7E389C50_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_713DFF1C7F5B479A69CB9CFE7E389C50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_713DFF1C7F5B479A69CB9CFE7E389C50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_713DFF1C7F5B479A69CB9CFE7E389C50" xlink:to="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_713DFF1C7F5B479A69CB9CFE7E389C50" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_DBBA10C519177148CAD49CFE7E38630F_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_DBBA10C519177148CAD49CFE7E38630F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of weighted average remaining contractual life and outstanding stock options by exercise price</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_DBBA10C519177148CAD49CFE7E38630F_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_DBBA10C519177148CAD49CFE7E38630F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_DBBA10C519177148CAD49CFE7E38630F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_DBBA10C519177148CAD49CFE7E38630F" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_DBBA10C519177148CAD49CFE7E38630F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_C39FE437AD18F6DD57499CFE7E3800D2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_C39FE437AD18F6DD57499CFE7E3800D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure weighted average assumptions and fair value of options</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_C39FE437AD18F6DD57499CFE7E3800D2_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_C39FE437AD18F6DD57499CFE7E3800D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_C39FE437AD18F6DD57499CFE7E3800D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_C39FE437AD18F6DD57499CFE7E3800D2" xlink:to="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_C39FE437AD18F6DD57499CFE7E3800D2" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_22BE17B27A56EA506B569CFE7E385230_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_22BE17B27A56EA506B569CFE7E385230" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of number of other equity instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_22BE17B27A56EA506B569CFE7E385230_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_22BE17B27A56EA506B569CFE7E385230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_22BE17B27A56EA506B569CFE7E385230" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_22BE17B27A56EA506B569CFE7E385230" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_22BE17B27A56EA506B569CFE7E385230" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_34E17CC8CC611F2789299CFE7E9E1AD8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_34E17CC8CC611F2789299CFE7E9E1AD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Expenses and Adjustments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_34E17CC8CC611F2789299CFE7E9E1AD8_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_34E17CC8CC611F2789299CFE7E9E1AD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other operating expense [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_34E17CC8CC611F2789299CFE7E9E1AD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_34E17CC8CC611F2789299CFE7E9E1AD8" xlink:to="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_34E17CC8CC611F2789299CFE7E9E1AD8" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_23E98ED6DB2E006F4F1EA683649C2F68_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_23E98ED6DB2E006F4F1EA683649C2F68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_23E98ED6DB2E006F4F1EA683649C2F68_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_23E98ED6DB2E006F4F1EA683649C2F68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for deferred income tax [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_23E98ED6DB2E006F4F1EA683649C2F68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_23E98ED6DB2E006F4F1EA683649C2F68" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_23E98ED6DB2E006F4F1EA683649C2F68" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_942ABF837FC4A25758EDA683649CC82E_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_942ABF837FC4A25758EDA683649CC82E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_942ABF837FC4A25758EDA683649CC82E_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_942ABF837FC4A25758EDA683649CC82E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial assets [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_942ABF837FC4A25758EDA683649CC82E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_942ABF837FC4A25758EDA683649CC82E" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_942ABF837FC4A25758EDA683649CC82E" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_18C1483FDFF6F4EE524EA683649C2C63_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_18C1483FDFF6F4EE524EA683649C2C63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_18C1483FDFF6F4EE524EA683649C2C63_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_18C1483FDFF6F4EE524EA683649C2C63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial liabilities [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_18C1483FDFF6F4EE524EA683649C2C63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_18C1483FDFF6F4EE524EA683649C2C63" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_18C1483FDFF6F4EE524EA683649C2C63" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_A69F87883AAA713E2626A683649CA720_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_A69F87883AAA713E2626A683649CA720" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_A69F87883AAA713E2626A683649CA720_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_A69F87883AAA713E2626A683649CA720" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for impairment of financial assets [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_A69F87883AAA713E2626A683649CA720" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_A69F87883AAA713E2626A683649CA720" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_A69F87883AAA713E2626A683649CA720" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_20154D5636F28C448750A683649D8EBB_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_20154D5636F28C448750A683649D8EBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurement</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_20154D5636F28C448750A683649D8EBB_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_20154D5636F28C448750A683649D8EBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for fair value measurement [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_20154D5636F28C448750A683649D8EBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_20154D5636F28C448750A683649D8EBB" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_20154D5636F28C448750A683649D8EBB" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_6CFA20DA79F0B367B0F5A683649DBC2F_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_6CFA20DA79F0B367B0F5A683649DBC2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_6CFA20DA79F0B367B0F5A683649DBC2F_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_6CFA20DA79F0B367B0F5A683649DBC2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_6CFA20DA79F0B367B0F5A683649DBC2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_6CFA20DA79F0B367B0F5A683649DBC2F" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_6CFA20DA79F0B367B0F5A683649DBC2F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_59F6BCA258C7B1E0E805A683649D6390_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_59F6BCA258C7B1E0E805A683649D6390" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per common share</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_59F6BCA258C7B1E0E805A683649D6390_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_59F6BCA258C7B1E0E805A683649D6390" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for earnings per share [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_59F6BCA258C7B1E0E805A683649D6390" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_59F6BCA258C7B1E0E805A683649D6390" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_59F6BCA258C7B1E0E805A683649D6390" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_5452E3C82261BE5D002CA683649DDCA0_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_5452E3C82261BE5D002CA683649DDCA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_5452E3C82261BE5D002CA683649DDCA0_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_5452E3C82261BE5D002CA683649DDCA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_5452E3C82261BE5D002CA683649DDCA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_5452E3C82261BE5D002CA683649DDCA0" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_5452E3C82261BE5D002CA683649DDCA0" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_F7AE1D5F4864B1D67608A691B8D37F30_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_F7AE1D5F4864B1D67608A691B8D37F30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_F7AE1D5F4864B1D67608A691B8D37F30_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_F7AE1D5F4864B1D67608A691B8D37F30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for leases [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_F7AE1D5F4864B1D67608A691B8D37F30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_F7AE1D5F4864B1D67608A691B8D37F30" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_F7AE1D5F4864B1D67608A691B8D37F30" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_3BC26DBAF5A89F811DE2A683649D0EE4_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_3BC26DBAF5A89F811DE2A683649D0EE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_3BC26DBAF5A89F811DE2A683649D0EE4_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_3BC26DBAF5A89F811DE2A683649D0EE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_3BC26DBAF5A89F811DE2A683649D0EE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_3BC26DBAF5A89F811DE2A683649D0EE4" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_3BC26DBAF5A89F811DE2A683649D0EE4" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_871B4FCF648A010C37AEA683649DD230_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_871B4FCF648A010C37AEA683649DD230" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_871B4FCF648A010C37AEA683649DD230_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_871B4FCF648A010C37AEA683649DD230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_871B4FCF648A010C37AEA683649DD230" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_871B4FCF648A010C37AEA683649DD230" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_871B4FCF648A010C37AEA683649DD230" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_28A768F8B3B269236D8FA683649E8677_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_28A768F8B3B269236D8FA683649E8677" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based payments</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_28A768F8B3B269236D8FA683649E8677_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_28A768F8B3B269236D8FA683649E8677" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_28A768F8B3B269236D8FA683649E8677" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_28A768F8B3B269236D8FA683649E8677" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_28A768F8B3B269236D8FA683649E8677" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_465D8208D04CB33AF42AA683649EA5F7_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_465D8208D04CB33AF42AA683649EA5F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting standards and interpretations issued but not yet effective</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_465D8208D04CB33AF42AA683649EA5F7_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_465D8208D04CB33AF42AA683649EA5F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_465D8208D04CB33AF42AA683649EA5F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_465D8208D04CB33AF42AA683649EA5F7" xlink:to="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_465D8208D04CB33AF42AA683649EA5F7" xlink:type="arc" />
    <link:label id="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_F80E5E556132F74794729CFE7F5BEA3A_label_en-US" xlink:label="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_F80E5E556132F74794729CFE7F5BEA3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Information And Statement Of IFRS Compliance [Abstract]</link:label>
    <link:label id="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_F80E5E556132F74794729CFE7F5BEA3A_documentation_en-US" xlink:label="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_F80E5E556132F74794729CFE7F5BEA3A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Information And Statement Of IFRS Compliance [Abstract]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:label="loc_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_F80E5E556132F74794729CFE7F5BEA3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_F80E5E556132F74794729CFE7F5BEA3A" xlink:to="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_F80E5E556132F74794729CFE7F5BEA3A" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_141E0C628308EAB930CD9CFE7F5B5287_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_141E0C628308EAB930CD9CFE7F5B5287" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of Financial Statement Presentation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_141E0C628308EAB930CD9CFE7F5B5287_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_141E0C628308EAB930CD9CFE7F5B5287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_141E0C628308EAB930CD9CFE7F5B5287" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_141E0C628308EAB930CD9CFE7F5B5287" xlink:to="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_141E0C628308EAB930CD9CFE7F5B5287" xlink:type="arc" />
    <link:label id="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_CE416691C2EFD69C39029CFE7E14F232_terseLabel_en-US" xlink:label="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_CE416691C2EFD69C39029CFE7E14F232" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in non-cash working capital</link:label>
    <link:label id="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_CE416691C2EFD69C39029CFE7E14F232_label_en-US" xlink:label="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_CE416691C2EFD69C39029CFE7E14F232" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Operating Capital1 [Table Text Block]</link:label>
    <link:label id="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_CE416691C2EFD69C39029CFE7E14F232_documentation_en-US" xlink:label="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_CE416691C2EFD69C39029CFE7E14F232" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Flow, Operating Capital1 [Table Text Block]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:label="loc_oncyf_CashFlowOperatingCapital1TableTextBlock_CE416691C2EFD69C39029CFE7E14F232" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CashFlowOperatingCapital1TableTextBlock_CE416691C2EFD69C39029CFE7E14F232" xlink:to="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_CE416691C2EFD69C39029CFE7E14F232" xlink:type="arc" />
    <link:label id="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_9B2F2D26D490573A3E229CFE7E146ED1_terseLabel_en-US" xlink:label="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_9B2F2D26D490573A3E229CFE7E146ED1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other cash flow disclosures</link:label>
    <link:label id="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_9B2F2D26D490573A3E229CFE7E146ED1_label_en-US" xlink:label="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_9B2F2D26D490573A3E229CFE7E146ED1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]</link:label>
    <link:label id="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_9B2F2D26D490573A3E229CFE7E146ED1_documentation_en-US" xlink:label="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_9B2F2D26D490573A3E229CFE7E146ED1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:label="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_9B2F2D26D490573A3E229CFE7E146ED1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_9B2F2D26D490573A3E229CFE7E146ED1" xlink:to="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_9B2F2D26D490573A3E229CFE7E146ED1" xlink:type="arc" />
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_25F246FA4A5D6BB49CD79CFE7F7861AE_terseLabel_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_25F246FA4A5D6BB49CD79CFE7F7861AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expenses and adjustments</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_25F246FA4A5D6BB49CD79CFE7F7861AE_label_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_25F246FA4A5D6BB49CD79CFE7F7861AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Table Text Block]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_25F246FA4A5D6BB49CD79CFE7F7861AE_documentation_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_25F246FA4A5D6BB49CD79CFE7F7861AE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Table Text Block]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_25F246FA4A5D6BB49CD79CFE7F7861AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_25F246FA4A5D6BB49CD79CFE7F7861AE" xlink:to="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_25F246FA4A5D6BB49CD79CFE7F7861AE" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_6C051E12EE1D8F5B4786A68364A609BB_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_6C051E12EE1D8F5B4786A68364A609BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_6C051E12EE1D8F5B4786A68364A609BB_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_6C051E12EE1D8F5B4786A68364A609BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of significant accounting policies [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_6C051E12EE1D8F5B4786A68364A609BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_6C051E12EE1D8F5B4786A68364A609BB" xlink:to="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_6C051E12EE1D8F5B4786A68364A609BB" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_2820BADC725E038AEB18AB79413E4201_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents_2820BADC725E038AEB18AB79413E4201" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_2820BADC725E038AEB18AB79413E4201" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents_2820BADC725E038AEB18AB79413E4201" xlink:to="lab_ifrs-full_CashAndCashEquivalents_2820BADC725E038AEB18AB79413E4201" xlink:type="arc" />
    <link:label id="lab_oncyf_EquityAuthorized_632649CB72042F0DE95CAB79413FE838_terseLabel_en-US" xlink:label="lab_oncyf_EquityAuthorized_632649CB72042F0DE95CAB79413FE838" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base Shelf securities authorized</link:label>
    <link:label id="lab_oncyf_EquityAuthorized_632649CB72042F0DE95CAB79413FE838_label_en-US" xlink:label="lab_oncyf_EquityAuthorized_632649CB72042F0DE95CAB79413FE838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Authorized</link:label>
    <link:label id="lab_oncyf_EquityAuthorized_632649CB72042F0DE95CAB79413FE838_documentation_en-US" xlink:label="lab_oncyf_EquityAuthorized_632649CB72042F0DE95CAB79413FE838" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Authorized</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_EquityAuthorized" xlink:label="loc_oncyf_EquityAuthorized_632649CB72042F0DE95CAB79413FE838" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_EquityAuthorized_632649CB72042F0DE95CAB79413FE838" xlink:to="lab_oncyf_EquityAuthorized_632649CB72042F0DE95CAB79413FE838" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AssetsAbstract_A7AC6EB3EB73421460FAACF623580922_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAbstract_A7AC6EB3EB73421460FAACF623580922" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_ifrs-full_AssetsAbstract_A7AC6EB3EB73421460FAACF623580922_label_en-US" xlink:label="lab_ifrs-full_AssetsAbstract_A7AC6EB3EB73421460FAACF623580922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-full_AssetsAbstract_A7AC6EB3EB73421460FAACF623580922" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract_A7AC6EB3EB73421460FAACF623580922" xlink:to="lab_ifrs-full_AssetsAbstract_A7AC6EB3EB73421460FAACF623580922" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_6EF6DA9006ECC53A597BACF623583893_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract_6EF6DA9006ECC53A597BACF623583893" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_6EF6DA9006ECC53A597BACF623583893_label_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract_6EF6DA9006ECC53A597BACF623583893" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_6EF6DA9006ECC53A597BACF623583893" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_6EF6DA9006ECC53A597BACF623583893" xlink:to="lab_ifrs-full_CurrentAssetsAbstract_6EF6DA9006ECC53A597BACF623583893" xlink:type="arc" />
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_24FA89A2999EC7B4FF81ACF62359A621_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables_24FA89A2999EC7B4FF81ACF62359A621" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_24FA89A2999EC7B4FF81ACF62359A621_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables_24FA89A2999EC7B4FF81ACF62359A621" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current receivables</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-full_OtherCurrentReceivables_24FA89A2999EC7B4FF81ACF62359A621" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentReceivables_24FA89A2999EC7B4FF81ACF62359A621" xlink:to="lab_ifrs-full_OtherCurrentReceivables_24FA89A2999EC7B4FF81ACF62359A621" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_60533CDC659A4CA34AC7ACF62359456A_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses_60533CDC659A4CA34AC7ACF62359456A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_60533CDC659A4CA34AC7ACF62359456A_label_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses_60533CDC659A4CA34AC7ACF62359456A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current prepaid expenses</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_60533CDC659A4CA34AC7ACF62359456A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepaidExpenses_60533CDC659A4CA34AC7ACF62359456A" xlink:to="lab_ifrs-full_CurrentPrepaidExpenses_60533CDC659A4CA34AC7ACF62359456A" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrentAssets_38AB290D736A19E9EE0FACF62359B020_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssets_38AB290D736A19E9EE0FACF62359B020" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssets_38AB290D736A19E9EE0FACF62359B020_label_en-US" xlink:label="lab_ifrs-full_CurrentAssets_38AB290D736A19E9EE0FACF62359B020" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets_38AB290D736A19E9EE0FACF62359B020" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets_38AB290D736A19E9EE0FACF62359B020" xlink:to="lab_ifrs-full_CurrentAssets_38AB290D736A19E9EE0FACF62359B020" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_2744E6ECD649A52E198DACF6235913AA_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract_2744E6ECD649A52E198DACF6235913AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_2744E6ECD649A52E198DACF6235913AA_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract_2744E6ECD649A52E198DACF6235913AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_2744E6ECD649A52E198DACF6235913AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_2744E6ECD649A52E198DACF6235913AA" xlink:to="lab_ifrs-full_NoncurrentAssetsAbstract_2744E6ECD649A52E198DACF6235913AA" xlink:type="arc" />
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_9BB2F84A3845A0776B2FACF6235A799D_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment_9BB2F84A3845A0776B2FACF6235A799D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_9BB2F84A3845A0776B2FACF6235A799D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment_9BB2F84A3845A0776B2FACF6235A799D" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment_9BB2F84A3845A0776B2FACF6235A799D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NoncurrentAssets_F7E99F885E15D41FAD5AACF6235A84FE_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets_F7E99F885E15D41FAD5AACF6235A84FE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssets_F7E99F885E15D41FAD5AACF6235A84FE_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets_F7E99F885E15D41FAD5AACF6235A84FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets_F7E99F885E15D41FAD5AACF6235A84FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssets_F7E99F885E15D41FAD5AACF6235A84FE" xlink:to="lab_ifrs-full_NoncurrentAssets_F7E99F885E15D41FAD5AACF6235A84FE" xlink:type="arc" />
    <link:label id="lab_ifrs-full_Assets_BCF06D612426CABF0BE8ACF6235A0065_totalLabel_en-US" xlink:label="lab_ifrs-full_Assets_BCF06D612426CABF0BE8ACF6235A0065" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_BCF06D612426CABF0BE8ACF6235A0065" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets_BCF06D612426CABF0BE8ACF6235A0065" xlink:to="lab_ifrs-full_Assets_BCF06D612426CABF0BE8ACF6235A0065" xlink:type="arc" />
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_811D753723F292D39386ACF6235AE1F2_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract_811D753723F292D39386ACF6235AE1F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities And Shareholders&#8217; (Deficit) Equity</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_811D753723F292D39386ACF6235AE1F2_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract_811D753723F292D39386ACF6235AE1F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_811D753723F292D39386ACF6235AE1F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_811D753723F292D39386ACF6235AE1F2" xlink:to="lab_ifrs-full_EquityAndLiabilitiesAbstract_811D753723F292D39386ACF6235AE1F2" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_AED781475BFDA24847AAACF6235A03D4_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract_AED781475BFDA24847AAACF6235A03D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_AED781475BFDA24847AAACF6235A03D4_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract_AED781475BFDA24847AAACF6235A03D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_AED781475BFDA24847AAACF6235A03D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_AED781475BFDA24847AAACF6235A03D4" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract_AED781475BFDA24847AAACF6235A03D4" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_02C53910D0B685A71BC2ACF6235B695F_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables_02C53910D0B685A71BC2ACF6235B695F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_02C53910D0B685A71BC2ACF6235B695F_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables_02C53910D0B685A71BC2ACF6235B695F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other current payables</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_02C53910D0B685A71BC2ACF6235B695F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_02C53910D0B685A71BC2ACF6235B695F" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayables_02C53910D0B685A71BC2ACF6235B695F" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_4D736DFFD5B9649AD897ACF6235B242A_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities_4D736DFFD5B9649AD897ACF6235B242A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liability</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="loc_ifrs-full_CurrentContractLiabilities_4D736DFFD5B9649AD897ACF6235B242A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentContractLiabilities_4D736DFFD5B9649AD897ACF6235B242A" xlink:to="lab_ifrs-full_CurrentContractLiabilities_4D736DFFD5B9649AD897ACF6235B242A" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_6964AF43532FA74FF34BACF6235B9AB5_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities_6964AF43532FA74FF34BACF6235B9AB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_6964AF43532FA74FF34BACF6235B9AB5_label_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities_6964AF43532FA74FF34BACF6235B9AB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_6964AF43532FA74FF34BACF6235B9AB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLeaseLiabilities_6964AF43532FA74FF34BACF6235B9AB5" xlink:to="lab_ifrs-full_CurrentLeaseLiabilities_6964AF43532FA74FF34BACF6235B9AB5" xlink:type="arc" />
    <link:label id="lab_ifrs-full_CurrentLiabilities_4C6A86EF29FEA4B427CAACF6235CFD74_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities_4C6A86EF29FEA4B427CAACF6235CFD74" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilities_4C6A86EF29FEA4B427CAACF6235CFD74_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities_4C6A86EF29FEA4B427CAACF6235CFD74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities_4C6A86EF29FEA4B427CAACF6235CFD74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities_4C6A86EF29FEA4B427CAACF6235CFD74" xlink:to="lab_ifrs-full_CurrentLiabilities_4C6A86EF29FEA4B427CAACF6235CFD74" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_667195CBC527B9AE8C2CACF6235C5CC0_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract_667195CBC527B9AE8C2CACF6235C5CC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_667195CBC527B9AE8C2CACF6235C5CC0_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract_667195CBC527B9AE8C2CACF6235C5CC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract_667195CBC527B9AE8C2CACF6235C5CC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_667195CBC527B9AE8C2CACF6235C5CC0" xlink:to="lab_ifrs-full_NoncurrentLiabilitiesAbstract_667195CBC527B9AE8C2CACF6235C5CC0" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_22425B80C3F5D6F44880ACF6235C0F53_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities_22425B80C3F5D6F44880ACF6235C0F53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liability</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_22425B80C3F5D6F44880ACF6235C0F53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentContractLiabilities_22425B80C3F5D6F44880ACF6235C0F53" xlink:to="lab_ifrs-full_NoncurrentContractLiabilities_22425B80C3F5D6F44880ACF6235C0F53" xlink:type="arc" />
    <link:label id="lab_ifrs-full_OtherNoncurrentLiabilities_FCF2332F9256FBA102FEACF6235C757D_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentLiabilities_FCF2332F9256FBA102FEACF6235C757D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentLiabilities_FCF2332F9256FBA102FEACF6235C757D_label_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentLiabilities_FCF2332F9256FBA102FEACF6235C757D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_FCF2332F9256FBA102FEACF6235C757D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentLiabilities_FCF2332F9256FBA102FEACF6235C757D" xlink:to="lab_ifrs-full_OtherNoncurrentLiabilities_FCF2332F9256FBA102FEACF6235C757D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_88E612BD629557A82066ACF6235C4840_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities_88E612BD629557A82066ACF6235C4840" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_88E612BD629557A82066ACF6235C4840_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities_88E612BD629557A82066ACF6235C4840" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_88E612BD629557A82066ACF6235C4840" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLeaseLiabilities_88E612BD629557A82066ACF6235C4840" xlink:to="lab_ifrs-full_NoncurrentLeaseLiabilities_88E612BD629557A82066ACF6235C4840" xlink:type="arc" />
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_02E7592415525B7170DCACF6235D14EF_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities_02E7592415525B7170DCACF6235D14EF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_02E7592415525B7170DCACF6235D14EF_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities_02E7592415525B7170DCACF6235D14EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-full_NoncurrentLiabilities_02E7592415525B7170DCACF6235D14EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilities_02E7592415525B7170DCACF6235D14EF" xlink:to="lab_ifrs-full_NoncurrentLiabilities_02E7592415525B7170DCACF6235D14EF" xlink:type="arc" />
    <link:label id="lab_ifrs-full_Liabilities_AED4CBA17DEF6DC83593ACF6235D9992_totalLabel_en-US" xlink:label="lab_ifrs-full_Liabilities_AED4CBA17DEF6DC83593ACF6235D9992" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_AED4CBA17DEF6DC83593ACF6235D9992" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Liabilities_AED4CBA17DEF6DC83593ACF6235D9992" xlink:to="lab_ifrs-full_Liabilities_AED4CBA17DEF6DC83593ACF6235D9992" xlink:type="arc" />
    <link:label id="lab_oncyf_CommitmentsAndContingencies1_873E3A3BE1530130BF5DACF6235D310C_terseLabel_en-US" xlink:label="lab_oncyf_CommitmentsAndContingencies1_873E3A3BE1530130BF5DACF6235D310C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_oncyf_CommitmentsAndContingencies1_873E3A3BE1530130BF5DACF6235D310C_label_en-US" xlink:label="lab_oncyf_CommitmentsAndContingencies1_873E3A3BE1530130BF5DACF6235D310C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies1</link:label>
    <link:label id="lab_oncyf_CommitmentsAndContingencies1_873E3A3BE1530130BF5DACF6235D310C_documentation_en-US" xlink:label="lab_oncyf_CommitmentsAndContingencies1_873E3A3BE1530130BF5DACF6235D310C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies1</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CommitmentsAndContingencies1" xlink:label="loc_oncyf_CommitmentsAndContingencies1_873E3A3BE1530130BF5DACF6235D310C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommitmentsAndContingencies1_873E3A3BE1530130BF5DACF6235D310C" xlink:to="lab_oncyf_CommitmentsAndContingencies1_873E3A3BE1530130BF5DACF6235D310C" xlink:type="arc" />
    <link:label id="lab_ifrs-full_EquityAbstract_7185F1256A1CB6B178D3ACF6235DF056_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAbstract_7185F1256A1CB6B178D3ACF6235DF056" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders&#8217; (deficit) equity</link:label>
    <link:label id="lab_ifrs-full_EquityAbstract_7185F1256A1CB6B178D3ACF6235DF056_label_en-US" xlink:label="lab_ifrs-full_EquityAbstract_7185F1256A1CB6B178D3ACF6235DF056" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [abstract]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-full_EquityAbstract_7185F1256A1CB6B178D3ACF6235DF056" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract_7185F1256A1CB6B178D3ACF6235DF056" xlink:to="lab_ifrs-full_EquityAbstract_7185F1256A1CB6B178D3ACF6235DF056" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IssuedCapital_0BC9FEA07DD850EE4500ACF6235DF8E4_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapital_0BC9FEA07DD850EE4500ACF6235DF8E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital Authorized: unlimited Issued: December 31, 2019 &#8211; 32,198,453 December 31, 2018 &#8211; 17,399,749</link:label>
    <link:label id="lab_ifrs-full_IssuedCapital_0BC9FEA07DD850EE4500ACF6235DF8E4_label_en-US" xlink:label="lab_ifrs-full_IssuedCapital_0BC9FEA07DD850EE4500ACF6235DF8E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital_0BC9FEA07DD850EE4500ACF6235DF8E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital_0BC9FEA07DD850EE4500ACF6235DF8E4" xlink:to="lab_ifrs-full_IssuedCapital_0BC9FEA07DD850EE4500ACF6235DF8E4" xlink:type="arc" />
    <link:label id="lab_oncyf_WarrantsandRightsOutstanding_7861CB379C1F8CCB3A5CACF6235EE783_terseLabel_en-US" xlink:label="lab_oncyf_WarrantsandRightsOutstanding_7861CB379C1F8CCB3A5CACF6235EE783" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_oncyf_WarrantsandRightsOutstanding_7861CB379C1F8CCB3A5CACF6235EE783_label_en-US" xlink:label="lab_oncyf_WarrantsandRightsOutstanding_7861CB379C1F8CCB3A5CACF6235EE783" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:label id="lab_oncyf_WarrantsandRightsOutstanding_7861CB379C1F8CCB3A5CACF6235EE783_documentation_en-US" xlink:label="lab_oncyf_WarrantsandRightsOutstanding_7861CB379C1F8CCB3A5CACF6235EE783" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsandRightsOutstanding" xlink:label="loc_oncyf_WarrantsandRightsOutstanding_7861CB379C1F8CCB3A5CACF6235EE783" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantsandRightsOutstanding_7861CB379C1F8CCB3A5CACF6235EE783" xlink:to="lab_oncyf_WarrantsandRightsOutstanding_7861CB379C1F8CCB3A5CACF6235EE783" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AdditionalPaidinCapital_E671913D707FC08F71F4ACF6235E56F3_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapital_E671913D707FC08F71F4ACF6235E56F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributed surplus</link:label>
    <link:label id="lab_ifrs-full_AdditionalPaidinCapital_E671913D707FC08F71F4ACF6235E56F3_label_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapital_E671913D707FC08F71F4ACF6235E56F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionalPaidinCapital" xlink:label="loc_ifrs-full_AdditionalPaidinCapital_E671913D707FC08F71F4ACF6235E56F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionalPaidinCapital_E671913D707FC08F71F4ACF6235E56F3" xlink:to="lab_ifrs-full_AdditionalPaidinCapital_E671913D707FC08F71F4ACF6235E56F3" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_5478A9A6C7B5C4D6323DACF6235E1F5E_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_5478A9A6C7B5C4D6323DACF6235E1F5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_5478A9A6C7B5C4D6323DACF6235E1F5E_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_5478A9A6C7B5C4D6323DACF6235E1F5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_5478A9A6C7B5C4D6323DACF6235E1F5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_5478A9A6C7B5C4D6323DACF6235E1F5E" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_5478A9A6C7B5C4D6323DACF6235E1F5E" xlink:type="arc" />
    <link:label id="lab_ifrs-full_RetainedEarnings_2EA19806F42F25CBE1E0ACF6235ECF1A_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarnings_2EA19806F42F25CBE1E0ACF6235ECF1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_ifrs-full_RetainedEarnings_2EA19806F42F25CBE1E0ACF6235ECF1A_label_en-US" xlink:label="lab_ifrs-full_RetainedEarnings_2EA19806F42F25CBE1E0ACF6235ECF1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings_2EA19806F42F25CBE1E0ACF6235ECF1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarnings_2EA19806F42F25CBE1E0ACF6235ECF1A" xlink:to="lab_ifrs-full_RetainedEarnings_2EA19806F42F25CBE1E0ACF6235ECF1A" xlink:type="arc" />
    <link:label id="lab_ifrs-full_Equity_7E2D8FD06AEAB3C331F9ACF6236304A5_totalLabel_en-US" xlink:label="lab_ifrs-full_Equity_7E2D8FD06AEAB3C331F9ACF6236304A5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders&#8217; (deficit) equity</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_7E2D8FD06AEAB3C331F9ACF6236304A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity_7E2D8FD06AEAB3C331F9ACF6236304A5" xlink:to="lab_ifrs-full_Equity_7E2D8FD06AEAB3C331F9ACF6236304A5" xlink:type="arc" />
    <link:label id="lab_ifrs-full_EquityAndLiabilities_5EAA18F89E1FF7F213E9ACF6236365CA_totalLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities_5EAA18F89E1FF7F213E9ACF6236365CA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and shareholders' (deficit) equity</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_5EAA18F89E1FF7F213E9ACF6236365CA_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities_5EAA18F89E1FF7F213E9ACF6236365CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-full_EquityAndLiabilities_5EAA18F89E1FF7F213E9ACF6236365CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities_5EAA18F89E1FF7F213E9ACF6236365CA" xlink:to="lab_ifrs-full_EquityAndLiabilities_5EAA18F89E1FF7F213E9ACF6236365CA" xlink:type="arc" />
    <link:label id="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_2B589CF4A5380787A6F09CFE7E8404A7_verboseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_2B589CF4A5380787A6F09CFE7E8404A7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of capital components</link:label>
    <link:label id="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_2B589CF4A5380787A6F09CFE7E8404A7_label_en-US" xlink:label="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_2B589CF4A5380787A6F09CFE7E8404A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Capital Components [Table Text Block]</link:label>
    <link:label id="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_2B589CF4A5380787A6F09CFE7E8404A7_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_2B589CF4A5380787A6F09CFE7E8404A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Capital Components [Table Text Block]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:label="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock_2B589CF4A5380787A6F09CFE7E8404A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock_2B589CF4A5380787A6F09CFE7E8404A7" xlink:to="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_2B589CF4A5380787A6F09CFE7E8404A7" xlink:type="arc" />
    <link:label id="lab_oncyf_ExercisePriceofOutstandingWarrants_4984249835BACB353242A1D3E674017B_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceofOutstandingWarrants_4984249835BACB353242A1D3E674017B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_oncyf_ExercisePriceofOutstandingWarrants_4984249835BACB353242A1D3E674017B_label_en-US" xlink:label="lab_oncyf_ExercisePriceofOutstandingWarrants_4984249835BACB353242A1D3E674017B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price of Outstanding Warrants</link:label>
    <link:label id="lab_oncyf_ExercisePriceofOutstandingWarrants_4984249835BACB353242A1D3E674017B_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceofOutstandingWarrants_4984249835BACB353242A1D3E674017B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price of Outstanding Warrants</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ExercisePriceofOutstandingWarrants" xlink:label="loc_oncyf_ExercisePriceofOutstandingWarrants_4984249835BACB353242A1D3E674017B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceofOutstandingWarrants_4984249835BACB353242A1D3E674017B" xlink:to="lab_oncyf_ExercisePriceofOutstandingWarrants_4984249835BACB353242A1D3E674017B" xlink:type="arc" />
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_D11BB88EB0F57D525134A1D3E67BBDCE_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_D11BB88EB0F57D525134A1D3E67BBDCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_D11BB88EB0F57D525134A1D3E67BBDCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_D11BB88EB0F57D525134A1D3E67BBDCE" xlink:to="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_D11BB88EB0F57D525134A1D3E67BBDCE" xlink:type="arc" />
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_11A7A223B5CA9D282633A6836485FBC4_terseLabel_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember_11A7A223B5CA9D282633A6836485FBC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office equipment and furniture</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="loc_ifrs-full_OfficeEquipmentMember_11A7A223B5CA9D282633A6836485FBC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OfficeEquipmentMember_11A7A223B5CA9D282633A6836485FBC4" xlink:to="lab_ifrs-full_OfficeEquipmentMember_11A7A223B5CA9D282633A6836485FBC4" xlink:type="arc" />
    <link:label id="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_8D774DDED0389C308BBFA68364864384_terseLabel_en-US" xlink:label="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_8D774DDED0389C308BBFA68364864384" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual depreciation rate</link:label>
    <link:label id="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_8D774DDED0389C308BBFA68364864384_label_en-US" xlink:label="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_8D774DDED0389C308BBFA68364864384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Annual Depreciation Rate</link:label>
    <link:label id="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_8D774DDED0389C308BBFA68364864384_documentation_en-US" xlink:label="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_8D774DDED0389C308BBFA68364864384" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Annual Depreciation Rate</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:label="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_8D774DDED0389C308BBFA68364864384" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_8D774DDED0389C308BBFA68364864384" xlink:to="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_8D774DDED0389C308BBFA68364864384" xlink:type="arc" />
    <link:label id="lab_oncyf_ClassOfWarrantOrRightOutstanding1_2F08EBE178AD77F606CEA8273883DB91_periodStartLabel_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightOutstanding1_2F08EBE178AD77F606CEA8273883DB91" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Issued, August 16, 2019 (shares)</link:label>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightOutstanding1_2F08EBE178AD77F606CEA8273883DB91_label_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightOutstanding1_2F08EBE178AD77F606CEA8273883DB91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Outstanding1</link:label>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightOutstanding1_2F08EBE178AD77F606CEA8273883DB91_documentation_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightOutstanding1_2F08EBE178AD77F606CEA8273883DB91" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Outstanding1</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassOfWarrantOrRightOutstanding1" xlink:label="loc_oncyf_ClassOfWarrantOrRightOutstanding1_2F08EBE178AD77F606CEA8273883DB91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassOfWarrantOrRightOutstanding1_2F08EBE178AD77F606CEA8273883DB91" xlink:to="lab_oncyf_ClassOfWarrantOrRightOutstanding1_2F08EBE178AD77F606CEA8273883DB91" xlink:type="arc" />
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_E8ABA4A793BF342E727BA827388433C8_negatedTerseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_E8ABA4A793BF342E727BA827388433C8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (shares)</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_E8ABA4A793BF342E727BA827388433C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_E8ABA4A793BF342E727BA827388433C8" xlink:to="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_E8ABA4A793BF342E727BA827388433C8" xlink:type="arc" />
    <link:label id="lab_oncyf_ClassOfWarrantOrRightOutstanding1_CCDE6B00338E501AEC2BA827388473E0_periodEndLabel_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightOutstanding1_CCDE6B00338E501AEC2BA827388473E0" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">As at December 31, 2019 (shares)</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassOfWarrantOrRightOutstanding1" xlink:label="loc_oncyf_ClassOfWarrantOrRightOutstanding1_CCDE6B00338E501AEC2BA827388473E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassOfWarrantOrRightOutstanding1_CCDE6B00338E501AEC2BA827388473E0" xlink:to="lab_oncyf_ClassOfWarrantOrRightOutstanding1_CCDE6B00338E501AEC2BA827388473E0" xlink:type="arc" />
    <link:label id="lab_oncyf_WarrantsAndRightsOutstanding1_CA56ECA0FB35CDD68D24A82738846B12_periodStartLabel_en-US" xlink:label="lab_oncyf_WarrantsAndRightsOutstanding1_CA56ECA0FB35CDD68D24A82738846B12" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Issued, August 16, 2019</link:label>
    <link:label id="lab_oncyf_WarrantsAndRightsOutstanding1_CA56ECA0FB35CDD68D24A82738846B12_label_en-US" xlink:label="lab_oncyf_WarrantsAndRightsOutstanding1_CA56ECA0FB35CDD68D24A82738846B12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants And Rights Outstanding1</link:label>
    <link:label id="lab_oncyf_WarrantsAndRightsOutstanding1_CA56ECA0FB35CDD68D24A82738846B12_documentation_en-US" xlink:label="lab_oncyf_WarrantsAndRightsOutstanding1_CA56ECA0FB35CDD68D24A82738846B12" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants And Rights Outstanding1</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsAndRightsOutstanding1" xlink:label="loc_oncyf_WarrantsAndRightsOutstanding1_CA56ECA0FB35CDD68D24A82738846B12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantsAndRightsOutstanding1_CA56ECA0FB35CDD68D24A82738846B12" xlink:to="lab_oncyf_WarrantsAndRightsOutstanding1_CA56ECA0FB35CDD68D24A82738846B12" xlink:type="arc" />
    <link:label id="lab_oncyf_ClassofWarrantorRightWarrantsExercised_6D9D819648BCB5AA140CA827388446CC_negatedLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightWarrantsExercised_6D9D819648BCB5AA140CA827388446CC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightWarrantsExercised" xlink:label="loc_oncyf_ClassofWarrantorRightWarrantsExercised_6D9D819648BCB5AA140CA827388446CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRightWarrantsExercised_6D9D819648BCB5AA140CA827388446CC" xlink:to="lab_oncyf_ClassofWarrantorRightWarrantsExercised_6D9D819648BCB5AA140CA827388446CC" xlink:type="arc" />
    <link:label id="lab_oncyf_WarrantsAndRightsOutstanding1_F179964C1071317B05CBA82738857C97_periodEndLabel_en-US" xlink:label="lab_oncyf_WarrantsAndRightsOutstanding1_F179964C1071317B05CBA82738857C97" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">As at December 31, 2019</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsAndRightsOutstanding1" xlink:label="loc_oncyf_WarrantsAndRightsOutstanding1_F179964C1071317B05CBA82738857C97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantsAndRightsOutstanding1_F179964C1071317B05CBA82738857C97" xlink:to="lab_oncyf_WarrantsAndRightsOutstanding1_F179964C1071317B05CBA82738857C97" xlink:type="arc" />
    <link:label id="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_61A9EF54C6AF873A16819CFE7E7B9696_terseLabel_en-US" xlink:label="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_61A9EF54C6AF873A16819CFE7E7B9696" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating losses carried forward</link:label>
    <link:label id="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_61A9EF54C6AF873A16819CFE7E7B9696_label_en-US" xlink:label="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_61A9EF54C6AF873A16819CFE7E7B9696" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused Net Operating Loss Carry Forwards [Member]</link:label>
    <link:label id="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_61A9EF54C6AF873A16819CFE7E7B9696_documentation_en-US" xlink:label="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_61A9EF54C6AF873A16819CFE7E7B9696" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unused Net Operating Loss Carry Forwards [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:label="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_61A9EF54C6AF873A16819CFE7E7B9696" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_61A9EF54C6AF873A16819CFE7E7B9696" xlink:to="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_61A9EF54C6AF873A16819CFE7E7B9696" xlink:type="arc" />
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_23859A827F9E270607FF9CFE7E7C4A1D_verboseLabel_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_23859A827F9E270607FF9CFE7E7C4A1D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Scientific research and experimental development</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_23859A827F9E270607FF9CFE7E7C4A1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_23859A827F9E270607FF9CFE7E7C4A1D" xlink:to="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_23859A827F9E270607FF9CFE7E7C4A1D" xlink:type="arc" />
    <link:label id="lab_oncyf_InvestmentTaxCreditsMember_764BE0C2135B047D2A0B9CFE7E7C0E8F_terseLabel_en-US" xlink:label="lab_oncyf_InvestmentTaxCreditsMember_764BE0C2135B047D2A0B9CFE7E7C0E8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment tax credits</link:label>
    <link:label id="lab_oncyf_InvestmentTaxCreditsMember_764BE0C2135B047D2A0B9CFE7E7C0E8F_label_en-US" xlink:label="lab_oncyf_InvestmentTaxCreditsMember_764BE0C2135B047D2A0B9CFE7E7C0E8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Tax Credits [Member]</link:label>
    <link:label id="lab_oncyf_InvestmentTaxCreditsMember_764BE0C2135B047D2A0B9CFE7E7C0E8F_documentation_en-US" xlink:label="lab_oncyf_InvestmentTaxCreditsMember_764BE0C2135B047D2A0B9CFE7E7C0E8F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment Tax Credits [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_InvestmentTaxCreditsMember" xlink:label="loc_oncyf_InvestmentTaxCreditsMember_764BE0C2135B047D2A0B9CFE7E7C0E8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_InvestmentTaxCreditsMember_764BE0C2135B047D2A0B9CFE7E7C0E8F" xlink:to="lab_oncyf_InvestmentTaxCreditsMember_764BE0C2135B047D2A0B9CFE7E7C0E8F" xlink:type="arc" />
    <link:label id="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_477B54D5277C652A91569CFE7E7C73C8_terseLabel_en-US" xlink:label="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_477B54D5277C652A91569CFE7E7C73C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undepreciated capital costs in excess of book value of property and equipment and intellectual property</link:label>
    <link:label id="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_477B54D5277C652A91569CFE7E7C73C8_label_en-US" xlink:label="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_477B54D5277C652A91569CFE7E7C73C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, Equipment And Intellectual Property Related Temporary Differences [Member]</link:label>
    <link:label id="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_477B54D5277C652A91569CFE7E7C73C8_documentation_en-US" xlink:label="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_477B54D5277C652A91569CFE7E7C73C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property, Plant, Equipment And Intellectual Property Related Temporary Differences [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" xlink:label="loc_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_477B54D5277C652A91569CFE7E7C73C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_477B54D5277C652A91569CFE7E7C73C8" xlink:to="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_477B54D5277C652A91569CFE7E7C73C8" xlink:type="arc" />
    <link:label id="lab_oncyf_ShareIssueCostsMember_6A560FA56BD6795341EC9CFE7E7C60AF_terseLabel_en-US" xlink:label="lab_oncyf_ShareIssueCostsMember_6A560FA56BD6795341EC9CFE7E7C60AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issue costs</link:label>
    <link:label id="lab_oncyf_ShareIssueCostsMember_6A560FA56BD6795341EC9CFE7E7C60AF_label_en-US" xlink:label="lab_oncyf_ShareIssueCostsMember_6A560FA56BD6795341EC9CFE7E7C60AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Issue Costs [Member]</link:label>
    <link:label id="lab_oncyf_ShareIssueCostsMember_6A560FA56BD6795341EC9CFE7E7C60AF_documentation_en-US" xlink:label="lab_oncyf_ShareIssueCostsMember_6A560FA56BD6795341EC9CFE7E7C60AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Issue Costs [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ShareIssueCostsMember" xlink:label="loc_oncyf_ShareIssueCostsMember_6A560FA56BD6795341EC9CFE7E7C60AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShareIssueCostsMember_6A560FA56BD6795341EC9CFE7E7C60AF" xlink:to="lab_oncyf_ShareIssueCostsMember_6A560FA56BD6795341EC9CFE7E7C60AF" xlink:type="arc" />
    <link:label id="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_B4C3CCC958C5C00064CE9CFE7E7D1CBB_terseLabel_en-US" xlink:label="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_B4C3CCC958C5C00064CE9CFE7E7D1CBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net capital losses carried forward</link:label>
    <link:label id="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_B4C3CCC958C5C00064CE9CFE7E7D1CBB_label_en-US" xlink:label="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_B4C3CCC958C5C00064CE9CFE7E7D1CBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused Capital Loss Carry Forward, Net [Member]</link:label>
    <link:label id="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_B4C3CCC958C5C00064CE9CFE7E7D1CBB_documentation_en-US" xlink:label="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_B4C3CCC958C5C00064CE9CFE7E7D1CBB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unused Capital Loss Carry Forward, Net [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:label="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_B4C3CCC958C5C00064CE9CFE7E7D1CBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_B4C3CCC958C5C00064CE9CFE7E7D1CBB" xlink:to="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_B4C3CCC958C5C00064CE9CFE7E7D1CBB" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_C1576EA69B47C18E30119CFE7E7D50D3_terseLabel_en-US" xlink:label="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_C1576EA69B47C18E30119CFE7E7D50D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized deferred tax asset</link:label>
    <link:label id="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_C1576EA69B47C18E30119CFE7E7D50D3_label_en-US" xlink:label="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_C1576EA69B47C18E30119CFE7E7D50D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deductible temporary differences for which no deferred tax asset is recognised</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_C1576EA69B47C18E30119CFE7E7D50D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_C1576EA69B47C18E30119CFE7E7D50D3" xlink:to="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_C1576EA69B47C18E30119CFE7E7D50D3" xlink:type="arc" />
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_C85411ABA5023210E0CFACF623245769_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable_C85411ABA5023210E0CFACF623245769" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_C85411ABA5023210E0CFACF623245769_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable_C85411ABA5023210E0CFACF623245769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_C85411ABA5023210E0CFACF623245769" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_C85411ABA5023210E0CFACF623245769" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable_C85411ABA5023210E0CFACF623245769" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_9C208DA46E0FA0E304CDACF6232474E9_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis_9C208DA46E0FA0E304CDACF6232474E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_9C208DA46E0FA0E304CDACF6232474E9_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis_9C208DA46E0FA0E304CDACF6232474E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_9C208DA46E0FA0E304CDACF6232474E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_9C208DA46E0FA0E304CDACF6232474E9" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis_9C208DA46E0FA0E304CDACF6232474E9" xlink:type="arc" />
    <link:label id="lab_ifrs-full_EquityMember_B9453EAB0D75A8AB8647ACF6232426AB_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityMember_B9453EAB0D75A8AB8647ACF6232426AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [member]</link:label>
    <link:label id="lab_ifrs-full_EquityMember_B9453EAB0D75A8AB8647ACF6232426AB_label_en-US" xlink:label="lab_ifrs-full_EquityMember_B9453EAB0D75A8AB8647ACF6232426AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_B9453EAB0D75A8AB8647ACF6232426AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityMember_B9453EAB0D75A8AB8647ACF6232426AB" xlink:to="lab_ifrs-full_EquityMember_B9453EAB0D75A8AB8647ACF6232426AB" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IssuedCapitalMember_80FBA3F09F72996CB436ACF62324A552_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember_80FBA3F09F72996CB436ACF62324A552" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Capital $</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_80FBA3F09F72996CB436ACF62324A552" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember_80FBA3F09F72996CB436ACF62324A552" xlink:to="lab_ifrs-full_IssuedCapitalMember_80FBA3F09F72996CB436ACF62324A552" xlink:type="arc" />
    <link:label id="lab_oncyf_WarrantsMember_CFDD84710FFE8EAB51DCACF62325858D_terseLabel_en-US" xlink:label="lab_oncyf_WarrantsMember_CFDD84710FFE8EAB51DCACF62325858D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants $</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_CFDD84710FFE8EAB51DCACF62325858D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantsMember_CFDD84710FFE8EAB51DCACF62325858D" xlink:to="lab_oncyf_WarrantsMember_CFDD84710FFE8EAB51DCACF62325858D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_SharePremiumMember_70C2E7623CCED1A17587ACF623253CB2_terseLabel_en-US" xlink:label="lab_ifrs-full_SharePremiumMember_70C2E7623CCED1A17587ACF623253CB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributed Surplus $</link:label>
    <link:label id="lab_ifrs-full_SharePremiumMember_70C2E7623CCED1A17587ACF623253CB2_label_en-US" xlink:label="lab_ifrs-full_SharePremiumMember_70C2E7623CCED1A17587ACF623253CB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share premium [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharePremiumMember" xlink:label="loc_ifrs-full_SharePremiumMember_70C2E7623CCED1A17587ACF623253CB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremiumMember_70C2E7623CCED1A17587ACF623253CB2" xlink:to="lab_ifrs-full_SharePremiumMember_70C2E7623CCED1A17587ACF623253CB2" xlink:type="arc" />
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_AF3071FEAB454B2B4743ACF62325AECC_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_AF3071FEAB454B2B4743ACF62325AECC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income $</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_AF3071FEAB454B2B4743ACF62325AECC_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_AF3071FEAB454B2B4743ACF62325AECC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_AF3071FEAB454B2B4743ACF62325AECC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_AF3071FEAB454B2B4743ACF62325AECC" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_AF3071FEAB454B2B4743ACF62325AECC" xlink:type="arc" />
    <link:label id="lab_ifrs-full_RetainedEarningsMember_C88B5CD38E874BA4BDBBACF62325A449_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember_C88B5CD38E874BA4BDBBACF62325A449" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit $</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_C88B5CD38E874BA4BDBBACF62325A449_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember_C88B5CD38E874BA4BDBBACF62325A449" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings [member]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember_C88B5CD38E874BA4BDBBACF62325A449" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsMember_C88B5CD38E874BA4BDBBACF62325A449" xlink:to="lab_ifrs-full_RetainedEarningsMember_C88B5CD38E874BA4BDBBACF62325A449" xlink:type="arc" />
    <link:label id="lab_oncyf_SharesUnderSharePurchaseAgreementMember_8DF9D9EA8EA46E6B460CACF623260850_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderSharePurchaseAgreementMember_8DF9D9EA8EA46E6B460CACF623260850" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Purchase Agreement</link:label>
    <link:label id="lab_oncyf_SharesUnderSharePurchaseAgreementMember_8DF9D9EA8EA46E6B460CACF623260850_label_en-US" xlink:label="lab_oncyf_SharesUnderSharePurchaseAgreementMember_8DF9D9EA8EA46E6B460CACF623260850" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Under Share Purchase Agreement [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderSharePurchaseAgreementMember_8DF9D9EA8EA46E6B460CACF623260850_documentation_en-US" xlink:label="lab_oncyf_SharesUnderSharePurchaseAgreementMember_8DF9D9EA8EA46E6B460CACF623260850" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Under Share Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderSharePurchaseAgreementMember" xlink:label="loc_oncyf_SharesUnderSharePurchaseAgreementMember_8DF9D9EA8EA46E6B460CACF623260850" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderSharePurchaseAgreementMember_8DF9D9EA8EA46E6B460CACF623260850" xlink:to="lab_oncyf_SharesUnderSharePurchaseAgreementMember_8DF9D9EA8EA46E6B460CACF623260850" xlink:type="arc" />
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:type="arc" />
    <link:label id="lab_ifrs-full_ComprehensiveIncome_6F0DE793C7308E56FEA0ACF62327033B_terseLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome_6F0DE793C7308E56FEA0ACF62327033B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss and other comprehensive income</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_6F0DE793C7308E56FEA0ACF62327033B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome_6F0DE793C7308E56FEA0ACF62327033B" xlink:to="lab_ifrs-full_ComprehensiveIncome_6F0DE793C7308E56FEA0ACF62327033B" xlink:type="arc" />
    <link:label id="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_C2255625113F736101D3ACF623275483_terseLabel_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_C2255625113F736101D3ACF623275483" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued pursuant to incentive share award plan</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_C2255625113F736101D3ACF623275483_label_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_C2255625113F736101D3ACF623275483" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Incentive Share Awards, Equity</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_C2255625113F736101D3ACF623275483_documentation_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_C2255625113F736101D3ACF623275483" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Incentive Share Awards, Equity</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:label="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_C2255625113F736101D3ACF623275483" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_C2255625113F736101D3ACF623275483" xlink:to="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_C2255625113F736101D3ACF623275483" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_7879F91B43F52554FD34ACF623275B77_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_7879F91B43F52554FD34ACF623275B77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued pursuant to stock option plan</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_7879F91B43F52554FD34ACF623275B77_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_7879F91B43F52554FD34ACF623275B77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through exercise of options, equity</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_7879F91B43F52554FD34ACF623275B77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_7879F91B43F52554FD34ACF623275B77" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_7879F91B43F52554FD34ACF623275B77" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IssueOfEquity_AD583F47885FD2776FD2ACF62327D60B_terseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfEquity_AD583F47885FD2776FD2ACF62327D60B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_AD583F47885FD2776FD2ACF62327D60B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssueOfEquity_AD583F47885FD2776FD2ACF62327D60B" xlink:to="lab_ifrs-full_IssueOfEquity_AD583F47885FD2776FD2ACF62327D60B" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_D49C7AD827E580137511ACF62328EE7D_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_D49C7AD827E580137511ACF62328EE7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued pursuant to warrant agreement</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_D49C7AD827E580137511ACF62328EE7D_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_D49C7AD827E580137511ACF62328EE7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through exercise of warrants, equity</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_D49C7AD827E580137511ACF62328EE7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_D49C7AD827E580137511ACF62328EE7D" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_D49C7AD827E580137511ACF62328EE7D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_E126DD9EDEEE9F405437ACF62328F49D_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_E126DD9EDEEE9F405437ACF62328F49D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_E126DD9EDEEE9F405437ACF62328F49D_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_E126DD9EDEEE9F405437ACF62328F49D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_E126DD9EDEEE9F405437ACF62328F49D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_E126DD9EDEEE9F405437ACF62328F49D" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_E126DD9EDEEE9F405437ACF62328F49D" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_17E0D09227DB23319BC9A20A0D3595D3_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_17E0D09227DB23319BC9A20A0D3595D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of share capital</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_17E0D09227DB23319BC9A20A0D3595D3_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_17E0D09227DB23319BC9A20A0D3595D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [text block]</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_17E0D09227DB23319BC9A20A0D3595D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_17E0D09227DB23319BC9A20A0D3595D3" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_17E0D09227DB23319BC9A20A0D3595D3" xlink:type="arc" />
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_28EA1831119F5FC59B20A20A0D358913_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_28EA1831119F5FC59B20A20A0D358913" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of outstanding warrants</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_28EA1831119F5FC59B20A20A0D358913" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_28EA1831119F5FC59B20A20A0D358913" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_28EA1831119F5FC59B20A20A0D358913" xlink:type="arc" />
    <link:label id="lab_oncyf_Currency1Table_F094A305589401A92997A81F7EAEB869_terseLabel_en-US" xlink:label="lab_oncyf_Currency1Table_F094A305589401A92997A81F7EAEB869" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency1 [Table]</link:label>
    <link:label id="lab_oncyf_Currency1Table_F094A305589401A92997A81F7EAEB869_label_en-US" xlink:label="lab_oncyf_Currency1Table_F094A305589401A92997A81F7EAEB869" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency1 [Table]</link:label>
    <link:label id="lab_oncyf_Currency1Table_F094A305589401A92997A81F7EAEB869_documentation_en-US" xlink:label="lab_oncyf_Currency1Table_F094A305589401A92997A81F7EAEB869" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Currency1 [Table]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_Currency1Table" xlink:label="loc_oncyf_Currency1Table_F094A305589401A92997A81F7EAEB869" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Currency1Table_F094A305589401A92997A81F7EAEB869" xlink:to="lab_oncyf_Currency1Table_F094A305589401A92997A81F7EAEB869" xlink:type="arc" />
    <link:label id="lab_oncyf_Currency1LineItems_A03B3995CDFEDBADD26BA81F7EB07BFD_terseLabel_en-US" xlink:label="lab_oncyf_Currency1LineItems_A03B3995CDFEDBADD26BA81F7EB07BFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Currency1LineItems_A03B3995CDFEDBADD26BA81F7EB07BFD_label_en-US" xlink:label="lab_oncyf_Currency1LineItems_A03B3995CDFEDBADD26BA81F7EB07BFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Currency1LineItems_A03B3995CDFEDBADD26BA81F7EB07BFD_documentation_en-US" xlink:label="lab_oncyf_Currency1LineItems_A03B3995CDFEDBADD26BA81F7EB07BFD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Currency1 [Table]</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_Currency1LineItems" xlink:label="loc_oncyf_Currency1LineItems_A03B3995CDFEDBADD26BA81F7EB07BFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Currency1LineItems_A03B3995CDFEDBADD26BA81F7EB07BFD" xlink:to="lab_oncyf_Currency1LineItems_A03B3995CDFEDBADD26BA81F7EB07BFD" xlink:type="arc" />
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_A20D7F659CB474F753E6A81F7EB0D707_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables_A20D7F659CB474F753E6A81F7EB0D707" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_A20D7F659CB474F753E6A81F7EB0D707" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_A20D7F659CB474F753E6A81F7EB0D707" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayables_A20D7F659CB474F753E6A81F7EB0D707" xlink:type="arc" />
    <link:label id="lab_oncyf_BalanceHeldInForeignCurrencyNet_5C27DAB1BF714F3F9418A81F7EB10030_terseLabel_en-US" xlink:label="lab_oncyf_BalanceHeldInForeignCurrencyNet_5C27DAB1BF714F3F9418A81F7EB10030" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balances in foreign currencies</link:label>
    <link:label id="lab_oncyf_BalanceHeldInForeignCurrencyNet_5C27DAB1BF714F3F9418A81F7EB10030_label_en-US" xlink:label="lab_oncyf_BalanceHeldInForeignCurrencyNet_5C27DAB1BF714F3F9418A81F7EB10030" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Held In Foreign Currency, Net</link:label>
    <link:label id="lab_oncyf_BalanceHeldInForeignCurrencyNet_5C27DAB1BF714F3F9418A81F7EB10030_documentation_en-US" xlink:label="lab_oncyf_BalanceHeldInForeignCurrencyNet_5C27DAB1BF714F3F9418A81F7EB10030" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Balance Held In Foreign Currency, Net</link:label>
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_BalanceHeldInForeignCurrencyNet" xlink:label="loc_oncyf_BalanceHeldInForeignCurrencyNet_5C27DAB1BF714F3F9418A81F7EB10030" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_BalanceHeldInForeignCurrencyNet_5C27DAB1BF714F3F9418A81F7EB10030" xlink:to="lab_oncyf_BalanceHeldInForeignCurrencyNet_5C27DAB1BF714F3F9418A81F7EB10030" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>28
<FILENAME>oncyf-20191231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:href="oncyf-20191231.xsd#AdditionalCashFlowDisclosures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:href="oncyf-20191231.xsd#AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:href="oncyf-20191231.xsd#AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:href="oncyf-20191231.xsd#AdditionalCashFlowDisclosuresTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/BasisOfFinancialStatementPresentation" xlink:href="oncyf-20191231.xsd#BasisOfFinancialStatementPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:href="oncyf-20191231.xsd#CapitalDisclosures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:href="oncyf-20191231.xsd#CapitalDisclosuresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:href="oncyf-20191231.xsd#CapitalDisclosuresTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalents" xlink:href="oncyf-20191231.xsd#CashEquivalents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsNarrativeDetails" xlink:href="oncyf-20191231.xsd#CashEquivalentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Commitments" xlink:href="oncyf-20191231.xsd#Commitments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsDetails" xlink:href="oncyf-20191231.xsd#CommitmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="oncyf-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfChangesInDeficitEquity" xlink:href="oncyf-20191231.xsd#ConsolidatedStatementsOfChangesInDeficitEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPosition" xlink:href="oncyf-20191231.xsd#ConsolidatedStatementsOfFinancialPosition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPositionParenthetical" xlink:href="oncyf-20191231.xsd#ConsolidatedStatementsOfFinancialPositionParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss" xlink:href="oncyf-20191231.xsd#ConsolidatedStatementsOfLossAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Contingencies" xlink:href="oncyf-20191231.xsd#Contingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContingenciesDetails" xlink:href="oncyf-20191231.xsd#ContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivable" xlink:href="oncyf-20191231.xsd#ContractLiabilityAndReceivable" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableNarrativeDetails" xlink:href="oncyf-20191231.xsd#ContractLiabilityAndReceivableNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableScheduleOfContractRevenuesAndLiabilitiesDetails" xlink:href="oncyf-20191231.xsd#ContractLiabilityAndReceivableScheduleOfContractRevenuesAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableTables" xlink:href="oncyf-20191231.xsd#ContractLiabilityAndReceivableTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/DocumentAndEntityInformation" xlink:href="oncyf-20191231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:href="oncyf-20191231.xsd#EconomicDependence" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:href="oncyf-20191231.xsd#EconomicDependenceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:href="oncyf-20191231.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:href="oncyf-20191231.xsd#FinancialInstrumentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleOfBalancesInForeignCurrenciesDetails" xlink:href="oncyf-20191231.xsd#FinancialInstrumentsScheduleOfBalancesInForeignCurrenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:href="oncyf-20191231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:href="oncyf-20191231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionForIncomeTaxesDetails" xlink:href="oncyf-20191231.xsd#IncomeTaxesProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleOfUnrecognizedDeferredTaxAssetsDetails" xlink:href="oncyf-20191231.xsd#IncomeTaxesScheduleOfUnrecognizedDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonCapitalLossesDetails" xlink:href="oncyf-20191231.xsd#IncomeTaxesSummaryOfNonCapitalLossesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonRefundableFederalInvestmentTaxCreditsDetails" xlink:href="oncyf-20191231.xsd#IncomeTaxesSummaryOfNonRefundableFederalInvestmentTaxCreditsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:href="oncyf-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncorporationAndNatureOfOperations" xlink:href="oncyf-20191231.xsd#IncorporationAndNatureOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IndemnificationOfOfficersAndDirectors" xlink:href="oncyf-20191231.xsd#IndemnificationOfOfficersAndDirectors" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Leases" xlink:href="oncyf-20191231.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:href="oncyf-20191231.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesRightOfUseAssetsAndLeaseLiabilitiesDetails" xlink:href="oncyf-20191231.xsd#LeasesRightOfUseAssetsAndLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesTables" xlink:href="oncyf-20191231.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:href="oncyf-20191231.xsd#LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShare" xlink:href="oncyf-20191231.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails" xlink:href="oncyf-20191231.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustments" xlink:href="oncyf-20191231.xsd#OtherExpensesAndAdjustments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsDetails" xlink:href="oncyf-20191231.xsd#OtherExpensesAndAdjustmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsTables" xlink:href="oncyf-20191231.xsd#OtherExpensesAndAdjustmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyAndEquipment" xlink:href="oncyf-20191231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentDetails" xlink:href="oncyf-20191231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentTables" xlink:href="oncyf-20191231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:href="oncyf-20191231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:href="oncyf-20191231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:href="oncyf-20191231.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPayments" xlink:href="oncyf-20191231.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsAndFairValueOfOptionsDetails" xlink:href="oncyf-20191231.xsd#ShareBasedPaymentsDisclosureWeightedAverageAssumptionsAndFairValueOfOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails" xlink:href="oncyf-20191231.xsd#ShareBasedPaymentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfNumberOfOtherEquityInstrumentsDetails" xlink:href="oncyf-20191231.xsd#ShareBasedPaymentsScheduleOfNumberOfOtherEquityInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsAndWeightedAverageExercisePricesDetails" xlink:href="oncyf-20191231.xsd#ShareBasedPaymentsScheduleOfStockOptionsAndWeightedAverageExercisePricesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails" xlink:href="oncyf-20191231.xsd#ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables" xlink:href="oncyf-20191231.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:href="oncyf-20191231.xsd#ShareCapital" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalNarrativeDetails" xlink:href="oncyf-20191231.xsd#ShareCapitalNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalDetails" xlink:href="oncyf-20191231.xsd#ShareCapitalScheduleOfShareCapitalDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalFootnotesDetails" xlink:href="oncyf-20191231.xsd#ShareCapitalScheduleOfShareCapitalFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryOfOutstandingWarrantsDetails" xlink:href="oncyf-20191231.xsd#ShareCapitalSummaryOfOutstandingWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:href="oncyf-20191231.xsd#ShareCapitalTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesAndAssumptions" xlink:href="oncyf-20191231.xsd#SignificantJudgmentsEstimatesAndAssumptions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEvents" xlink:href="oncyf-20191231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails" xlink:href="oncyf-20191231.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="oncyf-20191231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesIfrs16LeasesDetails" xlink:href="oncyf-20191231.xsd#SummaryOfSignificantAccountingPoliciesIfrs16LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="oncyf-20191231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="oncyf-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" xlink:href="oncyf-20191231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="oncyf-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivative" xlink:href="oncyf-20191231.xsd#WarrantDerivative" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails" xlink:href="oncyf-20191231.xsd#WarrantDerivativeNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationOfChangeInFairValueOfWarrantDerivativeDetails" xlink:href="oncyf-20191231.xsd#WarrantDerivativeReconciliationOfChangeInFairValueOfWarrantDerivativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForWarrantsDetails" xlink:href="oncyf-20191231.xsd#WarrantDerivativeSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables" xlink:href="oncyf-20191231.xsd#WarrantDerivativeTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_50BB4912F3A2E889B8189CFE7F99A01B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory_115FFA229E6B52A98BF29CFE7F99B952" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_50BB4912F3A2E889B8189CFE7F99A01B" xlink:to="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory_115FFA229E6B52A98BF29CFE7F99B952" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_6E80EA1DAE055D56FB419CFE7E731227" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable" xlink:label="loc_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable_2DE52C6FF47771BA1CE19CFE7E742456" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_6E80EA1DAE055D56FB419CFE7E731227" xlink:to="loc_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable_2DE52C6FF47771BA1CE19CFE7E742456" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_581C19E59644BBA676E99CFE7E749184" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_6E80EA1DAE055D56FB419CFE7E731227" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_581C19E59644BBA676E99CFE7E749184" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IncreaseDecreaseinPrepaidExpense1" xlink:label="loc_oncyf_IncreaseDecreaseinPrepaidExpense1_05DFC203BF89D141BF299CFE7E745CD5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_6E80EA1DAE055D56FB419CFE7E731227" xlink:to="loc_oncyf_IncreaseDecreaseinPrepaidExpense1_05DFC203BF89D141BF299CFE7E745CD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_2E3F56CCE1CD56B70AA99CFE7E74CB66" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_6E80EA1DAE055D56FB419CFE7E731227" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_2E3F56CCE1CD56B70AA99CFE7E74CB66" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities" xlink:label="loc_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities_E212F578F15B66B69E639CFE7E7554CC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_6E80EA1DAE055D56FB419CFE7E731227" xlink:to="loc_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities_E212F578F15B66B69E639CFE7E7554CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_9CD92B7AA5BAB1C4C5229CFE7E7591AB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_6E80EA1DAE055D56FB419CFE7E731227" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_9CD92B7AA5BAB1C4C5229CFE7E7591AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_3D8F50953BC3C86969E59CFE7E750786" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_6E80EA1DAE055D56FB419CFE7E731227" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_3D8F50953BC3C86969E59CFE7E750786" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_145DD60D9D76E577CCC59CFE7E759205" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_6E80EA1DAE055D56FB419CFE7E731227" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_145DD60D9D76E577CCC59CFE7E759205" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_9479FC7C77A43C790E179CFE7E1DAB30" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ProceedsfromInterestReceived" xlink:label="loc_oncyf_ProceedsfromInterestReceived_C8CC80491659D009108D9CFE7E1EF4EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_9479FC7C77A43C790E179CFE7E1DAB30" xlink:to="loc_oncyf_ProceedsfromInterestReceived_C8CC80491659D009108D9CFE7E1EF4EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefund" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefund_EC7E088E6F5A46BEDA599CFE7E1E16DF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_9479FC7C77A43C790E179CFE7E1DAB30" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefund_EC7E088E6F5A46BEDA599CFE7E1E16DF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_513F48FCC8B815361E6E9CFE7E133EC3" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:label="loc_oncyf_CashFlowOperatingCapital1TableTextBlock_CE416691C2EFD69C39029CFE7E14F232" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_513F48FCC8B815361E6E9CFE7E133EC3" xlink:to="loc_oncyf_CashFlowOperatingCapital1TableTextBlock_CE416691C2EFD69C39029CFE7E14F232" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:label="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_9B2F2D26D490573A3E229CFE7E146ED1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_513F48FCC8B815361E6E9CFE7E133EC3" xlink:to="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_9B2F2D26D490573A3E229CFE7E146ED1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/BasisOfFinancialStatementPresentation" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:label="loc_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_F80E5E556132F74794729CFE7F5BEA3A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_141E0C628308EAB930CD9CFE7F5B5287" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_F80E5E556132F74794729CFE7F5BEA3A" xlink:to="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_141E0C628308EAB930CD9CFE7F5B5287" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_DD6CDF78F31DF130AE689CFE7F215493" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_5BDA0BF3D4FEEA3960DE9CFE7F22F9E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_DD6CDF78F31DF130AE689CFE7F215493" xlink:to="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_5BDA0BF3D4FEEA3960DE9CFE7F22F9E3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_0BFD4B95AC886E9961CBAB79413ECD7F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_2820BADC725E038AEB18AB79413E4201" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_0BFD4B95AC886E9961CBAB79413ECD7F" xlink:to="loc_ifrs-full_CashAndCashEquivalents_2820BADC725E038AEB18AB79413E4201" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_FE8248E4673BEFFA2CA2AB79413F4FB1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_0BFD4B95AC886E9961CBAB79413ECD7F" xlink:to="loc_ifrs-full_Equity_FE8248E4673BEFFA2CA2AB79413F4FB1" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_EquityAuthorized" xlink:label="loc_oncyf_EquityAuthorized_632649CB72042F0DE95CAB79413FE838" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_0BFD4B95AC886E9961CBAB79413ECD7F" xlink:to="loc_oncyf_EquityAuthorized_632649CB72042F0DE95CAB79413FE838" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_E48CE92D689D818533809CFE7E84EE81" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:label="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock_2B589CF4A5380787A6F09CFE7E8404A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_E48CE92D689D818533809CFE7E84EE81" xlink:to="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock_2B589CF4A5380787A6F09CFE7E8404A7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalents" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="loc_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_4C17B256DC4D12C145DD9CFE7EADB9F1" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="loc_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_4699A9EA06F44ABFBF5A9CFE7EADE899" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_4C17B256DC4D12C145DD9CFE7EADB9F1" xlink:to="loc_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_4699A9EA06F44ABFBF5A9CFE7EADE899" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="loc_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_E14983DB7F1423683F2D9CFE7E154CCF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashEquivalents" xlink:label="loc_ifrs-full_CashEquivalents_D9A79DFAC73EA161FF129CFE7E16123F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_E14983DB7F1423683F2D9CFE7E154CCF" xlink:to="loc_ifrs-full_CashEquivalents_D9A79DFAC73EA161FF129CFE7E16123F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CashEquivalentsInterestRate" xlink:label="loc_oncyf_CashEquivalentsInterestRate_4C5FF56C1852F44559259CFE7E1601AB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_E14983DB7F1423683F2D9CFE7E154CCF" xlink:to="loc_oncyf_CashEquivalentsInterestRate_4C5FF56C1852F44559259CFE7E1601AB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/Commitments" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CommitmentsAbstract" xlink:label="loc_oncyf_CommitmentsAbstract_9B43D59EE8CB6AE8E0D49CFE7F1FF2DA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_0002E3CCA421442E4C6F9CFE7F2052BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CommitmentsAbstract_9B43D59EE8CB6AE8E0D49CFE7F1FF2DA" xlink:to="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_0002E3CCA421442E4C6F9CFE7F2052BC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CommitmentsDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CommitmentsAbstract" xlink:label="loc_oncyf_CommitmentsAbstract_A5A7200F46550B9085999CFE7E2123F2" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_PurchaseObligation1" xlink:label="loc_oncyf_PurchaseObligation1_756042FEFF1490CC9CAE9CFE7E216BE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CommitmentsAbstract_A5A7200F46550B9085999CFE7E2123F2" xlink:to="loc_oncyf_PurchaseObligation1_756042FEFF1490CC9CAE9CFE7E216BE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_5ACC3592B5984E8B409E9CFE7E229E79" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CommitmentsAbstract_A5A7200F46550B9085999CFE7E2123F2" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_5ACC3592B5984E8B409E9CFE7E229E79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_B2985E1165D7CDF440049CFE7E22F1EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_5ACC3592B5984E8B409E9CFE7E229E79" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_B2985E1165D7CDF440049CFE7E22F1EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherProvisionsMember" xlink:label="loc_ifrs-full_OtherProvisionsMember_555BE089A395562308BF9CFE7E223119" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_B2985E1165D7CDF440049CFE7E22F1EB" xlink:to="loc_ifrs-full_OtherProvisionsMember_555BE089A395562308BF9CFE7E223119" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CollaborationAgreementMember" xlink:label="loc_oncyf_CollaborationAgreementMember_6C2210EF879BAD5BB4A99CFE7E22990A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_555BE089A395562308BF9CFE7E223119" xlink:to="loc_oncyf_CollaborationAgreementMember_6C2210EF879BAD5BB4A99CFE7E22990A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_2F95792481FC493CAD919CFE7E237784" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_5ACC3592B5984E8B409E9CFE7E229E79" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_2F95792481FC493CAD919CFE7E237784" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherReceivables" xlink:label="loc_ifrs-full_OtherReceivables_3B5D5386014FFBE38C509CFE7E231A20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_2F95792481FC493CAD919CFE7E237784" xlink:to="loc_ifrs-full_OtherReceivables_3B5D5386014FFBE38C509CFE7E231A20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_97A7A3C418BCBF8806E69CFE7E239236" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_2F95792481FC493CAD919CFE7E237784" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_97A7A3C418BCBF8806E69CFE7E239236" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_FundedandRoyaltyRepayment" xlink:label="loc_oncyf_FundedandRoyaltyRepayment_FE2DC9DD32A123780B4E9CFE7E23FF98" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CommitmentsAbstract_A5A7200F46550B9085999CFE7E2123F2" xlink:to="loc_oncyf_FundedandRoyaltyRepayment_FE2DC9DD32A123780B4E9CFE7E23FF98" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OverheadRepayment" xlink:label="loc_oncyf_OverheadRepayment_B77FDF51ACD02B2E9E349CFE7E231FFF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CommitmentsAbstract_A5A7200F46550B9085999CFE7E2123F2" xlink:to="loc_oncyf_OverheadRepayment_B77FDF51ACD02B2E9E349CFE7E231FFF" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_AnnualContingentPaymentGrossSalesPercent" xlink:label="loc_oncyf_AnnualContingentPaymentGrossSalesPercent_22BC4F1577E5CD8A9CFB9CFE7E24340F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CommitmentsAbstract_A5A7200F46550B9085999CFE7E2123F2" xlink:to="loc_oncyf_AnnualContingentPaymentGrossSalesPercent_22BC4F1577E5CD8A9CFB9CFE7E24340F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_AnnualContingentPayment" xlink:label="loc_oncyf_AnnualContingentPayment_EAC8588795C7E20DB3A69CFE7E24467E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CommitmentsAbstract_A5A7200F46550B9085999CFE7E2123F2" xlink:to="loc_oncyf_AnnualContingentPayment_EAC8588795C7E20DB3A69CFE7E24467E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_66F3A63B71C6D114DBDF9CFE7F3FD301" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_Statement1Table" xlink:label="loc_oncyf_Statement1Table_3117261B4B66306B3DFE9CFE7F3FAC50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_66F3A63B71C6D114DBDF9CFE7F3FD301" xlink:to="loc_oncyf_Statement1Table_3117261B4B66306B3DFE9CFE7F3FAC50" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockAxis" xlink:label="loc_oncyf_SaleOfStockAxis_B086B7FD46E18CD12C2D9CFE7F401C2C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1Table_3117261B4B66306B3DFE9CFE7F3FAC50" xlink:to="loc_oncyf_SaleOfStockAxis_B086B7FD46E18CD12C2D9CFE7F401C2C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_E99B018FBDAC7B45BF849CFE7F40692F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_B086B7FD46E18CD12C2D9CFE7F401C2C" xlink:to="loc_oncyf_SaleOfStockDomain_E99B018FBDAC7B45BF849CFE7F40692F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderWarrantAgreementMember" xlink:label="loc_oncyf_SharesUnderWarrantAgreementMember_2564080B2639513B86149CFE7F4076A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_E99B018FBDAC7B45BF849CFE7F40692F" xlink:to="loc_oncyf_SharesUnderWarrantAgreementMember_2564080B2639513B86149CFE7F4076A6" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderCommonStockPurchaseAgreementMember" xlink:label="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_435B752D7D821FE18EA39CFE7F40181A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_E99B018FBDAC7B45BF849CFE7F40692F" xlink:to="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_435B752D7D821FE18EA39CFE7F40181A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderAtthemarketAgreementMember" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_B87836EFE6E2A91C4D619CFE7F405665" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_E99B018FBDAC7B45BF849CFE7F40692F" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_B87836EFE6E2A91C4D619CFE7F405665" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesPublicOfferingMember" xlink:label="loc_oncyf_SharesPublicOfferingMember_BC06988F5C3AC4881AD79CFE7F416F5D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_E99B018FBDAC7B45BF849CFE7F40692F" xlink:to="loc_oncyf_SharesPublicOfferingMember_BC06988F5C3AC4881AD79CFE7F416F5D" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_Statement1LineItems" xlink:label="loc_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1Table_3117261B4B66306B3DFE9CFE7F3FAC50" xlink:to="loc_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_8527488FB430AE417B6C9CFE7F4159D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:to="loc_ifrs-full_ProfitLoss_8527488FB430AE417B6C9CFE7F4159D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_511F49FFDDE4761531309CFE7F424160" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_511F49FFDDE4761531309CFE7F424160" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_2F7AE4103A02FE2EC9BA9CFE7F42ADB6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_2F7AE4103A02FE2EC9BA9CFE7F42ADB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_3EA110865B32CFA0B1F99CFE7F427EE2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_3EA110865B32CFA0B1F99CFE7F427EE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_C862DA753096F1C975209CFE7F426BF0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_C862DA753096F1C975209CFE7F426BF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_7C51434FD82E2BA572789CFE7F426C2A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_7C51434FD82E2BA572789CFE7F426C2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="loc_ifrs-full_AdjustmentsForProvisions_28EAD194F1A23409E9519CFE7F424E8A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:to="loc_ifrs-full_AdjustmentsForProvisions_28EAD194F1A23409E9519CFE7F424E8A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_AdjustmentsforLeaseAmortization" xlink:label="loc_oncyf_AdjustmentsforLeaseAmortization_AAF21EB1F4794F0ED71F9CFE7F43A5C6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:to="loc_oncyf_AdjustmentsforLeaseAmortization_AAF21EB1F4794F0ED71F9CFE7F43A5C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_6EEE1FB2818D2BC6B7E79CFE7F43676C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_6EEE1FB2818D2BC6B7E79CFE7F43676C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_ADAAC49E1CA4D9272FD59CFE7F4370DF" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_ADAAC49E1CA4D9272FD59CFE7F4370DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_4015E62566044D69F2F19CFE7F43D7C9" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_5A75C378D7675A47AFEB9CFE7F41FC2D" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_4015E62566044D69F2F19CFE7F43D7C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_64BE9F6DD7B8179B407E9CFE7F4354FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_64BE9F6DD7B8179B407E9CFE7F4354FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_9ED595B3F2726B9BAF7E9CFE7F43CB97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_64BE9F6DD7B8179B407E9CFE7F4354FC" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_9ED595B3F2726B9BAF7E9CFE7F43CB97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:label="loc_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_7DDF74F66B967B6A5A709CFE7F448EC8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_64BE9F6DD7B8179B407E9CFE7F4354FC" xlink:to="loc_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_7DDF74F66B967B6A5A709CFE7F448EC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_7111E4979D9DF46B6E8A9CFE7F440E86" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_64BE9F6DD7B8179B407E9CFE7F4354FC" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_7111E4979D9DF46B6E8A9CFE7F440E86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_29EAF9F900576EC666279CFE7F4488D3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_29EAF9F900576EC666279CFE7F4488D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_EBD25F37EB23A2BB9A029CFE7F4484B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_29EAF9F900576EC666279CFE7F4488D3" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_EBD25F37EB23A2BB9A029CFE7F4484B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_81C964343C59B17095D29CFE7F44C502" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_29EAF9F900576EC666279CFE7F4488D3" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_81C964343C59B17095D29CFE7F44C502" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashOutflowForLeases" xlink:label="loc_ifrs-full_CashOutflowForLeases_01A4DB36F8AC7FDB0CCD9CFE7F458C49" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_29EAF9F900576EC666279CFE7F4488D3" xlink:to="loc_ifrs-full_CashOutflowForLeases_01A4DB36F8AC7FDB0CCD9CFE7F458C49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_A6706F34A95877FD2DC09CFE7F453B75" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_29EAF9F900576EC666279CFE7F4488D3" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_A6706F34A95877FD2DC09CFE7F453B75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_4DBD622DB4465BB62CF09CFE7F45E49C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_4DBD622DB4465BB62CF09CFE7F45E49C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_BD89341FD15DEEA698269CFE7F45A099" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4" xlink:to="loc_ifrs-full_CashAndCashEquivalents_BD89341FD15DEEA698269CFE7F45A099" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_681CBFA55F627A07D5E49CFE7F455831" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_681CBFA55F627A07D5E49CFE7F455831" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_34AF911C15F7F307394E9CFE7F457601" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_D6622B7D7196F648E6579CFE7F41C6D4" xlink:to="loc_ifrs-full_CashAndCashEquivalents_34AF911C15F7F307394E9CFE7F457601" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfChangesInDeficitEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_7269E378F5F5F6BF6281ACF62323F76B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_C85411ABA5023210E0CFACF623245769" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_7269E378F5F5F6BF6281ACF62323F76B" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_C85411ABA5023210E0CFACF623245769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_9C208DA46E0FA0E304CDACF6232474E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_C85411ABA5023210E0CFACF623245769" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_9C208DA46E0FA0E304CDACF6232474E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-full_EquityMember_B9453EAB0D75A8AB8647ACF6232426AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_9C208DA46E0FA0E304CDACF6232474E9" xlink:to="loc_ifrs-full_EquityMember_B9453EAB0D75A8AB8647ACF6232426AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_80FBA3F09F72996CB436ACF62324A552" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_B9453EAB0D75A8AB8647ACF6232426AB" xlink:to="loc_ifrs-full_IssuedCapitalMember_80FBA3F09F72996CB436ACF62324A552" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_CFDD84710FFE8EAB51DCACF62325858D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_B9453EAB0D75A8AB8647ACF6232426AB" xlink:to="loc_oncyf_WarrantsMember_CFDD84710FFE8EAB51DCACF62325858D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharePremiumMember" xlink:label="loc_ifrs-full_SharePremiumMember_70C2E7623CCED1A17587ACF623253CB2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_B9453EAB0D75A8AB8647ACF6232426AB" xlink:to="loc_ifrs-full_SharePremiumMember_70C2E7623CCED1A17587ACF623253CB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_AF3071FEAB454B2B4743ACF62325AECC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_B9453EAB0D75A8AB8647ACF6232426AB" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_AF3071FEAB454B2B4743ACF62325AECC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-full_RetainedEarningsMember_C88B5CD38E874BA4BDBBACF62325A449" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_B9453EAB0D75A8AB8647ACF6232426AB" xlink:to="loc_ifrs-full_RetainedEarningsMember_C88B5CD38E874BA4BDBBACF62325A449" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockAxis" xlink:label="loc_oncyf_SaleOfStockAxis_E84D8E4B519C72A874D6ACF623258A2A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_C85411ABA5023210E0CFACF623245769" xlink:to="loc_oncyf_SaleOfStockAxis_E84D8E4B519C72A874D6ACF623258A2A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_517650B56FB0FA86BE27ACF6232665B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_E84D8E4B519C72A874D6ACF623258A2A" xlink:to="loc_oncyf_SaleOfStockDomain_517650B56FB0FA86BE27ACF6232665B4" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderAtthemarketAgreementMember" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_C459A844B50C11A00C87ACF62326DF5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_517650B56FB0FA86BE27ACF6232665B4" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_C459A844B50C11A00C87ACF62326DF5B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesPublicOfferingMember" xlink:label="loc_oncyf_SharesPublicOfferingMember_82DD24F9816288714018ACF62326ADDE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_517650B56FB0FA86BE27ACF6232665B4" xlink:to="loc_oncyf_SharesPublicOfferingMember_82DD24F9816288714018ACF62326ADDE" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderSharePurchaseAgreementMember" xlink:label="loc_oncyf_SharesUnderSharePurchaseAgreementMember_8DF9D9EA8EA46E6B460CACF623260850" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_517650B56FB0FA86BE27ACF6232665B4" xlink:to="loc_oncyf_SharesUnderSharePurchaseAgreementMember_8DF9D9EA8EA46E6B460CACF623260850" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_C85411ABA5023210E0CFACF623245769" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_18ADFE32B582CF682AA5ACF62327A313" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:to="loc_ifrs-full_Equity_18ADFE32B582CF682AA5ACF62327A313" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_6F0DE793C7308E56FEA0ACF62327033B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:to="loc_ifrs-full_ComprehensiveIncome_6F0DE793C7308E56FEA0ACF62327033B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:label="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_C2255625113F736101D3ACF623275483" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:to="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_C2255625113F736101D3ACF623275483" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_7879F91B43F52554FD34ACF623275B77" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_7879F91B43F52554FD34ACF623275B77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_AD583F47885FD2776FD2ACF62327D60B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:to="loc_ifrs-full_IssueOfEquity_AD583F47885FD2776FD2ACF62327D60B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_D49C7AD827E580137511ACF62328EE7D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_D49C7AD827E580137511ACF62328EE7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_E126DD9EDEEE9F405437ACF62328F49D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_E126DD9EDEEE9F405437ACF62328F49D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_A78BAABA563CD57EBFA5ACF6232DDF4E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_A78BAABA563CD57EBFA5ACF6232DDF4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_E4C42DDBFD229EBE9F97ACF6232D154B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_F710EFD3BFE547F206DFACF623265866" xlink:to="loc_ifrs-full_Equity_E4C42DDBFD229EBE9F97ACF6232D154B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPosition" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_12BCDD80B9749FC81F69ACF623584BE1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-full_AssetsAbstract_A7AC6EB3EB73421460FAACF623580922" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_12BCDD80B9749FC81F69ACF623584BE1" xlink:to="loc_ifrs-full_AssetsAbstract_A7AC6EB3EB73421460FAACF623580922" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_6EF6DA9006ECC53A597BACF623583893" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_A7AC6EB3EB73421460FAACF623580922" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_6EF6DA9006ECC53A597BACF623583893" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_4C4D9CFAE72270B95887ACF62359454A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_6EF6DA9006ECC53A597BACF623583893" xlink:to="loc_ifrs-full_CashAndCashEquivalents_4C4D9CFAE72270B95887ACF62359454A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-full_OtherCurrentReceivables_24FA89A2999EC7B4FF81ACF62359A621" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_6EF6DA9006ECC53A597BACF623583893" xlink:to="loc_ifrs-full_OtherCurrentReceivables_24FA89A2999EC7B4FF81ACF62359A621" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_60533CDC659A4CA34AC7ACF62359456A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_6EF6DA9006ECC53A597BACF623583893" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_60533CDC659A4CA34AC7ACF62359456A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-full_CurrentAssets_38AB290D736A19E9EE0FACF62359B020" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_6EF6DA9006ECC53A597BACF623583893" xlink:to="loc_ifrs-full_CurrentAssets_38AB290D736A19E9EE0FACF62359B020" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_2744E6ECD649A52E198DACF6235913AA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_A7AC6EB3EB73421460FAACF623580922" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_2744E6ECD649A52E198DACF6235913AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_9BB2F84A3845A0776B2FACF6235A799D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_2744E6ECD649A52E198DACF6235913AA" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_9BB2F84A3845A0776B2FACF6235A799D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_A16D3E20C5AE3353B3D9ACF6235A6584" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_2744E6ECD649A52E198DACF6235913AA" xlink:to="loc_ifrs-full_RightofuseAssets_A16D3E20C5AE3353B3D9ACF6235A6584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-full_NoncurrentAssets_F7E99F885E15D41FAD5AACF6235A84FE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_2744E6ECD649A52E198DACF6235913AA" xlink:to="loc_ifrs-full_NoncurrentAssets_F7E99F885E15D41FAD5AACF6235A84FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_BCF06D612426CABF0BE8ACF6235A0065" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_A7AC6EB3EB73421460FAACF623580922" xlink:to="loc_ifrs-full_Assets_BCF06D612426CABF0BE8ACF6235A0065" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_811D753723F292D39386ACF6235AE1F2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_12BCDD80B9749FC81F69ACF623584BE1" xlink:to="loc_ifrs-full_EquityAndLiabilitiesAbstract_811D753723F292D39386ACF6235AE1F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_AED781475BFDA24847AAACF6235A03D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_811D753723F292D39386ACF6235AE1F2" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_AED781475BFDA24847AAACF6235A03D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_02C53910D0B685A71BC2ACF6235B695F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_AED781475BFDA24847AAACF6235A03D4" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_02C53910D0B685A71BC2ACF6235B695F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="loc_ifrs-full_CurrentContractLiabilities_4D736DFFD5B9649AD897ACF6235B242A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_AED781475BFDA24847AAACF6235A03D4" xlink:to="loc_ifrs-full_CurrentContractLiabilities_4D736DFFD5B9649AD897ACF6235B242A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_0338483420C77D822399ACF6235BDCD2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_AED781475BFDA24847AAACF6235A03D4" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_0338483420C77D822399ACF6235BDCD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_6964AF43532FA74FF34BACF6235B9AB5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_AED781475BFDA24847AAACF6235A03D4" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_6964AF43532FA74FF34BACF6235B9AB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_54BC88B27BE081D7B64FACF6235C46AA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_AED781475BFDA24847AAACF6235A03D4" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_54BC88B27BE081D7B64FACF6235C46AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-full_CurrentLiabilities_4C6A86EF29FEA4B427CAACF6235CFD74" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_AED781475BFDA24847AAACF6235A03D4" xlink:to="loc_ifrs-full_CurrentLiabilities_4C6A86EF29FEA4B427CAACF6235CFD74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract_667195CBC527B9AE8C2CACF6235C5CC0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_811D753723F292D39386ACF6235AE1F2" xlink:to="loc_ifrs-full_NoncurrentLiabilitiesAbstract_667195CBC527B9AE8C2CACF6235C5CC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_22425B80C3F5D6F44880ACF6235C0F53" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_667195CBC527B9AE8C2CACF6235C5CC0" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_22425B80C3F5D6F44880ACF6235C0F53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_FCF2332F9256FBA102FEACF6235C757D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_667195CBC527B9AE8C2CACF6235C5CC0" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_FCF2332F9256FBA102FEACF6235C757D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_88E612BD629557A82066ACF6235C4840" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_667195CBC527B9AE8C2CACF6235C5CC0" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_88E612BD629557A82066ACF6235C4840" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-full_NoncurrentLiabilities_02E7592415525B7170DCACF6235D14EF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_667195CBC527B9AE8C2CACF6235C5CC0" xlink:to="loc_ifrs-full_NoncurrentLiabilities_02E7592415525B7170DCACF6235D14EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_AED4CBA17DEF6DC83593ACF6235D9992" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_811D753723F292D39386ACF6235AE1F2" xlink:to="loc_ifrs-full_Liabilities_AED4CBA17DEF6DC83593ACF6235D9992" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CommitmentsAndContingencies1" xlink:label="loc_oncyf_CommitmentsAndContingencies1_873E3A3BE1530130BF5DACF6235D310C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_811D753723F292D39386ACF6235AE1F2" xlink:to="loc_oncyf_CommitmentsAndContingencies1_873E3A3BE1530130BF5DACF6235D310C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-full_EquityAbstract_7185F1256A1CB6B178D3ACF6235DF056" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_811D753723F292D39386ACF6235AE1F2" xlink:to="loc_ifrs-full_EquityAbstract_7185F1256A1CB6B178D3ACF6235DF056" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-full_IssuedCapital_0BC9FEA07DD850EE4500ACF6235DF8E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_7185F1256A1CB6B178D3ACF6235DF056" xlink:to="loc_ifrs-full_IssuedCapital_0BC9FEA07DD850EE4500ACF6235DF8E4" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsandRightsOutstanding" xlink:label="loc_oncyf_WarrantsandRightsOutstanding_7861CB379C1F8CCB3A5CACF6235EE783" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_7185F1256A1CB6B178D3ACF6235DF056" xlink:to="loc_oncyf_WarrantsandRightsOutstanding_7861CB379C1F8CCB3A5CACF6235EE783" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionalPaidinCapital" xlink:label="loc_ifrs-full_AdditionalPaidinCapital_E671913D707FC08F71F4ACF6235E56F3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_7185F1256A1CB6B178D3ACF6235DF056" xlink:to="loc_ifrs-full_AdditionalPaidinCapital_E671913D707FC08F71F4ACF6235E56F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_5478A9A6C7B5C4D6323DACF6235E1F5E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_7185F1256A1CB6B178D3ACF6235DF056" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_5478A9A6C7B5C4D6323DACF6235E1F5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-full_RetainedEarnings_2EA19806F42F25CBE1E0ACF6235ECF1A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_7185F1256A1CB6B178D3ACF6235DF056" xlink:to="loc_ifrs-full_RetainedEarnings_2EA19806F42F25CBE1E0ACF6235ECF1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_7E2D8FD06AEAB3C331F9ACF6236304A5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_7185F1256A1CB6B178D3ACF6235DF056" xlink:to="loc_ifrs-full_Equity_7E2D8FD06AEAB3C331F9ACF6236304A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-full_EquityAndLiabilities_5EAA18F89E1FF7F213E9ACF6236365CA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_811D753723F292D39386ACF6235AE1F2" xlink:to="loc_ifrs-full_EquityAndLiabilities_5EAA18F89E1FF7F213E9ACF6236365CA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPositionParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_BDCBED0B1C4B1224A2539CFE7E187E82" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_12B97AF58E65F24909599CFE7E186D5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_BDCBED0B1C4B1224A2539CFE7E187E82" xlink:to="loc_ifrs-full_NumberOfSharesIssued_12B97AF58E65F24909599CFE7E186D5E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-full_IncomeStatementAbstract_3F96A799B4F919E53D6BACF62339B609" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseByNatureAbstract" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract_988E08021469E376C56AACF623395C92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3F96A799B4F919E53D6BACF62339B609" xlink:to="loc_ifrs-full_ExpenseByNatureAbstract_988E08021469E376C56AACF623395C92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_68D0091B202381F323D5ACF623391AA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_988E08021469E376C56AACF623395C92" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_68D0091B202381F323D5ACF623391AA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OperatingExpense" xlink:label="loc_ifrs-full_OperatingExpense_4AEB5E273614219D07B2ACF6233AF167" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_988E08021469E376C56AACF623395C92" xlink:to="loc_ifrs-full_OperatingExpense_4AEB5E273614219D07B2ACF6233AF167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_0BD6A340C133BF7B86E5ACF6233A0102" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3F96A799B4F919E53D6BACF62339B609" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_0BD6A340C133BF7B86E5ACF6233A0102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_C0BE5BDAF98C0F2169FBACF6233A67F1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3F96A799B4F919E53D6BACF62339B609" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_C0BE5BDAF98C0F2169FBACF6233A67F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_D18146F81A86F03B93F5ACF6233A082D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3F96A799B4F919E53D6BACF62339B609" xlink:to="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_D18146F81A86F03B93F5ACF6233A082D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_6C1A5F76EA26B8960BBFACF6233A3E57" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3F96A799B4F919E53D6BACF62339B609" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_6C1A5F76EA26B8960BBFACF6233A3E57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_E696B9602E534574FD33ACF6233B06BF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3F96A799B4F919E53D6BACF62339B609" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_E696B9602E534574FD33ACF6233B06BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-full_ProfitLoss_81670788B58C1B17E850ACF6233B4080" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3F96A799B4F919E53D6BACF62339B609" xlink:to="loc_ifrs-full_ProfitLoss_81670788B58C1B17E850ACF6233B4080" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_31043ADA1A12C61329FDACF6233B546D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3F96A799B4F919E53D6BACF62339B609" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_31043ADA1A12C61329FDACF6233B546D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_0B50952336C157D30ED1ACF6233B518D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_31043ADA1A12C61329FDACF6233B546D" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_0B50952336C157D30ED1ACF6233B518D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-full_ComprehensiveIncome_887D3E9778000AF8A05CACF6233BC731" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3F96A799B4F919E53D6BACF62339B609" xlink:to="loc_ifrs-full_ComprehensiveIncome_887D3E9778000AF8A05CACF6233BC731" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:label="loc_ifrs-full_BasicAndDilutedEarningsLossPerShare_3A3E1240B55B2A4A6991ACF6233BC606" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3F96A799B4F919E53D6BACF62339B609" xlink:to="loc_ifrs-full_BasicAndDilutedEarningsLossPerShare_3A3E1240B55B2A4A6991ACF6233BC606" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares_377EB3E299F7CF5E35EDACF6233C3CE0" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3F96A799B4F919E53D6BACF62339B609" xlink:to="loc_ifrs-full_WeightedAverageShares_377EB3E299F7CF5E35EDACF6233C3CE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_5F00C1427F2B71791BE2ACF6233C346D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3F96A799B4F919E53D6BACF62339B609" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_5F00C1427F2B71791BE2ACF6233C346D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ContingenciesAbstract" xlink:label="loc_oncyf_ContingenciesAbstract_5A6FA890DFAF92DD979C9CFE7EB94D55" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_85726CF90CE4ECB4EF509CFE7EB95964" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_5A6FA890DFAF92DD979C9CFE7EB94D55" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_85726CF90CE4ECB4EF509CFE7EB95964" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ContingenciesAbstract" xlink:label="loc_oncyf_ContingenciesAbstract_005F7F38284EBD45DEB0A339610AC0C0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_6DDE0BF97177E2BA5E88A339610A9472" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_005F7F38284EBD45DEB0A339610AC0C0" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_6DDE0BF97177E2BA5E88A339610A9472" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-full_CounterpartiesAxis_AB03847E6DD28513DB3CA339610A961F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_6DDE0BF97177E2BA5E88A339610A9472" xlink:to="loc_ifrs-full_CounterpartiesAxis_AB03847E6DD28513DB3CA339610A961F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-full_CounterpartiesMember_B28AE487282FCDAE622DA339610B5D47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_AB03847E6DD28513DB3CA339610A961F" xlink:to="loc_ifrs-full_CounterpartiesMember_B28AE487282FCDAE622DA339610B5D47" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SYNSORBMember" xlink:label="loc_oncyf_SYNSORBMember_FD1C0B69E8A942658A7BA339610BBECF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_B28AE487282FCDAE622DA339610B5D47" xlink:to="loc_oncyf_SYNSORBMember_FD1C0B69E8A942658A7BA339610BBECF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_E84E5E68FF768B670164A339610B217D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_6DDE0BF97177E2BA5E88A339610A9472" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_E84E5E68FF768B670164A339610B217D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:label="loc_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_DF4AE4A54F5EA15CE95FA339610B6E1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_E84E5E68FF768B670164A339610B217D" xlink:to="loc_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_DF4AE4A54F5EA15CE95FA339610B6E1A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_D719AD6C1877201ED969A339610CE4EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_E84E5E68FF768B670164A339610B217D" xlink:to="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_D719AD6C1877201ED969A339610CE4EC" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_A91FABEF192E17D7ADC0A339610C3597" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_E84E5E68FF768B670164A339610B217D" xlink:to="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_A91FABEF192E17D7ADC0A339610C3597" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_E4A82B815EDD22760AF3A339610CE71F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_E84E5E68FF768B670164A339610B217D" xlink:to="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_E4A82B815EDD22760AF3A339610CE71F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue" xlink:label="loc_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_AA8C05918D47B5C3FF0EA339610CC88E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_005F7F38284EBD45DEB0A339610AC0C0" xlink:to="loc_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_AA8C05918D47B5C3FF0EA339610CC88E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ContingentRoyaltyPaymentAnnualMaximum" xlink:label="loc_oncyf_ContingentRoyaltyPaymentAnnualMaximum_A6E4238FC1662D35EE0DA339610C9309" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_005F7F38284EBD45DEB0A339610AC0C0" xlink:to="loc_oncyf_ContingentRoyaltyPaymentAnnualMaximum_A6E4238FC1662D35EE0DA339610C9309" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ContingentRoyaltyPaymentContributionRate" xlink:label="loc_oncyf_ContingentRoyaltyPaymentContributionRate_C84D88FD9B72FAE11559A339610C03AD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_005F7F38284EBD45DEB0A339610AC0C0" xlink:to="loc_oncyf_ContingentRoyaltyPaymentContributionRate_C84D88FD9B72FAE11559A339610C03AD" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_AccruedRoyalties1" xlink:label="loc_oncyf_AccruedRoyalties1_8C04B756E712D7220377A339610D0DD0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_005F7F38284EBD45DEB0A339610AC0C0" xlink:to="loc_oncyf_AccruedRoyalties1_8C04B756E712D7220377A339610D0DD0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivable" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_172203A7981368D7D2C69CFE7F0AAEA1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_F14B75D661F53C8FC3D79CFE7F0A2419" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_172203A7981368D7D2C69CFE7F0AAEA1" xlink:to="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_F14B75D661F53C8FC3D79CFE7F0A2419" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_AB477C7320F239270D8EA7434C205B47" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantPurchaseAgreement" xlink:label="loc_oncyf_WarrantPurchaseAgreement_97CD8CD5F0ED4F42BB32A7434C20271D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_AB477C7320F239270D8EA7434C205B47" xlink:to="loc_oncyf_WarrantPurchaseAgreement_97CD8CD5F0ED4F42BB32A7434C20271D" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharePricePremiumPercent" xlink:label="loc_oncyf_SharePricePremiumPercent_F49F14A66C3E33C67FE4A7434C20FE4B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_AB477C7320F239270D8EA7434C205B47" xlink:to="loc_oncyf_SharePricePremiumPercent_F49F14A66C3E33C67FE4A7434C20FE4B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WeightedAverageClosingPriceDuration" xlink:label="loc_oncyf_WeightedAverageClosingPriceDuration_914B7B4A2B6D9418A6F9A7434C20CAA1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_AB477C7320F239270D8EA7434C205B47" xlink:to="loc_oncyf_WeightedAverageClosingPriceDuration_914B7B4A2B6D9418A6F9A7434C20CAA1" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_NumberofPatients" xlink:label="loc_oncyf_NumberofPatients_CD5F52BE286B095F24ACA7434C200913" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_AB477C7320F239270D8EA7434C205B47" xlink:to="loc_oncyf_NumberofPatients_CD5F52BE286B095F24ACA7434C200913" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ContractLiabilityRecognitionPeriod" xlink:label="loc_oncyf_ContractLiabilityRecognitionPeriod_57FB06CF0788A648FAC3A7434C203EAC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_AB477C7320F239270D8EA7434C205B47" xlink:to="loc_oncyf_ContractLiabilityRecognitionPeriod_57FB06CF0788A648FAC3A7434C203EAC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableScheduleOfContractRevenuesAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_8B683ECD4A21B1F0C4A29CFE7E321793" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContractLiabilities" xlink:label="loc_ifrs-full_ContractLiabilities_CD22C8BC58630B74AC899CFE7E322666" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_8B683ECD4A21B1F0C4A29CFE7E321793" xlink:to="loc_ifrs-full_ContractLiabilities_CD22C8BC58630B74AC899CFE7E322666" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_CCD289440265DE97FA5D9CFE7E32BFFB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_8B683ECD4A21B1F0C4A29CFE7E321793" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_CCD289440265DE97FA5D9CFE7E32BFFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:label="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_410CB30432C7EB8DFB269CFE7E32E268" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_8B683ECD4A21B1F0C4A29CFE7E321793" xlink:to="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_410CB30432C7EB8DFB269CFE7E32E268" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContractLiabilities" xlink:label="loc_ifrs-full_ContractLiabilities_E9C69913798542F464039CFE7E323375" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_8B683ECD4A21B1F0C4A29CFE7E321793" xlink:to="loc_ifrs-full_ContractLiabilities_E9C69913798542F464039CFE7E323375" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="loc_ifrs-full_CurrentContractLiabilities_033853B4D35A239E38A89CFE7E338928" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_8B683ECD4A21B1F0C4A29CFE7E321793" xlink:to="loc_ifrs-full_CurrentContractLiabilities_033853B4D35A239E38A89CFE7E338928" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_3F408A687637DE95768B9CFE7E335CFD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_8B683ECD4A21B1F0C4A29CFE7E321793" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_3F408A687637DE95768B9CFE7E335CFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContractLiabilities" xlink:label="loc_ifrs-full_ContractLiabilities_B88EB08138F1F66D854A9CFE7E338D21" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_8B683ECD4A21B1F0C4A29CFE7E321793" xlink:to="loc_ifrs-full_ContractLiabilities_B88EB08138F1F66D854A9CFE7E338D21" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableTables" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_B4178007548E3C6B4D6A9CFE7EA0D23B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:label="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_2104FF7A9AF8F9F187259CFE7EA0A999" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_B4178007548E3C6B4D6A9CFE7EA0D23B" xlink:to="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_2104FF7A9AF8F9F187259CFE7EA0A999" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DocumentAndEntityInformationAbstract" xlink:label="loc_oncyf_DocumentAndEntityInformationAbstract_CE3419E08C21BB84806FA33962B84CF6" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_EFA9079EE1708E38C542A33962B8F59D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_CE3419E08C21BB84806FA33962B84CF6" xlink:to="loc_dei_EntityRegistrantName_EFA9079EE1708E38C542A33962B8F59D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_CF3213EC33564260E03BA33962B91D80" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_CE3419E08C21BB84806FA33962B84CF6" xlink:to="loc_dei_EntityCentralIndexKey_CF3213EC33564260E03BA33962B91D80" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_79C14B86A52B40A11907A33962B9C82C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_CE3419E08C21BB84806FA33962B84CF6" xlink:to="loc_dei_CurrentFiscalYearEndDate_79C14B86A52B40A11907A33962B9C82C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_131A5769AE322912B762A33962B97577" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_CE3419E08C21BB84806FA33962B84CF6" xlink:to="loc_dei_EntityFilerCategory_131A5769AE322912B762A33962B97577" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_BD19F778984D6ADDFF6DA33962B97272" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_CE3419E08C21BB84806FA33962B84CF6" xlink:to="loc_dei_DocumentType_BD19F778984D6ADDFF6DA33962B97272" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_BDA7EC3A5B7A48F0AA2EA33962B961DB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_CE3419E08C21BB84806FA33962B84CF6" xlink:to="loc_dei_DocumentPeriodEndDate_BDA7EC3A5B7A48F0AA2EA33962B961DB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_A09574CB8A66CE7D7781A33962B9E641" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_CE3419E08C21BB84806FA33962B84CF6" xlink:to="loc_dei_DocumentFiscalYearFocus_A09574CB8A66CE7D7781A33962B9E641" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_921577928460BBC99605A33962BACE11" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_CE3419E08C21BB84806FA33962B84CF6" xlink:to="loc_dei_DocumentFiscalPeriodFocus_921577928460BBC99605A33962BACE11" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_31E78E9C535C76BD7D8FA33962BA9C6E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_CE3419E08C21BB84806FA33962B84CF6" xlink:to="loc_dei_AmendmentFlag_31E78E9C535C76BD7D8FA33962BA9C6E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_E1A1B7829DF3D9A138F0A33962BAB003" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_CE3419E08C21BB84806FA33962B84CF6" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_E1A1B7829DF3D9A138F0A33962BAB003" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_BFD00E3B76E9EF05B913A33962BA8FAA" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_CE3419E08C21BB84806FA33962B84CF6" xlink:to="loc_dei_EntityShellCompany_BFD00E3B76E9EF05B913A33962BA8FAA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_4CA097D72D0EE0B7C076A33962BA122F" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_CE3419E08C21BB84806FA33962B84CF6" xlink:to="loc_dei_EntityEmergingGrowthCompany_4CA097D72D0EE0B7C076A33962BA122F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_929FBC109515472EE927A33962BAF8BF" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_CE3419E08C21BB84806FA33962B84CF6" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_929FBC109515472EE927A33962BAF8BF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_E47855B564597DB0A565A33962BAB335" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_CE3419E08C21BB84806FA33962B84CF6" xlink:to="loc_dei_EntityVoluntaryFilers_E47855B564597DB0A565A33962BAB335" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_8D694C069EDD81B4717CA33962BB01DE" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_CE3419E08C21BB84806FA33962B84CF6" xlink:to="loc_dei_EntityCurrentReportingStatus_8D694C069EDD81B4717CA33962BB01DE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_E0DBB909E637D5CCE2CFA33962BB7A3D" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DocumentAndEntityInformationAbstract_CE3419E08C21BB84806FA33962B84CF6" xlink:to="loc_dei_EntityPublicFloat_E0DBB909E637D5CCE2CFA33962BB7A3D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureOfEconomicDependenceAbstract" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceAbstract_FB857AD21A355AE90D2A9CFE7ED10A2B" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceTextBlock_5427863652C87344FEAF9CFE7ED24005" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceAbstract_FB857AD21A355AE90D2A9CFE7ED10A2B" xlink:to="loc_oncyf_DisclosureOfEconomicDependenceTextBlock_5427863652C87344FEAF9CFE7ED24005" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureOfEconomicDependenceAbstract" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceAbstract_CB92B630BFFCA2C2D2199CFE7E289ADF" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ConcentrationRisk1Table" xlink:label="loc_oncyf_ConcentrationRisk1Table_321AE68CE01BCF4D08E59CFE7E28BA0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceAbstract_CB92B630BFFCA2C2D2199CFE7E289ADF" xlink:to="loc_oncyf_ConcentrationRisk1Table_321AE68CE01BCF4D08E59CFE7E28BA0F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ConcentrationRiskType1Axis" xlink:label="loc_oncyf_ConcentrationRiskType1Axis_DD1628D636E0238452189CFE7E28C25C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRisk1Table_321AE68CE01BCF4D08E59CFE7E28BA0F" xlink:to="loc_oncyf_ConcentrationRiskType1Axis_DD1628D636E0238452189CFE7E28C25C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ConcentrationRiskType1Domain" xlink:label="loc_oncyf_ConcentrationRiskType1Domain_2F6B9A8F93D56871CF349CFE7E29A8DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRiskType1Axis_DD1628D636E0238452189CFE7E28C25C" xlink:to="loc_oncyf_ConcentrationRiskType1Domain_2F6B9A8F93D56871CF349CFE7E29A8DF" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SupplierConcentrationRisk1Member" xlink:label="loc_oncyf_SupplierConcentrationRisk1Member_B9A38C910366D73492559CFE7E292D7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRiskType1Domain_2F6B9A8F93D56871CF349CFE7E29A8DF" xlink:to="loc_oncyf_SupplierConcentrationRisk1Member_B9A38C910366D73492559CFE7E292D7D" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ConcentrationRiskType1LineItems" xlink:label="loc_oncyf_ConcentrationRiskType1LineItems_61BB0FEB7E430980EE279CFE7E29B3E1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRisk1Table_321AE68CE01BCF4D08E59CFE7E28BA0F" xlink:to="loc_oncyf_ConcentrationRiskType1LineItems_61BB0FEB7E430980EE279CFE7E29B3E1" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ConcentrationRiskNumber" xlink:label="loc_oncyf_ConcentrationRiskNumber_A25AF3CCD2CD91961BC69CFE7E294858" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems_61BB0FEB7E430980EE279CFE7E29B3E1" xlink:to="loc_oncyf_ConcentrationRiskNumber_A25AF3CCD2CD91961BC69CFE7E294858" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_4AC27191725BE36B39089CFE7F807FE4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_7F37A9C26D88240235769CFE7F8036E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_4AC27191725BE36B39089CFE7F807FE4" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_7F37A9C26D88240235769CFE7F8036E1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_C48E0765F1AAB51324D1A7434B169902" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5330F63BA4F1976374A9A7434B17D188" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_C48E0765F1AAB51324D1A7434B169902" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5330F63BA4F1976374A9A7434B17D188" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_09B0E26E1E43869B2D3FA7D00E87C175" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5330F63BA4F1976374A9A7434B17D188" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_09B0E26E1E43869B2D3FA7D00E87C175" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_120CC4EEFB1C5AF12C4FA7D1B8A6C4E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_09B0E26E1E43869B2D3FA7D00E87C175" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_120CC4EEFB1C5AF12C4FA7D1B8A6C4E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_8BA3A1E7521EFB98AA8CA7D05615D2E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_120CC4EEFB1C5AF12C4FA7D1B8A6C4E6" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_8BA3A1E7521EFB98AA8CA7D05615D2E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-full_TypesOfRisksAxis_963D21F4188DF90FBA48A7434B17B8D9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5330F63BA4F1976374A9A7434B17D188" xlink:to="loc_ifrs-full_TypesOfRisksAxis_963D21F4188DF90FBA48A7434B17B8D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfRisksMember" xlink:label="loc_ifrs-full_TypesOfRisksMember_4006E99ADE823319600EA7434B17C4EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_963D21F4188DF90FBA48A7434B17B8D9" xlink:to="loc_ifrs-full_TypesOfRisksMember_4006E99ADE823319600EA7434B17C4EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrencyRiskMember" xlink:label="loc_ifrs-full_CurrencyRiskMember_844CB93577A121C80EFAA7434B17D05B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_4006E99ADE823319600EA7434B17C4EA" xlink:to="loc_ifrs-full_CurrencyRiskMember_844CB93577A121C80EFAA7434B17D05B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_Currency1Axis" xlink:label="loc_oncyf_Currency1Axis_A7238C6A26FEDE6BE9E1A7434B177CDA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5330F63BA4F1976374A9A7434B17D188" xlink:to="loc_oncyf_Currency1Axis_A7238C6A26FEDE6BE9E1A7434B177CDA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_4883E80C372768C88001A7434B170EAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1Axis_A7238C6A26FEDE6BE9E1A7434B177CDA" xlink:to="loc_currency_AllCurrenciesDomain_4883E80C372768C88001A7434B170EAD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_USD" xlink:label="loc_currency_USD_B91EA2F65641422E5111A7434B179A18" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_4883E80C372768C88001A7434B170EAD" xlink:to="loc_currency_USD_B91EA2F65641422E5111A7434B179A18" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_ED00049E5BCBD7D27BF2A7434B17637F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_4883E80C372768C88001A7434B170EAD" xlink:to="loc_currency_GBP_ED00049E5BCBD7D27BF2A7434B17637F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_71A78E87A242258860A0A7434B17EE5D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_4883E80C372768C88001A7434B170EAD" xlink:to="loc_currency_EUR_71A78E87A242258860A0A7434B17EE5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_43A35A9342D53467920AA7434B17635A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5330F63BA4F1976374A9A7434B17D188" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_43A35A9342D53467920AA7434B17635A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_8E1A76470D0EDF71DAF4A7434B1BB4A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_43A35A9342D53467920AA7434B17635A" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_8E1A76470D0EDF71DAF4A7434B1BB4A7" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_510A3D9A64A7AED3A721A7434B1B24B7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_43A35A9342D53467920AA7434B17635A" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_510A3D9A64A7AED3A721A7434B1B24B7" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_6D96D594EA1456A9E006A7434B1BFFFC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_43A35A9342D53467920AA7434B17635A" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_6D96D594EA1456A9E006A7434B1BFFFC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleOfBalancesInForeignCurrenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_D93549572DE2D666B071A81F7EAE937D" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_Currency1Table" xlink:label="loc_oncyf_Currency1Table_F094A305589401A92997A81F7EAEB869" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_D93549572DE2D666B071A81F7EAE937D" xlink:to="loc_oncyf_Currency1Table_F094A305589401A92997A81F7EAEB869" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_Currency1Axis" xlink:label="loc_oncyf_Currency1Axis_6F1EA6CAFDE192AF758FA81F7EAE0EC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1Table_F094A305589401A92997A81F7EAEB869" xlink:to="loc_oncyf_Currency1Axis_6F1EA6CAFDE192AF758FA81F7EAE0EC9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_59B68FCC08E88309E261A81F7EAFED81" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1Axis_6F1EA6CAFDE192AF758FA81F7EAE0EC9" xlink:to="loc_currency_AllCurrenciesDomain_59B68FCC08E88309E261A81F7EAFED81" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_USD" xlink:label="loc_currency_USD_0AA03C3095082BD7D60DA81F7EAFB51E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_59B68FCC08E88309E261A81F7EAFED81" xlink:to="loc_currency_USD_0AA03C3095082BD7D60DA81F7EAFB51E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_98F2425978A76C20F16FA81F7EAFC6D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_59B68FCC08E88309E261A81F7EAFED81" xlink:to="loc_currency_GBP_98F2425978A76C20F16FA81F7EAFC6D1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_E3CF8DA4DF7BF8909834A81F7EB00EA2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_59B68FCC08E88309E261A81F7EAFED81" xlink:to="loc_currency_EUR_E3CF8DA4DF7BF8909834A81F7EB00EA2" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_Currency1LineItems" xlink:label="loc_oncyf_Currency1LineItems_A03B3995CDFEDBADD26BA81F7EB07BFD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1Table_F094A305589401A92997A81F7EAEB869" xlink:to="loc_oncyf_Currency1LineItems_A03B3995CDFEDBADD26BA81F7EB07BFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-full_CashAndCashEquivalents_06C4206758D45B59247AA81F7EB01D0E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_A03B3995CDFEDBADD26BA81F7EB07BFD" xlink:to="loc_ifrs-full_CashAndCashEquivalents_06C4206758D45B59247AA81F7EB01D0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-full_OtherCurrentReceivables_66A734E662D8585F8908A81F7EB0E75C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_A03B3995CDFEDBADD26BA81F7EB07BFD" xlink:to="loc_ifrs-full_OtherCurrentReceivables_66A734E662D8585F8908A81F7EB0E75C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_A20D7F659CB474F753E6A81F7EB0D707" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_A03B3995CDFEDBADD26BA81F7EB07BFD" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_A20D7F659CB474F753E6A81F7EB0D707" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_AC6E82A33B3A9EEFE30EA81F7EB07BAD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_A03B3995CDFEDBADD26BA81F7EB07BFD" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_AC6E82A33B3A9EEFE30EA81F7EB07BAD" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_BalanceHeldInForeignCurrencyNet" xlink:label="loc_oncyf_BalanceHeldInForeignCurrencyNet_5C27DAB1BF714F3F9418A81F7EB10030" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_A03B3995CDFEDBADD26BA81F7EB07BFD" xlink:to="loc_oncyf_BalanceHeldInForeignCurrencyNet_5C27DAB1BF714F3F9418A81F7EB10030" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_52D388AD659B7290749B9CFE7E2509E2" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:label="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_F1622D2A51510F1012D09CFE7E25AB45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_52D388AD659B7290749B9CFE7E2509E2" xlink:to="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_F1622D2A51510F1012D09CFE7E25AB45" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofincometaxAbstract" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_FD1758CC8554E6045EDD9CFE7F9B4043" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_D723DAAA1FDEC629D57A9CFE7F9BC646" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_FD1758CC8554E6045EDD9CFE7F9B4043" xlink:to="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_D723DAAA1FDEC629D57A9CFE7F9BC646" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofincometaxAbstract" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_BDEC052ECCE3D32142D59CFE7EF37113" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccountingProfit" xlink:label="loc_ifrs-full_AccountingProfit_3774068E36A4707A633A9CFE7EF36C64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_BDEC052ECCE3D32142D59CFE7EF37113" xlink:to="loc_ifrs-full_AccountingProfit_3774068E36A4707A633A9CFE7EF36C64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-full_ApplicableTaxRate_E72C1B682F3F9116C95C9CFE7EF39FE7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_BDEC052ECCE3D32142D59CFE7EF37113" xlink:to="loc_ifrs-full_ApplicableTaxRate_E72C1B682F3F9116C95C9CFE7EF39FE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_6B980CAE5AA6414668EC9CFE7EF38A87" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_BDEC052ECCE3D32142D59CFE7EF37113" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_6B980CAE5AA6414668EC9CFE7EF38A87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxEffectOfForeignTaxRates" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates_FA9FD3DF3851E45BB4169CFE7EF30FD5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_BDEC052ECCE3D32142D59CFE7EF37113" xlink:to="loc_ifrs-full_TaxEffectOfForeignTaxRates_FA9FD3DF3851E45BB4169CFE7EF30FD5" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TaxEffectOfStockBasedCompensation" xlink:label="loc_oncyf_TaxEffectOfStockBasedCompensation_EBA15295945DDF09EE8D9CFE7EF44BDC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_BDEC052ECCE3D32142D59CFE7EF37113" xlink:to="loc_oncyf_TaxEffectOfStockBasedCompensation_EBA15295945DDF09EE8D9CFE7EF44BDC" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:label="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_5EA4419FA8656974F4869CFE7EF409BD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_BDEC052ECCE3D32142D59CFE7EF37113" xlink:to="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_5EA4419FA8656974F4869CFE7EF409BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxEffectFromChangeInTaxRate" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate_ADB22AEBA3AF4CFCF1649CFE7EF4D476" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_BDEC052ECCE3D32142D59CFE7EF37113" xlink:to="loc_ifrs-full_TaxEffectFromChangeInTaxRate_ADB22AEBA3AF4CFCF1649CFE7EF4D476" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TaxEffectOfTaxPools" xlink:label="loc_oncyf_TaxEffectOfTaxPools_AC8D43D590129693D68D9CFE7EF44993" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_BDEC052ECCE3D32142D59CFE7EF37113" xlink:to="loc_oncyf_TaxEffectOfTaxPools_AC8D43D590129693D68D9CFE7EF44993" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_DCA844C83563F928E65F9CFE7EF4230D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_BDEC052ECCE3D32142D59CFE7EF37113" xlink:to="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_DCA844C83563F928E65F9CFE7EF4230D" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:label="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_163991F796241785D70B9CFE7EF45A16" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_BDEC052ECCE3D32142D59CFE7EF37113" xlink:to="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_163991F796241785D70B9CFE7EF45A16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_7BDBD46EA332CBB8FCB89CFE7EF52F5E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_BDEC052ECCE3D32142D59CFE7EF37113" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_7BDBD46EA332CBB8FCB89CFE7EF52F5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:label="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_85E5A6A5F8E471CE39FF9CFE7EF571DF" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_BDEC052ECCE3D32142D59CFE7EF37113" xlink:to="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_85E5A6A5F8E471CE39FF9CFE7EF571DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_95B36AC021BEBD85610C9CFE7EF5F4DE" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_BDEC052ECCE3D32142D59CFE7EF37113" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_95B36AC021BEBD85610C9CFE7EF5F4DE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleOfUnrecognizedDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofincometaxAbstract" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_A335C401D408697EDBFA9CFE7E7AD067" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_9B9BA40BE875104C52A79CFE7E7A3CA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_A335C401D408697EDBFA9CFE7E7AD067" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_9B9BA40BE875104C52A79CFE7E7A3CA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ABDC7E9C671BE186296E9CFE7E7BBDEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_9B9BA40BE875104C52A79CFE7E7A3CA7" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ABDC7E9C671BE186296E9CFE7E7BBDEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_C5154722F1CFBD0D66529CFE7E7B58BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ABDC7E9C671BE186296E9CFE7E7BBDEA" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_C5154722F1CFBD0D66529CFE7E7B58BD" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:label="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_61A9EF54C6AF873A16819CFE7E7B9696" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_C5154722F1CFBD0D66529CFE7E7B58BD" xlink:to="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_61A9EF54C6AF873A16819CFE7E7B9696" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_23859A827F9E270607FF9CFE7E7C4A1D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_C5154722F1CFBD0D66529CFE7E7B58BD" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_23859A827F9E270607FF9CFE7E7C4A1D" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_InvestmentTaxCreditsMember" xlink:label="loc_oncyf_InvestmentTaxCreditsMember_764BE0C2135B047D2A0B9CFE7E7C0E8F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_C5154722F1CFBD0D66529CFE7E7B58BD" xlink:to="loc_oncyf_InvestmentTaxCreditsMember_764BE0C2135B047D2A0B9CFE7E7C0E8F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" xlink:label="loc_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_477B54D5277C652A91569CFE7E7C73C8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_C5154722F1CFBD0D66529CFE7E7B58BD" xlink:to="loc_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_477B54D5277C652A91569CFE7E7C73C8" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ShareIssueCostsMember" xlink:label="loc_oncyf_ShareIssueCostsMember_6A560FA56BD6795341EC9CFE7E7C60AF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_C5154722F1CFBD0D66529CFE7E7B58BD" xlink:to="loc_oncyf_ShareIssueCostsMember_6A560FA56BD6795341EC9CFE7E7C60AF" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:label="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_B4C3CCC958C5C00064CE9CFE7E7D1CBB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_C5154722F1CFBD0D66529CFE7E7B58BD" xlink:to="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_B4C3CCC958C5C00064CE9CFE7E7D1CBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_D2CB68D40A091E2EDEE19CFE7E7D2B83" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_9B9BA40BE875104C52A79CFE7E7A3CA7" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_D2CB68D40A091E2EDEE19CFE7E7D2B83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_C1576EA69B47C18E30119CFE7E7D50D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_D2CB68D40A091E2EDEE19CFE7E7D2B83" xlink:to="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_C1576EA69B47C18E30119CFE7E7D50D3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonCapitalLossesDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofincometaxAbstract" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_4A925B745C5067F49BAE9CFE7F70D629" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ADCDFF9E8E669B9977899CFE7F709427" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_4A925B745C5067F49BAE9CFE7F70D629" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ADCDFF9E8E669B9977899CFE7F709427" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_853028AF1E641F3AC6499CFE7F719BF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ADCDFF9E8E669B9977899CFE7F709427" xlink:to="loc_ifrs-full_MaturityAxis_853028AF1E641F3AC6499CFE7F719BF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_853028AF1E641F3AC6499CFE7F719BF9" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentySixMember" xlink:label="loc_oncyf_TwentyTwentySixMember_260326053A1D3DE1B5559CFE7F71154A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyTwentySixMember_260326053A1D3DE1B5559CFE7F71154A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentySevenMember" xlink:label="loc_oncyf_TwentyTwentySevenMember_01A40582701C528ECCCB9CFE7F718398" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyTwentySevenMember_01A40582701C528ECCCB9CFE7F718398" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyNineMember" xlink:label="loc_oncyf_TwentyTwentyNineMember_B084DAC1F4A717001E9E9CFE7F722E79" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyTwentyNineMember_B084DAC1F4A717001E9E9CFE7F722E79" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyMember" xlink:label="loc_oncyf_TwentyThirtyMember_9385978711F07FA456DF9CFE7F729C9D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyThirtyMember_9385978711F07FA456DF9CFE7F729C9D" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyOneMember" xlink:label="loc_oncyf_TwentyThirtyOneMember_C83828689FCEE12224459CFE7F72B907" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyThirtyOneMember_C83828689FCEE12224459CFE7F72B907" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyTwoMember" xlink:label="loc_oncyf_TwentyThirtyTwoMember_3160433D34F3DBCDBD219CFE7F72FD16" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyThirtyTwoMember_3160433D34F3DBCDBD219CFE7F72FD16" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyThreeMember" xlink:label="loc_oncyf_TwentyThirtyThreeMember_BBC21835AE93F4D40EC99CFE7F7229B5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyThirtyThreeMember_BBC21835AE93F4D40EC99CFE7F7229B5" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyFourMember" xlink:label="loc_oncyf_TwentyThirtyFourMember_CD12154D0B53AF29B97F9CFE7F72A917" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyThirtyFourMember_CD12154D0B53AF29B97F9CFE7F72A917" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyFiveMember" xlink:label="loc_oncyf_TwentyThirtyFiveMember_EAD393919CB8C0A2B3289CFE7F725EAB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyThirtyFiveMember_EAD393919CB8C0A2B3289CFE7F725EAB" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtySixMember" xlink:label="loc_oncyf_TwentyThirtySixMember_1D3C9E404E0DEFC6C15F9CFE7F73F09F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyThirtySixMember_1D3C9E404E0DEFC6C15F9CFE7F73F09F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtySevenMember" xlink:label="loc_oncyf_TwentyThirtySevenMember_8771EBDF1FDF956DE5649CFE7F73A085" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyThirtySevenMember_8771EBDF1FDF956DE5649CFE7F73A085" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyEightMember" xlink:label="loc_oncyf_TwentyThirtyEightMember_5F6693E3A43FE72A306E9CFE7F73A956" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyThirtyEightMember_5F6693E3A43FE72A306E9CFE7F73A956" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyNineMember" xlink:label="loc_oncyf_TwentyThirtyNineMember_6F226F44C5F84DE128319CFE7F736A8E" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_565AE1C4A843483BA4779CFE7F716012" xlink:to="loc_oncyf_TwentyThirtyNineMember_6F226F44C5F84DE128319CFE7F736A8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0E868D7B0D37106158919CFE7F73C37E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ADCDFF9E8E669B9977899CFE7F709427" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0E868D7B0D37106158919CFE7F73C37E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1A65B9CCF7664250A94F9CFE7F7316DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0E868D7B0D37106158919CFE7F73C37E" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1A65B9CCF7664250A94F9CFE7F7316DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_8E1C2C5FEF2159EB9B3D9CFE7F74E948" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1A65B9CCF7664250A94F9CFE7F7316DE" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_8E1C2C5FEF2159EB9B3D9CFE7F74E948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_CA94C02FC650DD0C50B89CFE7F741F80" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_ADCDFF9E8E669B9977899CFE7F709427" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_CA94C02FC650DD0C50B89CFE7F741F80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_CEC69F8272B5BD4C8C2A9CFE7F74EE9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_CA94C02FC650DD0C50B89CFE7F741F80" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_CEC69F8272B5BD4C8C2A9CFE7F74EE9C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonRefundableFederalInvestmentTaxCreditsDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofincometaxAbstract" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_3C670FA950ED6E31E90F9CFE7EBF7F4A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_4F6AEEF77540B6BC8BB99CFE7EBF4DC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_3C670FA950ED6E31E90F9CFE7EBF7F4A" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_4F6AEEF77540B6BC8BB99CFE7EBF4DC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_32A4AC23E96E90E592219CFE7EBF0760" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_4F6AEEF77540B6BC8BB99CFE7EBF4DC8" xlink:to="loc_ifrs-full_MaturityAxis_32A4AC23E96E90E592219CFE7EBF0760" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_32A4AC23E96E90E592219CFE7EBF0760" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyMember" xlink:label="loc_oncyf_TwentyTwentyMember_095D7C258B9B08E0C8699CFE7EBF73B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyTwentyMember_095D7C258B9B08E0C8699CFE7EBF73B1" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyOneMember" xlink:label="loc_oncyf_TwentyTwentyOneMember_0AC7BE4B64D281F0CB9C9CFE7EC0B688" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyTwentyOneMember_0AC7BE4B64D281F0CB9C9CFE7EC0B688" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyTwoMember" xlink:label="loc_oncyf_TwentyTwentyTwoMember_C6E219FE86738E2D18E19CFE7EC07F6E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyTwentyTwoMember_C6E219FE86738E2D18E19CFE7EC07F6E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyThreeMember" xlink:label="loc_oncyf_TwentyTwentyThreeMember_B44AA8B3F2FD0B4A73A19CFE7EC00ADD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyTwentyThreeMember_B44AA8B3F2FD0B4A73A19CFE7EC00ADD" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyFourMember" xlink:label="loc_oncyf_TwentyTwentyFourMember_000FC33C99EBD6627CD89CFE7EC0704A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyTwentyFourMember_000FC33C99EBD6627CD89CFE7EC0704A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyFiveMember" xlink:label="loc_oncyf_TwentyTwentyFiveMember_8D0C07B5FE41566F61719CFE7EC0A192" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyTwentyFiveMember_8D0C07B5FE41566F61719CFE7EC0A192" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentySixMember" xlink:label="loc_oncyf_TwentyTwentySixMember_9C58A062645DC00CF7559CFE7EC1E17B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyTwentySixMember_9C58A062645DC00CF7559CFE7EC1E17B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentySevenMember" xlink:label="loc_oncyf_TwentyTwentySevenMember_C4ABC32C8DEAC3758E869CFE7EC1B644" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyTwentySevenMember_C4ABC32C8DEAC3758E869CFE7EC1B644" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyEightMember" xlink:label="loc_oncyf_TwentyTwentyEightMember_41EF8A95140304163C4C9CFE7EC16213" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyTwentyEightMember_41EF8A95140304163C4C9CFE7EC16213" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyTwentyNineMember" xlink:label="loc_oncyf_TwentyTwentyNineMember_35554267BE9ABC9E80699CFE7EC1AC97" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyTwentyNineMember_35554267BE9ABC9E80699CFE7EC1AC97" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyMember" xlink:label="loc_oncyf_TwentyThirtyMember_182E77111B11997C1AC79CFE7EC12CBE" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyThirtyMember_182E77111B11997C1AC79CFE7EC12CBE" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyOneMember" xlink:label="loc_oncyf_TwentyThirtyOneMember_6593E99D61CE52668BAF9CFE7EC1B850" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyThirtyOneMember_6593E99D61CE52668BAF9CFE7EC1B850" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyTwoMember" xlink:label="loc_oncyf_TwentyThirtyTwoMember_91D634D4636F22B5B2C49CFE7EC24B2F" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyThirtyTwoMember_91D634D4636F22B5B2C49CFE7EC24B2F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyThreeMember" xlink:label="loc_oncyf_TwentyThirtyThreeMember_379C96969339844BC6E59CFE7EC28795" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyThirtyThreeMember_379C96969339844BC6E59CFE7EC28795" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyFourMember" xlink:label="loc_oncyf_TwentyThirtyFourMember_F89ACE52C2F41F971E089CFE7EC2F353" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyThirtyFourMember_F89ACE52C2F41F971E089CFE7EC2F353" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyFiveMember" xlink:label="loc_oncyf_TwentyThirtyFiveMember_028F372222628BD005869CFE7EC2D7B2" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyThirtyFiveMember_028F372222628BD005869CFE7EC2D7B2" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtySixMember" xlink:label="loc_oncyf_TwentyThirtySixMember_1A3CDA0F2AE58CA093439CFE7EC2266D" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyThirtySixMember_1A3CDA0F2AE58CA093439CFE7EC2266D" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtySevenMember" xlink:label="loc_oncyf_TwentyThirtySevenMember_951DB9A958329245320E9CFE7EC32347" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyThirtySevenMember_951DB9A958329245320E9CFE7EC32347" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_TwentyThirtyEightMember" xlink:label="loc_oncyf_TwentyThirtyEightMember_8746C19FC91592ECBD059CFE7EC31AC4" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_4D7A9005F23AE8E31D729CFE7EBFB7A9" xlink:to="loc_oncyf_TwentyThirtyEightMember_8746C19FC91592ECBD059CFE7EC31AC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_DF3FF0C05F988813F4149CFE7EC3D737" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_4F6AEEF77540B6BC8BB99CFE7EBF4DC8" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_DF3FF0C05F988813F4149CFE7EC3D737" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1C0E7B8373EEBB336B209CFE7EC3E438" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_DF3FF0C05F988813F4149CFE7EC3D737" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1C0E7B8373EEBB336B209CFE7EC3E438" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnusedTaxCreditsMember" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember_B9FD6EAAC43E338F430B9CFE7EC376C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1C0E7B8373EEBB336B209CFE7EC3E438" xlink:to="loc_ifrs-full_UnusedTaxCreditsMember_B9FD6EAAC43E338F430B9CFE7EC376C5" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_6EE0A320448F9FEA6A299CFE7EC3EACB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1C0E7B8373EEBB336B209CFE7EC3E438" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_6EE0A320448F9FEA6A299CFE7EC3EACB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_963084CD10B5BDB4C13D9CFE7EC4B0E2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_4F6AEEF77540B6BC8BB99CFE7EBF4DC8" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_963084CD10B5BDB4C13D9CFE7EC4B0E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:label="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_9BF85856D8E2DAA4E7369CFE7EC41910" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_963084CD10B5BDB4C13D9CFE7EC4B0E2" xlink:to="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_9BF85856D8E2DAA4E7369CFE7EC41910" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofincometaxAbstract" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_C23A0F4BDC14E1E108749CFE7F769430" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:label="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_964A9C2D4F8E83A9A3DB9CFE7F76E4A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_C23A0F4BDC14E1E108749CFE7F769430" xlink:to="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_964A9C2D4F8E83A9A3DB9CFE7F76E4A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_2454F996A8A243D125909CFE7F76CCE0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_C23A0F4BDC14E1E108749CFE7F769430" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_2454F996A8A243D125909CFE7F76CCE0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncorporationAndNatureOfOperations" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_C3E4CBEE2F3F007A55A59CFE7E0C9341" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_A47D27F45FB095E4030B9CFE7E0C058B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_C3E4CBEE2F3F007A55A59CFE7E0C9341" xlink:to="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_A47D27F45FB095E4030B9CFE7E0C058B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IndemnificationOfOfficersAndDirectors" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:label="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_3AA8C0FD701600358D0B9CFE7E972786" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:label="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_7B1307084AD3726B276A9CFE7E971574" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_3AA8C0FD701600358D0B9CFE7E972786" xlink:to="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_7B1307084AD3726B276A9CFE7E971574" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/Leases" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_309CE59066A57231BA8E9CFE7F4909A8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory_429713E11AC053A6A93B9CFE7F498932" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_309CE59066A57231BA8E9CFE7F4909A8" xlink:to="loc_ifrs-full_DisclosureOfLeasesExplanatory_429713E11AC053A6A93B9CFE7F498932" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_F7861620AFB3B6145F3A9CFE7F83B5BF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_DE90D4A9A4071970BEBF9CFE7F839897" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_F7861620AFB3B6145F3A9CFE7F83B5BF" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_DE90D4A9A4071970BEBF9CFE7F839897" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_F2034FE58736AC9B09809CFE7F83B7D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_DE90D4A9A4071970BEBF9CFE7F839897" xlink:to="loc_srt_RangeAxis_F2034FE58736AC9B09809CFE7F83B7D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_B4CA3763CD7DECB373FE9CFE7F84E826" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_F2034FE58736AC9B09809CFE7F83B7D5" xlink:to="loc_ifrs-full_RangesMember_B4CA3763CD7DECB373FE9CFE7F84E826" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_50321E0B317A01A2331B9CFE7F84868A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_B4CA3763CD7DECB373FE9CFE7F84E826" xlink:to="loc_srt_MinimumMember_50321E0B317A01A2331B9CFE7F84868A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_385051B8D8BF46727A5D9CFE7F842427" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_B4CA3763CD7DECB373FE9CFE7F84E826" xlink:to="loc_srt_MaximumMember_385051B8D8BF46727A5D9CFE7F842427" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2CF1BBBBFA29D357F00B9CFE7F84798F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_DE90D4A9A4071970BEBF9CFE7F839897" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2CF1BBBBFA29D357F00B9CFE7F84798F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OperatingLeaseRemainingLeaseTerm" xlink:label="loc_oncyf_OperatingLeaseRemainingLeaseTerm_B5CCBB94944AFAFFE5EB9CFE7F8517F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2CF1BBBBFA29D357F00B9CFE7F84798F" xlink:to="loc_oncyf_OperatingLeaseRemainingLeaseTerm_B5CCBB94944AFAFFE5EB9CFE7F8517F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:label="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_12DCEC6745A922BCF9FD9CFE7F8585AA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2CF1BBBBFA29D357F00B9CFE7F84798F" xlink:to="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_12DCEC6745A922BCF9FD9CFE7F8585AA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesRightOfUseAssetsAndLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_2B9026DFD0010C4C6751A1A52F4144F4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_A60B310B5177C99E69EAA1A52F417754" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_2B9026DFD0010C4C6751A1A52F4144F4" xlink:to="loc_ifrs-full_RightofuseAssets_A60B310B5177C99E69EAA1A52F417754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_A77B9BE24960A8F7A444A1A52F427426" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_2B9026DFD0010C4C6751A1A52F4144F4" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_A77B9BE24960A8F7A444A1A52F427426" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ForeignExchangeImpactRightofUseAssets" xlink:label="loc_oncyf_ForeignExchangeImpactRightofUseAssets_A4848A8A1C006CDCA3FFA1A52F42EA6A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_2B9026DFD0010C4C6751A1A52F4144F4" xlink:to="loc_oncyf_ForeignExchangeImpactRightofUseAssets_A4848A8A1C006CDCA3FFA1A52F42EA6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_19DF4AC0F525C93F89EDA25609047A85" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_2B9026DFD0010C4C6751A1A52F4144F4" xlink:to="loc_ifrs-full_RightofuseAssets_19DF4AC0F525C93F89EDA25609047A85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-full_LeaseLiabilities_1EDBFD18B4323967F847A1A52F42C510" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_2B9026DFD0010C4C6751A1A52F4144F4" xlink:to="loc_ifrs-full_LeaseLiabilities_1EDBFD18B4323967F847A1A52F42C510" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashOutflowForLeases" xlink:label="loc_ifrs-full_CashOutflowForLeases_09BA399C590F95986D9FA1A52F42C75D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_2B9026DFD0010C4C6751A1A52F4144F4" xlink:to="loc_ifrs-full_CashOutflowForLeases_09BA399C590F95986D9FA1A52F42C75D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_86B7EDD83C55CC435028A1A52F425FCB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_2B9026DFD0010C4C6751A1A52F4144F4" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_86B7EDD83C55CC435028A1A52F425FCB" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_GainsLossesfromForeignExchangeImpact" xlink:label="loc_oncyf_GainsLossesfromForeignExchangeImpact_EB900C981774FB394FD4A1A52F42F2AD" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_2B9026DFD0010C4C6751A1A52F4144F4" xlink:to="loc_oncyf_GainsLossesfromForeignExchangeImpact_EB900C981774FB394FD4A1A52F42F2AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-full_LeaseLiabilities_2C04F88D4D04D2F8CE0CA256855127D7" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_2B9026DFD0010C4C6751A1A52F4144F4" xlink:to="loc_ifrs-full_LeaseLiabilities_2C04F88D4D04D2F8CE0CA256855127D7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_5BA193E900956BE267A19CFE7F8E0A9A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_6F9927B55D4524FCDB0D9CFE7F8EAD6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_5BA193E900956BE267A19CFE7F8E0A9A" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_6F9927B55D4524FCDB0D9CFE7F8EAD6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_CECCA55D4AB4BBD2602A9CFE7F8F2C69" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_5BA193E900956BE267A19CFE7F8E0A9A" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_CECCA55D4AB4BBD2602A9CFE7F8F2C69" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_0BD422602BA23B42BE65A8191CD2590D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_28781C854F8F0F3B312CA8191CD3A9F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_0BD422602BA23B42BE65A8191CD2590D" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_28781C854F8F0F3B312CA8191CD3A9F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-full_MaturityAxis_110A30C841F93F8946CFA8191CD3EEBF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_28781C854F8F0F3B312CA8191CD3A9F5" xlink:to="loc_ifrs-full_MaturityAxis_110A30C841F93F8946CFA8191CD3EEBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_8D63E57DF4C23AA2551CA8191CD3C4CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_110A30C841F93F8946CFA8191CD3EEBF" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_8D63E57DF4C23AA2551CA8191CD3C4CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_49511A9A4D0AD36F7673A8191CD423CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_8D63E57DF4C23AA2551CA8191CD3C4CA" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_49511A9A4D0AD36F7673A8191CD423CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_3015620E393808566EE9A8191CD45F7B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_8D63E57DF4C23AA2551CA8191CD3C4CA" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_3015620E393808566EE9A8191CD45F7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_ADE4FAE8F15BB4131D68A8191CD486BA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_8D63E57DF4C23AA2551CA8191CD3C4CA" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_ADE4FAE8F15BB4131D68A8191CD486BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_EF9E900068473FD703E8A8191CD4F6D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_28781C854F8F0F3B312CA8191CD3A9F5" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_EF9E900068473FD703E8A8191CD4F6D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossLeaseLiabilities" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_A2CC5E688919238E00A4A8191F6CC773" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_EF9E900068473FD703E8A8191CD4F6D7" xlink:to="loc_ifrs-full_GrossLeaseLiabilities_A2CC5E688919238E00A4A8191F6CC773" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerCommonShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_A3A4069BAC1F2003E1969CFE7EABACB3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_22C5F379DF0A137C4A989CFE7EAB578B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_A3A4069BAC1F2003E1969CFE7EABACB3" xlink:to="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_22C5F379DF0A137C4A989CFE7EAB578B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_342AB707FD3134F6B2009D034CACFE6E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-full_WeightedAverageShares_7EE9E13EEC557FC927909D034CAC6D21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_342AB707FD3134F6B2009D034CACFE6E" xlink:to="loc_ifrs-full_WeightedAverageShares_7EE9E13EEC557FC927909D034CAC6D21" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_2708AAFC057F56D1499D9CFE7E9E168C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_34E17CC8CC611F2789299CFE7E9E1AD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_2708AAFC057F56D1499D9CFE7E9E168C" xlink:to="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_34E17CC8CC611F2789299CFE7E9E1AD8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_B25B9B922185F14E434C9D034C29712C" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OtherExpensesAndAdjustmentsTable" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTable_3A313FE7984EAB98D82D9D034C2967FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_B25B9B922185F14E434C9D034C29712C" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsTable_3A313FE7984EAB98D82D9D034C2967FA" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IncomeStatementLocation1Axis" xlink:label="loc_oncyf_IncomeStatementLocation1Axis_828B53062F2AC6CEC78F9D034C2A46E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_3A313FE7984EAB98D82D9D034C2967FA" xlink:to="loc_oncyf_IncomeStatementLocation1Axis_828B53062F2AC6CEC78F9D034C2A46E8" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IncomeStatementLocation1Domain" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_3E4F4688CED2E17A34809D034C2A4F06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_828B53062F2AC6CEC78F9D034C2A46E8" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_3E4F4688CED2E17A34809D034C2A4F06" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ResearchAndDevelopmentMember" xlink:label="loc_oncyf_ResearchAndDevelopmentMember_E7B327F4DCB1A2CCCF2C9D034C2A4983" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_3E4F4688CED2E17A34809D034C2A4F06" xlink:to="loc_oncyf_ResearchAndDevelopmentMember_E7B327F4DCB1A2CCCF2C9D034C2A4983" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OperatingExpensesMember" xlink:label="loc_oncyf_OperatingExpensesMember_EF3773D7A2102B6F63299D034C2A868E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_3E4F4688CED2E17A34809D034C2A4F06" xlink:to="loc_oncyf_OperatingExpensesMember_EF3773D7A2102B6F63299D034C2A868E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockAxis" xlink:label="loc_oncyf_SaleOfStockAxis_17A7B6578C9F597D59C99D034C2B467A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_3A313FE7984EAB98D82D9D034C2967FA" xlink:to="loc_oncyf_SaleOfStockAxis_17A7B6578C9F597D59C99D034C2B467A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_FF7E082CDC133798204B9D034C2B7885" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_17A7B6578C9F597D59C99D034C2B467A" xlink:to="loc_oncyf_SaleOfStockDomain_FF7E082CDC133798204B9D034C2B7885" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_253149D438136F5070389D034C2B2E43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_FF7E082CDC133798204B9D034C2B7885" xlink:to="loc_oncyf_WarrantsMember_253149D438136F5070389D034C2B2E43" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_3A313FE7984EAB98D82D9D034C2967FA" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_B34F4D46118D8F1250BC9D034C2C0D56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_B34F4D46118D8F1250BC9D034C2C0D56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_B2B6FC3F7C74D4E311FC9D034C2C121F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_B2B6FC3F7C74D4E311FC9D034C2C121F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_FA4C5C819BBCCC410C0F9D034C2C7F47" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_FA4C5C819BBCCC410C0F9D034C2C7F47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AmortisationExpense" xlink:label="loc_ifrs-full_AmortisationExpense_CB7177A13F4BA7750D699D034C2C8B92" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:to="loc_ifrs-full_AmortisationExpense_CB7177A13F4BA7750D699D034C2C8B92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_9704915AF66214B4C7B59D034C2CFF35" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_9704915AF66214B4C7B59D034C2CFF35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_5344F24627328C5B324A9D034C2DEBF5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_5344F24627328C5B324A9D034C2DEBF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="loc_ifrs-full_AdjustmentsForProvisions_B05FCDE80428B3F7CD869D034C2D7DF4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:to="loc_ifrs-full_AdjustmentsForProvisions_B05FCDE80428B3F7CD869D034C2D7DF4" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_AdjustmentsforLeaseAmortization" xlink:label="loc_oncyf_AdjustmentsforLeaseAmortization_87EDFFC44276E0443F969D034C2D8BE3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_99CBDEACEF36F0992A579D034C2BE82C" xlink:to="loc_oncyf_AdjustmentsforLeaseAmortization_87EDFFC44276E0443F969D034C2D8BE3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_60BEB80398C4DD688E379CFE7F788C8F" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_25F246FA4A5D6BB49CD79CFE7F7861AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_60BEB80398C4DD688E379CFE7F788C8F" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_25F246FA4A5D6BB49CD79CFE7F7861AE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_BFD0BAFFEC83F118BA4E9CFE7EEE3C43" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_59D55D2B6365CB34345B9CFE7EEE7759" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_BFD0BAFFEC83F118BA4E9CFE7EEE3C43" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_59D55D2B6365CB34345B9CFE7EEE7759" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_5A8FF5D1AA622ECDE6D19CFE7EB1E968" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_E036C4C538383B9B9DD09CFE7EB15F36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_5A8FF5D1AA622ECDE6D19CFE7EB1E968" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_E036C4C538383B9B9DD09CFE7EB15F36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5A67AB9A0710E93BCC149CFE7EB235DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_E036C4C538383B9B9DD09CFE7EB15F36" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5A67AB9A0710E93BCC149CFE7EB235DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_904BA2778CD804ACA8C69CFE7EB2E4C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5A67AB9A0710E93BCC149CFE7EB235DA" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_904BA2778CD804ACA8C69CFE7EB2E4C9" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_MedicalEquipmentMember" xlink:label="loc_oncyf_MedicalEquipmentMember_49000A47021E8964AE429CFE7EB2C38F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_904BA2778CD804ACA8C69CFE7EB2E4C9" xlink:to="loc_oncyf_MedicalEquipmentMember_49000A47021E8964AE429CFE7EB2C38F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-full_ComputerEquipmentMember_67E4113C5F2A6B8692B69CFE7EB2DDD9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_904BA2778CD804ACA8C69CFE7EB2E4C9" xlink:to="loc_ifrs-full_ComputerEquipmentMember_67E4113C5F2A6B8692B69CFE7EB2DDD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FixturesAndFittingsMember" xlink:label="loc_ifrs-full_FixturesAndFittingsMember_B78D68CA068E16B9093B9CFE7EB3C872" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_904BA2778CD804ACA8C69CFE7EB2E4C9" xlink:to="loc_ifrs-full_FixturesAndFittingsMember_B78D68CA068E16B9093B9CFE7EB3C872" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="loc_ifrs-full_OfficeEquipmentMember_4CE896552FEA39E30D9B9CFE7EB3CAE7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_904BA2778CD804ACA8C69CFE7EB2E4C9" xlink:to="loc_ifrs-full_OfficeEquipmentMember_4CE896552FEA39E30D9B9CFE7EB3CAE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_130F1D3CAA00832C33789CFE7EB3AA1F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_904BA2778CD804ACA8C69CFE7EB2E4C9" xlink:to="loc_ifrs-full_LeaseholdImprovementsMember_130F1D3CAA00832C33789CFE7EB3AA1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CDD06685E80DE81D046B9CFE7EB30406" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_E036C4C538383B9B9DD09CFE7EB15F36" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CDD06685E80DE81D046B9CFE7EB30406" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-full_CarryingAmountMember_DF68B4E84C871CB675439CFE7EB3184E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CDD06685E80DE81D046B9CFE7EB30406" xlink:to="loc_ifrs-full_CarryingAmountMember_DF68B4E84C871CB675439CFE7EB3184E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_C8D77C29F6ACECE0AD3B9CFE7EB4A1DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_DF68B4E84C871CB675439CFE7EB3184E" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_C8D77C29F6ACECE0AD3B9CFE7EB4A1DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_3640086B7DA683CF71949CFE7EB487C5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_DF68B4E84C871CB675439CFE7EB3184E" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_3640086B7DA683CF71949CFE7EB487C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_14DD8E1CD0CD63F57FF19CFE7EB45667" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_E036C4C538383B9B9DD09CFE7EB15F36" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_14DD8E1CD0CD63F57FF19CFE7EB45667" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_61FA93BE16FE9234DBEF9CFE7EB46F08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_14DD8E1CD0CD63F57FF19CFE7EB45667" xlink:to="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_61FA93BE16FE9234DBEF9CFE7EB46F08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_9AF8A5675D60819A60259CFE7EB487F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_61FA93BE16FE9234DBEF9CFE7EB46F08" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_9AF8A5675D60819A60259CFE7EB487F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_9F5B2D266D16FBAEF5F89CFE7EB5A88D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_61FA93BE16FE9234DBEF9CFE7EB46F08" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_9F5B2D266D16FBAEF5F89CFE7EB5A88D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_255B3E31CCD04B63FCD69CFE7EB50053" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_61FA93BE16FE9234DBEF9CFE7EB46F08" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_255B3E31CCD04B63FCD69CFE7EB50053" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_7A648843F9B75998567A9CFE7EB54093" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_61FA93BE16FE9234DBEF9CFE7EB46F08" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_7A648843F9B75998567A9CFE7EB54093" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_C99E48F642AEEB2FA4269CFE7F1E163E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_20EB8C8B7D65D6A78E689CFE7F1EF419" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_C99E48F642AEEB2FA4269CFE7F1E163E" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_20EB8C8B7D65D6A78E689CFE7F1EF419" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofrelatedpartyAbstract" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract_8FACA2765D7DB63AE5AB9CFE7EDC2E70" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_8B51C37D3E7215E3319D9CFE7EDC0DBD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_8FACA2765D7DB63AE5AB9CFE7EDC2E70" xlink:to="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_8B51C37D3E7215E3319D9CFE7EDC0DBD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofrelatedpartyAbstract" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract_0BE3AB23066374E54163A3396011CDF7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_EACDADBB1F80ED0F5173A33960114ACA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_0BE3AB23066374E54163A3396011CDF7" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_EACDADBB1F80ED0F5173A33960114ACA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_C8693E426EB5E61425AEA33960126455" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_0BE3AB23066374E54163A3396011CDF7" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_C8693E426EB5E61425AEA33960126455" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_F4BBB6DD9DE69F93B6A2A3396012582A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_0BE3AB23066374E54163A3396011CDF7" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_F4BBB6DD9DE69F93B6A2A3396012582A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_6513CD1E53C874142E67A33960122C5D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_0BE3AB23066374E54163A3396011CDF7" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_6513CD1E53C874142E67A33960122C5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_D91886DA9D8110A64FB6A3396012BFA0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_0BE3AB23066374E54163A3396011CDF7" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_D91886DA9D8110A64FB6A3396012BFA0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofrelatedpartyAbstract" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract_03E65B5E55D8AB4361A09CFE7E1B758F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_DC34FEFD2B8394B598AB9CFE7E1C6C8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_03E65B5E55D8AB4361A09CFE7E1B758F" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_DC34FEFD2B8394B598AB9CFE7E1C6C8F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:label="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_83C2C70E7FC1F17D34589CFE7F88B7A3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_74CC908B5BA6F28C34999CFE7F894606" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_83C2C70E7FC1F17D34589CFE7F88B7A3" xlink:to="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_74CC908B5BA6F28C34999CFE7F894606" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsAndFairValueOfOptionsDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:label="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_BE4CD56F5A8550F4F87A9CFE7F6AD9FC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_8AEC44FCF7EAF12359549CFE7F6A7A91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_BE4CD56F5A8550F4F87A9CFE7F6AD9FC" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_8AEC44FCF7EAF12359549CFE7F6A7A91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_82ED12DACA37796F9E8C9CFE7F6B2542" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_BE4CD56F5A8550F4F87A9CFE7F6AD9FC" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_82ED12DACA37796F9E8C9CFE7F6B2542" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_B5ECF462A52CC7453BCC9CFE7F6B7B2E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_BE4CD56F5A8550F4F87A9CFE7F6AD9FC" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_B5ECF462A52CC7453BCC9CFE7F6B7B2E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ExpectedForfeitureShareOptionsGranted" xlink:label="loc_oncyf_ExpectedForfeitureShareOptionsGranted_6872A691DEC25795DB919CFE7F6B36C3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_BE4CD56F5A8550F4F87A9CFE7F6AD9FC" xlink:to="loc_oncyf_ExpectedForfeitureShareOptionsGranted_6872A691DEC25795DB919CFE7F6B36C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_199E91DC36EB9C980E8E9CFE7F6BD54D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_BE4CD56F5A8550F4F87A9CFE7F6AD9FC" xlink:to="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_199E91DC36EB9C980E8E9CFE7F6BD54D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_EF2C07BC566561F4D8AD9CFE7F6B42E6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_BE4CD56F5A8550F4F87A9CFE7F6AD9FC" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_EF2C07BC566561F4D8AD9CFE7F6B42E6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:label="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_DD7B1D6C8D181390E08FA68362E4B8F7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_ADC346E79448E28C6A3AA68362E40C49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_DD7B1D6C8D181390E08FA68362E4B8F7" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_ADC346E79448E28C6A3AA68362E40C49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_AA2912FB4048CC0E0F2EA68362E427A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_ADC346E79448E28C6A3AA68362E40C49" xlink:to="loc_ifrs-full_RangeAxis_AA2912FB4048CC0E0F2EA68362E427A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_44DEDA420C89BC457916A68362E49C99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_AA2912FB4048CC0E0F2EA68362E427A4" xlink:to="loc_ifrs-full_RangesMember_44DEDA420C89BC457916A68362E49C99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_94573E18DAE59814FDD5A68362E5D8E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_44DEDA420C89BC457916A68362E49C99" xlink:to="loc_ifrs-full_BottomOfRangeMember_94573E18DAE59814FDD5A68362E5D8E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_2AC4DFFFF76ABCA7BD5DA68362E5819B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_44DEDA420C89BC457916A68362E49C99" xlink:to="loc_ifrs-full_TopOfRangeMember_2AC4DFFFF76ABCA7BD5DA68362E5819B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_FB1E0B9C6A1C10F86AC1A68362E5D794" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_ADC346E79448E28C6A3AA68362E40C49" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_FB1E0B9C6A1C10F86AC1A68362E5D794" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_F8738FBA9FEF50C8FA3FA68362E5E1B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_FB1E0B9C6A1C10F86AC1A68362E5D794" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_F8738FBA9FEF50C8FA3FA68362E5E1B2" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_RestrictedShareUnitsMember" xlink:label="loc_oncyf_RestrictedShareUnitsMember_A686AA923F50B3998B4AA68362E6E983" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_F8738FBA9FEF50C8FA3FA68362E5E1B2" xlink:to="loc_oncyf_RestrictedShareUnitsMember_A686AA923F50B3998B4AA68362E6E983" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_PerformanceShareUnitsMember" xlink:label="loc_oncyf_PerformanceShareUnitsMember_B78DBD2FAC203B6EE087A68362E6C0C1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_F8738FBA9FEF50C8FA3FA68362E5E1B2" xlink:to="loc_oncyf_PerformanceShareUnitsMember_B78DBD2FAC203B6EE087A68362E6C0C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_B5934BBA4FC6DD07FA6CA68362E65AB8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_F8738FBA9FEF50C8FA3FA68362E5E1B2" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_B5934BBA4FC6DD07FA6CA68362E65AB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8B15DF416AB54A7D4C96A68362E6BCC2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_ADC346E79448E28C6A3AA68362E40C49" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8B15DF416AB54A7D4C96A68362E6BCC2" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_DDD30FF7AD349B5D2937A68362E741AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8B15DF416AB54A7D4C96A68362E6BCC2" xlink:to="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_DDD30FF7AD349B5D2937A68362E741AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:label="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_72464A34CE37DE43ED1CA68362E767E1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_8B15DF416AB54A7D4C96A68362E6BCC2" xlink:to="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_72464A34CE37DE43ED1CA68362E767E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_D53C7E6D1D00D76EEB76A68362E7F041" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_DD7B1D6C8D181390E08FA68362E4B8F7" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_D53C7E6D1D00D76EEB76A68362E7F041" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfNumberOfOtherEquityInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:label="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_B9DBD7AE64E3D5200A119CFE7ED594F0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_F72D952E5549C0D336A29CFE7ED6332F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_B9DBD7AE64E3D5200A119CFE7ED594F0" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_F72D952E5549C0D336A29CFE7ED6332F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_7C8A8ADAEC40824FA29B9CFE7ED6DB06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_F72D952E5549C0D336A29CFE7ED6332F" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_7C8A8ADAEC40824FA29B9CFE7ED6DB06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_76C51A52D909D2077DB59CFE7ED61EC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_7C8A8ADAEC40824FA29B9CFE7ED6DB06" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_76C51A52D909D2077DB59CFE7ED61EC3" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_RestrictedShareUnitsMember" xlink:label="loc_oncyf_RestrictedShareUnitsMember_58A101EC7A0B7BDE05EE9CFE7ED745A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_76C51A52D909D2077DB59CFE7ED61EC3" xlink:to="loc_oncyf_RestrictedShareUnitsMember_58A101EC7A0B7BDE05EE9CFE7ED745A4" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_PerformanceShareUnitsMember" xlink:label="loc_oncyf_PerformanceShareUnitsMember_7D40F457C6A0FCDA7B299CFE7ED74BBD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_76C51A52D909D2077DB59CFE7ED61EC3" xlink:to="loc_oncyf_PerformanceShareUnitsMember_7D40F457C6A0FCDA7B299CFE7ED74BBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_91674D281DB922AFE3219CFE7ED7F53E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_F72D952E5549C0D336A29CFE7ED6332F" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_91674D281DB922AFE3219CFE7ED7F53E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_352A29F5C696827C21209CFE7ED7E87F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_91674D281DB922AFE3219CFE7ED7F53E" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_352A29F5C696827C21209CFE7ED7E87F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_430070B269544EFF86FD9CFE7ED7C663" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_91674D281DB922AFE3219CFE7ED7F53E" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_430070B269544EFF86FD9CFE7ED7C663" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_29F57E8A8FF3172D3F769CFE7ED8ADB7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_91674D281DB922AFE3219CFE7ED7F53E" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_29F57E8A8FF3172D3F769CFE7ED8ADB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_CD181AFCBFCC8874AC5E9CFE7ED861DD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_91674D281DB922AFE3219CFE7ED7F53E" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_CD181AFCBFCC8874AC5E9CFE7ED861DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_5BD261D12266E27EE2D59CFE7ED86BBF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_91674D281DB922AFE3219CFE7ED7F53E" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_5BD261D12266E27EE2D59CFE7ED86BBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_CA00C1DEC256F65B91799CFE7ED876BA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_91674D281DB922AFE3219CFE7ED7F53E" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_CA00C1DEC256F65B91799CFE7ED876BA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsAndWeightedAverageExercisePricesDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:label="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_7AA328FED4A25F7535699D034CD09AEE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_4222F07048955A1FB5F89D034CD098BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_7AA328FED4A25F7535699D034CD09AEE" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_4222F07048955A1FB5F89D034CD098BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_28459D86E1F9FC968A089D034CD1C542" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_7AA328FED4A25F7535699D034CD09AEE" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_28459D86E1F9FC968A089D034CD1C542" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_3A6CA2FBE4B3B47E17359D034CD18BA1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_7AA328FED4A25F7535699D034CD09AEE" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_3A6CA2FBE4B3B47E17359D034CD18BA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_FB951303E618B55ADD279D034CD16C64" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_7AA328FED4A25F7535699D034CD09AEE" xlink:to="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_FB951303E618B55ADD279D034CD16C64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_6B2964902623AEBFAECA9D034CD132A8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_7AA328FED4A25F7535699D034CD09AEE" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_6B2964902623AEBFAECA9D034CD132A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_AC9817B3CB6DFC524D8C9D034CD1F767" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_7AA328FED4A25F7535699D034CD09AEE" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_AC9817B3CB6DFC524D8C9D034CD1F767" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_D6F77F955D969C839ECA9D034CD2A9DE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_7AA328FED4A25F7535699D034CD09AEE" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_D6F77F955D969C839ECA9D034CD2A9DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_38652D5F549C683C8A249D0BCBADDE6C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_7AA328FED4A25F7535699D034CD09AEE" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_38652D5F549C683C8A249D0BCBADDE6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_401C4F16BE1818CB9E909D0C0943DA3C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_7AA328FED4A25F7535699D034CD09AEE" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_401C4F16BE1818CB9E909D0C0943DA3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_D497B0FD493E54E2BE629D0C4858CAB3" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_7AA328FED4A25F7535699D034CD09AEE" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_D497B0FD493E54E2BE629D0C4858CAB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_537C250E9A5C5787E9589D0C83525412" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_7AA328FED4A25F7535699D034CD09AEE" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_537C250E9A5C5787E9589D0C83525412" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_85EEE039378DC81E888F9D0CE5590A29" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_7AA328FED4A25F7535699D034CD09AEE" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_85EEE039378DC81E888F9D0CE5590A29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_2F9BCF5DC8E1DE6B00FC9D287A73349A" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_7AA328FED4A25F7535699D034CD09AEE" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_2F9BCF5DC8E1DE6B00FC9D287A73349A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_3FC147D388D7414B5AF99D0D1436A90A" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_7AA328FED4A25F7535699D034CD09AEE" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_3FC147D388D7414B5AF99D0D1436A90A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:label="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_582AAD2FD270E4FB06469D034CBD5363" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_787727BD35A16555CD5C9D034CBDCA08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_582AAD2FD270E4FB06469D034CBD5363" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_787727BD35A16555CD5C9D034CBDCA08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_4883A1C62F74FA7733159D034CBD012A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_787727BD35A16555CD5C9D034CBDCA08" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_4883A1C62F74FA7733159D034CBD012A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_C336E682560CC5AB69349D034CBD2E55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_4883A1C62F74FA7733159D034CBD012A" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_C336E682560CC5AB69349D034CBD2E55" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ExercisePriceRangeOneMember" xlink:label="loc_oncyf_ExercisePriceRangeOneMember_CB417BC64E16568037609D034CBE8ED4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_C336E682560CC5AB69349D034CBD2E55" xlink:to="loc_oncyf_ExercisePriceRangeOneMember_CB417BC64E16568037609D034CBE8ED4" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ExercisePriceRangeTwoMember" xlink:label="loc_oncyf_ExercisePriceRangeTwoMember_0B52B52BAF8BE973C58B9D034CBEFC97" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_C336E682560CC5AB69349D034CBD2E55" xlink:to="loc_oncyf_ExercisePriceRangeTwoMember_0B52B52BAF8BE973C58B9D034CBEFC97" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ExercisePriceRangeThreeMember" xlink:label="loc_oncyf_ExercisePriceRangeThreeMember_8A0030A5F24DD0D48B509D034CBE001C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_C336E682560CC5AB69349D034CBD2E55" xlink:to="loc_oncyf_ExercisePriceRangeThreeMember_8A0030A5F24DD0D48B509D034CBE001C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ExercisePriceRangeFourMember" xlink:label="loc_oncyf_ExercisePriceRangeFourMember_A1C4301F796867209EC39D034CBEB0F1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_C336E682560CC5AB69349D034CBD2E55" xlink:to="loc_oncyf_ExercisePriceRangeFourMember_A1C4301F796867209EC39D034CBEB0F1" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ExercisePriceRangeFiveMember" xlink:label="loc_oncyf_ExercisePriceRangeFiveMember_984D3F661B6CD944B0FC9D034CBE6DD8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_C336E682560CC5AB69349D034CBD2E55" xlink:to="loc_oncyf_ExercisePriceRangeFiveMember_984D3F661B6CD944B0FC9D034CBE6DD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_C0348BC8204AC49E2EFB9D034CBFBD48" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_787727BD35A16555CD5C9D034CBDCA08" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_C0348BC8204AC49E2EFB9D034CBFBD48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_8FEF9B0478B38C84E9349D034CBFE53F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_C0348BC8204AC49E2EFB9D034CBFBD48" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_8FEF9B0478B38C84E9349D034CBFE53F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1F85CDFDE36FC18FF5959D24F556053F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_C0348BC8204AC49E2EFB9D034CBFBD48" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_1F85CDFDE36FC18FF5959D24F556053F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_A3B2781E07F1563F7A179D2551CDB58B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_C0348BC8204AC49E2EFB9D034CBFBD48" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_A3B2781E07F1563F7A179D2551CDB58B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_3BD728B6BEC25A2011FE9D034CBF9806" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_C0348BC8204AC49E2EFB9D034CBFBD48" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_3BD728B6BEC25A2011FE9D034CBF9806" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_7B1CE31B99587E7D2C269D258F38B9ED" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_C0348BC8204AC49E2EFB9D034CBFBD48" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_7B1CE31B99587E7D2C269D258F38B9ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_089D88B7F16DEBD253F09D034CC012D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_582AAD2FD270E4FB06469D034CBD5363" xlink:to="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_089D88B7F16DEBD253F09D034CC012D7" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_089D88B7F16DEBD253F09D034CC012D7" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_4883A1C62F74FA7733159D034CBD012A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-full_RangeAxis_5929444ED60B9C593E159D034CC1D4CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_089D88B7F16DEBD253F09D034CC012D7" xlink:to="loc_ifrs-full_RangeAxis_5929444ED60B9C593E159D034CC1D4CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_BC71AEC3DA4C466F99719D034CC221EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_5929444ED60B9C593E159D034CC1D4CA" xlink:to="loc_ifrs-full_RangesMember_BC71AEC3DA4C466F99719D034CC221EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-full_BottomOfRangeMember_138CB41166D1E80880DF9D034CC2E135" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_BC71AEC3DA4C466F99719D034CC221EF" xlink:to="loc_ifrs-full_BottomOfRangeMember_138CB41166D1E80880DF9D034CC2E135" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-full_TopOfRangeMember_E90E50B59EDC4BAFCF8C9D034CC2988D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_BC71AEC3DA4C466F99719D034CC221EF" xlink:to="loc_ifrs-full_TopOfRangeMember_E90E50B59EDC4BAFCF8C9D034CC2988D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_4743EC40FBE30D6FBCDC9D034CC2D346" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_089D88B7F16DEBD253F09D034CC012D7" xlink:to="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_4743EC40FBE30D6FBCDC9D034CC2D346" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_073354358577BDB7C00F9D2A48DB70C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_4743EC40FBE30D6FBCDC9D034CC2D346" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_073354358577BDB7C00F9D2A48DB70C5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:label="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_2D2F0E1749C3602680A39CFE7E38E82E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_28C2DE468CDADEDD0CFC9CFE7E3834D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_2D2F0E1749C3602680A39CFE7E38E82E" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_28C2DE468CDADEDD0CFC9CFE7E3834D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_713DFF1C7F5B479A69CB9CFE7E389C50" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_2D2F0E1749C3602680A39CFE7E38E82E" xlink:to="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_713DFF1C7F5B479A69CB9CFE7E389C50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_DBBA10C519177148CAD49CFE7E38630F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_2D2F0E1749C3602680A39CFE7E38E82E" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_DBBA10C519177148CAD49CFE7E38630F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_C39FE437AD18F6DD57499CFE7E3800D2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_2D2F0E1749C3602680A39CFE7E38E82E" xlink:to="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_C39FE437AD18F6DD57499CFE7E3800D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_22BE17B27A56EA506B569CFE7E385230" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_2D2F0E1749C3602680A39CFE7E38E82E" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_22BE17B27A56EA506B569CFE7E385230" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_4107ADDCCCA60CDE2261A1D3F30660CD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_88FCB4813D6808C4444FA1D3F307601A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_4107ADDCCCA60CDE2261A1D3F30660CD" xlink:to="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_88FCB4813D6808C4444FA1D3F307601A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_40C14D6B4B0E6170E7C9A1D3EE3DE743" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_StockholdersEquityNoteStockSplitConversionRatio" xlink:label="loc_oncyf_StockholdersEquityNoteStockSplitConversionRatio_035075D77784DD0AC71CA1D3EE3D910D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_40C14D6B4B0E6170E7C9A1D3EE3DE743" xlink:to="loc_oncyf_StockholdersEquityNoteStockSplitConversionRatio_035075D77784DD0AC71CA1D3EE3D910D" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_60BCFCAA5A4866ADC6FCA1D3EE3D66C3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_40C14D6B4B0E6170E7C9A1D3EE3DE743" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_60BCFCAA5A4866ADC6FCA1D3EE3D66C3" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_648828685368C7498245A1D3EE3DE817" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_40C14D6B4B0E6170E7C9A1D3EE3DE743" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_648828685368C7498245A1D3EE3DE817" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_5D8F8466827C8DB3628CA1D3EBF1ED3E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_324EADD657E2792BD9CBA1D3EBF1D1D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_5D8F8466827C8DB3628CA1D3EBF1ED3E" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_324EADD657E2792BD9CBA1D3EBF1D1D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_44F22FF1546D8C553DECA1D3EBF1536F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_324EADD657E2792BD9CBA1D3EBF1D1D1" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_44F22FF1546D8C553DECA1D3EBF1536F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_46AB4636E86F38A8D43CA1D3EBF1F1AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_44F22FF1546D8C553DECA1D3EBF1536F" xlink:to="loc_ifrs-full_RestatedMember_46AB4636E86F38A8D43CA1D3EBF1F1AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="loc_ifrs-full_PreviouslyStatedMember_497AEBD82329B8A90205A1D3EBF2572A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RestatedMember_46AB4636E86F38A8D43CA1D3EBF1F1AA" xlink:to="loc_ifrs-full_PreviouslyStatedMember_497AEBD82329B8A90205A1D3EBF2572A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_F73919743BD42AB279D0A1D3EBF27C7B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_324EADD657E2792BD9CBA1D3EBF1D1D1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_F73919743BD42AB279D0A1D3EBF27C7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_90140288279F2A7278E0A1D3EBF21BF7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_F73919743BD42AB279D0A1D3EBF27C7B" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_90140288279F2A7278E0A1D3EBF21BF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_EF42A40FC22AAC9998F2A1D3EBF32857" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_90140288279F2A7278E0A1D3EBF21BF7" xlink:to="loc_ifrs-full_IssuedCapitalMember_EF42A40FC22AAC9998F2A1D3EBF32857" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_0D2DAC654ECB83B7F958A1D3EBF3A9C3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_90140288279F2A7278E0A1D3EBF21BF7" xlink:to="loc_oncyf_WarrantsMember_0D2DAC654ECB83B7F958A1D3EBF3A9C3" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockAxis" xlink:label="loc_oncyf_SaleOfStockAxis_9D0F17569C740B42F100A1D3EBF3A4CD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_324EADD657E2792BD9CBA1D3EBF1D1D1" xlink:to="loc_oncyf_SaleOfStockAxis_9D0F17569C740B42F100A1D3EBF3A4CD" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_5204A7DE53C5621D9D18A1D3EBF33228" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_9D0F17569C740B42F100A1D3EBF3A4CD" xlink:to="loc_oncyf_SaleOfStockDomain_5204A7DE53C5621D9D18A1D3EBF33228" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderIncentiveAwardPlanMember" xlink:label="loc_oncyf_SharesUnderIncentiveAwardPlanMember_D808CC015BBD057CCD6CA1D3EBF3FCE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_5204A7DE53C5621D9D18A1D3EBF33228" xlink:to="loc_oncyf_SharesUnderIncentiveAwardPlanMember_D808CC015BBD057CCD6CA1D3EBF3FCE0" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderCommonStockPurchaseAgreementMember" xlink:label="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_CC9EEEF1073030051587A1D3EBF4287C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_5204A7DE53C5621D9D18A1D3EBF33228" xlink:to="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_CC9EEEF1073030051587A1D3EBF4287C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderAtthemarketAgreementMember" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_4026C1437C48B8D253FFA1D3EBF44C5E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_5204A7DE53C5621D9D18A1D3EBF33228" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_4026C1437C48B8D253FFA1D3EBF44C5E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderStockOptionPlanMember" xlink:label="loc_oncyf_SharesUnderStockOptionPlanMember_8757F78487C78FFD3112A1D3EBF4056C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_5204A7DE53C5621D9D18A1D3EBF33228" xlink:to="loc_oncyf_SharesUnderStockOptionPlanMember_8757F78487C78FFD3112A1D3EBF4056C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesPublicOfferingMember" xlink:label="loc_oncyf_SharesPublicOfferingMember_5189506C1E08492FEB0AA1D3EBF4600A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_5204A7DE53C5621D9D18A1D3EBF33228" xlink:to="loc_oncyf_SharesPublicOfferingMember_5189506C1E08492FEB0AA1D3EBF4600A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderWarrantAgreementMember" xlink:label="loc_oncyf_SharesUnderWarrantAgreementMember_C72DCC300B78A4D2DDB8A1D3EBF4DAE3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_5204A7DE53C5621D9D18A1D3EBF33228" xlink:to="loc_oncyf_SharesUnderWarrantAgreementMember_C72DCC300B78A4D2DDB8A1D3EBF4DAE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_65E65F39CC83AED90332A1D3EBF44749" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_324EADD657E2792BD9CBA1D3EBF1D1D1" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_65E65F39CC83AED90332A1D3EBF44749" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_22A704DD6395F6A67524A1D3EBF51E01" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_65E65F39CC83AED90332A1D3EBF44749" xlink:to="loc_ifrs-full_Equity_22A704DD6395F6A67524A1D3EBF51E01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_889CE6F97BB9F9DE9F2CA1D3EBF57154" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_65E65F39CC83AED90332A1D3EBF44749" xlink:to="loc_ifrs-full_NumberOfSharesIssued_889CE6F97BB9F9DE9F2CA1D3EBF57154" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-full_IssueOfEquity_07E7EA485BA0103CC751A1D3EBF50CA1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_65E65F39CC83AED90332A1D3EBF44749" xlink:to="loc_ifrs-full_IssueOfEquity_07E7EA485BA0103CC751A1D3EBF50CA1" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IssueOfEquityShares" xlink:label="loc_oncyf_IssueOfEquityShares_D4BF034A919EC3ED6C1FA1D3EBF58347" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_65E65F39CC83AED90332A1D3EBF44749" xlink:to="loc_oncyf_IssueOfEquityShares_D4BF034A919EC3ED6C1FA1D3EBF58347" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_714744BBF78547125AC8A1D3EBF53E4B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_65E65F39CC83AED90332A1D3EBF44749" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_714744BBF78547125AC8A1D3EBF53E4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_164ADE18045C48E03BA7A1D3EBF68EE2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_65E65F39CC83AED90332A1D3EBF44749" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_164ADE18045C48E03BA7A1D3EBF68EE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_84F15F501BED306837A8A1D3EBF68384" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_65E65F39CC83AED90332A1D3EBF44749" xlink:to="loc_ifrs-full_Equity_84F15F501BED306837A8A1D3EBF68384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_8D444D7DF3805019F96AA1D3EBF6189F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_65E65F39CC83AED90332A1D3EBF44749" xlink:to="loc_ifrs-full_NumberOfSharesIssued_8D444D7DF3805019F96AA1D3EBF6189F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_46568C32CACB16444085A7434D191B79" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_22D348D6D361BE484797A7434D198B6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_46568C32CACB16444085A7434D191B79" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_22D348D6D361BE484797A7434D198B6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_6F430E641D6D2A39620EA7434D1A5E9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_22D348D6D361BE484797A7434D198B6E" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_6F430E641D6D2A39620EA7434D1A5E9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_8C840E3DF2F577B45F79A7434D1B73CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_6F430E641D6D2A39620EA7434D1A5E9E" xlink:to="loc_ifrs-full_LiabilitiesMember_8C840E3DF2F577B45F79A7434D1B73CD" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_C0FC382A0D5BB09BF4E1A7434D1B9EEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_8C840E3DF2F577B45F79A7434D1B73CD" xlink:to="loc_oncyf_WarrantsMember_C0FC382A0D5BB09BF4E1A7434D1B9EEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_E7520725F6A6C8A9ECC5A7434D1BF1EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_22D348D6D361BE484797A7434D198B6E" xlink:to="loc_srt_RangeAxis_E7520725F6A6C8A9ECC5A7434D1BF1EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-full_RangesMember_0F5C47BC872D7232781BA7434D1B0001" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_E7520725F6A6C8A9ECC5A7434D1BF1EC" xlink:to="loc_ifrs-full_RangesMember_0F5C47BC872D7232781BA7434D1B0001" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_5B4CE0FEDB448DCE3DF9A7434D1BA5A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_0F5C47BC872D7232781BA7434D1B0001" xlink:to="loc_srt_MinimumMember_5B4CE0FEDB448DCE3DF9A7434D1BA5A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_B63C5396DD44FEDBBD4BA7434D1D7DBC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_0F5C47BC872D7232781BA7434D1B0001" xlink:to="loc_srt_MaximumMember_B63C5396DD44FEDBBD4BA7434D1D7DBC" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockAxis" xlink:label="loc_oncyf_SaleOfStockAxis_DE7F2474172B0C8A41D8A7434D1D8A88" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_22D348D6D361BE484797A7434D198B6E" xlink:to="loc_oncyf_SaleOfStockAxis_DE7F2474172B0C8A41D8A7434D1D8A88" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_6A64DBAC24CBF2C06DDBA7434D1E63A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_DE7F2474172B0C8A41D8A7434D1D8A88" xlink:to="loc_oncyf_SaleOfStockDomain_6A64DBAC24CBF2C06DDBA7434D1E63A7" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderAtthemarketAgreementCanadianMember" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementCanadianMember_DE8BF3733375CC65687FA7434D1E8936" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_6A64DBAC24CBF2C06DDBA7434D1E63A7" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementCanadianMember_DE8BF3733375CC65687FA7434D1E8936" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesPublicOfferingMember" xlink:label="loc_oncyf_SharesPublicOfferingMember_B5F9885783B887CC776DA7434D1E998F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_6A64DBAC24CBF2C06DDBA7434D1E63A7" xlink:to="loc_oncyf_SharesPublicOfferingMember_B5F9885783B887CC776DA7434D1E998F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_9FA2B90666443E789973A7434D20BB1C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_6A64DBAC24CBF2C06DDBA7434D1E63A7" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_9FA2B90666443E789973A7434D20BB1C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderCommonStockPurchaseAgreementMember" xlink:label="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_0EF705A43895D48EC1D0A7434D20B782" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_6A64DBAC24CBF2C06DDBA7434D1E63A7" xlink:to="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_0EF705A43895D48EC1D0A7434D20B782" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_InitialCommitmentFeeMember" xlink:label="loc_oncyf_InitialCommitmentFeeMember_F6831B2B23F0F57483A0A7434D20E94C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_0EF705A43895D48EC1D0A7434D20B782" xlink:to="loc_oncyf_InitialCommitmentFeeMember_F6831B2B23F0F57483A0A7434D20E94C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderWarrantAgreementMember" xlink:label="loc_oncyf_SharesUnderWarrantAgreementMember_2E59044F8C97BBEB3C5EA7C3BAA9A255" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_6A64DBAC24CBF2C06DDBA7434D1E63A7" xlink:to="loc_oncyf_SharesUnderWarrantAgreementMember_2E59044F8C97BBEB3C5EA7C3BAA9A255" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_B82FD73C9BC397BF788EA7434D21B0B2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_22D348D6D361BE484797A7434D198B6E" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_B82FD73C9BC397BF788EA7434D21B0B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="loc_ifrs-full_RestatedMember_B4714E35AF71AC466113A7434D212254" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_B82FD73C9BC397BF788EA7434D21B0B2" xlink:to="loc_ifrs-full_RestatedMember_B4714E35AF71AC466113A7434D212254" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="loc_ifrs-full_PreviouslyStatedMember_ECF89D3C3F0C76A312EDA7434D218EDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RestatedMember_B4714E35AF71AC466113A7434D212254" xlink:to="loc_ifrs-full_PreviouslyStatedMember_ECF89D3C3F0C76A312EDA7434D218EDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_7B755BF370FF7CE4ED21A7434D21624C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_22D348D6D361BE484797A7434D198B6E" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_7B755BF370FF7CE4ED21A7434D21624C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_3C66F1658C37A309CF72A7434D213DFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_7B755BF370FF7CE4ED21A7434D21624C" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_3C66F1658C37A309CF72A7434D213DFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_9FB5A3C034008DF4D134A7434D237DE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_3C66F1658C37A309CF72A7434D213DFE" xlink:to="loc_ifrs-full_IssuedCapitalMember_9FB5A3C034008DF4D134A7434D237DE3" xlink:type="arc" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_3C66F1658C37A309CF72A7434D213DFE" xlink:to="loc_oncyf_WarrantsMember_C0FC382A0D5BB09BF4E1A7434D1B9EEE" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IncomeStatementLocation1Axis" xlink:label="loc_oncyf_IncomeStatementLocation1Axis_0487E822F906756892FAA7434D24CCE6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_22D348D6D361BE484797A7434D198B6E" xlink:to="loc_oncyf_IncomeStatementLocation1Axis_0487E822F906756892FAA7434D24CCE6" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IncomeStatementLocation1Domain" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_662153533CEE304079B4A7434D24B285" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_0487E822F906756892FAA7434D24CCE6" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_662153533CEE304079B4A7434D24B285" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OperatingExpensesMember" xlink:label="loc_oncyf_OperatingExpensesMember_90ACFED8FAB9F68EC49FA7434D25F968" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_662153533CEE304079B4A7434D24B285" xlink:to="loc_oncyf_OperatingExpensesMember_90ACFED8FAB9F68EC49FA7434D25F968" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_22D348D6D361BE484797A7434D198B6E" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_5950C41C458069BEDA6CA7434D2622F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_ifrs-full_Equity_5950C41C458069BEDA6CA7434D2622F9" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IssueOfEquityShares" xlink:label="loc_oncyf_IssueOfEquityShares_D6D3D765981B294A01C4A7434D273518" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_IssueOfEquityShares_D6D3D765981B294A01C4A7434D273518" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_E9A98FE9D27A506D93C9A7434D2708F1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_E9A98FE9D27A506D93C9A7434D2708F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_7236E9E7319BFA0FA166A7434D290E8C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_7236E9E7319BFA0FA166A7434D290E8C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesIssuedPricePerShare1" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_A5D248A418E2C4AA71E0A7434D2AEBA3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_A5D248A418E2C4AA71E0A7434D2AEBA3" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CommonSharesPerUnit" xlink:label="loc_oncyf_CommonSharesPerUnit_FE5F3B557B8BC0C428B1A7434D2B2143" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_CommonSharesPerUnit_FE5F3B557B8BC0C428B1A7434D2B2143" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CommonSharePurchaseWarrantPerUnit" xlink:label="loc_oncyf_CommonSharePurchaseWarrantPerUnit_8E8C680CEEB6E4245C82A7434D2BBB4F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_CommonSharePurchaseWarrantPerUnit_8E8C680CEEB6E4245C82A7434D2BBB4F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesIssuedWarrantPricePerShare" xlink:label="loc_oncyf_SharesIssuedWarrantPricePerShare_9BC0F33B7DE6E622C286A7434D2BEED6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_SharesIssuedWarrantPricePerShare_9BC0F33B7DE6E622C286A7434D2BEED6" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_3D7906FD81DF54D8F249A7434D2B9613" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_3D7906FD81DF54D8F249A7434D2B9613" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_B201DA13845CCE528BE5A7434D2C8C4E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_B201DA13845CCE528BE5A7434D2C8C4E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_E179A5409EA9B6122E6FA7434D2C4C28" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_E179A5409EA9B6122E6FA7434D2C4C28" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantPricePerShareAccelerationThreshold" xlink:label="loc_oncyf_WarrantPricePerShareAccelerationThreshold_B5866DE8EF4E87FBB0DFA7434D2DB16B" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_WarrantPricePerShareAccelerationThreshold_B5866DE8EF4E87FBB0DFA7434D2DB16B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantPricePerShareAccelerationThresholdTradingDays" xlink:label="loc_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_346E89D5B982D48DB402A7434D2EDD9E" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays_346E89D5B982D48DB402A7434D2EDD9E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharePurchaseAgreementAmount" xlink:label="loc_oncyf_SharePurchaseAgreementAmount_1DD6C0BD67C480C5EF67A7434D2EF76E" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_SharePurchaseAgreementAmount_1DD6C0BD67C480C5EF67A7434D2EF76E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharePurchaseAgreementTerm" xlink:label="loc_oncyf_SharePurchaseAgreementTerm_C29597566DE123144A4EA7434D2EBE9C" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_SharePurchaseAgreementTerm_C29597566DE123144A4EA7434D2EBE9C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_NumberofSharesOutstandingPercent" xlink:label="loc_oncyf_NumberofSharesOutstandingPercent_270F667549839406ABCCA7434D2E5084" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_NumberofSharesOutstandingPercent_270F667549839406ABCCA7434D2E5084" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightWarrantsExercised" xlink:label="loc_oncyf_ClassofWarrantorRightWarrantsExercised_6BA1011FA8F6B85BCB5CA7434D2FB3E5" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_ClassofWarrantorRightWarrantsExercised_6BA1011FA8F6B85BCB5CA7434D2FB3E5" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ProceedsfromWarrantExercises1" xlink:label="loc_oncyf_ProceedsfromWarrantExercises1_A65F9371E29E51B40D99A7434D2F5786" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_ProceedsfromWarrantExercises1_A65F9371E29E51B40D99A7434D2F5786" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_DDC2145D7090E5BA6283A7434D2FF210" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_A2153C303BF190548F7AA7434D261A73" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_DDC2145D7090E5BA6283A7434D2FF210" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryOfOutstandingWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_9E6151FA48BC584BF4D9A1D3E670E522" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_4215A84C1E303F43220EA1D3E672089E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_9E6151FA48BC584BF4D9A1D3E670E522" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_4215A84C1E303F43220EA1D3E672089E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_7BED781A39BEA4C018E9A1D3E673296A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_4215A84C1E303F43220EA1D3E672089E" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_7BED781A39BEA4C018E9A1D3E673296A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_0D0AC2D221BFB0EBF348A1D3E673B399" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_7BED781A39BEA4C018E9A1D3E673296A" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_0D0AC2D221BFB0EBF348A1D3E673B399" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_317EAB8F43006C947DADA1D3E673D679" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_0D0AC2D221BFB0EBF348A1D3E673B399" xlink:to="loc_oncyf_WarrantsMember_317EAB8F43006C947DADA1D3E673D679" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_656820D426F467B811E3A1D3E6743631" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_4215A84C1E303F43220EA1D3E672089E" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_656820D426F467B811E3A1D3E6743631" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ExercisePriceofOutstandingWarrants" xlink:label="loc_oncyf_ExercisePriceofOutstandingWarrants_4984249835BACB353242A1D3E674017B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_656820D426F467B811E3A1D3E6743631" xlink:to="loc_oncyf_ExercisePriceofOutstandingWarrants_4984249835BACB353242A1D3E674017B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_D44BB0690CDE0A939D41A1D3E67B6E54" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_656820D426F467B811E3A1D3E6743631" xlink:to="loc_ifrs-full_NumberOfSharesIssued_D44BB0690CDE0A939D41A1D3E67B6E54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-full_NumberOfSharesIssued_8DAC278A1E569CAAC5F0A1D3E67B33D8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_656820D426F467B811E3A1D3E6743631" xlink:to="loc_ifrs-full_NumberOfSharesIssued_8DAC278A1E569CAAC5F0A1D3E67B33D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_D11BB88EB0F57D525134A1D3E67BBDCE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_656820D426F467B811E3A1D3E6743631" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_D11BB88EB0F57D525134A1D3E67BBDCE" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_B1635E1A025BB95F0876A1D3E67B1E52" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_656820D426F467B811E3A1D3E6743631" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_B1635E1A025BB95F0876A1D3E67B1E52" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_1C67162B8DD8BAC0F4D8A20A0D357747" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_17E0D09227DB23319BC9A20A0D3595D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_1C67162B8DD8BAC0F4D8A20A0D357747" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_17E0D09227DB23319BC9A20A0D3595D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_28EA1831119F5FC59B20A20A0D358913" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_1C67162B8DD8BAC0F4D8A20A0D357747" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_28EA1831119F5FC59B20A20A0D358913" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesAndAssumptions" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:label="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_1126701DB10B8824FEDE9CFE7ECD868C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_4004C00AD6EE697196B59CFE7ECE6C5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_1126701DB10B8824FEDE9CFE7ECD868C" xlink:to="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_4004C00AD6EE697196B59CFE7ECE6C5A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:label="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract_D70B3856B3F16AB0D8709D034C1C45ED" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_2EE313CA37BCBC8FECAC9D034C1D7B93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract_D70B3856B3F16AB0D8709D034C1C45ED" xlink:to="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_2EE313CA37BCBC8FECAC9D034C1D7B93" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:label="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract_3006BFAEEC91A2857F5BA68362264A6F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_903A8FF7DE0EF4A5535BA6836226136D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract_3006BFAEEC91A2857F5BA68362264A6F" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_903A8FF7DE0EF4A5535BA6836226136D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_F4AA4A99E78C9F7A97F8A68362273A57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_903A8FF7DE0EF4A5535BA6836226136D" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_F4AA4A99E78C9F7A97F8A68362273A57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-full_NonadjustingEventsMember_95E14724F5FA6C901597A68362273729" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_F4AA4A99E78C9F7A97F8A68362273A57" xlink:to="loc_ifrs-full_NonadjustingEventsMember_95E14724F5FA6C901597A68362273729" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_BA4C4A24ABE7932542CDA6836227052B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_95E14724F5FA6C901597A68362273729" xlink:to="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_BA4C4A24ABE7932542CDA6836227052B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember" xlink:label="loc_ifrs-full_EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember_225A0D8A8274F6DCC0BBA68362286307" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_95E14724F5FA6C901597A68362273729" xlink:to="loc_ifrs-full_EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember_225A0D8A8274F6DCC0BBA68362286307" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockAxis" xlink:label="loc_oncyf_SaleOfStockAxis_A979112AF2AADCC39913A6836228B7A8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_903A8FF7DE0EF4A5535BA6836226136D" xlink:to="loc_oncyf_SaleOfStockAxis_A979112AF2AADCC39913A6836228B7A8" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_1B89F87E483D9E972D69A68362284BB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_A979112AF2AADCC39913A6836228B7A8" xlink:to="loc_oncyf_SaleOfStockDomain_1B89F87E483D9E972D69A68362284BB0" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_578B33304B27DDB47162A6836228692C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_1B89F87E483D9E972D69A68362284BB0" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_578B33304B27DDB47162A6836228692C" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesPublicOfferingMember" xlink:label="loc_oncyf_SharesPublicOfferingMember_B1FF7B86605FBE426115A68362288FBC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_1B89F87E483D9E972D69A68362284BB0" xlink:to="loc_oncyf_SharesPublicOfferingMember_B1FF7B86605FBE426115A68362288FBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_556FA240AC1E3E805F24A6836229A71E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_903A8FF7DE0EF4A5535BA6836226136D" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_556FA240AC1E3E805F24A6836229A71E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherProvisionsMember" xlink:label="loc_ifrs-full_OtherProvisionsMember_91633B3FF8E7DE98FF2FA6836229411A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_556FA240AC1E3E805F24A6836229A71E" xlink:to="loc_ifrs-full_OtherProvisionsMember_91633B3FF8E7DE98FF2FA6836229411A" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CollaborationAgreementMember" xlink:label="loc_oncyf_CollaborationAgreementMember_B6E8047A8B452CE6005DA6836229D79C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_91633B3FF8E7DE98FF2FA6836229411A" xlink:to="loc_oncyf_CollaborationAgreementMember_B6E8047A8B452CE6005DA6836229D79C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_F3107E1131DC61F848FCA6836229F4F8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_903A8FF7DE0EF4A5535BA6836226136D" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_F3107E1131DC61F848FCA6836229F4F8" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IssueOfEquityShares" xlink:label="loc_oncyf_IssueOfEquityShares_060361E09DF1B21E948BA6836229BD0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_F3107E1131DC61F848FCA6836229F4F8" xlink:to="loc_oncyf_IssueOfEquityShares_060361E09DF1B21E948BA6836229BD0F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_FE24AB54EBCF6C6D203DA683622AA7A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_F3107E1131DC61F848FCA6836229F4F8" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_FE24AB54EBCF6C6D203DA683622AA7A7" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ProceedsFromCollaborationAgreement" xlink:label="loc_oncyf_ProceedsFromCollaborationAgreement_C291D57B5089EFF3498DA6B73617F3DA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_F3107E1131DC61F848FCA6836229F4F8" xlink:to="loc_oncyf_ProceedsFromCollaborationAgreement_C291D57B5089EFF3498DA6B73617F3DA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_2725E1F8037AB694DCB6A68364A6D1F6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_6C051E12EE1D8F5B4786A68364A609BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_2725E1F8037AB694DCB6A68364A6D1F6" xlink:to="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_6C051E12EE1D8F5B4786A68364A609BB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesIfrs16LeasesDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_6D668D060F8368D21A36AB7942A88BB1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:label="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_77EBE75A52E65F54D2CBAB7942A984F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_6D668D060F8368D21A36AB7942A88BB1" xlink:to="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_77EBE75A52E65F54D2CBAB7942A984F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_7C1098E25E407059327EAB7942A9AF5D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_6D668D060F8368D21A36AB7942A88BB1" xlink:to="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_7C1098E25E407059327EAB7942A9AF5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsAxis" xlink:label="loc_ifrs-full_InitiallyAppliedIFRSsAxis_091E66C37B7FB9BF69EBAB7942A99B63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_7C1098E25E407059327EAB7942A9AF5D" xlink:to="loc_ifrs-full_InitiallyAppliedIFRSsAxis_091E66C37B7FB9BF69EBAB7942A99B63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsMember" xlink:label="loc_ifrs-full_InitiallyAppliedIFRSsMember_71F78FD855DC9A26A511AB7942A98015" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InitiallyAppliedIFRSsAxis_091E66C37B7FB9BF69EBAB7942A99B63" xlink:to="loc_ifrs-full_InitiallyAppliedIFRSsMember_71F78FD855DC9A26A511AB7942A98015" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_EffectsofIFRS16TransitionMember" xlink:label="loc_oncyf_EffectsofIFRS16TransitionMember_6CFBD5AF93F32AB9C486AB7942A91AE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InitiallyAppliedIFRSsMember_71F78FD855DC9A26A511AB7942A98015" xlink:to="loc_oncyf_EffectsofIFRS16TransitionMember_6CFBD5AF93F32AB9C486AB7942A91AE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_7C1098E25E407059327EAB7942A9AF5D" xlink:to="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-full_RightofuseAssets_517F71CC52A4690A3AA2AB7942AAB822" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530" xlink:to="loc_ifrs-full_RightofuseAssets_517F71CC52A4690A3AA2AB7942AAB822" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OtherCurrentandNoncurrentAssets" xlink:label="loc_oncyf_OtherCurrentandNoncurrentAssets_67EB0798C12AE09E1E97AB7942AA69F9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530" xlink:to="loc_oncyf_OtherCurrentandNoncurrentAssets_67EB0798C12AE09E1E97AB7942AA69F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-full_Assets_F196BF840E89E479C06BAB7942AA9839" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530" xlink:to="loc_ifrs-full_Assets_F196BF840E89E479C06BAB7942AA9839" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherLiabilities" xlink:label="loc_ifrs-full_OtherLiabilities_CAD1E8D5518A80CCFE5AAB7942AA23AA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530" xlink:to="loc_ifrs-full_OtherLiabilities_CAD1E8D5518A80CCFE5AAB7942AA23AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-full_LeaseLiabilities_B3B7B5A98BEF2DCF6A2AAB7942AB0FFD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530" xlink:to="loc_ifrs-full_LeaseLiabilities_B3B7B5A98BEF2DCF6A2AAB7942AB0FFD" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OtherCurrentandNoncurrentLiabilities" xlink:label="loc_oncyf_OtherCurrentandNoncurrentLiabilities_7D8FE27B4B53862F4BACAB7942AB65B8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530" xlink:to="loc_oncyf_OtherCurrentandNoncurrentLiabilities_7D8FE27B4B53862F4BACAB7942AB65B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-full_Liabilities_3B501346646EAF1644ECAB7942AB44F4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530" xlink:to="loc_ifrs-full_Liabilities_3B501346646EAF1644ECAB7942AB44F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_92681CCC9EDC68BF57F8AB7942AB0C3D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_F379314A2E0D032140A7AB7942AA2530" xlink:to="loc_ifrs-full_Equity_92681CCC9EDC68BF57F8AB7942AB0C3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossLeaseLiabilities" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_15D34891B81717676E5DAB7942AB1D2B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_6D668D060F8368D21A36AB7942A88BB1" xlink:to="loc_ifrs-full_GrossLeaseLiabilities_15D34891B81717676E5DAB7942AB1D2B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_2AA489614424735195A1A683647CB4EE" xlink:type="locator" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_NumberOfStockOptionPlans" xlink:label="loc_oncyf_NumberOfStockOptionPlans_82011BB6D7B5A15FBE81A683647CC8DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_2AA489614424735195A1A683647CB4EE" xlink:to="loc_oncyf_NumberOfStockOptionPlans_82011BB6D7B5A15FBE81A683647CC8DE" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:label="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_BF19F19BF632D198F835A683647C462F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_2AA489614424735195A1A683647CB4EE" xlink:to="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_BF19F19BF632D198F835A683647C462F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_CD88C46E27F25065CE97A683649C9D2C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_23E98ED6DB2E006F4F1EA683649C2F68" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_CD88C46E27F25065CE97A683649C9D2C" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_23E98ED6DB2E006F4F1EA683649C2F68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_942ABF837FC4A25758EDA683649CC82E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_CD88C46E27F25065CE97A683649C9D2C" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_942ABF837FC4A25758EDA683649CC82E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_18C1483FDFF6F4EE524EA683649C2C63" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_CD88C46E27F25065CE97A683649C9D2C" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_18C1483FDFF6F4EE524EA683649C2C63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_A69F87883AAA713E2626A683649CA720" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_CD88C46E27F25065CE97A683649C9D2C" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_A69F87883AAA713E2626A683649CA720" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_20154D5636F28C448750A683649D8EBB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_CD88C46E27F25065CE97A683649C9D2C" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_20154D5636F28C448750A683649D8EBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_6CFA20DA79F0B367B0F5A683649DBC2F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_CD88C46E27F25065CE97A683649C9D2C" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_6CFA20DA79F0B367B0F5A683649DBC2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_59F6BCA258C7B1E0E805A683649D6390" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_CD88C46E27F25065CE97A683649C9D2C" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_59F6BCA258C7B1E0E805A683649D6390" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_5452E3C82261BE5D002CA683649DDCA0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_CD88C46E27F25065CE97A683649C9D2C" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_5452E3C82261BE5D002CA683649DDCA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_F7AE1D5F4864B1D67608A691B8D37F30" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_CD88C46E27F25065CE97A683649C9D2C" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_F7AE1D5F4864B1D67608A691B8D37F30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_3BC26DBAF5A89F811DE2A683649D0EE4" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_CD88C46E27F25065CE97A683649C9D2C" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_3BC26DBAF5A89F811DE2A683649D0EE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_871B4FCF648A010C37AEA683649DD230" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_CD88C46E27F25065CE97A683649C9D2C" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_871B4FCF648A010C37AEA683649DD230" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_28A768F8B3B269236D8FA683649E8677" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_CD88C46E27F25065CE97A683649C9D2C" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_28A768F8B3B269236D8FA683649E8677" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_465D8208D04CB33AF42AA683649EA5F7" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_CD88C46E27F25065CE97A683649C9D2C" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_465D8208D04CB33AF42AA683649EA5F7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_D1D428E13C1691D6A02AA68364849514" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_B4D793B9AE49251F889CA6836484C48E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_D1D428E13C1691D6A02AA68364849514" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_B4D793B9AE49251F889CA6836484C48E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_BEE67BCE5F9BD76DE56EA6836484B87A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_B4D793B9AE49251F889CA6836484C48E" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_BEE67BCE5F9BD76DE56EA6836484B87A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_595ECE6E1B021DE38060A68364855548" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_BEE67BCE5F9BD76DE56EA6836484B87A" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_595ECE6E1B021DE38060A68364855548" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OfficeEquipmentMember" xlink:label="loc_ifrs-full_OfficeEquipmentMember_11A7A223B5CA9D282633A6836485FBC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_595ECE6E1B021DE38060A68364855548" xlink:to="loc_ifrs-full_OfficeEquipmentMember_11A7A223B5CA9D282633A6836485FBC4" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_MedicalEquipmentMember" xlink:label="loc_oncyf_MedicalEquipmentMember_5E5B93AC84D7AE9FA636A6836485AEC0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_595ECE6E1B021DE38060A68364855548" xlink:to="loc_oncyf_MedicalEquipmentMember_5E5B93AC84D7AE9FA636A6836485AEC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-full_ComputerEquipmentMember_9FC707BF53D133A0195DA683648620D5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_595ECE6E1B021DE38060A68364855548" xlink:to="loc_ifrs-full_ComputerEquipmentMember_9FC707BF53D133A0195DA683648620D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_E705784DBB7631ADCB2EA6836486D671" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_B4D793B9AE49251F889CA6836484C48E" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_E705784DBB7631ADCB2EA6836486D671" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:label="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_8D774DDED0389C308BBFA68364864384" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_E705784DBB7631ADCB2EA6836486D671" xlink:to="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_8D774DDED0389C308BBFA68364864384" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_C7BE54D45B0F5438F88DA683648ED27F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_80CA16A38903114E69ADA683648E41DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_C7BE54D45B0F5438F88DA683648ED27F" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_80CA16A38903114E69ADA683648E41DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:label="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_06A289ECB1C7EC7B4710A683648E0ACB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_C7BE54D45B0F5438F88DA683648ED27F" xlink:to="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_06A289ECB1C7EC7B4710A683648E0ACB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivative" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_BEA38CEC21A3DDD43B80A7434DF8DABD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_2C9D441EF9C78449D009A7B39102CB70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_BEA38CEC21A3DDD43B80A7434DF8DABD" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_2C9D441EF9C78449D009A7B39102CB70" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_ADE178556D54CBE92135A82B191BE28D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_CCC45D0C806213D735FAA82F243E9FD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_ADE178556D54CBE92135A82B191BE28D" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_CCC45D0C806213D735FAA82F243E9FD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_D6E37D1C4511E381C870A82B191B83B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_CCC45D0C806213D735FAA82F243E9FD5" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_D6E37D1C4511E381C870A82B191B83B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_E744E544A32F9709D6FBA82B191BB2B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_D6E37D1C4511E381C870A82B191B83B5" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_E744E544A32F9709D6FBA82B191BB2B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-full_IssuedCapitalMember_F9783C2C8EA2F3DBBFA4A82B191C2E90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_E744E544A32F9709D6FBA82B191BB2B3" xlink:to="loc_ifrs-full_IssuedCapitalMember_F9783C2C8EA2F3DBBFA4A82B191C2E90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_EFF64443B067F509481DA82B191CEA6F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_CCC45D0C806213D735FAA82F243E9FD5" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_EFF64443B067F509481DA82B191CEA6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_03F500BF47EDC281D4E9A82B191C70FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_EFF64443B067F509481DA82B191CEA6F" xlink:to="loc_ifrs-full_LiabilitiesMember_03F500BF47EDC281D4E9A82B191C70FA" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_63E4E187543C6A74CC63A82B191C5BA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_03F500BF47EDC281D4E9A82B191C70FA" xlink:to="loc_oncyf_WarrantsMember_63E4E187543C6A74CC63A82B191C5BA6" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IncomeStatementLocation1Axis" xlink:label="loc_oncyf_IncomeStatementLocation1Axis_B5FFDCE386BFDD02EEAEA82B191D056E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_CCC45D0C806213D735FAA82F243E9FD5" xlink:to="loc_oncyf_IncomeStatementLocation1Axis_B5FFDCE386BFDD02EEAEA82B191D056E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IncomeStatementLocation1Domain" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_ACEB9811AF54CD105357A82B191D6C7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_B5FFDCE386BFDD02EEAEA82B191D056E" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_ACEB9811AF54CD105357A82B191D6C7F" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_OperatingExpensesMember" xlink:label="loc_oncyf_OperatingExpensesMember_3D7A1FFCE56AA07AD72BA82B191D8A8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_ACEB9811AF54CD105357A82B191D6C7F" xlink:to="loc_oncyf_OperatingExpensesMember_3D7A1FFCE56AA07AD72BA82B191D8A8B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockAxis" xlink:label="loc_oncyf_SaleOfStockAxis_10B7706FE6FAB7ADAB3FA82B191DF7AD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_CCC45D0C806213D735FAA82F243E9FD5" xlink:to="loc_oncyf_SaleOfStockAxis_10B7706FE6FAB7ADAB3FA82B191DF7AD" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SaleOfStockDomain" xlink:label="loc_oncyf_SaleOfStockDomain_C052C5EC0CF62FAA04FEA82B191E2F43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_10B7706FE6FAB7ADAB3FA82B191DF7AD" xlink:to="loc_oncyf_SaleOfStockDomain_C052C5EC0CF62FAA04FEA82B191E2F43" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesUnderWarrantAgreementMember" xlink:label="loc_oncyf_SharesUnderWarrantAgreementMember_3160BED89BAB15529014A82B191ED404" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_C052C5EC0CF62FAA04FEA82B191E2F43" xlink:to="loc_oncyf_SharesUnderWarrantAgreementMember_3160BED89BAB15529014A82B191ED404" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_CCC45D0C806213D735FAA82F243E9FD5" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_IssueOfEquityShares" xlink:label="loc_oncyf_IssueOfEquityShares_B281460633254AAF5038A82B19237F6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82" xlink:to="loc_oncyf_IssueOfEquityShares_B281460633254AAF5038A82B19237F6E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_SharesIssuedPricePerShare1" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_9960F02FF2FC1EF0DD87A82B19247CB0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_9960F02FF2FC1EF0DD87A82B19247CB0" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_BC9D6CC770E21432873AA82B19240CF5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_BC9D6CC770E21432873AA82B19240CF5" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_CommonSharesPerUnit" xlink:label="loc_oncyf_CommonSharesPerUnit_226597899CE2924DBC61A82B1924168E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82" xlink:to="loc_oncyf_CommonSharesPerUnit_226597899CE2924DBC61A82B1924168E" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8A40CB8EA62BC4489169A82B192412D2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_8A40CB8EA62BC4489169A82B192412D2" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2" xlink:label="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_E131D8C01E738CAACDC1A82B1924DE66" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82" xlink:to="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_E131D8C01E738CAACDC1A82B1924DE66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_C2B6D94C0EAC6EF44797A82B1925C298" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_C2B6D94C0EAC6EF44797A82B1925C298" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ProceedsfromWarrantExercises1" xlink:label="loc_oncyf_ProceedsfromWarrantExercises1_7AE00932F539022CE002A82B19255330" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07B0AFC02AC2250BD3AFA82F244A6A82" xlink:to="loc_oncyf_ProceedsfromWarrantExercises1_7AE00932F539022CE002A82B19255330" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationOfChangeInFairValueOfWarrantDerivativeDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_23ADE398C3028A3F183DA8273882B703" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_90C741990C833EE52880A82E2E1CDF0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_23ADE398C3028A3F183DA8273882B703" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_90C741990C833EE52880A82E2E1CDF0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_703C9EDE055DE686DCADA8273882B595" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_90C741990C833EE52880A82E2E1CDF0D" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_703C9EDE055DE686DCADA8273882B595" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_9633A20E079022843BA6A8273883D242" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_703C9EDE055DE686DCADA8273882B595" xlink:to="loc_ifrs-full_LiabilitiesMember_9633A20E079022843BA6A8273883D242" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_BD3A344288552D465C7EA82738837F61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_9633A20E079022843BA6A8273883D242" xlink:to="loc_oncyf_WarrantsMember_BD3A344288552D465C7EA82738837F61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07A7659EA50AED5637DBA82E2E2A7289" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_90C741990C833EE52880A82E2E1CDF0D" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07A7659EA50AED5637DBA82E2E2A7289" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassOfWarrantOrRightOutstanding1" xlink:label="loc_oncyf_ClassOfWarrantOrRightOutstanding1_2F08EBE178AD77F606CEA8273883DB91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07A7659EA50AED5637DBA82E2E2A7289" xlink:to="loc_oncyf_ClassOfWarrantOrRightOutstanding1_2F08EBE178AD77F606CEA8273883DB91" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_E8ABA4A793BF342E727BA827388433C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07A7659EA50AED5637DBA82E2E2A7289" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_E8ABA4A793BF342E727BA827388433C8" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassOfWarrantOrRightOutstanding1" xlink:label="loc_oncyf_ClassOfWarrantOrRightOutstanding1_CCDE6B00338E501AEC2BA827388473E0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07A7659EA50AED5637DBA82E2E2A7289" xlink:to="loc_oncyf_ClassOfWarrantOrRightOutstanding1_CCDE6B00338E501AEC2BA827388473E0" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsAndRightsOutstanding1" xlink:label="loc_oncyf_WarrantsAndRightsOutstanding1_CA56ECA0FB35CDD68D24A82738846B12" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07A7659EA50AED5637DBA82E2E2A7289" xlink:to="loc_oncyf_WarrantsAndRightsOutstanding1_CA56ECA0FB35CDD68D24A82738846B12" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_ClassofWarrantorRightWarrantsExercised" xlink:label="loc_oncyf_ClassofWarrantorRightWarrantsExercised_6D9D819648BCB5AA140CA827388446CC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07A7659EA50AED5637DBA82E2E2A7289" xlink:to="loc_oncyf_ClassofWarrantorRightWarrantsExercised_6D9D819648BCB5AA140CA827388446CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_B00C2E010090C1591502A8273884A731" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07A7659EA50AED5637DBA82E2E2A7289" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_B00C2E010090C1591502A8273884A731" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_GainsLossesfromForeignExchangeImpact" xlink:label="loc_oncyf_GainsLossesfromForeignExchangeImpact_4F2E06DD9B43119FEDF3A82738857339" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07A7659EA50AED5637DBA82E2E2A7289" xlink:to="loc_oncyf_GainsLossesfromForeignExchangeImpact_4F2E06DD9B43119FEDF3A82738857339" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsAndRightsOutstanding1" xlink:label="loc_oncyf_WarrantsAndRightsOutstanding1_F179964C1071317B05CBA82738857C97" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_07A7659EA50AED5637DBA82E2E2A7289" xlink:to="loc_oncyf_WarrantsAndRightsOutstanding1_F179964C1071317B05CBA82738857C97" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_7C0F5B83382D92335ADCA82B18EE06AF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_FDEF8BFA9633D77700CBA82EC244B484" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_7C0F5B83382D92335ADCA82B18EE06AF" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_FDEF8BFA9633D77700CBA82EC244B484" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_6B3D91CAB4378C65FC19A82B18EF8097" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_FDEF8BFA9633D77700CBA82EC244B484" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_6B3D91CAB4378C65FC19A82B18EF8097" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesMember" xlink:label="loc_ifrs-full_LiabilitiesMember_513E2D56FF8009F9F166A82B18EFBF4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_6B3D91CAB4378C65FC19A82B18EF8097" xlink:to="loc_ifrs-full_LiabilitiesMember_513E2D56FF8009F9F166A82B18EFBF4B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantsMember" xlink:label="loc_oncyf_WarrantsMember_83C96C5B008310387E99A82B18F0F23A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_513E2D56FF8009F9F166A82B18EFBF4B" xlink:to="loc_oncyf_WarrantsMember_83C96C5B008310387E99A82B18F0F23A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_58D72643E95A2B1A8F10A82EC24A16CB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_FDEF8BFA9633D77700CBA82EC244B484" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_58D72643E95A2B1A8F10A82EC24A16CB" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_FairValueofWarrantIssuedPerWarrant" xlink:label="loc_oncyf_FairValueofWarrantIssuedPerWarrant_9F0875F7D157F1D9CC22A82B18F55BC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_58D72643E95A2B1A8F10A82EC24A16CB" xlink:to="loc_oncyf_FairValueofWarrantIssuedPerWarrant_9F0875F7D157F1D9CC22A82B18F55BC1" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_WarrantIssuedUnderlyingSharePrice" xlink:label="loc_oncyf_WarrantIssuedUnderlyingSharePrice_481D127FA0C5099CDB46A82B18F5BF15" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_58D72643E95A2B1A8F10A82EC24A16CB" xlink:to="loc_oncyf_WarrantIssuedUnderlyingSharePrice_481D127FA0C5099CDB46A82B18F5BF15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_9EFABCDEA5A1908F17DBA82B18F614FF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_58D72643E95A2B1A8F10A82EC24A16CB" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_9EFABCDEA5A1908F17DBA82B18F614FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_6662CD1BCC5EA0CB379BA82B18F69C49" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_58D72643E95A2B1A8F10A82EC24A16CB" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_6662CD1BCC5EA0CB379BA82B18F69C49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_1E1D9DB0CE06E872BC16A82B18F6559B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_58D72643E95A2B1A8F10A82EC24A16CB" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_1E1D9DB0CE06E872BC16A82B18F6559B" xlink:type="arc" />
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DividendYieldPercent" xlink:label="loc_oncyf_DividendYieldPercent_F00887EB6C3ABE26C9D2A82B18F6A249" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_58D72643E95A2B1A8F10A82EC24A16CB" xlink:to="loc_oncyf_DividendYieldPercent_F00887EB6C3ABE26C9D2A82B18F6A249" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables" xlink:type="extended">
    <link:loc xlink:href="oncyf-20191231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_AAB19AC7D2F356B268A4A7434DDD8C12" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_F5109232D1E0D3B268FFA7AEBA33339C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_AAB19AC7D2F356B268A4A7434DDD8C12" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_F5109232D1E0D3B268FFA7AEBA33339C" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>eysignaturea25.jpg
<TEXT>
begin 644 eysignaturea25.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !( .(# 2(  A$! Q$!_\0
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MYS>?M%?#2S\/VVMOXUT=].NC*MO)'=*3,\6/,11G)9=RY7J-PI?#/[0?P_\
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M<<K#*H2#]YAR .HZ9JUX=^+&@>+O%D.B:-<KJ<<^C1ZW!J5JZR6TL#S/$ K
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E^H&,1^<P'7:.GISR<9/-%% '3T444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>oncolyticslogotaglinebluea05.jpg
<TEXT>
begin 644 oncolyticslogotaglinebluea05.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP"$  $! 0(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(!
M 0$! @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" O_  !$(!H\/  ,!(@ "$0$#$0'_Q  ?  $
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M9(2CU'7BI/_:  P# 0 "$0,1 #\ W^
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                       "&H!$
M$JN0EVP"H"GTGF*:J 7!*KD*( *NV@VT*.HU0 J;9#:4I[:$-M +%7:4;2E+
M;\RD-I>SX 9M^+HJ[2D"GM+V? -I>SX +?BZ*@)-5[$([_,!;\71,"7?YB&_
MS 6_%T3D=5*6TO8-I>SX +?BZ*VTHVE*.TO9\!';[4 M^+HJ[2D=M2CMH-M
M+?BZ+C;&VA1VD&H,%='H3:EN "X!;DZ/\P!5!3Z3S$R/0 F!#4B
M
M
M
M
M
M
M
M
M
M
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MXR*A%'*4MI4XH11X%BNCR9'(40#!< H:J3(\ J@E1R*3
M
M
M
M
M
M
M
M
M
M
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M@JC4IZ*GG(H_M L5D>5$<A0U !< I(]2='H 3
M
M
M
M
M
M
M
M
M
M
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M)HOF([T\Z ^D8JW J(I51Y;H]"<'R+C4%!%)VO[0"H""*1
M
M
M
M
M
M
M
M
M
M
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MB]@,W_%BJC]2<I:HO'B-I?2@/I*ULK%9':%5':ENCM28'R+@%)'E1% (@
M
M
M
M
M
M
M
M
M
M
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M"HCNW>#-RMJ"DB=B^HF1W;N L5T?VE0MR9KM 8*P)4=J3
M
M
M
M
M
M
M
M
M
M                                             IN?U $SG:>DI*I
M@JZ $2FKM=R#37CU$JJG4#EDN_LX$>'G)5<2JY$)->M?8##9-M;]$)51$\ZD
MBN]2%!SM08*KI>_44574E5="@YX!55_847/*3G:E%S^P JN>45D*+I"B]_6
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M1:XK(H
M
M
M
M
M
M
M
M
M                                                          (*
MN@5="BJZ@$5=J2@DUUX !7=A*FB;U]@543@4U4').W F52GKKP]I*N_CN)7/
MW>8'$F5=.'K4HN>2N=J4G.T )E7M*2O*;W^TH.D *BO["BKBDYY0<_7U %1[
MRBY^[>4EDW*6SY._6 5W2E!TGJ+=TNA;.F +E9>_66SIBW?(45> 5W2%!9"@
M^3]9;OE[_0 73GH4'S%D^8H/E +QTQ068LUD[J4G2=T +MTI0VRT6?0H.FU]
M'?OP +YTGH*#IT+%TB]NA363UJO5U\43AQZ_1VZ!?B[2^5F5;F]WJR;3]!?+
M-WW_ #%-9%7BB>E2TZ14X)ZTWI[4W?"?S&*\9VBQ4<EROMVMEEM\>O25]WN%
M);**/1-5VZNNF@IVZ)OWR:Z><YTZ;F]V,92;X**;^9._>LCYU*L8QWI2C%?I
M24?EE8_K%D7K4D<].M3RTS;YYKDY8.Z1M3F+;[Y51:HZDPK3U>(9-4W-^O4,
M2T;F.5-$?'5/;IO541%/,7-;PFW!M&LL."\M<17][55(ZF_72@PY0RZ[VO9X
MM#>K@Q$7559+0L<NFRUR(NVFR8#4W26)_)X2K9NR<TJ4?VJCC$U?2.O&B<+=
M5<=0WEQA3;JS7?""<OD-H3I=.!)TBKNXK[?@-%W,KPCO/J[NE9A^UX P?3.1
M>B?362OOMUC5=R+)67JZRVN;83[%$P_$FJN5Z2:M2/X-S$YUKE%8HZ5MTS:Q
M1'#/KTM-:)**Q4KD54W)!9Z6B8B-5-6HU&HB>3H;7A=DVD)I.I5P]'K3E*<E
M^PG'_N-*QNVC1=-M4J>)KM<&H1A%]OAR4DOU3I 7.]TE$B.K*NFHVKO1:JHB
MIFJG:BS/8BIYT4^>L>\L_*/"ZO;B/,[ ED<Q51S;EBFSTKD5KD8K=F2K15=M
MJC$:U%<KE1J(JJ<SC%6:6)[ZKG7O$N(+QM*JN2Z7JYW!N]=5:C*JJD8UJJNN
MB-T;P\H_/HJ:./<R.-B)PV6(WJ_ZNRB=2::::[S8L-L<INW38V3[*=-17IE*
M5_0K=O+5\5MTFG[!@(VZYU7+Z$8KY?\ 7HJXPYZKDPV17)4YK6RL5JJB-L=E
MQ1B/:5."-?8;'<8415W(]94CX[3T;J?.F(O")^3C1(J4E1CR][+7*BVS!TM/
MM[.RJ-:E]N-DT=(KG)'M]&UJL59'1MV-=#L'N4=D^C5X\\1.V7C1@GYHQ^TU
M^OMITH_R=+"T_P!2=2W[4T;JU[\)DRDB<[W.P)F+6HU9$8ZKBPY;E=L[HG*V
M.\W%&+(B;3VH]Z1.54;TR;S\TKO"?<*-72FR@Q-,BM5=J?%5H@T>NJ(FPRVU
M&TQ-$77I&NU<OD:&GH#T8;,]$+^IJOOK2^Q)9]QY=3:WIJ3OTU&/O*$%\[D;
M:%5X3]'T;N@R@FZ73ZVLV*8EB1R)N5Z,MB2*G#7>BJG!4/Y_ZI[N7X)*+_.2
M;\Q-4\'8CLZT0O\ TS??5J_Q'4>U'3?]K_\ U4_X3:Q^J>[E^"2A_P Y)_S$
MR]O\)\5&+XWE"KI-M=E:7%#61]'LMT1R36YS]O:V]51=G9V41-=34W!E[.]$
M/_TO_P"RI]LF<EM3TW_:_P#]5/[(HV_K9X3_ (<5L25F3V(&O_\ 724N*[6]
MC5\K18HIK2QRHK=$=M3(NNNBZ:'Z+9/":LKY$;[H9=8]H]SMKQ6?#]PV7(Y4
MC:Q7UMO54<S>YWD]$J[&DFG2+I> Z\MF>B'_ %$U[VK)?8S[T]K6FXN_3TY=
MDZ46OD:-ZO#_ (1QR>:Q6I54V8]H7K?7X3HIV(NRCM46SX@NDJMVE5F^-%7B
MK&IJJ?0.%.?-Y+UV<V-N92VZ9VNL=ZPGC.U-:B(J^565-@;;]51JZ(VM>KG*
MUKM-I%.>F#SZNR?1C\26)I]U12^246CTJ&V?2L7>I#"U/^5*.75>,[G37P7S
MA&1N(GMCLN;F7U?,_32FAQ3:6U2:KHW;I9*ED\:KHNB/C:JZ:Z'U#9\8VJX[
M"V^Z6ZNVT1S/$ZZEJMM':;*M2"5ZJBZIINWZIVG*$DC:]-'M:Y..CDUU]NNG
ML^ _H,.8HNEF=MV:Z7*T/UU1]JKZJW.1VJ.VMJCEIW;6TFNNK=%1':JNFGBX
MG8]2=^AQLT^JI3A+T[CB_D-APNW.M?V;1].2_P"%6<7_ /L4D_2=7]7*FY4T
M7SIH.EZCF99><XMGMA5&-L6:^-:6)FB)3SWB:X4SD:W1B207'QILB-151=O7
M:5=K=O1?N_+GPA+E'6)86W&X8-Q?#'LM<S$>%64\SH^"IXUA:NPW+TNF]LTS
M:G1Z(^1DS=J-^O8S9'CX?D:U"MW[]+N7A1:7G:76T;/@]M6CI_E\/BJ#Y^#3
MJI=?BU%)KNA?J3-^':3T$Z2+U+P-2_*OPGB%>CCQQE140Z:)+6X1Q!#5](O^
M&VVWNFH5IVM7BSW6K%<F]';2[)Z:Y2\_#R<L3]'%5XJK<)5#D3:CQ19ZZBIX
MW+IHQ:ZFCJZ5SE775S51F[553B:GC=2-*8>^_A*LTO;4DJD>_>@Y+TV-QT=M
M!T/BDNCQU*+?M:V]1EW6J*-_-='L^V1>Q%7TE1)5\_?T'XUE;GK@O&U,E5@[
M%F',3P*SI%6Q7FWW22)G6L\%'42STRM_A-GBB<WK0_5E?HNB\>.G7V)N_0:S
M.A.#W9PG"7Z4-WY&U+SV9MU&O3J+>IU*<U^C-/Y4G'Y491LY69+ZC#H].ZHI
M4;)V*?(^M_Q_L9KI/056RF%24KLJ._?](!F6S%=LQATE3T%9) #-,F*[9$4P
MC92NV8 S22>LK-D_48ALO?K+EL@!EFS=I<-EW=1B4?ZRJR0 S+7\/B*[93#M
ME+IDH!E62%=KS%-D["Z9)N ,DUY6:_V&-:_1-2NU_8 9)KRLCM3'-D[]17:\
M OT>5FN]A8H_M*K7: %WKIYT*B*6['E1.U "ON7TD4=IQX%%%]I41>T&;E8B
MBZ%+AZ"=% :\Y<([4B4$70JM=J#!,
M
M
M
M
M
M
M
M
M
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M$UZW5TE1M*_5&^ZO,D01$ZD3NNOQD0#TSR0 !Z?2/,O1\P  ]'H08
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MJM<BDQ23?O3BA.UVH,M?[%9KRH6Y4:_J!Q*@
M
M
M
M
M
M
M
M
M
M              !(YW40<[J*8 5257:!7:$B;MZ\>P')99\>P>=?42JO:052
MGQ] .)'55X$BJG5N[0YWL+9SM0"97]A25VA*YY;N?V $SWENYY(YY;ODT )W
MN+=TA(LGJ+5[P"HZ3L+=TA2?*63Y0"L^4M72%)S_ &%%TB( 5'/+=\I;23%H
MZ4 N))2T?*47/+5\N@!<ND+5\R(6[Y%[]9;.?V)O +ATBKVZ+UH4%>G7W^,_
MG<3XJMMFH:JZ7FXT-JME#!)45MQN573T%!1TT;5=)/5UE7)%3P0QMVGR22R,
M:UJ(J.137SY8?A$.7&$5J;3E?1NS'O+.EC6\))+;\)4\K=$1\5<Z/QR\-1RJ
MYLE%%XM*C7)%5R1RM>>QHC0&+QL]S#T:E5OVUE&$??2>44EPE=WYI'B::UBP
M6CX=)BZ].DN4)/PY=71TX^'-OJ2LC8=N%R@I8)JFJGAI::GC=+/45$C(*>")
MB:NEFFE<R**-O\)\CV,1.*HAXP<K;GV\E,M'5%LLM759E8EA66);7A22!+73
M5#%V4CN>)*G:H*9O2(^.1MOCNM="]CG/H71NC>FG1RIN<3SBSCGE_9OC*NEM
M+WN?#A:S+[C87HVKM-Z..UTCMJL1&N<B5%WJ;A6N1ZM?4NC1K$^)6HB(B(FB
M(FB(B:(B=B)V$P:#V24U:>/J[[_-4KJ'#A*;5V^M)*/4V07K!MKJRWJ>C:2I
M1O95\0E*I;KC3CX/<Y2E+FTCV;Y4O/K9Y9BMJJ&TW.FR[L%2CF>Y^$EE9<GT
M[EU;'48@JD\?<Y4:Q7R4:6]4E1SHT@:O1)XX5]?45=3/6UE1/65M7(L]765<
MTM5654SM[I:JJG<^>HF=_"EED>YR[U<NY2T!*^CM$87"04,-1I4HVLW!6E+W
M[S;\[\Q#>E-.8S&U.DQ6(K5IO-=)*Z7<E:*[-V*RXL=_1NTW=F[< #T;GDV
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MW4 5
M
M
M
M
M
M
M
M
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M7:[4 N44J<?26R=O=2HUVH!7:[J4G*6NOI[29KNI0+%=KNTJ%N5&OZ@"H
M
M
M
M
M
M
M
M
M
M                        2N71"*KH454 @JDKG:$570I^=?4G &4/.O'J
M0D<[K"KVE)5]@,,CKUKPZOTE-[_T(0<[0H:@!5[2@Y^X.=["V<X BYY;/?\
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MT7=Y_F*B* 5FN)REQ37K0G:[4&;<RNUQ.6Z*5FNU!@F
M
M
M
M
M
M
M
M
M
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M% :\Y<(NI$HM70K P
M
M
M
M
M
M
M
M
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M=="DU>KK0JHNNY?4#*?H*I.UW446KU$X#5BX!(QVI.#
M
M
M
M
M
M
M
M
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MFE!SD_,F8LR@2Y8PP/)6XSRWB<^IE1(>DQ-A6E<[>R[PP)I=;?3JYJ>[5)'
MZ.!46X4,2Q2U,U@M4MH]#&[M#%)8?$^*I7?1U9=E\HR?N>%^#M8K-KKLKQ&
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M9%+=%U)VJ 5@
M
M
M
M
M
M
M
M
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MW %9NY="H4DW[NOJ)VNU!GM*[%)R@BZ%9%!@B
M
M
M
M
M
M
M
M
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M6KV>;U&<?%UH63X@#"/B3J+&1O:9Q\99R1:]0!A7L+9[._?>99T:IWX%H^,
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MTLT4N&._2 7"*5.&_M*#=V[V%5%Z@$5B=CNHHM7J)P&7 )6KJA,
M
M
M
M
M
M
M
M
M                                                    "F]2=5T*
M&H *:;UU["+NSM)7;D1 9OEP)7*4M>OV$577=[2F]WLZ@8*4BE!ZDZJ6CU *
M;W>PM7O*CW? 6;G:;P"G(\L9'E61Y82O *4KRR>[V%1[BQDD *<LAC97E2:0
ML7NZP"G*_0QSW\5^,JRNU7OO,%>KS2T%)55]=414=#14\U765=0](X*6E@8Z
M2>HGD=HD<44;'.<Y=-$:NF_<$FW9<<E;GO-V22YAR45>7"SE=VW=Q>,V^S,^
M?^5ERI,,9.X%OF/,5SJV@M-,Y:6@A6/QZ]W25%;;K+;8Y',;)65]3L1M<]S(
M*:/I*RJEAI8)I6<X'E6<J'%&<6.+OCO%DZ.N%RD2.DH87N=166U0.<E!9[>C
MM%2EHXU7671'550^:I>B.D5$^T^=IYQFNSZQ[-#:JB:++C"M1/1X1H==A+F]
M$Z&KQ17QHJ[53<G,5+=$]52AM:0L:C*JHKG/\H"S.S_4]8"BJ]>"]55H+>_X
M,7:2IKJE)>%-KNZRI6TW7=Z2Q'J:A-^HZ$FE;)5YQ=NF:MG"+\&FK\F^H  D
M<BSMYOB^OS    !._P 7T? ?TV"\&7?$=WME@L%MJ[O>[S60V^U6R@@?45E;
M65#D;'%!$S>J-WR3R.5(:>!LE34/BAA?(WC.:BG*3M&*NY.R22XMWY+C)\D<
MZ=-R:44VW)12BFY.3X145=MNZM8_I,H,H<28]Q':\)81M-1>L07BH;3T-!3-
MWJO_ *R>HE7ZW34=,WZ[5U<ND<$6T]VKDC:[?WYL3FR</<G[#*/F\5O.8EZI
MF?LHQ,R)=B)KW=+[AV1TJ)+!:*5R-8YZHR:Y2QK55+(E?'30?S?-7<UU8\@<
M/K<[G%377,^^T;(L17YKW3PVRD<YLJX=L72(UL%OAD:U]=51L947>JC;)4R.
MIX*&&F]<F-["N>OFO4L9.6#PDVL+!^R367323M:_YM<5'F[-]2M/LVV<K1].
M.-QL(O'37L<':2H0>=URZ3DY+@LES;,;U?"7<<??M(,9["\9'KWT(M[LEU+K
M)>ZWS?/LZ@V/J^ O8XM/F(QQ\"]CC )61EZR,GCBX%\R/3Z "G''UETQA.UG
MZB[CC )8XRY9&5F1%PU@!39&7+&>8JMC*[8_6 4T9P+AK/45&,]I6;'^H I-
M9U:%9&%9K"JB %-K/U$^A51A51FGF **,*C8^ZE5$[/;W^@;':H!)PXDZ)V)
MIZ2HB=2$VSZ@"DB+UK[";1.Q"=%1/.3IKU)H#ENVXE)$UW$^RG:1V5[2.P@,
M9?A?ZD-$[2&J)Y^_H)T:A,#-UU7^0I:^;X"._L0J "ZZOE*>B]B#1>Q/@*@
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MT(U*34J4XJ4))W3B^:*D8O#5*-6=*K%PJ4Y.$X25I1E')J2^;K68 !]CK@
M']+@[&-UP]=[9?[)73VR]6>NIKE:[C32.CJ*.NI9&RT\\;V^4BM>U-I/L7L5
MS'HK'.1>AOS6G.)VO/\ P&RMJ%AH<=8<Z&W8RLS5:W2H5G][7RW,1=9+3=HV
M](Q=&NHZUM502-V8(9ZGG1GT]R/>5GBG)7'=HQWA63;J*)Z076TR2/918ALL
MSV>/V>M1J.V4J(V[5+4I'(ZBK&0521RMCDIYM+UTU4AI+#6BDL32O*A/FV_&
MA)Y>#+CGDI9Y9F^Z@ZYST1BO";>$K6CB*>;2:RC5BL\X<TLW&Z=[1MU F/\
M;U&1ADU/G[D\9^X;S.P=8L<82K$K+)?J1M33;6RE333-\BKMU;&U7+%<*"='
MTU7#KJR5FJ)LN:J_ND3NOON*L5Z,J<Y0FG&492C*+R:E%V::>:S+C8>O"K3A
M5IR4H3C&49+-.,E=-/FFN#,W$XR$4AA(WZH7T4A\CZF=8[<BEY&\Q$3^'?U%
M\QWL ,Q&\OHWF'B=O+Z-WP &6C?J7;'&,C=V%ZQW6 9)CBNU=Y8,7J+MJ@%Z
MG#T%1%+9B]G$K\%UZE *RKNU3B5$4I,7>3-W+H#EQ\R*S5WE8MRLUVH.),
M
M
M
M
M
M
M
M
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MS#R]FKPOB)Q?Y*BWE!_I5,T^:CWHQ"K\&G'T(GMT1$U[$X(0 + _)W%9>_,
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M1T O^+(EV4(DZ,]1,C$!@I$^PI5 !31A'80G !+L)V#83L)@ 2["=@V$["8
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M*7+'?  7#7:E7BGG0H*O65F*#*94:NI4:NA23<NG:3@P7 )6KN)@
M
M
M
M
M
M
M
M
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MW[# (LC_ %E]''W[!%&7S&:( 1C9YB[C9^D@QA?1Q $8HR]9'YA&SS%VQOM
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M7109Y>C[2LQ2L6Y7:NX&"(
M
M
M
M
M
M
M
M
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MD)MG7C["9&^TF!EV\_6"9&ZD485$30'$@C="8
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M$JHI48I19UH3HH,%P B@
M
M
M
M
M
M
M
M
M         $KEW$Q2>O4 2%-=Z^@G5=Q3ZE7M!E?CSHE<N\I=JDSE^$I.=N]'
MT P47J6[U^ JJO6I:2.^$ HO<6DCBL]=Y82.W]^P HRN,?*XN9'=_,8^5P!;
M2*6,KMQ<O=UF,E> 6TK^)CY7%>1WZ3'3/U^+T!A%L]_6>='.B<LN'(_*&_XI
MA?&N)+EIAS!U*]6JL^(KI')'!4R1*YCGTEGIFU%WK4:]BNBI&T\4B5-3 CO1
M&1>_Q(OF7K-"#GVN6>W,S-R?"MGJUGPMEE)6V"G='(JP5V)>E2/$E8Q&N5KV
MTM3$EF:_K?156RLD#XGNW+4;0'J_'THR6]1HM5:W5NKA!^_:M;L-%VA:R?R;
MHZK.+2KU[T*"OGO33WIKG[&EO)]=EU)^)U?<)ZN>>KJIY:JJJIIJFJJIW])-
M4U-1(Z:>>5^[:DFE>^21=-5D<]RHFNB6@[]^_P .JJ+6J*2LDDEP2X6Y6\Q3
M)R;=W>[XW=W?G=]=^( !DP "#G(B*JKHB)JOH3CY_,FB*JJJ;A^/QW\!^.KS
M^;B?9'(*Y(=SSOS.P_@2A26&WU$BW'$]TC:JLL^&:!S'W.L<Y?)2>9'1VZW,
M7[9<*VFU3HFRR1=)?+_ EIPQ9;5AZQ4<5!9K)0TUMME%"B-CIZ2DA9!$Q-E&
MHKD8Q%>_9;MOU>J;>KCR7YE'D)?W(,K::]7NA\6QUF##17R_-EC1M5:K6YCY
MK#8)7*NVR6BI:CQNX0.1B4]QJZJFT>Z)SY/9QK?9WT^DK%M$UE]7XN5*$KX?
M#MPIV>4Y)^'4:3X-I1CV0OS+=;+M4OY.P2K55;&8M1G4DUG2I\84HWX-)[T^
MMSZDBI&TO&1[D)(F>WOWT+Z&/OV$>7?-W^SL).Z_QER_U*T3-"_B84HHS)11
M@%6&,OF-^ D8TNXF %:-OZ2_8SOV%.-FA>1L )V-X%XQOFWDC6%VQOM )F,+
MF-I!C2X:WJ (M34KL9N\P8SV%5$U]'4@!!$U]'8540@3::\.P&4B;S)P[2=$
MT((W0G1-09;ZN! JM;H3(FA$'$
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M#%+MJ[@"]3>GH*B*4(W%5J[] "NJ[T7M*A23@OM)V+N!FV5RNQ2<H-7>5P8
M
M
M
M
M
M
M
M
M                                               !052JY=Q1 )']
M2$CNPF3CJ2.7B#DUDBGKO]!;R*5M=WG4MG+O!Q*3UZBR>O$N)5XEF]0"@]Q9
M3*7#W=?L,>]W$ MYG<3'2.+F9WT%B]=X!:S.,7(XO9G]_C,7([X0"VE>8U[N
M*\.OU=1<SO,?(O?XA>W?P7G^[CZ0U?Y_1_H>?_.:\KJ/);)_$^+8)HV7ZIA]
MPL*1N5-N3$-U9+#221QJYJR>YT?2W.5&M78CI%DD3H44YL\DLCW.?*]\LLCW
MR2S2.5[Y97N59))'KY3WO?J][WZO>YSG.57:FP1X0[RLUQEFI;\NK94J^PY:
MT;FUS6/UCJ\7WB..:X2/:FJ:VFW>*6Z#:\ID\UT<U713M<FOH6>V::#]1Z/A
M5E&U;%>R3;6?1\*:]%Y<O&MRN5%VL:P^KM)3H0DW1P=Z,;/+I+IU)+M32A?/
M.%T\[  $@HC$  R$/AX[N&N[YOLMW8>R7,D\B-F;N;$=WO-'XQ@[+GQ#$%[2
M1J^+5UVEGF=ARSR;+D63QBIHZBX3QL31M-;7-G562MCE\=J*AGJIH::EA?45
M-3-#34U/$BNEGJ:B5L,$$3415=+-*]L<;=-[W(='OFQ>1O#DCE+8<*S00MQ'
M7I[OXQJ8T17U&(;C%$L\+Y$1'2,ME/'!;*=':]'#2HQ'.1%>[0MH>L/J' RA
M"5J^)O3I6:3C'+I)I9\$]U<,W>^1).R_5;^4<?&I5C?#86U6JGFIRSZ*'+C)
M*3X^"LUF>A+$TX;NI$W::(N[31$141----6JFBHNFB)>1MZB@Q-Y>L;\)5UO
MKMZ"W]O0LDNPKQ-U,C&W@A2B87\3.!@%>-ADHFZ(48H^_P Y?,;[$ )XV_"9
M&*,H1L,DQH!.QI>1,[26-O?T%VUOP $[&_H+IC?:2L:73$W $40N&,]I+&TK
M^9.'6H!%%1?5U%5K=?02HA/YD]8,I#CN0J(F@1-"9$ ;_'6$34K(F@1-"(,
M
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MT4NV;TT *S2=NY="BU=4*SEX*#**A71=2AJ5&+U P5
M
M
M
M
M
M
M
M
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MQO)=,;["_B9P+>)O?SF3A8@!<1M+V)G?SE&-/T&0B8 5HVE]&THQL[]I?QM
M*C&?H+MC/TDC$ZRZC8 5&)UE=J:DK4WZ<"Z:W=Z.H ::>GXBHU-$")UE5$TW
M_  .&[K)VIH2L3K*B RWR";]Q71-"#6Z$P,
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MHW%TQ=X!=)N70JIU^TH:\%[-Q78N\ J,7<5&KO*2;E5"<&6N'<7 ((NJ$08
M
M
M
M
M
M
M
M
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M$: %Q&W]!D8VEM&W]!?QH 5XFE\UO44(4W:EZQ "K&WX"[:FGK*;&^PN6)J
M3QL[^8K:;].I"")HGIW%1J:( 3-0GTU] TZNOK)T30&5^/E(E1C>LE:F\K P
M
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MB>8:-=WH,E"[=H5V+1&8B4R<;OI0PL;OA,I"[AWX@&6B7YC(QNU0P\;C)1.
M,HQ>_M+^->'G,9"[M+]B[@"_C7XR[12Q8I>,7< 7K=Z*A4:O MXW%9O6@!5<
MO7U[_@*Q1ZE\Q5:NX&?]/M*S%W$Y28N\J@P
M
M
M
M
M
M
M
M
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M$T?AJ/!JFI3Y7G+PIO\ :;*/:Y:6]6Z3Q>(O>,JLH0[*='V*"7ZL4^]OAP
M-@-9   /V/D[Y*W',?'F$,!VIKW5F+,0VZRI(U$<E)1U,[%NER>W<YT%JMC*
MRXSHGE]#12+%J](]>H3@_"E!8K5;;):H&TMLL]OH[7;J9FFD-'04[*2F9NW.
M<VGB:CW_ &3WZO?Y;C3;\&[Y.;;WF!BO,FLAVJ7!=JCLMJ>K46/W:Q"U75$J
M:M56S4UJIY6,=&Y-&U4S951LR--TAC>HKMM7TPZN,IX56Z/#4VIVYUJGA?\
M;#<3[;WX%HMBVA%0P-3&27AXR=H/JH4KJ+[I3WVGP:W2XB;P]I>1-U4H1IW\
MQD(&? I%!,Q=QM,E"TM(FF2B: 7D:;B^8W@6T;?@,A"T NHF[B]C9])1C3X"
M_C3X@"LQI>1H4&(7L;4]@!4:FXNHV_2I28F\N--$](!.F]=?456]I(B=1/IU
M=@,I$S6]?P$X*C$ZP)/,G1-"( ,
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M)%+K7=Z "X9Q(L7J*;5X%37?Z087WE5%WE<MRNBZ@R1
M
M
M
M
M
M
M
M
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M1-2LA(Q.LJ P
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M  $47JZS%_QWF+_C\=Q, #)D $BN7L,-@G!+KV_J)C*8
M                  )5<1U%P1!*U5ZR&JZ^8Q=7L"<$"&UW[]^P-@F!)M=^
M_P W!>HCM=]QFYBY,"GM]GZ?F(H[OW^#M3>#)."77?H-I--0"8$NNXBAB_($
M0 9                                  !!5&TAAM+B"()-KOW4;:=T%
MQZ2<$NTA#;,@G!21_?NN[JW$=M?UF+BY4!)M]]WTDJR=G;\WM]'?3+8N5005
M>'G(:KZC%P3 AJ%\QFXN1!!"(                                ( $
M02(J^8F13%S"9$ @9,D0074B  00B                             0)
M=K@8OV?-_N+DX((1,@    $JKZ "8$-2)A,  &0                   ""
MKH 1!(JJGSD6KJ84D"8 &0 "&H%R(((I$        $NJZ[N!AL$P(:]A$R
M  "!$           $ "(                  !*J^P F!+KN)D,7  !D
M        E<J]0N"8$NUWWDPN    "57>TCK^@Q<$0 9
M                 !+M(-3%_,$R8$NTA%%,@B"55[]_H)=OCU>I?H[[MQCS
M"Y4!+M=]4^D;7?=])DQ=$P*>VOF^'KX=7H3T^8F:NH,DP)5=H05W9\0!."3:
MW?H(HNH!,"":]9$                             E7J&O?NOT@$P)&JN
MOFZB;4Q<(B"15Z^/?OU!'=_4G?=N,W!."7:[ZI](VN_Z@8NB8$B.[[^^J#5>
MZ*8O^+,S<G!(CEZR"/X_ 9N"H"1'$=KUBX)@
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MT@RE<G:G63D$X%5@,-DZ$0
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M5->W?UG):JXT?%(U>#F.;V<6JG'J.HQR0\V?V=96Y?8O67II;_A&Q5U7*O\
M#N"V^"&YKNW;[C%5+NWIN143@0?M@P"O@\2EX6[*C)V]JK5()]N=3-]18;89
MI%VQ^$;RBZ6(C'J<DZ=1KO<:2?>?2\+MYE8EX>HQ,:Z:+YE,E$O @\L$9>!>
M_?T&2C7@8B%?F^ RD:[@#)PJ9&-?A,3&IDXUX &2CZB^C7@8YB_,7L:@&1CZ
MRYC4LXUX%TQ0"[3CZ2JSLZBW_P $N&<0$3LX'@+X0QRKLQLH\KL)7S+;%=?A
M&[5^,X[=65U!36RIDJ*%;95S+3/9=:"O@1G2QLDVF1-D1S$1'[*JB^_+>*FL
M%X5']QG _P","+Y'KS9M3:$*FD\%"I"-2$J\8RA.*E"2::M*+R:[S5-?<14H
MZ(TA4I3G3J0H2E"=.3A.+33O&2S75D:PG[=ORK_PVXD_HC!W^[1+^W;<J_\
M#;B3^B,'?[LGEH"T"U<T?E_,,%_TM#^ J#_XKTI_[CC>?_J:W7;G,]R.3'X0
M+R@\'XULU]QSC.[YCX2IYNBOV$ZRBPU125MNFT;436VJH;5;'PW>E9K-;O&:
MIM%/.G0571Q2.J8.A7DAG;AG,;"MDQI@VZPWG#F(**&OME?"CF*^*1NJQSP2
MM9-25=._:@JZ.ICCJ*6HCDIYXV2,5#D&'NAS*'.T5_)_Q:W"V*ZR6IRBQ76-
M2\02:R.PA=I=(XL3VW75S:-VC8<04*+T<M.D=QITBJJ29E?'^O>H-*O0>)P%
M&%*M13WJ5*"A"M".<E&$4ETL?:V7A\.-B2-G>TFMA\0L-I"O.MAZ\DE6JR<Y
MT:LLH[TI7;I2]LY.T&KJRN=( &'L-^HKK0T=RMM73UUOKZ:&KHJVDE9/2U5+
M41ME@GIYHU5DL4T3VOC>U5:YKD5%74RB::^WNI7EY.S33ZGQ[5WKF6?4DTFG
M=.UFN&?#S,J  '(                        \S><TYRNP\F7#>&L2W_#%
MZQ1!B7$,F'H*:R5-OIIZ::.V5ET6HF=<988W0K%1OB1L;NDZ5S/)V-IS?&SZ
MK$RX_!'C_P W_"F&>K_^\,KX6%]RS*K\9-5^25[-%\F[4;4C1^/T?"OB*=25
M5U*D6XU916[&=DK)VX*V5BONT37_ $GH[2<\-A:L(THTJ,E&5*$W><&Y9R3>
M9O%_58V7'X),?_TGAG\]'U6-EQ^"3'_])X9_/31T!M_K7:'_ #-3]_4^\T7U
MW--_GZ7_ $]+^$WB_JL;+C\$F/\ ^D\,_GIZ%<VYSV^%.4GC.[8,L6!L3X9J
MK3A^7$$M;>ZRSU%--#%6TM%XO&RWSS2I*KJILFT]&L1K=-55=W-J-FKP6+[N
M>,?Q;U?R]:#7]:=GVC,+H_%8BC2J1JTJ:E!NK.23WHK-.Z>3-FU-VE:6QFD\
M'A:]:G*E6JN,TJ-.+LJ<Y9-)-9Q1OP_#P]>[C["J2IW]JDQ *998  R
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MO>/9)Y$:[3M8\7HS!T:^$G&%2>(5.3E",UNNG)VM*ZXQZC98^JQLN/P28_\
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MX),?_P!)X9_/31T ]:[0_P"9J?OZGWCUW--_GZ7_ $]+^$WB_JL;+C\$F/\
M^D\,_GH^JQLN/P28_P#Z3PS^>FCH!ZUVA_S-3]_4^\>NYIO\_2_Z>E_";Q?U
M6-EQ^"3'_P#2>&?ST?58V7'X),?_ -)X9_/31T ]:[0_YFI^_J?>/7<TW^?I
M?]/2_A-XOZK&RX_!)C_^D\,_GH^JQLN/P28__I/#/YZ:.@'K7:'_ #-3]_4^
M\>NYIO\ /TO^GI?PF\7]5C9<?@DQ_P#TGAG\]'U6-EQ^"3'_ /2>&?STT= /
M6NT/^9J?OZGWCUW--_GZ7_3TOX3>+^JQLN/P28__ *3PS^>CZK&RX_!)C_\
MI/#/YZ:.@'K7:'_,U/W]3[QZ[FF_S]+_ *>E_";Q?U6-EQ^"3'_])X9_/1]5
MC9<?@DQ__2>&?STT= /6NT/^9J?OZGWCUW--_GZ7_3TOX3>+^JQLN/P28_\
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M._$Q\2?$92%O#OP +^-"^B3>6K$X>8OXD^D OHT^$OF-UTT]9;1MWIYC(1H
M7$:%[&G M&)N+YB %=J;RX37VE&-/H+GKT[ "HU."%3BOH)&]O83,3K!E,J%
M9J;BFWB5@8
M                                  !;EP4G\0"@[CJ0?Q)W<"FJ[D]G
MQ S]A05.KUEN].LNUW+KZBWD3X 8+21"RD3X"_?P+-Z<4 ,?(WV&/D;Q[^@R
MCRPE: 8F9ICY$X^TRLS3'2-^@ Q$S3&RIN,Q*G48J5/C ,1(B:KW\Y8RIQ,E
M.WCYMY8R( ?R6*<-T]XMMPM-4B>*W2@K;;4ZIM:05],^EE\A=SE1DCET5414
M71%14.61F=@F;#.)<18;J(UBGP_?KQ9)8U5VK9+5<*B@<CMK>KO[W757(CNI
MRO5%<O56=U]^!SL^>=RL_8GRE<S88X>AH\05]MQA1>3LI,W$=HHZNYS(FB)L
MOQ$V]M39U15CW:;T28MD&.W<1B:#?Y2DII=;@VFWUV4B#-N&C]["X3$I?DJT
MJ<G[F-1*675G \O  3]V+@N'<5J   &NF_LW]^Z^A>!OS>#_ .:2XAY.UEMT
MLSI:K"5\ON'Y&JJ*V"E;5)7VZ%FFJHGBE:UZL791KGN1J*S94T&?7IY^SOV]
M7$VU/!A,S%6'-S!<DB(VGJ,-8LHXG/\ MBUT=?9;E(QG!J0I;+2V1R+Y7C$+
M51-A%6/-IV#Z715226=&I3J7ZDGN27=NRX==[DG[(<?T6F*<&[1Q%&K2EVRB
ME.#[]Z#^8VSF+P[\3)Q.W(8F/>GM^#@9*%?B*Q%N3*PJ96+A[##Q</896%0#
M)1+\1D8OH,7&O#TF2C7@ 9.-2_8N\Q</;V&2CZN_4 7L:_ 7;5WH63%+Q% +
MKJ]961>!1;U]^!4:NY $RLB^4IK!^%1_<9P/^,"+Y'KS9\5=Z>KXS6#\*C^X
MS@?\8$7R/7FUZD>5<#\8I_::;M$?_DFDG_\ ;5/F1H;@ MKU=R^9%*>2\_SL
M  =O/+S6YI<+]MA]V:Z^WO\ D[#:U\'[YX),&55MR*S-NJMPG<:M*7+[$5QJ
M$Z+#=PJY&[&%ZVIF5$@LE=42+[D232+#;*N3W/:Z*CFHXX]Y9KD[^OXM%0XV
M;FM<BM<FJ.314U5.I4773CJG7U:JB-5-#>PY@?GB&X^H*#)/,VZ*N.K11+'@
MV_U\J:XPM%%&B+:JJ=VFN);73MU:CU<Z[4$+IXG/J::H8L%;2M2=USTCA(73
M;EBJ4/:RRO7BEUN_217!^%PN6'V5:_7Z/1>-J6DDE@ZTWXR=[8>I)\)++HF^
M/B^YOM/[2$474I,<BKU\._L[>!50A-/EZ?N+ )D0 9,@
M    &J?X6%]RS*K\9-3^2=[-%\WH/"PON695?C)J?R3O9HOEF]EWDFG\+6^F
MRI.V#RU5^ P_T&  2*1:#9J\%B^[GC'\6]7\O6@UE39J\%B^[GC'\6]7\O6@
MU+7OR1CO@E].!NNSGRWH[X:7U50WY$[^U28E3O[5)BI:^_YRZ8 !D
M            E5VA,2N (ZH05R%)7:>GON3OZ#X6Y=?.)Y9\GS#K;WCN\,9<
M*UD_['\+4#HY\18BGIVMZ1MNM^TCVTL#Y(FUESJ>BH*%)8O&)T?+!%+]\)A:
MM>I&C1A*K5D[1A"+<I/J[,LV^2XV5SJXW&TL-2G6KU(4J--7E4F[02[^>>22
MS;R69]L7W$%#:Z.JN%RK*:@H**"2IK*VLGCIJ2EIXF[4DU143.9%#&QJ:N>]
MS6HG%35LYP?PF#"6$9J["N2%L@QW?H$DIZG&EQ<Z#!EMG^N,5MK@CV:[$U7
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M*#\9?\2VZGPWF1KKEM)PFC-ZA3W<3C+/V&,TH0R_K9K*+7%T_&:ZD;%_+_\
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M!TM#V&?1UXI;^'J-*:X7<>52-VEO0O;@[/(_? 2)P[Z_#\_L)S5S<0
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M"V&R?6OU=@_4E:7\YP:4&F_"G0RC2GQN]VVY)VY1OQ/VG4B2H3$;(E@
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MZ_?)^_>'@?WH8;^1:(A/;)XFC_?8KYJ!8#83XVD^["_XQ^P  @LL0
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MM-^[KX\/5\7J*Q%-^/83.F  9,@
M   @JD25W  HDG\(G)4XKZ@<DLKE!5*2KN1._65'\"B[YOF!Q+=5+1ZETO!2
MSD4 LY%XEC*NY?A]1>/X%E+IO +"5?B,;+UF0F7OZC'2_. 64RF*F7<9*9=Y
MB9E +"9VGL,9(N[TK[->OU<4+^=>/?J,?*FB?K]?!%^CM5$WHL#5"\)_S V:
M')["<;]4GKL6XFK(M416K1TMIM%LDV=%5=I+E>6HNUY")P^N;M1_OW^ V%/"
M2<<I<,[,.65';L.8#H8W,379;)=[E77!7JB^2CGQ]$W5NNK(VHJZMT->LM?J
M#A^BT3A%;QX3J/M<ZLFGYU<IEM*QO3:9QDKW49TZ2[%3I137FD_3<  W$T0
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MX%JQ.LO "O'U=^LK,[21C=WHX%5J: %3J])41-"14X(5 9ZB=B=95)&<"<&
M
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M!KOO5,,>^O'OY57$]["G^M?E+'?&:OTF7CU,\E:/^*TOH@ &OFS
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MYVE\$\3A<1AU)1=:C4I;S5TNDA*-VN=KWM=''FU0:H=6M.;%Y-G_ $>\D/\
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MA_8JO[RG]P]8RO\ V^E^YE_&<I3:3M0(O?CU[^"*NY/-Z51-YU;$YL7DV?\
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M?\.I'>7:X>.EV-$:Z2T)B\')QQ6'J8=_\:$XQ?O:ENCEW)F. !WUZ>Z_VGF
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MTTO8J/ZL7O37NVT[V1#9)@#022P
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M G3[(J$C.LJ-XH#+XLK(1 !@
M                                                   MRG)U%9_$
MIOX Y0XE-_$I=O?J*KNKT(45XKYT!Q+9_$M9.LNW]1;/ +"3J+&3BN[C])?O
M+.1=_?S@&,D,=+Q]IE).OT?,8Z8 QC^!BYC+R)Q[^<QDR<>_$ Q$R<=.^XQK
MTX^@RLG7Z#&R\?;\0!CI?G/'SGU\%-O')FQY-L[3K%588O\ &G6GBV(;?0R.
M1%W?6Z>Y3O<JJBHUKO7["R>8^).<=PBZ^Y YSVQC%EFERRQE4TL:::R5MLL=
M9=*%C=7,1'.K**!&JYR-1517:HBH>OJ_B>BQ^#J<-W$4G?A;PXIN_8FWV'B:
MRX;IM'XZE:[GA*Z2XW?1RLK=KR7:<T-?7Z_5O3AHB]G:BZ<"!*QR*B*G!=Z*
MG!45$5%X)QUUX)QX$Q<A?CT%$GQ?>  9 /VGDW8J?8\Q,!7=CNC6@QEAF=S]
M=-B)+S1LF?KOTV87O7@[739T37:;^+$S*Z2E<VJBW2TKFU,2[]TL#DEC7<J*
MFCV)O145OV2;T1#XXBETE.=-\)PE#]N+C]IV,)6Z.K2J+C3J0J+OA)27RHZR
M\-0R1$D8NK)$1[%[4<B.1==$7?M+N7U:(NRV_A[_  'YQE?>H[CAO#M?$Y7Q
MUECM52U[DV7.2:@@?Y2:KH[?O;JNGK/T6/C["E56.[*2ZI;O[.7^I?NA.\(>
M]3])EHU^8R42F,B^9#)0KP]1\CZF5B^8R$+N'?@8V/J+^$ RL:E_&O?T&-CZ
MB^C7>NG: 9"/J[]9>Q]98,X%\SB 7D:\"NWBI:Q]9=)Q7U %9O!>_4:P7A4/
MW&,#>_\ A^1Z\V?&KN7UFL'X5!]QC _O_A^2*\VO4?RK@?C$/M--VA>1=(_%
MIFAROT?$0(JI MHN"*5/B  9,    ^UN0)RY\6\GS,*@QSA9[JFG<V*@Q-AZ
M25T=!B:PK+MS6^J:BHQM5 JOGM-:J;=OK%5[56">ICD^*0=;&82G7I3HU8*=
M.I%QG%\XOC;M7%6S3LUF=K XVKAZL*]&;IU:4E.$ERE'A=<T^#7!K)Y'7)Y+
M7*;PGG!@:PY@8+N#*^QWVD25J;2)56^MC\BNM-RA1=JEN5NJ4?3U=/(B*US4
MD9M0R12/^AD.93S0G.E7?DWXW1MQ6KN666)ZJFAQE985?++0*GUJ+$]GIE>C
M'7*W1Z^-4[48MRH6+!TC9H8')TJ<"8[L^)K-;,06"XTUVLMXHJ>X6RY4<G2T
MU91U4;98)XG[ET>QR*K7HV1CM62-:]KFI5;7#52IHO$..<L-4;>'JVXQ]Q+D
MJD+I27/*2R=BXFHFN=+2^%4FXPQ5*,5B:5^$G=*<5QZ.=FX]6<6[J[_K@012
M)J)O0                 !JG^%A?<LRJ_&34_DG>S1?-Z#PL+[EF57XR:G\
MD[V:+Y9O9=Y)I_"UOILJ3M@\M5?@,/\ 08 !(I%H-FKP6+[N>,?Q;U?R]:#6
M5-FKP6+[N>,?Q;U?R]:#4M>_)&.^"7TX&Z[.?+>COAI?55#?D3O[5)B5._M4
MF*EK[_G+I@ &0               ""D%<B'YKG%F[8,!X6OV,<45\5LL&'+;
M4W6Z5LRM:V&FIHED<C4<K4?+*J)%!'M(LLSV1HNKCE3@Y248IRE)J,8I7;D\
MDDN;?)'"I44(RG)J,8IR<F[))9MM\$ES/A/G3><<L7)PRXJ\1S,IKGC"[I/;
ML#X<EE5J7.\+'NJZU&.2=EEM.TVKN4D>R^2-C:.![*BHB>WF79NYN8DQYB6\
MXPQ==JB]XCO];)772XU2IMS32.<K8XHV_6Z:EIXU;!2T<*=!301QPPM8UB[7
MTUSAO+CQ%R@<SKUCR]OG@MJO=;L(V&21708=PU3O7Q.BB8FC/'*M4\?N]3OD
MJJ^9[5<E-3T<,'P\6DU%U2AHW#*4XIXNLE*K/W,7XM&/4H\9<-Z6?!1M3W:'
MKK/2N*<:<G'!4&XT8/V\EDZSZW+VON899-NX &]$>   RE?) RMCLE;=*VCM
MEKHJRYW2XU,5';K;;J6>NN%?63JC(*2BHJ5DM35U,SG(D,%/%)*]RMV44^P>
M0YR LQN4#BIF&<!VO:IJ=T;L08FKTD@P_AJB>YFU47&K1JK+4JQZ.I;52)+<
M*Q?M<3(4EJ(NA3S=/-)Y8<G:UPS62WLQ!CF>G='=L>7BG@EN\_2[*RTEJ;HL
M=EM7DM8VDH5:Z9K4?635$FKFZ3K5KUA=&+<_+XFSM0A)>#?@ZCSW%U9;[Y*Q
MONINSW&:6:J)=!A+YXFI&7A6XQHK+I'UYJ"YMO(UGN07X,IC#%K*/$&=UVJL
M"6.1(YVX2LCJ2HQ?61[37)#<*^9E9:[%'(U521L4%RKD1-A%IGN;-'M[<ESD
M+949,VQELRYP5:,/HC42>XMA6MO=<]&=&LUPO=:ZHNE;,]GD/?/5.5S$1FZ-
M&M3ZWV=$]>O:3*TKWIW6[':1E[/6DJ5\J$+PI)<O!RWK=<FWVEG-7=2='Z-B
MN@H*56ROB*MI5I=\GXB[(I1[&3@ UDVXAH-"(          !@,2X8MMXHI[=
M=J"CN=!4L6.HHJ^EAK*69BIHK9:>=CXGIHJ_9-73JT7>9\E<FJ&5)K--IK@U
MQ7<<914DTTFGDTU=>AFMSRX_!M,H\P(ZZ\Y8RR95XMDZ69M+0L6LP/<IWHB[
M-987ZRVAS]%1E3A^IHX872RSU-LN$RMV-,GEH<W_ )I9!WIEIS$P]-0TE7+)
M'9L242NK,-7Q6;3]F@NK6]&RL5C7R.MM8VFN#&LDE2GDI6+(=7S9\Q^>9HY3
MX<QK8Z_#.+;';,1X?NL"T]PM-WI(:RBJ8UWM5T4K7;,L;M'P3QJR:GE:V:"2
M.5C7$AZM[2,;@W&%=O%8=9;M3.K%</ J/PW9<(S;7);JS47:T[*L!CE.IAXK
M!XEJZE33Z&<K/\I162OSE349<\^#Y>7-E<B*NY0&;^'<!1MG98X]J^8SN,*.
M;[G85MDL*5Z](FK6U%SJ)::T43&K'+XQ7)*QW103/BZEN$L*V^QVNW66TTD5
M#:[314MNM]' Q&0TM%10LIZ:"-K=$1D44;6(GKWGPKR$.;/RWY.[<8-P!2UK
M5QC>([C53W.9M764=!20K';K#35BM;.^UV^2:MGIF3O?*DM;.Y[W*[4]#D.E
MKSK6M*8F+I;T<-1ANTHR5I-O.<Y15TF\HI)NT8KK/2V>:F_R1A9*JJ;Q=:5Z
MTZ>:W(94X1DTFXI7EG9N4F[$0 :02"             -23;0 F537XY\_G;&
MY%89CP/@BK@FS5Q=13^+RL<V7]A=C>B128@JXT1R)<:ISU@L-+*K>DE;+<)&
MK!2-9/Z4<X3RV</9!Y87_,&]HRJJJ2%:/#=EZ3HYL08EJFN;:K6QVBK%3NG3
MQBX5:([Q*WP552V.66.*&7ER9W9UXES&Q;?<;XPN#[IB+$=?+<+C5+JV-KI%
M1(J6CB<K_%J&BAV::AIVO^L01,1RR2*^5\E[.M4%CJ_JK$1OA:$LHVRKUDKQ
MIOKIQR<^NRCUVB+:EKS_ "=1]1X:7\\Q$'>2:O0I7:E/X26<8+BLY<HW_-;A
M<*BKJ*BLJYYJNLJZB>KJZNID=-4U5752OGJ:JHF>KGRU%1-))+/*]5?))(][
ME57*I: %DXQLDK6MRZBJKDVVV[MW=\\[\7GGGV@ '(P!W[^T=^_S=N_3@>MW
M-A<T+C[E(72.OA63"^6E#6)!?,:U4"O\9? ]JU5JPO2R-V+G=MAW0R5+M+=:
MY7.?5.J98TH*CHZ1TG0PE*5>O4A3IPSWI_,K>$W)7LHIMG?T9HJOC:T,/AJ4
MJM6;RA'YY/@HKG)M)=9Y[9"\GW&F:&)J/!^ </7'$V(*U%D;16Z%9&TM(U\<
M<MPN52JMI[;;8'21LEK:N6*G9(^.'62IGAA?N4\@+P93">'4M^)L];BF,KVS
MHZEF!K5(Z#!]#,BL>R.\U:,CN.(Y(5:UCZ=CJ"SO^NQU%+<X'L<S8-Y(?(HR
MZR-PTS"^7>'J6T4TG0ONEQ5K)KU?:N%BL96WJYO3QFOG:CGI"V1Z04S'OCIH
MHFN<U?K)6^WV%?=9]IN)Q3E2P6]AL/PWLNGFNMS2M3B^48/>MQEG967U1V2X
M7"*-;'[F,Q.3=+/U-3>62@_RK5LY36[?A!6N_P"/P%@"QX8MM/9L.VBVV.TT
MC&1TMNM5%3T%'"QK48B,IZ:..-%V6M:K]%<Y&IJNX_LR"(1(PE)R;<FVWQ;=
MV^]\R8(044HQ2C%9**222ZDEDO,0T\Q$ P<B&A$     $-"( )53O\1\=\K/
MD%Y49VVMUKS&P?;;TYL;FT=W8Q:&_P!L>]$1)K9>J3HKA22,V&[FS+"]NL<L
M4D3Y(W?8Q*Y-3ZT,14I3C4I3G3G%WC.G+=DGWG6Q>#I5Z<J5:G"K3GE*%1*4
M6NYF@!SB'@XV/LLX;ABC*>LK\S,'TW2U,EFDIHDQW:*)KE>Y'TM#'#28F;!$
MFKI[734-;.UCD99W2:)-K9R1N8Y\;V.CDB>^*2-[7,DBEC56R12,<B/CDC<B
MMDC>UKV.16N:BHJ'9'<Q5[=W#V=]W;HNIX.\Z9S&&",^(*[%6%&6_!&:BQOE
M2]0P+%9L33,;JRGQ31TC%Z265R-8E\IX7W&G1=J5E<QJ0+,FJFU"<7"AI)N<
M;V6*]M'DNEBEX2ZYQ5TN,7Q()USV/0DIXC15H26;PCONOFW1DV[-\H2RY;RR
M1SE]0?L>?7)_QEEABBYX,QY8:S#V([3,Z.JHJM&OCEC15;%66^LB=)2W&WU+
M-)*6NHY9:>6)45CT5SV-_'/T+ZEX=_1VH3G2K1J1C.G*,H26]&46I*47PDFF
MTT^M9%>JU"I2G*G4C*,X/=E&2<91DN,7%I-/L:N  ?0^=AJ?8_(4Y;V,<@<P
MK9CS"51TC(I(Z3$=AFD>VVXGL#Y6K76NN8U=&S;"OEM=>C5DMU>R*J1LT734
M\_QP11=-%3BBZIQ3>F]-Z<%[%ZEWG7Q6$IUZ<Z-:*G3J1<9PEXLD^%WV/T/,
M[.$QM6A5A6HR<*M*2G3J1?A1FK6:ZU:Z:]LO!:LV=<KDO<I7"V;N![#C_!M<
MVNL=_I.FBU5$J:&J8O1UMLKX]56&NM]2U]-51+HK98U5-6.:I] :]O7Q]1S@
M>8OYS9^0V83L-8EKY(\K\?UE'2WQDLCUH\.7]=FDM^*XHU<L=+&^-T-NQ!4,
M:SI[?#0U%6[HK/3OBZ/%+-')&R2-[)(Y&MDCD8J.8]CT1S'M<W5KFO:J.1R*
MJ.1=4*H:WZLST9B^BLY4*EY4*CXRCQW6^#E#)2MV/*]BY>H^ME/2^#55M1Q%
M)*&)IQX*?*<5Q4)VNK\'>-W:Y<M33VDP!JR-T               !!>KOU*1
M(+U=^I0"'5ZOF.7)SS/WT^=_OPC^0+*=1OJ]7S'+DYYG[Z?._P!^$?R!926-
MC_\ 3L1\5_Q($,;;O)N&^-Q^JJ'F8 "Q!5X  /@N_P"XP^7XY,Z,G@UWWJF&
M/?7CW\JKB>]AX)^#7?>J88]]>/?RJN)[V%/]:_*6.^,U?I,O'J9Y*T?\5I?1
M  -?-F                           !*Y-RZ:=_9\9,04-@\(.?GYN?\
MNV95SXCP]0NJ<P\N:>OO5B93QH^KO=G9&L][PW&C6]+45%5! E5:8&O3;N5/
M# B.=4'.+AE:]C'M5'->U'-<U45'([>BHJ<45%UU3<NNO'4[)ZMW::)V>;37
M?JG7JB\/B.=GX05S=ZY/YH-QQAZAZ' 69]777"G2GCTI;+BYKO&KW9W(U5;
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M/\7B#Y'J#I?)P0KEM;\HTOBL/K*I:;8IY,K_ !RI]"F1 !%A,0
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M5^/BQ648*_*$;)=?>2_H'0U+1^$HX2DK1HP2;]U-YSF^-W.6;SR[BH #S3V
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M35"LA(C?-U$Z$2+S][_'^Y-=_F5^_L["( ,F0
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M?67+ "LG%._G*[>OT%%$W^@K)P7OQ )V<"JSB4V<"JP&7Q95  ,
M
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M3;S;;>;=RV5"A3I0C3I0C"G!*,(12C&,5DDDK))  ' ^H
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MI3$1]DJK=PB:\2B_&JQ[:CRB^4(]4B"*NXJ$$0B0XE;TW)V0 !D
M                   U:O"L/N/9>?C#;\@W(VE35J\*P^X]EY^,-OR#<C:M
M1O*^"^%_N3-+VB>1=(? KZR!HBK]'Q$"*_1\1 MJN"*5+[_G  ,F3V1Y@?[Z
MG+G^+Q!\CU!TODX(<T'F!_OJ<N?XO$'R/4'2^3@A7+:WY1I?%8?652TVQ3R7
M7^.5/H0(@ BPF(                           'YYF[^]3$_O?O/R=4GZ
M&?GF;O[U,3^]^\_)U2?2CX\??1^='QQ'Y.?O)?19Q]ZC[9+_ !LO]HXI%6H^
MV2_QLO\ :.*1=FGXJ/S_ )^-+WS  .9Q+2O^T3?Q4G]13K]\G[]X>!_>AAOY
M%HCD"5_VB;^*D_J*=?OD_?O#P/[T,-_(M$0GMD\31_OL5\U L!L)\;2?=A?\
M8_8  066(               !(K=5\Q.4W.W_'\'?K^,P_QZ.0_'V?:?*G+3
MY5=BR6RSQ;F1?D26FP[;9I:&WI*V&:]7J9JQ6>S4SUUV9KG<)(:=9=ER4T+I
MJI[>B@>Y.5AG7G1B/,3%N(,<8MK?=#$6)KE472Z5#4>V%LLRIT5)1QR23/@H
M*&)&4M% LKW14T$+'R2/1TB[%?A,7+O?C#,6DR5L=0KL/Y<+!78EDBE^M7#&
MERH8ZIE'];5S)(</VFKIHU5RZLN]=6TSV0SVU'2:P19/9EJTL+@_552*Z?%P
M3C>S=.@\X1[Y>/+K3C?-%4MK&M?JS'>I*<F\/@FXM)M1JXB[4YVYJG;HX\<U
M)IV8 !)UWSXD2( #5$XKPW^K?Z=R)IJJ(JZJNC51JJ/].[-VMW\[=68_U^17
M_P!._(N:.CFJ)X*6FAFJ*JIFCIJ:FIHI)ZBIJ9GMBAIZ>")KI9YY9'LCBBC8
MY[Y7MC:U7+H;W_,H\QE0Y;TULS5S?MD-=F141MJ\.88JMB>AP)33LU;/61(B
MP5N+)8WJDTCNDI[+$[Q2DZ2IZ:K=\_\ @\?-&,H:>U\H',BW1R5];%XQEG8*
MV+;2@HIX_)QA7T\L:L]T:N-S_<!J.D\3HGK<FO2IJH?%]P5K>OV^GOUH0+M#
MU[<YU,!@YVIQ=L16A+.;2MT=)KQ::X2?MLXWW;[UC=E^SN,(0TECH7G);V&P
M\X_DT_ZRJGXTGQIJW@Y2:WK;LC45J+W[^O\ 054(;),0PO23TE;(  R9
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M4*5MMW;=VVVV^-V[E^8P44HI622274EDD  #D
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MX)W[0"=G K1]92;P0JQ]8#94
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M?T3HRE@\-1PU".[2HP4(\+NW&4NN4I7E)OC)M@ '2/1
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M&-.$:<(J,(14(05DHQBK122X)))+L0 !P/J
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M^HIU^^3]^\/ _O0PW\BT1">V3Q-'^^Q7S4"P&PGQM)]V%_QC]@ !!98@
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M)/<
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M-Z_2I57[%._:4F\5*J_8IW[0"HG!"K'UE)."%6/K *@
M
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M]18'8AH6[Q6D)K-6H4F[9-VE4MS\7<2[')9IA$T7ON*@!!J5BPX !D
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MMMN]R\E&E&G"-."480BHQBE9*,59))<DLDN  !P/H
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M\&N^]4PQ[Z\>_E5<3WL*?ZU^4L=\9J_29>/4SR5H_P"*TOH@ &OFS
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M\U14U$TBMCB@@BC?)+*]S6,8QSG*B(IR\N=>Y?-;RA,V[SBB&:H;@ZS/FL.
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MNHJ,>1<K9[JI'16 A"27JFONU<3+FI6\&E?JI)[MN#EO2MFR8 &GF^
M                            U:O"L/N/9>?C#;\@W(VE35J\*P^X]EY^
M,-OR#<C:M1O*^"^%_N3-+VB>1=(? KZR!HBK]'Q$"*_1\1 MJN"*5+[_ )P
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MZCT30;5JF+OBJE^-JBBJ<?U::CE[J[RX$Z*1 -))&
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MM545-%1="LU=33S>T[DP !D
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M67,?S@%RG%?45-=W?SE).*E5."^H J-7<A6CZRBS@5F*#+*@ !@
M
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M^Y9E5^,FI_).]FB^;T'A87W+,JOQDU/Y)WLT7RS>R[R33^%K?394G;!Y:J_
M8?Z#  )%(M!LU>"Q?=SQC^+>K^7K0:RILU>"Q?=SQC^+>K^7K0:EKWY(QWP2
M^G W79SY;T=\-+ZJH;\B=_:I,2IW]JDQ4M??\Y=,  R            "1Z?!
M\?5V\>' YHO/[YFNQ-RI\PV;:2189AL&%8%:K%CV;?:(*^785BN1594W2:&5
M5T>DL3XWHFPATN7KP[_/WXKP.2ARV<=NQ-G-FU?UDZ5ESS*QO/3/U5=:"/$=
MPIK:FJN?O2W04K5T<K55%V$;'L-26MD.%W\=B*EOR=#=3MPE4G%Y?JPDNZY"
MNVW&;N!PM&_Y7$N37)PITY)Y=DJD7UIVS/F( %AKE80 /9Z]R=_A7@FBKJ@7
M-ISP5?)AMRS1S"QW40*YF%\(4M@M\SV;4:5N)KBRIK5C<J:-J(*.R4[%<FCD
M@KI&(NQ+(B[V;5-8;P6'+9+?DIB_$JHFWB7'U7"CE3RTCL5MH:+8WIY+5?*Y
M^RBJFVYVJZH;/*>8JGM"QG3:7Q7-4G&BN=NCBE)?MN=^TN3LQP/0:&PF5G64
MZ[OQ?22;B^+]HHV[+$0 :6;^
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MG$-?D,.DGU3K3W?3N4WZ>&=SZ= !7LLZ
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ME19<LJ6KB:J22KK%>\7-C57*U&(CK/99'M:JHMTJVM<Q;=.FN9S>G(FO6?\
MFGA_+VUNFI+?4RMN&*KS$Q'>X>%Z.6);K6LVVK$ZMEB<E':X9%5LU?4P[;?%
MHJAS.I[EQEW9L)V"SX8P]0PVRQV&W4EJM5# FD5+144+(((VJOE/=L,19)'J
MLDLBODD<Y[W.6(]J.M'04?4%*2Z7$1O6:;O3HJUH]2=65[_H)]:9-6R#5'U3
M7_E&O'V'"S]@3652NT[RSXJC'ARWVE[1I_VB,T[[N&GM\Y.A$%>RSP
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M5E]\-15*G3IQ5HTX1A%=D(J*^1  'S/N
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MHU'WQBU;G<DO1&U30^*<8NO+"S=ENXI*$;]E5.5+LSDG?E;,VA]2&UOX>L_
M\C.4_E]F;;DNF <8X?Q91;#9)'6:XT]544S7*K4\;HT<E92*KD5J)500[2M<
MB<#]Y:NO7KJF[=NX<4WKN7J\W6:/4I3@]V<7&2XJ2<6N]/-><D*C7A4CO4YQ
MG%\)1:DFNQK)KM*B*1((FA$X'V
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M2C7CH7C.!8QKP])>Q]8!D(^LN(^LM(UX%TSB 7"<?5\Q7;U^@MT3AWZRY9Q
M)F<"LSB4&=95:N] 9?%E<  P
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MU7IJ&C<!%</4>&?IHP8 !XY[P
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MSLDB[FAM%4<#AJ.%H1M3HP48O*\G;PIRLEG)W;=EFRH #I'J
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MI71T%SQ=%_LS3_NG1^9P[]_,3$D?#OV)\Y.4_+Q@
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MC4IRC.$U>,HR4HR76G%M/S,F!#:0(NI\S[D0
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M"\8N\LF%X@!=IP]"E5O%"BU=RE1J\% *J+O4J%->*+VE0&65T4B2M7<3 P
M
M                       ""J 454I/ZBH2+Q0'*/$E>N\H=:^@JN7>4>KT
M@XE"3B6DB\?07+EWEI([B 6DG463UT]I>/+!_;J 64B\3&RK\9?2*8^5?B +
M*1>)BYE^(R,KC%RKQ]@!CY>LQLCM_P !?RK\.IC'KQ +21?A4\N^>7QBEEY,
M^:\R/5DEQLE!8HD17-61+[?;5;*F/5J+HCJ"IJW*U^C9&-=&NYV_U"?U&O\
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ML?L,JKH-(0Y]-1DEV.$U?_M+\ $,$\@
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MVC454\[3$]S"8J;Y8:N_-&G*_GR9ZFA*6_C<)#W6)PR7>ZU-(ZK " I@7T
M          !!>KOU*1(+U=^I0"'5ZOF.7)SS/WT^=_OPC^0+*=1OJ]7S'+DY
MYG[Z?._WX1_(%E)8V/\ ].Q'Q7_$@0QMN\FX;XW'ZJH>9@ +$%7@  ^"[_N,
M/E^.3.C)X-=]ZIACWUX]_*JXGO8>"?@UWWJF&/?7CW\JKB>]A3_6ORECOC-7
MZ3+QZF>2M'_%:7T0 #7S9@
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MM%^J,7&.Y?C2H+.-N:=7*4OT=Q=8;P)@"+R80
M                :M7A6'W'LO/QAM^0;D;2IJU>%8?<>R\_&&WY!N1M6HWE
M?!?"_P!R9I>T3R+I#X%?60-$5?H^(@17Z/B(%M5P12I??\X !DR>R/,#_?4Y
M<_Q>(/D>H.E\G!#F@\P/]]3ES_%X@^1Z@Z7R<$*Y;6_*-+XK#ZRJ6FV*>2Z_
MQRI]"!$ $6$Q                            _/,W?WJ8G][]Y^3JD_0S
M\\S=_>IB?WOWGY.J3Z4?'C[Z/SH^.(_)S]Y+Z+./O4?;)?XV7^T<4BK4?;)?
MXV7^T<4B[-/Q4?G_ #\:7OF  <SB6E?]HF_BI/ZBG7[Y/W[P\#^]##?R+1'(
M$K_M$W\5)_44Z_?)^_>'@?WH8;^1:(A/;)XFC_?8KYJ!8#83XVD^["_XQ^P
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M--W?3LW>;L)R1B]G:OZOU>CJ)RGI>4
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MJL(SA)<U+DUQ33NFGFGD^HF !USN
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M"HBE)%XH3L7<#/V?>7#%)RBSB5@8
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M0<\/)9-Q<)-Q3_4E#+_<B #1B1
M         ? G.DY?.Q3R=\YK'%$DU35Y?8C?1L5-K2NI*"2LH7Z;M>BJX(I4
M35-[#[[/Y;&.'H[O:+K:I-$CNENK[>]7)JB,K:62G<JIHNJ(DJJIV<'7=*M2
MJ+)TZD)IKENR3O\ (=32%!5:%:D^%2E4I]?CQ<>'G..K&_::UR<'(BIZTU)S
M^SS(P7-AK$>(,.SQOBEL-[NUF<R5KFR-]S+A443=M%W[2MA1RJO':3S'\874
MIU%)*4<XRC%Q?8XIKY&4%J4W"4H/C"4H-=3@]U_*@ #F<"257;+MA5:]$56.
M3BUZ;V.3SM=HJ>=#K0\A?,^/&N3F6&*H=.CO>",.5GV6UH];931O157^%MQO
MVT5$<UVK5374Y,1T,O!G\^6XKY.L>&IZA)+EEQBN]8<FC>]%F]RK@L.([)4;
M&JJVE;3W:>U4SU1$>^SSHFJL5RQ+M=P+G@L/B$K]#5:D_<QJK=S_ %HQ]*)H
MV)Z05/2&(P[?](H7@NN5'P[_ +$Y&PZ "O):
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M[XS5^DR\>IGDK1_Q6E]$  U\V8
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MJ(9<E30F*LW;S>;?'O+BI)*R5DLDEDDN278N0  ,@
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M4N-.<X2[XMK["_&!Q*K4:56.<:E.G43ZU.*E]I.""$3X':
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M]15*Z*4"JQ0<2<
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MM)/M3R9>>A6C4A"I"2E"I%3A*+NI1DKQ:?4UFNPF !P/J
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M][#P3\&N^]4PQ[Z\>_E5<3WL*?ZU^4L=\9J_29>/4SR5H_XK2^B  :^;,
M                                       04_@\T/WM8BX_\17?T?\
M%]0?WI_"YH?O9Q%_,5W^3Z@^V'_*4_?P^DCK8Q>Q5?@Y_19QV+1^Y*7^3P?V
M33(F/LW[DI?Y-#_9-,@76I>+%=27T44$K>//WTOG8 !]#YEI7K]8G_B9/ZCC
MKY<G1O\ YOL"+_\ @;A?Y#H4.0;7_:)OXJ3^HIU]N3G]SW GO-PO\B4)"FV1
M7IX%?IUOHP)\V%KV72/P>'^E4?V'[&U-._?L)B1.*^CZ"<@E?/F6,  ,@
M                                    &K5X5A]Q[+S\8;?D&Y&TJ:M7
MA6'W'LO/QAM^0;D;5J-Y7P7PO]R9I>T3R+I#X%?60-$5?H^(@17Z/B(%M5P1
M2I??\X !DR>R/,#_ 'U.7/\ %X@^1Z@Z7R<$.:#S _WU.7/\7B#Y'J#I?)P0
MKEM;\HTOBL/K*I:;8IY+K_'*GT($0 183$
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MP<G0DGQW$DZ4NNVYX-^N$N1<@ CXE
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M@)VKHI11=%])5!E_<7 )6KN)@8
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MPR:W9UE*O-9IJ563:7["@^K/@4VVFZ46*TQBG%[T*#CAH-<&J44I/]XZB\R
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MR'XN_P Y>QI\):QIUE[&G  NXT^ N&%%A=1)\(!5TWHG9O*["DG%?456[D4
MF8G7VFL%X5']QG _XP(OD>O-GYO!#6!\*C^XS@?\8$7R/7FUZD>5<#\8I_::
M=M#\BZ2^+5#0W !;7J[E\R*4]7XYL  &#:*\%5^[!F)[P*7Y:C-\7K]GSFAU
MX*K]V#,3W@4ORU&;XO7[/G*O;3?*];X.E]!%N=D7D6A\-B/ILB #0"3P
M     04B0=P,,'YWFGEA8,9X>N^%<46NEO-@OU%-;;I;:R-LE/54D[5:YCFK
M]B]NY\4K%;+%*ULD3FR-:Y.9[SK?-F7[DVX]EMVE5<LO\03U55@;$<K%<LM(
MSZX^Q7:9K&Q-OMJ8Y(I516)<J5C;E!%&CIZ>GZ@:IJN_X%X'S!RPN27A'.O
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M-2U[\D8[X)?3@;KLY\MZ.^&E]54-^1._M4F)4[^U28J6OO\ G+I@ &0
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M*-G\G%,N_H#35'2&%I8JB_!J1SC?.$UE*$NIQE=?Z  'EGL@
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M.[(-;EB,/_)M>2Z?#QOA[V\/#>Y3YRI/)KW#C;Q6>A()$>G=%3X.HG(F)K
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MOZWT8$^["ORND?>8?Z50_8D^R7OV$Y(GV2]^PG((7!%BP #(
M                           !JU>%8?<>R\_&&WY!N1M*FK5X5A]Q[+S\
M8;?D&Y&U:C>5\%\+_<F:7M$\BZ0^!7UD#1%7Z/B($5^CXB!;5<$4J7W_ #@
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MSC*+X-/_ %L3  'T
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MCBY5>"@%9$U0G:NXIM7>3)N4 K-712L6Y68NX F
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M:'7@JOW8,Q/>!2_+49OB]?L^<J]M-\KUO@Z7T$6YV1>1:'PV(^FR( - )/
M       !!4(@ AHA!40F L#S,YT+FV\+\I' 3\/W+HK;BNR^,7#!&*&LUJ+-
M=98D9)3U&QH^JLMT:R*GNU _:8]J4]9$C*VCHYHN9;G+E!B'+_%=_P $XMMT
M]HQ)AFXS6R[4$R>5%/&B.BGA?LHVHHJVF?%76^KC1T%725%/40O='(QR]@/1
M.!X/<]QS2]-G]A-V*L(TM+3YM82H7+9I7;,#<5VB![ZB?"MPJ4;NF>V2HEL-
M1-M0TURE\7F?3TE;4U,,F[/M=7@JBPF)F_4M67@2?]14;XN_]7)OV1*UGX2]
MM>(=IFH"Q].6-PL4L93C[)%+/$4XQ\56_K8I+<R\)+=RRMSD@96^6.MME;5V
MRYTE107&W54]%<*&KB?#54=;2R.BJ*6HAD1'Q30RL='(QR(K7)IPT,462332
M:S4DFFG>]UQ5LL^*L56E%IVDK23::X-6=K-/--6LT\TP._S@&?\ ;_0Q_OYS
M--Q'<$MKK.E;4I:7W".[/MO3/\2==(J62BCN"T^O1^-LHYI:9)M-OH7K&JJW
M1$PH!B,4KV25\W96NWU]9RE-NUVW965W>R7!+L74  9.(-FKP6+[N>,?Q;U?
MR]:#65-FKP6+[N>,?Q;U?R]:#4M>_)&.^"7TX&Z[.?+>COAI?55#?D3O[5)B
M5._M4F*EK[_G+I@ &0            "&A$ 'S'RQ>319LXLM<8Y;7QRPTF*;
M-4T$-:QC7S6NY(WIK5=J=K_)?-;;C%35C8E\B=(74\NU%+(U>4AF[E1?,"8I
MQ#@O$U(ZBQ!A>[5EFNU-I(C&U5%(K%FA61K'R4E7$Z&MHY7,:DU%/3S-:B3:
M)V"%U[.^XT[?":N;MFJJ>@Y0>$Z!)'6^&&R9DTM-']=6WHYK+)BK88W5S*"5
MSK7>9/*>VFJ+?5JQ*:CK:B.4ME^LGJ;$RP=625'%>(VTE&LO%6?!5$MR_NE'
MK9#>U[55XK"QQU&%ZV$6[-16<J$G>4LLWT;=[>Y<S3$ !8XJV  !9/)_CO/U
M7)#.O$F7.+;#CC"%P?:\28:KX[C;*QJ*]B2,18Y::IB1\?C-'74[Y:.NI7/1
MM11SRPKLJYDC>FYS9G.-87Y1V7]+B:U.AMV);<D-%C/"O3MDJK#=^C17.B1V
MS+46>OT=46JO6-K9H=8)=BKIZF)G+./J7D=\L7&V1F.*#'>!:YM/<*5$IKA;
MJGI'6R_VE[VR5-HN\#')TM-,K4?%+&Y*BCJ&QU4,C7J^)VC:[ZG0TI0WH6AB
MJ*O2J<IKCT,^>[)YJ7M'GP;O(6H&O-31&(<:F]/!U6E6IJ[<7P5:'+>BLFO;
MK)YQC;K4IZ28\Y.;FYR[ '*-PLEWPS5-MV([=#"W%6#:Z5B7BPUCVHCGM;N]
MT+1-)M>(W6G189FZ1S)!5-EIXO1E')VH5AQF#JX>I*C6A*G4@[3A)6:?VI\4
MUDUFLBW6 Q]'$TH5J%2-2E-7A*+337V-<&GFGDR8$-4"*=8[A$
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M[5[N$O;0EU.+NL^J_!E'M.Z&JX#%UL)634Z4GG9VG!YQJ1ZXR6=UDG=<4T
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M^'TO05G&&+A%=/0OG=9.=.]MZFWFFK[M]V6?']F!#:3M0B:@;R
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MG@??UOHP)]V%?E=(^\P_TJA^Q)]DO?L)R1/LE[]A.00N"+%@ &0
M                              #5J\*P^X]EY^,-OR#<C:5-6KPK#[CV
M7GXPV_(-R-JU&\KX+X7^Y,TO:)Y%TA\"OK(&B*OT?$0(K]'Q$"VJX(I4OO\
MG  ,F3V1Y@?[ZG+G^+Q!\CU!TODX(<T'F!_OJ<N?XO$'R/4'2^3@A7+:WY1I
M?%8?652TVQ3R77^.5/H0(@ BPF(                           'YYF[^
M]3$_O?O/R=4GZ&?GF;O[U,3^]^\_)U2?2CX\??1^='QQ'Y.?O)?19Q]ZC[9+
M_&R_VCBD5:C[9+_&R_VCBD79I^*C\_Y^-+WS  .9Q+2O^T3?Q4G]13K]\G[]
MX>!_>AAOY%HCD"5_VB;^*D_J*=?OD_?O#P/[T,-_(M$0GMD\31_OL5\U L!L
M)\;2?=A?\8_8  066(               !(YJ:DY*J?/^@7!I$>$^<@]+1B&
MTY^V"E>VBQ)XCAK'C8F,Z&&\T5.VFP_?';+6N;)<+?3LLU4^5[V*^W6M6,C>
M^HDEU*#KL\I7D_6#-3 N*<OL3TZSV3%5HJ[55JW9\8I7S,7Q6XT3W-<D5=;J
MIL%=0RJB]%44\3E:K6JQW*LY5O)DQ+DYC_$>76+(MF[8>K%A95LC='2W:VR;
M3[9>:)JN>K*2YTJMJ&1=)+XO-TM,Y[GQ2.6Q>RW67U3AO4567LV%7L=VO"H^
MU[^C\3L6ZBK&U[53U+B_5]*%Z&,;Z2V2IXB]WPR2J6W^U[USYY !*B>1#W?Q
MY]7F  ,@V9N8,YWM,K;O3Y/9CU^QES?ZMW[&+W53(C<%WZKF;_>E6]ZHQN&K
MP][W.F\E;3<D;(Z*2CKZE]NWX*>H:]C)&/;)&]J/C>Q4>U['HCFN:]NK7-<B
MHYKFZ-5JHJ;M#C<*U%314147<J+O14ZT5.M%ZT-KGF6.?B;@F"S91YUW-W[$
M84I[9A''53MODPW&Y[(:.SXFG^R6PPHJ14UZ>CO<F%K&W*1*"-:R*%=H6H<J
MLI8_!4[S>>)H16;?*K32\:7YQ1S?%9D];,MH\:*CH['SM35EA<1*64.705'+
MA'G";=HY0?%6WF 8VV7*"K@AJJ6>*IIJB*.:GJ()&2P30R-1T<L4L:NCDCD:
MJ.8]CE:Y%1454T,BBD$O)M/EQOR+&QDFDUFFKIKJ9$$-I"(,@
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M]' M]KK]6A61= +E5JZH3HNA1X+KU+W^ J@S+B7 *;'=14!@
M
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M]V#,3W@4ORU&;XO7[/G*O;3?*];X.E]!%N=D7D6A\-B/ILB #0"3P
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M[BYVIVJU/1.#AAXN,JLFJF(JI6Z2I;.WZ,?%BK\,^;(M4B :Z;8
M      ""]7?J4B07J[]2@$.KU?,<N3GF?OI\[_?A'\@64ZC?5ZOF.7)SS/WT
M^=_OPC^0+*2QL?\ Z=B/BO\ B0(8VW>3<-\;C]54/,P %B"KP  ?#N:^5HP^
MOJX^A_C(Z,G@UWWJF&/?7CW\JKB>]AX)>#7K_P"BIACWUX^_*JXGO9M(4_UK
M\I8[XS5^DR\>IGDK1_Q6E]$B"&T@VD-?-F(@AM(-I "((;2#:0 B"&T@VD (
M@AM(-I "((;2#:0 B"&T@VD (@AM(05WK%P3 EVMY,
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M"%<MK?E&E\5A]95+3;%/)=?XY4^A B "+"8@
M   ?GF;O[U,3^]^\_)U2?H9^>9N_O4Q/[W[S\G5)]*/CQ]]'YT?'$?DY^\E]
M%G'WJ/MDO\;+_:.*15J/MDO\;+_:.*1=FGXJ/S_GXTO?,  YG$M*_P"T3?Q4
MG]13K]\G[]X>!_>AAOY%HCD"5_VB;^*D_J*=?OD_?O#P/[T,-_(M$0GMD\31
M_OL5\U L!L)\;2?=A?\ &/V  $%EB                   :]'/X\UJ[.K!
M,6/L&T*29FX#HJI\-/3M1)<689T6HK;"]J;YKE1R,\=L4BNU;(ZMH-'-KVNA
MV%RF[T=_F/0T5I2M@\12Q-"6[.G*_P"C*/"4)+FI*Z?WV9Y6F]#T<?AJN$KQ
MO3JQ:OEO0DLXSBWPE%V:?F>5SC:N8YJN:]KV/8Y6/8]KF/8]JJUS'L<B.8]K
MD5KFN1%:Y'-5$<UR)*;9GA!',_NPW6WC/S+6V(W#E?,^OS'P]0PNV;'7S+M5
M&+Z*!B*V*U5LJ]+?XXD;#0U3WW-&,AGJW,U-._?UZ^KSZHEM=7]/4-(X>.(H
MNU\JD&[NE-);T7V>Y?"2LUU%+-9-7,1HS$RPU9-V_)32RJTVWNRC:^>5FN,7
MD^1  'MFO@*B+N7@N[JZ]W6BINXZ:;]-.L  ]T>:TY\7'F0D])A;$RU6-LJ7
M.;&ZQU$B.O6%&J]-:S"]QF=JZE1%TJ;!7ODI)EZ)]LFMDS:CQ_?;Y*O+(RYS
MIPY'B?+G$]!?Z'R&UU+&](;M9JI[-MU#>;7+LUENJFKM)LSQ)%-LNDI99X%;
M(O)3[]BIU:HJ<%T54]"KZ%_5\D\]<8Y;XAI<58$Q'=<+8@H_)CN5IJ5@?+#J
MCG4M;"Y'TMPHGJB+)15\%32R/:R18>D8QS8WUJV<X;'N5:@XX;$O-N,4J-65
MO;Q2O%M\:D4V^,E)DJ:F[4<5HY0H8A3QF%648M^STH]5.3NI)<H2LEPBTLCK
MZ;:?!K\7=.WJW%4TU>1-X4A U*2R9]85J&+]:A_9U@JG\8CUT1'5%[PO)*VK
M9&FRJRU%@FKYU=LQQV9^JS)M/\GWE;9;9JVR.[9>XRL.*:1[$>Y+97PR5=/N
M:KHZNWO5E=231JY&315-/%)#)K'(UKVJA NF-5\;@)-8BA.,4[*JEOTG[VI&
MZMS2>Z[<BQV@=;]'Z1BGA<3"4WQI2>Y6AV2IRM*ZX;R3B^3/HL%/;^?X/-W]
M 1YX)LMRH"&H53&\NM&2(((I$70 !#7L,W!$$-2FD@,77852"KH6M161PQOE
ME<V**)KGR2R.1D;&-35SWO=HUK&M17.>Y4:UJ*Y5V=YY)\L7GNL@,G&5-)<,
M5)B[$L&K6X4P.E-?;KTJ)JC*RJ2II[/:FZ*CEDN5RIU5FO01SR[,3NW@M'5\
M3-4\/1JUIO+=A"4K=KLLEVO(Z&D=*X;"4W5Q-:G1@E?>J34;]BOFV[<$FWR/
M7)SNO?Z.'G[_ $'CORZ>>XR4R,NU-ARYW:3%6)_'Z2GO%CPLL%RGPW0RU44=
M=67N=DGB]+445*LM6EG21]VG2-C$I8DG@>_4FY='A"&<V;45=8\+2?W*\(56
MW$ZBP[732XFK*5RZ[%?B=(Z6I@<]-$E;9Z>W?8["2O:LBR>"SEU<YRZJY[G/
MD<Y=ISW/<Y[WN<NKG/>][G.>Y55SG*YVKE<JR[J[LFE-*II&;A[G#TVG+OJ5
M%=)KW,-Z_.2S1".L^V>$;TM%T^D=TI8FJFH9.[Z.FU&4D_%<I;KYQB^)V,,.
M8CM]WH*"ZVRK@N%MN='2W"WUU-(V6FK:*L@944E7!(SR)(:B"2.6*1ODO:]J
MMW*9I%W_  &J9X-#SAK<4X7K,B,2UJKB'!5')=L&RSO15NF#UJ&155MA<YR.
M?58<K*B-JPJU%6V5M*^'IDI*MT&ULW3YR+M/:'J8#%U<-46<'X,LK3IMWA-=
MZZN#NFDU8F'5O3M/2."HXNG9=)%;\4[]'55ND@^=T_2FFFT3  \@]T
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M\9I?#MQ;I89O$U';+P%[&G[ZHX6YV3MP9L1MZNO=W\WL*I+IP7S$Q5<N(E8
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M@!7!!%(@
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MRZFN*+B-N]/09*)-VA:1LU7X/5V>PR,:=9!Q80O(6]_092)-Q8Q-[^@R<:<
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M5M"JM2>!(G122V<U.UWH:3@J<FJ6+BO"HWRG[J=%OBN?1\8*_%+>*D:\;/\
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M"<D3[)>_83D$+@BQ8 !D
MU:O"L/N/9>?C#;\@W(VE35J\*P^X]EY^,-OR#<C:M1O*^"^%_N3-+VB>1=(?
M KZR!HBK]'Q$"*_1\1 MJN"*5+[_ )P #)D]D>8'^^IRY_B\0?(]0=+Y."'-
M!Y@?[ZG+G^+Q!\CU!TODX(5RVM^4:7Q6'UE4M-L4\EU_CE3Z$"( (L)B
M                       !^>9N_O4Q/[W[S\G5)^AGYYF[^]3$_O?O/R=4
MGTH^/'WT?G1\<1^3G[R7T6<?>H^V2_QLO]HXI%6H^V2_QLO]HXI%V:?BH_/^
M?C2]\P #F<2TK_M$W\5)_44Z_?)^_>'@?WH8;^1:(Y E?]HF_BI/ZBG7[Y/W
M[P\#^]##?R+1$)[9/$T?[[%?-0+ ;"?&TGW87_&/V  $%EB
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MJ&,>ZKW:IXB*2@^SI%:#[=SJ-[8%!J]JK^DJM77>5O[&OQYLD6JO]W-<.\F
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M#LWU2_DK!>RJV+Q.[5K\]S+P*2?5!-WMEO-D0 :,2(
M                           47IO*;N!7?P*0"915=40I.XHI61.*%-R
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M47V$Z+IZ.H'*W^Q68N\K%N3-=H#B5@
M                                   "DYVI%SNI"F "EKJOF)G+KN0E
M<J<$!E,@Y?845W^A/A(N7])3>Y/4@,$KG%LY="=5+:1X!(]Q9O=\!5<[VEF]
MP!3>_P"@L7NZRK(XL99._P X!;2O[^8LI'%615+.5P!;2O,;(O$N)7]^_:8^
M1W%0"VG>6$CRM([4L9' %&5W%4WZ)Z=3P1Y_OE@)@'*AN!;95I'B3,U]1:W1
MQNTJ:?"M(L;[]5[2)M1LJ5EI[4C]O:<M8]C6JQDFS[MW6Y04=/4555*RGI:6
M"6IJ9Y7(R*&GA8LDLTCE^Q8R-%>J]B:HFIS=N<NY74V=><&)<81S/=8:9T>'
ML)0*J[$&&[1),RDF:W7926Z5,M7=JAS4\N6NV45L<<4;)"V<: >,QT:LHOH<
M+:I.ZR=2_L<<\FF_"MQ:BR,]JNLBP&CI4(.V(Q:=*%GG&FU[+)6S3BGN]\D?
M!2:<--$3=[/0 "SWX_';;*Y4-?ZOO?X^4    'ZGD?E%<\?XRPO@BSL5USQ5
M?+?9*7915Z):V=L<U2[<ND=)3K+5RO71L<,$CI/K:.5/G6JQIQE.3M&$)3G)
M\%&-V_0DV^RQ]:%"56<*<%O3J2C"$5QE.34817;)O(V[?!N>2V^Q8#Q-FI=*
M5(KACFX)9\/OD:J2LPK8'JVHJ4VDU:V[7Y]4C$1KMJ"S4=5&_HZI-=EYB:)W
M^E?C/S')O*NUX(PKAW"%EB;#:L-V>@L]$QC.C:L%#3L@238U7969S72N3:=H
MYZIM*?JD32GVL>E7C<;7Q+X3G+<5V[07@PX]44O/GS+RZK:&CH_ 8;"1M['"
M+FTDMZH_"J/ASDY>;(O(&:;S(Q-+:)O!/:9")IXA[Q?0MX%_&GT%M&WZ$+Z-
MO  NXFF1B3K+6-/H+Z- "Z8G67C$X(6[&\$+QB?H +AB%PQ"DU"[C3X "9&[
MT\R%9O:4F)U]I57AZ_F 1.PJ-XH2M3<5&)U@RV535[\*D^XQ@?\ &!#\CUQM
M"&KWX5)]QC _XP(?D>N-IU)\K8#XQ#[33-H7D72/Q:?V&AF "V_5W+YD4J?+
M\<V  #!M%>"J_=@S$]X%+\M1F^+U^SYS0Z\%5^[!F)[P*7Y:C-\7K]GSE7MI
MOE>M\'2^@BW.R+R+0^&Q'TV1 !H!)X                    !!3XIY>W(:
MPAR@<OKE@7%E.UCW+X_AV^Q0QNN>&;_#&]M)=K;*YJN8NR^2EKJ=%;%7VZ>J
MH:A'13KI]K@^^%Q-2C4A6I3<*E.2E"<79Q:ZG^+K)Y'6Q>$I8BE4HUH1J4JL
M'"I"2NI1?%/\71R-^5;R7<6Y-8\ON7N-*):6\V2H1(YV,E2AN]MFU?;KU:IG
MM1)[?<8MET4C%<L$K)J2;HJJDE8WYW.F_P [CS75DY2&!GQ4S:6VYC8:IZJJ
MP1B![6,VIW-Z27#]UFV=MUENSV-9)O7Q"JZ*XQ-5T4D4O-/S!R_O>$[[=L,8
MEME79<06&NGMMWM5='T550UM.Y&R12-7<YKD5DM/-&KH:FGEAJ:=\D$T<CK2
MZEZVT])X?.T<5125>FN>5E4@GQA*V?N'X+Y-T\U\U+J:(Q.2<L)6E)X>KQYW
M=&;Y3@FLWX\?"6=U'^0 !NAH8-FKP6+[N>,?Q;U?R]:#65-FKP6+[N>,?Q;U
M?R]:#4M>_)&.^"7TX&Z[.?+>COAI?55#?D3O[5)B5._M4F*EK[_G+I@ &0
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MV$":1T9B,)4=+$T:E"I')QJ1S[U;*2[8MJW,F [[]WP*#N'0
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M='A:5I.W25YVE6JOCX4[7W5[6*M&/)7S)--/@[\"H >$;*
M       ""]7?J4B07J[]2@$.KU?,<N3GF?OI\[_?A'\@64ZC?5ZOF.7)SS/W
MT^=_OPC^0+*2QL?_ *=B/BO^) AC;=Y-PWQN/U50\S  6(*O
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M"0KMC_)X'W];Z,"?=A7Y72/O,/\ 2J'[$GV2]^PG)$^R7OV$Y!"X(L6  9
M                                      -6KPK#[CV7GXPV_(-R-I4U
M:O"L/N/9>?C#;\@W(VK4;RO@OA?[DS2]HGD72'P*^L@:(J_1\1 BOT?$0+:K
M@BE2^_YP #)D]D>8'^^IRY_B\0?(]0=+Y."'-!Y@?[ZG+G^+Q!\CU!TODX(5
MRVM^4:7Q6'UE4M-L4\EU_CE3Z$"( (L)B
M!^>9N_O4Q/[W[S\G5)^AGYYF[^]3$_O?O/R=4GTH^/'WT?G1\<1^3G[R7T6<
M?>H^V2_QLO\ :.*15J/MDO\ &R_VCBD79I^*C\_Y^-+WS  .9Q+2O^T3?Q4G
M]13K]\G[]X>!_>AAOY%HCD"5_P!HF_BI/ZBG7[Y/W[P\#^]##?R+1$)[9/$T
M?[[%?-0+ ;"?&TGW87_&/V  $%EB                       #%@4W-ZM-
M47CW[IH:^?.?\P9@;.R6X8RP,ZCP#F94-66IJH:968:Q14M:Y6OQ!;Z5NU3U
M\R[+)+Y;X_&W*C):R&N>Q%780!Z.B]*XC!58UL-5E2G'JX27N9+A*+YIIW[S
MRM,:$PN/HRH8JC&K!\-Y9Q?*4)<8R7)IKT-WY&_*6Y*.8>3^(9\+YCX5N.&K
MK&^1M.^I9TMLNL#'+L5EDNT#GT-UHI&M1[)*:5TT>]E9%3U3)J>/YW[_ #_%
MO.NUG[R;,#9HX>J<+8_PS:L462J14=2W*G;*^"3<K*BBJ41M30U<;FM?%4TD
ML4\<C&.:_5J*FGQR\/!@\0V>2NQ!D/>UQ%:?KU0F!<33QP7ZB3>_Q>SXA564
M=W@TUCIJ>ZT])71(D;)[A<9)9)XY[U:VH87$*-/&VPM;);]VZ,_/FZ;YVG=?
MIE;];=D>,PK=; 7Q=#-NFK*M3XOQ<E427.&?Z',U+ ?H.:.4^*,$7NIPYC+#
M]VPQ?J15Z>U7JCEHJM&;;F)/$DJ;%52R/14CK*5\])*OVF:1J(I^>]^_9NW^
MC?PWDI4ZD9Q4X24HR5XRB[Q:[_FZR(*M*4).,XRA.+M*$TU)/N[/-;J(@=^_
MS=J Y]QP8  ,                #Y^_P']EEYESB#%UXIL/X5LEUQ)?:Q=*
M:TV2AJ+E7RIM-8LOB]+'(^*G8Y[>FJIDCIH&KTD\L<:*Y.,YQC%SFU&,?&DV
MK1[7U+M;1SITY2DHQC)REXJ2;<NY1NV^I<6?QW?>?1_)8Y.>9F9F+[59LJ;%
M>;OBFEKJ*NI*ZU.6CBP[44M1'4TEYK[ZYT-+8HZ">&.JAK9ZF"5DD4?B:2U:
MP0OV*.0MX,-BR_RV^_9YWS]B-D\BHDP7AV:&KQ17-T1Z4MQO7UZV6.-VUL52
M445TK7,22&GFH)71UK=Q?DY<EW 64V'J?"V7N&;;AFS4^RKH:&+Z_63-:B.J
M[C6RK)67&LD7:=+55DTLTCW/<YVJJJQ9K+M.PF'4J6#W<55:E%R=^@@G=6;?
MY5M\HWB_=<B7M4]DF-Q4HUL:Y8*A=247;U34M9WBD_8<N<[37N.9_<91TV)H
ML,8?BQG+;:G%D5GH(\25-G;(VUU%Z931MKYJ%)8H'MII:E))(FK#%HCM&QL9
MLM3]&:B]9."NLG>3EDKW=EDLW?)<K<$N2+2PCNI1NWNI)-N[LDEF^;=KM\V
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MLZ>'OV/*=5<IK*.:C?BX-1=.SOW[->S30J-UZR8$7DP
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MJ
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M)63]XENI<%=OF4KUZUE>E,?5KQ;Z&F^CH)\%265[<+U))RD^-E%/@  ;4::
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M3CNSLI)Q23X.2^4G3470%71FCX82O*$ZD*E6=Z>]NVG-N/C)/)9$P -9-Q
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MDB"1Z:+KP^C3OZ5)]GAYB8&JV-R(:;@B$09
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MFVW6?,S ]S8FUT<=707JW3.T:]6[2HRJA9M.2-BKMJC5<KOL6GSW>_!D>4G
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MS!:.AT>$H0I)^-*UZD[>[J.\I>=V)=-Y%$(@\BQ[@ !D
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M$VNGG0')YY\.PK-=H544H:A%!Q+@$J.)@
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M"(                               (;*#0B  2JU%)@ 05"(
M                           (:$0 0V4&RA$ $-!HA$ $$1.'4-"( (:$
M-E.SOP]7I)@8L"&R@V4(@R"&R@T(@ AHA$
M         $$30B ""H1  (:(-"( (:!$(@ AH@1J=U]1$&+ @J$%:BDP,@AH
MA$  AH@1J$0                                  0T"(1
M                        !#0B                             ""(
M1                                              !!4"(1
M!#0B $@                                   $@     +
M                        $--^I$  @J:D08L"&R@V4[._'XR(,@EV$&PG
M'3>3 "Y#0:$08LNH$NPG8-E"8&1<ALIV)["&PA,#%@01"(!D$$30B
M                   "&A$ $- J:\2( (:#93L(@ AH$:B=^PB "&A#93AH
MFG9Z>/MZ^TF L"&B!$(@PU?B@0V4(@&0
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M7]I11VG$G 2+C4%!%*K7:@P3
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MIGQ%)B=97TW(G: 3M[>TJ\$])*B=1.G'T RB9J:(5&)O)2JQ-P,$X
M
M
M
M
M
M
M
M
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M279ZN^A51.H F;N15]1.U/A)535=$X(5 9N10KE-B=94!@
M
M
M
M
M
M
M
M
M                                           HN3>4W)N+AR:E$!,I
M<4\Z%%R%==RZDKD^$ MW;^KT^DMG)H7G7IU+\90D0 L9&\2T>AD7-U+21 #&
MO:64C-#*/;U>PLWM ,3*PQTC3,O;U%A*S0 Q,K-3&31F;<WV%C*P P;V]1CY
M&::F:E86,K-4 /Y:\VFFKJ:JH:VGAJZ*LIYJ6KIIXVS4]535,3H)Z>>)?)DA
MFAD=%+$[<]JNU7150YX?.R<WM4Y!YA/@MD,TF ,525=QP;5O1SVT<;'-?68;
MGG7>ZJLZSQMIUE^NU%N=32*KY8JB5_13='U'R#RVN2!AS._+^[8%Q'$QBS_W
M[8KMT3)*O#]_IXI&6^[T4CD<]CXTEDIZF-FGC=OGJZ*9'Q5,C5W34G6B6C<4
MG*[PU5J->,>"?"%3O3=GV75S0]H&J$=+8)Q@EZKHIRP]1NR?.=)OEO[J_62=
MCF. _7,^,C\19;8OOV!\5T3Z&^X>KGT59&J+T-0Q$1]+<:*3["IMUPI%BJZ&
MJC5T<M/(U6NW./R/OZNWT;N/ M/1K0J0C4A)2A-)QDGE*+5[Q?-?ZE.*]&5.
MI*G.,HS@W&49*THRC+=DI)\+._R=H !]3Y   =:Y-6:_'R=1])<DSE4XJR:Q
MQ:L=X2J$;74&U3U]OF<]*&^V>=\:UUFN+6+JZFJFL:Z.1&N?2U4<%7$U7P[+
MNB[R0^5CA3.? ]JQSA.H5U+6MZ"Y6V=S/=&PWB-C%K;/<XF.<D=52N>W9>U7
M05,#XJFFDD@D8XYB!]\\WER_L3\G_&D5]M:3W/#5S?!38NPMTW1P7B@C=Y-1
M3;:.BI[S0-<^2@J5:B2)MTD^U!+K''NO6ID=(T^EI14<72B]R7!58K/HV^<O
M<-W:>7 DW9UK[/15?H*\I2P5:2WXK/HIRLNDC%9N/NX*V\LXYIWZ3+'^PNF/
M[?4?BV1V>.%\QL+VG&6#KK%>,/7JF;44=7&UT4C/X,M+64TGUVCK:21'055+
M*B.AF8YJ*YFP]WZ^Q_L*RU:4H2<*B<)Q;4HR3333M9KD[\+\5P+<TJD*D54I
MM3IR2E&2::E%\&FLI<LT9>*73K,@R0P3'E[%-H?,Y&<CE,A'*8-CR]CDT ,T
MQY=QRF)CE+MC^P S,<A=L?YS",E+V.4 S+)//]!7;(8EK^PNHY #*,D]1<-?
MZC&M?VE=K_8 9)K]2HCBP:_V%=KP"^:_]14UUZ]/,6:+J5$>H!=([M)T=V%N
MU_ZB?5.K<H!<:HO$CZ%U*"+V^W]1,B@YJ961W:A-J4]OUC=U*#@52.JE+?U+
MJ11W:#*5RNC^T(\H[2$P#5BOJ@U0H &"XU!0U(H]0"L"EMJ-M0"J"EMJ-M0"
MJ"EMJ2ZJ 5R&J%  %57D-LID%5 ";:4@2*_L&_T Y;K)]217DN[MU\PV^Q-
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MY8WV%)B%QYD]8!%O:56KHBD&IU$Z[UTZD!E*Y,U"=$(%1C>L&"H
M
M
M
M
M
M
M
M
M                                                   47(5B5R:@
M%!4U0IIO30JDCDZP<HJY1<FI35-=_7UE=W:4G;EU[>(.):.0MWM+U[?T%NJ
M&.>TM'H9.1A9R- ,6].)8R,,N]A9/;H 8:1I:/9KN,M+&6#V>T P\L9CY&_I
M,Y)&8Z6/O\P!A9H^PQ\C>M-4T^/L[^U%WF;>PQ\L867-K*SMU7O?M8M?+C=W
ML^%^&74>&'/0\V=%G/A%^+L*TC4S+P?0SRV^.)(XY,46>/:GJ<.S/=LL=61K
MM5-DFE5.CJD?2OD;3U<VNA3-%)&^2*6.2&:&22*:&9CXIH)HGK'+!+%(C9(I
M87L6.2)Z(^-[7,>B.:J)UF9&:<./SJBIU[M%54157<B*J^<U'.?@YK.2*:MS
MQR\MC702*Z;,:PT,*I)$_1NSC"@IHFZ.C54=%B&"-J/8]8KHQKHFUKDF;9MK
MFJ3AH_%2M3E?U-5D_$;SZ#/A%VWD[Y/+F03M8U%==3TGA(+I(I/%4H1SE%*S
MKI+.4H+*2XN-GQ1JB@(NJ(J:*BIJFG#1=Z*GI14W\%X@GM_[/KZ[KDUV<BMO
MR/J?S]W5SS  , #T\._M]&GH5 !^/]A^/].[[<SU)YL#G,+_ ,G[%&S4NJ[O
MEY?9&QXGP[MN<M,]SFL;B*QQO<C8;M2Z(D\#']'<J5\M/(B5'BE13] #*?-C
M#V-\.VG%F%;I37G#]\I6UEMN-(]'Q31JKF/8N_6.HIYF24U732(V>FJ8I()F
M,D8Y$Y6R=_A^9=-."[M471#U0YL'G/,0<G[$7BM2VKO67%[K(GXEP[$]'3TD
MC]F.6_6)CG] RZ00M1)J1[XHKI%!%3RR02MAG;&&OFHBQT98K"Q2Q27APX+$
M)<+\E47M9<'SS)@V;[1Y:/G'!XV4I8-OV.I)[WJ:^32Y]"^,X<4\UEPZ(;7E
MRQ_ZS\KRHS9P[C?#]KQ3A2ZTMZL%YIF5=ON%(_:CFB>B+LN:NDD$\2JK*BFG
M;'/3RHL4L3'HY$_2VO\ 85RJTI0E*,TXN+<6I*SWEQC;)W7H9:6G4C.,9PDI
M1DE*+BTTXOQ7=9>$LU\IEHI5+YK^PPK)."=]2Z9)W[]9\SF9R.3SE_'*8)DA
M>1R]_H ,ZV3L+EC_ -1AHY._?K+UC^H R[)"\8_SF%8_]9<LET ,TU_G+ADA
MB8Y=>)<M> 95KRNV3U?$8MK_ %H7#7^P R39.Z%9KO88UK^PK-?Z@#((XJH_
MM+!']I61X!?MD_41U3SHOF+-'(3HY0"Z1?/\9/M>DM4>54?Z% *Z.["9'J6V
M[]7Z29/-[% +G:1>*$-$ZE*.TJ<4&V@%ROLKV_"$U*2/3M)D?YP"IM+V$-OS
M$-M1MJ#E==7RD4?YB.VA)M^9!M>9/8!==7RD^VA#;)=KS)[!M>9/8!==7RDW
M2>8CM+V$NWZ!MJ!==7RDV\ALKV_"2*Y>TE5_G!B_XR^XJ*G:I!%3L^$I[:$-
MI>I +_BR*VVI(KBGQZT0E70&"IM)Z2#M?0A)M:=A2=)ZP"MJB>=21TG="BKE
M)%5 "JK^PI*[M*;G]A1<\ K.?V%%SRB]_P"HHN?Z@"LYY;N?^HIN>4'2( 5'
MR?J+9\A3?(6SI>_6 5'O+1\A3?(6KI% )Y'_ *"V<_M)'R:%E)* 59)>_P!!
M8OEU*4DG?M+5\@!,]_:8^2022:ZZ>WJ]9:2/[J 'N]I:O>'/,/=[O2T--45M
M;4PTE%1PR5-75U,K(:>FIH6+)-//*]6MCAB8U722.5&,:BJY43>946\HIMO@
MDKOT<^NQAR2S;LEQ>2MYWD372Z4U'35%965$%)1TD$U55U=3*R"FI:6G8LM1
M4U,\KFQ04\$372S2R.:R.-KGO5&HJFCSSPW.ZSYMU<^767E7/2Y:6^I<ESND
M+I8*C'5=$JM1ST\AS,,4BLVJ.E5K5N<SUJZK;@;21LN>> YWZHS7JJ[+C+>L
MJ*7+2CGZ"[7:-705..JJF?J[91%;+#AF&9JK2P2(DET6-E95,CA='2IK_;M-
M$7=YNM//\:]J\=2P&H&H*PZAC<9&];)T:,E^23S4ZBX=)U1MX'%^%E&M&TK:
M3ZI=3 :/G_-XO=KUXNSKM<84[?U-\G*_AM67@)N0 $O)$(7_ !W@ &3   !!
M5\^G?XNTVX^8.YL9*:&ASWQW;T2JJ&.DRWM%7&BNIZ*1%8N,)XGMUCFK6*^*
MQM^SCI%?7HK/&8=?-_F9^; J<YL418TQ=0OCRNPQ5(^9LS4;^R^^0.8^"QTS
M/*Z2TTV^:^5:Z1O1(;=!TKZFI=2[Z-%1QP1100QLA@ACCBBAC:UD44<;&QLC
MCC:B,8QC&M8UK41J-:B::[UAC:7KFH)Z/PTKS:MB*D6K03XTD_=/V_-1\'BV
ME/&RC41U)1TGBX6IJ5\+3E'\I**SJM/VL7^3R:DUO+))NYC9IO7OU_3\VG!+
MZ&->/L]!(QFJZ=7?]1D(V_I(&+(?C[O03QM^ R$3"E$PR,48!5C9H7C&^TD8
MW]!?1Q]^T J0L+^-I38WJZD+V- ">)FF\NV)UDC6^PNV-_0 5&,_27+4)&MT
M+AC?A )T3V(5&IVD$XZ=2%9J:J 1X)Z2=J:(2\5\R%0')NQ%$U*Z$C$ZR<'$
M
M
M
M
M
M
M
M
M
M   HO3>2E=4U* !31-^B^HIJG4I5<G607>FO6#+Y%OIU=?5Z/U%N]O672H2.
M1%0&"Q>G66CV^PR#DWEM(S] !C7MZBSD89-[?:6KV[@#%/86$L9F)&?H+.1G
M?YP#"N;IZ"SE89>1GZ2RD9^@ P4S._SEFYOF,U+$8Z2, PDC-/0OS_2G'S;N
M"F,K[?#4PRT]1#'/3SQOAF@F8DD,T4C59)#)&YKV/CE8KF.8YJM>U7,5-%4_
MHGQZ[M#'R1Z+IU=^WM,J5G=<4T[YWNN&:SOU&))/BK\<GGD^/'KY_*:%7/*\
MU?-DQ?9L=X,I9I,L,1W!?[W367]AMYKI7O2SOE57.=9ZF57-LL\JN?$Y/<R6
M621D,TWABIU9LQLO;-BNQW?#.(K=37>Q7ZAGMEUMM9&DE/6452W9DAE:J+HJ
M:))%(U$E@G9%/"^*6-LC>?)SHW-I7OD^XL1U*E1=,N\05$C\*7]R;:TSUVY7
MX;N[T7:9<Z%FJTTS]EMSHF-J&*LT=3"RQ.SW7;U7".$Q4UZIBK4YO^OBK)1?
MN:D5SX22OUWJ[M.V?/!5)8_"0?J.H]ZM35_YO.5_9(VXTI/.W&#RX-6\LP 2
MJNSARYOSLAJ_W=CMS2[>8 !D =]_#J]G!/1H /QU_)S%_P ?C@>G7-M\YQBW
MD^W]61K47[ %UG;^R'"4TZM8QSG)K=[&Z15907B!%<KVLV::Y,VH:UG2-AJ(
M]^[(+/[">9F%K9C+!5XI[U8;I'K#40KLS4U0Q&I4T%PIETFHKC22*L=323M;
M(QR(]FW!)#+)RU_1Z.SNA]R<@_E^8VR#Q0E[PS-X[9*^2)N)<*5DCTM=\IF:
MHKT5NUXC<X6*OBMRA;TC=T<[)X4;&R--=]0:>/4L1A]V&,2N[91K+E&262F^
M4N;\&762QL^VD5=&..%Q>]4P+>5VY3PZEQ=-O-P]U'C%9PMP.E:U_9PZRZC?
M[#XXY&O+7P-GEA6'%."J]7+'T<-YL-:L<=[P]<',1SZ"Z4L;Y&(O735L$DM)
M6PJR>"1S)-WUZUW#354TW>=.WU[E]*E<L3A:E"I.E5IRIU(.TX3RE%\LN"36
M:L6GPF-I5Z4*U&I&I2G%2A.#O!Q?!WYOW5^?G,JQ^SPWEXR5%,-'(7#']AUS
MLF=;(7L<I@8Y>"?&7K) #/,E+AK^PPD4I>1R@&7CD+MDQB&R%=LGZP#,,E+I
MDFAAF2ETV4 RK92NU^XQ;)/45FR=T ,HU_854D,8V3XBNR0 R39"HDICT?YR
MHCP#);9%'(I8))YU*B2>@ OD70F1Y9I+YRHDGK +OI?23=)YRS1Y/J@!=[2=
M:>PCJWL+1%([2@%WJG4NGJ(;7G^#]!;;2DVWY@"Y_P#>3X"&_M0M^D\PZ3S
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MI,U.L&5UDR)H3M3524K-3<#!,          0U (@               AJ1
M               !#4 B   "&I$7                      !#4B  -0
M!J  "&H!$                :@ #4
M                                               #4  $-2(  &H
M!#4B              !J     "&H!$             :@     AJ 1
M                               &H  U               (:@$00U(@
M              AJ 1    &H                    (:@$00U0B  "&H!$
M$-2(
M
M
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MX^U]_P",[<D51UWVB8G2TG3@Y4,'%^!1CDZG+?KN]I99QAXL6^;28 !O9'0
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M.NX CL]7M*B)U$&IH5.&[K4&5;F1TUW=2%0@U-"9$U ;^0F8G652")HA$&
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M+&$E9O)9R=^LE+9=KICM*U<9#%RIR5"%&4.CI*GG4<U)/-MVW4?48 (L)C
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M)::**-8-1<?H^]2=-5:"O[-1O**7Z<7:</UENWX29,VK.T;1VD[0A4="N_\
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MV(HTI[M%1ENSJ1B[.^63.FFUJ>TJDBKN]&A%O KNOQ\I: F !D
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MK#4+]%2FHPWI.3LX1EQ?'-LL=J9I:KCM&83%UW%U:T)2GNQW8W52<5:/+)(
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M
M
M
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M:SY#Q7O\/]?3-54 %I2GY2G^UR?Y#_ZJG6RY$/W',K?>#A3Y$HSDFS_:Y/\
M(?\ U5.MER(?N.96^\'"GR)1D.;9?R& ^$K?0ID\["OR^DO>4/IU3ZC ! 18
M\         $%7@1*<B]^_9Q]6]4,/\?C\=HN4U7ANZ^M=WM^+OIXO<ZQSRF"
M^3I;WV.WI2XJS3N%(V>U83CJ-*>U4\RN9#=\35$*/?043MF5U'2MTK;BL3T@
M:R%KYVX'GG>=OMO)VPQ%8,.)2W;-;%='4)8;=(]74N'+>K70OQ1>FL15Z*&5
M>CM%M562W6M8N]E!2UU1%SG<:XVO.)+O<L08AN=;>KY>:R6X76[7*HDJJZOK
M)W(]\]1-(JN<J;+&0QII%301Q4U.R.GBCC;*>H>H,L:UB\7O1PJ=Z=+.+Q%G
M9YI75-6:<DTY/*-EF0[M&VD+1[E@L&XSQF[[)5R:P^\KK*[O4::<4TU%.[S5
MC]AY3G*OS SCQ/4XNS%Q)6XANT[GI31S/=%:[/2N>][+=8K4UWBMJH(.D<V.
M&G8DDFU)-5RU-5--42?._P"CUZ(B>;L]&_AU@%B</0IT8QA2A&G""M&$(J,8
MKJBEDDO]2K^(Q%2M.52M4G4G-[TISDYRE)\7)R=V !V>G3OUIYM$7:71-W$^
MMCX]OX?< ?U6"<"WW$U8ZW8:L=YQ'<6HU74&'[57WJL:UZJC7.I+93UD[479
M5&*K-'[M-%VD3[MPAS1?*9OL;)K=DOC/H7['UVMI[?;$:DBJC'.CN5PHYVHF
MR[;3H7.:B>4C55J.Z6)TEAJ/Y;$4*794JTX/T.2^_L._A=%8JO\ D,-7K+KI
M4IU/HQ9YT ]/KUS+O*EH6+))DQB>=B1K(YU)56*H6-&HFJ.C9=ND>[5=S8V*
MJHFJ)OT3XLS:Y->8F TDDQK@3%^%8(WHQU9?,/W2@MNVJM1&LNDU*RVRJJNT
MTCJW*CM&[UW+\L-IG"5LJ6)H5'PM"K!N_59,^F*T+C*"O6PN(IK].A47GNXV
MMVW/Q0$&N14U145.U%U3XD(GI?A<,_QVV/+;MQOZ&_FN#)6>\5ENJZ:OMU75
MVZX44T=115]OJ9Z*NHZB-VU'/25=+)#44T\;M%9-#)',B_PW:-TQH.+2=TU=
M-6<7PSZU;/YCG";34HNUN$X\;KJ>5K=?+D;H/-%>$..N51:LM>4#<H(JN5L-
MOL&9]1T=-3UDZ*R&EH<9*C8H(*NHU2-F(8VQTLTZ,]U&P23/K';@E/4,F8V2
M-S9(Y&M?%(QS7L>QR(YCV/8JM<Q[516N:JM<W147LXW6RBZHJ(K5W*B\%;IH
MJ+N=JFSKNTWIJBJB*IMV\PEST4]KJ[/D5FS=GS6RLE@MN7F+;E4;3K?5RN2.
MEPG>:N9RN?25;W,BL-?._6GG7W-F<L<E$I!VOFSR,8SQN A91\*OAX*RZW4I
M)<++.5-96ON^Y+![.=ILI2A@=)5+[UHT,5.7!OP52K-YO>>4)N[3LI<5)[L2
M?.1**+P\^_U*3(OG])"/FY?A=Y8)?[]A4 !DR    "1573=H :J'A8?W+,J?
MQEU'Y(7\T83?[\)?Y/\ CC,++?+6WX&PI?,65UNS GKZZDL5#)6STE$N%[U2
MI53,9HK(5J9X84<NNLDC6IVIIQ?M:?*#_ SF%_0%06.V9Z1H4]%0C4K4H2Z:
ML]V52$79R364FG\A57:QHW$5=,5)4\/6J1Z&BMZ%.<HW46GG%-<NL^(0?;W[
M6GR@_P #.87] 5 _:T^4'^!G,+^@)R0/Y8PO]HH?OJ?\1&G\BXS^R8C]S4_A
M/B$'V]^UI\H/\#.87] 5 _:T^4'^!G,+^@*@?RQA/[30_?4OXA_(N,_LF)_<
M5/X3XA!]5YB<AG.3"-FKL1XHRQQG8+#;&PON-WNEGFIJ"B9454%%"^HG<J-C
M22JJ:>!BKKK+-&FY%54^55[]^KL5-5T7=J=O#XJE5CO4JD*D;V;ISC-)V3LW
M%M)V:R.GB,+5HRW*M*I2EN[R52$H-Q;:NE))\4R  ^#SKP0^Y\/QYLE]H!^^
M9.\E?,K,*FK:W N!L2XLH[;4,HZ^HL=NDK8Z6JDB;.R"=S-$CE6%[)-C>NRY
MJZZ'[%^UI\H/\#.87] 5!T*FE,-"3C*O1C)<8RJ0C)/J:DTUEGW'?I:*Q4XJ
M4,-7G%^+*-*<HR2RNG%--7/B$'V]^UI\H/\  SF%_0$X_:T^4'^!G,+^@*@X
M?RQA?[10_?4_XCZ?R+C/[)B/W-3^$^(0?;W[6GR@_P #.87] 3D?VM+E!_@9
MS"_H"H'\L87^T4/WU+^(?R+C/[)B?W%3^$]D?!8/NW8V_%U-\N6TWWF_1\2&
ME5X-]R1\S\ 9OXNNF-\ XIPK;JK <U%35M[MDM%33U7NQ;Y?%XY7^2LO1L>_
M8X[+'*B:(INJM7S:%;MI=>G4TM5G3G"I#HJ"4H2C*+:I)-)Q;3:?'J+6;)\/
M4I:&HPJPG3FJM>\*D7"272RLW&235UFLN!, #0B20     #^7QM_Q-=_YKK_
M /59CCC6?]R4O\G@_LFG8YQM_P 37?\ FNO_ -5F..-9_P!R4O\ )X/[)I.6
MQKAI'OPGS8DKSMW_ /IG?B?\$R( )N^Q7]!7T _2\I\FL68[NJV+!F';MBB]
M-HY[BMLLU(^LK$H:62"*HJEA8J*D$,E33QOD7<UT[$T550^D_P!K3Y0?X&<P
MOZ!G.IB,?0I2W:E:E"5D]V52$79WL[.2?)G<P^CL16COTJ%:I"[6]"E.4;KB
MKJ+5SXA!]O?M:?*#_ SF%_0$X_:T^4'^!G,+^@*@^'\L87^T4/WU/^(^_P#(
MN,_LF(_<U/X3XA!]O?M:?*#_  ,YA?T!4$?VM/E!_@9S"_H"H'\L87^T4/WU
M/^(?R+C/[)B/W-3^$^( ?;W[6GR@_P #.87] 5 _:T^4'^!G,+^@*@?RQA?[
M10_?4_XA_(N,_LF(_<U/X3XA/7?F&_OLLH_Y7B?\B\0GS-^UI\H/\#.87] 3
MGJ)S+W(:SDPCRF<L,0XHRQQE8+%;JK$3J^[72SS4U#2-GPG?:6%T\[EV8TEJ
M9X8&:IY4DK&\%4\;6+2N%E@,;%8BBV\+722JTVV^CE9)*3;;>2[3WM5M$8N.
MDL!*6%Q"C'&8=MNE-))58MMMQ222SS9T*NI?5\2$Z?3\931=4[?@^#OIH5$*
MDIY_C\<RZ]R( ,@      $'$BKW^,_BLRLQK+A&P7?$^([C36BPV*WU-SNMQ
MJY$C@HZ*DC=+-*]R[U79399&U'22R.;%&UTCVM7*BY-1BFY2:48KBVW9)+G=
MY'"I4C"+E)J,8IRDWPBEFV^62S/YS._/'"F7&&+KC+&U\H,/8<LM.M17W.X3
M-AB9JY&0T\*+]<JJVKF<RGHJ*G;)55E3)'3T\4DKVM70 YU+GV,;YX55PPG@
M6>XX)RJ:Y8%I()5I<0XOB:O[IO\ 5P/Z2CMLKO+@L-)*C.C1K[G/4RN2FI/G
M/G8^=3Q'RD\7?6O&[1EKA^ME=@[#$C]E\KVMDIVXEO4;-&27JMIY)>AB7;2T
M4=1)0P2/?)533^2W L1J/L\IX6$,5C8QJXIVE"C**<*'8T\G465Y--1?"[5R
MKVT#:95QE2>$P,Y4L'%N,ZL)6J8F]UE)9PI/.T5G-*\FDTB"-1-S41$3<B-1
M&HB=B-:B-TW;D5%V45=G95=4B 2OW9]2Y_+;AUWSY)$-M\W9=BX+JZWGSX]X
M )7O1J*KE1J(FJN<Y$1$W:JJJBIHFY%UXJJ)JU5VD=^77=K+Y;&4GPL_O[4G
M9LF!^M9;9!8\QDQLN$<$8PQ1 ]6HVJL&&;S=Z1-I=E.DK*&DEHXD5V[;DJ&L
M3MW:K]=6+FCN4U<FM?19*8VD:YG2(L]/;:+5FNSO;77*E<U5=HFRJ(]&^5L'
M0Q&E,-2OTF(HT[<=^K3C;]J2/1P^A\75_)X:O._#<I5)7[K19YU@]"<1<TYR
ME;2U[J_)7'$38]E7K!1T5>J(]$5JHVWU]4K]=';:,558O%4UT3X]S$R<QA@_
M3]EV$<4X51SD8U^),/7>Q1R/<NRQL4MSI*:*17N161K$^5)'*FPCE5&+G#Z3
MP]6W1UZ-2_#<JPE?NW9,XXC1.*I?E<-7IVX[]*<;<L[Q7/(_. $<B[VJBHO9
MPWHBIIO775JH[77?KN1$T!W;JU[_ &7[NOYCS^QY?9WVO8'N[X//R3+]F)GS
M0XFHJVZVG#F6<$-]Q%<[56U=M?55%:L\%EPW)5T,U/)+'>*BFJZFJI%D?3S6
M^V5:5#%9(V.;PNMUMJ*RIIJ*C@DJJRMJ:>CHZ6%JOEJ:JJF9!34T+$17/EGG
MD9#&U-ZR.:G6=0[FG.0G2<G_ ">L>$Y(XG8HNNF(<;5S&LZ2JQ%<88>FIUD3
M57P6FGC@M5&FTYK8J7::KG2.>[0-H^L"P. E27Y?%[U&FKIK<LNEDUG>T96C
M^DU;@R2]ENK4L?I&G7DFJ&":KSE9K>FFU2@I9<9)N5L]V+7//TPC;HJKW]GG
M75>Z%8D:J$Y5R'#[>;[7VLM[^+=7.WW  ',    E7J[]:$Q*O5WZT -5OPL#
M[DF5OXT7?D;B8T53>J\+ ^Y)E;^-%WY&XF-%4L[LM\CT?A:_TRH^V#RW5^ P
M_P! $4Z^_6A BG7WZT)#(O7%=YTB?!ROO1\N_P">,Q_^\G%A[C'ASX.5]Z/E
MW_/&8_\ WDXL/<8IUK+Y1QWQO$?6S+SZI>3,!\5H_00 !XAL(      /)GGR
M/O5\W?>]%\I4)ZS'DSSY'WJ^;OO>B^4J$]?0'].P?QFA]9$\367R?C?BU;ZN
M1S%0 7*?%E$5P0-U_P $P_>OG7[Y<(_(]T-* W7_  3#]Z^=?OEPC\CW0CW:
M?Y(J_"T/IDE;)/+>&^!K_0D;>( *P%OP                           0
M7Z/C(D%^CXP#RKY[3[UG.3WK2?ZU2G,%7BIT^N>T^]9SD]ZTG^M4IS!5XJ6'
MV0?T'$_&?\.)6+;AY0PGQ7_%F0 !+2^_YB%'P_:^B;N/@FG[S<YO?7ACY#JS
M;?-2#P33]YN<WOKPQ\AU9MOE3-?/*^-^$A]53+G;-/(>C_@I?6U  #43>@
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M;$? 5?JY')QI_M<?^0W^JA6*-/\ :X_\AO\ 50K%TEP104&XCX);^[<\OXG
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MYYO/F\_LX=R+I15E;JY=0 !R,@
M
M
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MV7(A^XYE;[P<*?(E&0YME_(8#X2M]"F3SL*_+Z2]Y0^G5/J, $!%CP
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M4)=GSK[1L^=?:3 6[?F^X$NSYU]I#9\Z^W]!.!;M^;[@2[/G7V_H)53Y^)4
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M?OEPC\CW0CW:?Y(J_"T/IDE;)/+>&^!K_0D;>( *P%OP
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MYB=)XE8?#1O:W25'XE&+\:4W]%*[D^'-KR=YO;F0\X,^DI;ZZC_8'E],J/\
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M5J;]2JXJ,I12M3A:[M&"X9YMN7,E3C\/K12< U8W,
M
M
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MJ<7G"2>3BT5;TQH;%8"LZ&*HRHU%=V?BRC?*4)\))]:_T40 >B>8[<@  8
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MVJKY>O!S!SI\<R']ZEDM[VJKY>O!$6V#^AX7XS_A5":]AO\ 3\;\47UU(]6
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M^VG^2*OPM#Z9).R3RWAO@:_T)&WB "L!;\
M $%^CXR)!?H^, \J^>T^]9SD]ZTG^M4IS!5XJ=/KGM/O6<Y/>M)_K5*<P5>*
MEA]D']!Q/QG_  XE8MN'E#"?%?\ %F0 !+2^_P"8A1\/VOHF[CX)I^\W.;WU
MX8^0ZLVWS4@\$T_>;G-[Z\,?(=6;;Y4S7SROC?A(?54RYVS3R'H_X*7UM0
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M15;$2MX6]*\H0[%3C+=MU[SYDFG G -.2-^
M
M
M
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M.U4Z*K](Z.E8UF(XH6(J*^VPLKY&L1S;=*][T;/VK&TK"XS<I8FV%Q#LK/\
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MW_6[\F;<;8IJ=>"=_<[S;]_UN_)FW&V*5.U[\K8WX2/U<"Y^S7R)@/@Y_6S
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M:-;2VCZ<E=/$TW;D]SP\^SP?/P-_EJ=_0I,2\-WI)BH1=\  R
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M+T*P  ,@
M
M
M                                               HN;H5@ 6Y35--
MZ<"LK="4 HJG6GZBFYNOI*RIIO3@2Z=:< "W7?Z>O7M*3F%RYNI*[3U@%DJ:
MEN]GZ"^<PI*G4 8YS2V>PR3V%L]G;\ !C'L+9S#*/84'Q@&(?&6;XS,N9ZBT
M?'J 896Z%L^,R[XRV?& 8>2(LGQ=^LSCX^_46KXN_P! !@WL_66SX4,R^(M'
MQ &'>SMW_$6[H^SJ[[E33?V;T])F',3L+22#L,7ZK-M6LU\N]RL+<^%N:?R;
MO-,\O.6[S464^>,=177JU+8,7NB5*?&6'XH:2[=(U'NB]TH=$I;U"Q[UVXJ]
MJS.9JD=3%(V-T>GGRU.9SS@R9\;N<MO;C;!].YSFXKPM2U,O0P)M;,MYLCDD
MK[/*K&K),K77&@ITVU2XR,:Z1.B,Z-.LH20(J*US6N:Y-%:Y$5'(O%%1475J
MZ)JG6F[<FTCMXU=U]QV M#?=>@K7I5<VESW*F3ASR5T\KI\"/]:-G&CM);U3
MHUA\2TVJ])63?+?IM;L[>9]4T<F-CD<B*U4<BZ*BM75%UX::<?-UJF_1"?3S
M'0&Y:G,BY/9LNK+S:[>W+[&52KY9+YAF!D%ON-4Y%5);UA]JLMM5)))Y5374
MD5%<ZC;D?4551(C%;J><LCF@\Y\FWSUM98)L7X38Y>CQ=A&FGN5)#'JJ(Z]6
MR&-]SL;MG1?&:R*6UM<YL4-SDG<L#9TT#K[@,?:*FJ%>RO2JI;V?N:F4)QZD
MMV76BNNLNSC26C;SE2]4T%?^<4'*2LWDJM/.I!VXMJ4;^V/+L!/B5473?LJF
MY4<B:JBHO%J[VZ>4B(1T[]^/J-U1H5B  !@            $C(VMDCF8U&S0
MO;+%,WR)8GLWM?%(W21DC5T5KV*US5WHI.##2?%)]C_V9E2:X'U+ESRX<Y,)
M+&N'LT<<V]D.BPT\F([A<:.+9?MHD=#=9:ZCC17\6LIT8[3>U^V?;N!>?:Y2
M=D:QDN+[7?FM1J.6_P"';=53/:FRJ_7::.CV7.V=E7-:U='+HWL\?0>5B= 8
M&M=U,+0FWQ<J5._[2BI>EGMX763'T,J6-Q4$N"Z:INKNBY2C\B-CK"'A+.:U
M&UC+Q@3 MZT5%?+%)>K3._AJC70U=73L7_!5:9^RNBNU1-#Z4POX3[!JUE\R
M8G;HC5?4V;'<3_*\AKD915^%X=VBR.15N#M'(QJMT59F:F(/#K;/M$5..#A'
MMA.:^6[-@H;3M-T[?SZ<[?G*5.7FMNJ_G-TO#WA,N4DVPVZ9?9GT#WK&USJ.
M+"-S@B1[MF1SY)<2VRH?'&Q455BI'2N3:1L2JB+)^OV3PBWD]571K5,Q[;-M
M7;25F%6S+&B:Z.?[F72XHJ/W;"1K(YO_ *QC315(HIY5797HEWW85X]U9V^5
M'L0VQZ9BLYX>7?05WVVA*+7I-^JW>$ <F.5KG38NQ!1JBZ)'48$Q?*]R?X37
M45HJ8T;YG*UR\$0_I+?S[O)AJ6N<W,"LB1B[.E3@W%](Y=W%K*BRL<]O_6;N
M1>)S\ =:6R?1O*>(7Z\/\L[<-M6E5QI87]B?^9]OH.@M5\^MR8H8W2.S"J'H
MS3R(<)XLGF=JJ,T9%#99)':(Y7.V6KHUJJNY#^=J^?ZY,+(WOCQI?)W-35L,
M6 <:QOD75-=EU18X8D7>KOKDD2::[U79TT"P86R;1O.6(?\ S(KYH7,RVU:5
MY4\,ER]C;:\SJ&]Q>/").3M3Z^+5&-[C]:5R>*83J(M7ZHJ0I[I3T"(]5:FC
MG:1)UR]9^0WWPE_)N%5;;\#9IW!R*FDDM#A&AIWHYB.U:]^+IZG5KU5KTDHH
M]=%V7*FBKI2D3M4]ENBE;>C7EV.O+[(+YSJ5-LFF9<)4(+]&A'[9OY$;<.)?
M"?K4U%;9<F+K4*OV,MWQS1T.SHB:*ZGH<,W+I455<BM2IAV=EKD>Y7JV/YLQ
M9X3'F94I(RS9=8(M37;HY:RNOEVGC\E-^Z:@IW>5JJ(ZG5$;LM7>BN76P!Z=
M#9YHB&?J12?Z=2<E](\G$;4--U/_ %LH]E.G3C_=/9_''/Y\H^\->RFQ!A^P
MQ+M;/N-ANCCJ&:JU=$J:N2J<OV+4;M,=Y*N55ZCXCS&YP?//%B/2^YL8XJ&2
M-5CXZ*^5%EAD8L?1JR2*Q):XWQ['DN8]'L?HNVQZN<J_'@/<PVKV!H_D\+AH
M6X-48M^F47+TMFNXS6G25?*MC<543XIUI1C^Q"2A+SHJW&HEK*F2MK)9*RLF
M5'35E9+)5UDSDW(Z6IG5\\BHFY%?(_<FNC2D >NDEDE9=AX<IR><G=L  R8
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M!PI\B49#FV7\A@/A*WT*9/.PK\OI+WE#Z=4^HP 0$6/      !!2)!>'=?@
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ML;\)'ZN!<_9KY$P'P<_K9@ &HF]               '\OC;_ (FN_P#-=?\
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M47>+G=6DD^:+!;-M!XG1VC5AL7!0K=/5G92C);LMW=SBVN7R$P -*-^
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M>'J-)<7N+?LN_=-GU+Q2HZ6T?4?!8FG']N\/[QT\T0B2M7OZU)BH*+P@ &0
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M&Z_X)A^]?.OWRX1^1[H1[M/\D5?A:'TR2MDGEO#? U_H2-O$ %8"WX
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M14U3RHY&KN54[%,X4O::;3XIM6ZK9%]8M-)KFD[]C28  .0
M
M
M
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M3G!KS22?GX+F1 !V%^.5^ZYU5^,U?OM>]@
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MU+PYVY[J@FG[Y+F27LHT.\5IBE-Q;IX2,L5)YVWX^QTT^5]Z2DD^.Z^H]YD
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M23K02IXB'MHUH*TG;CNS:WHOFGV%8$J.)C5S<        0U (@E1Q,
M    "5>KOUH3$J]7?K0 U6_"P/N296_C1=^1N)C15-ZKPL#[DF5OXT7?D;B8
MT52SNRWR/1^%K_3*C[8/+=7X##_0!%.OOUH0(IU]^M"0R+UQ7>=(GP<K[T?+
MO^>,Q_\ O)Q8>XQX<^#E?>CY=_SQF/\ ]Y.+#W&*=:R^4<=\;Q'ULR\^J7DS
M ?%:/T$  >(;"      #R9Y\C[U?-WWO1?*5">LQY,\^1]ZOF[[WHOE*A/7T
M!_3L'\9H?61/$UE\GXWXM6^KD<Q4 %RGQ91%<$#=?\$P_>OG7[Y<(_(]T-*
MW7_!,/WKYU^^7"/R/="/=I_DBK\+0^F25LD\MX;X&O\ 0D;>( *P%OP
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MF[M2@E>7NU+L/Z($B.4G-%)&       !  B"5%\Q,@
M
M
M
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MR:=CG&W_ !-=_P":Z_\ U68XXUG_ ')2_P G@_LFDY;&N&D>_"?-B2O.W?\
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M$=JJZZ:(F_4;KZGZ']PZ2/NH^E&0!1:N_=W^,JIYSBG_ *=QR3[NVV=GU$0
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MR<6'N,>'/@Y7WH^7?\\9C_\ >3BP]QBG6LOE''?&\1];,O/JEY,P'Q6C]!
M'B&P@      \F>?(^]7S=][T7RE0GK,>3//D?>KYN^]Z+Y2H3U] ?T[!_&:'
MUD3Q-9?)^-^+5OJY',5 !<I\6417! W7_!,/WKYU^^7"/R/=#2@-U_P3#]Z^
M=?OEPC\CW0CW:?Y(J_"T/IDE;)/+>&^!K_0D;>( *P%OP
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M!?U\4&B[2/)&)[Z7UD20=EWEO!_\WZJ9N=IQ3OU(5"FG%._4A4*L+[_G+C@
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M$G&<)*SC)9--$NX/%TZ].%:E)3IU(J<)Q=U)/A;\73R:31, #XG9
M
M
M
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M[@@ :G9Q[>I"9&^TBB:$^B=OJ (:$WHX=9%$U]'85 9_'XR)6MT)B*(54;H
MV2HSM*@ ,                               U>_"I/N,8'_&!#\CUQM"
M&KWX5)]QC _XP(?D>N-IU)\K8#XQ#[33=H7D72/Q:?V&AF "V_5W+YD4J?+\
M<V#[HRNYS7/[!-@M>%<)YK8KL.';+ ZEM5HH*BE;24-.Z:6H=% V2E>]&K--
M+)Y3W+J]=^FB)\+@ZN*P-"NE&O1I5HK-*K",TGPWDI)I.V5SL83&UJ$G*A6J
MT926[*5&I.DW&]]UN$HMJ^=GSS/27]N&Y4'X;,:_]JH_S(?MPW*@_#9C7_M5
M'^9'FT#H_P#A[ ?V+"?]/1_@/2_\2Z1_M^,_ZJM_&>DO[<-RH/PV8U_[51_F
M1@;YSL7*6N+%CJL[<?+&K%8Z."[MI&O375-OQ6"%5W_PM571$0\^ 9CJ_@$T
MU@L(FLT_4]+)\GXG(XRUCT@U9X_&-/BGB:S375G,_0,P,V,4XLF6HQ3B6_XD
MEZ59D6^7BONC62NUVI(HJR>6.%5U_P#5,9Q77K1?S\ ].G2C"RA&,4N"BE%+
MS*R/*J593>].3FWQ<VY-]CDVY-=E[  B?3_=\O\ =]B[SY]?!<+9_);DNUY$
M/T_!Q[^PV^O!@.0A/55]ZS_O]')'0TB5V%,!=/#HVMJE6./$=]IND8J24]&Y
MON'3U<2[*US+M3(Y'4<[7>7/-+\S7B[E!WN@Q#?Z:LP[E#0U'372_P K9::L
MQ.VGD:JV/"\;D8Z9U4Y%CJ[TJI0VZ)LSH7U5;T%.[HR9>Y?6;"MCM.&\/6^F
MM-CL5OI;7:K91Q-BI:*AHHFP4]/%&Q$:B-C8U-=-575SM55VL.[2]<:<*,M'
MX::G5J*V(G%W5*%[N":><YI6DO:Q;3S:M.>RC4:K.O#2>)CNT:7A8:$DU*K4
MLTJC365.G?P'[>5FLHW?]NW@GH(D$X$2 2RH        !*[J]*&BWX5Y]U+*
MCWA7C\HC>D=U>E#1;\*\^ZEE1[PKQ^41O>S;RQAO>U_J*A&^UGR'BO?X?Z^F
M:JH +2E/RE/]KD_R'_U5.MER(?N.96^\'"GR)1G)-G^UR?Y#_P"JIULN1#]Q
MS*WW@X4^1*,AS;+^0P'PE;Z%,GG85^7TE[RA].J?48 ("+'@         D>F
MJ;O3[/F\VJ:\.!.2.70 \H.=?YKS#G*3P4VD<L%IQ_AV*JGP7B=6Z+3S3;+Z
MBS716-5]18[FZ.-)X7(Y]).V.NI=B>)5=S8\ZLE<4Y=8IO&#,:6:KL.);'52
M4U?;JR)8U79D>V*LHGZ(RNME8UJSVZX4RRTU93*V6*5_E:=?E[?@X?.>:G..
M<V!E_P H_#7N=B*'W)Q5;H7IAK&M!!"Z[6>17)*ZFF:]$;<;/4O;LUELJ%1B
ML>^6EEI:I&3MDG4;7N6CVL/B-Z>#E+OE0;=W*"YP=VY0Z\XM.Z<4;0MG,-)I
MXK"J-/&QCGRA7262GU35DHSZLI)K-<M\'WARY^;AS2Y/E\?;,=699;/-,]EF
MQE:(ZBJPQ>XD>C8G0UCH6.M]8]KXUDM=P;#5Q2N=''XS$UE3+\'KWZM/5\W9
MOX%CL)C*6(IQJT*D*U.6:G!JSORMQ37!IYI\2K&.P%;#5'1KTY4JT9;LJ4XN
M,KYYI\))\4UDU:S:=P #L_CS]_%>9KMN=1YY9VOP>6:[/F?$@UJ))',WR)8G
M(^*5NK9(WM75',D:J/8Y%WHYCF*G5OWG[IAOE0YF6;82U9AXYH61JBQLI\5W
MML;-E%1NQ$M:L+4:BJFRUC6Z*FNNRA^& ^56A3G;?A"5O=0C)>B29V*6)J0\
M2<X</$E*'#AG%I_*?2MZY9F;MQCZ&NS1Q_4QZ/39=BN]1Z[6B.WPUD;D5R;M
M=I43J:FI\_7^^U]VJ$K+M75MUK$1VE7<ZNHN%4W:5%=I/6232^4K6JJ(_153
M5=YBP<*6$I0ON4J<;^YA&/S)/Y3G6QM>HK5*U6?OJDY>F[:?G'?OHB)\ U /
MO9=7GXOT\?2=7\-<GYEEZ+  _2\H,FL5X_O]'A?!6'[IB;$%P72FM=JIGU-0
MYFJ(L\SFZ0TM*S7Z[554L%/%_#D13%2K"$7.<HPC%7;E)0C&*XR<I9*W.[.=
M&C*<E"$93E)VC"*<I-MY*,8IR=_/GWGYIIY36HBN<]R,8UJ*Y[W/T1C8VMU=
M(YZJC6L8BN<ODM17;C>'YA;F7)<&I;<[<V;0L6+IHFU6!<*U\2=+A>FG:JMO
MUUI9&JL.(JJ%R+0T[E26T4TCNE9'6RO9#^X\T;S!=FRAFH,PLV/<[%&93&Q5
M-JM,"I68<P1*NS(DM.^2-K;QB&-=&275[%I*-4?':V.U=6S[*2)IP\W']) 6
MOFT)5U+!8"3Z&5XUZ\;KI5SA#@^C?.7M^7@YRLALZV9/#2AC](P]F2O0PTDG
MT;Y5*BS3J+C&+\3B_"MNS(S<-%T[]^!.A$AU>GO)U_#((1 ,@
M    \@>?M^])SB_F[#/Y<88.9<O%3IH\_;]Z3G%_-V&?RXPP<RY>*EB-D'D_
M$?')?4T"KVW#RGA?B,/_ )&((  E=\OQR9"[^[YS>+\$[^YWFW[_ *W?DS;C
M;%-3KP3O[G>;?O\ K=^3-N-L4J=KWY6QOPD?JX%S]FOD3 ?!S^MF  :B;T
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M+>_SX_.0/4M+\W#]B/W#U;6_/5?WL_XC]&_NQXQ_QPQ9_G+>_P ^']V/&/\
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M2@-U_P $P_>OG7[Y<(_(]T(]VG^2*OPM#Z9)6R3RWAO@:_T)&WB "L!;\
M                        $%^CXR)!?H^, \J^>T^]9SD]ZTG^M4IS!5XJ
M=/KGM/O6<Y/>M)_K5*<P5>*EA]D']!Q/QG_#B5BVX>4,)\5_Q9D  2TOO^8A
M1\/VOHF[CX)I^\W.;WUX8^0ZLVWS4@\$T_>;G-[Z\,?(=6;;Y4S7SROC?A(?
M54RYVS3R'H_X*7UM0  U$WH         \1?"+/O0\S?YRRV_[TL%G-J7J[]:
MG25\(L^]#S-_G++;_O2P6<VI>KOUJ6*V1>3Z_P ;E]52*M;:_*='XK#Z<R
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MGQLLRT.Q+%59Z/Q%.;;ITL0NBO[53IJ4HK]:[:7-LF !%),X
M
M
M
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MXN5]U2G%Q3=L\F^1R#".[NGZ3I<LY@KDK]66<*?_ %8O"?\ V:I/^T$\E?\
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M>?.3;RO8LMJMJY1T5@Z>$I/>M>=2H^-2I*V]-]5\E&/",4DB( /#-C
M
M
M
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M2= G:9/HR78[[_H ,=T/?>.A[[S)=&.B3N@!C>A[[QT/?>9+HD[H.C[ #&]
MG:3=%WT+_8[[_H(I& 6/1+W0BD/?@7R1DW1^90"Q2'O^HF2)"^Z+S?"12+S
M%DD9/T?F+U(NZ(3I%Y@"R2/U$_1=]"];%YOG*J0^;X@"P;%YB=(B_2)"HV).
MI "Q;#VE5L)=I%YBJV/]0!:I%H56Q^;UERD:%5L0!:HPK)%H7+8RJUG8@!:I
M'YO@^<JI&7",[2HC>Q "@C.K3VE5(^Z%=K.TK-9Z@"W1JE5L>G:5T:B$Z-4
MIHPJ:$[6?J*VSIQW %%L?ZBMLHG'=YB9J=F[SDR-]8!+HJ\-R=A.UNA-LJ3)
MYMZ@RD$;V[B.O8GK&SKQ*@&7G)$83@J-9V@-DK6ZE5$T(@&
M                                         "&A$  AH1
M
M                (:$0
M                                  0T(@    AH1
M
M
M                 (:$0
M
M
M
M           05"( *:L["F7!!4 +=4)=GL*RL["54T!F+LRBJZ\=P5GK*FA*
MK>SV Y2E<HJW4AIIU:E55[4T"L[-X.%BV1-?,2NC\WK+A6]J$NSV>Q0"T5A3
M5O:A>KIUIIZ"56=F\ L584W1^8O5C)-A0"Q5G84E9YC(*WM0E5B &.Z/SE-6
M>8R*L\Q25G8 8]8R3HN)D%8O84UC +#HRGT>O49%6*2+'YO8 8Y8T_5^HD=$
M9)8_,O?TDBQ=_P!(!C>B\R$G1^93)='W4D<S3J ,=T9!8C(['?7]!*L:=GQ?
M2 8[H2583(]'YB'0^D QG1CH>^AD5C&QW[J 8WHN^@Z).Z&3Z%1T*]_U@&,Z
M).Z#HD[H9/H5[_K'0KW_ %@&-Z'S? .C[Z&1V._=2*1)V]_8 8](>TFZ$ONC
M3M[^PFZ/S %BD7H)NC\Y?)'IW_23;'?N@!8]%Z29(_-W^,O49YBIT?F +%(R
M=(T[>_L+Q(^_$J)'Z^_F +)(T[_I4J='V%UT?F^+YR=(_0 6J1;B=(RY2,JI
M'IU?$ 6J1^8J(PN4C[H5$C\WM +5&>;4JHPN4C)D:G8 4&Q^;UE7H_.5MA>P
MG2, H(U"HC?45VQ^HFW)YP"DV/UE16Z<2?3U>@F1OFU )&IZM29&Z%5&=HW=
M6\&;$$;J1W)YU(HBKQW$^B=@'XX$NBKQ]A,B:$2=&=H,$A.C"HB:$0""(B$0
M
M
M
M
M
M
M
M
M
M
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MJ(3
M
M
M
M
M
M
M
M
M
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M(!D2;UX)IY]Q'8[5)P!?L((FA$F1BE1&Z P4D34F1G:50 01$0B
M
M
M
M
M
M
M
M
M
M
M                                      "56HI, "FK.PDV5["N "W(
M:%PK44E5B %#93L&SZ4*NPI!6J#-RBNO4-I>SX"H +]GSE+5.Q0B)YRJ05$
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MC.TCLH#!21J]A,C.TJ@ E1J(3
M
M
M
M
M
M
M
M
M
M
M                                 $-!HG81 !3Z/SCHRH "BK%(:+V*
M5P 4-%[!H5P 6X*RM0AL( 4@5=A!L( 4B&B=A6V$&P@!1T3L(E780;" %(%7
M80;" %(%780BC4 *)'1>PK@ H:+V*1V%*P *6P1Z/SE0 $J-0CHG81
M
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M.CL?5='"8N%>JH.;A&-2+4$TG+PJ<4[-I//*Z/N9%(D$(GA(V8  R
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M.K!/H5&$J<7&,\E-WG>\4XY/,]GT74F)6IYNLF-9CP^<VX  R
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MM'XO'>H,+5=>HH3G*<%>DE#=36^_&=Y>UNNT][D!+KV$QK!N(
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MGN6HK?IT\FVYU/%Y-6BY._&QM\*OGX?$3E!K>&O??H5D\YJR_'G-R_U(@ R
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M6I&K1DVHSBFDW%V=KI/)IIY<28 '3.^
M
M
M
M
M
M
M
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MY4C)FVN7_DRG?^V4[6ZNCKV((V+6_E:LU_8*J:XYJI0OZ38$ !6\M4
M "&\ B""*1       !KH>%!(B\FNBU373,W":IZ?<_$7L[-?CX+L7FNEX4!]
M[71_C-PG\GXA-BU12>E-'W5UZKH9=?LD35]=G_Y1I+XEB.'P<CGN]^_I75?7
MVZZ[\W@M'W"\4_C N'^H4!H,&_/X+/\ <+Q3^,"X?ZA0$Z[5%;1+7+U31\WC
ME==CC7\M*RM_-<1QS;_)YW-F5O'V?$I4*;>/L^)2H5G7/\<D6Q7!  &3(
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M=9;S9?IOU9HF@I.]3"_S>I?C:FET<NW>A97[.?$J)P0B$!I!(B  !D
M @NHW@$3YKY97W(\SO>#BWBFO_L*NZCZ40^;.63]R/,[W@XM^0JX[6!_+T?A
M:?TT=+27]'K_  -7A[R1R.:-$Z&)$X)''IV(B,:B(B:*N[?_  M-Z^2BFR/X
M+.G_ *2V(U__ $(XP^''65WT&MS2?:HOXMG]5#9%\%H^^6Q'^)'&'Y=96EI]
M>$OY(QMLET$<N2\4ISL]\M:/XWZ9MW=V\JAT#^OO_A%0I]??_"*A4XNF
M   2J[OW0AM=^Z $X                       (+\6\I*FJ[MVGQ+I]'J[
M%*JDJ]_:B&&89R/^6(B)G%G B)HG]UC,O@FFNN-K[KJB?X2[]ZKHJ;T=JNOT
MSS/'WT.2?OR3S?\ L>['S-RQ_NQYO_C8S*_+:^GTQS/"_P#I09)^_)/D:[%P
M,:DM%5DE9>H*EEU)X4I%@?+=*]\])TTKN[NL5F=2L %0"[P   .2)RS,*WJQ
MYOYI6G$;9FWRAS"Q>RYK/M]++437RMJTK$Z1-J2*OAJ(JZGG35M33U,-3&]\
M4L<K^MV>-O.,<R?E9RB+DS%%QFN>$,;LIH*2;$^'TINDNM+2L<RC@O5!51R4
MEP6E;I#!5*V.LCIFMIFSK%' V+?=0-9Z.C<15>(B^BKPC'?BFY4Y0DW&5EFX
MM2DI)7SW<LB--INJ%?2V%HK#./2X>I.2ISENQJ0G%*2N\E).,6F^5US.:"[<
MFO4B*NO4FG'?PW<5UX)O71$U.HAS,>%;Q9>2YDM0WR.:&N=@^*N;#4HYLT5M
MNUPK[K9(W,D1'QHVRUMO1D3T1\3-F-V]JGF=R6O!A\I\'7ZCON.L17?,E*">
M.HI\/U]#16S#DTD#T?#[ITL'2U-RA141)**HJ?$ZAC59/#)&Y[';-,5*R-C8
MV-1D;&M8R-C4:QC6)HUK&M1&M:UJ(UK431$1$3<>OM%UQPND(4:&$4I1I3E5
MG5E%QWGNN,81C+-63=W99V/$V7ZB8O1E3$8C%]'!U8*E"E3DI.*WU.4Y27@\
M8I15WE<K,)B")H1(K)F                      (+KYB( ! B    4I-Z+
MHF]45/@70Y@MVYEWE4R5=;*S)/%3F2UE5(QWCN&$VHY*B1['(BW]%WM5%T5-
M4UT5#I_*A3Z+SKW^/X_.;5JOK=B-%.LZ%.C4Z?<WNF4VET>_NVW*D/SCXWY&
MEZW:D8;3/0>J:E:'J?I-SH90C?I=S>WMZG4O;HXVX<SEZ?M*_*K_  )8IT_E
MV%_]X-3X-SBR8Q5E]B&OPGC2R56'<26SH?="T5KZ62II?&(FSP[;Z.HJJ=W2
M1/:]JQSO31=^BZHG7\V4W>WJW:;TZCF?<_=]]1F3Z;%\C4I+NHVO>+TGBIX>
MO2P\(1P\JD>B51/?4HI>/.:]MGX.?9Q(3VA;.L'HG!T\30JXB<Y5X4FJKIM*
M#A-R:4:<'=[O6? ')TY).9.;E?<K9EIA"Y8PN%HI8:ZYTMMFMT,E'25$KX()
MY5N5;0QJR6:-\;$B?(_::NTUK=Y]<+S*O*K_  )8I]5=A=?_ /?GK7X*(FN9
MF:Z?_@78%]?NS7F]!L(=77#:)C-'X^IA:-'#3A"%-J4XU-Z\Z:EFXU8WSEU(
M[NHVR_ Z2T;1Q=:MB:=2<JL7&E.GN>#4E%64J+?!<Y,T"N:/YK'E#8#Y264^
M,,8Y4X@L&&+#=[_47>\5E78)*:AAJ\%8GM=-)*RDO-34N26NKJ6G:D,$BH^9
MKG(V-KWM^U/"U/M61'\?F%_J^$S<?2+S[NPTX/"U?M61'\?F%_883-9U?UEK
M:4T]@:U>%*$H4ZU-*DII-=!5>>_.;O=VR:5N1M>M6JU#1.KF/P]"=6<)U:-1
MNJX-W>(HK+<C%6LN:-.K#^(*VTU]#=;;4/I+C;*REN%OJX_LZ:MHIV5-+.WS
MQSQ1NTUT=IHJ.:JH=5_F\>5E19V9.X(S$I7QI57BUM@OE-&_:6WXBM;W6^^T
M,G\)O0W"GF=$KT3IJ:2"I:G13,5>42G;^CX>K<;7W@NO+*98\68IR4N]9L4.
M+T=BO"L4S](FXBMM)#37JE@1RHU)KC:*:EJ.B8CGRI:G.:W2.5SM]VI:!6*P
M+Q,8WJX1N67&5&3M5[]WP9=BBV1QLBUB]2:1]2S=J.,71V?!5EG2EU*[4H=K
MDER2-Y!O!"8E9P0BJ[BM9:Y'Y#GOG':,OL&8GQO?96PVC"]EN%ZK7.=L;45#
M3R3)"UR->K7SO8V"-48Y4>]/)=IH<F?/G.2[YB8UQ7CR_2NEN^+K_<K]6JY=
M4B=75#GPTD>]49!04R0T%-$W1L--30PL1&L1K=QSPI#EG.M.%L*9(6:J6.LQ
M74?LIQCT3G(L>'+1,D=EM4BHB:>[%ZVZ^5J.1S:>PMCD:L%Q;M:12]^_;P3S
MZ)J6&V3:"5'#2QLUX>)>["_*C3E9->_GO=ZC%E7MLVL73XN& A+V/"+?J6X.
MO4@KI_!PMW2E)<4;4O@H?W5LT_Q?6W\HX#>J3@AHJ^"A_=6S3_%];?RC@-ZI
M."$;[3?+&(^#H?5(EC9+Y#PWPF(^NF1 !H))0
M
M
M
M
M
M
M
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M>>1JQKS@]+3JPPL*WL,%*<JD%&"WK[L;J3SDDVNQ'U."DS7K]7GW%4U4W0
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MLJ&AITAMU^RSLL52Z-$=!)BG#K&4>)W-F:QC)99JJLIZMRM1=(:BGU75=_\
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M=D;/ZJ&R-X+/]\MB/\2.,/RZRM)KUX\D8WMH)^AQ1 .S[RW@.RLUW^#-_:=
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MM7LE\AX;X3$?73(@ T$DH
M
M
M
M
M
M
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MJJ="'9(Z=>Y/1V$/8W:MCJ]&K0G0PNY5ISINT:EXJ<7%N-ZC5TG=732?(G#
M;&]'X:O1Q$,3B]ZC5A5BM^FHR<)QFE*U--IN*3SX97YD6KN0F((1(O)>/SO-
M3-"Q8*PW?,6XFN-/:</X=MM7=[M<*E^S%345#$Z:9^G&21R-Z.&"-'2U$SXX
M(8Y)9&,=S-.=)YSC%7*0QM/7U,]9;, 6:HEBP9A+I5;2TE,U71^[5RB;LMJ;
M]<H]9*B>7;=10O914BQQQJLFP-X4ARU):*@POD19ZE6.O44.,<:-AE<W6V4M
M6^+#MKJ6M1$DAK+E2U5P=$Y[F+[EPNDBUZ%YI<HNF_AIJO'M1-=Z\-R:*O\
M@[U3J)^V6ZJ4Z=%:1K0O5J[RP]U^3I\'-+W4WSX[CRXLK/M>UPJ5<0]&4)N-
M&CNO$[KMTE3BH2:XPA=)1X;ZSX(+KU\55$TTW[3D31NS]EM+JC4;IOT1$U74
M]?>2]S%O*-S3H:>\T>#H\(6&J9#-373'54ZP2UE-*FJ5%%:%@J+TZ-K%;+&^
MKH[?'4,>U]//*S>FP1S /,\6.S8;L&>^9-J@NF)L14D-XP#8[E DU'AFQU;6
MRV^_S4<\:1R7Z[4RLK*"61LC;9;IZ=U.C*R>=[=L1K%]'?\ 5YE[.M?CK7M1
M=&M/#Z/C";IO<J5ZD;Q4UQC3A=7<7E*4FU=-)6S?8U+V1+$4*>)TG.I"-6*E
M3PL'%2W'FI59M.V^K-0BHR2SD[Y+0QKO!6\YV4CIH,=X!J*M(VN;1JR\0M=(
MK45T:U3H9&-1KM6[:1>5IKHFNAX[<L?FSLZ,B'MDS"P?4P625Z,I\665[[UA
M225[FMC@?=J:)C;?4R.T;%!=Z:W3U*II2MJ$:YQU7#^:Q7A"VWRVUMHO-!1W
M:U7&"2DK[=<*>*KHJREF39D@J*:=CXI8W)Q:]CD]"HBIJVC]JVD*=1/$1I8B
MFWX<5!4IM?HSA;-+@I*2?"W,W#2NQG1E2DUA75PU5)[DG4E5I[W+>A4WLGSW
M7%\SCJ_.GM3M3M]2Z:[E73<;)?,.<[Q<<KL36K*/']VDGRRQ+6PV^PUUPJ=8
M\"WRLE2.D:R>=W][X9N=0]E/5Q.D936JIDBK8V14[ZU[/GGGQN:_IN3YCNAN
MV$H9&9;8Z?52V&G<^25</W>D;')<</++(KI'TR12-K;4Z21[TI5FIMM4H]&^
M'+V;37-553::Y%TUZT73MXKIOTW:IHO$FFI2PFF]'KA*E7C>,K)3I3BG:2X[
MDH2O%I<>=TR!*5;&Z TD\W3K4)6G&+>Y5IMIN#SM.,XV:;R5U9*2.R<WX]Y,
MJGD_S+?*ZGSBY/\ @^^W*H\9Q'88Y<(8ED?(CYY;G84931U=1IJK9;A;UHZ[
MZXKI)$GZ5ZJZ13U<:NNY>PJCC\'/#UJM"HK3HU)4Y=\9..78[778T7-T9I"&
M*P]'$4W>%:E"K'WLTLN]-V:Y-,JFNEX4!][71_C,PG\GXB-BTUTO"@/O:Z/\
M9F$_D_$1[.J'E71_QNA]9$\77;R1I+XEB/JY'/<-^?P6?[A>*?Q@7#_4* T&
M#?G\%G^X7BG\8%P_U"@)TVJ^2G\8H_WRNFQORTOBN(^>F;,K>/L^)1I\':&\
M?9\2E0K/U]_W%LEP7<:F7A3/)-2[8.P9G%;J76OPC7+A7$$L;$VY</7R5T]M
M?-LM<^1MMO2.2%5V8H&76O>Y465-='M41=>"Z[NU/5U*GP*G#?HK>N5RM.3_
M $&:F6F-\N[BK(Z?%V'+E9XZA[5>VBKIZ=SK9<-A-[UM]Q92UK6[]IU.C514
M547DIXIPK<K#=+G8;S2NHKQ8[C7V:[43U17T=SM57-0W"E<YJJURP5<$T:N8
MNPY6[;$1KD5;%[)],.M@IX2<KRPDO!3S?156Y1]%3>5[9)I<+%7-LV@?4^/A
MC*<7&.+I/?:;2Z:DE&7#A>FXNW-J_$Z*O@[O*F=F)R=+%9:^K2IO^6=74X)K
M]I^LRVBD<ZKPI*]%U5&LL$]+:D>]5?/):IJA=GI$1/=U.'T<#GM>#3\JE,%9
MYS8#KZGHK1FC:9K;3->Y>B9B>R1372U[MS&+6T$=SI.E<J*^=M%2LVI)V-7H
M0,7<BZ^C7CU\>^A%&O\ HAX/2=>*CNTJSZ>GU;M1MM+WLU-=B2)HV;Z;6-T3
MAVY;U2A%8:IGG>DDDW[Z#A+SE8 @[@:8;X?Q.8N.+?ABPWK$EWJ(J.U6"U7"
M\W*KGD;%#34-LHY:RJFED=Y+(V0PO5[U^Q1-==VJ<E3E)YYW#,W,#&.8%T=(
MM7BW$%QO.Q(C4?!2U,[O$*1R,^MM6DH6TU,Y(_(VXG.:B(NB;WWA*G*C_85D
M')@FAJ70WG-.[4F'G=&_9E9ANW307;$3M475(Z^*GI;)*U[=B:ENE6W7::B+
MST_;KZU7CIUZKYU\ZD^;(]$='AZV-G'PJ\NAI7Y4Z=G/S2J-+]1V96C;9ISI
M,3A\!"5XT(.M6BN#J54U375>---_KYJYZ1<T?R6US?Y0>7N%)J=\]GH[B_%F
M)5:B[$5@POL7&=9G(CMAE9<4MEHC>K58M1<H8I-6R:)U)HHFM8UC&HQK6HUK
M6HB-:UJ(C6HB:(C431$1$T1$T3<AJ:^"R<E%+5A#&N<-P@1*W%M:S"F'Y7M3
M;9A^QR>,7*2%SFM?&VXWJ1K)D17QS16FA?JCV*C=M)#1]IFEUB=)2I0:=/"0
M5!6X.=W*HUYVH_JDB;(]!>I-%1K2CNU<9+IWPOT:2A23R3SC%RL[YRNK$J)P
M\Q, 1V2F      "54^@F(.70 UR_"7N5)^PO(ZGP/15217?-&[LL[HFO8DJX
M>M/17*^3*QRH_P 7>Y*"@DDC7:CDKH&[D>NO/DX=7#J7=]"I\&A[K^$2<J!V
M8?*-N]GHZETMCRRM-'@NWQ->KH%NRODNV)JYK-7,943U]93VJ=S-6RTUAH'J
MB/:YIXDX1PE7W^[6JPVF+I[I>[C0VBVP^4J25UQJ8Z2E:[9:YR,Z:5JR.1J[
M,:.?HJ(6HU T6L%HJBYI1E6A+$U6\EX:3I[W5NT]WN=^LISM)TQZOTQ75.\X
MT9+"44L\Z>4]WC=SJ[W>K+B;R7@L_)E;9,K\59JUE/LUV/;_ #6:SS/8J.?A
MW"<LE#/)$]43:BJ,0K=('(J+LRVQ=A4:[939DS)P';L58>O>&KM$RHME^M==
M:*Z*1C9&OI;A324TJ*Q_DJK62*YNJ:(Y&\%X?F?)3R(MV6&7&",O[6W9I,)8
M;M=E1RHW;GGI:9B5E7,K$1KZBLK%GJZF5$^O3S22+O=J?0#V=FY>KOW^<KCK
M!I9XK'XG%IOPZKE3?-0@[4DNJT4NXM'JUH6.#T;AL&XI[E",:JY2G-7JWMQO
M*4K_ ''(/S\R@K\OL<XOP+<XW15V$,1W?#T[7[U=[F5LM/#*CN$C)Z=L51%*
MU59+'*R6-58YKE]'.8WY47]RWE&8+J:FI2FLV,GR8$O:O>K85AOTD"6M\J:I
MJL=[@MW1)KLK(]JN;HB*OVWX3GR6OV*9TVK,FAI]BV9GV2G2Y/9&]&,Q3A>G
MIK3,^1^B1M?7V)EGZ*)JJ]S[;6U#]5D536S@J9H)(YJ>:2FJ()&34U1"Y8YJ
M:>)[98*B&1JHK)H96,EB>U45CVHY/*1%2SF!K0TMHB&]PQ6%W*CY1J..Y*U\
M_ JJZOU)N_$J3I"C4T+IJ2C?>P>+<Z:X;U)2Z2.:MX])I-I+BUEP.R0CD(ZG
MQ/S=W*<CS@R4RYS!VF>.WS#5 V^Q,V=FEQ+;F^YF(J=K4>YS8&W>DK'4G2;,
MDM&^FF=&Q948GVQH5/Q-"5*I4I35I4JDZ<E^E!V=NPNA@\5"M2I5H-.%6G"I
M"WN9Q37GY$0 ?$[(**KQU7S[^I/9N3K_ %H5CQ$Y_;EC3939!WNDM52ZFQ+F
M+*_!%GEBDZ.>FIKC32NOM;"YOEMDI[.VJBBD;LN9+/&]DD<C8W)W=&X">*Q%
M'#T_'K5(P3ZKO.3[(J\GV)GFZ7TE3P>&K8JKXE"G*H^VRRBNMR=HI=;-7#GS
M^=EK,Z\6567V"KL],IL*5SX>DH952GQO?:1ZQRWJHEC<K:ZS4<C7Q6-G[DFT
MDN;6R=+22-U^25D:-1&MW(W1$1$3@B(B)NX(B(B(B=6]5T:C5]E^9BYKV;E&
M8_DGORSTN6F"Y:2MQ=/#M1SWN>5ROH<*T-0W3Q=UQ2-\MSJV*LU/;&21TR1U
M59!54EL84\'H7 <J-"A#-VO.<G;>S5KU*DFDFEQ:RW58IA*KCM.Z0B_RV*Q4
M]V/A;L(0C=VLVU"E3@KWXY.]V[OX@Y+/(2S<SIJ9H<M,"WK$E-2R-AKKTR..
M@P[;Y51KNCJK]<)*6V)5,C<V9:""HGN#H521M(]CV*[UDMO@R'*6FI4FEER[
MI9WLVTI'XGKI7HNRUS8I966-T3'ZJK']&V1C'MVD=*U=#?\ LOLO+'A6ST&'
ML-VJ@L=DM5,RDMUJMM-'2T5)3Q[FLB@A1C4U^R>]=9)'JZ21SGN<YW]MLH0K
MI#:SCIU&\/3HT*:>2E'I:C2R\.;DD[\<HJU[7=KD\Z+V*Z/A2CZJJUZU5I.6
MY)4J<9/CN147)+ME)WMO65['+JY3_,Z\HC*.BJ+MB;+ZLN5AHV[=5B'!]0S%
M%JI&(CE?+61T+&WBBIH6IMSUU7:J>@B:J=)5L^Q3S$:YKDU:J.3<J*BHO6FB
M[M>"]?4J;]%0[)BMX^Q-QJ0\_+S+5EK\/WS._*:SP6S$%D9+=L=85MD#8*+$
M-I:Y7W+$-LI8T;#37RU,5]=<((F1,NMNCK9&:W&"""OVC57:EZHK0PV.A"FZ
MCW85J2:BYMV49Q;DX;S]NI;K;LXI9FI:Y;(/4M"IB='5*E6%*\IX>HU*I&"S
ME.G-;JGNJ[<)1WMW-2;5C23[_I-C[P6?[Y;$?XD<8?EUE<:X"+KHJ<%1%1=V
M]%UX>SCPZM=38^\%H7_TEL1_B1QA^765IO&O,E_)&-^!LOVHF@;/%_YUH_X=
MMW[82[CH']??_"*A3Z^_^$5"I9=0E=P7T&I-X5?R?KC<<&Y;YE44M;+;\,7R
MLPUB"@2:9]!#%B2)DUDO3Z7:\7AEIKC03V=U5T?32NOU+!M)&Q4-MIW!?0?)
MO+?Y+E)G-E5C3+6LJ(*+]E%HDI**XST[JN.UW2&2.JM5T6G;)$Z5U!70P5+6
MMD8JNB16JU3W=6=*K!8_"XF6<*=5=)E=]'*\9M+KC%MKML:YK=H=Z0T;BL)'
MQJM*3AX6ZG4A:=--\E*22?9D<F'7>U.MRHUK4WN<Y=S6M:GE.<Y539:U%5VT
MW91=INOJ5R:N9@Y2&:4,-?8\NJ^PV>=J.@O6.7KA*BF8Y-IDE/27"%;Y402L
M5'0U<%H?13M5.BJG:J;QO-_<R]D_D+2T-=26N+%^.X49+4XXQ'2T]37Q5B+M
MJZQT2M=2V*FA>NS2)2(M;'$UO3UU3.Z6>3US:W?QXKW]&[=PW^TE'3>UUW=/
M 4(RBLE7KK)I<XTH[MEU.<G?FD0]J[L432J:1Q$HMYO#X=K)OVLZSWDVNJ$4
ME[KF:)&&/!3\W*NF;)<\R,!VBH5C5=31T-ZN;6.77::D\?BK7HW=Y21MVNQ#
M\PS?\& S[L--+4X:O6"L;+"QSUI*6LK+!6U"-9JC*9MRCDIGSN5K6-9/64T.
MJZND:B*XZ!;>!%>!J<-J&EE+>=6C./N)4*>Y_P!JC+_N-VGLBT*X;L:-:G+\
MY'$5-_\ [I2C_P!MCC[YKY/XKP)?JW#&-,.WC"^(;>[9K+3>J*6BJHVJYS65
M$>VG15='+L.6EKZ1\U%51_7:>HE9Y1_*X7Q5=+%<J"]6.X5EIO%JJH:ZV72W
MSOIJZWUT#NDIZJEFC<Q[)8WM16Z+HYJJU[7QN<UW24Y[_D"VG.C)C$5?2V^%
M<?8$MU7B;"%SCA:M;,MNC=57/#LDB(CY**^444U/'$YW1TUR6CKM/K#VR<TN
M.1'M:YJ[37)M-['-<B*BKUIM)V:;.Y$30F_5#6F&E\+*<X*%2G)4J]*RE'PD
MLXWSW*D7)).[5FKNUW7S775*IH7%PIQJ2G3J+I,/63M+)M.+:MX=-J+;5D[I
MI*^74JYJ+EQLS]R:P]C.K= F)J5'V'&-/3M9&R+$=M9&RKJ&0LT;!#<HG0W.
M")&L:R.K1D34C:P]*$-(#P4/.F>FQKFMES),Y]+=L,6O'%%3J[1D%5A^Z4V'
M[O4,CTT<ZMAQ#88Y7*OUIMO@8W:Z153=^;P*Z:X:(C@=(XBA!6I[V_37)0J)
M3279%MQ78BT6HFFY:0T7A<34=ZF[*E4?74HR<)2_6LI><F,/?&_WC6?R2HZO
M_N+S,&*OO[AK/Y+4?V+S6X>,N_[3:ZWB2]Z_F..I=_W96_RVK_UF4MZ:JEA<
MKX99(7+'/"Y\4CHGK!4P24U7#ML5%6*II)IZ>IC^QEI99X9$?%))&^XN_P"[
M*W^6UG^LRG][DMD[B#,'%N'<#X4H5N.(\4W2GM%II$56L?4S;3WS3O1%Z&CH
MJ:.>NKZE6JVEHJ:HJ7ZMB5%NPZD8TU*I)1IQ@W*4G>,8J-YMWX)1\W64"W9S
MJN$(RE.<MV,8I[UY2M%1W?"DY/P;+.Q_)84PC=K]<:2S6"TW2^WBNDZ&AM%D
MMU9=KI6S:*[HJ.W6^"HJZF3917='! Y=EJNV4:BZ>T>4G@[W*AQ31Q5]1A:Q
M80AE1CFP8MQ%34MRZ*1B/;(Z@M5/>'1:HJ;5/4STE3&[5M1%%*U\:;J?-J<U
MY@7DYX3IZ"T4M-=L:U]-$[%>-:BG9[I7.K5-J6DH9'M62WV2GD5S*2AA5B2-
M:V>K2:H57)Z:KZNI->_P:$%Z<VN5G-PP%*$:<6TJM6\I2M[91O%0B^*OO-I\
MN!875[8M1Z*,](UJDJDTFZ%&T8PNO%<VI.4EP;CNY\Y+,YS&9G@WW*=P_125
MU#9L*XJ2*-'>(X?Q-&ET>Y'2*K88+O1VNDD1K4:J:5T;G*[HVQ.5%5_B5CS
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MB #022@
M
M
M
M
M
M
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M &BDC@
M
M
M
M
M
M
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M,86IH/3DMRZ6&Q,*]*%K;U"<G-1NN3IWA+-VNUF=D!R_-Z34K\*AY5WN7A+
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MU$1$1$1$1$3@B(FY$3J1.!. +$-!H1 !!41>*!$(@
M
M
M
M
M
M
M
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M6.U0F-7-S!KI>% ?>UT?XS,)_)^(C8M-=+PH#[VNC_&9A/Y/Q$;'JAY5T?\
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ME:Z3M>QNLIQ)BE&NO!=?TIJB_"5343>$P  9
M
M
M
M
M
M
M
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MJ8:IJTD]=07.EC>LD#$<Z6BF385R(U':.3PN^I7N3SK^^[.3S?\ E)@Y?_X
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M+@3#J-LJ6CZT,9BZW2XBF[TJ=)RC2@[6WIR=I5&N"64.;3Y0CX)W^GA[.PG
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MSY+)<BR%"C&G"%."M&$5"*NW:,59*[S>2Y@ 'S/J
M
M
M
M
M
M
M
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M1T[]T(@IZEDB[Q)KYE[^A""MWK]!4!RL"GO[./Q$S4)@82M_NW\YBP !DR
M 0(*3  IJWNI'3A[-Q. P4U[=^[J)F<"8  I-3J*H!AHIJW<15.Z(A.##5S)
M*U-/C)@#(2!!5(@ $JH3 Q;F"DJ*A43@1!DPE^.0  ,@   E=PW;B8 %-.W?
M\_ FZ^!,##0*:-[[R;90F L/QED0T(@"P  ,@
M
M
M
M
M
M
M
M
M
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M2'ZL;+S$NZ$T7'!83#X6%K4*4(-KVTU'PY?K2;?G)@ = ]4
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M@
M
M
M
M
M
M
M
M
M
M                                     @J#93L(@   6
M                                                        (:$0
M 0T0:$0+
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
D                                             __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>pelareorep-lga02.jpg
<TEXT>
begin 644 pelareorep-lga02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!817AI9@  34T *@    @ ! $Q  (
M   1    /E$0  $    ! 0   %$1  0    !     %$2  0    !
M  !!9&]B92!);6%G95)E861Y  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" 00!@0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKXZ_P""R?[17C+]G;X,^ IO
M"=QJ&EP>(_&5II.JZE93+#):PM',ZIO;A1)(B*3D9&5S\U;O_!*_]HKQ/^TM
M\*?$.N:]J,VL6*ZJ\.G7DD:J2H+!XP5 !"E5^A)'6O8ADM666O,E)<JERM=>
MGEYGB3SRE',UE;B^9QYD]+=?GT['U11117CGMA1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD;\>?A]X7^&_AOX;:WI_BS0)=5NY/$NGWMS-'*EPT0$9M[N !=H!P03GOVH
M_6VBOY^/VL/^#S?Q1X+^'_P]TWX6>!_ >N^-KKPSI6I^,=6U1;N31;;4[BSB
MFNK*SMHITEQ#*[(7DG8JRLF&*[S^A_[=?_!<GP[_ ,$Q_P!@WX7^.OBEI=OK
MWQ<^(GARSO;3PCH;M9PWE\;6&2[8/(96MK2.27;O?S7^90 YW$ 'WQ17\U5_
M_P 'H_[2%UXC?7;'X._"B+P%;ZA!;S12VFJ37*!E+FW-\MRL*S2+',4)@X"D
M['"'/Z\?\$7_ /@N#X"_X+#?#W6?[+TFZ\&_$+PBD+Z]X;NIQ<!8Y,A+JUF
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M'X>F[GM['4/&,%[=W>LI&4RZ_9YX(X6 ;+)F8KYB9/K^JG_!$_\ X++>&?\
M@L5\!];URRT&3P?XR\&745EXBT)[M;I(/.5F@N89 %+0R[)0-ZJRO#(N" '8
M ^TJ**^0_P#@L+_P6%\!_P#!('X$V'B3Q)I]QXF\5^)I9;;PUX:M;A;>75)(
ME4R222D-Y5O'OC#R!'(,B *2U 'UY17\T^I_\'H?[2ESK;Z]8?!_X2P>!8]0
MBMF2:RU2:=<C>;<WJW21><R+(5/D< 9V,%.?U@_X(C_\%Y/!O_!8?PYKNE_\
M(_+X$^)GA.!;O4] >\%Y!<VC/Y8N[6;:C.@<JKJR QM(@RX8,0#[XHK\0_\
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M/IOQ<M;S0_@CX%TOX=WB_:+2QUI[Z35]1MO,D02I=I)'"H8ICBWD561QN;L
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS]D#XB^%?$FK6D-OJ$7A7X6Z[9VM_)$"!<2K,LSM.RE59]_(C3C@D^W>#?\
M@G[_ ,%&_P#@@O\ 'GQ!J'P=\*^*O$6DZM<P6<^H^$-%3Q1IGBBVC9Y(C-9J
MDL\( \U2SQQ/&9&"R 2*S^V_L1_LW?\ !5']O[]L;0?B)X\\=_%OX+Z'A;;5
M=9U4)X?BALHW=6@BT,(BRRL"Y0RVNS=MD9\[6(!SO_!W7XS\8:C\/?V/-+\4
M+J5E=-X&FU'4[.Y9E9=3>.Q6X$B, ?-0KM)8 C<PP.17ZD?\&O/PO\,>%?\
M@B5\*[C2;.QDE\6G5;_6YQ$NZ_N?[2NH&$O'S;(XDBP?X8P*TO\ @OQ_P1I/
M_!6[]E[1['P_J=EIGQ0^'\TMYX<OM0 6WOEE15N+2=T0E%E\N-@RC"O&O&TF
MOQ/^!4__  54_P""4OP]U7X0^!?AW\8=-\/W0DN(;?2O!$7BNUTR:293)-:W
M<$%S&CMY3J4$A7$S2! [)( #Y]T6QB_9Y_X.%!IO@&/^Q['PI^T ^F:);V!,
M20VL?B%H(X$"_P#+,Q 1E>A4E3D$BON3_@]S_P"3P?@O_P!B=<_^EKUW/_!
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M6EOI7Q&\?VD.G6NC1S1SR:'IRN)66:1,KYTL@C9D5B%$*9.XD+^LU 'X;_\
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MO^"9_A/X?_\ !*[4/V6?#-U-8^';GP1?>$8]2>)!,TUW!*LM\ZJ ID>>9YF
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M:UI/B">70]6NS\*T0W]NX6 V[7\=H+?[/N4O]I1@3O9C.R8P ?J9_P &Z?\
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MYR<'TH ^+O\ @K_X5M_'7_!>+XO:'>%Q::Q\2/L,Y0X8)+-$C8/KAC7[U?\
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M&;XE_#/X@_#M=:A\/#3CXF\.WFDB_,3:GYGE?:(T\S9YD>[;G;O7.,BOD?\
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M/#.I?#WPOHGB&'QQ>R:R(K75M?OUF^V)$EDGSP;I]C2>:D052RJ"P*K]3?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8(K["H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6UA<:UXDNVTK1O$D.GKIMW!J0RJV=[;H%CS(ZE%9$0K(55E(;*>O_P#!H?\
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MQQ3P3QQJL9=3+&RNBKD;PP) )_8^348(6VO/"C=PS@$5_+-_P9O_ /*7*_\
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MJG_!8*X*J%+^#-)+$#[QS.,_D /PK]C_ /@H?_RJ]ZQ_V1W1/_2:RH _GO\
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M^#-/3;>U_P""4&N3QPQI-=?$+4FF=5PTA%I8J"3WP  /:OQ9_P""7MG#<_\
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MI2QYEGFMLK MPK[5$C!8,.-REL!OT#_;ITRWTS_@U9O+:WABAMX?@QH(2-%
M5<6UB> ..O/UYK\Z/^#(^TC;]L+XSS-&AFC\&VZ*Y'S*K7J%@#V!*J<=\#TH
M \U^"_\ P<C?MF?L"_MGR>&OVA=3OO$UCH^J1VGBSPMKFCVEK>6<3%2[VTMO
M&A601L'C.6B<%3@JP-?LO_P73_X+9Z9_P2>_9G\.ZQX>TVQ\4?$+XC&1/"UC
M=.RVD4*(C2WLX4AVC021 ("I=I%&0 Q'X-?\'6R*G_!;;XEE57YM,T0G ZG^
MS+8<_E7T%_P>">"]8M_$'[+OB"2.8^'[OX?G3K>3!\L743122C/0,4FA..I
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MC]S[.BB0?ZOYGRW3GFO[%*_G*_X/>U/_  TA\"6YP?#6H@''<74?^- '-_\
M!%OXP_\ !2'2],_9^T7P=IOBR3]F?^W-/@,T7AW2I+3^QFU$?;#]H>+S]H#3
MY;=N'.T\"M'_ (*7_P#!>W]J[]G_ /X+!^/?A;X1^*7]E>!]%\8VVE6>F_\
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M=_P5A^/WB32?V;=)OO#6DZ'FZ_L/P]I=E))IUL6*QF[O;Q3^]8@\!D#$-M3
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M#P7JNK7&J_8X(?,N86NQ$_E1HL0V^6G 0 XY!R<_EO\ \&[O_!<7]I_]N?\
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M1NFAEA!*QW")F0&/".BO\J%1O^3_ /@IC_P<(?M&?L:_\%I?&'@>W^(D]O\
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M_P &7'PS\:> _"%I\*?B1K/@K7=!L?L>L7FM6 U6/Q'(79S<LJ21>1(-Q4!
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MQ!^)7C>Z^+.N>&[A+[3-+&EKIVD6]RA#1RRH9)'N"C ,JED3(&Y6 Q7Z_44
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MPYTW_A8W_"O?^$!N;^X\S^PO[4^V_:5@7&//AV;?)SG)SNZ#'/WE10!\S_\
M!)W_ ()Y_P##L+]B?1?@]_PEG_":?V/>WMW_ &K_ &;_ &?YOVF=I=OD^9)C
M;NQG><XS@=*^$_V /^#4?_AAG]O;P=\;O^%Y?\)-_P (GJ=UJ/\ 8_\ PB/V
M3[3YT$T6SSOMC[<>=G.PYVXP,Y'["44 ?GU_P7(_X(7?\/F;WX;3?\+,_P"%
M>_\ "O4U%-O]@?VI]N^UFV.?^/B'9L^S^^=W;'/O_P#P2S_82_X=J_L/>#_@
MU_PD_P#PF7_"*/>O_:W]G_8/M/VF\FN?]3YDFW;YNW[YSMSQG ^AJ* /R9_X
M+"?\&MGA_P#X*5?M+W_Q<\)?$>3X=^*O$$4$>N6EUI']H6.H20QK$LZ;98WB
MD,:(&'SABH/RDDG+LO\ @TD\!W?_  3AMO@GJGQ,U2X\7:?XKN?%]EXPM]&2
M-;:>XM;>UDMFM3*3);E+:-L&4/O&0P&5/Z]44 ?A;^S-_P &6VE^#_&VGR?%
M+XXZAXN\%V-XE[-X;T71WTV/4V7'$DS7$FP,!M8HF\J2 ZG!&Y!_P9PZ+X%_
M;2TKQ[X)^,]]H/@/3]?CUA/#\NBM+?6\"S"0V*72W"!D*CRP[(&"GD.02?VV
MHH _(_\ X*N?\&MO_#SG]MKQ+\8O^%V?\(7_ ,)#:V5M_9/_  B?]H?9_LUM
M'!GSOM<>[=Y>[&P8SC)QFOM;_@HI_P $[?\ AO;_ ()TZO\  +_A+O\ A%_[
M5M=+MO[<_LW[9Y?V.XMYL^1YJ9W^1C&\8W9R<8/TU10!^?7_  0W_P""%W_#
MF:]^),W_  LS_A87_"PDTY-O]@?V7]A^R&Y.?^/B;?O^T>V-O?/'S]^W9_P:
MC_\ #:O[?7B[XX?\+R_X1W_A*=8M]5_L;_A$?M?V;RHH4V>=]L3=GRLYV#&>
MAQS^PU% 'A7_  4%_P"">'PT_P""F7[/=U\.?B=I<UUIQF6\T^_M'$-_HUTH
M*K<6\A!"L S*0P*LK$,"#7XX>+_^#'BX?Q:W]@_M$0QZ"[@A;_P@7NXDSR"4
MNU1R!WP@)["OZ!** /B?_@D1_P $,/A5_P $A]&U:\\-7>I>+O'GB*!;75/$
M^J1I',T 8-]GMXERL$)8!F&69BJEF(50/!?^"OW_  :[>!/^"D_QLO/BCX2\
M93?"_P >:PJ?VUG3!J&FZS(BJBS-$)(VBF*J S*Q#[02NXEC^J5% 'XE_#7_
M (,P_ /A?]F+QEX?UCXHW6K_ !,\4):PV/B=M 'V+PY%%<QS2B"S\\,\DJQF
M)I'E!"L0JC+;OM?_ ((C?\$=O^'.7PB\:^%?^%@_\+ _X3#6(M5^T_V+_9?V
M79"(MFWSYMV<9SD8Z8[U]NT4 %?&7_!8_P#X(N>!?^"Q'PN\/Z;X@UK4/!_B
MSP?+-+H6OV5NMR;=9@@FAFA9E$L3^7&V Z,&0$, 6#?9M% 'X?\ [#G_  9U
M-^S'^U#X-^(WB+X]7&J+X%URSUZPL]%\."SEN9K:=9D5Y99Y JDH P"$D$@$
M=:]R_P""R'_!L1X0_P""GOQUF^*GACQU-\-?'FJ00V^L^9I8U#3]8,*+''*R
M"2-XYA&JH6!8,$3Y0<D_J=10!^)/PB_X,O\ P'X0_9]\;Z/XB^*5UK_Q&\46
M4-GI.O\ ]@A-/\,;;F&:26*T\_=-,Z1M%O:50JROA<G-?9W_  1"_P"",/\
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MCU_PO/\ MC^P?%<GB;^Q/^$1\CS]\DC^3Y_VQL8WXW>6<XZ#/'TI_P %P_\
M@BC_ ,/EO#/PZT[_ (6-_P *\_X0&ZOKGS/["_M3[;]I6!<8\^'9M\G.<G.[
MH,<_>5% 'R;_ ,$Y?^"5F@_L1_\ !.A?V=?%.KV?Q2\-W1U*/4Y;O2OL4&HV
M][*[R0M!YLF  Y7(?)ZC!QC\VOVD_P#@R7\*^*/&USJ'PI^,VI>$=%NIBZ:/
MKVB_VH;-3D[4N4FC9E'0!T)QU8GD_NO10!^4?_!+#_@U.^%_[ /QCT;XE>-/
M%U]\5_&WAV5;K1XY-.73])TNY'*SB'?(\LJ'E&=PJG#;-P4CZ0_X+!_\$5OA
MW_P5_P#AMH]EXCU"^\)^,O"ID.A>);&!9Y;59,&2":)BHFA8JK;=RL&&5898
M-]F44 ?B'^Q?_P &8?@OX/\ Q;M_$7Q:^)S?$C2=+D,MIH-EH9TZUNY!G8;I
MVFD9XP<$Q*%#8P6*D@^Q?\$AO^#93_AU7^V3!\6O^%S?\)QY.D7FE_V7_P (
MM_9V?/"C?YOVN3[NWILYSU%?JU10 5Y3^VM^Q]X-_;T_9C\5_"CQY;W4WAOQ
M9;+%-);.([FTE1UEAGB8@@21R(CKD$$K@@@D'U:B@#^?^?\ X,>&/CW,?[1"
MKX7\W=AO"&;\1YSMS]K\LMVW8 [[>U?H!^WG_P &_7P\_;J_87^%?P@U3Q7K
M^EZY\%](@TCPQXO>WCN;P11V\4#K<0C8LL<BPQ$JI0AHU(8<@_H!10!^'?['
M'_!ESX0^%/QDTSQ%\7/BH_Q$T#1[E+E/#NG:'_9L&ILIRJ7,K32,8B0-R(H+
M#(WC)KV3_@E+_P &P\?_  3$_;BT_P",<7QD_P"$OBT^SO[--&'A7[ "MS$8
MP?.^UR8V9SC9SC'%?K!10!^1_P#P5<_X-;?^'G'[;7B7XQ?\+L_X0O\ X2&U
MLK;^R?\ A$_[0^S_ &:VC@SYWVN/=NV;L;!C.,G&:^UO^"BG_!.W_AO;_@G3
MJ_P"_P"$N_X1?^U;72[;^W/[-^V>7]CN+>;/D>:F=_D8QO&-V<G&#]-44 ?G
MU_P0W_X(7?\ #F:]^),W_"S/^%A?\+"33DV_V!_9?V'[(;DY_P"/B;?O^T>V
M-O?/'S]^W9_P:C_\-J_M]>+OCA_PO+_A'?\ A*=8M]5_L;_A$?M?V;RHH4V>
M=]L3=GRLYV#&>AQS^PU% 'A?_!07_@GA\-/^"F/[/=W\.?B=I<UUIIF%YI]_
M:.(K_1KI056XMY""%8*S*00596(8$&OQO\5?\&/-P_C!_P"Q/VB(8_#[R947
MWA R7D2YY!*7:HY QSA03V%?T"44 ?%O_!(__@AU\)_^"17A_5+CPK-J7BKQ
MUX@A6VU7Q1JJ(MQ)"&#"W@C0;8(2P#%069B%+.P5 OR7^W9_P:C_ /#:O[?7
MB[XX?\+R_P"$=_X2G6+?5?[&_P"$1^U_9O*BA39YWVQ-V?*SG8,9Z''/[#44
M  &!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YP-_P6V\
M7C_F1?#?_@?/_P#$T@_X+<^+B?\ D1?#G_@=/_\ $U\6O%NHCAYJ[(^L_L_#
M_P OY_YGV@__  6X\9#IX#\-_P#@?/\ _$T1_P#!;GQDQY\!^&@/^O\ G_\
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M4N4/[/P_\OYGVF?^"VWBX?\ ,B^'/_ Z?_XFF_\ #[SQ9NQ_P@OAW_P.G_\
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M/&)/_(B>&_\ P.G_ /B:^+XTW4]XPE%D"R^@_L_G_F?:(_X+7^+O^A%\._\
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M%+,0: ^*?*@^HX?^7\S[7_X?8>+O^A%\._\ @=/_ /$TI_X+7^+O^A%\._\
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M[\*_AJ5Q_P#$U?@_X+[>,Y?^:>^%Q_W$;C_XFOS8TO4\@'=6[8:EC%'*=?\
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M(OAO_P #Y_\ XFD?_@MKXO7_ )D7PW_X'S__ !-?&14-]*0Q\9HY4']GX?\
ME_,^R#_P6^\8*?\ D0O#?_@?/_\ $TG_  ^_\8?]"'X;_P# ^?\ ^)KXSE@#
M=JB^RY[4<J#^S\/_ "_G_F?:/_#\#QA_T(?AO_P/G_\ B:>G_!;KQ>R_\B+X
M;_\  ^?_ .)KXGDAP>G%.@7;1RH/J&'_ )?S/MK_ (?;>+?^A%\._P#@=/\
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MI_\ XFFG_@MEXO"_\B+X=_\  Z;_ .)KXSV?+[U#(<*U&@?V?A_Y?S/M,?\
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M#O\ X'3_ /Q-*/\ @M=XN/\ S(OAW_P.G_\ B:^)U;FIHJ.5 LOP_P#+^?\
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M /B:^+P=RXQ2[03CY=U%D-9?A_Y?S/LF3_@MQXQ3_F0_#?\ X'S_ /Q--/\
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M13U.10-(S]0M]@!JHGWJU[E-T1K,:':YH"2Z%VP&8\>E1WL=2V)VQTMQ%YE
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M[,'Q*^&W[5OQ=L?AC=?"'PKX9T'Q$D]OI&JZ;),=9TV58GDBDEG9\3$A,,"
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MO;^MA_B3P7X;^.G[27@[PWX9\,ZI\.[SQ!);V6N:7=*PBT^Z9CYKVZO\XCV
MD!@.>@Q7O6M?!W4O#'CN3P[IG[+]IJO@&TNOL;:C<[GUJ_A4A&NEN/-&UFP7
M5=N,8&1V\J^.W[6-@?BQ\+=8T'5;KQMJOPSB07OB*^M3:2>()!*'V[6^?8%W
M*&;D^83ZDW/&7A_X4_$[QY=^++'XS:IX8T/5KAK^[T&ZTZ[DU*R=R7>"$H3&
MP))"G. " <@9+)?.TKW2MYO6_E9[;7_,UOAK^RIX<\)_\%&-1^&^M0C5O#=M
M;W4T8N1N80M9F>(MCJ\>X<XY*YQVJC\&OB/\-?BQ\7])^';_  G\.VOA+7KO
M^R[34DEF_MV(L"L=P]QNP6+ %E"@#..0,'G/V8_BQX/^&'[7TOB*2^U:Q\(1
MP7\%I/JA:ZO CV[I%YIC4DL20.!@ @$\$UQ'[-'B_3_A_P#M">"]<U:X^R:7
MI.L075U-L9_*C5LLVU06.!V )]JE(VE3D[\U](JW377\=CUK]@N^LOA7^VS;
M^$)M!T76KK^W+FRM]8ND<7>GB%)U)APVT%POS;@?:O(_B_\ &?1/B9XCATJS
M^'/@WPK)%K@,U[I23">[42LC1OO<@JV[)P <@8.*WOAQ\<M%^&G[<L'CRY::
MY\.P>([N\>6&,ES;S-*HD"$ G D#8P#@8QGBN9^,_@/P%X"\16^J>&?B5:^-
M)KS6_M)MK;29[86=H7+AY)'X,@. 44'C)]J=@Y5[7F:=VEWWU^78]5\?_"/P
MQI7_  5!M_!=KHMC!X6;Q#86C:8JGR#$\41=,9Z,6)//>K_BSXK_  S^&?QS
MU#P38_"7PKJ_A2UUAM,OKZ_:9]5N#YQ222&4,%A522$0+T5>022,#QG\=_"O
MB#_@IA#\0+/5/-\(IK]A>F^^SRKB*.*)7;RRH?@JPQMR<< UYM\1/$UCK_QZ
MUO6K2;S=,N_$,U]%-M*[X6N2X?:0#RIS@C/;&:1-.G*5E._PKOO_ )GJWAS]
MD;PU+_P45NOAE?3W4OAFRO9Y(HO.V3W4:VYN([;S,CYCD(2""0"<@G([[]EW
MQU:_$SXQ:_X;M?A7HGPQFT_2-12W\1Z1;S6^I>%L1,-\\TA*DD#;G"D$Y!ZD
M8_AWQAX?^+O_  4QU;Q=8))K'A>W\W5O[1\ORX]+2&T4"^D63;\D+@,01DD#
M )P#>\1>(;CX_6,?@Y_VK(]8.M2BSALI_#UU8PW\CL D<LJHHVL<#!)'(&#Q
M085.9I*5_A5]]'U=DOSL?%NLZU=:WJ<]Y?7=Q?7ERYDFN)I#)).Q/+LS$DD]
M<DDU]!_LLWTG@S]C#X\>)M-9X=;:/3-$6YC)62VM;B8B;!Z@.#@GV'I7AGQ
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M[MG(6:)QT*NA((/?!Z@&O-SK(*&,IR<5:??OY-=;]_\ AAT\3.GL]#U;XH?
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MB=FU7Q1)-'@LJ6ECL<@''5F(!^@-<9X_T#P_\,K0?8_#5UJ,JXW3:E=.1R<
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MMH-@JPHP*6)0BDU!)+M(]ZH)#IDW#'K55[5E]ZL*^ZI%7=B@-BHELS8[5.L
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M./+(];_:J_95D^!=U8^(O#MZOB3X;^),2Z/K,3>8$#9(@F(& X&0&(&[!X#
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M .?6E<R=2*;3Z*[_ !_R.4^S[A5.]@P#Q6[XNTQ?#'B[6-,C=IDTV^GM%=@
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M KA<-2JNX_PU6EO<$XZTZVN\_6B(7+D46YZOV'AB\U[*VL#.J\,[$+&GU8D
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MI2+J<_V+?/\ X!G^!OV<_$'C7XZ:%X"OK"^\/ZMK5U'"Z7]LT4MK$P+-*48
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MB.F06^UJD(P_I210YI@HH,F[%9NHWWES<&M+P7IEQXRUZUTRT7=<7;[5ST0
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MV^D_V='$F94A*!9$B7IEV=F8GDE0.P ^/R/(UF^9*C.HU!)R=MW:RM\[]?\
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MW(:I3V.Z7TP<UJ!&#<CBAK<$]*-B[%6PAV=JOKTJ!1L(JU"FZF,@E4AJB,@
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M_=*#'"C'3/..<=3VVD?'36H]5T^#2[S5+72K:'?$AD$4T[L5+.[1\;F/08(
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MS)N6)., @' "CJ?K4,^;S2NY5>1;(]A\9_&K6O[2FO6MKFZM0,&:(C,6<Y+
MG...2.G>N%N)KKQUXU$]E>:K'8W,0>:20LNU2.1\H&X=P>.!7$_'3XL73^-;
M/2X;EWAD7?<K81A4+, %16;. %!SZ#MWKN/@O>65@(X8[B2(AMK7%S<863=]
MV,#!!8<C&,<'.*Z\/A_:.[VZGGTZ?,]=CHK_ .&NGS)Y=L\=U:VR[+B78<R'
M&2,,=Q(]CT]3Q7.^'/"^O^%5FDT>W2>VN5 $ENP(< DX8\$''<@D5Z-XFM[7
MP'ILUUJEY:V, A=+>:(,^R1<@1[5R"6/))'&.< UY-X(U.+4+S^T%C>:.9S-
M<R L@WY +*, <G (Y SVKV*&'H5WR4D].KTO_78[*?+5DZ<8Z+KU.H3XI>))
M-*BTF-;?2EA8[_,V[R>I!(Z\>H'' KM?A/X+U7Q3?QR0:W<0LY6225&+*03D
M$Q\8'OD@5M6OPM.KZ9)XBO(8TWG9Y<K;U\G:-I*^I/4CD@FIO@^-2@U.YETF
MSDM]+23RTD'[N.)2"1@M@$$!B1G@#/05Y^(P\:<^239SU(PA5]DV_4V/&W[-
M?BS4O%7RVZ:A;N5GDOH2,%L#.0QR#@<\$=P36/X^^#-U\1O!,UC8A7U#2U:Z
MTY)92S2*N?-C0XZ.%RHZ$@=,U]#? [XVVWQ-1M%AC33KV)2AN9I2BR(N 1EN
M,D #/N:YGX]Z'_8GCB\O-+\ZVDN4MWMQ&NW[.RDAP%. -S*#GIR>*X)1Y=B8
MR=*:J09\ QRESR&5L\@]1SC!'K6E9P"4>K5W_P"TU\,IO#GCBVUM($@L?%"R
M7*A!M43*P$H Z#)96P./F..*XZPT\Q5D?7T:JJP4X]1UM:;3]WK4TUJI0\=*
MF157OS1,RB'ZT&[T5CFM48I*=HJ*PFD>5:O:C:%Y"13+&V:)\XH(ZFG:PEEW
M-4=XG7 Q5NV;*U%?A5B;UQ3N7T.*U6Y8W?EKN9G;:% R7)Z #J2?05Z_\-_A
M]>>$/!.HR7$%Q'XIUR-;>RLPA,]O 2,Y7&1)(VT 8R%'(RV*L?L]_M#>$?@7
M']HU3PMJ&H:U'.[K=VCP RH>0A:12R8Z?+P1SC.:U/B3^W/JGQ)BFL_#?A_2
MO!5C,2);BW;[1J<X(((:Y8 J""1^[ ."1G'%?'9Y'-LPF\OP]-4Z+MS5')7:
MNKI16NOKJM-#7!XB%"JJC7,UMV^?_#$FH_$[4O@YX3NO#.GZ@TGB#4 J:UJ,
M;[WLU4'%I%+S\V23(P. ?E7D$UY;<IO!QSGD^_UI8(PD(XJMJ%VT*?+7TF79
M;1P5!4*.RW?5ON_ZTZ$UZTJM1U)[L^L/V//B_<:W^S/XUT+47DG?PC+;W6GR
M$Y9(Y6*[,^BLAQ['':KGPL@AGT?^W-8DW3ZE,T=M:2@MYZAB% '?)Z#H:\S_
M &1G)^$GQ)^94%V^F6[$G&1OG<C\=M>Q_#G3IO$7CK1;^.*WE:TPFFVQ_P!7
M$H&T.?<[6([\G':ORKB6CAZ&9UIRT2BG;S>K?XZ(]O RD\$XK=R>ODDM/F[W
M?ZGO_AS0;7X,>!$NM0N-+\.WFL2JDDLTJ;X'?)6!"Q"M)P<#( .3T%6(M*\*
MZ!$;ZRNEAO1^\DENI2MS<$\$L[<-R>QP.P%?%_\ P45^.-QXO^-5MX>M94FT
MSP+MCV'YHKB_.&G9@>#M($?/0*WJ:]T\97%Q\2M!T/XC>'A=36OB/3DBET^%
M?,@D8LBC$6=IE20^42!P#ST!KW:F'^H4*5:K%OF7:_*[72OW:OK;=6/F</0G
M7FO>Y7+SLGY?=TN>OM\7?"NCVQ_M2^L]6X+0V\ $]XY!& BK\QYQSP/7 K,B
M_:F\/?VQ:Z/=7C)KFI%C:Z)#!]IO8T52Q\\(2L9V@G!(/X5\4_M3:I-X(\5P
M^%['4KC[9IL _MBZMV\G[1<N 6B&S'[M.@7)!SFL#X(Z[<?#3POXG\1VH:.6
M:)=&\Y"J/$LX9G8.W"Y$8!((.#C(S79A^$_[5E"M7ERIZI+?7K)]5U2\]SDS
MC$8?+\-/%SO)1MY7U6W;?5V/;OV^]<3XIQQG39$MV2VB75(%0FYMEE0F!I ,
M!Q@E0P)"D,N<@9^'OVE/#/\ 9-GX1UJ"1S.EH^G3RC(82PR%D)[@E'&/]T^E
M?3_[-?QQCUS2HX?$T,ES_9D9CBU5H3(;>SE; MKKG,T1P7#*2RA0PR02=7XU
M_LD+XV663PCJ/A[Q)I.I$7$FD_;$>2(C/^K92&R"#M. PR0003GLR["5^'LQ
M]I6IMTTW>2UNFM=?+>SMV\SRLRQF!XFR183!55%M*T9;QDG?7NFKQYE?>^KW
M^)_@IIEU?_%6":W=K_49M.NFCB#^6?-,1 3)P&X)R#P1DC.!6?\ $>!]+^UV
M.HS)9+(N(H[R16>Y8 'R]JD@+G/S9/( X)KW:U_8@UC4M9?[!>/H5RJF);'4
MX) T63VEC!+9/<J"*IW?[#^N"2TF72=)U^6W+0S"WO DX.?OJ+A4#D=<9&<=
M:_4,-Q)DM;6.)BK_ ,WN_P#I5C\DK<!YI1O[6C*T>UI?E?\ S\CG_P!C[5I+
M33A9QZC)ITA8R.DY8QRL>&(."%/I@=.,U]E?!;Q3<F_NH+Z\00M#RL;[DN$.
M3\PP#@#D8 QU%?$VI:SJ7P1\8W=K=:-<Z7=3.(H;:Z4BXD1E*E^,@'J<G@YX
MZ5NQ?M":EX2T&"+3M*DA\KYDDC >5V & S,22,\9]. *];%82CB*;BK2BUY:
MK^O4Y,/CJ.":E!M2@[WV=_PU]>I]>:#:Z/X&\=BWT_Q&L</B%))!I-RQ"7BK
M@.89>F5R"48 X.01TKSG]I+5_#_@ 6,>KVUUJ%IJ+DBQNF$LB2)DAT9"&PP)
MSSVP>*X/3/BOKGQ3T7P_YWA'4-(CM[L7(O[=WO(!@$NNW:S(&X)!.#M Q7EO
M[0.@>*?$?Q-D^SIJ$]C!;R;KFVA+-)$?F4C;D@C>V3C(/&!D5\[E_#JPE?VM
M"HU!WO!ZW[.]]+::ZOS/8SWBC^TL)RUJ:E/3EFO=:ZN\;:IZZ)J-]EH?67P2
MU?1;BXL%T/\ T&"]5FFL9$#0<$#8 V2<DG()/?-> _M8_"VQ^&/Q\U&TTJW^
MR:5?11ZA;0 $+;^8#OC7V617 '88':N5^$_Q0LOA]JFEQ^)OM]OHD5U]KNK^
MT5I;V!5B($:QR.$(+!26(+Y[XR#[AXZT>]_:J^'.D>(-#M?MNIVAD<H!B>[B
M*AMH']\%<A<\[B!SP>C,L*[<RZ&W N=PI8E4:CLIZ/M>VFG373MJSQ'3SY8V
M^U1ZS,5@;WJ2$>4YW#!&1@]01U!^E5M6/FQM7A6TL?MG0Y>\G9G;US4^CS9.
M#4%U%LG(VU9TVU+2 ]J9)?D!_2JVYDQQ6@;?Y0.]--ID],4 -MI3O&36@MSE
M?6L]H#$U36A);%2V5$L'DT4,C \451);U&;8G6N<U?4S&#@\GK6]J2[HS7(Z
MP^R5LK4Q'(H&Y:24D]ZNZ</-E&/QK*W9<UK^'XB<51$3;BMF=*>D+*<8S4U@
MC8YZ&K!@YX-!I$;:J0:EF5<'M3X%QVIMQ'N]JG<.A1FB5J=# & XHG7:..::
MESL7)%+9B2N-OV$,=9\=RI?ZU/JUSOAZ5EC+?6J8CI]*B$BU<FM<#.*S=$EQ
M&/6ME6W1TD7'8H?9&+^U6DME5?>K$5MYHS5@V02/I1*P[=BF/D IRE6%1W )
M?VJ6U@W8HY@$-ON.0.M6K:UQCUJY;66X<U-]F">U0Y%<IGO;8[<U6NM,,BUJ
MR%8QCUJ)I=HZ9S[4N8-S!.G[7_BXK1M$V+5B6,-4D5KE?6JYK;ARF;=V^&SV
M--LK9?,S6A=6[-&<BJ:(8C3O<3+V=J#%5;J^\CZT-<$0GU K$N[QC-@]6SBE
MLQ&K]K>;'/RU8:V$HZ5FZ/(SG!' -=#;QJ(L]:<GI<J*N94ZB \"@7WD+S5S
M4(56$M7*:QJ+"8J&Q2)>AHWFJM*&YXP:Y?5)O,E/%:=M(UU'M'S9JI>::^\\
M?A57(U9:\,J77 ]:ZV&UW6H]JYKPQ8F-@PZ9YKJHY?+CVT-EP6AEWMAYIZ5'
M!I_[WI6RNQFY%2_95;[NVI<BN4IV]HN[IFJ>LV[1J^T<X.![UM+"L +5GWC+
M.2-W- -(R]+1ALW?>(&:V4Y'2H+"R^?=UK2%MB/Y:+A$JXS5>6# /'S5<,;%
MNG6D\HX^:@90CB8MTQ4RVN4/O4RP9<<U>@M,KTXJ>87*<W=VK!CBH8(&1N:Z
M*\L<$\53ELMRY ^:JN+E*#2^2G2JDTN_D]*O75OCC%9]Y"P0X'2J3$Q(95/T
MJ_%"K)D"L6W;;)SP36Q9G,54 VX"1=JK/-M'%6+N+<,FJDPP&J>A,B"\F&SU
MS5+^S5G;=CK4S_.6JQ9\FG8+7)=-T[R^W2M"*V\M@:?:@*O/I399\\#BDM :
M+ELP5A6KILWG2@=*YB&[83>U=)X>;S) *(F,O(Z[P_&S,*ZJT543_:KG]$BV
M >M;T()Q4F,ATG#5VWPBTZ+Q1:^(=!F"M%KFES6S \@[E*GCZ/7#R9Q75_!O
M5_[+^(6G-G D8Q'_ ($"!^N*#GJ?"S\E+.SET74;FQF5EELIGMW!X(9&*D'W
MR*V+:ZV=ZZK]KSP;_P *\_:T^(.EJGEQ1ZU//$H&!LE/FKCVP]<3$QVUH>I&
M5XW-A=28C;GBM71[GIDUS%O/^?%;>D2;MN/44&;.^\-#=CL*ZNSMF**:Y7PP
M/W*^M=EI2DQ8:@N.I9LXSG[M:UH/D&:J6\.TC%:$(^7@5.P]R.X"[:JLBF3-
M6IXMP-5G;8W3@4/0DECA ^;'-4M2F"M5EKO8!67JTI:44T.Y-:3B60"MZRMU
M:+_:KE;3*SK74:9+\@[T;#B27%K@\"HX+7Y^:NL=QJ>*QW,*3V*L55A5,8IV
MX \U:N;81#[O-4<;I>:5^P$P532Q6N6Z8%3V=MN85HQ62JI9N@&?RZTY2L!Z
MO^RC^T?)\*7NO"NOZ=)XF^'_ (DS%J>D,AE:/<.9X5ZA@!DJ,9QD$,H-1?M+
M?LGS_#/4-+UKP:;CQ;X!\52I_96IVH\T6VY@/*G;HI7) 8@ X((# @>-^#O&
M'_"P_&::'X1M$U/6].N'-Y-=*4M+.+RN)DE5@T;*6(+$'&>.0 ?M']@[XT6/
MP$FUS2_B!XV^U6>L)!+9K,";*WE&X2+&@3=E\ABYY<@D@'KZ%/ RY/:-7>]O
M+_,_/<9Q1*IC)T,#[L=G/1J_>ST\D_GL>'^$_A):"ZM]-TZST76=8MY5?4;:
M:$R;TWJ45=V=P.0"(W0X))(!X]:\.>%[/P%X[FL9O!>DZ*_VTQR6]O%^_>T)
MW12K(YPN3D$ ,/E )!.*YOXT1?#_ .(WQ^U:X\'RMH\BSJML+>-H1=2% 6=$
M8!1'NY.  "=Q!/%=-H?A"Z\.VT*ZY>MJMREF8HKC393J$97>9&!?!;S8V 9@
M,$_+C@$5[,<#3<8ZV;6UO^#8^=C&O4GR5*\I-ONVO+?37^D3:WH7A'Q]JFJ:
MG96EAXLM)[5&?2VL4%Y;LJ!F$3H$9G0G#&,GU*G@5Y'X]_96L_'%W'=_#@M)
M]I0R-HE[?1-<P, <QHV02P((*2 ,..23BO8?"GA*U\6W%C=Z=J:IJD<;D7/F
M;TMVYW&( #9N !P2,<@X(-5O'/PUN-$U&+4EO[G6M:&U[F[D>!([L(6.3&#D
M2!0H/)#XR<$US8O+X0?+Y>C^9W4\;F.724X2YH[M.]K==&VTUY;>6Q\@P:>^
MF74L,\4D$\#F.2.12KQL#@@C@@@]0:GF? ]!7T-^TWX/E^,7A72/%FEV<U[X
MCA2.TU+R%#/?H$)24*I)++C!X#$'/( -?->HW++!QUZ?_KKP:E-P=F?HV5YG
M2QE!5J?S7;^N@L^H[7VK1!(TTOS'.ZL4W3/(PQRIK:TAC(H+#KBI6QZ&K)6M
M%)SBH#)L?@5L&-2@'6LO6P+52PXJ;E-$<VJ^2A7H:F\#^&9OB5XXTK0XUF9M
M1N!&WE+ND"8)8@>H4'&>,XS7)W.H,]Q][(SZU]._\$Q/!-OXE^)GBS6KC:&\
M.^'WFMRW5)'D0;QWR%5A^.*9RXJM[.E*:Z(SOB/\+]6TOQH/"\<MXWV6T66R
MM8K9W&G #(MT,9RQ&"7/(R>>M3?#/XF>(]/T.'3=/BN)X7F^U3NEL)I'?A<@
ML0H88(!((7J1G%>I>,;#4/B/=:M=ZAJ#^&Q)=23Z?;/<-:I%&$):>9>'D+;L
M\$#YN!SD-_9]\#V1N/\ 2%6VM]-@^;8IF8I$06<*N#B5R7!) (;GH17J95"/
M/*K-:17XO0^3HI2DY35U_F<#KWPJU3QKX[T]EF\F?5%=XYY08MA1"22^X%B!
MG<1P!VP:]5T;]E.;5O %G<:@NDZ7-!:(T#1R-.)Y. 9 %Y;>3G@D<]N*]+TZ
M!O$D,L$IM[RPDE:2*5H1YD2D$.J,06Y!P1DCG . *YJ?[3H<K1Z/YUY)&YMM
MEW*65/G 39QN4 8R#G'8D<5ZLLQKU%&C1T:M]^W_  #2I4YW%1WC^?\ PQ\^
M>./@DUOK,C6M_-?1<R3H+1X%1^!E2_0$@@@XYJ[I_A67Q?;6L7FVVGSVR)YA
M\_:HZX##H"&& #C).<\YKK]3^(UY9^+4M?&&G26.EW!8O-&!,X89SM.".>1_
M@:X74-<6RUH7&G*SP7-R( # 2R0Y)0YZ@GN#GL?:OH(^WJTO98M;_P!7.?$5
M*E27L)Q:=KQ?1LH_$S3=0T35A$]S&\]S@Q26[;'N-YP0W/&TCJ,'N#FO0?V<
M/&DWA;6[6WURU75+:V@$\$!G(2.%@Y4J^3AL@G)&" 01GFN&\7>(9#\0='NK
MAH;[[2ZF665!NRQ "J<#MDXQ['CII>#]7U*Z\9W!^QV,5G!%&;]?LY'D(2R!
ML@;B /F)YQV!QBO,S;"Q6$Y8+6._]>K-J/-+"+F^);GT!XWU[P7>Z>UHL4-Q
MHNN 0W-F]K&$=E<$NH."Y7 ;!XR ,8(KXW^-VG36WBL?:FCDN]CQ3O% (8Y"
MDKJCH@X"M'Y9 ' ' Z5U/Q@\4PV7BM=!O]1ALAI%XP6X#GRTCX#!MIR",+@
M XQVXJY^TE,NI>"?#,T[1R7\,DD44B2>8)+<HK9#=&7=@@^YS7Q)TY3-QQ*7
M>Z_4\2F@Z;11' 73G@U<:'CFG6UON;UJ;GU?*4Y[/=%TZ5EW%JX;BNL-EF.J
M%Q9A7Y6A2#EN8T$90<TMQ<;1MQ5^XL=HX%4+FWR?>F3J5)I /K4ELRRL,\U4
MOHV5J6QDPP]JM"L:IA&WIQ5:=UC.,5</^J %4KF(!LTP>Q#)/@U2O'660KUS
M5BYX6JH.6I(@;;Z2-^[%;5C9;(P,5!8#=ANM::NL2^]2BHH=:1>4.:U+&;RJ
MQI;CY">E6=,NMSX-/<RD==HY,P!KKM"AR@W=JY7PS^^5:['2TQ&,4C"2-%MH
M3BIO"VH?V7XHT^XS_J;A&/TR,_I54J0M0\I+GOU%(QD?'/\ P5B\'?\ "(?M
MKZU<(NV'7[&TU)2!@%BGEL??YHSFO ]+EV./?%?8G_!9[P[]NU3X8^+(UXU'
M3)K"5A_>0K(H)^CM7QMI9^:FG8[,.VZ2_K8[GPQ<L&45V%O<;4%</X:?E:ZZ
MV;*"GS'1T+LNI$# -,M;AGER35.67RY3Z4^S?=)]:HQD=/H[>?(/YUU%G;>8
ME<OX83I77:9"PZ]&I-7*B+';%3MJW:H5-.$:Y]#4UO\ +2V*";:.HJC,%>K\
M\>X52G79TJN@I;A#%FFZ@_E14U;DHO2JVIW!D@Z<TH[ U8JI=X>MS2%5P*YE
M06'O6]H3;8A2D);FO);?+P*KFRRU7(V^2IH+?S13Z&A8;QW9^#?AW>)J5_<:
M=IPN%#R0QAVD9P0%V\<G:<GT&.*\+T;QL;R"]G:2VLA&DES8Q-.6CD4]F.<[
MPN<@G!YP,\'NOVCXE7X4RVNQB\UW#(CY.$92>O'7YN/QKS'X&WWAR^TW5-'U
MRWO(M54;;&YBN1$D:CYB'5E.X@ @#H2P!P0#3IQYI)'RN912Q#7H9VFZUJVA
M>(WUNUGADNE5E9GC#1RHRD#:IR""-QR.1C/%>C>$?BU<:#<:=J5M9?:EMY0\
MEK<9\B7&=P+ ACG)YX[=ASG6^EZ+I^L0?8)6:&.V)>&=70;F*DQD\@ Y/)R,
M]\<UZ;X4^'.G_%'14M;>ZNIHYAYDDEO'ODX<* =O.021QGL37U7]F3DG"GLU
M^GZLSJ4&]+%WQU^T[K7QS\&6'A=='TO2]+LY&D6."$&:1B "3*Q+$D 9R?R%
M>J?#[0M,TK0A9PVUOYDEJ%$LTH6/) R$50,L"22<XSU'2N7\7_ "'X=6,4.G
MW,D;QW A:Z"@[^C%0>=Q*D@\=\G KTN/X&_\([8RE=0M]Y^73[1,$B,+DN58
MC )W#)QDCC@YKHPN&EAX)2BW*3_*P1Y(4M4_>E;31Z?I^9I^%/&5MX=TZRLY
M(/M"VD0AB>Z0NL>3D$C 4G' R",?B:W=%\+:EK4=K=7T5PMG?\02,I6':>?E
M& ,@<#N.E,^"7P]NO$BZ2M]8HUU;7#7$R2H7FDA5\% .@)&.N.N!P:ZSX9?L
MU>+_ (:?%OXG>*/%?Q(O/&7ASQB5FT'P^(G6'0H_-WHI7&Q#&H$8$9.XY)P.
M*\7/JTJ5:-*%/F4GJ[KW5_P6?04\KP=6C7JXBNJ<HQ4HQ:;<W=)QC;9ZWN^W
MS3M#\&V-G>"UMKQ[B[C8EIBJHH S\B$<D\@DGWQFNNT2!O%&NR:?K$<EU--&
MJK,Q/F (,!<XZX]3^M/3P4='*ZC-8W%C;R!GB1EV'=C&1[9Y]LXZUW7@GX6S
M>)?!=UK4]S-;W-KN:,%MO ')SZD#@\5YM:FDKQV/G:]'E5UT/BC]LR35O^$S
MT:UNHX8=$M+:0:9%&^XABX\YW[[BP7KD8"@'K7D^<1BO5/VW+J^N/C)!#<?\
M>]MIL(M0 !\A)+'ZE@>M>0F4I&<US\I]-@?]WAZ#;R]\GH:A6Y:?'.:S;N61
MKA5569G8* !DY/0 =ZWKKP'X@\*V\%QJNBZKIMO=8,,EU:O$DG?@L!D^U3S)
M.S.O5B"W\U%SS236<JPM)'#(T:?>=4)4?4XP*O6H'E9SS7HMIX:\5:E\5O /
MB'2/B%:Z'X#TGP^TVK>",#[;J/E^8)K@0\M<1RGC>0 N"03C%>?F&.EAHJ48
M.5VE9>9Z^3Y;2QM:5*K6C22C*5Y7:;BFU%63U=K(\B-X;=<DU3N=2:1B<_+@
MU0U[4-URX4[5W$@>@)R!^50V!:Z7 KT#Q;ZE#59FE<_B:M^&%\QB.^:+[2'#
M5;\.Z6T<@.UE*GGBJ3%8ZBTM<VWTJI>6'F'ID5=BF\I<"NBTWP']MO-'LKG6
M?#NG:OXB0RZ5I=Y?B*]U!1N *)@\,5(7)&<<5C6Q%.BN:K)16VNAW8?!UL1)
MPH0<FDW9)MV2NWIT2W?0ZK]F5V'@SQQIH.S>-/O5/;*3M$1_Y&!_"O1?V;OB
MBW@WP;XD\87IV0>'79+.,GBXG!,5O$/?<,G'4;B>E>;_  4W65IXYMV_<7!T
M-D9&&&0K=0;OH5&?I3O'.I_8/@=X3T^W3RK2_N)]2D /^L<*J@GUQO<C_>K\
MZSC QQ?$%/#S7NR49/SY5)V^=K'J86RRZM/JO=7_ &\XW_"YY?XDEGU.^N+F
MXE::ZNG:::5N3([$LS'W))->U?L7?M8S?"/2!X4U>_>QTQKE[BROBAD6Q:4J
M)D8#)V,%# @':XST)(\6O)EE8CUJ.QM5,FZOT#&X2&)HRH5+VEVT:\TSPHRY
M9J22T[JZ^X^H_C1^S'H_Q?\ $FN>)_ OB*.[:[E:Y-M<7,4\<I(!(21#N4>@
M=3@=2.M<%X/^$\WCWP!X8\/J_EG5+J;4KQI0?)MX8I<,&'1]P0 8/5P!G)(\
MKAME524^5L8)7@_B:]\^'_Q?A^'?A[P5<:PGG>'+C26TZ]E@\M9;/%V<N=Q!
M)50F2,X';%;Y#AL10J2C.ISJWN^ZDUY::/RT3\WT^,X\E#^SHQEI%RBGN^CW
MOY[LR?BGX3_L3P]XNA4VUE=NMOY:QY$NT>8REL?*BX/3J3CC&:\A\-7.FI+)
M<W NH;^ZLEN_.B"E3<KE=@YXC8'.3DY &,5O?M"?$9=;\7^*H](\6Z3>M.42
M2"W?S4U.%W!C=" 0'C PP)! Y!.37,>&M+32ET;4-3V2V]Y@B$Y& I*D$<9
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M\?1D[\BZGD/BK2=<\!ZE-8VY1Y-*NS P+X\L/AE=1W#*,8QUQCO7*Z]K]_\
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MQ"V"'@%G0$DG/T(QGTKL/"7Q2\-W-_\ 9[J&V.GV<(BAEDMXWFGWJRJZ'Y2
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M,=J?I\JRS 'L:J0M"U8Z=MCZ5>M5:,[3TJY:K&(_E&:)$52#C%+F(DC6T1\
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MS_9IE9"RNC!E8'!4@\$'J"#7T[\*/VN])^(&L6^G^*F;0I)(]D=[&H-L\IP
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M+9P,<Y/ )XKP_P")'AEOBY\4-2\)Z'JWA[5(O#,1\_1H]0#ZA;C(#3318"#
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MU2SBN[4NHP'$<@(W ="!G%>S0?"S3=9D^V:BJ:A?2JH:>X48VJ!M"H,!5&
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M7W3:MJ<Y9^'=)L?!]UX@\1>(+;P[H5I=Q:?]IDMY+F26XE!*HL<8R1@$DG@
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M.^-\ICC49?! SR<9QUJJFEZ]H7B2)KC1;^,/;3O:-<6LL<5X[ (%5L '@D@
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M955:T')VC?1;:>FM[KS:6IW=YX8T_P )WR;=7U6&XN<QP*=5(DR 6(4E3D@
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MK,FX&53R&7N!G/;@UU1JTJT_91EK\]#:MEN)AA(XVK3]QR<5+HY*S:];._\
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M@SW,2X@LA!$H3  !=N69B.I/YUXO\3/$$U_IS7EK-=/J$TPW77EGRHMWMR,
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M-?:M<"8J/+7Y0D2] %7& !TKYW%X_$X=\E2SZIH^TP-3!XJG[6+:MHXO=/\
MKK^3,'PS\)?#.C6_F:Q,^K798XA1C' ,9P!C#,2""<X (XR*V[^33;5&2RTV
MPL;=B?N6J?)DY.>,\GT%97BS25NH/M&@ZM;7$J@%8KE=FXCL&7(!)SC('UKR
MOQ7\;->^'TA76M-FLT$FP3.NZWD[\2*2IZ\#.?:N*-'$8I\SE\F[?<O^ =\:
M]*GK!+U/6M>\+:;=:5+--;PHI&XS6R%3DXY[@].XKM?A?XUU30/!@BTYK>[L
M8W"HFH!FWJ."%9<$8'&2./PQ7D7[/_C1OB1!<ZE=,MOI,,A0L&P;EP 3&H]@
M02<8 (ZDBN^;Q-+>YMK*U:WM;5=B1HI50O.,=SGUHCC<3@ZCA"5WUOJO^',,
M9EN%S*GRU8W6Z:T=_5?J<?\ 'SPC??%35A<06]O:QP[I 'N58.WH#D$>V1^5
M>8Z)^SI>>,=1E@N?ME@JXVL555)'4!@2"/R_I7H'CGQ)+9RMY<-U"_()*D#)
M]>/QKA[GQBUM,YFE96!&1DCCZU]7@.(,;4@VJ5TENKZ>KU/SG%>&6!JSYXU9
MQ=];I._;;EMZ_@+JG[&$^A6T-U)J]Q9_9V+R21$,\BD_+P"6(]< ?6K/AS6O
M"O@WPSJVDZM%_P )99ZU:K:W]MJ:F>WN-KAEPF[=D$< '.?IQD:[\8[?0+,R
MVT\B3$'.#SP.Q[5S7PNN_P#A97B+7K[5DODL]-LI[V]^PJIO+A8@,V\ [,=^
M6;!(&3P.OA<0<45W0=*:]V2VWO\ ?^A]OP/X88##XJ&.HRE*I3DFG=QM+IRV
M:U\VSI/B3^VSJ>F8T_P[IECHEO%$D$:01K&L<:*%5 JDA0J@  DGUKR#4OVR
M/%6EW6]M;#2E^ R\#/KW%7_V@]!T_P )>$/#_B;0K?4-)L=9O+O3&T^^N4NR
M'@('FQR* &1@<$$9# C)'->5_P#"!IKOEG?']IG8>6CL$))[<D<YKXBGB)3<
M;7O)V22U;VM;\C]IQ%' 9?S1Q,$N6_,VTVFM[N[6FMVG;S/H#P/^VG>:W-H9
MU[P_HOB>]\,WAU+1Y[@'[3IURRA3)$-RAB>."3R < @5[+X!_:YLO$EZEO?0
MR6<TG5)E* GOC.,'Z&OFC5/V;-1^'/A.SU.XNK!Y+C34U,00N&D>(EE?:&()
MD3;EEQ@ @@FNS_8#L_"_QJ^,,7A'6+Z.&?7X)H[< C9)<"-BF3R5;(&".<]"
M,\^OC,OQN"KPI8J'*ZEFKZ7OI?RMLTUHU;H?/87/<BS;"U:N JN2HJ6BNTK7
MDU%:K767NZ/FYNI]:Z=^T#:V6GSZ3I.IPV>M:A:7,.F7,YS'9W;P.('<C.%$
MFWDC XS7D/@Z+XA_#S3OB%J'CWQ!K<VGWNF0:?I\.NX2*]NECCQ/#$LTC;HW
M$H+I@2 @DY(QZ-^TA^R':_L]_#OPOINCZDD.VS>76M3FPTUT^,R3,W4(!PBC
MMP 3DGX6U7X[VFIWR!?._LV-REN9929)%!^^W;)]!P.@KS,TAB5B'!*W);K^
MFW^?X'N<)QH3RNI.CRN%?>\4YI1E?W97O&]OE>_Q)-=/XK^(&HZI<,H3[3..
M2TJ Y [[<E5'MS[DTS1?'MVS1Q:AH^EWS2Y5%:U12_'." "2!WJSIWCK0I8D
MDMX+=KB1#MC9L[I,?+D=<9QG^5;'B#Q/%XF\2)I>E>%K[4(=8L!J[%9$6+2/
M*F((61VV&/&"J@ACLY&"!7T>0\%U<WP4L9-M-723>K>C5V_A5G\^Z/CN*_%+
M 9%C:>5QPZ?-9N5ME=IVLFV[JUUMVDSGGCFTBX:XM1J&ES#YA]EN& 3ZHP9<
M?@*]+^$OQ.\<:/IT=QIKKK23,?,4KY=VB]" ,E6'?C!/H:\-F^-F^X::.97W
M] _<>I^M=U\!_C5</XMMXUM[::WW$SA&V[ .0?05\HY5Z$I4W9VTNG=:=NZ\
MS]-C1PV-HQ=:C9R2:NK23:ND^J?1KHSZ(TSQWXD^+?B_3_"6FPR:?X@U4B)$
MNMR1KD9+L",_*.2,9_2OG?XUZCXF^'GQ;U7POJ5Y>1W6FS"-YI&,2E2,JRJ.
M@8'(&3]:_2C]G?X2+XP\1>"?'ED]NT.GQW2W!E.Z4J\6V-%_W69CR1C)P.>/
MR^_;J\;6VJ?ME_$2XM+AKJ/^VID61WW$[3M('H%(P .@ KV\10DL'3KW<7+I
M\OQL?"\,XFG6S.O@YQ35-;M7:ES-6UTV1JVDLD5J?+U)IG"[GD:=P4SZ?-Q6
M0_Q*\0: TD>G:Y<J8W^<0W!W D \JV03@@].AJA\)UOM1M-5U!5TNUM-'TZ6
MZNM5U*Y\FUT97(B61UP?,SO.U ,DA<$8-;WQ/\):?X)T7POK<9MK^R\3V O[
M35K2Y#VNJ@81W1,!XRC*0RN."0,D@FG+(JU+ _7%B8N;BI>SYE>W-;FOL^W(
MM;]6URODJ<45O[3>#C@92H*?L_:ND^1SY.?DT5T[:\STLMK/F4ND_M7^)M&U
M&-KK4VU"* @/'.A'7N2I)(^@%>[_  E_;*6>\TU=4TBW;2);F-+J[M'$I@CW
M ,S+@. !R>/6ODFSOM#U:ZF\Z*XEEDPH,>6;.>..O?%=9I?@77/AA-'YEK<6
M+3,7CCOE,9*'J&&20#V)QZUXU&MB*D)2A%M1M?317[M;;;[+J>WBJF5RFL/B
M_P!U*6UFE?;9/UZ:GUI::MX]^).M?$72OB@VBV7PEUK2+JQMDTFW\O,<DLBV
MYMKDX,DK1K&S*I9"&^;:P(K=_9B\-^"/V?O#.J:3X7B6:/6+S[?<2R6(M4B5
M2QCBC3>[':7?YF<GG P.*^,M5T.X?4O,LKB]T69,OY*SB>TW'G*KD 9/4KCZ
M5ZU\+_C!I_@_XD>"/AOK\GB*X\8^-[-=1M;FQLQ)IMI&Y<1!WX9MQ0[BOW.I
M& :UPM;#**J5)>]MK?KZ;_\ !-LPH9KB7/ X.$?8./-*%-)1?LUS.;6_-:*;
MUUY5\32/L"#XQ:?>E=C*.W& 3^/7\JFO/%%E?;59H8V?IND 8GT&>]>&^*/@
MYKG_  FK3_VA;Z7H\\*3F5FW-YAX957.>HSD\5N/X3TB 1S745]X@F7'[RYD
MZ8QC"+@8_,U[E'!X23_?R?RU?IJTD?"14E=J.G]?-FUX]LO+DD\F13P=RN>"
M#VK@;/X;Z&8;_P 3:S<)IN@:%&)KE20%GD.?+B!_VF'(&3@$#DBKVH>+DO+M
MX=BVZ0\!2O"+Z?2M/78;S6=.T;19/#7AFY^%=]ILMWKVOSWI%Y;7^)$\I(PP
M*.N(BG#!]Q7 Y([,#46%Q$5)-QNM$KO7TT//S:A5Q.$J0PE2$:BC)ISDHKW4
MV[-]6DU%+5NQ\-_%O5;'XG>(;G7K6S:U::>17;)Q<,"!O /('48Z>PK@HK9O
M[2&V%;A8<-MVY''0GC&#7LFK_#*.3P!<-.[:>+"=+1(V!S(S?,6)[%MQ(&3C
M!![&H_AU\'KC11->3.TT<8D0F1,118 8[LGJ!C ]J_;\#1B_?>RLC^5<OII-
MUZNVR]6<?X<,VF>$&N&TZ&Y$EP98)<LHC8@*V0,\$ 8)'&.^>,[Q5X:O_%U^
MRW,MO"-.4SQ1*P3:H&<@<''''<\5V6B637\EMI\C?:XI;AF,4+A)(E.3D#D8
M';)Y'05LZQX"A\,*FJ/:?:(HXQ)$,Y653\I7D$DXR0,''7&*]:NH1?LVM7_F
M>Y6M&?+RZOM;J_Z3L<UX4^+TP\-Z?IFGO<&ZN' A2.,.\C8P8U7!(R2>QSZU
MUUQ\;O$'@*:-)K":XMT*K<6R7R.T1! !=D)\M@>P'/.:\P\-W%Y;>/CJ-C;7
M(O$W20QG&^!<X9!\HX*MP?0G&"*^@_!5G9ZAX&%K;SKLN"'>-(T*2(% 8G=D
MX!R,]>#TZ57U.ER+G_KU.N6'H4J2YTWKTZ7]-7^ISMM)JWCO7-4NH]'U71EO
M;='64CS8O-&</N4<ACR<#MSS61X+^'>L&*7^T$5I(7VMF0 1JPR%(X)4\?7.
M> "*]L^ \FFRV\NFM?6<,MJSNL:2DOL4 @DXX4CD$<$U1^-LVB^"?,>Q*75V
M_EB&W$^6D89 E88)"Y( )/(P,'FO+J8APJO#PCV_K4Y:CE3<H4>NG]7]>IXY
MXF^)>O?#3Q5;Z>@AO;+Q)?170NIX=]]$(TV>0LN=P4#C:.,;>N!7N\G[/]O\
M8=!FOK!OL_B5D$L<;D[+U@ #&QR0'./E/&2<-GJ/+=2M8]7TR.\N$MY[G2KD
M'<P CMV8A&9AU&TG.0.@/<8KW;X#:];Z ]K8C5[/4;Z*X+*]L2T7E@]0Y )+
M$YZ9P!7AXZ@FG%HX\LQM? X[VE-V[KIOJK=5_P .?.\<303^6RLC1L596&""
M#@@CL1T-;%D-Z+7J/Q)_9.\37_C[7+^RDT?[%>W<UW;![K;(ZNY8*05 !Y]<
M5PFN?#CQ!X&CW:IITT$8;:)%(DC)QGAE)%?'QQ=&4N2,E?U/Z!C&4H*I;1J_
MWE6*18L5JZ9(C$>M<\7+-6QHGS-SQ6]]#)ZG16W*UJ:8^<K6;8Q$@$<UJZ>,
M-3.>42S=0LR<=Z\]_;U\+?\ "9_L!:A,J[IO"^KP78_V%+[&_#$M>F")9HN,
M[JK^+/"O_">?LW_$WPWMWO>:/-+$O^VJ%EQ[[D6@QGHU+LT?D_9MY6*Z#1[W
MRB#GI7-V%V)57<.2!6D)=A JM4>BST#0]6\]L9KL=%A,KK7FGA.9C.N.]>I>
M&X695['BI''4Z;2;;RPO\5;=E'SGUJCI-MA!ZUKZ;8S:A?0VMO$\UQ.XBCC4
M9:1B< 8]2:GF+L2>7GK4B6^.>]:7BOP1JW@.."34;>-8[AGC22&=)TWH<,A9
M"0&4GH<$5G6T_GJ>V*(RC*/-%W0ZD'&7+)69#(F)OK6YK?Q1\1>)-'_L^_U:
MYN;/"AD8*&E"_=#L &8+V#$XK(N8,@-TQ4^B^'[S6YMEK;7%P3P B%N?P%$N
M3XII:$QE):+J4;.4FX"]ST'KCK7HOP;^#.N_%[4WCTNV865JZB]O9"%@M%)Y
M))(RV,D*,D^G>K'P[_9>\2>,F,T-HMI&Q*>;=L(@,'! 7[QY]N:^C? FH6/[
M.7PXL/#-\]M=W2K+?73Q/B%Y&)((.,L4 48[XQV!K.G6IU).,'=K<X\?B)X:
MFI6U>U_S/GOXV:U>>"M9LO#>EV=_I]EL:.V=F)NKP*_#-QA5=F)V)R21G.!7
MTU^R9\%H?@5\+7UK5&=M?UB$M)&^&-I'DD(.3DL<%CGK@=CGRS]FSX$QZG)!
M\0/&&MW5[=-*USI\!?S/E+$!W9B<#IM QCC!KUZ]U";QKID>G:7.UHK':)&!
M81*O.<#)/ / ZGCK70M%S,^1]ZI+NV<O\3QJ5E ?$TTFV!')CM,99%SP2<C)
M)YQT[5@7/QUNM,T%;S4-7AO8(8S*Y@<J"HXVA1EMPR!@CKD5%X*_:*T'XT_!
MS^T-)-WJ^GO?RZ5&+JP-G<)/$@=F568ED*L#CDCG(!&*\[TWX?VM]J5Y+JTW
MV6T$C- D<6 Q&=N?<YST![&MLMQ%.K36*I/FB]GT/7QF68O*\7/#9C3<*E-V
ME&6C3[,MZM^T=8_$YO*L8+F?R9 9;,L5N(ESRY!&"!CN".>N:])^'NI7GBC2
M5C;2H=*EA7]Q-*F3<XYP"",DC'8<]<5X+XB^$T?A?Q!IVHR7DEI<W\^8?*<J
M\4;#D%E((!ZE>0.,BNL\.7]YHT1>QU6ZN&LAM_?[C)M(R-O'''0XY]Z]:%&6
M(I\ZZ=+:??T]#'V=3$P<Z?3OM]^Z\SV3Q)\6&^&MHEYJ#1WBPKLE$!S(BGH2
MIZ8((R.G?->7_'/XEV/QFMENEW!H(@L3E@SR0A>0>?O!N1CL2.E8'C?1KZ&Q
MM;Q;R19KB7;.67?A<9Z8/)^GY5Z?\ _#?AS6]"_LJ\L;;5'UA60R&("X1N>
MR@$>@(P0>]>;7@E[JU.*5K66K74\A^"FIW6EZ)YC2-)!O/\ HTBB2.1,<YXX
M)_GWKV+P?\*]'\>^)],AN;*ZM=/OIA++<B0A4C# ,".<$?W<@C.1Q7J%U^SK
MX8\/^!I+2U1M$DO8A!!NQ))DGDA<EB#R,GL<@UY?J-SJGPW\;S>&S);.M],\
M<<,4Q8(L:J4D!QU8%@0<$ ?0GQ<=AY3@ZE-VDEWW\F>KD^92H5%0EK"3^YO2
MZ_7HRQ\*=0\5:EXI\96/BKPAHO@[PWH]F?LCVNGR6\]M<"X98XQ<,BK<"2(
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M. Q<Z"E&7*WMJM]M.O<^MX;SQYME=+'6<542?+)./1.Z3;T?1]5]Q]U_L^_
M'QK^T#K.DV6AZS>'PO?7D::J7<&XTZW./,>-C][ Z C/(.3C%>!?MM^"?^%+
M?M,^)_"%KJ*W>GZ)<(L:13&0H&16".V/O -SGD$\\YKZ8_X)!_$G5?"_Q%L8
M5GFFTO7Y?LDZ%"R(Q'RDG'RD-M].,@U\H_\ !0;XBZ?XO_;'^(FI6;);64VL
M3",!=OF;3M+D=RY4G/?([8K6-.C+"JI)^]S/Y:?H<.%CB*/$-6E91H^SC)6[
MM]7WT:LM+:E;PMXNTN>U2U>W6W/5GSU/H3FH-<U'3+B556V9A(2$=2>< G(/
M0\ UPO@55\0ZM#%!)'<7,[K%:V[@;)YF(5%?D84DC/-?2%UH.DZQ'\2=/_X2
M+P[JFN?#ZRCFO]-5);>RT>&+]RPM)S_KY(\KN5A\QX4@9I8'AO"XBC*O6Q*I
MSNU&+?Q-*]F_L+?WG=-;)6N_(XGXGS;!XYT,IPLZU.,8SJ3BFU3BY*/-I?GU
M:7*K6?5WM'Q._CN-%TXS6DTGS_,L>XDGG!&.E7/!_P 9]?\ A_JT:R-,UNS
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M_A%(]'7QC)9+_8DNNP'^STD\U#)N8@*&,>\(6(7=CD"NBI3C1ESX5.W1;O\
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MW81H2RE04/ 9>Y!((SGIFN\\2:I#!X&DAMFLX#?1 I/>LS7+J7.0J[F0$@'
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M8,"",]P02*ZOX0_LO:+<>.M+U+XJ>/-'FMKU)+F4WM^\\LL87$3.B[I KG!
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M\(R+/<+IOB:!"^FWD0"DD=(I1W1B,,#T'(YZ^$Q^)K6W>W^SB219?G$C2B/
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M ?,@SG(YX))'8YY%>8^)=)O;S3+NWGF2SF6[DN5O)&8B=F0!E<LQ5%&T;0
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M)=W%U*=B@@ X4\#)XXZD#O7S9X3\"?\ "J]3U5M0=1%'JLEO9JH)S#@.A(Z
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MPD0(C07!FCCSQD#)  ]/SJA,MS9W.A^'X;C^S;+5KN*.YN-O5F8*">0/ES@
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M2NT#!(SG SR.O%?/XRI&NG&?O7Z6T^1PQQ]:G65>C-QFG=-:6?=/OYG@>O\
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MT^%E56(CV!4()7D?,<\8KR[Q1+<^#]5AUSPQJ5S%,ETZ+<VLA2:W#,0H# #
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MZ)N^SZ7I=FK  B*T1<@=,G';)Z^M0W?Q%TW6K-(;ZUTV_MAD^7<6J-LR,<'
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M,2"1>0#A6Z'KU[U\W_"'XR-/J4LECX6L]2;S8$9;F 3#R(E**)%)P=JC).<
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MQ8[,*6+K/$1BHWMHOZW)JTZW*KK\;G%_M&Z_')X=T+76G^S"9Y+)U7@R,H#
M@Y'0&LWX?>'?B%XLC#:'X;FNM/D4;Y]0 LT<C. &?!8$@C(YZ<CBOH34]#T?
MX>>$/#^FZAI=C?ZY#YE[%)-$)&L/, 7*YR Q5>N,C/!%0V?B6:ZDROF-$#W)
MXQVS_C583-*V#=\-I*W7L];?D'*IOFF[>GEIOZW.;\+?!;QII-I+<;?#\.I"
M$B*!;W=M8C)&[9R?X1S@#J><UGR?!CXD1K"U]I:W$* DO;3QSX!.>0ISG)/
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M)I?NT[ZI)-ZM[O7?J:NBZ;I?Q5NH/%*Z>NCZ=J5VTS*#O1"K!5!W''!R,@$
M,23WKZ"_8N\/1:T\&K6<%Y,-/O;NW:W8@I<^:Q82D\D@ #D<= .F#P7@[X'R
M:9X>BUCQM?75G"%:&UTNV !OVC#NX5>5.], J1SR0.,CU3X>>.-=\ :1''8Z
M1-X8T^[D_>/=.EQ,F 2HV* $4#H "1W//'H9ABYN+A'5=/ZZOT^1Y=2I)1Y8
M;6MV_I^2-C]K_P#:!\?? /X9Z;>>#_#]EK%U?7<\,L]S#)/;Z2J1[XD:./+L
M96RJC(Z8!!(KHM?\97VH^&M*O-7TI;:ZDL89-4L+=R?LEQ+'\\08@$;22%)
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ME0R#-PDH9$&>2>X&/6NN\5>*='A\5ZB=(TZUM2\@2:[BB"S7C(H169NI "#
MS@>E>?3K1@_:+^G_ , TI\UE"6G7:^B_S9X_X%^$_P 3M>2#[5H>EV%BK81K
MZZ2"6-,9SY:@D'/!!'X#K7H%U\%?'$&@06NE3Z).[R"2<K=>6=PY&-R@;1@
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M"9('!&"986.5R><CCGH*O_#TV_C#6]2US2]<TFU\,-(+5K,VKI<229&)1D<
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M-6G2551;AP1;Q>=^\V(!G)P,Y(')%>(_"SX,Z7XVM_$6OZUJL<6G6"QPBWC
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M;B*=K>X4E) CAL J0RMQP0<#]#E_$#XL:QK-Q!_I<D:/*\-C;RN76VA9BWE
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M%]>J]&S]+-%^)WPU\-_!AM<LU:S^'NA2O"L=I;,HO9%?84PV&8%V_P"!'/.
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MC. <#GVQ751RO,:,/KBIR4>_^:O>WJK'F8B4*T.2K35OR\UV.\M/#%SX8O\
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M#X3FT&37+BXM4O)9Y9GMX(YQ%(Q:.U5855?+A7*H6R2#DXR /A_5O#NDZO\
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MU;F18T^=O[V<_P"<U6-]A.TJ4>5]>QQ2Q5]$=]=3KXO\+2*H_P!,M%+PL.I
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MG QJ5YJ%2F[OFT=_+I)6T_%I,\V^ GPFL_BQX_T[1[K;I-O*QDDNKV%V@>
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M?H[GH?CNYD^'"K-$[RZ7<G$4H/*9Z(Q]>P/?ZUS.F>*]/U==[S2-=*,D,^<
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MW_71GU+S/ZS5EB'&*=EI!**TBDK)62O:_F[MN]S5N?&^K2:=%;QR_9X5)9Y
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M6/$7CV"\O+_4+1+BVB%I.D$8B,WF2-.AB3Y8Q*-KEP5)/!&:](_:5_X)X/\
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MQ)9FTCDC.PJ<Y5NX8,IR<Y!(&#QT7A+XSMX3^'5H+6WCNF2=7E+,2X0%64J
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M23(&YL'/%:WPR^&5EJ_AG6]:\5);Q>$M-MA/JLLF2MP.%6)!U,SL0%P1@G/
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MKK/BBPLI 64SKN&>P.<@^V*^2?VSO'<OB7]L7Q8H?SK;3Y8M.7'(Q%& 0/\
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M&K76E_&2;7TM6M$NI(TN?XHI;H1 NP'/$BD.![D=J^2J8-XCE=[2CI>U]/\
M@?J?88[+E4Q/UJ'VDGO9-K_.ZOYK4X/Q?X*O]#2*^F2XFL5D:!9LX7<HW%-O
M4  @Y( P<YKR_7];FEU16Q)Y43$A(VV9(Z9/7K7N]EK]]\3VFDAAU*]OGL6L
MDQ/N\IF<%6#;<&,+\A!YQ@9[UYO\4/@[JWA?41%>PI8.SE98ERS1'J.>@!'0
MYQ[U]CF.$R_"3IQPM7GNM?)WM\MMGJKZM]/E^&<^QN,I58YK1]DXNT=M5:_S
M>OQ+W7;1*VN)\ O$TL7QFBFUKSIK:Z;]W,YSE@ /E)ZA>,]<<5]I>)=7TO2]
M$M9(3&RN#N^8,, X.??/7]/2OF;P#X2TCPOX#N;BWT1_%&IM=06XU#(E&EJT
MX$JK;$@@L%0"8=W/85ZYXT^&]MX9\9ZCH;6>L12:;*8S9RW<3E%(#'YHP0=V
M<YZD'D U]_F&1SP&5X?,<5)<KLDHRB[IJ]][/RLWN?GF2^(6#S3/Z^386$^:
MDY7;C**NI6M9J\;=>9+8LZ9XT-S\09KBS1?(4)!*\$,<GF;B"ZJ) 5.5&">#
MGD$$9KU']GCP)<7EY&NHZA?"_BDD>[AF_>I<LTKE94D(#$LFT$$MMVX!YK*^
M$WP4O?&UU;0Z#I#PV\8&^1QMAA/7ESP2?;)-?1GPU^"EYH6M*NJLJ+'@M-''
MA5SC'S-C(XXQFO&_UEQ$\NJ9;3A%0FT[V7,K6TO:ST76[3V:2L;9KPC@/[;A
MGLJDO;0BURJ3Y>NMKWOKTM%K>+;;/"/C7_P1ZT#XS_$J3Q=J/C]_!G@72%.M
MZCIJ0!/(E4J\SI<%L11NR>80$+!V<J1NX^9/^"I>O^)?BO=7WBUO%FF^,?".
MC:Q)IMG$EE]GNO#;NH*PN6&]TE5-P?<59@Q !K])OVTO&;?#?]DOQ7-9^%]0
M\>P7D45I?Z99 _:WLFD02R(H#$L@^?&",+R,9K\BOVF?VLM-^(?P>3PUX5\.
M:YI_A_6-;.JZEJ.I6L,37,RNQ$$:VZ+$D<;LV0"2#Q@ 8KY#&O$PJ4Z=):/=
M]/1Z].A^@<+SP^(H3KXF4G6A)*FK+E4;+F;=KW>JW73=-GD4OABX\5:G)HMK
M\UU J-#&,9ED"#<@/3.2W7C@UZMK?[+FFZ]X-AFN))!XNU4M<W.I+:-)IT1*
MA CK@R&3S@JELA1O!  QCRGPKXHCNO&C7DC;&DER#G[@SP!]!7KWQ4^+VO:]
MH-YH_A^[71I=0T\6T4]O(8WN$.#-9/+G*1SA0"ZX(;;DXS7U/"N:9?@L5*69
M4W+2\.RE?33RO>[O;HKGE^).4\09C@:,,BJJ%OXFFKCI=)WN[M)<J2OK>26A
M7^'6G7&B>&8$CEDEO+8KOD@+;=PSD#W!R.,@]B:]#\(>$M*\47C7WBW48[*Q
MN)3+,\<J/+:1>7(YEV,<E0RHF "0SJ" "37AWP<\7WOPX\/:/:Z]#]B@O+1'
M1Y%R+-R,F-P1D'&,$].AKW;P;KLFH6J7=G'9WL#V\\$43H"G[U<$Y'*L"JD$
M#(QG.,@_=93G. Q.,CBL7K3UVUL^S7KV]=CYCC?"YY1RJ6&R)J%?W;-Z.UTV
MT]KM=[JUUN>?_''X"PZ/=1VN;.26\LEN4%M)NV)(,H7Y.UMI!(^A &0*\;T#
MX>1^!+>/1 BK&%+)(,@2-_%P?>OJ'XAZQK?C#7AJFM2)/>RVD5L[B)8@5B4*
MH(4 8PO&03UR37G7QB\)I*-%_LV/[3=F0F<Q(6\A6(4%L9(&YL&L>*WAL=A:
MBP\=M8V3OIT\UO\ GT/:X3^M87!X?$9M->V44IR=MY6O?HGTT[:;V.9G^"?B
M/1OATOB>/3=4&A)E1>JA,  ;:3CLN\X) QDX)S7"WOB2;6K=K6XB41$$.0.7
M ''TK[6^*_PJ\:?"_P" *:#JG_"!F^@TQ=$FO+2^>YNFMIF,^PC'EQL JJQ;
M:=N2H)()^+;(VO\ :\D:G$J$J'ZQ2'T!P#@]CBORO'91F.7V>8TW'FUB^ZLO
MRO;U31]!EG$V5YQ3G+*:RJ\CM*RM9MO3=IWM=/=IWLKH;]OU*SL/#^O66I7E
MI/X>9K&SE@N7C?3]C>;&82#F,Y=B=N,D$]2:_1G]ES_@HK\+/ W[+GAKQ!^T
M=X@T_P 5?$774N=$LENK ZQJMYH9NU,0N4"LHC-PCL&<!F$:D9X)_-/5H-]A
MJ&GJLD<KRK-".1\PRK#\0V?^ UZO_P $M_V9=)^(G[6#^,O'D=RW@GX3V#>*
MM4B%I+=-<21.J6L9BC5F91*RN0 <K$0>,T\+44I6O>ZV,\VITY8>->3:<7=-
M:2OV3WU=MC] /%7_  4G\=>.?VQ-5^&_@SP#I?B.VTC59K'4MEW*EYI]M$X1
M[V=BODPJ1DK$<D@#)!.!S?[2OB::]\6ZU/JZ7/AU7U0ZW#<S7DNJ-:7+6XC'
MEQ;D\JV:($&.(OG.0V, ?6T&@_#WXB^#)O$*W6E6FE>/[475Y,ED+6?5XI$&
MUY3A9"^ N"PR, $$9!\C\<?#;X?V5[YVG0MJ2Z;;0:?ID=XI^R1+&@1,Y"C
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M@#D#!/4 _'WP]_8"^*7CKPQ'K']E6UG;WJF>4W,QBD2$_<+A5+#(Q@$@XZ@
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M3[_6O=E3A&-FU?\ KL?*RITX1LWK_78@M/VE8==O(H;VPMA82Y^X"< <$$$
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MVR,'$L(C=0VW!P0ZY!< XX/@G[3,%_9?%"]O=?D;4-2U>7[3,ZVS6N<\ A6
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MU4$R*6?YMI&-I(SSGZV_9G^"EOX<@6]CO6UBXA9HVO5^2%&4D.$!^9B#D$G
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MP)2($J22KR%!QDG.!SQ7BP4^3VC6G?IW_(^C]FI5O8P?O/TOV_,^)?\ @O\
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M3WL[O5K3?6I6PTL<\,W&$M9:_9BE>4VNLFEU^%67Q;<O^U?^T]X6_9S\'?\
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M \$@>^>?I^/2O+5UY8KL*S(I<Y;)_+COQ70^$_$46KWLD4D4<LB$($+''?D
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MI)&X)Y+;"R[B1G)P>V,5K>%OVS;?X??$9=4T^+4+J.YD6YN$D=(8)I@"IDV
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M"BG['5A^P5^U+J7@C2?$5]XDT-K&WU6PN+RW$5S'#,6 BD( 5W0HP+* "-O
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MI5_J"A+NYU)A CP)<AC*ETH#;UC4@QC'W2#U)#O!/QSTJZ\1EKJ^U;3+*>W
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M^Z_AO^SY\-/V>K"QUZX$>D-:JSA+VZDGN+"<K@J48 LQP "JC)  '0U]0_\
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M[*UJ1;BT>-DD(W3+MGB(^Z3M. P&,X/TKTCX7>([;2KME01^5-\K X)4YSD
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MI2HQI+EBFH7LW%6<K-NSEN[65^AP7_"8<>OU-%<;JVM>7?R(K+ 8V*,D@Y#
MD'MTHKV?JYX#Q6I^D.D>#],\,V ;3[.."V,;*9E^Z,C'7L:\(^+%Z]QK$EM\
MT<</&/4^M?0'P^UB/6-.N-)U2)'@NEV-@?*3V..W->/_ !RT".T\0S:>HV7D
M2%H2W_+PHZX/<KW'I@UY-.E[:/M.J>Q[];$<D_9OX6E9^?F>>W>D27FF1_NU
M= 00W.X'U![4[3-5U![673YI%E21AABN)$4<8ST(_"H9/$&H^'+9+>XLVA@<
M;E=T)!!]#@C-;?PZ\%77CK5HI+/SE6-\R7!0B)%'7J!FNNCBL31@Z=.32?\
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M?4=LCD>XKTWQ)XBD\8>(+O7KTPK>7D@18D4(MLL>4$*@YQ@!>"1D<$=:\_\
M'=Z+.WQ8M;M*N,*.?+.<<'@#!.0.QK]&R_A.']GK$8B7O./-96LM+Z[_ #V_
M4\&K4CR\W3^OQ-[X??%O[25LYU4^8"/;'^>U4?'&AIX0T'7M2\-WWA'2_$=Z
M]NNE/XD3-E I<FXV*05,FW&W(XR<5ROAO0[G2;X7<@R[\L!Z]\=N?2ND^-GP
M_G^)WPKT>WM;N&!Q>R3,L@^=\( .^< DU\G]751.C%N-^JW^1&!Q$L/5CBH0
MC4Y&FE)<T79[275/JCC_ !AX_P!$O_BM>OIHL[BW9(59K$&&SGE$2+,45N0C
M.&(QVQVK/\66K>([U&PZMQA1Z 8&?7BLK0_V9/$&DZAN4)+@X7:_!KZ)^'OP
M$MM#\/6]SJQFN]1D4?N4&$C]BW4D#KBOH<1F6(>&CAYNZ5M>KMW9X]1UZU1N
M4;7=[+;Y'#_#CP=<SPQ*8&8C&2!T'UKV3Q-\(KQO .E6:VT<RW5QYLN]L>6,
M8'\ZW/"?A>U\+P'4+A8Q& /)MT/#GL2>_-.\4?%'RM>TNQDE66XF??(!@!%
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M%SI?PT7Q/K*QFTM9YWE.CW#LI+&56()>/Y0$8A3P02>3]AD,O90=)='IZ/\
MR9^-^(&%]I6CC%IS))[Z./R>ZV]&>(? OP;%XW6]T^X:VVV]N9)>2T\>X8&!
MT*XYR 2._'7T[P3J%UIGPZTQ8SJJ16JO;QNTQ5, G:<8QLSG&2>O  XKS/\
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M\PWL2!P!@\_J?[*7AOXE?&#4]#\,65]_9=I>%+AIOGMX%Y#[FR05C((WDY.
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MP1@$XR"#DUL_M%_!C0?VD["W\(F/5;>72+E;.TG60R&PO!"98I-V/F4 E6!
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MQAR078# !)XQ7*^+O'4WC_0(-WG+&$&0\A<Q\DDJS9(//(Z9Y&*V7TWPW8^
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MMW0G#  @$[F!(X' Q]>:L>!?A-=ZEK6I:]XHO?#-A\2M<\0QZGI5_!91:F-
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M_B;:=LWP7T*\LLB>N,X/4=0:Z#P9\,=0\:7,2Z=:75U*2"6C0_NQ[GH!]:]
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M;\PR.#'G##L2!5GQK\:]4\3:E?#^U4N[VXNHD18CNDC5PQ=G&,878<8R3GH
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MQ['#G"A0<DCVS@"JOPRGC,37$ENCQE@(PV2,=SCTKG?&'Q G^)^JP1L/*M
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M:YDDF.Q"-C1H1&> "%3DG-9WC_X\^'_A?'J6@^ UTNSGU*8W6K:K#&J&[NF
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M-K))!"5,C2R@D \#L" >W6OLG]E#]I#PYI,3>']2^&MKXBL2IGFE@GE>:V4
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MG:>AS7E_BKQIKGB.U;4M>6.*\OG)2$$DQA1R"['D#@#@9)QUXK*_:'\9ZOX
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MX<^ ^@V))OI-5O"Y!;=,=KG/<<"N@U;PMI]KHU_K&N:TN@Z5IJ*]W?7%W)%
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MLK,&*/6-0MC))<+D$F* D*B\<%\D]2!TKB_A/_P6Q^)'@6Y6/Q%H/A'Q59G
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M9!(R",$')W]5^ GAWXNZ#;GPYJEKK=YYKW-O9ZE"6M(V,3IEP&5@"'. #@G
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M^BMHD[:I:I^3_%:GAZP7W[0/QNT/PIYKZ?=:K?+:_:@04B4Y+E1P"0H) [G
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M8*&$6) >A)*'! ST_P"S;\</#?A#X=Z+#_PE,?AJYLM7EO/$%L^E&[?Q#:G
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MC!JFJ:[XS.K7L]Y<F9%C"RRM*+= #M1,\JBYX'0<]\U<\$:LUQ"_*@0J&.6
M)!. 0.IY]/?TKM-:BA\6^+M/L]/U"UTZ1 ;B_>:Z-NC6P(5D+;2 7#E2"" ,
MG!'7ZW^)W@CP;XS\%7FCZ%X<T32?#+^';?4H;R[5(K7PXT Q,D=P@#&1U).&
M#?.1W8@S_JO5SBO6Q\)*#2;=[).6KWZ=6W;I9:[>+Q)QUE_##PV30I.46XQB
MHMMQBK*R3W=K**YNMWMKP'_!/?\ X*$:Q^Q+\1%%P;C4_ FM2!=8TL$MY?\
MT\PC.!(HZC@..#S@C]AO#?BCPK\7O =CXJ\)W%KK6@ZM$)K>XMOFC<=P1U#
M\$$ @\$5_.['KEMJMQ(;6*2&U8YB60Y<+@<,?7-?H-_P05^.VM>'OB3XI^'C
M?Z7H.K1PZG#$['%E,'\J1U'3#AHP1P"0._7X>48U8^PD[ZZ/S\O)GM9UE;E3
M^NTDXS2NT]+KJG9_$O7RUT/L?XF_%C2_AW.?MNA6[1;\>:T>S;WXZ?F*P(?V
MG_A_XBC@_M"PDNHXV#*ID>2)3Z@,VWBN0^.OQJUSX8^,M;M(=2U)8X[F3]U,
MZW$."2<['! !]!7@6K?M\ZQX3OILZ7X8N&F8L99/#]KYFXYY)V\GZU\G4PZ=
MUK]R?YLZZ>"7)&3BMM^:2?X)GU%'^T+H]G97%C\._"MUYMU<//)+'ITLL>]W
M+N[%02WS-D1J<9(' XKR;QG\ ?C)\=O%,]W-X9UFRTQ""+W5)(+26<=W8RNK
M*HSP@  '09YKR#Q3_P %8_B58Z4T.GZXFFQJ" L%G$BKGT4* #7SYXW_ &Y?
MBA\1-99=1\>>)WMIFVNPNB?E[D*"!P.PQ1A<NC*;DTY2EUDTM7U>DOONC%8G
MZG#DPT8P2W:4IRLNGV?N6_8_2OX<^*/A/^R'%HR>+O'^E2:A#(]JFGV%P?LZ
MS,?+D,KC#28+$$D!1U.0 :Z?]N#]C#3_ -I3P#'XN\(FWN=2-JMRDD;#_3XM
MN5._HWRG@GJ,<C@U^=GPO0?$Z;PCI%OI.E:UINIZJ%UG4[F]474H,!")>LX8
MVZJ=[!D(7@8)[=[^QW_P6&O/V7_'G_"$^(+M_%7@6WNY;:-UD\Z72T$A55CF
M/^N10,9P P&1P03^CYUP=_9&"I5:\HM5/>]UIRA=*S5WS5$[ZM;+9:Z?FV0\
M;2SS,:T<,IJ=%\KYTU&:N[K1<M-JVBDVV_M76O4^+/'=]X[^&$.AW]]JVF>(
M]-MI=,N;4716TU%/)\I),,#B5"L>8OESABIR2#@Z]\#+7QS\)8-0\,ZC)J>K
M6-HL.K:$\FZ>T$2A&DMU;#F,M\Q!&22<=A7W1X@_9D\!_M<>'[7QIX5OHX;/
M6X2YE@C!^;T]05/52" <XP.ORI\5_P!E+QE^SIXB;5[%;HW-LQ^RWMI\R%3P
M23@C!'!4\9X(KRL1Q3F$<KAE->WL4TU):\V[6O;71-75E9Z'J87AG*7G<\XH
MW5>2LXNZY7HGIWTUL[:O34^,[;1[77]>M=-NY/[.CLKCS'>:9+:5U12S1JS$
MJ&90< @G(X]#T_Q#N_"?B3PK)J?PWM_$CB.Q.HZDKJMU;Z5M5 T$TN1B8Y&"
M !@\^WL'C#X"^%_CMX1BD<Z/:>)M8E*:E"+H:<()021*$<X!)"DE<@GD <BK
M_A[]D3X<_";X-SV=YJ^J0^(?$#M/=VFGW<,+0.I8*TT>662,GYO+X!SQCBOI
MLAX@RK"994AB?XGV?=T=]5=Q=[)J[>]N^B/'X@RWB"IF]&KE\OW-TY)2UTTD
MTI*UW%V2NU?71MR/C71_"GBSXP:XVGZ+ITTKN=L0B0O*BYZL1\JCN23@>IKZ
M1\._L%3^%O".CK)>VT=_<Y;4I[R1]AF;A(D95.2#D$],D' &*]JTKXK6?@+2
MK?1_A[X0L]'LHV'VJZN&-S<:B0/XFP,#/8' Z"H?$/C;QCXILQ'?:G'I-DCB
M1;>R7R>0<@D\L3D>M?'U.)HUL1">,O*"=^5:+\?U^]'Z%B<GQ=7!RAAWRU&K
M)O=.WDU9^FW;H4_@G^Q#X)\3W-QJ&KW6J-8:?*7A@NXD@2[B!*@NPYR65L(I
MR0N<\FJ[_ [X?^)_C7::7X7@;3"S/->30R 6R1JAPB+DX<L <@@ 9S67?ZQ9
M:7X6U+4O$GBIM&\,:&R?:;BY,LL:/*Y"HJ DDL<GI@#)Q7=? 70;7PE\4;FQ
M#6U]J6HVZ"TN(-TO[F0*RN"0 H967&1DDX P*\/-,TP]?$S^IQY8Z65[VT_K
MOZG7DO#^8X3 0GF,G)MM<_*TFU9M)[-I25TMDUHCWCPMX%CTW0[70-,FDO9Y
M55=2OS@&3 X0'HJ+_/GDFO2O G@F#0O /B>_NE06IU*<QLZ@%XXHTC4_0LK$
M>U;WP7\,:3+!Y=O;B?2M+4QW%Z9 8IKE3AH@.K;3G<>@/')!QX[_ ,%)/VA[
M/0OAK+HECK4>DM=,03"FZ27GE ..O//;K6M3+:6%P?/BM:E3X8]K]7]]WV2M
MNS@6*GBL4L%A4U&+O*7DM?O?1=-/E\H^+?"VC_$35;GQ!(;^"^U#5ET^W@B6
M,Q>6$;;*SDDJ0V<C!!Z8 P:[[X96&H>'I$2.\A;:5!\B82H 0"!N4D'KD$<$
M$$5XG\+RG]J:?J4*P_;K!V\J209 5UV2@KT;='P001TSTKZ1^&T=BWAW=;1Q
ML(Y5C>.$ F-V(4<9  ]!P !@# Q7W.:5LIKY90PV7T6JD%:3MIYJ[;=F]5?:
M[6V_RV3X7/<)F^)Q>:XA2HS=X1OKY.RC%72TE;>R=K[=IK?Q=O\ 6=%\6^%8
M;#4M3\1Q^#;V>"^:T*VEHLL;Q1JT^,/(3N(C4D@+DX&,_BS:V\UUH^Y1M9%"
ME3U4C@D_2OVE\8?$_5O@]X7_ +2T?PKJGC345N(K6/2;)T1I1(VUG9G("QJ,
MECR0.WI^=O[8'[)TW[*_[0UQ:R0O-X3\5EM1T2Z'S(58YD@)Z;XF8J1U(VGH
M:^3C\/*C],RN5.-1JR7-MKO;?\[_ '[V9\EZ[J,GAN,7$D:7#JX"1R#*2-G@
M,/3VKUKX4^'_ !9\2?A7=6^N:LT&AS,D\L;Q+LD6,G8IXW$ L<X(!PA(.!CF
M_B1X-6.\DA5,J"'3@''H<5T?P/U&XO-6M8=0FOGTVQ+?:T281!XRC!0IQD8"
MG<!R1@ CJ/K>%92=5X2E*TJFGJM+Z;-JU]?/Y\/%DL'0H?VECJ:DJ%VKK9V:
M^5[VV:3LVM+KG/%/PLL?"EG<W%C=NIL^2'<[+@;MOR@]>> 1[UY_XE\)V?C5
ME6Z:^C95*'[/<-'O7.<,.C 'D9'%>\Z]X8M/'UA>ZA9Z1-:6^DW$EO8W8WW%
MH(1N8I(<E0H 8*=N26Y8\$>3"6W\&>([/[9(B6<MW%:22N< "5P@<\= 6!(]
M*7%F5U,#BX*"2NM+:7\[:>:VZ)]3#A7BC Y_@JE;E]V+LTULUKT;6UGH^K70
MO?!'5KCX?Q#2)H[G6-/CD9[:<MNN+2$K\T3+_&H;E2.1D@C'36\/^*;O]E[X
MV:)\3?"]W;07>EW8G$'FHS%2<.DD>=P5@2"".036/^T9X0CT+PA%>6_VB.&\
M*XDA<HT+=<@CG@]N]?I5_P $OOV!_A1\5O\ @G7H-IXKTS0_%VMZH]U-?:PN
MR34M.E>9FB1)\%XVC3RRHS@'J""0?FZ<75?-?WCZ3$8J&6TO93IN5)Z7[>5G
MNNWW'I7AW]H;P?\ '']FNQ^('AGPSX<M=.\0QRB]L(XTMY(+D'9*"T8!)##(
M; )&TFO&=+^)WA_P#\0YM0T?PU'J%]XA8-JEWK%Q'<J[ G:R@C:C+DX. #N(
MQDDE?$/[/UC_ ,$C?A[XF\0S7&M?$/1/&NK1I<0V<*:?;Z'#$DC><R;G5[B7
M=C"!$8I@ <"NCT?X1Z9XCTS2/B1H<D-SX>N+,:Q ]SF&(1J-^^4=0$*Y8<C*
M_C7=3S+'4*,\/0FXQFO>2>]SX+,N',LQ5:&-E!3496A*2VMK;OI?KONMSWKX
MC_MBP> OA9<>)/&VGV^EV=_&%LO#H_TB\U!P0R%\]"<#$8& .7..*^-_&EYX
MO_;0\2Q^+/B !;Z7:R%]'T*(G[-8*>CL/^6DI'5SP!PH S7;VWAO2_CKI<'C
MUO$%MXMMKS<EO=0D^3 006B"$ QD9&5(#<@FNBENK?[!%;I&BQ(@"JH]!7GX
M+ JFO:3UE^"]/\S3$5H49.C15NC;W?\ DOZ9Y_X?^&$=G%)-#"BQQ85 HQSW
M./:F>(M8M-$1K>5)%"##9Y4^X/:NP\273:5I0EA7& =RDD;QD\ ]C]:\WUF^
M;Q(V]2HD'5"0" 0<@CIQQGO7U66X##XN#C]I?>%*22LBJEK#:7IO],D6"X ^
M\F,N".0R]&!'!!ZBN4\;_ K^WK:;Q)X:B2UO;<>9?6$1_=R#NZ#J >X[5OVF
MK6\$DD")MD3'08X(!%=/\)_$:Z?XPM_,&V.5_+=>H*G@@C\:\VHI8>M*E+7E
M=C&4HUDZ<CQ[0-7640;MPE)*M&>J$>U>H?#KP==>);E(88))9.,X'" ]R>@%
M=[/\.?#Z^,+@RZ7;1W E(:58\@\]<=>:]?\ "_A73?#FG VL21QD9)VA%Z=^
MYK1)/X3R?8R3M(\[F^$-SHFEI)(RLV> O//]:]4\/Z3:>"?A3<374:Q3WB;<
MM]XYZX]C6?J?C;2]",,UU_IF/F"8(2-?6O,?B'\?6\>:V8%;9;0_+&@X&![4
M>S?VON.AR5.&GW_HOU/</@Y;6L/@>*X9D::XFDDP!T!) 'Z5Y7_P5B\=?\(/
M^P_:V"R;9/%&NP0 9P71-TK8]1\BY'O70?##Q?'!X3ME5V/E[@1[Y)_K7A?_
M  6=U^37H?ACX763"6MM<:G,F?XFV1*<?@]84U>HWV,H<TJD7?5NY\:^&-NO
MV;PY42X)4^I]*HFQN=+OV\P.I#"MCPOX<DTN:%E;)!' ]Z]-O/!PEMK&6XLG
MF2\)0[$)/ SGVQ6\9J;Y>I[#IM1Y_P"KF5X 7[;"I;:"5ZG!_/M7=^"/#=]<
M>+%LK:)YMX7RU0  YX&,<9]:N^!OA5X;9(C->S0H_.UG"?J:]\^!?A7PW\/]
M;6\MPUS+M.QGF#[,\' S6<J%75(Y8UZ<'S;_ "9UWP4^"Q\"/#>7PWZA(F[;
MP1&.IR?6K_C/QJVOZTD+2-%!&=B#^^>A(H\1?'&WEO[JQMT:6[EM9)!(BDQ1
MJI *DXQDDBO.HM;-W>QRO)L>,8QG.,]Z\G%<T$H=]SZ'!U.:#KO[.B]7JW^G
MWGL7A&\M[2QFCDD6&W0'YVQDX_QKB?&WA[P+XV\3^']>\2>'_P"VM=\)QO!I
M-_%>F&3[*\AD,$H (>,MD\8."PS@D5GVNL1R:C:13?OEE)0!LE-QZ9Y&#Z'T
MS^.EXB\-KJ-F74S+.48J[G:4/0<<Y!.T#UQP.37N8'A2..P7MN?WI-V5M-'U
M]?ZN5A\9B*%;ZQA:CC/573L]59ZK75-IF+XS\9R^)?$%W>W3Q^==R&5PBX4$
M] ![#@?2N+^(GAO3_B7X*NM'OK?[0I4LC=T8<@@@YR*ZSX9^'=#UC0M6\1>*
MM>MM'T?0(C/>EY%C,<*@EYF8Y 1<<X!).!C)KH;7PKH>OZ)I6I:#J-CJVCZ[
M#]HT^_M7+)<PY*@@8!!!&"",YKYGFA3J.C/XH]/0Y:/MXP6)4'R7Y>:SMS6O
M:^U[:VWZ]#\\_!G@B*V^UV.J&XB@TFZDTV[F4';&$?Y6S@@!@Z?CD"N@USX8
M0ZUIUU#?*JSQS1>6ZY1]K$%7SQD8YR><U]"_'CP]K_[)WC)-9L%T]]$\6JHG
M6[M%E6WG4A0QSD&-\J",9! (/6N ^)WQNT_XA:U#)J$^AZ2;94C*6\05PPQE
MT<DL00,8(*CL,\UQUHU*>M.ZENGJ??4ZL<134H-6[76ZW6O8[G]FK]DV22 Z
MM>6UY?V%G'YMMITU^5>_('  !R5Z9+=N!SD5Z5\(O#=YJ7Q"EN)-#THV6FQ)
M;VUM*Y\Z!)D+M+OP!)(K?N\\8'&W KQ_P1\3?#/A%;-K'38[BX<A/M[:N9)9
M02>%5<!,YP0 2?QKTGX1>)=2\:Z_XMTCXA:M:ZEX1U^0FPM+"SET_4]*B."(
MQ<1NKN. "2,GDYP<5[65Y_*C@ZN&K4U4E-63E=V_X.KVM;N]CYOB;@Z=?&X?
M,8XF5.-)WY(M+FU3:WV=D[.][:<NY[3^V!X7TB[_ &#OB?8Z@'2"70)3%(JA
MG$RLK0;1GO*J#Z'BORY_:)\+W&A_"OP[%>*WV@Q #G[@(!..^":^D/VT?VN;
M[Q_XOTGX*?#?0+C6+/2E,VI6E@S2SWK6_P ZQ=R(H2H+DX+N !D*<_%?[2'[
M5]Y':V4/B31[^UU%9'5(-B@1JN.2"1CL #S7%&G*5H11Z^'E3PU.I7KR24FG
MKT6R^\N?#;4_''@SP=J__"$^)=>TQ-:NHK1H+2- +G(*B1@23&R!F <$$ D9
M(.*X[XP?!_QEX(O-+T_3_&%O9>=;_:+E=3@C,T0)*F171"&1NH4_,",'IQH_
MLZ?&/QQXTU.'7HXM/TOPW$UU;;G&]KMEB "!,;?E+@D\@GC'%8_B76F\0Z^T
MDCG?,_EC<Q81J">%'8 =!VKZ+VV&6&^K0I+VKLG^.M]>NZ??3:Y\A'+L7B\?
M]>>(G[#6UG:^RMRZ+:]I);K5*[1] ?LE_#WPCJ_A"+3]-TZ'6]:U#4%&I:EK
MDL:XB";7:0R\>0Y;"B,;E.,D &N.\>?LP0P?$;4HH;]Y=*MYF@@2*03BW"Y'
ME;\X9%((5QC<.0!U-OX9^$KF*VM94:5RJ+;K))(0$0$_)G/*X/3IZC/-=9KQ
MCTCQ[:Z.LV]@AD;R\$22$9"GTQZ9KZ'$1PM3#4\+&FG4CJWWVV6VKOIWU1CE
MN6U\MS*KC*V);IU+*,-^5:[MZNRM9Z:733W,]?%?B'X:>&KGP_HMY-9:!,8V
M%JDA9K24#"RQ2D;XW&2201DGD$<5\^FUNO#^JND@F9=XP[ L2Q.<%L<GOZFO
MHN_UV&(3+,J!4(,@/'S-D\]Q_2M/]C=/"]]^T5::QXB;1]5\*I<O;P:9>7>S
M9<JF!=B-E*,(BXP21@<\X .V-P]?-H4\%.][^ZW;W=KVVLM+)+;9([\=7RGA
MG#5LUP]-*]N=1WFTFTWO>5I.3D]6M9-H\@\.:AYMA$9/+Q.&^7(+#!*D$=0<
M@]:_1S_@EM_P5!L=$TZU^$OQ7OEDT.;;;Z#K-XVX63$X6VG8\A.?D<_=^Z3C
M!'SI^V1I.EP?#C3?$.I:;8V-]I]]<:+9M(JP:IKN"62Y=8\*T:(1N. <[3CY
MB#\WVLRZA;_,.67##UKYW.LJGD^,>$<U/3IV:ZKI?HKO2VIYO#N=4.*\J6/]
MC*FFW:]M&F]8O=\NB;LKOIT/WT\?>!;?1T=/EM8V^96,#2)TR""IQ@^HKYG\
M3_&BXT7Q7=6JQQYM3B2=-V[;G ..N,_EWK<_80^-/B3XV?\ !.&S;46:YU+P
MI!+I:7X8^?<1QNZ("W."J^6,]<8SSR?(9/%GC;Q3J5W#IGB*/2;73(Q+<W^I
M/&T-FI8*H+,I;+$@!0,D]J^-S3#T%*[6C5S[+AN-;EG&K:4HRY==;]MDW=W6
MF_3<]1DU;PU8^';R^U8Z3>?VP-D\<</VBXN6(Z$@EF[8Y '3BN8^*&N?$;XA
MZ<W]C^$O%MS]I@+6EJNERJURP!"D@* L2GG'\1QVP*\*^+G[8GQ5^$%SI<:^
M*+#4M.U6 W>F:OHUO L5[$&*MMD5%<,K## X(/45XQ\5?^"F/Q:OK=K>/QGX
M@L1(I(:.<I(ZG_;QG!]CS7B_5*4YQG3BW'=:Z:VN^NKLM;7T/HG7CA*SK.G'
MVVUW=M6>BM:+5FWHWO?8^O/A9\)O'EI>QP^-]&3P!H\JM_:6M:S/#%+&B\MA
M=WG,S=%"@9Z9 R1T4OQ@^$'C'XJ:=\-;6^;5;-=15_[02[:._MYMIB$L2J0B
MJJMS&%P0,DGK7YJ?#_\ :=\0^,O&%O'XN\6^(I[3S5P)[AI878D_ZUBP*QYQ
MN(R2"<8KZ"^),T/_  K?QKXKU&+P_P"$;;P[9Z:_AC4M.O\ 8+=B2@>Q"J)+
MAV(R\98G[W(Y(_2.'^"ZF89?6Q_/&*IWT<DV]-$[V4$W?WFM5V2N_P XXL\6
M(Y5G.%RO$TZE25:R3A!QC"[LYQLY2JR2:]U22C;[3=E[O^V1^P+XB_9>\;Z5
MXTT5=-UK3SJ:1P_NP@N"V2J2(O0D[AD9P3D$]!SNH:7-XPMDOM/T_5)SX6N3
M?W'AJ:Y>"[M4,+I*L*A0%VLRL'!.?F)4GK0_9._X+>1^/;>+X=_'2RM_%7A'
M4'33UUV. 1SA00(;ET7ALX&['SHP!.<@#[+U#]DRV^$FLS^)-$NIM2T#5/*D
MBE@W[O*;!(9U)R"O3<-AX!P.1RY7GV,R.K/$Y5JFK2B]>775KNNS3%Q3D&!X
MCP=/!<1ZS3YH2A>*GIMM[LM?>A**3M='YE_$[X50^.=+C\3>"+22?0V8B\CO
M+B-;G3;H#+BX9B 0V<K(."#T!XKB?@CIO@B'Q/=:[X_"-ID$D>DRVMCJ/D/$
MSAB+UUP69%"MPI )49&:^P_VK_@OX:^!_B>RF\.IJ6F^&M;N'77(3;M=0_9S
M@J)(),8"DG&TD8)*D$ 'P[Q]^RU#XT^+4>GV.BZ+'X0LB@?48KQ666SE"%R0
MSY)4#/&"-H.0>M<+YSA(XSV^+;E&6CT3WZO:UGJ[?/0WXRRS'ULG]GD/N223
MCK*+26G*E9WNKI7T72SLUYC\=?#_ /8+1ZMX=MM>@\,WYGAT^34$15O6B"DS
MQ/D%HB&  () P<\D5Q/P ^!'BC]HK6[3Y;RU\.1S8U*_ **Z @LB-_$Y'&!T
MZDU](^,M#^&^K2V5K##=:GH^@9@M;5K]Q:7B*"%(6-%:$D\L5.#T)QS77^%M
M-^(TWB-9])T]-$T>Z@6VLK5+"*VLK- =P"%@V3W)Y)//-;9]QC3KXFI'+[JC
MTT:?G>_=ZZ:6:V=TO1X'X9S2GE=.GG3;K1T=VG'RY;6NDK)\VMT]U9OG1^RK
M%=:[=W-RK:#I>DA8-#T^PR+P*-JQRDXVD-(26)._G(SD8]YUCP9X9^&6@>#_
M !1K>L>,O$7B+P_%<PQZ:]\L<>HO*'!,\1!9@A)"D\D*,\9KS[QAX'N?!6E3
M:UXDUO5-:N+C"$0LTL8P00"69%&"!CRU.,?F[0;30O&-UHVEW6M^7XN\9P2W
MFBV-S:--))!&6+E0IVF1@C;?,8C R17RN<9A@*^$I4X4>6<6KR;WW[+7?RZ;
MV/6R7AG/Z&;5\:\0W1E&248Q=U%QM/NTN5-R=VK7?NL/V0OACX>\,2C6]/+Z
M()KN5GMS<"XNK>%8@&VOM #LS9 &=I8#J./8AIU]XX\37NNQV%Q#X?\ #-C.
M]M%O(CR$);(Y+$GJ6))).!@$GA?@GJD=OX_MO"<FG6]C_9?F-=7<CJJ6B ;B
MS!20&#.BD9Y;<!SD5]W/>^#_ -GOX/QQ^)+&WM)-0C?RM/GVO-=*#D;UZ N0
M"5Y(W8.2#7/E.4JM6EC<4[0CW[]E^O7IU.G.\P6 E"E0@ZM:II%+HNKM^I\\
M_MBRQ_"SP#:M?M -0NDM=.L8S\GR+$HD<\C ,C $GKANP-?/</P9T?1M61=)
MN[K[5#86]S<2W\T,,9>1&9X4"DERK D#@D9QD#-0_MX_&Z;XO_&F'5K[4H8W
MC@2&/3(EWBWVY!).2!U[]\XK-^%>LQZ?!/%LMX['4FCFNT*C,\B)Y:R$]B(_
MER,''!)%?=<.YED].EB%BZ+G*6D&E^=W:]]5IIMK<_-^-LEXHK5L"L#B52A2
MUJIRTON[6BW:WNRO*SWLCVCX1WM]87T30W+1G V$,>A'0GH5/H>U>=?\%,_'
MUY\5?V'=+O-/T;4]+TBQ\8#[7)>VIM9;P+'+"CI&?F6+>6P6 +Y!QC&?6= @
MQ- RQLT4D'FK(H 4KD*,'OSG! QP:D^+'AK5OVC=(NOA(_A^Y.@Z[I+7Q\32
M7");V%TAS! J'+O(9%4G@ +W.3CYJ*G3DU)-7Z'V'MH5XQJW4N5IWOII^??=
MZ^9^2>K:;-Y,;(<(1Q@< >E<\-?U;1_$,%GI 2/4)BK+.4W-%SQMXXSW]1P:
M]QN?AE>^#[_6/"_B"QDL=<T:5H9XG!!##H0>ZD8((X(((ZUYCJFDW&GZG]JM
M]T,T!V;P,]#^8-=.#J1I8B-6=]'TT/0Q5.-;#NDTI1DM4]4UU374]/\ %OPH
MO/%WAW3;SQ=JTEW<VMK]EM(),,\2*2VQ2HX8L_0Y)!&2< #S+Q;X:M_!MQ M
MK/\ NY]V8'8EX64@$$=0,\8]0:]4\(Z[;V7@#5=2U:&YNKB3;)I:37@#02J"
M 2H',@(&TD$<X R":POBE\,19Z4FH_V7)HTFI*MQ)!)$QCGD()!A<LQV\,&
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M@# Y.!DU[0^H"QTJUN$5A:RA$CF?&!D<@OT!R.<D?3O7#^,=4TOQAKMAIO\
M:]KH<A9KFXO9&95CA09()4@[FZ#')'2M:DJCP?U.HG[-VLGHK]+7T3UW\]7J
M?32HY=3G+-:<8^VBG>2]Z5F]4[7DU>/PZVY=$FCA?!$]Q#:FZ8-':!2R2NI"
M2X<*55L8)!.,9['O7O7[,7[3VK?LX^/(-;T]1?:=/MBU337?;'J$.>1G^%UY
M*OC(/!R"0?I34-:\._$GX:VVGZ7:^&=)\(3^%A;:U</LN-*T.2 !EF6+&]9'
M!.6&"0ZG[P!/P5)K-O?:K/+I<#6MCG;#&6+':!@$D\Y;&3GN:\GB+AAY+&DI
MU5)S6VM[K=]5;HM;O>VI\EP9QY'BN>)E3P\J:I2MS77*T_A5])<UDV_=LMKG
M[4_!;Q)X7^.G@ZW\:>"=>F;2I<I,[E8)]+E RT4XR-I4'J>".02"*I?'/P-X
M-\1.ECK'C[PQ=LZ%F,FF1W"$XZ,^P@^G)KX6_P""3WC:X7XI>+/"[W,D5EK^
M@R7)@'S*\\#IM8+W(C>0?2O7OB]X8-[J"V.GW"27US,((K=<H[R,0H!!&.21
M[5\/B*=.,N;EW\VOR:_&Y^CY7E+Q=5NM6<>7M&-[>;:?Z7.@^)&GWNJ>!QX;
MTWX])I7AB!=IT[3'%N2HZ(KL244$=$ KP'QYX5\(VUPL^L?$2YUI[92B+J&O
MR3H@/).UFQDGD\<\<<"L?XU? .\TG2_$$OA_QSX?\2ZMX9C\_6])L';S+*/?
MY;NKGY9-C<.!@CKC!&?DGXGW%UID4GG6[R"'!=D'RC<<#<<<9/2NS+\ZC=0A
M%2]7)^>S?];D9GX>4JBNL3.*[<D(/7S48MWZ/K<^S[#_ (*M7/PDT--#L?'&
ME:WI=DH$%I/I^_!!&,RKM9^X^8G@]^*\+^/_ /P57^(NL:OI-Y9W.FVEFA-X
MB65G')'(@)BVSJH)*#;C:2".#W!KY U5VU35HVGDFBLPX$BP ;@A(W$9(!;&
M<9.,U][_ +&%]HVI?!_0-)\$PZ'!HBZW;7'B3[>PCU*./>48WLRA5DMP69B
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MYT]!<0O;S)("TB8VCD$D-@G)(P?4<5Y-8_#M?$LL^O>?#<6LLQ5 P#>4F2%
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MBP#*.Q&!DYKT+2OAM!\2/A?\%KS7+RZ2\LO%]KH9NTF=)[FSF;)MVD4ABK$
M<Y' !P,FN#_X*O?M1ZY\&?VD[/PKX'U33[&PTK38WO;3^S[:YB@ED)8*1)&V
M#M*G (P".*\O$992GAX8JA)QC/[.]GKL[K30]S XRIA\2\%5]^<4W=Z*RLO-
MW_J^ART?Q730+Y[;0;75IKF>/RA';(97E4]@JJ2<GL!FM.#P)XXNX8Y=3M--
M\'6]XHVS>*-2@TKS%ZY"3,)".>R&O'G_ &Q?BIXV@BM+3Q1<Z3'( &AT"TBT
MSS>@RWV=%9B>.I-8WQ-^#OB+PSJ8OO%?F3W=Y$MPQN;Q;JZ"M]UY"K,0KG.T
MDX.".H-3ALGJ5:<JM.G*<8[NVB7=Z-)=W=6ZACN)*6'J1HUZD(3ELMVWV5VG
M?LK._0]@O[+PG\/_ .U;?5OC#\.[NWOD47EA;:/=Z]:W#*<KQY(C)7)P0W'3
MG-=E\%/C/X!\>^*[[3=%\?:A<^(=<>.VGU6_T4Z9;V5L"!(\(WMAQ$&"9 "D
M@C&*^(M4L=]U_"4S@1\X:NN^&%^W@_QCHNI;;?\ T68;HU4!<'L1W'8_6LH4
MX+]Y"*4EJM^G?74[*.(K37+*HVM=/=MKOTZV7K97T/TU^*?[8OAGP%\.K?PU
M\.M(UK7-/L+86=JVD63/:1[1@#SCA">,LQ)R223DU^<?QL\;^*/C/XR&L:QI
MMYI,-B!  Q:94+. !NX4,=R\#DCUQ7T/^S\^J?#KXH>*M,T19+WPG-''J*V$
M9#S6\$RAEEA1B [1L61D!R0O<@5Y[\4+&Q\0?%6*RNO$=A#9WNOI?W3J?.@W
M+@P@IC W!%P#RN&'6OH^'\MH9GB_;XR;YM$M.G9+3;?=O35:W/D>(<TQ&28-
MPP%)2OJVWJ^NKL]]MDM;WTL8'PKG>UL9?,E51"A8$=\= 17J-A\0=>O["RL]
M)MHWBCBD2\N(&*37-JQ5Q IW 1R^8AVRE6P"1]?&;>X;QC\3M3L($M8(/-+W
M;Z<[F&5E"AO*9\MM+9 )R?>O1O#7A)=&U2W%C?WUH6^^1)N?:20#@G!P.@/I
M7TV54<1EF*G[+EE=63DMUIKH]%VUUTNNW+FV6PXBR^FZW-3UYK)ZK=6=UJUU
MTWT3:W^K/AW-&F@VOERZE*&4$?;)"\L8  "D\'C'XG)SS5;]KSPUX1^('[+F
MKZ?XTUG1?#]K#)')I6K:G.L$5A?L=L.';IN;"D=U+9XY'/?#'QK''J4&BW$U
MQ)<20F6*Y,/EI*J@;@W. P!SCH0"1T-9_P ?_@=:_MX_#"S\/:9XTN?#=KI.
ML&6]DM[9+AY5\J2+A=P RLC/&Q)!# D$$5\U6P^(C*5:<7:^KZ:NV_R/3P>(
MPD*D,+*HHM?>K)-V6^WKOV/S=\53K8:Q+HNJ6CV^NO>+81*3\\<T8D:1/<%4
M/U^4BN;UNY/AFZ1LW#X99(D64H@(8,2<<G..G3U!KW;_ (*)_LZ^'?A%^U'\
M/M6\%^)&\1:;X+T^+1=>@DNTN9K/48K4I:27)4 &>:$'>".# 20,X/SG\<]6
MDTO7M/M;8-*\NU 5!*ID@9.,G ZGVJJ.+GAIQJX>5I:[>OX^CT/I:>"AFE&I
M2Q4.:#:LFM]%MU5^ZUU9U/CG]K:W\(_$;PSX8DEL?#/A;Q5''#KB;A-"B,Y4
M3J5 "@2?,V2< ,% !(J?]I_X,0W'A2>YN+=?LX@620PL&20$ HZ/G!YP003Z
MUY!X?_9YU+]I'XUW=O)I=]KC:-;+IL=K:1.S7#!Y )"JY8  @CL20<XKZ1UC
M]D?XD_ +P9HGPKNX]1EMO%U_IALM,N#]MFTV.:XEA<QN 2%3:&>,-A RDX!X
MZ\VQU3'-5ZDO>_JWW;>?774\7A? 4LJKU<LC!*FV]_2SWZ.U[.Z6RLC@_ FD
MZG\8_@<UE<:7JL]T5:.UC>RF>75)4( %N50K([;EX!&#G.!7T=_P3=\/3?L0
M^+?'.DV^KMXB^,&L:68-*\#QM/;Z4\T;H\L4MTRB)[R$9#K$2$"NH8D\>Y?$
M7QS\4O#?A[QQ\*O"^@77AO2M*AM-&\!^)- F$QFE5'D;[9(K,+1'6%E>1E7R
MS, 0<@U['\"M!UC3/ACX;NO%-KII\<7&GP2:[=6\$6ZXO2@$KEXU 8D\$C@C
MID5RX' RK2?)T/:S#-^;#\DTFGLD]6M&K^71I.][JZ,+P]XM^*'QY^!8_P"$
MV\)^'O!'B.+5!!?Z-J*#5-+UBR4J6)7)92P)V')(9 >017(?&'X+PWOQXT;Q
M;X8O=6\.WND>';G2+<016UQI%O%D*L+6C%2S/&\H !\LD*6P0,^K^.?&3:9#
M+M+,5QC.,X/J/45Y/X@\;7%R[MC !R*UKT94I^SJ;H^1CC)1J-TTHIWT6VN^
M][_._P!QH_L>>&/";_L]R:#X>T#Q-X:L;G4]0NUL/$#%KZVN3.P8GDXC;8"@
M!("[>2<D\CXEUVZ\-ZK/IMS;)%/"Q"D@;7'8CZG\*[?X;>(KJZUNV\O?+<;U
M58U&6?/& *K_ !U@LK_7?LFH0/#+.3]GG3:QW*<':02&P>" <CN*=&<7'E6Z
M)Q49UI^U75OKUWW??S['@/Q.^)%W9Q_9_,<'&#D<?2N*\(6&K^+?$,%M92R&
MZN&XQZ>_; ]Z]1\7? S^T6:1]2\_=T'E$$?6K_PC^&UO\/\ 51>R3+(^,9/R
MA!WK2+</?@[/RT.5TY]F9TOP UKPA9M=7<<<X8Y:16W#V^E:'PI^'%UKOC2R
M:-?W8E#N3QA1R2?8"O3-<\?-XBM6T[2[9IWE 5I7^6-/?)ZUE^*_'&F? KPT
M]G8R1ZAXAOD_?RJ?EB![#T&>OK6.K?-/6^[_ *ZG13IRAJ]_ZU?D2:-\+O$'
MC?XCZCJ%KNCB6<X42!40#@9)S@D#/ KT7_A5.OV-MNDDTU)FZ^9*\QX&,],#
M\JRO@[KDVE^ [&::YW7EZ@N9@"<;FYY.,8 P *Z._P#%5Y>KE8W5>!N!SFBK
MC*SE:#LO(S]@I)2:N^[_ $1PGBGPSXL64LTVDWR#CR]F/E] 2,>U<;KOAS3=
M5(CU+36T6^4_)<Q*?+SZ,.1CW!KU35=:CD7=NPPXX;/\N]<WKS_;'7<V5;@M
MCG'N/2M*=2:UDS"I&WNO8Y'PYK=YX5\2Z7I=U;HT=W.D<<T9W1R@D#(/TZ@U
MXO\ \%%M;_X6-^U'-#%S'HVG6]D@'0,09&Y^KU]7?"_P=::GXULK>:%9(T)F
M*GH" <,/<$]17R;XKTE/$GQS\6:N^Y_-U:>. -S^[1MBD_4**Z)1]I'W-V+!
MTTJ]^EOS.=^'_P '%B1+R\_=PI@X/4GL,>]>P6.H6K6T-K#!''%" ,L!DD]<
M5QM_KF-1:W#82V 0#IER,DD>PX_.G7>J/Y,:Q2*H)&2.]>;BOW4O9TWKU9]#
MA:,:B]I4VZ+]3T*^TZRDTKR8TAD9P-R^6&&#Z\8XXKG1\,=),F_;-I\W9[64
MISV)&<'\J@L?$=Y>P".W,:K;@@M(" ^!G@<>GH:%\7O>KMDBD252 RX('/H>
MX/44ZF7XFE259Q?*^I52I*WO'I_P2\+36FF7Z27,E]&5**T@^=.XR>X[5CWL
M7V37Y6*;0AP!]?YU>^"WCM]"U%8KB-DBE.Q@??I78^(/"*7>L0W=K$KV]PWE
M,I]3_(^GY5R:R=WNOR-(W5._V7^#_P""CB;/68Y$E@D5BSL""AY0CH1SQ@UV
M&C>-1HVDFSUA6410AU,B<2#D@[CR2<C '(.,5P^NVW_"(>*7#[4VL0Q*_EQ3
M/&_C-/$,"1/,C!3A3DYZ8!)')QUQ^E>[DV=5<!=P7-%]'M?O_6YYE.M.$KHV
M/#$\1O+R2&VLKJQOHI()K.\MUFAN(7.&C=.A!'!_.O3/@]X.?QA=6FV"STO2
M]%@$<%K:0B*VL(%SA$4< >W4GDFO,/@3\/\ 5/%VIQQVJR%"W[QR#Y:+GDD_
MTZU],WFB6'PL\/)I5K,[W.M2*))&P"$'!X]":\3$1=2I*M*UWN_5FRK5(1]F
MF]7>W2_>VU[-Z[]#DOC1\.+7XMZ1Y=U#'# EMY&GO)&'>(!@?,/N2..X['-?
M'GC;_@GWK2:\[6$.EZA$S\MO\MY&)Y W#'3G)-??'C&6WM--,[R8'E[$4=@!
M@ #Z5YY%K.O:KX]\%Z3I_@V\UO0_%!N$U?7H]06WB\-M&0L2E,_.6.#ANH.!
M48:O*M.[>BLMF]W9:+\7TW.^C@YU::I4;*5I2DW)1ORIR>LFDW9.RW;LDKM(
M^</V=/V9O%WP[^*-U=:?INCV.I1Z+.FE2:G;EXH]0,D9C)E&416B$B!B"59@
M>E>Y?M)R^*?V>OV4-4\?>*_+\4>*M.U$SZ?!=>5"T-O,8XX[9GBRK(KYD."P
M .U3DUVW@35&U"TCU*QO[76-'FFN(O,CCD7#P2M%*/WBJ^5=",D8.."0<U8U
M;4O%FM?'O1+72M7\ 7O@C2].,_B;1+Q3<ZU')*2UE(J9*QPL5!_> 9P2,Y&+
MQ&5.G7CB92NI*R:=T_ZW*^N8NC2E@JM)>X[R;A[ZY79Q<K7BFVD]M6DWT?+_
M  !_9CT'X77/A?2-/UGP_P"#[OQQI\^NZMHE\HN/$&L&5%D)CED82+#!EQ@
M@ 8'()KX7_X*^_L]:+XD\(V]O:1V>FZU_:$ZVD,5\M^;I$EV0REU5=ADB9G:
M,@[-HR3TK[[_ &BO#WA/X)_#"X\<6^H:WX9U+1M7DU:35+/.IZM=+<S![BRA
M>=\I'(>1&K!%"G(*Y!_+S]KC]MBV_:&^.NH>)O!?AC5(]!LE9(K:90Z6XR2T
MKLH(7.?7 ]:RYZL97EI;:ST?KMM\MST<+@<-C;2I3<XR34W)<LHM-VLKN+4D
MU:[FTXO6*LG!8_!>V^'GP1L[>QW6-C##)'9B?'F2%SEG;_:/4GU-?.FEZ5)>
M?$5K>'8UOI\<MQ*TD;NI1%^=@%()*@Y SC(&>*]\\6_$34OBA\-(+RZM_(>+
M"?N6W(..",9 !KPM9SH_C&&:2>YB\P218CR #(A4G'8<@D@9XKORF4%C*=2L
M_=YE?[];G1Q!&K3P%2C@U[\8OE7HM$K(]R\5_$?1_A[\-M>F\/W[Z[:Z<UM'
M!/*@C:6:0  JF22 QR0.HYZ @\;\)_B-HJ_$30]4\7Q27,D4X+6\A<IO&<K,
MJ#>R,<!@I! Y )XK!\'^/X?B:=8^'>DZ)86>EPK9R:D\@#SW$Z$E-CK@JOR9
M*],''05B?%OP!)X-U"RBT\31ZA]H,:-$Q$F]N %/7))QU[U]MB<^R["XF+PM
M/F5E?L_6^O\ 7W? Y+D^;X[ UGFDW&;<DFG9IZ:IJZ5GLK>M^OU+^VU)IVM_
M#*RUJXC1+>]OX-/T/4;"QE*)IRVV]9(Y\*DR%BRL9&WD],E2*^;_ -GCX1^+
MOB7\-['Q[I7A2YU313=7L,2I=)"]XL&02J[@[%0<L%!!VD=S7TS^U'K*^%?@
MEXPCL-2FU&]:WTK2=7T 78-IX69=A4JF '.Y"@V@8W$FOGSX+?M(:E\+?!6F
MZ'8^&M$N6\-VU[_8VJ32R^=HS3N78B+=LDR78 D9&5R"!7PN=\78O/)K,*-*
M-.46DE>Z7+NV^KO;=7MH[Z'VW#/ =#AF@LFQ&)J5J4H.4N:#4KU(IQBHR:<8
M:V<HNUO?BG<=.WB+QQHUAJ5UJ-QK%G:VJ:?"L[F0V<2\A5!^[ZDCD]R:VM.T
M#;IX;';-4?V1;J\\8?&&P\(PV\<][>QM*B3/Y<4]LJL\SLQ^4&(*S-WV\XXK
MWKQS\$%@\5Z#8Z-J&EZSI_BZ>.'2K_3IO-@N \WDG!P""KY!!':L(8B=6I:O
M-RDU=7=WYO77??S/4Q%&E0H.6$IJ$(M)\L;).VBT5E=+1=EIHC[8_8LTSQ9\
M)_\ @E=H\?AOPN_B34/&VIW-S*AU*&P&GP/,09R9 2Y\N+(5023Z#FO/O''A
MSPW!I&N^'?$EC#KGAOQ"L2WEJS^6VZ&0212*2K*2K#)5@01D$8K[!^)D^F_"
M7P=X5\ Z?'?V4;(UEI,MM9236\#6MN6_?R+\L"%%(#,>6)&.I'RA\=O#\=_J
MTLUB4FMYXDN(U0CY-R!F0CJ-K%A^%>-FT[OD;^'1_G_7R#A)RC>M.\?:2<XM
M73T=D[[:.-E;JF>/>.="L?B%=>&=#TVSATGPQX9MGLK!))XYIY&8@O+*8E R
MQ51@*!QW))K/^*'[./@7Q)X1E;2=)2.ZTNS$KWJH\HGG:4HBLTC !<9+QA"5
M;G@#%=)X-@_LJZ>XFBMSL8@QR. 2!UXZ$5WGC#4_#=SX4GE4/9O=PB*.5\;X
MI791N.%Y /0GD#([UPY/Q-3RR=3#5</[1U5RP;TY6^M[-ZWOTLTFCS^.,DQ6
M,Q=#&4,1*FH2YIVN_::W:>J7>^_,FTU8^!-;^'6G^"-9BF^RIYULV=GE^:,C
M.,K@Y'U%9Y^"VN?$SP[/>6JZMJ>BZ3"$DEF#RP:8KOM7:&/#$CC8#UYYZ?;(
M^"</AEHHWFMIH[P9BD*AC(22""<YR<9SFJL'PKAM_%>EV<UU>+I>G7$DQ:"7
MR9;,M&2!%E&0N)4CDP_ &\XYP?TSA+)\%7FZ>-Q,H12;WLGM=:Z:K3\EL?+\
M>YYC<+AH8C*\)&M6E*,;6U2UL^[M*STT6K;M<_/_ $CX-:QI&L[;6-S!YAWQ
M2PDJ6^Z3MQE3CN,$?A7Z;?L!?\%&_%7[,7PZLO#OC0-XC\-VR[+1FG+3VB#D
MH&;)VCL#D#I@5Q5SX1T=UFO'BD+3 NF\*).>2S8 &XD\D  G.!S@>._%W3KJ
MSU)KA8O(TZ+'VB,Y4%3Z =^N/UXKYO,,KQ$:\G@)N\6]>Z7^?9W\SZ6BXXG#
M1^MTDXR2;BW>U^S5M5W5NMG8_4OPE\6OA/\ MX:#,WAK6;?3=84$3:9>A.?<
M)GD>Z$'U4]*^9_C7^RM;Z%J$DD;6K:<SO&TEK:Q74+LI(9 R@,&!&"K $'C%
M?+?@RSAC73]6L9)+/4(YEEM+F!B)$(.06&0""<'/!'?(XK]"OV9O"OAT?'7Q
M9XPUNXALYI/ 5EKM\'8QV]M,S2K/<L,[0^VW7+$;AEB.I->?@84LQYN9<M2.
MMUI?O=;7]+'KQJU\@PL,7!N="3M[-ZN+TM:6]GYIVM;6Y\-:_=:#\.-8BME9
MKO4XY=Y22T,0&/N@JW'X8(]J]&^'6NZAXYGTZVT.S\3^(1IN9;JUTZV9;>W)
M!P=Y9D&">2P '/3I7@4O_!1GX@WOBO5IH]:DUFRO[F1D77534X/++':1%,K!
M21@YXQZ9K4T3QW\7/VMM9308_$WB#4[.Z!1=,M9TL-.  'R")=D0&2H"D9)(
M R36&'PW-45*E&4I2Z)?Y7_(^BS7B1X:+KXF4(4XK5]DO51N_P#MY'TAX]\#
M0W/AZVL_$WQ2\%Z$T@+RV&IZM!?S6>>1F*V+,<="25 YX' .#!\5OAG\$-"M
MK>;]H+2]0U"R@EMK)M-\)2W-Q90R'+I#.RJT8<<'## X!Q7R;XI^ =K\-([L
MZC-;K>C=Y,EF@N+>X*DABL@(!PP() .""#7FMU>1B\6.."-9"1F0L=V/<_X5
ME5ING7EAZ]+EDMU*_,GYZJS^5SCP.=_VC"-?"5E.F[V<5!Q:\KQE=='[VOWG
MZ9?L7^)/@O;>,[C5M#UG6O$'V KJ,!U'2Q#-J%UN*J2C.Q_<Y)13P6?>>5&>
M?_;A^+GCKQ?XJNM0C\.:C%LG\R%[R9401 $@J=Q!(QG ''I7S7^R)=6,LU_H
M-XL;?:_](B=N3D+P >HY []:^O!XCOY?V?\ ['<:C;WT4]A(N8F!NK!-N&61
M<%@JJ25=<D<9&!QVT*BK5(X2KI!.^GZ[_P!;]UV8FE4PE.><8=<]9QY==UY1
M2LES=5W?NZV3^(KG3[Z^\0G4=42YTZ:_4W"1SQ,-Z[@-VYN6!+ AL '/'I7J
M_@^Z&F/:A;Z&2;AE9>8P!T))'&#U!&/6HUETNWN?%.K3ZOI]TEGI$.GVME>P
M2%9[8,-QB. RR$C"C.,@9'IE_ SPE;_$"!KO4$NDC7-O"B,4\MAC.X9YR3C'
M3V]/L\=D-*A[.KA)75E>ZV?HV[IZ6TMW9^6Y%Q%C,SEB,/CZ;A)/=/=.VBLD
MTT[WUO?96V]]\%>,M4\>^-A-?6UQ::++<N]M!ILQB^QS/@RS,P9O,C>0$A %
M"9)P1BO=]*GU+1]8T%-+T^UO()M0$&J3W=\8)=-M0 1+&O!D8_-USR%&/FR/
MFWX7:5;^'M<D:/4=0C@60&)85$L;XR""I[#@<?7.:]JT/XFZ5/X-?6)5O+>;
M39Q;W$;[<22$C8(LD9W!ACG)Y[@BN?B#Z]F&(C)Q6R24;]^J=]7U:T]#BR'+
M\#PW3E"4KQE=MS>GPVWCRZ+=+NM;K0\M_P""HNB^%]>N=&UFRU'2X_B%IU@U
MQ=:8LF+S4]*4E3,$[F%@3R<[/,."$./A::>Q\47LMO:Q+'/IT$8O"O1VE,CQ
ML1ZE5(S["OT;\=?LB>%_'G[2/A_XN^(_%7B*;PNMN;U8X&@AT734M;1]KW\[
MN&^SRK+*%1%^9I7#-M(%?G?IWPMM?A!\7/'UIIVJ+K?ASQ-?PZMH&IN^[[;I
M6QFM7!P,#]XZXP#B('&"*\6,HN,G+=:?/0^JP\GST84'S1EJWT2?,K?>M/O6
MEC.\!>,X_#/C:(7%@FIH4:&>.[N"J2Y(8 9! (*C!QG/<\"K/P1_:(7]H/XJ
M>(/!^JZK:RSZ+,X\.V4Y :5#)(MQ$KX"NX"QNH4 $9 &0:\SOM=OO^$RU6:U
M20#2D:[W&,L)2CC" ] 2"3GT!XKNOV%_^"73?M/>&XM8GB\01SW^LP00:AI=
MF]S]@EG,C+))(DB"&WB"9>7)(++@5ZU3/J]3!O#XB;<5;S>NBVU?X[^2/"Q?
M"M'!YI2S# T5[1WOT6FKO?177:VVF[O@_&OP)-\,_B/I.K6=E>2WWFG[/#"I
M$LD;</$1@DAAR!C.0"*](^(/[+FO_'B*UD6PN-);3[:6XU>^U2PNK:#P_:Q)
MO::[+1 @$'"K'O=SPH[U]!?L=_!SQIKO[64UQKVF/XMO_A!X2OKG31?+]FBU
M35X9YH;2UGE8* [L@?).2NTYP<U]$/J/QD^.NF_#?6/$T-]X$UTZU>2WVBVV
MG3KI&IZ*BQFYM[PNIC\\?=A<J/,!8+@Y)^=<HJI&E*]V[+YM+\V?;QK572J5
M\/R)))R3EK=QE+2-KM*,7=[+3=)V\S_9E^-/C+X3?LE^&_"?P#T'_A;$OA6^
MG3Q3_P )4'TVXLIS()4BM[>4@K&3N,1)8H%!(#$X^F+K3]1UGXH:1KVM-H;Z
M:EE'(MC?6*7-WH=^Q4N\%T!D1@9##')4,I&:M>+]+-MX!OEL_$TOP^L=+:/4
M;O5[2&..*VM(,M(CDX"QE<$D'JJ@@@D5R_Q4^(!CU)VM1";:]474#0N)(WBD
M =&5AU4JP((['M7L5L/.A-TY]EV\^F_WGPF8U%.BL332]Z4D])76D7K)I1;=
MW91U26NZO\_?%W]F/P[\+/A7XDL[C1_B+XB\)>)?$4]_J?A6&\M+R_D?SHXH
M+^*YA(:*$(CR%!ND=9&#D\&OI?Q;::?KUA9ZO]C^W)I,BK<0)]ZXB48 &2,D
M8'!/.,$C.:\@?Q+=W6IQ)&KM+*P4+&I+.2<  =22>,=37HO@"]O(=.U))HFB
M2"/$_GL(%A;H Q<@ D\ $Y)XK&BX0]V;^?Z]CGQ.)GB]HZW;23;6MM-6WTM=
MMMZ)MV1X]XN\?R:BL.R9+B\MH%2\N8]/2P^U3#.YQ;HS+&""HV@G.TD\GCQ+
MX@>/[S6;]XO-D7!X'^!KWCQEH-CXMUVZA4S:7J5NQCG CS[_ #+U!_,$<@UY
MWKGP BDO%_TUI"6R7V#&.Y'.171"FHI1Z+OK^)Y];VM2I*I)+WFWHDEJ^B5D
MDNB226R5CG?A3\+=<^)?GK:3[;:/ <NQ"%O0<'D]\5U^L_">^\$QK;W,2J"N
M R\Y^AKN_A3%9?"[2_)+Y3.21DLY]AS6]<SO\4-1A$VS3-)A):2:4@2.HY(
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M.=LJQN5=5/7!/5\ X.1DXQEV7Q[F^%.JZ!-I-C;_ /"1:Q=VL%C>W:B5[(J
MA.QE(8  ,"",'ICG/1^,O@]#IOA6XU6:"%IM166X=TCP&=R79CUY+$FOT7,,
M\RZC&$L-'FEKK]V]T[_YWW/RKAO*LZQ&*JK,Y>Y%1T_\"LE9JW?57M;OI]4_
ML_\ BW3/BK\%++2?#NF2?V/I\&_7-.M]'>YGN%6"1K5YUW9N TV\*8B"05R#
MC(^)_ '@/5/C=\<[[PYX?L6B>UT&;6]0_M*X2W33-KA0ID<@*JDXPQ).<'D$
MU]$?L,:/9+\"='A\1:C?:6VI^+C+X>^RW#I)J=Q%%&OE2%5;RXE8  GIEL
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MYYM]SJN]?,8(1C>6!(()4C@5E:=8?V5XBDEF^SQF%LA9&VYY['&*]K\'>--
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MO"9  0#SDYP>,GFOH'X:ZWI_AZ^T;18;G5-5N-0(1G>':\9V@CGJ03E5..N
M3R*RS>ICL3@J6%C9J/2*Y6[)]%H[+96NWM=L\^GD6795CJV;)R4JCU<FY*-[
M=7>2N]VY62TT2N=SX\U?0;7]G34H_BDVE66FS:>R:W_9T<EQ;VSO*4A,*KO=
MI!NB("$_/T]!^:/CZ^A\&:K+H]\UOJ"7LEO8Z?>(#Y=XL\D9M[F(D A74AAQ
MG#$'!! _0CQQX!\/_M;>"M<\)0ZYJUC:Z?>BZ2?3IXEFNI;<NR1*[$Q@O(C(
M-Q&QU5B  ,_(?[>_P#\ ^%E^%VG^"9;ZUUKX*I92>*-'N[[[=<:=#<L9K=+J
M91Y<EPERY4[3@(YP H KPH4Y4*JP^(3C*.Z:UVOK_5STJN.IXRA+%Y>U+G>G
M*URKWMUJW:+NNJLDK[7\%\6V4?A\,&A:7S5*A2Y"(W0DC(SBJ_QF_;&OOA_'
MX.99(].M[MS'JWV(&3^T+4-&LRNI"@,59AN^8G;CKS3?V@]5FMX+1K5&NYYR
M6(3^\QR?S)KGOA_^SQ+^T3^T[X;\)WTL<L%ILMX!.H'FK-(I+E"075-S' .3
M@ XYKTLOSFO0IRH1G:#3NOD_Z^2/-XHX8PU=+'>RO5@U9]M4[_*WXM]3V;XO
M_#C2_&WPV&MZ/-9ZQH4ELTMM>P8>"YA.0%;L&.,,IP0<@BL/]F;X:^*OB%\)
M[C31X7\3W&DJ&M;*ZBTJYOHKO"DI$K1JQ##&P$X4?+DC!KU+XC_\$]?%W[+/
MPK:V\"Z3XSM8_B%9RPS>'+RW$DL=S'>PQJKK$SQH\D;-,N""44@Y(K[FTSP)
M\2/AOXOM/AKHNA:?_P *1T7PB(KNZTE%EUC49#9D7*A]ZO#=?:-YB*D!B5'0
MDCP<16BE[75J3[.^OKJ?48&I.2]FW3A5A&=[R2C:&CC&2NI-OX4G:5M[*Y\<
M?L(_!2W_ &)?VC6FUBVUZX^*VJ:5+8:1ID-D_P#8NAWMS )([;4+B,DR.RF/
M)1?*C);+%AD?1W[2O[5O[3'PB/@'1;[1O#VG1:SI<=UJWBF"U^TV O#-(LEH
M8MLFZ,+Y>4R"59F!)Z>M?LN>#]<^'?PB\-V.L:M?^*]4MXQ,;N[4O=SP,YEA
M@G^9B9(HV6)AN;#(PR>M1^+M'T"Y^%_Q$^&OB+Q!XD\9:;J,QC\2VUU?21:A
MI8O42:WB1\;!A8MXV$C)8%5!Q79CLMK/#PE3DUS*ZUMTO:VC;MKI9JUSCRO-
ML)0S*6+Q]"->-)I3BXN:Y>;E<EHXQ46U9334W)1O=W6+\=?@MX1^.VI?#GQU
M9FVL[C1+*[ELM;\/:Y%%#X?OEB \B.VV,+C%P\A ^4QF,%L@D'#_ &1].TO1
M[#QAI\G@N^\*7.M:]*^HRWEVMR_B"411J-2!7Y%\PY)1 %!W8 R0,NVDT/X9
M?##2?!?A&UO+?0]'DDN/-O#']HN97"KN(C4* JHH& 20,DD\UJ>"X]6:.RNS
M:7@ANY!';R^6=DK@_=4]"<]A[^AI864HP4ZWQ?+LCY?,,3AY5IX?!N]%-J+]
MY-QYFTVG)J]G:R26B=E*[</Q1\1R> D;1Y([B./[/Y*1^1";:6;S_,^UF7'G
M"3R_W7EYV8YZUX7\3_'5YIUN8_,D&_))!X&?3MBOH'XV^)=.NI)([M]/OK9)
MA97+VUY%,+2XQDQ.RD^7(.NUL9KR?Q)\%K'58?/6\O'0C(5E P.V#R#7?"$/
MBINZ;OO<\?$4\1S*-6-G%)622=NETDKWO>[U?<\T\+?#G_A+=;\.:;<>+-'T
MOQ+XT62;0-(GD?[1J*(2"X905C!*L%W'DCM7H4G[+^J^';&6\DF@NY5&9#R6
M!'4'/7!KI?AW:0>#'T:XETW1+S5/#D<D&E:I<60:\TR-R2P1\XY+-@D$C)Q7
M2:I\39=0M_L.GPJTLBE6FF(5!GJ>>37/3^L7E&I+W;Z)7V\_,[,5A\+*%'ZI
M&:ER_O.:UN:[UCVCRVWUO<\D\(?#&Z\4>*;>&+AS,H(/H.2<>@')KO-9^"NJ
M?$OXKW4EK<1QPV")'&1(45%48!8]22<X YQ3O%/Q!TGX%>%Y%LYH]2\3:@A#
MS9^6!3R0*O? +Q%,G@*/4+NX>74-3E>>3;G 7.%!/8 "M/;2I)\OQ;>G_!.?
ME;<8K;\_/R7Y_GT<_P !-4TNU+/J^EQ3X 4K"\K;1TR6(Q@UYA\1OAEXLCF/
MV?Q7;OL^[$]MM3W[G'Y5ZAKWBS4+NUW *(5'^L+;3Z5PWB7Q9;O"4DDC,B<9
M#Y.[N#7'&IB)N\I7-EAE%:67I_F>27MEXBT^X:*\\/:+?3+QYQB4[Q^E%=;=
MZTLDVY9\#'<T5K[:2TO^9',_YCU&Y\9MJ$[*QSDE<>OOZ51TN*X7Q:9))"(?
M)+ 9) P<8Z$#)/)//3WKFIS)9)<SAF$D<A&#W6H](\81J%FW.\\+-A&;"N#U
M!]C73P_6IX3&PJU/AU3^:W.NIB)0K:G9>(O#']HZ4[2?NY3.%0%B3Q@Y'3C
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MI)IL @LN % &/4GDG-=5\??VB;K0=372M.O([^.ZM8KFVN;7_CWE@E4-&Z#
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M& "2,8_/->::7XIU#P>PTG6TV/L*K*#NBN%/0@X_2KNHZX\%H_EW6^.50N6
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M-<0ZG,K#S':7@0LZ/$R0G!() R017TGXJ\,Z1XA^"5CXLT^_VRZM%C:D?W'
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MO$.LB>1?5(U9OKC<Z?C7Q)X6TV2Z*LQPV/Y>W6OI[_@K#\08?^$Q\$>&K/;
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M5K$4&0CL&P>QV@XS]37ROXU^+/@.?Q]?ZZL=[J>N7Y/F7-S,7!!&-H' "@=
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M>H_%2X36O$^DW'B+1;=I;?4B+.*]O8RJ';N.!,JDD8DR>._!%>=>,OA1X/\
M"/BB/5H+2ZUS08+=W-K,9(Y[978;!(>,E"&^900"R[B<C-G2/BA>?"+XEW&D
M^+(=4\)ZOI,C6]PUDVV:.0'(.[.UE[C!&00<BK$/Q>L[[5Y7AU5+BS1S)',8
MBL^[DDD*202>,@X.>>,U>49QC<LKK$8=6>SZZ.VU[K6W^0\\P. XBPOU+&7<
M;WM=JS2T>EGI?:YY)^T7\:(_B'XDL+6U6_ETGPYIL>DZ1]LO1-+;*C%V,K8
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MN)%BW$;B2Q ! ]>>E?*,'QST&^U.*3[))IZ ;8KB(%_+ & '7J1[CGV->M>
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M+2:VE6.4&*0LLT3*[OYA(8L&# './,]&_:\G\0^$Y/%?AO45MKRVM+4W,"Q
MKJ$3&12=C @A2%.#@C>PR,5[/XK_ ."@.K?'']I+X:_#.Q\(Z?J+ZKHMOJWC
M6^U&%S;V<,ML)I!:.NU0$R2SD#+$#'6O!-?_ &?=2^(7Q7N)/!\VGZ;:V"R2
MW4]\XM[*"R5\9E*@X'*@  G)  Y-<?MH5Z<N65^3K:R?7\CZ:I]8RJ=*.(I6
MCB4Y0CSJ<E%R<5S62][F3ULKK=7O;EO$_P 1=#^/?B:TD\2^&M#NYYIX[:2X
MMY9-/= Q RQRR9 .<G''4XK$^-?[--G\/=.N-5TO5+?Q'X8U M;0,+@2RZ>
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M!1[Y)["OCO6-&\5?%F"WCOK^YN/#VBA+6!O,"V VX BC7),S@<$G'O@5[G\
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M[J?<?K5[0OA5;V%Y"LZQRK&0W(!Y'2L>?XA+XA\;:A>:AJ#6\$LA$;VK[&8
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M;CPW=()PN^2U#9$RGH\9[@^W2O-=<O?$&GHUO);S(R'T.,CV]:;X,^,FB>
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MPCI;L9#&K'!);IGM@9ZUC4BYR<GL>]2E*$(Q6^AZ/8>)%U)VCM9%%AI[>3&
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MS;KWP^O-;OWO%3;@D!6.#MSQV[U]-F>5X?!TE%/79+R/+Q4G3GSQD[O4\O\
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MU3"3ISC"I'5]#Y#GJTYJ%_Q/ECPE'H?@GP^NE:"8[3RYFBM[2*W3,"@#)"J
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M>/)X[?6FN;/S'@Y1(W;< N<[2,>O.?6O>Y?BA%XDTYH]4TRWN(V_B@;:2/4
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M";X.MH]K,;>Z^T8?S8P5P0>X!SR#7*^.O%]G<: ]C?63QSP9V2<A@XR 0<8
M /3D5#X._:*DGA\FSN[:5<_+#<K^\0>F,C(^AK<UWQAI?BBW7^UM*RV/]9;O
MR/P;!Q[9-.G)TY*<&XR1R5J-=/WM5W1\[W=[+I-[+&D;7"2$M\Y+$D]2#ZGO
M6EH7PCU+QYF2QTN9\'+;%R >N2>E>P:=X>\*B96M6C=F;[EPA7'XX(_6O8O
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M"2<D\]ZJZOX7QX@>V:-E123NQQ@>]<.48)8&DZ47=MMM^9YF:M5;58*R>O\
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M8O\ 9M/F@BMI81YCQ>7$JLH';)W9]ZY7X8>)=/\ AD1#&VJ2S*</]IN7./\
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M2B\7-25&FJ4=$K15VEHE?5O5W=NIY;\??&6I1:?_ &4MLEW=BWD@\Z3 D.<
MDGH"""#[\9JQ\+;;7/!'PO\  ]C9^(?"N@:<-9GN_&%IJFGF[NM<LVC0QI <
M'@#<#@@Y(YP,'<G\,)X^^*]Q'Y#"QTORQ()$$SQQJ26^4Y!/)/.<D9.353]H
MR[CU+QK!)8V?V6RAMUMHDV[6&UB<D=L@\#TKY_-*+JX>4=5ML['G\/XN6&QJ
MKQC&32:M**DM5:]GI=;KL]>AXI\0/ ^H^'?&9\0^%T&^*Y\Y;=A\DBJ6V@CK
MPK$<<C/'-<EJ^I>*]#\(72Z;X$:R>VMWAL]8GN0][&)9"[E954$ $G !!&23
MUQ7O7AF8JZK<)MYXR*]?O-!M=?\ V>;G%O&&MI&&['/(SQ7@0I\TN5^9^B9?
MGE:C05*2NDTEY)M+]3\W-)^ E_KA&I:U--<3-SAY68*/3))))ZDGDGDU[_\
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MJJ=WLU:UO4XZ$:%*K>I[R2OH]]B;X@_$J_\ %NJ/!#,MS<L/*\T\+$H_A4=
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M*O?8_P"R?B;8ZS-$%CO@4GR./, X./<>G/7%:GBSXBQ7\TT*Q0ID@;QP#M
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MCQK7@^T#+=[GXP6&['M7"XRY5S:L]_%4Z<I2M*W;S7Z'WYIWQ#^P'$ENT(3
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M2KRJ8:'+%]//KZ>AG[-1]]:(YWX1-<V;*GS%<C+<_J*ZSQSX*.ML)[&94NE
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ME;L<7XUTK_A((MT;K'*X.[:WRGWQD$'L3W&0<YKSW4O!$D-WYDK/@-G!/R<
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MS_+%=<*BO?J<M;+:\7IJNZU.HT'PQ9>']/>Y\L23MC;N Y;USUP/3IQ7BO\
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M!,06 #8/" 9!W9YY%</JGPZN/'FMS76G1.T:$-)YXV_OBHWJO^RI! / .,@
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M4X\"^*HGSDYMXV'ORKFG:]\*/'TL6VQ^'WBAGQSFW1 3]=_%?H)11_9\>[_
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M5"'_ )-_F?G?-^SO\1VMEAO_  #JUT@_BMGC/Z,PY_&M33_@]XRTV$*OP_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MABI5@H4DDLYR .!DBA1?E_7X@ETT-2STGQ=>:<UQ;WVDPQ:@#-<;XR\AR/\
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M;*X162>VTU9'W'G!0E#@^QS_ +..:JS_  \"Z,NH3:E?Z9MROV5[MXK>X Y
M$>=I)QZ9..N*;<:E=>((5@U!M*M++3X&,+66K!KBX8* !NPHC8]@<D'G/'+U
MZ/\ ,YY83#3WA%_)'3:-^TS\4[;Y=0T7PHLWEF86\D[K<&,=3M4D ^PS]36I
MI7[8GBN_L1=6_@S3]>M]_EM)I6K(WEGN&#8(([@X(]*\]\'>&M0N5A>SFO\
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M@YJ2J,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_B7_ (.8_A%8JW]D^!_B-JV.[VD%J#^+2&N6IG&"A\56/WGN8;P[XFK_ ,/
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M/#>O:?J/V.*#P>]XL>TK;PO;Q6L9))*Q[F D);.20".>:D3Q+XTL$DMX]/\
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M./%LC?VQXZ\<ZFK\N+C7KEE/U&\#]*Y'6;*+4YMUP]S=D]3<7$DN?KN8UO7
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MK7':W_P7S^#MLQ72]!^(^M<<&'0C$I_&1U_E7)4S?!0^*K'[T>[A^!.(Z_\
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M;&%FEB8]%157YE[8 !'4Y'-,U6]U#65N[F+28;>WDV"4:CM$L '1@@# N<Y
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MA8[AMZF<GC,Q4$@YX&,CZ5M?\(U)JVI0V]WJEQ>+YS&0+;HL<DB@8<X)QC(
M XSSUQ5C4_ $EA874TFM:Q=P[#FUE=#"0>VT*, >Q%&@W5C>W?U,DZSJ/VMK
MJ\72H]3M$EC6..9O(+ 97)X8Y!X&#TXHN?"OB#Q39_:+JW\.^?. 'BN[5KF#
M:!QM4L&!]R?PIT5O'J-RZR>(M'O#"@Q(UE$HB(X$9?<06]\Y'7'-:>G^/KRV
MB:.^T2_=H?E^T:>HN83Z'&0PSZ8(]Z&NR$YM+W3E-2\"M/H]S>2+X?-JBA&D
MA@G7#+P22K@E%[ $$#C)'%7K+P;=:5:6:VJZ:(9MIMW@5O++$9!(+'*GKSR>
M>36D-9U*TTC[+'I>R*0DS75U*(HWW\XB0$LQ/O@#WJO'>312I##XET/4FLW'
ME6C@?Z,PXS(ZL6('0D@8./I5>\5[66P'2-?>>:*>/09)(X]LA@C:*/RR3\ZJ
M=V)!C !)&.?:LO3M/FT>PDOH]&\/M%YI5TM7, E..6E&TA6 YX!!]LUT6F>$
M[C7X9II/$VH1W*R$S-8S(J#N!ROW0/N\=.<FJ]EI/G-+=6OB)[*WE?9NN!#)
M!?@<$X/?W4CMD5*["52RM_F9<VHZMJ<T=LP\+W%G-@6T<.^1MIS@J^XAN.H*
M@ >O%6HD\0:!'/'"WAC2S%&)I08I&A@C (&Q5*Y]R3D<<$8J;3- M?,CABU=
M+7[8[",Z?%%#+;R$<AFR22P!Y('IC)JUK7AV3PFL,KZQ<WS2;XV.I7"KB-AA
M@'P !G!&003CI1IL#J*_*9.EZIKUEID]S8G1[V(D/<3WCS*[$]-JJ#A>< '!
M X/2I((-9NM,FN/LFB1VTV7N&4N)(V&.$XY4XYR0>3BM9_%=\FG"SL])N(KH
M8C>[E53: #C>&4_.3V'&#U('6&\\.00([-XHNB8Q\UC'<Q>42.JE!R3GKSG-
M'R#VAF:];ZQ>R6W]I:?X3GEN#Y=O%<EY+=P<8)W*3O[=,8[U/#?ZU:./*T33
M[&\LXF656E\NS*D\R*0"Q4 =" <\9Q6AI?@8:S+=*=9O[J"-@L<C3J[Q\ @H
M5 "@'IUZ>QIUYX)U#3IHXX==U*4R(Q=[LI(95'5"=O YSD8(/>C38GVD=O\
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MN);HQ"WVSPF)3(#]YN!P!TQ@'IG-"01E\S,,/AJ73/*#Z:-65?+V,$6XXX*
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MV$L.E0LL<$*-C *H!C]*XY<=5;VC32]6W_D>M1\%<#%?O<1.7I9?HSZ:OO\
M@J7\#YGE^R^&_%VM6RJ!!%%X9<!&ZG;NP%!/^-8&I_\ !4[PM>6X-C\'/&FI
M7A3RQ/=I;VORD\KEF) (XQ7SAK&I36_^KW'WJII^KW$LX5E;!KCGQGF$E>*B
MOD_U9[%#P@R&G\;J2]9?Y)'O=W_P5)\26Z21:3\$[=+? 6)=2\0)M5>A!55.
M1^/M7*^)?^"@OQ2\0Q1B#X=_"W2K:$';%-)<7(0GN  HS].*YG0-*CU-6\SM
M5C4O!ZLF(OR-9_ZP9Q5A[2,]/)+_ "/2I>'?#%&?*Z%WYRF__;C-N_VV_C=J
M48MH]4\ Z-"I(5;3P\)3&IZJ#(QP#W&.>]4S\=/B]?*GF?%G5-/C5MXCTO3K
M:T5#G/&U3BFZIX3:!3NBQGN*P;CPQ("=KL*\VMGN82=IU9+YV/>P_!V14U>G
MA:;_ .W4_P [C?$M]XD\0QRG6_B7\1=8$X(=)M:<(03TVJ  /8"L"+P3H]^!
M'=7.O7O3BYU:X<''J-P'Z5N1>'9=_P"\;*BDN?L=K, 1AA7%/&5YZ2J2E\V>
MU1RO!T?X5&,?2*7Z'*WOPS\.VEQF/0+&3T,J&4_FQ-:7AW0]-L7 31]-A5>Z
MVJ#]<5O76HPK:AE3=5!-1^VYC6/;N[@5AS.2U/0C%1V-FSUZ'36Q"8X_]U0*
MZ'1?$YOV$<C<GH0?O5P9\*NTF[>U;>CI_9;1Y.X+54<0Z4ERRT"I152+NM37
M\4Z*L@:7Y<'J#7+3:#;,3\JKFNBUO7?[1B"*,#O7#Z]=W4=RP3<%]J,0XSJM
MTGH5AU*--*H)K&BPV2[E&[VJI%JLD2;(8F_*KNCI<7+?OAE?>M^S\,M/%YD<
M:@>XZU,;M\EN9FNB][8X^4M<-ONEPHJSINK6D(\M1^-7_$>C27,94?*R]17,
MW7AZ:V&<TX\LE9CU3NC0O-+M;J8N9%YK2TM(;6/;&5(%<FUG<1L"P>M 126U
MAYD98'%*I3T2N53EUL=L?$R^3L*+TQ7.:_'+/ WDG!.3Q7+)KEQ'-R[=:UD\
M8QJ@##)[U5557:^MBJ7(KVT,E9KZVN?^6AP:Z&$R7ME\WRL13(M;M9TW':#5
M.Y\5QPR[57(6LY<T]D:1M'=E>YTB2PD\QI6VJ<U:L_$\,>%5]K58@N(]8M_F
M'6JO_"*PO."HR?04N9/26Y7*_LB:MXF6U.YMS,>]4!XP60$*C9[5M7?A7SXQ
MNA;BH+;P>L+[O);/O51C&VJ=RN9]&CF+W6KF:;B/CZ52O(Y[Y@6CVFNUN-/C
MB)RJY%<KXIDDM+CY3A?:M:=1.7*D3*#2NV49[">. ;5;\*J+8S*<[>?>M_PS
MJ:2ILE;+>]'BE7"CR5_*J]HU+E8>S7+S(H:3+=><% ^7N*VV\.1WOS>7EN_%
M8OAI;B.[&\,%]Z[+3-62T4@C(-9RMSV;LC2G?DNE<P)M+@TE#(%Y6LU_&<8D
MVLORUT^K^7J#':.&'(KFKOP;'+(64XS41Y+M3=S27/9.&@XZI:WL1VA0QK$N
M[^>VD8*^%]JU)O!^R/Y&8-6/K.C26(!)9LUM1Y+V3,:G/;5$< ;4)L9DW'O6
MA%X8GWAO,;;]:JZ'JL=FX5DY/<UTDNIQPVWF9XI5ISB[11=*$9*\AUK;>1;@
M-SCO67K/B7[ Y0)DU(/%MO(VUCBH[RYL;Q=S%<UC&#4O?1LY)KW&4;;Q)#<O
M^]CQ[XJEXFOX+E L87\*FU>WMY8?]'"UE6^CSSR?=KJIQA\2T.:<I6Y1NER?
M9IPS+\M=)::Q:W*[1M!ING>'U-KME"DUEZIX;FMIMT/W?:IE*%1V;-*<9P5T
M@UO1%N+C<CJ,U-H>@O:2;V;(JC!IMP)0TSLJCU-=#IUW#&%56#GCBBI)J/+<
MJG&+ES-&=K%O=-/^[Z50O],F%J9)GZ5VZ6EO>1;OE4U@^)+;=:R*/FQZ5*YH
MVVL4U&5]SA7(\WVS5A+2,@%9,;JC-C(TI&QNOI6A;>%W<!F;:#79*44MSAC&
M3>QHZ'I_E1[F;<#3YY+."7+;0U1W(.B:>=C;B:YIYVN;G<Q;DUS1I\[<KG5*
MHH)1L;.N:U#/%Y:M^58:0><.'_6DOHPC_+5?<0W7%=-.FHJR.6I4<I:DL#R1
MW V[F(-=%"IOK ^8N#CO6'9W2V'S;=Q-32>)9'0JJ]:BK&4GH:T91BM3-U*U
M$$[ '/-1V[1QMEN:EFMIIR6VMSSTJM);LO566MUM9F#T=TC7L4M]0/*XQ5;5
M].82;8_NU!9--)\D?!I+J2:"7:S-FLU%J6C->=..J'0>'I)DSFK5EH;V66)Y
M%+I%U]G.9).*?J?B!4!6/YB:SE*HWRHUA&FES,S;B^D6X*G;UJRVIPVZ#<J[
MOI6=)#->2%@&7-136,P/S XK3V<7HS)5)+5&Y:7D5VAVA0:S-8L%5BV^JMJS
MPOM5L9JQ-I,USSNW"H45"5[E\[G&S0_2;.-T_O5/+9P@\A:A"-I-L>YK)N;Z
M29V.6I*G*;NF5[10C9K4V)H81$1\N*Y^^14G.WI4\!DN#MW-BJ]Q&T,AW<UK
M3CRNUS&K/F5[$,C;CTJ-CBGN*(Y AZ9K4Q6Y7?K1LW+UK2BMX73=5:Z\HR<?
M+BI]I=V-/965[E01L#QS39)67K5Z%8TC^]R:S[H_.?FI1ES,&N5"FX5TPPQ4
M$FW^&I/L_P N[M3=ZXIV2V)=WN0'Y32NA<<&FR_,]2+*JK1+NBJ=GHRO(&C/
M6HY6\RI;E]U09/-..UR);VZ$93%-SQ3Y :95)7W(EIL1DYIK]*=37Z4^4GF8
MP\'-,I[_ ':83BA6V!W>HC+NJ.08J1C\M1;Z=T+4::88R6J7CMUIKC8*+"<F
M1^7AJ1ONTCDOTI/+X^:F Q LAZ4\;4Z4R0;$^6H%N&4T"Y6RR5Q3'/E]J59-
MRC(IKRY&,4&7*1FX4#K33<J.>M$EN&!.*:OR\8I\S)L@%SYK8 IWEC-*$P/N
MXI:LSDE<@NN(SQ6?$["89W"KMW,R#@9J&"/S6W,*#.42P5RM-"+3SQQ42P8D
MW9JDS&4!T@VH=M50TS-GM5RHR&)XJ[LPE ;'NQ\U.HZ4,-P]*:D82IC7--*[
MNM,$;++UXI]7=G/*F-:+=CVH(P,TKML6H/ML9;;GYJM2,94Q6VS?*14,\"PP
MN5XX/\JL@?K3+E=\3Y]/Z57,S-TC^G?_ ((P?\HV/AC_ -@\_P#H9HJ3_@B\
M,?\ !-?X8_\ 8//_ *&U%?J6#_@0]%^1_#?$G_(VQ/\ U\G_ .E,Z6PL[B^_
M:6\>QV^HS6#^3:L1&J'S0$Z?,"1CU%=*VF6EI:0^9KUS8%T^6W2Y2,.>>@QD
MD^N>:Y>WBAD_:-\=F6&ZF*):F/[/D.&V<?,/NCW_ #KO-$BTV\:2.&P:WNV3
M>WGPX:0^H;O@^E$=OF_S.V<K1C_ACV_E1G1Q2:6JW5G=6,T^!FVF*(P&,$;@
M-V1UR<G\*9J%S-KP!N!#:*@"O'%=I*)0#DC(&<9[<$]^*TCI5C#I*W/V2U^T
M$X,PC&X<\G/7@=<<U7:[T0'=;Q0Q0KGS'%FP7D<,#@ \]QD8ZUH3S:WL-TW6
M+C2I)H$BO=:BW%DFCFB=@/[O)48'L3CI2"^N#IK6*V]\DDK';)Y1"(I/(+Y(
MW=1QQ[U/9V6CW-HR70L;B%<,A8@H5[%>V?8<U76+3#R-(D%PP(CGCMC@*>@W
M?PX'!]*+"YE?0+/PS>S*LHU"Y2$YVHT@9(,="%QV/8D^](1=-<1^=K%@SJ"B
MW,<8QM]'&[:"1T.0/;-2G79M+@=4:S^R.,+]M9H&BSU7&/G[\#!/8FJ]G%HX
MB_X]VDBZR+%9,$D;L -N3]>GO1ZCN^I$="MY+^-OM%B&#J#(L<4A=<'.';)&
M.^.<XYJSJ^B1V,R+)K%X_P P*VK2H% '<+@$ =<YISG2T@DCFLI+>&7B,FS.
MV)3C(; .W)Y.?K45I#:1F:-1]INY5"ETMSA0.!E\ #C@ &@?,V[_ *$6HZ+=
MVE]Y,=]K?S<AH74^8?[S<?AD?E3C8R*DD:ZLDDBKAQ?2+(DI[JQ&""O;'([Y
MZ5-Y>FHNR>VU5K,D*_VB20B,^N"<[<>G'J,5I:3HNEZA!Y?V2QDCC<F-=@(4
M'H0N.!V]^M(EU++_ (!D11W#ND:W&F6D+.%D"'S9".F%)XV^AQGMQ4NH>'KZ
MRE7[-?7R98;7#(H=NRE<8([8Q^-,NXK7[7Y*K:H^&3RTMF,H&>,,,A5QT''U
MIXO;B?\ T>>XU">&'[KI9,CY''WR1DCIP!FF5S,9>3R:A+ONK6QMID 1S)<A
ML'/WP%YX]#@@')I;'4-0M+.:"WMK&XM\D)/;R8$0[EE8G</<'!]*DTN/3;25
MO-M(;>W8$JSJ$$0 _C).=Q'4G/I1Y&A)-YEQ)9EERMMR-VT]"NTY([>GK1IL
M',MK?U]XV7PVT$<>[5K^!V*@QI*@^S@YZ<$KGZX-1OID*7"1_P#"07]P6R3(
MURC?9Q_>!Q@$GCG\J(-/T>-TW)\R\7 E5CA3UPS DKGK@D#VK6T_1-*3399'
M@L! SG=\BK%@'CVZ=S4[$N5M?T,DV%Q:R7"V.M/Y7E^8^U$F)/.=I)P">IZC
MO@5:_P"$1?['YS:EJ) CWM$9,Q%L9)(QDG//7KVJ.=-)\[_1[?S800T#V"!O
M+;&"<KTZ]?2HD-F6*3ZIJ2R1\1VQ+1+GL  !O'KDGCKBJ'S/I^17M[*\!8W&
MH:A%  78W3)(L>!G>#MXP.0,X]12V[_VNS%=<6?8I7[6UJD> >-I)X)/K@8]
M.:M-%%*6#1:A<%,8%RI\N-ASE..5R/7CK6A:7&D:ZWERVZ>8B[F2XA(4>IRP
MVG'J">*!RG9&&NDWBRQI;WVI*C':D<%RJ1QXX(QM/3'(S[YK0NO#,UM8M-+?
MWVU5&;<R PCZ#&<]QSUIL\D)G9K-IUC8@Q&&(O;Y7H3R,>G'4<5"MNNI7)N)
MKIKF9?GVEWC5.QVQ-R/K@_4T!S-CUT19;B../7-0N6D) 83HS6_&<K@<9Z<B
MD?0'N+>21)'N8[:0@M);QO++MZD'C!'KC)]:T+[0M+L9"LMG9PV:Q>9.S1#]
MYV /<@'GI5&9;"2X\^SAU"%-HC1K5"H<#LPZ;<=,_ABDB8SOM^17GMU6UAN&
MUK6 ]UEDMII$C)&<'*X&%'?'058U/P='##%=K>7S3IA1/'(%FVD] PP"!V!!
M%.1]+8N5M-2AGEQ^\EMW/F8X )P0 /P IJ7,T:>69=4CAC.5,MK$8@ .  OS
M''4 ]?>CT&I.V@^;PTUK-Y<NI:I(!&TADDD!(4?P=/NGTQFH([2>*S+)X@5U
M<;FM[E(YFX_A&2"/8']*>]QI]U S:CJ@O&;!B=HC&@(ZX4#H#ZYYI]H-&C.^
M:VCN)92&CECM&D)]\A3R#W.*!<SMK^0FE>'%O9KCR[R2$Y7>8(XE,BXY&X L
M1GC.<]L@5)J/AZ*SEAC:]DMFDR?-5@ACP.,'H 3QSD=JB:*U'ELD&J6TT((:
M6UC*D@\X4X((]>/>FV^G6NGM)+<6TUS'(?WOF*9GD^H/)P>PZ>E,KF=]_P "
M.\TN*\\Z.XU*VO$V#=)<1Q'S1UP"H&"/0 Y],XJO9Z4=,MBEO/I]E;GYW$>6
MNY1W!R3@$<Y R1QQ6COTEY0T=BL]J!A$CLR3$W<[< C'J/YU +"U:X:1$MFF
M4\N$ <'TS@'.*.@*702ZTUF>'[+K5_)'(P#-#=HK(">,\'@=AQZ9S3[O2Y5F
M-O'JU]?,5.<M&6('5"P /3GCD]#Q4V--V8.E-;X_U[&U(61>X! .[)YQWIJ_
MV2?]5I<S62X'EQV9&6SD-MP#@>IZ4OZZ"4GO^AGM9M81INEU2"'&U(+50$D8
M]B,=_4G ]JN3Z--I]B';4[I3( ?L<T@*\=-O 9<=\'^E21)9Q._^@ZK%<2'Y
MI8DD=?8]2!QUP 13;6.QM+G[1?S/<2QKL5W@;S/9,XRW'<=>],;E?4CCT]=1
MNY;BXO;>PFE(RT5]O*8  V;@ !WR!U/3-1W6B0+%<EK^YFC7:=K,KI(6Z,H'
M\1(Z\"FWFO\ AA+JW::31[.-24DBOO+A*@Y.1N.!SZ<5R?B/]I3X5^$KEOM'
MB[PC9B(GRB=1A"*1][*[^0>@(!_"I<XQW=OZ\S6E2K5':$6_17.P;3H8;!9/
M[5O V,-:1S+B1B<<KU.>YR.*D:R<0QK)X@N)8R0-B-"#;C'7<!G(/0DGWKRG
M7O\ @H/^SWHT#W!\>^&)+G:<&UC>>;..VU2<_C7(WW_!4[X&V4L"V,FK:M)(
M#Y_]G^')W#Y&<<A<\^N17++,,-#XZB7S1Z5#(,UK?P\-4?\ VX_\CWBRM8YI
M?)_M+5K%I,R&Z,J;9S_M/USCID >E6);4(F[^UKB,"7RA.PCF"?[1R"!N/<C
MZ5\TW'_!4OPG+#,;/X:?$;7H\C8)-,B@C(]?WC9!_"N4UO\ X*EZU-</_8GP
M7U*&.1?**ZCJUO"NST(4$@@\CT]*Y:N>8"G\=5?U\CU\/P-G]9^YAI?/E7YM
M'V5?^'_[*BW3:YJ4I8<)-*A!Y&2%P,XZ\<?A43:<JF*-O$$TRL3B1#!&;?CJ
M"J@ GIS7Q<G_  4 ^,?BN:.:'X>> -/$*!(7O-3FN'"^Y51R?; JEJ'[2_QR
MUAOW=U\+]"C;_6):Z+)<;_\ >\Q@#BLXY]A&N:+;^7^=CMI^&^>;5(QCZRC^
MES[>GT^XMV6&#4GD\QQ&&>WCGDEXSG/   [X.:M3^$KQ(7FFUK5+AE4DHNR.
M-QZ%57I^.?>OSE\1?&+XY6MQG_A:3:?&<X73=#@A5,GMG/Y]:Y76_&?Q.\1)
MMU7XP_$2Z0\,L-ZELI!ZC"*#^M>7B.,<'2ER<LFUY+_,]W#^$&;54I.K32^;
M?_I/ZGZ@+X3?S(6?5-2598RZ;I !;]#\O&!CISGBLW6/$-OX&ND;^W],9F3]
MX-2U".)7[!BV1R/8#(_"ORLU#X<OXCD8ZIXD\::L7&UOM6O7# CTP& (]JI1
M? 'PG;L/,T6.ZQWN)I)L_7<QS7GU..J2^"DWZM?Y'L4?!6L_XV+7RA?_ -N1
M^EGB7]I/X>^%8(Y-0^)WA>U7EI;>/5(-@8G)W*N6;)[ 5Q-]_P %&?@[X2>+
M;\1='U""V;=%;6UM+<&,]P"BY/!. <X/>OC/P1\,_#>EZ@BV_AW18P>O^AH?
MZ&NWU*>Q\-1".VL[6%NRQPJH_3%72XQ<Z3J<BBEWU_R.W_B$.%A45.=:4K]E
M&/Z,]XU'_@J'\+;V_E^SWOCW6$D8O&+309SY7<;/E7!'J<^]96J_\%-K&[MP
M-(\#_%S4@&QF:""S$XQU9B=Q],<?G7@[>-[C?PRCVS6MH/BC^TGV2</_ #KF
MI\85*L^6-E\O^"STUX3Y72CS24I6[R7Z)'I-W_P43\:7C%=,^%.MQQ$';%?^
M(K>* >F552>O.,YS6/JG_!1;XW6:B2+P=\.[&7'EAKB_N)VV]LA0!D=R#S6.
MPXR*XGQ:[MJ+C/0<5EF7$&-IT[QGJ_)?Y'I9;X?9#*=I4$_64G_[<=)=?MU_
MM!W,LK0:SX TD3L6;R-(EN""?0R/_6N<N_VA_CMKK.;KXLW5F'D,A&GZ/;08
M)&.#@D<5APO)YGS'BK4[,(SMZU\Q4X@S&6]9_)V/JL/P7D5+X,)3^<4_SN6I
MM>\:>*X?^)]\7OB1>,PPR1ZF+9#^$:CBN>UOX9Z5JA8WVM^,-89AS]KUVY<?
M0C<!^E22ZC)$_P U137\EP<+Q6<LTQ4X<LI7\VW_ )GI4,CP-&5Z5*,?2,5^
M2.?N_@WX1MR#)HEK<L.GVB1YOSW,<U8L?"7AO31_H^@:/%_NVB?X5KQV,ET/
MFICZ0RGKMKA<K_$[_,]:,5%60V"[M[7"PVUO$!T"1A<?H*L"S6_7=EAFG6]C
M#"HW%2:V/#J6YOT$FTKV^M3&/-)1CH5*7+%R9@SZ&4'RE@?>G6.G212<FO1I
MM)MYH\M&N*R;N]L=)?:J*S#T%>A6R^5/XYJQQT\<IZ0B[G):A;8Z)\P]J;9>
M9(NV1?:M^\U*RU!LM&RGU J@]]#92[HUZ=VK@J4XIV4DT=U.<FM5J9USX9\Q
MMWEL,^U-CTZ.P4Y7!]Q6]:^+LN-T:,/:H-<N+?4L.G#'@BKJ1I\EX3^00G/F
MM*)REYK?E2D1C %0OK$UR=J]ZOZEH:R(60<U4L-.FAG&5XK.+C:YMJ7M/61(
M29&ZUGWBS23G;)U/K6I?VS3VNU3@USLT<T-QC+<&E3U=RVS<TZU;R?WGS5'=
MZA!8/T7-3Z?.!;+N;M4=[I45_P ]ZS^U[QITT'Z5XHVS?NVVGT]:[+1=874(
M!DX?N*\]ETZ/2#Y@#-5C2]>=YQM#(17;A<5*B[QUCV,*V'C55GN>C2Q+.O(%
M<WXOACM%&Q,9/7%7-/\ %$/D#S3M8=:-1>VUR':KKGM[5ZF(J4L12:@U<X,/
M&=&I>2=CS^]\0-%*5$;'%8.HWAN92VS!->A7'@UF)8;&]ZQ[O0H1*0RJ"#S7
MC<KI?'%H]>,E/X6<SHZ23'_8'7-;$-U:0,/NAJ;J4L.FPE47KZ5SJVLE[<-L
M#<FE;GU>AIK'0[:TOH51LJKYZ<UF:W+,D!:.L@VM]:+\I8BKEAYUW"RS'&:S
MY;):W-5N9-OK\T5T%D;C/-7=0U!IU#1*&IDWA!GE+;L@U6U.RFTB+]V?E]:T
M?(WH"YDM33TF>22/]XJCZ5UL6KQ6VEA@>@Z5YC8ZS/\ :57=P374PR-+;CYN
MHJHU94)-KJ$J:JI)]!FL:PDLKLS*K'M7,7*S7%P2LN5SZUH:MX<DO)BROU[5
MDZEH\FF+N9VJ:=GK?5ERNM%L;UC:J;4;]K'%.N[91;LH52,5SUMXB:S@VKN8
MT^#Q5,'_ 'B-MK.5&=[FT:D;&5>Z3))?8$9 )K5@\)PF)2W6JVI^(VN)@(5_
M2HY=2OD@.1U%;2YVET)CR+S)[CPG&3\CXK)U$#2B4V9]Z6+6+F.X&Y_ESS6C
M?B'6K=5#+OH]Z+7-JBE9KW=S!M]<FAD 4X&:['PU>&5HG8Y)X-8$/@]E?<[?
M**U+&X@L0(U?E?>BI*-TX%4HO52.X9E\L?=K#US75M]RH5'J:QK_ ,7+ =K2
MM]!5.XFCUVV(C?FMJV,E)6BK+N9TL.HN\G=]BAXEUW9$?+DRQZUR]WJ$EX/F
M+5<U?2I+.X(PS"K.@V*W3[9(OQQ1'EA&Y?O3E9F+:[EG&-PK5;7YH8PIC9@/
M:MX>'[:W._;TJA>:O:P3%61>/:LG64WHC6--PZF1=:Q<7!"QQLI]A3K9]0C^
M;YC6L^IV=O")-J_E38/%%O*^WY12YG:RB5RJ^LC)?7;RWF^<8&:?<>,O+QQS
MWJSK\<-^HVR*#7.7>F&-OO*?QK2$83W1,I3CHF;%SXP\RU.WY6JA8ZG)J-V%
ME^8&HXH8K.WS)M8FI-+O8%NAMCYS5<D4G9"YFVN9DFOZ!Y2F:,X JCHNH;YO
M*F.5/%=1J-I]NL"O0$5Q=Q&;"]_W34T9<\>5[EUH\DKHU+[PG)+-NC^Z>E9.
MIZ?)IQVN6K0'BZ9%"CH*L0HGB*/=(=N*M2G'6>Q'+"6D=SG89VC;@L*L)JTE
MNORODUK7.C6D5LP5U+?6N>ECV2E>O-:QE&?0SE&4"Y%XEN(GSEB*T;7QB''[
MQ:@TOP^EU:EBR[CTJIJ.D/II.1D&LW&E)\IK&52*N:5QJ$&M?NPVTTV#38M+
M;S&FSCWK!M(I)9_W88&KS:)>7+;6W8J94U'2^A4:CEK;4TQXMA#[1]*BO_$F
MT?*C,#67?Z,VFXPNXTR#6?+^62-3BA48[QU*]M):2T-BPO(;B,R-&J8]:S-:
MU)I9<0R8 ["J\US<7BD1HP0^E4FL)XGR4:KITDG=F=2LVK(OZ7J)F8QSG<#1
M?&UM)/N5-8V[/:EC&H<>M9^H1W$F=R9%"2<@U40FLX]1^:-L>U4KC2I;9_NL
MWTIUE:S//A0PYKK;2Q MU5MI('>G4J>STW"G2]HCG]&TQ;DYD3'UJ;5(;?2E
MW!%)K6OYX["$G&*Y'5[S[5,2&XK.GS5)7Z%U.6G&W4UM,UB*[?84 JMXE'E)
M\BKANM95O<M$<*.:FE>XF'[SD>]:^QY971E[:\;,CT:<QW8XZU:U^*%3NS\Q
MJI)>K;\*N&]:KS&6[^;YFJ^5N7,2I6CR[B1RJ3@[@*L65I!//]ZHK&R\V7#*
MV*+BS\JZ_=M52MLF3%-:M%^_BDMQ^ZVX%%C$US#MDV\TV+3[J> [FQ3K;3IK
M,EBV:Y6URVOJ=D;WO;0S=6T<VI+KTJ.PU:2W5LAFJ74]0FD)4C%+H]EN^9MI
M!K;['OF"C[]H%>ZUEKC(*556VDN6RJ<9K?FTN'[VVJ%SJBV;E%3I4PJ=((N5
M-K6;(9+(Q6V?NFLB?+2<G-:MQJ_VA-NUN:SWM)&8LJMBM*=U\1E4L_A*\S*>
M,<U ?O5;>QD 9B*JNAW?=K:+5C*2=R1;L0C@5!)B9\],T%#Z5&5VTN5+5 Y/
MJ3V]GNZM23V<:G.ZBV3=&?FQ5:<-G[V:C5O<TNE'8>[QHC**I2)O;Y14AA;/
M2I))/)7[O-4O=>A/Q;Z%5HL#FH3UJ9V:4U"1BJUZF3M;085YIA.SM5A) IYJ
M.X&[MQ1?6S&HZ717DYIM2'D5&:I>1F_,C/%(U*1@TC<K0V"L1O\ =IA.*DJ,
MG)J31Z(1ONU"3EJE8Y4U'LQUJGY&:\QM-<\=*5N!Q2;R:(A(C"L33OO<4Y.A
MJ-U8M_LU1-QQ6H6B!;WJ3#"FT$V&LN%IH45)4$\FQ:"25CFHPG-0VY9LDU/N
M% .(UVVCFFGE:>?F7^]33TJ^8S:(9=HZTWSXTI6@+,=U(]JK+3)<;BAUEY#5
M%<S&!-V*6*#R-W-+,GG)@T&;B4)M5++4MC=F88IMQI8VDK3K*$1+[T[F<H$S
MS+&>322R?N_EZU!<6K-*&SG%36[$KR,5=S*4"NLC8^8-30\DAXX%7'7VIHXJ
MN8Q=,AD#;.F:@AT_$FYJNTQNM5&1E*F)39SB%_\ =/\ *G$9-5]2F\JV?GG:
M?Y47,_9G]0'_  1?_P"4;'PQ_P"P>?\ T-J*C_X(O'/_  36^&'_ &#C_P"A
MFBOU3"?P(>B_(_@OB3_D;8G_ *^3_P#2F=IX>N)K?]I'Q_Y5NURK16H=5?:P
M&P<C/!_,5U=QI,D]F"MK;W$>=X>2X*F/'IMS^."*Y3P[9F]_:5\>*LUQ"5CM
M3NB.#]P<&NTA633))$C:&16."LL^U0>^!@_D,"M(O\W^9U3>D;?RQ_\ 244G
MTQX)DN%L[4< B=G+L3U&!T7T)ZD5)%<R)<"XN9MI#;G9<A5'< <G&*M>7<+
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MC5 =AA2+:<#WR3CWJ6;2'CMPZW5TS-C8&8?NR?3CBD+KJ0RPZA<3_O+?3&F
MW*I)*=>I.,DCM2"*^ D;R[/'(E&XG:<<[>,\CUJ::2[D.YE6S90$:1F#$#U
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M?_$4_P"SL5_(_N#_ %TR/_H*A_X$C!HK=_X9,_:&_P"B>^%?_"H3_P"(I/\
MADW]H?\ Z)[X5_\ "H3_ .(H_L[%?R/[@_UTR/\ Z"H?^!(PZ*WO^&3?VAO^
MB>^%?_"G3_XBD_X9,_:&_P"B>^%?_"H3_P"(H_L[%?R/[@_UTR/_ *"H?^!(
MPJK7MS#:0EFVUTQ_9,_:&(_Y)[X5'_<SI_\ $5C:M^Q/^T7J<N[_ (0?PJJ_
MW?\ A)D_^(KFQ&!QL8_NZ3;-:/&.02E[^+@EZG ZWK#:G/Z1KT%5[>V:[F6-
M!EFKO/\ A@_]H@G_ )$;PI_X4J?_ !%6M/\ V(_VAM/;='X"\*>9ZGQ,G_Q%
M?._ZNYG4J<U6F_,]K_7_ (<A"U/%P^\Q="TG^QK5F8Y;J:P]>\0R7LSQ#B,$
MBO0#^Q[^T@^=W@7PB1Z?\)*G_P 16;<?L)_M#3R[AX%\*KGDC_A)4_\ B*[L
M5D^8.DJ5"E)+Y?YG'A^..'E4<ZV+IM^IYVQW'ZU);V<EP_R(S9]*[^+]@_\
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M4B?_ !-7+/\ 8%_:"@_UO@3PK)Z >)4 _P#0*I<-YDW_  G^ ?\ $1>&TO\
M?(?>>8:19M+,JMW//TKM;:^MK2%8]Z]*WKO]A#]H:1<0^!?"<([_ /%2IG_T
M"J3?\$_OVC&/_(E^$O\ PI%_^)KLP^2YGAV^2BVWU.>MQYPW6MS8V"^9QOB>
MQ6\F\R.16SP1FN=FTI8/F ;(KU4?\$_OVBQ_S)GA/_PI$_\ B:=_PP#^T0WW
M_!/A-A_V,B?_ !-<U7A_,YS<E1:N=%/Q"X;A%1>-@_F>0+>SK)MV\9J2\LFO
M$!)QZUZW_P .^OV@MV?^$'\+_P#A2Q__ !%7;7]@[X^VJX_X5_X5;W/B6/\
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M[-^5?O5SC>-V,F/.7->N:Q_P3D_:*U:1V_X0_P )KNX_Y&)/_B:P_P#AU?\
MM%?:-_\ PBOA+KG_ )&!/_B:FMDF:U)M^SDET_JY='Q$X5C%7QE._77_ (!Y
MSJ=_->QE]VYL<5RVH6%UJ+G<OXU]!P?\$U?VB(HPI\(^$3C_ *F%/_B:D/\
MP37_ &@MO'@WPON]?^$B3_XFN6/#N:IW]B[_ ".M^)G"MK?78?>_\CYOM=%N
M+6<-C:/6KVL79GM5C63YN_->\7__  3*_:*NHBJ^$_"2?]S A_\ 9:R8O^"4
M?[1*3[W\,^$V[X_X2!/_ (FJ_P!7<SEK*D_P#_B)G"R5EC8?>_\ (\1TK09O
M,#L[ ?6MJ9&$!53\V*]J3_@F1^T1%"%7PCX3X_ZF%/\ XFJ[?\$P/VD"^?\
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M_'_(^<O$.KR6(_=C-<O?7UQJ<BJV[FOIR_\ ^"17[1U[(6_X1_PF!Z?VZO\
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MCH/YO_(^>GTV&5MVU2:N6*Q6RGG# <5[Y!_P1C_:3@7 TCPB?^XVO^%3V_\
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M*'##=UCH?>_\CX3V[C392!VK[M7_ (-V?VBB?^/?PC_X-5I6_P"#=;]HD_\
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MY(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%?'.C*P1[S0]4AOXHG(SL<QLVUL?PM@^U5[C]J?X9VGQBG^'<OQ"\$Q>/K:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !17Y:_\'2O_!13XQ?\$YOV=/AAKWP=\7?\(CJGB+Q'
M<6&H3?V;:7WVB%;8NJ;;B*15PPSE0#[XK[>^#_[4.B>$?V'/AK\2?BMXR\.^
M&H=:\+:->ZKK>MWMOIEF]W=6D+L2[%(D+R.<*,#)P!T% 'ME%>*_$[_@HS\
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M4@XP:\X^&W_!3_\ 9S^,?Q!3PIX5^.7PKU[Q'+)Y,.GV7B:TEGN7SC9$H?\
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M^"3GBCX"^/OV?],U'X>ZIJ5U>I*MMJ=S<>7<V/V26WNXWF=W24&1MQ#8)"G
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M^-7Q>^*7BC4;F:;4M/G_ -#LX&V[71Q?P227#OO=Y) >2 .A+?L5_P $$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<6^N>(M0N=5U9_#6F64EU<.9)94MO$4%M$68\L1'"@R22<9Y-?3G_!J(,?\
M!$KX:_\ 83UO_P!.=S5#X+?\$IO'GQ)_X-NK']EWQE!;>"_B)<>'KBV:*XN8
M[J"RO4U62^MA)) SJ8V*Q!BA8@,>"1BOC3_@G'\"_P#@J5^Q5\$+K]FOPG\,
M_ ?AWPO)?W/V/QQK5];7 \-QW+EIIX&ANCYH#,TB*8'<,QRI'"@&/_P9Z_\
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M(EBD=,JH*L22!S?@_6O^"L7[:WQL\&V^I^'? O[+_A+0KM9=9U2T@L[M=07
M$F^VEGNGN/EW%(P$0,06<$!@ >4_\'3G@;XU_M6_L]?LV_$S1_"_B;Q)\(QH
M46N>*='T196&GWUS';S"2X1 S*IA9XTF*,(CO!(+@-\X^#K_ /X)8_MKV?@_
MP_I%K\3/V1_'EC?VO_$]N;J>^M92DBEXWN6GF2-FY"W#I#Y;[6;*KL/[%?\
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MQGRH$=@9&Z#"@\LHZL 6M^T9X!C^.2?#-O&7AD?$.33SJJ^&_P"T8O[3-J"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU\&Z3:>*[/1%MR#"EG'J]LL*H>Z! H4CJ #7T[\.?^#3OQK\ ?B!KVF_#/\
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M,;LY.,$ _'7X*>*O$>C_ /!E%XPDT.6X\X7EW8SM&3NCL9?$,:W(_P!UHY)
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M!_P7?_:(U3QEX?TWQ(W@:;7-4TBWU"W2XM[>[?6%A$Y1@5+I&\@4D'!;<,$
MC]@O^"17_!&'X;_\$AOAMJ^G^%;S4/%/B[Q2T;:]XFU*-8[B]$>2D,4:Y$,*
MEF8)EB2Q+,V%"^>_\$M_^"%G_#MG]MSXN?&+_A9O_"8_\+2CO(_[)_L#[!_9
MOGWXO/\ 7?:)/,V[=GW%SUXZ4 ?=^D^!=#T+3C9V.CZ79V9N?MA@@M(XXC/N
M#^;M  W[@#NQG(!SD5>FTRWN;V&XDMX9+BU#"&5D!>(-C=M;J,X ..N*LT4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 QXUDQN56VG(R,X/K08E9U;:NY<X..
M1FGT4 ?SM_\ !TQX'TWXG?\ !<S]F/PWK$*W6D>(=*T/3+Z$])8)M>N8Y%]>
M58BOK3_@[T^$_A?1_P#@D%HK6?A_1['_ (13Q?IEOHWV:SCA&F1-%<1M%"%
M"1LH *+@':O&0,>T?\%+/^"%/_#PW_@H-\(_CK_PL[_A$_\ A5J::G]B_P!@
M?;?[1^R:C)>Y\_[1'Y>[?L^XV,9YSBO8/^"P?_!-3_AZY^Q\_P *?^$Q_P"$
M&W:U::Q_:?\ 9?\ :/\ J!(/+\KS8OO;_O;N,=#F@#\O_P!N'Q1X@TO_ (,U
M_A2-+N+I;>_L="LM5=&.?L0O'(5C_<\Q(%QT(P.AQ7W)_P &ZWP9^'$O_!$3
MX6V>GZ)X?U#2_%VE7<WB=9;:.9-4NWN9H[E;H,,2;=OEX?.$15Z 5[=\#/\
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M_9O_  C$&G0_\)1_87F_:?LD_FY^R^>NW?TQYIQUYZ4 ><?\$+?V;O ^F_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>reolysinmoapanel4smalla02.jpg
<TEXT>
begin 644 reolysinmoapanel4smalla02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!817AI9@  34T *@    @ ! $Q  (
M   1    /E$0  $    ! 0   %$1  0    !     %$2  0    !
M  !!9&]B92!);6%G95)E861Y  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" (; I\# 2(  A$! Q$!_\0
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M%ZS.0*N^<95(]:I2V+>9\O/-!!>TFY9E^:K5U<;!4>E6+ #=UJQJ%IN@/;%
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MI7_@CQ!Y/_!0OP![_P!H_P#IMNZ^:K>;SACK7T]_P2(BV?\ !0GX?'_L(_\
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M%^R1^V3\+=+N_%GB6]^*FJ>';C6I[06,9T<Q2V\J-$L@(D1UPY!.X,(SG:6
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MB7-U<16)9,>J.W^KQV\K9S[U\NZ-XSUZ[^)]D_B-;(6<*E8RKMY0)^Z_))8
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MVM:M::;>V.GMI5GYXDN]P2ZN';9;V:8'^NG?*IGCY23P*XS23OB&ZO8/A_\
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M3TMMIYH-K!;VBQ**^D_^"2+@?\%"_A\O_81_]-MW7S=)/Y5?1/\ P2*DW_\
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MM@L6%<3\.?V4?^%@^'O!<[>,=$TK6/B))<V^@:7<6MP[3S0S-"5FE12D",P
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M-TO28E2)HN6VJN /K[^I-?F7'/%=+&91'#X;2<VN:Z?NVZ;:MO:W1:V/;R_
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M7P/^V-=?#H:;'IG@_0%M=!U:?5M+MGOK_P FU:?;YBR(LP%P?EPCS!FCW''
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MK;\;EO%.A72,TGEVL[S0D _.VT\'U')Y[5\Z-:"&:XFU76ETIKI\1G.UH6.
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MH^#^B1PR^/(;R\3QU\3]/O-,MUDTU]-UJXCT\6SB5(?[1S#+Y4@AAE:+<55
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MKN%^8G)SJ^)?VIM4U_Q%KE]J?A[PAJMKXJC@;6M-N+.4V>IW$))2\(64/'<
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M/6G@Y4DITW[OXO\ R\NI]R?"OPQ\._%-];S7G@'PO+JEQ)Y(E@.XN!@Y /
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M?LCW5C9W#:U,NB:I!;&^US49E#1^&[$9+1 GC[0R@[AV.%Z*^?F;XL^(]/\
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M[CPE+;Z=! VM7(L[9XWA=<>?(,,$))(.57GBOF,1M/(L:*TDDC!551EF)X
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M>I\X_"">\N_A_INE^'9O MI8ZA+=0^.'U@6YO6A,B&!0L[*K6;1@API)#*>
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M!LM/'9'V_*V/^>:80=RU9_B/X^R>/=$NM)\26[76CRNDD=K"Y@6 IG:$V\*
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MDS0L L4(^9BX[#MGKD@5[5JNL>#[SQ3<:+?W^GRR>&XT/]D6TJ.--! *RSQ
M@[B"""1@ CN:^OR_B+-I1]FJG*EILE;YZVZ;6>I\KC)4*=1Q4.;3?=V\E^K-
M3X2^&/ WPG\(;O"FDR0/*"S74T+RR7)[GS'!.">_?KBM2/4]:\7W%U<-L;1K
MR%HI[.9]R3*PVD*V 4.,]017#ZU\:?#_ ("N\1W&H2"$#R1;V\C,_'3# #]:
M^>OC5_P5PTC0;R\DT&"P\1:H$\JQM82WV*U/>6ZF! F;_IG$"!W>L<REF>*J
MQ5"?/-VT^S;^9O6UNE]]M3RXX%/WHQ^;W].GW]/(E^(/[/#_ +*USJ%P^K--
MX6U;SI;(S ;[.Y8J0I !*9"KN9>#L# @BOGWQ-X!\2>'/&6B2Z+XHO=<B\:7
MUK=W<VH67VF;^SG@NK9[6SOTB$5M(@G>3;&0SAY#F,YS[OH?QMU+]L[X)6=[
M?Z;';QMJ;V4MO*52221(T8'3V) D,9RQC89?<RY#*IKR_P",7P^\2?"_PC=:
M7_R$_#M\XG7S;1[K2[H]&AN(%*G:V 2G#J0#@D$'TLJS+$8)QP./T2=XWOIT
M?>ZT7?2^ZT.G%9;%477HOFFTXRY6M=;I:VL[7:O;WK.\=SYR_:MO+WP5K/@W
M5M%OO#.N6NO1QZ1KOV LFA:CJD$5O]MC1U(_=^;(K%D.%D!*,,#'S/\ MA_!
MN\_:$U%I-:UJ33[719UN;31+&2410W@PDEW/<R.TUU=,$6-99F;9&H10!7I?
MQD^#/[1'Q_\ VC/!?B1=/\+7WA#X?(^DZ%X8\,6PL;+1+!R')C4R%FFW(@)D
M4 C/0UW'Q,_96^(VH74UUX>\#Z[J5PKDF*^>U38SDLV8HY"SE<G Y_0"OUC!
M\0TI8+ZE6Q47!M-Q]HE%O3WN7FM?;>[T78_",VR[,*&,E/ 4*D82;=N26E^C
M;7ENK+7L7?V"++P5HWPXAM=0^'VB>(-4M[DL]]J%HMT\I!^4C=V![8QQWK[-
MLO'2_%#15T>\T6*33]/"K%!;I]G^Q* <",I]WM@8P/TKX,^!UEK/[/OB]M/\
M0K<Z)/M$LMM-;D,L9)'W&^8 'HW/%>OZ#^UK)X3M9KR9K>Y5GPT:JWES*/\
M;/?K]T9!'O79BLKIXFC:<5)/^M'T]4SS,OQV-P%7V]&;B[O9:V[.ZLUW3N?1
M-[^TYX/\,I_PB,VM:]:ZC#&&6.\LW>X4-]U8Y8\*W.,$J/<5\Z^)8_!_A7XH
MM#?M/#J4C;@VGRF*)B26\UD(^]S@CA20:-3^-_ASXE>+?#^IZ3]NAU)T:SN9
MKVP:*-H>6 W;V#%7YR,< 9]*\1^(WAOQ;J?Q.U:7[#J$EG;LCM+:HSK(%R-V
MX'/EE<$CIR<XP17+EN4T\"G&DY6?1O1>FFGWLSS[.L3F,HRQ,8\T?M)6;O;?
M5IM=-%;4^OKWP1H_QO\ ACKFD7$EO?7EK"\FF7;QJEU9RH/W;YZ['/RL.A#9
M[ U\=I936S-'*C1RH2KHPP4(Z@UUG@;]HF3X52M%?:6TUY<I:V%C>6]P85A
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MJ1_,*DNAF(LOI3KCPYJNF^'+/6)M-OHM'U">2VM;YX66WN98\&1$?&&9=RY
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MIF>2,.[/R>%$6 !C.:\M^)]Q#?Q^'+W3+A6OK56T\J[*[,5!SYB8P 5QM4C
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MTKFIU2*?Y8UX.1QTHW+J4.:5V_Z_R_4CTR&2:[FFD6-7N)&D8)&(T!)).%4
M*.> !@#@<5Z[^SW^T9XJ_9B\8+K'AF\55F 2^T^XR]GJ<0_Y9RIW[X889>Q[
M'S*P=63++C%:",)8NOM3\C7V<91Y9;'ZN_LX_M&>$?VLO#;WGA=S8:]9Q^9J
M?AVXD!NK/U>(_P#+:'/1EY'0@'BNA_X2B\C^)L?A_P#X1G7&TU]*;43X@'E?
MV:DPE\L69^;S/.(^?IC&/<C\?]#\8:M\/?%-EK6AZA>:3J^FR"6VO+60QS0,
M.X(]>X/!'!R*_0K]D#_@IOH/QX-KX<^(TEAX7\:2;8K?6 !#IFLMT E[6\Q]
M?N,>A7[M95(RE;E=M?O\OG]YY%3"1H.<^3VD6FE=M.+>TE9J]NB=UW3/I,A8
M59G9(XT!9W=@JH!R22> !ZGI5RT+02+)&Q1EPRLIZ>A!%97Q(^&UCXT\+:QX
M7\3::M[I.M6K6=]:2,RK<PMC(#(0<' (*D=*TO#&@0V=OI^DV,<=K:VZ165M
M&"=D,:A41><G 4 <\\5/O\]K+EM\[^EMOG\CS+4/8*2D_:7=U9<O+96?->][
MW37+9))W=[(US7H=*TZ^U74[S[-9Z7:RWUW<L&?[/!"AD=\+DG:JDX SQQ7S
M#^U7\"?!O[7/PAUKXP>$%\3?\5'HDVD>(SI5H]EJ]W:0SQL]W#'E7+A8O+E"
M,#+!(<'<N#[%\"/VE]$_:$?Q1-X;TWQ)IL7A2_%C)/JMNL/VQB71BJ?>0AD8
M%''*D$$@D#M-/U*31Y[=[,0V8L^(([>)88HADDA44!0"220!SDUQ)QQD+TY7
MI--.UT[WZ/R]#W*U*KD=9T<52E'%PE"2NXN*BX\UI1L[N5XOXM%=-7/RE^-'
M@_4/'?@+PSKOAS3;I_"?AW0!;VUU?748U*^MDE<FY^SM(\PMT+A5+$X4 \+C
M'FO@?6['2O$D%QJ4+3VJI(ORPI.89&1ECE\IR$EV.5?8Q ;;@D9K]#/^"AGP
M"O--^'NK^.OAKX7T0-<Z8=,\3+;P/]OT^S.<R0(#L,.TLK87=&"2.,[?SC6R
M4JK)R&'!'>C X>I"A+#U4E%74;-WY?-]_2WR/H,5FE'%UXX^A)RG*TI\T8V]
MHW>24=4X^JL^UC<\1ZQ9ZYXFNKJQMUM;60KL01+%DA5#/L7Y4WL"^U>%W8'
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M<JG*HSE?FIV=WR:V7-LW:]O)N_#^/+3PWXIT^WLM4TS3_#]NO""&R2T:!B,
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MO$$D>1UW]Z]NNOVB;GQ1\&]4\;:'XCUKQ)8:WJD&GVVC7D'EQ^%!%ES%L P
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MJ:UN$\GQ=25/!8A-QWM9V?9V>C\MSZM^%G[./_":Z:)M2O%M8MH(AA(,G/\
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M59$FG6\JPJ?:M?Q=\1)-;\.^%=+G@CMT\*VLUK!+&QWS"6YDN"S>A#2$#'8
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MB_M=.B\CWLRR'+,(U"CC%.,X*<>6-WS-V]G47-[CNI-N\M$G;73P?]G>XNO
M_A?&GZAJUPUU(98XIU7Y3RO'/!XZGUKMM)N+NYN;6^6XNHX)[D_:K>5%/F]
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M5IQ_9]Q$A93;1*(D)49*DA-V" ><TGBK7]"?P;))</Y&L!&:21Y"TDDA*[5
MR<KC<<@#@>HYXGPQK+:VBVLEPODR/\JNP!&?3=W]J^<Q<<3@Z,5)QDIVE:-]
M-+?+^O1?6Y=3PV8U:F*IJ5.='FIWE%*ZNI-KHUHM;K[FFZ/P%\0O\1/&-KX?
MTG[5;7EYF&?RV,1=.K;SQP/?H*]6\4>*-/\ $FKN\WF?\*W^'@QR<)JUT?\
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MT5;[1-#T^5U $(!W*?<@\5Q_ZQ8>^D7^'^9U+)L1'W9V3_KL?"^K>']0U.W
ML;&[O)&X AA9\G\!6Y\-/V4_B)XP9;AM'?2[64_(]^WDEA[*?F_2OO6VN=+\
M/> [>STF&PL[5?E M@J>8?KW_$UP-K<:EXR\3M$LW]EPK*(A/.K*SMQ@(O\
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MFI[@;R\GD_?L2,8)Q@+C[J+P/U/'VWB#P;:?#SP_JFC^9HEK>VJ1P70^_$5
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M#[_PW\(-=\O1+6'2]-,C"6Z<AYF/7!D;D*., '%9?C;]HR_2_P#,BN)&M6)
M?G('OVYYJ*N#YZEL'%RCW:L[>BO;[_N"-3D?O6]#U'QC^T;H_P /P+&\GN$O
M(QD\']Y^)X__ %UP&O\ [15U\3/#<G]@QW$EV;J.)X]F90I!P5QU&<#-8/A?
MQ_<?$&[:&ZCAO--C7S+C[0HD5$SC//Y#'4UTVC:QX=^'"I)I-C)8V5X[%A#\
MTTC#J">N,'@=*Z:=/ PH7<).M==5RV]+)_GKUZ#JXCFE=.T?34[K1$U;2M"B
MM;B"X-_Y6)+L*H;=U\M6Z[1TSWK#_:'\<6>GW$BKI&LW!6W262<0/Y".ZABI
M?!!(YZ=*\X\3?%"2/Q!*EAJ+2*"1AF,A5O0D<9_&J_AWXJ:SK&H^7)-<1V=N
MW^E3$XP,XPO9F/8?X55.A7I-5\30;IOO>*^32[$5JRC)13UVO=.^Q0^'/Q?U
M3XB2S6,,%U+:V/[YH[=3)(V&P%X'<_I7>7&L^(IWCN-0TW4(WMW62"-<*P']
MT<\8XX]JMZ/\0=-M-/U*&%H=*:XCRDL$86260=#*X&6STSV]J\TU3XC26MPP
MDOXVD>0GY9"S-SQ[5G*+K5)?5Z;4;W2U=EZV_$QE)*"=65^FA-\</%_B3Q5J
MQN[O3+[3LJ/WL=ON#>I<C(!/I6-\-K:\T3X5W5YI]IJ&KZEK&H/:O+# SLBH
M%*H ,XR22?7BO5?ASXQDL-"GU;4%:38PB@3.TRR'G'T Y/M]:Z*R^*.DW'AZ
M[LY)8[-[W,R?8U$,,$G\1;&.#^=>KC,WI5L-'"T\-&$E]J-[OUOK]]]>QC'#
MT]*T)7_/:WX:?<>)ZGH_Q$3P-J$>D^%]666XB5XT;:LDK!@> 6RIX/H:R_AA
MX/NK_?<:UI-Y:WFF9DN(;R$QN HSLPPS@G'/<5O77C1)M:DC>\97C;*%,_-Z
M'(KWKX5QV?BOX?K+XE6.2WD5X[:21]L\Z#AL=]@/&3U(XIX'.:^"P]7"."2E
MO=.ZNK=^VWF$XP:33=UI9]?Z_(^4]0\6>(_'?BYK73])U#4+AGW,88F9?QQT
M_&L^T^'WQ4UCQ??MJ/@_5;2& E$<A?+*@D*3R2ZA3G&.I/J:^P/B+\6M"^'?
MA5=-T>.UCAV9VV<>W:#TR0/F)]^:\HM_B\FL#R;0SK-(>KN..:G*<TQ. ;Q.
M'AO[JDT[=].E_+4PG:53FUU>RM_7Y'-:3X(N?A-X9O/%6I6[BZL;<_8UE)SY
MK?*'*YXQDD>E=U;>,=,\9:=:I8R:2VF:ZT5IX9OM-M)+JZ-VIC$OV]M^5YE4
M.I4%25*;@#GN-)\%VOBWP!CQ)(39S'9$@&][H=6&?0>O:K7PZ^&>@_!G0[IO
M#>AZA:V>I-YDC3W#2!FP1O56^56VD@,H#8[XKQ,UK3KOVSF_:7N_^#_7R/5R
M_$4:,I1Q-)3IR36K2:VLXO6S36NCO%M)J^GQOX&_:@\/&#Q!X1\61ZPQU2\5
M;F;2),2Q3VYE3:P+()8"7?Y XR50\@8/LUQX07XLZC9WJVLNDZ':Z=;V,"W!
MW3?9H(PH:0_WB!G . ,+DXKT#7[7P[:1M9KH%C9\[Q^XB6/GG( '7O4MGXET
M.7P-K#7$[6\UC;NNPGB6,]=ON.ON*]3%8_Z]B%5A35.5E'1Z66WEZ&'UJO'!
MK#SJN5.#<U"W5I)M=7HB"]^R_$/P%#H,?BZQ\/:;;G-OI>JD"UU$%?+W>8<F
M.=1RK=.QXKL/V=/@[%J\VO6/B[1;I[VS=4%Y+.6A^S1NJP22$$,K#Y%#XY&3
MDC<:^#OBU#?^,-1D_M:^FLO#_F>5%:Q';<W2>[=(U(QT!8YZ#K7LOPE_:ZL=
M-T/3/"?BC6+[3]-2VCT_3-2M79FT6-3\GVICEIHAW Y4$_>&173E_$$*<HT:
MSUV36WS?Z[=SS\W\+<TK49YC@H7^UR?::M=N*_\ ;79OHGHG]>>/O@1;^$?&
MVM>*-#M?[/UC6%5-3U)[E)&MT4HTK1+M ^?RDSERH .%%7;/Q!I^AV=MJ$>J
M7VN2:C:G[##:$S_:TR-PBQ\H4=SGL1STKB+SPIXDL_#,VJ>'];AO[*XE1VL]
M+O?M^GZC;[5+RIG*G+@@JN,@D$ \'V3X2_%^+5]?ACDL+.X\/JF(?(TW;]F
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M$?M?_'WQ%\3I(]8^#$GA[QQI5[:M(IT9H]3U**=2"8Y[(LLD< 3HP4G=P=@
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MOX<+-X=UQ6DP[07MQ"^1Z88Y!X[\USE_\-/%VF7;+J7AS4-,CP&#R0G:I(Z
MC(KZ<U+XV70LY9)),B3YM[R\#Z5R%Q^T1#IFHMYUY)</C(MU/#'T;/;Z5\S4
MS+&XJ*EB6Y6T6KLO+6Y^CRA1MRN3]6_^ <1X]_9<TOQ38^#[WQ)KVI6LUOIK
M,^E6N(9)0\K,KO,<E5VXPH&>>HKJ?AW\)OASX/&_3?!_AVSF7_EYGM_M%S)S
MDDR2EB3D=?6M/7O$-C\9S]KA6.UUQ8DV.6VI=!5^XP[>@(Z8 Z5YKKOQ0M[K
M5'TN\F739H,Q2J\0#*P_AY]?U]:TPM&OB:JP].5KZ;V7G?U_X!<:T8.^E^_]
M=MCT^3X6_#?QUJ31_P#"%^';K4)VW/+%%]GD#=-VZ,K^73BLCXW?#K0?BQH7
MAOP%%JT_AKPGX9U%M0O38+NFOW*; @<G"XRR!B,?.3SBN#N?$S16K0V6K"&1
MLKY8V@/_ "/O7+IKE]I2W N+F9IC@^7CC@YQGOGG\J[L1D>.P5JTFFMKIWMZ
MWV^[YA.M3<7&7^7Y'T!X2\3:#X-T^XT?PU;P^&[2Q_=BUMX_+DR!U9L;G8]2
MS$YJCJ/Q)N6A6UFN+B1V?AI9/+ _$UX[XZ\87&M_#\>(+&:>WU#0]OVCRSS-
M #C/U0GKZ9'85P]K^U#->S_9]0@M[N-R >0C9_ENZUGEN6X>O>6)FXOTO]_]
M(4LR2LF].G0^H!\6K?2=1M1'(UY;Z7_I!D?E?M!^0.F>ZJQ /<UCZ[\68/ -
MVS:DMQ>6^J1-+:7:-A"0>0WH1W'XUX?9_$>U^PR+O96VD)&7W *>?\*V-:FU
M+XX_!V32M#CDN-?TV[BN((8FVM(I.QQGZ$'\*QE@U&I[._-&_P"'?RN9RQT:
MEVEKOIY=/N/3;?4T\3&*ZCNH9/,8DQK)\H &>O?-7]8^*,RZ)>0V^V*&Q5(X
MTDXDW,26<CT.  1VSWKSWX>_LI7.BHLFN>*&M+V-@##8 %D;N"QX)'J!7H%Y
M^SCI^K6<UO#XHUQFDC"AI8TF"_CP375F$\JG2M1A*,U\UY[O\C:-:LX^]9?F
M9=E\2Y+C2#JB3-<+:X^UQAOF"] RGV. 1TP<U:TO]HNQCO)AI]U87C(^WRKA
MC'(P[_[N/<=ZA^$/[+FI:#XHNH;K6K:_TBXMYH7EA!C8 H1RO8\^M:S?!GP'
M\-]24Z?H%MKE]:X62^U;_2)IF'4@MP!GH *Y\-6P=.+^L4E43T6Z:_R.VG5F
MVNCM=OIO9?,P_'GQ^E\2:79QV6^Q+R.7!<-DK@ 9].O\ZL^)?'=Q>?"K^WK4
MKOTMHUOU7DX8X5Q^/6NNAU6QOY&AETGP_!;M@^0EI'D?7 K8T[2/"^CZ%-+=
M:7ILEK>2I=&U&8UN!"^X,1G&W=QZ'%>6ZM!5TN1J-[VWT[-_J=$JE2;ERZNW
MIJ>8>$T^('CW2;6Z\.Z+?7D(RZRS0(ELW?AGQQZ8KTKQ3X2\;:MJEE>7MSH6
MFK;01P^5]MR,@?,%QGO5;Q-\?;O4YI%DNH;&)A_HP=]JNO\ L_3]*Y*\^(<$
ML;7%U+/<&-OF*2#Y/P/6O4Q$JV9U5#"8>,+;**UMYNZ7X=3EE4DW[.<G)?UL
M3?'7P=XNLM-TG5_#UK<:E=W$_P!DO+.SD^\2/EE4]!W!/N*=X3^$&I:8L=]K
MWB-M)N'3!M;)OM$L!]&8G;GU'-1I^U$ES<W5AI?F0VNF:<T@,IVR33,R@\ G
MY0IP"/>J>A>*8?B/X>O-0L?._M:SC:5K16&VXQRQ /\ $!DXZ''K13QV-PM!
MX/EC%W=VXIR]'>^WY'1*I#FYDV^VNFF_F=EJVF>%;\MYEUKTLV%)G$R(00,$
M[=N.?TJ8^'O"OAF2#7/[-GU;6_)V">XDW#9U4^6.&?W->0R_%ZW&E2(FH+#=
M*666-75E3TSQ^/6N%\0_'&?6+V$M=21M%A0(R2,CC\C6E;)<9@Z4,2IZ371Z
MZJ_9;^1SU,9"+YWO_7Y'T'%\>(/$+/;)J4,:PN4%H_R2;NAXQU'\Z]C_ ."?
MGBVZF_:O\*VUQ?3-'>_:S' \+?,!9SM][IQC]*^(_B3?VO\ PA"^/%DNK*?3
M9(X+N:TB60S._P L;,I^\<\9&#R.>*^A_P#@D5X+\=:_^UKX,\5>([V&QTQ1
M>M;6,R_Z7=*UC<*K%>D8^;=SR<=*Z<NP67NE[7$3:J77*K:-]-;.^N^WJ<.9
M8Y_5:L?B<H2?HFGOV_JPOPW9;%;?4M:VQR7"EH[)ARR>KC^Z?3O7:ZUX^TT^
M![NQM6M],6*,7-O!"JV]N%4X8= ,G.0._->7'X;>(+6Z:\U35-)CF9LM&KO)
MM4>X%</\1M"^*#7_ -NT6#1]6LTR%MH+I=[+T&5;!)[\5\YAZ-&M6C&K4Y8-
MZOM\NYZ7M)T*:LF_ZU]#LM1^--SI992[!LX"A2H(^M=-\.]9_P"$]BDEUGRY
MM%"XD\]=V_/\*9YR/4=*\M^$D6O>/=>FC\1V'V*"Q'G74>.8@@SM^89'I79:
MG\2X=6O=MO'N6-0D<,*_)$@X  7L*[,RPN'PM=++ZCEUO:UG_76R.6C6>M5R
MT[=_4]8\,>!_#WP_TC4+S1[.&;[4@)ENYO-E:+DA?11D8Q],UY]XJ^*]E=R2
M1:AHNCSV\QV[6MPBD?5<5YAXX_:DDT>_FL+B'5+2&W&SY8&CRN<G+XQ@^@YJ
M71?$VC_$ZV1H;J<I(-L$<0)ST//ISQZUZ]/AW$5:+S#$UXIVO=R;??==?)79
MU3QU/V?+"U_E^NIV.G?#OP7\6[B&TM'O-"N0=D)MYVD4'_<?/7V-=IX9_9UU
M#X>?#S7[2?4-.M9VNDDBN8P6\Z(+@$J.1U/'K6'I=M:_"W3EM-/\EO$$W_'S
M./F^S+_SS3/?^\W7C XZY/B7X\Z]X<D2S6]C\UXF$N1G>A.=I].GU]*\J.99
MCBE]1C4E4B^CU_%ZZ>>B&O9PM4G[LEKH5?%GP=CUC09K7_A-61F;<I-D1M/;
M^+L>:X^^^"_Q.T@A+/6-$\2:4F6>2VW+<LOJ8V[X_NFJ^J>.+25))I]4M(W<
MY6+>5+'/W<_3)S[5ZE\ O#7V>WA\2:M.T6G[]EG LV[[6XZLV/X!^9-=L:F9
M9.^5R2;UMH_^&9BY4Y.[^]/_ #.-U30?&0\':;I?A?PQJ,ZW1::YEBA\L,X.
M%!+' 4#/&>I-7;GX2?%:;P2IBTFS74&(*1OJ4*-%G )(SU]J^@_&OQ^TBS\.
M36-XT[S3)O@\HA0#G'(R/R%>"S>.[R75&:-KB-=QX+E?,^F>E>=&IBZM1X[V
M?,KW;:;5[WUM9?(<I1EJGY?\'^NIY?KGAOQUX"O4;Q!I4VCHL@6WD 6:&5N^
M'3^(^_ITKK_&GBJ^\/V&BZ2RR-=74*WC(BER[MT(4<\#C'UKZ"^#'C)M0T*9
M=;LXKC2[H^7'',0S7!Z%E]-O][L:Z_Q'J>@Z'H$WE_V7I]Y:CRHC'$#*Z=AY
MAYS[9KIS3/L1CVEB-ULEHO76[N_F1&$X[/1Z7[/^O3<^1/$VI>)O[!M[>S\*
M^(+R?4)50F.QE4"+'/S!3@$X^M,\/F[UJ-+6_P!+6RU"!\2PSQE9%QP JX&!
M[\YS7H5[\1M4\-^(I9'NI/L\DF=N3E?\*]T^$GB"R^*$,::E:1:F((R=\R#]
MPO<[SR,>N:TP?$&-P-"5"A:,9=;*^O9V_KH7/#S2O=NW=6/!O&NJQ>$?#N@V
M,I\O;;F8QG^*5V.2??@"O%OCC\8;SPKK$+6=O')I448 <%<"4_>W \YQTXQ@
M]>M?8'Q ^&W@[QKKKK);W&H_V?N5)9I#'$@SG&%Y_$D5R.L^ ?AM<:<VDWW@
MK2;B)N"QMBS-_P #))S[@UQ8',E@\0JU-<TE_6FVQ4J%24;WY7M;_@+O]YX!
M\$-7U/XR^(H_MB'R]HPT3;3",YR<<''/!KVOXK_%&'PIHQG\P^39VXMX S8V
MHJX'^/U->D?"3X5>$O!7@>\7PWI<%C"H9[EY3NDMH\')#=2!^E?/OQO_ &6O
MB-\;-9M8]'6RL_#;#>+V_G\B%\GA@/O/QZ"M,7B*F.K/%5GI=7;TZ:?AH9>T
M]G%P=W/HN_>WX.W8X/PA\5Y+ZWOI)KQ6PQ6./?D  9/&<#)XSWSBNX_9S\*:
M?XQUV]U[5GN%L]/(N)(F^7>Q.%0'W[_C4GPN_P""=.E_#_6/MGB#QE'K"M@R
MV]C"T:Y&,#).2!]/2O;O%_@?38?AM):^$[**SCLV620]9+D@'J#SW.,C%>AF
M.=0Q>%I8'"*W(M?-I=%;U?S^^:-"K3G&IBE:*W^>FO8L^./',>GRW]^D.O0^
M=8Z?:'[1-C1GB EE4V:9QYJY*S-@8)4>M<A??M$0V<-Y=6,.EV=SKCP'4;R.
M,F341#$8H2QSM^5!M&,<=1GFO!_''Q=GMI+BQU(^5(RON4C^'TKSS6]<O+CP
MZ)6DOIS*-T,"-AE';(')[=JY>'L/EU*<JF91<VM8JVEWO?N_73N:9CF<ZE64
M(72Y8P:3>JBHZ/RO%22V32MLCW/XI?$[4H?!JZY+J$,EO(H>-$B/EA3*8MID
MS@2[@6\O&=GS9[5Q_@+XEQ:QH5SXJURY\O2K&<VUG9PR?O-2G507/^S&NY06
M]2< D5\QR?#OQUXDU1KJUTF\M;56W&\N#]G7TZN1N_ &O<O$WP#U[P7^RAX1
M\0WL9^PF_O+&YGC8&*XFD/GQ[,<@A"X;<!]P$<,*\[.J=&?.L,TE)WLMXQ[;
MO^F>[PI@JT\93JU:,J<-DW>SE9NZ;2W2;2UV,;5/%LWQ$\7M<7DUK;QR.=BJ
M-D,"D]%'7\3DGO5^ZT>U\0:A]GTN&YU%H]REK>%GX7&YR!R%&1R17+>#/"4V
MN:Y;PM_JY74!B=JG) X/<\]*^C1\.;/]FK2]4FCO[>:&X8V-Y>1Q.T4,ZE60
ME\*X4,#D+G.<X(%+(<AIX_$KVD^2E'>6B2Z_UMWN?4<?>(SX=PRCA(^UQ$E[
ME.*NY:I=-O+1WVMJ<K\+?VA/&O[->D36OAV_M[_2YW>0Z;J$#26ROP#)&%9'
MC<X .T@$#D$XJ'7_ /@I-\4/%TT-O8ZE'X2N]-NQ?1?V+ 8VDD"[<LTA<L#R
M2IX)/.<"NDUWQ%HGQCAO==L7N)XY)22LI5IG8\%B0%^7(.T8R%P.3FO+_&OA
MRUL-2AU/3K-II(/EGR"HQW_PKV<YH^RI5,'@92;@]&G:]M;;[/HUN/A_!X/,
M*-/.\RPD56FDY*45)IM:W;BKR76Z[J_4^@/A%_P45^*$?B72;?Q-8^'[J.\N
MXW_M1M&2.XVAAOY4A<D<AMN0:Z#]ICX47S>"+C3;2ZFC"W$LE[(,R/*H).22
M.^<[CUKY]\9_$A?"-K;-'-:31SHIA)'^I!'4?3IFO7/C[^T?K.I? ?PEXVLY
MXY+F]LI]&U!6(99+FV1&61EXY>$@\]2K<U^*9A7Q^:TX59N[INZNVU;9[]5I
M^)]?@\@I4ZU"OE6'IT^>33Y4HJ32<HW2792L^]M-3XY\511^"]<:UTRW^4$[
MI9E5F8>H'I[FMKPC^TIJ'A2R_LN"XNI!>QF&X<%?W"Y5MT?&Y6!7DA@"#BN<
M\9>)9/'>K?VH[22S3@ J/E11Z #T]*X[5K.2WF\M89"S#CC:&'U[BOL,CQM>
M@^>E4<)-6=F?8<2</8'-L+&EF=*-11:E:6MI=SWW]G;0T^*$NJ:A-$LDPF:.
M"W0[D&<DN?\ :)Y-;GB;X,3:#<+>>9'"/-",%8+G)]/\\UYI^R-X^U'X2^)9
MX_LLA@U%N QV[&]\_ED5[/!%?>/=1DDN)+<0QS"1XU;<Y;/?_9[U])[3#>SE
M3C)6Y5IUOZ>O7YGQ].IBJ,W%K1=;?ETM8VOAU\+=<M=9TEM)NK*WL?M:OJ"2
MQ>:;F,?PI_=;WXQ[]#J_!_X]ZQXM^*UQ\-X=>?X?^*M-^VZZ-4U"Q35H- 6(
MAI(YW(C\F*.%9P-RR*YE4!Q\I/KG[/OA.1+ZS6U#>:PVG]V6W9ZURO\ P4?_
M &L?#?A?]F+4-$\+FSM_%7C&^&C:Y']F47$<$',JRRKP^2L:J0S#:2.*Y<'A
MZJBY.-U'=]O7U/@N),\@JT<-)KFJ.T5YZ;)WO;>Q\<_MK?'35/VBOVG]>UG4
MKFVN+#3)6L]*2"99K5+5&(C:,@E2'_UF1U+&N4TW]ISQMX3^#5YX1\+ZU>6N
MF^*A)'?VX*9A#Y0QPDC=YTRH00AY4!0"S<<5+J,<QO-K@2//"J^N!N8_J17K
MGA>_T;X8P:+XJL[6-]6M[A;V2".,R-)'&?WX3@XD,+NR!1D%..M;8)4:^-HP
MQ7NPE)7;Z*^K^XWS3GPN15982GSU*<&XQ7VI*-TM>[W>_3K8U-"^%5I:VBV^
MLV=WHVJB$M-;3IY160+EMZE=R,2"=I&<_E7GWCWP7K%K#(VF73B#'R2&/>4.
M?O+G@GZ\ \XKV4_''0?VAM#TF2P74+:.UM4:07T@DN+@O\QESR1&QR0"S'+-
MEN@#=<TQ8[55CCWC!V@#&!USBOTC$X+*Y8ETX)2IZ6=OQ3W/FN&\_P VJ9?3
MEF471KR7O13^'RNOOT];GS;;?$/Q-JGB)=%OM0UG5]-T;3(K>+^T'5O)<%.C
M  L2B(N3D@(HS@ 5I3V5EK<2M-&UK)G@$84GV->@?$GX>16NCR:U:QJ@M)4\
MQL<ON(!!/?J/I5GQ/I/@>?\ 9XM[R"^D3Q8\FUH-S_,WFX92FS8(Q%AA(&)+
MG&.P^!XCPL,!B8TJ&L))6[KO>WGU_4^LRY2G1:EO%OTMT2_*VOW;>5Q^%;.]
M\46>DWUXNGZ/?,3=W:1&=K%5!9I$0<N^!A4&-Q(!(&2/O+_@FG\(?@+I7BVS
M\2_"VRUCQMXR6R2*\&OW8M]=T,SW*022QVR@6PM5A=V>97D;HN5W<_ L=O)H
M\,-V&5A;SK)M)W*VTCC/K_C6[\&?VC?B!^SW\3]2M_A7:V=OXR\6*GA[3;PV
MZW,EHDTZ'$"N"@9R(QO93M4' R<CAP]2]HK[SS<PC.I3D[ZQZ/;YVL].A^PW
MB;X,Z-K'BVQ\436,D.OWT2R3:9J*VS3'=\GV=]I:-2 =I=2W.PECMKP7XF?&
M,_$"SU32/#^C2:+:Z'<3226T=FL!OV$A\^[;8%QE@'<D%B"K8YJUK7[$-U_P
MM*Q\=^,/%=YXX\3:3I-G%9Q,K6<,NJ0VZ127$T\(+&-V5V6-55-S$D$G(\S^
M,W@3QAIMMK4FD;O#N@PWD]U!=ZE;9N-0.#S&A7SF9@,$C&0!NX&!]1E^<8*K
M/V&<N510C:GVB_DU]UMM-K'Y_/A/'X?%T\=PJZ=*52IS5KVO)):V3C.[U:3?
M6[U?,S#\7^!K?QYH=P+B%I#L+.68 [?4>F!7S[\2_@I8Z9/*ZZ@M]'(J&)Y8
M>".1@GKP,=:P;O\ ;&\;>$M::/4XX[JWS\PDC"E@?7.#BIM1_:(N?%]FDUII
MUF1<2+$8PP5F)//?H,_>-=$,1A</\,XI=-?S1^GXC'5ZDO>B[[/3^OZL<=XD
M^&$WA2]6UCTZ:2XN,NT[/F)1_=QT''-?0O[-_P"W%XL^&/PY_LE]-TWQ7X>M
M(#!!97SR)/;Q#ILG0[@H(X#!@.V!7D%]JFN:_I]XS+:^= C6RQCYE91R2..2
M5&,]Q72Z1XB\1?%3P'JDVDZ)H</]B0BWNVL(5MFDX9ERN[YG(#$[?X<'&*^5
MQF95*F/E+)[WO]G\=.QGC*.48G +#Y[&,X7O:=K+HK/=/5K1IZV/O[X+?$+P
MA^W3^SD/%_A":'0[[PVDEIXDTN_E$]QX?NEYBN8KA$64EVVE2Q"D '&5.*NB
M?'K4O#NGVNN>,=)MO%%DUTVC-?Q6ZK<PR(@,9DP=LOF<XW <@X.!FOA7_@E5
M\/;\?MC6NK32:I8^$9X9])\4BVD*Q36LT4@4RK_$(9 DW()79N'O^E7ANR^&
M_P +[JY\/>/-/EU705U(WNFZG83+<6<O[H"-V91^^8+D CY2&/H:_3N'<ZE7
MHMO64=&ODC^2/$CA.7#^<<F%:A2J*\;WLM7:+WT5M'O9[]2'P7\*M/\ BCI,
MGB*V75;..Z_X]K"YC59(N^589(4C[O0XP>F*L:/K>F:7I[>&8-4LVM;"[^U3
M6=FC22/M4H%*,0NW<1N.220#@=1YS\=/B5'JEC)XH^VV7@GP+I$K06>J:IJ<
M>GK=,1DEI790\C;>(X\XQBKWP6T_6_'&MV5OI"Z7J5WH=M;^(O#NHV+PM_;-
MD\GS S*VV1-C'YQN(+8;IFOJ)9BY1M4Z:VOMZGR4<VEH_9-IO22NDW;5+372
M]DV_Q/4M1^-^H?"'PO-<QZ38-)=,L;6T2'[1;A\D%!C+&3#,-P&W')Z$ZWP1
M^,.K:C\-=8U+4K.ZMM)OKQ8)9+C#W-Z(LL0%W;56-" 6 '+8_A%>$_&_XW>!
M_P!DW3==\1^*+RYUC4-4O7%A'8;9#>S$EA9QRLOW$4J78 ("PSG !\=^'W_!
M9:'PS\)VBO?AXTGC1(F@A>&\VZ5-DAHWFC8&3Y65257/F;<%E!-?/YEFV'IO
MDK.S>NS_ *]#Z3)^&\_SJ'UO"T_W:?+NEJ[]7:Z76VBV\CIOVG_^"B+^"_VI
M;K01#<7NEZ1>QSW@8F.'46^3S(4;D!44>3D<[@Y[UV'COXV_#7]K_P 527W@
MFZM/AWXAN56./0-<>.WT_46' ,%VA\N.5N!Y<H521D-DFOSOUW7[WQVA?5)&
MF-X[2.V[8SR%BQ=3V;))]^G(XKUWX$_L8>-O&^^2:ZTNWTV-@HO+MS')*N >
M(P#D\X/09S7Y_4Q-*O*4Z]DWK]VBL_)'[GF/"=3*J%%823E!+EOUON[K;5W=
M_5:=?8_%1U#X6>);C1O%NCZMHNK)AE@NHBI"G^->S*>"'0E3[UQ'BJ:S25KR
M%I&FY^=@,$<8QWKZ)^$WP?\ &GAO08_#>O>*/#OCSP/&<+H6O6,LJ6GJ;2=6
M$UJ_H8F"^JFN@UO_ ()N>'/&B_:/!OB:[:XDY&A:M=1BXB/]R&?"K,/0,$?Z
MFO2IYLGA/J<;./IKO?T;O\_(\:M*NHVJK3O_ %M\]/,^2/"7C^:VU&']XRGS
M ,CK[UJ_MD?"_5+3PSX6\3V-C=7FJ^))I+2,6UN99;A(U!!*#DXSC.*]\T?_
M ()L^)++Q99PS>'O$WEM*!,QTU]D: \G<!C\NM>P^+O _CJ]FN+'1_!OB:SL
M+!5L;(G2IAF% .AV\;FY/J17FN+@_:I;?C?^KFE&4)+V4FM>M]DNOKT1^8WA
M_P"%/Q6N[-9H_!'B!X=OF;_L_E;Q]&(.?;K74V'A?QY<6L9NO"/B"R5CB62X
MM6P/?/-?=]O\-?BE"CM)X/\ $4@'R;?[-FY_\=K!UWX=?$YI-L?@OQ@HQG$6
MD7&W/_?-%3'8B2Y91NOF7'"X=.WM/Q1Y1^S]^S=>>,?AYX@DU3$,.L6K:99B
M1?F>>3@D+_LKEOPKKHOV9OA3\&[*/2]/\,1Z]>1@12:A?Q_:)KEQC<<G@<]@
M.!6Q:>'/BMIZO')X)\:K:KN8G^QKE/)X.YP=F!P,$UH_L\+>?&WXA-X4NO$%
MKH,+:9<:K#JDUN)4C2$+NW9("@;OF.> /0USOVDK4X)KJ_-]/D:N5*A>M=22
M5O3NWOJSS/Q'HO@>"\:&7PKIJMT 6W6(+]<8K0^&-CX;\)W-\OA^&#2[Z\M6
MBC+,SK$<\'GOGN,U)\2_V=O$"_#R_P!5U!;IO&5OXQ/@\Z-!#NDEN#"95=&!
M^8MQM4+\P8'-<-XJ_9\^)W@'Q7X9TS5/"]S'=>(M1_L?3IH;^WN(I;T\?96D
MCD98I@>J.5(Y]":]/%9%BL-1C6E-7[)MM?A9_(TEFE%);:Z=/^ 7U\2CP5<3
M6VMS*MU'N?:WS;_0@YY!/>DTSXP2W-H\EJ_G!&V- &$3%3R"&YY//&*Z+QY^
MQM\2OB=X/N+.[\.-:^)-!M5OG22_MDDMH6D:(^>3)B,$HQ.\C:%W' YKRR]_
M9*^+WP,T+Q!KFL>%;JWTWPS#]JU+?>V[-';#'^E1JLA>2 !O]<@*#GG@X>48
M:CSOZW&\7IUT\]#EEFM*,UJK/SN=3H'[1.J0:Q>0Q1PZ?:_9W40AB7=^#\S'
MKQG& !UK)\1_&*2Z\*76K0M-]HL4+W"0D%I8A]YAGNHY]QFN>^+WP@\?^"_A
M-'X^U#PA=6^APVUO=W4OVJWDN+*WN#BWEN+=9#-#'(3\K.BAMU='\:? &B?L
M^_MCZM\.=-N+ZZTRW@LU$]X5:5UNK**60/M"J0/-8#CH!GUK+,,KI4:C]B^:
M.C7SZ?\ !.BCFCK55333W_3\KGG'A_\ :&L?%6HW:*]Q#\PEMC(P67I@_,N.
M_3ZBKT_Q;U3^U=0NKN^DNOM]L(-SG)0*<HHX  QGH.OZU_A=_P $B_C!=>$[
MSQ1XRMYO#?A&W(EMC'Y4M_<P,Q$4S0;BT,;<89ADDC@5[4O_  2);1-/T]/$
M4GC*TTN[O[:WFD6_MFFLO.<!1*B@F)F!X\Q1_2O4Q>/PT\,L+5A>4$K-+ITO
M^NZ?KL4<96G#G;BKM_:6O?3Y_B>;^!O&A^)'A>\T5&CDOEB>XL)'PS12J"1U
M['&#[&N'^$_CGQ_\:$GM='\*:EJFGJYSJ7^IMX7(P0)7PK8QT7-?:7AG_@FQ
MX"_9YN_B%JVDZUXEU.7PAK46C6\-_/&4=)$?<9"J EO<8'M7'ZM\0_\ A';F
MVT^.SMM(T"PC6VLDC(2*-5'10.YZXZUY.%S"IETW/"VYGI9]NNGJC3#J52*F
MI.T5TZWLTON=V[>1X1+^S#\5--U;^T;&WT:YE"^7Y1U) SJ>#UP/UKH_@/\
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M%23YBOL.X]ZU/A39W&N:M&MHUPUQNQY.TACCGI7+?\,X>-O"PGELM8;6-/\
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MJX^7(Z"O(?V+OA[X9\#_  _;P[JW@K3UD^(9<:AIVI6SQIJ2VK?N;6=)%)5
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MO+/'?A^+0EDN;F[?IMWMS@]B .^>,?SZUSUW^T>N@Z]Y<"-,PS%<1(<,!D9
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MI:='=G3=.O"+568.ZIYC(4B=/+9I2/NAV0#<<']OX7G0KY31JT=K:[_%K?\
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MC?X[0Z3JGAW1&M[C1]4UMIY#/-IR1I#!; $1AW3#-.#RP90"3G KT3]E^_\
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MNZT3Q,9!IZ(BM,DL(59]Q[ 2' '?K7*^'OV*O!-M-]ML--#3<95Y0R(?H?\
MZ]7A\\GA'^Y;BWOVV\U:YV4\EJ+WJ51-._X:/\3POPKJ2OKOG8=?,D^][$U]
M(>)_@GH_Q5\-^!=(U2W6^BNYKF\*<AU 15 4]!D@YK6T[X0:+!I9MY/#^F.L
M8VAUA_>(/[V16M?_ !'TGP5\4?"-M'8W3:5INGNLMYLQ&9>FW/8_,3S7CU*T
M9>_!ZI,Z,#A_J<^:M[T?P_K8SO#O[(_AOPQ?1R6/AFQM3&I&]X@VX>F378:+
M\(- TF%HY="TF.%A\\45NJG'KT_6K?C']IO3;&U4Z>GEQ[",[P=WN<_TKSW7
MOB;>:KI7VIF^SS2+YBJ!GY,?=/?<>>:VRW)<9F;DZ#MRI7N[;[+U.Z&8>V?-
M'0U/BEX>T/Q#:66FZ5>3:)-H[!K6(?-"3NW<KWR>X-=C_P $Y_BKXHM?V^O!
M'A/7I6=9!?O$P;*2H-/NF#+[<?A7SEXZ\;6^H:2U]]M^SS1J I9OF8]OR_E7
MO?\ P29^($'Q&_:\\%+?".74-+-\]K-CY\&PN%89],-G'J!486G.%:*J;II/
MNFF>3FF,]KA9P;VC+3Y,KWG[1-QXJ,D-K<'R[0!5;;PS'G X]L9ZU%X=\9:K
MXRU==)*CC&78=B<<X[]^..:\5\$^*;CP5K4BM%',ET1Y;\JR-P.3Z=.*^I/V
M8?!LGB3QD9IHO.9U$KR)&-O/\.!7JY@\IHY/"G0C>MH[VU3ZW?7LEKWZ(ZJ,
MHSC:"U.C\&>&;S09_L\($[,F]I1\L2#ODG^=.UK]F7PWXW\33:GK&GVVJ7$R
MJ"EQ;"1<@<LJ]>?]K/K@5T/QC^*>E^ /B*VAM)#!;6$*2S 8^=R,@?@,?C7G
MT_[7L?AO4II+6;RVNB4B&=S,/IZ@=Z^4PL<14E[*BGS2['I2Q"5*":4GNK_G
M_7_#;S? OP5X6#"'PWI2QCY2OV)>OMZ5A6NI:'X:UV.WT^RM-/9F"((HO+);
MW(KF/&_QXU7Q%I?VJ:-H5WY,4;[FYSRW'H.@)_2L7P3=77BS4MT<#2,6#AE/
M8>GO7=C,OQ^ DEB[Q;5UJFFODVO5;DJM&<K5H+7RL_O5CH_VKO#&L_$?2+:Q
MB9EN(Y(V@F=LNJL0IP , <]CGBOBWXW_ +-6L?M7:3=ZYX=L]3%WX;M9/#VD
M:+>S6SS7LENWE_:(92X4EV\]FB5FRA;8%9F8_IAX9\*MXMMM)N%E2,6L\>R2
MX4D.-W*@<9&<<^QK\;="\,+XDUWQ1X9US5-)TCQAINK2WFB7>JWJ);Z;=QR7
M$5Q&$<L'+><.BC<(AM/R@U^J^%OU>M.O5LN=**WV3;;?SLOF?@_C?6K4J>%P
M\6_97G+U:44E\N9W^9W/P;^*_P 4O@1XZO/ VM>&-)^PS:(LLLTUBS3:=<K+
M*PDMEN>MU&A+>4Z/\B; ,<UQ7Q>\>^'M3T2&ZU[Q GC6X9Q'IMU<:>TMZ'*B
M9[ _OU@2#8J.H,((9]JA=F#RO@?X=W7PX^*NG_\ "0>*?$UKK5Y&%A:[M!?-
MMP5B%HN?)D>1B=B[@H$N6<XKH-+^#<OQ&\?S:'?7.F?VQ#XDBGUW4)G\ZQTF
MY:4($5D4LNYY#&Z(A,CA]I*QDU^Q3BW'EBO>OU:>FEEIVWL]M.Q_.,7%5.:_
MNVW2MKK=Z][VNM[VZG:>*_CAK'P:^#5M>:?8>$[75GGL-:O-0U;3S=2)JDL@
MD$DZ%1''.%C6 *F?-8%B""2OT9^SG/JW[4LWBZZBW:CK'AN]?Q8D-_!%;PG6
MU4Q&$O\ +LLB+BYN'MX=RQ%2Q;/ \;T+]GSXF?'62Q\1:/I\/B30YHHM8U70
MSJBIJ&JW]AF-X]C,'6 I/)DHBE44%]N!7T)^Q!^RWH>D_#'4_%&M^ /$>C^(
M+>[LGG:VLF=8I&M0[V]E;.P*P2%9$D;<OG.%SP?GJM.$+O2ZMKN]_7KIIH]/
MNBCS22T;O=]EM9WTZ:ZZK7UOK?!;P-:R_ K5M!AM]8DN+.Z;58KZZABCD\1)
M'$@N4<P9&Z!R"BR.QPS$!12?#^=;*\AN/)65MXDCC=2V_G(!]?0U],_#CPU=
M6'Q!O-)&DVNEQZD;X#3/E1-+1V#,BA$5#]]3D L9IIE+,L0KG/#7P!L?AGX8
MCO-3G^U:E$,QQ _*A[>YQ7XYQ_-5,;2E&*7,G)]7VW[:???R/Z1\-\=562O"
M57=4966EG9ZV^3]+)I/8J^'=$TV;P?JMOJUC<:O%XA26&_74V2XN+JVD;)MA
M(5RL"\X ZMAL948\4\?_ +,7BCPO\$_$>BZ'(?&6CM:R-9111*M[8)'#-LB5
M"ZM&7:7:YMQ\R*,8)->X7GB*W@CF:22&-8_FDE=@%7\:Y2Z^(5YKL\EKHIV(
MHW-=2K@#MF-.I(]6P.,X-=N0YYF%.O*47S<]FU+;39JVUO+3NF>7G'".#S5P
MP>%I/FC>W+T3W3;Z/NVG?9H\Z_X)W_L^>-/V;?'FN>,-2MK/PK!KL:331:BX
MCC^U[ A#!@KB4+Y<C)M;AQ\V %/L?Q<O]#D\(ZQ_PCME8^(EN)9)-9FOK82)
M?K)*)9 L394;Y!DR8W#"A2H KEM:\!QRVVH2":Y-YKFIC4+V6\NA)F7RBF8E
MQ\BE0H]/E4?PBK/@;0KCP]K$,%O(+I;C]TZ 9W9]:\GCKB[%QQ7U:-H)QBVX
MZ-_/I9W]=]G8^DX+\,*& BGCUS5$W:,FG%:V6W\R2]/4\4\,^,XM&LK+0=,;
M5TMK59<SZI>F^NY3)(7(:1N2BYPH[<^M;UAXCU/P#>0BVDF>#4&V8?\ >!3C
MMGGOP#TYKT?QA^SI9K\0+N*_TS5-)^SL"EU;P[HY0R[\?AZUN^"? 7P[\-^*
M;&34O$DEW):RJ[65Y<)#N(Z?(V#^7:OC(YACE7EB:52TIZMII7^7_ TZ'Z'A
M:5#!0C1PR:A'1)*3M\];_>:O[,'P+EAU9?$.K6[6^GR*9(HY3S+_ +6/2NX\
M>_$5O&FN);VTGDZ78MM10V-PZ$X]35KXI_M(V6J07UCHMHTS+9$+/ ,V\"AE
M!3<.-QW9&., UXEI7BXF_FF6;:TA&0!]W':OG,5SP]Q[O?\ K\3ZC!UE*E]8
MMMHO)]7ZV:5_4]0\?N=!M;=;3;&DT>=V<N!_+GWKQ_6M59DD,DDC2.3U8%:Z
M;3H5\::1))(UTTZY64EOW@8'N<DKUXQQ7G<%A]L\475O>76V&SE,:D?\M!U!
M_(BO8S;AFK@*$,2YJ<963MT;5_FON]#FK8BI"*E?YGS_ /M$>'E\,7JW5C;V
M[?:98UE!3Y53<25(Z$%RI^M<7HFBZDU\K0-]BOQ"9(O*4-$8CRFX=N<G]*^N
M_B!\!+/XA6ENNF6\-]]GD266V=CMN K E#CG!QCCUKR+Q7XC^'NG6#QZ7I>M
M:/JD-]-$RW=TC16P;&<$\21@C 08(Z@GI7B1J2IMU:3?,C[/+,=]8P<4]UT_
M4H_ /7OB#X_N=-TK;ILTUU\@8!EROJR]!QWX  KZJ^"WP8FEAUC2;B'3M0T6
MU#0W)*MY%YN<$HK*1U8 C!!^6O%?A1XVT[X0W+7=OXJM85NHU>*/3[-;B&9.
MZ-+)C:O3(7TQV!KV;P3\5UF\-:K=>-?%,MGH^BWYUZR32M-ETF.&U5"1!<!7
M/G 9SD@!R!G-0\56Q27MW\K:,]'%49X.$:L&H[-.[NMG==;]FMMSRW_@HA\-
M6LOVF-/U1%AF3Q-X2>2Z13\T,D$S1AR/X5*L,=OD:OBOX6_$6S^$OCJ;4[[P
M^OB2#R6MTA_<AX6+H?-3SD>/.%93N4_*[8P<&OI#]H3XN?%[XB:;?_%2Y^'.
MJ6?@S5U?2M.D8;9X;&(%H\0L ^)"[-OQM=B=O %?'OPD^*^L?%CQ?+#I&DV%
MGI&GO%+J,MXN^4JSX\M=O<@'N,8)KLJ8>5:,DU[O7I^6OW'@T\QI8?V=)R3F
MV[)*^M]K:K32]].XW6M<UCQ)XFDFC\$MI\>HW$DP,>IQG3]/1W+ ,P7<JH#C
M'7 &,UZYXI_9#GL_A=_;FE7[:Y>6=O;R7J6MNT=IOF!*JDAR-PX8 GYU/\+#
M%>=W=G'=Z^EL&56FE.#@= ?2O?O#MI>Z#X%N5N[Z:'3[6/[5';O*0LCDY&U!
M\HR>PX';%>]D^#PE2C*6)AOI&S=[]];GB9G_ &I3JTIX/$VA&5YJ44[Q[*R5
MWW=UW6JU\$;X*ZQ:Z;]IN/+BR,@+\_Z^U8MA?3^'=6:"X78\9ZYX8>M?0+>+
MK.;0K66:9;CS(@S,Y&<D$GCIVP/:I/V;;/X?^+OCC))XJGTF;0XX98;>TG=5
M<7WE'9<?,NUXT+ ;&8*S=0=M>A'(:56,:%)<LY-)-MV_%ZZ;=>QZ.=\14\MR
M^>95TY0BKN*6MK>6WJ]%U=CL/V*OVO\ 4_@!J:V[1MJ'A?49XI]2TJ5>I P)
MHN1MD"GJ" PP#V(_2+2/^+K^'K.ZMY%\5>'=:3SM-O+><&50>-B,V3D'AHI
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MC'!#O@@<< FO#SS/*N*K1JQU?2RT7Z?B>R\CQF'A[.A23EUYGT]%K;[CY&\
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M,U[BO\D>;3PJY^6K)KU;_P _R*O[.EC\.=0NM3UU_AC-HS>'D:57;Q7=S*7
MX'S( *]"_9[UWP5=^!)M>A\#S6W]JWDSD3>)KBY:;:=@<EESSM/':OCG]H_]
MM6'2M%A\(Z/I<^BV-P=UV[J09W]"^!FNV_9L^-$=A\,]-@5Y&\O>"K=.7)_+
MFO-QLI1ALG\E_D>K*R?LH2DE;7WI;??U_P NMSZB\8>//"+HT:^!9/.9"05U
MV<;#CAON\UY[^S=\3M%^&7QXM[K7]872EU#3[O2X]2F)\NPGFB*1S,1RH#<$
M]@V>E<9??%^SU.2ZF>\N?M"(T;0J K)G@8&,L,<Y_7M7@7QM^(+: Q,DBW37
M3D(-P8I@^O'OV_&O:I\,XREAXXZ\'%)/31V?R2_'T+Q$5"BX)NTE9^\W^;9[
M1=?L,2?"CXM?#RYC^)_@VQ\/7'C"+4KSP[<W9UO0K.01/G594$@A&[ C59"#
MND4DA=PKZ$O/B#X!M/C3\$]6U[Q)X%N+S3M9U?2?%%S<ZEI/F[6MVDM/M*6P
M6$Q[0VUE#!"RJ7+'%?'_ , _$LGB72'BN8T:&13$\+#*R(1@C'<&O/?VA/V1
M]-UK5&71=4DT>X4AE@NHO.@DC/0HP^91VP>A%9Y;CO9U+=5M?7IOZKH^AXV)
MP<ZB]M2=Y:WLNZ:Z>OWK<^SO _[8WPW^)>E?"G5O'.H>$F">,M5TV=#;P0I:
MV:VY:R-U#& ?LRS^6-[#&!R2,US_ ,,O$,^H_M)^![SXYZY\&M1O+6TU@:8^
MA/9RM:W#8^Q/?2Q*;3R\Y\@."4X+BOC?PI^QQKEG$LWVRTE7@22$-N"_3O\
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M]$UI:U^BO\KZ9;0ZSX;\(MJUWIVM:MX\N?*U:););B2UBCN$*Q,1(H:0,%9
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MI6-Y*$@EB#*;*1%1'C)R&R=V3U5F[5T&K^#)/#NIW%O<Q/#.&)96'6M7X?\
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M57AECC2>#@2H1E&!X(^A&>/>LZD*N%G['$Q^_P#X!RU(4ZDO9MV?1GSK>_M
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MXLM[Y>HMY[00D>P;D'\<5Z%:FOBN_DO^">!!Q<O=:^;_ $2?XG7_  F_9_\
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M"M9N_$?DP6-Q-'(0,%2=O_ZA7U6*XPC+%U*\E4JQ:CRJ5E9I:[:*[VT;L<7
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MGAB;:N'$; @[AN!(Q]WK6'??"'PYX@\&R7FK:;-X3UBX+7=C>Z?92/I^HQA
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MO,&[#IW/O7UF<\1SS' 0P:A^\33<NEDFO76_^6YS8C'*5-*70\B^%GP=BO\
M4DM[Z$.H(W$'GV&?4UX_^UMJFJ>!/VE+632=4\01V?AS3TLO[.TH>8;CYR[/
M*""JH&;:.,G%?8VN1:3\.H-:\0+<1PZ9X?M3<,@;Y3/S@<^GI7R]\']1:]T^
M_P#%U])YU[XJNGG;?]Y(P2(T^G4_4U\WAZOU>GSJSEJE^O\ P/F:>S]J_9KX
M;)M>?3_@V\CS[QE_P43\2FT^RV6GM;MM^=[DXP?9>*\8\2_M'^//$E[YUQJ,
MOV?.Y?)^38?48KZ^\7ZMH%S<V\,NCV^I71&X0^2C'ZDD?_7KE_%7@?1KG2V;
M_A$],CC89+0Q*=N>O& 3CH<<^U>A0IYABZ?M:5&4H^J_!:7^2-*-&5"7-12^
M[]=7^)X-\-/VEK:^OO[-\3V*R0SL/],@C##([R0]&!(&2N#D=,U]7_ /X5Z7
MXSUB2^;Q0MII^HP.MM]AB\IK=FCV++'N#H)$ZKN# $=*^9]>_9UTG6U>[L?^
M);(7W1F-C@XZC!Z5] ?LC-)X2>WTVZD,T;,%63;C';D=#]:Q6.J4H.E"4H)[
MJ[7D[I?<+EH5*WUCE4:VRDDONNUWZ;'T#\>?V;M#^()\)V%IX>N-6DDU:WO%
MO)#;W&G:-+:;KB*[GMIN)3)(!$?*7?B0D%-H(S?V1?V8;?\ 8X^%4WA)]:A\
M2>*]<OY=:\2:K! ;>&:XD 41QQEF*HJJ%&3D@$GDUYMX>_:@\5>$/'_C#2[R
M_MY[;PW<?9K<Q0!7D=\[ Q]EY..XK2\$?'&:'3)KJZFD^UW=PQED<X(Z "NB
MI+V4=-9/]?U/.<JT8>RE+W=_5ZV^2OLM&TCN?C#!8:7IDTCP6K%NI:-<G]*^
M2/C)/X;GOK.70HX;6^5OWBQ,ZC:(TR'#';O\SS,&/ V;<_-FO1_B_P#$?38_
M$UK-J5U]LO%E^T10/)OM2BD$*5SM/ ^8-SV^G&'1(_C3XEM7L]'FO'LT5'E:
M<SS2CS&?#S'!/WR 3]T*J]%S7K8?AB<H0Q-2LE%J[L]$]+)ZKN[]K'=15+V$
MG=7=O\V[]&K)>:;-[Q'+IOAO]G'7(M#N/#>DZI,/L^BW5[,BP+>W'EI',,Q
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MB\5CJLY5Y.\E:W1*][)=OZW/CW1? 7]I6ICDC#$]B.M>\_LX^#HOV,O#-O\
M%_4(4/B+4/,M_ FBR']W<RCY)=5N$[VT&2L:G_6S?[*$UU'[-_P"TJ\TR_\
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MN[--07[1:J/,GB896;:1@$<YQG=@\$@"O8_V(OB=:>/OVUO![*L?VD&]&YF
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MT_7(98V$N=J72!@3$Y_A##C=V[\4Z=.G=*LVH]U_P>A,7@Y*])-2[/\ *_\
MPQT?Q3_:0\JRN([660W$VZ*1Q\KS ]47NB>IZGVZ5XQJ7PQC^(C#4M>O%6'J
MD4? 0=@*].UGX _V)\5]3TN\811K.65I#]Q'R0?H.?RK7\6?#*+P1:C['<1W
MD<:;F5H\DJ0,''IZ^QJL%AH3Q,:,Y<MW9M]/Z[G5B<S51+#TDHP\NOFV>!^*
M/A]X5T;3WCMH;[[0P^0JV"??KTKB[?P3XJ12VA:Q?0QQY;RS)R,5ZAJ$TK:I
MM%FIWL=KE=HBSG&?IQG@\]/6MEM)L_!&GR:D;B-V$9W*#RXY->YFV#P&$AR4
M:G--O;1KY]OS.+VCA_#FUZ-K\CCO@-\2=>MO&%C:>)/+U6U,NPF9=S+V/_UC
MVKJ8/A(VB?&;7M"TEO+M[Z475H_\)B<9Y/MS7GOA?Q1%KGC=9[-=J^:) /QY
M!KZ%O-/FT#3])\6VJS7?V(FWD$8RXC<'&>_!'X9-?-UOBY%U.A5:E;#R]I)M
MQLU?MM^I9^&UMJ'P]=+"_@^Z['<.0V.OZT_Q3XPO/'$]U*]U<6Z6KO';PJQ5
M$"\;L \D\\\_SKS_ %OXQW&IZC_I)NI'5LKD?=/I3/"W@O7M=GNX[))6749Q
M("V1M!Z\CD#V'6OH.%OJ]/&MXFWPZ-[7NN_D<U&M%:2(?$GBW4=:NI-+8),T
M?S"X'!<?X]OPKIO"VF6MI\-_$%IJD;)9W5H!+N;;@GA6!Z<$@BK5W\)8/ 2*
MLTWVW5$ $OR_NU/]P <LQS^&:\\^.GQ#DUOPM=>$[>[9A"ZMJSQ@>7!MP5M4
M;NV<%\< A5[&O/S*5!XZ<L)\'-=?K\K[>1U9=A^9R;>FIQ?PB\>MH^J*UQKU
MO'-@)_KMLAQV9AE6Q_M U[AI?CV^L+=KZSB^W,5+!X98I3GT W=Z^6+/P[IU
MSI,B&V82*Y",H.X=/2LRVM-6\-72QZ?<W?F2L%6-6.XD]!BM*D9\OM)0T]&E
M]^Q4L1AEI*+]=&_Q7ZGU'XC^)^J:G\/;FY^Q7ME<70E%QYIS<+&C@$ C[NY>
M3CJ.]+X,^&5YXD\/C5+.U-PFT/\ *?\ 5@#( 'ICTKQOX5_&+Q'X7UAK2\C>
MZCW^5<P70^\IZ@YZ?A7T5\8+.3X?>!=!\1>'-T>CW<"JZ*?]7GJK8QR&[_2N
M&M#F7N*WD9XRK"5%.G)VO9W5O-?K_P #KZ=!XP:*\1I(QMU"U1DSSY;(,L!Z
M97/UP:\H^(FHLES/=QWD<<"-^\C/1@ 2.!T(XKBKGXP7E];PPV\EU<760T95
M\G=V_*L&_P#AMX[^*>H&&=1903/YDLI4JN3Z <GUP*]S+<RP\<MGA,2KM)I:
M;]G\G^7<YY9@G#D>YG)\89?&.JW-M]Z!24!QUQ5OXO>);OP!X \/W2LD,C7;
MV\>X[3(I0,V/4#CC!ZUW'A?]G.R^&MQ;QK.=3N,@R!X@J[R>%X->._M;:JOQ
M:\=6MCI9$FE>%\VT$D9_=M*2#*X]<L H]EKYVFH*JK;&V#YH4YU+]/Z1O?#V
MT\-^+;B.]6[\)M>R'+AYFMFSW!!!7/N*]\\&>$=8\+VL4^G:5I6H0D;A]DUF
M!VY]$)!_K7SK\)OV8+;Q=J$,FJ+)Y"CS&$?RDCW-=QXU_9BC2V,V@WEPLD8P
MJM(0P-=52:9/L</-<ZIM?._X:?F>M?$:^O-;\+7*7VFW:76/W<3H?]']2S=
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M0?&:PMO[8\/W&GWT2!M\J;89F]48\\]:^BM3\90:/8*6BMH_+^9U27S&(Z]
M*_.7X;>-=6LYO,COKA79L$AJ[K4O&NK7^F_O=0N6W'GYL9_*O1J5KR=H_C_P
M#GCE>'DTW)WZZ?\ VUOP/I7XG_MF:I>Z/?:/I_AE?[(FADMYM36?YXCL.,Q
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'[/\ %'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6753180224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Non-capital Losses (Details) - Non-capital losses<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">$ 69,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySixMember', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">9,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySevenMember', window );">2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">12,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyNineMember', window );">2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">4,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyMember', window );">2030</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">4,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyOneMember', window );">2031</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">4,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyTwoMember', window );">2032</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">2,873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyThreeMember', window );">2033</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">2,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFourMember', window );">2034</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">2,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFiveMember', window );">2035</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">3,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySixMember', window );">2036</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">6,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySevenMember', window );">2037</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">4,812<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyEightMember', window );">2038</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">5,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyNineMember', window );">2039</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">$ 6,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6751292544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrelatedpartyAbstract', window );"><strong>Disclosure of related party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term employee compensation and benefits</a></td>
<td class="nump">$ 3,786,667<span></span>
</td>
<td class="nump">$ 2,680,621<span></span>
</td>
<td class="nump">$ 2,596,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits', window );">Termination benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">779,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based payments</a></td>
<td class="nump">1,123,408<span></span>
</td>
<td class="nump">1,067,195<span></span>
</td>
<td class="nump">459,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Compensation of key management personnel</a></td>
<td class="nump">$ 4,910,075<span></span>
</td>
<td class="nump">$ 3,747,816<span></span>
</td>
<td class="nump">$ 3,835,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties', window );">Liability to officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 178,125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of termination benefits. [Refer: Termination benefits expense; Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables due to related parties. [Refer: Related parties [member]; Payables to related parties]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrelatedpartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of related party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrelatedpartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6761973568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="3"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative</a></td>
<td class="nump">$ 8,508,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_Currency1Axis=currency_USD', window );">US dollars $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,551,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_Currency1Axis=currency_GBP', window );">British pounds &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_Currency1Axis=currency_EUR', window );">Euro &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | US dollars $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount', window );">Impact of increase in value of currency, amount</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings', window );">(Increase) decrease in net loss due to change in currency value</a></td>
<td class="num">(125,339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | British pounds &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount', window );">Impact of increase in value of currency, amount</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings', window );">(Increase) decrease in net loss due to change in currency value</a></td>
<td class="num">(8,581)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | Euro &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount', window );">Impact of increase in value of currency, amount</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings', window );">(Increase) decrease in net loss due to change in currency value</a></td>
<td class="num">(32,426)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative</a></td>
<td class="nump">$ 8,508,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A reference variable for a specific type of market risk, defined in non-percentage terms. Positive value indicates an increase; negative value indicates a decrease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_Currency1Axis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_Currency1Axis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_Currency1Axis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_Currency1Axis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_Currency1Axis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_Currency1Axis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6620436928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Economic Dependence (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>manufacturer</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ConcentrationRiskType1Axis=oncyf_SupplierConcentrationRisk1Member', window );">Toll manufacturer</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ConcentrationRiskType1LineItems', window );"><strong>Concentration Risk Type1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ConcentrationRiskNumber', window );">Concentration, number</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ConcentrationRiskNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ConcentrationRiskNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ConcentrationRiskType1LineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Concentration Risk Type1 [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ConcentrationRiskType1LineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ConcentrationRiskType1Axis=oncyf_SupplierConcentrationRisk1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ConcentrationRiskType1Axis=oncyf_SupplierConcentrationRisk1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6768285328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Schedule of Share Capital Footnotes (Details)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 16, 2019 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 16, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 24, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 27, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 05, 2018 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 05, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 01, 2017 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 21, 2018 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>May 22, 2018 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Feb. 25, 2016 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (107,894)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,195,363<span></span>
</td>
<td class="num">$ (107,894)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,195,363<span></span>
</td>
<td class="num">$ (107,894)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,195,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,283,846<span></span>
</td>
<td class="nump">$ 6,195,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,689,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 854,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,366,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,391,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1', window );">Number of common shares issuable per warrant (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1', window );">Warrants exercisable into common shares (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,730,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,730,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,730,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ProceedsfromWarrantExercises1', window );">Gross proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,642,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 311,077,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,193,061<span></span>
</td>
<td class="nump">$ 311,077,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,193,061<span></span>
</td>
<td class="nump">$ 311,077,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,193,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 272,268,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,477,665<span></span>
</td>
<td class="nump">2,477,665<span></span>
</td>
<td class="nump">678,182<span></span>
</td>
<td class="nump">678,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,055,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,055,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,333,474<span></span>
</td>
<td class="nump">$ 854,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,617,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,617,570<span></span>
</td>
<td class="nump">3,617,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,617,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember', window );">Pre-Consolidation | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 272,268,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,710,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,321,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,391,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember', window );">Pre-Consolidation | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,617,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,617,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementCanadianMember', window );">Canadian ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,684<span></span>
</td>
<td class="nump">54,684<span></span>
</td>
<td class="nump">347,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 553,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementCanadianMember', window );">Canadian ATM | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,348,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementCanadianMember', window );">Canadian ATM | Pre-Consolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">519,500<span></span>
</td>
<td class="nump">519,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementCanadianMember', window );">Canadian ATM | Pre-Consolidation | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,301,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,532,278<span></span>
</td>
<td class="nump">1,532,278<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,933,181<span></span>
</td>
<td class="nump">$ 11,511,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,418,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,145,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad per share) | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.83<span></span>
</td>
<td class="nump">$ 0.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember', window );">Public Offering | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,532,278<span></span>
</td>
<td class="nump">4,619,773<span></span>
</td>
<td class="nump">4,619,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember', window );">Public Offering | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommonSharesPerUnit', window );">Common shares per unit (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommonSharePurchaseWarrantPerUnit', window );">Common share purchase warrant per unit (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedWarrantPricePerShare', window );">Purchase price (cad per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantPricePerShareAccelerationThreshold', window );">Acceleration threshold weighted average price (cad per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays', window );">Acceleration threshold weighted average price, trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember', window );">Public Offering | Pre-Consolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1', window );">Number of common shares issuable per warrant (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember', window );">Public Offering | Pre-Consolidation | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember', window );">Public Offering | Pre-Consolidation | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommonSharesPerUnit', window );">Common shares per unit (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommonSharePurchaseWarrantPerUnit', window );">Common share purchase warrant per unit (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedWarrantPricePerShare', window );">Purchase price (cad per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember', window );">United States ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,425,040<span></span>
</td>
<td class="nump">4,425,040<span></span>
</td>
<td class="nump">18,002<span></span>
</td>
<td class="nump">18,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,390,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 344,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementAmount', window );">Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">19 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember', window );">Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementAmount', window );">Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember', window );">Agreement | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">797,691<span></span>
</td>
<td class="nump">2,494,943<span></span>
</td>
<td class="nump">2,494,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_InitialCommitmentFeeMember', window );">Initial commitment fee | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,278<span></span>
</td>
<td class="nump">17,278<span></span>
</td>
<td class="nump">119,509<span></span>
</td>
<td class="nump">119,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 483,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderWarrantAgreementMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="nump">4,619,773<span></span>
</td>
<td class="nump">4,619,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,742,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="nump">$ 699,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1', window );">Number of common shares issuable per warrant (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderWarrantAgreementMember', window );">Warrants | Included in operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="nump">233,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderWarrantAgreementMember', window );">Warrants | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="nump">2,935,647<span></span>
</td>
<td class="nump">2,935,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommonSharesPerUnit', window );">Common shares per unit (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderWarrantAgreementMember', window );">Warrants | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Public Offering | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_NumberofSharesOutstandingPercent', window );">Shares outstanding, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightWarrantsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,687,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,687,003)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofWarrantsExercised', window );">Warrants exercised (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,935,647<span></span>
</td>
<td class="nump">2,935,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,935,647)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember', window );">Warrants | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="nump">$ 466,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommonSharesPerUnit', window );">Common shares per unit (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Securities Called by Warrants or Rights1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommonSharePurchaseWarrantPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Share Purchase Warrant Per Unit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommonSharePurchaseWarrantPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommonSharesPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Shares Per Unit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommonSharesPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Issue Of Ordinary Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GrossProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberofSharesOutstandingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Shares Outstanding, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberofSharesOutstandingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ProceedsfromWarrantExercises1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Warrant Exercises1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ProceedsfromWarrantExercises1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharePurchaseAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharePurchaseAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharePurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharePurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharesIssuedPricePerShare1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Price Per Share1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharesIssuedPricePerShare1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharesIssuedWarrantPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Warrant Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharesIssuedWarrantPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantPricePerShareAccelerationThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Price Per Share, Acceleration Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantPricePerShareAccelerationThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantPricePerShareAccelerationThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Price Per Share, Acceleration Threshold Trading Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantPricePerShareAccelerationThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementCanadianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementCanadianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_InitialCommitmentFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_InitialCommitmentFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderWarrantAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderWarrantAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncomeStatementLocation1Axis=oncyf_OperatingExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncomeStatementLocation1Axis=oncyf_OperatingExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6754545264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value of warrant derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,608,808)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GainsLossesfromForeignExchangeImpact', window );">Foreign exchange impact</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (23,482)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassOfWarrantOrRightOutstanding1', window );">Issued, August 16, 2019 (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,619,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofWarrantsExercised', window );">Exercised (shares)</a></td>
<td class="num">(2,935,647)<span></span>
</td>
<td class="nump">2,935,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassOfWarrantOrRightOutstanding1', window );">As at December 31, 2019 (shares)</a></td>
<td class="nump">1,684,126<span></span>
</td>
<td class="nump">1,684,126<span></span>
</td>
<td class="nump">1,684,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantsAndRightsOutstanding1', window );">Issued, August 16, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,657,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightWarrantsExercised', window );">Exercised</a></td>
<td class="num">$ (5,687,003)<span></span>
</td>
<td class="nump">5,687,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value of warrant derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,608,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GainsLossesfromForeignExchangeImpact', window );">Foreign exchange impact</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(70,255)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantsAndRightsOutstanding1', window );">As at December 31, 2019</a></td>
<td class="nump">$ 8,508,764<span></span>
</td>
<td class="nump">$ 8,508,764<span></span>
</td>
<td class="nump">$ 8,508,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassOfWarrantOrRightOutstanding1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Outstanding1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassOfWarrantOrRightOutstanding1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GainsLossesfromForeignExchangeImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gains (Losses) from Foreign Exchange Impact</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GainsLossesfromForeignExchangeImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantsAndRightsOutstanding1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants And Rights Outstanding1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantsAndRightsOutstanding1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>336</ContextCount>
  <ElementCount>347</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>83</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPosition</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001001 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfFinancialPositionParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN (DEFICIT) EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfChangesInDeficitEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN (DEFICIT) EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Incorporation and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncorporationAndNatureOfOperations</Role>
      <ShortName>Incorporation and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Basis of Financial Statement Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/BasisOfFinancialStatementPresentation</Role>
      <ShortName>Basis of Financial Statement Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Significant Judgments, Estimates and Assumptions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesAndAssumptions</Role>
      <ShortName>Significant Judgments, Estimates and Assumptions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CashEquivalents</Role>
      <ShortName>Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2122100 - Disclosure - Warrant Derivative</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivative</Role>
      <ShortName>Warrant Derivative</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2125100 - Disclosure - Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapital</Role>
      <ShortName>Share Capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2128100 - Disclosure - Share Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedPayments</Role>
      <ShortName>Share Based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2131100 - Disclosure - Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LossPerCommonShare</Role>
      <ShortName>Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2134100 - Disclosure - Contract Liability and Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivable</Role>
      <ShortName>Contract Liability and Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2137100 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2140100 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2143100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2146100 - Disclosure - Capital Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CapitalDisclosures</Role>
      <ShortName>Capital Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2149100 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2152100 - Disclosure - Additional Cash Flow Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures</Role>
      <ShortName>Additional Cash Flow Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2155100 - Disclosure - Indemnification of Officers and Directors</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IndemnificationOfOfficersAndDirectors</Role>
      <ShortName>Indemnification of Officers and Directors</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2156100 - Disclosure - Economic Dependence</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/EconomicDependence</Role>
      <ShortName>Economic Dependence</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2157100 - Disclosure - Other Expenses and Adjustments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustments</Role>
      <ShortName>Other Expenses and Adjustments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2158100 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2159100 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2207201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2307302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2316301 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/PropertyAndEquipment</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/Leases</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2322301 - Disclosure - Warrant Derivative (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables</Role>
      <ShortName>Warrant Derivative (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/WarrantDerivative</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2325301 - Disclosure - Share Capital (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalTables</Role>
      <ShortName>Share Capital (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ShareCapital</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2328301 - Disclosure - Share Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ShareBasedPayments</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2334301 - Disclosure - Contract Liability and Receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableTables</Role>
      <ShortName>Contract Liability and Receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivable</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2343301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/IncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2346301 - Disclosure - Capital Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables</Role>
      <ShortName>Capital Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/CapitalDisclosures</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2349301 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/FinancialInstruments</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2352301 - Disclosure - Additional Cash Flow Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables</Role>
      <ShortName>Additional Cash Flow Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2357301 - Disclosure - Other Expenses and Adjustments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsTables</Role>
      <ShortName>Other Expenses and Adjustments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustments</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2358301 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfDepreciationRatesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2407405 - Disclosure - Summary of Significant Accounting Policies - IFRS 16 Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryOfSignificantAccountingPoliciesIfrs16LeasesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - IFRS 16 Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2413401 - Disclosure - Cash Equivalents - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CashEquivalentsNarrativeDetails</Role>
      <ShortName>Cash Equivalents - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2416402 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2419403 - Disclosure - Leases - Right-of-use Assets and Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LeasesRightOfUseAssetsAndLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Right-of-use Assets and Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2419404 - Disclosure - Leases - Total Undiscounted Lease Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails</Role>
      <ShortName>Leases - Total Undiscounted Lease Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2422402 - Disclosure - Warrant Derivative - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails</Role>
      <ShortName>Warrant Derivative - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2422403 - Disclosure - Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationOfChangeInFairValueOfWarrantDerivativeDetails</Role>
      <ShortName>Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2422404 - Disclosure - Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForWarrantsDetails</Role>
      <ShortName>Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2425402 - Disclosure - Share Capital - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalNarrativeDetails</Role>
      <ShortName>Share Capital - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2425403 - Disclosure - Share Capital - Schedule of Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalDetails</Role>
      <ShortName>Share Capital - Schedule of Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2425404 - Disclosure - Share Capital - Schedule of Share Capital Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleOfShareCapitalFootnotesDetails</Role>
      <ShortName>Share Capital - Schedule of Share Capital Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2425405 - Disclosure - Share Capital - Summary of Outstanding Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryOfOutstandingWarrantsDetails</Role>
      <ShortName>Share Capital - Summary of Outstanding Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2428402 - Disclosure - Share Based Payments - Schedule of Stock Options and Weighted Average Exercise Prices (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsAndWeightedAverageExercisePricesDetails</Role>
      <ShortName>Share Based Payments - Schedule of Stock Options and Weighted Average Exercise Prices (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2428403 - Disclosure - Share Based Payments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails</Role>
      <ShortName>Share Based Payments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2428404 - Disclosure - Share Based Payments - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfStockOptionsOutstandingAndExercisableByRangeOfExercisePriceDetails</Role>
      <ShortName>Share Based Payments - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2428405 - Disclosure - Share Based Payments - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsAndFairValueOfOptionsDetails</Role>
      <ShortName>Share Based Payments - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2428406 - Disclosure - Share Based Payments - Schedule of Number of Other Equity Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleOfNumberOfOtherEquityInstrumentsDetails</Role>
      <ShortName>Share Based Payments - Schedule of Number of Other Equity Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2431401 - Disclosure - Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails</Role>
      <ShortName>Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/LossPerCommonShare</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2434402 - Disclosure - Contract Liability and Receivable - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableNarrativeDetails</Role>
      <ShortName>Contract Liability and Receivable - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2434403 - Disclosure - Contract Liability and Receivable - Schedule of Contract Revenues and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiabilityAndReceivableScheduleOfContractRevenuesAndLiabilitiesDetails</Role>
      <ShortName>Contract Liability and Receivable - Schedule of Contract Revenues and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2437401 - Disclosure - Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CommitmentsDetails</Role>
      <ShortName>Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/Commitments</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2440401 - Disclosure - Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContingenciesDetails</Role>
      <ShortName>Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/Contingencies</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2443402 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2443403 - Disclosure - Income Taxes - Summary of Non-capital Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonCapitalLossesDetails</Role>
      <ShortName>Income Taxes - Summary of Non-capital Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2443404 - Disclosure - Income Taxes - Summary of Non-refundable Federal Investment Tax Credits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryOfNonRefundableFederalInvestmentTaxCreditsDetails</Role>
      <ShortName>Income Taxes - Summary of Non-refundable Federal Investment Tax Credits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2443405 - Disclosure - Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleOfUnrecognizedDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2446402 - Disclosure - Capital Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails</Role>
      <ShortName>Capital Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2449402 - Disclosure - Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2449403 - Disclosure - Financial Instruments - Schedule of Balances in Foreign Currencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleOfBalancesInForeignCurrenciesDetails</Role>
      <ShortName>Financial Instruments - Schedule of Balances in Foreign Currencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2452402 - Disclosure - Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails</Role>
      <ShortName>Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2452403 - Disclosure - Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails</Role>
      <ShortName>Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2456401 - Disclosure - Economic Dependence (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails</Role>
      <ShortName>Economic Dependence (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/EconomicDependence</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2457402 - Disclosure - Other Expenses and Adjustments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsDetails</Role>
      <ShortName>Other Expenses and Adjustments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/OtherExpensesAndAdjustmentsTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2458402 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2459401 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/SubsequentEvents</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="oncyf-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - oncyf-20191231.xml</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - oncyf-20191231.xml</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>oncyf-20191231.xml</File>
    <File>oncyf-20191231.xsd</File>
    <File>oncyf-20191231_cal.xml</File>
    <File>oncyf-20191231_def.xml</File>
    <File>oncyf-20191231_lab.xml</File>
    <File>oncyf-20191231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.ifrs.org/taxonomy/2019-03-27/ifrs-full</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6729981744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of property and equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation is recorded using the declining balance method at the following annual rates:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.40350877192983%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:51%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office equipment and furniture</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Straight-line over the term of the lease</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:164px;" rowspan="1" colspan="1"></td><td style="width:80px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:87px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:76px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:90px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Computer Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Office Furniture</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Office Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Leasehold Improvements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,870</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">681,985</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">225,896</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">534,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,729,517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions, net of foreign exchange impact</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,202</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,542</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,763</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,163</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174,670</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposals</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(424,246</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85,096</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(646,834</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,378</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">345,941</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">247,438</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,229</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">498,367</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,257,353</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions, net of foreign exchange impact</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposals</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,378</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">352,955</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">247,438</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,229</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">498,367</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,264,367</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,334</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">549,564</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147,334</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,787</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">476,057</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,396,076</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,622</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,041</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,662</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposals</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,492</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(424,246</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85,096</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(646,834</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,464</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174,953</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,749</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">414,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">844,617</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,244</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,093</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,668</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,342</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,635</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,982</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposals</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,708</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224,046</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,417</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,170</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">448,258</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">967,599</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net book value</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15,670</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">128,909</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">75,021</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27,059</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">50,109</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">296,768</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,914</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170,988</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,689</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,401</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,744</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">412,736</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6751081808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofsharebasedpaymentarrangementAbstract', window );"><strong>Disclosure of share-based payment arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Schedule of stock options and weighted average exercise prices of share options</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:650px;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:158px;" rowspan="1" colspan="1"></td><td style="width:75px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:84px;" rowspan="1" colspan="1"></td><td style="width:74px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:80px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:81px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,249,361</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">647,156</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">912,995</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.42</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted during the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,020,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.42</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">750,467</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.97</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,625</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.60</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited during the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(12,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(105,338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(211,847</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.80</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired during the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(9,575</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">29.07</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,122</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.78</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,302</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.13</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised during the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(41,802</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.96</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(84,315</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.07</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,246,947</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5.31</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,249,361</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.73</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">647,156</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.20</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,327,845</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.22</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">777,245</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.04</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">573,984</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.36</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory', window );">Schedule of stock options outstanding and exercisable by range of exercise price</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about the stock options outstanding and exercisable at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:182px;" rowspan="1" colspan="1"></td><td style="width:96px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td><td style="width:96px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$0.54 - $1.42</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">100,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.81</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.96</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">66,667</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.75</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.43 - $1.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">900,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">300,009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.45</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.80 - $3.39</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">376,411</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.73</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">284,412</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.72</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$3.40 - $7.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">395,111</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">322,880</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.95</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$7.14 - $63.84</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">475,425</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.53</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16.74</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">353,877</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19.95</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,246,947</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.45</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.31</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,327,845</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.22</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Schedule of weighted average remaining contractual life and outstanding stock options by exercise price</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our outstanding equity warrants at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">: </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">         </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:425px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:74px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:90px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:138px;" rowspan="1" colspan="1"></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding, Beginning of the Year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding, End of the Year</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,443,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,443,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.42</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:78px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1)&#160;&#160;&#160;&#160; Exercisable into </font><font style="font-family:inherit;font-size:8pt;">1,730,894</font><font style="font-family:inherit;font-size:8pt;"> common shares.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about the stock options outstanding and exercisable at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:182px;" rowspan="1" colspan="1"></td><td style="width:96px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td><td style="width:96px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$0.54 - $1.42</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">100,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.81</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.96</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">66,667</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.75</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.43 - $1.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">900,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">300,009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.45</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.80 - $3.39</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">376,411</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.73</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">284,412</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.72</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$3.40 - $7.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">395,111</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">322,880</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.95</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$7.14 - $63.84</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">475,425</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.53</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16.74</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">353,877</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19.95</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,246,947</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.45</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.31</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,327,845</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.22</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Disclosure weighted average assumptions and fair value of options</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of stock options issued during the year was determined using the following weighted average assumptions: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:464px;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:245px;" rowspan="1" colspan="1"></td><td style="width:74px;" rowspan="1" colspan="1"></td><td style="width:72px;" rowspan="1" colspan="1"></td><td style="width:72px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.62%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.02%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.18%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected hold period to exercise</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.0 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected share price volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">97.90%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81.15%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90.73%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected forfeiture rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.67%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.67%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.67%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nil</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average fair value of options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$0.87</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.67</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.65</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Schedule of number of other equity instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following RSUs are outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:515px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:269px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">260,755</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190,407</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,237</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Granted during the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">270,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,855</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited during the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,210</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Vested during the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(321,196</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,297</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">209,657</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">260,755</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190,407</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:36px;"><font style="text-align:justify;font-family:inherit;font-size:8pt;padding-right:24px;">(1)</font><font style="font-family:inherit;font-size:8pt;">The weighted average fair value of the RSUs granted was </font><font style="font-family:inherit;font-size:8pt;">$0.80</font><font style="font-family:inherit;font-size:8pt;"> in </font><font style="font-family:inherit;font-size:8pt;">2019</font><font style="font-family:inherit;font-size:8pt;"> (</font><font style="font-family:inherit;font-size:8pt;">2018</font><font style="font-family:inherit;font-size:8pt;"> - </font><font style="font-family:inherit;font-size:8pt;">$3.35</font><font style="font-family:inherit;font-size:8pt;"> ; </font><font style="font-family:inherit;font-size:8pt;">2017</font><font style="font-family:inherit;font-size:8pt;"> - </font><font style="font-family:inherit;font-size:8pt;">$5.96</font><font style="font-family:inherit;font-size:8pt;">).</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The following PSUs are outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:521px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:274px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:75px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">63,156</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,734</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,419</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Granted during the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited during the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31,578</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested during the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(2,105</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">61,051</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,156</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,734</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:36px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) &#160;&#160;&#160;&#160;The weighted average fair value of the PSUs granted was </font><font style="font-family:inherit;font-size:8pt;">nil</font><font style="font-family:inherit;font-size:8pt;"> in </font><font style="font-family:inherit;font-size:8pt;">2019</font><font style="font-family:inherit;font-size:8pt;"> (</font><font style="font-family:inherit;font-size:8pt;">2018</font><font style="font-family:inherit;font-size:8pt;"> - </font><font style="font-family:inherit;font-size:8pt;">nil</font><font style="font-family:inherit;font-size:8pt;">; </font><font style="font-family:inherit;font-size:8pt;">2017</font><font style="font-family:inherit;font-size:8pt;"> - </font><font style="font-family:inherit;font-size:8pt;">$3.33</font><font style="font-family:inherit;font-size:8pt;">).</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the range of exercise prices for outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofsharebasedpaymentarrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of share-based payment arrangement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofsharebasedpaymentarrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6608395840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommitmentsAbstract', window );"><strong>Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsExplanatory', window );">Commitments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Commitments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are committed to payments totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4,867,131</font><font style="font-family:inherit;font-size:10pt;"> for activities related to our clinical trial, manufacturing and collaboration programs which are expected to occur over the next two years. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our commitments include one-half of the committed payments related to our collaboration with Merck KGaA, Darmstadt, Germany,  and Pfizer Inc ("Pfizer"), known as BRACELET-1, as the cost of this phase 2 clinical trial will be shared equally between Oncolytics and Pfizer. </font><font style="font-family:inherit;font-size:10pt;">As at December 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we recorded US$</font><font style="font-family:inherit;font-size:10pt;">1,500,000</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> - </font><font style="font-family:inherit;font-size:10pt;">nil</font><font style="font-family:inherit;font-size:10pt;">) in other receivables related to an upfront payment of BRACELET-1 cost from Pfizer per the terms of the collaboration agreement with an offsetting US$</font><font style="font-family:inherit;font-size:10pt;">652,306</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> - </font><font style="font-family:inherit;font-size:10pt;">nil</font><font style="font-family:inherit;font-size:10pt;">) in other liabilities representing future trial costs to be incurred.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under a clinical trial agreement entered into with the Alberta Cancer Board (&#8220;ACB&#8221;), we have agreed to repay the amount funded under the agreement together with a royalty, to a combined maximum amount of </font><font style="font-family:inherit;font-size:10pt;">$400,000</font><font style="font-family:inherit;font-size:10pt;"> plus an overhead repayment of </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;">, upon sales of a specified product.&#160;&#160;We agreed to repay the ACB in annual installments in an amount equal to the lesser of: (a) </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> of gross sales of a specified product; or (b) </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;"> per annum once sales of a specified product commence.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6736321456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Share Capital</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Share Capital</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Authorized:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unlimited number of no par value common shares</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Consolidation:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 22, 2018, we completed the consolidation of our common shares on the basis of </font><font style="font-family:inherit;font-size:10pt;">9.5</font><font style="font-family:inherit;font-size:10pt;"> pre-consolidation common shares for each one post-consolidation common share (the "Share Consolidation"). Fractional interests were rounded down to the nearest whole number of common shares. Outstanding stock options, restricted share units and performance share units were similarly adjusted by the consolidation ratio. Outstanding warrants were adjusted such that, following the Share Consolidation, </font><font style="font-family:inherit;font-size:10pt;">9.5</font><font style="font-family:inherit;font-size:10pt;"> equity-classified warrants will entitle the holder to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> whole common share until June 1, 2022.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:665px;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:293px;" rowspan="1" colspan="1"></td><td style="width:88px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:88px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:88px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:88px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued:</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121,258,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,321,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to stock option plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">801,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">536,949</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,301,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,348,821</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to public offering</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,893,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,391,057</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,805,722</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,710,138</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">519,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,335</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to stock option plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, May 22, 2018 - pre-consolidation</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,396,222</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272,268,722</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, May 22, 2018 - post-consolidation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,988,995</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272,268,722</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to public offering</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,532,278</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,606,882</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to warrant agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to stock option plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,329</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">158,976</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to incentive share award plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,297</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,751</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to Common Stock Purchase Agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(d)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">797,691</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,314,097</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(e)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,360</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,333,474</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,399,749</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,193,061</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,443,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,570</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to incentive share award plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">323,301</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,917</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to Common Stock Purchase Agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(d)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,494,943</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,403,385</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(e)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,425,040</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,476,454</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to public offering</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(f)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,619,773</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,314,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to warrant derivative exercised</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(f)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,935,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,152,869</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(854,256</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance, December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">32,198,453</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">311,077,859</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16,443,500</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,617,570</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 25, 2016, we entered into an "at-the-market" ("ATM") equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to </font><font style="font-family:inherit;font-size:10pt;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;"> which allows us to sell our common shares through the facilities of the Toronto Stock Exchange or other "marketplace&#8221; (as defined in National Instrument 21-101 Marketplace Operation) in Canada (our "Canadian ATM"). Subject to the terms of our Canadian ATM, we are able to determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility. During 2018, we sold </font><font style="font-family:inherit;font-size:10pt;">519,500</font><font style="font-family:inherit;font-size:10pt;"> pre-consolidation shares (approximately </font><font style="font-family:inherit;font-size:10pt;">54,684</font><font style="font-family:inherit;font-size:10pt;"> post-consolidation shares) (2017 - </font><font style="font-family:inherit;font-size:10pt;">3,301,500</font><font style="font-family:inherit;font-size:10pt;"> pre-consolidation shares (approximately </font><font style="font-family:inherit;font-size:10pt;">347,526</font><font style="font-family:inherit;font-size:10pt;"> post-consolidation shares) common shares for gross proceeds of $</font><font style="font-family:inherit;font-size:10pt;">553,650</font><font style="font-family:inherit;font-size:10pt;"> (2017 - $</font><font style="font-family:inherit;font-size:10pt;">2,348,821</font><font style="font-family:inherit;font-size:10pt;">). We incurred share issue costs of $</font><font style="font-family:inherit;font-size:10pt;">33,335</font><font style="font-family:inherit;font-size:10pt;"> (2017 - </font><font style="font-family:inherit;font-size:10pt;">$245,655</font><font style="font-family:inherit;font-size:10pt;">).</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 1, 2017, pursuant to an underwritten public offering, </font><font style="font-family:inherit;font-size:10pt;">16,445,000</font><font style="font-family:inherit;font-size:10pt;"> units were sold at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$0.70</font><font style="font-family:inherit;font-size:10pt;"> per unit for gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$11,511,500</font><font style="font-family:inherit;font-size:10pt;">.  Each unit included </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> pre-consolidation common share with an ascribed value of </font><font style="font-family:inherit;font-size:10pt;">$0.48</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">0.106</font><font style="font-family:inherit;font-size:10pt;"> post-consolidation common share with an ascribed value of </font><font style="font-family:inherit;font-size:10pt;">$4.56</font><font style="font-family:inherit;font-size:10pt;">) and </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> pre-consolidation common share purchase warrant with an ascribed value of </font><font style="font-family:inherit;font-size:10pt;">$0.22</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> post-consolidation common share purchase warrant with an ascribed value of </font><font style="font-family:inherit;font-size:10pt;">$2.09</font><font style="font-family:inherit;font-size:10pt;">). These warrants were classified as equity. Each pre-consolidation common share purchase warrant entitled the holder to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> pre-consolidation common share at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.95</font><font style="font-family:inherit;font-size:10pt;">. Following the Share Consolidation, </font><font style="font-family:inherit;font-size:10pt;">9.5</font><font style="font-family:inherit;font-size:10pt;"> pre-consolidation common share purchase warrants entitles the holder to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> post-consolidation common share in the capital of the Company until June 1, 2022, at an exercise price of approximately </font><font style="font-family:inherit;font-size:10pt;">$9.025</font><font style="font-family:inherit;font-size:10pt;">. The post-consolidation common share purchase warrants will be subject to acceleration if the volume weighted average price of the Company's common shares equals or exceeds </font><font style="font-family:inherit;font-size:10pt;">$23.75</font><font style="font-family:inherit;font-size:10pt;"> for </font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading dates.  The ascribed value was determined using the relative fair value method. The ascribed value of the common share purchase warrants was determined using the Black-Scholes valuation model. We incurred share issue costs of </font><font style="font-family:inherit;font-size:10pt;">$1,145,402</font><font style="font-family:inherit;font-size:10pt;">. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 5, 2018, pursuant to an underwritten public offering, </font><font style="font-family:inherit;font-size:10pt;">1,532,278</font><font style="font-family:inherit;font-size:10pt;"> common shares were sold at a purchase price of US</font><font style="font-family:inherit;font-size:10pt;">$5.83</font><font style="font-family:inherit;font-size:10pt;"> per share for gross proceeds of US</font><font style="font-family:inherit;font-size:10pt;">$8,933,181</font><font style="font-family:inherit;font-size:10pt;">. We incurred share issue costs of </font><font style="font-family:inherit;font-size:10pt;">$1,418,356</font><font style="font-family:inherit;font-size:10pt;">.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 27, 2018, we entered into a Common Stock Purchase Agreement (the "Agreement") with Lincoln Park Capital Fund, LLC ("LPC"). Subject to the terms and conditions of the Agreement and at our sole discretion, we may sell up to US$</font><font style="font-family:inherit;font-size:10pt;">26,000,000</font><font style="font-family:inherit;font-size:10pt;"> worth of common shares to LPC over the </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">-month term. The purchase price of the common shares will be based on the prevailing market prices immediately preceding the notice of sale without any fixed discount. Subject to the terms of the Agreement, we control the timing and amount of any future investment and LPC is obligated to make such purchases, if and when we elect. The Agreement does not impose any upper price limit restrictions, negative covenants or restrictions on our future financing activities. However, in no event will shares be sold to LPC on a day the closing sale price for the common shares is less than the floor price of US</font><font style="font-family:inherit;font-size:10pt;">$1.00</font><font style="font-family:inherit;font-size:10pt;"> per common share; or at a price per share that is less than the volume weighted average trading pricing of the common shares on the TSX for the five immediately preceding trading days, less the maximum applicable discount allowed by the TSX. The Agreement limits our sale of common shares to </font><font style="font-family:inherit;font-size:10pt;">19.99%</font><font style="font-family:inherit;font-size:10pt;"> of our total outstanding common shares as at the date that the Common Stock Purchase Agreement was entered into, unless and until we have obtained shareholder approval under applicable Nasdaq rules. </font><font style="font-family:inherit;font-size:10pt;">As at December 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we have reached that limit. We can terminate the Agreement at any time at our sole discretion without any monetary cost or penalty. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, we sold </font><font style="font-family:inherit;font-size:10pt;">2,477,665</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> - </font><font style="font-family:inherit;font-size:10pt;">678,182</font><font style="font-family:inherit;font-size:10pt;">) common shares for gross proceeds of US</font><font style="font-family:inherit;font-size:10pt;">$4,055,725</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> - US</font><font style="font-family:inherit;font-size:10pt;text-transform:default;">$2,055,207</font><font style="font-family:inherit;font-size:10pt;">) and issued </font><font style="font-family:inherit;font-size:10pt;text-transform:default;">17,278</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> - </font><font style="font-family:inherit;font-size:10pt;text-transform:default;">119,509</font><font style="font-family:inherit;font-size:10pt;">) commitment shares. The commitment shares were fair valued at US</font><font style="font-family:inherit;font-size:10pt;">$29,758</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> - US</font><font style="font-family:inherit;font-size:10pt;">$483,690</font><font style="font-family:inherit;font-size:10pt;">) and were recorded as share issue costs in addition to cash share issue costs of </font><font style="font-family:inherit;font-size:10pt;">$3,757</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> - </font><font style="font-family:inherit;font-size:10pt;">$208,726</font><font style="font-family:inherit;font-size:10pt;">).  </font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allows us, at our sole discretion, to issue common shares, at prevailing market price, with an aggregate offering value of up to US</font><font style="font-family:inherit;font-size:10pt;">$30,000,000</font><font style="font-family:inherit;font-size:10pt;"> over the next </font><font style="font-family:inherit;font-size:10pt;">19 months</font><font style="font-family:inherit;font-size:10pt;"> through the facilities of the NASDAQ in the United States. In </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, we sold </font><font style="font-family:inherit;font-size:10pt;">4,425,040</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> - </font><font style="font-family:inherit;font-size:10pt;">18,002</font><font style="font-family:inherit;font-size:10pt;">) common shares for gross proceeds of US</font><font style="font-family:inherit;font-size:10pt;">$6,390,691</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> - US</font><font style="font-family:inherit;font-size:10pt;">$50,046</font><font style="font-family:inherit;font-size:10pt;">). We incurred share issue costs of </font><font style="font-family:inherit;font-size:10pt;">344,834</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> -  </font><font style="font-family:inherit;font-size:10pt;">$135,000</font><font style="font-family:inherit;font-size:10pt;">). </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 16, 2019, pursuant to an underwritten public offering, </font><font style="font-family:inherit;font-size:10pt;text-transform:default;">4,619,773</font><font style="font-family:inherit;font-size:10pt;"> units were sold at a purchase price of US</font><font style="font-family:inherit;font-size:10pt;">$0.81</font><font style="font-family:inherit;font-size:10pt;"> per unit for gross proceeds of US</font><font style="font-family:inherit;font-size:10pt;">$3,742,016</font><font style="font-family:inherit;font-size:10pt;">. Each unit included </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> common share with a fair value of US</font><font style="font-family:inherit;font-size:10pt;">$0.54</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> common share purchase warrant with a fair value of US</font><font style="font-family:inherit;font-size:10pt;">$0.27</font><font style="font-family:inherit;font-size:10pt;">. These warrants were classified as a financial liability (see Note 8). Each common share purchase warrant entitled the holder to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> common share at an exercise price of US</font><font style="font-family:inherit;font-size:10pt;">$0.90</font><font style="font-family:inherit;font-size:10pt;"> until August 16, 2024. We incurred transaction costs of </font><font style="font-family:inherit;font-size:10pt;">$699,427</font><font style="font-family:inherit;font-size:10pt;"> of which </font><font style="font-family:inherit;font-size:10pt;">$466,284</font><font style="font-family:inherit;font-size:10pt;"> were allocated to share issue costs and </font><font style="font-family:inherit;font-size:10pt;">$233,143</font><font style="font-family:inherit;font-size:10pt;"> were allocated to operating expenses, based on their relative fair values. In the fourth quarter of 2019, our share capital included fair value of $</font><font style="font-family:inherit;font-size:10pt;">5,687,003</font><font style="font-family:inherit;font-size:10pt;"> in addition to gross proceeds of US</font><font style="font-family:inherit;font-size:10pt;">$2,642,082</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">2,935,647</font><font style="font-family:inherit;font-size:10pt;"> warrants that were exercised (see Note 8). </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Warrants</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our outstanding equity warrants at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">: </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">         </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:425px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:74px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:90px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:138px;" rowspan="1" colspan="1"></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding, Beginning of the Year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding, End of the Year</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,443,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,443,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.42</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:78px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1)&#160;&#160;&#160;&#160; Exercisable into </font><font style="font-family:inherit;font-size:8pt;">1,730,894</font><font style="font-family:inherit;font-size:8pt;"> common shares.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6736278160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash Equivalents And Short Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Cash Equivalents </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Equivalents</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents consist of interest bearing deposits with our bank totaling $</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">13,058,092</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> &#8211; </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$9,977,409</font><font style="font-family:inherit;font-size:10pt;">).&#160;&#160;The current annual interest rate earned on these deposits is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.17%</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> &#8211; </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2.71%</font><font style="font-family:inherit;font-size:10pt;">).</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents And Short Term Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents And Short Term Investments [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6736269056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expenses and Adjustments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory', window );">Other Expenses and Adjustments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Other Expenses and Adjustments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We present our expenses based on the function of each expense. We include realized foreign exchange gains and losses, unrealized non-cash foreign exchange gains and losses and non-cash share based compensation associated with research and development activity as a component of research and development expenses. We include depreciation of property and equipment, depreciation of right-of-use-asset, share based compensation associated with operating activities, and transaction costs related to our warrant derivative as a component of operating expenses.  </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:639px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:420px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Included in research and development expenses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Realized foreign exchange (gain) loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(39,362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,995</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(120,794</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized non-cash foreign exchange loss (gain)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">356,081</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(608,111</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,538</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">561,420</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">680,541</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230,141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Included in operating expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation - property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">122,982</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,768</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation - right-of-use assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">362,592</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">908,733</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">735,292</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">348,562</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transaction cost, warrant derivative</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">233,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Onerous lease contract</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,588</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization - lease incentive liability</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,189</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating expense. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6736336048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial instruments consist of cash and cash equivalents,&#160;other receivables, other liabilities, accounts payable and warrant derivative.&#160;As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the carrying amount of our cash and cash equivalents,&#160;other receivables, other liabilities and accounts payable approximated their fair value. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and therefore do not trade on an active market. </font><font style="font-family:inherit;font-size:10pt;">As at December 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the fair value of our warrant derivative was $</font><font style="font-family:inherit;font-size:10pt;">8,508,764</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> - </font><font style="font-family:inherit;font-size:10pt;">nil</font><font style="font-family:inherit;font-size:10pt;">).  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Credit risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;We are exposed to credit risk on our cash and cash equivalents and other receivables from Pfizer connected to the BRACELET-1 study (see Note 13) in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and other receivables. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our exposure to credit risk connected to our cash and cash equivalent by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our exposure to credit risk connected to our Pfizer other receivable by entering into collaborations with global biopharmaceutical companies.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest rate risk </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We are exposed to interest rate risk through our cash and cash equivalents.&#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign exchange risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. We are primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar, British pound and Euro as a portion of our financial assets and liabilities are denominated in such currencies. The impact of a </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> increase in the value of the U.S. dollar against the Canadian dollar would have increased our net comprehensive loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;"> by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$125,339</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;The impact of a </font><font style="font-family:inherit;font-size:10pt;">$0.10</font><font style="font-family:inherit;font-size:10pt;"> increase in the value of the British pound against the Canadian dollar would have increased our net comprehensive loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;"> by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$8,581</font><font style="font-family:inherit;font-size:10pt;">. The impact of a </font><font style="font-family:inherit;font-size:10pt;">$0.10</font><font style="font-family:inherit;font-size:10pt;"> increase in the value of the Euro against the Canadian dollar would have increased our net comprehensive loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;"> by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$32,426</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balances in foreign currencies at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:622px;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:222px;" rowspan="1" colspan="1"></td><td style="width:133px;" rowspan="1" colspan="1"></td><td style="width:133px;" rowspan="1" colspan="1"></td><td style="width:133px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">US dollars <br clear="none"/></font><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">British pounds<br clear="none"/></font><font style="font-family:inherit;font-size:10pt;">&#163;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Euro<br clear="none"/>&#8364;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,676,360</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,751</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,664</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,500,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and other liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,378,860)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,345)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(310,086)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant derivative</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,551,250)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,246,250</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,406</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(276,422)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;We manage liquidity risk through the management of our capital structure as outlined in Note 16. Accounts payable are all due within the current operating period.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Section Scope<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6752435824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN (DEFICIT) EQUITY - CAD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At-the-market agreement</div></th>
<th class="th"><div>Public Offering</div></th>
<th class="th"><div>Share Purchase Agreement</div></th>
<th class="th"><div>Share Capital $</div></th>
<th class="th">
<div>Share Capital $ </div>
<div>At-the-market agreement</div>
</th>
<th class="th">
<div>Share Capital $ </div>
<div>Public Offering</div>
</th>
<th class="th">
<div>Share Capital $ </div>
<div>Share Purchase Agreement</div>
</th>
<th class="th"><div>Warrants $</div></th>
<th class="th"><div>Contributed Surplus $</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income $</div></th>
<th class="th"><div>Accumulated Deficit $</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Dec. 31, 2016</a></td>
<td class="nump">$ 10,689,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262,321,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 26,643,044<span></span>
</td>
<td class="nump">$ 554,060<span></span>
</td>
<td class="num">$ (278,829,309)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and other comprehensive income</a></td>
<td class="num">(15,797,181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(180,330)<span></span>
</td>
<td class="num">(15,616,851)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Issued pursuant to stock option plan</a></td>
<td class="nump">343,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">536,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(193,509)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,348,821<span></span>
</td>
<td class="nump">$ 11,511,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,348,821<span></span>
</td>
<td class="nump">$ 7,893,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,617,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share based compensation</a></td>
<td class="nump">578,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">578,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="num">(1,391,057)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,391,057)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Dec. 31, 2017</a></td>
<td class="nump">8,283,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,710,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,617,900<span></span>
</td>
<td class="nump">27,028,238<span></span>
</td>
<td class="nump">373,730<span></span>
</td>
<td class="num">(294,446,160)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Dec. 31, 2017</a></td>
<td class="nump">8,283,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,710,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,617,900<span></span>
</td>
<td class="nump">27,028,238<span></span>
</td>
<td class="nump">373,730<span></span>
</td>
<td class="num">(294,446,160)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and other comprehensive income</a></td>
<td class="num">(16,803,451)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,774<span></span>
</td>
<td class="num">(17,037,225)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity', window );">Issued pursuant to incentive share award plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(109,751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Issued pursuant to stock option plan</a></td>
<td class="nump">123,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,707)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">620,010<span></span>
</td>
<td class="nump">11,606,882<span></span>
</td>
<td class="nump">$ 3,314,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">620,010<span></span>
</td>
<td class="nump">11,606,882<span></span>
</td>
<td class="nump">$ 3,314,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Issued pursuant to warrant agreement</a></td>
<td class="nump">1,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share based compensation</a></td>
<td class="nump">1,415,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,415,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="num">(2,366,809)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,366,809)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Dec. 31, 2018</a></td>
<td class="nump">6,195,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,193,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,617,570<span></span>
</td>
<td class="nump">28,260,613<span></span>
</td>
<td class="nump">607,504<span></span>
</td>
<td class="num">(311,483,385)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Dec. 31, 2018</a></td>
<td class="nump">6,195,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,193,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,617,570<span></span>
</td>
<td class="nump">28,260,613<span></span>
</td>
<td class="nump">607,504<span></span>
</td>
<td class="num">(311,483,385)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and other comprehensive income</a></td>
<td class="num">(33,266,291)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(143,403)<span></span>
</td>
<td class="num">(33,122,888)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity', window );">Issued pursuant to incentive share award plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">391,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(391,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,476,454<span></span>
</td>
<td class="nump">$ 3,314,429<span></span>
</td>
<td class="nump">$ 5,403,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,476,454<span></span>
</td>
<td class="nump">$ 3,314,429<span></span>
</td>
<td class="nump">$ 5,403,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Issued pursuant to warrant agreement</a></td>
<td class="nump">9,152,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,152,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share based compensation</a></td>
<td class="nump">1,470,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,470,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="num">(854,256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(854,256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Dec. 31, 2019</a></td>
<td class="num">$ (107,894)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 311,077,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="nump">$ 29,338,849<span></span>
</td>
<td class="nump">$ 464,101<span></span>
</td>
<td class="num">$ (344,606,273)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Incentive Share Awards, Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6750991568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ONCOLYTICS BIOTECH INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001129928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">32,198,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document And Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6736278160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements have, in management's opinion, been properly prepared within reasonable limits of materiality and within the framework of the significant accounting policies summarized below.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Deferred income taxes</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We follow the liability method of accounting for income taxes.  Under the liability method, deferred income taxes are recognized for the difference between financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences).  Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled.  The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.  </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Financial instruments </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Classification and measurement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial assets</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under IFRS 9 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments ("IFRS 9")</font><font style="font-family:inherit;font-size:10pt;">, financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#8217;s business model for managing the assets; and whether the financial asset&#8217;s contractual cash flows represent &#8216;solely payments of principal and interest&#8217; on the principal amount outstanding (the &#8216;SPPI criterion&#8217;). </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial assets include cash and cash equivalents and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion. </font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial liabilities</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include trade accounts payable, other liabilities and warrant derivative. The classification and measurement of trade accounts payable and other liabilities are at amortized cost. The classification and measurement of warrant derivative is at FVPL.  </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under IFRS 9, accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IFRS 9 requires that we record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#8217;s original effective interest rate.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Derecognition</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A financial asset is derecognized when:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the contractual rights to the cash flows from the financial asset expire, or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A financial liability is derecognized when our obligations specified in the contract are discharged or canceled or expired. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments we prioritize the related inputs used in measuring fair value into the following hierarchy: </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Foreign currency translation</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exceptions to this are where the monetary items form part of the net investment in a foreign operation and the foreign operation's functional currency is the local currency.  These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.  </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Loss per common share</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per common share is determined using the weighted average number of common shares outstanding during the period.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the treasury stock method to calculate diluted loss per common share.  Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants, if dilutive. The number of additional common shares is calculated by assuming that any outstanding &#8220;in the money&#8221; options, restricted share units, performance share units and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Property and equipment </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives.  Depreciation is recorded using the declining balance method at the following annual rates:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.40350877192983%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:51%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office equipment and furniture</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Straight-line over the term of the lease</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At inception of a contract, we assess whether a contract is, or contains a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the contract involves the use of an identified asset;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we have the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we have the right to direct the use of the identified asset. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A right-of-use asset and corresponding lease liability is recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Research and development costs</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the treatment phase of clinical trials based on the total estimated cost of the treatment phase on a per patient basis and we expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized.  To date, all development costs have been expensed. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Revenue recognition</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The contract also provides for development and regulatory milestone payments, royalties and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract receivable</font><font style="font-family:inherit;font-size:10pt;"> - Contract receivable includes amounts billed and currently due from customers. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts. We perform a review of our customer&#8217;s credit risk and payment histories, including payments made subsequent to year-end.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract liability</font><font style="font-family:inherit;font-size:10pt;"> - Our contract liability includes upfront license fees and billings in excess of revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or noncurrent based on the timing of when we expect to recognize revenue.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Share based payments </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock option plan</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> stock option plan (the &#8220;Option Plan&#8221;) available to officers, directors, employees and consultants with grants under the Option Plan approved from time to time by our Board of Directors (the &#8220;Board&#8221;). Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines. Vesting is provided for at the discretion of the Board and the expiration of options is to be no greater than </font><font style="font-family:inherit;font-size:10pt;">10 years</font><font style="font-family:inherit;font-size:10pt;"> from the date of grant. Exercised stock options are settled with common shares issued from treasury. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the fair value based method of accounting for stock option awards granted under the Option Plan.  We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black- Scholes valuation model. The fair value of stock options with a graded vesting schedule is determined based on different expected lives for the options that vest each year, as it would be if the award were viewed as several separate awards, each with a different vesting date, and it is accounted for over the respective vesting period taking into consideration forfeiture estimates.   Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of options that are expected to vest.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Incentive share award plan</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our incentive share award plan (the "Share Plan") is available to directors, officers and employees. Under our Share Plan, performance share units and restricted share units may be approved from time to time by the Board. Performance share units  ("PSUs") are an award to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share units ("RSUs") are an award to certain officers and employees and to non-employee directors to which common shares shall be issued in accordance with the Share Plan.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the date of grant based on the number of PSUs/RSUs expected to vest, recognized over the term of the vesting period. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Adoption of New Accounting Standards</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IFRS 16 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IFRS 16 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;IFRS 16&#8221;) replaces IAS 17 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;IAS 17&#8221;) and related interpretations for annual periods beginning on or after January 1, 2019. We have adopted IFRS 16 using the modified retrospective approach, under which the cumulative effect of the initial application is recognized in retained earnings at January 1, 2019. We have not restated comparatives for 2018. On transition to IFRS 16, we elected to apply the following practical expedients: </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Applied the exemption for short-term leases that have a remaining lease term of less than 12 months as at January 1, 2019; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Excluded initial direct costs for the measurement of right-of-use assets as at January 1, 2019; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Relied upon our assessment of whether leases are onerous under the requirement of IAS 37, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Provisions, contingent liabilities and contingent assets</font><font style="font-family:inherit;font-size:10pt;"> as at December 31, 2018 as an alternative to reviewing our right-of-use assets for impairment; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Measured the right-of-use assets at an amount equal to the lease liability, adjusted by the amount of lease incentive liability related to that lease recognized in the statement of financial position immediately before the date of initial application. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On transition to IFRS 16, we recognized </font><font style="font-family:inherit;font-size:10pt;">$882,437</font><font style="font-family:inherit;font-size:10pt;"> of lease liabilities. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate at January 1, 2019 as rates implicit in the leases were not readily determinable. The weighted-average rate applied was </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the impacts of adopting IFRS 16 on the consolidated financial statements:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Impact of changes</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported as at December 31, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Effects of IFRS 16 transition</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent to transition as at January 1, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Right-of-use assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current and non-current assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865,253</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865,253</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865,253</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,673,278</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,750</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(74,412</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,338</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">882,437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">882,437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current and non-current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,556,140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,556,140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,669,890</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,477,915</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total shareholders' equity</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,195,363</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,195,363</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to adopting IFRS 16, our total minimum operating lease commitments as at December 31, 2018 were </font><font style="font-family:inherit;font-size:10pt;">$961,575</font><font style="font-family:inherit;font-size:10pt;">. The difference between the total of the minimum lease payments set out in Note 11 of our 2018 annual consolidated financial statements and the total lease liabilities recognized on transition was a result of the effect of discounting on the minimum lease payments.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6734179936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision for Income Taxes (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofincometaxAbstract', window );"><strong>Disclosure of income tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AccountingProfit', window );">Loss before income taxes</a></td>
<td class="num">$ (33,122,888)<span></span>
</td>
<td class="num">$ (16,489,183)<span></span>
</td>
<td class="num">$ (15,475,353)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Statutory Canadian corporate tax rate</a></td>
<td class="nump">26.50%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Anticipated tax recovery</a></td>
<td class="num">$ (8,777,565)<span></span>
</td>
<td class="num">$ (4,452,079)<span></span>
</td>
<td class="num">$ (4,178,345)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxEffectOfForeignTaxRates', window );">Foreign jurisdiction tax rate difference</a></td>
<td class="nump">3,088,811<span></span>
</td>
<td class="nump">3,312,963<span></span>
</td>
<td class="nump">2,899,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_TaxEffectOfStockBasedCompensation', window );">Employee share based compensation</a></td>
<td class="nump">389,591<span></span>
</td>
<td class="nump">382,275<span></span>
</td>
<td class="nump">156,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative', window );">Change in fair value of warrant derivative</a></td>
<td class="nump">3,341,334<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxEffectFromChangeInTaxRate', window );">Impact of Alberta rate change</a></td>
<td class="nump">3,758,175<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_TaxEffectOfTaxPools', window );">Adjustment to opening tax pools</a></td>
<td class="nump">11,973<span></span>
</td>
<td class="num">(238,222)<span></span>
</td>
<td class="nump">162,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss', window );">Other permanent differences</a></td>
<td class="nump">149,294<span></span>
</td>
<td class="num">(35,912)<span></span>
</td>
<td class="nump">53,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1', window );">Change in deferred tax benefits deemed not probable to be recovered</a></td>
<td class="num">(1,961,613)<span></span>
</td>
<td class="nump">1,579,017<span></span>
</td>
<td class="nump">1,051,725<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">548,042<span></span>
</td>
<td class="nump">144,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod', window );">Adjustment in respect to prior periods</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,523)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods', window );">Net current tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 548,042<span></span>
</td>
<td class="nump">$ 141,498<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccountingProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccountingProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments of tax expense (income) recognised in the period for current tax of prior periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 80<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_80_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 80<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 80<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_80&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectFromChangeInTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectFromChangeInTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfForeignTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfForeignTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofincometaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofincometaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Change in Fair Value Of Warrant Derivative</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TaxEffectOfStockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Stock Based Compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TaxEffectOfStockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TaxEffectOfTaxPools">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Tax Pools</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TaxEffectOfTaxPools</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6658924416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability and Receivable - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($) </div>
<div>year </div>
<div>patient</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantPurchaseAgreement', window );">Warrant purchase agreement | $</a></td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePricePremiumPercent', window );">Common share premium</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WeightedAverageClosingPriceDuration', window );">Weighted average closing price term</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_NumberofPatients', window );">Patients | patient</a></td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ContractLiabilityRecognitionPeriod', window );">Expected recognition period | year</a></td>
<td class="nump">5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContractLiabilityRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Liability, Recognition Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContractLiabilityRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberofPatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Patients</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberofPatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharePricePremiumPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Price Premium, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharePricePremiumPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WeightedAverageClosingPriceDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Closing Price Duration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WeightedAverageClosingPriceDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6733879680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (options) | shares</a></td>
<td class="nump">2,246,947<span></span>
</td>
<td class="nump">1,249,361<span></span>
</td>
<td class="nump">647,156<span></span>
</td>
<td class="nump">912,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">4 years 5 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 5.31<span></span>
</td>
<td class="nump">$ 8.73<span></span>
</td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="nump">$ 17.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (options) | shares</a></td>
<td class="nump">1,327,845<span></span>
</td>
<td class="nump">777,245<span></span>
</td>
<td class="nump">573,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 7.22<span></span>
</td>
<td class="nump">$ 11.04<span></span>
</td>
<td class="nump">$ 14.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember', window );">$0.54 - $1.42</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (options) | shares</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">4 years 9 months 22 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (options) | shares</a></td>
<td class="nump">66,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember', window );">$0.54 - $1.42 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">0.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember', window );">$0.54 - $1.42 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 1.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember', window );">$1.43 - $1.79</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (options) | shares</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">4 years 11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (options) | shares</a></td>
<td class="nump">300,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember', window );">$1.43 - $1.79 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">1.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember', window );">$1.43 - $1.79 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 1.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember', window );">$1.80 - $3.39</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (options) | shares</a></td>
<td class="nump">376,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">5 years 1 month 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 2.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (options) | shares</a></td>
<td class="nump">284,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 2.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember', window );">$1.80 - $3.39 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember', window );">$1.80 - $3.39 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 3.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember', window );">$3.40 - $7.13</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (options) | shares</a></td>
<td class="nump">395,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">4 years 10 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 3.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (options) | shares</a></td>
<td class="nump">322,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 3.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember', window );">$3.40 - $7.13 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">3.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember', window );">$3.40 - $7.13 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 7.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember', window );">$7.14 - $63.84</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (options) | shares</a></td>
<td class="nump">475,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">2 years 6 months 11 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 16.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (options) | shares</a></td>
<td class="nump">353,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 19.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember', window );">$7.14 - $63.84 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">7.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember', window );">$7.14 - $63.84 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 63.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6624969488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expenses and Adjustments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OtherExpensesAndAdjustmentsTableTextBlock', window );">Other expenses and adjustments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:639px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:420px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Included in research and development expenses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Realized foreign exchange (gain) loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(39,362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,995</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(120,794</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized non-cash foreign exchange loss (gain)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">356,081</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(608,111</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,538</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">561,420</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">680,541</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230,141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Included in operating expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation - property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">122,982</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,768</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation - right-of-use assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">362,592</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">908,733</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">735,292</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">348,562</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transaction cost, warrant derivative</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">233,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Onerous lease contract</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,588</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization - lease incentive liability</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,189</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OtherExpensesAndAdjustmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Expenses And Adjustments [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OtherExpensesAndAdjustmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6753000304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - IFRS 16 Leases (Details) - CAD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16', window );">Weighted average rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">$ 430,713<span></span>
</td>
<td class="nump">$ 808,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OtherCurrentandNoncurrentAssets', window );">Other current and non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,865,253<span></span>
</td>
<td class="nump">$ 14,865,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">19,657,865<span></span>
</td>
<td class="nump">15,673,278<span></span>
</td>
<td class="nump">14,865,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherLiabilities', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,338<span></span>
</td>
<td class="nump">113,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">506,275<span></span>
</td>
<td class="nump">882,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OtherCurrentandNoncurrentLiabilities', window );">Other current and non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,556,140<span></span>
</td>
<td class="nump">8,556,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">19,765,759<span></span>
</td>
<td class="nump">9,477,915<span></span>
</td>
<td class="nump">8,669,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Shareholders&#8217; (deficit) equity</a></td>
<td class="num">(107,894)<span></span>
</td>
<td class="nump">6,195,363<span></span>
</td>
<td class="nump">6,195,363<span></span>
</td>
<td class="nump">$ 8,283,846<span></span>
</td>
<td class="nump">$ 10,689,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total minimum operating lease commitments</a></td>
<td class="nump">$ 565,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 961,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InitiallyAppliedIFRSsAxis=oncyf_EffectsofIFRS16TransitionMember', window );">Effects of IFRS 16 transition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">808,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OtherCurrentandNoncurrentAssets', window );">Other current and non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">808,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherLiabilities', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74,412)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">882,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OtherCurrentandNoncurrentLiabilities', window );">Other current and non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">808,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Shareholders&#8217; (deficit) equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2020-01-01: The amount of resources: (a) controlled by the entity as a result of past events; and (b) from which future economic benefits are expected to flow to the entity.
Effective 2020-01-01: The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 58<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_58&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph B11D<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B11D_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2020-01-01: The amount of present obligations of the entity arising from past events, the settlement of which is expected to result in an outflow from the entity of resources embodying economic benefits.
Effective 2020-01-01: The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average lessee's incremental borrowing rate applied to lease liabilities recognised in the statement of financial position at the date of initial application of IFRS 16. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph C12<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_C12_a&amp;doctype=Appendix&amp;subtype=C<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OtherCurrentandNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Current and Non-current Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OtherCurrentandNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OtherCurrentandNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Current and Non-current Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OtherCurrentandNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InitiallyAppliedIFRSsAxis=oncyf_EffectsofIFRS16TransitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InitiallyAppliedIFRSsAxis=oncyf_EffectsofIFRS16TransitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6736296928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Economic Dependence<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfEconomicDependenceAbstract', window );"><strong>Disclosure Of Economic Dependence [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfEconomicDependenceTextBlock', window );">Economic Dependence</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Economic Dependence</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are economically dependent on our toll manufacturers. We primarily use </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> toll manufacturer in the US to produce the clinical grade pelareorep required for our clinical trial program.&#160;Any significant disruption of the services provided by our primary toll manufacturer has the potential to delay the progress of our clinical trial program.&#160;We have used another toll manufacturer in the U.K. that has also produced clinical grade pelareorep at a smaller scale.&#160;We have attempted to mitigate this risk by producing sufficient pelareorep in advance of patient enrollment in a particular clinical trial.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfEconomicDependenceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Economic Dependence [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfEconomicDependenceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfEconomicDependenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Economic Dependence [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfEconomicDependenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6730046080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory', window );">Capital Disclosures</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Capital Disclosures</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our objective when managing capital is to maintain a strong statement of financial position. We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs and intellectual property expansion and protection.&#160;We include shareholders&#8217; equity and cash and cash equivalents in the definition of capital.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14,148,021</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,699,881</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; (deficit) equity</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(107,894</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,195,363</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not have any debt other than trade accounts payable and we have potential contingent obligations relating to the completion of our research and development of pelareorep.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;There are no assurances that funds will be made available to us when required.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 4, 2018, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to </font><font style="font-family:inherit;font-size:10pt;">$150,000,000</font><font style="font-family:inherit;font-size:10pt;"> of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the US or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Renewing our Base Shelf  provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until May 25, 2020. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Base Shelf allowed us to enter into our Common Stock Purchase Agreement in September 2018, our ATM equity offering sales agreement in October 2018, and our public offering in August 2019 (see Note 9). We will use these equity arrangements to assist us in achieving our capital objective. Each arrangement provides us with the opportunity to raise capital at our sole discretion providing us with the ability to better manage our cash resources. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information that enables users of financial statements to evaluate the entity's objectives, policies and processes for managing capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 134<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_134&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6657531568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Financial Statement Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate Information And Statement Of IFRS Compliance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of Financial Statement Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Basis of Financial Statement Presentation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our consolidated financial statements include our financial statements and the financial statements of our subsidiaries Oncolytics Biotech (Barbados) Inc., Oncolytics Biotech (US) Inc., and Oncolytics Biotech (UK) Ltd. and are presented in Canadian dollars, our functional currency.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accounts are prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of consolidation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our accounts include the accounts of Oncolytics Biotech Inc. and our subsidiaries. Subsidiaries are entities over which we have control which is achieved when we are exposed, or have the rights, to variable returns from our involvement with the investee and has the ability to affect those returns through our power to govern. Accounting policies of subsidiaries are consistent with our accounting policies and all intra-group transactions, balances, income and expenses are eliminated on consolidation.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A change in ownership interest of a subsidiary, without a change in control, is accounted for as an equity transaction.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Corporate Information And Statement Of IFRS Compliance [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6750877904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseByNatureAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 11,134,716<span></span>
</td>
<td class="nump">$ 9,417,888<span></span>
</td>
<td class="nump">$ 9,392,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Operating</a></td>
<td class="nump">9,558,641<span></span>
</td>
<td class="nump">7,244,791<span></span>
</td>
<td class="nump">6,212,831<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Loss before the following</a></td>
<td class="num">(20,693,357)<span></span>
</td>
<td class="num">(16,662,679)<span></span>
</td>
<td class="num">(15,605,454)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value of warrant derivative</a></td>
<td class="num">(12,608,808)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestIncomeOnCashAndCashEquivalents', window );">Interest income, net</a></td>
<td class="nump">179,277<span></span>
</td>
<td class="nump">173,496<span></span>
</td>
<td class="nump">130,101<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income taxes</a></td>
<td class="num">(33,122,888)<span></span>
</td>
<td class="num">(16,489,183)<span></span>
</td>
<td class="num">(15,475,353)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(548,042)<span></span>
</td>
<td class="num">(141,498)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="num">(33,122,888)<span></span>
</td>
<td class="num">(17,037,225)<span></span>
</td>
<td class="num">(15,616,851)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive (loss) income items that may be reclassified to net loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Translation adjustment</a></td>
<td class="num">(143,403)<span></span>
</td>
<td class="nump">233,774<span></span>
</td>
<td class="num">(180,330)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net comprehensive loss</a></td>
<td class="num">$ (33,266,291)<span></span>
</td>
<td class="num">$ (16,803,451)<span></span>
</td>
<td class="num">$ (15,797,181)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicAndDilutedEarningsLossPerShare', window );">Basic and diluted loss per common share (cad per share)</a></td>
<td class="num">$ (1.50)<span></span>
</td>
<td class="num">$ (1.06)<span></span>
</td>
<td class="num">$ (1.12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of shares (basic) (shares)</a></td>
<td class="nump">22,137,990<span></span>
</td>
<td class="nump">16,016,366<span></span>
</td>
<td class="nump">13,936,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of shares (diluted) (shares)</a></td>
<td class="nump">22,137,990<span></span>
</td>
<td class="nump">16,016,366<span></span>
</td>
<td class="nump">13,936,387<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicAndDilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of earnings per share when the basic and diluted measurements are equal. [Refer: Basic earnings (loss) per share; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicAndDilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNatureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNatureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income on cash and cash equivalents. [Refer: Interest income; Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2019-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2019-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2019-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2019-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6655910096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of common shares outstanding (shares)</a></td>
<td class="nump">22,137,990<span></span>
</td>
<td class="nump">16,016,366<span></span>
</td>
<td class="nump">13,936,387<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6733451312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Non-cash share based compensation | $</a></td>
<td class="nump">$ 1,470,153<span></span>
</td>
<td class="nump">$ 1,415,833<span></span>
</td>
<td class="nump">$ 578,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember', window );">Restricted share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_PerformanceShareUnitsMember', window );">Performance share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ReserveOfSharebasedPaymentsMember', window );">Reserve of share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares', window );">Common shares reserved for issuance (shares) | shares</a></td>
<td class="nump">3,219,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issue under options and contracts for the sale of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_79_a_vii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_PerformanceShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_PerformanceShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ReserveOfSharebasedPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ReserveOfSharebasedPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6753676304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue', window );">Royalty payment on sales revenue, percent</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ContingentRoyaltyPaymentAnnualMaximum', window );">Royalty payment maximum</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ContingentRoyaltyPaymentContributionRate', window );">Royalty, multiple of work in kind contribution</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AccruedRoyalties1', window );">Estimated accumulated work in kind total</a></td>
<td class="nump">$ 301,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=oncyf_SYNSORBMember', window );">SYNSORB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions', window );">Milestone payment in connection with Share Purchase Agreement</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue', window );">Payment due period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage', window );">Royalty payment due to founding shareholders, percent</a></td>
<td class="nump">10.75%<span></span>
</td>
<td class="nump">10.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage', window );">Royalty payment on net sales due to founding shareholders, percent</a></td>
<td class="nump">2.15%<span></span>
</td>
<td class="nump">2.15%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of related-party commitments made by the entity to do something if a particular event occurs or does not occur in the future, including executory contracts (recognised and unrecognised). [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2019-01-01<br> -Paragraph 21<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_21_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AccruedRoyalties1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Royalties1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AccruedRoyalties1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments Made By Entity, Related Party Transactions, Period Due</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments Made By Entity, Related Party Transactions, Royalty Payment Net Sales, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments Made By Entity, Related Party Transactions, Royalty Payment Received, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContingentRoyaltyPaymentAnnualMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Royalty Payment, Annual Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContingentRoyaltyPaymentAnnualMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContingentRoyaltyPaymentContributionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Royalty Payment, Contribution Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContingentRoyaltyPaymentContributionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Royalty Payment, Percent Of Sales Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=oncyf_SYNSORBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=oncyf_SYNSORBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6729963024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrelatedpartyAbstract', window );"><strong>Disclosure of related party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Schedule of related party transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:520px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:301px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term employee compensation and benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,786,667</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,680,621</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,596,082</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Termination benefits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">779,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,123,408</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,067,195</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">459,298</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,910,075</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,747,816</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,835,046</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2019-01-01<br> -Paragraph 18<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrelatedpartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of related party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrelatedpartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6668607008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents - Narrative (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash Equivalents And Short Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents</a></td>
<td class="nump">$ 13,058,092<span></span>
</td>
<td class="nump">$ 9,977,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CashEquivalentsInterestRate', window );">Current annual interest rate</a></td>
<td class="nump">1.17%<span></span>
</td>
<td class="nump">2.71%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents And Short Term Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CashEquivalentsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CashEquivalentsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6734966752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expenses and Adjustments (Details)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OtherExpensesAndAdjustmentsLineItems', window );"><strong>Other Expenses And Adjustments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Unrealized non-cash foreign exchange loss (gain)</a></td>
<td class="nump">$ 353,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (374,337)<span></span>
</td>
<td class="num">$ (124,793)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Non-cash share based compensation</a></td>
<td class="nump">1,470,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,415,833<span></span>
</td>
<td class="nump">578,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation - right-of-use assets</a></td>
<td class="nump">362,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="nump">854,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,366,809<span></span>
</td>
<td class="nump">1,391,057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForProvisions', window );">Onerous lease contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,588<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AdjustmentsforLeaseAmortization', window );">Amortization - lease incentive liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,189<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IncomeStatementLocation1Axis=oncyf_ResearchAndDevelopmentMember', window );">Included in research and development expenses:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OtherExpensesAndAdjustmentsLineItems', window );"><strong>Other Expenses And Adjustments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Realized foreign exchange (gain) loss</a></td>
<td class="num">(39,362)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,995)<span></span>
</td>
<td class="num">(120,794)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Unrealized non-cash foreign exchange loss (gain)</a></td>
<td class="nump">356,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(608,111)<span></span>
</td>
<td class="nump">55,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Non-cash share based compensation</a></td>
<td class="nump">561,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">680,541<span></span>
</td>
<td class="nump">230,141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IncomeStatementLocation1Axis=oncyf_OperatingExpensesMember', window );">Included in operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OtherExpensesAndAdjustmentsLineItems', window );"><strong>Other Expenses And Adjustments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Non-cash share based compensation</a></td>
<td class="nump">908,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">735,292<span></span>
</td>
<td class="nump">348,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmortisationExpense', window );">Depreciation - property and equipment</a></td>
<td class="nump">122,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,375<span></span>
</td>
<td class="nump">90,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation - right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 362,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForProvisions', window );">Onerous lease contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,588<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AdjustmentsforLeaseAmortization', window );">Amortization - lease incentive liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,189<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IncomeStatementLocation1Axis=oncyf_OperatingExpensesMember', window );">Included in operating expenses | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OtherExpensesAndAdjustmentsLineItems', window );"><strong>Other Expenses And Adjustments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="nump">$ 233,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation expense. Amortisation is the systematic allocation of depreciable amounts of intangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2019-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdjustmentsforLeaseAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for Lease Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdjustmentsforLeaseAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OtherExpensesAndAdjustmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Other Expenses And Adjustments [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OtherExpensesAndAdjustmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncomeStatementLocation1Axis=oncyf_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncomeStatementLocation1Axis=oncyf_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncomeStatementLocation1Axis=oncyf_OperatingExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncomeStatementLocation1Axis=oncyf_OperatingExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6762509648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Non-refundable Federal Investment Tax Credits (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember', window );">Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">$ 5,482,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember', window );">Unclaimed scientific research and experimental development expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">27,560,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyMember', window );">2020 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">189,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyOneMember', window );">2021 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">471,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyTwoMember', window );">2022 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">465,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyThreeMember', window );">2023 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">361,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyFourMember', window );">2024 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">228,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyFiveMember', window );">2025 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">271,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySixMember', window );">2026 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">520,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySevenMember', window );">2027 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">596,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyEightMember', window );">2028 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">622,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyNineMember', window );">2029 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">173,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyMember', window );">2030 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">91,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyOneMember', window );">2031 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">114,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyTwoMember', window );">2032 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">381,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyThreeMember', window );">2033 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">487,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFourMember', window );">2034 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">270,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFiveMember', window );">2035 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">183,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySixMember', window );">2036 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">41,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySevenMember', window );">2037 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyEightMember', window );">2038 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">$ 19,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax credits for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax credits [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6762552016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 25, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 05, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 01, 2017 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 05, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember', window );">United States ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,425,040<span></span>
</td>
<td class="nump">18,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,390,691<span></span>
</td>
<td class="nump">$ 50,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,532,278<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,933,181<span></span>
</td>
<td class="nump">$ 11,511,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember', window );">Share transactions | United States ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,921,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,726,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember', window );">Share transactions | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,145,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,030,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember', window );">Receipt of upfront payment | BRACELET-1 collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ProceedsFromCollaborationAgreement', window );">Other receivables | $</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Issue Of Ordinary Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GrossProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ProceedsFromCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ProceedsFromCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=oncyf_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=oncyf_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6733801984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Balances in Foreign Currencies (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 14,148,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,699,881<span></span>
</td>
<td class="nump">$ 11,836,119<span></span>
</td>
<td class="nump">$ 12,034,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">2,068,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(3,173,218)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,825,853)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative</a></td>
<td class="nump">$ 8,508,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_Currency1Axis=currency_USD', window );">US dollars $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,676,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,378,860)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,551,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_BalanceHeldInForeignCurrencyNet', window );">Balances in foreign currencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,246,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_Currency1Axis=currency_GBP', window );">British pounds &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 26,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,345)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_BalanceHeldInForeignCurrencyNet', window );">Balances in foreign currencies | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 20,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_Currency1Axis=currency_EUR', window );">Euro &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 33,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(310,086)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_BalanceHeldInForeignCurrencyNet', window );">Balances in foreign currencies | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (276,422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_BalanceHeldInForeignCurrencyNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance Held In Foreign Currency, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_BalanceHeldInForeignCurrencyNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_Currency1LineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Currency1 [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_Currency1LineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_Currency1Axis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_Currency1Axis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_Currency1Axis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_Currency1Axis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_Currency1Axis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_Currency1Axis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6759749408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Schedule of Share Capital (Details)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 16, 2019 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 16, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 05, 2018 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 05, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 01, 2017 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 21, 2018 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,283,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,195,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,283,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,689,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued, beginning (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,399,749<span></span>
</td>
<td class="nump">17,399,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (854,256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,366,809)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,391,057)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,195,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,195,363<span></span>
</td>
<td class="num">$ (107,894)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,195,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,283,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued ending (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,399,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,399,749<span></span>
</td>
<td class="nump">32,198,453<span></span>
</td>
<td class="nump">32,198,453<span></span>
</td>
<td class="nump">17,399,749<span></span>
</td>
<td class="nump">17,399,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember', window );">At-the-market agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,476,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 620,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,348,821<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,314,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,606,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,511,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,532,278<span></span>
</td>
<td class="nump">1,532,278<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,933,181<span></span>
</td>
<td class="nump">$ 11,511,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,418,356)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,145,402)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderWarrantAgreementMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="nump">4,619,773<span></span>
</td>
<td class="nump">4,619,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,742,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="num">$ (699,427)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,193,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued, beginning (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,399,749<span></span>
</td>
<td class="nump">17,399,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,477,665<span></span>
</td>
<td class="nump">2,477,665<span></span>
</td>
<td class="nump">678,182<span></span>
</td>
<td class="nump">678,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,055,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,055,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,333,474)<span></span>
</td>
<td class="num">$ (854,256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,193,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,193,061<span></span>
</td>
<td class="nump">$ 311,077,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,193,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued ending (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,399,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,399,749<span></span>
</td>
<td class="nump">32,198,453<span></span>
</td>
<td class="nump">32,198,453<span></span>
</td>
<td class="nump">17,399,749<span></span>
</td>
<td class="nump">17,399,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Incentive award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,751<span></span>
</td>
<td class="nump">$ 391,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,297<span></span>
</td>
<td class="nump">323,301<span></span>
</td>
<td class="nump">323,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Common Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,314,097<span></span>
</td>
<td class="nump">$ 5,403,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">797,691<span></span>
</td>
<td class="nump">2,494,943<span></span>
</td>
<td class="nump">2,494,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (208,726)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,757)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | At-the-market agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,360<span></span>
</td>
<td class="nump">$ 8,476,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,002<span></span>
</td>
<td class="nump">4,425,040<span></span>
</td>
<td class="nump">4,425,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Stock option plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,606,882<span></span>
</td>
<td class="nump">$ 3,314,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,532,278<span></span>
</td>
<td class="nump">4,619,773<span></span>
</td>
<td class="nump">4,619,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,747<span></span>
</td>
<td class="nump">$ 9,152,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="nump">2,935,647<span></span>
</td>
<td class="nump">2,935,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued, beginning (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,443,500<span></span>
</td>
<td class="nump">16,443,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued ending (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,443,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,443,500<span></span>
</td>
<td class="nump">16,443,500<span></span>
</td>
<td class="nump">16,443,500<span></span>
</td>
<td class="nump">16,443,500<span></span>
</td>
<td class="nump">16,443,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember', window );">Warrants | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember', window );">Pre-Consolidation | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271,710,138<span></span>
</td>
<td class="nump">$ 272,268,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271,710,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262,321,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued, beginning (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,805,722<span></span>
</td>
<td class="nump">142,396,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,805,722<span></span>
</td>
<td class="nump">141,805,722<span></span>
</td>
<td class="nump">121,258,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (33,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,391,057)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 272,268,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271,710,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued ending (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,396,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,805,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember', window );">Pre-Consolidation | Shares | At-the-market agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 553,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">519,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember', window );">Pre-Consolidation | Shares | Stock option plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 536,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">801,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember', window );">Pre-Consolidation | Shares | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,893,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember', window );">Pre-Consolidation | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,617,900<span></span>
</td>
<td class="nump">$ 3,617,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,617,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued, beginning (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,617,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,617,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued ending (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember', window );">Pre-Consolidation | Warrants | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,617,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Issue Of Ordinary Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GrossProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderWarrantAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderWarrantAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6753598496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Derivative - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 16, 2019 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 16, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>May 22, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1', window );">Number of common shares issuable per warrant (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 854,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,366,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,391,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ProceedsfromWarrantExercises1', window );">Gross proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,642,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderWarrantAgreementMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="nump">4,619,773<span></span>
</td>
<td class="nump">4,619,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,742,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1', window );">Number of common shares issuable per warrant (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="nump">$ 699,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IncomeStatementLocation1Axis=oncyf_OperatingExpensesMember', window );">Included in operating expenses | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="nump">233,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember', window );">Warrants | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommonSharesPerUnit', window );">Common shares per unit (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2', window );">Exercise price (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="nump">$ 466,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,477,665<span></span>
</td>
<td class="nump">2,477,665<span></span>
</td>
<td class="nump">678,182<span></span>
</td>
<td class="nump">678,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,055,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,055,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,333,474<span></span>
</td>
<td class="nump">$ 854,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="nump">2,935,647<span></span>
</td>
<td class="nump">2,935,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommonSharesPerUnit', window );">Common shares per unit (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Price of Warrants or Rights2</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommonSharesPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Shares Per Unit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommonSharesPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Issue Of Ordinary Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GrossProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ProceedsfromWarrantExercises1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Warrant Exercises1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ProceedsfromWarrantExercises1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharesIssuedPricePerShare1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Price Per Share1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharesIssuedPricePerShare1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderWarrantAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderWarrantAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncomeStatementLocation1Axis=oncyf_OperatingExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncomeStatementLocation1Axis=oncyf_OperatingExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6730060000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory', window );">Right-of-use assets and Lease liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Right-of-use assets</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">                   </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:374px;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:301px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Office Spaces</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at January 1, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(362,592</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange impact</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,720</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">430,713</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Lease liabilities</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">                    </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:372px;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:298px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Office Spaces</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at January 1, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">882,437</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of lease liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(447,497</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense on lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,817</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange impact</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">506,275</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory', window );">Total undiscounted lease liability</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our total undiscounted lease liability as at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.94736842105263%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:30%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Maturity analysis - contractual undiscounted cash flows</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less than one year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One to five years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174,157</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">More than five years</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total undiscounted lease liability as at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">565,179</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 97<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_97&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6752170752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability and Receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory', window );">Contract liability balances</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">Our contract liability balance at December 31, which w</font><font style="font-family:inherit;font-size:10pt;">e expect to record in revenue over the next </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">, is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:443px;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:236px;" rowspan="1" colspan="1"></td><td style="width:102px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:96px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, beginning of the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,730,287</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,182,580</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regional licensing agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547,707</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue recognized in the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,730,287</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,730,287</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability - current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">927,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability - non-current</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,730,287</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,802,887</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,730,287</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,730,287</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2019-01-01<br> -Paragraph 118<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6736277360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Derivative<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Warrant Derivative</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Warrant Derivative</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 16, 2019, pursuant to an underwritten public offering, </font><font style="font-family:inherit;font-size:10pt;">4,619,773</font><font style="font-family:inherit;font-size:10pt;"> units were sold at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">US$0.81</font><font style="font-family:inherit;font-size:10pt;"> per unit for gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">US$3,742,016</font><font style="font-family:inherit;font-size:10pt;">. Each unit included </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> common share and </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> common share purchase warrant (see Note 9). Each common share purchase warrant entitled the holder to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> common share at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">US$0.90</font><font style="font-family:inherit;font-size:10pt;"> until August 16, 2024. We incurred transaction costs of </font><font style="font-family:inherit;font-size:10pt;">$699,427</font><font style="font-family:inherit;font-size:10pt;"> of which </font><font style="font-family:inherit;font-size:10pt;">$466,284</font><font style="font-family:inherit;font-size:10pt;"> were allocated to share issue costs and </font><font style="font-family:inherit;font-size:10pt;">$233,143</font><font style="font-family:inherit;font-size:10pt;"> were allocated to operating expenses, based on their relative fair values.   </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under IFRS 9 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments</font><font style="font-family:inherit;font-size:10pt;"> and IAS 32 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments: Presentation</font><font style="font-family:inherit;font-size:10pt;">, warrants with an exercise price denominated in a currency that differs from an entity's functional currency are treated as a derivative measured at fair value with subsequent changes in fair value accounted for through profit and loss. Our warrants with an exercise price of </font><font style="font-family:inherit;font-size:10pt;">US$0.90</font><font style="font-family:inherit;font-size:10pt;"> meet this requirement and we have presented the fair value of these warrants as a current liability on the consolidated statement of financial position. As these warrants are exercised, the fair value at the date of exercise and the associated non-cash liability will be included in our share capital along with the proceeds from the exercise. If these warrants expire, the non-cash warrant liability is reversed through the consolidated statement of loss. There is no cash flow impact as a result of the accounting treatment for changes in the fair value of the warrant derivative or when warrants expire unexercised. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the change in fair value of the warrant derivative is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:513px;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:258px;" rowspan="1" colspan="1"></td><td style="width:122px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:123px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Warrants Outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value of Warrant Derivative<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued, August 16, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,619,773</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,657,214</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,935,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,687,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,608,808</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange impact</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(70,255</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,684,126</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,508,764</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2019, we received cash proceeds of US</font><font style="font-family:inherit;font-size:10pt;">$2,642,082</font><font style="font-family:inherit;font-size:10pt;"> with respect to the warrants exercised. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the Black-Scholes valuation model to estimate fair value. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on U.S. Department of Treasury benchmark treasury yield rates with an approximate equivalent remaining term in effect at the time of valuation and the expected life represents the estimated length of time the warrants are expected to remain outstanding. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of the warrant derivative was determined using the following assumptions: </font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:455px;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:273px;" rowspan="1" colspan="1"></td><td style="width:90px;" rowspan="1" colspan="1"></td><td style="width:90px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">August&#160;16, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value per warrant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US$3.89</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US$0.27</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Underlying share price</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US$4.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US$0.54</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.59%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.42%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected hold period to exercise</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.0 year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.0 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected share price volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90.00%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82.00%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6658145488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Judgments, Estimates and Assumptions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract', window );"><strong>Significant Judgments, Estimates And Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Significant Judgments, Estimates and Assumptions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Significant Judgments, Estimates and Assumptions</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Judgments</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of our consolidated financial statements requires us to make judgments, estimates and assumptions that affect the reported amount of expenses, assets, liabilities, and the disclosure of contingent liabilities, at the end of the reporting period.  However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Estimates and assumptions</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates and such differences could be significant. Significant estimates made by management affecting our consolidated financial statements include:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue recognition</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered into a Licensing Agreement which provides, among other payments, for upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress towards completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Valuation of share based payments </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimating fair value for stock options granted requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility, dividend yield, and forfeiture rate and making assumptions about them. The assumptions and  inputs used for estimating fair value for stock options granted are disclosed in Note 10. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Valuation of warrant derivative </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimating fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period requires determining the most appropriate valuation model. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility and dividend yield, and making assumptions about them. The assumptions and  inputs used for estimating fair value of the warrant derivative are disclosed in Note 8.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income taxes</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income.  Currently, we are accumulating tax loss carry forward balances in various tax jurisdictions creating a deferred tax asset. Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date we have determined that none of our deferred tax assets should be recognized. Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable investment tax credits. These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries. As well, there are no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We make judgments in determining whether a contract contains an identified asset. The identified asset should be physically distinct or represent substantially all of the capacity of the asset, and should provide us with the right to substantially all of the economic benefits from the use of the asset.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also make judgments in determining whether or not we have the right to control the use of the identified asset. We have that right when we have the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In cases where the decisions about how and for what purpose the asset is used are predetermined, we have the right to direct the use of the asset if we have the right to operate the asset or if we designed the asset in a way that predetermines how and for what purpose the asset will be used.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We make judgments in determining the incremental borrowing rate used to measure our lease liability for each lease contract, including an estimate of the asset-specific security impact. The incremental borrowing rate should reflect the interest that we would have to pay to borrow at a similar term and with a similar security.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant Judgments, Estimates And Assumptions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6729956832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability and Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory', window );">Contract Liability and Receivable</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Contract Liability and Receivable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Regional licensing agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered into a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Warrant purchase agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also entered into a warrant purchase agreement with Adlai. </font><font style="font-family:inherit;font-size:10pt;">As at December 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we were entitled to receive the following:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One common share purchase warrant of US</font><font style="font-family:inherit;font-size:10pt;">$6 million</font><font style="font-family:inherit;font-size:10pt;"> whereby, upon exercise, Adlai may purchase our common shares priced at a </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> premium to the </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-day weighted average closing price immediately preceding the exercise date. We have the right to call this warrant upon the enrollment of the </font><font style="font-family:inherit;font-size:10pt;">50</font><font style="font-family:inherit;font-size:10pt;">th patient in the phase 3 metastatic breast cancer study. This common share purchase warrant expires on </font><font style="font-family:inherit;font-size:10pt;">November&#160;14, 2020</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contract liability</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">Our contract liability balance at December 31, which w</font><font style="font-family:inherit;font-size:10pt;">e expect to record in revenue over the next </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">, is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:443px;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:236px;" rowspan="1" colspan="1"></td><td style="width:102px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:96px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, beginning of the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,730,287</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,182,580</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regional licensing agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547,707</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue recognized in the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,730,287</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,730,287</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability - current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">927,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability - non-current</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,730,287</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,802,887</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,730,287</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,730,287</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue from contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2019-01-01<br> -Section Presentation<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g105-109_TI<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2019-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g110-129_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6732051648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the year</a></td>
<td class="num">$ (33,122,888)<span></span>
</td>
<td class="num">$ (17,037,225)<span></span>
</td>
<td class="num">$ (15,616,851)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation - property and equipment</a></td>
<td class="nump">122,982<span></span>
</td>
<td class="nump">95,375<span></span>
</td>
<td class="nump">90,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation - right-of-use assets</a></td>
<td class="nump">362,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share based compensation</a></td>
<td class="nump">1,470,153<span></span>
</td>
<td class="nump">1,415,833<span></span>
</td>
<td class="nump">578,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on lease liabilities</a></td>
<td class="nump">94,817<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Unrealized foreign exchange gain</a></td>
<td class="nump">353,189<span></span>
</td>
<td class="num">(374,337)<span></span>
</td>
<td class="num">(124,793)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForProvisions', window );">Onerous lease contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">67,588<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AdjustmentsforLeaseAmortization', window );">Amortization - lease incentive liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,189<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value of warrant derivative</a></td>
<td class="nump">12,608,808<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInWorkingCapital', window );">Net change in non-cash working capital</a></td>
<td class="num">(1,795,777)<span></span>
</td>
<td class="nump">3,904,339<span></span>
</td>
<td class="nump">180,855<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperations', window );">Cash used in operating activities</a></td>
<td class="num">(19,906,124)<span></span>
</td>
<td class="num">(11,920,238)<span></span>
</td>
<td class="num">(14,891,318)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisition of property and equipment</a></td>
<td class="num">(10,905)<span></span>
</td>
<td class="num">(107,466)<span></span>
</td>
<td class="num">(105,765)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments', window );">Redemption of short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,088,800<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Cash (used in) provided by investing activities</a></td>
<td class="num">(10,905)<span></span>
</td>
<td class="num">(107,466)<span></span>
</td>
<td class="nump">1,983,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfOptions', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">123,538<span></span>
</td>
<td class="nump">343,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Payment of lease liabilities</a></td>
<td class="num">(447,497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">21,015,596<span></span>
</td>
<td class="nump">13,299,136<span></span>
</td>
<td class="nump">12,812,704<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Increase (decrease) in cash</a></td>
<td class="nump">1,098,567<span></span>
</td>
<td class="nump">1,271,432<span></span>
</td>
<td class="num">(95,579)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">13,699,881<span></span>
</td>
<td class="nump">11,836,119<span></span>
</td>
<td class="nump">12,034,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Impact of foreign exchange on cash and cash equivalents</a></td>
<td class="num">(650,427)<span></span>
</td>
<td class="nump">592,330<span></span>
</td>
<td class="num">(102,584)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">14,148,021<span></span>
</td>
<td class="nump">13,699,881<span></span>
</td>
<td class="nump">11,836,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderWarrantAgreementMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from share issuance</a></td>
<td class="nump">3,465,867<span></span>
</td>
<td class="nump">1,417<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember', window );">Common Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from share issuance</a></td>
<td class="nump">5,360,247<span></span>
</td>
<td class="nump">2,533,980<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember', window );">At-the-market agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from share issuance</a></td>
<td class="nump">8,131,620<span></span>
</td>
<td class="nump">451,675<span></span>
</td>
<td class="nump">2,103,166<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember', window );">Public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from share issuance</a></td>
<td class="nump">$ 4,505,359<span></span>
</td>
<td class="nump">$ 10,188,526<span></span>
</td>
<td class="nump">$ 10,366,098<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash from (used in) the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2019-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2019-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2019-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdjustmentsforLeaseAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for Lease Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdjustmentsforLeaseAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderWarrantAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderWarrantAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6751294576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - CAD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 14,148,021<span></span>
</td>
<td class="nump">$ 13,699,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">2,068,772<span></span>
</td>
<td class="nump">51,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">2,713,591<span></span>
</td>
<td class="nump">700,986<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">18,930,384<span></span>
</td>
<td class="nump">14,452,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">296,768<span></span>
</td>
<td class="nump">412,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">430,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">727,481<span></span>
</td>
<td class="nump">412,736<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">19,657,865<span></span>
</td>
<td class="nump">14,865,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">3,173,218<span></span>
</td>
<td class="nump">1,825,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Contract liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">927,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">847,215<span></span>
</td>
<td class="nump">61,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">339,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative</a></td>
<td class="nump">8,508,764<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">12,869,043<span></span>
</td>
<td class="nump">2,814,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Contract liability</a></td>
<td class="nump">6,730,287<span></span>
</td>
<td class="nump">5,802,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">52,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">166,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">6,896,716<span></span>
</td>
<td class="nump">5,855,315<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">19,765,759<span></span>
</td>
<td class="nump">8,669,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommitmentsAndContingencies1', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders&#8217; (deficit) equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital Authorized: unlimited Issued: December 31, 2019 &#8211; 32,198,453 December 31, 2018 &#8211; 17,399,749</a></td>
<td class="nump">311,077,859<span></span>
</td>
<td class="nump">285,193,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantsandRightsOutstanding', window );">Warrants</a></td>
<td class="nump">3,617,570<span></span>
</td>
<td class="nump">3,617,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalPaidinCapital', window );">Contributed surplus</a></td>
<td class="nump">29,338,849<span></span>
</td>
<td class="nump">28,260,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AccumulatedOtherComprehensiveIncome', window );">Accumulated other comprehensive income</a></td>
<td class="nump">464,101<span></span>
</td>
<td class="nump">607,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(344,606,273)<span></span>
</td>
<td class="num">(311,483,385)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total shareholders&#8217; (deficit) equity</a></td>
<td class="num">(107,894)<span></span>
</td>
<td class="nump">6,195,363<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and shareholders' (deficit) equity</a></td>
<td class="nump">$ 19,657,865<span></span>
</td>
<td class="nump">$ 14,865,253<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalPaidinCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalPaidinCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2020-01-01: The amount of resources: (a) controlled by the entity as a result of past events; and (b) from which future economic benefits are expected to flow to the entity.
Effective 2020-01-01: The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2019-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2020-01-01: The amount of present obligations of the entity arising from past events, the settlement of which is expected to result in an outflow from the entity of resources embodying economic benefits.
Effective 2020-01-01: The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2019-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsAndContingencies1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsAndContingencies1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantsandRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants and Rights Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantsandRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6736328000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrelatedpartyAbstract', window );"><strong>Disclosure of related party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related Party Transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Related Party Transactions</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Compensation of Key Management Personnel</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole. We have determined that key management personnel consists of the members of the Board of Directors along with certain officers of the Company.   </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:520px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:301px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term employee compensation and benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,786,667</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,680,621</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,596,082</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Termination benefits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">779,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,123,408</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,067,195</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">459,298</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,910,075</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,747,816</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,835,046</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assumption Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2017, with the signing of the Licensing Agreement with upfront license fees (see Note 12), the Company triggered a liability of US$</font><font style="font-family:inherit;font-size:10pt;">178,125</font><font style="font-family:inherit;font-size:10pt;"> to an officer as detailed in the Assumption Agreement (see Note 14). The liability was fully repaid in 2018.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2019-01-01<br> -Section Disclosures<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrelatedpartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of related party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrelatedpartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6608395840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfCashFlowsAbstract', window );"><strong>Statement of cash flows [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory', window );">Additional Cash Flow Disclosures</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Additional Cash Flow Disclosures</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change In Non-Cash Working Capital</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:629px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:392px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Change in:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,767,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,767,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(2,017,122</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,924</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,680</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(2,012,605</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">475,077</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(915,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,347,365</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,858,170</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(384,641</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547,707</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,182,580</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">807,877</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,982</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash impact of foreign exchange</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">78,708</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,531</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,558</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in non-cash working capital related to operating activities</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1,795,777</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,904,339</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180,855</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Cash Flow Disclosures</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:517px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:342px;" rowspan="1" colspan="1"></td><td style="width:58px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:51px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:51px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash interest received</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">274,094</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173,496</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130,101</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash taxes paid</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5,448</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,728</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136,163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Section Presentation of a statement of cash flows<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IAS07_g10-17_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashFlowStatementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6730016784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ContingenciesAbstract', window );"><strong>Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory', window );">Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Assumption Agreement</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 1999, we entered into an agreement that assumed certain obligations (the &#8220;Assumption Agreement&#8221;) in connection with a Share Purchase Agreement (the &#8220;Share Purchase Agreement&#8221;) between SYNSORB and our former shareholders to make milestone payments and royalty payments.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, a milestone payment was still outstanding for </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">, due within </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> of the first receipt from an Appropriate Regulatory Authority, for marketing approval to sell pelareorep to the public or the approval of a new drug application for pelareorep.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This milestone payment, when payable, will be accounted for as research and development expense and will not be deductible for income tax purposes.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the milestone payment, payments may become due and payable in accordance with the Share Purchase Agreement upon realization of sales of pelareorep.&#160;&#160;If we receive royalty payments or other payments as a result of entering into partnerships or other arrangements for the development of the reovirus technology, we are obligated to pay to the founding shareholders </font><font style="font-family:inherit;font-size:10pt;">10.75%</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> - </font><font style="font-family:inherit;font-size:10pt;">10.75%</font><font style="font-family:inherit;font-size:10pt;">) of the royalty payments and other payments received.&#160;Alternatively, if we develop the reovirus treatment to the point where it may be marketed at a commercial level, the payments referred to in the foregoing sentence will be amended to a royalty payment of </font><font style="font-family:inherit;font-size:10pt;">2.15%</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> - </font><font style="font-family:inherit;font-size:10pt;">2.15%</font><font style="font-family:inherit;font-size:10pt;">) of Net Sales received for such products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">BRI &#8220;Work in Kind&#8221; Contribution</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered into an engineering and process development agreement with the Biotechnology Research Institute of the National Research Council of Canada (&#8220;BRI&#8221;).&#160;&#160;The terms of this agreement include a &#8220;work in kind&#8221; contribution from BRI.&#160;&#160;In exchange for this &#8220;work in kind&#8221; contribution, we agreed to provide a royalty, contingent upon receiving Sales Revenue, at the lesser of </font><font style="font-family:inherit;font-size:10pt;">0.5%</font><font style="font-family:inherit;font-size:10pt;"> of Sales Revenue or </font><font style="font-family:inherit;font-size:10pt;">$20,000</font><font style="font-family:inherit;font-size:10pt;"> per year.&#160;&#160;The total royalty under this Agreement is equal to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> times the &#8220;work in kind&#8221; contribution.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we estimate that the accumulated work in kind totals approximately </font><font style="font-family:inherit;font-size:10pt;">$301,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2019-01-01<br> -Paragraph 86<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_86&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingencies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6729989616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfCashFlowsAbstract', window );"><strong>Statement of cash flows [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CashFlowOperatingCapital1TableTextBlock', window );">Net change in non-cash working capital</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change In Non-Cash Working Capital</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:629px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:392px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Change in:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,767,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,767,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(2,017,122</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,924</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,680</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(2,012,605</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">475,077</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(915,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,347,365</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,858,170</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(384,641</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547,707</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,182,580</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">807,877</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,982</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash impact of foreign exchange</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">78,708</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,531</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,558</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in non-cash working capital related to operating activities</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1,795,777</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,904,339</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180,855</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock', window );">Other cash flow disclosures</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Cash Flow Disclosures</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:517px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:342px;" rowspan="1" colspan="1"></td><td style="width:58px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:51px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:51px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash interest received</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">274,094</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173,496</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130,101</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash taxes paid</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5,448</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,728</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136,163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CashFlowOperatingCapital1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Operating Capital1 [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CashFlowOperatingCapital1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6723905952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>plan</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_NumberOfStockOptionPlans', window );">Number of plans</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement', window );">Maximum option expiration term</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Term Of Options Granted For Share-based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfStockOptionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Stock Option Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfStockOptionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6732554656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16', window );">Weighted average rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average lessee's incremental borrowing rate applied to lease liabilities recognised in the statement of financial position at the date of initial application of IFRS 16. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph C12<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_C12_a&amp;doctype=Appendix&amp;subtype=C<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6734217872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability and Receivable - Schedule of Contract Revenues and Liabilities (Details)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Balance, beginning of the year</a></td>
<td class="nump">$ 6,730,287<span></span>
</td>
<td class="nump">$ 6,730,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,182,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Regional licensing agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 547,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities', window );">Revenue recognized in the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Balance, end of the year</a></td>
<td class="nump">6,730,287<span></span>
</td>
<td class="nump">6,730,287<span></span>
</td>
<td class="nump">6,730,287<span></span>
</td>
<td class="nump">6,730,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Contract liability - current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 927,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Contract liability - non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,730,287<span></span>
</td>
<td class="nump">5,802,887<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">$ 6,730,287<span></span>
</td>
<td class="nump">$ 6,730,287<span></span>
</td>
<td class="nump">$ 6,730,287<span></span>
</td>
<td class="nump">$ 6,730,287<span></span>
</td>
<td class="nump">$ 6,730,287<span></span>
</td>
<td class="nump">$ 6,730,287<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2019-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2019-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2019-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in contract liabilities resulting from the performance obligation being satisfied. [Refer: Contract liabilities; Performance obligations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2019-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2019-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2019-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2019-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>86
<FILENAME>0001129928-20-000012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001129928-20-000012-xbrl.zip
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MYO> U()0[*.*%$4MI8T*S_&6QLOI9Y.YI[3!^TZ7//>[H6RFO" 12\DD]H@
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M&T)_.@(8#(P0YHP $!5T;M-!A]/"XCL]"V*OW^EWT^F%[KCW9=((<^?=CTC
MX4V],!Q+YZD)\3S?\ 3=4PCI8Z(PD:A@F3:/[##4;-A?2R%9;! %#XIY<,T9
MRT^O2L59D1I*M : <RYJ-B1<PZ@!>6F6:G C+AC RSR34TI1T+  ES'G^AC4
M3*7R59(&T-A',!>!8O /1>I1D<\-4=$7YT8KBI:K.FPWL,,0LR&-@VE).::
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MF'/.#,YWLK1UQ0.$^W$7(_$/'+./1.1%VSL/&4C'>-#]<[64^^CW_ETV-&,
M4X^=X9_9V'P:9I-5[CK]SEVO4T+1#5\$\#0P0B4'0^%I#$(IBW, 3W4LA)G
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MTS8?:(2'B^+,]ACG,*D;<,DGO[\Y5'5+RCCV%E1X (<5&UAG-L_2HK;HY-V
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M ;P$8;57%,\;]CA$B_Z09J#;,3_4L(XOI-09KJ2GBF#'&7$NN'R[W@6M"WN
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MNA=)'%$FS\-^6U->-%*+LW2LRME*J[P-\^%MGH:^8 EGU!HA^9E@/2?[I9Q
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MWB 9T1U9?GX\=FRVTSP@V)(D0A1(VQ1*(AXSU=WS,& #2?7 \Y@,KBHPX=Z
M:3X)]Y,)F)9@8>+SA]7H8= _&RY!EX#T3(0;4N(K%BO-.O(4>]-7YT-N@^4A
M4&\IS%+->AL)W*,SH3''4)P*18WM%G=0#4:R>22H6Q>J>?3R<^-?7K:__2/]
M]FXC*\64>);2"^L)$2&#QUA2JL2096E:W4\0+4*,>A)8_<V_W3C+"71U<)9D
MBXD4E;EJE]7[2, Z76:Q#^_OOODWM2ZLOA1.O_VRN?@Y)452$ YW.4MA([@"
MI8')@%Q;PNE^6H<EM3&*G!ZM7\>M4_QV,.G4J+=[(GX>?^)D\PXD*K$X*J9,
M0*^ 397+?'T3B&$=3+2A;._S60=O%;'?1O?@&8. "Y/J:EC[H7__.+S\^/,X
M5M<5?!"^5I?KO:LNQQ]&0WAZE[?^TV!V/RGQJ^9X?_T=(/K\Z\?A9/8Y81E@
M)ZW\:W5[-YX,)I_C$(NOX/2K.6QH\]5M7>O0KOG\ZR]W'?U7?%GP"K!+C4(R
M,Q6#5L05RTGEV*W&H78MKGT,\;XX^?/P4_44J(_FM4HX_P.<1I(U=6WC5: $
M%%]W=:KA+X+\X_O)ER*_6!GVI2SQWJ1$?';2$I?;SABJP?[HQ(&8)B^!_$^!
M\S7645L&=H,#ZP&WGJKB9DIN>,?YL?0E4/[-Z$F(':%P@0VAK![8&+QW;=X,
MQ YV"?:4>K\$ZO^"/1M?BOYT);CN&!BC)'.>'4O@_I<AQQ0$DNXROWD!Q!_^
M\118/\=(K6)@VW-'N*!I7IE(F::\N]'W1<B=7S].JB<A>902T@&_>UP$D92@
M4K93B:@)D767S1C](NC_^_@I4)]0%[GUN(9)@)/OB!"E&]I8HSO4Y^:Y<W_]
M[R?C;(7@A#*.9"%UM 1<W#(=#?P H3L9,<782Z#_4_&VE"#)Y9P",X$+9SD-
M90X7C5%V-_?H%\'^7]+;6N'^;'&O W'4,Y)Q%NF<_#S(+O=C =L+(/]3(#VC
MP>EL4Z:<R>Q"U(H41Y>3;K,VJ(.70/J?AT_#WV+2:V<8^+!."IPBKKDM_I87
MN1OFT<\]S%/_^XEXNRY8&K)(B20P/K.T.<XG7$G9'1LN7H;8_Z+>[C+]+6&&
M9JJDD9I'+HA1)=J@C%"=6A%IU8N@_Y=S>)=CG%0*ETD(#/Z?,)^7LRLV?_+=
M&*=DSSW&V?I=3\7C=9E;P542&:0]DXFZ(GT8<:E;;:U>A/1Y(AZOQ"D6*0H1
M%9$B9:+GX1ZE4W>!CU#K?1M/D_J/0\J56@=#6"#!^.REES+F((OO2G&Y9W?>
M#Q@\SR%N>3PI&Z[_;71Y,QC>5E>_7 Z!\X?7P\NER5983S,98LGUX&9]RA5\
MT/VDKW!]18!'EBP'6A(&A,?-/DZ7N2PD2-L)VC MU1E%>$.2EY$B;]ZP0X08
M3;@#W>D%B'#/,V&T+,$"^2T[R1))Y$;[97_B?6GJGS]FLQ?Q25"4!Y.84SRK
M1 SQ\^7DS*JN]J1LHP!_1L0_>\1F+^(')C2N%:."T+H\+ZM2&DD499U<"3R^
M,5[Y?(C_! C/N:'",\\<59QG:]1\,3".+NRNZM%Z8X+V^1#^_-&:C<27*PVT
MA$;OL[)8WYQ2\*HT!Q'/=&?6AL)0V;,G_MEC-7LQO@9K7:>0G..!XUP?F^;[
M-EU/G%)PL3%2]GQH_PB1FKVHSSS-,7%:VS>:4)ZUGRO;Q+LKL U] ?+^['&:
MC;1?MO*=$%0F%KEG"5RKF#TIZWHH+FOK2)V:\9\[[1\A2K.?W)'$JIP,T2%$
M+ZE6:6[I)-6=8,J$W%B7\(RH?^X8S7Y2!P>"80$LV)K6>"<\*3-5$TZR[3:<
M;<Z./ O:/U)J:B_B1P,:UAG)/57"<IF"<D7LB)R[DP8)V9@9?#[$_Y(*=UGH
M!\V%B<D+F@2PM8BA':8#YHYFW=GUE-'-%<C/B/Q?3..NQ'6<8V#>" TGH#./
MBMFRWY%$Y3K>K37/@O4?GXNU%\0':G$,%@DF*K3BVY79LF>^OK+L]+;+WRL,
M%U97[E,U&7RHTA_5Y!*>>CL97I:!$NW$B?:E0=UDO6V:!I*V2VV]V@[(5I(-
MTFO/I-,^D,A()K:T8'K"[/)LK.#B/]ZF=_\HLS.H>,U7.NC.A,\7(IK93+3D
M,@T)NSR]C%YQ+DE9?L"%U7(;T>AK(EXNT>P63J.9<^.UBU(0%S-S959["DP+
ML85H^C5C+YIFR_-O\&$<);7\?2A<WMS/IK/!Z&HX^K#\Y<L+ I;?4G_.(B*^
MZ50<%\$'H3CF9HR)VLIVLC5X%8:3;:QL7UOY]5B..99YK'RCA)$X,5E1FC61
MS$5%2I-LM"FL3+18/Q;^]52..Y5Y.''3H< =<58)KZBC*1H%@HR6(714L[3E
M4,AK_?50CCF4I6C+IF,!T\SAVCBNK.11)"R0*W.&"5])-J\?"WNMORJ6HXZE
MA&$VWA5+K1<:;"-/N(Y91%$J $RV;MM=H:_%,[@KU=6A1](_GV:9:#$JGG%K
ML(DN9?!$N).%:,J%;5)?O%Y=5'46?+X(R;JC<%9ELE"!&>&-MV"$IQA%+"-D
M+%!OZ^6W#W-?GBS)NE-W5J^F!)$),I+KG+4)U/%V^G-63'NS58VMNL!/C&1W
MP\DYKF5@UFG<26H4>'Y&*&Q_;>=*1KI23=/A,?IZ=:O9&=#Y O3:?B>-=U'C
MGC>N#.%@+Y&RI"[Y8%>*ISNRG[]>7=?],NBU_4(Z4)!4",^U1;$O1&9LOF\K
MKRQ*Z/"7?8#</S.]P+2XKG#6[>EO9,K9:,JBQ=%.PHK(]7Q#F;)\FW7!V6MS
MI P[ *$O0K-=FC*"Z +QI37SQ"0B.2_&A:%^JT5&7ZLCN>RITVS'S=0I.T*3
M"3(E;[(#YZ(L2DC9;C/(@&;\2#/V$6CV-QR[?8Z;Z;5PU'*<6@:74H:L? F-
M4I;]MM"H>*V.O)A[8_,%R+7C4F:NB8^9"1SD(R5N\B[D<EYMNY3BM3WR3CYE
M<FV_CQ9'*UKBK>6,D1"=::M]<'F""ELMB]?B2%?_[.1:<L"/<?/5YI@[W#V7
M@O>>"^YE9LJJ$G/'62Y;H[OZ:((=A,\7(MJ6E%@2++&@-5@5 >AF;!)E=7$T
MS&Y5E/PU.U*&/0>B;4F),:<YRXRP''-4P8!?-!=D0I!M?KAYK8]TD9X#S;9D
MQ*P24O$D#=8095'K@99FPLJ5]J1UFLG7G+YHFGVYC)A5F5%.4O;$><VI<*EL
MD2#<ZFWA$:I>ZR.3NW_V8]F9$?-.F SZ+%$-<L;A8.YV' 01@:PL,.YFQ,R1
M,84_^:GLS(B!P<IQ<X3*+L/I4!3\90(N%6&;U"='1U__Y(>R1T:,BFRS4"$H
MR80)/CBBRXQOKU=6V?9DQ%ZV,OYB&3%0(DSPR!PZ>89K):4I9J7(?&NEU=$9
ML=,=2AX,)_\YN+FOW.RG:C"]G]1OBX-950^O;C:?_3":SB;W];*FUFOJM;R/
MV1#5T/UM-;D>3VX'H\NJ?@LNT]JY%TH)(J0%SE<15Q 9)6-9N:<IZ:[<XZ_Y
MMCMP)"6> 75Q]3/P$*XGVT+<E?B%9CP&7$N6O &'TN%JC78UF\F\4XLMMTO]
M)TU:\[BD)<$P+SBUCDLFN4XBS&,=+,ON?ICM\<8G3=HCM\8=2UH&O"FBL]@5
M3PFN(,EE87=6ICM GFQ/&3PN:7M"4P>%-Z(&4PWX*3-P=!B.<)ROY9;)=DN?
MV6MU'%_U 'I.E+<$)[#GSWDK'6[+ 2%%."DS1"UNBNI!>5MH]<F@O"6VH#AS
M(N, %# T:$HAV]9=8C'QW,?BCX/RC]5T6E73'T:7S6<,;OQX,AG_#A8*[NJI
ME_=45[^.?X2OJ7X<#MX/;X:X_F)11.^:JW7] R P'-RTZWX0 /A;?O<+50=1
MRL"K >R P,$@XQ3\&5IVA#O%_+*<'=W74@6(1;==B<= \6G1N"$Q_??!B&Z,
MJL:<P5)P@B3J$W@DHKV#/F)O''N&9'Y7W0[J77=E&^C]X.;'X35\X 8'8GO*
M8Y%UM%F!"!<:+JY1%@=;EAQ:5E@I_V]OQ7_)GRB+6ZAS%'"/A^Y>2Z?[EP0O
MH@_",263(E9I8R/--I4I-S)*F8!.#.GT,LATMC#HXHK2[!@/8!!9';5*GK;Q
M:-S72EFHZ:E^HE\)NCV N;C(/GC",4)&"1&8SRU+R9*2/(3Z(E/R$]5?*;HM
M^+A47<"S"$)H,%F]LBPXZ\KNL"R8KPEJ?V(O1#*>+VZXM%L].5R$J2@Z @I,
M8U;R=LHDCS)4_A?]B9*O%-T6\EO8W:""'&'<)94#=JIK6YK38S*"-%>>/KKR
MKA\^?+&NML8Q[Z(7P05*;+EO 9P)J99MXT4*W'+%MSH3#2Q'@;MC+VH"&6 "
MJYO7E#$ZQG8L S&,K PD6:3L"%6@WLX#[HYEN@*G](F0";@=G!,&#-*"JT#U
MYAYP&:-<6[LM&K$ M^;;[]SEY>2^NGHW_CRX0?.7[O2.5B<A6TJ\X8:# \F<
M9%J697LL*M6=@,]),PMVPY<OP77UW_?361T0N1Y/8@56_*!>XEK_=S@JK _F
M>C7\A#T=AW)O(A%\.07&C!-*&:N#GH\1CB#XNFMRM<(YVG/@#X;PM-AM9W9P
M$*S.2C$9@PE4R>S*,F-)I.B.P7A:R&V_&CDF)H3,&CMAC,++6[;<6?" 8B=\
M<7JTRGO*9RS>N^1+'LJ20G"%G00T<JY=\N"GM$-[2(I"=PY-U4N#-V"W%X0G
M1F^' *:*\0B:3SDA3 "&D^WH2Y*-,IUCDT)KK%]_*MAM9TIA<,.S(:!=I'<R
M>RK*WE%#B.J,/CG'L=7!#'<[GLR&_UM'*@[E0*6Q4"L%'ST'\C/&?5'IF:;N
MUNH-2'3@>## K9G5;/'^93:8U4&='\=-0(8N66)O[D#1S< ":A=_[Y@"+9RT
MS,%I,9T-<TRH.!\\D+3N#&MZ!(RWWR)#,F=PA6(V5G%J<Z1E]0:GP7<B](8:
M^U@PG^V4P#96+@1":M^. ?YVWM)!P9K[,DAO%PB6"V%9 I@]%XK1A.]H57 .
MO&,;/0)GV?.>DI7@%S+P"QT@*J53Q:3R&9B6=O37$1B/1N#LH$0$H*IZ'3:^
M:Z?1NIKRQ\R^H#KG3 CH(>H-*6-M1!:Z<X5H.P]U*PP[@?S;9#R=_C*XJ:9O
MP5<\'&H1<=64H&#Y>&XM^C(M=6/2A/6G(HC< 78'J@4>?G"#I13_7W5S]<,(
MO&#P)$9EH_O/53_XVQ>_I]_>;71W**.2,0FR37+'N51E $RDRJW(X>H>4 /O
M4PD<_+(7K.=$ZF_^[48K''?#"&M\=$%[;$76;385;J->6=3SX?T=.'#@]*DG
M@-)OOVR4:MHQZCVQC#/K:,0[5 J5ZF%NZVOM.6A4)LG!2(7!]"/FQC\!:X)8
M^ %0 ,=UAKF;?33FZE Z0G,&?1&HJV\\+<MIF>9TQ3);NCA,TP+T%EB.!+BK
M.5:V>&O<9NR<B]+XI)4)J34E09&0E<:R)8 IU8<!C)F5-]=M N7-Y!T&"I8B
M2/VA@+[4S))ENB4SLTFN92.),EI*YCS8FP1LL*(GK: K&U07<1D#K\QORDY,
MCD6ZP9F[^P]4G1[QH+$76L*)8IL7LV'N#U%PQYGH01SW7&NLP3P.\7%Y=-P\
MNA*UG+\X;5^=LI,3H_TCZILWU[_,QI?_L_1H$YOZ;7153=IWN0^3JC9.ME?L
MJ)1<P!5H6GGP&27.[FOO2_(\^U69!'JN_J:ZRIBLD/)0^NP@[\_UY1Q?_U)=
MXO1(($P8W-Q45^\_I\'EQ]5GNXRG_X/]^_V(+L>GJQEHZ[OJ<C;\5"WEH]WH
M:N4EK'EJK;JU.8AO)]6GX?A^>O.YMONN]CZ5M_?OX=O>X !&X*M=G!UE BVA
MHL@&&-P&(E2I3N."R=XKO?4@#J+D64_%_ ?[:?"9L<W(@\('.S(XYV.6A"?T
MRTHM V&F-RS^3)"?7_^37>-5TDDO*';1@5.N@G$D<*5;3>W QI5/E'3K<F%W
M$'T5;1IH, 0N"I$>IXYB9+-8]D;(/D6 "S6-%4<BWP'X3*AONC!T^<PCUV 3
M*; =T;:!GTOE>R(,)'H/\O:U?&3$R_OF@VI6T(R,$CA@O!KZ5:PN.3V]L0"V
M4$@\9YL3T4Z3I%1RF@>GO=..F!XRO6(6W"BA]Z)5!\.34*88N__17]/S0/N)
M>^9]-"9@[LD+ED0I&@/#<66WQCQ#=D:*? D>6?;,P#$+X&KA:E*<VPGVM+4-
MAX04#.TFM"18W83PK<0X+1%.S XK.:$LG) Z,)J));@;M!1J4A6]Z42N'XK\
M^/9VV$2LP/J:1U4N^U.H=?7QTIQNRQ,W1'.P%(B6-K(V?<6U#E:L@7KQQW3X
MW6AX\Z_?S";WU3<7?ST6"KL"A<082\):+E"R/DM=.@@ "IDZ^SGV@^*GP57E
M/R> 8_;Y776#)N;; 2YF #I.X5NQ&@'L[^'X*MYO=(N766-\C[[K'7S&*E/\
M\E\___+FG>]46,0(ET!Q'Z4DH$L--:G-FC,O@U7?_-M;B]4J#X/\:-R;5/?G
M-O;V<S5;CKP-/FP,;1Q!DDU2TX*8" 'L"A">5&5+J2\C^@.&03=$0Z@\DFB[
M4'Y$6A[-7AL#R<XX8T3B7DHC.+/@\Q1:,I7Y,Z5ED_ZNKAZ5+VED0CJP;;*F
M@=-$HBXW-V0M<R\M*=&GH647Y4>DY<GYTEKC7)TM"(G% #\I6J1@C*H_@/AH
MM!PWO:9O[R>7'P?3JM6R\#0V9^T1!CFL)/PYQD\P?N6,4%81#C:_\]&7H<4\
M&,^V^L&[*/Q%#^/4E/))<9MH5#ERT._,.]%6J$;#A>RKDGL@I:9?&77)W"*2
M)>M"!EO2N.2QK:PE?R8F[,NHTR]#\)-3PU$?,F$19^6:'#P)):_,'?%]H0P4
MN^ID%'DZX?E5PB1+1*8I4YV]=U@U;,H>1I7!'#TKFVPC2H=/%L_\,)W>5U?M
M:^<E#[>$T@07**L@DA!*YQ+_LY[R[6'/[>09H0:>U,+CW7#Z/TUL8T=A2.==
MV'*]7!;RRWW=/3?I/$AW&GF #<V:@U8+)"9KP55KO?1HA5O.'M\.1O?76-P^
M0?-D"=]>E%9P;BL<5JV2IO[AI\$?P]O[VWTRLJN0NV"HE]18C1&&F)3/Q3R-
M3MCN4K_EDI&]8-J-0ET).'Q_7Z.^9UYY%0OFE J**(/1**8\IZ$T_H*W[/N<
M/[8+B76H=N/1&H9PA]!]>8>[Z]:C ;MK>)Q7<&FP6SVE $:MFZ]V#9Z3#4E]
M(G=ATPO;*DK+Q9B?VWY11+X)#ZQ%_>H"QI_'G^@KG'>Q$1O&*8M*\.2",XEK
MS=OJ%_@7H<N:XW,U %Q6\-@.T +X./PTO*I&5_\UK&ZN^HJ0XEGSW=X+K*_*
MH PC2SS'H+R- G0!I69U'M3\R J:?: ?C)@X4VP^)I' ]=<$;'7*A!)4DAHQ
MJTT40AZ/6#,=PMW//HXGP_]=BZ8NLBM;[HE+6EO)#0;XC,H I"IER9Q)TEF!
M#*"3E7*W=1"6@%O-CB_5'13"[5U!LF=S[P+)Y284:@C8$6!X.B Y)8*&>3Q5
M"ATZ=>7V-6'S^[,;B66$T>ZNKMH1S*"9=@YBZ"^Y7H[#Q@S*Q&AGH_2&P;T
MB%OHG>!B0SR.*[W 8 ^H'HS$]A(K9926GB>NG"1:@$*DOO@!3).G@L3VLBN-
MQ\"",%2#H%*<REPZQ@D+49P:B?G8C'G>H;$YW\XMR+-58*W,N_&92NIL\#&
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MOL'6Y%\'?Z3!!"-7^Z10SB=T5F;:66*ETT[A7#4E0'(7ZYX*R3)9/P3.Q*(
M[!$(]8)/94TFK?@P(3OEP/PG(BD7K'=E5SN)X)QWQA$8:<YS-?YTA[(FL59"
M=-:::)W@.(E9,B.]3N50E$Q=1YA)SNV7.19,3M3#^MM!'IOR,/LDC0A.O=)2
M.Z_!@ /OE+DR7X\H%7H7-RS,T$V@K .[7AO0HZY^."QQ].#R VQ)YIXZGIPC
M'%02;P_<@[/N28^CN[H48AMB1Z,OWES.F'BL-#*S"9@]6"T,+L)PQD519K\;
M%3M3OC@Y'0DZF:8#$X=[G_]"&;I 1)1>>1]L)J@-2[%P=$1R3$J1G[;CMIJ/
M.@BS\QSM(I!G$EQC;^  P:UD7.8RQBA100QB1^WAV-7)=0R5@(!KXI&+#/O[
MS]W\.Y:UU/_ZSVJZ",%N'!ZS7!L\SRPN_N;'L]GX%F0_OK:[X)DGK9-C1&50
ML3'FU'JF&8?YFAY)1E^O\O*)L'U2-/QU?+<G 45@PCCBK.0:]U\KW.'33@?3
MTO7%;?@+(V"KL;?5E2SG*>"#K\>3V\'HLIEGA3=T]ZHDXW-06DB9E2$&@V.J
M-,9Q+_KXE/^9B8S- &!AH.C;F\9"^* I 0L[.Y(<"$ 22HN5TZ9O*_5CT'C:
M[D6I#:9VE0KMF %_QBVJ&M=@NA@,<REZ347QB7R4S/GE;I7@XC_>IG?_*)5M
MY+4P*V?72^4O<Q*G)A.7-.6D HAF%9CFENIBK7-EM-I")O%:JC.3Z>38PE7U
M2D9N02]I8@6-97P4,\ZFK4RAR9FP/==,*:STXBPGH;('VTTE6F16@C,G:QGD
MQ28F^=KPLZ':VN./? %VEYIME".&$:V)"MP2(&'@09<]-0;LX+B)B& )GHM?
MGNI&XJ@#F'A4YQ0\D3F9Q8;US,1*FF[CYJ]')-73J#5/TAJB),G" :FHIB:4
M8?/"QQ@V$TV*<Q/M3"B;*.'J2$5)HI1%7$53*HFH%8)M1GDI;'D@RF4)_?*C
M7^TDE&^.<F*-3%YE*7QRV18WWRI@P*TJD;&^\^BC]9<\E5.3+!+<-Z=<T-*Z
M9+/(I.QL(TP:LH5D[/6B'?H DB'0'\<W<-?:V<8_CV=5_==?@+-P6_0G>*E)
MS0_'?4,KZ\%6RRC)Y4"'XV '90<B*":M0 @)6_9P1Z5C;\B6DJ7>_@,A7*"&
M\>BZ;/+-=1.Y'H[FRQ_?E.6/$8[ETP"ORZ'5:(G9D##R'H@/CI (JJC-5V67
M>6?:\5QE'PC7"1':L7> )"FXIBSACG2)VP]+D4<.QG6SH%\>H>WU;")FZ5CT
M%I<J.^VIF>]2QOEFG4)@SG$ FC@E6C6;^G7__%!6\X$+"UX%!XRC3,'1^?)T
M8;WML-HK\+B8[#N??G@>!/IVIHI@L3'<MVV"L(Z+Z&S98"]%WV1M;AC3\G%
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MVY".'#)N1HK5\N_WUJKZ]F)XW1 !),_K6H8N6&KCUR!="M6O+MY_;KZN83)
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M:T%7UV%AQB N)FZ TQ'F8K&D6>Q]U^("3 \)[ 3<KY&VBNT9H C7 ZP=F%
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MQR&NDA % VL$+A5!)I((B<G58'>F<QT8O1@K$W\!W4+>*(PA@#^C<--RIUS
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M])$3XQ]<.;)<[^Z5/'1-1.\J%*QBD&S<91 6>/4;D+X. 8@191V%"V*1>ZI
MMH(N6"I9$:P3VV$<H$TSQ?R2("M69K&C\B+]F<()B<AIQ(>*OJF- 4VXR):+
MR^H^ #I_B F:N$C$4BXT.=SD%T<4J^\K+;1F7.D*O2>2$('W-YYI7UUQ!"7@
M2<I.\!N*J)3:7V6&.#[^\;GI0/\5)]]Q\?UG$/D-IQG[ME2MLB\D O+7>N"#
M1P\P"%[EEE!J8IHN[<,K1YO4ZB&(Z]T8_(_"XL3.UD&69Q6):=7SNKKD!G9F
M+R"OHNQMW9@LF+MF8&.C;?)M^2 V:);1EVD7;A,!3P4"OJ\@P&L@0/A5\/.;
MS2%,VR[:?@M+!7[UP%\0-DMUH(#.54 CK<Z"\&H1)2YM-]07.#-"?_R!K**Y
MZ-F]=*@@1^\-KB2>*"R-6),6 3 D'QM@%M1VD!'_9;D1-[N<UWA+ZW,>*:/*
MGF(Y;Y=1R'\EF+@/3C>*HV?!*XP @Z::+=&6@G.5SW*1)=(4E,!!VDH+*.RK
M+@O0+SW2VGU$M?UPZY9G+GBT_N<(P\TTE]?W<9[]GF!)0+;X'1Z174?^W3_S
M@#:4PPZ^K!O]VKP;?+)'=XXQ&.L#4[\1!U_ZQ^M/UT;K!U]E56P6SS_HYOQ'
MV[OT+>:2@$LA.G"E=99:W6D)5@WF.\"G>S>D<(#HZE3N#).J3UUQ3)T@E\@'
M&7:)1Q;$/H)<JR:FI\""@B?0Y^;/1 B=<%G62Q7(TDJ^5T8._AQ80&*0;I[%
MY1<)#8N^$77?MGYE#<SA8.0X^M@8C\R__7R/\Y*\IT2P><H_E/]8.RNMWZ)9
MTUV5,AM+)<[5Y.Q=%2X&:(W_=FA=^M+]0_VP^P\K5;^/LRR>_7SO>M\?$HS.
MO"]V \_C?#)981F F6]"H?E9/&CI*S%7QCYU^0U\[CC0?GDZ\&2"Q7V\5'ED
M6T_R) HP-6RWHMZC+/ZRA D::%^)'87)?DGK5^Y3(ER%/5EHZY>8V@;5A:Q-
M[/J98[VF=+A=B !-I=P.D-8OW$WI. =;O"3Q(W^^T.YB-=S7+'%Q4._1SJXK
MP#!T5H;G0A3G$?!;KI'=Y&;N\"YD^V<GR!Y8$L_9N3B%_S)"<,IR6713BL^B
MVT>P:2T]831XX0->/ #GE0?@C%][ /8K#V#\VAAP1B<>P'$FJ5C[Q>:ESW]H
MU"E>*P.R%V)QX7V'\RHLS5TS<G,V(M\MYF?B>L<<S:YE]9>NZ=T1OH(2^5$B
MK_PS)?.3R;P(_GTZ(MRG)/X2B2N,GTSBM2/^^3A'7,G]*+E_P[-H%3!ZR8:8
MMJ(>3HZVL[:+E;24M)2TE+24M,Y-6NHP]%#"LG76TRZ<B!XI,Q*Z5*'I8X>-
MG/442-E"Z@I()*BK"T2)/=+9>+3>4EJA1*&DD=1C#-EHO,Z/IU"B4%+?-QHS
MRU8@42#9R:YF6LS<4)FA4*)0TC!>F6.,V? $-GY?<'*F,>FE$=@KF5[O\0NI
MCF3!&)(R+>)4^X^T 3"8N@PUF,U=[U5SNSNS",M*1MV0IJWZLMIZ/>^C$3,V
M]$164][?*3=T-K34E%_2E.M#YMCKW;C4E/=WRJTQT]647]24ZX[%;'FG 'V9
M<Y7G?;SL;X-T'J=N**T\[*1R[<S*?*N;#K/&THRN%TNQ1EI[8I0.QG>=$=]Y
M@M R+&98\H+V"H0*A!V(,QTMR*Y JFVC5B'MM06ID-9GI+T=#=E 8L:$VE<5
M!@_&H&W9;&1:G9%BOT%XIB>P,F6U.5%WG8;\$B-Q]H"9CC11=&7&5?!U%P>5
M-61C:[V[O9KS_LZY83G,,M4ZOZ0YUP=#9ACK)-IJSOL[Y]9XQ$Q;6GZBFO,S
MF'.=&4.'F4-UA"[#];F0X]*3YYSV,YC11NCVXD.SO42*PP:ZO)B7PD@?,:*T
MB4**0HI"BD**0HJR4+J-$0FYNL;:666_?,R64W+EB*\SRZ_U+*!U>74%**WK
M:X4;A1N%&X4;A1N%&X4;A1N%&X6;"\!-*SYJ_P](Z>,:E?SF+%)IZ34G%7MG
M%K?<]-.C9=@!T'5BH^@GR,RAP<9#>6RR"F4*9:VGV"J4*91MN$]R4J]"F4+9
MAOLDIQ$KE"F4;=)ES+ MA;/7=OA/[[=C=_I)&#]]F :^SZ.?BY;I!C9VEA\Z
MTNW!(0NU&GHWN@,I62E9*5DI62E9*5F=3E:J=.J0DX%9#.+X_URLIVH#C-WI
M>=PY@U>)48E1B5&)48E1B?&R8RIGW.GVO(.80XN9\MCLNC+E;4>\SWK.A]:8
M#6TUYY<TY[KEJ'5^87-NCY@S4F1*ES3EEF.SP5#-^27-N<[,,<RZ(XT7NR^S
MKJ+ .XJ;^3SA7D!!7XW_F/,HY;+PT\]T#X?9AKR^0GU/Y;A,C(!C99OR,K45
M2/H($GW +%V!1(%DIR9A WD<YPHCO<2(83+;5B:) LDNJ8V'S'34;M.NSZAX
ML5X$JC[7_[?;D7:[L/K=%NJR(=5J?UD%J0N$E&(I4>PV"C<*-R?;PMKLY*IV
ML$M$5*M]62\54ET\0BUF!N]9;Y?;%0FWW+15JHC;$&@;!#7,DI>TN%6 9X&N
MLPJ%G@>\=,=B8WE-Z!2^%+Y6$NT=YECRF(\4OA2^EM*3##8RVK<O%+PN$UZ6
M;C';4-NCPE<[^!I9@"]Y-7F7C2]5\]EJ?O-9Q\F, 3,L50=V25-NC=E@K-JK
M7]*4H[5F2_,&U)2?P90/F6E)RS)2,WX&,VZ:,JM-U)2?P93KAL'&([7,93@\
MEU+I*3U=MY=Y\JK1>,?C6 HI"BD**0HI"BD**0HI"BD**0HI'7$D3U+^V3BY
M[&11!'WL6MO9%QZ82Q-T"X<Z%G,&IVO7V''PG6:;N%BP&0;RD9RL7$>A[:+1
MICL&LR3F BFT*;3M2)P=,=T9*+ IL)W$:ALQ8ZC,-H6V4Z!M;#ML.#Y=M^U+
M0)LZ:E8M?Y08E1B5&)48E1B5&"]3C)==8;3YJ.,WGFGW<?Q=>W3#_)!BH[T!
M>7+<>3S*>-(IY"EY*7E=K+PZMP\H:2EI=<K&>#9&U?M(S&;CY)7S,'J78;59
MROJ0V2<\2^I[-I9"W7ZH,T9L/'C]M:Q@=U&P<X9L8,CK4:10IU"W!^H,APV&
M2M<IU)T4=<,!T]4.JU!W8ETWMIDCC\;EXF'7X>J.KHBX;=[R/K<@,(=LK)^L
M 4%7$//:>\%90T9W!FP\.MGR4ICI 69&8V:/3F:+*LCT #*FP:S!R4(U"C(]
M@,S(9(X\GE@%F0N C*4;S#%/5B7:%\PTO-*_9^Y]R#=>O^'?__+W8)*D[R=Y
M&'ZX#5(OC-,\X5\FMSQS@Y#[GZ-)G,R( OOZ/LZSWY-X#I)>_!ZZ478=^7?_
MS(/YC$?9W8\Y?.5F<;+XM__Y/_YE\U/OW"0"Y*6_\^3KU$UXXR80?H02_H-/
M_O7-IUL\6/XOZ_]^NWVC!3Y\X7K9>^NC[ES?W)@C:VC=W5@W@_&=-;[Y=&=\
M_'3]T1R.W_S;RHPUI?\MF/%4^XT_:7_$,S?:.@N-V\,@XN^G(J"B&X.__;P#
M ?:1"+"W!FY^B=-4 T%I-_%L%D<:"6PG'O8<^C_R- LF"[GX)9X0W1[L1NPK
MCI#$"= %G)$X4Q2G%J0:Z PO#]V,^UJ> CBUB&=:B%<#\K5LRK4%+$K-C7SZ
M(.8)+G9!X[@/7(MRBG+$DZ4GIQHLEC2#N_"12T_BD0^WK\GIP)<JHFN%'B/A
M^=R+$UJJ'U"#B/<NPS#U#&W-VSA&K/C>IWH5PV#8"'T\7L^..&KH;T\V\$W1
MKZ.&_/YDPM9M-H#_F?;Z7GS,R'\^'4H&&\K^NRYLDXU-$/9(SLC?76G?0-OP
MR81[&:Y0-UIH\SB#;3IP0XW_X(D7I!S_$N<)/#WVOFOQ' >5DJ)[<I,$]O=E
M)>;G"?ZGTF-3-]7N.<?6&%Z8HTZ;)/&,_E[J5&R< 3_B!V&.*C/<I(.9!L\)
M,NTISD,?'@@#R(+W=$OPR*]V6T#/6#$[[(T=1LHCR"F]GF0\^8//8S KHP=X
M0!#[AYDK-Y]&@Z%^HQN?KFW+N39TZ^:.S!7X:J!?7[=NKJS8^1;8^2>U8+[F
M]RG_9P[2U(1,C[8-#GN3U['&R>S6/!Z&Q6C_]<W@#7T&G\(K/Q<CV?!"NV9?
MVS;*34=03X&?33\8UCYNW;(KM?_%AYV"@>-YB*.U-OTK;[_DX [P-5\RV6_=
MES?'AA<\R)4\M?'[D6=/J*FE["[_X4:YFRQJ@Y+L24.248;;CY0G_>HFWK0>
MY%#B(!EX > ZI+D$.U[$5MG8T)DCR[!==D30^7A(:.M-8H]S/\4]^<^O/TGY
M,8S7&&BZK#<'.FKLV32)\X<I&29?O"Q&WPKM9^WZVZ\:["9!MH#A3SC9(JD;
MP@NZ#PGG&(,0M@O7$O!YP';PVWQM-C 'S+8E>5%@ KDP[#0/,QD>53%$W1HR
M?</)X%%#O,X?0#.1YZC-\_LP\.IYJ.S%;.J")<?!LRZ-3/\9"VZ/&);:6<]T
M9[WO_\[Z1=*F^HG?)\N[JB%]QZK4(KIH?WZ5\N"?=#8<#!BXMW*T3#X')Q+N
MF[L+TNB@##_^<7US]\O=M_<ZS#UH(/(R?Y_ C8GV-N5<^PT\6TTW::/S*6Z=
MOGNYUGG6M]S'3=SN97YR@^2_L<C[5^[B-_BV7R:_!.Y]$ 99P-/#G,W;X6!L
M7=]]O/XX&-CZ)_W:&1K"V33!";6-4\;&VUAGUXC>./) .%58@2(-4S=Z &,L
MTB8@4%$V7_ZMV)4 $TGPZ&(T >.]+EI$80@:Y8.,6/4SY<>-IZPI5WI*$/GP
M!/K<_)D(3UW"I:,[?4DA'[0I'C#9,S=Y""(Q2#?/XO(+D69(WXAM<*B;-8D9
M*.70G:?\0_F/-?]\\\9:*?/AQBK3_??%8FL>C@[?FY>>H!M['8?N>,(1UL'*
M",P3CT!"2NMZ'^3^%\G*.NS?GTNF0R+?+6:YG R;HXN_5>=N?Y7>QY<Z6JWD
MW[;\T8#1_KO<;XLYT&ZKO7;;RECWO[O'#]1&A_<VK*+/%(-BI6^NVW(K\H\1
M9ANB:R'-B-GZF#F.M([6;;QV%S>K"\6+SNRAPPSIE1G]QDN/>&[;T-YW98A4
M&JCZ5M(HPH@&&YM#9EORNCD\)Z<:+NT)2OIJ?7FPM=\P @B-'#88R-OS+QM&
MY\??V882O]D4@'Q-@ZHS"ZZ%WH%=62-=-*0[,^^ZP>S!B(WD=9;KR[1?4*"U
M#57[*4XX/!OS30NE.YN[7B;9)3N-H#NS6MOH\'JL(/NRSA72-AK@SH 9PV%G
MA*BL\_/BJ6DEK>#\6@MW9CWKX$];3#=4L:XJ\#Z $X -P3EP;$4+<*H2[Y5W
M;([W#!*_J) -'CNC"MV]DKR>W!3S 'DR@[&65;UXK<C[PD]NFN8S4?#V87>T
M9I^R)%QWH^6:I(M-"[.&0XEI8::<M##GI2E5X\&I']#W6$$,;S"!U?AA&O@
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M:P 2[G B*W@5=BG%/%PMA?$$$]"<\(N"+*"TLD6O!;JWFJY4\W->6L[I-$[
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M?!:+1R^:@TJIL4F:PJ"*'%H/1%QJ71!3WJ#L?713+P^%D8COSJ,I:6WL, )
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MP<MRP9V7/D!_:3J[\V*R:OWL1G!!)Q3R*TB/2:A7[,9')767(9,7,1@K\;]
M_",E_M<4O_-B\9]?5HATC?W+%M-4UNGG,=+J/.'R9DB^Q2YVAL%&(VFT<D<1
M 76=N'FS]*1QP_82<0)@NLVLT9CI(VD$L;T$F,+3OG@:,LL9,G.H\-0I6K.+
M]1^_5I$T.J<+7#S5*$XBJZB:+*Q>',?A%DO:OAJNGR@KRL.7R%1:LO#%851
MTKD:*$B^2(0*@0J!9X) %87Y^3H2'&ITOH]F#A>9,*_IPW1A+6X)M(R8XSAL
M:$MC:C[7A=;!4$H78"-08C%K:+"!(YUFY-Q0HD#1!(7NC)AI7;SJ.$50XS*"
M%F73CW_D29#Z@4=IB54*D$@NXE%'26>ZL#(W[V(F&XQ&;*3KK<NM*T#"^UIE
M;>\;< J<F+K!QG;[3?,43LX9)P8;C<=,'\MSZ_N.$^68_WPWFX?Q@O.",4,0
MEF,1"X]22IJ_=*MZR]X]&K/A6-K.W14TM*UXSQ4$Q9P;S'"D^55JSL]@SO6A
MS0QYIX=]F7/E+1_8C3B>;.C/H,S9 _UET]*9:<IK6]5W^U8!IU&T(;>_JH*.
M@HZ"CO*J-]_WF;IBXZY?T@A1J%QP?URZ8;UM=W>&(Z8K_^JR8=""PE5 4$#H
M%1"4][TCT:QJSDF\07,N6F.Z/[1Y#(-2YN]!BU#7V=A1YXX*-3M3C@QSQ QC
MO1MS6U+J=R;298)(MPT&_U.J1CG9^XKP"Q+%89>6F1OA?E\GHKUJ<7\7EM26
MW=P:,V,L+7S>%1PHOVK7YFP.V5B7IE?5%GSVB!B:;&!**QGHRMR^CD]]OD7M
M2R/0\6E-@L3W](W,^:E/Q7T.NW12U('=\XA/B/*6<R2K11KC>1+?$]\B./#;
MIE5#OLJBB(R?9W>8+BB$S7;"6_#Z;9W9NCS/_](*1#<+5IX/>&E %?8K&SIC
M5O"BO:H8.X"PTP2L+A1G@Z'.'$/:4>3%XTQ%*WZ^R<'H(6;];G 0=F&UJ9,_
M%:IH.*;6B TL::$*->=G,.>Z9;&!H>IHI$0CNAMMD"G;Q@E_$&%W,VP8B[&"
M>1)0"Q_LVJX.^E]]S^V]47MQT%%(44@Y*"^$#8WVDX?.-41X6$10POF$L19W
MD&,8G 6[\6\\T[S"!<>#!_X#*]Q;HMJ5(^G.<VR?SI1X1KIG@<#3QFHO!()M
M! X4VA3:=H8L=&:-I75 46A;MF[^3KT6-UU_LH$UA*::DYZ[1*]3[*2^-KH#
M'^7MV<[^EGM\=L^3>AY-'5O:Z^L)5\>\#-.>N.CWC5U716=5K&^! ;SWB@;T
MV(N5IRMM8[5YGLQC_+[J;Z\:LKZD(:MA73E#VS2'QLBPA_K ,?XFK3VK*:<]
MJ_.W%_45M8V7W:\?=OL%)>"=HGW@W8]Y<!"]>C5ZU:;Q$#GWN!6C7/'1?<;
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M_7*^G.+-;S>HF$]:<IZ+VQ<L27ZQ-F5551F0MC]G2=,UC1&SK8K\30<0O3*
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M?5F["JDZ7J&F.X/O;+;+K0N%*V[:*I7$51"TB@(US)(7M+B5@(U 5Z-<H<V
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M8FV"@93:!(8Y/#&Q7N_O%7=486V \:E+4+4!UOFN=M4Z53ZTJ@;02/*?7@U
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MN+W20G) (%K2E,#SA+>8EL5L4U(U@_IMK:P8(%->CN5;Y:]7)D!#3(!9)TR
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M[&KH,#Y.+HVSPWGS*,[,T$]HAA[@J,VI;2AJ[TWMCZL3F&GO^:/K^X6LI7^
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MI =X3TL'F+M1'(0H>+6I$SMKC^/@_/N23S!;&-;J3K$([K/+O6E:R2G]V[?
M@T]Z;OR,)3Z")-1$"2C7UZ8<A-U"U#_ \593R*KIKE6+ZFE8<2ITHS^N9X@\
M%V4E<F"($W(C[<'!;HBP.GSU/Y$=_04(5!SLUO&=J:,]<'\R7SCA']I#D$\7
M7\=R51J<#3!G+#R% \!":1Z/P,HQK6EMS1X6:4BGF<F#D"]A0O#)2#R;$@L>
MYOYC/*?'<=3B.TY8&!0H'%))B&)EK-XFN]8$:$UCC*]KF[(.M_7"9&X4)9N=
M-;4G)\I1"W].HARZ>1VTIRR%WDE3Z!T8:B&&?2=E)SM; <P:6DMY%< L*17
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MOA-&3OB,P=%<!/KCWT6\,/TN"+6G.1>O91_0)MR).$W@ 6:H+:CC;!9)_!#
MC"D FZCC>%&0D2B;]@2$*$4(SV8N_#L2X=;I.J)LH-M@ 6+LN6S=!PT@R$&I
M#8[$M $I(XF87'$E*H+#5V&XM%C$P%J+X0-:"N_Z<%F?8"D#JP[!I\0'#_2!
MQ/C@D9SXX.'XU.A<^\0!3HXO[MP$VF[[UBZ^.9]NBQMD7CZ^65'Y'/'-BLIM
MCF]N1.9]H:4W RL#E"7*L4PU>]2:+^D@/T>IARH .NRST4!V[8=Z ^DH7U#7
MX2-"H,=]9O55%TB%EKW08HZ982JT'(*6%D66R:3M]OK:."!Y S<3VZ4!KX;U
MSZM0!49]UA]77S6^!G ZBV!O'6R$4.\;S):H,"J4M!$E YWI(]5=H0&F?UU(
M>"]"Q:L[Q9O*3^6'M7!(VX9N2)-$=4%"'0VN.@"!WKNRF*%+$ZR;XJ Z6DC'
MR5L%""4(Y-O2-;J_J*.M_;\\JM+4/B?UZ\##Y:?[E6F  CT>UH:L33L@RLDJ
M[<3H'$P%*@V;&>/Z1$@W#90*@[54=XXF9%T@50,]:;-.?5<#$S#ILX*0A"K(
M7?M;Q"WW%/TQ&P[.URZH"1"LW$O=1?A5&""CT*;05GJ[5DF 3;?1ME=.X:$9
M900]RRY/*2LFG)C#8C9)<?W;<M&VDL0&BKQ0D:QL\"M]T[#8G]AV1FM,-]JH
M];_9P8+RD![3J ML'R#CVYC4O.G9/F(@['HA8YS20/1CYG,E:3:;L1G'S.9:
MSFZ9/7/S5#QF/C_*VJQ-L7E!\@QZ)>Z[(P9Z>WP#H;6DMFH;2HD?\?&U=-Y/
M/)QA@IT_X?+S><_0(JLL8W596--Z5N^G/*OWZ&Q6'$(+^;\2%\:=P-\]3IV-
MX$_9F,7O3V#B,'F'QI]X[FR6=N^:P:_E9(6:$GMA8>IP0S)OF3;E2RX2;-,4
M:3KO>KA%XI_E:<=/KN>)11;2K+5D"8,XVF3N^(]TBD[@^V'@;4#AI]GFD)1;
MG<*'6C\]N?&\^!JC#])4)Y,$WJ"/+<, J^XYV$'*C;"L*) ?IER>[IU.1.1Y
M/R09AJ@-D!N*CG#9PR_3DC]U+"VY*(9>J(#=35,V]/JE*9_>A>C4/.?&90EO
M3.#43E J37F=[U6:<FM2.U6:LDI3;@N559JR2E.N@QN\'*!#D^D#V>%0]<;1
MJ6[O3J*'WAM;;&1:"BP*+/NTQ;"9);V?9KO!HG*458YR>]*>6A_>USGH**0H
MI!Q M2$S=97/W@#SORXD5*G*ESZSZX*$.II==0"""$DS=3882:LGH[)^&H\(
M)0DDV]0UNL2X(.U52O(Y4I(-IO<K2H/H0.YG.5%5,FC=SI/.)X,JI"FD-4;E
M46G'*NWX;"$(.NL/-B./56:>R@.MP"==1;R+ IL"6]E[E<3+=!ML4G..2Y+<
MMJ0A%W..5\NRCZ-&_MJ5_E8K1);O_->>"<2?JD@@]DOZ@!\QC$H?/D-^K*2]
M:F?NL-DS31D#G9 [7'%B[5'R]8+SS1*!0Q[Q\!O(K!.VIY!;RPQ]S&SKE#SZ
M0OKJ)%@L E\D)4?:+ @I99D2A4/N.90@&@?44[B8J(G9QO$S91MS/W(HWQB[
M"T<]RB_-?\>_X[_3L8 $,%04!Y,_M&")?X]8VIX6+%$2[SB!S!Y%^U06U<H2
M0IEVHK0MD/'$XV@UT@\ZLT9]4.1/8>;"Q$XY!PH%C4X[" KS.4G:K9-)'S#[
M))FW&NZD(V&-3*><"160:3"RV:@OATBOG S9O__R9W<61M>SQ//>?7"CB1=$
M2<@_SJB6PX,3\>DGAU+2;\(0,]OQG]'==Y0>3AR$SW_[]W_[RY81DL7""9_A
M'R"RW1F8$3#(9!(D/HJI3V 43%Q>'(HRYD'(?^:SO[ZY_X#L_G?K'U\_O-'<
M*?S"F<37X\'-_?!^.+#N/MQ^T&_'AF[>C&_O[XQ;\WW_O:V_^=N+4Z1(K5?R
MH,L,D ,/H>&1A]!PJTLJ)2(JU04R:BLZ:ADACSY7US+.S>HK;J#] #M-5B&=
M,C/7AQ/,=3P8"7Y!"*.SF*&>#COE"-C]1P3GD.O#08195]S'\@=+'GK/\ ^^
M!+A.J6P"O!-R)PI\RI?WW(4K"F\L'"JDX>%)B"=8^BR5/PB=!7\*PC\RXR4J
MT-I9T7J9TEJ+:%M@75.8B1<\G:V"BW$D]8VM"/O 9SQ$VKD^Z =<BYWO#0+3
M[UF1"MHVSW4>7-K@!8_G ?G+"]M'^E)AE3U-^PV4EK#T72P/4D(9*H(1\DD
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M:]@#FHB=Z#)4?#.K"CC-CN$P,W%36RC8OEOY/FQ\+U?UM;0LE$<IX]0P)TT
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MQ9^(EC]P2J9KI&NV+'<1+_1A6D(37]5R7^(%A:CM"\?LE'*33N@964=YH^H
MJ3I ]:H#=(/R@6?^;BX"1_=($0[YPA'5+]>3A:FX";G#5VG#3IE<^?'T*D**
MFQ0WU8N;[KZG76Y+RQ%E'N47O9A+,_<5RRB6Z03+?.9T_I O='M-F*QT1(C9
MWCP,DN)]>)J)F[V#^KPY8E69(9_P)CD2S< *4?=K$3SB&C_[D^!I.8:+$ P?
M^(23F\H4HL%.BVHX'IS#OK '1#"TRTFWIN())7*&^I/GY;JHV*42,DK(M$W(
M_)(EE^6IG2_/VYC8)RUP5?2%OZC,Q5:NYO0J:57I\$4]OT*LW5HZ'WQ+/+GI
M''ZMAZZ[6(!A+ +A"X41\Z: FT:_*M99@RI-JF97)]&PTQE68'XIFL$/MFTP
MRQS)43-R:590:WK:SQNUQ%9U*%;YN\]Y$4<*4BJM4"A<GB\+,:X*,&:-Q5]8
M0!0,30ETA9*0*S&=MCD5CLKUNH^4.D^W=5E_V^NLOZGX5NH'P6H(4DBH#S8;
M'QTSCHJODYDJM_(V"R4U2A8+)X3GTNK%E(0M\M7H7A,>S+STZ;WV6A?SU1&]
MZF2OVI">TH9T/.Y9^L#H6\.1;0Z-P4A>&]*1G#:D_=/:D.HGMC$]L(MIMS_?
M]-:&&!.#]0+?S=TI,+1<\4WVGS[L'V+^Y=,=OGF%B()ILURQY7>-I*;V__3I
M?W*)7,K8Y6WH7A&LQ[B(-@,S1"D/K%HB(H&.,,$.@.LKE%:H74W7.!&U%=#R
M\G"]P;" 91#&(DZ]S+VH:"V)UG<4I$$*9J97KDQ$165)5/ZREOE<L,%+K]6J
ME<[5*A/I]I(BO[&W=>G4^GG3X7JRQ[D*\E9!3-JJ"DY V]"-T_WVKU&Q$? Z
MR@^A,+:+I';?9GUCH/"E\*7P57=\M<1JK)+$'RF(I%BD#J_%\I_EJB054+8V
MC*M;S!X.F#$PST6NND"H\E.@S;"I0F=5N&D_;I2XJ9524*.;D8IH7^Y/^DKE
MLL^K)E1W0=(MAMY*QQJ@K18'1#N!)MO"5"A3*"L+\F+#D<F,T2$W9 IHTA67
M#EVF"%=&(093%O+:ZVW4=9.-!GW)+%IOF%0M[]N+EJN1Q2S=D$VHE9BY$*6D
M0^RMPM)K)#+'S#1EZP;U1L5E'!>M=TS0>QOY%]*0U4KM_)R1$G6!2.5V7BN1
MLBUW2J%$H42AI%9W$.TZT7<')E1QTK?YNM!F@\&0Z99L4[_UMX6=1HT*3E"X
M4=*FZ7I!^UT ]..6V(0+: HMU?'9<#AF]OAL3-UZ*T#AK!1G*CY!H:QRE(V9
M-1JQL:YP5FO=I1OA"[OT%VHK,X=?\C#Z#RS 5];'MT9&2#.N'\$Z&0^8.3Q?
ML&7-(5B+HZ:]>+N )T4AKM.(4Q*N8B5GO13LVO/2J]J=;:E[3K>*(H2?0A>[
M  0;]0495<.,21M:N+Z[2!9:L*16K7F3#>S!Y\:+O(1K62%PJH"YL?ICIOK#
M>*BSP6C3=CAF,%%[,VMO.\&BH?$3U@VECG^TZK1S4;;X%Q5#L:EXD%"]SU^#
MF&NZGG4F%/7/14>F5ZLSYLV]Q3<WBIRN=21<J]_Z1$5S0X[-V;.YKGHN%4N>
MII4BRQ>RNY]M]N^__-F=A='U+/&\=Q]@:"_ XJH?9U^H7N4S_ , ZLY ?OGQ
MJN/>IP!KHO+H[CLV9W7B('S^V[__VU_*A_K*%\L@A,$^Y)ORFY]$?/K5^?YS
M@%7X;_QI_IO;D$_=N#@R5;@'9OG,9W]]<_\!*^G\W?K'UP]O-'<*O_C_V[O6
M'S>1;/_Y[E^!HATI(U4G4+R3O2/9;EL;W=%D[R2CT?U(0[G-!@,#N!_[U]]3
M!7:[TV['V(7-XXPT4;<;<''J=YYU'IY?7(TM55?IS+"TL3NS[>G(T*D[F4WI
M>$9GNCY]\\MWW+B-IA]TE-PE4\_-S-<,""?:BGL/FT[BV79O7[)N(PX+$>V(
M>/?O<I!SFB4WY8Q<_AD\0?P2QL#D?(AJ.6%U,TF7*-ZMQSM!;PW_"EBP\HM0
M/&.]F5LL]H1UW\NRQZMYDHFIL(#6E=A6L6R_W%AQ[=;'D4  W!GS9:P*8 ]X
MG9*+MQI)5RRXBK?8)GA!E7(J;5YU7\4.J2=U2+6T+?.L)4U1=<,\).RUI[&G
M8YSX@%/O']X"\!CN5$_W4FTHSTGD_80]1S>_=8^^76;^WY'\9R"_@^2_)/GM
MD\E_P:+*MDCLW[C_^.1/K\W;+ O+J?'<-)851.KJF>%N!&HNL:A)+$-:35Q;
M,-%T7+:K.*@$#[$L@X!IC]L^H&T';@>SEM!:3;\'L>U8F?@Z;;_X?%P[#TCR
M""D0V%^(B!*?Y)Z%U7BG@-VQ*$GY;[*PU;NTG=TJV.)EQ,24IX%[GZ<S.."(
M^VQBJ!;([X-[VB-.!HP3U46<H =], D_Q7<L%Z?/VP='0S>:=RML@U!*B:I9
M:$0/ P;B/IVXCD,L%7=]>+NNRROFZ,NN]\UA?K8"<0J_G4EP)3Z12?\_X,%I
MQJIQWKZ7AH5(<<J+G*=!L0>?Y2(%XR9)OBEW7K024^#3C,>YB\?2 ?]K%0J/
MNQHE7K"(SR;GN5+KZ]!4KA<.)Z[*V5U>A6#?;>?! 6>-$\,EEJ8A3A G^W%"
M;6));"/0=YR@+_[Q"Z^74\(\7['2(!BZ)?Y*W%S3B&KCN?5 0%#NN6L1W4 7
M?$A[;K@Z[+FT(K"^[#EF^!Y/>YXOMG:YF\T6&UQKBE=T-3%LX^(T;0O\&O>E
MA@:ZZMS3='%4"V(,,=85C$DP86C/>PC_L;_XLADHRB%J&YAVMS6B4V)KE*B6
M-$?R1_1K"YS.JQ7Z@Z,2-H: C;6C:P+"!F'S*FPH<1V=4-I0'YO^PJ9VJYI7
M6@ULK[<#G2=&HOO+"R+5?%1E,E:0$$L.P)3@-7))_(%OQKK/1=EEYJGJN6HW
M\S)_])B7(<H]4Q;>'1/-*LHF$;Q(3XQ">!Z"F2?9ND4&-W#2598F_/,P5B9>
M[ 4>]I8XI;<$-=[9IJ7K)G6H96JJ37^2UFE"E]-IPO[II"8)%CWM?JW>[0.*
MP)ZC&'KZD(99G80E+#H_BLX]+BQOH <=5:DT+['39JQ+'-4EP"ZRJ-%#*[7K
MF;#-\$_S0]4ZS5@:)9JMRN0L#!P/1#-)*_'K- ,9P#NHF5 SU>8?O7F)VW'&
MLFT#%1,JIMJ,):TNHN/\HQLZ*B943+7YI_E>,)UF+$H<6RICH6(:B&*2=@;;
M<?XQ3!L5$RJFVOPC+XF[IXK)L"DJ)E1,M1E+6DY9I_E')QHU43&A8JK-/_)2
M>7NIF"QBZ'C&A(JI/F-).[WM-/\8Q-&D&G:#9I,A*29YY6*]5$Q@[9D6*J;&
M.>XL4^I;Q7CR^A\W0+O6\)]%7%6N8?@#:B$;[JG<:5@Q2AMPG<#KS:/D_L,B
M# +V>A7-41MSS/B]]E"]];/5Q:\O.W2XA$KV$(^E.HYAW_7S!0O2CGI77"^N
M%]>+Z\7U8D'PH07!&9N#.2 *9><,;  O4L*=@TG.5"O<-? -MK99<]4GT[LE
MU<RN?8B?OV]HO'/B W!H_)E"3KM=*BQHQH)FZ9&7QFO*I/G_O0R>B/LT1VJY
MV=#B'7A.N(OOFA\ETNES"L/6\)2P:7[K(5M)JZ3I-O=8F%6)2JD^]\AK6=A+
MI:1;J)10*=5G*VE5-)WF'DH=5$JHE&ISC[SVR[U42A0])51*1[ 5MCGD]YE4
M:A+4H)ED2$H)FQSN9RL7D_Q1*=5G*VG5,YWF'HMB[1DJI?K<(Z\$II=*2<,F
M4JB4ZK.5O+:AG>8>5VJ88= \,B"=)*\U:$]UDH8==U$GU6<KS'/@]^D.*B54
M2O6Y!_,<]J</.5*[A:)2&HA2PCP'00BYTWT&S21#4DJ8Y_"#*@R,WJ%2JL]6
MF.<@3#ITE% GU6<>3'/8'Q-W4!\URVL_:"K50Y:3UT"T =JUAO.T)DIR7R45
M\N#EFACVA?:M(G,;^%C\^J*[@TD,AQ*9BO58NO8%>+5;#ZY__L?[<)[E5_-5
M%'VX#G,_2O)5QC[/O[)EFF1>]G@=SN<L8['/_HA7.0N^>@^_)GG.\E$<;#Z9
ME"V<I@]IY,5>D62/O_SMO_[QRI,S+\X]GW>HRL>LN&<L_IU%7L&"?WFPMVS[
M*; C,2?[[VS^WV]FU[QAU?\:__?U^HT2!O !/.5J/'7&*J4Z=>E,O]:GU%(G
M[F0VI1-=UPS;>//+=]NXO24_Z%6T"P78JVE'KR:3RNS59$OIU:2KVB%"<$^O
M)>O<S9IP 0-J5]4Z'8+=JHZU9]:-%'=1_^!.5DC^$\CO(/DO27[[9/)W[R1#
MNOS^LDBRX@JV:ZF \1TECPQLNF29,C"7N;6L>'&@W+"8S<'4EN4Y]<NQU(GM
M6,2RI(6TVX*-I@,3785!*8"(Y:C$DM=N#7>]$[LN"E =:5FR?=GU'AUX2J?M
M5]"N85RJ4]FJ="#!V[*'O$,U*B\LWO?P[."@@TA!I-2@FFV[8+4W/^^Y+RA!
M;QF\92]C5S=>S@(E]1[Y-!%TBG<J;(UH5">&*BWII"T00/=H7_(,42V;:*ZT
MC'/<]0[LNF&ZA+K(Z5)<XIX,=FWSQK1J#UH_J62W?C>(JZE$M>75%N&45X2L
M3)+KQ#9LXFCR'#Q$*")4+D(=W22J@0CM:+IJC:32YZFIZS_ G9_G7X!:X1QV
M,RXF"R^^9?FG> *OD\&C1WG."I[UNO[@U]"[":.P?LJJ94V,:WWFC&>Z[;J&
M.;8U0Z2LCJ]5:Z1-SIFR*GD<:H5E7?Q7/N7S*A,TX213HHIFC\J-!Q3S&9^"
MNYY.J_"AM/>+T%\H]R^0= Q,F<(>4@9?6R1*QN?B!GR8;,;N6+QB2@*<*P;6
MQD".DT?QBB^<AW=,>02F>!F*.N9Q1 ESQ<NKB;JYE/FW@\U1-@Q=8HZR*25'
MF>K6B0FVFGI0_*'!'&'WU%? '.'G?,?ETASX_<,B#(#7&CB2XP/ :Q@ZF!>)
M6<&=)/_I6<%XT/9Q7!IJ1+EAH%=C6*22S(7=Q V=H4?==V//(K:N$NI@'NI
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M6.J%@9C<$.?R5'+O#.,]NIH22Y4W#:QOEG+#2KQW0"L]==LDJHT=,Q$E>VU
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M"_"*@BW3*H-A&1;A+9\!5RS"7,G"_!NG3/E5/*\A7\VYK<MAN?4]L$@ON/-
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M@6@5C9@V:Q*06H+5!R)J%0G3IF)#;I^^$ /'6C;U#)4G8T<4NDXK"3V*@U'
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M+ Y8\(8_^OV+9__RMW^\Y\\)/_!_?_E_4$L#!!0    ( +U\9E 8NS(_A!D
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M'CE<7LP^^@A_RZ&]/%+_#:$+#GER=BR*'P&#,3@F&(<K/8(7T.-@LX;''&C
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MW\4VBY C$ -B89PWQLN/)"U:]#%625=%W<+@<@GP D[P+<$"0$9.\.(2K%$
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M2@;7.$[.WNG&28K=S_;N/"K*)(P#X>R=;B"D1'K:[S$C/O+$=G?B\_,U1KQ
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MX[.E/KW(GV=/V;$/V4&=$AT[GD02:>,,<MXQ%(-=B@R)M(ELA'7".SF[>;6
MZD.&QZ.@0A8V-<E 9,_\K(O$9?^ELAV[NOVK2[W4'(04(R5I@HP5$5(Q 6YC
M09,H9LKK;DYH7BWF!A'J\8#P(=_A/E![)$H)-YCZ)$+,4HQBZ6 J@MF)B+5>
M:!=KW<R+LO-\Y2<!5"O1=1:H4.O1Q9[AWT_<^SN"$E[0I4(F%I9PBRA1L,?E
M'"Q$2MSRJ%P1K(4Z?/S%JQW_OJ0WIN:HM=U"\5WD:RX_/(;';U<F>]238LME
M[(1"S"<8<<T9$H91%$GIK9(QU38Z'%]RJ//;/A5,O^(\IB""XXS4W^#+C'X&
M;/4@Q#$!M494BZ2Y(1V)@2FR>U_7K(HT]C"C(A<ACB.&;) XPT*@.$Z$T-P:
M1EK$G0SESQSO3*4;F8YZN#(O8:L NU9_GZKN<J(6#T#<YZM[/U%5E?G,V=-J
M7QRVKSZ5V"3:>HOB) [!9)%!,3,QLC02AA#&(M/" 3'8W9T^T//R6&<,<1^9
MJGQY2>3S#1BS,U=.S]QM>/4J)/AXS$*^MR+=NP$PH(U/*($U35N)J)4*\5A+
M)&7$/!@ZAD0MXI]'/#;J'L$CR?O(,+R,<FNSW*^I(@4[BE*,%9+6&.2C6"(>
MMG2)HB"7R#/E6N!PJ'.F\9;[;F0Z<BR%<<[6?;I/8?>0RG)7>,5FRI12*A/M
M:! U+!V"@6UM"093.\*QC&+O^"L(SNECR->%7G0JR&.!TWE5S4%.]8%:<R@]
MH4JM-=;#[$0JL1;9"-8.1:E'3C EF<?&^19^VA$7RGYAU%:(8Z]^%_.9!WE]
M7#H?=Z]USPE221R)O*>(LB1"4@F")(X4HHGF6A!AG6T1\378)=E!D-.1 (>\
M)='FU>&!@Y9W/!P\<O#R0D!/7]3<.MO6$:1QPKFA#B.L8U SF#+X)# BD@OA
MB%4.-]J2#]WO!CU-!1,X]BQ&/H8YP+2'/8P-\X(*+S2UL+%X!99,^V%[H38.
MEL^HOGE8&9UMY(A?+9D:[%V<Q!8Y[A0BF@J0E^>(QL9%/B(\%BT,D6%1L-^0
MO72NMQ1,B^/@^WQ;*K=UT-]J7NZ-9\';B& *Z%@8&B.NF4=>@(&4:$7O[TQ+
M(OPK\,2T&-=>9#1NH,C]_<1+E0'_3>;Z!IHTIIXP;BG2AG#8@7F%N"<>248]
M5V!3,](B3& H_T@GL[X[$8T*#F/FTWG]XLKB+FTQO2W=C<NK[)M;O/&X'2B[
MZ5.FM5<".R2\LLCC1*&$*X(,$=+*V'#7)D!RJ(C;;D#3B[C&!-!5N :9._M!
ME3GHQNVV\O/"*?9"@BZ-D.4B"2D0&&),4L2I4XQH$26TA3X9*G:V$VAT()LQ
M<=!TN[1J;O.8*&ZM!E69)$AYG2!+!$6".(L5BXFT+9(.#FMK=+J3:">D49U5
M]8OK._(D;2N>>N]QI*1&V%.PFGTDD*" ?9S$+E&,4M[& !UJ8W'P"+YT1G4A
MHC$A\22]U[(WC;(7;2-,66R4Y,P@S2.-'/,2U"[7*$D(%U1RDY!7X(5H.[@O
MT-*QS(Y E31+O=:$++7:1M :[-8HV%-Q0@PH914CH;0W3A&)Y2L(YNH<,YU*
M;$S$K(*^*5PVT*3,<J:"#*GV#C&I"9*:PJXN$1&.&$P5W@(K@]TX[1HKW8GK
M"%3+7A<!-]"DW!(E' ;CW("1YSG8?!&I[X#XQ&-**-8MPH\'NT_:DU+I0%Q'
M )3'T/N'PZL]8;.]AE0:;:E0'K0K)\@KCY%3V"$*G"5&8I!."VTSV!W2GD#4
MN?#&A-2G(C?[+5%K*5)!K8HM;"-@)6:(Q]@CC[U%,*.TC)F-J&AQ!70H8Z:[
M?5)74CH.;.QK]6ZE3'&".8]#!AO+,:S.6(/ZC4->7.T,K-.1=2UN7PVU6>I@
MA+>@IANYC6[^[J]>-I.E/J+4Q:"XE8K \H\<0X3A! D6$1ZQQ(%I=_PZI@_<
M="JTXU Y>UG#F\G2.,8TW(% ($2"'"<481N:CF*JL#3$MKE*/M3.J5]ETX'0
M6D0-K&2Q#$'A1?V>GLO#:WJ;W^'81I1RD\C$6(42HV7(DV91K-G]2S<VMI'L
M)KKP=7CR>Y'8J,?$N_-W+5--P12(26)!YVD>(9(D8(=[YA"7 K8"%-900H\K
M\FVYR6C0Q2<E4P$*'7/FP1J@&%')$Q0K+% B+75:.$--B_>)AC*J#AFV3?NT
M@P4S=GCUGKEI-]RF22*N8^D5<MX&&48)(K"?0<Y:BIF+$L=?04A<B[%<&TC=
MB:!&-ZN74FGZZMD&FE02FC -G0[*'RD.5F)"P[(B14(U2)3J%NODP"<0G4"D
M.TD=@9_PZ:M:C1:39R1I9)4VB?>(0)\1B^ 3QQ8ZSR7(4RF2M#FC&OC<H1LE
MTI6@CF.;U<#.>%XXQ<IKS:U$F$F%C"4Q;"Z)1P:69MAI)MKC5Q HTXFIT8%L
M1KX/N#[KP%9 ;*1*H;_448EA&QK!C_!LB]3A-2'#M9(<<YZ\@FB9=H.Z[N9?
M9^(:-;9RG_S)+Y/^DBCA@FB$A;#(1!HVEQ[^9"RVWB;,<]XBMG)XYUTGT.A
M2L=PK>_%';I+%41TXZ"6Q]#^4:[WA0QFM;MC);)Y]6F"H[CEMV^8^[HX;4&-
M%0 /9#!W*-( 1,[B<"E$>*)B+FPS2VW0Q>?_YSL1;4?OYWD=XI'Q=\X7I?NB
M?C3$PD/YE&@5$:&@Q])ZI+ &(5(/:CA.0AHZZS!O<?(\%"@.'<(M6&@CHN,
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M6-<-F!()$G2[$9763<K7%Q]_6IPZ*N_3H1JR?'A<+G9[Q&[9E^OJ'AV228.
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M.(PU:DNRE;5N/(9Q%TQ- $F:CW9GLC6OWGQN?":LEU8Z%4Q^PAS3A('2[&=
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M*/;F=WEQ(VJ6Z_,E 8Z.R!076L5[&H:-I=S%0/K]BJWUI+D_K<-*FAU'(2?
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M<2?+NN OTT#0*?LF7RZS[_DSF6;8T* /6DM(7(&VI%R]Y5:/*" R)?M:0#!
M.HAUW"/"">1(@[#-!"U>E 0*)9I'H(\E':2N2I0"IH&R"<)!0:Q6!L46",B
M('6EL#F&U4@3<UL"?B&MH!DF(V7@J+258?G6153BL5!F,UE,;F=U HDOSQ)
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M+5A21F.*$4&E:@8@;W%I.0J+M*[FV1%N0^[K.TMZ#] ^7.WLAGYL0&9C%V;
M)##6 26QM 3NUZN9:U&+:QQWV\TME 1H#2D=_\BCMR6_59_SU>13_BZ/V 9!
M-\$$6DVFFVU$Z:Y%T%:*%V060JV%<#H68+44T5@S8H^GMJ:Y53R.B]+FTC<
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MRC#G">&RU,JH0;)YYFY/E:5Z"2U/ 5V[U*U"B8I8[&6VE.3UZ6/K[*B,*P>
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M9"@TL\TM*G2/SAI&X[>4^<"LDT=*/P.GYC2\;QB$73<@0>3X@8VQ#U$0N]X
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MA!WS0AW97*C=']VI0BW#GJ)4&R).AUAS:+KD6H;)B8)MB%&=DBW&[ 31?N)
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MCGE.W:O&27S.[:">!+"***$QLKTP0FZ$(X\\G2JBQ'>IW*0YU9KA6:]OFWB
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MM@#.P;K$'M[37,2&QV]%Q76,F>_'RH"WP]^ZLD(."BAV:8A#AHBX - ]%.
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MA-8QY^]>W#%PTP%=@) JT"N^1M4=K\6(K5$GQU>E9CA5%.3.YL?\^G4(#DD
M2W(Q=,,P9O,!RX)[",CQ/<DO?#0:-IR)\H\:U@R'=5MNV\L!\G)C->7^&I))
M"CR1<B7=G8]M.;7M@%A;!NS[4-A1(L5U54\\%JFFFEP;UU"=_"DJYZ 1?RMY
MEQ-^-/0U*,@GF'J! WT'X]#S783W4$+DD D*J@? 7$K:#>[N+I"'/>))0JHI
M DJ".C_Y<L*ZY_V)Z^]#8(6(%1=:O7%:I.!J=G%<>$WP*;:3,EBF976=Y<VN
M>E7Z@RAT8!"#A&#'#V,_03$8++L!EOA>08^]N>3U>H]2HD2@E5B13:OY.554
MS2> [ZP6HM5CM'Y^0S7-$2RSV34_T6K;7QH(%]T2$Z+DY":97D*7L&VFV:/2
MW.NGTEB*6T_RAWR3%1M8?V++=OYNWKR* \0Q82BP&Q 4XSBR240&'(GO25[C
MK=OZ7#/(IL=K/>;95E#?#'(NFI6?DV[%R67/=%KSVE(/=K'IN23#H[FYJ6@M
M)3$WYM^K[:',,2DNMK]GO'U"MH$/6<5,TS2O_I9N=QEL?LE2ON'(DX+D1(F;
M4 ?;(<)^$/@!H%X2P60 Y3E$\B9SHU ,R_" W4H[\-8U0V\]</CMU:F]*$R\
MK-9LL$0E>S%QDM/OL1"EC77WA-W:+'G'< K]H^(^2UR7HO3S.'LD^S-R+'K
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MJ]R[P%+PMM/5X,2[O5PO*\?4$H[QFN:L 5^*Y,_L]2M?!,S/^K25.HEQ$,?
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M5:CI7"]%H31X<J10NMB1.!?PPASD!Q.>0-#\H?WQ()2N#?S L8D;NY$=^4%
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MI9Q8G:+1RCIHY]>K4>9&54L/YTO1+DW>'+<PULB21.^[H?XP&/(@03YQ0C<
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M[9K[K]_R^U94RVU+F]LO];;3U_8"/ [SF,4(,:&G.2DXY..>-$@P9IK3N=.
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M\;6;/A-0[L3G*Z/R:Y$"2K,0YQ('CS%-0)9UKZ]QG $4*AW!\ QABIFN()=
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M;DSS1%3X,.]?-BZ*-(46 N[$O&?A'C%V<GT :*/6;D@W4>G)^;91Y[L![)M
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MN!-_JCT=:TNH\I3VA%P:S&ZW00<O>."T QA(A,'G?^J<\7=(KO:T]X0D6\R
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M[3X. QY!,3*CO&!)B'"2$GSX\0D>"]IBN]+LXE[ZP?H%[(CAOW$/ITK:7(:
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MUOE^<>J"X1FV5 H&&Y+G,LA<N'*N8+#G1[^SD6_#']M#P@KA((%)S$D*.$_
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M?E?=K(<I%=E9-%NY >F3O(_O4_5SGPMG_[V(<X@SRH7V)3A,<4H0#\6OB[3
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MYS6W<&JT/>-PZT)<OXLS#KZFJJC=0]M##]Y!6/I74:>X#?,YOO+H: \U.L<
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MBHX&.Z9>Z;>V$F+7:LY-N_$MSJCDFH'Z2*1>ZQU6MV+;_+88%XOUY=C?CW1
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MK[FY-S>K;,'1Y'I4A+'7T1][VF0N>@ 06PZX-T!X#CVII*;,7UR=U-8T23N
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M"GG%N$\I!3O(S:CV&=@=VKVF24S#;.3SQ1JO(%CS2M;UNL@L%&%-B95R!?,
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M7\^*<?A/_E L'S:N[_XM_CT-,D]DT#N*,8,=QH9Q[T@UY/!7?4DQB'-RI"7
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M"/XX =H6(>Z4-]?+3Y-B["?E:%=>Q,[G,@>LUA)(%_,MJ3$.F0H/'51D4N;
MCQ.I3<7UO D\;AQSX8JQS3_'])SIN*,*9%>W+]_4()'P4//,:T&YL@@J3*ER
M$EBTR=6R$"AT4N;@B2)]#'CIT->?)\JT;9]1@KA@F%%D!,>$>*?\1BA$ $A:
MWP?W+;8\SV7W@/?]E79Z5K[+C]5HB70\H.R]4<B@,)V;4\I(2&5KN3BU13+A
MCU6*SJH0:#'_$^Z[$O#@\QD.G'-,& >@-IY8(!RM!JT5N)#;EKJ9Q^=U+EH
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M2Y5N@&Z'+>M3!<5T6Q[MZO:/6)/X::"]#G?J])-1IPB!TBO!*).<>"*JSX$
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M*:Q MA*#<7]Q.Y)MSFS9(=()IS76@FTOAGA;KHN-P#U9$<<;90()33%@\62
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M/&>60*P!U>WLP6$X&>.$^-Z3$=QN:M2NE^G_6LW-WM#>D7:9X,YZ;PA!G#E
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M8CR:'"?+H<<S$@O?*,(!@DY(1I0CJ!JNP?5"&:^)'ZU-7]DZN+TNB>7#YV7
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M$FL'F7<286*U\Q5VS(,+J8W7/;5></AL<S+(7=_3]GLSJ;Q0-*QGE@$!I6(
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M(Y$Z).5I__L%2!8M6R)91=0%*KF[H[LM5:& +S\D$HE$)E5NCQABA$[DC+T
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MDL/]^!"";G*NX@LD>T0M703@F 31R\UF>;^?2@UX\L+S 6*1PK,@8Q8Z 80
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MOYU?1SOB_S[>?$FAMFNWWLSO4ZVSB(.*^[K[W9"Z7*Y;?/;L&GU!6P%"Q#B
M5D,0C7B4*@<[:;SCSEC!FF7,&4?-J>OK%"\?Z98&NXV-3H,\#/@2[=6BS4
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M?AU]) A@%&0J4AQ@"(EC4AVP)=!.I!9MO[0[N9X-*)UB3B?;I8UJ?A39KMT
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M->;R@(TT).>@J'70Q3"[CW$YVZ4TBF%J2F9Z'?O_S^5=),%=G>;I4L8V:BY
M%XT:JX%Q@#G!431IZK6)42ISMBZM\U.\!>;V(94,J]/.O\UOJL7-_YM7=\GL
MO:Y.;%=>>CAX (3@3C.#E7:(&6EK YDIE*7Z6L=>3(I G6$^\LEF]T7-RSR5
M5$I#J0RWR&/*-&(BQ2*G>IK6"M,L\+)0Y]E%E5I;-!H\A4 BC"QTP.*$G?>*
M*Z<5CG_)G"##@KP<P](LSY%VN70:J)O]+]*_/L_6U?_Y7_\?4$L! A0#%
M  @ O7QF4+TSBXSUI0$ L709 !(              ( !     &]N8WEF+3(P
M,3DQ,C,Q+GAM;%!+ 0(4 Q0    ( +U\9E 8NS(_A!D  !,M 0 2
M      "  26F 0!O;F-Y9BTR,#$Y,3(S,2YX<V102P$"% ,4    " "]?&90
MZHNY0#T:   M&P$ %@              @ '9OP$ ;VYC>68M,C Q.3$R,S%?
M8V%L+GAM;%!+ 0(4 Q0    ( +U\9E#&*3[F@54  , W!  6
M  "  4K: 0!O;F-Y9BTR,#$Y,3(S,5]D968N>&UL4$L! A0#%     @ O7QF
M4 [Q]&$MR@  ;Z8* !8              ( !_R\" &]N8WEF+3(P,3DQ,C,Q
M7VQA8BYX;6Q02P$"% ,4    " "]?&90<I_DL\Z'  !8U08 %@
M    @ %@^@( ;VYC>68M,C Q.3$R,S%?<')E+GAM;%!+!08     !@ & ) !
(  !B@@,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6730100592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($) </div>
<div>year</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($) </div>
<div>year</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($) </div>
<div>year</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract', window );"><strong>Disclosure Of Share-based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">1.62%<span></span>
</td>
<td class="nump">2.02%<span></span>
</td>
<td class="nump">1.18%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected hold period to exercise | year</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected share price volatility</a></td>
<td class="nump">97.90%<span></span>
</td>
<td class="nump">81.15%<span></span>
</td>
<td class="nump">90.73%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ExpectedForfeitureShareOptionsGranted', window );">Expected forfeiture rate</a></td>
<td class="nump">3.67%<span></span>
</td>
<td class="nump">3.67%<span></span>
</td>
<td class="nump">3.67%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value of options (cad per share) | $</a></td>
<td class="nump">$ 0.87<span></span>
</td>
<td class="nump">$ 2.67<span></span>
</td>
<td class="nump">$ 2.65<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Share-based Payment Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ExpectedForfeitureShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected Forfeiture, Share Options Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ExpectedForfeitureShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6751459536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Summary of Outstanding Warrants (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>May 22, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued, beginning (shares)</a></td>
<td class="nump">17,399,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued ending (shares)</a></td>
<td class="nump">32,198,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life of outstanding share options</a></td>
<td class="text">4 years 5 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1', window );">Warrants exercisable into common shares (shares)</a></td>
<td class="nump">1,730,894<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ExercisePriceofOutstandingWarrants', window );">Exercise Price</a></td>
<td class="nump">$ 9.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued, beginning (shares)</a></td>
<td class="nump">16,443,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued ending (shares)</a></td>
<td class="nump">16,443,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life of outstanding share options</a></td>
<td class="text">2 years 5 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Securities Called by Warrants or Rights1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ExercisePriceofOutstandingWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise Price of Outstanding Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ExercisePriceofOutstandingWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>89
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M]8??5=CUQN[M/S:^",H6?MV%_ )02P,$%     @ O7QF4)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MF0*T,C.^GG7CB1N5+FI/NY$B3CC?#0@>'H)V!"D]!"T8M,H1A%#=1XE#!F=
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M#LY[:SOCA)([)_'H+E_7C]+LN_Y5N?=FO(&,'YT]3;>KY'K%6_T&4$L#!!0
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M[I&))D,IK;3&M::8439H=#L]4FP$09FNG!L^;$/#1@-=&;I>E([U11F_IAR
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M9?76Q??Y[O>:W469;9O?HL;['\0N_P=02P,$%     @ O7QF4)-7X0\4!0
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MOBI(K!4ND HP-[)"JO?T6P&(\U;6A?K-2.=\"P5= [Y6\M7O\\TA(1N+^LU
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M2FR-D*384"@M,&P)!(XW%&0"^9'DPEEE9*8K $PG"F99'5% K<B&TM3!9D3
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M@)1!"&W\F#7I4C(0U_M7]?>Q=^SEPAT\&/E=U+XKZ!TE-31\D/[)C!]@[N=
MR=S\)[B"1'AP@C4J(UW\DFIPWJA9!:TH_C*M0L=UG/[<'F;:-B&9"<E"N(MU
MV%0H.G_DGI>Y-2.QT]GW/%SQ_IC@V50A&8\B_D/S#K/7<I^F.;L&H1ESFC#)
M&K,@&*HO)9*M$J?D'WKZ'WZZ:3&-_/0/B]FV0+8ID$6![,T>MS"'OXJPU:$J
ML&T<)T<J,^@XRJOL,K'W2;R4W_!IW#]SVPKMR,5XO-IX 8TQ'M#*[@9GJ,,7
MM@02&A^V[W!OISF; F_Z^0FQY1V7OP!02P,$%     @ O7QF4+R/G3RU 0
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MM0_;6]S;<<[&P)MN>D)L?L?%&U!+ P04    " "]?&90;#N)1;0!  #3 P
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M'J\V7D!MC >TLKG"&6KQA<V!A-J'7YP(8L<Y&P-ONND)L?D=%V]02P,$%
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MO( *T0-9V=S1##7TPN9 0^7#+TT$L^.<C8'';GI"8G['^4]02P,$%     @
MO7QF4%&O=$:V 0  TP,  !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M?5/M;IPP$'P5RP\0<]Q'KR= RJ6J6JF53JG:_O;! E9L+[7-D;Y];4,H:DC_
M8.\R,SMKK[,!S9-M 1QY5E+;G+;.=2?&;-F"XO8..]#^3XU&<>=#TS#;&>!5
M)"G)TB0Y,,6%ID46<Q=39-@[*31<#+&]4MS\/H/$(:<;^I)X%$WK0H(56<<;
M^ ;N>W<Q/F*S2B44:"M0$P-U3N\WI_,NX"/@AX#!+O8D=')%? K!YRJG23 $
M$DH7%+A?;O  4@8A;^/7I$GGDH&XW+^H?XR]^UZNW,(#RI^B<FU.CY144/->
MND<</L'4SYZ2J?DO< /IX<&)KU&BM/%+RMXZ5).*MZ+X\[@*'==A_+,_3K1U
M0CH1TIEPC'786"@Z_\ =+S*# S'CV7<\7/'FE/JS*4,R'D7\Y\U;G[T5F_W[
MC-V"T(0YCYATB9D1S*O/)=*U$N?T%7W[!G^[:G$;^=ME^4.R+K!;%=A%@=U_
M>US!'/YUR1:'JL T<9PL*;'7<907V7EB[]-X*7_AX[A_Y:81VI(K.G^U\0)J
M1 ?>2G+G9ZCU+VP.)-0N;-_YO1GG; P<=M,38O,[+OX 4$L#!!0    ( +U\
M9E!RM>-\LP$  -,#   9    >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;'U3
MT6Z<,!#\%<L?$-\9FD8G0,JEJEJIE4ZIVCS[8 $K-J:V.=*_[]IPA+8T+]B[
MS,S.VNML-/;9M0">O&C5N9RVWO<'QES9@A;NQO30X9_:6"T\AK9AKK<@JDC2
MBO'=[I9I(3M:9#%WLD5F!J]D!R=+W*"UL+^.H,R8TSV])AYET_J08$76BP:^
M@?_>GRQ&;%&II(;.2=,1"W5.[_>'8QKP$?!#PNA6>Q(Z.1OS'(+/54YWP1 H
M*'U0$+A<X &4"D)HX^>L29>2@;C>7]4_QMZQE[-P\&#4DZQ\F],[2BJHQ:#\
MHQD_P=S/.TKFYK_ !13"@Q.L41KEXI>4@_-&SRIH18N7:95=7,?I3W*E;1/X
M3. +X2X2V%0H.O\@O"@R:T9BI[/O1;CB_8'CV90A&8\B_D/S#K.78G_+,W8)
M0C/F.&'X&K,@&*HO)?A6B2/_AY[\AY]L6DPB/_G#8K(MD&X*I%$@?;/'+4SZ
M5Q&V.E0-MHGCY$AIABZ.\BJ[3.P]CY?R"I_&_:NPC>P<.1N/5QLOH#;& UK9
MW> ,M?C"ED!![</V/>[M-&=3X$T_/R&VO./B-U!+ P04    " "]?&907*:,
MD+4!  #3 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q]4^UNG# 0
M?!7+#Q#?P>42G0 IEZI*I58Z)6K[VP<+6/$'L<V1OGW6AA#:TO[!WF5F=M9>
M9X.QSZX%\.152>URVGK?'1AS90N*NRO3@<8_M;&*>PQMPUQG@5>1I"1+-IL]
M4UQH6F0Q=[)%9GHOA8:3):Y7BMM?1Y!FR.F6OB<>1=/ZD&!%UO$&GL!_[TX6
M(S:K5$*!=L)H8J'.Z=WV<-P%? 3\$#"XQ9Z$3L[&/(?@2Y7333 $$DH?%#@N
M%[@'*8,0VGB9-.E<,A"7^W?US[%W[.7,'=P;^5-4OLWI+245U+R7_M$,#S#U
M<TW)U/Q7N(!$>'""-4HC7?R2LG?>J$D%K2C^.JY"QW48_^S3B;9.2"9",A-N
M8QTV%HK./W'/B\R:@=CQ[#L>KGA[2/!LRI",1Q'_H7F'V4NQW5]G[!*$)LQQ
MQ"1+S(Q@J#Z72-9*')._Z.D_^.FJQ33RT]\L[M<%=JL"NRBP^V^/:YB;/XJP
MQ:$JL$T<)T=*T^LXRHOL/+%W2;R4#_@X[M^X;81VY&P\7FV\@-H8#VAE<X4S
MU.(+FP,)M0_;&]S;<<[&P)MN>D)L?L?%&U!+ P04    " "]?&90SAJ L+8!
M  #3 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q]4V&/E# 0_2M-
M?\"5A?5NW0#)[1FCB2:;,YZ?NS! <VT'V[*<_]ZV<(B*?J&=X;TW;]II/J)Y
MMAV (R]*:EO0SKG^R)BM.E#<WF /VO]IT"CN?&A:9GL#O(XD)5F:)+=,<:%I
MF<?<V90Y#DX*#6=#[* 4-S].('$LZ(Z^)AY%V[F08&7>\Q:^@/O:GXV/V*)2
M"P7:"M3$0%/0^]WQM _X"'@2,-K5GH1.+HC/(?A8%S0)AD!"Y8("]\L5'D#*
M(.1M?)\UZ5(R$-?[5_7WL7??RX5;>$#Y3=2N*^B!DAH:/DCWB.,'F/MY0\G<
M_">X@O3PX,37J%#:^"758!VJ6<5;4?QE6H6.ZSC]2;.9MDU(9T*Z$ ZQ#IL*
M1>?ON.-E;G D9CK[GH<KWAU3?S952,:CB/^\>>NSUW)W>\C9-0C-F-.$2=>8
M!<&\^E(BW2IQ2O^B9__@9YL6L\C/?K/X=EM@ORFPCP+[__:X@;E+_BC"5H>J
MP+1QG"RI<-!QE%?996+OTW@IO^#3N'_FIA7:D@LZ?[7Q AI$!]Y*<N-GJ/,O
M; DD-"YL[_S>3',V!0[[^0FQY1V7/P%02P,$%     @ O7QF4%*\](6T 0
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MM0_;6]S;:<ZFP)M^?D)L><?%&U!+ P04    " "]?&90KV-.EK4!  #3 P
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MP[V=YFP*O.GG)\26=US^ E!+ P04    " "]?&90*O8ZHK4!  #3 P  &0
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MKS9>0&V,![2RN< 9:O&%S8&$VH?M->[M.&=CX$TW/2$VO^/B#5!+ P04
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M^_%=KJ4T8%.);FPNK1WCU>!0&[>]LWLU/^;9,')8YI2L/XOB-U!+ P04
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MW;-#>G[,LV'5L,PI67\6Y1]02P,$%     @ O7QF4 NRD3+K 0  9P4  !D
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MU%L,"I4RV[W>BZGW)T/Q?AYK>)FM^3]02P,$%     @ O7QF4)>WA9"Y 0
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M_H?-AH3:A>.=/YMQSD;#83=](3;_X^(O4$L#!!0    ( +U\9E#5P;0ZPP$
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MY5I* ]9*=&.]M':,UX!#;=SVSN[5_)CGP,AAF5.R_ED4OP%02P,$%     @
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M:>,#U%H[\*DD5WZ&6O_#9D- [<)QY\]FG+/1<+J;OA"9_W'Q#U!+ P04
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M<FMS:&5E=',O<VAE970T-"YX;6R-E-MNVS ,AE_%\ -4/B1.&M@&F@[%!FQ
MT&';M6+3!U2R7$F)N[>?)#NNVS% ;B*1)C_R5R2F@Y OJ@'0WAMGG<K\1NM^
M1X@J&N!4W8D>.O.E$I)3;4Q9$]5+H*5+XHQ$09 03MO.SU/G.\@\%2?-V@X.
MTE,GSJG\NP<FALP/_8OCN:T;;1TD3WM:PT_0O_J#-!:9*67+H5.MZ#P)5>8_
MA+M]Z!)<Q.\6!K78>U;*48@7:WPK,S^P'0&#0EL$-<L9'H$Q2S)]O$Y0?ZYI
M$Y?["_W)B3=BCE3!HV!_VE(WF;_UO1(J>F+Z60Q?81*T]KU)_7<X S/AMA-3
MHQ!,N5^O."DM^$0QK7#Z-JYMY]9AXE_2\(1H2HCFA#!Q6L9"KO,O5-,\E6+P
MY'CX/;7_<;B+S-D4UNF.PGTSS2OC/>?1-DS)V8*FF/T8$RUBWB.(H<\E(JS$
M/OHO/;Z2'Z,MQBY_]:'%" >L4,#* >(/@!@'K%' &NE@]>F0L)@U7B1!BR0(
M(,$!&Q2PN5WF%@5L;Y")Q5R1>8\6N4< &QP0!OB5#6X7&EZY]>$-4M&@[:<Z
M9/'0.,C:C1CE%>+4N?FV\,YC["%R#_4]?)R!/ZBLVTYY1Z'-<W>/LA)"@^DE
MN#/7JS%C=S885-IN-V8OQ]DS&EKTTUPE\W#/_P%02P,$%     @ O7QF4-3<
MV"'+ 0  -P0  !D   !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL?53;;IPP
M$/T5RQ\0@W=)-RM RB:*6JF55JF:/GMAN"B^4-LLZ=_7-H22#<D+ML=GSCEC
M>T@'I9]- V#1B^#29+BQMML38HH&!#-7J@/I=BJE!;-NJ6MB.@VL#$F"$QI%
MUT2P5N(\#;&CSE/56]Y*.&ID>B&8_GL KH8,Q_@U\-C6C?4!DJ<=J^$GV%_=
M4;L5F5G*5H TK9)(0Y7AVWA_2#P^ )Y:&,QBCGPE)Z6>_>);F>'(&P(.A?4,
MS UGN /./9&S\6?BQ+.D3US.7]D?0NVNEA,S<*?X[[:T389W&)50L9[;1S5\
MA:F>!*.I^.]P!N[@WHG3*!0WX8N*WE@E)A9G1;"7<6QE&(=QYSJ9TM83Z)1
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MQTB=**4!J3(&IE+J5,^QIU45&&8O?/8,A7H'L4K] V=- "5HP:7?Y;<"/X[
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M]H%\(@M,+RWR(UECX&@ '+9YR6'BO'$IKQ@E.@,EFB/"ZH)B] /9F!\,$@U
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M>*8OG1B35(7I/:E2%.IM&Q<5/4D]C=2<]PV^7TC6#H\7&%_0[!]02P,$%
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M\7; Q#VFZC$$SA'!.2(@AS,'EP.&'^5(XHBZL.LIC#+.D]!I]><ICK"4A+&
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M?=P3PK$P%+/-MH[B%-<W*KSG\C81][0[RG0-3EI]3'/ZLV+^'U!+ P04
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M@E515XX)$L"0 V!RP)DOX*R027TER%POAAT LP-R_RG@% V,]\[94BTA<$8
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M7+;,)K;4)D;6Q>6R\J8,P00J*@O!<2IQYS9$OPU;EBB4+=((@R!JZTK5KP7
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M1H</;?-P<7A^:O3\$-?E?U!+ P04    " "]?&90?:4IG]P)   ?/P  &0
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M220$KW8$:$\*Q!K*@PTB?0*L3ZX#$0!6)X'6<R+(>=AX"BYD^7$A\+P4>-D
M_6O 02EP6 J\!<"D0%)!(+10'ELL(3.!H$&Q@ZE!V*#TNJDO&M!NQFN2_91[
M3*! B@PCMB\2U&NC:X)!Z3@(7#H/7)DO7^@\;M2N;!B_W BPG<F7!MRN<VZW
MV@ 9Z)S1X:"A <_I@J/&A<[IBS_5S>X4 K\(0. A&G"ASKG0&F0$0(:Z QEJ
M0(:Z@ R_ZIP6K%?+'Z ,T(*64D[F.,,&M/V(.NLCBTG79; ; 58'.*=!Z-*
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M1J$.IGV5]KWN+S)]P^CS<$D+QYOBZ@]02P,$%     @ O7QF4/>J9 ^0 @
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ML7WK^J;V45Q3ZO+'^7M_&+]//OY',5R ^P+\4D#\O(#P!<3< M(7D',+*%]
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MG!!\$FJXDF/6-[1^(F@[]&IG_,.P_0-02P,$%     @ O7QF4$&*.HXZ P
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MW:4@=&2ZL0? C6H"'M_3P'U^ ;141%:Q@;9?-#7<5Q,;>&M-W,4 V-7 .F/
MK@88P2C$<S$V;BXF&)5M?5-_)_Q4-L+;,:EN %.GCXQ)JNC")W6."O5Q,'0J
M>I2ZF:@V[V[(KB-9V]_^P? )DO\#4$L#!!0    ( +U\9E# %<* 60(  .('
M   9    >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;(U5[8Z;,!!\%<0#')C/
MY$20DE15*[52=%6OOQVR">@,IK83KF]?VW <(9MK_\3V,CNS0UAOUG'Q(DL
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M@^B>F$O\ #W4"498.D..ERI@"'E0E%E(!*D$"4'<0R4(E1)0/CPB) (4G?D
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MBWE@Z-LPLQL#N[&M5DP- ]106ZV8!Y8NZ"LP#QQ]'V:=!9G9Y919&@..J>&
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M!$_.]=9+II_\K3O;XG@[J>RI'PXS?]Q.&Y_32>\N\Z9N<MM9WO\/4$L#!!0
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ME?IUHMZKIKEO!E(<[,4E:&]/RW]02P,$%     @ O7QF4&H+75N) P  0@\
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MN%*DOX9K5O;7\_!%2BN&"S KP"X"C/Y3@%L!OE0@M@+Q4@%A!<12 ; "L%1
M6@&Y5$!9 >4(1$,Y^OK>I&VZ6=75.:B'%CVE'1/HE3(=M.M>]@W3?S,E;LS;
MEPT K**73I'%7 \8-L(((::8K8_AL9QB;GP,"#;%W&(8/L7<^9B8DRGF/>*/
M:^L>TQ-?,)')VR5Y#$T>ZQ7P2?(DKH"C"GBO()YDS4G^ ($>4O80&M-8$4:=
MK"! #DFBE -\CP"IXD!IXN0' 3+"8Z88'F.,QAC[,3K-<SU Q,@0(Z"D= IV
MY^,$!4%P;P3JC?"\B=V,"\_*&TXE9U0Y[B! JIA0HX:=> 2H1^![Y!BZ!J\0
M2A EP?'\SL?-Y$:BGDC/$QCQ?*) H0K4<CXDJ(+D53YL$R_&!"1PF(F4$GSL
MD5>[<FLQX_I20;K?C*F9"4M?;;FMQ4Q;B4NE9L/"!Q)EKS;3UF+&MDR9*9OC
M$<5'%_5G%X!GRQ\AG,4P;PL?(=2?(2!@1@7.>RJ6]R;%B4I]I@(X,_/6@B@?
M#S.0@LZ8PIE($2I*XIJ27B'GTHK3E2K$"G6M*+\U@<<S<X'BO*8^L4%(UU*R
M-!Z&DYKYI 9W#;FUH&F!2$QFVHGAI&8^J4&H&14SFX?_V#TPG(,,X:!T=DLW
M%D3C,0DYP-Q.!Z<@0R@H8]>4OT#/51!G*?.79\,=UPJZ0!.BYDJ(TYDA=!:)
M:PL61X0SF6%,!M>*]$OTAIGUG;D[K6BTK^].EY_2^BDKF^"Q:LT1H=_('ZJJ
MU48K>6N\/IH#[>4AUX>VNY7FOAY.=<-#6YWLB36Z')LW?P!02P,$%     @
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M]K*?%?U!BW88@VB<Q<4_4$L#!!0    ( +U\9E SH=.;Q $  !,$   9
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M$-0H$NM=58MF"$/\F+7[FO9=>%M@TW\JFC5P-+SNZC;Z6+6@:J$KF84N6 +
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M:;-UMPL5M %MAQP@'7(<1=<N<>*.H#2A34*1*#L%>A4M&)F.U5:^1?FSOB^
M9X,D VZ&E]$3?MU58!G%R/3I-APAV<) )+!_C_ RBIK5.3"B4I@O#@ULIVK[
MR*>5F<]]+@95SNP8>#]/F&U1XNR@2J^1L\-+S2-!-E3[NWMZZJYZ0F6SBNYP
M2N7(W8(=+.ZZ8(G7=)<"%Q_5%QU-99??NY<.W!8D,!K69W?PYAVJ4&63T>%"
M<R?;(E7!7^(Y)M$B'GI>--3@2M66O6V' 3L&=O4$[+FY+W;X.O8=P-@S.WK0
ME7"TU;Z%;^U]LG>L-O D1$O-< 82;W''W>/SU_N'!XRJP_NNP2(K0*%#SY"S
MG)]D28;NO'KQS@/,_?C7$PL[C@G@CH""4X*>A%_^#BAA!]I(5<;*'M"' #J;
MX1.XN'!/3> $HF-2OHF$0(*!69<1:>(6R[4D(4!)R=$IHHI'X\PA1%4-39=L
MB1O0BIY&Z O-:V95-MZ!>C"'8.BIQDT#K!6(@ P*Y^EDE3AWCZ)?C"G6O37&
M$&#@A4BN8*%4,'PU=%B-1ILV1^9YD[=/N'B!50>]LJZ?<2C$Z:T$!4K>Y>O6
MNF0I9'.CC'! DIS 4U&% +*P[V].@VLU] Q/#J$Y>D>'"9@SC@:V/B^!'/U'
MH=(B3\J>2%CE= GRH]UN^ZQ""XU&9-7",H.C5:9IGL!Q)&16R V 8^=M"Y8;
M2^:<V1TPB<#N#$V1.(3E!78&L+CP=7W'+P(U=5/((#3T)E*=&'S1X@UUSJYY
MO(@"8 -/R MR/PP[W?&&#1F[6^+DS()&CJ M2N %>SZM%Q)86UNOA.R:X*7T
M)EF#WA?DQ2D+-):VSP.:QPAD)6W<.F-G6^80,3V'3#I?6U%A [SB%I8(9H7N
MY;BC&/+=1?/B&"**IL!30"# 'PY'YL" GEE2BU?./"^=U6)U)%J!0A)W!\%+
M@30.*PY7=T:2D2.8XQ4-V)POSC0Z>?_G3Q].2> '+CY  '#CU<7E*5/VVM]@
M6"F.FJ#6^80V5$',]0VMJX#(!'L EZH?"6PA,&Z1*1%7Q]-,"@--G*TFH&4:
M4F!_S//42[Y')1=]A[? 89'V1:MF],;\+8@89!$[=KLV[':&V14[?"2::"*E
M%24A.K1ST0,R9U N#-:._3[R@NM/GRYU[E4I3SEEP[FWKZH3#OI'G3"8@_H*
MKG_W@+'8:GI+QM1DZ.8_#=VPJF9"'W39?;XU4A'5J<ZV&:6ONOFK" /@"X@.
M"6T6,590V%F[ ZUWBYQQ8.?8!9+G[ /P5]5E.2[;#'][#!\Q1MB1IPR/#AZB
M[KZZ[S4*/WKGK,HO&+18MK6+K^FC+8[>[>![' KJ+DJ/!HY]4W^,I*6VLB08
M"RAJNMCE?'%/L;'7(5O*V4O7(QKR_67X&\9!S[9518$J(X%9A@EG>W?QX11%
M>EV!K3-2GEOCD:ISH:HGEM=@P642:T9UC,Q('  \@GR-:"+T!H/2A Z%F2U=
M;F/&QDG9TZ[:^WR(V#=AM[-[A[%:1-IYY\3AL+(N9'DSRQ "HDC9+=D]=-!+
M=J2R78&D4/*Z_5J(7X=-]PZ?K< P+- N9KV&98/8-:BBH"8GRB8[AT(2=9,[
M^BAJ*F^(>Z;SM[U%8CM4Q^+,VW@ N\^'^<-6DW#3AS[E+)5OPT*$<6VJ0A*7
MT(6NB^8;G\LZ?R+3'YU$QJ03TZ#[/-0J2SYS9)X_C[QUL(I[:"V(SU8WV^).
MO(&H9S- J2@[)%&S-]S1YY!XMOPW+P2HH>^1S?V9V-S/K@9FN1]3! JY=2YG
MI-IO-Z+9(@V1AM@@>#P3-Q&M,(&-<7-T>3-W=L@\F.%O/4O5' E!S8"AUA8H
M72G0)_3L\IP-4=8EZM 8ZBU*51,<#M[A4;X+T%5,GVBB0,C(^,2680VY*'=[
M9CBTUOQ$XE;.4I5"BP9'%]T7>8V!GN<WT0?TB$=)=!;]Q[["1]*2 E_:EPP;
M0RP5G70Z.@\2FR%NN$%:65M64WD<^ZT\.X5G7_(X*]&*8)'_YKU-)(^1W#HJ
MVEFR7EC5-\H\69GVTPTB<U%XZ$LG\-)?2ON]KI0QE&",8/+@<\I*=U5BTL\<
M7V#]NF8 (/-C"ER7<D20BB2>0,Y[3"B A=ASJ!_.X UZ2(0AF6\E4-*C(J'?
M/4$B:%G@97 2)#:MSE,F2L'U?1GR"^/NY"!.@@YBS^'*UB@,LACPU5[Y3EQD
M+#O7S6T&)B>RXP8>FH$XKF@P.B6B8:75_EADK"9*S_8E#.8Q XK#G>'5WM#W
MPNC<EXU,[- SCF$V^RV+>.70; _KP6SV:%A[HX95,!>[.Y*UW?'5>W=LS0LX
M8!P[N7FJ,J?\D@%S&TY>I=Z\PJPM&>+VB VM8\>]8DZ19=;6K>4-V,#<^I!1
M6MM<:1SWL.#-?<(CQ.Q1Y\0V/89CZ 3H5B&2U2)BB.<8:$:EF  ;#^G^\KLF
M.%DA2PP)=T(036[WJNLLL=JWLU!%:1P(7X[82P=94EE(0]'TZ+T;.;&'TB>F
M[R(B72>Q@]V(4N#('1B"0FW]H:A/;D?98Z/HJVPS[KK<4+#NF;F.3%]?DXT7
M+":2DOJ>^(?>"1=5U17,=-KCP&(-7(O#0G$YP SP+N<\AQ>G<X#0O0TL V@9
MGX]G RB==T?IY8IT5]@AV"?V^70I \-NS]Y2A(9'BKRA0[N5XJ=3I?.WG> /
M05 W@[_#@&_2!EF_<64)*"R#.&WW_L;S26Q8<_&H*B>!J# (T&V>!9PFOF>T
MRK/MFL/.!\'IU@\-@S;NYX-P=G1=PC+MA<EFZ.\I\[H7M;DYL$+BW#0V3V]E
MAM>#^1 CX-1A2N9YMMD4RN:\NXU((H4CWWB@OFIG99>8PQ@MNN5%,$:7W:G!
MU^"ZZ*)3#))>QWM'9MFS-P^R:<9O1;J@%""G6IJ\U3'%*(-;4'F(7FG=]L"
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M?<$J0)H'R)X8V29"6FU%>]7XI]UMG6+1C_5S8$UEC^IH]\#8*-6*V;@-\\E
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M![9.V*#L%K60?\_@HOHYDM*@UKV?X33AR3IT*T9!6K)U Z^K*R,5-.T\%JW
MFKB#.3D&P\FGWX5TVYW 29%$!7E8DK$!.SPX;'2:((_,3'W1.FN-N,52WY1
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MU/05P,DAVT-O(%[Z5Y#]S::0>FC4?886W]8,-\7"G5+I;@'Q?HUWC-3L2\;
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MI-/B[QI?$-H2+>[-4H+<0=OTVY5)?0.#"M2BY,VWL]LZ[W18](;SR^B:&D+
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M*?>. B*LV6)Z0O+]C<&L855#=/?:)\31C[9@,S.YOR"NQ;ODG:WI1C^>)*=
M,*+WG8O>]]E@F2X<I/T'A">=$$+F%!:9W11.$,#Y,QU-4WJTC%8J#J :%B^
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M)<$-!LP:("LEOK$[F* ));F9'ZC!G"W3T' HA,MS2<T'J?G4*!Y+GN_,B35
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M*UW?0;QW1Z?>#:9)D#!\@=-<94/J,];V8A\ TT1GX+%VAGHV[Y5EU>JMDAQ
M;+%TRBO>VE9:H.B!1&K%35OG#Y5L%2' N1@_+P>WJJZI%-*!2P@WPAJMX+=I
M)=&D:;&Z\)9*"9I)&Z"5V\5D>$,\[[A;N-9RX<9C<\*!W=J$_BJ:E!!; H)'
MAKS(ZXL36Q+NC8MK09,"T?<:T_J[>ZX )/3 &4=<$R87PE 6A&@7/$N?UL-D
MRA*? U9>TFN'W(RGB\K8HY-2;AXX*IW;*>_9>FKM1L!"(+"A4T! #7=Z"C7U
M4>,)2S=+QR+0$S?%]ME1R&,I!K#FQ1+A&5%=XKIFJ6J,I8%E>B&THD$(UZ+M
M.Y&9H ;?8;9TPS'S5C,DW "\),7W%K)HC&/'O1P9/ARU7REUEPY^<1M^,.&E
MG6-.*HZT;O,1!AJ<V4O90)A;L>%JG$@I)G=$>PC)._J50U4RFEQ34]O2)/3$
MG&_52$I(ZT#@6&DFC8#GY#*5#GX3Y\HM@RQ@,-_RI*CT3V7M6J[.AWA<P_6U
M #@M;^];CM;""<U,#23KF.Q<+<7S#/CYP,O8VH;);//N4P8G8217$&M+SK4N
MA^#V1Q:F2!?(R99Z$Y:I$>HJ1>.EO6?/>=XP>MR^.< FPO5KY4U9PZ69&/I?
M2?EIAP\+DD>53I?%]B&N [AM$EI'::>''V$0-V7##A&5E#&Y]0B-2_@;S736
M:!PFM6)]&_4G65N!G_M2+60'_2K&((L,L.-KAOZ:*A'64^8VX73[1AL@AU9W
MTVJ/=* >T7?I-3TWZJD&Z_PDJ'V),$:#A)/@':/SX8=-A2E%GY08;*=+VU.=
MDY)P\S%Y!C&W9&%*MHZ4&#<)U2("&3N)Y3_76+8%#2Z_2[-DM4@B@5]XVI2'
M[+3^=&HJP^Y)>5I4>2DK>;@>L],4;:<5%/QG=[)0N-F43P;6F=]Y5LGVA\G3
MX2,A\$D].J),FXOHB<#2*-W3'!_[1KW.>1NKXF:<X;0@'B'.")1LR2$R1YU
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M283W('E/%C&V<'TL&LY+<?S9W9H/SD_>B/O=[1CHE6VID:36Z&#S7FO\A1;
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MAA&(<RM@%\'(R3/0Y^JHDW?&6!H+L7TG6)Y6O6QYG+1]FS9]CH<[Q[KN[5_
M.U:PD&!G9D72-&!V3SH 0'AP!JJVFG+(8?-;(-B>/(-%!^8#L)BLR1EEE;23
MC++JUDE9@6TH"^*#9 _U>=1RQ>P#V+E@EO95F=1IE<$KNBA1,'TGJK0JL#Y?
M!OHV^GVKVG9RQYRUFV/-N&#44Q51DL>AO2L$4NQ7624]&)9%VCF85X!DNKH"
MR>IR-'L)AAR=>0\K4L-D@'-D+<BENG<3#/+TMU;]-Q&$1!H;AXX&>GFV.)S
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M/B./LD$Y=4;ACC%V?EE5% *J:"$OF5V.M'!#M#"XJY^H=BJ_9:2ECS/(YJ!
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M=GH-BD!5("YJ!KHW@E;"_L#_]7G;@5TF-MJ)3V,6B)$< K//"&QQ\*P+;5Z
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M!"W2I<^,88%:FO)$T6"O0)RP^G_!]G0J>$&(3DO9=*$1QH55994[K K=V&
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MC!.44W5MMFB=(:S'[XSP8%2MFE>($-;C]S@F.;.W':^^$\]^ E!+ P04
M" "]?&90,=U:&3\&  #E-0  #P   'AL+W=O<FMB;V]K+GAM;,6;;7/B-A"
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M K8MRRLC_?:FC:?_L/KX'U!+ P04    " "]?&90)=-& XT"  #[,   &@
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M@^)R4*0'U<M!-3WH<3GHD1YDMT#&+3\)8<W7V@*N+=]K"\"V?+$M(-ORS;8
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MUV>4=3Z6O6N'_R7YX_W^=3Z;_Z!_^0102P$"% ,4    " "]?&90'R// \
M   3 @  "P              @ $     7W)E;',O+G)E;'-02P$"% ,4
M" "]?&90)^B'#H(   "Q    $               @ 'I    9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( +U\9E!*KJ(7[P   "L"   1
M  "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( +U\9E"97)PC
M$ 8  )PG   3              "  ;<"  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ O7QF4"&?"*!V @  4@D  !@              ( !^ @
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( +U\9E -+77-
M000  #\3   8              "  :0+  !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4    " "]?&90G>&03;<!  #8 P  &
M@ $;$   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ O7QF
M4/J$;56( P  [@T  !@              ( !"!(  'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0    ( +U\9E!-2BAXAP4  !P;   8
M      "  <85  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M" "]?&90DU?A#Q0%  !)&   &               @ &#&P  >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#%     @ O7QF4"=OI$2U 0  TP,  !@
M             ( !S2   'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0    ( +U\9E"\CYT\M0$  -,#   8              "  ;@B  !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " "]?&90;#N)1;0!  #3
M P  &               @ &C)   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#%     @ O7QF4&J25R&S 0  TP,  !D              ( !C28
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " "]?&90*!$%
M3K4!  #3 P  &0              @ %W*   >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0    ( +U\9E )!B+\L@$  -,#   9
M  "  6,J  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @
MO7QF4"#FOKJT 0  TP,  !D              ( !3"P  'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4    " "]?&90S=HPR;4!  #3 P  &0
M            @ $W+@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0    ( +U\9E#(QV&*M0$  -,#   9              "  2,P  !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ O7QF4%&O=$:V 0
MTP,  !D              ( !#S(  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4    " "]?&90<K7C?+,!  #3 P  &0              @ '\
M,P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( +U\9E!<
MIHR0M0$  -,#   9              "  >8U  !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#%     @ O7QF4,X:@+"V 0  TP,  !D
M     ( !TC<  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +U\9E!VEG,XM $  -,#   9              "
M 6U!  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ O7QF
M4&=BE_FU 0  TP,  !D              ( !6$,  'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6Q02P$"% ,4    " "]?&90!(B6UK4!  #3 P  &0
M        @ %$10  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0
M   ( +U\9E *>\-0M $  -,#   9              "  3!'  !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ O7QF4,BG! FU 0  TP,
M !D              ( !&TD  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q0
M2P$"% ,4    " "]?&90%(  %;<!  #3 P  &0              @ $'2P
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( +U\9E":PG%_
M7@(  *0(   9              "  ?5,  !X;"]W;W)K<VAE971S+W-H965T
M,S N>&UL4$L! A0#%     @ O7QF4*4=K=3' 0  . 0  !D
M ( !BD\  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " "]
M?&905C,'([0!  #3 P  &0              @ &(40  >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( +U\9E!NQ^(RQ@$  #@$   9
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M970S-RYX;6Q02P$"% ,4    " "]?&90U<&T.L,!   X!   &0
M    @ %O70  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (
M +U\9E"2!*PAN0$  -,#   9              "  6E?  !X;"]W;W)K<VAE
M971S+W-H965T,SDN>&UL4$L! A0#%     @ O7QF4$T3H%.Y 0  TP,  !D
M             ( !66$  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"
M% ,4    " "]?&90._UUB,<!   X!   &0              @ %)8P  >&PO
M=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( +U\9E!B,H'TN0$
M -,#   9              "  4=E  !X;"]W;W)K<VAE971S+W-H965T-#(N
M>&UL4$L! A0#%     @ O7QF4 LF@G"Z 0  TP,  !D              ( !
M-V<  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " "]?&90
M<II+#/@!  #H!0  &0              @ $H:0  >&PO=V]R:W-H965T<R]S
M:&5E=#0T+GAM;%!+ 0(4 Q0    ( +U\9E#4W-@ARP$  #<$   9
M      "  5=K  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%
M  @ O7QF4##D=9ET P  QPX  !D              ( !66T  'AL+W=O<FMS
M:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " "]?&90,G>K]O8!  #U!
M&0              @ $$<0  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+
M 0(4 Q0    ( +U\9E"W9DWZ(P<  (,M   9              "  3%S  !X
M;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ O7QF4&E@C,0-
M @  '@8  !D              ( !BWH  'AL+W=O<FMS:&5E=',O<VAE970T
M.2YX;6Q02P$"% ,4    " "]?&9031''6V0"  !-!P  &0
M@ '/?   >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( +U\
M9E"+*]?_%P(  )@&   9              "  6I_  !X;"]W;W)K<VAE971S
M+W-H965T-3$N>&UL4$L! A0#%     @ O7QF4/^4,PO8 P  &1(  !D
M         ( !N($  'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4
M    " "]?&90S<C<U_ "   &"P  &0              @ ''A0  >&PO=V]R
M:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( +U\9E =)!%0D@(  #<*
M   9              "  >Z(  !X;"]W;W)K<VAE971S+W-H965T-30N>&UL
M4$L! A0#%     @ O7QF4.="-DGB 0  H00  !D              ( !MXL
M 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " "]?&90PI#8
M\8$(  #0-0  &0              @ '0C0  >&PO=V]R:W-H965T<R]S:&5E
M=#4V+GAM;%!+ 0(4 Q0    ( +U\9E!]I2F?W D  !\_   9
M  "  8B6  !X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @
MO7QF4+-]*T5@ @  N <  !D              ( !FZ   'AL+W=O<FMS:&5E
M=',O<VAE970U."YX;6Q02P$"% ,4    " "]?&907J"9Y'\#   U#@  &0
M            @ $RHP  >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4
M Q0    ( +U\9E#WJF0/D (  ($)   9              "  >BF  !X;"]W
M;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ O7QF4)C&D:E/!0
M.1X  !D              ( !KZD  'AL+W=O<FMS:&5E=',O<VAE970V,2YX
M;6Q02P$"% ,4    " "]?&903U@1Z6("   \"   &0              @ $U
MKP  >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( +U\9E!!
MBCJ..@,  !0-   9              "  <ZQ  !X;"]W;W)K<VAE971S+W-H
M965T-C,N>&UL4$L! A0#%     @ O7QF4*VJNL7Z 0  Z@0  !D
M     ( !/[4  'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +U\9E!U3MW&:@,  ',-   9              "
M ;C!  !X;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ O7QF
M4',&?8\; P  <P\  !D              ( !6<4  'AL+W=O<FMS:&5E=',O
M<VAE970W,"YX;6Q02P$"% ,4    " "]?&90W!L??^$#  !E%@  &0
M        @ &KR   >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0
M   ( +U\9E"J'[98W@(  -8+   9              "  </,  !X;"]W;W)K
M<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @ O7QF4!=>2&Y* @  \P8
M !D              ( !V,\  'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q0
M2P$"% ,4    " "]?&90!4_<K1<#  !)#0  &0              @ %9T@
M>&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( +U\9E!J"UU;
MB0,  $(/   9              "  :?5  !X;"]W;W)K<VAE971S+W-H965T
M-S4N>&UL4$L! A0#%     @ O7QF4'6;6C+< @  X0D  !D
M ( !9]D  'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"% ,4    " "]
M?&90M?]$EA4"  "7!0  &0              @ %ZW   >&PO=V]R:W-H965T
M<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( +U\9E SH=.;Q $  !,$   9
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M970X,BYX;6Q02P$"% ,4    " "]?&90RVAU,A24  !N,@( %
M    @ &/[   >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " "]?&90
MV\V@Z)$"   @#P  #0              @ '5@ $ >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( +U\9E QW5H9/P8  .4U   /              "  9&# 0!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "]?&90)=-& XT"  #[,   &@
M            @ ']B0$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " "]?&90S2/QLRH"  "H+P  $P              @ '"C $ 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     6P!; .\8   =CP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6731950560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>year </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 16, 2019 </div>
<div>year </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>year </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>year</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>year</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.62%<span></span>
</td>
<td class="nump">2.02%<span></span>
</td>
<td class="nump">1.18%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected hold period to exercise | year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility in the price of the Company's shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.90%<span></span>
</td>
<td class="nump">81.15%<span></span>
</td>
<td class="nump">90.73%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_FairValueofWarrantIssuedPerWarrant', window );">Fair value per warrant (usd per share) | $ / shares</a></td>
<td class="nump">$ 3.89<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="nump">$ 3.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantIssuedUnderlyingSharePrice', window );">Underlying share price (usd per share) | $ / shares</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.42%<span></span>
</td>
<td class="nump">1.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected hold period to exercise | year</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility in the price of the Company's shares</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DividendYieldPercent', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DividendYieldPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend Yield, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DividendYieldPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_FairValueofWarrantIssuedPerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrant Issued, Per Warrant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_FairValueofWarrantIssuedPerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantIssuedUnderlyingSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Issued, Underlying Share Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantIssuedUnderlyingSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6732889056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Right-of-use Assets and Lease Liabilities (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation expense</a></td>
<td class="num">$ (362,592)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ForeignExchangeImpactRightofUseAssets', window );">Foreign exchange impact</a></td>
<td class="num">(14,720)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">430,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Payment of lease liabilities</a></td>
<td class="num">(447,497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on lease liabilities</a></td>
<td class="nump">94,817<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GainsLossesfromForeignExchangeImpact', window );">Foreign exchange impact</a></td>
<td class="num">(23,482)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">$ 506,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ForeignExchangeImpactRightofUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign Exchange Impact, Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ForeignExchangeImpactRightofUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GainsLossesfromForeignExchangeImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gains (Losses) from Foreign Exchange Impact</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GainsLossesfromForeignExchangeImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6731576640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Disclosures (Details) - CAD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>May 04, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 14,148,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,699,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,836,119<span></span>
</td>
<td class="nump">$ 12,034,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Shareholders&#8217; (deficit) equity</a></td>
<td class="num">$ (107,894)<span></span>
</td>
<td class="nump">$ 6,195,363<span></span>
</td>
<td class="nump">$ 6,195,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,283,846<span></span>
</td>
<td class="nump">$ 10,689,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_EquityAuthorized', window );">Base Shelf securities authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_EquityAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_EquityAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6735243168">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="th" style="border-bottom: 0px;">ifrs-full_NumberOfSharesIssued</td>
<td class="nump">16,445,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Issued capital [member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="th" style="border-bottom: 0px;">ifrs-full_NumberOfSharesIssued</td>
<td class="nump">14,988,995<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6730051840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfCashFlowsAbstract', window );"><strong>Statement of cash flows [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ProceedsfromInterestReceived', window );">Cash interest received</a></td>
<td class="nump">$ 274,094<span></span>
</td>
<td class="nump">$ 173,496<span></span>
</td>
<td class="nump">$ 130,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefund', window );">Cash taxes paid</a></td>
<td class="nump">$ 5,448<span></span>
</td>
<td class="nump">$ 15,728<span></span>
</td>
<td class="nump">$ 136,163<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ProceedsfromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Interest Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ProceedsfromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6736275760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract', window );"><strong>Disclosure Of Share-based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share Based Payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:1px;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Share Based Payments</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Stock Option Plan</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:650px;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:158px;" rowspan="1" colspan="1"></td><td style="width:75px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:84px;" rowspan="1" colspan="1"></td><td style="width:74px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:80px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:81px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,249,361</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">647,156</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">912,995</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.42</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted during the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,020,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.42</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">750,467</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.97</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,625</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.60</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited during the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(12,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(105,338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(211,847</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.80</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired during the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(9,575</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">29.07</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,122</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.78</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,302</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.13</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised during the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(41,802</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.96</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(84,315</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.07</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,246,947</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5.31</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,249,361</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.73</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">647,156</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.20</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,327,845</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.22</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">777,245</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.04</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">573,984</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.36</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about the stock options outstanding and exercisable at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:182px;" rowspan="1" colspan="1"></td><td style="width:96px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td><td style="width:96px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$0.54 - $1.42</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">100,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.81</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.96</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">66,667</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.75</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.43 - $1.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">900,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">300,009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.45</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.80 - $3.39</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">376,411</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.73</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">284,412</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.72</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$3.40 - $7.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">395,111</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">322,880</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.95</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$7.14 - $63.84</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">475,425</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.53</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16.74</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">353,877</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19.95</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,246,947</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.45</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.31</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,327,845</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.22</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-exercisable options vest annually over periods ranging from </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the Black-Scholes valuation model to estimate fair value. We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of stock options issued during the year was determined using the following weighted average assumptions: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:464px;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:245px;" rowspan="1" colspan="1"></td><td style="width:74px;" rowspan="1" colspan="1"></td><td style="width:72px;" rowspan="1" colspan="1"></td><td style="width:72px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.62%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.02%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.18%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected hold period to exercise</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.0 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected share price volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">97.90%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81.15%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90.73%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected forfeiture rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.67%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.67%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.67%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nil</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average fair value of options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$0.87</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.67</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.65</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incentive Share Award Plan</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Share Units</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have issued restricted share units ("RSUs") to non-employee directors through our incentive share award plan. Grants of RSUs to non-employee directors vest either immediately, on the third anniversary date from the grant date or when the director ceases to be a member of the board. We have also issued RSUs to certain officers and employees of the Company. Grants of RSUs to certain officers and employees of the Company vest over a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> year period. The following RSUs are outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:515px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:269px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">260,755</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190,407</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,237</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Granted during the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">270,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,855</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited during the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,210</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Vested during the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(321,196</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,297</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">209,657</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">260,755</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190,407</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:36px;"><font style="text-align:justify;font-family:inherit;font-size:8pt;padding-right:24px;">(1)</font><font style="font-family:inherit;font-size:8pt;">The weighted average fair value of the RSUs granted was </font><font style="font-family:inherit;font-size:8pt;">$0.80</font><font style="font-family:inherit;font-size:8pt;"> in </font><font style="font-family:inherit;font-size:8pt;">2019</font><font style="font-family:inherit;font-size:8pt;"> (</font><font style="font-family:inherit;font-size:8pt;">2018</font><font style="font-family:inherit;font-size:8pt;"> - </font><font style="font-family:inherit;font-size:8pt;">$3.35</font><font style="font-family:inherit;font-size:8pt;"> ; </font><font style="font-family:inherit;font-size:8pt;">2017</font><font style="font-family:inherit;font-size:8pt;"> - </font><font style="font-family:inherit;font-size:8pt;">$5.96</font><font style="font-family:inherit;font-size:8pt;">).</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Performance Share Units</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have also issued performance share units ("PSUs") to certain officers and employees of the Company. Grants of PSUs require completion of certain performance criteria and cliff vest after </font><font style="font-family:inherit;font-size:10pt;">3 years</font><font style="font-family:inherit;font-size:10pt;"> or vest over a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> year period, depending on the grant. PSU grants to certain officers will vest immediately upon a change of control of the Company. If certain officers cease employment with the Company, vesting occurs on a pro rata basis prior to the third anniversary of the grant but after the first anniversary. The following PSUs are outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:521px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:274px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:75px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">63,156</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,734</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,419</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Granted during the year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited during the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31,578</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested during the year</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(2,105</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">61,051</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,156</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,734</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:36px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) &#160;&#160;&#160;&#160;The weighted average fair value of the PSUs granted was </font><font style="font-family:inherit;font-size:8pt;">nil</font><font style="font-family:inherit;font-size:8pt;"> in </font><font style="font-family:inherit;font-size:8pt;">2019</font><font style="font-family:inherit;font-size:8pt;"> (</font><font style="font-family:inherit;font-size:8pt;">2018</font><font style="font-family:inherit;font-size:8pt;"> - </font><font style="font-family:inherit;font-size:8pt;">nil</font><font style="font-family:inherit;font-size:8pt;">; </font><font style="font-family:inherit;font-size:8pt;">2017</font><font style="font-family:inherit;font-size:8pt;"> - </font><font style="font-family:inherit;font-size:8pt;">$3.33</font><font style="font-family:inherit;font-size:8pt;">).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have reserved </font><font style="font-family:inherit;font-size:10pt;">3,219,845</font><font style="font-family:inherit;font-size:10pt;"> common shares for issuance relating to our outstanding equity compensation plans. Compensation expense related to stock options, RSUs and PSUs for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$1,470,153</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> - </font><font style="font-family:inherit;font-size:10pt;">$1,415,833</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> - </font><font style="font-family:inherit;font-size:10pt;">$578,703</font><font style="font-family:inherit;font-size:10pt;">).</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 44<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Share-based Payment Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6620162544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:164px;" rowspan="1" colspan="1"></td><td style="width:80px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:87px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:76px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:90px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Computer Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Office Furniture</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Office Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Leasehold Improvements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,870</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">681,985</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">225,896</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">534,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,729,517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions, net of foreign exchange impact</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,202</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,542</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,763</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,163</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174,670</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposals</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(424,246</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85,096</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(646,834</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,378</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">345,941</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">247,438</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,229</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">498,367</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,257,353</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions, net of foreign exchange impact</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposals</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,378</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">352,955</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">247,438</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,229</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">498,367</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,264,367</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,334</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">549,564</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147,334</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,787</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">476,057</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,396,076</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,622</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,041</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,662</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposals</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,492</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(424,246</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85,096</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(646,834</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,464</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174,953</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,749</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">414,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">844,617</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,244</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,093</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,668</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,342</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,635</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,982</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposals</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,708</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224,046</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,417</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,170</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">448,258</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">967,599</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net book value</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15,670</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">128,909</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">75,021</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27,059</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">50,109</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">296,768</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,914</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170,988</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,689</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,401</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,744</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">412,736</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6730047712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of depreciation rates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation is recorded using the declining balance method at the following annual rates:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.40350877192983%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:51%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office equipment and furniture</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Straight-line over the term of the lease</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:164px;" rowspan="1" colspan="1"></td><td style="width:80px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:87px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:79px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:76px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:90px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Computer Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Office Furniture</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Office Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Leasehold Improvements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,870</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">681,985</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">225,896</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">534,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,729,517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions, net of foreign exchange impact</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,202</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,542</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,763</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,163</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174,670</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposals</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(424,246</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85,096</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(646,834</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,378</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">345,941</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">247,438</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,229</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">498,367</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,257,353</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions, net of foreign exchange impact</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposals</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,378</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">352,955</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">247,438</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,229</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">498,367</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,264,367</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,334</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">549,564</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147,334</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,787</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">476,057</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,396,076</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,622</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,041</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,662</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposals</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,492</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(424,246</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85,096</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(646,834</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,464</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174,953</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,749</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">414,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">844,617</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,244</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,093</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,668</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,342</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,635</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,982</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposals</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,708</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224,046</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,417</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,170</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">448,258</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">967,599</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net book value</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15,670</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">128,909</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">75,021</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27,059</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">50,109</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">296,768</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,914</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170,988</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,689</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,401</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,744</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">412,736</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations', window );">Adoption of new accounting standards</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the impacts of adopting IFRS 16 on the consolidated financial statements:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Impact of changes</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported as at December 31, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Effects of IFRS 16 transition</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent to transition as at January 1, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Right-of-use assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current and non-current assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865,253</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865,253</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865,253</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,673,278</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,750</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(74,412</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,338</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">882,437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">882,437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current and non-current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,556,140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,556,140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,669,890</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,477,915</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total shareholders' equity</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,195,363</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,195,363</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the initial application of an IFRS. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6646921520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Schedule of share capital</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Authorized:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unlimited number of no par value common shares</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Consolidation:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 22, 2018, we completed the consolidation of our common shares on the basis of </font><font style="font-family:inherit;font-size:10pt;">9.5</font><font style="font-family:inherit;font-size:10pt;"> pre-consolidation common shares for each one post-consolidation common share (the "Share Consolidation"). Fractional interests were rounded down to the nearest whole number of common shares. Outstanding stock options, restricted share units and performance share units were similarly adjusted by the consolidation ratio. Outstanding warrants were adjusted such that, following the Share Consolidation, </font><font style="font-family:inherit;font-size:10pt;">9.5</font><font style="font-family:inherit;font-size:10pt;"> equity-classified warrants will entitle the holder to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> whole common share until June 1, 2022.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:665px;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:293px;" rowspan="1" colspan="1"></td><td style="width:88px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:88px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:88px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:88px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued:</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121,258,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,321,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to stock option plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">801,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">536,949</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,301,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,348,821</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to public offering</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,893,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,391,057</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,805,722</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,710,138</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">519,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,335</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to stock option plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, May 22, 2018 - pre-consolidation</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,396,222</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272,268,722</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, May 22, 2018 - post-consolidation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,988,995</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272,268,722</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to public offering</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,532,278</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,606,882</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to warrant agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to stock option plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,329</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">158,976</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to incentive share award plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,297</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,751</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to Common Stock Purchase Agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(d)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">797,691</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,314,097</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(e)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,360</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,333,474</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,399,749</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,193,061</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,443,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,570</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to incentive share award plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">323,301</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,917</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to Common Stock Purchase Agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(d)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,494,943</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,403,385</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(e)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,425,040</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,476,454</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to public offering</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(f)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,619,773</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,314,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to warrant derivative exercised</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(f)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,935,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,152,869</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(854,256</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance, December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">32,198,453</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">311,077,859</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16,443,500</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,617,570</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 25, 2016, we entered into an "at-the-market" ("ATM") equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to </font><font style="font-family:inherit;font-size:10pt;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;"> which allows us to sell our common shares through the facilities of the Toronto Stock Exchange or other "marketplace&#8221; (as defined in National Instrument 21-101 Marketplace Operation) in Canada (our "Canadian ATM"). Subject to the terms of our Canadian ATM, we are able to determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility. During 2018, we sold </font><font style="font-family:inherit;font-size:10pt;">519,500</font><font style="font-family:inherit;font-size:10pt;"> pre-consolidation shares (approximately </font><font style="font-family:inherit;font-size:10pt;">54,684</font><font style="font-family:inherit;font-size:10pt;"> post-consolidation shares) (2017 - </font><font style="font-family:inherit;font-size:10pt;">3,301,500</font><font style="font-family:inherit;font-size:10pt;"> pre-consolidation shares (approximately </font><font style="font-family:inherit;font-size:10pt;">347,526</font><font style="font-family:inherit;font-size:10pt;"> post-consolidation shares) common shares for gross proceeds of $</font><font style="font-family:inherit;font-size:10pt;">553,650</font><font style="font-family:inherit;font-size:10pt;"> (2017 - $</font><font style="font-family:inherit;font-size:10pt;">2,348,821</font><font style="font-family:inherit;font-size:10pt;">). We incurred share issue costs of $</font><font style="font-family:inherit;font-size:10pt;">33,335</font><font style="font-family:inherit;font-size:10pt;"> (2017 - </font><font style="font-family:inherit;font-size:10pt;">$245,655</font><font style="font-family:inherit;font-size:10pt;">).</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 1, 2017, pursuant to an underwritten public offering, </font><font style="font-family:inherit;font-size:10pt;">16,445,000</font><font style="font-family:inherit;font-size:10pt;"> units were sold at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$0.70</font><font style="font-family:inherit;font-size:10pt;"> per unit for gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$11,511,500</font><font style="font-family:inherit;font-size:10pt;">.  Each unit included </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> pre-consolidation common share with an ascribed value of </font><font style="font-family:inherit;font-size:10pt;">$0.48</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">0.106</font><font style="font-family:inherit;font-size:10pt;"> post-consolidation common share with an ascribed value of </font><font style="font-family:inherit;font-size:10pt;">$4.56</font><font style="font-family:inherit;font-size:10pt;">) and </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> pre-consolidation common share purchase warrant with an ascribed value of </font><font style="font-family:inherit;font-size:10pt;">$0.22</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> post-consolidation common share purchase warrant with an ascribed value of </font><font style="font-family:inherit;font-size:10pt;">$2.09</font><font style="font-family:inherit;font-size:10pt;">). These warrants were classified as equity. Each pre-consolidation common share purchase warrant entitled the holder to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> pre-consolidation common share at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.95</font><font style="font-family:inherit;font-size:10pt;">. Following the Share Consolidation, </font><font style="font-family:inherit;font-size:10pt;">9.5</font><font style="font-family:inherit;font-size:10pt;"> pre-consolidation common share purchase warrants entitles the holder to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> post-consolidation common share in the capital of the Company until June 1, 2022, at an exercise price of approximately </font><font style="font-family:inherit;font-size:10pt;">$9.025</font><font style="font-family:inherit;font-size:10pt;">. The post-consolidation common share purchase warrants will be subject to acceleration if the volume weighted average price of the Company's common shares equals or exceeds </font><font style="font-family:inherit;font-size:10pt;">$23.75</font><font style="font-family:inherit;font-size:10pt;"> for </font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading dates.  The ascribed value was determined using the relative fair value method. The ascribed value of the common share purchase warrants was determined using the Black-Scholes valuation model. We incurred share issue costs of </font><font style="font-family:inherit;font-size:10pt;">$1,145,402</font><font style="font-family:inherit;font-size:10pt;">. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 5, 2018, pursuant to an underwritten public offering, </font><font style="font-family:inherit;font-size:10pt;">1,532,278</font><font style="font-family:inherit;font-size:10pt;"> common shares were sold at a purchase price of US</font><font style="font-family:inherit;font-size:10pt;">$5.83</font><font style="font-family:inherit;font-size:10pt;"> per share for gross proceeds of US</font><font style="font-family:inherit;font-size:10pt;">$8,933,181</font><font style="font-family:inherit;font-size:10pt;">. We incurred share issue costs of </font><font style="font-family:inherit;font-size:10pt;">$1,418,356</font><font style="font-family:inherit;font-size:10pt;">.  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 27, 2018, we entered into a Common Stock Purchase Agreement (the "Agreement") with Lincoln Park Capital Fund, LLC ("LPC"). Subject to the terms and conditions of the Agreement and at our sole discretion, we may sell up to US$</font><font style="font-family:inherit;font-size:10pt;">26,000,000</font><font style="font-family:inherit;font-size:10pt;"> worth of common shares to LPC over the </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">-month term. The purchase price of the common shares will be based on the prevailing market prices immediately preceding the notice of sale without any fixed discount. Subject to the terms of the Agreement, we control the timing and amount of any future investment and LPC is obligated to make such purchases, if and when we elect. The Agreement does not impose any upper price limit restrictions, negative covenants or restrictions on our future financing activities. However, in no event will shares be sold to LPC on a day the closing sale price for the common shares is less than the floor price of US</font><font style="font-family:inherit;font-size:10pt;">$1.00</font><font style="font-family:inherit;font-size:10pt;"> per common share; or at a price per share that is less than the volume weighted average trading pricing of the common shares on the TSX for the five immediately preceding trading days, less the maximum applicable discount allowed by the TSX. The Agreement limits our sale of common shares to </font><font style="font-family:inherit;font-size:10pt;">19.99%</font><font style="font-family:inherit;font-size:10pt;"> of our total outstanding common shares as at the date that the Common Stock Purchase Agreement was entered into, unless and until we have obtained shareholder approval under applicable Nasdaq rules. </font><font style="font-family:inherit;font-size:10pt;">As at December 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we have reached that limit. We can terminate the Agreement at any time at our sole discretion without any monetary cost or penalty. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, we sold </font><font style="font-family:inherit;font-size:10pt;">2,477,665</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> - </font><font style="font-family:inherit;font-size:10pt;">678,182</font><font style="font-family:inherit;font-size:10pt;">) common shares for gross proceeds of US</font><font style="font-family:inherit;font-size:10pt;">$4,055,725</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> - US</font><font style="font-family:inherit;font-size:10pt;text-transform:default;">$2,055,207</font><font style="font-family:inherit;font-size:10pt;">) and issued </font><font style="font-family:inherit;font-size:10pt;text-transform:default;">17,278</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> - </font><font style="font-family:inherit;font-size:10pt;text-transform:default;">119,509</font><font style="font-family:inherit;font-size:10pt;">) commitment shares. The commitment shares were fair valued at US</font><font style="font-family:inherit;font-size:10pt;">$29,758</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> - US</font><font style="font-family:inherit;font-size:10pt;">$483,690</font><font style="font-family:inherit;font-size:10pt;">) and were recorded as share issue costs in addition to cash share issue costs of </font><font style="font-family:inherit;font-size:10pt;">$3,757</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> - </font><font style="font-family:inherit;font-size:10pt;">$208,726</font><font style="font-family:inherit;font-size:10pt;">).  </font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allows us, at our sole discretion, to issue common shares, at prevailing market price, with an aggregate offering value of up to US</font><font style="font-family:inherit;font-size:10pt;">$30,000,000</font><font style="font-family:inherit;font-size:10pt;"> over the next </font><font style="font-family:inherit;font-size:10pt;">19 months</font><font style="font-family:inherit;font-size:10pt;"> through the facilities of the NASDAQ in the United States. In </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, we sold </font><font style="font-family:inherit;font-size:10pt;">4,425,040</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> - </font><font style="font-family:inherit;font-size:10pt;">18,002</font><font style="font-family:inherit;font-size:10pt;">) common shares for gross proceeds of US</font><font style="font-family:inherit;font-size:10pt;">$6,390,691</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> - US</font><font style="font-family:inherit;font-size:10pt;">$50,046</font><font style="font-family:inherit;font-size:10pt;">). We incurred share issue costs of </font><font style="font-family:inherit;font-size:10pt;">344,834</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> -  </font><font style="font-family:inherit;font-size:10pt;">$135,000</font><font style="font-family:inherit;font-size:10pt;">). </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 16, 2019, pursuant to an underwritten public offering, </font><font style="font-family:inherit;font-size:10pt;text-transform:default;">4,619,773</font><font style="font-family:inherit;font-size:10pt;"> units were sold at a purchase price of US</font><font style="font-family:inherit;font-size:10pt;">$0.81</font><font style="font-family:inherit;font-size:10pt;"> per unit for gross proceeds of US</font><font style="font-family:inherit;font-size:10pt;">$3,742,016</font><font style="font-family:inherit;font-size:10pt;">. Each unit included </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> common share with a fair value of US</font><font style="font-family:inherit;font-size:10pt;">$0.54</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> common share purchase warrant with a fair value of US</font><font style="font-family:inherit;font-size:10pt;">$0.27</font><font style="font-family:inherit;font-size:10pt;">. These warrants were classified as a financial liability (see Note 8). Each common share purchase warrant entitled the holder to purchase </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> common share at an exercise price of US</font><font style="font-family:inherit;font-size:10pt;">$0.90</font><font style="font-family:inherit;font-size:10pt;"> until August 16, 2024. We incurred transaction costs of </font><font style="font-family:inherit;font-size:10pt;">$699,427</font><font style="font-family:inherit;font-size:10pt;"> of which </font><font style="font-family:inherit;font-size:10pt;">$466,284</font><font style="font-family:inherit;font-size:10pt;"> were allocated to share issue costs and </font><font style="font-family:inherit;font-size:10pt;">$233,143</font><font style="font-family:inherit;font-size:10pt;"> were allocated to operating expenses, based on their relative fair values. In the fourth quarter of 2019, our share capital included fair value of $</font><font style="font-family:inherit;font-size:10pt;">5,687,003</font><font style="font-family:inherit;font-size:10pt;"> in addition to gross proceeds of US</font><font style="font-family:inherit;font-size:10pt;">$2,642,082</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">2,935,647</font><font style="font-family:inherit;font-size:10pt;"> warrants that were exercised (see Note 8). </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Summary of outstanding warrants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our outstanding equity warrants at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">: </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">         </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:425px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:74px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:90px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:138px;" rowspan="1" colspan="1"></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding, Beginning of the Year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding, End of the Year</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,443,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,443,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.42</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:78px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1)&#160;&#160;&#160;&#160; Exercisable into </font><font style="font-family:inherit;font-size:8pt;">1,730,894</font><font style="font-family:inherit;font-size:8pt;"> common shares.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about the stock options outstanding and exercisable at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:182px;" rowspan="1" colspan="1"></td><td style="width:96px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td><td style="width:96px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:100px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$0.54 - $1.42</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">100,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.81</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.96</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">66,667</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.75</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.43 - $1.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">900,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">300,009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.45</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.80 - $3.39</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">376,411</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.73</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">284,412</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.72</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$3.40 - $7.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">395,111</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">322,880</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.95</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$7.14 - $63.84</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">475,425</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.53</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16.74</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">353,877</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19.95</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,246,947</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.45</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.31</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,327,845</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.22</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Share capital [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6732111920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfCapitalComponentsTableTextBlock', window );">Schedule of capital components</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14,148,021</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,699,881</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; (deficit) equity</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(107,894</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,195,363</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfCapitalComponentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Capital Components [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfCapitalComponentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6729955056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share Capital - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>May 22, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_StockholdersEquityNoteStockSplitConversionRatio', window );">Stock conversion ratio</a></td>
<td class="nump">0.10526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1', window );">Warrants exercisable into common shares (shares)</a></td>
<td class="nump">9.5<span></span>
</td>
<td class="nump">1,730,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1', window );">Number of common shares issuable per warrant (shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Securities Called by Warrants or Rights1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_StockholdersEquityNoteStockSplitConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders' Equity Note, Stock Split, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_StockholdersEquityNoteStockSplitConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6733236288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Total Undiscounted Lease Liability (Details) - CAD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total undiscounted lease liability as at December 31, 2019</a></td>
<td class="nump">$ 565,179<span></span>
</td>
<td class="nump">$ 961,575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less than one year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total undiscounted lease liability as at December 31, 2019</a></td>
<td class="nump">391,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">One to five years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total undiscounted lease liability as at December 31, 2019</a></td>
<td class="nump">174,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">More than five years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total undiscounted lease liability as at December 31, 2019</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 58<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_58&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph B11D<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B11D_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6753639632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments - Schedule of Stock Options and Weighted Average Exercise Prices (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract', window );"><strong>Disclosure Of Share-based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, beginning of the year (shares) | shares</a></td>
<td class="nump">1,249,361<span></span>
</td>
<td class="nump">647,156<span></span>
</td>
<td class="nump">912,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted during the year (shares) | shares</a></td>
<td class="nump">1,020,000<span></span>
</td>
<td class="nump">750,467<span></span>
</td>
<td class="nump">42,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year (shares) | shares</a></td>
<td class="num">(12,839)<span></span>
</td>
<td class="num">(105,338)<span></span>
</td>
<td class="num">(211,847)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Expired during the year (shares) | shares</a></td>
<td class="num">(9,575)<span></span>
</td>
<td class="num">(1,122)<span></span>
</td>
<td class="num">(12,302)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised during the year (shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(41,802)<span></span>
</td>
<td class="num">(84,315)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, end of the year (shares) | shares</a></td>
<td class="nump">2,246,947<span></span>
</td>
<td class="nump">1,249,361<span></span>
</td>
<td class="nump">647,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Options exercisable, end of the year (shares) | shares</a></td>
<td class="nump">1,327,845<span></span>
</td>
<td class="nump">777,245<span></span>
</td>
<td class="nump">573,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Outstanding, beginning of the year (cad per share) | $ / shares</a></td>
<td class="nump">$ 8.73<span></span>
</td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="nump">$ 17.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Granted during the year (cad per share) | $ / shares</a></td>
<td class="nump">1.42<span></span>
</td>
<td class="nump">4.97<span></span>
</td>
<td class="nump">4.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">Forfeited during the year (cad per share) | $ / shares</a></td>
<td class="nump">11.35<span></span>
</td>
<td class="nump">11.67<span></span>
</td>
<td class="nump">32.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019', window );">Expired during the year (cad per share) | $ / shares</a></td>
<td class="nump">29.07<span></span>
</td>
<td class="nump">13.78<span></span>
</td>
<td class="nump">21.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Exercised during the year (cad per share) | $ / shares</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">2.96<span></span>
</td>
<td class="nump">4.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Outstanding, beginning of the year (cad per share) | $ / shares</a></td>
<td class="nump">5.31<span></span>
</td>
<td class="nump">8.73<span></span>
</td>
<td class="nump">13.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Options exercisable, end of the year (cad per share) | $ / shares</a></td>
<td class="nump">$ 7.22<span></span>
</td>
<td class="nump">$ 11.04<span></span>
</td>
<td class="nump">$ 14.36<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Share-based Payment Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6733880784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details) - CAD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">$ 32,712,066<span></span>
</td>
<td class="nump">$ 34,712,675<span></span>
</td>
<td class="nump">$ 32,983,223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedNetOperatingLossCarryForwardsMember', window );">Net operating losses carried forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">19,625,642<span></span>
</td>
<td class="nump">20,664,345<span></span>
</td>
<td class="nump">19,160,218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember', window );">Scientific research and experimental development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">6,338,542<span></span>
</td>
<td class="nump">7,406,169<span></span>
</td>
<td class="nump">7,406,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_InvestmentTaxCreditsMember', window );">Investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">4,222,016<span></span>
</td>
<td class="nump">3,988,606<span></span>
</td>
<td class="nump">3,988,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember', window );">Undepreciated capital costs in excess of book value of property and equipment and intellectual property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">1,908,320<span></span>
</td>
<td class="nump">1,949,611<span></span>
</td>
<td class="nump">1,927,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_ShareIssueCostsMember', window );">Share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">611,072<span></span>
</td>
<td class="nump">696,346<span></span>
</td>
<td class="nump">493,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedCapitalLossCarryForwardNetMember', window );">Net capital losses carried forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">$ 6,474<span></span>
</td>
<td class="nump">$ 7,598<span></span>
</td>
<td class="nump">$ 7,598<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedNetOperatingLossCarryForwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedNetOperatingLossCarryForwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_InvestmentTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_InvestmentTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_ShareIssueCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_ShareIssueCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedCapitalLossCarryForwardNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedCapitalLossCarryForwardNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6734247296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfCashFlowsAbstract', window );"><strong>Statement of cash flows [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable', window );">Contract receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,767,100<span></span>
</td>
<td class="num">$ (4,767,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables', window );">Other receivables</a></td>
<td class="num">(2,017,122)<span></span>
</td>
<td class="num">(13,924)<span></span>
</td>
<td class="nump">16,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IncreaseDecreaseinPrepaidExpense1', window );">Prepaid expenses</a></td>
<td class="num">(2,012,605)<span></span>
</td>
<td class="nump">475,077<span></span>
</td>
<td class="num">(915,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">1,347,365<span></span>
</td>
<td class="num">(1,858,170)<span></span>
</td>
<td class="num">(384,641)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities', window );">Contract liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">547,707<span></span>
</td>
<td class="nump">6,182,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables', window );">Other liabilities</a></td>
<td class="nump">807,877<span></span>
</td>
<td class="num">(27,982)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets', window );">Non-cash impact of foreign exchange</a></td>
<td class="nump">78,708<span></span>
</td>
<td class="nump">14,531<span></span>
</td>
<td class="nump">48,558<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInWorkingCapital', window );">Change in non-cash working capital related to operating activities</a></td>
<td class="num">$ (1,795,777)<span></span>
</td>
<td class="nump">$ 3,904,339<span></span>
</td>
<td class="nump">$ 180,855<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in financial assets resulting from foreign exchange. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph IG20B<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IG20B&amp;doctype=Implementation%20Guidance<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 35H<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for Decrease (Increase) in Contract Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for Increase (Decrease) in Contract Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncreaseDecreaseinPrepaidExpense1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Prepaid Expense1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncreaseDecreaseinPrepaidExpense1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6736328000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">Loss Per Common Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Loss Per Common Share</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss per common share is calculated using net loss for the year and the weighted average number of common shares outstanding for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">22,137,990</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;"> - </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">16,016,366</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;"> - </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">13,936,387</font><font style="font-family:inherit;font-size:10pt;">). The effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6736287264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">Leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Leases</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our portfolio of leases consists of office spaces with lease terms generally between </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;"> years. We currently do not have leases with variable lease payments, residual value guarantees, extension or termination options, or leases not yet commenced to which we are committed.  Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate as rates implicit in the leases were not readily determinable. The weighted-average rate applied was </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Right-of-use assets</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">                   </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:374px;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:301px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Office Spaces</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at January 1, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(362,592</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange impact</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,720</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">430,713</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Lease liabilities</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">                    </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:372px;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:298px;" rowspan="1" colspan="1"></td><td style="width:68px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Office Spaces</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at January 1, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">882,437</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of lease liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(447,497</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense on lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,817</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange impact</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">506,275</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our total undiscounted lease liability as at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.94736842105263%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:30%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Maturity analysis - contractual undiscounted cash flows</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less than one year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One to five years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174,157</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">More than five years</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total undiscounted lease liability as at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">565,179</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Section Presentation<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6750858768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofincometaxAbstract', window );"><strong>Disclosure of income tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock', window );">Provision for income taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:583px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:316px;" rowspan="1" colspan="1"></td><td style="width:76px;" rowspan="1" colspan="1"></td><td style="width:13px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:11px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:11px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(33,122,888</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,489,183</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,475,353</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Statutory Canadian corporate tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">26.50</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.00</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.00</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Anticipated tax recovery</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(8,777,565</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,452,079</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,178,345</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign jurisdiction tax rate difference</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,088,811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,312,963</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,899,190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee share based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">389,591</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382,275</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of warrant derivative</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,341,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impact of Alberta rate change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,758,175</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment to opening tax pools</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11,973</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(238,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other permanent differences</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">149,294</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35,912</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,039</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in deferred tax benefits deemed not probable to <br clear="none"/>  be recovered</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1,961,613</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,579,017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,051,725</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">548,042</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">144,021</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment in respect to prior periods</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net current tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">548,042</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,498</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory', window );">Schedule of unrecognized non-capital losses, non-refundable credits and deferred tax assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available, against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilized. The components of our unrecognized deferred tax asset are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:612px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:345px;" rowspan="1" colspan="1"></td><td style="width:84px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:84px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:84px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating losses carried forward</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19,625,642</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,664,345</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,160,218</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific research and experimental development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,338,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,406,169</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,406,099</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,222,016</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,988,606</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,988,325</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Undepreciated capital costs in excess of book value of property and equipment and intellectual property</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,908,320</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,949,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,927,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">611,072</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">696,346</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">493,343</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net capital losses carried forward</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,474</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,598</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,598</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrecognized deferred tax asset</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">32,712,066</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,712,675</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,983,223</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we have the following non-capital losses for income tax purposes in Canada:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:24.756335282651072%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expiry</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,809,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,170,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2029</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,009,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2030</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,774,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2031</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,343,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2032</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,873,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2033</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,457,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2034</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,472,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2035</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,125,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2036</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,430,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2037</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,812,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,056,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2039</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,900,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">69,230,000</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we have the following non-refundable federal investment tax credits for income tax purposes in Canada:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:190px;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:97px;" rowspan="1" colspan="1"></td><td style="width:88px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expiry</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">189,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">471,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">465,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">596,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2028</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">622,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2030</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2032</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">487,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2034</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2035</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2036</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2037</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">980</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2038</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,000</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5,482,980</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_g&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofincometaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofincometaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6752433200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory', window );">Deferred income taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We follow the liability method of accounting for income taxes.  Under the liability method, deferred income taxes are recognized for the difference between financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences).  Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled.  The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory', window );">Financial assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under IFRS 9 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments ("IFRS 9")</font><font style="font-family:inherit;font-size:10pt;">, financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#8217;s business model for managing the assets; and whether the financial asset&#8217;s contractual cash flows represent &#8216;solely payments of principal and interest&#8217; on the principal amount outstanding (the &#8216;SPPI criterion&#8217;). </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial assets include cash and cash equivalents and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion. </font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory', window );">Financial liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include trade accounts payable, other liabilities and warrant derivative. The classification and measurement of trade accounts payable and other liabilities are at amortized cost. The classification and measurement of warrant derivative is at FVPL.  </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory', window );">Impairment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under IFRS 9, accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IFRS 9 requires that we record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#8217;s original effective interest rate.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory', window );">Fair value measurement</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments we prioritize the related inputs used in measuring fair value into the following hierarchy: </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign currency translation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exceptions to this are where the monetary items form part of the net investment in a foreign operation and the foreign operation's functional currency is the local currency.  These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.  </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;"></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Loss per common share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per common share is determined using the weighted average number of common shares outstanding during the period.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the treasury stock method to calculate diluted loss per common share.  Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants, if dilutive. The number of additional common shares is calculated by assuming that any outstanding &#8220;in the money&#8221; options, restricted share units, performance share units and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property and equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives.  Depreciation is recorded using the declining balance method at the following annual rates:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.40350877192983%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:51%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office equipment and furniture</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Straight-line over the term of the lease</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At inception of a contract, we assess whether a contract is, or contains a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the contract involves the use of an identified asset;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we have the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we have the right to direct the use of the identified asset. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A right-of-use asset and corresponding lease liability is recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development costs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the treatment phase of clinical trials based on the total estimated cost of the treatment phase on a per patient basis and we expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized.  To date, all development costs have been expensed. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The contract also provides for development and regulatory milestone payments, royalties and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract receivable</font><font style="font-family:inherit;font-size:10pt;"> - Contract receivable includes amounts billed and currently due from customers. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts. We perform a review of our customer&#8217;s credit risk and payment histories, including payments made subsequent to year-end.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract liability</font><font style="font-family:inherit;font-size:10pt;"> - Our contract liability includes upfront license fees and billings in excess of revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or noncurrent based on the timing of when we expect to recognize revenue.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share based payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock option plan</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> stock option plan (the &#8220;Option Plan&#8221;) available to officers, directors, employees and consultants with grants under the Option Plan approved from time to time by our Board of Directors (the &#8220;Board&#8221;). Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines. Vesting is provided for at the discretion of the Board and the expiration of options is to be no greater than </font><font style="font-family:inherit;font-size:10pt;">10 years</font><font style="font-family:inherit;font-size:10pt;"> from the date of grant. Exercised stock options are settled with common shares issued from treasury. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the fair value based method of accounting for stock option awards granted under the Option Plan.  We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black- Scholes valuation model. The fair value of stock options with a graded vesting schedule is determined based on different expected lives for the options that vest each year, as it would be if the award were viewed as several separate awards, each with a different vesting date, and it is accounted for over the respective vesting period taking into consideration forfeiture estimates.   Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of options that are expected to vest.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Incentive share award plan</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our incentive share award plan (the "Share Plan") is available to directors, officers and employees. Under our Share Plan, performance share units and restricted share units may be approved from time to time by the Board. Performance share units  ("PSUs") are an award to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share units ("RSUs") are an award to certain officers and employees and to non-employee directors to which common shares shall be issued in accordance with the Share Plan.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the date of grant based on the number of PSUs/RSUs expected to vest, recognized over the term of the vesting period. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations', window );">Accounting standards and interpretations issued but not yet effective</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IFRS 16 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;IFRS 16&#8221;) replaces IAS 17 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;IAS 17&#8221;) and related interpretations for annual periods beginning on or after January 1, 2019. We have adopted IFRS 16 using the modified retrospective approach, under which the cumulative effect of the initial application is recognized in retained earnings at January 1, 2019. We have not restated comparatives for 2018. On transition to IFRS 16, we elected to apply the following practical expedients: </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Applied the exemption for short-term leases that have a remaining lease term of less than 12 months as at January 1, 2019; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Excluded initial direct costs for the measurement of right-of-use assets as at January 1, 2019; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Relied upon our assessment of whether leases are onerous under the requirement of IAS 37, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Provisions, contingent liabilities and contingent assets</font><font style="font-family:inherit;font-size:10pt;"> as at December 31, 2018 as an alternative to reviewing our right-of-use assets for impairment; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Measured the right-of-use assets at an amount equal to the lease liability, adjusted by the amount of lease incentive liability related to that lease recognized in the statement of financial position immediately before the date of initial application. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On transition to IFRS 16, we recognized </font><font style="font-family:inherit;font-size:10pt;">$882,437</font><font style="font-family:inherit;font-size:10pt;"> of lease liabilities. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate at January 1, 2019 as rates implicit in the leases were not readily determinable. The weighted-average rate applied was </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the impacts of adopting IFRS 16 on the consolidated financial statements:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Impact of changes</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported as at December 31, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Effects of IFRS 16 transition</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent to transition as at January 1, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Right-of-use assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current and non-current assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865,253</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865,253</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865,253</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,673,278</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,750</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(74,412</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,338</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">882,437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">882,437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current and non-current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,556,140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,556,140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,669,890</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,477,915</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total shareholders' equity</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,195,363</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,195,363</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to adopting IFRS 16, our total minimum operating lease commitments as at December 31, 2018 were </font><font style="font-family:inherit;font-size:10pt;">$961,575</font><font style="font-family:inherit;font-size:10pt;">. The difference between the total of the minimum lease payments set out in Note 11 of our 2018 annual consolidated financial statements and the total lease liabilities recognized on transition was a result of the effect of discounting on the minimum lease payments.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for deferred income tax. [Refer: Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for fair value measurement. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for the impairment of financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 30<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_30_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6592233680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Derivative (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory', window );">Reconciliation of change in fair value of warrant derivative</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the change in fair value of the warrant derivative is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:513px;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:258px;" rowspan="1" colspan="1"></td><td style="width:122px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:123px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Warrants Outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value of Warrant Derivative<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued, August 16, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,619,773</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,657,214</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,935,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,687,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,608,808</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange impact</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(70,255</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,684,126</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,508,764</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of the warrant derivative was determined using the following assumptions: </font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:455px;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:273px;" rowspan="1" colspan="1"></td><td style="width:90px;" rowspan="1" colspan="1"></td><td style="width:90px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">August&#160;16, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value per warrant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US$3.89</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US$0.27</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Underlying share price</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US$4.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US$0.54</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.59%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.42%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected hold period to exercise</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.0 year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.0 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected share price volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90.00%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82.00%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6736288928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Incorporation and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract', window );"><strong>Disclosure Of Notes And Other Explanatory Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">Incorporation and Nature of Operations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Incorporation and Nature of Operations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oncolytics Biotech Inc. was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd.  On April 8, 1998, we changed our name to Oncolytics Biotech Inc.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our consolidated financial statements for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;5, 2020</font><font style="font-family:inherit;font-size:10pt;">. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Markets and the Toronto Stock Exchange. Our registered office is located at 210, 1167 Kensington Crescent NW, Calgary, Alberta, Canada.   </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. Our lead product, pelareorep, is a potential immuno-oncology viral-agent that may be a novel treatment for certain types of cancer and may be an alternative to or in combination with existing cytotoxic or cytostatic therapies. Our clinical development program for pelareorep emphasizes three programs: chemotherapy combinations to assist the escape of the virus from the vasculature and enhance its distribution in the tumor; immuno-therapy combinations to create an inflamed phenotype promoting synergies with immune checkpoint inhibitors; and immune modulator/targeted combinations to upregulate natural killer cells promoting synergies with targeted therapies.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 51<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Notes And Other Explanatory Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6730197808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfFinancialPositionAbstract', window );"><strong>Statement of financial position [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued (shares)</a></td>
<td class="nump">32,198,453<span></span>
</td>
<td class="nump">17,399,749<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6747455168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indemnification of Officers and Directors<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract', window );"><strong>Disclosure Of Indemnification Of Officers and Directors [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock', window );">Indemnification of Officers and Directors</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Indemnification of Officers and Directors</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our corporate by-laws require that, except to the extent expressly prohibited by law, we will indemnify our officers and directors against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment reasonably incurred in respect of any civil, criminal or administrative action or proceeding as it relates to their services to the Company.&#160;The by-laws provide no limit to the amount of the indemnification.&#160;We have purchased directors&#8217; and officers&#8217; insurance coverage to cover claims made against the directors and officers during the applicable policy periods.&#160;The amounts and types of coverage have varied from period to period as dictated by market conditions.&#160;We believe that we have adequate insurance coverage; however, there is no guarantee that all indemnification payments will be covered under our existing insurance policies.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There is no pending litigation or proceeding involving any of our officers or directors as to which indemnification is being sought, nor are we aware of any threatened litigation that may result in claims for indemnification.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Indemnification Of Officers and Directors [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Indemnification Of Officers and Directors [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6650181472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofincometaxAbstract', window );"><strong>Disclosure of income tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:583px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:316px;" rowspan="1" colspan="1"></td><td style="width:76px;" rowspan="1" colspan="1"></td><td style="width:13px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:11px;" rowspan="1" colspan="1"></td><td style="width:78px;" rowspan="1" colspan="1"></td><td style="width:11px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(33,122,888</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,489,183</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,475,353</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Statutory Canadian corporate tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">26.50</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.00</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.00</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Anticipated tax recovery</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(8,777,565</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,452,079</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,178,345</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign jurisdiction tax rate difference</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,088,811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,312,963</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,899,190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee share based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">389,591</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382,275</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of warrant derivative</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,341,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impact of Alberta rate change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,758,175</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment to opening tax pools</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11,973</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(238,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other permanent differences</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">149,294</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35,912</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,039</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in deferred tax benefits deemed not probable to <br clear="none"/>  be recovered</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1,961,613</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,579,017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,051,725</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">548,042</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">144,021</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment in respect to prior periods</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net current tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">548,042</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,498</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we have the following non-capital losses for income tax purposes in Canada:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:24.756335282651072%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expiry</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,809,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,170,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2029</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,009,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2030</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,774,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2031</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,343,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2032</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,873,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2033</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,457,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2034</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,472,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2035</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,125,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2036</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,430,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2037</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,812,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,056,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2039</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,900,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">69,230,000</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we have the following non-refundable federal investment tax credits for income tax purposes in Canada:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:190px;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:97px;" rowspan="1" colspan="1"></td><td style="width:88px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expiry</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">189,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">471,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">465,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">596,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2028</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">622,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2030</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2032</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">487,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2034</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2035</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2036</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2037</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">980</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2038</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,000</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5,482,980</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As well, we have unclaimed scientific research and experimental development expenditures available to reduce future years&#8217; taxable income of approximately </font><font style="font-family:inherit;font-size:10pt;">$27,560,000</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;We have not recorded the potential benefits of these tax pools in these consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available, against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilized. The components of our unrecognized deferred tax asset are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:612px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:345px;" rowspan="1" colspan="1"></td><td style="width:84px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:84px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:84px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br clear="none"/>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017<br clear="none"/>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating losses carried forward</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19,625,642</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,664,345</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,160,218</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific research and experimental development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,338,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,406,169</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,406,099</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,222,016</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,988,606</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,988,325</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Undepreciated capital costs in excess of book value of property and equipment and intellectual property</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,908,320</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,949,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,927,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">611,072</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">696,346</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">493,343</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net capital losses carried forward</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,474</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,598</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,598</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrecognized deferred tax asset</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">32,712,066</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,712,675</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,983,223</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofincometaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofincometaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6736269056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofeventsafterreportingperiodAbstract', window );"><strong>Disclosure of events after reporting period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Between </font><font style="font-family:inherit;font-size:10pt;">January&#160;1, 2020</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">March&#160;5, 2020</font><font style="font-family:inherit;font-size:10pt;">, we issued </font><font style="font-family:inherit;font-size:10pt;">3,921,790</font><font style="font-family:inherit;font-size:10pt;"> common shares for gross proceeds of US$</font><font style="font-family:inherit;font-size:10pt;">12,726,383</font><font style="font-family:inherit;font-size:10pt;"> through our October 2018 ATM equity offering sales agreement and we received gross proceeds of US$</font><font style="font-family:inherit;font-size:10pt;">1,030,669</font><font style="font-family:inherit;font-size:10pt;"> as a result of </font><font style="font-family:inherit;font-size:10pt;">1,145,188</font><font style="font-family:inherit;font-size:10pt;"> August 2019 public offering warrants that were exercised.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">February&#160;25, 2020</font><font style="font-family:inherit;font-size:10pt;">, we received the US</font><font style="font-family:inherit;font-size:10pt;">$1,500,000</font><font style="font-family:inherit;font-size:10pt;"> upfront payment of BRACELET-1 cost from Pfizer (see Note 13 for details).</font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2019-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofeventsafterreportingperiodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of events after reporting period [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofeventsafterreportingperiodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6754516224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">$ 412,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">296,768<span></span>
</td>
<td class="nump">$ 412,736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">1,257,353<span></span>
</td>
<td class="nump">1,729,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">7,014<span></span>
</td>
<td class="nump">174,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(646,834)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">1,264,367<span></span>
</td>
<td class="nump">1,257,353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">844,617<span></span>
</td>
<td class="nump">1,396,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">122,982<span></span>
</td>
<td class="nump">95,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(646,834)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">967,599<span></span>
</td>
<td class="nump">844,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">35,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">15,670<span></span>
</td>
<td class="nump">35,914<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical equipment | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">60,378<span></span>
</td>
<td class="nump">197,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(137,492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">60,378<span></span>
</td>
<td class="nump">60,378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical equipment | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">24,464<span></span>
</td>
<td class="nump">154,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">20,244<span></span>
</td>
<td class="nump">7,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(137,492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">44,708<span></span>
</td>
<td class="nump">24,464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">170,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">128,909<span></span>
</td>
<td class="nump">170,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">345,941<span></span>
</td>
<td class="nump">681,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">7,014<span></span>
</td>
<td class="nump">88,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(424,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">352,955<span></span>
</td>
<td class="nump">345,941<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">174,953<span></span>
</td>
<td class="nump">549,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">49,093<span></span>
</td>
<td class="nump">49,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(424,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">224,046<span></span>
</td>
<td class="nump">174,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember', window );">Office Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">89,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">75,021<span></span>
</td>
<td class="nump">89,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember', window );">Office Furniture | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">247,438<span></span>
</td>
<td class="nump">225,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">247,438<span></span>
</td>
<td class="nump">247,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember', window );">Office Furniture | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">157,749<span></span>
</td>
<td class="nump">147,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">14,668<span></span>
</td>
<td class="nump">10,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">172,417<span></span>
</td>
<td class="nump">157,749<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">32,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">27,059<span></span>
</td>
<td class="nump">32,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office Equipment | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">105,229<span></span>
</td>
<td class="nump">89,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">105,229<span></span>
</td>
<td class="nump">105,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office Equipment | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">72,828<span></span>
</td>
<td class="nump">68,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">5,342<span></span>
</td>
<td class="nump">4,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">78,170<span></span>
</td>
<td class="nump">72,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">83,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">50,109<span></span>
</td>
<td class="nump">83,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold Improvements | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">498,367<span></span>
</td>
<td class="nump">534,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">49,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(85,096)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">498,367<span></span>
</td>
<td class="nump">498,367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold Improvements | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">414,623<span></span>
</td>
<td class="nump">476,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">33,635<span></span>
</td>
<td class="nump">23,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(85,096)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">$ 448,258<span></span>
</td>
<td class="nump">$ 414,623<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6657975216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock', window );">Schedule of balances in foreign currencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balances in foreign currencies at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:622px;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:222px;" rowspan="1" colspan="1"></td><td style="width:133px;" rowspan="1" colspan="1"></td><td style="width:133px;" rowspan="1" colspan="1"></td><td style="width:133px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">US dollars <br clear="none"/></font><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">British pounds<br clear="none"/></font><font style="font-family:inherit;font-size:10pt;">&#163;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Euro<br clear="none"/>&#8364;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,676,360</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,751</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,664</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,500,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and other liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,378,860)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,345)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(310,086)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant derivative</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,551,250)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,246,250</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,406</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(276,422)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Foreign Currency Held [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6732784576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office equipment and furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant and Equipment, Annual Depreciation Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_PropertyPlantandEquipmentAnnualDepreciationRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6768312144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommitmentsAbstract', window );"><strong>Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_PurchaseObligation1', window );">Commitment for payment</a></td>
<td class="nump">$ 4,867,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">847,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_FundedandRoyaltyRepayment', window );">Repayment, maximum</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OverheadRepayment', window );">Overhead repayment</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AnnualContingentPaymentGrossSalesPercent', window );">Annual installment of gross sales of product, percent</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AnnualContingentPayment', window );">Annual installment of annual product sales</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=oncyf_CollaborationAgreementMember', window );">BRACELET-1 collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">$ 652,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AnnualContingentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Contingent Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AnnualContingentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AnnualContingentPaymentGrossSalesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Contingent Payment, Gross Sales, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AnnualContingentPaymentGrossSalesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_FundedandRoyaltyRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funded and Royalty Repayment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_FundedandRoyaltyRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OverheadRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Overhead Repayment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OverheadRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_PurchaseObligation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_PurchaseObligation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=oncyf_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=oncyf_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6732957040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments - Schedule of Number of Other Equity Instruments (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember', window );">Restricted share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of the year (shares)</a></td>
<td class="nump">260,755<span></span>
</td>
<td class="nump">190,407<span></span>
</td>
<td class="nump">139,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted during the year (shares)</a></td>
<td class="nump">270,098<span></span>
</td>
<td class="nump">102,855<span></span>
</td>
<td class="nump">51,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,210)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested during the year (shares)</a></td>
<td class="num">(321,196)<span></span>
</td>
<td class="num">(28,297)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of the year (shares)</a></td>
<td class="nump">209,657<span></span>
</td>
<td class="nump">260,755<span></span>
</td>
<td class="nump">190,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted', window );">Weighted average fair value at measurement date, other equity instruments granted | $</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="nump">$ 3.35<span></span>
</td>
<td class="nump">$ 5.96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_PerformanceShareUnitsMember', window );">Performance share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of the year (shares)</a></td>
<td class="nump">63,156<span></span>
</td>
<td class="nump">94,734<span></span>
</td>
<td class="nump">88,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted during the year (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(31,578)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested during the year (shares)</a></td>
<td class="num">(2,105)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of the year (shares)</a></td>
<td class="nump">61,051<span></span>
</td>
<td class="nump">63,156<span></span>
</td>
<td class="nump">94,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted', window );">Weighted average fair value at measurement date, other equity instruments granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_PerformanceShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_PerformanceShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
